Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

To O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
PCOS O
. O

A O
randomized O
controlled O
trial O
of O
five O
high-fluence O
treatments O
( O
intervention O
) O
vs. O
five O
low-fluence O
treatments O
( O
control O
) O
was O
performed O
over O
6 O
months O
in O
a O
National O
Health O
Service O
teaching O
hospital O
. O

Subjects O
were O
88 O
women O
with O
facial O
hirsutism O
due O
to O
PCOS O
recruited O
from O
hospital O
outpatient O
clinics O
and O
a O
patient O
support O
group O
in O
2001-2002 O
. O

The O
main O
outcomes O
were O
self-reported O
severity O
of O
facial O
hair O
( O
measured O
on O
a O
scale O
of O
1-10 O
) O
, O
depression O
, O
anxiety O
( O
measured O
on O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
) O
and O
quality O
of O
life O
( O
measured O
on O
the O
WHOQOL-BREF O
) O
. O

Self-reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7.3 I-Premise
to I-Premise
3.6 I-Premise
over I-Premise
the I-Premise
6-month I-Premise
study I-Premise
period I-Premise
";" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7.1 I-Premise
and I-Premise
6.1 I-Premise
. I-Premise

The B-Premise
change I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
[ I-Premise
ancova I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
24.5 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Self-reported B-Premise
time I-Premise
spent I-Premise
on I-Premise
hair I-Premise
removal I-Premise
declined I-Premise
from I-Premise
112 I-Premise
to I-Premise
21 I-Premise
min I-Premise
per I-Premise
week I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
from I-Premise
92 I-Premise
to I-Premise
56 I-Premise
min I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,80 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
/= I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Mean B-Premise
depression I-Premise
scores I-Premise
fell I-Premise
from I-Premise
6.7 I-Premise
to I-Premise
3.6 I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
6.1 I-Premise
to I-Premise
5.4 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
14.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

A B-Premise
similar I-Premise
change I-Premise
was I-Premise
seen I-Premise
for I-Premise
mean I-Premise
anxiety I-Premise
scores I-Premise
: I-Premise
intervention I-Premise
11.1 I-Premise
to I-Premise
8.2 I-Premise
, I-Premise
control I-Premise
9.6 I-Premise
to I-Premise
9.3 I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
17.8 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Psychological B-Premise
quality I-Premise
of I-Premise
life I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
from I-Premise
49.6 I-Premise
to I-Premise
61.2 I-Premise
vs. I-Premise
50.1 I-Premise
to I-Premise
51.5 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
PCOS I-Claim
. I-Claim

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

Despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim

Therefore O
, O
we O
performed O
a O
randomized O
, O
phase O
III O
non-inferiority O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
( O
PT O
) O
with O
paclitaxel O
plus O
carboplatin O
( O
TC O
) O
in O
patients O
with O
advanced O
ovarian O
cancer O
. O

A O
total O
of O
798 O
patients O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stage O
IIB-IV O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
either O
PT O
or O
TC O
at O
3-week O
intervals O
. O

The O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O

Secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression-free O
survival O
time O
. O

Quality O
of O
life O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire O
( O
QLQ O
) O
-C30 O
, O
version O
2.0 O
. O

Survival O
curves O
were O
calculated O
using O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
Cox O
proportional O
hazards O
model O
. O

The B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40.0 I-Premise
% I-Premise
for I-Premise
PT I-Premise
versus I-Premise
37.5 I-Premise
% I-Premise
for I-Premise
TC I-Premise
, I-Premise
difference I-Premise
= I-Premise
2.5 I-Premise
% I-Premise
, I-Premise
one-sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
17.2 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15.2 I-Premise
to I-Premise
19.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
the I-Premise
PT I-Premise
arm I-Premise
( I-Premise
19.1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
16.7 I-Premise
to I-Premise
21.5 I-Premise
months I-Premise
) I-Premise
were I-Premise
also I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
";" I-Premise
the B-Premise
same I-Premise
was I-Premise
TRUE I-Premise
of I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
( I-Premise
43.3 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
37.2 I-Premise
to I-Premise
47.8 I-Premise
months I-Premise
versus I-Premise
44.1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
40.2 I-Premise
to I-Premise
49.4 I-Premise
months I-Premise
, I-Premise
for I-Premise
the I-Premise
TC I-Premise
and I-Premise
PT I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Mean B-Premise
global I-Premise
quality-of-life I-Premise
scores I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
treatment I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PT I-Premise
arm I-Premise
( I-Premise
65.25 I-Premise
versus I-Premise
51.97 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-13.28 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-18.88 I-Premise
to I-Premise
-7.68 I-Premise
) I-Premise
. I-Premise

The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first-line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
2-year O
functional O
performance O
and O
quality O
of O
life O
in O
patients O
with O
operable O
squamous O
cell O
carcinoma O
of O
the O
esophagus O
, O
who O
have O
received O
either O
surgery O
or O
definitive O
chemoradiation O
( O
CRT O
) O
. O

The O
functional O
outcomes O
and O
quality O
of O
life O
in O
patients O
receiving O
esophagectomy O
or O
definitive O
CRT O
is O
uncertain O
. O

Data O
were O
extracted O
from O
the O
database O
of O
a O
prospective O
randomized O
controlled O
trial O
that O
included O
patients O
with O
resectable O
mid O
or O
lower O
thoracic O
esophageal O
cancers O
. O

The O
patients O
were O
randomized O
to O
either O
standard O
esophagectomy O
or O
definitive O
CRT O
. O

Quality O
of O
life O
assessments O
were O
performed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-OES24 O
modules O
. O

Other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

From O
July O
2000 O
to O
December O
2004 O
, O
a O
total O
of O
81 O
patients O
were O
enrolled O
into O
the O
study O
. O

No B-Premise
significant I-Premise
longitudinal I-Premise
changes I-Premise
were I-Premise
detected I-Premise
in I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
in I-Premise
both I-Premise
groups I-Premise
upon I-Premise
available I-Premise
follow-up I-Premise
. I-Premise

Surgery B-Premise
was I-Premise
associated I-Premise
with I-Premise
worsened I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
fatigue I-Premise
symptoms I-Premise
up I-Premise
to I-Premise
6 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
these I-Premise
scales I-Premise
improved I-Premise
at I-Premise
2 I-Premise
years I-Premise
. I-Premise

In B-Premise
terms I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
, I-Premise
dyspnoic I-Premise
and I-Premise
coughing I-Premise
symptoms I-Premise
were I-Premise
significantly I-Premise
worsened I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.036 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
whereas I-Premise
symptoms I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
progressively I-Premise
deteriorated I-Premise
over I-Premise
time I-Premise
. I-Premise

Concerning B-Premise
the I-Premise
eating I-Premise
function I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
improvements I-Premise
in I-Premise
dysphagia I-Premise
but I-Premise
there I-Premise
were I-Premise
frequent I-Premise
need I-Premise
for I-Premise
endoscopic I-Premise
intervention I-Premise
. I-Premise

Neither B-Premise
surgery I-Premise
nor I-Premise
definitive I-Premise
CRT I-Premise
significantly I-Premise
impaired I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
of I-Premise
patients I-Premise
. I-Premise

Surgery B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
short-term I-Claim
negative I-Claim
impact I-Claim
in I-Claim
some I-Claim
aspects I-Claim
of I-Claim
health I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
assessments I-Claim
but B-Claim
these I-Claim
changes I-Claim
became I-Claim
insignificant I-Claim
2 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

However O
, O
CRT B-Claim
was I-Claim
associated I-Claim
with I-Claim
progressive I-Claim
deteriorations I-Claim
in I-Claim
pulmonary I-Claim
function I-Claim
in I-Claim
the I-Claim
longer I-Claim
term I-Claim
. I-Claim

To O
observe O
the O
effect O
of O
TCM O
therapy O
for O
removing O
toxic O
substance O
and O
unblocking O
meridians O
on O
post-radiation O
quality O
of O
life O
( O
QOF O
) O
in O
55 O
patients O
with O
lung O
cancer O
. O

All O
patients O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
55 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
radiotherapy O
combined O
with O
the O
TCM O
therapy O
, O
and O
the O
53 O
in O
the O
control O
group O
were O
given O
radiotherapy O
alone O
. O

The O
clinical O
efficacy O
was O
evaluated O
by O
indexes O
including O
KPS O
scores O
, O
QLQ-C30 O
questionnaire O
, O
LC13 O
specific O
scale O
for O
lung O
cancer O
, O
evaluation O
criteria O
for O
TCM O
efficacy O
, O
the O
6-min O
walking O
distance O
, O
and O
body O
weight O
, O
etc O
. O

The B-Premise
KPS I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
QLQ-C30 I-Premise
questionnaire I-Premise
and I-Premise
LC30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
scores I-Premise
of I-Premise
TCM I-Premise
efficacy I-Premise
( I-Premise
24.52 I-Premise
+/- I-Premise
8.98 I-Premise
vs I-Premise
29.76 I-Premise
+/- I-Premise
7.09 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
the I-Premise
6-min I-Premise
walking I-Premise
distance I-Premise
( I-Premise
233.4 I-Premise
+/- I-Premise
29.2 I-Premise
m I-Premise
vs I-Premise
205.8 I-Premise
+/- I-Premise
31.9 I-Premise
m I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
. I-Premise

After B-Premise
treatment I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
, I-Premise
the I-Premise
body I-Premise
weight I-Premise
was I-Premise
increased I-Premise
in I-Premise
11 I-Premise
patients I-Premise
( I-Premise
20.0 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
28 I-Premise
( I-Premise
50.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
16 I-Premise
( I-Premise
29.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
it I-Premise
was I-Premise
increased I-Premise
in I-Premise
5 I-Premise
( I-Premise
9.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
26 I-Premise
( I-Premise
49.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
22 I-Premise
( I-Premise
41.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
, I-Premise
too I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

TCM B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post-radiation I-Claim
QOL I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim

The O
AVEREL O
trial O
[ O
A O
Study O
of O
Avastin O
( O
Bevacizumab O
) O
in O
Combination O
With O
Herceptin O
( O
Trastuzumab O
) O
/Docetaxel O
in O
Patients O
With O
HER2-Positive O
Metastatic O
Breast O
Cancer O
] O
evaluated O
first-line O
bevacizumab-containing O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
locally O
recurrent/metastatic O
breast O
cancer O
( O
LR/MBC O
) O
. O

Patients O
with O
measurable/evaluable O
HER2-positive O
LR/MBC O
who O
had O
not O
received O
trastuzumab O
or O
chemotherapy O
for O
LR/MBC O
were O
stratified O
by O
prior O
adjuvant O
trastuzumab O
, O
prior O
( O
neo O
) O
adjuvant O
taxane O
, O
hormone O
receptor O
status O
, O
and O
measurable O
disease O
and O
were O
randomly O
assigned O
to O
receive O
docetaxel O
100 O
mg/m O
( O
2 O
) O
plus O
trastuzumab O
8 O
mg/kg O
loading O
dose O
followed O
by O
6 O
mg/kg O
either O
with O
bevacizumab O
15 O
mg/kg O
or O
without O
bevacizumab O
, O
all O
administered O
every O
3 O
weeks O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Additional O
end O
points O
included O
overall O
survival O
, O
response O
rate O
( O
RR O
) O
, O
safety O
, O
quality O
of O
life O
, O
and O
translational O
research O
. O

Results O
Baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O

Most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease-free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O

Median O
follow-up O
was O
26 O
months O
. O

The B-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
investigator-assessed I-Premise
PFS I-Premise
was I-Premise
0.82 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.65 I-Premise
to I-Premise
1.02 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0775 I-Premise
";" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13.7 I-Premise
v I-Premise
16.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
non-bevacizumab I-Premise
and I-Premise
bevacizumab I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
72 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
Independent I-Premise
Review I-Premise
Committee-assessed I-Premise
PFS I-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.54 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0162 I-Premise
";" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13.9 I-Premise
v I-Premise
16.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
53 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
RR I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.3492 I-Premise
) I-Premise
. I-Premise

Grade B-Claim
≥ I-Claim
3 I-Claim
febrile I-Claim
neutropenia I-Claim
and I-Claim
hypertension I-Claim
were I-Claim
more I-Claim
common I-Claim
with I-Claim
bevacizumab-containing I-Claim
therapy I-Claim
. I-Claim

High B-Premise
baseline I-Premise
plasma I-Premise
vascular I-Premise
endothelial I-Premise
growth I-Premise
factor I-Premise
A I-Premise
( I-Premise
VEGF-A I-Premise
) I-Premise
concentrations I-Premise
were I-Premise
associated I-Premise
with I-Premise
greater I-Premise
bevacizumab I-Premise
benefit I-Premise
( I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
) I-Premise
. I-Premise

Combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator-assessed I-Claim
PFS I-Claim
. I-Claim

The O
potential O
predictive O
value O
of O
plasma O
VEGF-A O
is O
consistent O
with O
findings O
in O
HER2-negative O
LR/MBC O
, O
warranting O
prospective O
evaluation O
. O

Vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim

We O
compared O
the O
effectiveness O
and O
toxicity O
of O
the O
combination O
of O
vinorelbine O
plus O
gemcitabine O
with O
those O
of O
each O
drug O
given O
alone O
in O
an O
open-label O
, O
randomized O
phase O
III O
trial O
in O
elderly O
patients O
with O
advanced O
NSCLC O
. O

Patients O
aged O
70 O
years O
and O
older O
, O
enrolled O
between O
December O
1997 O
and O
November O
2000 O
, O
were O
randomly O
assigned O
to O
receive O
intravenous O
vinorelbine O
( O
30 O
mg/m O
( O
2 O
) O
of O
body O
surface O
area O
) O
, O
gemcitabine O
( O
1200 O
mg/m O
( O
2 O
) O
) O
, O
or O
vinorelbine O
( O
25 O
mg/m O
( O
2 O
) O
) O
plus O
gemcitabine O
( O
1000 O
mg/m O
( O
2 O
) O
) O
. O

All O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

The O
primary O
endpoint O
was O
survival O
. O

Survival O
curves O
were O
drawn O
using O
the O
Kaplan-Meier O
method O
and O
analyzed O
by O
the O
Mantel-Haenszel O
test O
. O

Secondary O
endpoints O
were O
quality O
of O
life O
and O
toxicity O
. O

Of O
698 O
patients O
available O
for O
intention-to-treat O
analysis O
, O
233 O
were O
assigned O
to O
receive O
vinorelbine O
, O
233 O
to O
gemcitabine O
, O
and O
232 O
to O
vinorelbine O
plus O
gemcitabine O
. O

Compared B-Premise
with I-Premise
each I-Premise
single I-Premise
drug I-Premise
, I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
did I-Premise
not I-Premise
improve I-Premise
survival I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
was I-Premise
1.17 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.95 I-Premise
to I-Premise
1.44 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
and I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.29 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
gemcitabine I-Premise
. I-Premise

Although B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
across I-Premise
the I-Premise
three I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
the B-Premise
combination I-Premise
treatment I-Premise
was I-Premise
more I-Premise
toxic I-Premise
than I-Premise
the I-Premise
two I-Premise
drugs I-Premise
given I-Premise
singly I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single-agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
of O
a O
psychoeducational O
intervention O
in O
improving O
cancer-related O
fatigue O
. O

This O
randomized O
controlled O
trial O
involved O
109 O
women O
commencing O
adjuvant O
chemotherapy O
for O
stage O
I O
or O
II O
breast O
cancer O
in O
five O
chemotherapy O
treatment O
centers O
. O

Intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
-10 O
to O
20-minute O
sessions O
1 O
week O
apart O
. O

Instruments O
included O
a O
numeric O
rating O
scale O
assessing O
confidence O
with O
managing O
fatigue O
";" O
11-point O
numeric O
rating O
scales O
measuring O
fatigue O
at O
worst O
, O
average O
, O
and O
best O
";" O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Fatigue O
and O
Piper O
Fatigue O
Scales O
";" O
the O
Cancer O
Self-Efficacy O
Scale O
";" O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
";" O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
. O

For O
each O
outcome O
, O
separate O
analyses O
of O
covariance O
of O
change O
scores O
between O
baseline O
( O
T1 O
) O
and O
the O
three O
follow-up O
time O
points O
( O
T2 O
, O
T3 O
, O
and O
T4 O
) O
were O
conducted O
, O
controlling O
for O
the O
variable O
's O
corresponding O
baseline O
value O
. O

Compared B-Premise
with I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
mean I-Premise
difference I-Premise
scores I-Premise
between I-Premise
the I-Premise
baseline I-Premise
( I-Premise
T1 I-Premise
) I-Premise
and I-Premise
immediate I-Premise
after I-Premise
the I-Premise
test I-Premise
( I-Premise
T2 I-Premise
) I-Premise
assessments I-Premise
increased I-Premise
significantly I-Premise
more I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
for I-Premise
worst I-Premise
and I-Premise
average I-Premise
fatigue I-Premise
, I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Fatigue I-Premise
, I-Premise
and I-Premise
Piper I-Premise
fatigue I-Premise
severity I-Premise
and I-Premise
interference I-Premise
measures I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
T3 I-Premise
and I-Premise
T4 I-Premise
assessments I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
identified I-Premise
for I-Premise
any I-Premise
pre- I-Premise
or I-Premise
post-test I-Premise
change I-Premise
scores I-Premise
for I-Premise
confidence I-Premise
with I-Premise
managing I-Premise
fatigue I-Premise
, I-Premise
cancer I-Premise
self-efficacy I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer-related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim

However B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer-related I-Claim
fatigue I-Claim
. I-Claim

To O
evaluate O
the O
incidence O
and O
temporal O
resolution O
of O
dysuria O
after O
permanent O
prostate O
brachytherapy O
, O
and O
to O
identify O
predictors O
of O
brachytherapy-related O
dysuria O
. O

The O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral-sparing O
techniques O
( O
100-150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103Pd O
or O
125I O
for O
clinical O
T1c-T2c O
prostate O
cancer O
. O

The O
median O
follow-up O
was O
22.6 O
months O
. O

An O
alpha-blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy-related O
urinary O
morbidity O
. O

Dysuria O
was O
evaluated O
on O
a O
0-10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O

Clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha-blocker O
, O
age O
, O
IPSS O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
V O
( O
100/200 O
) O
, O
D90 O
, O
and O
time O
to O
obtaining O
a O
normal O
IPSS O
. O

The O
maximum O
incidence O
of O
dysuria O
was O
85 O
% O
at O
1 O
month O
after O
brachytherapy O
, O
with O
subsequent O
resolution O
over O
time O
. O

The B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2.7 I-Premise
vs I-Premise
4.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise

Patients B-Premise
with I-Premise
dysuria I-Premise
had I-Premise
a I-Premise
statistically I-Premise
higher I-Premise
IPSS I-Premise
. I-Premise

The B-Premise
dysuria I-Premise
resolved I-Premise
faster I-Premise
in I-Premise
patients I-Premise
implanted I-Premise
with I-Premise
103Pd I-Premise
but B-Premise
was I-Premise
unaffected I-Premise
by I-Premise
the I-Premise
use I-Premise
of I-Premise
supplemental I-Premise
radiotherapy I-Premise
and/or I-Premise
androgen I-Premise
deprivation I-Premise
therapy I-Premise
. I-Premise

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
prophylactic I-Premise
alpha-blockers I-Premise
resulted I-Premise
in I-Premise
statistically I-Premise
lower I-Premise
maximum I-Premise
dysuria I-Premise
scores I-Premise
, I-Premise
while B-Premise
the I-Premise
maximum I-Premise
IPSS I-Premise
after I-Premise
implantation I-Premise
and I-Premise
isotope I-Premise
type I-Premise
( I-Premise
but I-Premise
only I-Premise
at I-Premise
6 I-Premise
months I-Premise
) I-Premise
were I-Premise
the I-Premise
best I-Premise
predictors I-Premise
of I-Premise
the I-Premise
resolution I-Premise
of I-Premise
dysuria I-Premise
. I-Premise

Dysuria B-Claim
is I-Claim
common I-Claim
after I-Claim
brachytherapy I-Claim
but I-Claim
is I-Claim
typically I-Claim
mild I-Claim
. I-Claim

Prophylactic B-Claim
alpha-blockers I-Claim
gave I-Claim
significantly I-Claim
lower I-Claim
maximum I-Claim
dysuria I-Claim
scores I-Claim
but B-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
time I-Claim
to I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

The B-Claim
maximum I-Claim
IPSS I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression-free I-Claim
survival I-Claim
( I-Claim
PFS I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim

We O
examined O
the O
efficacy O
and O
safety O
of O
adding O
gemcitabine O
to O
paclitaxel/bevacizumab O
( O
PB O
) O
. O

In O
this O
multicenter O
, O
open-label O
, O
randomized O
phase O
II O
trial O
, O
women O
with O
locally O
advanced O
or O
MBC O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
90 O
mg/m O
( O
2 O
) O
( O
days O
1 O
, O
8 O
, O
15 O
) O
and O
bevacizumab O
10 O
mg/kg O
( O
days O
1 O
, O
15 O
) O
with O
or O
without O
gemcitabine O
1500 O
mg/m O
( O
2 O
) O
( O
days O
1 O
, O
15 O
) O
in O
28-day O
cycles O
. O

Patients O
with O
prior O
cytotoxic O
therapy O
for O
MBC O
were O
ineligible O
. O

The O
primary O
endpoint O
was O
investigator-assessed O
overall O
response O
rate O
( O
ORR O
) O
";" O
secondary O
endpoints O
were O
PFS O
, O
overall O
survival O
( O
OS O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O

Ninety-four O
patients O
received O
PB O
, O
and O
93 O
received O
paclitaxel/bevacizumab/gemcitabine O
( O
PB+G O
) O
. O

The B-Premise
ORRs I-Premise
were I-Premise
48.9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
38.5 I-Premise
% I-Premise
-59.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
58.7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
47.9 I-Premise
% I-Premise
-68.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.117 I-Premise
) I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
8.1-10.4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.7-12.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.247 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.82 I-Premise
) I-Premise
";" I-Premise
the I-Premise
median I-Premise
OS I-Premise
was I-Premise
25.0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
18.8-not I-Premise
assessable I-Premise
[ I-Premise
N/A I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
20.3-N/A I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.475 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.84 I-Premise
) I-Premise
, I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
was I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
P I-Premise
= I-Premise
.014 I-Premise
) I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
PB I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
FACT-B I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Breast I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
Social/Family I-Premise
Well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
.041 I-Premise
) I-Premise
, I-Premise
and I-Premise
Breast I-Premise
Cancer-Additional I-Premise
Concerns I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
PB+G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Maintenance O
therapy O
, O
commenced O
immediately O
after O
the O
completion O
of O
first-line O
chemotherapy O
, O
is O
a O
promising O
strategy O
for O
improving O
treatment O
outcomes O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
global O
phase O
III O
SequentiAl O
Tarceva O
in O
UnResectable O
NSCLC O
( O
SATURN O
) O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
tyrosine-kinase O
inhibitor O
erlotinib O
as O
maintenance O
treatment O
in O
NSCLC O
patients O
without O
progression O
after O
first-line O
chemotherapy O
. O

We O
report O
a O
retrospective O
subanalysis O
of O
Asian O
patients O
enrolled O
in O
SATURN O
. O

Patients O
with O
advanced O
NSCLC O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

The O
co-primary O
endpoints O
of O
SATURN O
were O
progression-free O
survival O
( O
PFS O
) O
in O
all O
patients O
and O
in O
those O
with O
positive O
EGFR O
immunohistochemistry O
( O
IHC O
) O
status O
. O

Secondary O
endpoints O
included O
overall O
survival O
( O
OS O
) O
, O
disease O
control O
rate O
, O
safety O
, O
quality O
of O
life O
( O
QoL O
) O
and O
biomarker O
analyses O
. O

In O
total O
, O
126 O
patients O
from O
East O
and O
South-East O
Asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent-to-treat O
population O
) O
: O
88 O
from O
Korea O
, O
28 O
from O
China O
and O
10 O
from O
Malaysia O
";" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
Indian O
ethnicity O
. O

PFS B-Premise
was I-Premise
significantly I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
both I-Premise
overall I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
: I-Premise
0.57 I-Premise
";" I-Premise
p=0.0067 I-Premise
) I-Premise
and I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
IHC-positive I-Premise
disease I-Premise
( I-Premise
HR=0.50 I-Premise
";" I-Premise
p=0.0057 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
OS I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
IHC-positive I-Premise
subgroup I-Premise
( I-Premise
p=0.0233 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
with I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
versus I-Premise
5 I-Premise
% I-Premise
";" I-Premise
p=0.0025 I-Premise
) I-Premise
. I-Premise

Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

The B-Premise
most I-Premise
common I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
rash I-Premise
, I-Premise
diarrhea I-Premise
and I-Premise
pruritus I-Premise
. I-Premise

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first-line I-Claim
chemotherapy I-Claim
. I-Claim

To O
evaluate O
the O
safety O
and O
efficacy O
of O
abatacept O
during O
2 O
years O
of O
the O
ATTAIN O
( O
Abatacept O
Trial O
in O
Treatment O
of O
Anti-TNF O
INadequate O
responders O
) O
trial O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Patients O
completing O
the O
6-month O
, O
double-blind O
period O
were O
eligible O
to O
enter O
the O
long-term O
extension O
";" O
patients O
received O
abatacept O
approximately O
10 O
mg/kg O
, O
plus O
disease-modifying O
antirheumatic O
drugs O
. O

Safety O
and O
efficacy O
( O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
criteria O
responses O
, O
DAS28 O
( O
C-reactive O
protein O
) O
, O
HAQ-DI O
, O
SF-36 O
, O
Medical O
Outcomes O
Study O
Sleep O
Problems O
Index O
, O
fatigue O
VAS O
) O
were O
assessed O
through O
2 O
years O
. O

317 O
patients O
( O
218 O
from O
the O
abatacept O
and O
99 O
from O
the O
placebo O
group O
) O
entered O
and O
222 O
( O
70 O
% O
) O
completed O
18 O
months O
of O
long-term O
extension O
treatment O
. O

The B-Premise
incidence I-Premise
and I-Premise
type I-Premise
of I-Premise
adverse I-Premise
events I-Premise
were I-Premise
consistent I-Premise
between I-Premise
the I-Premise
double-blind I-Premise
and I-Premise
cumulative I-Premise
( I-Premise
double-blind I-Premise
plus I-Premise
long-term I-Premise
extension I-Premise
) I-Premise
periods I-Premise
. I-Premise

Rates B-Premise
of I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
25.6 I-Premise
and I-Premise
23.4 I-Premise
per I-Premise
100 I-Premise
patient-years I-Premise
in I-Premise
the I-Premise
double-blind I-Premise
versus I-Premise
cumulative I-Premise
period I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non-responder I-Premise
analyses I-Premise
, I-Premise
ACR I-Premise
responses I-Premise
in I-Premise
abatacept-treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59.4 I-Premise
% I-Premise
and I-Premise
56.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23.5 I-Premise
% I-Premise
and I-Premise
33.2 I-Premise
% I-Premise
";" I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11.5 I-Premise
% I-Premise
and I-Premise
16.1 I-Premise
% I-Premise
";" I-Premise
HAQ-DI I-Premise
responses I-Premise
were I-Premise
54.4 I-Premise
% I-Premise
and I-Premise
47.9 I-Premise
% I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
post-hoc I-Premise
as-observed I-Premise
analyses I-Premise
, I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
) I-Premise
achieving I-Premise
DAS28 I-Premise
( I-Premise
C-reactive I-Premise
protein I-Premise
) I-Premise
low I-Premise
disease I-Premise
activity I-Premise
score I-Premise
( I-Premise
< I-Premise
or I-Premise
= I-Premise
3.2 I-Premise
) I-Premise
and I-Premise
DAS28 I-Premise
( I-Premise
C-reactive I-Premise
protein I-Premise
) I-Premise
-defined I-Premise
remission I-Premise
( I-Premise
< I-Premise
2.6 I-Premise
) I-Premise
increased I-Premise
from I-Premise
18.3 I-Premise
% I-Premise
( I-Premise
13.0 I-Premise
, I-Premise
23.5 I-Premise
) I-Premise
to I-Premise
32.0 I-Premise
% I-Premise
( I-Premise
24.6 I-Premise
, I-Premise
39.4 I-Premise
) I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
( I-Premise
6.8 I-Premise
, I-Premise
15.3 I-Premise
) I-Premise
to I-Premise
20.3 I-Premise
% I-Premise
( I-Premise
13.9 I-Premise
, I-Premise
26.6 I-Premise
) I-Premise
. I-Premise

Clinically B-Premise
meaningful I-Premise
improvements I-Premise
in I-Premise
SF-36 I-Premise
, I-Premise
pain I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
were I-Premise
also I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
of I-Premise
abatacept I-Premise
treatment I-Premise
. I-Premise

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open-label I-Premise
exposure I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
the I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
of I-Premise
rheumatoid I-Premise
arthritis I-Premise
, I-Premise
physical I-Premise
function I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
observed I-Premise
after I-Premise
6 I-Premise
months I-Premise
, I-Premise
were I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
in I-Premise
this I-Premise
population I-Premise
with I-Premise
difficult-to-treat I-Premise
disease I-Premise
. I-Premise

Gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
APC O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
particularly O
important O
. O

We O
evaluated O
HRQOL O
with O
the O
EuroQol O
( O
EQ-5D™ O
) O
in O
patients O
with O
APC O
participating O
in O
Cancer O
and O
Leukemia O
Group O
B O
80303 O
, O
a O
multicenter O
, O
double-blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
OS O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

A O
consecutive O
subsample O
of O
patients O
was O
invited O
to O
complete O
the O
EQ-5D O
surveys O
. O

Because O
neither O
clinical O
nor O
HRQOL O
outcomes O
differed O
based O
on O
the O
study O
arm O
, O
analyses O
were O
pooled O
. O

Changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
EQ-5D O
were O
evaluated O
. O

Mean B-Premise
index I-Premise
scores I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.78 I-Premise
at I-Premise
baseline I-Premise
[ I-Premise
n=267 I-Premise
] I-Premise
, I-Premise
0.79 I-Premise
at I-Premise
eight I-Premise
weeks I-Premise
[ I-Premise
n=186 I-Premise
] I-Premise
, I-Premise
P=0.34 I-Premise
, I-Premise
Wilcoxon I-Premise
signed I-Premise
rank I-Premise
test I-Premise
) I-Premise
, I-Premise
attributable I-Premise
to I-Premise
a I-Premise
modest I-Premise
deterioration I-Premise
of I-Premise
physical I-Premise
function I-Premise
domain I-Premise
scores I-Premise
coincident I-Premise
with I-Premise
small I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
and I-Premise
anxiety/depression I-Premise
scores I-Premise
. I-Premise

A B-Premise
small I-Premise
decline I-Premise
in I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
was I-Premise
observed I-Premise
( I-Premise
70.7 I-Premise
vs. I-Premise
68.2 I-Premise
, I-Premise
P=0.026 I-Premise
) I-Premise
. I-Premise

HRQOL B-Premise
changes I-Premise
within I-Premise
chemotherapy I-Premise
response I-Premise
strata I-Premise
revealed I-Premise
stable I-Premise
index I-Premise
scores I-Premise
but B-Premise
a I-Premise
trend I-Premise
of I-Premise
worsened I-Premise
physical I-Premise
function I-Premise
among I-Premise
patients I-Premise
with I-Premise
disease I-Premise
progression I-Premise
compared I-Premise
with I-Premise
those I-Premise
with I-Premise
stable I-Premise
or I-Premise
improved I-Premise
disease I-Premise
. I-Premise

Visual B-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
trended I-Premise
downward I-Premise
over I-Premise
time I-Premise
irrespective I-Premise
of I-Premise
chemotherapy I-Premise
response I-Premise
status I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
meaningful I-Premise
deterioration I-Premise
in I-Premise
patients I-Premise
who I-Premise
progressed I-Premise
( I-Premise
68.9 I-Premise
vs. I-Premise
64.4 I-Premise
, I-Premise
P=0.029 I-Premise
) I-Premise
. I-Premise

Baseline O
scores O
from O
both O
EQ-5D O
scales O
were O
significant O
predictors O
of O
OS O
in O
Cox O
proportional O
hazard O
models O
. O

Response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
APC I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
HRQOL I-Claim
. I-Claim

Small O
improvements O
in O
pain O
and O
mood O
are O
observed O
despite O
progressive O
functional O
decline O
. O

Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

Bone-cancer O
pain O
is O
a O
common O
and O
refractory O
cancer O
pain O
. O

Opioids O
, O
on O
their O
own O
, O
do O
not O
control O
this O
type O
of O
pain O
well O
enough O
, O
and O
co-analgesics O
are O
necessary O
. O

Patients O
with O
bone O
metastasis-related O
pain O
at O
Numeric O
Rating O
Scale O
≥4 O
were O
enrolled O
to O
this O
randomized O
placebo-controlled O
trial O
. O

They O
had O
also O
received O
morphine O
or O
transdermal O
fentanyl O
patches O
for O
at O
least O
1 O
week O
. O

During O
the O
3-day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1-3 O
tablets O
of O
oxycodone/paracetamol O
( O
5/325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O

All O
patients O
kept O
a O
daily O
pain O
diary O
. O

The O
primary O
endpoint O
was O
the O
Pain O
Intensity O
Difference O
( O
PID O
) O
. O

Secondary O
endpoints O
were O
cases O
of O
breakthrough O
pain O
and O
rescue O
morphine O
consumption O
. O

Additional O
analyses O
included O
the O
Short O
Form-6 O
Dimensions O
( O
SF-6D O
) O
quality-of-life O
scale O
and O
a O
general O
impression O
( O
GI O
) O
of O
patient O
satisfaction O
with O
treatment O
at O
the O
end O
of O
the O
phase O
. O

Of O
the O
246 O
patients O
in O
the O
intent-to-treat O
set O
, O
89·4 O
% O
completed O
the O
3-day O
efficacy O
phase O
. O

PIDs B-Premise
were I-Premise
0·9 I-Premise
and I-Premise
0·3 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
on I-Premise
day I-Premise
1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
, I-Premise
and I-Premise
1·5 I-Premise
and I-Premise
0·3 I-Premise
respectively I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

Thirty-eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

The B-Premise
SF-6D I-Premise
score I-Premise
decreased I-Premise
to I-Premise
21·2 I-Premise
± I-Premise
2·5 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
phase I-Premise
( I-Premise
P I-Premise
= I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
, I-Premise
67 I-Premise
% I-Premise
rated I-Premise
GI I-Premise
as I-Premise
good I-Premise
, I-Premise
very I-Premise
good I-Premise
, I-Premise
or I-Premise
excellent I-Premise
. I-Premise

Patients B-Claim
with I-Claim
bone-cancer I-Claim
pain I-Claim
, I-Claim
already I-Claim
on I-Claim
opioids I-Claim
, I-Claim
obtain I-Claim
clinically I-Claim
important I-Claim
, I-Claim
additional I-Claim
pain-control I-Claim
, I-Claim
with I-Claim
regular I-Claim
oxycodone/paracetamol I-Claim
dosing I-Claim
. I-Claim

To O
examine O
the O
effects O
of O
a O
seated O
exercise O
program O
on O
fatigue O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O

Randomized O
, O
controlled O
, O
longitudinal O
trial O
. O

Outpatient O
clinic O
of O
a O
comprehensive O
cancer O
center O
. O

Convenience O
sample O
of O
38 O
women O
who O
were O
beginning O
outpatient O
chemotherapy O
. O

Subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
";" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

All O
subjects O
completed O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Fatigue O
Version O
IV O
( O
FACIT O
F O
) O
at O
baseline O
and O
at O
the O
time O
of O
the O
next O
three O
cycles O
. O

Subjects O
were O
asked O
to O
document O
the O
frequency O
, O
duration O
, O
and O
intensity O
of O
all O
exercise O
participation O
on O
monthly O
calendars O
. O

Exercise O
, O
fatigue O
, O
and O
QOL O
. O

32 O
subjects O
, O
16 O
per O
group O
, O
completed O
the O
study O
follow-up O
. O

With B-Premise
a I-Premise
mixed I-Premise
modeling I-Premise
approach I-Premise
, I-Premise
total I-Premise
FACIT I-Premise
F I-Premise
scores I-Premise
for I-Premise
the I-Premise
entire I-Premise
sample I-Premise
declined I-Premise
at I-Premise
a I-Premise
significant I-Premise
rate I-Premise
( I-Premise
p I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
beginning I-Premise
with I-Premise
cycle I-Premise
3 I-Premise
but B-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well-being I-Claim
. I-Claim

Few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
QOL O
) O
. O

This O
study O
examined O
( O
i O
) O
whether O
patient-caregiver O
dyads O
( O
i.e. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
FOCUS O
Program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O

Advanced O
cancer O
patients O
and O
their O
caregivers O
( O
N O
= O
484 O
dyads O
) O
were O
stratified O
by O
patients O
' O
baseline O
risk O
for O
distress O
( O
high O
versus O
low O
) O
, O
cancer O
type O
( O
lung O
, O
colorectal O
, O
breast O
, O
or O
prostate O
) O
, O
and O
research O
site O
and O
then O
randomly O
assigned O
to O
a O
brief O
( O
three-session O
) O
or O
extensive O
( O
six-session O
) O
intervention O
or O
control O
. O

The O
interventions O
offered O
dyads O
information O
and O
support O
. O

Intermediary O
outcomes O
were O
appraisals O
( O
i.e. O
, O
appraisal O
of O
illness/caregiving O
, O
uncertainty O
, O
and O
hopelessness O
) O
and O
resources O
( O
i.e. O
, O
coping O
, O
interpersonal O
relationships O
, O
and O
self-efficacy O
) O
. O

The O
primary O
outcome O
was O
QOL O
. O

Data O
were O
collected O
prior O
to O
intervention O
and O
post-intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O

The O
final O
sample O
was O
302 O
dyads O
. O

Repeated O
measures O
MANCOVA O
was O
used O
to O
evaluate O
outcomes O
. O

Significant B-Premise
group I-Premise
by I-Premise
time I-Premise
interactions I-Premise
showed I-Premise
that I-Premise
there I-Premise
was I-Premise
an I-Premise
improvement I-Premise
in I-Premise
dyads I-Premise
' I-Premise
coping I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
self-efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
social I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
in I-Premise
caregivers I-Premise
' I-Premise
emotional I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Effects O
varied O
by O
intervention O
dose O
. O

Most O
effects O
were O
found O
at O
3 O
months O
only O
. O

Risk B-Premise
for I-Premise
distress I-Premise
accounted I-Premise
for I-Premise
very I-Premise
few I-Premise
moderation I-Premise
effects I-Premise
. I-Premise

Both B-Premise
brief I-Premise
and I-Premise
extensive I-Premise
programs I-Premise
had I-Premise
positive I-Premise
outcomes I-Premise
for I-Premise
patient-caregiver I-Premise
dyads I-Premise
, I-Premise
but B-Premise
few I-Premise
sustained I-Premise
effects I-Premise
. I-Premise

Patient-caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
'unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

To O
observe O
the O
clinical O
efficacy O
of O
Shenqi O
Fuzheng O
Injection O
( O
SFI O
) O
combined O
with O
chemotherapy O
in O
treating O
patients O
with O
advanced O
breast O
cancer O
. O

Sixty O
patients O
were O
randomly O
assigned O
to O
two O
groups O
by O
digital O
table O
, O
the O
control O
group O
and O
the O
treatment O
group O
, O
30 O
in O
each O
group O
. O

All O
patients O
were O
treated O
with O
the O
same O
CTF O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
SFI O
additionally O
in O
the O
meanwhite O
. O

The O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short-term O
efficacy O
, O
TCM O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O

The B-Premise
total I-Premise
short-term I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
improvement I-Premise
rate I-Premise
of I-Premise
clinical I-Premise
syndrome I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
50.0 I-Premise
% I-Premise
, I-Premise
70.0 I-Premise
% I-Premise
and I-Premise
76.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
43.3 I-Premise
% I-Premise
, I-Premise
46.7 I-Premise
% I-Premise
and I-Premise
50.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
showing I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
occurrence I-Premise
of I-Premise
adverse I-Premise
reaction I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
level I-Premise
of I-Premise
CD3+ I-Premise
CD4+ I-Premise
and I-Premise
CD4+/CD8+ I-Premise
ratio I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
CD8+ I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
while I-Premise
they I-Premise
showed I-Premise
insignificant I-Premise
change I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

The O
American O
College O
of O
Surgeons O
Oncology O
Group O
phase O
III O
Surgical O
Prostatectomy O
Versus O
Interstitial O
Radiation O
Intervention O
Trial O
comparing O
radical O
prostatectomy O
( O
RP O
) O
and O
brachytherapy O
( O
BT O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O

We O
report O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
at O
a O
mean O
of O
5.3 O
years O
for O
168 O
trial-eligible O
men O
who O
either O
chose O
or O
were O
randomly O
assigned O
to O
RP O
or O
BT O
following O
a O
multidisciplinary O
educational O
session O
. O

After O
initial O
lack O
of O
accrual O
, O
a O
multidisciplinary O
educational O
session O
was O
introduced O
for O
eligible O
patients O
. O

In O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O

Of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
RP O
, O
and O
94 O
chose O
BT O
. O

Five O
years O
later O
, O
these O
190 O
men O
underwent O
HRQOL O
evaluation O
by O
using O
the O
cancer-specific O
50-item O
Expanded O
Prostate O
Cancer O
Index O
Composite O
, O
the O
Short O
Form O
12 O
Physical O
Component O
Score O
, O
and O
Short O
Form O
12 O
Mental O
Component O
Score O
. O

Response O
rate O
was O
88.4 O
% O
. O

The O
Wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O

Of O
168 O
survey O
responders O
, O
60.7 O
% O
had O
BT O
( O
9.5 O
% O
randomly O
assigned O
) O
and O
39.3 O
% O
had O
RP O
( O
9.5 O
% O
randomly O
assigned O
) O
. O

Median O
age O
was O
61.4 O
years O
for O
BT O
and O
59.4 O
for O
RP O
( O
P O
= O
.05 O
) O
. O

Median O
follow-up O
was O
5.2 O
years O
( O
range O
, O
3.2 O
to O
6.5 O
years O
) O
. O

For B-Premise
BT I-Premise
versus I-Premise
RP I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
bowel I-Premise
or I-Premise
hormonal I-Premise
domains I-Premise
, I-Premise
but O
men B-Premise
treated I-Premise
with I-Premise
BT I-Premise
scored I-Premise
better I-Premise
in I-Premise
urinary I-Premise
( I-Premise
91.8 I-Premise
v I-Premise
88.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
( I-Premise
52.5 I-Premise
v I-Premise
39.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
domains I-Premise
, I-Premise
and I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
( I-Premise
93.6 I-Premise
v I-Premise
76.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
RP O
, O
BT O
, O
or O
random O
assignment O
. O

HRQOL B-Claim
evaluated I-Claim
3.2 I-Claim
to I-Claim
6.5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
BT I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim

A O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer-related O
problems O
and O
to O
improve O
quality O
of O
life O
. O

The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer-related O
physical O
and O
psychosocial O
problems O
. O

a O
15-week O
rehabilitation O
program O
including O
individual O
exercise O
, O
sports O
, O
psycho-education O
, O
and O
information O
. O

Group-wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O

Health-Related O
Quality O
of O
Life O
[ O
RAND-36 O
and O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand-held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O

Measurements O
were O
performed O
before O
( O
T0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
T1 O
) O
, O
and O
at O
a O
3-month O
follow-up O
( O
T2 O
) O
. O

After B-Premise
the I-Premise
rehabilitation I-Premise
program I-Premise
, I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
n=63 I-Premise
) I-Premise
displayed I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
with I-Premise
effect I-Premise
sizes I-Premise
( I-Premise
ES I-Premise
) I-Premise
varying I-Premise
from I-Premise
0.38 I-Premise
to I-Premise
0.99 I-Premise
( I-Premise
RAND-36 I-Premise
) I-Premise
and I-Premise
from I-Premise
-0.34 I-Premise
to I-Premise
-0.57 I-Premise
( I-Premise
RSCL I-Premise
) I-Premise
, I-Premise
most I-Premise
persistent I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
. I-Premise

Furthermore B-Premise
, I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
muscle I-Premise
force I-Premise
of I-Premise
upper I-Premise
and I-Premise
lower I-Premise
extremities I-Premise
were I-Premise
displayed I-Premise
after I-Premise
rehabilitation I-Premise
. I-Premise

If B-Premise
offered I-Premise
a I-Premise
choice I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
prior I-Premise
to I-Premise
start I-Premise
and I-Premise
58 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
program I-Premise
indicated I-Premise
that I-Premise
they I-Premise
preferred I-Premise
the I-Premise
entire I-Premise
multidimensional I-Premise
program I-Premise
. I-Premise

A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

Surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O

Few O
well-designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

Stretching B-Claim
is I-Claim
an I-Claim
effective I-Claim
technique I-Claim
for I-Claim
increasing I-Claim
range I-Claim
of I-Claim
motion I-Claim
, I-Claim
hence O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
a O
stretching O
program O
reduced O
acute O
musculoskeletal O
impairments O
in O
patients O
undergoing O
radiotherapy O
for O
breast O
cancer O
. O

Sixty-four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O

Participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O

Participants O
in O
both O
groups O
were O
reviewed O
by O
the O
physical O
therapist O
on O
a O
weekly O
basis O
for O
approximately O
6 O
weeks O
, O
and O
were O
given O
general O
information O
about O
skin O
care O
and O
lymphedema O
. O

The O
control O
group O
received O
no O
advice O
about O
exercise O
. O

The O
stretch O
group O
received O
instruction O
on O
low-load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O

Shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
any I-Premise
outcome I-Premise
between I-Premise
groups I-Premise
. I-Premise

Breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise

Postoperative B-Claim
outcomes I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
laparoscopic-assisted I-Claim
colectomy I-Claim
( I-Claim
LAC I-Claim
) I-Claim
have I-Claim
shown I-Claim
modest I-Claim
improvements I-Claim
in I-Claim
recovery I-Claim
but I-Claim
only I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
compared I-Claim
with I-Claim
open I-Claim
colectomy I-Claim
. I-Claim

We O
therefore O
sought O
to O
assess O
the O
effect O
of O
LAC O
on O
QOL O
in O
the O
short O
and O
long O
term O
, O
using O
individual O
item O
analysis O
of O
multi-item O
QOL O
assessments O
. O

QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93-46-53 O
( O
INT O
146 O
) O
. O

Both O
cross-sectional O
single-time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention-to-treat O
analysis O
using O
Wilcoxon O
rank-sum O
tests O
. O

Stepwise O
regression O
models O
were O
used O
to O
determine O
predictors O
of O
QOL O
. O

Of O
449 O
colon O
cancer O
patients O
, O
230 O
underwent O
LAC O
and O
219 O
underwent O
open O
colectomy O
. O

Subdomain B-Premise
analysis I-Premise
revealed I-Premise
a I-Premise
clinically I-Premise
moderate I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
for I-Premise
LAC I-Premise
in I-Premise
total I-Premise
QOL I-Premise
index I-Premise
at I-Premise
18 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
other I-Premise
small I-Premise
symptomatic I-Premise
improvements I-Premise
. I-Premise

Poor O
preoperative O
QOL O
as O
indicated O
by O
a O
rating O
scale O
of O
≤ O
50 O
was O
an O
independent O
predictor O
of O
poor O
QOL O
at O
2 O
months O
postoperatively O
. O

QOL O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
P O
= O
0.001 O
) O
and O
baseline O
outlook O
( O
P O
= O
0.01 O
) O
. O

Eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
LAC I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
LAC I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
the I-Premise
benefits I-Premise
was I-Premise
small I-Premise
. I-Premise

Patients B-Claim
with I-Claim
poor I-Claim
preoperative I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
at I-Claim
higher I-Claim
risk I-Claim
for I-Claim
difficult I-Claim
postoperative I-Claim
courses I-Claim
, I-Claim
and I-Claim
may I-Claim
be I-Claim
candidates I-Claim
for I-Claim
enhanced I-Claim
ancillary I-Claim
services I-Claim
to I-Claim
address I-Claim
their I-Claim
particular I-Claim
needs I-Claim
. I-Claim

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast-enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O

The O
authors O
conducted O
a O
prospective O
randomized O
study O
in O
which O
45 O
patients O
, O
each O
harboring O
a O
solitary O
contrast-enhancing O
intracerebral O
tumor O
, O
were O
randomized O
for O
surgery O
with O
or O
without O
neuronavigation O
. O

Peri- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
";" O
surgeon O
's O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
";" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
";" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
's O
quality-of-life O
self-assessment O
, O
application O
of O
the O
Barthel O
index O
and O
the O
Karnofsky O
Performance O
Scale O
score O
, O
and O
the O
patient O
's O
time O
of O
death O
. O

The B-Premise
mean I-Premise
amount I-Premise
of I-Premise
residual I-Premise
tumor I-Premise
tissue I-Premise
was I-Premise
28.9 I-Premise
% I-Premise
for I-Premise
standard I-Premise
surgery I-Premise
( I-Premise
SS I-Premise
) I-Premise
and I-Premise
13.8 I-Premise
% I-Premise
for I-Premise
surgery I-Premise
involving I-Premise
neuronavigation I-Premise
( I-Premise
SN I-Premise
) I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast-enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29.2 I-Premise
and I-Premise
24.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Gross-total B-Premise
removal I-Premise
( I-Premise
GTR I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
five I-Premise
patients I-Premise
who I-Premise
underwent I-Premise
SS I-Premise
and I-Premise
in I-Premise
three I-Premise
who I-Premise
underwent I-Premise
SN I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
( I-Premise
5.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
9 I-Premise
months I-Premise
, I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
1.6 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
may I-Premise
be I-Premise
attributable I-Premise
to I-Premise
the I-Premise
coincidental I-Premise
early I-Premise
death I-Premise
of I-Premise
three I-Premise
patients I-Premise
in I-Premise
the I-Premise
SN I-Premise
group I-Premise
. I-Premise

No B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3-month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise

There B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim

To O
test O
the O
ability O
of O
the O
cytoprotectant O
, O
amifostine O
, O
to O
reduce O
chemoradiotherapy-induced O
esophagitis O
and O
evaluate O
its O
influence O
on O
quality O
of O
life O
( O
QOL O
) O
and O
swallowing O
symptoms O
. O

A O
total O
of O
243 O
patients O
with O
stage O
II O
to O
IIIA/B O
non-small-cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
AUC O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg/m O
( O
2 O
) O
IV O
) O
and O
carboplatin O
( O
AUC O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69.6 O
Gy O
at O
1.2 O
Gy O
bid O
) O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ-C30/LC-13 O
) O
were O
also O
collected O
. O

Swallowing O
AUC O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
PDLs O
. O

A O
total O
of O
120 O
patients O
were O
randomly O
assigned O
to O
receive O
AM O
, O
and O
122 O
, O
to O
receive O
no O
AM O
( O
one O
patient O
was O
ineligible O
) O
";" O
72 O
% O
received O
AM O
per O
protocol O
or O
with O
a O
minor O
deviation O
. O

AM B-Premise
was I-Premise
associated I-Premise
with I-Premise
higher I-Premise
rates I-Premise
of I-Premise
acute I-Premise
nausea I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
toxicity I-Premise
( I-Premise
P I-Premise
= I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
infection I-Premise
or I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
> I-Premise
/= I-Premise
grade I-Premise
3 I-Premise
esophagitis I-Premise
was I-Premise
30 I-Premise
% I-Premise
with I-Premise
AM I-Premise
versus I-Premise
34 I-Premise
% I-Premise
without I-Premise
AM I-Premise
( I-Premise
P I-Premise
= I-Premise
.9 I-Premise
) I-Premise
. I-Premise

Patient B-Premise
diaries I-Premise
demonstrated I-Premise
lower I-Premise
swallowing I-Premise
dysfunction I-Premise
AUC I-Premise
with I-Premise
amifostine I-Premise
( I-Premise
z I-Premise
test I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
, I-Premise
except I-Premise
for I-Premise
pain I-Premise
, I-Premise
which I-Premise
showed I-Premise
more I-Premise
clinically I-Premise
meaningful I-Premise
improvement I-Premise
and I-Premise
less I-Premise
deterioration I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
follow-up I-Premise
( I-Premise
v I-Premise
pretreatment I-Premise
) I-Premise
in I-Premise
the I-Premise
AM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17.3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17.9 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

However B-Claim
, I-Claim
patient I-Claim
self-assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
AM I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim

The O
impact O
of O
the O
side O
effects O
of O
megestrol O
acetate O
on O
the O
quality O
of O
life O
of O
noncachectic O
women O
with O
advanced O
breast O
cancer O
was O
studied O
in O
a O
dose-response O
clinical O
trial O
of O
the O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
8741 O
) O
. O

Side O
effects O
of O
appetite O
increase O
and O
weight O
gain O
at O
higher O
doses O
were O
predicted O
to O
have O
a O
negative O
effect O
on O
quality O
of O
life O
. O

Stage O
IV O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1,600 O
mg/d O
of O
megestrol O
acetate O
. O

Quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
Functional O
Living O
Index-Cancer O
( O
FLIC O
) O
, O
Rand O
Functional O
Limitations O
Scale O
, O
Rand O
Mental O
Health O
Inventory O
( O
MHI O
) O
, O
the O
Body O
Image O
Subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
women I-Premise
treated I-Premise
with I-Premise
160 I-Premise
mg/d I-Premise
reported I-Premise
less I-Premise
severe I-Premise
side I-Premise
effects I-Premise
( I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
better I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
FLS I-Premise
, I-Premise
P I-Premise
< I-Premise
.0005 I-Premise
) I-Premise
, I-Premise
less I-Premise
psychologic I-Premise
distress I-Premise
( I-Premise
MHI I-Premise
, I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FLIC I-Premise
, I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
from I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
as I-Premise
compared I-Premise
with I-Premise
those I-Premise
treated I-Premise
with I-Premise
1,600 I-Premise
mg/d I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800-mg/d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low- I-Premise
and I-Premise
high-dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160-mg/d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Unless B-Claim
additional I-Claim
follow-up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160-mg/d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Study O
Type O
-- O
Therapy O
( O
RCT O
) O
Level O
of O
Evidence O
1b O
. O

What O
's O
known O
on O
the O
subject O
? O

and O
What O
does O
the O
study O
add O
? O

Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

ADT O
is O
also O
used O
in O
patients O
with O
PCa O
as O
neo-adjuvant O
hormone O
therapy O
to O
reduce O
prostate O
volume O
and O
down-stage O
the O
disease O
before O
radiotherapy O
with O
curative O
intent O
. O

The O
present O
study O
showed O
that O
ADT O
with O
the O
gonadotropin O
hormone-releasing O
hormone O
( O
GhRH O
) O
antagonist O
degarelix O
is O
non-inferior O
to O
combined O
treatment O
with O
the O
LHRH O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O

Degarelix O
treatment O
evokes O
, O
however O
, O
significantly O
better O
relief O
of O
lower O
urinary O
tract O
symptoms O
in O
patients O
having O
moderate O
and O
severe O
voiding O
problems O
. O

To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

This O
was O
a O
randomized O
, O
parallel-arm O
, O
active-controlled O
, O
open-label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240/80 O
mg O
) O
or O
goserelin O
( O
3.6 O
mg O
) O
for O
12 O
weeks O
. O

For O
flare O
protection O
, O
goserelin-treated O
patients O
also O
received O
daily O
bicalutamide O
( O
50 O
mg O
) O
during O
the O
initial O
28 O
days O
. O

Key O
trial O
variables O
monitored O
monthly O
were O
TPV O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
and O
the O
Benign O
Prostate O
Hyperplasia O
Impact O
Index O
. O

In O
all O
, O
175 O
patients O
completed O
the O
trial O
( O
96.1 O
% O
) O
. O

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
changes I-Premise
in I-Premise
TPV I-Premise
for I-Premise
degarelix I-Premise
and I-Premise
goserelin I-Premise
were I-Premise
similar I-Premise
( I-Premise
-37.2 I-Premise
% I-Premise
vs I-Premise
-39.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
met I-Premise
the I-Premise
predefined I-Premise
non-inferiority I-Premise
criterion I-Premise
. I-Premise

Decreases B-Premise
in I-Premise
IPSS I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin-treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
IPSS I-Premise
> I-Premise
13 I-Premise
( I-Premise
-6.7 I-Premise
± I-Premise
1.8 I-Premise
vs I-Premise
-4.0 I-Premise
± I-Premise
1.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
number I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
IPSS I-Premise
change I-Premise
of I-Premise
≥ I-Premise
3 I-Premise
over I-Premise
baseline I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
degarelix I-Premise
( I-Premise
61.0 I-Premise
vs I-Premise
44.3 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Both B-Claim
treatments I-Claim
were I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Medical B-Claim
castration I-Claim
reduces I-Claim
TPV I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
LUTS I-Claim
in I-Claim
patients I-Claim
with I-Claim
PCa I-Claim
. I-Claim

While O
the B-Claim
short-term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
TPV I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
LUTS I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin-releasing I-Claim
hormone I-Claim
( I-Claim
GnRH I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and/or I-Claim
the I-Claim
prostate I-Claim
. I-Claim

To O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
'low-risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
T0-2 O
) O
treated O
by O
breast-conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost-effective O
. O

A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic/vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O

A O
non-randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O

The O
setting O
was O
breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
UK O
. O

Patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast-conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O

The O
standard O
treatment O
of O
postoperative O
breast O
irradiation O
or O
the O
omission O
of O
radiotherapy O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost-effectiveness O
. O

Secondary O
outcome O
measures O
were O
recurrence O
rates O
, O
functional O
status O
, O
treatment-related O
morbidity O
and O
cosmesis O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

The B-Claim
hypothesised I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
with I-Claim
the I-Claim
omission I-Claim
of I-Claim
radiotherapy I-Claim
was I-Claim
not I-Claim
seen I-Claim
in I-Claim
the I-Claim
EuroQol I-Claim
assessment I-Claim
or I-Claim
in I-Claim
the I-Claim
functionality I-Claim
and I-Claim
symptoms I-Claim
summary I-Claim
domains I-Claim
of I-Claim
the I-Claim
European I-Claim
Organisation I-Claim
for I-Claim
Research I-Claim
in I-Claim
the I-Claim
Treatment I-Claim
of I-Claim
Cancer I-Claim
( I-Claim
EORTC I-Claim
) I-Claim
scales I-Claim
. I-Claim

Some O
differences O
were O
apparent O
within O
subscales O
of O
the O
EORTC O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open-ended O
questions O
. O

Differences B-Premise
were I-Premise
most I-Premise
apparent I-Premise
shortly I-Premise
after I-Premise
the I-Premise
time I-Premise
of I-Premise
completion I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise

Radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side-effects I-Claim
. I-Claim

Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise

Functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise

Within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
Barthel I-Premise
Index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

Cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Claim
use I-Claim
of I-Claim
home-based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high-quality I-Claim
data I-Claim
. I-Claim

Costs O
to O
the O
NHS O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O

In B-Premise
the I-Premise
follow-up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
EuroQol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise

Although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise

Over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost-effective I-Premise
treatment I-Premise
. I-Premise

However O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost-effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long-term I-Claim
follow-up I-Claim
. I-Claim

Extrapolations B-Claim
from I-Claim
these I-Claim
data I-Claim
suggest I-Claim
that I-Claim
radiotherapy I-Claim
may I-Claim
not I-Claim
be I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
unless I-Claim
it I-Claim
results I-Claim
in I-Claim
a I-Claim
recurrence I-Claim
rate I-Claim
that I-Claim
is I-Claim
at I-Claim
least I-Claim
5 I-Claim
% I-Claim
lower I-Claim
in I-Claim
absolute I-Claim
terms I-Claim
than I-Claim
those I-Claim
treated I-Claim
without I-Claim
radiotherapy I-Claim
. I-Claim

Further B-Claim
research I-Claim
is I-Claim
needed I-Claim
into I-Claim
a I-Claim
number I-Claim
of I-Claim
areas I-Claim
including I-Claim
the I-Claim
long-term I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
clinical I-Claim
outcomes I-Claim
, I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
radiotherapy I-Claim
. I-Claim

A O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
EOF O
) O
compared O
with O
traditional O
oral O
feeding O
( O
TOF O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O

Patients O
aged O
18-75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O

Exclusion O
criteria O
included O
infectious O
conditions O
, O
intestinal O
obstruction O
, O
severe O
malnutrition O
, O
American O
Society O
of O
Anesthesiologists O
score O
C4 O
, O
intestinal O
resection O
, O
and O
postoperative O
stay O
in O
the O
intensive O
care O
unit O
lasting O
24 O
h. O
Patients O
allocated O
to O
EOF O
received O
liquid O
diet O
in O
the O
first O
postoperative O
day O
and O
then O
regular O
diet O
. O

Patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O

The O
primary O
end-point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O

Between O
January O
1 O
, O
2007 O
, O
and O
November O
17 O
, O
2007 O
, O
a O
total O
of O
143 O
patients O
were O
randomized O
to O
receive O
either O
EOF O
or O
TOF O
. O

Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n=71 I-Premise
) I-Premise
was I-Premise
4.7 I-Premise
vs. I-Premise
5.8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n=72 I-Premise
) I-Premise
( I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
EOF I-Premise
group I-Premise
( I-Premise
82.8 I-Premise
vs. I-Premise
71.7 I-Premise
mm I-Premise
, I-Premise
P I-Premise
B I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
TOF I-Premise
scheme I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
overall I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
39 I-Premise
vs. I-Premise
17 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P=0.003 I-Premise
) I-Premise
and I-Premise
infective I-Premise
complications I-Premise
( I-Premise
14 I-Premise
% I-Premise
in I-Premise
TOF I-Premise
group I-Premise
vs. I-Premise
3 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P=0.017 I-Premise
) I-Premise
. I-Premise

Variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
EOF I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim

Insomnia B-Claim
is I-Claim
a I-Claim
common I-Claim
complaint I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Fortunately O
, O
cognitive-behavioral O
therapy O
for O
insomnia O
( O
CBT-I O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O

However O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O

To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT-I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

Twenty-eight O
cancer O
survivors O
with O
insomnia O
were O
randomly O
assigned O
to O
either O
an O
Internet O
insomnia O
intervention O
( O
n O
= O
14 O
) O
or O
to O
a O
waitlist O
control O
group O
( O
n O
= O
14 O
) O
. O

The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT-I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

Pre- O
and O
post-assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O

Participants B-Premise
in I-Premise
the I-Premise
Internet I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
at I-Premise
post-assessment I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
overall I-Premise
insomnia I-Premise
severity I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
22.8 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11.45 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
onset I-Premise
latency I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
5.18 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
soundness I-Premise
of I-Premise
sleep I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
9.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
restored I-Premise
feeling I-Premise
upon I-Premise
awakening I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11.95 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
and I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
13.88 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Although B-Premise
other I-Premise
group I-Premise
× I-Premise
time I-Premise
interactions I-Premise
were I-Premise
not I-Premise
significant I-Premise
, I-Premise
overall I-Premise
adjusted I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
all I-Premise
sleep I-Premise
variables I-Premise
as I-Premise
well I-Premise
as I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
depression I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
ranged I-Premise
from I-Premise
small I-Premise
to I-Premise
large I-Premise
. I-Premise

CBT-I B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
Internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single-agent O
gemcitabine O
as O
first-line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

Patients O
with O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
1,000 O
mg/m2 O
and O
cisplatin O
50 O
mg/m2 O
given O
on O
days O
1 O
and O
15 O
of O
a O
4-week O
cycle O
( O
GemCis O
arm O
) O
or O
gemcitabine O
alone O
at O
a O
dose O
of O
1,000 O
mg/m2 O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
a O
4-week O
regimen O
( O
Gem O
arm O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
";" O
secondary O
end O
points O
were O
progression-free O
survival O
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O

One O
hundred O
ninety-five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O

Combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.3 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.75 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.053 I-Premise
) I-Premise
. I-Premise

Also B-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
superior I-Premise
for I-Premise
patients I-Premise
treated I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
Gem I-Premise
arm I-Premise
( I-Premise
7.5 I-Premise
v I-Premise
6.0 I-Premise
months I-Premise
) I-Premise
, I-Premise
an B-Premise
advantage I-Premise
which I-Premise
did I-Premise
not I-Premise
, I-Premise
however I-Premise
, I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
HR I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.15 I-Premise
) I-Premise
. I-Premise

Tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10.2 I-Premise
% I-Premise
v I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
stable I-Premise
disease I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
greater I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
( I-Premise
60.2 I-Premise
% I-Premise
v I-Premise
40.2 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. O

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every-2-weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

Median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

Extracellular O
adenosine O
5'-triphosphate O
( O
ATP O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O

In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

We O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
ATP O
in O
patients O
with O
advanced O
NSCLC O
( O
stage O
IIIB O
or O
IV O
) O
. O

Fifty-eight O
patients O
were O
randomly O
assigned O
to O
receive O
either O
10 O
intravenous O
30-hour O
ATP O
infusions O
, O
with O
the O
infusions O
given O
at O
-2 O
to O
4-week O
intervals O
, O
or O
no O
ATP O
. O

Outcome O
parameters O
were O
assessed O
every O
4 O
weeks O
until O
28 O
weeks O
. O

Between-group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated-measures O
analysis O
, O
and O
reported O
P O
values O
are O
two-sided O
. O

Twenty-eight O
patients O
were O
allocated O
to O
receive O
ATP O
treatment O
and O
30 O
received O
no O
ATP O
. O

Mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
were I-Premise
-1.0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-1.5 I-Premise
to I-Premise
-0.5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0.2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.2 I-Premise
to I-Premise
+0.6 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

Serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
-1.2 I-Premise
g/L I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-2.0 I-Premise
to I-Premise
-0.4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
g/L I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.3 I-Premise
to I-Premise
+0.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

Elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
-5.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-9.6 I-Premise
% I-Premise
to I-Premise
-1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-1.4 I-Premise
% I-Premise
to I-Premise
+1.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.0002 I-Premise
, I-Premise
P I-Premise
=.0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

QOL B-Premise
score I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group-physical I-Premise
scores I-Premise
( I-Premise
-0.2 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
";" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+0.4 I-Premise
% I-Premise
versus I-Premise
-5.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
";" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
-0.7 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.11 I-Premise
) I-Premise
";" I-Premise
overall I-Premise
QOL I-Premise
score I-Premise
( I-Premise
+0.1 I-Premise
% I-Premise
versus I-Premise
-3.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

This O
randomized O
trial O
demonstrates O
that O
ATP B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression-free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy-naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration-resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

We O
describe O
analyses O
of O
data O
for O
patient-reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O

Between O
April O
28 O
, O
2009 O
, O
and O
June O
23 O
, O
2010 O
, O
patients O
with O
progressive O
, O
metastatic O
castration-resistant O
prostate O
cancer O
were O
enrolled O
into O
a O
multinational O
, O
double-blind O
, O
placebo-controlled O
trial O
. O

Patients O
were O
eligible O
if O
they O
were O
asymptomatic O
( O
score O
of O
0 O
or O
1 O
on O
item O
three O
of O
the O
Brief O
Pain O
Inventory O
Short O
Form O
[ O
BPI-SF O
] O
questionnaire O
) O
or O
mildly O
symptomatic O
( O
score O
of O
2 O
or O
3 O
) O
and O
had O
not O
previously O
received O
chemotherapy O
. O

Patients O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4-week O
cycles O
. O

Pain O
was O
assessed O
with O
the O
BPI-SF O
questionnaire O
, O
and O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Prostate O
( O
FACT-P O
) O
questionnaire O
. O

We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O

All O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O

1088 O
patients O
underwent O
randomisation O
: O
546 O
were O
assigned O
to O
abiraterone O
plus O
prednisone O
and O
542 O
to O
placebo O
plus O
prednisone O
. O

At O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow-up O
was O
22·2 O
months O
( O
IQR O
20·2-24·8 O
) O
. O

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19·3-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18·4 I-Premise
months I-Premise
[ I-Premise
14·9-not I-Premise
estimable I-Premise
] I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0·82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·67-1·00 I-Premise
";" I-Premise
p=0·0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10·3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
9·3-13·0 I-Premise
] I-Premise
vs I-Premise
7·4 I-Premise
months I-Premise
[ I-Premise
6·4-8·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·67-0·93 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
worst I-Premise
pain I-Premise
was I-Premise
also I-Premise
longer I-Premise
with I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19·4-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
with I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
19·4 I-Premise
months I-Premise
[ I-Premise
16·6-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
but I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
significant I-Premise
( I-Premise
HR I-Premise
0·85 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·69-1·04 I-Premise
";" I-Premise
p=0·109 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
HRQoL I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-P I-Premise
total I-Premise
score I-Premise
( I-Premise
12·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
11·1-14·0 I-Premise
] I-Premise
vs I-Premise
8·3 I-Premise
months I-Premise
[ I-Premise
7·4-10·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·66-0·92 I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate-cancer-specific I-Premise
subscale I-Premise
( I-Premise
11·1 I-Premise
months I-Premise
[ I-Premise
8·6-13·8 I-Premise
] I-Premise
vs I-Premise
5·8 I-Premise
months I-Premise
[ I-Premise
5·5-8·3 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·60-0·83 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

Abiraterone B-Claim
plus I-Claim
prednisone I-Claim
delays I-Claim
patient-reported I-Claim
pain I-Claim
progression I-Claim
and I-Claim
HRQoL I-Claim
deterioration I-Claim
in I-Claim
chemotherapy-naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration-resistant I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

These B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

Postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim

Intravenous B-Claim
5-fluorouracil I-Claim
( I-Claim
5-FU I-Claim
) I-Claim
and I-Claim
leucovorin I-Claim
has I-Claim
been I-Claim
a I-Claim
mainstay I-Claim
of I-Claim
chemotherapy I-Claim
, I-Claim
but O
oral B-Claim
5-FU I-Claim
derivatives I-Claim
have I-Claim
been I-Claim
shown I-Claim
a I-Claim
comparable I-Claim
antitumor I-Claim
activity I-Claim
. I-Claim

Intravenous O
5-FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

A O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5-FU O
( O
450 O
mg/m2/day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg/m2/day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg/m2/day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
TNM O
) O
stage O
II O
and O
III O
patients O
between O
October O
1997 O
and O
February O
1999 O
. O

Consecutive O
daily O
intravenous O
infusion O
for O
5 O
days O
per O
every O
month O
for O
a O
total O
of O
12 O
cycles O
( O
IV O
arm O
, O
n O
= O
74 O
) O
and O
oral O
doxifluridine O
daily O
for O
3 O
weeks O
and O
1 O
week O
rest O
for O
a O
total O
of O
12 O
cycles O
( O
oral O
arm O
, O
n O
= O
92 O
) O
. O

Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

Quality O
of O
life O
was O
scored O
according O
to O
22 O
daily O
activity O
items O
( O
good O
, O
> O
or O
71 O
";" O
fair O
, O
< O
70 O
";" O
poor O
, O
< O
52 O
) O
. O

There O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
IV O
arm O
: O
male/female O
= O
45/29 O
, O
oral O
arm O
: O
male/female O
= O
59/33 O
) O
. O

The O
mean O
age O
was O
52.3 O
vs. O
59.5 O
, O
respectively O
. O

There O
was O
also O
no O
difference O
of O
TNM O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
P O
> O
.05 O
) O
. O

Mean B-Premise
numbers I-Premise
of I-Premise
chemotherapy I-Premise
cycles I-Premise
were I-Premise
6.5+/-3.7 I-Premise
( I-Premise
IV I-Premise
arm I-Premise
) I-Premise
vs. I-Premise
7.2+/-4.3 I-Premise
( I-Premise
oral I-Premise
arm I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9/74 I-Premise
( I-Premise
12.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6/92 I-Premise
( I-Premise
6.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.937 I-Premise
) I-Premise
. I-Premise

Local B-Premise
recurrence I-Premise
was I-Premise
2/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
2.7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
1/92 I-Premise
( I-Premise
stage I-Premise
II I-Premise
";" I-Premise
1.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Systemic B-Premise
recurrence I-Premise
was I-Premise
7/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
9.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
5/92 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise

Toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30/74 I-Premise
vs. I-Premise
17/92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21/74 I-Premise
vs. I-Premise
13/92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
. I-Premise

Diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise

Poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23.9 I-Premise
% I-Premise
vs. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15.8 I-Premise
% I-Premise
vs. I-Premise
3.7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise

Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19.5 I-Premise
% I-Premise
vs. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5-FU I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

This O
phase O
III O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy-naive O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Eligible O
patients O
had O
previously O
untreated O
stage O
IIIB O
or O
IV O
NSCLC O
suitable O
for O
cisplatin-based O
chemotherapy O
. O

Randomly O
assigned O
patients O
were O
to O
receive O
four O
cycles O
, O
each O
at O
3-week O
intervals O
, O
of O
carboplatin O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
plus O
gemcitabine O
1,200 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
( O
GCa O
) O
or O
mitomycin O
6 O
mg/m O
( O
2 O
) O
, O
ifosfamide O
3g/m O
( O
2 O
) O
, O
and O
cisplatin O
50 O
mg/m O
( O
2 O
) O
on O
day O
1 O
( O
MIC O
) O
. O

Between O
February O
1999 O
and O
August O
2001 O
, O
422 O
patients O
( O
GCa O
, O
n O
= O
212 O
";" O
MIC O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
United O
Kingdom O
. O

The O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
GCa O
, O
64 O
% O
";" O
MIC O
, O
61 O
% O
) O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
GCa I-Premise
compared I-Premise
with I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.76 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
10 I-Premise
months I-Premise
with I-Premise
GCa I-Premise
and I-Premise
7.6 I-Premise
months I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
2.4 I-Premise
months I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.0 I-Premise
to I-Premise
4.0 I-Premise
) I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
was I-Premise
40 I-Premise
% I-Premise
with I-Premise
GCa I-Premise
and I-Premise
30 I-Premise
% I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
10 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3 I-Premise
% I-Premise
to I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
GCa I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
MIC I-Premise
";" I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

More B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
GCa I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise

GCa B-Premise
caused I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
constipation I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
admissions I-Premise
for I-Premise
administration I-Premise
and I-Premise
better I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better-tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim

To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O

A O
total O
of O
306 O
patients O
with O
localized O
prostate O
cancer O
were O
randomized O
. O

No O
androgen O
deprivation O
was O
allowed O
. O

The O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
and O
Phoenix O
definitions O
. O

Toxicity O
was O
graded O
using O
the O
Radiation O
Therapy O
Oncology O
Group O
1991 O
criteria O
and O
the O
late O
effects O
on O
normal O
tissues-subjective O
, O
objective O
, O
management O
, O
analytic O
scales O
( O
LENT-SOMA O
) O
scales O
. O

The O
patients O
' O
quality O
of O
life O
was O
scored O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
30-item O
cancer-specific O
and O
25-item O
prostate-specific O
modules O
. O

The O
median O
follow-up O
was O
61 O
months O
. O

According O
to O
the O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
-70 O
and O
80-Gy O
arms O
, O
respectively O
( O
p O
= O
.036 O
) O
. O

Using O
the O
Phoenix O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23.5 O
% O
, O
respectively O
( O
p O
= O
.09 O
) O
. O

The O
subgroup O
analysis O
showed O
a O
better O
biochemical O
outcome O
for O
the O
higher O
dose O
group O
with O
an O
initial O
prostate-specific O
antigen O
level O
> O
15 O
ng/mL O
. O

At O
the O
last O
follow-up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

According B-Premise
to I-Premise
the I-Premise
Radiation I-Premise
Therapy I-Premise
Oncology I-Premise
Group I-Premise
scale I-Premise
, I-Premise
the I-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19.5 I-Premise
% I-Premise
for I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
.22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
and I-Premise
17.5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
.046 I-Premise
) I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
LENT-SOMA I-Premise
scale I-Premise
. I-Premise

Bladder B-Premise
toxicity I-Premise
was I-Premise
more I-Premise
frequent I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
than I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
.039 I-Premise
) I-Premise
. I-Premise

The B-Premise
quality-of-life I-Premise
questionnaire I-Premise
results I-Premise
before I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
were I-Premise
available I-Premise
for I-Premise
103 I-Premise
patients I-Premise
with I-Premise
no I-Premise
differences I-Premise
found I-Premise
between I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
. I-Premise

High-dose B-Claim
radiotherapy I-Claim
provided I-Claim
a I-Claim
better I-Claim
5-year I-Claim
biochemical I-Claim
outcome I-Claim
with I-Claim
slightly I-Claim
greater I-Claim
toxicity I-Claim
. I-Claim

Several O
multicomponent O
regimens O
have O
been O
reported O
to O
be O
useful O
in O
advanced O
androgen-independent O
prostate O
cancer O
. O

We O
used O
a O
randomized O
phase O
II O
design O
to O
evaluate O
and O
compare O
two O
such O
regimens O
. O

Patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

Patients O
were O
prospectively O
stratified O
on O
the O
basis O
of O
disease O
volume O
. O

The O
primary O
end O
points O
were O
response O
and O
overall O
survival O
time O
. O

A O
total O
of O
75 O
patients O
were O
registered O
";" O
71 O
are O
included O
in O
the O
analysis O
. O

By O
the O
criterion O
of O
an O
80 O
% O
prostate-specific O
antigen O
reduction O
maintained O
for O
at O
least O
8 O
weeks O
, O
11 O
( O
30 O
% O
) O
of O
37 O
patients O
in O
the O
TEE O
arm O
responded O
, O
whereas O
11 O
( O
32 O
% O
) O
of O
34 O
assigned O
to O
KA/VE O
responded O
. O

Median B-Premise
survival I-Premise
was I-Premise
16.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
10.5 I-Premise
to I-Premise
21.2 I-Premise
months I-Premise
) I-Premise
in I-Premise
the I-Premise
TEE I-Premise
arm I-Premise
and I-Premise
23.4 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.9 I-Premise
to I-Premise
30.6 I-Premise
months I-Premise
) I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
KA/VE I-Premise
. I-Premise

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment-related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

Each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18.9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first-generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
is I-Claim
vital I-Claim
to I-Claim
palliative I-Claim
care I-Claim
, O
but O
documentation O
confirming O
completion O
of O
systematic O
assessment O
in O
hospice O
settings O
is O
often O
inadequate O
or O
absent O
. O

The O
objective O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
systematic O
feedback O
from O
standardized O
assessment O
tools O
for O
hospice O
patient-caregiver O
dyads O
in O
improving O
hospice O
outcomes O
compared O
with O
the O
usual O
clinical O
practice O
. O

The O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O

The O
interdisciplinary O
teams O
( O
IDTs O
) O
caring O
for O
these O
dyads O
were O
randomly O
assigned O
to O
either O
experimental O
( O
n O
= O
338 O
) O
or O
control O
( O
n O
= O
371 O
) O
conditions O
. O

Data O
were O
collected O
from O
both O
groups O
of O
dyads O
using O
standardized O
assessments O
on O
admission O
and O
1 O
week O
after O
each O
of O
the O
first O
2 O
IDT O
meetings O
in O
which O
these O
dyads O
were O
discussed O
. O

The O
experimental O
intervention O
consisted O
of O
reporting O
data O
from O
the O
standardized O
assessments O
to O
the O
IDTs O
. O

Results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

Assessment O
of O
depression O
added O
to O
usual O
care O
probably O
had O
an O
effect O
because O
it O
is O
not O
normally O
a O
focus O
of O
hospice O
staff O
. O

Hospice B-Premise
care I-Premise
was I-Premise
so I-Premise
good I-Premise
during I-Premise
the I-Premise
study I-Premise
that I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
standard I-Premise
care I-Premise
and I-Premise
left I-Premise
little I-Premise
room I-Premise
for I-Premise
improvement I-Premise
in I-Premise
other I-Premise
variables I-Premise
. I-Premise

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

No O
caregiver O
variables O
changed O
, O
which O
may O
indicate O
a O
need O
for O
a O
focus O
on O
caregivers O
. O

This O
study O
aims O
to O
examine O
the O
effectiveness O
of O
a O
self-management O
multimodal O
comprehensive O
coping O
strategy O
program O
( O
CCSP O
) O
on O
quality O
of O
life O
( O
QOL O
) O
among O
breast O
cancer O
patients O
1 O
year O
after O
treatment O
. O

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

The O
CCSP O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O

The O
CCSP O
components O
included O
educational O
information O
, O
cognitive O
restructuring O
, O
coping O
skills O
enhancement O
, O
and O
relaxation O
with O
guided O
imagery O
. O

Instruments O
administered O
at O
baseline O
included O
the O
following O
: O
Quality O
of O
Life O
Index-Cancer O
Version O
( O
QOLI-CV O
) O
, O
State-Trait O
Anxiety O
Inventory O
, O
Beck O
Depression O
Inventory O
, O
and O
Coping O
Strategies O
Questionnaire O
. O

At O
1-year O
follow-up O
, O
patients O
( O
n O
= O
73 O
) O
completed O
and O
returned O
the O
follow-up O
QOLI-CV O
. O

Patients O
were O
mainly O
≥ O
40 O
years O
of O
age O
, O
married O
, O
Caucasian O
, O
and O
diagnosed O
with O
advanced O
breast O
cancer O
. O

A B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
CCSP I-Premise
on I-Premise
QOL I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
showed I-Premise
that I-Premise
the I-Premise
CCSP I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
psychological/spiritual I-Premise
well-being I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
patients I-Premise
frequently I-Premise
used I-Premise
the I-Premise
CCSP I-Premise
to I-Premise
manage I-Premise
psychological I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

Patients B-Premise
overwhelmingly I-Premise
reported I-Premise
that I-Premise
CCSP I-Premise
was I-Premise
beneficial I-Premise
. I-Premise

The B-Claim
CCSP I-Claim
as I-Claim
an I-Claim
effective I-Claim
coping I-Claim
intervention I-Claim
has I-Claim
potential I-Claim
as I-Claim
a I-Claim
self-management I-Claim
program I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
( I-Claim
EP I-Claim
) I-Claim
is I-Claim
considered I-Claim
to I-Claim
be I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

To O
determine O
whether O
drug O
intensification O
improves O
survival O
of O
patients O
with O
extensive O
SCLC O
, O
we O
compared O
this O
treatment O
with O
a O
four-drug O
regimen O
containing O
EP O
plus O
cyclophosphamide O
and O
4'-epidoxorubicin O
( O
PCDE O
) O
. O

In O
a O
phase O
III O
clinical O
trial O
organized O
by O
the O
French O
Federation O
of O
Cancer O
Institutes O
, O
patients O
were O
randomly O
assigned O
to O
receive O
either O
EP O
( O
n O
= O
109 O
";" O
etoposide O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
plus O
cisplatin O
at O
100 O
mg/m O
( O
2 O
) O
on O
day O
2 O
) O
or O
PCDE O
( O
n O
= O
117 O
";" O
etoposide O
and O
cisplatin O
given O
as O
in O
EP O
plus O
cyclophosphamide O
at O
400 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
and O
4'-epidoxorubicin O
at O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
every O
4 O
weeks O
. O

Both O
groups O
received O
a O
total O
of O
six O
cycles O
. O

Survival O
differences O
were O
analyzed O
by O
Wilcoxon O
and O
log-rank O
tests O
. O

Associations O
of O
treatment O
group O
and O
putative O
prognostic O
variables O
with O
survival O
were O
tested O
in O
the O
Cox O
proportional O
hazards O
model O
. O

Quality O
of O
life O
was O
assessed O
from O
the O
responses O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
quality-of-life O
questionnaire O
( O
C30 O
, O
health O
status O
and O
lung O
cancer O
module O
13 O
) O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
combined I-Premise
complete I-Premise
plus I-Premise
partial I-Premise
responses I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
21 I-Premise
% I-Premise
plus I-Premise
55 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
plus I-Premise
48 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
for I-Premise
difference I-Premise
in I-Premise
combined I-Premise
objective I-Premise
responses I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
survived I-Premise
longer I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
: I-Premise
40 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
survival I-Premise
: I-Premise
10.5 I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.0067 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
Cox I-Premise
model I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
was I-Premise
0.70 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0.51 I-Premise
to I-Premise
0.95 I-Premise
) I-Premise
";" I-Premise
the B-Premise
disease I-Premise
also I-Premise
progressed I-Premise
more I-Premise
slowly I-Premise
in I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
. I-Premise

Hematologic B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
with I-Premise
documented I-Premise
infections I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
";" I-Premise
P I-Premise
=.0038 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
toxicity-related I-Premise
death I-Premise
rate I-Premise
was I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
versus I-Premise
5.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
P I-Premise
=.22 I-Premise
) I-Premise
. I-Premise

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

Compared B-Claim
with I-Claim
the I-Claim
EP I-Claim
regimen I-Claim
, I-Claim
the I-Claim
PCDE I-Claim
regimen I-Claim
yielded I-Claim
higher I-Claim
response I-Claim
rates I-Claim
and I-Claim
better I-Claim
survival I-Claim
rates I-Claim
in I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
SCLC I-Claim
without I-Claim
affecting I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
the I-Claim
patients I-Claim
during I-Claim
chemotherapy I-Claim
. I-Claim

Although O
many O
drug O
combination O
therapies O
have O
been O
proposed O
, O
there B-Claim
is I-Claim
no I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
. I-Claim

The B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim

To O
explore O
the O
role O
of O
monochemotherapy O
, O
the O
authors O
evaluated O
5-fluorouracil O
( O
5-FU O
) O
, O
modulated O
by O
6S-leucovorin O
( O
6S-LV O
) O
and O
a O
cisplatin-containing O
regimen O
, O
which O
was O
comprised O
of O
epirubicin O
, O
etoposide O
, O
and O
cisplatin O
with O
the O
addition O
of O
the O
reversal O
agent O
lonidamine O
( O
EEP-L O
) O
. O

After O
stratification O
according O
to O
performance O
status O
( O
PS O
) O
and O
resection O
of O
the O
primary O
tumor O
, O
72 O
patients O
with O
advanced O
gastric O
carcinoma O
were O
randomized O
to O
2 O
parallel O
Phase O
II O
trials O
with O
5-FU/6S-LV O
and O
EEP-L O
, O
respectively O
. O

Thirty-six O
patients O
in O
Study O
A O
received O
bolus O
6S-LV O
, O
100 O
mg/m2 O
, O
followed O
by O
bolus O
5-FU O
, O
370 O
mg/m2 O
, O
on O
Days O
1-5 O
and O
36 O
others O
in O
Study O
B O
received O
epirubicin O
, O
30 O
mg/m2 O
, O
on O
Days O
1 O
and O
5 O
";" O
etoposide O
, O
100 O
mg/m2 O
, O
on O
Days O
1 O
, O
3 O
, O
and O
5 O
";" O
cisplatin O
, O
30 O
mg/m2 O
, O
on O
Days O
2 O
and O
4 O
";" O
and O
lonidamine O
, O
150 O
mg/day O
. O

There O
were O
6 O
partial O
responses O
( O
18.2 O
% O
) O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
+/- O
13.2 O
) O
in O
Study O
A O
and O
7 O
partial O
responses O
( O
21.9 O
% O
) O
( O
95 O
% O
CI O
+/- O
14.3 O
) O
in O
Study O
B O
. O

Partial O
responses O
were O
more O
frequent O
in O
patients O
with O
resected O
tumors O
or O
with O
an O
Eastern O
Cooperative O
Oncology O
Group O
PS O
of O
0-1 O
. O

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8.8 I-Premise
and I-Premise
8.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
Study I-Premise
B I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
reached I-Premise
8 I-Premise
months I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
9 I-Premise
months I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

In B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
EEP-L I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise

The B-Premise
most I-Premise
frequent I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
Grade I-Premise
3-4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
gastrointestinal I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
hematologic I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

No B-Premise
treatment-related I-Premise
death I-Premise
was I-Premise
observed I-Premise
. I-Premise

The B-Claim
efficacy I-Claim
of I-Claim
5-FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S-LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin-containing I-Claim
regimens I-Claim
. I-Claim

PS B-Claim
and I-Claim
other I-Claim
prognostic I-Claim
factors I-Claim
could I-Claim
influence I-Claim
the I-Claim
response I-Claim
rate I-Claim
, I-Claim
which I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
be I-Claim
a I-Claim
reliable I-Claim
parameter I-Claim
for I-Claim
evaluating I-Claim
the I-Claim
outcome I-Claim
of I-Claim
chemotherapy I-Claim
trials I-Claim
. I-Claim

To O
assess O
the O
effects O
of O
an O
expressive O
writing O
( O
EW O
) O
intervention O
on O
perceptions O
of O
emotional O
support O
in O
women O
completing O
treatment O
for O
early O
stage O
breast O
cancer O
. O

Women O
were O
recruited O
to O
the O
study O
during O
their O
final O
week O
of O
treatment O
. O

Of O
260 O
eligible O
patients O
, O
104 O
( O
40 O
% O
) O
agreed O
to O
participate O
, O
and O
93 O
were O
randomised O
. O

Women O
in O
the O
writing O
group O
wrote O
for O
20 O
min O
on O
four O
consecutive O
days O
. O

The O
control O
group O
received O
normal O
care O
. O

Women O
's O
perceptions O
of O
emotional O
support O
, O
quality O
of O
life O
( O
QOL O
) O
, O
mood O
, O
and O
healthcare O
utilisation O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
3 O
months O
and O
6 O
months O
. O

Interviews O
were O
conducted O
to O
explore O
women O
's O
experience O
of O
writing O
. O

Eighty O
participants O
completed O
all O
follow-ups O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Satisfaction B-Premise
with I-Premise
emotional I-Premise
support I-Premise
was I-Premise
negatively I-Premise
correlated I-Premise
with I-Premise
depression/dejection I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
anger/hostility I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
positively I-Premise
correlated I-Premise
with I-Premise
social I-Premise
and I-Premise
family I-Premise
well-being I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
6 I-Premise
months I-Premise
post I-Premise
intervention I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
effects I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
mood I-Premise
, I-Premise
QOL I-Premise
or I-Premise
healthcare I-Premise
utilisation I-Premise
. I-Premise

Most B-Premise
participants I-Premise
found I-Premise
writing I-Premise
valuable I-Premise
and I-Premise
did I-Premise
not I-Premise
report I-Premise
any I-Premise
long-term I-Premise
negative I-Premise
effects I-Premise
. I-Premise

EW B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
higher I-Claim
level I-Claim
of I-Claim
satisfaction I-Claim
with I-Claim
emotional I-Claim
support I-Claim
compared I-Claim
with I-Claim
controls I-Claim
. I-Claim

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

This O
study O
tested O
hyperbaric O
oxygen O
( O
HBO O
) O
as O
an O
adjunct O
to O
surgery O
and O
antibiotics O
in O
the O
treatment O
of O
bisphosphonate-related O
osteonecrosis O
of O
the O
jaw O
( O
ONJ O
) O
and O
evaluated O
its O
effects O
on O
gingival O
healing O
, O
pain O
, O
and O
quality O
of O
life O
. O

The O
investigators O
implemented O
a O
randomized O
controlled O
trial O
and O
enrolled O
a O
sample O
composed O
of O
patients O
with O
ONJ O
, O
where O
the O
predictor O
variable O
was O
HBO O
administered O
at O
2 O
atm O
twice O
a O
day O
for O
40 O
treatments O
as O
an O
adjunct O
to O
conventional O
therapy O
of O
surgery O
and O
antibiotics O
versus O
conventional O
therapy O
alone O
. O

Over O
the O
next O
24 O
months O
, O
oral O
lesion O
size O
and O
number O
, O
pain O
, O
and O
quality O
of O
life O
were O
assessed O
. O

Forty-six O
patients O
( O
mean O
age O
, O
66 O
yrs O
";" O
57 O
% O
women O
) O
contributed O
data O
to O
the O
trial O
. O

There O
were O
no O
statistically O
significant O
differences O
in O
the O
distribution O
of O
variables O
used O
to O
assess O
randomization O
success O
between O
the O
HBO O
and O
standard O
treatment O
groups O
. O

Seventeen B-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
improved I-Premise
versus I-Premise
8 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
38.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.043 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
. I-Premise

Mean B-Premise
time I-Premise
to I-Premise
improvement I-Premise
was I-Premise
39.7 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
22.4 I-Premise
to I-Premise
57.0 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
HBO-treated I-Premise
patients I-Premise
versus I-Premise
67.9 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
48.4 I-Premise
to I-Premise
87.5 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
complete I-Premise
gingival I-Premise
healing I-Premise
occurred I-Premise
in I-Premise
only I-Premise
14 I-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
52 I-Premise
% I-Premise
) I-Premise
versus I-Premise
7 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
33.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.203 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
healing I-Premise
was I-Premise
59 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
42.8 I-Premise
% I-Premise
to I-Premise
75.8 I-Premise
% I-Premise
) I-Premise
for I-Premise
HBO-treated I-Premise
patients I-Premise
versus I-Premise
70 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
52.2 I-Premise
% I-Premise
to I-Premise
88.36 I-Premise
% I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
.32 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

Pain B-Premise
decreased I-Premise
faster I-Premise
for I-Premise
HBO-treated I-Premise
subjects I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
, I-Premise
linear I-Premise
regression I-Premise
) I-Premise
. I-Premise

Quality-of-life B-Premise
scores I-Premise
for I-Premise
physical I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
perceived I-Premise
health I-Premise
( I-Premise
P I-Premise
= I-Premise
.043 I-Premise
) I-Premise
decreased I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
control I-Premise
group I-Premise
but I-Premise
for I-Premise
not I-Premise
the I-Premise
HBO I-Premise
group I-Premise
. I-Premise

ONJ B-Claim
is I-Claim
multifactorial I-Claim
and I-Claim
no I-Claim
single I-Claim
treatment I-Claim
modality I-Claim
is I-Claim
likely I-Claim
to I-Claim
reverse I-Claim
it I-Claim
";" I-Claim
however B-Claim
, I-Claim
it I-Claim
is I-Claim
treatable I-Claim
and I-Claim
even I-Claim
advanced I-Claim
presentations I-Claim
can I-Claim
improve I-Claim
with I-Claim
intensive I-Claim
multimodal I-Claim
therapy I-Claim
. I-Claim

Clinically B-Claim
, I-Claim
HBO I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
ONJ I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim

Therapy O
for O
polycystic O
liver O
is O
invasive O
, O
expensive O
, O
and O
has O
disappointing O
long-term O
results O
. O

Treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
PKD O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
PKD O
rodent O
model O
. O

We O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal-dominant O
( O
AD O
) O
PKD O
or O
autosomal-dominant O
polycystic O
liver O
disease O
( O
PCLD O
) O
. O

We O
performed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
2 O
tertiary O
referral O
centers O
. O

Patients O
with O
polycystic O
liver O
( O
n O
= O
54 O
) O
were O
randomly O
assigned O
to O
groups O
given O
lanreotide O
( O
120 O
mg O
) O
or O
placebo O
, O
administered O
every O
28 O
days O
for O
24 O
weeks O
. O

The O
primary O
end O
point O
was O
the O
difference O
in O
total O
liver O
volume O
, O
measured O
by O
computerized O
tomography O
at O
weeks O
0 O
and O
24 O
. O

Analyses O
were O
performed O
on O
an O
intention-to-treat O
basis O
. O

Baseline B-Premise
characteristics I-Premise
were I-Premise
comparable I-Premise
for I-Premise
both I-Premise
groups I-Premise
, I-Premise
except B-Premise
that I-Premise
more I-Premise
patients I-Premise
with I-Premise
ADPKD I-Premise
were I-Premise
assigned I-Premise
to I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
liver I-Premise
volume I-Premise
decreased I-Premise
2.9 I-Premise
% I-Premise
, I-Premise
from I-Premise
4606 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
: I-Premise
547-8665 I-Premise
) I-Premise
to I-Premise
4471 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
542-8401 I-Premise
mL I-Premise
) I-Premise
, I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
. I-Premise

In B-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
liver I-Premise
volume I-Premise
increased I-Premise
1.6 I-Premise
% I-Premise
, I-Premise
from I-Premise
4689 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
613-8765 I-Premise
mL I-Premise
) I-Premise
to I-Premise
4895 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
739-9053 I-Premise
mL I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Post B-Premise
hoc I-Premise
stratification I-Premise
for I-Premise
patients I-Premise
with I-Premise
ADPKD I-Premise
or I-Premise
PCLD I-Premise
revealed I-Premise
similar I-Premise
changes I-Premise
in I-Premise
liver I-Premise
volume I-Premise
, I-Premise
with I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
for I-Premise
both I-Premise
diseases I-Premise
) I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
polycystic I-Claim
liver I-Claim
, I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
with I-Claim
lanreotide I-Claim
reduces I-Claim
liver I-Claim
volume I-Claim
. I-Claim

A B-Claim
combination I-Claim
of I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
is I-Claim
preferable I-Claim
to I-Claim
prednisone I-Claim
alone I-Claim
for I-Claim
reduction I-Claim
of I-Claim
pain I-Claim
in I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
, I-Claim
hormone-resistant I-Claim
, I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
these O
treatments O
on O
health-related O
quality O
of O
life O
( O
HQL O
) O
. O

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

HQL O
was O
assessed O
before O
treatment O
initiation O
and O
then O
every O
3 O
weeks O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
Quality O
of O
Life O
Module-Prostate O
14 O
( O
QOLM-P14 O
) O
, O
a O
trial-specific O
module O
developed O
for O
this O
study O
. O

An O
intent-to-treat O
analysis O
was O
used O
to O
determine O
the O
mean O
duration O
of O
HQL O
improvement O
and O
differences O
in O
improvement O
duration O
between O
groups O
of O
patients O
. O

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
improvement I-Premise
in I-Premise
several I-Premise
HQL I-Premise
domains I-Premise
, I-Premise
and O
only B-Premise
physical I-Premise
functioning I-Premise
and I-Premise
pain I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
mitoxantrone-plus-prednisone I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
. I-Premise

After B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
taking I-Premise
prednisone I-Premise
showed I-Premise
no I-Premise
improvement I-Premise
in I-Premise
HQL I-Premise
scores I-Premise
, I-Premise
whereas I-Premise
those I-Premise
taking I-Premise
mitoxantrone I-Premise
plus I-Premise
prednisone I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
, I-Premise
four I-Premise
functioning I-Premise
domains I-Premise
, I-Premise
and I-Premise
nine I-Premise
symptoms I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
. I-Premise
1 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
improvement I-Premise
( I-Premise
> I-Premise
10 I-Premise
units I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
to100 I-Premise
) I-Premise
lasted I-Premise
longer I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
( I-Premise
.004 I-Premise
< I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
addition I-Premise
of I-Premise
mitoxantrone I-Premise
to I-Premise
prednisone I-Premise
after I-Premise
failure I-Premise
of I-Premise
prednisone I-Premise
alone I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
pain I-Premise
impact I-Premise
, I-Premise
pain I-Premise
relief I-Premise
, I-Premise
insomnia I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
was I-Claim
associated I-Claim
with I-Claim
greater I-Claim
and I-Claim
longer-lasting I-Claim
improvement I-Claim
in I-Claim
several I-Claim
HQL I-Claim
domains I-Claim
and I-Claim
symptoms I-Claim
than I-Claim
treatment I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

Studies O
on O
quality O
of O
life O
( O
QOL O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O

In O
the O
Post O
Operative O
Radiation O
Therapy O
in O
Endometrial O
Cancer O
( O
PORTEC O
) O
trial O
, O
patients O
with O
endometrial O
carcinoma O
were O
randomly O
assigned O
to O
receive O
external-beam O
radiotherapy O
( O
EBRT O
) O
or O
vaginal O
brachytherapy O
( O
VBT O
) O
. O

QOL O
was O
evaluated O
by O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
subscales O
from O
the O
prostate O
cancer O
module O
, O
PR-25 O
, O
and O
the O
ovarian O
cancer O
module O
, O
OV-28 O
. O

PORTEC-2 O
accrued O
427 O
patients O
between O
2002 O
and O
2006 O
, O
of O
whom O
214 O
were O
randomly O
assigned O
to O
EBRT O
, O
and O
213 O
were O
randomly O
assigned O
to O
VBT O
. O

Three-hundred O
forty-eight O
patients O
( O
81 O
% O
) O
were O
evaluable O
for O
QOL O
. O

QOL O
outcomes O
were O
analyzed O
at O
a O
median O
follow-up O
of O
2 O
years O
. O

At O
baseline O
after O
surgery O
, O
patient O
functioning O
was O
at O
the O
lowest O
level O
, O
and O
it O
increased O
during O
and O
after O
radiotherapy O
to O
reach O
a O
plateau O
after O
12 O
months O
. O

Patients B-Premise
in I-Premise
the I-Premise
VBT I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At O
baseline O
, O
15 O
% O
of O
patients O
were O
sexually O
active O
";" O
this O
increased O
significantly O
to O
39 O
% O
during O
the O
first O
year O
( O
P O
< O
.001 O
) O
. O

Sexual B-Premise
functioning I-Premise
and I-Premise
symptoms I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
EBRT I-Premise
reported I-Premise
significantly I-Premise
higher I-Premise
levels I-Premise
of I-Premise
diarrhea I-Premise
and I-Premise
bowel I-Premise
symptoms I-Premise
. I-Premise

This O
resulted O
in O
a O
higher O
need O
to O
remain O
close O
to O
a O
toilet O
and O
, O
as O
a O
consequence O
, O
more O
limitation O
of O
daily O
activities O
because O
of O
bowel O
symptoms O
and O
decreased O
social O
functioning O
. O

Vaginal B-Claim
brachytherapy I-Claim
provides I-Claim
a I-Claim
better I-Claim
QOL I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
preferred I-Claim
treatment I-Claim
from I-Claim
a I-Claim
QOL I-Claim
perspective I-Claim
. I-Claim

To O
assess O
the O
safety O
and O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
continuous O
combined O
hormone O
replacement O
therapy O
( O
ccHRT O
) O
with O
estradiol O
valerate/medroxyprogesterone O
acetate O
( O
E O
( O
2 O
) O
V/MPA O
) O
over O
nine O
years O
and O
at O
follow-up O
one O
year O
after O
discontinuation O
. O

A O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once-daily O
1 O
mg O
E2V/2.5 O
mg O
MPA O
( O
1 O
+ O
2.5 O
group O
) O
";" O
1 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
1 O
+ O
5 O
group O
) O
";" O
2 O
mg O
E2V/2.5 O
mg O
MPA O
daily O
( O
2 O
+ O
2.5 O
group O
) O
";" O
2 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

For O
the O
last O
six O
months O
, O
all O
received O
the O
1 O
+ O
2.5 O
dosage O
. O

The O
2 O
+ O
2.5 O
dosage O
was O
discontinued O
at O
the O
end O
of O
year O
7 O
. O

A O
total O
of O
198 O
women O
continued O
after O
year O
7 O
. O

Annualized O
percentage O
rates O
for O
cardiovascular O
events O
[ O
corrected O
] O
and O
endometrial O
cancers O
[ O
corrected O
] O
were O
below O
national O
rates O
for O
Finland O
and O
those O
reported O
for O
the O
Women O
's O
Health O
Initiative O
. O

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2.5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
";" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

HRQOL B-Premise
ratings I-Premise
improved I-Premise
with I-Premise
ccHRT I-Premise
, I-Premise
irrespective I-Premise
of I-Premise
dosage I-Premise
, I-Premise
including I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
health I-Premise
perception I-Premise
and I-Premise
sexual I-Premise
interest I-Premise
. I-Premise

Scores B-Premise
on I-Premise
a I-Premise
scale I-Premise
assessing I-Premise
daily I-Premise
functioning I-Premise
and I-Premise
enjoyment I-Premise
( I-Premise
Q-LES-Q I-Premise
) I-Premise
improved I-Premise
from I-Premise
year I-Premise
7 I-Premise
to I-Premise
year I-Premise
9 I-Premise
. I-Premise

They B-Premise
deteriorated I-Premise
during I-Premise
follow-up I-Premise
in I-Premise
women I-Premise
not I-Premise
continuing I-Premise
ccHRT I-Premise
. I-Premise

Lower B-Claim
dosages I-Claim
of I-Claim
HRT I-Claim
were I-Claim
as I-Claim
effective I-Claim
as I-Claim
higher I-Claim
doses I-Claim
in I-Claim
improving I-Claim
climacteric I-Claim
symptoms I-Claim
and I-Claim
HRQOL I-Claim
ratings I-Claim
and I-Claim
had I-Claim
fewer I-Claim
safety I-Claim
concerns I-Claim
. I-Claim

Following B-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
HRT I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow-up I-Premise
. I-Premise

This B-Claim
supports I-Claim
the I-Claim
need I-Claim
for I-Claim
an I-Claim
individualized I-Claim
approach I-Claim
to I-Claim
therapy I-Claim
recommendations I-Claim
. I-Claim

Few O
randomized O
trials O
have O
compared O
the O
survival O
benefit O
of O
interferon-alfa O
over O
controls O
in O
metastatic O
renal O
cell O
carcinoma O
, O
and O
none O
has O
been O
performed O
using O
interleukin-2 O
. O

The O
Programme O
Etude O
Rein O
Cytokines O
( O
PERCY O
) O
Quattro O
trial O
was O
designed O
to O
evaluate O
both O
cytokines O
for O
their O
survival O
benefit O
to O
intermediate O
prognosis O
patients O
, O
who O
represent O
the O
majority O
of O
candidates O
for O
these O
treatments O
. O

Patients O
were O
randomized O
in O
a O
2-by-2 O
factorial O
design O
to O
medroxyprogesterone O
acetate O
200 O
mg O
daily O
, O
interferon-alfa O
9 O
million O
IU O
3 O
times O
a O
week O
, O
subcutaneous O
interleukin-2 O
9 O
million O
IU O
daily O
, O
or O
a O
combination O
of O
both O
cytokines O
. O

Tumor O
response O
was O
evaluated O
at O
Week O
12 O
and O
Month O
6 O
";" O
progression-free O
patients O
received O
further O
identical O
treatment O
for O
a O
maximum O
of O
3 O
additional O
months O
. O

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Survival O
was O
analyzed O
on O
an O
intent-to-treat O
basis O
. O

From O
January O
2000 O
to O
July O
2004 O
, O
492 O
patients O
were O
enrolled O
. O

Analysis O
was O
performed O
after O
a O
29.2-month O
median O
follow-up O
( O
range O
, O
0 O
months O
to O
54.6 O
months O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
survival I-Premise
differences I-Premise
between I-Premise
the I-Premise
244 I-Premise
interferon-alfa-treated I-Premise
patients I-Premise
and I-Premise
248 I-Premise
noninterferon-alfa I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.00 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.81-1.24 I-Premise
) I-Premise
or I-Premise
between I-Premise
the I-Premise
247 I-Premise
interleukin-2 I-Premise
and I-Premise
245 I-Premise
noninterleukin-2-treated I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.07 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87-1.33 I-Premise
";" I-Premise
log I-Premise
rank I-Premise
, I-Premise
0.99 I-Premise
and I-Premise
0.52 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3-4 I-Premise
toxicities I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
cytokine-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
medroxyprogesterone-treated I-Premise
patients I-Premise
. I-Premise

Subcutaneous B-Claim
interleukin-2 I-Claim
and/or I-Claim
interferon-alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

Newly B-Claim
available I-Claim
angiogenesis I-Claim
inhibitors I-Claim
should I-Claim
be I-Claim
preferred I-Claim
for I-Claim
these I-Claim
patients I-Claim
. I-Claim

To O
investigate O
whether O
the O
effect O
of O
hypofractionated O
thoracic O
radiotherapy O
( O
TRT O
) O
is O
comparable O
to O
more O
standard O
fractionated O
radiotherapy O
( O
RT O
) O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

A O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
III O
or O
stage O
IV O
NSCLC O
tumors O
were O
included O
. O

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

Patients O
were O
randomly O
assigned O
to O
three O
arms O
: O
A O
, O
17 O
Gy O
per O
two O
fractions O
( O
n O
= O
146 O
) O
";" O
B O
, O
42 O
Gy O
per O
15 O
fractions O
( O
n O
= O
145 O
) O
";" O
and O
C O
, O
50 O
Gy O
per O
25 O
fractions O
( O
n O
= O
130 O
) O
. O

Four O
hundred O
seven O
patients O
were O
eligible O
for O
the O
study O
";" O
395 O
patients O
( O
97 O
% O
) O
participated O
in O
the O
health-related O
quality-of-life O
( O
HRQOL O
) O
study O
. O

The O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
EORTC O
QLQ-lung O
cancer-specific O
module O
( O
LC13 O
) O
were O
used O
to O
investigate O
airway O
symptom O
relief O
and O
changes O
in O
HRQOL O
. O

Assessments O
were O
performed O
before O
TRT O
and O
until O
week O
54 O
. O

Clinicians O
' O
assessments O
of O
symptom O
improvement O
were O
at O
2 O
, O
6 O
, O
and O
14 O
weeks O
after O
completion O
of O
TRT O
. O

The O
patients O
were O
observed O
for O
a O
minimum O
of O
3 O
years O
. O

Results O
Baseline O
prognostic O
data O
were O
equally O
distributed O
in O
the O
treatment O
groups O
. O

Patient O
compliance O
with O
respect O
to O
the O
HRQOL O
investigation O
was O
minimum O
74 O
% O
. O

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8.2 I-Premise
, I-Premise
7.0 I-Premise
, I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
TRT I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
HRQOL I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short-term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Cisplatin B-Claim
reduces I-Claim
plasma I-Claim
ghrelin I-Claim
levels I-Claim
through I-Claim
the I-Claim
5-hydroxytryptamine I-Claim
( I-Claim
5-HT I-Claim
) I-Claim
receptor I-Claim
. I-Claim

This O
may O
cause O
cisplatin-induced O
gastrointestinal O
disorders O
and O
hinders O
the O
continuation O
of O
chemotherapy O
. O

The O
authors O
of O
this O
report O
conducted O
a O
prospective O
, O
randomized O
phase O
2 O
trial O
to O
evaluate O
the O
effects O
of O
exogenous O
ghrelin O
during O
cisplatin-based O
chemotherapy O
. O

Forty-two O
patients O
with O
esophageal O
cancer O
who O
were O
receiving O
cisplatin-based O
neoadjuvant O
chemotherapy O
were O
assigned O
to O
either O
a O
ghrelin O
group O
( O
n O
= O
21 O
) O
or O
a O
placebo O
group O
( O
n O
= O
21 O
) O
. O

They O
received O
either O
intravenous O
infusions O
of O
synthetic O
human O
ghrelin O
( O
3 O
μg/kg O
) O
or O
saline O
twice O
daily O
for O
1 O
week O
with O
cisplatin O
administration O
. O

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy-related O
adverse O
events O
";" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
";" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ-C30 O
) O
. O

Two O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
One O
patient O
suspended O
ghrelin O
administration O
because O
of O
excessive O
diaphoresis O
, O
and O
another O
patient O
in O
the O
placebo O
group O
failed O
to O
monitor O
the O
self-questionnaire O
. O

Food B-Premise
intake I-Premise
and I-Premise
appetite I-Premise
VAS I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
18.2 I-Premise
± I-Premise
5.2 I-Premise
kcal/kg/day I-Premise
vs I-Premise
12.7 I-Premise
± I-Premise
3.4 I-Premise
kcal/kg/day I-Premise
[ I-Premise
P I-Premise
= I-Premise
.001 I-Premise
] I-Premise
and I-Premise
6.2 I-Premise
± I-Premise
0.9 I-Premise
vs I-Premise
4.1 I-Premise
± I-Premise
0.9 I-Premise
[ I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
had I-Premise
fewer I-Premise
adverse I-Premise
events I-Premise
during I-Premise
chemotherapy I-Premise
related I-Premise
to I-Premise
anorexia I-Premise
and I-Premise
nausea I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

Short-term B-Claim
administration I-Claim
of I-Claim
exogenous I-Claim
ghrelin I-Claim
at I-Claim
the I-Claim
start I-Claim
of I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
stimulated I-Claim
food I-Claim
intake I-Claim
and I-Claim
minimized I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Chemoradiotherapy O
( O
CRT O
) O
-induced O
oral O
mucositis O
( O
OM O
) O
adversely O
affects O
a O
patient O
's O
oral O
functions O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Low-level O
laser O
therapy O
( O
LLLT O
) O
showed O
some O
preventive O
and O
curative O
effects O
against O
clinically O
reported O
objective O
measures O
of O
OM O
in O
few O
trials O
including O
our O
recently O
published O
study O
. O

There O
is O
dearth O
of O
evidence O
regarding O
the O
effects O
of O
LLLT O
on O
patient O
's O
subjective O
experience O
of O
OM O
and O
QOL O
. O

Hence O
, O
we O
did O
this O
study O
to O
evaluate O
the O
effects O
of O
LLLT O
on O
a O
patient O
's O
reported O
measures O
of O
OM O
and O
QOL O
in O
head O
and O
neck O
cancer O
( O
HNC O
) O
patients O
receiving O
CRT O
. O

This O
triple O
blinded O
study O
randomized O
220 O
HNC O
patients O
scheduled O
for O
CRT O
( O
three O
weekly O
Cisplatin O
+ O
RT O
= O
66 O
Gray O
( O
2 O
Gy/session O
) O
, O
five O
fractions/week O
for O
6.5 O
weeks O
, O
total O
33 O
fractions O
) O
into O
laser O
( O
110 O
) O
and O
placebo O
( O
110 O
) O
groups O
. O

The O
laser O
group O
received O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He-Ne O
, O
λ O
= O
632.8 O
nm O
, O
power O
density O
= O
24 O
mW/cm O
( O
2 O
) O
, O
dosage O
= O
3.0 O
J O
at O
each O
point O
, O
total O
dose/session O
= O
36-40 O
J O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time/point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O

Methodology O
was O
similar O
to O
our O
recently O
published O
study O
( O
Gautam O
et O
al O
. O

Radiother O
Oncol O
104:349-354 O
, O
2012 O
) O
. O

In O
this O
part O
of O
our O
study O
, O
a O
blinded O
assessor O
collected O
subjective O
outcomes O
of O
the O
patient O
's O
reported O
measures O
of O
OM O
using O
Oral O
Mucositis O
Weekly O
Questionnaire-Head O
and O
Neck O
( O
OMWQ-HN O
) O
and O
QOL O
using O
Functional O
Assessment O
of O
Cancer O
Treatment-Head O
and O
Neck O
( O
FACT-HN O
) O
Questionnaire O
. O

Data O
were O
analyzed O
using O
repeated O
measure O
ANOVA O
through O
general O
linear O
model O
. O

Statistical O
significance O
was O
kept O
at O
p O
< O
0.05 O
. O

Results B-Premise
analysis I-Premise
revealed I-Premise
that I-Premise
OMWQ-HN I-Premise
( I-Premise
F I-Premise
= I-Premise
12.199 I-Premise
, I-Premise
df I-Premise
= I-Premise
6,1314 I-Premise
, I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
FACT-HN I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
LLLT I-Premise
than I-Premise
placebo I-Premise
group I-Premise
patients I-Premise
. I-Premise

Also O
, O
a B-Premise
significant I-Premise
reduction I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
in I-Premise
incidence I-Premise
of I-Premise
severe I-Premise
OM I-Premise
, I-Premise
need I-Premise
for I-Premise
opioid I-Premise
analgesics I-Premise
, I-Premise
and I-Premise
total I-Premise
parenteral I-Premise
nutrition I-Premise
was I-Premise
observed I-Premise
. I-Premise

LLLT B-Claim
was I-Claim
effective I-Claim
in I-Claim
improving I-Claim
the I-Claim
patient I-Claim
's I-Claim
subjective I-Claim
experience I-Claim
of I-Claim
OM I-Claim
and I-Claim
QOL I-Claim
in I-Claim
HNC I-Claim
patients I-Claim
receiving I-Claim
CRT I-Claim
. I-Claim

Due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

These O
patients O
experience O
significant O
functional O
impairment O
and O
muscle O
atrophy O
, O
which O
may O
lead O
to O
an O
increased O
likelihood O
of O
skeletal O
complicaTIOns O
( O
i.e. O
, O
pathological O
fracture O
, O
bone O
pain O
) O
and/or O
falls O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

The O
aim O
of O
this O
feasibility O
trial O
was O
to O
determine O
the O
safety O
and O
efficacy O
of O
resistance O
exercise O
by O
prostate O
cancer O
survivors O
with O
bone O
metastatic O
disease O
. O

Twenty O
men O
with O
established O
bone O
metastases O
secondary O
to O
prostate O
cancer O
were O
randomly O
assigned O
to O
a O
12-week O
resistance O
exercise O
program O
in O
which O
exercise O
prescription O
was O
based O
on O
the O
location O
of O
bone O
lesions O
( O
n=10 O
) O
or O
usual O
care O
( O
n=10 O
) O
. O

Outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

Participants O
had O
significant O
disease O
load O
with O
65 O
% O
of O
participants O
presenting O
with O
two O
or O
more O
regions O
affected O
by O
bone O
metastases O
and O
an O
average O
Gleason O
score O
of O
8.2±0.9 O
. O

Five O
participants O
( O
exercise=2 O
";" O
usual O
care=3 O
) O
did O
not O
complete O
the O
intervention O
, O
three O
of O
which O
were O
due O
to O
advancing O
disease O
( O
exercise=2 O
";" O
usual O
care=1 O
) O
. O

No B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise

The B-Premise
exercise I-Premise
program I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
as I-Premise
evidenced I-Premise
by I-Premise
high I-Premise
attendance I-Premise
( I-Premise
83 I-Premise
% I-Premise
) I-Premise
and I-Premise
compliance I-Premise
rates I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
ability I-Premise
of I-Premise
the I-Premise
participants I-Premise
to I-Premise
exercise I-Premise
at I-Premise
an I-Premise
intensity I-Premise
within I-Premise
the I-Premise
target I-Premise
range I-Premise
for I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
rating I-Premise
of I-Premise
perceived I-Premise
exertion I-Premise
=13.8±1.5 I-Premise
) I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
physical I-Premise
function I-Premise
( I-Premise
muscle I-Premise
strength I-Premise
∼11 I-Premise
% I-Premise
";" I-Premise
submaximal I-Premise
aerobic I-Premise
exercise I-Premise
capacity I-Premise
∼5 I-Premise
% I-Premise
and I-Premise
ambulation I-Premise
∼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
activity I-Premise
level I-Premise
( I-Premise
∼24 I-Premise
% I-Premise
) I-Premise
and I-Premise
lean I-Premise
mass I-Premise
( I-Premise
∼3 I-Premise
% I-Premise
) I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
following I-Premise
the I-Premise
intervention I-Premise
, I-Premise
with I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

No B-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
psychological I-Premise
distress I-Premise
. I-Premise

This B-Claim
initial I-Claim
evidence I-Claim
involving I-Claim
a I-Claim
small I-Claim
sample I-Claim
size I-Claim
suggests I-Claim
that I-Claim
appropriately I-Claim
designed I-Claim
and I-Claim
supervised I-Claim
resistance I-Claim
exercise I-Claim
may I-Claim
be I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastatic I-Claim
disease I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
function I-Claim
, I-Claim
physical I-Claim
activity I-Claim
levels I-Claim
and I-Claim
lean I-Claim
mass I-Claim
. I-Claim

Future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O

We O
report O
on O
the O
quality O
of O
life O
( O
QOL O
) O
outcomes O
for O
this O
trial O
. O

From O
December O
1997 O
through O
February O
2003 O
, O
244 O
men O
with O
newly O
diagnosed O
localized O
prostate O
cancer O
were O
randomly O
assigned O
to O
cryoablation O
or O
EBRT O
( O
median O
dose O
68 O
Gy O
) O
. O

All O
patients O
received O
neoadjuvant O
antiandrogen O
therapy O
. O

Patients O
completed O
the O
EORTC O
QLQ O
C30 O
and O
the O
Prostate O
Cancer O
Index O
( O
PCI O
) O
before O
treatment O
and O
at O
1.5 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
, O
and O
36 O
months O
post-treatment O
. O

Regardless B-Premise
of I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
participants I-Premise
reported I-Premise
high I-Premise
levels I-Premise
of I-Premise
QOL I-Premise
with I-Premise
few I-Premise
exceptions I-Premise
. I-Premise

cryoablation B-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
acute I-Premise
urinary I-Premise
dysfunction I-Premise
( I-Premise
mean I-Premise
PCI I-Premise
urinary I-Premise
function I-Premise
cryoablation=69.4 I-Premise
";" I-Premise
mean I-Premise
EBRT=90.7 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
which I-Premise
resolved I-Premise
over I-Premise
time I-Premise
. I-Premise

No B-Premise
late I-Premise
arising I-Premise
QOL I-Premise
issues I-Premise
were I-Premise
observed I-Premise
. I-Premise

Both B-Premise
EBRT I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation=7.2 I-Premise
: I-Premise
mean I-Premise
EBRT=32.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
sexual I-Premise
function I-Premise
score I-Premise
was I-Premise
15 I-Premise
points I-Premise
lower I-Premise
at I-Premise
3 I-Premise
years I-Premise
for I-Premise
the I-Premise
cryoablation I-Premise
group I-Premise
and I-Premise
13 I-Premise
% I-Premise
more I-Premise
of I-Premise
the I-Premise
cryoablation I-Premise
men I-Premise
said I-Premise
that I-Premise
sexuality I-Premise
was I-Premise
a I-Premise
moderate I-Premise
or I-Premise
big I-Premise
problem I-Premise
. I-Premise

In B-Claim
this I-Claim
randomized I-Claim
trial I-Claim
, I-Claim
no I-Claim
long-term I-Claim
QOL I-Claim
advantage I-Claim
for I-Claim
either I-Claim
treatment I-Claim
was I-Claim
apparent I-Claim
with B-Claim
the I-Claim
exception I-Claim
of I-Claim
poorer I-Claim
sexual I-Claim
function I-Claim
reported I-Claim
by I-Claim
those I-Claim
treated I-Claim
with I-Claim
cryoablation I-Claim
. I-Claim

Men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual O
function O
might O
be O
counseled O
to O
choose O
EBRT O
over O
cryoablation O
. O

It B-Claim
has I-Claim
been I-Claim
shown I-Claim
that I-Claim
nonpharmacologic I-Claim
interventions I-Claim
are I-Claim
effective I-Claim
management I-Claim
techniques I-Claim
for I-Claim
cancer-related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
in I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

However O
, O
few O
studies O
have O
investigated O
their O
effectiveness O
in O
patients O
who O
are O
receiving O
chemotherapy O
. O

In O
this O
study O
, O
the O
authors O
tested O
the O
effectiveness O
of O
a O
brief O
behaviorally O
oriented O
intervention O
in O
reducing O
CRF O
and O
improving O
physical O
function O
and O
associated O
distress O
in O
individuals O
who O
were O
receiving O
chemotherapy O
. O

For O
this O
randomized O
controlled O
trial O
, O
60 O
patients O
with O
cancer O
were O
recruited O
and O
received O
either O
usual O
care O
or O
the O
intervention O
. O

The O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue-related O
thoughts O
and O
behavior O
. O

Primary O
outcomes O
were O
assessed O
as O
follows O
: O
CRF O
using O
the O
Visual O
Analogue O
Scale-Global O
Fatigue O
";" O
physical O
functioning O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Core O
30 O
Questionnaire O
, O
and O
CRF-associated O
distress O
using O
the O
Fatigue O
Outcome O
Measure O
. O

Assessments O
were O
made O
on O
4 O
occasions O
: O
at O
baseline O
( O
T0 O
) O
, O
at O
the O
end O
of O
chemotherapy O
( O
T1 O
) O
, O
1 O
month O
after O
chemotherapy O
( O
T2 O
) O
, O
and O
9 O
months O
after O
recruitment O
( O
T3 O
) O
. O

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random-slope/random-intercept O
mixed O
models O
. O

The B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
CRF I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
coefficient I-Premise
, I-Premise
10.0 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
2.5-17.5 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
, I-Premise
and I-Premise
this I-Premise
effect I-Premise
remained I-Premise
once I-Premise
the I-Premise
confounding I-Premise
effects I-Premise
of I-Premise
mood I-Premise
disturbance I-Premise
and I-Premise
comorbid I-Premise
disorders I-Premise
were I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

No B-Premise
decrease I-Premise
in I-Premise
fatigue-related I-Premise
distress I-Premise
was I-Premise
detected I-Premise
. I-Premise

The B-Claim
behaviorally I-Claim
oriented I-Claim
intervention I-Claim
brought I-Claim
about I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
indicated I-Claim
a I-Claim
trend I-Claim
toward I-Claim
improved I-Claim
CRF I-Claim
, I-Claim
but I-Claim
detected I-Claim
no I-Claim
effect I-Claim
for I-Claim
fatigue-related I-Claim
distress I-Claim
. I-Claim

Radiotherapy B-Claim
is I-Claim
an I-Claim
effective I-Claim
palliative I-Claim
treatment I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

Although O
single- O
and O
multiple-fraction O
radiotherapy O
are O
thought O
to O
provide O
equal O
palliation O
, O
which O
treatment O
schedule O
provides O
better O
value O
for O
the O
money O
is O
unknown O
. O

We O
compared O
quality-adjusted O
life O
expectancy O
( O
the O
overall O
valuation O
of O
the O
health O
of O
the O
patients O
) O
and O
societal O
costs O
for O
patients O
receiving O
either O
single- O
or O
multiple-fraction O
radiotherapy O
. O

A O
societal O
cost-utility O
analysis O
was O
performed O
on O
a O
Dutch O
randomized O
, O
controlled O
trial O
of O
1157 O
patients O
with O
painful O
bone O
metastases O
that O
compared O
pain O
responses O
and O
quality O
of O
life O
from O
a O
single-fraction O
treatment O
schedule O
of O
8 O
Gy O
with O
a O
treatment O
schedule O
of O
six O
fractions O
of O
4 O
Gy O
each O
. O

The O
societal O
values O
of O
life O
expectancies O
were O
assessed O
with O
the O
EuroQol O
classification O
system O
( O
EQ-5D O
) O
questionnaire O
. O

A O
subset O
of O
166 O
patients O
also O
answered O
additional O
questionnaires O
to O
estimate O
nonradiotherapy O
and O
nonmedical O
costs O
. O

Statistical O
tests O
were O
two-sided O
. O

Comparing B-Premise
the I-Premise
single- I-Premise
and I-Premise
multiple-fraction I-Premise
radiotherapy I-Premise
schedules I-Premise
, I-Premise
no I-Premise
differences I-Premise
were I-Premise
found I-Premise
in I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
43.0 I-Premise
versus I-Premise
40.4 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.20 I-Premise
) I-Premise
or I-Premise
quality-adjusted I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
17.7 I-Premise
versus I-Premise
16.0 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.21 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
cost I-Premise
of I-Premise
radiotherapy I-Premise
, I-Premise
including I-Premise
retreatments I-Premise
and I-Premise
nonmedical I-Premise
costs I-Premise
, I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
for I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
than I-Premise
for I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
$ I-Premise
2438 I-Premise
versus I-Premise
$ I-Premise
3311 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
873 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
$ I-Premise
449 I-Premise
to I-Premise
$ I-Premise
1297 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
difference I-Premise
in I-Premise
total I-Premise
societal I-Premise
costs I-Premise
was I-Premise
larger I-Premise
, I-Premise
also I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
, I-Premise
but B-Premise
it I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
$ I-Premise
4700 I-Premise
versus I-Premise
$ I-Premise
6453 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
1753 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
- I-Premise
$ I-Premise
99 I-Premise
to I-Premise
$ I-Premise
3604 I-Premise
";" I-Premise
P I-Premise
=.06 I-Premise
) I-Premise
. I-Premise

For B-Premise
willingness-to-pay I-Premise
between I-Premise
$ I-Premise
5000 I-Premise
and I-Premise
$ I-Premise
40 I-Premise
0 I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
, I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
cost-effective I-Premise
than I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Compared B-Claim
with I-Claim
multiple-fraction I-Claim
radiotherapy I-Claim
, I-Claim
single-fraction I-Claim
radiotherapy I-Claim
provides I-Claim
equal I-Claim
palliation I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
has I-Claim
lower I-Claim
medical I-Claim
and I-Claim
societal I-Claim
costs I-Claim
, I-Claim
at I-Claim
least I-Claim
in I-Claim
The I-Claim
Netherlands I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
single-fraction I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

For B-Claim
malignant I-Claim
pleural I-Claim
mesothelioma I-Claim
( I-Claim
MPM I-Claim
) I-Claim
patients I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
maintaining I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQOL I-Claim
) I-Claim
is I-Claim
important I-Claim
. I-Claim

This O
article O
compares O
the O
impact O
on O
HRQOL O
of O
first-line O
treatment O
with O
cisplatin O
versus O
raltitrexed O
and O
cisplatin O
. O

Patients O
with O
histologically-proven O
unresectable O
MPM O
, O
not O
pretreated O
with O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
cisplatin O
80 O
mg/m2 O
intravenously O
on O
day O
1 O
, O
with O
or O
without O
preceding O
infusion O
of O
raltitrexed O
3 O
mg/m2 O
. O

HRQOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
Lung O
Cancer O
Module O
( O
QLQ-LC13 O
) O
tools O
. O

Assessments O
were O
conducted O
at O
baseline O
, O
immediately O
before O
every O
treatment O
cycle O
, O
at O
the O
end O
of O
treatment O
, O
and O
every O
six O
weeks O
for O
12 O
months O
. O

Two O
hundred O
fifty O
patients O
were O
randomly O
assigned O
, O
80 O
% O
were O
male O
with O
a O
median O
age O
of O
58 O
years O
, O
WHO O
performance O
status O
0 O
, O
1 O
, O
and O
2 O
, O
in O
25 O
% O
, O
62 O
% O
, O
and O
13 O
% O
of O
cases O
. O

The B-Premise
clinical I-Premise
results I-Premise
found I-Premise
raltitrexed I-Premise
and I-Premise
cisplatin I-Premise
to I-Premise
be I-Premise
superior I-Premise
to I-Premise
cisplatin I-Premise
with I-Premise
regard I-Premise
to I-Premise
overall I-Premise
survival I-Premise
( I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

The B-Premise
global I-Premise
HRQOL I-Premise
scale I-Premise
was I-Premise
comparable I-Premise
at I-Premise
baseline I-Premise
on I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
.848 I-Premise
) I-Premise
";" I-Premise
at B-Premise
no I-Premise
point I-Premise
was I-Premise
any I-Premise
significant I-Premise
difference I-Premise
apparent I-Premise
on I-Premise
this I-Premise
end I-Premise
point I-Premise
. I-Premise

Both B-Premise
treatments I-Premise
led I-Premise
to I-Premise
an I-Premise
improvement I-Premise
, I-Premise
over I-Premise
time I-Premise
, I-Premise
in I-Premise
dyspnoea I-Premise
. I-Premise

This B-Claim
effect I-Claim
is I-Claim
an I-Claim
important I-Claim
clinically I-Claim
meaningful I-Claim
reduction I-Claim
from I-Claim
baseline I-Claim
in I-Claim
the I-Claim
cisplatin/raltitrexed I-Claim
arm I-Claim
. I-Claim

However B-Premise
, I-Premise
the I-Premise
majority I-Premise
of I-Premise
scales I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
or I-Premise
LC13 I-Premise
showed I-Premise
stabilization I-Premise
of I-Premise
HRQOL I-Premise
with I-Premise
few I-Premise
clinically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

This B-Claim
study I-Claim
provides I-Claim
important I-Claim
information I-Claim
about I-Claim
the I-Claim
HRQOL I-Claim
of I-Claim
chemotherapy-treated I-Claim
MPM I-Claim
patients I-Claim
. I-Claim

The O
physiological O
and O
psychological O
stress O
that O
brain O
tumor O
patients O
undergo O
during O
the O
entire O
surgical O
experience O
can O
considerably O
affect O
several O
aspects O
of O
their O
hospitalization O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
live O
music O
therapy O
on O
quality O
of O
life O
indicators O
, O
amount O
of O
medications O
administered O
and O
length O
of O
stay O
for O
persons O
receiving O
elective O
surgical O
procedures O
of O
the O
brain O
. O

Subjects O
( O
N O
= O
27 O
) O
were O
patients O
admitted O
for O
some O
type O
of O
surgical O
procedure O
of O
the O
brain O
. O

Subjects O
were O
randomly O
assigned O
to O
either O
the O
control O
group O
receiving O
no O
music O
intervention O
( O
n O
= O
13 O
) O
or O
the O
experimental O
group O
receiving O
pre O
and O
postoperative O
live O
music O
therapy O
sessions O
( O
n O
= O
14 O
) O
. O

Anxiety O
, O
mood O
, O
pain O
, O
perception O
of O
hospitalization O
or O
procedure O
, O
relaxation O
, O
and O
stress O
were O
measured O
using O
a O
self-report O
Visual O
Analog O
Scale O
( O
VAS O
) O
for O
each O
of O
the O
variables O
. O

The O
documented O
administration O
of O
postoperative O
pain O
medications O
";" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre-operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

Control O
subjects O
received O
routine O
hospital O
care O
without O
any O
music O
therapy O
intervention O
. O

Differences O
in O
experimental O
pretest O
and O
posttest O
scores O
were O
analyzed O
using O
a O
Wilcoxon O
Matched-Pairs O
Signed-Rank O
test O
. O

Results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
mood I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
or I-Premise
pain I-Premise
( I-Premise
p I-Premise
> I-Premise
.05 I-Premise
) I-Premise
levels I-Premise
. I-Premise

Administration O
amounts O
of O
nausea O
and O
pain O
medications O
were O
compared O
with O
a O
Two-Way O
ANOVA O
with O
One O
Repeated O
Measure O
resulting O
in O
no O
significant O
differences O
between O
groups O
and O
medications O
, O
F O
( O
1 O
, O
51 O
) O
= O
0.03 O
";" O
p O
> O
.05 O
. O

Results O
indicate O
no O
significant O
differences O
between O
groups O
for O
length O
of O
stay O
( O
t O
= O
.97 O
, O
df O
= O
25 O
, O
p O
> O
.05 O
) O
. O

This B-Claim
research I-Claim
study I-Claim
indicates I-Claim
that I-Claim
live I-Claim
music I-Claim
therapy I-Claim
using I-Claim
patient-preferred I-Claim
music I-Claim
can I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
indicators I-Claim
such I-Claim
as I-Claim
anxiety I-Claim
, I-Claim
perception I-Claim
of I-Claim
the I-Claim
hospitalization I-Claim
or I-Claim
procedure I-Claim
, I-Claim
relaxation I-Claim
, I-Claim
and I-Claim
stress I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
surgical I-Claim
procedures I-Claim
of I-Claim
the I-Claim
brain I-Claim
. I-Claim

Spiritual O
well-being O
and O
sense O
of O
meaning O
are O
important O
concerns O
for O
clinicians O
who O
care O
for O
patients O
with O
cancer O
. O

We O
developed O
Individual O
Meaning-Centered O
Psychotherapy O
( O
IMCP O
) O
to O
address O
the O
need O
for O
brief O
interventions O
targeting O
spiritual O
well-being O
and O
meaning O
for O
patients O
with O
advanced O
cancer O
. O

Patients O
with O
stage O
III O
or O
IV O
cancer O
( O
N O
= O
120 O
) O
were O
randomly O
assigned O
to O
seven O
sessions O
of O
either O
IMCP O
or O
therapeutic O
massage O
( O
TM O
) O
. O

Patients O
were O
assessed O
before O
and O
after O
completing O
the O
intervention O
and O
2 O
months O
postintervention O
. O

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

Of O
the O
120 O
participants O
randomly O
assigned O
, O
78 O
( O
65 O
% O
) O
completed O
the O
post-treatment O
assessment O
and O
67 O
( O
56 O
% O
) O
completed O
the O
2-month O
follow-up O
. O

At B-Premise
the I-Premise
post-treatment I-Premise
assessment I-Premise
, I-Premise
IMCP I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
b I-Premise
= I-Premise
0.39 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0.76 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

Significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
IMCP I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
-6.56 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
symptom-related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
-0.47 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise

At B-Premise
the I-Premise
2-month I-Premise
follow-up I-Premise
assessment I-Premise
, I-Premise
the I-Premise
improvements I-Premise
observed I-Premise
for I-Premise
the I-Premise
IMCP I-Premise
group I-Premise
were I-Premise
no I-Premise
longer I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
those I-Premise
observed I-Premise
for I-Premise
the I-Premise
TM I-Premise
group I-Premise
. I-Premise

IMCP B-Claim
has I-Claim
clear I-Claim
short-term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

Clinicians O
working O
with O
patients O
who O
have O
advanced O
cancer O
should O
consider O
IMCP O
as O
an O
approach O
to O
enhance O
quality O
of O
life O
and O
spiritual O
well-being O
. O

Recently B-Claim
, I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
by I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5-fluorouracil I-Claim
( I-Claim
5-FU I-Claim
) I-Claim
with I-Claim
low-dose I-Claim
cisplatin I-Claim
( I-Claim
CDDP I-Claim
) I-Claim
has I-Claim
improved I-Claim
efficacy I-Claim
without I-Claim
severe I-Claim
toxicities I-Claim
. I-Claim

The B-Claim
possible I-Claim
effectiveness I-Claim
of I-Claim
5-FU+low-dose I-Claim
CDDP I-Claim
for I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
CRC I-Claim
) I-Claim
is I-Claim
intriguing I-Claim
. I-Claim

One O
hundred O
fifty-five O
patients O
with O
far-advanced O
CRC O
including O
at O
least O
one O
measurable O
lesion O
were O
enrolled O
in O
a O
prospective O
randomized O
clinical O
trial O
funded O
by O
the O
Japanese O
Foundation O
for O
Multidisciplinary O
Treatment O
of O
Cancer O
. O

These O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low-dose O
CDDP O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5-FU O
at O
a O
dose O
of O
300 O
mg/m O
( O
2 O
) O
/24 O
hrs O
in O
a O
one-week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O

CD-DP O
was O
given O
intravenously O
at O
a O
dose O
of O
3 O
mg/m O
( O
2 O
) O
on O
days O
1-5 O
and O
days O
8-12 O
, O
and O
then O
at O
a O
dose O
of O
7 O
mg/m O
( O
2 O
) O
twice O
a O
week O
. O

Three O
patients O
were O
excluded O
from O
the O
trial O
. O

The B-Premise
response I-Premise
rate I-Premise
in I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
( I-Premise
n=75 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
n=77 I-Premise
) I-Premise
( I-Premise
25.3 I-Premise
% I-Premise
vs. I-Premise
11.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
between I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
479 I-Premise
and I-Premise
491 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O

Low-dose B-Claim
CDDP I-Claim
improved I-Claim
the I-Claim
response I-Claim
rate I-Claim
while I-Claim
keeping I-Claim
toxicities I-Claim
within I-Claim
clinically I-Claim
acceptable I-Claim
limits I-Claim
. I-Claim

However B-Claim
, I-Claim
this I-Claim
combined I-Claim
treatment I-Claim
did I-Claim
not I-Claim
confer I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
treatment I-Claim
with I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5-FU I-Claim
alone I-Claim
for I-Claim
patients I-Claim
with I-Claim
far-advanced I-Claim
CRC I-Claim
";" I-Claim
that I-Claim
might I-Claim
be I-Claim
attributable I-Claim
to I-Claim
the I-Claim
short I-Claim
CDDP I-Claim
administration I-Claim
setting I-Claim
of I-Claim
12 I-Claim
weeks I-Claim
. I-Claim

Recent B-Claim
studies I-Claim
have I-Claim
shown I-Claim
that I-Claim
administering I-Claim
the I-Claim
aromatase I-Claim
inhibitor I-Claim
exemestane I-Claim
after I-Claim
2-3 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
significantly I-Claim
improves I-Claim
disease-free I-Claim
survival I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
primary I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
comparison I-Claim
with I-Claim
standard I-Claim
5-year I-Claim
tamoxifen I-Claim
treatment I-Claim
. I-Claim

Although O
many O
of O
the O
adverse O
effects O
associated O
with O
exemestane O
and O
tamoxifen O
have O
been O
analysed O
, O
there O
are O
no O
comparative O
data O
concerning O
body O
weight O
and O
body O
composition O
. O

The O
aim O
of O
this O
randomised O
study O
was O
to O
evaluate O
the O
longitudinal O
changes O
in O
body O
composition O
and O
lipid O
profiles O
in O
postmenopausal O
women O
switched O
from O
tamoxifen O
to O
exemestane O
. O

In O
total O
, O
60 O
overweight O
or O
obese O
postmenopausal O
patients O
were O
enrolled O
. O

Their O
anthropometric O
data O
, O
body O
composition O
, O
including O
fat O
mass O
( O
FM O
) O
and O
fat-free O
mass O
( O
FFM O
) O
, O
and O
lipid O
profiles O
, O
caloric O
intake O
and O
physical O
activity O
were O
assessed O
1 O
week O
before O
randomisation O
, O
and O
6 O
and O
12 O
months O
later O
. O

In O
all O
, O
55 O
patients O
( O
27 O
on O
tamoxifen O
and O
28 O
on O
exemestane O
) O
completed O
the O
1-year O
study O
period O
. O

Fat B-Premise
mass I-Premise
had I-Premise
significantly I-Premise
decreased I-Premise
by I-Premise
month I-Premise
12 I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
, I-Premise
but I-Premise
not I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
FFM/FM I-Premise
ratio I-Premise
had I-Premise
significantly I-Premise
increased I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Triglycerides B-Premise
and I-Premise
high-density I-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and O
low-density B-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
1-year I-Premise
study I-Premise
period I-Premise
. I-Premise

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

Anti-aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
BMD O
) O
and O
osteoporosis O
. O

Cyclooxygenase-2 B-Claim
( I-Claim
COX-2 I-Claim
) I-Claim
inhibitors I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
chemoprevention I-Claim
in I-Claim
animal I-Claim
and I-Claim
clinical I-Claim
studies I-Claim
. I-Claim

A O
proof O
of O
principle O
study O
was O
performed O
to O
investigate O
the O
efficacy O
of O
combing O
anti-aromatase O
therapy O
( O
exemestane O
) O
and O
COX-2 O
inhibitors O
neoadjuvantly O
. O

The O
changes O
in O
the O
BMD O
, O
bone O
turnover O
proteins O
and O
quality-of-life O
( O
QoL O
) O
were O
analyzed O
and O
presented O
here O
. O

82 O
postmenopausal O
patients O
with O
histologically O
confirmed O
invasive O
hormone-sensitive O
breast O
cancers O
were O
included O
for O
the O
neoadjuvant O
therapy O
( O
NHT O
) O
. O

30 O
patients O
received O
exemestane O
( O
EXE O
) O
25 O
mg O
daily O
and O
celecoxib O
( O
CXB O
) O
400 O
mg O
twice O
daily O
( O
group O
A O
) O
, O
24 O
patients O
received O
EXE O
25 O
mg O
daily O
( O
group O
B O
) O
and O
28 O
patients O
received O
letrozole O
( O
LET O
) O
2.5 O
mg O
daily O
( O
group O
C O
) O
. O

The O
same O
assigned O
treatment O
was O
intended O
to O
continue O
for O
2 O
years O
to O
study O
the O
changes O
in O
the O
bone O
metabolism O
. O

BMD O
of O
48 O
patients O
were O
analyzed O
";" O
23 O
belongs O
to O
group O
A O
, O
10 O
to O
group O
B O
and O
15 O
to O
group O
C. O
The O
serum O
bone O
turnover O
proteins O
bone-specific O
alkaline O
phosphatase O
( O
BAP O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O

Functional O
Assessment O
of O
Cancer O
Therapy O
core O
questionnaire O
( O
FACT-G O
) O
with O
its O
additional O
breast O
cancer O
subscale O
were O
performed O
at O
baseline O
, O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
NHT O
. O

Difference B-Premise
between I-Premise
groups I-Premise
( I-Premise
p=0.007 I-Premise
) I-Premise
for I-Premise
BMD I-Premise
at I-Premise
femur I-Premise
was I-Premise
significant I-Premise
. I-Premise

The B-Premise
changes I-Premise
of I-Premise
BMD I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
patients I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
p=0.011 I-Premise
, I-Premise
CI=0.063-0.437 I-Premise
) I-Premise
, I-Premise
and I-Premise
group I-Premise
C I-Premise
( I-Premise
p=0.003 I-Premise
, I-Premise
CI=0.146-0.620 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
BAP I-Premise
increased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
but I-Premise
decreased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
C I-Premise
patients I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
15 I-Premise
months I-Premise
. I-Premise

No B-Premise
statistical I-Premise
significance I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
FACT-G I-Premise
scores I-Premise
and I-Premise
FACT-B I-Premise
scores I-Premise
among I-Premise
different I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
week I-Premise
4 I-Premise
, I-Premise
week I-Premise
8 I-Premise
and I-Premise
week I-Premise
12 I-Premise
after I-Premise
NHT I-Premise
. I-Premise

The B-Premise
Breast I-Premise
Cancer I-Premise
Subscale I-Premise
scores I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
group I-Premise
C I-Premise
patients I-Premise
( I-Premise
p=0.021 I-Premise
) I-Premise
. I-Premise

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT-B I-Premise
and I-Premise
FACT-G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

Significant B-Premise
differences I-Premise
of I-Premise
FACT-B I-Premise
score I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
and I-Premise
FACT-G I-Premise
score I-Premise
( I-Premise
p=0.019 I-Premise
) I-Premise
were I-Premise
observed I-Premise
at I-Premise
that I-Premise
time I-Premise
point I-Premise
. I-Premise

Article O
from O
the O
Special O
issue O
on O
Targeted O
Inhibitors O
. O

Hot O
flushes O
and O
night O
sweats O
( O
HFNS O
) O
affect O
65-85 O
% O
of O
women O
after O
breast O
cancer O
treatment O
";" O
they O
are O
distressing O
, O
causing O
sleep O
problems O
and O
decreased O
quality O
of O
life O
. O

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Safe B-Claim
, I-Claim
effective I-Claim
non-hormonal I-Claim
treatments I-Claim
are I-Claim
needed I-Claim
. I-Claim

We O
investigated O
whether O
cognitive O
behavioural O
therapy O
( O
CBT O
) O
can O
help O
breast O
cancer O
survivors O
to O
effectively O
manage O
HFNS O
. O

In O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
London O
, O
UK O
, O
who O
had O
problematic O
HFNS O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast-cancer O
treatment O
. O

Participants O
were O
randomly O
allocated O
to O
receive O
either O
usual O
care O
or O
usual O
care O
plus O
group O
CBT O
( O
1:1 O
) O
. O

Randomisation O
was O
done O
in O
blocks O
of O
12-20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer-generated O
sequence O
. O

The O
trial O
statistician O
and O
researchers O
collecting O
outcome O
measures O
were O
masked O
to O
group O
allocation O
. O

Group O
CBT O
comprised O
one O
90 O
min O
session O
a O
week O
for O
6 O
weeks O
, O
and O
included O
psycho-education O
, O
paced O
breathing O
, O
and O
cognitive O
and O
behavioural O
strategies O
to O
manage O
HFNS O
. O

Assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O

The O
primary O
outcome O
was O
the O
adjusted O
mean O
difference O
in O
HFNS O
problem O
rating O
( O
1-10 O
) O
between O
CBT O
and O
usual O
care O
groups O
at O
9 O
weeks O
after O
randomisation O
. O

Analysis O
of O
the O
primary O
endpoint O
was O
done O
by O
modified O
intention O
to O
treat O
. O

The O
trial O
is O
registered O
, O
ISRCTN13771934 O
, O
and O
was O
closed O
March O
15 O
, O
2011 O
. O

Between O
May O
5 O
, O
2009 O
, O
and O
Aug O
27 O
, O
2010 O
, O
96 O
women O
were O
randomly O
allocated O
to O
group O
CBT O
( O
n=47 O
) O
or O
usual O
care O
( O
n=49 O
) O
. O

Group B-Premise
CBT I-Premise
significantly I-Premise
reduced I-Premise
HFNS I-Premise
problem I-Premise
rating I-Premise
at I-Premise
9 I-Premise
weeks I-Premise
after I-Premise
randomisation I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1·67 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2·43 I-Premise
to I-Premise
-0·91 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
and I-Premise
improvements I-Premise
were I-Premise
maintained I-Premise
at I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1·76 I-Premise
, I-Premise
-2·54 I-Premise
to I-Premise
-0·99 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

We B-Premise
recorded I-Premise
no I-Premise
CBT-related I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Group B-Claim
CBT I-Claim
seems I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
women I-Claim
who I-Claim
have I-Claim
problematic I-Claim
HFNS I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
with I-Claim
additional I-Claim
benefits I-Claim
to I-Claim
mood I-Claim
, I-Claim
sleep I-Claim
, I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
treatment O
could O
be O
incorporated O
into O
breast O
cancer O
survivorship O
programmes O
and O
delivered O
by O
trained O
breast O
cancer O
nurses O
. O

Most B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
develop I-Claim
recurrent I-Claim
disease I-Claim
. I-Claim

For B-Claim
those I-Claim
patients I-Claim
who I-Claim
recur I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
after I-Claim
initial I-Claim
therapy I-Claim
, I-Claim
paclitaxel I-Claim
platinum I-Claim
has I-Claim
shown I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
platinum I-Claim
without I-Claim
paclitaxel I-Claim
";" I-Claim
however B-Premise
, I-Premise
many I-Premise
patients I-Premise
develop I-Premise
clinically I-Premise
relevant I-Premise
neurotoxicity I-Premise
, I-Premise
frequently I-Premise
resulting I-Premise
in I-Premise
treatment I-Premise
discontinuation I-Premise
. O

Thus O
, O
an O
alternative O
regimen O
without O
significant O
neurotoxicity O
was O
evaluated O
by O
comparing O
gemcitabine O
plus O
carboplatin O
with O
single-agent O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
. O

Patients O
with O
platinum-sensitive O
recurrent O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
plus O
carboplatin O
or O
carboplatin O
alone O
, O
every O
21 O
days O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
. O

Three O
hundred O
fifty-six O
patients O
( O
178 O
gemcitabine O
plus O
carboplatin O
";" O
178 O
carboplatin O
) O
were O
randomly O
assigned O
. O

Patients O
received O
a O
median O
of O
six O
cycles O
in O
both O
arms O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
7.9 I-Premise
to I-Premise
9.7 I-Premise
months I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.2 I-Premise
to I-Premise
7.1 I-Premise
months I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ration I-Premise
( I-Premise
HR I-Premise
) I-Premise
for I-Premise
PFS I-Premise
was I-Premise
0.72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.58 I-Premise
to I-Premise
0.90 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0031 I-Premise
) I-Premise
. I-Premise

Response B-Premise
rate I-Premise
was I-Premise
47.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
39.9 I-Premise
% I-Premise
to I-Premise
54.5 I-Premise
% I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
30.9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
24.1 I-Premise
% I-Premise
to I-Premise
37.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
P I-Premise
= I-Premise
.0016 I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.7349 I-Premise
) I-Premise
. I-Premise

While B-Premise
myelosuppression I-Premise
was I-Premise
significantly I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
combination I-Premise
, I-Premise
sequelae I-Premise
such I-Premise
as I-Premise
febrile I-Premise
neutropenia I-Premise
or I-Premise
infections I-Premise
were I-Premise
uncommon I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
arms I-Premise
were I-Premise
noted I-Premise
. I-Premise

Gemcitabine B-Claim
plus I-Claim
carboplatin I-Claim
significantly I-Claim
improves I-Claim
PFS I-Claim
and I-Claim
response I-Claim
rate I-Claim
without I-Claim
worsening I-Claim
quality I-Claim
of I-Claim
life I-Claim
for I-Claim
patients I-Claim
with I-Claim
platinum-sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

There O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O

Consequently O
, O
there O
are O
no O
guidelines O
available O
with O
regard O
to O
the O
exercises O
that O
can O
be O
recommended O
and O
difficulties O
are O
encountered O
in O
the O
clinical O
practice O
as O
to O
which O
exercise O
is O
more O
suitable O
to O
the O
patients O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O

Randomized O
controlled O
trial O
. O

Out O
patient O
group O
, O
Department O
of O
Physical O
Medicine O
and O
Rehabilitation O
and O
Medical O
Oncology O
Department O
, O
University O
Hospital O
. O

Fifty-two O
patients O
with O
breast O
cancer O
were O
divided O
into O
either O
pilates O
exercise O
( O
group O
1 O
) O
and O
control O
group O
( O
group O
2 O
) O
. O

Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O

Pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O

Subjects O
were O
assessed O
before O
and O
after O
rehabilitation O
program O
, O
with O
respect O
to O
, O
6-min O
walk O
test O
( O
6MWT O
) O
, O
modified O
sit O
and O
reach O
test O
, O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
, O
Beck O
Depression O
Index O
( O
BDI O
) O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
QLQ O
BR23 O
. O

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6-minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

In O
contrast O
, O
no B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
Group I-Premise
2 I-Premise
after I-Premise
the I-Premise
exercise I-Premise
program I-Premise
in I-Premise
any I-Premise
of I-Premise
parameters I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
pre-exercise I-Premise
period I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

When B-Premise
the I-Premise
two I-Premise
exercise I-Premise
groups I-Premise
were I-Premise
compared I-Premise
, I-Premise
there I-Premise
were I-Premise
significant I-Premise
differences I-Premise
in I-Premise
6MWT I-Premise
in I-Premise
pilates-exercise I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Pilates B-Claim
exercises I-Claim
are I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
female I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

There B-Claim
is I-Claim
a I-Claim
need I-Claim
for I-Claim
further I-Claim
studies I-Claim
so I-Claim
that I-Claim
its I-Claim
effect I-Claim
can I-Claim
be I-Claim
confirmed I-Claim
. I-Claim

This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

Treatment-induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O

A O
number O
of O
studies O
testing O
alpha-tocopherol O
( O
vitamin O
E O
) O
and O
pentoxifylline O
suggest O
evidence O
of O
clinical O
regression O
of O
superficial O
radiation-induced O
fibrosis O
but O
there O
is O
only O
very O
limited O
evidence O
from O
randomised O
trials O
. O

Arm O
lymphoedema O
after O
lymphatic O
radiotherapy O
and O
surgery O
has O
been O
used O
in O
the O
present O
study O
as O
a O
clinical O
system O
for O
testing O
these O
drugs O
in O
a O
double-blind O
placebo-controlled O
randomised O
phase O
II O
trial O
. O

Sixty-eight O
eligible O
research O
volunteers O
with O
a O
minimum O
20 O
% O
increase O
in O
arm O
volume O
at O
a O
median O
15.5 O
years O
( O
range O
2-41 O
) O
after O
axillary/supraclavicular O
radiotherapy O
( O
plus O
axillary O
surgery O
in O
51/68 O
( O
75 O
% O
) O
cases O
) O
were O
randomised O
to O
active O
drugs O
or O
placebo O
. O

All O
volunteers O
were O
given O
dl-alpha O
tocopheryl O
acetate O
500 O
mg O
twice O
a O
day O
orally O
plus O
pentoxifylline O
400 O
mg O
twice O
a O
day O
orally O
, O
or O
corresponding O
placebos O
, O
for O
6 O
months O
. O

The O
primary O
endpoint O
was O
volume O
of O
the O
ipsilateral O
limb O
measured O
opto-electronically O
using O
a O
perometer O
and O
expressed O
as O
a O
percentage O
of O
the O
contralateral O
limb O
volume O
. O

At B-Premise
12 I-Premise
months I-Premise
post-randomisation I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
and I-Premise
control I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
arm I-Premise
volume I-Premise
. I-Premise

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.40 I-Premise
to I-Premise
5.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2.8 I-Premise
to I-Premise
5.1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
mean I-Premise
volume I-Premise
change I-Premise
between I-Premise
randomisation I-Premise
groups I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.6 I-Premise
) I-Premise
, I-Premise
-1.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.1 I-Premise
to I-Premise
3.5 I-Premise
) I-Premise
, I-Premise
nor I-Premise
was I-Premise
there I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
response I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.7 I-Premise
) I-Premise
, I-Premise
where I-Premise
mean I-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
treatment I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
-2.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-7.9 I-Premise
to I-Premise
3.4 I-Premise
) I-Premise
and I-Premise
-1.1 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-3.9 I-Premise
to I-Premise
1.7 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
randomised I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
including I-Premise
tissue I-Premise
induration I-Premise
( I-Premise
fibrosis I-Premise
) I-Premise
in I-Premise
the I-Premise
irradiated I-Premise
breast I-Premise
or I-Premise
chest I-Premise
wall I-Premise
, I-Premise
pectoral I-Premise
fold I-Premise
or I-Premise
supraclavicular I-Premise
fossa I-Premise
, I-Premise
change I-Premise
in I-Premise
photographic I-Premise
breast/chest I-Premise
wall I-Premise
appearance I-Premise
or I-Premise
patient I-Premise
self-assessment I-Premise
of I-Premise
function I-Premise
and I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
at I-Premise
either I-Premise
6 I-Premise
or I-Premise
12 I-Premise
months I-Premise
. I-Premise

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl-alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation-induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

Many O
patients O
with O
advanced O
ovarian O
cancer O
will O
develop O
recurrent O
disease O
. O

For B-Premise
those I-Premise
patients I-Premise
who I-Premise
have I-Premise
recurrence I-Premise
of I-Premise
disease I-Premise
at I-Premise
least I-Premise
6 I-Premise
months I-Premise
after I-Premise
initial I-Premise
therapy I-Premise
, I-Premise
the I-Premise
paclitaxel-platinum I-Premise
combination I-Premise
has I-Premise
been I-Premise
shown I-Premise
to I-Premise
be I-Premise
a I-Premise
superior I-Premise
treatment I-Premise
to I-Premise
platinum I-Premise
monotherapy I-Premise
. I-Premise

However B-Claim
, I-Claim
many I-Claim
patients I-Claim
develop I-Claim
clinically I-Claim
relevant I-Claim
neurotoxicity I-Claim
, I-Claim
frequently I-Claim
resulting I-Claim
in I-Claim
treatment I-Claim
discontinuation I-Claim
. I-Claim

The O
efficacy O
and O
safety O
of O
an O
alternative O
regimen O
that O
does O
not O
show O
significant O
neurotoxicity O
were O
evaluated O
by O
comparing O
gemcitabine-carboplatin O
with O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
in O
a O
Gynecologic O
Cancer O
InterGroup O
trial O
of O
the O
Arbeitsgemeinschaft O
Gynakologische O
Onkologie O
Ovarian O
Cancer O
Study O
Group O
, O
the O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
, O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Gynaecological O
Cancer O
Group O
. O

Participants O
with O
recurrent O
platinum-sensitive O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine-carboplatin O
or O
carboplatin O
every O
21 O
days O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
between O
the O
groups O
. O

From O
September O
1999 O
to O
April O
2002 O
, O
356 O
patients O
( O
178 O
participants O
received O
gemcitabine-carboplatin O
, O
178 O
received O
carboplatin O
only O
) O
were O
randomized O
to O
treatment O
. O

Patients O
received O
six O
cycles O
of O
either O
gemcitabine-carboplatin O
or O
carboplatin O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
for I-Premise
gemcitabine-carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
7.9-9.7 I-Premise
months I-Premise
) I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
5.2-7.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0.72 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.58-0.90 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0032 I-Premise
] I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
for I-Premise
the I-Premise
gemcitabine-carboplatin I-Premise
group I-Premise
was I-Premise
47.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
39.9-54.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
30.9 I-Premise
% I-Premise
for I-Premise
carboplatin I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
24.1-37.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0016 I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.75-1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.7349 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
gemcitabine-carboplatin I-Premise
reported I-Premise
significantly I-Premise
faster I-Premise
palliation I-Premise
of I-Premise
abdominal I-Premise
symptoms I-Premise
and I-Premise
a I-Premise
significantly I-Premise
improved I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Gemcitabine-carboplatin B-Claim
treatment I-Claim
significantly I-Claim
improves I-Claim
the I-Claim
PFS I-Claim
of I-Claim
patients I-Claim
with I-Claim
platinum-sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

The O
combination O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
has O
been O
a O
standard O
treatment O
for O
patients O
with O
poor-prognosis O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
. O

This O
non-inferiority O
design O
trial O
aimed O
to O
determine O
whether O
the O
combination O
of O
gemcitabine O
and O
carboplatin O
( O
GC O
) O
results O
in O
similar O
survival O
but O
is O
less O
toxic O
with O
better O
quality O
of O
life O
. O

Previously O
untreated O
patients O
with O
SCLC O
with O
extensive O
disease O
or O
limited O
stage O
with O
poor O
prognostic O
factors O
were O
randomly O
assigned O
to O
six O
3-weekly O
cycles O
of O
GC O
or O
PE O
. O

241 O
patients O
( O
121 O
GC O
, O
120 O
PE O
) O
were O
recruited O
, O
of O
which O
216 O
( O
90 O
% O
) O
had O
died O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1.01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.77 I-Premise
to I-Premise
1.32 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
with I-Premise
GC I-Premise
and I-Premise
PE I-Premise
was I-Premise
8.0 I-Premise
and I-Premise
8.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
5.9 I-Premise
months I-Premise
with I-Premise
GC I-Premise
and I-Premise
6.3 I-Premise
months I-Premise
with I-Premise
PE I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
myelosuppressions I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
GC I-Premise
( I-Premise
anaemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
2 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
13 I-Premise
% I-Premise
PE I-Premise
";" I-Premise
thrombocytopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
GC I-Premise
vs I-Premise
4 I-Premise
% I-Premise
PE I-Premise
) I-Premise
, I-Premise
but B-Premise
these I-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admissions I-Premise
, I-Premise
infections I-Premise
or I-Premise
fatalities I-Premise
. I-Premise

Grade B-Premise
2-3 I-Premise
alopecia I-Premise
( I-Premise
68 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
17 I-Premise
% I-Premise
GC I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
43 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
26 I-Premise
% I-Premise
GC I-Premise
) I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
PE I-Premise
. I-Premise

Patients O
given O
GC O
received O
more O
chemotherapy O
as O
outpatients O
( O
89 O
% O
GC O
vs O
66 O
% O
PE O
of O
treatment O
cycles O
) O
. O

In B-Premise
QoL I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
PE I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

GC B-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
PE I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
has I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
more I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
. I-Claim

To O
assess O
the O
efficacy O
of O
a O
novel O
coloplasty O
colonic O
pouch O
design O
in O
optimizing O
bowel O
function O
after O
ultralow O
anterior O
resection O
. O

A B-Claim
colonic I-Claim
J-pouch I-Claim
may I-Claim
reduce I-Claim
excessive I-Claim
stool I-Claim
frequency I-Claim
and I-Claim
incontinence I-Claim
after I-Claim
anterior I-Claim
resection I-Claim
, I-Claim
but I-Claim
at I-Claim
the I-Claim
risk I-Claim
of I-Claim
evacuation I-Claim
problems I-Claim
. I-Claim

Experimental B-Claim
surgery I-Claim
on I-Claim
pigs I-Claim
has I-Claim
suggested I-Claim
that I-Claim
a I-Claim
coloplasty I-Claim
pouch I-Claim
( I-Claim
CP I-Claim
) I-Claim
may I-Claim
be I-Claim
a I-Claim
useful I-Claim
alternative I-Claim
. O

Although O
CP O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
J-pouch O
. O

After O
anterior O
resection O
for O
cancer O
, O
patients O
were O
allocated O
to O
either O
J-pouch O
or O
CP-anal O
anastomoses O
. O

Continence O
scoring O
, O
anorectal O
manometry O
, O
and O
endoanal O
ultrasound O
assessments O
were O
made O
before O
surgery O
. O

All O
complications O
were O
recorded O
, O
and O
these O
preoperative O
assessments O
were O
repeated O
at O
4 O
months O
. O

The O
assessments O
were O
repeated O
again O
at O
1 O
year O
, O
and O
a O
quality O
of O
life O
questionnaire O
was O
added O
. O

Eighty-eight O
patients O
were O
recruited O
from O
October O
1998 O
to O
April O
2000 O
. O

Both O
groups O
were O
well O
matched O
for O
age O
, O
gender O
, O
staging O
, O
adjuvant O
therapy O
, O
and O
mean O
follow-up O
. O

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

At B-Premise
4 I-Premise
months I-Premise
, I-Premise
J-pouch I-Premise
patients I-Premise
had I-Premise
10.3 I-Premise
% I-Premise
less I-Premise
stool I-Premise
fragmentation I-Premise
but I-Premise
poorer I-Premise
stool I-Premise
deferment I-Premise
and I-Premise
more I-Premise
nocturnal I-Premise
leakage I-Premise
. I-Premise

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

Coloplasty B-Claim
pouches I-Claim
resulted I-Claim
in I-Claim
more I-Claim
anastomotic I-Claim
leaks I-Claim
and I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
bowel I-Claim
function I-Claim
. I-Claim

At O
present O
, O
the B-Claim
J-pouch I-Claim
remains I-Claim
the I-Claim
benchmark I-Claim
for I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
, I-Claim
and O
due B-Claim
care I-Claim
( I-Claim
including I-Claim
defunctioning I-Claim
stoma I-Claim
) I-Claim
should I-Claim
be I-Claim
exercised I-Claim
in I-Claim
situations I-Claim
requiring I-Claim
CP I-Claim
. I-Claim

From O
1984 O
to O
1989 O
, O
the O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
( O
SAKK O
) O
performed O
a O
randomized O
phase O
III O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small-cell O
lung O
cancer O
. O

406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O

Regimen O
A O
consisted O
of O
PAV O
( O
cisPlatin O
, O
Adriamycin O
, O
VP O
16-213 O
, O
and O
Regimen O
B O
of O
CyMOC O
( O
Cyclophosphamide O
, O
Methotrexate O
, O
Oncovin O
, O
CCNU O
) O
. O

Cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O

patients O
were O
randomized O
to O
receive O
either O
ABABAB O
( O
early O
alternating O
chemotherapy O
) O
or O
AAABBB O
( O
late O
alternating O
chemotherapy O
) O
. O

After O
six O
cycles O
patients O
with O
limited O
disease O
in O
complete O
or O
partial O
remission O
and O
those O
with O
extensive O
disease O
in O
complete O
remission O
received O
irradiation O
to O
the O
primary O
( O
45 O
Gy O
) O
and O
the O
CNS O
( O
36 O
Gy O
) O
. O

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
rate I-Premise
of I-Premise
complete I-Premise
remission I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
long-term I-Premise
survival I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
in I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

In B-Premise
limited I-Premise
disease I-Premise
the I-Premise
estimated I-Premise
percentages I-Premise
of I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
were I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
early I-Premise
and I-Premise
24 I-Premise
% I-Premise
in I-Premise
the I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
arms I-Premise
. I-Premise

Patients B-Premise
with I-Premise
extensive I-Premise
disease I-Premise
survived I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
than I-Premise
on I-Premise
the I-Premise
early I-Premise
alternation I-Premise
regimen I-Premise
( I-Premise
median I-Premise
survival I-Premise
336 I-Premise
days I-Premise
versus I-Premise
301 I-Premise
days I-Premise
, I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
latter I-Premise
patients I-Premise
the I-Premise
received I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
RDI I-Premise
) I-Premise
of I-Premise
cisplatin I-Premise
, I-Premise
adriamycin I-Premise
and I-Premise
etoposide I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
late-alternation I-Premise
arm I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
early I-Premise
alternating I-Premise
chemotherapy I-Premise
rated I-Premise
their I-Premise
tumor I-Premise
symptoms I-Premise
, I-Premise
functional I-Premise
states I-Premise
, I-Premise
fatigue/malaise I-Premise
and I-Premise
restriction I-Premise
of I-Premise
social I-Premise
activity I-Premise
significantly I-Premise
better I-Premise
, I-Premise
reflecting I-Premise
an I-Premise
improved I-Premise
subjective I-Premise
adjustment I-Premise
. I-Premise

Alternating B-Claim
chemotherapy I-Claim
with I-Claim
PAV-CyMOC I-Claim
plus I-Claim
consolidating I-Claim
radiotherapy I-Claim
is I-Claim
a I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
with I-Claim
acceptable I-Claim
toxicity I-Claim
. I-Claim

Whereas O
patients B-Claim
with I-Claim
early I-Claim
alternating I-Claim
chemotherapy I-Claim
achieve I-Claim
a I-Claim
better I-Claim
subjective I-Claim
adjustment I-Claim
, I-Claim
late B-Claim
alternating I-Claim
chemotherapy I-Claim
allows I-Claim
for I-Claim
a I-Claim
higher I-Claim
RDI I-Claim
of I-Claim
cisplatin I-Claim
, I-Claim
adriamycin I-Claim
and I-Claim
etoposide I-Claim
, I-Claim
which I-Claim
results I-Claim
in I-Claim
a I-Claim
significantly I-Claim
longer I-Claim
median I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
disease I-Claim
. I-Claim

Assess O
toxicity O
and O
efficacy O
of O
cisplatin O
( O
Cis O
) O
doublet O
combinations O
in O
advanced O
and O
recurrent O
cervical O
carcinoma O
. O

Patients O
were O
randomly O
assigned O
to O
paclitaxel O
135 O
mg/m O
( O
2 O
) O
over O
24 O
hours O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
2 O
every O
3 O
weeks O
( O
PC O
, O
reference O
arm O
) O
";" O
vinorelbine O
30 O
mg/m O
( O
2 O
) O
days O
1 O
and O
8 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
VC O
) O
";" O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
day O
1 O
and O
8 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
GC O
) O
";" O
or O
topotecan O
0.75 O
mg/m O
( O
2 O
) O
days O
1 O
, O
2 O
, O
and O
3 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
TC O
) O
. O

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

Quality-of-life O
data O
were O
prospectively O
collected O
. O

A O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O

The B-Premise
experimental-to-PC I-Premise
hazard I-Premise
ratios I-Premise
of I-Premise
death I-Premise
were I-Premise
1.15 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.67 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.32 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.91 I-Premise
to I-Premise
1.92 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.26 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.86 I-Premise
to I-Premise
1.82 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratios I-Premise
for I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
were I-Premise
1.36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.97 I-Premise
to I-Premise
1.90 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.39 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.99 I-Premise
to I-Premise
1.96 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.27 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.90 I-Premise
to I-Premise
1.78 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

Response B-Premise
rates I-Premise
( I-Premise
RRs I-Premise
) I-Premise
for I-Premise
PC I-Premise
, I-Premise
VC I-Premise
, I-Premise
GC I-Premise
, I-Premise
and I-Premise
TC I-Premise
were I-Premise
29.1 I-Premise
% I-Premise
, I-Premise
25.9 I-Premise
% I-Premise
, I-Premise
22.3 I-Premise
% I-Premise
, I-Premise
and I-Premise
23.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
arms I-Premise
were I-Premise
comparable I-Premise
with I-Premise
respect I-Premise
to I-Premise
toxicity I-Premise
except I-Premise
for I-Premise
leucopenia I-Premise
, I-Premise
neutropenia I-Premise
, I-Premise
infection I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
. I-Premise

VC B-Claim
, I-Claim
GC I-Claim
, I-Claim
and I-Claim
TC I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
PC I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
( I-Claim
OS I-Claim
) I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
RR I-Claim
, I-Claim
PFS I-Claim
, I-Claim
and I-Claim
OS I-Claim
favors I-Claim
PC I-Claim
. I-Claim

Differences B-Claim
in I-Claim
chemotherapy I-Claim
scheduling I-Claim
, I-Claim
pre-existing I-Claim
morbidity I-Claim
, I-Claim
and I-Claim
toxicity I-Claim
are I-Claim
important I-Claim
in I-Claim
individualizing I-Claim
therapy I-Claim
. I-Claim

To O
report O
5-year O
contrast-enhanced O
magnetic O
resonance O
imaging O
findings O
of O
the O
REST O
trial O
recruits O
who O
underwent O
either O
uterine O
artery O
embolization O
( O
UAE O
) O
or O
myomectomy O
. O

A O
total O
of O
157 O
patients O
were O
randomized O
to O
UAE O
or O
surgery O
( O
hysterectomy O
or O
myomectomy O
) O
. O

Ninety-nine O
patients O
who O
had O
UAE O
and O
eight O
patients O
who O
had O
myomectomy O
were O
analyzed O
. O

MRI O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O

Dominant O
fibroid O
diameter O
, O
uterine O
volume O
, O
total O
fibroid O
infarction O
( O
complete O
100 O
% O
, O
almost O
complete O
90-99 O
% O
, O
partial O
< O
90 O
% O
) O
, O
and O
new O
fibroid O
formation O
were O
the O
main O
parameters O
assessed O
and O
related O
to O
the O
need O
for O
reintervention O
. O

In B-Premise
the I-Premise
UAE I-Premise
group I-Premise
, I-Premise
mean I-Premise
± I-Premise
standard I-Premise
deviation I-Premise
uterine I-Premise
volume I-Premise
was I-Premise
670 I-Premise
± I-Premise
503 I-Premise
, I-Premise
422 I-Premise
± I-Premise
353 I-Premise
, I-Premise
and I-Premise
292 I-Premise
± I-Premise
287 I-Premise
mL I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Mean B-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
was I-Premise
7.6 I-Premise
± I-Premise
3.0 I-Premise
, I-Premise
5.8 I-Premise
± I-Premise
2.9 I-Premise
, I-Premise
and I-Premise
5 I-Premise
± I-Premise
2.9 I-Premise
cm I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
. I-Premise

Fibroid B-Premise
infarction I-Premise
at I-Premise
6 I-Premise
months I-Premise
was I-Premise
complete I-Premise
in I-Premise
35 I-Premise
% I-Premise
of I-Premise
women I-Premise
, I-Premise
almost I-Premise
complete I-Premise
in I-Premise
29 I-Premise
% I-Premise
, I-Premise
and I-Premise
partial I-Premise
in I-Premise
36 I-Premise
% I-Premise
. I-Premise

Need B-Premise
for I-Premise
reintervention I-Premise
was I-Premise
19 I-Premise
, I-Premise
10 I-Premise
, I-Premise
and I-Premise
33 I-Premise
% I-Premise
in I-Premise
these I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.123 I-Premise
) I-Premise
. I-Premise

No B-Premise
myomectomy I-Premise
cases I-Premise
had I-Premise
further I-Premise
intervention I-Premise
. I-Premise

At B-Premise
5 I-Premise
years I-Premise
, I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
new I-Premise
fibroid I-Premise
was I-Premise
60 I-Premise
% I-Premise
in I-Premise
the I-Premise
myomectomy I-Premise
group I-Premise
and I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
) I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

Complete B-Claim
fibroid I-Claim
infarction I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
total I-Claim
freedom I-Claim
from I-Claim
a I-Claim
subsequent I-Claim
reintervention I-Claim
. I-Claim

New B-Claim
fibroid I-Claim
formation I-Claim
is I-Claim
significantly I-Claim
higher I-Claim
after I-Claim
myomectomy I-Claim
. I-Claim

The O
current O
study O
examined O
the O
effect O
of O
recombinant O
human O
deoxyribonuclease O
( O
rhDNase O
) O
on O
quality O
of O
life O
( O
QOL O
) O
measures O
, O
clinical O
improvement O
, O
and O
DNA O
content O
of O
thick O
oropharyngeal O
secretions O
( O
OPS O
) O
in O
patients O
with O
head-and-neck O
( O
H O
& O
N O
) O
cancers O
. O

Thirty-six O
patients O
with O
local-regional O
advanced O
H O
& O
amp O
";" O
N O
cancer O
receiving O
chemoradiationtherapy O
( O
CRT O
) O
were O
randomized O
to O
receive O
either O
placebo O
or O
rhDNase O
. O

Endpoints O
included O
MD O
Anderson O
Symptom O
Inventory-Head O
and O
Neck O
( O
MDASI-HN O
) O
and O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-NH O
) O
scores O
, O
along O
with O
clinical O
assessment O
and O
DNA O
concentration O
of O
OPS O
. O

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
outcomes I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

Both B-Premise
groups I-Premise
showed I-Premise
an I-Premise
increase I-Premise
in I-Premise
symptom I-Premise
and I-Premise
interference I-Premise
scores I-Premise
, I-Premise
although O
patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
both I-Premise
scores I-Premise
during I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow-up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibited I-Premise
significant I-Premise
clinical I-Premise
improvement I-Premise
in I-Premise
OPS I-Premise
, I-Premise
blindly I-Premise
assessed I-Premise
by I-Premise
a I-Premise
physician I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
67 I-Premise
% I-Premise
vs I-Premise
27 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P=.046 I-Premise
) I-Premise
. I-Premise

The B-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
no I-Premise
change I-Premise
in I-Premise
OPS-DNA I-Premise
concentration I-Premise
, I-Premise
although O
the B-Premise
placebo I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
DNA I-Premise
concentration I-Premise
during I-Premise
the I-Premise
drug I-Premise
trial I-Premise
( I-Premise
P=.045 I-Premise
) I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
differences I-Claim
in I-Claim
acute I-Claim
toxicities I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim

Our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhDNase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
QOL I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

Further O
investigation O
in O
larger O
numbers O
of O
patients O
is O
warranted O
. O

Thalidomide O
with O
melphalan/prednisone O
( O
MPT O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
MM O
) O
based O
on O
five O
randomized O
trials O
. O

In O
one O
of O
these O
trials O
, O
HOVON49 O
, O
a O
prospective O
health-related O
quality-of-life O
( O
HRQoL O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
QoL O
. O

Patients O
aged O
> O
65 O
years O
with O
newly O
diagnosed O
MM O
were O
randomized O
to O
receive O
melphalan O
plus O
prednisone O
( O
MP O
) O
or O
MPT O
, O
followed O
by O
thalidomide O
maintenance O
in O
the O
MPT O
arm O
. O

Two O
hundred O
eighty-four O
patients O
were O
included O
in O
this O
side O
study O
( O
MP O
, O
n=149 O
";" O
MPT O
n=135 O
) O
. O

HRQoL O
was O
assessed O
with O
the O
EORTC O
Core O
QoL O
Questionnaire O
( O
QLQ-C30 O
) O
and O
the O
myeloma-specific O
module O
( O
QLQ-MY24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
physical I-Premise
function I-Premise
( I-Premise
P=0.044 I-Premise
) I-Premise
and I-Premise
constipation I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
during I-Premise
induction I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MP I-Premise
arm I-Premise
. I-Premise

During B-Premise
thalidomide I-Premise
maintenance I-Premise
, I-Premise
the I-Premise
scores I-Premise
for I-Premise
the I-Premise
QLQ-MY24 I-Premise
paraesthesia I-Premise
became I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
MPT I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P=0.12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ-MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P=0.086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

The B-Premise
overall I-Premise
QoL-scale I-Premise
QLQ-C30-HRQoL I-Premise
showed I-Premise
a I-Premise
significant I-Premise
time I-Premise
trend I-Premise
towards I-Premise
more I-Premise
favourable I-Premise
mean I-Premise
values I-Premise
during I-Premise
protocol I-Premise
treatment I-Premise
without I-Premise
differences I-Premise
between I-Premise
MP I-Premise
and I-Premise
MPT I-Premise
. I-Premise

For B-Premise
the I-Premise
QLQ-C30 I-Premise
subscales I-Premise
emotional I-Premise
function I-Premise
and I-Premise
future I-Premise
perspectives I-Premise
, I-Premise
difference I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MPT I-Premise
arm I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
treatment I-Premise
was I-Premise
observed I-Premise
( I-Premise
P=0.018 I-Premise
and I-Premise
P=0.045 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
with I-Premise
no I-Premise
significant I-Premise
'time I-Premise
× I-Premise
arm I-Premise
' I-Premise
interaction I-Premise
, I-Premise
indicating I-Premise
a I-Premise
persistent I-Premise
better I-Premise
patient I-Premise
perspective I-Premise
with I-Premise
MPT I-Premise
treatment I-Premise
. I-Premise

This B-Claim
study I-Claim
shows I-Claim
that I-Claim
the I-Claim
higher I-Claim
frequency I-Claim
of I-Claim
toxicity I-Claim
associated I-Claim
with I-Claim
MPT I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQoL I-Claim
and I-Claim
that I-Claim
MPT I-Claim
holds I-Claim
a I-Claim
better I-Claim
patient I-Claim
perspective I-Claim
. I-Claim

Paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-associated O
Kaposi O
sarcoma O
( O
KS O
) O
. O

A O
randomized O
trial O
comparing O
the O
efficacy O
and O
toxicity O
of O
paclitaxel O
and O
PLD O
was O
performed O
, O
and O
the O
effects O
of O
therapy O
on O
symptom O
palliation O
and O
quality O
of O
life O
were O
determined O
. O

Patients O
with O
advanced O
HIV-associated O
KS O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg/m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
PLD O
at O
a O
dose O
of O
20 O
mg/m2 O
iv O
every O
3 O
weeks O
. O

The O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O

The O
study O
included O
73 O
analyzable O
patients O
enrolled O
between O
1998 O
and O
2002 O
, O
including O
36 O
in O
the O
paclitaxel O
arm O
and O
37 O
in O
the O
PLD O
arm O
";" O
73 O
% O
of O
patients O
received O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
and O
32 O
% O
had O
an O
undetectable O
viral O
load O
( O
< O
400 O
copies/mL O
) O
. O

Treatment B-Premise
was I-Premise
associated I-Premise
with I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
( I-Premise
P=.024 I-Premise
) I-Premise
and I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Of B-Premise
the I-Premise
36 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
that I-Premise
pain I-Premise
interfered I-Premise
with I-Premise
their I-Premise
normal I-Premise
work I-Premise
or I-Premise
activities I-Premise
at I-Premise
baseline I-Premise
, I-Premise
25 I-Premise
( I-Premise
69 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

Of B-Premise
the I-Premise
41 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
swelling I-Premise
at I-Premise
baseline I-Premise
, I-Premise
38 I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

Comparing B-Premise
the I-Premise
paclitaxel I-Premise
and I-Premise
PLD I-Premise
arms I-Premise
revealed I-Premise
comparable I-Premise
response I-Premise
rates I-Premise
( I-Premise
56 I-Premise
% I-Premise
vs I-Premise
46 I-Premise
% I-Premise
";" I-Premise
P=.49 I-Premise
) I-Premise
, I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
17.5 I-Premise
months I-Premise
vs I-Premise
12.2 I-Premise
months I-Premise
";" I-Premise
P=.66 I-Premise
) I-Premise
, I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
( I-Premise
79 I-Premise
% I-Premise
vs I-Premise
78 I-Premise
% I-Premise
";" I-Premise
P=.75 I-Premise
) I-Premise
, I-Premise
but B-Premise
somewhat I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
5 I-Premise
toxicity I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
84 I-Premise
% I-Premise
vs I-Premise
66 I-Premise
% I-Premise
";" I-Premise
P=.077 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
either I-Claim
paclitaxel I-Claim
or I-Claim
PLD I-Claim
appears I-Claim
to I-Claim
produce I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
pain I-Claim
and I-Claim
swelling I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
symptomatic I-Claim
, I-Claim
HIV-associated I-Claim
KS I-Claim
treated I-Claim
in I-Claim
the I-Claim
HAART I-Claim
era I-Claim
. I-Claim

The O
phase O
3 O
VISTA O
study O
in O
transplant-ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib-melphalan-prednisone O
( O
VMP O
";" O
nine O
6-wk O
cycles O
) O
vs. O
melphalan-prednisone O
( O
MP O
) O
but O
also O
increased O
toxicity O
. O

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

The O
phase O
3 O
VISTA O
study O
in O
transplant-ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib-melphalan-prednisone O
( O
VMP O
";" O
nine O
6-wk O
cycles O
) O
vs. O
melphalan-prednisone O
( O
MP O
) O
but O
also O
increased O
toxicity O
. O

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

EORTC O
QLQ-C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end-of-treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

EORTC O
QLQ-C30 O
scores O
were O
evaluated O
among O
patients O
with O
a O
valid O
baseline O
and O
at O
least O
one O
post-baseline O
HRQoL O
assessment O
. O

At O
baseline O
, O
domain O
scores O
were O
similar O
between O
arms O
. O

By B-Premise
cycle I-Premise
4 I-Premise
, I-Premise
mean I-Premise
differences I-Premise
were I-Premise
clinically I-Premise
meaningful I-Premise
for I-Premise
most I-Premise
domains I-Premise
, I-Premise
indicating I-Premise
poorer I-Premise
health I-Premise
status I-Premise
with I-Premise
VMP I-Premise
. I-Premise

From B-Premise
cycle I-Premise
5 I-Premise
onwards I-Premise
, I-Premise
improvements I-Premise
relative I-Premise
to I-Premise
baseline/MP I-Premise
were I-Premise
observed I-Premise
for I-Premise
all I-Premise
domains I-Premise
with I-Premise
VMP I-Premise
. I-Premise

Mean B-Premise
scores I-Premise
were I-Premise
generally I-Premise
improved I-Premise
by I-Premise
the I-Premise
end-of-treatment I-Premise
assessment I-Premise
vs. I-Premise
baseline I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end-of-treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

Multivariate B-Premise
analysis I-Premise
showed I-Premise
a I-Premise
significant I-Premise
impact I-Premise
of I-Premise
duration I-Premise
of I-Premise
response/CR I-Premise
on I-Premise
improving I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
pain I-Premise
, I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
scores I-Premise
. I-Premise

Analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
HRQoL I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim

These B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
HRQoL I-Claim
decrements I-Claim
with I-Claim
VMP I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
HRQoL I-Claim
vs. I-Claim
MP I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim

However B-Claim
, I-Claim
HRQoL I-Claim
is I-Claim
not I-Claim
compromised I-Claim
in I-Claim
the I-Claim
long I-Claim
term I-Claim
, I-Claim
recovering I-Claim
by I-Claim
the I-Claim
end-of-treatment I-Claim
visit I-Claim
to I-Claim
be I-Claim
comparable I-Claim
vs. I-Claim
MP I-Claim
. I-Claim

Chemotherapy B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
for I-Claim
good I-Claim
performance I-Claim
status I-Claim
( I-Claim
PS I-Claim
) I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Targeted B-Claim
therapies I-Claim
may I-Claim
improve I-Claim
chemotherapy I-Claim
effectiveness I-Claim
without I-Claim
worsening I-Claim
toxicity I-Claim
. I-Claim

SGN-15 O
is O
an O
antibody-drug O
conjugate O
( O
ADC O
) O
, O
consisting O
of O
a O
chimeric O
murine O
monoclonal O
antibody O
recognizing O
the O
Lewis O
Y O
( O
Le O
( O
y O
) O
) O
antigen O
, O
conjugated O
to O
doxorubicin O
. O

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

SGN-15 B-Premise
was I-Premise
active I-Premise
against I-Premise
Le I-Premise
( I-Premise
y I-Premise
) I-Premise
-positive I-Premise
tumors I-Premise
in I-Premise
early I-Premise
phase I-Premise
clinical I-Premise
trials I-Premise
and I-Premise
was I-Premise
synergistic I-Premise
with I-Premise
docetaxel I-Premise
in I-Premise
preclinical I-Premise
experiments I-Premise
. I-Premise

This O
Phase O
II O
, O
open-label O
study O
was O
conducted O
to O
confirm O
the O
activity O
of O
SGN-15 O
plus O
docetaxel O
in O
previously O
treated O
NSCLC O
patients O
. O

Sixty-two O
patients O
with O
recurrent O
or O
metastatic O
NSCLC O
expressing O
Le O
( O
y O
) O
, O
one O
or O
two O
prior O
chemotherapy O
regimens O
, O
and O
PS O
< O
or O
2 O
were O
randomized O
2:1 O
to O
receive O
SGN-15 O
200 O
mg/m2/week O
with O
docetaxel O
35 O
mg/m2/week O
( O
Arm O
A O
) O
or O
docetaxel O
35 O
mg/m2/week O
alone O
( O
Arm O
B O
) O
for O
6 O
of O
8 O
weeks O
. O

Intrapatient O
dose-escalation O
of O
SGN-15 O
to O
350 O
mg/m2 O
was O
permitted O
in O
the O
second O
half O
of O
the O
study O
. O

Endpoints O
were O
survival O
, O
safety O
, O
efficacy O
, O
and O
quality O
of O
life O
. O

Forty O
patients O
on O
Arm O
A O
and O
19 O
on O
Arm O
B O
received O
at O
least O
one O
treatment O
. O

Patients B-Premise
on I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
had I-Premise
median I-Premise
survivals I-Premise
of I-Premise
31.4 I-Premise
and I-Premise
25.3 I-Premise
weeks I-Premise
, I-Premise
12-month I-Premise
survivals I-Premise
of I-Premise
29 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
, I-Premise
and I-Premise
18-month I-Premise
survivals I-Premise
of I-Premise
18 I-Premise
% I-Premise
and I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. O

Toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

QOL B-Premise
analyses I-Premise
favored I-Premise
Arm I-Premise
A. I-Premise
SGN-15 B-Claim
plus I-Claim
docetaxel I-Claim
is I-Claim
a I-Claim
well-tolerated I-Claim
and I-Claim
active I-Claim
second I-Claim
and I-Claim
third I-Claim
line I-Claim
treatment I-Claim
for I-Claim
NSCLC I-Claim
patients I-Claim
. O

Ongoing O
studies O
are O
exploring O
alternate O
schedules O
to O
maximize O
synergy O
between O
these O
agents O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

We O
compared O
the O
use O
of O
radiotherapy O
plus O
short-term O
androgen O
suppression O
with O
the O
use O
of O
radiotherapy O
plus O
long-term O
androgen O
suppression O
in O
the O
treatment O
of O
locally O
advanced O
prostate O
cancer O
. O

We O
randomly O
assigned O
patients O
with O
locally O
advanced O
prostate O
cancer O
who O
had O
received O
external-beam O
radiotherapy O
plus O
6 O
months O
of O
androgen O
suppression O
to O
two O
groups O
, O
one O
to O
receive O
no O
further O
treatment O
( O
short-term O
suppression O
) O
and O
the O
other O
to O
receive O
2.5 O
years O
of O
further O
treatment O
with O
a O
luteinizing O
hormone-releasing O
hormone O
agonist O
( O
long-term O
suppression O
) O
. O

An O
outcome O
of O
noninferiority O
of O
short-term O
androgen O
suppression O
as O
compared O
with O
long-term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1.35 O
for O
overall O
survival O
, O
with O
a O
one-sided O
alpha O
level O
of O
0.05 O
. O

An O
interim O
analysis O
showed O
futility O
, O
and O
the O
results O
are O
presented O
with O
an O
adjusted O
one-sided O
alpha O
level O
of O
0.0429 O
. O

A O
total O
of O
1113 O
men O
were O
registered O
, O
of O
whom O
970 O
were O
randomly O
assigned O
, O
483 O
to O
short-term O
suppression O
and O
487 O
to O
long-term O
suppression O
. O

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.4 I-Premise
years I-Premise
, I-Premise
132 I-Premise
patients I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
98 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
had I-Premise
died I-Premise
";" I-Premise
the B-Premise
number I-Premise
of I-Premise
deaths I-Premise
due I-Premise
to I-Premise
prostate I-Premise
cancer I-Premise
was I-Premise
47 I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
29 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
. I-Premise

The B-Premise
5-year I-Premise
overall I-Premise
mortality I-Premise
for I-Premise
short-term I-Premise
and I-Premise
long-term I-Premise
suppression I-Premise
was I-Premise
19.0 I-Premise
% I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
the O
observed O
hazard O
ratio O
was O
1.42 O
( O
upper O
95.71 O
% O
confidence O
limit O
, O
1.79 O
";" O
P=0.65 O
for O
noninferiority O
) O
. O

Adverse B-Premise
events I-Premise
in I-Premise
both I-Premise
groups I-Premise
included I-Premise
fatigue I-Premise
, I-Premise
diminished I-Premise
sexual I-Premise
function I-Premise
, I-Premise
and I-Premise
hot I-Premise
flushes I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

Cancer O
cachexia O
is O
a O
common O
problem O
among O
advanced O
cancer O
patients O
. O

A O
mixture O
of O
beta-hydroxyl O
beta-methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
( O
HMB/Arg/Gln O
) O
previously O
showed O
activity O
for O
increasing O
lean O
body O
mass O
( O
LBM O
) O
among O
patients O
with O
cancer O
cachexia O
. O

Therefore O
a O
phase O
III O
trial O
was O
implemented O
to O
confirm O
this O
activity O
. O

Four O
hundred O
seventy-two O
advanced O
cancer O
patients O
with O
between O
2 O
% O
and O
10 O
% O
weight O
loss O
were O
randomized O
to O
a O
mixture O
of O
beta-hydroxyl O
beta-methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
or O
an O
isonitrogenous O
, O
isocaloric O
control O
mixture O
taken O
twice O
a O
day O
for O
8 O
weeks O
. O

Lean O
body O
mass O
was O
estimated O
by O
bioimpedance O
and O
skin-fold O
measurements O
. O

Body O
plethysmography O
was O
used O
when O
available O
. O

Weight O
, O
the O
Schwartz O
Fatigue O
Scale O
, O
and O
the O
Spitzer O
Quality O
of O
Life O
Scale O
were O
also O
measured O
. O

Only O
37 O
% O
of O
the O
patients O
completed O
protocol O
treatment O
. O

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

However O
, O
loss O
of O
power O
was O
not O
an O
issue O
because O
of O
the O
planned O
large O
target O
sample O
size O
. O

Based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8-week O
lean O
body O
mass O
between O
the O
two O
arms O
. O

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
there I-Premise
were I-Premise
again I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
. I-Premise

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

This B-Claim
trial I-Claim
was I-Claim
unable I-Claim
to I-Claim
adequately I-Claim
test I-Claim
the I-Claim
ability I-Claim
of I-Claim
beta-hydroxy I-Claim
beta-methylbutyrate I-Claim
, I-Claim
glutamine I-Claim
, I-Claim
and I-Claim
arginine I-Claim
to I-Claim
reverse I-Claim
or I-Claim
prevent I-Claim
lean I-Claim
body I-Claim
mass I-Claim
wasting I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8-week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow-up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O

However O
, O
there O
was O
a O
strong O
trend O
towards O
an O
increased O
body O
mass O
among O
patients O
taking O
the O
Juven O
compound O
using O
the O
secondary O
endpoint O
of O
AUC O
. O

To O
assess O
the O
safety O
, O
tolerability O
and O
efficacy O
of O
abatacept O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
who O
had O
failed O
anti-tumour O
necrosis O
factor O
( O
TNF O
) O
therapy O
and O
were O
switched O
to O
abatacept O
directly O
or O
after O
completing O
washout O
. O

In O
this O
international O
, O
6-month O
, O
open-label O
trial O
, O
patients O
had O
active O
RA O
, O
an O
inadequate O
response O
to O
anti-TNF O
therapy O
for O
3 O
months O
or O
longer O
and O
a O
disease O
activity O
score O
in O
28 O
joints O
( O
DAS28 O
( O
C-reactive O
protein O
";" O
CRP O
) O
of O
5.1 O
or O
greater O
. O

" O
Washout O
" O
patients O
discontinued O
anti-TNF O
therapy O
2 O
months O
or O
longer O
pre-screening O
";" O
" O
direct-switch O
100" O
patients O
began O
abatacept O
( O
approximately O
10 O
mg/kg O
) O
at O
their O
next O
scheduled O
anti-TNF O
therapy O
dose O
. O

1046 O
patients O
were O
treated O
( O
449 O
washout O
, O
597 O
direct-switch O
";" O
baseline O
characteristics O
were O
similar O
between O
groups O
) O
. O

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AE I-Premise
";" I-Premise
78.0 I-Premise
% I-Premise
vs I-Premise
79.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
serious I-Premise
AE I-Premise
( I-Premise
11.1 I-Premise
% I-Premise
vs I-Premise
9.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
discontinuations I-Premise
due I-Premise
to I-Premise
AE I-Premise
( I-Premise
3.8 I-Premise
% I-Premise
vs I-Premise
4.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
serious I-Premise
AE I-Premise
( I-Premise
2.0 I-Premise
% I-Premise
vs I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
were I-Premise
comparable I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct-switch I-Premise
patients I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct-switch I-Premise
patients I-Premise
, I-Premise
similar I-Premise
clinically I-Premise
meaningful I-Premise
improvements I-Premise
were I-Premise
seen I-Premise
in I-Premise
DAS28 I-Premise
( I-Premise
CRP I-Premise
) I-Premise
( I-Premise
> I-Premise
or I-Premise
=1.2 I-Premise
unit I-Premise
improvement I-Premise
, I-Premise
59.5 I-Premise
% I-Premise
vs I-Premise
53.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
low I-Premise
disease I-Premise
activity I-Premise
state I-Premise
, I-Premise
22.5 I-Premise
% I-Premise
vs I-Premise
22.3 I-Premise
% I-Premise
";" I-Premise
DAS28-defined I-Premise
remission I-Premise
, I-Premise
12.0 I-Premise
% I-Premise
vs I-Premise
13.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
function I-Premise
( I-Premise
health I-Premise
assessment I-Premise
questionnaire I-Premise
disability I-Premise
index I-Premise
> I-Premise
or I-Premise
=0.22 I-Premise
improvement I-Premise
";" I-Premise
46.3 I-Premise
% I-Premise
vs I-Premise
47.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
mean I-Premise
change I-Premise
in I-Premise
short-form I-Premise
36 I-Premise
scores I-Premise
: I-Premise
physical I-Premise
component I-Premise
summary I-Premise
, I-Premise
5.5 I-Premise
vs I-Premise
6.1 I-Premise
";" I-Premise
mental I-Premise
component I-Premise
summary I-Premise
, I-Premise
4.8 I-Premise
vs I-Premise
5.4 I-Premise
) I-Premise
. I-Premise

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti-TNF I-Claim
therapy I-Claim
. I-Claim

Results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti-TNF I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

To O
assess O
patient-reported O
prostate O
cancer-specific O
quality O
of O
life O
2 O
and O
3 O
years O
after O
radiotherapy O
to O
the O
prostate O
in O
a O
randomized O
dose-escalation O
trial O
of O
70 O
versus O
78 O
Gy O
conducted O
from O
1993 O
to O
1998 O
. O

Two O
years O
after O
completing O
radiotherapy O
, O
a O
questionnaire O
that O
assessed O
bladder O
, O
rectal O
, O
and O
sexual O
function O
was O
sent O
to O
301 O
patients O
in O
the O
study O
. O

Three O
years O
after O
treatment O
, O
a O
second O
questionnaire O
was O
sent O
to O
the O
175 O
patients O
with O
adequate O
follow-up O
. O

Three B-Premise
years I-Premise
after I-Premise
radiotherapy I-Premise
, I-Premise
urinary I-Premise
incontinence I-Premise
was I-Premise
reported I-Premise
by I-Premise
35 I-Premise
% I-Premise
of I-Premise
patients I-Premise
, I-Premise
but I-Premise
only I-Premise
6 I-Premise
% I-Premise
required I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
pad I-Premise
or I-Premise
other I-Premise
protective I-Premise
device I-Premise
. I-Premise

Patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3-year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
33 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
rectal I-Premise
bleeding I-Premise
compared I-Premise
with I-Premise
47 I-Premise
% I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
78-Gy I-Premise
arm I-Premise
reported I-Premise
more I-Premise
frequent I-Premise
bowel I-Premise
movements I-Premise
at I-Premise
3 I-Premise
years I-Premise
and I-Premise
less I-Premise
change I-Premise
in I-Premise
bowel I-Premise
function I-Premise
at I-Premise
2 I-Premise
years I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
70-Gy I-Premise
arm I-Premise
. I-Premise

Before B-Premise
radiotherapy I-Premise
, I-Premise
84 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
erections I-Premise
adequate I-Premise
for I-Premise
intercourse I-Premise
at I-Premise
least I-Premise
a I-Premise
few I-Premise
times I-Premise
during I-Premise
the I-Premise
previous I-Premise
year I-Premise
. I-Premise

After B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

By B-Claim
patient-reported I-Claim
questionnaire I-Claim
, I-Claim
78 I-Claim
Gy I-Claim
produced I-Claim
an I-Claim
increase I-Claim
in I-Claim
bowel I-Claim
movement I-Claim
frequency I-Claim
and I-Claim
no I-Claim
increase I-Claim
in I-Claim
bladder I-Claim
or I-Claim
sexual I-Claim
side I-Claim
effects I-Claim
at I-Claim
3 I-Claim
years I-Claim
compared I-Claim
with I-Claim
70 I-Claim
Gy I-Claim
. I-Claim

Comparing B-Claim
the I-Claim
results I-Claim
2 I-Claim
and I-Claim
3 I-Claim
years I-Claim
after I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
rectal I-Claim
bleeding I-Claim
had I-Claim
improved I-Claim
, I-Claim
erectile I-Claim
function I-Claim
had I-Claim
decreased I-Claim
, I-Claim
and I-Claim
urinary I-Claim
urge I-Claim
incontinence I-Claim
had I-Claim
increased I-Claim
. I-Claim

Due O
to O
the O
various O
inter-individual O
differences O
in O
the O
biological O
characteristics O
of O
tumor O
cells O
, O
as O
well O
as O
issues O
on O
the O
efficacy O
, O
adverse O
reactions O
, O
and O
defects O
of O
existing O
drugs O
, O
we O
compared O
the O
clinical O
efficacy O
and O
toxicity O
of O
pemetrexed O
and O
gemcitabine O
combined O
with O
cisplatin O
for O
the O
treatment O
of O
previously O
untreated O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

251 O
patients O
were O
randomly O
divided O
into O
pemetrexed O
combined O
with O
cisplatin O
group O
( O
PP O
group O
) O
with O
127 O
cases O
and O
gemcitabine O
combined O
with O
cisplatin O
group O
( O
GP O
group O
) O
with O
124 O
cases O
. O

PP O
group O
received O
pemetrexed O
500 O
mg/m² O
iv O
infusion O
d1 O
and O
cisplatin O
75 O
mg/m² O
iv O
infusion O
d1 O
, O
whereas O
GP O
group O
received O
gemcitabine O
1,000 O
mg/m² O
iv O
infusion O
d1,8 O
and O
cisplatin O
75 O
mg/m² O
iv O
infusion O
d1 O
. O

The O
treatment O
cycle O
was O
once O
every O
three O
weeks O
. O

In O
addition O
, O
folic O
acid O
, O
vitamin O
B12 O
, O
and O
dexamethasone O
were O
administered O
in O
both O
groups O
. O

The B-Premise
total I-Premise
clinical I-Premise
effective I-Premise
rates I-Premise
in I-Premise
PP I-Premise
group I-Premise
and I-Premise
GP I-Premise
group I-Premise
were I-Premise
25.20 I-Premise
% I-Premise
and I-Premise
17.74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
total I-Premise
efficiencies I-Premise
of I-Premise
non-squamous I-Premise
cell I-Premise
carcinoma I-Premise
were I-Premise
27.62 I-Premise
% I-Premise
and I-Premise
16.00 I-Premise
% I-Premise
. I-Premise

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
16.9 I-Premise
and I-Premise
17.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
59.62 I-Premise
% I-Premise
and I-Premise
65.87 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
1 I-Premise
year I-Premise
and I-Premise
27.28 I-Premise
% I-Premise
and I-Premise
27.93 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
2 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
total I-Premise
efficacy I-Premise
of I-Premise
non-squamous I-Premise
cell I-Premise
carcinoma I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
GP I-Premise
group I-Premise
. I-Premise

The B-Premise
results I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

However O
, O
there O
were O
no O
significant O
differences O
in O
total O
response O
rates O
, O
tumor O
progression O
duration O
, O
and O
median O
survival O
rates O
of O
1 O
and O
2 O
years O
. O

The B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
GP I-Premise
group I-Premise
. I-Premise

The O
results O
were O
statistically O
significant O
. O

The B-Claim
clinical I-Claim
efficacy I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gemcitabine I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
previously I-Claim
untreated I-Claim
advanced I-Claim
NSCLC I-Claim
was I-Claim
roughly I-Claim
the I-Claim
same I-Claim
, I-Claim
but B-Claim
the I-Claim
adverse I-Claim
reactions I-Claim
decreased I-Claim
significantly I-Claim
in I-Claim
the I-Claim
PP I-Claim
group I-Claim
compared I-Claim
with I-Claim
those I-Claim
in I-Claim
the I-Claim
GP I-Claim
group I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

We O
compared O
a O
policy O
of O
three O
vs O
six O
courses O
of O
new-generation O
platinum-based O
combination O
chemotherapy O
with O
regard O
to O
effects O
on O
quality O
of O
life O
( O
QoL O
) O
and O
survival O
. O

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0-2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
's O
formula O
, O
equivalent O
to O
Calvert O
's O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
-2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3-week O
cycle O
. O

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
QLQ-LC13 O
, O
and O
overall O
survival O
. O

Secondary O
end O
points O
were O
progression-free O
survival O
and O
need O
of O
palliative O
radiotherapy O
. O

Two O
hundred O
and O
ninety-seven O
patients O
were O
randomised O
( O
C3 O
150 O
, O
C6 O
147 O
) O
. O

Their O
median O
age O
was O
65 O
years O
, O
30 O
% O
had O
PS O
2 O
and O
76 O
% O
stage O
IV O
disease O
. O

Seventy-eight O
and O
54 O
% O
of O
C3 O
and O
C6 O
patients O
, O
respectively O
, O
completed O
all O
scheduled O
chemotherapy O
courses O
. O

Compliance O
with O
QoL O
questionnaires O
was O
88 O
% O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
group I-Premise
differences I-Premise
in I-Premise
global I-Premise
QoL I-Premise
, I-Premise
pain I-Premise
or I-Premise
fatigue I-Premise
up I-Premise
to I-Premise
26 I-Premise
weeks I-Premise
. I-Premise

The B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
C3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise

Median B-Premise
survival I-Premise
in I-Premise
the I-Premise
C3 I-Premise
group I-Premise
was I-Premise
28 I-Premise
vs I-Premise
32 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C6 I-Premise
group I-Premise
( I-Premise
P=0.75 I-Premise
, I-Premise
HR I-Premise
1.04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.82-1.31 I-Premise
) I-Premise
. I-Premise

One- B-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
and I-Premise
9 I-Premise
% I-Premise
vs I-Premise
25 I-Premise
and I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
16 I-Premise
and I-Premise
21 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P=0.21 I-Premise
, I-Premise
HR I-Premise
0.86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.68-1.08 I-Premise
) I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

We O
carried O
out O
a O
randomized O
phase O
II O
trial O
to O
select O
one O
of O
the O
following O
treatment O
regimens O
for O
further O
investigation O
: O
weekly O
irinotecan O
at O
a O
dose O
of O
70 O
mg/m O
( O
2 O
) O
days O
1 O
, O
8 O
, O
15 O
, O
22 O
, O
29 O
( O
arm O
A O
) O
or O
3-weekly O
irinotecan O
at O
a O
dose O
of O
300/240 O
mg/m O
( O
2 O
) O
day O
1 O
and O
days O
22 O
( O
arm O
B O
) O
in O
combination O
with O
capecitabine O
1000 O
mg/m O
( O
2 O
) O
twice O
daily O
days O
1-14 O
and O
days O
22-35 O
every O
6 O
weeks O
. O

Seventy-five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O

The O
two O
arms O
were O
well O
balanced O
for O
relevant O
patient O
and O
disease O
characteristics O
. O

The B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2/3 I-Premise
alopecia I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

Other B-Premise
grade I-Premise
3/4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
rare I-Premise
( I-Premise
< I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
34 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
20 I-Premise
% I-Premise
to I-Premise
51 I-Premise
% I-Premise
] I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
20 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
6.9 I-Premise
( I-Premise
4.6-10.1 I-Premise
) I-Premise
and I-Premise
9.2 I-Premise
( I-Premise
7.9-11.5 I-Premise
) I-Premise
months I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
17.4 I-Premise
( I-Premise
12.6-23.0+ I-Premise
) I-Premise
and I-Premise
24.7 I-Premise
( I-Premise
16.3-26.4+ I-Premise
) I-Premise
months I-Premise
. I-Premise

Patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non-responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise

The O
primary O
end O
point O
of O
this O
study O
was O
the O
objective O
response O
rate O
and O
based O
on O
the O
statistical O
design O
of O
the O
trial O
, O
the O
3-weekly O
irinotecan O
schedule O
was O
selected O
over O
weekly O
irinotecan O
administration O
. O

The B-Claim
3-weekly I-Claim
irinotecan I-Claim
schedule I-Claim
also I-Claim
seemed I-Claim
advantageous I-Claim
in I-Claim
terms I-Claim
of I-Claim
grade I-Claim
3/4 I-Claim
diarrhea I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
overall I-Claim
survival I-Claim
and I-Claim
patient I-Claim
convenience I-Claim
, I-Claim
but B-Claim
the I-Claim
study I-Claim
was I-Claim
not I-Claim
designed I-Claim
to I-Claim
detect I-Claim
differences I-Claim
in I-Claim
these I-Claim
parameters I-Claim
. I-Claim

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

To O
compare O
protracted O
venous O
infusion O
( O
PVI O
) O
5-fluorouracil O
( O
5-FU O
) O
with O
and O
without O
mitomycin O
C O
( O
MMC O
) O
in O
a O
prospectively O
randomised O
study O
and O
analyse O
for O
tumour O
response O
, O
survival O
, O
toxicity O
and O
quality O
of O
life O
( O
QL O
) O
. O

Two O
hundred O
patients O
with O
advanced O
colorectal O
cancer O
received O
PVI O
5-FU O
300 O
mg/m2/day O
for O
a O
maximum O
of O
24 O
weeks O
and O
were O
randomised O
to O
PVI O
5-FU O
alone O
or O
PVI O
5-FU O
+ O
MMC O
10 O
mg/m2 O
( O
7 O
mg/m2 O
from O
June O
1995 O
) O
6 O
weekly O
for O
4 O
courses O
. O

Overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
44.1 I-Premise
% I-Premise
-63.9 I-Premise
% I-Premise
) I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
28.3 I-Premise
% I-Premise
-47.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
failure I-Premise
free I-Premise
survival I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
in I-Premise
PVI I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
and I-Premise
5.4 I-Premise
months I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.033 I-Premise
) I-Premise
and I-Premise
at I-Premise
one I-Premise
year I-Premise
31.9 I-Premise
% I-Premise
for I-Premise
the I-Premise
combination I-Premise
compared I-Premise
to I-Premise
17.7 I-Premise
% I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
with I-Premise
MMC I-Premise
and I-Premise
15 I-Premise
months I-Premise
in I-Premise
5-FU I-Premise
alone I-Premise
";" I-Premise
one-year I-Premise
survival I-Premise
51.7 I-Premise
% I-Premise
vs. I-Premise
57.2 I-Premise
% I-Premise
. I-Premise

PVI B-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3/4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

Two B-Premise
patients I-Premise
treated I-Premise
with I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
MMC I-Premise
of I-Premise
40 I-Premise
mg/m2 I-Premise
developed I-Premise
haemolytic I-Premise
uraemic I-Premise
syndrome I-Premise
warranting I-Premise
the I-Premise
reduction I-Premise
in I-Premise
cumulative I-Premise
MMC I-Premise
dose I-Premise
to I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

The B-Premise
global I-Premise
QL I-Premise
scores I-Premise
were I-Premise
better I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
arm I-Premise
at I-Premise
24 I-Premise
weeks I-Premise
, I-Premise
but B-Premise
the I-Premise
remaining I-Premise
QL I-Premise
data I-Premise
showed I-Premise
no I-Premise
differences I-Premise
. I-Premise

PVI B-Claim
5-FU I-Claim
+ I-Claim
MMC I-Claim
results I-Claim
in I-Claim
failure-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
advantage I-Claim
, I-Claim
tolerable I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QL I-Claim
when I-Claim
compared I-Claim
to I-Claim
PVI I-Claim
5-FU I-Claim
alone I-Claim
but I-Claim
no I-Claim
overall I-Claim
survival I-Claim
advantage I-Claim
. I-Claim

There B-Premise
is I-Premise
no I-Premise
irreversible I-Premise
toxicity I-Premise
with I-Premise
MMC I-Premise
at I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

To O
compare O
in O
a O
phase O
III O
study O
the O
safety O
and O
efficacy O
of O
fludarabine O
to O
that O
of O
cyclophosphamide O
, O
vincristine O
, O
and O
prednisone O
( O
CVP O
) O
in O
recurrent O
, O
low-grade O
, O
non-Hodgkin O
's O
lymphoma O
after O
previous O
response O
to O
systemic O
treatment O
. O

Patients O
were O
randomized O
to O
fludarabine O
( O
25 O
mg/m O
( O
2 O
) O
intravenously O
on O
days O
1 O
to O
5 O
, O
every O
28 O
days O
) O
or O
CVP O
( O
cyclophosphamide O
750 O
mg/m O
( O
2 O
) O
and O
vincristine O
1.2 O
mg/m O
( O
2 O
) O
both O
intravenously O
on O
day O
1 O
and O
prednisone O
40 O
mg/m O
( O
2 O
) O
orally O
on O
days O
1 O
to O
5 O
, O
every O
21 O
days O
) O
. O

The O
primary O
outcome O
assessed O
was O
progression-free O
survival O
( O
PFS O
) O
";" O
secondary O
outcomes O
included O
treatment-free O
survival O
( O
TFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
treatment-related O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
according O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
's O
Quality O
of O
Life O
Questionnaire O
C-30 O
version O
1.0 O
instrument O
. O

Ninety-one O
patients O
were O
randomized O
, O
47 O
to O
fludarabine O
and O
44 O
to O
CVP O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
response I-Premise
rates I-Premise
, I-Premise
with I-Premise
64 I-Premise
% I-Premise
( I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
9 I-Premise
% I-Premise
) I-Premise
for I-Premise
fludarabine I-Premise
versus I-Premise
52 I-Premise
% I-Premise
( I-Premise
CR I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
CVP I-Premise
( I-Premise
P I-Premise
=.72 I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
detected I-Premise
( I-Premise
57 I-Premise
months I-Premise
for I-Premise
fludarabine I-Premise
v I-Premise
44 I-Premise
months I-Premise
for I-Premise
CVP I-Premise
";" I-Premise
P I-Premise
=.95 I-Premise
) I-Premise
. I-Premise

Three B-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
died I-Premise
of I-Premise
treatment-related I-Premise
toxicity I-Premise
compared I-Premise
with I-Premise
none I-Premise
of I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
CVP I-Premise
. I-Premise

Peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CVP I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
fludarabine I-Premise
had I-Premise
higher I-Premise
scores I-Premise
for I-Premise
social I-Premise
function I-Premise
( I-Premise
P I-Premise
=.008 I-Premise
) I-Premise
";" I-Premise
no B-Premise
other I-Premise
differences I-Premise
in I-Premise
QoL I-Premise
were I-Premise
detected I-Premise
. I-Premise

In B-Claim
recurrent I-Claim
low-grade I-Claim
lymphoma I-Claim
, I-Claim
fludarabine I-Claim
improves I-Claim
PFS I-Claim
, I-Claim
TFS I-Claim
, I-Claim
and I-Claim
social I-Claim
function I-Claim
scores I-Claim
in I-Claim
comparison I-Claim
with I-Claim
CVP I-Claim
but I-Claim
does I-Claim
not I-Claim
improve I-Claim
OS I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
metastatic I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
capecitabine I-Claim
plus I-Claim
docetaxel I-Claim
significantly I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
docetaxel I-Claim
alone I-Claim
. I-Claim

The O
current O
study O
evaluated O
the O
cost-effectiveness O
of O
the O
capecitabine/docetaxel O
combination O
versus O
docetaxel O
monotherapy O
, O
comparing O
the O
gain O
in O
quality-adjusted O
survival O
with O
associated O
health O
care O
costs O
. O

Patients O
were O
randomized O
to O
receive O
21-day O
cycles O
of O
oral O
capecitabine O
1250 O
mg/m2 O
twice O
daily O
, O
on O
Days O
1-14 O
, O
plus O
docetaxel O
75 O
mg/m2 O
Day O
1 O
( O
n O
= O
255 O
) O
, O
or O
docetaxel O
100 O
mg/m2 O
on O
Day O
1 O
( O
n O
= O
256 O
) O
. O

Health O
and O
cost O
outcomes O
in O
the O
two O
arms O
were O
compared O
, O
and O
cost-effectiveness O
was O
estimated O
. O

Data O
on O
survival O
time O
and O
medical O
care O
resource O
use O
were O
prospectively O
collected O
in O
the O
trial O
. O

Costs O
associated O
with O
medical O
care O
resource O
use O
and O
quality-of-life O
adjustments O
were O
obtained O
from O
the O
published O
literature O
. O

The O
incremental O
cost-effectiveness O
ratio O
was O
calculated O
as O
the O
cost O
per O
quality-adjusted O
life O
year O
( O
QALY O
) O
gained O
. O

Capecitabine/docetaxel B-Premise
increased I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
by I-Premise
3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
docetaxel I-Premise
alone I-Premise
( I-Premise
14.5 I-Premise
vs. I-Premise
11.5 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
quality-adjusted I-Premise
survival I-Premise
was I-Premise
increased I-Premise
by I-Premise
1.8 I-Premise
months I-Premise
in I-Premise
the I-Premise
capecitabine/docetaxel I-Premise
group I-Premise
. I-Premise

The B-Premise
total I-Premise
medical-resource I-Premise
utilization I-Premise
cost I-Premise
per I-Premise
patient I-Premise
was I-Premise
8.9 I-Premise
% I-Premise
higher I-Premise
with I-Premise
the I-Premise
combination I-Premise
: I-Premise
24,475 I-Premise
dollars I-Premise
for I-Premise
combination I-Premise
therapy I-Premise
versus I-Premise
22,477 I-Premise
dollars I-Premise
for I-Premise
single-agent I-Premise
docetaxel I-Premise
. I-Premise

The B-Premise
mean I-Premise
cost I-Premise
per I-Premise
QALY I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13,558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise

Cost B-Premise
savings I-Premise
due I-Premise
to I-Premise
reduced I-Premise
docetaxel I-Premise
dose I-Premise
and I-Premise
hospital I-Premise
use I-Premise
were I-Premise
the I-Premise
major I-Premise
cost I-Premise
offsets I-Premise
with I-Premise
the I-Premise
combination I-Premise
. I-Premise

Sensitivity B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
varying I-Premise
the I-Premise
mean I-Premise
hospital I-Premise
cost I-Premise
per I-Premise
day I-Premise
from I-Premise
the I-Premise
5th I-Premise
to I-Premise
the I-Premise
95th I-Premise
percentile I-Premise
resulted I-Premise
in I-Premise
cost-utility I-Premise
ratios I-Premise
ranging I-Premise
from I-Premise
20,326 I-Premise
dollars I-Premise
to I-Premise
as I-Premise
low I-Premise
as I-Premise
6360 I-Premise
dollars I-Premise
. I-Premise

Capecitabine/docetaxel B-Claim
was I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost-effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim

The O
benefit O
of O
epoetin O
alfa O
in O
maintaining O
hemoglobin O
levels O
in O
cancer O
patients O
with O
hemoglobin O
less O
than O
12 O
g/dL O
has O
not O
been O
evaluated O
. O

Breast O
cancer O
patients O
( O
N O
= O
354 O
) O
receiving O
chemotherapy O
were O
randomly O
assigned O
in O
1:1 O
ratio O
to O
epoetin O
alfa O
( O
40,000 O
U O
qw O
) O
or O
standard O
of O
care O
( O
SOC O
) O
. O

QOL O
was O
assessed O
at O
baseline O
and O
week O
12 O
. O

Hemoglobin O
responses O
, O
transfusion O
requirements O
, O
and O
prognostic O
factors O
for O
responses O
were O
measured O
. O

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Anemia I-Premise
( I-Premise
FACT-An I-Premise
";" I-Premise
mean I-Premise
, I-Premise
2.16 I-Premise
+/- I-Premise
12.84 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
-4.43 I-Premise
+/- I-Premise
13.42 I-Premise
for I-Premise
SOC I-Premise
) I-Premise
and I-Premise
FACT-An I-Premise
fatigue I-Premise
( I-Premise
mean I-Premise
, I-Premise
1.85 I-Premise
+/- I-Premise
10.52 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
-3.55 I-Premise
+/- I-Premise
11.14 I-Premise
for I-Premise
SOC I-Premise
) I-Premise
change I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Hemoglobin B-Premise
responses I-Premise
defined I-Premise
as I-Premise
mean I-Premise
hemoglobin I-Premise
> I-Premise
or I-Premise
= I-Premise
12 I-Premise
g/dL I-Premise
or I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
increase I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
SOC I-Premise
: I-Premise
52.0 I-Premise
% I-Premise
v I-Premise
5.1 I-Premise
% I-Premise
and I-Premise
65.7 I-Premise
% I-Premise
v I-Premise
6.3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
for I-Premise
both I-Premise
comparisons I-Premise
) I-Premise
. I-Premise

Percentage B-Premise
transfused I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
SOC I-Premise
( I-Premise
8.6 I-Premise
% I-Premise
v I-Premise
22.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

More B-Premise
than I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
did I-Premise
not I-Premise
require I-Premise
a I-Premise
dose I-Premise
increase I-Premise
and I-Premise
28.7 I-Premise
% I-Premise
had I-Premise
a I-Premise
dose I-Premise
reduction I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
qw I-Claim
is I-Claim
effective I-Claim
in I-Claim
improving I-Claim
QOL I-Claim
, I-Claim
maintaining I-Claim
hemoglobin I-Claim
level I-Claim
, I-Claim
and I-Claim
reducing I-Claim
transfusion I-Claim
requirements I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

During B-Premise
the I-Premise
last I-Premise
decade I-Premise
, I-Premise
survival I-Premise
rates I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
have I-Premise
increased I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
earlier I-Premise
detection I-Premise
and I-Premise
increased I-Premise
use I-Premise
of I-Premise
adjuvant I-Premise
therapy I-Premise
. I-Premise

Limited O
data O
exist O
on O
the O
psychosocial O
aspects O
of O
the O
transitional O
period O
between O
the O
end O
of O
primary O
treatment O
and O
survivorship O
. O

We O
investigated O
the O
baseline O
psychosocial O
status O
of O
women O
enrolled O
in O
a O
randomized O
trial O
testing O
two O
psychosocial O
interventions O
for O
women O
at O
the O
end O
of O
primary O
treatment O
. O

Participants O
, O
identified O
within O
1 O
month O
after O
surgery O
( O
registration O
) O
, O
provided O
demographic O
information O
and O
limited O
measures O
of O
quality O
of O
life O
. O

They O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O

A O
total O
of O
558 O
patients O
( O
mean O
age O
= O
56.9 O
years O
) O
were O
enrolled O
in O
the O
study O
between O
July O
1 O
, O
1999 O
, O
and O
June O
30 O
, O
2002 O
. O

Health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
P=.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
worse I-Premise
for I-Premise
women I-Premise
who I-Premise
received I-Premise
chemotherapy I-Premise
than I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
regardless I-Premise
of I-Premise
type I-Premise
of I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
women I-Claim
in I-Claim
all I-Claim
treatment I-Claim
groups I-Claim
report I-Claim
good I-Claim
emotional I-Claim
functioning I-Claim
but I-Claim
report I-Claim
decreased I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
particularly I-Claim
among I-Claim
women I-Claim
who I-Claim
have I-Claim
a I-Claim
mastectomy I-Claim
or I-Claim
receive I-Claim
chemotherapy I-Claim
. I-Claim

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

In B-Premise
a I-Premise
multinational I-Premise
trial I-Premise
of I-Premise
anaemic I-Premise
patients I-Premise
with I-Premise
cancer I-Premise
receiving I-Premise
nonplatinum-containing I-Premise
chemotherapy I-Premise
, I-Premise
epoetin-alfa I-Premise
effectively I-Premise
increased I-Premise
haemoglobin I-Premise
levels I-Premise
, I-Premise
reduced I-Premise
red I-Premise
blood I-Premise
cell I-Premise
transfusion I-Premise
requirements I-Premise
, I-Premise
and I-Premise
improved I-Premise
QOL I-Premise
. I-Premise

Although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin-alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0.126 I-Premise
] I-Premise
) I-Premise
. I-Premise

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

Patient O
data O
regarding O
transfusions O
, O
epoetin-alfa O
usage O
, O
chemotherapy O
treatment O
cycles O
, O
and O
adverse O
events O
were O
recorded O
, O
with O
survival O
follow-up O
for O
12-36 O
months O
post-study O
. O

Stage O
IV O
breast O
cancer O
therapy O
costs O
were O
collected O
by O
surveying O
UK O
oncologists O
, O
and O
utilities O
for O
associated O
health O
states O
were O
from O
published O
sources O
. O

Costs O
were O
in O
British O
pounds O
and O
year O
2000 O
values O
. O

Costs O
and O
benefits O
were O
jointly O
determined O
for O
the O
stage O
IV O
breast O
cancer O
subgroup O
( O
n O
= O
55 O
) O
. O

Incremental O
cost-utility O
ratios O
( O
ICURs O
) O
were O
calculated O
assuming O
a O
6 O
% O
annual O
discount O
rate O
for O
costs O
and O
a O
1.5 O
% O
annual O
discount O
rate O
for O
benefits O
. O

Bootstrap O
simulations O
( O
10,000 O
iterations O
) O
were O
conducted O
to O
account O
for O
uncertainty O
, O
and O
sensitivity O
analyses O
were O
conducted O
to O
establish O
robustness O
. O

The B-Premise
ICUR I-Premise
for I-Premise
epoetin-alfa I-Premise
treatment I-Premise
was I-Premise
pounds I-Premise
8,851 I-Premise
per I-Premise
QALY I-Premise
, I-Premise
with I-Premise
a I-Premise
99 I-Premise
% I-Premise
probability I-Premise
of I-Premise
a I-Premise
positive I-Premise
net I-Premise
benefit I-Premise
in I-Premise
QALYs I-Premise
( I-Premise
net I-Premise
benefit I-Premise
= I-Premise
0.4805 I-Premise
years I-Premise
of I-Premise
perfect I-Premise
life I-Premise
) I-Premise
and I-Premise
a I-Premise
94 I-Premise
% I-Premise
probability I-Premise
of I-Premise
being I-Premise
acceptable I-Premise
using I-Premise
a I-Premise
threshold I-Premise
ICUR I-Premise
of I-Premise
pounds I-Premise
30,000/QALY I-Premise
. I-Premise

The B-Premise
main I-Premise
cost I-Premise
drivers I-Premise
distinguishing I-Premise
epoetin-alfa I-Premise
from I-Premise
placebo I-Premise
were I-Premise
the I-Premise
costs I-Premise
of I-Premise
drug I-Premise
and I-Premise
patient I-Premise
care I-Premise
due I-Premise
to I-Premise
increased I-Premise
survival I-Premise
. I-Premise

The B-Claim
available I-Claim
data I-Claim
suggest I-Claim
a I-Claim
high I-Claim
probability I-Claim
of I-Claim
favourable I-Claim
cost-utility I-Claim
outcomes I-Claim
with I-Claim
epoetin-alfa I-Claim
treatment I-Claim
for I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IV I-Claim
breast I-Claim
cancer I-Claim
receiving I-Claim
nonplatinum-containing I-Claim
chemotherapy I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
are I-Claim
warranted I-Claim
. I-Claim

The O
EORTC O
24971/TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression-free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5-fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

The O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
and O
symptoms O
was O
investigated O
. O

HRQOL O
was O
assessed O
at O
baseline O
, O
at O
end O
of O
cycle O
2 O
, O
and O
4 O
, O
6 O
, O
and O
9 O
months O
after O
completion O
of O
RT O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
QLQ O
Head O
and O
Neck O
Cancer-Specific O
Module O
( O
EORTC O
QLQ-H O
& O
amp O
";" O
N35 O
) O
. O

The O
primary O
HRQOL O
scale O
was O
global O
HRQOL O
per O
protocol O
. O

Compliance O
to O
HRQOL O
assessments O
was O
97 O
% O
at O
baseline O
, O
but O
dropped O
to O
54 O
% O
by O
6 O
months O
. O

Data O
were O
analysed O
up O
to O
6 O
months O
. O

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
improved I-Premise
global I-Premise
HRQOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
period I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
end I-Premise
of I-Premise
RT I-Premise
, I-Premise
global I-Premise
HRQOL I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
low I-Premise
compliance I-Premise
does I-Premise
not I-Premise
allow I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

Swallowing B-Premise
and I-Premise
coughing I-Premise
problems I-Premise
decreased I-Premise
more I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
cycle I-Premise
2 I-Premise
, I-Premise
but B-Premise
to I-Premise
a I-Premise
limited I-Premise
extent I-Premise
. I-Premise

Induction B-Claim
chemotherapy I-Claim
with I-Claim
TPF I-Claim
before I-Claim
RT I-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
and I-Claim
reduces I-Claim
toxicity I-Claim
compared I-Claim
with I-Claim
PF I-Claim
but I-Claim
also I-Claim
seems I-Claim
to I-Claim
improve I-Claim
global I-Claim
HRQOL I-Claim
in I-Claim
a I-Claim
more I-Claim
sustainable I-Claim
manner I-Claim
. I-Claim

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

This O
study O
aimed O
to O
identify O
which O
patient O
characteristics O
predict O
fatigue O
improvement O
after O
CBT O
. O

In O
addition O
, O
the O
long-term O
effectiveness O
was O
investigated O
. O

Patients O
with O
various O
malignancies O
participated O
in O
the O
RCT O
( O
n O
= O
210 O
) O
. O

Participants O
were O
assessed O
before O
cancer O
treatment O
( O
T1 O
) O
, O
postintervention O
( O
T2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1-year O
follow-up O
( O
T3 O
) O
. O

Monthly O
fatigue O
assessments O
were O
completed O
between O
T2 O
and O
T3 O
. O

A O
regression O
analysis O
with O
interactions O
was O
performed O
to O
determine O
if O
domains O
of O
quality O
of O
life O
( O
EORTC-QLQ-C30 O
) O
functioning O
( O
Health O
Survey O
Short O
Form-36 O
) O
or O
psychological O
distress O
( O
Symptom O
Checklist-90 O
) O
moderated O
the O
effect O
of O
CBT O
on O
fatigue O
. O

Analyses O
of O
covariance O
were O
used O
to O
study O
the O
long-term O
effectiveness O
of O
CBT O
. O

Fatigue B-Premise
at I-Premise
T2 I-Premise
was I-Premise
predicted I-Premise
by I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
self-reported I-Premise
cognitive I-Premise
functioning I-Premise
and I-Premise
CBT I-Premise
. I-Premise

No B-Premise
interactions I-Premise
were I-Premise
found I-Premise
between I-Premise
other I-Premise
domains I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
functioning I-Premise
, I-Premise
psychological I-Premise
distress I-Premise
and I-Premise
CBT I-Premise
. I-Premise

At B-Premise
T3 I-Premise
, I-Premise
no I-Premise
significant I-Premise
difference I-Premise
on I-Premise
fatigue I-Premise
was I-Premise
found I-Premise
between I-Premise
CBT I-Premise
and I-Premise
usual I-Premise
care I-Premise
. I-Premise

Exploratory B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
the I-Premise
difference I-Premise
nearly I-Premise
reached I-Premise
significance I-Premise
until I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

Patients B-Premise
who I-Premise
experienced I-Premise
more I-Premise
concentration I-Premise
and I-Premise
memory I-Premise
problems I-Premise
at I-Premise
T1 I-Premise
benefited I-Premise
more I-Premise
from I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
and I-Premise
are I-Premise
indicators I-Premise
. I-Premise

After B-Premise
a I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

The B-Claim
implication I-Claim
is I-Claim
that I-Claim
CBT I-Claim
for I-Claim
fatigue I-Claim
should I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
with I-Claim
the I-Claim
highest I-Claim
chance I-Claim
to I-Claim
benefit I-Claim
. I-Claim

A O
phase O
III O
randomized O
trial O
was O
carried O
out O
to O
compare O
two O
schedules O
of O
the O
vinorelbine O
( O
VNR O
) O
-cisplatin O
( O
CDDP O
) O
regimen O
in O
patients O
with O
locally O
advanced O
unresectable O
poor O
prognosis O
stage O
IIIB O
or O
metastatic O
stage O
IV O
non-small O
cell O
lung O
cancer O
. O

The O
primary O
endpoints O
were O
overall O
survival O
( O
OS O
) O
and O
analysis O
of O
toxicity O
, O
while O
secondary O
endpoints O
included O
response O
rates O
, O
time-to-progression O
( O
TTP O
) O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Eligible O
patients O
were O
randomized O
to O
receive O
: O
( O
a O
) O
VNR O
25mg/m O
( O
2 O
) O
on O
day O
1 O
, O
8 O
and O
15 O
plus O
CDDP O
100mg/m O
( O
2 O
) O
on O
day O
1 O
every O
4 O
weeks O
or O
( O
b O
) O
VNR O
30 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
8 O
plus O
CDDP O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
. O

All O
patients O
were O
chemotherapy-naïve O
and O
had O
an O
ECOG O
performance O
status O
( O
PS O
) O
of O
0-1 O
. O

Overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O

Overall O
response O
rate O
was O
34 O
% O
( O
95 O
% O
CL O
26-42 O
% O
) O
in O
the O
weekly O
VNR/CDDP O
arm O
, O
and O
32 O
% O
( O
95 O
% O
CL O
24-40 O
% O
) O
in O
patients O
treated O
with O
day O
1-8 O
VNR/CDDP O
without O
any O
statistically O
significant O
difference O
. O

Median B-Premise
TTP I-Premise
was I-Premise
4.5 I-Premise
and I-Premise
4.6 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

This B-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.818 I-Premise
) I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
9.45 I-Premise
and I-Premise
10 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
without I-Premise
statistically I-Premise
a I-Premise
significant I-Premise
difference I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.259 I-Premise
) I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
and I-Premise
36 I-Premise
% I-Premise
, I-Premise
and I-Premise
10 I-Premise
and I-Premise
11 I-Premise
% I-Premise
respectively I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
neutropenia I-Premise
( I-Premise
34 I-Premise
% I-Premise
versus I-Premise
68 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
5 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
";" I-Premise
p=0.026 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
the I-Premise
rate I-Premise
of I-Premise
therapy I-Premise
omissions I-Premise
( I-Premise
10 I-Premise
% I-Premise
versus I-Premise
24 I-Premise
% I-Premise
";" I-Premise
p=0.0037 I-Premise
) I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

The B-Premise
weekly I-Premise
VNR/CDDP I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
lower I-Premise
received I-Premise
dose I-Premise
intensity I-Premise
in I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
fashion I-Premise
( I-Premise
9 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
with I-Premise
a I-Premise
lower I-Premise
non-statistically I-Premise
significant I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
schedule I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
day I-Claim
1-8 I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
is I-Claim
less I-Claim
toxic I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
the I-Claim
regimen I-Claim
of I-Claim
weekly I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
4 I-Claim
weeks I-Claim
. I-Claim

The B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time-to-progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
VNR I-Claim
on I-Claim
day I-Claim
1-8 I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
a I-Claim
reference I-Claim
regimen I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
and I-Claim
those I-Claim
who I-Claim
deserve I-Claim
a I-Claim
postoperative I-Claim
therapy I-Claim
, I-Claim
and I-Claim
for I-Claim
future I-Claim
studies I-Claim
. I-Claim

Cancer O
related O
fatigue O
( O
CRF O
) O
is O
a O
common O
problem O
for O
cancer O
patients O
across O
diagnoses O
during O
chemotherapy O
and O
is O
associated O
with O
physical O
inactivity O
, O
lower O
functional O
level O
and O
lack O
of O
energy O
. O

Few O
RCT O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF O
level O
. O

Data O
is O
based O
on O
analyses O
of O
a O
prospective O
randomised O
controlled O
trial O
'The O
Body O
Cancer O
Trial O
' O
. O

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait-list O
control O
group O
. O

The O
primary O
outcome O
, O
Fatigue O
score O
( O
CRF O
) O
, O
was O
evaluated O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anaemia O
Questionnaire O
( O
FACT-An- O
) O
( O
FACT-G O
score O
& O
FACT-An O
Anemia O
subscale O
) O
. O

Supervised O
exercise O
, O
comprising O
high-intensity O
cardiovascular O
and O
heavy O
resistance O
training O
, O
relaxation- O
and O
body O
awareness O
training O
and O
massage O
, O
9 O
h O
weekly O
for O
6 O
weeks O
. O

CRF B-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
Fatigue I-Premise
score I-Premise
reduction I-Premise
of I-Premise
3.04 I-Premise
( I-Premise
effect I-Premise
size I-Premise
of I-Premise
0.44 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.17-0.72 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
score I-Premise
by I-Premise
5.40 I-Premise
( I-Premise
P I-Premise
= I-Premise
.015 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
Toi I-Premise
score I-Premise
by I-Premise
5.22 I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
Anaemia-ANS I-Premise
by I-Premise
3.76 I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
General I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
score I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
";" I-Premise
Physical I-Premise
( I-Premise
P I-Premise
= I-Premise
.13 I-Premise
) I-Premise
, I-Premise
Emotional I-Premise
( I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
, I-Premise
Social I-Premise
( I-Premise
P I-Premise
= I-Premise
.83 I-Premise
) I-Premise
and I-Premise
Functional I-Premise
( I-Premise
P I-Premise
= I-Premise
.26 I-Premise
) I-Premise
. I-Premise

In B-Claim
summary I-Claim
, I-Claim
this I-Claim
six-week I-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
can I-Claim
lead I-Claim
to I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
self-reported I-Claim
CRF I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
chemotherapy I-Claim
. I-Claim

Chemotherapy O
with O
a O
platinum O
agent O
and O
a O
taxane O
( O
paclitaxel O
) O
is O
considered O
the O
standard O
of O
care O
for O
treatment O
of O
ovarian O
carcinoma O
. O

We O
compared O
the O
combination O
of O
docetaxel-carboplatin O
with O
the O
combination O
of O
paclitaxel-carboplatin O
as O
first-line O
chemotherapy O
for O
stage O
Ic-IV O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O

We O
randomly O
assigned O
1077 O
patients O
to O
receive O
docetaxel O
at O
75 O
mg/m2 O
of O
body O
surface O
area O
( O
1-hour O
intravenous O
infusion O
) O
or O
paclitaxel O
at O
175 O
mg/m2 O
( O
3-hour O
intravenous O
infusion O
) O
. O

Both O
treatments O
then O
were O
followed O
by O
carboplatin O
to O
an O
area O
under O
the O
plasma O
concentration-time O
curve O
of O
5 O
. O

The O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
";" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single-agent O
carboplatin O
was O
permitted O
. O

Survival O
curves O
were O
calculated O
by O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
Cox O
proportional O
hazards O
model O
. O

All O
statistical O
tests O
were O
two-sided O
. O

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
23 I-Premise
months I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
similar I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
medians I-Premise
of I-Premise
15.0 I-Premise
months I-Premise
for I-Premise
docetaxel-carboplatin I-Premise
and I-Premise
14.8 I-Premise
months I-Premise
for I-Premise
paclitaxel-carboplatin I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
0.97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.83 I-Premise
to I-Premise
1.13 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.707 I-Premise
) I-Premise
, I-Premise
overall I-Premise
survival I-Premise
rates I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
64.2 I-Premise
% I-Premise
and I-Premise
68.9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
HR I-Premise
= I-Premise
1.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.39 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.238 I-Premise
) I-Premise
, I-Premise
and I-Premise
objective I-Premise
tumor I-Premise
( I-Premise
58.7 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
between I-Premise
docetaxel I-Premise
and I-Premise
paclitaxel I-Premise
= I-Premise
-0.8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-8.6 I-Premise
% I-Premise
to I-Premise
7.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.868 I-Premise
) I-Premise
and I-Premise
CA-125 I-Premise
( I-Premise
75.8 I-Premise
% I-Premise
and I-Premise
76.8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
-1.0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-7.2 I-Premise
% I-Premise
to I-Premise
5.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.794 I-Premise
) I-Premise
response I-Premise
rates I-Premise
. I-Premise

However B-Premise
, I-Premise
docetaxel-carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
substantially I-Premise
less I-Premise
overall I-Premise
and I-Premise
grade I-Premise
2 I-Premise
or I-Premise
higher I-Premise
neurotoxicity I-Premise
than I-Premise
paclitaxel-carboplatin I-Premise
( I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neurosensory I-Premise
toxicity I-Premise
in I-Premise
11 I-Premise
% I-Premise
versus I-Premise
30 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
19 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neuromotor I-Premise
toxicity I-Premise
in I-Premise
3 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
4 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
% I-Premise
to I-Premise
7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Treatment B-Premise
with I-Premise
docetaxel-carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
94 I-Premise
% I-Premise
versus I-Premise
84 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
11 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
7 I-Premise
% I-Premise
to I-Premise
14 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
neutropenic I-Premise
complications I-Premise
than I-Premise
treatment I-Premise
with I-Premise
paclitaxel-carboplatin I-Premise
, I-Premise
although B-Premise
myelosuppression I-Premise
did I-Premise
not I-Premise
influence I-Premise
dose I-Premise
delivery I-Premise
or I-Premise
patient I-Premise
safety I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but B-Premise
substantive I-Premise
differences I-Premise
in I-Premise
many I-Premise
symptom I-Premise
scores I-Premise
favored I-Premise
docetaxel I-Premise
. I-Premise

Docetaxel-carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel-carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow-up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim

Thus B-Claim
, I-Claim
docetaxel-carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first-line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Exercise O
for O
Health O
was O
a O
randomized O
, O
controlled O
trial O
designed O
to O
evaluate O
two O
modes O
of O
delivering O
( O
face-to-face O
[ O
FtF O
] O
and O
over-the-telephone O
[ O
Tel O
] O
) O
an O
8-month O
translational O
exercise O
intervention O
, O
commencing O
6-weeks O
post-breast O
cancer O
surgery O
( O
PS O
) O
. O

Outcomes O
included O
quality O
of O
life O
( O
QoL O
) O
, O
function O
( O
fitness O
and O
upper O
body O
) O
and O
treatment-related O
side O
effects O
( O
fatigue O
, O
lymphoedema O
, O
body O
mass O
index O
, O
menopausal O
symptoms O
, O
anxiety O
, O
depression O
and O
pain O
) O
. O

Generalised O
estimating O
equation O
modelling O
determined O
time O
( O
baseline O
[ O
5 O
weeks O
PS O
] O
, O
mid-intervention O
[ O
6 O
months O
PS O
] O
, O
post-intervention O
[ O
12 O
months O
PS O
] O
) O
, O
group O
( O
FtF O
, O
Tel O
, O
Usual O
Care O
[ O
UC O
] O
) O
and O
time-by-group O
effects O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

There B-Premise
were I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
interaction I-Premise
effects I-Premise
on I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
with I-Premise
differences I-Premise
being I-Premise
observed I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
and I-Premise
the I-Premise
UC I-Premise
group I-Premise
. I-Premise

Trends B-Premise
observed I-Premise
for I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
similar I-Premise
. I-Premise

The B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post-intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
the I-Premise
UC I-Premise
group I-Premise
experienced I-Premise
no I-Premise
change I-Premise
, I-Premise
or I-Premise
worsening I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
mid-intervention I-Premise
. I-Premise

Although B-Premise
improvements I-Premise
in I-Premise
the I-Premise
UC I-Premise
group I-Premise
occurred I-Premise
by I-Premise
12-months I-Premise
post-surgery I-Premise
, I-Premise
the B-Premise
change I-Premise
did I-Premise
not I-Premise
meet I-Premise
the I-Premise
clinically I-Premise
relevant I-Premise
threshold I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
other I-Premise
treatment-related I-Premise
side I-Premise
effects I-Premise
between I-Premise
groups I-Premise
. I-Premise

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post-treatment I-Claim
. I-Claim

Malignant B-Claim
pleural I-Claim
effusion I-Claim
( I-Claim
MPE I-Claim
) I-Claim
is I-Claim
a I-Claim
common I-Claim
complication I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
humanized I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
( I-Claim
VEGF I-Claim
) I-Claim
, I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
efficient I-Claim
in I-Claim
suppressing I-Claim
the I-Claim
accumulation I-Claim
of I-Claim
pleural I-Claim
fluid I-Claim
. I-Claim

However O
, O
whether O
intrapleural O
delivery O
of O
bevacizumab O
can O
be O
used O
to O
treat O
MPE O
remains O
unknown O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
combined O
intrapleural O
therapy O
with O
bevacizumab O
and O
cisplatin O
, O
an O
antineoplastic O
agent O
, O
in O
controlling O
MPE O
. O

A O
total O
of O
72 O
NSCLC O
study O
subjects O
with O
MPE O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O

The O
first O
group O
received O
intrapleural O
bevacizumab O
( O
300 O
mg O
) O
with O
cisplatin O
( O
30 O
mg O
) O
therapy O
and O
the O
second O
group O
received O
intrapleural O
cisplatin O
( O
30 O
mg O
) O
therapy O
alone O
. O

Pleural O
fluid O
was O
collected O
from O
both O
groups O
prior O
to O
and O
following O
treatment O
. O

The O
levels O
of O
VEGF O
and O
carcinoembryonic O
antigen O
( O
CEA O
) O
in O
the O
pleural O
fluid O
were O
determined O
by O
ELISA O
. O

In B-Premise
70 I-Premise
evaluable I-Premise
study I-Premise
subjects I-Premise
, I-Premise
the I-Premise
curative I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
found I-Premise
in I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
( I-Premise
83.33 I-Premise
vs. I-Premise
50.00 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Therapy B-Premise
with I-Premise
combined I-Premise
bevacizumab I-Premise
plus I-Premise
cisplatin I-Premise
significantly I-Premise
reduced I-Premise
VEGF I-Premise
levels I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
addition I-Premise
, I-Premise
combination I-Premise
therapy I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
high I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
expression I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
III/IV I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

Combined B-Claim
intrapleural I-Claim
therapy I-Claim
with I-Claim
bevacizumab I-Claim
and I-Claim
cisplatin I-Claim
was I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
managing I-Claim
NSCLC-mediated I-Claim
MPE I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

In B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response/partial I-Claim
response I-Claim
[ I-Claim
CR/PR I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
CR/PR I-Claim
or I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

We O
evaluated O
the O
impact O
of O
response O
and/or O
clinical O
benefit O
on O
quality O
of O
life O
( O
QL O
) O
in O
postmenopausal O
patients O
under O
second-line O
endocrine O
treatment O
after O
failure O
of O
tamoxifen O
. O

One O
hundred O
twenty-eight O
of O
177 O
eligible O
patients O
of O
a O
randomized O
trial O
( O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
20/90 O
) O
receiving O
either O
formestane O
( O
250 O
mg O
intramuscularly O
biweekly O
) O
or O
megestrol O
acetate O
( O
160 O
mg O
orally O
daily O
) O
were O
analyzed O
. O

The O
baseline O
characteristics O
( O
with O
the O
exception O
of O
site O
of O
metastases O
) O
were O
balanced O
among O
patients O
with O
CR/PR O
, O
SD O
( O
6m O
) O
, O
and O
progressive O
disease O
( O
PD O
) O
. O

Patients O
completed O
QL O
indicators O
at O
baseline O
and O
at O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
9 O
, O
and O
11 O
months O
. O

Responders O
were O
separately O
compared O
with O
nonresponders O
( O
patients O
with O
SD O
( O
6m O
) O
or O
PD O
) O
and O
with O
patients O
with O
SD O
( O
6m O
) O
, O
and O
patients O
with O
clinical O
benefit O
were O
compared O
with O
patients O
with O
PD O
by O
analysis O
of O
covariance O
with O
adjustment O
for O
baseline O
scores O
. O

Overall O
, O
88 O
% O
( O
557 O
of O
634 O
) O
of O
expected O
QL O
forms O
were O
received O
. O

In O
the O
comparison O
of O
responders O
versus O
patients O
with O
both O
SD O
( O
6m O
) O
and O
PD O
, O
responders B-Premise
indicated I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
mood I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
at I-Premise
month I-Premise
3 I-Premise
. I-Premise

Compared B-Premise
only I-Premise
with I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
, I-Premise
responders I-Premise
showed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
baseline I-Premise
QL I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
328.5 I-Premise
v I-Premise
340 I-Premise
days I-Premise
) I-Premise
. I-Premise

While B-Premise
under I-Premise
treatment I-Premise
, I-Premise
responders I-Premise
reported I-Premise
significantly I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
months I-Premise
3 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
coping I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
9 I-Premise
) I-Premise
, I-Premise
and I-Premise
appetite I-Premise
( I-Premise
months I-Premise
7 I-Premise
to I-Premise
11 I-Premise
) I-Premise
and I-Premise
less I-Premise
dizziness I-Premise
( I-Premise
month I-Premise
9 I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

The B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
CR/PR I-Premise
and I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
groups I-Premise
had I-Premise
similar I-Premise
times I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
, I-Premise
patients B-Claim
with I-Claim
CR/PR I-Claim
reported I-Claim
better I-Claim
QL I-Claim
, I-Claim
suggesting I-Claim
more I-Claim
beneficial I-Claim
response I-Claim
to I-Claim
second-line I-Claim
endocrine I-Claim
treatment I-Claim
. I-Claim

Patients O
' O
subjective O
perspective O
should O
be O
taken O
into O
account O
in O
this O
mainly O
palliative O
setting O
. O

Future O
trials O
should O
be O
designed O
so O
that O
the O
CR/PR O
and O
SD O
( O
6m O
) O
groups O
are O
investigated O
separately O
. O

To O
describe O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
review O
and O
approval O
of O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

The O
FDA O
reviewed O
raw O
data O
in O
electronic O
format O
from O
a O
randomized O
controlled O
clinical O
trial O
comparing O
erlotinib O
with O
placebo O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Patients O
were O
randomized O
in O
a O
2:1 O
ratio O
( O
erlotinib O
, O
n O
= O
488 O
and O
placebo O
, O
n O
= O
243 O
) O
. O

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

Exploratory B-Claim
analyses I-Claim
indicate I-Claim
that I-Claim
epidermal I-Claim
growth I-Claim
factor I-Claim
receptor I-Claim
status I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
predictor I-Claim
of I-Claim
the I-Claim
erlotinib I-Claim
survival I-Claim
effect I-Claim
. I-Claim

Rash B-Premise
( I-Premise
75 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
54 I-Premise
% I-Premise
versus I-Premise
18 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotnib I-Premise
and I-Premise
placebo I-Premise
group I-Premise
respectively I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Severe B-Premise
rash I-Premise
occurred I-Premise
in I-Premise
9 I-Premise
% I-Premise
and I-Premise
severe I-Premise
diarrhea I-Premise
in I-Premise
6 I-Premise
% I-Premise
of I-Premise
erlotinib-treated I-Premise
patients I-Premise
and I-Premise
each I-Premise
resulted I-Premise
in I-Premise
study I-Premise
discontinuation I-Premise
in I-Premise
1 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise

Dose B-Premise
reductions I-Premise
were I-Premise
required I-Premise
for I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
rash I-Premise
and I-Premise
4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
diarrhea I-Premise
. I-Premise

On O
November O
18 O
, O
2004 O
, O
the O
FDA O
granted O
erlotinib O
regular O
approval O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

The O
applicant O
has O
committed O
to O
conduct O
post-marketing O
clinical O
trials O
to O
assess O
further O
the O
effect O
of O
epidermal O
growth O
factor O
receptor O
expression O
, O
measured O
with O
immunohistochemical O
staining O
, O
on O
erlotinib O
treatment O
effect O
. O

Gastrojejunostomy O
( O
GJJ O
) O
and O
stent O
placement O
are O
the O
most O
commonly O
used O
palliative O
treatments O
for O
malignant O
gastric O
outlet O
obstruction O
( O
GOO O
) O
. O

In O
a O
recent O
randomized O
trial O
, O
stent O
placement O
was O
preferred O
in O
patients O
with O
a O
relatively O
short O
survival O
and O
GJJ O
in O
patients O
with O
a O
longer O
survival O
. O

As O
health O
economic O
aspects O
have O
only O
been O
studied O
in O
general O
terms O
, O
we O
estimated O
the O
cost O
of O
GJJ O
and O
that O
of O
stent O
placement O
in O
such O
patients O
. O

In O
the O
SUSTENT O
study O
, O
patients O
were O
randomized O
to O
GJJ O
( O
n O
= O
18 O
) O
or O
stent O
placement O
( O
n O
= O
21 O
) O
. O

Pancreatic O
cancer O
was O
the O
most O
common O
cause O
of O
GOO O
. O

We O
compared O
initial O
costs O
and O
costs O
during O
follow-up O
. O

For O
cost-effectiveness O
, O
the O
incremental O
cost-effectiveness O
ratio O
was O
calculated O
. O

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
of I-Premise
obstructive I-Premise
symptoms I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
occurred I-Premise
and I-Premise
more I-Premise
reinterventions I-Premise
were I-Premise
performed I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

Initial B-Premise
costs I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro8315 I-Premise
vs. I-Premise
euro4820 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
follow-up I-Premise
costs I-Premise
. I-Premise

Total B-Premise
costs I-Premise
per I-Premise
patient I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro12433 I-Premise
vs. I-Premise
euro8819 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
of I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
or=2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise

Medical B-Claim
effects I-Claim
were I-Claim
better I-Claim
after I-Claim
GJJ I-Claim
, O
although B-Claim
GJJ I-Claim
had I-Claim
higher I-Claim
total I-Claim
costs I-Claim
. I-Claim

Since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
GOO I-Claim
. I-Claim

We O
conducted O
a O
prospective O
, O
randomized O
, O
multicentre O
clinical O
trial O
comparing O
the O
effects O
and O
costs O
of O
GM-CSF O
as O
an O
adjunct O
to O
intensive O
chemotherapy O
in O
elderly O
patients O
with O
acute O
myeloid O
leukaemia O
( O
AML O
) O
. O

The O
patients O
were O
randomized O
to O
either O
daunomycin-cytosine O
arabinoside O
( O
control O
arm O
: O
n O
= O
161 O
) O
or O
daunomycin-cytosine O
arabinoside O
with O
GM-CSF O
( O
GM-CSF O
arm O
: O
n O
= O
157 O
) O
. O

The O
primary O
end-point O
was O
the O
effect O
of O
GM-CSF O
on O
the O
percentage O
of O
complete O
remissions O
( O
CR O
) O
. O

Survival O
duration O
, O
disease-free O
survival O
, O
quality O
of O
life O
and O
costs O
were O
evaluated O
separately O
. O

CR B-Premise
after I-Premise
remission I-Premise
induction I-Premise
treatment I-Premise
was I-Premise
achieved I-Premise
in I-Premise
55 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
in I-Premise
56 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

The B-Premise
duration I-Premise
of I-Premise
survival I-Premise
and I-Premise
disease-free I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
after I-Premise
randomization I-Premise
were I-Premise
estimated I-Premise
at I-Premise
22 I-Premise
% I-Premise
and I-Premise
19 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
22 I-Premise
% I-Premise
and I-Premise
14 I-Premise
% I-Premise
for I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

Considering B-Premise
the I-Premise
short-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
the I-Premise
administration I-Premise
of I-Premise
GM-CSF I-Premise
resulted I-Premise
in I-Premise
more I-Premise
problems I-Premise
with I-Premise
regard I-Premise
to I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
diarrhoea I-Premise
and I-Premise
rash/eczema I-Premise
. I-Premise

With B-Premise
regard I-Premise
to I-Premise
the I-Premise
long-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

The B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
GM-CSF-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i.e I-Premise
. I-Premise
US I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
US I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
costs I-Premise
during I-Premise
the I-Premise
follow-up I-Premise
period I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

The B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
plus I-Claim
GM-CSF I-Claim
is I-Claim
not I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim

Androgen O
treatment O
for O
prostate O
cancer O
can O
adversely O
affect O
functional O
domains O
of O
quality O
of O
life O
. O

We O
aimed O
to O
assess O
quality O
of O
life O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
in O
an O
open-label O
phase O
III O
randomised O
comparison O
between O
lifelong O
endocrine O
treatment O
with O
and O
without O
radiotherapy O
. O

We O
obtained O
quality-of-life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
";" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

Prospective O
outcomes O
included O
patient-reported O
symptoms O
and O
quality O
of O
life O
assessed O
with O
questionnaires O
from O
baseline O
to O
4 O
years O
after O
randomisation O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

This O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
ISRCTN01534787 O
. O

438 O
of O
439 O
men O
assigned O
endocrine O
treatment O
and O
434 O
of O
436 O
assigned O
endocrine O
plus O
radiotherapy O
completed O
at O
least O
one O
questionnaire O
. O

Missing O
data O
at O
baseline O
and O
during O
follow-up O
was O
equally O
distributed O
between O
groups O
. O

At B-Premise
4 I-Premise
years I-Premise
, I-Premise
64 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
of I-Premise
353 I-Premise
patients I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
39 I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
of I-Premise
337 I-Premise
on I-Premise
endocrine-alone I-Premise
therapy I-Premise
had I-Premise
moderate I-Premise
to I-Premise
severe I-Premise
urinary I-Premise
bother I-Premise
( I-Premise
p=0.005 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
( I-Premise
4 I-Premise
% I-Premise
) I-Premise
of I-Premise
355 I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
five I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
of I-Premise
338 I-Premise
on I-Premise
endocrine I-Premise
treatment I-Premise
alone I-Premise
had I-Premise
pain I-Premise
while I-Premise
urinating I-Premise
( I-Premise
p=0.024 I-Premise
) I-Premise
. I-Premise

37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
of I-Premise
350 I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
of I-Premise
35 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
overall I-Premise
bother I-Premise
from I-Premise
all I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p=0.022 I-Premise
) I-Premise
. I-Premise

281 B-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
of I-Premise
332 I-Premise
in I-Premise
the I-Premise
combined-treatment I-Premise
group I-Premise
and I-Premise
227 I-Premise
( I-Premise
72 I-Premise
% I-Premise
) I-Premise
of I-Premise
313 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
erectile I-Premise
dysfunction I-Premise
( I-Premise
p=0.0002 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
at I-Premise
4 I-Premise
years I-Premise
was I-Premise
similar I-Premise
, I-Premise
with I-Premise
the I-Premise
exception I-Premise
of I-Premise
decreased I-Premise
social I-Premise
function I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
endocrine I-Premise
treatment I-Premise
plus I-Premise
radiotherapy I-Premise
. I-Premise

Although B-Claim
addition I-Claim
of I-Claim
radiotherapy I-Claim
to I-Claim
endocrine I-Claim
treatment I-Claim
significantly I-Claim
increased I-Claim
some I-Claim
treatment-related I-Claim
symptoms I-Claim
, I-Claim
none I-Claim
were I-Claim
serious I-Claim
. I-Claim

Given O
the O
substantial O
survival O
benefit O
of O
combined O
treatment O
, O
the B-Claim
increase I-Claim
of I-Claim
symptoms I-Claim
seems I-Claim
acceptable I-Claim
and I-Claim
has I-Claim
little I-Claim
extra I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
after I-Claim
4 I-Claim
years I-Claim
compared I-Claim
with I-Claim
endocrine I-Claim
treatment I-Claim
alone I-Claim
. I-Claim

The O
aim O
of O
this O
randomised O
trial O
was O
to O
evaluate O
the O
activity O
and O
toxicity O
of O
a O
biweekly O
regimen O
including O
6S-leucovorin-modulated O
5-fluorouracil O
( O
LFA-5-FU O
) O
, O
combined O
with O
either O
irinotecan O
( O
CPT-11 O
+ O
LFA O
5-FU O
) O
or O
raltitrexed O
( O
Tomudex O
) O
( O
TOM O
+ O
LFA-5-FU O
) O
, O
in O
advanced O
colorectal O
cancer O
patients O
, O
and O
to O
make O
a O
preliminary O
comparison O
of O
both O
these O
experimental O
regimens O
with O
a O
biweekly O
administration O
of O
LFA-5-FU O
modulated O
by O
methotrexate O
( O
MTX O
+ O
LFA-5-FU O
) O
. O

One O
hundred O
fifty-nine O
patients O
with O
advanced O
colorectal O
carcinoma O
previously O
untreated O
for O
the O
metastatic O
disease O
( O
34 O
of O
them O
previously O
exposed O
to O
adjuvant O
5-FU O
) O
were O
randomly O
allocated O
to O
receive O
: O
CPT-11 O
, O
200 O
mg/m2 O
i.v O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

infusion O
and O
5-FU O
, O
850 O
mg/m2 O
s O
i.v O
. O

bolus O
( O
arm O
A O
) O
";" O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

infusion O
and O
5-FU O
, O
1050 O
mg/m2 O
i.v O
. O

bolus O
( O
arm O
B O
) O
";" O
or O
MTX O
, O
750 O
mg/m2 O
i.v O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

infusion O
and O
5-FU O
, O
800 O
mg/m2 O
i.v O
. O

bolus O
( O
arm O
C O
) O
. O

Courses O
were O
repeated O
every O
two O
weeks O
in O
all O
arms O
of O
the O
trial O
. O

Response O
rate O
( O
RR O
) O
was O
evaluated O
after O
every O
four O
courses O
. O

The O
sample O
size O
was O
defined O
to O
have O
an O
80 O
% O
power O
to O
detect O
a O
35 O
% O
RR O
for O
each O
experimental O
treatment O
, O
and O
to O
show O
a O
difference O
of O
at O
least O
4 O
% O
in O
RR O
with O
the O
standard O
treatment O
if O
the O
TRUE O
difference O
is O
15 O
% O
or O
more O
. O

The O
RRs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
-48 O
% O
) O
in O
arm O
A O
, O
including O
3 O
complete O
responses O
( O
CRs O
) O
and O
15 O
partial O
responses O
( O
PRs O
) O
, O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
in O
arm O
B O
, O
including O
2 O
CRs O
and O
11 O
PRs O
, O
and O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
, O
with O
2 O
CRs O
and O
11 O
PRs O
, O
in O
arm O
C. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18-108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

With B-Premise
94 I-Premise
patients I-Premise
still I-Premise
alive I-Premise
, I-Premise
the I-Premise
one-year I-Premise
probability I-Premise
of I-Premise
survival I-Premise
was I-Premise
61 I-Premise
% I-Premise
, I-Premise
54 I-Premise
% I-Premise
, I-Premise
and I-Premise
59 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

WHO B-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
diarrhoea I-Premise
affected I-Premise
46 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CPT-11 I-Premise
+ I-Premise
LFA I-Premise
5-FU I-Premise
. I-Premise

Median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
CPT-11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

Severe B-Premise
toxicities I-Premise
of I-Premise
TOM I-Premise
+ I-Premise
LFA-5-FU I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhoea I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
median I-Premise
relative I-Premise
DI8 I-Premise
was I-Premise
93 I-Premise
% I-Premise
for I-Premise
TOM I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

CPT-11 B-Premise
+ I-Premise
LFA-5-FU I-Premise
compares I-Premise
favorably I-Premise
in I-Premise
term I-Premise
of I-Premise
activity I-Premise
and I-Premise
toxicity I-Premise
with I-Premise
other I-Premise
combination I-Premise
regimens I-Premise
including I-Premise
CPT-11 I-Premise
and I-Premise
continuous I-Premise
infusional I-Premise
5-FU I-Premise
. I-Premise

The B-Claim
hypothesis I-Claim
of I-Claim
a I-Claim
RR I-Claim
15 I-Claim
% I-Claim
higher I-Claim
than I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA-5-FU I-Claim
treatment I-Claim
can I-Claim
not I-Claim
be I-Claim
ruled I-Claim
out I-Claim
after I-Claim
this I-Claim
interim I-Claim
analysis I-Claim
. I-Claim

The B-Claim
TOM I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
RR I-Claim
and I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
very I-Claim
close I-Claim
to I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
combination I-Claim
, I-Claim
and I-Claim
does I-Claim
not I-Claim
deserve I-Claim
further I-Claim
evaluation I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Adjuvant O
chemotherapy O
for O
early O
stage O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
is O
now O
the O
standard O
of O
care O
, O
but O
there O
is O
little O
information O
regarding O
its O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
. O

We O
report O
the O
QOL O
results O
of O
JBR.10 O
, O
a O
North O
American O
, O
intergroup O
, O
randomized O
trial O
of O
adjuvant O
cisplatin O
and O
vinorelbine O
compared O
with O
observation O
in O
patients O
who O
have O
completely O
resected O
, O
stages O
IB O
to O
II O
NSCLC O
. O

QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
a O
trial-specific O
checklist O
at O
baseline O
and O
at O
weeks O
5 O
and O
9 O
for O
those O
who O
received O
chemotherapy O
and O
at O
follow-up O
months O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
. O

A O
10-point O
change O
in O
QOL O
scores O
from O
baseline O
was O
considered O
clinically O
significant O
. O

Four O
hundred O
eighty-two O
patients O
were O
randomly O
assigned O
on O
JBR.10 O
. O

A O
total O
of O
173 O
patients O
( O
82 O
% O
of O
the O
expected O
) O
in O
the O
observation O
arm O
and O
186 O
( O
85 O
% O
of O
expected O
) O
in O
the O
chemotherapy O
arm O
completed O
baseline O
QOL O
assessments O
. O

The B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise

Changes O
in O
QOL O
during O
chemotherapy O
were O
relatively O
modest O
";" O
fatigue B-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
worsened I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
and I-Premise
no I-Premise
change I-Premise
in I-Premise
global I-Premise
QOL I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
observation I-Premise
arm I-Premise
showed I-Premise
considerable I-Premise
improvements I-Premise
in I-Premise
QOL I-Premise
by I-Premise
3 I-Premise
months I-Premise
. I-Premise

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

The B-Claim
findings I-Claim
of I-Claim
this I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
the I-Claim
negative I-Claim
effects I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
on I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
temporary I-Claim
, I-Claim
and I-Claim
that I-Claim
improvements I-Claim
( I-Claim
with I-Claim
a I-Claim
return I-Claim
to I-Claim
baseline I-Claim
function I-Claim
) I-Claim
are I-Claim
likely I-Claim
in I-Claim
most I-Claim
patients I-Claim
. I-Claim

Promising O
results O
in O
a O
randomized O
phase O
II O
trial O
with O
the O
hypoxic O
cytotoxin O
tirapazamine O
( O
TPZ O
) O
combined O
with O
cisplatin O
( O
CIS O
) O
and O
radiation O
led O
to O
this O
phase O
III O
trial O
. O

Patients O
with O
previously O
untreated O
stage O
III O
or O
IV O
( O
excluding O
T1-2N1 O
and O
M1 O
) O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
oropharynx O
, O
hypopharynx O
, O
or O
larynx O
were O
randomly O
assigned O
to O
receive O
definitive O
radiotherapy O
( O
70 O
Gy O
in O
7 O
weeks O
) O
concurrently O
with O
either O
CIS O
( O
100 O
mg/m O
( O
2 O
) O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
or O
CIS O
( O
75 O
mg/m O
( O
2 O
) O
) O
plus O
TPZ O
( O
290 O
mg/m O
( O
2 O
) O
/d O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
and O
TPZ O
alone O
( O
160 O
mg/m O
( O
2 O
) O
/d O
) O
on O
days O
1 O
, O
3 O
, O
and O
5 O
of O
weeks O
2 O
and O
3 O
( O
TPZ/CIS O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

The O
planned O
sample O
size O
was O
850 O
, O
estimated O
to O
result O
in O
334 O
deaths O
, O
which O
would O
provide O
90 O
% O
power O
to O
detect O
a O
difference O
in O
2-year O
survival O
rates O
of O
60 O
% O
v O
70 O
% O
for O
CIS O
versus O
TPZ/CIS O
, O
respectively O
( O
hazard O
ratio O
= O
0.69 O
) O
. O

Eight O
hundred O
sixty-one O
patients O
were O
accrued O
from O
89 O
sites O
in O
16 O
countries O
. O

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
the I-Premise
2-year I-Premise
OS I-Premise
rates I-Premise
were I-Premise
65.7 I-Premise
% I-Premise
for I-Premise
CIS I-Premise
and I-Premise
66.2 I-Premise
% I-Premise
for I-Premise
TPZ/CIS I-Premise
( I-Premise
TPZ/CIS I-Premise
-- I-Premise
CIS I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-5.9 I-Premise
% I-Premise
to I-Premise
6.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure-free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
and I-Premise
Neck I-Premise
. I-Premise

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

The O
combination O
of O
carboplatin O
and O
paclitaxel O
is O
the O
standard O
of O
care O
for O
the O
treatment O
of O
ovarian O
cancer O
, O
yet O
rates O
of O
recurrence O
and O
death O
remain O
high O
. O

We O
performed O
a O
prospective O
randomized O
phase O
III O
study O
to O
examine O
whether O
sequential O
administration O
of O
topotecan O
can O
improve O
the O
efficacy O
of O
carboplatin O
and O
paclitaxel O
in O
first-line O
treatment O
of O
advanced O
epithelial O
ovarian O
cancer O
. O

A O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stages O
IIB-IV O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
TC-Top O
";" O
658 O
patients O
) O
or O
surveillance O
( O
TC O
";" O
650 O
patients O
) O
on O
a O
3-week O
per O
cycle O
schedule O
. O

The O
primary O
endpoint O
was O
overall O
survival O
, O
and O
secondary O
endpoints O
were O
progression-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Time-to-event O
data O
were O
analyzed O
using O
the O
Kaplan-Meier O
method O
, O
and O
a O
stratified O
log-rank O
test O
was O
used O
to O
compare O
distributions O
between O
treatment O
groups O
. O

Hazard O
ratios O
( O
HRs O
) O
with O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
using O
a O
Cox O
proportional O
hazards O
model O
. O

Categorical O
data O
were O
compared O
using O
a O
stratified O
Cochran-Mantel-Haenszel O
test O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
18.2 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
18.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
0.97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.85 I-Premise
to I-Premise
1.10 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.688 I-Premise
) I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43.1 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
44.5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
1.01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.18 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.885 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
overall I-Premise
survival I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
57 I-Premise
% I-Premise
( I-Premise
58.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
and I-Premise
55.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
had I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
hematologic I-Premise
toxic I-Premise
effects I-Premise
( I-Premise
requiring I-Premise
more I-Premise
supportive I-Premise
care I-Premise
) I-Premise
and I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
infections I-Premise
( I-Premise
5.1 I-Premise
% I-Premise
versus I-Premise
2.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
but I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3.3 I-Premise
% I-Premise
versus I-Premise
3.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.80 I-Premise
) I-Premise
. I-Premise

Among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
";" I-Premise
TC-Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i.e. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
61.4 I-Premise
% I-Premise
to I-Premise
76.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
and I-Premise
76.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
69.3 I-Premise
% I-Premise
to I-Premise
83.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.166 I-Premise
) I-Premise
. I-Premise

The B-Claim
sequential I-Claim
addition I-Claim
of I-Claim
topotecan I-Claim
to I-Claim
carboplatin-paclitaxel I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
superior I-Claim
overall I-Claim
response I-Claim
or I-Claim
progression-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

To O
examine O
health-related O
quality O
of O
life O
, O
we O
investigated O
the O
effect O
of O
adjuvant O
chemotherapy O
regimens O
on O
utility O
scores O
assessed O
by O
the O
EuroQoL-5D O
( O
EQ-5D O
) O
instrument O
in O
a O
randomized O
, O
controlled O
trial O
for O
breast O
cancer O
patients O
after O
surgery O
. O

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ-5D O
utilities O
. O

Patients O
were O
randomly O
assigned O
to O
the O
following O
four O
chemotherapy O
regimens O
: O
four O
cycles O
of O
anthracycline O
followed O
by O
paclitaxel O
( O
ACP O
) O
, O
four O
cycles O
of O
anthracycline-containing O
regimens O
followed O
by O
docetaxel O
( O
ACD O
) O
, O
eight O
cycles O
of O
paclitaxel O
( O
PTX O
) O
, O
and O
eight O
cycles O
of O
docetaxel O
( O
DTX O
) O
. O

Of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O

Utility O
scores O
were O
assessed O
using O
the O
EQ-5D O
instrument O
at O
baseline O
";" O
cycles O
3 O
, O
5 O
, O
and O
7 O
";" O
7 O
months O
";" O
and O
1 O
year O
. O

We O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
FACT-G O
, O
-B O
, O
and O
-Taxane O
scores O
at O
each O
time O
point O
. O

Utility B-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ACP I-Premise
and I-Premise
ACD I-Premise
groups I-Premise
. I-Premise

Mean B-Premise
utility I-Premise
scores I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
were I-Premise
lowest I-Premise
at I-Premise
7 I-Premise
months I-Premise
and I-Premise
tended I-Premise
to I-Premise
remain I-Premise
low I-Premise
for I-Premise
a I-Premise
long I-Premise
time I-Premise
. I-Premise

The B-Premise
combined I-Premise
anthracycline I-Premise
followed I-Premise
by I-Premise
taxane I-Premise
group I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
utility I-Premise
scores I-Premise
that I-Premise
the I-Premise
taxane-alone I-Premise
group I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
depending I-Premise
on I-Premise
the I-Premise
type I-Premise
of I-Premise
taxane I-Premise
. I-Premise

Only B-Premise
the I-Premise
FACT-G I-Premise
social/family I-Premise
well-being I-Premise
subscale I-Premise
had I-Premise
no I-Premise
relationship I-Premise
with I-Premise
EQ-5D I-Premise
responses I-Premise
and I-Premise
utility I-Premise
scores I-Premise
. I-Premise

Although B-Claim
the I-Claim
regimens I-Claim
in I-Claim
this I-Claim
study I-Claim
were I-Claim
similar I-Claim
in I-Claim
that I-Claim
they I-Claim
included I-Claim
taxane I-Claim
, I-Claim
the I-Claim
mean I-Claim
utility I-Claim
scores I-Claim
and I-Claim
longitudinal I-Claim
patterns I-Claim
of I-Claim
utility I-Claim
scores I-Claim
were I-Claim
different I-Claim
among I-Claim
regimens I-Claim
. I-Claim

Topical O
photodynamic O
therapy O
( O
PDT O
) O
with O
aminolevulinic O
acid O
( O
ALA O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
AKs O
) O
, O
but O
no O
split-face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O

To O
compare O
the O
efficacy O
and O
tolerability O
of O
ALA-PDT O
and O
imiquimod O
5 O
% O
cream O
for O
the O
treatment O
of O
AKs O
. O

Sixty-one O
patients O
were O
enrolled O
from O
the O
Salt O
Lake O
City O
Veterans O
Affairs O
Hospital O
";" O
51 O
completed O
the O
study O
and O
were O
included O
in O
the O
analysis O
. O

All O
patients O
were O
randomized O
to O
receive O
half O
of O
a O
sachet O
of O
imiquimod O
5 O
% O
cream O
twice O
weekly O
on O
half O
of O
their O
face O
and O
two O
sessions O
of O
PDT O
with O
20 O
% O
solution O
of O
ALA O
applied O
for O
1 O
hour O
to O
the O
other O
side O
of O
the O
face O
. O

The B-Premise
75 I-Premise
% I-Premise
AK I-Premise
clearance I-Premise
rate I-Premise
was I-Premise
34.6 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
25 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.30 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
AK I-Premise
count I-Premise
was I-Premise
59.2 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
41.4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Dermatology B-Premise
Life I-Premise
Quality I-Premise
Index I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1.95 I-Premise
and I-Premise
1.38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
.20 I-Premise
) I-Premise
. I-Premise

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
treatment I-Claim
response I-Claim
when I-Claim
the I-Claim
100 I-Claim
% I-Claim
or I-Claim
75 I-Claim
% I-Claim
clearance I-Claim
rate I-Claim
cutoff I-Claim
was I-Claim
used I-Claim
, I-Claim
but B-Claim
our I-Claim
secondary I-Claim
outcome I-Claim
suggests I-Claim
that I-Claim
two I-Claim
sessions I-Claim
of I-Claim
ALA-PDT I-Claim
is I-Claim
superior I-Claim
to I-Claim
imiquimod I-Claim
5 I-Claim
% I-Claim
cream I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
AKs I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
assessed I-Claim
using I-Claim
the I-Claim
DLQI I-Claim
. I-Claim

We O
aimed O
at O
investigating O
the O
efficacy O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
QOL O
) O
of O
gemcitabine O
( O
GEM O
) O
compared O
with O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
in O
the O
salvage O
treatment O
of O
recurrent O
ovarian O
cancer O
. O

A O
phase O
III O
randomized O
multicenter O
trial O
was O
planned O
to O
compare O
GEM O
( O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
) O
with O
PLD O
( O
40 O
mg/m O
( O
2 O
) O
every O
28 O
days O
) O
in O
ovarian O
cancer O
patients O
who O
experienced O
treatment O
failure O
with O
only O
one O
platinum/paclitaxel O
regimen O
and O
who O
experienced O
recurrence O
or O
progression O
within O
12 O
months O
after O
completion O
of O
primary O
treatment O
. O

One O
hundred O
fifty-three O
patients O
were O
randomly O
assigned O
to O
PLD O
( O
n O
= O
76 O
) O
or O
GEM O
( O
n O
= O
77 O
) O
. O

Treatment O
arms O
were O
well O
balanced O
for O
clinicopathologic O
characteristics O
. O

Grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
GEM-treated O
patients O
versus O
PLD-treated O
patients O
( O
P O
= O
.007 O
) O
. O

Grade O
3 O
or O
4 O
palmar-plantar O
erythrodysesthesia O
was O
documented O
in O
a O
higher O
proportion O
of O
PLD O
patients O
( O
6 O
% O
) O
versus O
GEM O
patients O
( O
0 O
% O
";" O
P O
= O
.061 O
) O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
16 I-Premise
% I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
29 I-Premise
% I-Premise
in I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.056 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
TTP I-Premise
) I-Premise
curves I-Premise
according I-Premise
to I-Premise
treatment I-Premise
allocation I-Premise
was I-Premise
documented I-Premise
( I-Premise
P I-Premise
= I-Premise
.411 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
a I-Premise
trend I-Premise
for I-Premise
more I-Premise
favorable I-Premise
overall I-Premise
survival I-Premise
was I-Premise
documented I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
, I-Premise
although B-Premise
the I-Premise
P I-Premise
value I-Premise
was I-Premise
of I-Premise
borderline I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

GEM B-Claim
does I-Claim
not I-Claim
provide I-Claim
an I-Claim
advantage I-Claim
compared I-Claim
with I-Claim
PLD I-Claim
in I-Claim
terms I-Claim
of I-Claim
TTP I-Claim
in I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
experience I-Claim
recurrence I-Claim
within I-Claim
12 I-Claim
months I-Claim
after I-Claim
primary I-Claim
treatment I-Claim
but I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
spectrum I-Claim
of I-Claim
drugs I-Claim
to I-Claim
be I-Claim
possibly I-Claim
used I-Claim
in I-Claim
the I-Claim
salvage I-Claim
setting I-Claim
. I-Claim

The O
aim O
of O
this O
multicenter O
randomized O
trial O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
sentinel O
lymph O
node O
( O
SLN O
) O
biopsy O
compared O
with O
axillary O
lymph O
node O
dissection O
( O
ALND O
) O
. O

All O
studies O
on O
SLN O
biopsy O
in O
breast O
cancer O
report O
a O
variable O
FALSE O
negative O
rate O
, O
whose O
prognostic O
consequences O
are O
still O
unclear O
. O

From O
May O
1999 O
to O
December O
2004 O
, O
patients O
with O
breast O
cancer O
< O
or O
3 O
cm O
were O
randomly O
assigned O
to O
receive O
SLN O
biopsy O
associated O
with O
ALND O
( O
ALND O
arm O
) O
or O
SLN O
biopsy O
followed O
by O
ALND O
only O
if O
the O
SLN O
was O
metastatic O
( O
SLN O
arm O
) O
. O

The O
main O
aim O
was O
the O
comparison O
of O
disease-free O
survival O
in O
the O
2 O
arms O
. O

A O
total O
of O
749 O
patients O
were O
randomized O
and O
697 O
were O
available O
for O
analysis O
. O

SLNs O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
SLNs O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28.5 O
% O
) O
. O

In O
the O
ALND O
group O
, O
positive O
non-SLNs O
were O
found O
in O
18 O
patients O
with O
negative O
SLN O
, O
giving O
a O
FALSE O
negative O
rate O
of O
16.7 O
% O
( O
18 O
of O
108 O
) O
. O

Postoperative B-Premise
side I-Premise
effects I-Premise
were I-Premise
significantly I-Premise
less I-Premise
in I-Premise
the I-Premise
SLN I-Premise
group I-Premise
and I-Premise
there I-Premise
was I-Premise
no I-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
SLN I-Premise
procedure I-Premise
on I-Premise
psychologic I-Premise
well I-Premise
being I-Premise
. I-Premise

At O
a O
median O
follow-up O
of O
56 O
months O
, O
there O
were O
more O
locoregional O
recurrences O
in O
the O
SLN O
arm O
, O
and O
the O
5-year O
disease-free O
survival O
was O
89.9 O
% O
in O
the O
ALND O
arm O
and O
87.6 O
% O
in O
the O
SLN O
arm O
, O
with O
a O
difference O
of O
2.3 O
% O
( O
95 O
% O
confidence O
interval O
: O
-3.1 O
% O
to O
7.6 O
% O
) O
. O

However B-Premise
, I-Premise
the I-Premise
number I-Premise
of I-Premise
enrolled I-Premise
patients I-Premise
was I-Premise
not I-Premise
sufficient I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

However B-Claim
, I-Claim
its I-Claim
safety I-Claim
should I-Claim
be I-Claim
confirmed I-Claim
by I-Claim
the I-Claim
results I-Claim
of I-Claim
larger I-Claim
randomized I-Claim
trials I-Claim
and I-Claim
meta-analyses I-Claim
. I-Claim

Nocturnal O
administration O
of O
branched-chain O
amino O
acid O
( O
BCAA O
) O
granules O
improves O
serum O
albumin O
levels O
in O
patients O
with O
cirrhosis O
. O

However O
, O
it O
is O
unclear O
whether O
or O
not O
this O
administration O
method O
can O
improve O
the O
patients O
' O
quality O
of O
life O
( O
QOL O
) O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
BCAA O
granules O
, O
given O
nocturnally O
, O
in O
improving O
QOL O
in O
these O
patients O
. O

We O
performed O
a O
multicenter O
, O
randomized O
controlled O
trial O
examining O
the O
comparative O
effects O
of O
BCAA O
granules O
given O
orally O
for O
3 O
months O
with O
daytime O
or O
nocturnal O
administration O
in O
patients O
with O
compensated O
cirrhosis O
. O

Health-related O
QOL O
was O
measured O
by O
a O
Japanese O
version O
of O
the O
questionnaire O
on O
subjective O
and O
objective O
symptoms O
, O
and O
the O
Short O
Form-8 O
( O
SF-8 O
) O
questionnaire O
. O

Twenty-one O
patients O
received O
BCAA O
granules O
three O
times O
a O
day O
( O
one O
sachet O
after O
each O
meal O
: O
the O
daytime O
group O
) O
, O
and O
16 O
patients O
received O
the O
granules O
twice O
a O
day O
( O
one O
sachet O
after O
breakfast O
, O
and O
two O
sachets O
before O
bedtime O
: O
the O
nocturnal O
group O
) O
. O

Baseline O
characteristics O
did O
not O
differ O
between O
the O
groups O
( O
whole O
cohort O
: O
Child-Pugh O
grade O
A/B O
, O
21/16 O
";" O
mean O
age O
, O
68.2 O
years O
) O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

The B-Premise
daytime I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
effect I-Premise
on I-Premise
general I-Premise
health I-Premise
, I-Premise
vitality I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
mental I-Premise
health I-Premise
, I-Premise
and I-Premise
role I-Premise
emotional I-Premise
as I-Premise
revealed I-Premise
on I-Premise
the I-Premise
SF-8 I-Premise
. I-Premise

Conversely B-Premise
, I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
exhibited I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
muscle I-Premise
cramps I-Premise
in I-Premise
the I-Premise
legs I-Premise
( I-Premise
P I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
improved I-Premise
Fisher I-Premise
's I-Premise
ratio I-Premise
after I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Nocturnal B-Claim
administration I-Claim
of I-Claim
BCAA I-Claim
granules I-Claim
in I-Claim
patients I-Claim
with I-Claim
cirrhosis I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
muscle I-Claim
cramps I-Claim
in I-Claim
the I-Claim
leg I-Claim
but I-Claim
did I-Claim
not I-Claim
improve I-Claim
the I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

Treatment O
of O
patients O
with O
advanced O
or O
metastatic O
esophagogastric O
adenocarcinoma O
should O
not O
only O
prolong O
life O
but O
also O
provide O
relief O
of O
symptoms O
and O
improve O
quality O
of O
life O
( O
QOL O
) O
. O

Esophagogastric O
adenocarcinoma O
mainly O
occurs O
in O
elderly O
patients O
, O
but O
they O
are O
underrepresented O
in O
most O
clinical O
trials O
and O
often O
do O
not O
receive O
effective O
combination O
chemotherapy O
, O
most O
probably O
for O
fear O
of O
intolerance O
. O

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
within O
the O
randomized O
FLOT65+ O
phase O
II O
trial O
. O

Within O
the O
FLOT65+ O
trial O
, O
a O
total O
of O
143 O
patients O
aged O
≥65 O
years O
were O
randomly O
allocated O
to O
receive O
biweekly O
oxaliplatin O
plus O
5-fluorouracil O
( O
5-FU O
) O
continuous O
infusion O
and O
folinic O
acid O
( O
FLO O
) O
or O
the O
same O
regimen O
in O
combination O
with O
docetaxel O
50 O
mg/m O
( O
2 O
) O
( O
FLOT O
) O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

Time O
to O
definitive O
deterioration O
of O
QOL O
parameters O
was O
analyzed O
and O
compared O
within O
the O
treatment O
arms O
. O

The O
median O
age O
of O
patients O
was O
70 O
years O
. O

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease-free I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

The O
proportions O
of O
patients O
with O
evaluable O
baseline O
EORTC O
QLQ-C30 O
and O
STO22 O
questionnaires O
were O
balanced O
( O
83 O
% O
in O
FLOT O
and O
89 O
% O
in O
FLO O
) O
. O

Considering O
evaluable O
patients O
with O
assessable O
questionnaires O
( O
n O
= O
123 O
) O
, O
neither O
functioning O
nor O
symptom O
parameters O
differed O
significantly O
in O
favor O
of O
one O
of O
the O
two O
treatment O
groups O
. O

Particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise

Notably O
, O
patients B-Premise
receiving I-Premise
FLO I-Premise
or I-Premise
FLOT I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
QOL I-Premise
results I-Premise
. I-Premise

Although B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
FLOT I-Premise
, I-Premise
no B-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
addition I-Premise
of I-Premise
docetaxel I-Premise
on I-Premise
QOL I-Premise
parameters I-Premise
could I-Premise
be I-Premise
demonstrated I-Premise
. I-Premise

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient-reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

To O
compare O
the O
toxicities O
, O
tumor O
control O
, O
survival O
, O
and O
quality O
of O
life O
of O
nasopharyngeal O
cancer O
( O
NPC O
) O
patients O
treated O
with O
sequential O
neoadjuvant O
chemotherapy O
followed O
by O
concurrent O
cisplatin-radiotherapy O
( O
CRT O
) O
or O
CRT O
alone O
. O

Previously O
untreated O
stage O
III O
to O
IVB O
NPC O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg/m O
( O
2 O
) O
/wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
CRT O
alone O
. O

Planned O
accrual O
was O
30 O
patients O
per O
arm O
to O
detect O
20 O
% O
difference O
of O
toxicities O
based O
on O
95 O
% O
CIs O
. O

From O
November O
2002 O
to O
November O
2004 O
, O
65 O
eligible O
patients O
were O
randomly O
assigned O
to O
neoadjuvant O
chemotherapy O
followed O
by O
CRT O
( O
n O
= O
34 O
) O
or O
CRT O
alone O
( O
n O
= O
31 O
) O
. O

There B-Premise
was I-Premise
a I-Premise
high I-Premise
rate I-Premise
of I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
97 I-Premise
% I-Premise
) I-Premise
but I-Premise
not I-Premise
neutropenic I-Premise
fever I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
during I-Premise
neoadjuvant I-Premise
chemotherapy I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
in I-Premise
rates I-Premise
of I-Premise
acute I-Premise
toxicities I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
during I-Premise
CRT I-Premise
. I-Premise

Dose B-Premise
intensities I-Premise
of I-Premise
concurrent I-Premise
cisplatin I-Premise
, I-Premise
late I-Premise
RT I-Premise
toxicities I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
were I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
3-year I-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
88.2 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.20 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
) I-Premise
. I-Premise

The B-Premise
3-year I-Premise
overall I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
94.1 I-Premise
% I-Premise
and I-Premise
67.7 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.24 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.078 I-Premise
to I-Premise
0.73 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
. I-Premise

Neoadjuvant B-Claim
docetaxel-cisplatin I-Claim
followed I-Claim
by I-Claim
CRT I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
a I-Claim
manageable I-Claim
toxicity I-Claim
profile I-Claim
that I-Claim
allowed I-Claim
subsequent I-Claim
delivery I-Claim
of I-Claim
full-dose I-Claim
CRT I-Claim
. I-Claim

Preliminary B-Claim
results I-Claim
suggested I-Claim
a I-Claim
positive I-Claim
impact I-Claim
on I-Claim
survival I-Claim
. I-Claim

A O
phase O
III O
study O
to O
definitively O
test O
this O
neoadjuvant-concurrent O
strategy O
is O
warranted O
. O

Fatigue O
is O
a O
frequent O
problem O
after O
surgical O
treatment O
of O
solid O
tumours O
. O

Aerobic B-Claim
exercise I-Claim
and I-Claim
psychosocial I-Claim
interventions I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
this I-Claim
symptom I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Therefore O
, O
we O
compared O
the O
effect O
of O
the O
two O
therapies O
on O
fatigue O
in O
a O
randomised O
controlled O
study O
. O

Seventy-two O
patients O
who O
underwent O
surgery O
for O
lung O
( O
n=27 O
) O
or O
gastrointestinal O
tumours O
( O
n=42 O
) O
were O
assigned O
to O
an O
aerobic O
exercise O
group O
( O
stationary O
biking O
30 O
min O
five O
times O
weekly O
) O
or O
a O
progressive O
relaxation O
training O
group O
( O
45 O
min O
three O
times O
per O
week O
) O
. O

Both O
interventions O
were O
carried O
out O
for O
3 O
weeks O
. O

At O
the O
beginning O
and O
the O
end O
of O
the O
study O
, O
we O
evaluated O
physical O
, O
cognitive O
and O
emotional O
status O
and O
somatic O
complaints O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
Module O
( O
EORTC-QLQ-30 O
) O
questionnaire O
, O
and O
maximal O
physical O
performance O
with O
an O
ergometric O
stress O
test O
. O

Physical B-Premise
performance I-Premise
of I-Premise
the I-Premise
training I-Premise
group I-Premise
improved I-Premise
significantly I-Premise
during I-Premise
the I-Premise
programme I-Premise
( I-Premise
9.4+/-20 I-Premise
watts I-Premise
, I-Premise
p=0.01 I-Premise
) I-Premise
but I-Premise
remained I-Premise
unchanged I-Premise
in I-Premise
the I-Premise
relaxation I-Premise
group I-Premise
( I-Premise
1.5+/-14.8 I-Premise
watts I-Premise
, I-Premise
p=0.37 I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
and I-Premise
global I-Premise
health I-Premise
scores I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
during I-Premise
the I-Premise
intervention I-Premise
( I-Premise
fatigue I-Premise
: I-Premise
training I-Premise
group I-Premise
21 I-Premise
% I-Premise
, I-Premise
relaxation I-Premise
group I-Premise
19 I-Premise
% I-Premise
";" I-Premise
global I-Premise
health I-Premise
of I-Premise
both I-Premise
groups I-Premise
19 I-Premise
% I-Premise
, I-Premise
p I-Premise
for I-Premise
all I-Premise
< I-Premise
or I-Premise
=0.01 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
changes I-Premise
in I-Premise
the I-Premise
scores I-Premise
of I-Premise
both I-Premise
groups I-Premise
( I-Premise
p=0.67 I-Premise
) I-Premise
. I-Premise

We B-Claim
conclude I-Claim
that I-Claim
a I-Claim
structured I-Claim
aerobic I-Claim
training I-Claim
programme I-Claim
improves I-Claim
the I-Claim
physical I-Claim
performance I-Claim
of I-Claim
patients I-Claim
recovering I-Claim
from I-Claim
surgery I-Claim
for I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

However B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

The O
randomized O
, O
controlled O
BOLERO-2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression-free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
EVE O
+ O
EXE O
) O
versus O
placebo O
plus O
exemestane O
( O
PBO O
+ O
EXE O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O

This O
analysis O
investigated O
the O
treatment O
effects O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
. O

Using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
questionnaire O
, O
HRQOL O
was O
assessed O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
disease O
progression O
and/or O
treatment O
discontinuation O
. O

The O
30 O
items O
in O
15 O
subscales O
of O
the O
QLQ-C30 O
include O
global O
health O
status O
wherein O
higher O
scores O
( O
range O
, O
0-100 O
) O
indicate O
better O
HRQOL O
. O

This O
analysis O
included O
a O
protocol-specified O
time O
to O
definitive O
deterioration O
( O
TDD O
) O
analysis O
at O
a O
5 O
% O
decrease O
in O
HRQOL O
versus O
baseline O
, O
with O
no O
subsequent O
increase O
above O
this O
threshold O
. O

The O
authors O
report O
additional O
sensitivity O
analyses O
using O
10-point O
minimal O
important O
difference O
decreases O
in O
the O
global O
health O
status O
score O
versus O
baseline O
. O

Treatment O
arms O
were O
compared O
using O
the O
stratified O
log-rank O
test O
and O
Cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O

Baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64.7 O
vs O
65.3 O
) O
. O

The B-Premise
median I-Premise
TDD I-Premise
in I-Premise
HRQOL I-Premise
was I-Premise
8.3 I-Premise
months I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
versus I-Premise
5.8 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0084 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
10-point I-Premise
minimal I-Premise
important I-Premise
difference I-Premise
, I-Premise
the I-Premise
median I-Premise
TDD I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
was I-Premise
11.7 I-Premise
months I-Premise
versus I-Premise
8.4 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.80 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.1017 I-Premise
) I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
TDD I-Claim
in I-Claim
global I-Claim
HRQOL I-Claim
versus I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

Mucositis B-Premise
occurs I-Premise
in I-Premise
almost I-Premise
all I-Premise
patients I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
for I-Premise
head I-Premise
and I-Premise
neck I-Premise
cancer I-Premise
. I-Premise

The O
aim O
of O
this O
multicenter O
, O
double-blind O
, O
prospective O
, O
randomized O
trial O
was O
to O
evaluate O
the O
clinical O
efficacy O
of O
an O
economically O
viable O
antimicrobial O
lozenge O
( O
bacitracin O
, O
clotrimazole O
, O
and O
gentamicin O
[ O
BcoG O
] O
) O
in O
the O
alleviation O
of O
radiation-induced O
mucositis O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

One O
hundred O
thirty-seven O
eligible O
patients O
were O
randomized O
to O
treatment O
with O
either O
antimicrobial O
lozenge O
( O
69 O
patients O
) O
or O
placebo O
lozenge O
( O
68 O
patients O
) O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
the O
time O
to O
development O
of O
severe O
mucositis O
from O
the O
start O
of O
radiotherapy O
. O

Secondary O
end O
points O
included O
severity O
and O
duration O
of O
mucositis O
, O
pain O
measurement O
, O
radiation O
therapy O
interruption O
, O
and O
quality O
of O
life O
. O

Mucositis O
was O
scored O
using O
a O
validated O
mucositis O
scoring O
system O
. O

Toxicity B-Premise
profiles I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
development I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
radiotherapy I-Premise
was I-Premise
3.61 I-Premise
weeks I-Premise
on I-Premise
BCoG I-Premise
and I-Premise
3.96 I-Premise
weeks I-Premise
on I-Premise
placebo I-Premise
( I-Premise
P I-Premise
=.61 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
arms I-Premise
in I-Premise
the I-Premise
extent I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
as I-Premise
measured I-Premise
by I-Premise
physician I-Premise
, I-Premise
in I-Premise
oral I-Premise
toxicities I-Premise
as I-Premise
recorded I-Premise
by I-Premise
patients I-Premise
, I-Premise
or I-Premise
in I-Premise
radiotherapy I-Premise
delays I-Premise
. I-Premise

This O
study O
was O
conducted O
on O
the O
basis O
of O
a O
pilot O
study O
that O
demonstrated O
the O
BCoG O
lozenge O
to O
be O
tolerable O
and O
microbiologically O
efficacious O
. O

A O
validated O
mucositis O
scoring O
system O
was O
used O
. O

However O
, O
in B-Claim
this I-Claim
group I-Claim
of I-Claim
patients I-Claim
treated I-Claim
with I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
lozenge I-Claim
did I-Claim
not I-Claim
impact I-Claim
significantly I-Claim
on I-Claim
the I-Claim
severity I-Claim
of I-Claim
mucositis I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

Treatments O
are O
associated O
with O
morbidity O
. O

Results O
for O
functional O
outcome O
and O
quality O
of O
life O
are O
rarely O
reported O
beyond O
10 O
years O
and O
are O
lacking O
from O
randomised O
settings O
. O

We O
report O
results O
for O
quality O
of O
life O
for O
men O
in O
the O
Scandinavian O
Prostate O
Cancer O
Group O
Study O
Number O
4 O
( O
SPCG-4 O
) O
after O
a O
median O
follow-up O
of O
more O
than O
12 O
years O
. O

All O
living O
Swedish O
and O
Finnish O
men O
( O
400 O
of O
695 O
) O
randomly O
assigned O
to O
radical O
prostatectomy O
or O
watchful O
waiting O
in O
SPCG-4 O
from O
1989 O
to O
1999 O
were O
included O
in O
our O
analysis O
. O

An O
additional O
281 O
men O
were O
included O
in O
a O
population-based O
control O
group O
matched O
for O
region O
and O
age O
. O

Physical O
symptoms O
, O
symptom-induced O
stress O
, O
and O
self-assessed O
quality O
of O
life O
were O
evaluated O
with O
a O
study-specific O
questionnaire O
. O

Longitudinal O
data O
were O
available O
for O
166 O
Swedish O
men O
who O
had O
answered O
quality-of-life O
questionnaires O
at O
an O
earlier O
timepoint O
. O

182 O
( O
88 O
% O
) O
of O
208 O
men O
in O
the O
radical O
prostatectomy O
group O
, O
167 O
( O
87 O
% O
) O
of O
192 O
men O
in O
the O
watchful-waiting O
group O
, O
and O
214 O
( O
76 O
% O
) O
of O
281 O
men O
in O
the O
population-based O
control O
group O
answered O
the O
questionnaire O
. O

Men O
in O
SPCG-4 O
had O
a O
median O
follow-up O
of O
12·2 O
years O
( O
range O
7-17 O
) O
and O
a O
median O
age O
of O
77·0 O
years O
( O
range O
61-88 O
) O
. O

High B-Premise
self-assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Anxiety B-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
SPCG-4 I-Premise
groups I-Premise
( I-Premise
77 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
178 I-Premise
and I-Premise
69 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
161 I-Premise
men I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
68 I-Premise
[ I-Premise
33 I-Premise
% I-Premise
] I-Premise
of I-Premise
208 I-Premise
men I-Premise
";" I-Premise
relative I-Premise
risk I-Premise
1·42 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1·07-1·88 I-Premise
) I-Premise
. I-Premise

Prevalence B-Premise
of I-Premise
erectile I-Premise
dysfunction I-Premise
was I-Premise
84 I-Premise
% I-Premise
( I-Premise
146 I-Premise
of I-Premise
173 I-Premise
men I-Premise
) I-Premise
in I-Premise
the I-Premise
radical I-Premise
prostatectomy I-Premise
group I-Premise
, I-Premise
80 I-Premise
% I-Premise
( I-Premise
122 I-Premise
of I-Premise
153 I-Premise
) I-Premise
in I-Premise
the I-Premise
watchful-waiting I-Premise
group I-Premise
, I-Premise
and I-Premise
46 I-Premise
% I-Premise
( I-Premise
95 I-Premise
of I-Premise
208 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
prevalence I-Premise
of I-Premise
urinary I-Premise
leakage I-Premise
was I-Premise
41 I-Premise
% I-Premise
( I-Premise
71 I-Premise
of I-Premise
173 I-Premise
) I-Premise
, I-Premise
11 I-Premise
% I-Premise
( I-Premise
18 I-Premise
of I-Premise
164 I-Premise
) I-Premise
, I-Premise
and I-Premise
3 I-Premise
% I-Premise
( I-Premise
six I-Premise
of I-Premise
209 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Distress B-Premise
caused I-Premise
by I-Premise
these I-Premise
symptoms I-Premise
was I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
often I-Premise
by I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
than I-Premise
by I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
. I-Premise

In B-Premise
a I-Premise
longitudinal I-Premise
analysis I-Premise
of I-Premise
men I-Premise
in I-Premise
SPCG-4 I-Premise
who I-Premise
provided I-Premise
information I-Premise
at I-Premise
two I-Premise
follow-up I-Premise
points I-Premise
9 I-Premise
years I-Premise
apart I-Premise
, I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
85 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
and I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
of I-Premise
80 I-Premise
men I-Premise
allocated I-Premise
watchful I-Premise
waiting I-Premise
reported I-Premise
an I-Premise
increase I-Premise
in I-Premise
number I-Premise
of I-Premise
physical I-Premise
symptoms I-Premise
";" I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
of I-Premise
82 I-Premise
and I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
of I-Premise
74 I-Premise
men I-Premise
, I-Premise
respectively I-Premise
, I-Premise
reported I-Premise
a I-Premise
reduction I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

For B-Premise
men I-Premise
in I-Premise
SPCG-4 I-Premise
, I-Premise
negative I-Premise
side-effects I-Premise
were I-Premise
common I-Premise
and I-Premise
added I-Premise
more I-Premise
stress I-Premise
than I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
control I-Premise
population I-Premise
. I-Premise

In B-Claim
the I-Claim
radical I-Claim
prostatectomy I-Claim
group I-Claim
, I-Claim
erectile I-Claim
dysfunction I-Claim
and I-Claim
urinary I-Claim
leakage I-Claim
were I-Claim
often I-Claim
consequences I-Claim
of I-Claim
surgery I-Claim
. I-Claim

In B-Claim
the I-Claim
watchful-waiting I-Claim
group I-Claim
, I-Claim
side-effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim

The B-Claim
number I-Claim
and I-Claim
severity I-Claim
of I-Claim
side-effects I-Claim
changes I-Claim
over I-Claim
time I-Claim
at I-Claim
a I-Claim
higher I-Claim
rate I-Claim
than I-Claim
is I-Claim
caused I-Claim
by I-Claim
normal I-Claim
ageing I-Claim
and I-Claim
a I-Claim
loss I-Claim
of I-Claim
sexual I-Claim
ability I-Claim
is I-Claim
a I-Claim
persistent I-Claim
psychological I-Claim
problem I-Claim
for I-Claim
both I-Claim
interventions I-Claim
. I-Claim

An O
understanding O
of O
the O
patterns O
of O
side-effects O
and O
time O
dimension O
of O
their O
occurrence O
for O
each O
treatment O
is O
important O
for O
full O
patient O
information O
. O

For B-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
treatment I-Claim
is I-Claim
primarily I-Claim
palliative I-Claim
, I-Claim
relying I-Claim
mainly I-Claim
on I-Claim
the I-Claim
suppression I-Claim
of I-Claim
systemic I-Claim
androgen I-Claim
hormone I-Claim
levels I-Claim
. I-Claim

To O
help O
document O
the O
achievement O
of O
palliation O
and O
to O
characterize O
positive O
and O
negative O
effects O
of O
treatment O
, O
we O
evaluated O
quality-of-life O
( O
QOL O
) O
parameters O
in O
patients O
with O
metastatic O
prostate O
cancer O
who O
were O
randomly O
assigned O
to O
two O
methods O
of O
androgen O
deprivation O
. O

Patients O
( O
n O
= O
739 O
) O
with O
stage O
M1 O
( O
bone O
or O
soft O
tissue O
metastasis O
) O
prostate O
cancer O
were O
enrolled O
in O
a O
QOL O
protocol O
that O
was O
a O
companion O
to O
Southwest O
Oncology O
Group O
INT-0105 O
, O
a O
randomized O
double-blind O
trial O
comparing O
treatment O
with O
bilateral O
orchiectomy O
( O
surgical O
castration O
) O
plus O
either O
flutamide O
or O
placebo O
. O

Patients O
completed O
a O
comprehensive O
battery O
of O
QOL O
questionnaires O
at O
random O
assignment O
to O
treatment O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O

Data O
were O
collected O
on O
three O
treatment-specific O
symptoms O
( O
diarrhea O
, O
gas O
pain O
, O
and O
body O
image O
) O
, O
on O
physical O
functioning O
, O
and O
on O
emotional O
functioning O
. O

All O
P O
values O
are O
two-sided O
. O

Questionnaire O
return O
rates O
for O
this O
study O
never O
dropped O
below O
80 O
% O
";" O
only O
2 O
% O
of O
the O
patients O
did O
not O
submit O
baseline O
QOL O
assessments O
. O

Cross-sectional B-Premise
analyses I-Premise
( I-Premise
corrected I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
) I-Premise
identified I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
that I-Premise
favored I-Premise
orchiectomy I-Premise
plus I-Premise
placebo I-Premise
for I-Premise
two I-Premise
of I-Premise
the I-Premise
five I-Premise
primary I-Premise
QOL I-Premise
parameters I-Premise
as I-Premise
follows I-Premise
: I-Premise
patients I-Premise
receiving I-Premise
flutamide I-Premise
reported I-Premise
more I-Premise
diarrhea I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
worse I-Premise
emotional I-Premise
functioning I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
( I-Premise
both I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Longitudinal B-Premise
analyses I-Premise
replicated I-Premise
these I-Premise
findings I-Premise
. I-Premise

Other B-Premise
analyzed I-Premise
QOL I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise

We B-Claim
found I-Claim
a I-Claim
consistent I-Claim
pattern I-Claim
of I-Claim
better I-Claim
QOL I-Claim
outcomes I-Claim
at I-Claim
each I-Claim
follow-up I-Claim
assessment I-Claim
during I-Claim
the I-Claim
first I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
for I-Claim
orchiectomized I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
who I-Claim
received I-Claim
placebo I-Claim
versus I-Claim
flutamide I-Claim
. I-Claim

Improvement B-Claim
over I-Claim
time I-Claim
was I-Claim
evident I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
but I-Claim
more I-Claim
so I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
placebo I-Claim
. I-Claim

Regularly O
collecting O
patient-reported O
outcomes O
( O
PROs O
) O
of O
health-related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient-physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
regular O
completion O
of O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
and O
Hospital O
Anxiety O
and O
Depression O
Scale O
with O
feedback O
to O
oncologists O
) O
, O
attention-control O
( O
completion O
of O
same O
questionnaires O
without O
feedback O
) O
, O
and O
control O
( O
standard O
care O
) O
arms O
. O

The O
content O
of O
consultation O
audio O
recordings O
between O
28 O
oncologists O
and O
198 O
patients O
over O
four O
consecutive O
visits O
( O
792 O
consultations O
) O
was O
analyzed O
. O

Mixed-effects O
models O
and O
multivariate O
regressions O
were O
used O
to O
examine O
the O
longitudinal O
impact O
of O
the O
intervention O
on O
patient-physician O
communication O
, O
dynamics O
of O
patient-physician O
interaction O
, O
and O
the O
association O
between O
PROs O
and O
the O
content O
of O
clinic O
discussion O
. O

Patients B-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
discussed I-Premise
more I-Premise
symptoms I-Premise
over I-Premise
time I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
attention-control I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
and I-Premise
control I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
arms I-Premise
. I-Premise

No B-Premise
study I-Premise
arm I-Premise
effect I-Premise
was I-Premise
observed I-Premise
for I-Premise
function I-Premise
discussions I-Premise
. I-Premise

Discussion O
topics O
were O
predominantly O
raised O
by O
patients/relatives O
, O
regardless O
of O
arm O
allocation O
. O

Clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient-reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient-reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise

A B-Premise
positive I-Premise
longitudinal I-Premise
impact I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
symptom I-Premise
discussion I-Premise
was I-Premise
observed I-Premise
, I-Premise
but B-Premise
not I-Premise
for I-Premise
function I-Premise
discussion I-Premise
, I-Premise
suggesting I-Premise
that I-Premise
potentially I-Premise
serious I-Premise
problems I-Premise
may I-Premise
remain I-Premise
unaddressed I-Premise
. I-Premise

Training B-Claim
oncologists I-Claim
in I-Claim
responding I-Claim
to I-Claim
patient-reported I-Claim
functional I-Claim
concerns I-Claim
may I-Claim
increase I-Claim
the I-Claim
impact I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

Anemia B-Claim
is I-Claim
an I-Claim
expected I-Claim
consequence I-Claim
of I-Claim
intensive I-Claim
chemotherapy I-Claim
regimens I-Claim
administered I-Claim
to I-Claim
patients I-Claim
with I-Claim
acute I-Claim
leukemia I-Claim
. I-Claim

This O
study O
was O
designed O
to O
determine O
whether O
epoetin O
alpha O
would O
decrease O
the O
number O
of O
transfusion O
events O
and O
units O
of O
packed O
erythrocytes O
( O
PRBCs O
) O
transfused O
, O
and O
the O
secondary O
objective O
was O
to O
study O
the O
effects O
of O
epoetin O
alpha O
on O
quality O
of O
life O
( O
QOL O
) O
and O
complete O
remission O
( O
CR O
) O
rates O
. O

Patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphoblastic O
lymphoma O
( O
LL O
) O
, O
or O
Burkitt O
lymphoma O
( O
BL O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O

QOL O
was O
assessed O
by O
using O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
and O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Anemia O
questionnaires O
. O

Fifty-five O
patients O
were O
randomized O
to O
receive O
epoetin O
alpha O
, O
and O
54 O
patients O
received O
no O
epoetin O
. O

Transfusion O
data O
were O
available O
for O
79 O
of O
81 O
evaluable O
patients O
( O
98 O
% O
) O
who O
completed O
the O
treatment/observation O
period O
. O

The B-Premise
trial I-Premise
was I-Premise
stopped I-Premise
early I-Premise
because I-Premise
of I-Premise
poor I-Premise
accrual I-Premise
before I-Premise
the I-Premise
target I-Premise
of I-Premise
123 I-Premise
evaluable I-Premise
patients I-Premise
was I-Premise
met I-Premise
. I-Premise

A B-Premise
mean I-Premise
of I-Premise
10.6 I-Premise
units I-Premise
of I-Premise
PRBCs I-Premise
over I-Premise
5 I-Premise
months I-Premise
were I-Premise
administered I-Premise
to I-Premise
those I-Premise
who I-Premise
received I-Premise
epoetin I-Premise
alpha I-Premise
compared I-Premise
with I-Premise
13 I-Premise
units I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
receive I-Premise
epoetin I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-Anemia I-Premise
or I-Premise
ESAS I-Premise
instruments I-Premise
. I-Premise

The B-Premise
CR I-Premise
rate I-Premise
and I-Premise
the I-Premise
3-year I-Premise
CR I-Premise
duration I-Premise
were I-Premise
not I-Premise
affected I-Premise
adversely I-Premise
by I-Premise
use I-Premise
of I-Premise
epoetin I-Premise
alpha I-Premise
. I-Premise

Epoetin B-Claim
alpha I-Claim
decreased I-Claim
the I-Claim
number I-Claim
of I-Claim
PRBC I-Claim
transfusions I-Claim
and I-Claim
did I-Claim
not I-Claim
appear I-Claim
to I-Claim
have I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
remission I-Claim
duration I-Claim
. I-Claim

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

A O
single-item O
linear O
analogue O
self-assessment O
scale O
for O
mood O
was O
compared O
with O
a O
28-item O
adjective O
checklist O
for O
emotional O
well-being O
. O

To O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well-being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1,169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O

These O
patients O
were O
enrolled O
in O
two O
International O
Breast O
Cancer O
Study O
Group O
randomized O
clinical O
trials O
in O
operable O
breast O
cancer O
conducted O
from O
1986 O
to O
1993 O
. O

To O
assess O
concurrent O
validity O
, O
Pearson O
's O
correlation O
between O
the O
linear O
analogue O
self-assessment O
scale O
and O
the O
adjective O
checklist O
were O
calculated O
for O
each O
time-point O
within O
each O
treatment O
group O
and O
for O
the O
two O
assessments O
after O
recurrence O
. O

Responsiveness O
to O
treatment O
and O
recurrence O
were O
analyzed O
using O
paired O
t O
tests O
and O
the O
squared O
ratio O
of O
these O
t O
tests O
, O
an O
estimate O
of O
relative O
efficiency O
. O

Concurrent O
validity O
of O
the O
mood O
linear O
analogue O
self-assessment O
was O
consistently O
confirmed O
across O
four O
language O
groups O
. O

Both B-Claim
measures I-Claim
were I-Claim
responsive I-Claim
";" I-Claim
out B-Premise
of I-Premise
24 I-Premise
changes I-Premise
over I-Premise
time I-Premise
, I-Premise
19 I-Premise
were I-Premise
in I-Premise
the I-Premise
expected I-Premise
direction I-Premise
for I-Premise
the I-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
for I-Premise
9 I-Premise
of I-Premise
19 I-Premise
) I-Premise
and I-Premise
17 I-Premise
for I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
for I-Premise
10 I-Premise
of I-Premise
17 I-Premise
) I-Premise
. I-Premise

The B-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0.16 I-Premise
to I-Premise
2.45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0.66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/t/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

The B-Claim
mood I-Claim
linear I-Claim
analogue I-Claim
self-assessment I-Claim
scale I-Claim
is I-Claim
a I-Claim
valid I-Claim
indicator I-Claim
of I-Claim
emotional I-Claim
well-being I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
large I-Claim
multicenter I-Claim
, I-Claim
multicultural I-Claim
trials I-Claim
in I-Claim
which I-Claim
comprehensive I-Claim
scales I-Claim
are I-Claim
less I-Claim
feasible I-Claim
. I-Claim

This B-Claim
investigation I-Claim
supports I-Claim
the I-Claim
clinical I-Claim
relevance I-Claim
of I-Claim
linear I-Claim
analogue I-Claim
self-assessment I-Claim
scales I-Claim
as I-Claim
indicators I-Claim
of I-Claim
components I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
cancer I-Claim
clinical I-Claim
trials I-Claim
. I-Claim

To O
analyze O
the O
predictive O
value O
of O
PSA O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
metastatic O
prostate O
cancer O
. O

PSA O
and O
testosterone O
data O
were O
used O
from O
a O
phase O
III O
trial O
randomizing O
patients O
without O
progression O
and O
PSA O
< O
4 O
ng/ml O
( O
n O
= O
193 O
) O
, O
after O
6 O
months O
induction O
course O
, O
between O
continuous O
( O
CAD O
) O
( O
n O
= O
96 O
) O
and O
intermittent O
( O
IAD O
) O
( O
n O
= O
97 O
) O
ADT O
. O

The O
2-year O
risk O
of O
progression O
was O
calculated O
for O
baseline O
PSA O
, O
'fast O
' O
and O
'slow O
' O
PSA O
decline O
to O
< O
4 O
ng/ml O
( O
60 O
days O
cut-off O
) O
, O
PSA O
nadir O
, O
performance O
status O
and O
pain O
. O

Testosterone O
kinetics O
and O
QOL O
were O
also O
evaluated O
. O

Univariate O
Kaplan O
Meier O
survival O
analysis O
and O
log O
rank O
tests O
were O
used O
to O
compare O
the O
risk O
of O
progression O
. O

For O
progression O
analysis O
, O
173 O
patients O
' O
data O
were O
available O
. O

The O
2-year O
risk O
of O
progression O
for O
baseline O
PSA O
< O
50 O
ng/ml O
, O
50 O
to O
< O
500 O
ng/ml O
, O
and O
≥ O
500 O
ng/ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
P O
= O
0.03 O
) O
in O
CAD O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
P O
= O
0.006 O
) O
in O
IAD O
, O
respectively O
. O

The B-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
for I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
and I-Premise
> I-Premise
0.2 I-Premise
to I-Premise
4 I-Premise
ng/ml I-Premise
in I-Premise
CAD I-Premise
was I-Premise
31 I-Premise
% I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
IAD I-Premise
group I-Premise
, I-Premise
a I-Premise
similar I-Premise
trend I-Premise
was I-Premise
seen I-Premise
. I-Premise

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

PSA O
decline O
showed O
no O
predictive O
value O
. O

Patients B-Premise
without I-Premise
pain I-Premise
had I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

After O
the O
first O
and O
second O
IAD O
cycle O
92 O
% O
and O
46 O
% O
, O
respectively O
, O
had O
a O
normalized O
testosterone O
. O

No B-Premise
QOL I-Premise
difference I-Premise
was I-Premise
found I-Premise
, I-Premise
although I-Premise
more I-Premise
side I-Premise
effects I-Premise
occurred I-Premise
in I-Premise
CAD I-Premise
. I-Premise

Metastatic B-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
high I-Claim
baseline I-Claim
PSA I-Claim
, I-Claim
pain I-Claim
, I-Claim
and I-Claim
high I-Claim
PSA I-Claim
nadir I-Claim
have I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
with I-Claim
ADT I-Claim
. I-Claim

Patients B-Claim
with I-Claim
low I-Claim
PSA I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
IAD I-Claim
compared I-Claim
with I-Claim
CAD I-Claim
. I-Claim

Low O
testosterone O
after O
ADT O
and O
incomplete O
testosterone O
recovery O
may O
explain O
similar O
QOL O
. O

Therefore O
, O
IAD B-Claim
is I-Claim
not I-Claim
a I-Claim
good I-Claim
treatment I-Claim
option I-Claim
for I-Claim
many I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
low-frequency O
low-intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

Cross-over O
single-blind O
random O
clinical O
trial O
. O

Rehabilitation O
service O
. O

Thirty-six O
women O
with O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

Patients O
were O
randomized O
to O
undergo O
10 O
sessions O
of O
manual O
lymphatic O
drainage O
followed O
by O
10 O
sessions O
of O
low-frequency O
low-intensity O
electrotherapy O
or O
to O
undergo O
first O
low-frequency O
low-intensity O
electrotherapy O
followed O
by O
manual O
lymphatic O
drainage O
. O

There O
was O
a O
month O
of O
washout O
time O
between O
treatments O
. O

Each O
patient O
was O
examined O
just O
before O
and O
after O
each O
treatment O
. O

Researchers O
and O
outcome O
assessors O
were O
blinded O
for O
assigned O
treatment O
. O

Outcomes O
were O
lymphoedema O
volume O
, O
pain O
, O
heaviness O
and O
tightness O
, O
and O
health-related O
quality O
of O
life O
measured O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
Questionnaire O
for O
Breast O
Cancer O
version O
4 O
( O
FACT-B+4 O
) O
. O

Carry-over O
, O
period O
and O
treatment O
effects O
were O
analysed O
. O

Treatment O
effect O
was O
assessed O
using O
paired O
t-test O
. O

Thirty O
patients O
finalized O
treatment O
. O

Comparing B-Premise
the I-Premise
changes I-Premise
in I-Premise
low-frequency I-Premise
low-intensity I-Premise
electrotherapy I-Premise
with I-Premise
manual I-Premise
lymphatic I-Premise
drainage I-Premise
changes I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

Low-frequency B-Premise
low-intensity I-Premise
electrotherapy I-Premise
did I-Premise
not I-Premise
reduce I-Premise
lymphoedema I-Premise
volume I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
19.77 I-Premise
mL I-Premise
, I-Premise
P I-Premise
= I-Premise
0.36 I-Premise
) I-Premise
, I-Premise
but O
significant B-Premise
reductions I-Premise
were I-Premise
observed I-Premise
in I-Premise
pain I-Premise
, I-Premise
heaviness I-Premise
and I-Premise
tightness I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
13.1 I-Premise
, I-Premise
16.2 I-Premise
and I-Premise
6.4 I-Premise
mm I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
FACT-B+4 I-Premise
summaries I-Premise
improved I-Premise
significantly I-Premise
( I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
5.4 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.015 I-Premise
) I-Premise
. I-Premise

Manual B-Premise
lymphatic I-Premise
drainage I-Premise
showed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
outcomes I-Premise
. I-Premise

Although B-Claim
there I-Claim
are I-Claim
no I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
changes I-Claim
, I-Claim
the B-Claim
observed I-Claim
trend I-Claim
towards I-Claim
a I-Claim
better I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
is I-Claim
remarkable I-Claim
in I-Claim
low-frequency I-Claim
low-intensity I-Claim
electrotherapy I-Claim
. I-Claim

Molecular O
markers O
to O
predict O
response O
to O
5-fluorouracil O
( O
FU O
) O
-based O
treatment O
of O
recurrent O
or O
metastasised O
colorectal O
cancer O
( O
mCRC O
) O
are O
not O
established O
. O

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5-FU O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mCRC O
. O

Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase O
( O
TS O
) O
mRNA O
quantitation O
. O

Patients O
were O
randomised O
to O
receive O
either O
5-FU/folinic O
acid O
( O
FA O
, O
FUFA O
) O
alone O
or O
in O
combination O
with O
irinotecan O
5-fluorouracil/folinic O
acid O
and O
irinotecan O
( O
FOLFIRI O
) O
stratified O
by O
TS O
( O
low O
versus O
high O
) O
. O

Primary O
end-point O
was O
overall O
response O
to O
first-line O
treatment O
among O
TS O
high O
patients O
. O

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O

Biopsies O
( O
n=168 O
) O
were O
taken O
without O
complications O
. O

TS O
levels O
were O
available O
for O
147 O
patients O
( O
87.5 O
% O
) O
. O

Analysing B-Premise
response I-Premise
to I-Premise
FUFA I-Premise
and I-Premise
FOLFIRI I-Premise
in I-Premise
the I-Premise
per I-Premise
protocol I-Premise
set I-Premise
( I-Premise
n=119 I-Premise
) I-Premise
after I-Premise
un-blinding I-Premise
TS I-Premise
in I-Premise
the I-Premise
data I-Premise
base I-Premise
revealed I-Premise
a I-Premise
trend I-Premise
to I-Premise
better I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
( I-Premise
9/19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
TS I-Premise
high I-Premise
compared I-Premise
to I-Premise
FUFA I-Premise
( I-Premise
5/23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p=0.077 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
with I-Premise
biopsies I-Premise
taken I-Premise
from I-Premise
liver I-Premise
lesions I-Premise
( I-Premise
n=91 I-Premise
) I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
in I-Premise
TS I-Premise
high I-Premise
was I-Premise
53 I-Premise
% I-Premise
( I-Premise
9/17 I-Premise
) I-Premise
and I-Premise
18 I-Premise
% I-Premise
( I-Premise
3/17 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p=0.035 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
with I-Premise
low I-Premise
TS I-Premise
, I-Premise
no I-Premise
remarkable I-Premise
difference I-Premise
in I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
and I-Premise
FUFA I-Premise
was I-Premise
observed I-Premise
. I-Premise

Taking B-Claim
a I-Claim
pre-treatment I-Claim
biopsy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
feasible I-Claim
procedure I-Claim
in I-Claim
mCRC I-Claim
. I-Claim

After B-Claim
validation I-Claim
of I-Claim
our I-Claim
data I-Claim
in I-Claim
a I-Claim
larger I-Claim
group I-Claim
TS I-Claim
determination I-Claim
may I-Claim
have I-Claim
the I-Claim
potential I-Claim
to I-Claim
better I-Claim
help I-Claim
direct I-Claim
systemic I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
primarily I-Claim
non-resectable I-Claim
mCRC I-Claim
. I-Claim

It O
is O
not O
known O
whether O
low-dose O
radioiodine O
( O
1.1 O
GBq O
[ O
30 O
mCi O
] O
) O
is O
as O
effective O
as O
high-dose O
radioiodine O
( O
3.7 O
GBq O
[ O
100 O
mCi O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O

At O
29 O
centers O
in O
the O
United O
Kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low-dose O
and O
high-dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O

Patients O
( O
age O
range O
, O
16 O
to O
80 O
years O
) O
had O
tumor O
stage O
T1 O
to O
T3 O
, O
with O
possible O
spread O
to O
nearby O
lymph O
nodes O
but O
without O
metastasis O
. O

End O
points O
were O
the O
rate O
of O
success O
of O
ablation O
at O
6 O
to O
9 O
months O
, O
adverse O
events O
, O
quality O
of O
life O
, O
and O
length O
of O
hospital O
stay O
. O

A O
total O
of O
438 O
patients O
underwent O
randomization O
";" O
data O
could O
be O
analyzed O
for O
421 O
. O

Ablation B-Premise
success I-Premise
rates I-Premise
were I-Premise
85.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
low-dose I-Premise
radioiodine I-Premise
versus I-Premise
88.9 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
the I-Premise
high I-Premise
dose I-Premise
and I-Premise
87.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
86.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
. I-Premise

All B-Premise
95 I-Premise
% I-Premise
confidence I-Premise
intervals I-Premise
for I-Premise
the I-Premise
differences I-Premise
were I-Premise
within I-Premise
±10 I-Premise
percentage I-Premise
points I-Premise
, I-Premise
indicating I-Premise
noninferiority I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
found I-Premise
for I-Premise
low-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
84.3 I-Premise
% I-Premise
) I-Premise
versus I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
87.6 I-Premise
% I-Premise
) I-Premise
or I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
90.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

More B-Premise
patients I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
low-dose I-Premise
group I-Premise
were I-Premise
hospitalized I-Premise
for I-Premise
at I-Premise
least I-Premise
3 I-Premise
days I-Premise
( I-Premise
36.3 I-Premise
% I-Premise
vs. I-Premise
13.0 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
with I-Premise
adverse I-Premise
events I-Premise
were I-Premise
21 I-Premise
% I-Premise
in I-Premise
the I-Premise
low-dose I-Premise
group I-Premise
versus I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
P=0.007 I-Premise
) I-Premise
and I-Premise
23 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
P=0.11 I-Premise
) I-Premise
. I-Premise

Low-dose B-Claim
radioiodine I-Claim
plus I-Claim
thyrotropin I-Claim
alfa I-Claim
was I-Claim
as I-Claim
effective I-Claim
as I-Claim
high-dose I-Claim
radioiodine I-Claim
, I-Claim
with I-Claim
a I-Claim
lower I-Claim
rate I-Claim
of I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Therefore O
, O
a O
randomized O
double-blind O
placebo-controlled O
multicenter O
trial O
was O
performed O
to O
assess O
the O
efficacy O
of O
long-acting O
octreotide O
for O
the O
treatment O
of O
advanced O
HCC O
. O

One O
hundred O
twenty O
untreated O
patients O
with O
histologically O
confirmed O
HCC O
were O
randomized O
to O
receive O
either O
long-acting O
octreotide O
( O
Sandostation O
LAR O
30 O
mg O
) O
intramuscularly O
every O
4 O
weeks O
or O
placebo O
. O

The O
study O
groups O
were O
comparable O
with O
respect O
to O
clinical O
characteristics O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
cumulative I-Premise
survival I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
4.7 I-Premise
months I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
5.3 I-Premise
months I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Six-month B-Premise
survival I-Premise
rates I-Premise
were I-Premise
41 I-Premise
% I-Premise
for I-Premise
octreotide I-Premise
patients I-Premise
and I-Premise
42 I-Premise
% I-Premise
for I-Premise
control I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
unadjusted I-Premise
relative I-Premise
risk I-Premise
for I-Premise
mortality I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
1.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.76-1.63 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.59 I-Premise
) I-Premise
. I-Premise

When B-Premise
adjusted I-Premise
for I-Premise
Okuda I-Premise
, I-Premise
CTP I-Premise
, I-Premise
and I-Premise
Cancer I-Premise
of I-Premise
the I-Premise
Liver I-Premise
Italian I-Premise
Program I-Premise
( I-Premise
CLIP I-Premise
) I-Premise
scores I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
for I-Premise
octreotide I-Premise
did I-Premise
not I-Premise
change I-Premise
markedly I-Premise
and I-Premise
was I-Premise
1.05 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.71-1.55 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.83 I-Premise
) I-Premise
. I-Premise

The B-Claim
CLIP I-Claim
score I-Claim
seems I-Claim
to I-Claim
predict I-Claim
survival I-Claim
better I-Claim
than I-Claim
both I-Claim
Okuda I-Claim
and I-Claim
CTP I-Claim
score I-Claim
. I-Claim

The B-Claim
randomized I-Claim
controlled I-Claim
double-blind I-Claim
HECTOR I-Claim
trial I-Claim
showed I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
for I-Claim
HCC I-Claim
patients I-Claim
treated I-Claim
with I-Claim
long-acting I-Claim
octreotide I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

Also O
, O
we O
evaluated O
their O
effects O
on O
patient O
hormonal O
status O
, O
quality O
of O
life O
( O
QOL O
) O
, O
sexual O
function O
and O
prostate O
specific O
antigen O
relapse-free O
survival O
. O

This O
was O
a O
multicenter O
prospective O
trial O
. O

From O
January O
2002 O
to O
February O
2004 O
, O
102 O
patients O
who O
had O
undergone O
RP O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1-those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2-those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3-those O
receiving O
bicalutamide O
and O
RT O
. O

Patients O
in O
group O
1 O
in O
whom O
gynecomastia O
or O
breast O
pain O
developed O
were O
subsequently O
randomized O
to O
receive O
tamoxifen O
or O
RT O
soon O
after O
symptoms O
started O
. O

Gynecomastia O
, O
breast O
pain O
, O
prostate O
specific O
antigen O
, O
QOL O
, O
sexual O
function O
and O
hormonal O
levels O
were O
assessed O
. O

Minimum O
followup O
was O
12 O
months O
. O

Of B-Premise
group I-Premise
1 I-Premise
patients I-Premise
67 I-Premise
% I-Premise
had I-Premise
gynecomastia I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
and I-Premise
34 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
. I-Premise

Breast B-Premise
pain I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
( I-Premise
58 I-Premise
% I-Premise
vs I-Premise
7 I-Premise
% I-Premise
and I-Premise
30 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Differences B-Premise
were I-Premise
significant I-Premise
between I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
OR I-Premise
0.12 I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
groups I-Premise
1 I-Premise
and I-Premise
3 I-Premise
( I-Premise
OR I-Premise
0.52 I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
who I-Premise
had I-Premise
gynecomastia I-Premise
or I-Premise
breast I-Premise
pain I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
those I-Premise
receiving I-Premise
tamoxifen I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Treatments B-Premise
were I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
the I-Premise
3 I-Premise
groups I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
QOL I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
followup I-Premise
of I-Premise
26 I-Premise
months I-Premise
we I-Premise
observed I-Premise
12 I-Premise
biochemical I-Premise
relapses I-Premise
. I-Premise

Gynecomastia B-Claim
and I-Claim
breast I-Claim
pain I-Claim
induced I-Claim
by I-Claim
bicalutamide I-Claim
monotherapy I-Claim
after I-Claim
RP I-Claim
can I-Claim
be I-Claim
prevented I-Claim
and I-Claim
treated I-Claim
. I-Claim

Tamoxifen B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
and I-Claim
safe I-Claim
than I-Claim
RT I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

QOL B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O

To O
test O
the O
hypothesis O
that O
modulation O
of O
Bcl-2 O
with O
13-cis O
retinoic O
acid O
( O
CRA O
) O
/interferon-alpha2b O
( O
IFN O
) O
with O
paclitaxel O
( O
TAX O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
MEV O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate-resistant O
prostate O
cancer O
( O
CRPC O
) O
. O

70 O
patients O
were O
treated O
with O
either O
MEV O
( O
Arm O
A O
) O
in O
a O
3-week O
cycle O
or O
CRA/IFN/TAX O
with O
an O
8-week O
cycle O
( O
Arm O
B O
) O
. O

Patients O
were O
assessed O
for O
response O
, O
toxicity O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
the O
effect O
of O
treatment O
on O
Bcl-2 O
levels O
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
. O

The B-Premise
PSA I-Premise
response I-Premise
rates I-Premise
were I-Premise
50 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
measurable I-Premise
disease I-Premise
response I-Premise
rates I-Premise
( I-Premise
CR+PR I-Premise
) I-Premise
14 I-Premise
% I-Premise
and I-Premise
15 I-Premise
% I-Premise
, I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
19.4 I-Premise
months I-Premise
and I-Premise
13.9 I-Premise
months I-Premise
on I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Patients B-Premise
on I-Premise
Arm I-Premise
B I-Premise
reported I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
QOL I-Premise
between I-Premise
baseline I-Premise
and I-Premise
week I-Premise
9/10 I-Premise
( I-Premise
.71 I-Premise
s.d I-Premise
. I-Premise
) O
, I-Premise
and I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
level I-Premise
of I-Premise
QOL I-Premise
than I-Premise
Arm I-Premise
A I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

As B-Premise
hypothesized I-Premise
, I-Premise
Bcl-2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
CRA/IFN I-Premise
therapy I-Premise
only I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
MEV I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPC I-Claim
. I-Claim

Given B-Claim
the I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
CRA/IFN/TAX I-Claim
on I-Claim
QOL I-Claim
, I-Claim
the I-Claim
study I-Claim
of I-Claim
other I-Claim
novel I-Claim
agents I-Claim
that I-Claim
target I-Claim
Bcl-2 I-Claim
family I-Claim
proteins I-Claim
is I-Claim
warranted I-Claim
. I-Claim

The O
feasibility O
of O
measuring O
Bcl-2 O
protein O
in O
a O
cooperative O
group O
setting O
is O
hypothesis O
generating O
and O
supports O
further O
study O
as O
a O
marker O
for O
Bcl-2 O
targeted O
therapy O
. O

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
";" I-Premise
Bristol-Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise

In O
nonrandomized O
trials O
, O
doses O
studied O
have O
ranged O
from O
135 O
mg/m2 O
to O
250 O
mg/m2 O
administered O
over O
24 O
hours O
with O
premedication O
to O
avoid O
hypersensitivity O
reactions O
( O
HSRs O
) O
. O

This O
study O
addressed O
two O
questions O
: O
the O
dose-response O
relationship O
of O
Taxol O
in O
relapsed O
ovarian O
cancer O
and O
the O
safety O
of O
a O
short O
infusion O
given O
with O
premedication O
. O

Women O
with O
platinum-pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg/m2 O
of O
Taxol O
over O
either O
24 O
or O
3 O
hours O
. O

Major O
end O
points O
were O
the O
frequency O
of O
significant O
HSRs O
and O
objective O
response O
rate O
. O

Secondary O
end O
points O
were O
progression-free O
and O
overall O
survival O
. O

Of O
407 O
patients O
randomized O
, O
391 O
were O
eligible O
and O
382 O
assessable O
for O
response O
. O

Analysis O
was O
performed O
according O
to O
the O
bifactorial O
design O
. O

Severe B-Premise
HSRs I-Premise
were I-Premise
rare I-Premise
( I-Premise
1.5 I-Premise
% I-Premise
patients I-Premise
) I-Premise
and I-Premise
were I-Premise
not I-Premise
affected I-Premise
by I-Premise
either I-Premise
dose I-Premise
or I-Premise
schedule I-Premise
. I-Premise

Response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175-mg/m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg/m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.2 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
19 I-Premise
v I-Premise
14 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Significantly B-Premise
more I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
when I-Premise
Taxol I-Premise
was I-Premise
administered I-Premise
as I-Premise
a I-Premise
24-hour I-Premise
infusion I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
-24 I-Premise
and I-Premise
3-hour I-Premise
groups I-Premise
( I-Premise
19 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.6 I-Premise
) I-Premise
. I-Premise

No B-Premise
survival I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

The B-Claim
3-hour I-Claim
infusion I-Claim
of I-Claim
Taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim

There O
is O
a O
modest O
dose O
effect O
with O
longer O
time O
to O
progression O
at O
175 O
mg/m2 O
. O

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

Anaemia O
is O
common O
in O
patients O
receiving O
chemotherapy O
, O
causing O
symptoms O
that O
have O
a O
major O
impact O
on O
quality O
of O
life O
( O
QoL O
) O
. O

Epoetin O
beta O
rapidly O
increases O
haemoglobin O
( O
Hb O
) O
levels O
and O
improves O
QoL O
in O
anaemic O
patients O
with O
a O
variety O
of O
tumours O
. O

This O
was O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
dose-finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once-weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O

Adult O
patients O
with O
anaemia O
( O
Hb O
< O
11 O
g/dL O
) O
were O
randomized O
to O
receive O
epoetin O
beta O
30,000 O
IU O
or O
20,000 O
IU O
once O
weekly O
for O
12 O
weeks O
. O

All O
patients O
received O
oral O
iron O
supplementation O
. O

Haemoglobin O
levels O
, O
transfusion O
need O
and O
QoL O
[ O
Functional O
Assessment O
of O
Cancer O
Therapy-fatigue O
( O
FACT-F O
) O
subscale O
score O
] O
were O
assessed O
at O
regular O
intervals O
. O

Fifty O
patients O
were O
randomized O
";" O
30 O
patients O
received O
epoetin O
beta O
30,000 O
IU O
once O
weekly O
and O
20 O
received O
20,000 O
IU O
once O
weekly O
. O

Mean B-Premise
( I-Premise
+/- I-Premise
SD I-Premise
) I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
was I-Premise
1.75 I-Premise
+/- I-Premise
2.15 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
30,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.008 I-Premise
vs. I-Premise
baseline I-Premise
) I-Premise
and I-Premise
1.04 I-Premise
+/- I-Premise
1.75 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
20,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
non-significant I-Premise
) I-Premise
. I-Premise

Haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
> I-Premise
or=2 I-Premise
g/dL I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30,000 I-Premise
IU I-Premise
and I-Premise
66.7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20,000 I-Premise
IU I-Premise
. I-Premise

Improvements O
in O
FACT-F O
subscale O
score O
were O
significantly O
( O
P O
< O
0.001 O
) O
correlated O
with O
increases O
in O
Hb O
level O
. O

Transfusion O
use O
was O
low O
during O
the O
study O
in O
both O
groups O
. O

Both B-Premise
epoetin I-Premise
beta I-Premise
regiments I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
dose-dependent I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Epoetin B-Claim
beta I-Claim
30,000 I-Claim
IU I-Claim
once I-Claim
weekly I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
treatment I-Claim
of I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
solid I-Claim
tumours I-Claim
. I-Claim

Before O
the O
knowledge O
that O
5 O
years O
of O
adjuvant O
tamoxifen O
is O
less O
efficacious O
than O
2 O
to O
3 O
years O
of O
tamoxifen O
followed O
by O
2 O
to O
3 O
years O
of O
anastrozole/exemestane O
, O
we O
designed O
a O
multicenter O
double-blind O
randomized O
controlled O
trial O
in O
women O
taking O
tamoxifen O
with O
a O
thickened O
endometrium O
to O
compare O
uterine O
and O
quality-of-life O
parameters O
between O
those O
switching O
to O
anastrozole O
and O
those O
continuing O
tamoxifen O
. O

Asymptomatic O
postmenopausal O
women O
who O
took O
adjuvant O
tamoxifen O
for O
2 O
to O
3 O
years O
for O
operable O
breast O
cancer O
with O
a O
double O
endometrial O
thickness O
greater O
than O
7 O
mm O
were O
randomized O
to O
20 O
mg O
tamoxifen O
or O
1 O
mg O
anastrozole O
for O
the O
remaining O
duration O
, O
totaling O
5 O
years O
. O

Tablets O
were O
unrecognizable O
for O
drug O
assignment O
. O

The O
primary O
endpoints O
were O
the O
differences O
in O
double O
endometrial O
thickness O
and O
uterine O
volume O
after O
1 O
year O
. O

Uterine O
and O
quality-of-life O
data O
were O
analyzed O
using O
regression O
methods O
, O
and O
missing O
values O
were O
handled O
using O
multiple O
imputation O
. O

Seventy-two O
women O
( O
median O
age O
, O
60 O
y O
) O
were O
randomized O
in O
five O
hospitals O
. O

Relative B-Premise
to I-Premise
women I-Premise
continuing I-Premise
tamoxifen I-Premise
, I-Premise
women I-Premise
switching I-Premise
to I-Premise
anastrozole I-Premise
experienced I-Premise
a I-Premise
decrease I-Premise
of I-Premise
53 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
41 I-Premise
% I-Premise
-63 I-Premise
% I-Premise
) I-Premise
in I-Premise
double I-Premise
endometrial I-Premise
thickness I-Premise
and I-Premise
a I-Premise
decrease I-Premise
of I-Premise
51 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
39 I-Premise
% I-Premise
-60 I-Premise
% I-Premise
) I-Premise
in I-Premise
uterine I-Premise
volume I-Premise
. I-Premise

Vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0.064 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.016-0.112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0.054 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.007-0.102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise

Treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

Switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim

Safe B-Claim
and I-Claim
effective I-Claim
interventions I-Claim
are I-Claim
needed I-Claim
to I-Claim
alleviate I-Claim
sexual I-Claim
dysfunction I-Claim
. I-Claim

Depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

We O
aimed O
to O
identify O
the O
effects O
of O
an O
established O
antidepressant O
on O
these O
symptoms O
and O
survival O
in O
patients O
with O
advanced O
cancer O
who O
did O
not O
have O
major O
depression O
as O
assessed O
by O
clinicians O
. O

Between O
July O
, O
2001 O
, O
and O
February O
, O
2006 O
, O
189 O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
sertraline O
50 O
mg O
( O
n=95 O
) O
, O
or O
placebo O
( O
n=94 O
) O
, O
once O
per O
day O
. O

The O
primary O
outcome O
was O
depression O
as O
assessed O
by O
the O
Centre O
for O
Epidemiologic O
Studies O
Depression O
scale O
( O
CES-D O
) O
";" O
the O
main O
secondary O
outcomes O
were O
: O
anxiety O
as O
assessed O
by O
Hospital O
Anxiety O
and O
Depression O
Scales O
( O
HADS-A O
) O
";" O
overall O
quality O
of O
life O
and O
fatigue O
as O
assessed O
by O
Functional O
Assessment O
of O
Cancer O
Therapy O
General O
and O
Fatigue O
scales O
( O
FACT-G O
and O
FACT-F O
, O
respectively O
) O
";" O
and O
clinicians O
' O
ratings O
of O
quality O
of O
life O
by O
use O
of O
Spizter O
's O
Quality O
of O
Life O
Index O
( O
SQLI O
) O
. O

Multiple O
measures O
were O
used O
for O
corroboration O
of O
the O
most O
important O
outcomes O
. O

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

The O
benefits O
of O
sertraline O
compared O
with O
placebo O
are O
expressed O
on O
a O
range O
from O
100 O
( O
ie O
, O
maximum O
benefit O
) O
to O
-100 O
( O
ie O
, O
maximum O
harm O
) O
";" O
a O
difference O
of O
10 O
was O
deemed O
clinically O
significant O
. O

This O
clinical O
trial O
is O
registered O
at O
Current O
Controlled O
Trials O
website O
http O
: O
//www.controlled-trials.com/ISRCTN72466475 O
. O

Sertraline B-Premise
had I-Premise
no I-Premise
significant I-Premise
effect I-Premise
( I-Premise
scale I-Premise
, I-Premise
benefit I-Premise
over I-Premise
placebo I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
) I-Premise
on I-Premise
depression I-Premise
( I-Premise
CES-D I-Premise
0.4 I-Premise
[ I-Premise
-2.6 I-Premise
to I-Premise
3.4 I-Premise
] I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
( I-Premise
HADS-A I-Premise
2.0 I-Premise
[ I-Premise
-1.5 I-Premise
to I-Premise
5.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
FACT-F I-Premise
0.3 I-Premise
[ I-Premise
-4.3 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
) I-Premise
, I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
1.7 I-Premise
[ I-Premise
-1.3 I-Premise
to I-Premise
4.7 I-Premise
] I-Premise
) I-Premise
, I-Premise
or I-Premise
clinicians I-Premise
' I-Premise
ratings I-Premise
( I-Premise
SQLI I-Premise
2.0 I-Premise
[ I-Premise
-2.5 I-Premise
to I-Premise
6.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
95 I-Premise
% I-Premise
CI I-Premise
ruled I-Premise
out I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
benefit I-Premise
for I-Premise
all I-Premise
main I-Premise
outcomes I-Premise
. I-Premise

Sertraline B-Premise
was I-Premise
discontinued I-Premise
more I-Premise
often I-Premise
and I-Premise
earlier I-Premise
than I-Premise
was I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
1.46 I-Premise
[ I-Premise
1.03-2.06 I-Premise
] I-Premise
, I-Premise
p=0.03 I-Premise
) I-Premise
. I-Premise

Recruitment O
was O
stopped O
after O
the B-Premise
first I-Premise
planned I-Premise
interim I-Premise
analysis I-Premise
in I-Premise
February I-Premise
2006 I-Premise
( I-Premise
n=150 I-Premise
) I-Premise
showed I-Premise
that I-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
sertraline I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.60 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.04-2.45 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.04 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.62 I-Premise
[ I-Premise
1.06-2.41 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
at I-Premise
the I-Premise
final I-Premise
analysis I-Premise
in I-Premise
July I-Premise
2006 I-Premise
of I-Premise
all I-Premise
patients I-Premise
( I-Premise
n=189 I-Premise
) I-Premise
and I-Premise
with I-Premise
longer I-Premise
follow-up I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.35 I-Premise
[ I-Premise
0.95-1.91 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.09 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.27 I-Premise
[ I-Premise
0.87-1.84 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.20 I-Premise
) I-Premise
. I-Premise

The O
trial O
was O
closed O
because O
it O
had O
ruled O
out O
a O
significant O
benefit O
of O
sertraline O
. O

Sertraline B-Claim
did I-Claim
not I-Claim
improve I-Claim
symptoms I-Claim
, I-Claim
wellbeing I-Claim
, I-Claim
or I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
who I-Claim
do I-Claim
not I-Claim
have I-Claim
major I-Claim
depression I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
reserved I-Claim
for I-Claim
those I-Claim
with I-Claim
a I-Claim
proven I-Claim
indication I-Claim
. I-Claim

This O
double-blind O
randomized O
phase O
II O
trial O
examined O
whether O
vandetanib O
, O
an O
inhibitor O
of O
vascular O
endothelial O
and O
epidermal O
growth O
factor O
receptors O
, O
could O
prolong O
progression-free O
survival O
in O
responding O
patients O
with O
small-cell O
lung O
cancer O
. O

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+/- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg/d O
or O
matched O
placebo O
. O

With O
100 O
patients O
and O
77 O
events O
, O
the O
study O
had O
80 O
% O
power O
to O
detect O
an O
improvement O
in O
median O
progression-free O
survival O
from O
4 O
to O
6.5 O
months O
( O
one-sided O
, O
10 O
% O
-level O
test O
) O
. O

Between O
May O
2003 O
and O
March O
2006 O
, O
107 O
patients O
were O
accrued O
";" O
46 O
had O
limited O
disease O
and O
61 O
extensive O
disease O
. O

There O
were O
fewer O
patients O
with O
a O
performance O
status O
of O
0 O
( O
n O
= O
11 O
v O
20 O
) O
, O
and O
fewer O
had O
CR O
to O
initial O
therapy O
( O
n O
= O
4 O
v O
8 O
) O
in O
the O
vandetanib O
arm O
. O

Vandetanib B-Premise
patients I-Premise
had I-Premise
more I-Premise
toxicity I-Premise
and I-Premise
required I-Premise
more I-Premise
dose I-Premise
modifications I-Premise
for I-Premise
gastrointestinal I-Premise
toxicity I-Premise
and I-Premise
rash I-Premise
. I-Premise

Asymptomatic B-Premise
Corrected I-Premise
QT I-Premise
interval I-Premise
( I-Premise
QTC I-Premise
) I-Premise
prolongation I-Premise
was I-Premise
observed I-Premise
in I-Premise
eight I-Premise
vandetanib I-Premise
patients I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
and I-Premise
placebo I-Premise
was I-Premise
2.7 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
80 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
1.36 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.51 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
was I-Premise
10.6 I-Premise
versus I-Premise
11.9 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.43 I-Premise
";" I-Premise
80 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.00 I-Premise
to I-Premise
2.05 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
0.9 I-Premise
) I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
was I-Premise
noted I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
: I-Premise
limited-stage I-Premise
vandetanib I-Premise
patients I-Premise
had I-Premise
longer I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.45 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
and I-Premise
extensive-stage I-Premise
vandetanib I-Premise
patients I-Premise
shorter I-Premise
survival I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
2.27 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.996 I-Premise
) I-Premise
. I-Premise

Vandetanib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
as I-Claim
maintenance I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

Cancer O
cells O
rely O
on O
angiogenesis O
for O
growth O
and O
dissemination O
, O
and O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
is O
a O
highly O
angiogenic O
tumor O
. O

We O
evaluated O
thalidomide O
, O
an O
anti-angiogenic O
agent O
, O
when O
combined O
with O
chemotherapy O
and O
as O
maintenance O
treatment O
. O

A O
total O
of O
724 O
patients O
( O
51 O
% O
with O
limited O
and O
49 O
% O
with O
extensive O
disease O
) O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
thalidomide O
capsules O
, O
100-200 O
mg O
daily O
for O
up O
to O
2 O
years O
. O

All O
patients O
received O
etoposide O
and O
carboplatin O
every O
3 O
weeks O
for O
up O
to O
six O
cycles O
. O

Endpoints O
were O
overall O
survival O
, O
progression-free O
survival O
, O
tumor O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Hazard O
ratios O
( O
HRs O
) O
for O
comparing O
thalidomide O
against O
placebo O
were O
estimated O
using O
Cox O
regression O
modeling O
. O

Statistical O
tests O
were O
two-sided O
. O

The B-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
10.5 I-Premise
months I-Premise
( I-Premise
placebo I-Premise
) I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
( I-Premise
thalidomide I-Premise
) I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1.09 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.93 I-Premise
to I-Premise
1.27 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.28 I-Premise
) I-Premise
. I-Premise

Among B-Premise
patients I-Premise
with I-Premise
limited-stage I-Premise
disease I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
survival I-Premise
difference I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
0.91 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.73 I-Premise
to I-Premise
1.15 I-Premise
) I-Premise
, I-Premise
but B-Premise
among I-Premise
patients I-Premise
with I-Premise
extensive I-Premise
disease I-Premise
, I-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1.36 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.10 I-Premise
to I-Premise
1.68 I-Premise
) I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1.07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.24 I-Premise
) I-Premise
. I-Premise

Thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
";" I-Premise
HR I-Premise
= I-Premise
2.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.41 I-Premise
to I-Premise
3.20 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatments I-Premise
in I-Premise
hematological I-Premise
and I-Premise
nonhematological I-Premise
toxic I-Premise
effects I-Premise
, I-Premise
except B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
rash I-Premise
, I-Premise
constipation I-Premise
, I-Premise
or I-Premise
neuropathy I-Premise
. I-Premise

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Vinorelbine B-Claim
, I-Claim
a I-Claim
semisynthetic I-Claim
vinca I-Claim
alkaloid I-Claim
, I-Claim
represents I-Claim
a I-Claim
well-tolerated I-Claim
treatment I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

We O
explored O
the O
quality O
of O
life O
( O
QoL O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O

Eligible O
patients O
were O
70 O
years O
of O
age O
or O
older O
, O
had O
stage O
IV O
or O
IIIB O
NSCLC O
that O
was O
ineligible O
for O
radiotherapy O
, O
and O
had O
a O
performance O
status O
of O
0-2 O
( O
a O
status O
of O
fully O
active O
to O
a O
status O
of O
capable O
of O
all O
self-care O
but O
unable O
to O
work O
) O
. O

Vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21-day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O

QoL O
was O
evaluated O
with O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
questionnaires O
QLQ-C30 O
and O
QLQ-LC13 O
, O
and O
the O
QoL O
data O
were O
analyzed O
by O
fitting O
a O
linear O
mixed O
model O
for O
each O
QoL O
scale O
. O

Survival O
curves O
were O
plotted O
and O
were O
compared O
with O
the O
Mantel-Haenszel O
test O
. O

Relative O
hazards O
of O
death O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
by O
the O
Cox O
model O
. O

Investigators O
, O
blinded O
to O
the O
results O
, O
stopped O
the O
trial O
early O
because O
of O
a O
low O
enrollment O
rate O
. O

( O
From O
April O
1996 O
to O
November O
1997 O
, O
191 O
of O
the O
350 O
targeted O
patients O
were O
randomly O
assigned O
. O
) O

Data O
from O
161 O
patients O
have O
been O
analyzed O
. O

Vinorelbine-treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
QoL I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer-related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity-related I-Premise
symptoms I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
";" I-Premise
median B-Premise
survival I-Premise
increased I-Premise
from I-Premise
21 I-Premise
to I-Premise
28 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
vinorelbine-treated I-Premise
group I-Premise
. I-Premise

The B-Premise
relative I-Premise
hazard I-Premise
of I-Premise
death I-Premise
for I-Premise
vinorelbine-treated I-Premise
patients I-Premise
was I-Premise
0.65 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.45-0.93 I-Premise
) I-Premise
. I-Premise

Vinorelbine B-Claim
improves I-Claim
survival I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
possibly I-Claim
improves I-Claim
overall I-Claim
QoL I-Claim
. I-Claim

The O
management O
of O
cancer-related O
anorexia/cachexia O
syndrome O
( O
CACS O
) O
is O
a O
great O
challenge O
in O
clinical O
practice O
. O

To O
date O
, O
practice O
guidelines O
for O
the O
prevention O
and O
treatment O
of O
CACS O
are O
lacking O
. O

The O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
CACS O
utilizing O
megestrol O
acetate O
( O
MA O
) O
plus O
thalidomide O
. O

One O
hundred O
and O
two O
candidates O
with O
CACS O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O

Treatment O
duration O
was O
8 O
weeks O
. O

Analysis B-Premise
of I-Premise
the I-Premise
trial I-Premise
group I-Premise
demonstrated I-Premise
a I-Premise
significant I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
in I-Premise
body I-Premise
weight I-Premise
( I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
endpoints I-Premise
with I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
included I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
and I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
relatively I-Premise
negligible I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

A B-Claim
combination I-Claim
regimen I-Claim
of I-Claim
MA I-Claim
and I-Claim
thalidomide I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
MA I-Claim
alone I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
CACS I-Claim
. I-Claim

This O
randomised O
non-inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
RS O
+ O
WBRT O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
S O
+ O
WBRT O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O

Major O
inclusion O
criteria O
were O
a O
history O
of O
systemic O
cancer O
within O
5 O
years O
and O
enhanced O
magnetic O
resonance O
imaging-confirmed O
solitary O
brain O
metastasis O
suitable O
for O
both O
radiosurgery O
and O
surgery O
. O

All O
patients O
were O
to O
receive O
WBRT O
( O
30 O
Gy O
in O
10 O
fractions O
) O
. O

Between O
February O
2003 O
and O
April O
2009 O
, O
40 O
patients O
were O
considered O
eligible O
, O
22 O
consented O
to O
randomisation O
and O
21 O
were O
analysed O
( O
11 O
RS O
+ O
WBRT O
, O
10 O
S O
+ O
WBRT O
) O
. O

The O
trial O
was O
closed O
early O
due O
to O
slow O
accrual O
. O

The B-Premise
estimated I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
for I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
and I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
were I-Premise
6.2 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0.20-1.43 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

Corresponding B-Premise
median I-Premise
failure-free I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.1 I-Premise
and I-Premise
1.7 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

For B-Premise
19 I-Premise
'per I-Premise
protocol I-Premise
' I-Premise
patients I-Premise
, I-Premise
2/10 I-Premise
in I-Premise
the I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
arm I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
one I-Premise
also I-Premise
had I-Premise
local I-Premise
failure I-Premise
) I-Premise
and I-Premise
3/9 I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
no I-Premise
local I-Premise
failures I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
grade I-Premise
3-4 I-Premise
late I-Premise
radiation I-Premise
toxicities I-Premise
. I-Premise

Two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

The B-Claim
impact I-Claim
of I-Claim
treatment I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQoL I-Claim
) I-Claim
is I-Claim
an I-Claim
important I-Claim
consideration I-Claim
in I-Claim
the I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Here O
we O
report O
mature O
HRQoL O
outcomes O
from O
the O
ATAC O
trial O
, O
comparing O
anastrozole O
with O
tamoxifen O
as O
primary O
adjuvant O
therapy O
for O
postmenopausal O
women O
with O
localized O
breast O
cancer O
. O

Patients O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
questionnaire O
plus O
endocrine O
subscale O
( O
ES O
) O
at O
baseline O
, O
3 O
and O
6 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O

Baseline O
characteristics O
in O
the O
HRQoL O
sub-protocol O
were O
well O
balanced O
between O
the O
anastrozole O
( O
n O
= O
335 O
) O
and O
tamoxifen O
( O
n O
= O
347 O
) O
groups O
in O
the O
primary O
analysis O
population O
. O

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT-B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
ES I-Premise
total I-Premise
scores I-Premise
. I-Premise

Consistent O
with O
the O
2-year O
analysis O
, O
there B-Claim
were I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
in I-Claim
patient-reported I-Claim
side I-Claim
effects I-Claim
: I-Claim
diarrhea B-Premise
( I-Premise
anastrozole I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
tamoxifen I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
18.5 I-Premise
% I-Premise
vs. I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
diminished I-Premise
libido I-Premise
( I-Premise
34.0 I-Premise
% I-Premise
vs. I-Premise
26.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
dyspareunia I-Premise
( I-Premise
17.3 I-Premise
% I-Premise
vs. I-Premise
8.1 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Dizziness B-Premise
( I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1.2 I-Premise
% I-Premise
vs. I-Premise
5.2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

We O
therefore O
investigated O
whether O
avoiding O
axillary O
surgery O
in O
older O
women O
would O
result O
in O
improved O
quality O
of O
life O
( O
QL O
) O
with O
similar O
disease-free O
survival O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
. O

Between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with O
clinically O
node-negative O
operable O
breast O
cancer O
in O
whom O
adjuvant O
tamoxifen O
was O
considered O
indicated O
regardless O
of O
pathologic O
nodal O
status O
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
Sx O
+ O
Ax O
) O
followed O
by O
tamoxifen O
( O
Tam O
) O
versus O
Sx O
without O
Ax O
followed O
by O
Tam O
for O
5 O
consecutive O
years O
. O

The O
primary O
end O
point O
was O
QL O
reported O
by O
the O
patient O
and O
by O
physician O
assessment O
. O

A O
total O
of O
473 O
patients O
( O
234 O
to O
Sx O
+ O
Ax O
, O
239 O
to O
Sx O
) O
were O
randomly O
assigned O
. O

The O
median O
age O
was O
74 O
years O
";" O
80 O
% O
had O
estrogen O
receptor-positive O
disease O
. O

In B-Premise
both I-Premise
the I-Premise
patients I-Premise
' I-Premise
subjective I-Premise
assessment I-Premise
of I-Premise
their I-Premise
QL I-Premise
and I-Premise
the I-Premise
physicians I-Premise
' I-Premise
perception I-Premise
of I-Premise
the I-Premise
patients I-Premise
' I-Premise
QL I-Premise
, I-Premise
the I-Premise
largest I-Premise
adverse I-Premise
QL I-Premise
effects I-Premise
of I-Premise
Ax I-Premise
were I-Premise
observed I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
first I-Premise
postoperative I-Premise
assessment I-Premise
, I-Premise
but B-Premise
the I-Premise
differences I-Premise
tended I-Premise
to I-Premise
disappear I-Premise
in I-Premise
6 I-Premise
to I-Premise
12 I-Premise
months I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.6 I-Premise
years I-Premise
, I-Premise
results I-Premise
for I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
and I-Premise
Sx I-Premise
yielded I-Premise
similar I-Premise
DFS I-Premise
( I-Premise
6-year I-Premise
DFS I-Premise
, I-Premise
67 I-Premise
% I-Premise
v I-Premise
66 I-Premise
% I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.06 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.69 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
6-year I-Premise
OS I-Premise
, I-Premise
75 I-Premise
% I-Premise
v I-Premise
73 I-Premise
% I-Premise
";" I-Premise
HR I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.76 I-Premise
to I-Premise
1.46 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.77 I-Premise
) I-Premise
. I-Premise

Avoiding B-Claim
axillary I-Claim
clearance I-Claim
for I-Claim
women I-Claim
> I-Claim
or I-Claim
= I-Claim
60 I-Claim
years I-Claim
old I-Claim
who I-Claim
have I-Claim
clinically I-Claim
node-negative I-Claim
disease I-Claim
and I-Claim
receive I-Claim
Tam I-Claim
for I-Claim
endocrine-responsive I-Claim
disease I-Claim
yields I-Claim
similar I-Claim
efficacy I-Claim
with I-Claim
better I-Claim
early I-Claim
QL I-Claim
. I-Claim

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

In O
a O
previous O
phase O
II O
trial O
, O
5-fluorouracil O
( O
5-FU O
) O
plus O
cisplatin O
( O
FUP O
) O
yielded O
a O
26.5 O
% O
response O
rate O
and O
a O
29 O
% O
survival O
rate O
at O
1 O
year O
. O

The O
present O
study O
aimed O
to O
compare O
FUP O
with O
5-FU O
alone O
, O
which O
was O
the O
control O
arm O
in O
former O
Mayo O
Clinic O
trials O
. O

Patients O
with O
untreated O
cytologically O
or O
histologically O
proven O
metastatic O
or O
locally O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
deemed O
measurable O
or O
evaluable O
. O

Chemotherapy O
regimens O
consisted O
of O
a O
control O
FU O
arm O
( O
5-FU O
500 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
) O
and O
the O
investigational O
FUP O
arm O
( O
continuous O
5-FU O
1000 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
plus O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
or O
day O
2 O
) O
. O

In O
both O
arms O
, O
chemotherapy O
was O
repeated O
at O
day O
29 O
. O

Two-hundred O
and O
seven O
patients O
from O
18 O
centres O
were O
randomised O
: O
103 O
in O
the O
FU O
arm O
and O
104 O
in O
FUP O
arm O
. O

Treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0-1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O

The O
median O
number O
of O
cycles O
administered O
was O
two O
in O
both O
arms O
( O
range O
0-14 O
) O
. O

Five O
patients O
did O
not O
receive O
any O
chemotherapy O
and O
45 O
received O
only O
one O
cycle O
. O

Toxicity B-Premise
( I-Premise
WHO I-Premise
grade I-Premise
3-4 I-Premise
) I-Premise
was I-Premise
lower I-Premise
with I-Premise
FU I-Premise
than I-Premise
with I-Premise
FUP I-Premise
( I-Premise
20 I-Premise
% I-Premise
versus I-Premise
48 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
neutropenia I-Premise
( I-Premise
6 I-Premise
% I-Premise
versus I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
4 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
toxicity-related I-Premise
deaths I-Premise
( I-Premise
one I-Premise
versus I-Premise
four I-Premise
early I-Premise
in I-Premise
the I-Premise
trial I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention-to-treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
survival I-Premise
rates I-Premise
at I-Premise
6 I-Premise
months I-Premise
were I-Premise
28 I-Premise
% I-Premise
and I-Premise
38 I-Premise
% I-Premise
for I-Premise
the I-Premise
FU I-Premise
and I-Premise
FUP I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
9 I-Premise
% I-Premise
and I-Premise
17 I-Premise
% I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.10 I-Premise
) I-Premise
. I-Premise

One-year B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
FU I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
FUP I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

In B-Claim
advanced I-Claim
pancreatic I-Claim
carcinomas I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
FUP I-Claim
was I-Claim
superior I-Claim
to I-Claim
FU I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
but I-Claim
not I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
. I-Claim

The O
low O
response O
rate O
is O
partly O
related O
to O
the O
number O
of O
patients O
who O
received O
only O
one O
cycle O
of O
chemotherapy O
. O

A B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
FUP I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim

After O
surgery O
for O
differentiated O
thyroid O
carcinoma O
, O
many O
patients O
are O
treated O
with O
radioiodine O
to O
ablate O
remnant O
thyroid O
tissue O
. O

This B-Claim
procedure I-Claim
has I-Claim
been I-Claim
performed I-Claim
with I-Claim
the I-Claim
patient I-Claim
in I-Claim
the I-Claim
hypothyroid I-Claim
state I-Claim
to I-Claim
promote I-Claim
endogenous I-Claim
TSH I-Claim
stimulation I-Claim
and I-Claim
is I-Claim
often I-Claim
associated I-Claim
with I-Claim
hypothyroid I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

This O
international O
, O
randomized O
, O
controlled O
, O
multicenter O
trial O
aimed O
to O
compare O
the O
efficacy O
and O
safety O
of O
recombinant O
human O
TSH O
( O
rhTSH O
) O
to O
prepare O
euthyroid O
patients O
on O
L-thyroxine O
therapy O
( O
euthyroid O
group O
) O
to O
ablate O
remnant O
thyroid O
tissue O
with O
3.7 O
GBq O
( O
100 O
mCi O
) O
131I O
, O
compared O
with O
that O
with O
conventional O
remnant O
ablation O
performed O
in O
the O
hypothyroid O
state O
( O
hypothyroid O
group O
) O
. O

Quality O
of O
life O
was O
determined O
at O
the O
time O
of O
randomization O
and O
ablation O
. O

After O
the O
administration O
of O
the O
131-I O
dose O
, O
the O
rate O
of O
radiation O
clearance O
from O
blood O
, O
thyroid O
remnant O
, O
and O
whole O
body O
was O
measured O
. O

The O
predefined O
primary O
criterion O
for O
successful O
ablation O
was O
" O
no O
visible O
uptake O
in O
the O
thyroid O
bed O
, O
or O
if O
visible O
, O
fractional O
uptake O
less O
than O
0.1 O
% O
" O
on O
neck O
scans O
performed O
8 O
months O
after O
therapy O
and O
was O
satisfied O
in O
100 O
% O
of O
patients O
in O
both O
groups O
. O

A O
secondary O
criterion O
for O
ablation O
, O
an O
rhTSH-stimulated O
serum O
thyroglobulin O
concentration O
less O
than O
2 O
ng/ml O
, O
was O
fulfilled O
by O
23 O
of O
24 O
( O
96 O
% O
) O
euthyroid O
patients O
and O
18 O
of O
21 O
( O
86 O
% O
) O
hypothyroid O
patients O
( O
P O
= O
0.2341 O
) O
. O

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

Euthyroid B-Premise
patients I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
one I-Premise
third I-Premise
lower I-Premise
radiation I-Premise
dose I-Premise
to I-Premise
the I-Premise
blood I-Premise
, I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrates I-Claim
comparable I-Claim
remnant I-Claim
ablation I-Claim
rates I-Claim
in I-Claim
patients I-Claim
prepared I-Claim
for I-Claim
131I I-Claim
remnant I-Claim
ablation I-Claim
with I-Claim
3.7 I-Claim
GBq I-Claim
by I-Claim
either I-Claim
administering I-Claim
rhTSH I-Claim
or I-Claim
withholding I-Claim
thyroid I-Claim
hormone I-Claim
. I-Claim

rhTSH-prepared B-Claim
patients I-Claim
maintained I-Claim
a I-Claim
higher I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
received I-Claim
less I-Claim
radiation I-Claim
exposure I-Claim
to I-Claim
the I-Claim
blood I-Claim
. I-Claim

As O
patients O
with O
pancreas O
and O
periampullary O
cancer O
( O
PPC O
) O
experience O
improved O
survival O
rates O
and O
longevity O
, O
the O
focus O
shifts O
toward O
living O
life O
while O
surviving O
cancer O
. O

Fatigue O
is O
the O
most O
commonly O
reported O
symptom O
in O
all O
cancer O
patients O
. O

Exercise O
has O
been O
found O
to O
effectively O
decrease O
fatigue O
levels O
and O
improve O
physical O
functioning O
in O
cancer O
patients O
. O

One O
hundred O
two O
patients O
with O
resected O
PPC O
consented O
to O
participate O
in O
this O
study O
and O
were O
randomized O
to O
either O
an O
intervention O
group O
( O
IG O
) O
or O
a O
usual O
care O
group O
( O
UCG O
) O
. O

Subjects O
completed O
visual O
analog O
scales O
, O
the O
FACIT-Fatigue O
Scale O
and O
the O
Short O
Form-36v2 O
after O
surgery O
and O
again O
3 O
to O
6 O
months O
after O
hospital O
discharge O
. O

Patients O
in O
the O
IG O
and O
UCG O
were O
comparable O
with O
regard O
to O
demographics O
, O
comorbidities O
, O
cancer O
type O
and O
staging O
, O
type O
of O
resection O
, O
preoperative O
fatigue O
and O
pain O
levels O
, O
adjuvant O
therapy O
, O
and O
baseline O
walking O
distance O
. O

Patients B-Premise
in I-Premise
the I-Premise
IG I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
scores I-Premise
on I-Premise
the I-Premise
FACIT-Fatigue I-Premise
Scale I-Premise
at I-Premise
study I-Premise
completion I-Premise
, I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
pain I-Premise
scores I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
mental I-Premise
health I-Premise
composite I-Premise
scores I-Premise
. I-Premise

At B-Premise
study I-Premise
completion I-Premise
, I-Premise
participants I-Premise
in I-Premise
the I-Premise
IG I-Premise
were I-Premise
walking I-Premise
twice I-Premise
as I-Premise
far I-Premise
and I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
continued I-Premise
walking I-Premise
or I-Premise
another I-Premise
form I-Premise
of I-Premise
exercise I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
UCG I-Premise
. I-Premise

Using O
hierarchical O
cluster O
analysis O
, O
3 O
mutually O
exclusive O
symptom O
groupings O
were O
identified O
in O
the O
cohort O
. O

Kaplan-Meier B-Premise
survival I-Premise
analysis I-Premise
did I-Premise
not I-Premise
indicate I-Premise
an I-Premise
overall I-Premise
survival I-Premise
benefit I-Premise
for I-Premise
the I-Premise
IG I-Premise
. I-Premise

This B-Claim
is I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
to I-Claim
report I-Claim
that I-Claim
participation I-Claim
in I-Claim
a I-Claim
home I-Claim
walking I-Claim
program I-Claim
confers I-Claim
a I-Claim
significant I-Claim
benefit I-Claim
in I-Claim
resected I-Claim
PPC I-Claim
patients I-Claim
with I-Claim
regard I-Claim
to I-Claim
fatigue I-Claim
levels I-Claim
, I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
and I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
provides I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
in I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

To O
determine O
whether O
a O
new O
agent O
, O
paclitaxel O
, O
would O
further O
improve O
survival O
in O
NSCLC O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
conducted O
a O
randomized O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
to O
a O
standard O
chemotherapy O
regimen O
consisting O
of O
cisplatin O
and O
etoposide O
. O

The O
study O
was O
carried O
out O
by O
a O
multi-institutional O
cooperative O
group O
in O
chemotherapy-naive O
stage O
IIIB O
to O
IV O
NSCLC O
patients O
randomized O
to O
receive O
paclitaxel O
plus O
cisplatin O
or O
etoposide O
plus O
cisplatin O
. O

Paclitaxel O
was O
administered O
at O
two O
different O
dose O
levels O
( O
135 O
mg/m O
( O
2 O
) O
and O
250 O
mg/m O
( O
2 O
) O
) O
, O
and O
etoposide O
was O
given O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
daily O
on O
days O
1 O
to O
3 O
. O

Each O
regimen O
was O
repeated O
every O
21 O
days O
and O
each O
included O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
) O
. O

The O
characteristics O
of O
the O
599 O
patients O
were O
well-balanced O
across O
the O
three O
treatment O
groups O
. O

Superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38.9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7.6 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise

Comparing B-Premise
survival I-Premise
for I-Premise
the I-Premise
two I-Premise
dose I-Premise
levels I-Premise
of I-Premise
paclitaxel I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
duration I-Premise
for I-Premise
the I-Premise
stage I-Premise
IIIB I-Premise
subgroup I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
patients I-Premise
versus I-Premise
13.1 I-Premise
months I-Premise
for I-Premise
all I-Premise
paclitaxel I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.152 I-Premise
) I-Premise
. I-Premise

For B-Premise
the I-Premise
stage I-Premise
IV I-Premise
subgroup I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
was I-Premise
7.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
8.9 I-Premise
months I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
P I-Premise
=.246 I-Premise
) I-Premise
. I-Premise

With B-Premise
the I-Premise
exceptions I-Premise
of I-Premise
increased I-Premise
granulocytopenia I-Premise
on I-Premise
the I-Premise
low-dose I-Premise
paclitaxel I-Premise
regimen I-Premise
and I-Premise
increased I-Premise
myalgias I-Premise
, I-Premise
neurotoxicity I-Premise
, I-Premise
and I-Premise
, I-Premise
possibly I-Premise
, I-Premise
increased I-Premise
treatment-related I-Premise
cardiac I-Premise
events I-Premise
with I-Premise
high-dose I-Premise
paclitaxel I-Premise
, I-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
arms I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
declined I-Premise
significantly I-Premise
over I-Premise
the I-Premise
6 I-Premise
months I-Premise
. I-Premise

However O
, O
QOL B-Claim
scores I-Claim
were I-Claim
not I-Claim
significantly I-Claim
different I-Claim
among I-Claim
the I-Claim
regimens I-Claim
. I-Claim

As O
a O
result O
of O
these O
observations O
, O
paclitaxel B-Claim
( I-Claim
135 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
) I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
has I-Claim
replaced I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
as I-Claim
the I-Claim
reference I-Claim
regimen I-Claim
in I-Claim
our I-Claim
recently I-Claim
completed I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

To O
assess O
the O
long O
term O
risks O
and O
benefits O
of O
hormone O
replacement O
therapy O
( O
combined O
hormone O
therapy O
versus O
placebo O
, O
and O
oestrogen O
alone O
versus O
combined O
hormone O
therapy O
) O
. O

Multicentre O
, O
randomised O
, O
placebo O
controlled O
, O
double O
blind O
trial O
. O

General O
practices O
in O
UK O
( O
384 O
) O
, O
Australia O
( O
91 O
) O
, O
and O
New O
Zealand O
( O
24 O
) O
. O

Postmenopausal O
women O
aged O
50-69 O
years O
at O
randomisation O
. O

At O
early O
closure O
of O
the O
trial O
, O
56,583 O
had O
been O
screened O
, O
8980 O
entered O
run-in O
, O
and O
5692 O
( O
26 O
% O
of O
target O
of O
22,300 O
) O
started O
treatment O
. O

Oestrogen O
only O
therapy O
( O
conjugated O
equine O
oestrogens O
0.625 O
mg O
orally O
daily O
) O
or O
combined O
hormone O
therapy O
( O
conjugated O
equine O
oestrogens O
plus O
medroxyprogesterone O
acetate O
2.5/5.0 O
mg O
orally O
daily O
) O
. O

Ten O
years O
of O
treatment O
planned O
. O

major O
cardiovascular O
disease O
, O
osteoporotic O
fractures O
, O
and O
breast O
cancer O
. O

other O
cancers O
, O
death O
from O
all O
causes O
, O
venous O
thromboembolism O
, O
cerebrovascular O
disease O
, O
dementia O
, O
and O
quality O
of O
life O
. O

The O
trial O
was O
prematurely O
closed O
during O
recruitment O
, O
after O
a O
median O
follow-up O
of O
11.9 O
months O
( O
interquartile O
range O
7.1-19.6 O
, O
total O
6498 O
women O
years O
) O
in O
those O
enrolled O
, O
after O
the O
publication O
of O
early O
results O
from O
the O
women O
's O
health O
initiative O
study O
. O

The O
mean O
age O
of O
randomised O
women O
was O
62.8 O
( O
SD O
4.8 O
) O
years O
. O

When B-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=2196 I-Premise
) I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
n=2189 I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
number I-Premise
of I-Premise
major I-Premise
cardiovascular I-Premise
events I-Premise
( I-Premise
7 I-Premise
v I-Premise
0 I-Premise
, I-Premise
P=0.016 I-Premise
) I-Premise
and I-Premise
venous I-Premise
thromboembolisms I-Premise
( I-Premise
22 I-Premise
v I-Premise
3 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
7.36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
2.20 I-Premise
to I-Premise
24.60 I-Premise
) I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
numbers I-Premise
of I-Premise
breast I-Premise
or I-Premise
other I-Premise
cancers I-Premise
( I-Premise
22 I-Premise
v I-Premise
25 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
0.88 I-Premise
( I-Premise
0.49 I-Premise
to I-Premise
1.56 I-Premise
) I-Premise
) I-Premise
, I-Premise
cerebrovascular I-Premise
events I-Premise
( I-Premise
14 I-Premise
v I-Premise
19 I-Premise
, I-Premise
0.73 I-Premise
( I-Premise
0.37 I-Premise
to I-Premise
1.46 I-Premise
) I-Premise
) I-Premise
, I-Premise
fractures I-Premise
( I-Premise
40 I-Premise
v I-Premise
58 I-Premise
, I-Premise
0.69 I-Premise
( I-Premise
0.46 I-Premise
to I-Premise
1.03 I-Premise
) I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
deaths I-Premise
( I-Premise
8 I-Premise
v I-Premise
5 I-Premise
, I-Premise
1.60 I-Premise
( I-Premise
0.52 I-Premise
to I-Premise
4.89 I-Premise
) I-Premise
) I-Premise
. I-Premise

Comparison B-Premise
of I-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=815 I-Premise
) I-Premise
versus I-Premise
oestrogen I-Premise
therapy I-Premise
( I-Premise
n=826 I-Premise
) I-Premise
outcomes I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

Hormone B-Claim
replacement I-Claim
therapy I-Claim
increases I-Claim
cardiovascular I-Claim
and I-Claim
thromboembolic I-Claim
risk I-Claim
when I-Claim
started I-Claim
many I-Claim
years I-Claim
after I-Claim
the I-Claim
menopause I-Claim
. I-Claim

The B-Claim
results I-Claim
are I-Claim
consistent I-Claim
with I-Claim
the I-Claim
findings I-Claim
of I-Claim
the I-Claim
women I-Claim
's I-Claim
health I-Claim
initiative I-Claim
study I-Claim
and I-Claim
secondary I-Claim
prevention I-Claim
studies I-Claim
. I-Claim

Research B-Claim
is I-Claim
needed I-Claim
to I-Claim
assess I-Claim
the I-Claim
long I-Claim
term I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
of I-Claim
starting I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
near I-Claim
the I-Claim
menopause I-Claim
, I-Claim
when I-Claim
the I-Claim
effect I-Claim
may I-Claim
be I-Claim
different I-Claim
. I-Claim

Imatinib O
is O
the O
standard O
treatment O
of O
advanced O
GI O
stromal O
tumors O
( O
GISTs O
) O
. O

It B-Claim
is I-Claim
not I-Claim
known I-Claim
whether I-Claim
imatinib I-Claim
may I-Claim
be I-Claim
stopped I-Claim
in I-Claim
patients I-Claim
in I-Claim
whom I-Claim
disease I-Claim
is I-Claim
controlled I-Claim
. I-Claim

This O
prospective O
, O
randomized O
, O
multicentric O
phase O
III O
study O
was O
designed O
to O
compare O
continuous O
( O
CONT O
) O
compared O
with O
interrupted O
( O
INT O
) O
imatinib O
beyond O
1 O
year O
of O
treatment O
in O
patients O
with O
advanced O
GIST O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
. O

Secondary O
end O
points O
included O
overall O
survival O
, O
response O
rate O
after O
reinitiation O
of O
imatinib O
, O
and O
quality O
of O
life O
. O

Early O
stopping O
rules O
in O
cases O
of O
rapid O
progression O
of O
disease O
were O
defined O
, O
with O
preplanned O
interim O
analyses O
. O

Between O
May O
2002 O
and O
April O
2004 O
, O
182 O
patients O
with O
advanced O
GIST O
were O
enrolled O
. O

Between O
May O
2003 O
and O
April O
2004 O
, O
98 O
patients O
in O
response O
or O
stable O
disease O
under O
imatinib O
reached O
more O
than O
1 O
year O
of O
follow-up O
. O

Forty O
were O
not O
eligible O
for O
randomization O
, O
and O
58 O
patients O
were O
randomly O
assigned O
, O
32 O
and O
26 O
patients O
in O
the O
INT O
and O
CONT O
arms O
, O
respectively O
. O

As B-Premise
of I-Premise
October I-Premise
15 I-Premise
, I-Premise
2005 I-Premise
, I-Premise
eight I-Premise
of I-Premise
26 I-Premise
patients I-Premise
in I-Premise
the I-Premise
CONT I-Premise
group I-Premise
and I-Premise
26 I-Premise
of I-Premise
32 I-Premise
patients I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
had I-Premise
documented I-Premise
disease I-Premise
progression I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Twenty-four B-Premise
of I-Premise
26 I-Premise
patients I-Premise
with I-Premise
documented I-Premise
progression I-Premise
in I-Premise
the I-Premise
INT I-Premise
arm I-Premise
responded I-Premise
to I-Premise
imatinib I-Premise
reintroduction I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
overall I-Premise
survival I-Premise
or I-Premise
imatinib I-Premise
resistance I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
evaluated I-Premise
6 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
using I-Premise
the I-Premise
30-item I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
Questionnaire I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
of I-Premise
randomly I-Premise
assigned I-Premise
patients I-Premise
. I-Premise

Imatinib B-Claim
interruption I-Claim
results I-Claim
in I-Claim
rapid I-Claim
progression I-Claim
in I-Claim
most I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
GIST I-Claim
, I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
recommended I-Claim
in I-Claim
routine I-Claim
practice I-Claim
unless I-Claim
patient I-Claim
experience I-Claim
significant I-Claim
toxicity I-Claim
. I-Claim

This O
report O
describes O
the O
quality O
of O
life O
( O
QOL O
) O
findings O
of O
a O
randomized O
placebo O
controlled O
study O
of O
erlotinib O
, O
an O
epidermal O
growth O
factor O
receptor O
inhibitor O
, O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

This O
double-blind O
phase O
III O
trial O
randomly O
assigned O
731 O
patients O
with O
NSCLC O
who O
had O
progressed O
after O
prior O
chemotherapy O
to O
erlotinib O
150 O
mg O
daily O
or O
placebo O
, O
with O
survival O
as O
the O
primary O
study O
outcome O
. O

QOL O
was O
assessed O
by O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
the O
lung O
cancer O
module O
QLQ-LC13 O
. O

The O
primary O
end O
points O
for O
QOL O
analysis O
were O
time O
to O
deterioration O
of O
three O
common O
lung O
cancer O
symptoms O
: O
cough O
, O
dyspnea O
, O
and O
pain O
. O

Survival B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.70 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
arm I-Premise
. I-Premise

Compliance B-Premise
with I-Premise
QOL I-Premise
was I-Premise
87 I-Premise
% I-Premise
at I-Premise
baseline I-Premise
and I-Premise
more I-Premise
than I-Premise
70 I-Premise
% I-Premise
during I-Premise
treatment I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
median I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
for I-Premise
all I-Premise
three I-Premise
symptoms I-Premise
( I-Premise
4.9 I-Premise
v I-Premise
3.7 I-Premise
months I-Premise
for I-Premise
cough I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
";" I-Premise
4.7 I-Premise
v I-Premise
2.9 I-Premise
months I-Premise
for I-Premise
dyspnea I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
, I-Premise
and I-Premise
2.8 I-Premise
v I-Premise
1.9 I-Premise
months I-Premise
for I-Premise
pain I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
) I-Premise
. I-Premise

QOL B-Premise
response I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
44 I-Premise
% I-Premise
, I-Premise
34 I-Premise
% I-Premise
, I-Premise
and I-Premise
42 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
improvement I-Premise
in I-Premise
these I-Premise
three I-Premise
symptoms I-Premise
, I-Premise
respectively I-Premise
. I-Premise

This B-Premise
was I-Premise
accompanied I-Premise
by I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
the I-Premise
physical I-Premise
function I-Premise
( I-Premise
31 I-Premise
% I-Premise
erlotinib I-Premise
v I-Premise
19 I-Premise
% I-Premise
placebo I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
QOL I-Premise
( I-Premise
35 I-Premise
% I-Premise
v I-Premise
26 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
complete I-Premise
or I-Premise
partial I-Premise
response I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
improvement I-Premise
in I-Premise
the I-Premise
QOL I-Premise
response I-Premise
than I-Premise
patients I-Premise
with I-Premise
stable I-Premise
or I-Premise
progressive I-Premise
disease I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor-related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Menopausal B-Claim
symptoms I-Claim
( I-Claim
e.g. I-Claim
, I-Claim
hot I-Claim
flashes I-Claim
, I-Claim
vaginal I-Claim
dryness I-Claim
, I-Claim
and I-Claim
stress I-Claim
urinary I-Claim
incontinence I-Claim
) I-Claim
are I-Claim
very I-Claim
common I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
managed I-Claim
with I-Claim
standard I-Claim
estrogen I-Claim
replacement I-Claim
therapy I-Claim
( I-Claim
ERT I-Claim
) I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
CMA O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
QOL O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O

Using O
a O
two-group O
, O
randomized O
controlled O
design O
, O
we O
assigned O
76 O
postmenopausal O
breast O
cancer O
survivors O
with O
at O
least O
one O
severe O
target O
symptom O
either O
to O
the O
intervention O
group O
or O
to O
a O
usual-care O
group O
. O

Seventy-two O
women O
were O
evaluable O
at O
the O
end O
of O
the O
study O
period O
. O

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

Psychosocial O
symptoms O
were O
assessed O
with O
the O
use O
of O
a O
self-report O
screening O
instrument O
, O
and O
distressed O
women O
were O
referred O
for O
counseling O
if O
needed O
. O

The O
intervention O
took O
place O
over O
a O
4-month O
period O
. O

Outcomes O
measured O
were O
scores O
on O
a O
composite O
menopausal O
symptom O
scale O
, O
the O
RAND O
Short O
Form O
Health O
Survey O
Vitality O
Scale O
, O
and O
the O
Cancer O
Rehabilitation O
Evaluation O
System O
( O
CARES O
) O
Sexual O
Functioning O
Scale O
at O
baseline O
and O
at O
4-month O
follow-up O
. O

All O
statistical O
tests O
were O
two-sided O
and O
were O
performed O
at O
the O
alpha O
= O
. O

5 O
significance O
level O
. O

Patients B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
in I-Premise
menopausal I-Premise
symptoms I-Premise
but I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.77 I-Premise
) I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual-care I-Premise
group I-Premise
. I-Premise

A B-Claim
clinical I-Claim
assessment I-Claim
and I-Claim
intervention I-Claim
program I-Claim
for I-Claim
menopausal I-Claim
symptom I-Claim
management I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
is I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
, I-Claim
leading I-Claim
to I-Claim
reduction I-Claim
in I-Claim
symptoms I-Claim
and I-Claim
improvement I-Claim
in I-Claim
sexual I-Claim
functioning I-Claim
. I-Claim

Measurable B-Claim
improvement I-Claim
in I-Claim
a I-Claim
general I-Claim
QOL I-Claim
measure I-Claim
was I-Claim
not I-Claim
demonstrated I-Claim
. I-Claim

This O
study O
is O
the O
first O
large O
prospective O
RCT O
of O
sentinel O
node O
biopsy O
( O
SNB O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
I-III O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
QOL O
) O
assessments O
over O
18 O
months O
. O

Patients O
( O
n O
= O
829 O
) O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT-B+4 O
) O
and O
the O
Spielberger O
State/Trait O
Anxiety O
Inventory O
( O
STAI O
) O
at O
baseline O
( O
pre-surgery O
) O
and O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
post-surgery O
. O

There B-Claim
were I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
favouring I-Claim
the I-Claim
SNB I-Claim
group I-Claim
throughout I-Claim
the I-Claim
18 I-Claim
months I-Claim
assessment I-Claim
. I-Claim

Patients B-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
( I-Premise
TOI I-Premise
) I-Premise
scores I-Premise
( I-Premise
physical I-Premise
well-being I-Premise
, I-Premise
functional I-Premise
well-being I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
concerns I-Premise
subscales I-Premise
in I-Premise
FACT-B+4 I-Premise
) I-Premise
and I-Premise
recovered I-Premise
more I-Premise
slowly I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
SNB I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
total I-Premise
FACT-B+4 I-Premise
scores I-Premise
( I-Premise
measuring I-Premise
global I-Premise
QOL I-Premise
) I-Premise
closely I-Premise
resembled I-Premise
the I-Premise
TOI I-Premise
results I-Premise
. I-Premise

18 B-Premise
months I-Premise
post-surgery I-Premise
approximately I-Premise
twice I-Premise
as I-Premise
many I-Premise
patients I-Premise
in I-Premise
the I-Premise
standard I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
SNB I-Premise
group I-Premise
reported I-Premise
substantial I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
14 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
or I-Premise
numbness I-Premise
( I-Premise
19 I-Premise
% I-Premise
versus I-Premise
8.7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Despite O
the O
uncertainty O
about O
undergoing O
a O
relatively O
new O
procedure O
and O
the O
possible O
need O
for O
further O
surgery O
, O
there B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
increased I-Premise
anxiety I-Premise
amongst I-Premise
patients I-Premise
randomised I-Premise
to I-Premise
SNB I-Premise
( I-Premise
p I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

For B-Premise
6 I-Premise
months I-Premise
post-surgery I-Premise
younger I-Premise
patients I-Premise
reported I-Premise
less I-Premise
favourable I-Premise
QOL I-Premise
scores I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
greater I-Premise
levels I-Premise
of I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Claim
view I-Claim
of I-Claim
the I-Claim
benefits I-Claim
regarding I-Claim
arm I-Claim
functioning I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
the I-Claim
data I-Claim
from I-Claim
this I-Claim
randomised I-Claim
study I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
SNB I-Claim
in I-Claim
patients I-Claim
with I-Claim
clinically I-Claim
node I-Claim
negative I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

It O
is O
equieffective O
as O
oral O
( O
p.o O
. O
) O

and O
intravenous O
( O
i.v O
. O
) O

formulation O
. O

To O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p.o O
. O

or O
i.v O
. O

treosulfan O
for O
the O
treatment O
of O
relapsed O
ovarian O
carcinoma O
, O
women O
aged O
65 O
years O
or O
older O
were O
included O
in O
this O
prospective O
multicenter O
study O
. O

Since O
elderly O
patients O
usually O
have O
several O
concomitant O
diseases O
and O
experience O
more O
treatment O
toxicity O
, O
an O
interim O
safety O
analysis O
was O
planned O
and O
performed O
after O
25 O
patients O
finished O
therapy O
to O
assess O
the O
tolerability O
of O
the O
treatment O
regimens O
. O

Patients O
had O
a O
free O
choice O
of O
treosulfan O
i.v O
. O

( O
7,000 O
mg/m O
( O
2 O
) O
day O
1 O
of O
a O
28-day O
cycle O
) O
or O
p.o O
. O

( O
600 O
mg/m O
( O
2 O
) O
day O
1-28 O
of O
a O
56-day O
cycle O
) O
for O
a O
maximum O
of O
12 O
cycles O
( O
i.v O
. O
) O

or O
12 O
months O
( O
p.o O
. O
) O
. O

Indecisive O
patients O
were O
randomized O
. O

Toxicity O
was O
evaluated O
according O
to O
the O
NCI-CTC O
version O
2.0 O
. O

Twenty-five O
of O
51 O
recruited O
patients O
completed O
therapy O
at O
the O
time O
of O
the O
planned O
interim O
analysis O
( O
median O
age O
, O
75 O
years O
";" O
range O
, O
70-82 O
) O
. O

Median O
ECOG O
was O
1 O
, O
and O
median O
number O
of O
prior O
chemotherapy O
regimens O
was O
2 O
. O

A O
median O
number O
of O
4 O
cycles O
( O
range O
, O
1-12 O
) O
were O
administered O
per O
patient O
. O

Anemia B-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
hematological I-Premise
toxicity I-Premise
( I-Premise
88 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Most B-Premise
frequent I-Premise
non-hematological I-Premise
toxicities I-Premise
were I-Premise
nausea I-Premise
( I-Premise
76 I-Premise
% I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
. I-Premise

Treatment B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
despite I-Claim
the I-Claim
fact I-Claim
that I-Claim
most I-Claim
patients I-Claim
suffered I-Claim
from I-Claim
multiple I-Claim
comorbidities I-Claim
and I-Claim
were I-Claim
heavily I-Claim
pretreated I-Claim
. I-Claim

There B-Claim
were I-Claim
no I-Claim
unexpected I-Claim
hematological I-Claim
or I-Claim
non-hematological I-Claim
toxicities I-Claim
. I-Claim

Based O
on O
this O
safety O
analysis O
, O
the O
next O
step O
of O
study O
recruitment O
was O
continued O
. O

The O
purpose O
of O
this O
article O
is O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
and O
menopausal O
symptoms O
among O
premenopausal O
patients O
with O
lymph O
node-negative O
breast O
cancer O
receiving O
chemotherapy O
, O
goserelin O
, O
or O
their O
sequential O
combination O
, O
and O
to O
investigate O
differential O
effects O
by O
age O
. O

We O
evaluated O
QOL O
data O
from O
874 O
pre- O
and O
perimenopausal O
women O
with O
lymph O
node-negative O
breast O
cancer O
who O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
classical O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
( O
CMF O
) O
chemotherapy O
, O
ovarian O
suppression O
with O
goserelin O
for O
24 O
months O
, O
or O
six O
courses O
of O
classical O
CMF O
followed O
by O
18 O
months O
of O
goserelin O
. O

We O
report O
QOL O
data O
collected O
during O
3 O
years O
after O
random O
assignment O
in O
patients O
without O
disease O
recurrence O
. O

Overall B-Premise
, I-Premise
patients I-Premise
receiving I-Premise
goserelin I-Premise
alone I-Premise
showed I-Premise
a I-Premise
marked I-Premise
improvement I-Premise
or I-Premise
less I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
measures I-Premise
over I-Premise
the I-Premise
first I-Premise
6 I-Premise
months I-Premise
than I-Premise
those I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CMF I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
at I-Premise
3 I-Premise
years I-Premise
after I-Premise
random I-Premise
assignment I-Premise
according I-Premise
to I-Premise
treatment I-Premise
except I-Premise
for I-Premise
hot I-Premise
flashes I-Premise
. I-Premise

As B-Premise
reflected I-Premise
in I-Premise
the I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
, I-Premise
patients I-Premise
in I-Premise
all I-Premise
three I-Premise
treatment I-Premise
groups I-Premise
experienced I-Premise
induced I-Premise
amenorrhea I-Premise
, I-Premise
but B-Premise
the I-Premise
onset I-Premise
of I-Premise
ovarian I-Premise
function I-Premise
suppression I-Premise
was I-Premise
slightly I-Premise
delayed I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

Younger B-Premise
patients I-Premise
( I-Premise
< I-Premise
40 I-Premise
years I-Premise
) I-Premise
who I-Premise
received I-Premise
goserelin I-Premise
alone I-Premise
returned I-Premise
to I-Premise
their I-Premise
premenopausal I-Premise
status I-Premise
at I-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
cessation I-Premise
of I-Premise
therapy I-Premise
, I-Premise
while I-Premise
those I-Premise
who I-Premise
received I-Premise
CMF I-Premise
showed I-Premise
marginal I-Premise
changes I-Premise
from I-Premise
their I-Premise
baseline I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
. I-Premise

Age-adjusted B-Claim
risk I-Claim
profiles I-Claim
that I-Claim
consider I-Claim
patient-reported I-Claim
outcomes I-Claim
enable I-Claim
patients I-Claim
to I-Claim
adapt I-Claim
to I-Claim
their I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
, I-Claim
such I-Claim
as I-Claim
considering I-Claim
the I-Claim
trade-offs I-Claim
between I-Claim
delayed I-Claim
endocrine I-Claim
symptoms I-Claim
, I-Claim
but I-Claim
higher I-Claim
risk I-Claim
of I-Claim
permanent I-Claim
menopause I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
and I-Claim
immediate I-Claim
but I-Claim
reversible I-Claim
endocrine I-Claim
symptoms I-Claim
with I-Claim
goserelin I-Claim
, I-Claim
in I-Claim
younger I-Claim
premenopausal I-Claim
patients I-Claim
. I-Claim

With O
the O
adoption O
of O
enhanced O
recovery O
and O
emerging O
new O
modalities O
of O
analgesia O
after O
laparoscopic O
colorectal O
resection O
( O
LCR O
) O
, O
the O
role O
of O
epidural O
analgesia O
has O
been O
questioned O
. O

This O
pilot O
trial O
assessed O
the O
feasibility O
of O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
comparing O
epidural O
analgesia O
and O
use O
of O
a O
local O
anaesthetic O
wound O
infusion O
catheter O
( O
WIC O
) O
following O
LCR O
. O

Between O
April O
2010 O
and O
May O
2011 O
, O
patients O
undergoing O
elective O
LCR O
in O
two O
centres O
were O
randomized O
to O
analgesia O
via O
epidural O
or O
WIC O
. O

Sham O
procedures O
were O
used O
to O
blind O
surgeons O
, O
patients O
and O
outcome O
assessors O
. O

The O
primary O
outcome O
was O
the O
feasibility O
of O
a O
large O
RCT O
, O
and O
all O
outcomes O
for O
a O
definitive O
trial O
were O
tested O
. O

The O
success O
of O
blinding O
was O
assessed O
using O
a O
mixed-methods O
approach O
. O

Forty-five O
patients O
were O
eligible O
, O
of O
whom O
34 O
were O
randomized O
( O
mean O
( O
s.d O
. O
) O
age O
70 O
( O
11·8 O
) O
years O
) O
. O

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

Challenges O
with O
capturing O
pain O
data O
were O
identified O
and O
resolved O
. O

Mean B-Premise
( I-Premise
s.d I-Premise
. I-Premise
) I-Premise
pain I-Premise
scores I-Premise
on I-Premise
the I-Premise
day I-Premise
of I-Premise
discharge I-Premise
were I-Premise
1·9 I-Premise
( I-Premise
3·1 I-Premise
) I-Premise
in I-Premise
the I-Premise
epidural I-Premise
group I-Premise
and I-Premise
0·7 I-Premise
( I-Premise
0·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
WIC I-Premise
group I-Premise
. I-Premise

Median B-Premise
length I-Premise
of I-Premise
stay I-Premise
was I-Premise
4 I-Premise
( I-Premise
range I-Premise
2-35 I-Premise
, I-Premise
interquartile I-Premise
range I-Premise
3-5 I-Premise
) I-Premise
days I-Premise
. I-Premise

Mean B-Premise
use I-Premise
of I-Premise
additional I-Premise
analgesia I-Premise
( I-Premise
intravenous I-Premise
morphine I-Premise
equivalents I-Premise
) I-Premise
was I-Premise
12 I-Premise
mg I-Premise
in I-Premise
the I-Premise
WIC I-Premise
arm I-Premise
and I-Premise
9 I-Premise
mg I-Premise
in I-Premise
the I-Premise
epidural I-Premise
arm I-Premise
. I-Premise

Patient O
blinding O
was O
successful O
in O
both O
arms O
. O

Qualitative B-Claim
interviews I-Claim
suggested I-Claim
that I-Claim
patients I-Claim
found I-Claim
participation I-Claim
in I-Claim
the I-Claim
trial I-Claim
acceptable I-Claim
and I-Claim
that I-Claim
they I-Claim
would I-Claim
consider I-Claim
participating I-Claim
in I-Claim
a I-Claim
future I-Claim
trial I-Claim
. I-Claim

A B-Claim
blinded I-Claim
RCT I-Claim
investigating I-Claim
the I-Claim
role I-Claim
of I-Claim
epidural I-Claim
and I-Claim
WIC I-Claim
administration I-Claim
for I-Claim
postoperative I-Claim
analgesia I-Claim
following I-Claim
LCR I-Claim
is I-Claim
feasible I-Claim
. I-Claim

Rigorous B-Claim
standard I-Claim
operating I-Claim
procedures I-Claim
for I-Claim
data I-Claim
collection I-Claim
are I-Claim
required I-Claim
. I-Claim

In O
a O
previous O
study O
of O
treatment O
for O
advanced O
colorectal O
cancer O
, O
the O
LV5FU2 O
regimen O
, O
comprising O
leucovorin O
( O
LV O
) O
plus O
bolus O
and O
infusional O
fluorouracil O
( O
5FU O
) O
every O
2 O
weeks O
, O
was O
superior O
to O
the O
standard O
North O
Central O
Cancer O
Treatment O
Group/Mayo O
Clinic O
5-day O
bolus O
5FU/LV O
regimen O
. O

This O
phase O
III O
study O
investigated O
the O
effect O
of O
combining O
oxaliplatin O
with O
LV5FU2 O
, O
with O
progression-free O
survival O
as O
the O
primary O
end O
point O
. O

Four O
hundred O
twenty O
previously O
untreated O
patients O
with O
measurable O
disease O
were O
randomized O
to O
receive O
a O
2-hour O
infusion O
of O
LV O
( O
200 O
mg/m O
( O
2 O
) O
/d O
) O
followed O
by O
a O
5FU O
bolus O
( O
400 O
mg/m O
( O
2 O
) O
/d O
) O
and O
22-hour O
infusion O
( O
600 O
mg/m O
( O
2 O
) O
/d O
) O
for O
2 O
consecutive O
days O
every O
2 O
weeks O
, O
either O
alone O
or O
together O
with O
oxaliplatin O
85 O
mg/m O
( O
2 O
) O
as O
a O
2-hour O
infusion O
on O
day O
1 O
. O

Patients B-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
plus I-Premise
LV5FU2 I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
median I-Premise
, I-Premise
9.0 I-Premise
v I-Premise
6.2 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.0003 I-Premise
) I-Premise
and I-Premise
better I-Premise
response I-Premise
rate I-Premise
( I-Premise
50.7 I-Premise
% I-Premise
v I-Premise
22.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
arm I-Premise
. I-Premise

The B-Premise
improvement I-Premise
in I-Premise
overall I-Premise
survival I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
( I-Premise
median I-Premise
, I-Premise
16.2 I-Premise
v I-Premise
14.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise

LV5FU2 B-Premise
plus I-Premise
oxaliplatin I-Premise
gave I-Premise
higher I-Premise
frequencies I-Premise
of I-Premise
National I-Premise
Cancer I-Premise
Institute I-Premise
common I-Premise
toxicity I-Premise
criteria I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
41 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
5.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
11.9 I-Premise
% I-Premise
v I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
neurosensory I-Premise
toxicity I-Premise
( I-Premise
18.2 I-Premise
% I-Premise
v I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
this I-Premise
did I-Premise
not I-Premise
result I-Premise
in I-Premise
impairment I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
QoL I-Premise
) I-Premise
. I-Premise

Survival B-Premise
without I-Premise
disease I-Premise
progression I-Premise
or I-Premise
deterioration I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
treatment I-Premise
( I-Premise
P I-Premise
=.004 I-Premise
) I-Premise
. I-Premise

The B-Claim
LV5FU2-oxaliplatin I-Claim
combination I-Claim
seems I-Claim
beneficial I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
demonstrating I-Claim
a I-Claim
prolonged I-Claim
progression-free I-Claim
survival I-Claim
with I-Claim
acceptable I-Claim
tolerability I-Claim
and I-Claim
maintenance I-Claim
of I-Claim
QoL I-Claim
. I-Claim

Few O
reports O
have O
examined O
the O
use O
of O
recombinant O
human O
thyroid-stimulating O
hormone O
( O
rhTSH O
) O
for O
ablation O
of O
postsurgical O
thyroid O
remnants O
after O
low-dose O
radioactive O
iodine O
( O
RI O
) O
therapy O
, O
compared O
with O
conventional O
thyroid O
hormone O
withdrawal O
. O

We O
investigated O
whether O
patient O
preparation O
using O
rhTSH O
was O
comparable O
to O
conventional O
thyroid O
hormone O
withdrawal O
with O
respect O
to O
efficacy O
of O
postsurgical O
remnant O
ablation O
in O
low-risk O
patients O
receiving O
a O
30 O
mCi O
RI O
. O

In O
addition O
, O
we O
also O
evaluated O
the O
impact O
of O
rhTSH O
( O
rhTSH O
vs. O
conventional O
thyroid O
hormone O
withdrawal O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RI O
ablation O
. O

This O
study O
included O
three O
groups O
of O
patients O
, O
enrolled O
consecutively O
. O

From O
February O
2006 O
to O
March O
2007 O
, O
291 O
patients O
were O
enrolled O
and O
randomized O
, O
after O
total O
thyroidectomy O
: O
( O
1 O
) O
withdrawal O
of O
levothyroxine O
( O
LT4 O
) O
for O
4 O
weeks O
( O
T4-WD O
Group O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
withdrawal O
of O
LT4 O
for O
4 O
weeks O
plus O
2 O
weeks O
on O
and O
then O
2 O
weeks O
off O
liothyronine O
( O
LT3 O
) O
( O
T3-WD O
Group O
, O
n O
= O
133 O
) O
, O
and O
( O
3 O
) O
rhTSH O
administration O
( O
rhTSH O
Group O
, O
n O
= O
69 O
) O
. O

QoL O
was O
determined O
at O
the O
time O
of O
ablation O
. O

Patients O
in O
the O
three O
groups O
did O
not O
differ O
significantly O
in O
baseline O
characteristics O
or O
tumor O
, O
node O
and O
metastasis O
( O
TNM O
) O
staging O
. O

In B-Premise
all I-Premise
study I-Premise
groups I-Premise
, I-Premise
serum I-Premise
TSH I-Premise
levels I-Premise
showed I-Premise
very I-Premise
good I-Premise
stimulation I-Premise
( I-Premise
mean I-Premise
, I-Premise
82.24 I-Premise
+/- I-Premise
18.21 I-Premise
mU/L I-Premise
) I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.5213 I-Premise
) I-Premise
. I-Premise

Follow-up O
examinations O
were O
performed O
12 O
months O
after O
ablation O
to O
assess O
ablation O
outcome O
in O
each O
group O
by O
131 O
whole O
body O
scans O
( O
WBSs O
) O
, O
serum O
thyroglobulin O
measurement O
after O
TSH O
stimulation O
, O
and O
neck O
ultrasonography O
. O

The B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91.0 I-Premise
% I-Premise
in I-Premise
T4-WD I-Premise
Group I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
in I-Premise
T3-WD I-Premise
Group I-Premise
, I-Premise
and I-Premise
91.3 I-Premise
% I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.2061 I-Premise
) I-Premise
. I-Premise

QoL B-Premise
was I-Premise
better I-Premise
preserved I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
than I-Premise
in I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
QoL I-Premise
difference I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
ablation I-Premise
between I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
. I-Premise

Our B-Claim
study I-Claim
indicates I-Claim
that I-Claim
use I-Claim
of I-Claim
rhTSH I-Claim
preserves I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
RI I-Claim
ablation I-Claim
and I-Claim
affords I-Claim
an I-Claim
ablation I-Claim
success I-Claim
rate I-Claim
comparable I-Claim
to I-Claim
that I-Claim
seen I-Claim
after I-Claim
thyroid I-Claim
hormone I-Claim
withdrawal I-Claim
. I-Claim

Notably O
, O
ablation O
preparation O
using O
withdrawal O
of O
LT3 O
for O
2 O
weeks O
did O
not O
prevent O
development O
of O
profound O
hypothyroidism O
, O
as O
also O
occurred O
when O
LT4 O
alone O
was O
withdrawn O
for O
4 O
weeks O
. O

To O
determine O
whether O
an O
Internet-based B-Claim
tailored I-Claim
education I-Claim
program I-Claim
is I-Claim
effective I-Claim
for I-Claim
disease-free I-Claim
cancer I-Claim
survivors I-Claim
with I-Claim
cancer-related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
. I-Claim

We O
randomly O
assigned O
patients O
who O
had O
completed O
primary O
cancer O
treatment O
within O
the O
past O
24 O
months O
in O
any O
of O
four O
Korean O
hospitals O
and O
had O
reported O
moderate O
to O
severe O
fatigue O
for O
at O
least O
1 O
week O
to O
participate O
in O
a O
12-week O
, O
Internet-based O
, O
individually O
tailored O
CRF O
education O
program O
or O
to O
receive O
routine O
care O
. O

We O
based O
the O
program O
on O
the O
CRF O
guidelines O
of O
the O
National O
Comprehensive O
Cancer O
Network O
( O
NCCN O
) O
and O
incorporated O
the O
transtheoretic O
model O
( O
TTM O
) O
. O

At O
baseline O
and O
12 O
weeks O
, O
we O
used O
the O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
and O
Fatigue O
Severity O
Scale O
( O
FSS O
) O
as O
primary O
outcomes O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
and O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
for O
secondary O
outcomes O
. O

We O
recruited O
273 O
participants O
and O
randomly O
assigned O
136 O
to O
the O
intervention O
group O
. O

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
had I-Premise
an I-Premise
improvement I-Premise
in I-Premise
fatigue I-Premise
as I-Premise
shown I-Premise
by I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
BFI I-Premise
global I-Premise
score I-Premise
( I-Premise
-0.66 I-Premise
points I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1.04 I-Premise
to I-Premise
-0.27 I-Premise
) I-Premise
and I-Premise
FSS I-Premise
total I-Premise
score I-Premise
( I-Premise
-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.78 I-Premise
to I-Premise
-0.21 I-Premise
) I-Premise
. I-Premise

In B-Premise
secondary I-Premise
outcomes I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
experienced I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
HADS I-Premise
anxiety I-Premise
score I-Premise
( I-Premise
-0.90 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.51 I-Premise
to I-Premise
-0.29 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
5.22 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
to I-Premise
9.50 I-Premise
) I-Premise
and I-Premise
several I-Premise
functioning I-Premise
scores I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
. I-Premise

An B-Claim
Internet-based I-Claim
education I-Claim
program I-Claim
based I-Claim
on I-Claim
NCCN I-Claim
guidelines I-Claim
and I-Claim
TTM I-Claim
may I-Claim
help I-Claim
patients I-Claim
manage I-Claim
CRF I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
quality O
of O
life O
( O
QOL O
) O
of O
high-risk O
breast O
cancer O
patients O
included O
in O
a O
randomized O
clinical O
trial O
( O
PEGASE O
1 O
) O
comparing O
conventional O
chemotherapy O
versus O
adding O
an O
additional O
high-dose O
chemotherapy O
( O
HDC O
) O
cycle O
with O
blood O
stem O
cell O
support O
. O

A O
total O
of O
314 O
patients O
were O
included O
in O
the O
clinical O
trial O
. O

QOL O
evaluations O
were O
available O
for O
199 O
patients O
. O

QOL O
was O
assessed O
over O
a O
1-year O
follow-up O
period O
, O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C-30 O
. O

The O
results O
were O
analyzed O
using O
a O
linear O
mixed-effects O
model O
. O

Toxicity B-Premise
of I-Premise
HDC I-Premise
has I-Premise
a I-Premise
strong I-Premise
negative I-Premise
impact I-Premise
on I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
phase I-Premise
. I-Premise

This B-Premise
negative I-Premise
impact I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
, I-Premise
as I-Premise
for I-Premise
most I-Premise
of I-Premise
the I-Premise
QLQ-C30 I-Premise
scales I-Premise
, I-Premise
the I-Premise
QOL I-Premise
scores I-Premise
of I-Premise
HDC I-Premise
patients I-Premise
tend I-Premise
to I-Premise
improve I-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
than I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
standard I-Premise
chemotherapy I-Premise
. I-Premise

In O
particular O
, O
physical B-Premise
functioning I-Premise
remains I-Premise
deteriorated I-Premise
1 I-Premise
year I-Premise
after I-Premise
inclusion I-Premise
for I-Premise
HDC I-Premise
patients I-Premise
comparatively I-Premise
to I-Premise
conventional I-Premise
chemotherapy I-Premise
patients I-Premise
( I-Premise
85.99 I-Premise
vs. I-Premise
76.65 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
) I-Premise
, O
and B-Premise
the I-Premise
pain I-Premise
score I-Premise
was I-Premise
still I-Premise
higher I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
at I-Premise
that I-Premise
time I-Premise
( I-Premise
28.32 I-Premise
vs. I-Premise
15.97 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

HDC B-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QOL I-Claim
even I-Claim
after I-Claim
treatment I-Claim
phase I-Claim
. I-Claim

In O
the O
absence O
of O
an O
overall O
survival O
benefit O
of O
using O
HDC O
for O
high-risk O
breast O
cancer O
patients O
, O
QOL O
studies O
with O
a O
longer O
follow-up O
play O
an O
important O
role O
in O
informing O
the O
complex O
trade-off O
implied O
by O
HDC O
between O
higher O
toxicity O
, O
reduced O
risk O
of O
relapse O
, O
and O
QOL O
decrease O
after O
the O
active O
phase O
of O
treatment O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
analgesic O
and O
adverse O
effects O
, O
doses O
, O
as O
well O
as O
cost O
of O
opioid O
drugs O
, O
supportive O
drug O
therapy O
and O
other O
analgesic O
drugs O
in O
patients O
treated O
with O
oral O
sustained-release O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
. O

One O
hundred O
and O
eight O
cancer O
patients O
, O
no O
longer O
responsive O
to O
opioids O
for O
moderate O
pain O
, O
were O
selected O
to O
randomly O
receive O
initial O
daily O
doses O
of O
60 O
mg O
of O
oral O
sustained-release O
morphine O
, O
15 O
mg O
of O
oral O
methadone O
, O
or O
0.6 O
mg O
( O
25 O
microg/h O
) O
of O
transdermal O
fentanyl O
. O

Oral O
morphine O
was O
used O
as O
breakthrough O
pain O
medication O
during O
opioid O
titration O
. O

Opioid O
doses O
, O
pain O
intensity O
, O
adverse O
effects O
, O
symptomatic O
drugs O
, O
were O
recorded O
at O
week O
intervals O
for O
4 O
weeks O
. O

Costs O
of O
opioid O
therapy O
, O
supportive O
drugs O
, O
and O
other O
analgesic O
drugs O
were O
also O
evaluated O
. O

Seventy O
patients O
completed O
the O
4 O
weeks O
period O
of O
study O
. O

Five O
, O
five O
, O
and O
four O
patients O
, O
treated O
with O
oral O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
, O
respectively O
, O
required O
opioid O
switching O
. O

No B-Premise
differences I-Premise
in I-Premise
pain I-Premise
and I-Premise
symptom I-Premise
intensity I-Premise
were I-Premise
observed I-Premise
. I-Premise

Opioid B-Premise
escalation I-Premise
index I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
methadone I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
although I-Premise
requiring I-Premise
up I-Premise
and I-Premise
down I-Premise
changes I-Premise
in I-Premise
doses I-Premise
. I-Premise

At B-Premise
the I-Premise
doses I-Premise
used I-Premise
, I-Premise
methadone I-Premise
was I-Premise
significantly I-Premise
less I-Premise
expensive I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
while I-Premise
the I-Premise
use I-Premise
and I-Premise
costs I-Premise
of I-Premise
supportive I-Premise
drugs I-Premise
and I-Premise
other I-Premise
analgesics I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

No B-Premise
relevant I-Premise
differences I-Premise
in I-Premise
adverse I-Premise
effects I-Premise
were I-Premise
observed I-Premise
among I-Premise
the I-Premise
groups I-Premise
during I-Premise
either I-Premise
the I-Premise
titration I-Premise
phase I-Premise
and I-Premise
chronic I-Premise
treatment I-Premise
. I-Premise

All B-Claim
the I-Claim
three I-Claim
opioids I-Claim
used I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
were I-Claim
effective I-Claim
, I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
required I-Claim
similar I-Claim
amounts I-Claim
of I-Claim
symptomatic I-Claim
drugs I-Claim
or I-Claim
co-analgesics I-Claim
. I-Claim

Methadone B-Claim
was I-Claim
significantly I-Claim
less I-Claim
expensive I-Claim
, I-Claim
but I-Claim
required I-Claim
more I-Claim
changes I-Claim
, I-Claim
up I-Claim
and I-Claim
down I-Claim
, I-Claim
of I-Claim
the I-Claim
doses I-Claim
, I-Claim
suggesting I-Claim
that I-Claim
dose I-Claim
titration I-Claim
of I-Claim
this I-Claim
drug I-Claim
requires I-Claim
major I-Claim
clinical I-Claim
expertise I-Claim
. I-Claim

We O
sought O
the O
extent O
to O
which O
arm O
morbidity O
could O
be O
reduced O
by O
using O
sentinel-lymph-node-based O
management O
in O
women O
with O
clinically O
node-negative O
early O
breast O
cancer O
. O

One O
thousand O
eighty-eight O
women O
were O
randomly O
allocated O
to O
sentinel-lymph-node O
biopsy O
followed O
by O
axillary O
clearance O
if O
the O
sentinel O
node O
was O
positive O
or O
not O
detected O
( O
SNBM O
) O
or O
routine O
axillary O
clearance O
( O
RAC O
, O
sentinel-lymph-node O
biopsy O
followed O
immediately O
by O
axillary O
clearance O
) O
. O

Sentinel O
nodes O
were O
located O
using O
blue O
dye O
, O
alone O
or O
with O
technetium-labeled O
antimony O
sulfide O
colloid O
. O

The O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O

Secondary O
endpoints O
were O
the O
proportions O
of O
women O
with O
at O
least O
15 O
% O
increase O
in O
arm O
volume O
or O
early O
axillary O
morbidity O
, O
and O
average O
scores O
for O
arm O
symptoms O
, O
dysfunctions O
, O
and O
disabilities O
assessed O
at O
6 O
and O
12 O
months O
by O
patients O
with O
the O
SNAC O
Study-Specific O
Scales O
and O
other O
quality-of-life O
instruments O
. O

Sensitivity O
, O
false-negative O
rates O
, O
and O
negative O
predictive O
values O
for O
sentinel-lymph-node O
biopsy O
were O
estimated O
in O
the O
RAC O
group O
. O

The B-Premise
average I-Premise
increase I-Premise
in I-Premise
arm I-Premise
volume I-Premise
was I-Premise
2.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
and I-Premise
4.2 I-Premise
% I-Premise
in I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
gave I-Premise
lower I-Premise
ratings I-Premise
for I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
dysfunctions I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
disabilities I-Premise
( I-Premise
P I-Premise
= I-Premise
0.5 I-Premise
) I-Premise
. I-Premise

Sentinel B-Premise
nodes I-Premise
were I-Premise
found I-Premise
in I-Premise
95 I-Premise
% I-Premise
of I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
( I-Premise
29 I-Premise
% I-Premise
positive I-Premise
) I-Premise
and I-Premise
93 I-Premise
% I-Premise
of I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
25 I-Premise
% I-Premise
positive I-Premise
) I-Premise
. I-Premise

SNB O
had O
sensitivity O
94.5 O
% O
, O
false-negative O
rate O
5.5 O
% O
, O
and O
negative O
predictive O
value O
98 O
% O
. O

SNBM B-Claim
was I-Claim
successfully I-Claim
undertaken I-Claim
in I-Claim
a I-Claim
wide I-Claim
range I-Claim
of I-Claim
surgical I-Claim
centers I-Claim
and I-Claim
caused I-Claim
significantly I-Claim
less I-Claim
morbidity I-Claim
than I-Claim
RAC I-Claim
. I-Claim

This O
phase O
III O
, O
double-blind O
, O
randomized O
, O
multicenter O
study O
evaluated O
the O
efficacy O
, O
pharmacodynamics O
, O
and O
safety O
of O
the O
oral O
aromatase O
inactivator O
exemestane O
( O
EXE O
) O
versus O
megestrol O
acetate O
( O
MA O
) O
in O
postmenopausal O
women O
with O
progressive O
advanced O
breast O
cancer O
who O
experienced O
failure O
of O
tamoxifen O
. O

A O
total O
of O
769 O
patients O
were O
randomized O
to O
EXE O
25 O
mg/d O
( O
n O
= O
366 O
) O
or O
MA O
( O
n O
= O
403 O
) O
40 O
mg O
four O
times O
daily O
. O

Tumor O
response O
, O
duration O
of O
tumor O
control O
, O
tumor-related O
signs O
and O
symptoms O
( O
TRSS O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
survival O
, O
and O
tolerability O
were O
evaluated O
. O

Overall B-Premise
objective I-Premise
response I-Premise
( I-Premise
OR I-Premise
) I-Premise
rates I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
EXE I-Premise
than I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
MA I-Premise
( I-Premise
15.0 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
";" I-Premise
a B-Premise
similar I-Premise
trend I-Premise
was I-Premise
noted I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
metastases I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
v I-Premise
10.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
EXE I-Premise
( I-Premise
median I-Premise
not I-Premise
reached I-Premise
) I-Premise
than I-Premise
with I-Premise
MA I-Premise
( I-Premise
123.4 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.039 I-Premise
) I-Premise
, I-Premise
as I-Premise
were I-Premise
the I-Premise
median I-Premise
duration I-Premise
of I-Premise
overall I-Premise
success I-Premise
( I-Premise
OR I-Premise
or I-Premise
stable I-Premise
disease I-Premise
> I-Premise
or I-Premise
= I-Premise
24 I-Premise
weeks I-Premise
";" I-Premise
60.1 I-Premise
v I-Premise
49.1 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.025 I-Premise
) I-Premise
, I-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
( I-Premise
20.3 I-Premise
v I-Premise
16.6 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
16.3 I-Premise
v I-Premise
15.7 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.042 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
MA I-Premise
, I-Premise
there I-Premise
were I-Premise
similar I-Premise
or I-Premise
greater I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
TRSS I-Premise
, I-Premise
and I-Premise
QOL I-Premise
with I-Premise
EXE I-Premise
. I-Premise

Both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
MA I-Premise
( I-Premise
17.1 I-Premise
% I-Premise
v I-Premise
7.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

EXE B-Claim
prolongs I-Claim
survival I-Claim
time I-Claim
, I-Claim
time I-Claim
to I-Claim
tumor I-Claim
progression I-Claim
, I-Claim
and I-Claim
time I-Claim
to I-Claim
treatment I-Claim
failure I-Claim
compared I-Claim
with I-Claim
MA I-Claim
and I-Claim
offers I-Claim
a I-Claim
well-tolerated I-Claim
treatment I-Claim
option I-Claim
for I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
progressive I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
experienced I-Claim
failure I-Claim
of I-Claim
tamoxifen I-Claim
. I-Claim

A O
randomized O
phase O
III O
trial O
was O
conducted O
to O
determine O
whether O
combination O
therapy O
with O
13-cis-retinoic O
acid O
( O
13-CRA O
) O
plus O
interferon O
alfa-2a O
( O
IFNalpha2a O
) O
is O
superior O
to O
IFNalpha2a O
alone O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O

Two O
hundred O
eighty-four O
patients O
were O
randomized O
to O
treatment O
with O
IFNalpha2a O
plus O
13-CRA O
or O
treatment O
with O
IFNalpha2a O
alone O
. O

IFNalpha2a O
was O
given O
daily O
subcutaneously O
, O
starting O
at O
a O
dose O
of O
3 O
million O
units O
( O
MU O
) O
. O

The O
dose O
was O
escalated O
every O
7 O
days O
from O
3 O
to O
9 O
MU O
( O
by O
increments O
of O
3 O
MU O
) O
, O
unless O
> O
/= O
grade O
2 O
toxicity O
occurred O
, O
in O
which O
case O
dose O
escalation O
was O
stopped O
. O

Patients O
randomized O
to O
combination O
therapy O
were O
given O
oral O
13-CRA O
1 O
mg/kg/d O
plus O
IFNalpha2a O
. O

Quality O
of O
life O
( O
QOL O
) O
was O
assessed O
. O

Complete B-Premise
or I-Premise
partial I-Premise
responses I-Premise
were I-Premise
achieved I-Premise
by I-Premise
12 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
and I-Premise
6 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
( I-Premise
P I-Premise
=.14 I-Premise
) I-Premise
. I-Premise

Median B-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
complete I-Premise
and I-Premise
partial I-Premise
combined I-Premise
) I-Premise
in I-Premise
the I-Premise
group I-Premise
treated I-Premise
with I-Premise
the I-Premise
combination I-Premise
was I-Premise
33 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
9 I-Premise
to I-Premise
50 I-Premise
months I-Premise
) I-Premise
, I-Premise
versus I-Premise
22 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
5 I-Premise
to I-Premise
38 I-Premise
months I-Premise
) I-Premise
for I-Premise
the I-Premise
second I-Premise
group I-Premise
( I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
. I-Premise

Nineteen B-Premise
percent I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
were I-Premise
progression-free I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
compared I-Premise
with I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
alone I-Premise
( I-Premise
P I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
patients I-Premise
was I-Premise
15 I-Premise
months I-Premise
, I-Premise
with I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
=.26 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
decreased I-Premise
during I-Premise
the I-Premise
first I-Premise
8 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
, I-Premise
and I-Premise
a I-Premise
partial I-Premise
recovery I-Premise
followed I-Premise
. I-Premise

Lower B-Premise
scores I-Premise
were I-Premise
associated I-Premise
with I-Premise
the I-Premise
combination I-Premise
therapy I-Premise
. I-Premise

Response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13-CRA I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
RCC I-Claim
. I-Claim

13-CRA B-Claim
may I-Claim
lengthen I-Claim
response I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
IFNalpha2a-sensitive I-Claim
tumors I-Claim
. I-Claim

Treatment B-Claim
, I-Claim
particularly I-Claim
the I-Claim
combination I-Claim
therapy I-Claim
, I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
decrease I-Claim
in I-Claim
QOL I-Claim
. I-Claim

Transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O

Prospective O
studies O
comparing O
the O
two O
methods O
in O
Asian O
people O
are O
few O
. O

In O
addition O
, O
the O
data O
comparing O
their O
effects O
on O
the O
quality O
of O
life O
are O
lacking O
. O

A O
prospective O
randomized O
study O
was O
conducted O
from O
January O
2003 O
. O

Patients O
of O
resectable O
esophageal O
cancer O
of O
comparable O
stage O
were O
allocated O
to O
undergo O
the O
transthoracic O
or O
transhiatal O
procedure O
in O
turn O
. O

They O
were O
all O
reconstructed O
with O
stomach O
interposition O
through O
the O
retrosternal O
route O
. O

Discharged O
patients O
were O
followed-up O
in O
the O
outpatient O
clinic O
. O

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O

Also O
the O
demographic O
data O
, O
operative O
results O
and O
survival O
were O
recorded O
. O

Up O
to O
December O
2006 O
, O
eighty-seven O
patients O
of O
stage O
II O
and O
III O
, O
including O
71 O
patients O
of O
middle O
third O
lesions O
and O
16 O
lower O
third O
lesions O
were O
enrolled O
. O

The B-Premise
operation I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
, I-Premise
and I-Premise
the I-Premise
leakage I-Premise
rate I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
transthoracic I-Premise
group I-Premise
( I-Premise
Student I-Premise
's I-Premise
t-test I-Premise
and I-Premise
Fischer I-Premise
's I-Premise
exact I-Premise
test I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

However O
, O
intraoperative B-Premise
blood I-Premise
loss I-Premise
and I-Premise
postoperative I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
( I-Premise
Student I-Premise
t-test I-Premise
) I-Premise
. I-Premise

Also O
, O
the B-Premise
Kaplan-Meier I-Premise
survival I-Premise
curves I-Premise
of I-Premise
these I-Premise
two I-Premise
groups I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
by I-Premise
log-rank I-Premise
test I-Premise
( I-Premise
p=0.286 I-Premise
) I-Premise
. I-Premise

The B-Premise
score I-Premise
on I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
of I-Premise
transhiatal I-Premise
patients I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
transthoracic I-Premise
patients I-Premise
in I-Premise
the I-Premise
third I-Premise
, I-Premise
sixth I-Premise
and I-Premise
twelfth I-Premise
month I-Premise
. I-Premise

Transhiatal B-Claim
esophagectomy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
fast I-Claim
procedure I-Claim
. I-Claim

The B-Claim
survival I-Claim
was I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
transthoracic I-Claim
approach I-Claim
. I-Claim

Its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim

Hot B-Claim
flashes I-Claim
are I-Claim
a I-Claim
significant I-Claim
problem I-Claim
for I-Claim
many I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Hot B-Claim
flashes I-Claim
can I-Claim
cause I-Claim
discomfort I-Claim
, I-Claim
disrupted I-Claim
sleep I-Claim
, I-Claim
anxiety I-Claim
, I-Claim
and I-Claim
decreased I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

A O
well-tolerated O
and O
effective O
mind-body O
treatment O
for O
hot O
flashes O
would O
be O
of O
great O
value O
. O

On O
the O
basis O
of O
previous O
case O
studies O
, O
this O
study O
was O
developed O
to O
evaluate O
the O
effect O
of O
a O
hypnosis O
intervention O
for O
hot O
flashes O
. O

Sixty O
female O
breast O
cancer O
survivors O
with O
hot O
flashes O
were O
randomly O
assigned O
to O
receive O
hypnosis O
intervention O
( O
five O
weekly O
sessions O
) O
or O
no O
treatment O
. O

Eligible O
patients O
had O
to O
have O
a O
history O
of O
primary O
breast O
cancer O
without O
evidence O
of O
detectable O
disease O
and O
14 O
or O
more O
weekly O
hot O
flashes O
for O
at O
least O
1 O
month O
. O

The O
major O
outcome O
measure O
was O
a O
bivariate O
construct O
that O
represented O
hot O
flash O
frequency O
and O
hot O
flash O
score O
, O
which O
was O
analyzed O
by O
a O
classic O
sums O
and O
differences O
comparison O
. O

Secondary O
outcome O
measures O
were O
self-reports O
of O
interference O
of O
hot O
flashes O
on O
daily O
activities O
. O

Fifty-one O
randomly O
assigned O
women O
completed O
the O
study O
. O

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
improvements I-Premise
in I-Premise
self-reported I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
interference I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
on I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
sleep I-Premise
were I-Premise
observed I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
hypnosis I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
no I-Premise
treatment I-Premise
control I-Premise
group I-Premise
. I-Premise

Hypnosis B-Claim
appears I-Claim
to I-Claim
reduce I-Claim
perceived I-Claim
hot I-Claim
flashes I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
may I-Claim
have I-Claim
additional I-Claim
benefits I-Claim
such I-Claim
as I-Claim
reduced I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
, I-Claim
and I-Claim
improved I-Claim
sleep I-Claim
. I-Claim

The O
TAX O
327 O
study O
compared O
docetaxel O
administered O
every O
3 O
weeks O
( O
D3 O
) O
, O
weekly O
docetaxel O
( O
D1 O
) O
, O
and O
mitoxantrone O
( O
M O
) O
, O
each O
with O
prednisone O
( O
P O
) O
, O
in O
1,006 O
men O
with O
metastatic O
hormone-resistant O
prostate O
cancer O
( O
HRPC O
) O
. O

The O
original O
analysis O
, O
undertaken O
in O
August O
2003 O
when O
557 O
deaths O
had O
occurred O
, O
showed O
significantly O
better O
survival O
and O
response O
rates O
for O
pain O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
and O
quality O
of O
life O
for O
D3P O
when O
compared O
with O
MP O
. O

Here O
, O
we O
report O
an O
updated O
analysis O
of O
survival O
. O

Investigators O
were O
asked O
to O
provide O
the O
date O
of O
death O
or O
last O
follow-up O
for O
all O
participants O
who O
were O
alive O
in O
August O
2003 O
. O

By O
March O
2007 O
, O
data O
on O
310 O
additional O
deaths O
were O
obtained O
( O
total O
= O
867 O
deaths O
) O
. O

The B-Premise
survival I-Premise
benefit I-Premise
of I-Premise
D3P I-Premise
compared I-Premise
with I-Premise
MP I-Premise
has I-Premise
persisted I-Premise
with I-Premise
extended I-Premise
follow-up I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
. I-Premise

Median O
survival O
time O
was O
19.2 O
months O
( O
95 O
% O
CI O
, O
17.5 O
to O
21.3 O
months O
) O
in O
the O
D3P O
arm O
, O
17.8 O
months O
( O
95 O
% O
CI O
, O
16.2 O
to O
19.2 O
months O
) O
in O
the O
D1P O
arm O
, O
and O
16.3 O
months O
( O
95 O
% O
CI O
, O
14.3 O
to O
17.9 O
months O
) O
in O
the O
MP O
arm O
. O

More B-Premise
patients I-Premise
survived I-Premise
> I-Premise
/= I-Premise
3 I-Premise
years I-Premise
in I-Premise
the I-Premise
D3P I-Premise
and I-Premise
D1P I-Premise
arms I-Premise
( I-Premise
18.6 I-Premise
% I-Premise
and I-Premise
16.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
MP I-Premise
arm I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Similar B-Premise
trends I-Premise
in I-Premise
survival I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
were I-Premise
seen I-Premise
for I-Premise
men I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
65 I-Premise
years I-Premise
of I-Premise
age I-Premise
, I-Premise
for I-Premise
those I-Premise
with I-Premise
and I-Premise
without I-Premise
pain I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
for I-Premise
those I-Premise
with I-Premise
baseline I-Premise
PSA I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
the I-Premise
median I-Premise
value I-Premise
of I-Premise
115 I-Premise
ng/mL I-Premise
. I-Premise

The B-Claim
present I-Claim
analysis I-Claim
confirms I-Claim
that I-Claim
survival I-Claim
of I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
HRPC I-Claim
is I-Claim
significantly I-Claim
longer I-Claim
after I-Claim
treatment I-Claim
with I-Claim
D3P I-Claim
than I-Claim
with I-Claim
MP I-Claim
. I-Claim

Consistent O
results O
are O
observed O
across O
subgroups O
of O
patients O
. O

Both O
gastrojejunostomy O
( O
GJJ O
) O
and O
stent O
placement O
are O
commonly O
used O
palliative O
treatments O
of O
obstructive O
symptoms O
caused O
by O
malignant O
gastric O
outlet O
obstruction O
( O
GOO O
) O
. O

Compare O
GJJ O
and O
stent O
placement O
. O

Multicenter O
, O
randomized O
trial O
. O

Twenty-one O
centers O
in O
The O
Netherlands O
. O

Patients O
with O
GOO O
. O

GJJ O
and O
stent O
placement O
. O

Outcomes O
were O
medical O
effects O
, O
quality O
of O
life O
, O
and O
costs O
. O

Analysis O
was O
by O
intent O
to O
treat O
. O

Eighteen O
patients O
were O
randomized O
to O
GJJ O
and O
21 O
to O
stent O
placement O
. O

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
( I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
: I-Premise
median I-Premise
5 I-Premise
vs I-Premise
8 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
with I-Premise
more I-Premise
patients I-Premise
living I-Premise
more I-Premise
days I-Premise
with I-Premise
a I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
of I-Premise
2 I-Premise
or I-Premise
more I-Premise
than I-Premise
after I-Premise
stent I-Premise
placement I-Premise
( I-Premise
72 I-Premise
vs I-Premise
50 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
stent I-Premise
: I-Premise
6 I-Premise
in I-Premise
4 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
recurrent I-Premise
obstructive I-Premise
symptoms I-Premise
( I-Premise
stent I-Premise
: I-Premise
8 I-Premise
in I-Premise
5 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
1 I-Premise
in I-Premise
1 I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
reinterventions I-Premise
( I-Premise
stent I-Premise
: I-Premise
10 I-Premise
in I-Premise
7 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
2 I-Premise
in I-Premise
2 I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
were I-Premise
observed I-Premise
after I-Premise
stent I-Premise
placement I-Premise
compared I-Premise
with I-Premise
GJJ I-Premise
. I-Premise

When B-Premise
stent I-Premise
obstruction I-Premise
was I-Premise
not I-Premise
regarded I-Premise
as I-Premise
a I-Premise
major I-Premise
complication I-Premise
, I-Premise
no I-Premise
differences I-Premise
in I-Premise
complications I-Premise
were I-Premise
found I-Premise
( I-Premise
P I-Premise
= I-Premise
.4 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
median I-Premise
survival I-Premise
( I-Premise
stent I-Premise
: I-Premise
56 I-Premise
days I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
78 I-Premise
days I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Mean B-Premise
total I-Premise
costs I-Premise
of I-Premise
GJJ I-Premise
were I-Premise
higher I-Premise
compared I-Premise
with I-Premise
stent I-Premise
placement I-Premise
( I-Premise
$ I-Premise
16,535 I-Premise
vs I-Premise
$ I-Premise
11,720 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.049 I-Premise
[ I-Premise
comparing I-Premise
medians I-Premise
] I-Premise
) I-Premise
. I-Premise

Because O
of O
the O
small O
study O
population O
, O
only O
initial O
hospital O
costs O
would O
have O
been O
statistically O
significant O
if O
the O
Bonferroni O
correction O
for O
multiple O
testing O
had O
been O
applied O
. O

Relatively O
small O
patient O
population O
. O

Despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
GJJ B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long-term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim

Because B-Claim
stent I-Claim
placement I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
short-term I-Claim
outcomes I-Claim
, I-Claim
this B-Claim
treatment I-Claim
is I-Claim
preferable I-Claim
for I-Claim
patients I-Claim
expected I-Claim
to I-Claim
live I-Claim
less I-Claim
than I-Claim
2 I-Claim
months I-Claim
. I-Claim

Vasomotor O
symptoms O
are O
common O
adverse O
effects O
of O
antiestrogen O
hormone O
treatment O
in O
conventional O
breast O
cancer O
care O
. O

Hormone O
replacement O
therapy O
is O
contraindicated O
in O
patients O
with O
breast O
cancer O
. O

Venlafaxine O
( O
Effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O

Recent O
studies O
suggest O
acupuncture O
may O
be O
effective O
in O
reducing O
vasomotor O
symptoms O
in O
menopausal O
women O
. O

This O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor O
symptoms O
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O

Fifty O
patients O
were O
randomly O
assigned O
to O
receive O
12 O
weeks O
of O
acupuncture O
( O
n O
= O
25 O
) O
or O
venlafaxine O
( O
n O
= O
25 O
) O
treatment O
. O

Health O
outcomes O
were O
measured O
for O
up O
to O
1 O
year O
post-treatment O
. O

Both B-Premise
groups I-Premise
exhibited I-Premise
significant I-Premise
decreases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
other I-Premise
quality-of-life I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
mental I-Premise
health I-Premise
from I-Premise
pre- I-Premise
to I-Premise
post-treatment I-Premise
. I-Premise

These B-Premise
changes I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
indicating I-Premise
that I-Premise
acupuncture I-Premise
was I-Premise
as I-Premise
effective I-Premise
as I-Premise
venlafaxine I-Premise
. I-Premise

By B-Premise
2 I-Premise
weeks I-Premise
post-treatment I-Premise
, I-Premise
the I-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
whereas I-Premise
hot I-Premise
flashes I-Premise
in I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
remained I-Premise
at I-Premise
low I-Premise
levels I-Premise
. I-Premise

The B-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
18 I-Premise
incidences I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
( I-Premise
eg I-Premise
, I-Premise
nausea I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
dizziness I-Premise
, I-Premise
anxiety I-Premise
) I-Premise
, I-Premise
whereas I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
experienced I-Premise
no I-Premise
negative I-Premise
adverse I-Premise
effects I-Premise
. I-Premise

Acupuncture B-Premise
had I-Premise
the I-Premise
additional I-Premise
benefit I-Premise
of I-Premise
increased I-Premise
sex I-Premise
drive I-Premise
in I-Premise
some I-Premise
women I-Premise
, I-Premise
and I-Premise
most I-Premise
reported I-Premise
an I-Premise
improvement I-Premise
in I-Premise
their I-Premise
energy I-Premise
, I-Premise
clarity I-Premise
of I-Premise
thought I-Premise
, I-Premise
and I-Premise
sense I-Premise
of I-Premise
well-being I-Premise
. I-Premise

Acupuncture B-Claim
appears I-Claim
to I-Claim
be I-Claim
equivalent I-Claim
to I-Claim
drug I-Claim
therapy I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

It B-Claim
is I-Claim
a I-Claim
safe I-Claim
, I-Claim
effective I-Claim
and I-Claim
durable I-Claim
treatment I-Claim
for I-Claim
vasomotor I-Claim
symptoms I-Claim
secondary I-Claim
to I-Claim
long-term I-Claim
antiestrogen I-Claim
hormone I-Claim
use I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Surgical O
resection O
is O
regarded O
as O
the O
only O
curative O
option O
for O
resectable O
oesophageal O
cancer O
, O
but O
pulmonary O
complications O
occurring O
in O
more O
than O
half O
of O
patients O
after O
open O
oesophagectomy O
are O
a O
great O
concern O
. O

We O
assessed O
whether O
minimally O
invasive O
oesophagectomy O
reduces O
morbidity O
compared O
with O
open O
oesophagectomy O
. O

We O
did O
a O
multicentre O
, O
open-label O
, O
randomised O
controlled O
trial O
at O
five O
study O
centres O
in O
three O
countries O
between O
June O
1 O
, O
2009 O
, O
and O
March O
31 O
, O
2011 O
. O

Patients O
aged O
18-75 O
years O
with O
resectable O
cancer O
of O
the O
oesophagus O
or O
gastro-oesophageal O
junction O
were O
randomly O
assigned O
via O
a O
computer-generated O
randomisation O
sequence O
to O
receive O
either O
open O
transthoracic O
or O
minimally O
invasive O
transthoracic O
oesophagectomy O
. O

Randomisation O
was O
stratified O
by O
centre O
. O

Patients O
, O
and O
investigators O
undertaking O
interventions O
, O
assessing O
outcomes O
, O
and O
analysing O
data O
, O
were O
not O
masked O
to O
group O
assignment O
. O

The O
primary O
outcome O
was O
pulmonary O
infection O
within O
the O
first O
2 O
weeks O
after O
surgery O
and O
during O
the O
whole O
stay O
in O
hospital O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

This O
trial O
is O
registered O
with O
the O
Netherlands O
Trial O
Register O
, O
NTR O
TC O
2452 O
. O

We O
randomly O
assigned O
56 O
patients O
to O
the O
open O
oesophagectomy O
group O
and O
59 O
to O
the O
minimally O
invasive O
oesophagectomy O
group O
. O

16 B-Premise
( I-Premise
29 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
compared I-Premise
with I-Premise
five I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
relative I-Premise
risk I-Premise
[ I-Premise
RR I-Premise
] I-Premise
0·30 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·12-0·76 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

19 B-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in-hospital I-Premise
compared I-Premise
with I-Premise
seven I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
0·35 I-Premise
, I-Premise
0·16-0·78 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

For B-Premise
in-hospital I-Premise
mortality I-Premise
, I-Premise
one I-Premise
patient I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
died I-Premise
from I-Premise
anastomotic I-Premise
leakage I-Premise
and I-Premise
two I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
from I-Premise
aspiration I-Premise
and I-Premise
mediastinitis I-Premise
after I-Premise
anastomotic I-Premise
leakage I-Premise
. I-Premise

These B-Claim
findings I-Claim
provide I-Claim
evidence I-Claim
for I-Claim
the I-Claim
short-term I-Claim
benefits I-Claim
of I-Claim
minimally I-Claim
invasive I-Claim
oesophagectomy I-Claim
for I-Claim
patients I-Claim
with I-Claim
resectable I-Claim
oesophageal I-Claim
cancer I-Claim
. I-Claim

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

We O
conducted O
a O
pragmatic O
, O
randomized O
controlled O
trial O
comparing O
acupuncture O
with O
enhanced O
usual O
care O
. O

Three O
hundred O
two O
outpatients O
with O
breast O
cancer O
participated O
. O

We O
randomly O
assigned O
75 O
patients O
to O
usual O
care O
and O
227 O
patients O
to O
acupuncture O
plus O
usual O
care O
( O
random O
assignment O
of O
1:3 O
respectively O
) O
with O
minimization O
controlling O
for O
baseline O
general O
fatigue O
and O
maintenance O
treatment O
. O

Treatment O
was O
delivered O
by O
acupuncturists O
once O
a O
week O
for O
6 O
weeks O
through O
needling O
three O
pairs O
of O
acupoints O
. O

The O
usual O
care O
group O
received O
a O
booklet O
with O
information O
about O
fatigue O
and O
its O
management O
. O

Primary O
outcome O
was O
general O
fatigue O
at O
6 O
weeks O
, O
measured O
with O
the O
Multidimensional O
Fatigue O
Inventory O
( O
MFI O
) O
. O

Other O
measurements O
included O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
quality-of-life O
scale O
, O
and O
expectation O
of O
acupuncture O
effect O
. O

Analyses O
were O
by O
intention O
to O
treat O
. O

Two O
hundred O
forty-six O
of O
302 O
patients O
randomly O
assigned O
provided O
complete O
data O
at O
6 O
weeks O
. O

The B-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
General I-Premise
Fatigue I-Premise
score I-Premise
, I-Premise
between I-Premise
those I-Premise
who I-Premise
received I-Premise
the I-Premise
intervention I-Premise
and I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
was I-Premise
-3.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-3.97 I-Premise
to I-Premise
-2.25 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
intervention I-Premise
also I-Premise
improved I-Premise
all I-Premise
other I-Premise
fatigue I-Premise
aspects I-Premise
measured I-Premise
by I-Premise
MFI I-Premise
, I-Premise
including I-Premise
Physical I-Premise
Fatigue I-Premise
and I-Premise
Mental I-Premise
Fatigue I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-2.36 I-Premise
and I-Premise
-1.94 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
and I-Premise
depression I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-1.83 I-Premise
and I-Premise
-2.13 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
Physical I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.30 I-Premise
";" I-Premise
Functional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.57 I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
Emotional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
";" I-Premise
and I-Premise
Social I-Premise
Functioning I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
Intergroup O
conducted O
this O
breast O
cancer O
adjuvant O
trial O
to O
compare O
an O
investigational O
16-week O
regimen O
with O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
( O
5-FU O
";" O
CAF O
) O
. O

The O
16-week O
regimen O
features O
greater O
doxorubicin O
and O
5-FU O
dose-intensity O
than O
CAF O
and O
improved O
scheduling O
of O
antimetabolites O
with O
sequential O
methotrexate O
and O
5-FU O
, O
as O
well O
as O
infusion O
5-FU O
. O

A O
total O
of O
646 O
node-positive O
, O
receptor-negative O
patients O
were O
randomly O
assigned O
to O
receive O
either O
the O
1 O
6-week O
regimen O
or O
six O
cycles O
of O
CAF O
. O

Breast O
cancer O
outcomes O
included O
recurrence O
as O
well O
as O
disease-free O
and O
overall O
survival O
. O

Toxicity O
was O
evaluated O
by O
the O
Common O
Toxicity O
Criteria O
( O
CTC O
) O
. O

Treatment-related O
quality O
of O
life O
was O
assessed O
by O
the O
Breast O
Chemotherapy O
Questionnaire O
( O
BCQ O
) O
before O
, O
during O
, O
and O
4 O
months O
after O
treatment O
in O
163 O
patients O
. O

The O
trial O
was O
designed O
to O
use O
one-sided O
tests O
of O
significance O
for O
power O
calculations O
, O
but O
is O
now O
reported O
with O
both O
one-sided O
and O
the O
traditional O
two-sided O
tests O
of O
significance O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
3.9 I-Premise
years I-Premise
, I-Premise
the I-Premise
estimated I-Premise
4-year I-Premise
recurrence-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
67.5 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
62.7 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.19 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.095 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
4-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
78.1 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
71.4 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

CAF B-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
leukopenia I-Premise
, I-Premise
granulocytopenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
liver I-Premise
and I-Premise
cardiac I-Premise
toxicity I-Premise
, I-Premise
whereas O
the B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
weight I-Premise
loss I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
skin I-Premise
and I-Premise
neurotoxicity I-Premise
. I-Premise

There B-Premise
were I-Premise
three I-Premise
treatment-related I-Premise
deaths I-Premise
with I-Premise
CAF I-Premise
but B-Premise
none I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
. I-Premise

During B-Premise
treatment I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
declined I-Premise
significantly I-Premise
more I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
than I-Premise
CAF I-Premise
, I-Premise
but B-Premise
by I-Premise
4 I-Premise
months I-Premise
posttreatment I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
. I-Premise

The B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
marginally I-Premise
better I-Premise
breast I-Premise
cancer I-Premise
outcomes I-Premise
than I-Premise
CAF I-Premise
with I-Premise
similar I-Premise
toxicity I-Premise
but I-Premise
a I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
during-treatment I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

The B-Claim
16-week I-Claim
regimen I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
instead I-Claim
of I-Claim
a I-Claim
standard-dose I-Claim
regimen I-Claim
without I-Claim
careful I-Claim
consideration I-Claim
of I-Claim
the I-Claim
16-week I-Claim
regimen I-Claim
's I-Claim
pros I-Claim
and I-Claim
cons I-Claim
, I-Claim
which I-Claim
include I-Claim
its I-Claim
complicated I-Claim
schedule I-Claim
. I-Claim

It B-Claim
should I-Claim
probably I-Claim
not I-Claim
be I-Claim
tested I-Claim
further I-Claim
, I-Claim
but B-Claim
its I-Claim
antimetabolite I-Claim
schedules I-Claim
and I-Claim
frequent I-Claim
drug I-Claim
administration I-Claim
( I-Claim
ie I-Claim
, I-Claim
dose I-Claim
density I-Claim
) I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
development I-Claim
of I-Claim
new I-Claim
regimens I-Claim
. I-Claim

The O
aim O
of O
the O
study O
is O
to O
demonstrate O
that O
intrapatient O
dose O
escalation O
of O
carboplatin O
would O
improve O
the O
outcome O
in O
ovarian O
cancer O
compared O
with O
flat O
dosing O
. O

Patients O
with O
untreated O
stage O
IC-IV O
ovarian O
cancer O
received O
six O
cycles O
of O
carboplatin O
area O
under O
the O
curve O
6 O
( O
AUC O
6 O
) O
3 O
weekly O
either O
with O
no O
dose O
modification O
except O
for O
toxicity O
( O
Arm O
A O
) O
or O
with O
dose O
escalations O
in O
cycles O
2-6 O
based O
on O
nadir O
neutrophil O
and O
platelet O
counts O
( O
Arm O
B O
) O
. O

The O
primary O
end-point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Nine O
hundred O
and O
sixty-four O
patients O
were O
recruited O
from O
71 O
centers O
. O

Dose O
escalation O
was O
achieved O
in O
77 O
% O
of O
patients O
who O
had O
≥1 O
cycle O
. O

The B-Premise
median I-Premise
AUCs I-Premise
( I-Premise
cycle I-Premise
2-6 I-Premise
) I-Premise
received I-Premise
were I-Premise
6.0 I-Premise
( I-Premise
Arm I-Premise
A I-Premise
) I-Premise
and I-Premise
7.2 I-Premise
( I-Premise
Arm I-Premise
B I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
non-hematological I-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
31 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
12.1 I-Premise
months I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
B I-Premise
[ I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.85-1.15 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.93 I-Premise
] I-Premise
. I-Premise

The B-Premise
median I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
was I-Premise
34.1 I-Premise
and I-Premise
30.7 I-Premise
months I-Premise
in I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
, I-Premise
respectively I-Premise
( I-Premise
HR I-Premise
0.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.81-1.18 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.82 I-Premise
) I-Premise
. I-Premise

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
baseline I-Premise
neutrophil I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
baseline I-Premise
platelet I-Premise
counts I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
the I-Premise
difference I-Premise
between I-Premise
white I-Premise
blood I-Premise
cell I-Premise
( I-Premise
WBC I-Premise
) I-Premise
and I-Premise
neutrophil I-Premise
count I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
had I-Premise
a I-Premise
significant I-Premise
adverse I-Premise
prognostic I-Premise
value I-Premise
. I-Premise

Intrapatient B-Claim
dose I-Claim
escalation I-Claim
of I-Claim
carboplatin I-Claim
based I-Claim
on I-Claim
nadir I-Claim
blood I-Claim
counts I-Claim
is I-Claim
feasible I-Claim
and I-Claim
safe I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

Baseline O
neutrophils O
over-ride O
nadir O
counts O
in O
prognostic O
significance O
. O

These O
data O
may O
have O
wider O
implications O
particularly O
in O
respect O
of O
the O
management O
of O
chemotherapy-induced O
neutropenia O
. O

Lymphoma O
patients O
commonly O
experience O
declines O
in O
physical O
functioning O
and O
quality O
of O
life O
( O
QoL O
) O
that O
may O
be O
reversed O
with O
exercise O
training O
. O

We O
conducted O
a O
randomized O
controlled O
trial O
in O
Edmonton O
, O
Alberta O
, O
Canada O
, O
between O
2005 O
and O
2008 O
that O
stratified O
122 O
lymphoma O
patients O
by O
major O
disease O
type O
and O
current O
treatment O
status O
and O
randomly O
assigned O
them O
to O
usual O
care O
( O
UC O
";" O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
60 O
) O
. O

Our O
primary O
end O
point O
was O
patient-rated O
physical O
functioning O
assessed O
by O
the O
Trial O
Outcome O
Index-Anemia O
. O

Secondary O
end O
points O
were O
overall O
QoL O
, O
psychosocial O
functioning O
, O
cardiovascular O
fitness O
, O
and O
body O
composition O
. O

Follow-up O
assessment O
for O
our O
primary O
end O
point O
was O
96 O
% O
( O
117 O
of O
122 O
) O
at O
postintervention O
and O
90 O
% O
( O
110 O
of O
122 O
) O
at O
6-month O
follow-up O
. O

Median O
adherence O
to O
the O
supervised O
exercise O
program O
was O
92 O
% O
. O

At B-Premise
postintervention I-Premise
, I-Premise
AET I-Premise
was I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
patient-rated I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
group I-Premise
difference I-Premise
, I-Premise
+9.0 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.0 I-Premise
to I-Premise
16.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
, I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
, I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
fitness I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
lean I-Premise
body I-Premise
mass I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

Change O
in O
peak O
cardiovascular O
fitness O
mediated O
the O
change O
in O
patient-rated O
physical O
functioning O
. O

AET B-Premise
did I-Premise
not I-Premise
interfere I-Premise
with I-Premise
chemotherapy I-Premise
completion I-Premise
rate I-Premise
or I-Premise
treatment I-Premise
response I-Premise
. I-Premise

At B-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
AET I-Premise
was I-Premise
still I-Premise
borderline I-Premise
or I-Premise
significantly I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.054 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
, I-Premise
and I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
without I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
disease I-Premise
recurrence/progression I-Premise
. I-Premise

AET B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient-rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim

The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula O
Weleda O
cream O
vs. O
Essex O
cream O
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O

The O
primary O
endpoint O
was O
the O
difference O
in O
proportion O
of O
patients O
with O
ARSR O
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group/The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG/EORTC O
scale O
) O
at O
follow-up O
. O

The O
secondary O
endpoints O
included O
patient O
reported O
outcome O
measures O
";" O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
, O
Sleep O
disturbances O
( O
MOS-sleep O
questionnaire O
) O
and O
symptoms O
from O
the O
irradiated O
area O
( O
visual O
analogue O
scale O
) O
. O

Patients O
' O
experiences O
and O
adherence O
to O
the O
topical O
agents O
were O
also O
evaluated O
. O

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient-related O
factors O
. O

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
ARSR I-Premise
( I-Premise
RTOG/EORTC I-Premise
grade I-Premise
≤2 I-Premise
) I-Premise
at I-Premise
the I-Premise
follow-up I-Premise
visit I-Premise
was I-Premise
23 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
45 I-Premise
) I-Premise
in I-Premise
the I-Premise
Calendula I-Premise
group I-Premise
and I-Premise
19 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
in I-Premise
the I-Premise
Essex I-Premise
group I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
severe I-Premise
ARSR I-Premise
between I-Premise
the I-Premise
groups I-Premise
at I-Premise
any I-Premise
point I-Premise
of I-Premise
assessment I-Premise
. I-Premise

The B-Premise
patients I-Premise
reported I-Premise
low I-Premise
levels I-Premise
of I-Premise
skin I-Premise
related I-Premise
symptoms I-Premise
and I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
groups I-Premise
were I-Premise
found I-Premise
. I-Premise

No B-Claim
differences I-Claim
in I-Claim
ARSR I-Claim
between I-Claim
patients I-Claim
randomised I-Claim
to I-Claim
Calendula I-Claim
or I-Claim
Essex I-Claim
cream I-Claim
was I-Claim
found I-Claim
. I-Claim

ARSR B-Claim
seem I-Claim
to I-Claim
be I-Claim
a I-Claim
relatively I-Claim
limited I-Claim
problem I-Claim
, I-Claim
probably I-Claim
more I-Claim
influenced I-Claim
by I-Claim
treatment I-Claim
related I-Claim
factors I-Claim
than I-Claim
by I-Claim
choice I-Claim
of I-Claim
skin I-Claim
care I-Claim
products I-Claim
in I-Claim
this I-Claim
patient I-Claim
group I-Claim
. I-Claim

An O
open O
, O
randomized O
study O
was O
performed O
to O
assess O
the O
effects O
of O
supportive O
pamidronate O
treatment O
on O
morbidity O
from O
bone O
metastases O
in O
breast O
cancer O
patients O
. O

Eighty-one O
pamidronate O
patients O
and O
80 O
control O
patients O
were O
monitored O
for O
a O
median O
of O
18 O
and O
21 O
months O
, O
respectively O
, O
for O
events O
of O
skeletal O
morbidity O
and O
the O
radiologic O
course O
of O
metastatic O
bone O
disease O
. O

The O
oral O
pamidronate O
dose O
was O
600 O
mg/d O
( O
high O
dose O
[ O
HD O
] O
) O
during O
the O
earliest O
study O
years O
, O
then O
changed O
to O
300 O
mg/d O
( O
low O
dose O
[ O
LD O
] O
) O
because O
of O
gastrointestinal O
toxicity O
. O

Twenty-nine O
of O
81 O
pamidronate O
( O
HD/LD O
) O
patients O
first O
received O
600 O
mg/d O
and O
were O
then O
changed O
to O
300 O
mg/d O
";" O
52 O
of O
81 O
pamidronate O
LD O
patients O
received O
300 O
mg/d O
throughout O
the O
study O
. O

Tumor O
treatment O
was O
unrestricted O
. O

An O
overall O
intent-to-treat O
analysis O
was O
performed O
. O

In B-Premise
the I-Premise
pamidronate I-Premise
group I-Premise
, I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
hypercalcemia I-Premise
, I-Premise
severe I-Premise
bone I-Premise
pain I-Premise
, I-Premise
and I-Premise
symptomatic I-Premise
impending I-Premise
fractures I-Premise
decreased I-Premise
by I-Premise
65 I-Premise
% I-Premise
, I-Premise
30 I-Premise
% I-Premise
, I-Premise
and I-Premise
50 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
event-rates I-Premise
of I-Premise
systemic I-Premise
treatment I-Premise
and I-Premise
radiotherapy I-Premise
decreased I-Premise
by I-Premise
35 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
event-free I-Premise
period I-Premise
( I-Premise
EFP I-Premise
) I-Premise
, I-Premise
radiologic I-Premise
course I-Premise
of I-Premise
disease I-Premise
, I-Premise
and I-Premise
survival I-Premise
did I-Premise
not I-Premise
improve I-Premise
. I-Premise

Subgroup B-Claim
analyses I-Claim
suggested I-Claim
a I-Claim
dose-dependent I-Claim
treatment I-Claim
effect I-Claim
. I-Claim

Compared B-Premise
with I-Premise
their I-Premise
controls I-Premise
, I-Premise
in I-Premise
pamidronate I-Premise
HD/LD I-Premise
patients I-Premise
, I-Premise
events I-Premise
occurred I-Premise
60 I-Premise
% I-Premise
to I-Premise
90 I-Premise
% I-Premise
less I-Premise
frequently I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.03 I-Premise
) I-Premise
and I-Premise
the I-Premise
EFP I-Premise
was I-Premise
prolonged I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

In B-Premise
pamidronate I-Premise
LD I-Premise
patients I-Premise
, I-Premise
event-rates I-Premise
decreased I-Premise
by I-Premise
15 I-Premise
% I-Premise
to I-Premise
45 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

Gastrointestinal B-Premise
toxicity I-Premise
of I-Premise
pamidronate I-Premise
caused I-Premise
a I-Premise
23 I-Premise
% I-Premise
drop-out I-Premise
rate I-Premise
, I-Premise
but B-Claim
other I-Claim
cancer-associated I-Claim
factors I-Claim
seemed I-Claim
to I-Claim
contribute I-Claim
to I-Claim
this I-Claim
toxicity I-Claim
. I-Claim

Pamidronate B-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
efficaciously I-Claim
reduced I-Claim
skeletal I-Claim
morbidity I-Claim
. I-Claim

The B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose-dependent I-Claim
. I-Claim

Further B-Claim
research I-Claim
on I-Claim
dose I-Claim
and I-Claim
mode I-Claim
of I-Claim
treatment I-Claim
is I-Claim
mandatory I-Claim
. I-Claim

Dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim

It B-Claim
is I-Claim
more I-Claim
likely I-Claim
in I-Claim
full-breasted I-Claim
women I-Claim
and I-Claim
when I-Claim
the I-Claim
radiation I-Claim
is I-Claim
distributed I-Claim
nonhomogeneously I-Claim
in I-Claim
the I-Claim
breast I-Claim
. I-Claim

Breast O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
is O
a O
technique O
that O
ensures O
a O
more O
homogeneous O
dose O
distribution O
. O

A O
multicenter O
, O
double-blind O
, O
randomized O
clinical O
trial O
was O
performed O
to O
test O
if O
breast O
IMRT O
would O
reduce O
the O
rate O
of O
acute O
skin O
reaction O
( O
notably O
moist O
desquamation O
) O
, O
decrease O
pain O
, O
and O
improve O
quality O
of O
life O
compared O
with O
standard O
radiotherapy O
using O
wedges O
. O

Patients O
were O
assessed O
each O
week O
during O
and O
up O
to O
6 O
weeks O
after O
radiotherapy O
. O

A O
total O
of O
358 O
patients O
were O
randomly O
assigned O
between O
July O
2003 O
and O
March O
2005 O
in O
two O
Canadian O
centers O
, O
and O
331 O
were O
included O
in O
the O
analysis O
. O

Breast B-Premise
IMRT I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise

This B-Premise
translated I-Premise
into I-Premise
a I-Premise
lower I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
moist I-Premise
desquamation I-Premise
during I-Premise
or I-Premise
up I-Premise
to I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
their I-Premise
radiation I-Premise
treatment I-Premise
";" I-Premise
31.2 I-Premise
% I-Premise
with I-Premise
IMRT I-Premise
compared I-Premise
with I-Premise
47.8 I-Premise
% I-Premise
with I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

A B-Premise
multivariate I-Premise
analysis I-Premise
found I-Premise
the I-Premise
use I-Premise
of I-Premise
breast I-Premise
IMRT I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
and I-Premise
smaller I-Premise
breast I-Premise
size I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
a I-Premise
decreased I-Premise
risk I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
IMRT I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Breast B-Claim
IMRT I-Claim
significantly I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
moist I-Claim
desquamation I-Claim
compared I-Claim
with I-Claim
a I-Claim
standard I-Claim
wedged I-Claim
technique I-Claim
. I-Claim

Moist B-Claim
desquamation I-Claim
was I-Claim
correlated I-Claim
with I-Claim
increased I-Claim
pain I-Claim
and I-Claim
reduction I-Claim
in I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

This O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand-assisted O
laparoscopic O
( O
LRP O
) O
versus O
open O
restorative O
proctocolectomy O
( O
ORP O
) O
. O

The O
potential O
long-term O
advantages O
of O
LRP O
over O
ORP O
remain O
to O
be O
determined O
. O

The O
most O
likely O
advantage O
of O
LRP O
is O
the O
superior O
cosmetic O
result O
. O

It O
is O
, O
however O
, O
unclear O
whether O
the O
size O
and O
location O
of O
incisions O
affect O
body O
image O
and O
QOL O
. O

In O
a O
previously O
conducted O
randomized O
trial O
comparing O
LRP O
with O
ORP O
, O
60 O
patients O
were O
prospectively O
evaluated O
. O

The O
primary O
end O
points O
were O
body O
image O
and O
cosmesis O
. O

The O
secondary O
end O
points O
were O
morbidity O
, O
QOL O
, O
and O
functional O
outcome O
. O

A O
body O
image O
questionnaire O
was O
used O
to O
evaluate O
body O
image O
and O
cosmesis O
. O

The O
Short O
Form-36 O
Health O
Survey O
and O
the O
Gastrointestinal O
Quality O
of O
Life O
Inventory O
were O
used O
to O
assess O
QOL O
. O

Body O
image O
and O
QOL O
also O
were O
assessed O
preoperatively O
. O

A O
total O
of O
53 O
patients O
completed O
the O
QOL O
and O
functional O
outcome O
questionnaires O
. O

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
functional I-Premise
outcome I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
QOL I-Premise
between I-Premise
LRP I-Premise
and I-Premise
ORP I-Premise
. I-Premise

At O
a O
median O
of O
2.7 O
years O
after O
surgery O
, O
46 O
patients O
returned O
the O
questionnaires O
regarding O
body O
image O
, O
cosmesis O
, O
and O
morbidity O
. O

The B-Premise
body I-Premise
image I-Premise
and I-Premise
cosmesis I-Premise
scores I-Premise
of I-Premise
female I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
LRP I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
( I-Premise
body I-Premise
image I-Premise
, I-Premise
17.4 I-Premise
vs I-Premise
14.9 I-Premise
";" I-Premise
cosmesis I-Premise
, I-Premise
19.1 I-Premise
vs I-Premise
13.0 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
female I-Premise
patients I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
body I-Premise
image I-Premise
scores I-Premise
than I-Premise
the I-Premise
male I-Premise
patients I-Premise
( I-Premise
14.9 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
. I-Premise

This B-Claim
study I-Claim
is I-Claim
the I-Claim
first I-Claim
to I-Claim
show I-Claim
that I-Claim
ORP I-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
as I-Claim
compared I-Claim
with I-Claim
LRP I-Claim
. I-Claim

Functional B-Claim
outcome I-Claim
, I-Claim
QOL I-Claim
, I-Claim
and I-Claim
morbidity I-Claim
are I-Claim
similar I-Claim
for I-Claim
the I-Claim
two I-Claim
approaches I-Claim
. I-Claim

The B-Claim
advantages I-Claim
of I-Claim
a I-Claim
long-lasting I-Claim
improved I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
for I-Claim
this I-Claim
relatively I-Claim
young I-Claim
patient I-Claim
population I-Claim
may I-Claim
compensate I-Claim
for I-Claim
the I-Claim
longer I-Claim
operating I-Claim
times I-Claim
and I-Claim
higher I-Claim
costs I-Claim
, I-Claim
particularly I-Claim
for I-Claim
women I-Claim
. I-Claim

There O
are O
few O
randomized O
controlled O
trials O
on O
the O
effectiveness O
of O
palliative O
care O
interventions O
to O
improve O
the O
care O
of O
patients O
with O
advanced O
cancer O
. O

To O
determine O
the O
effect O
of O
a O
nursing-led O
intervention O
on O
quality O
of O
life O
, O
symptom O
intensity O
, O
mood O
, O
and O
resource O
use O
in O
patients O
with O
advanced O
cancer O
. O

Randomized O
controlled O
trial O
conducted O
from O
November O
2003 O
through O
May O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
National O
Cancer O
Institute-designated O
comprehensive O
cancer O
center O
in O
New O
Hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
VA O
medical O
center O
in O
Vermont O
. O

A O
multicomponent O
, O
psychoeducational O
intervention O
( O
Project O
ENABLE O
[ O
Educate O
, O
Nurture O
, O
Advise O
, O
Before O
Life O
Ends O
] O
) O
conducted O
by O
advanced O
practice O
nurses O
consisting O
of O
4 O
weekly O
educational O
sessions O
and O
monthly O
follow-up O
sessions O
until O
death O
or O
study O
completion O
( O
n O
= O
161 O
) O
vs O
usual O
care O
( O
n O
= O
161 O
) O
. O

Quality O
of O
life O
was O
measured O
by O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
for O
Palliative O
Care O
( O
score O
range O
, O
0-184 O
) O
. O

Symptom O
intensity O
was O
measured O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
score O
range O
, O
0-900 O
) O
. O

Mood O
was O
measured O
by O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
range O
, O
0-60 O
) O
. O

These O
measures O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
and O
every O
3 O
months O
until O
death O
or O
study O
completion O
. O

Intensity O
of O
service O
was O
measured O
as O
the O
number O
of O
days O
in O
the O
hospital O
and O
in O
the O
intensive O
care O
unit O
( O
ICU O
) O
and O
the O
number O
of O
emergency O
department O
visits O
recorded O
in O
the O
electronic O
medical O
record O
. O

A O
total O
of O
322 O
participants O
with O
cancer O
of O
the O
gastrointestinal O
tract O
( O
41 O
% O
";" O
67 O
in O
the O
usual O
care O
group O
vs O
66 O
in O
the O
intervention O
group O
) O
, O
lung O
( O
36 O
% O
";" O
58 O
vs O
59 O
) O
, O
genitourinary O
tract O
( O
12 O
% O
";" O
20 O
vs O
19 O
) O
, O
and O
breast O
( O
10 O
% O
";" O
16 O
vs O
17 O
) O
were O
randomized O
. O

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
usual I-Premise
care I-Premise
) I-Premise
for I-Premise
all I-Premise
participants I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
4.6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-27.8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.06 I-Premise
) I-Premise
, I-Premise
and I-Premise
-1.8 I-Premise
( I-Premise
0.81 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
in I-Premise
participants I-Premise
who I-Premise
died I-Premise
during I-Premise
the I-Premise
study I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
8.6 I-Premise
( I-Premise
3.6 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-24.2 I-Premise
( I-Premise
20.5 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
) I-Premise
, I-Premise
and I-Premise
-2.7 I-Premise
( I-Premise
1.2 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Intensity O
of O
service O
did O
not O
differ O
between O
the O
2 O
groups O
. O

Compared B-Claim
with I-Claim
participants I-Claim
receiving I-Claim
usual I-Claim
oncology I-Claim
care I-Claim
, I-Claim
those I-Claim
receiving I-Claim
a I-Claim
nurse-led I-Claim
, I-Claim
palliative I-Claim
care-focused I-Claim
intervention I-Claim
addressing I-Claim
physical I-Claim
, I-Claim
psychosocial I-Claim
, I-Claim
and I-Claim
care I-Claim
coordination I-Claim
provided I-Claim
concurrently I-Claim
with I-Claim
oncology I-Claim
care I-Claim
had I-Claim
higher I-Claim
scores I-Claim
for I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
mood I-Claim
, I-Claim
but B-Claim
did I-Claim
not I-Claim
have I-Claim
improvements I-Claim
in I-Claim
symptom I-Claim
intensity I-Claim
scores I-Claim
or I-Claim
reduced I-Claim
days I-Claim
in I-Claim
the I-Claim
hospital I-Claim
or I-Claim
ICU I-Claim
or I-Claim
emergency I-Claim
department I-Claim
visits I-Claim
. I-Claim

To O
determine O
the O
efficacy O
of O
topotecan O
in O
combination O
with O
standard O
chemotherapy O
in O
previously O
untreated O
patients O
with O
extensive-stage O
small-cell O
lung O
cancer O
( O
SCLC O
) O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
conducted O
a O
phase O
III O
trial O
. O

Eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ECOG O
performance O
status O
of O
0 O
to O
2 O
";" O
stable O
brain O
metastases O
were O
allowed O
. O

All O
patients O
received O
four O
cycles O
of O
cisplatin O
and O
etoposide O
every O
3 O
weeks O
( O
step O
1 O
";" O
PE O
) O
. O

Patients O
with O
stable O
or O
responding O
disease O
were O
then O
randomized O
to O
observation O
or O
four O
cycles O
of O
topotecan O
( O
1.5 O
mg/m O
( O
2 O
) O
/d O
for O
5 O
days O
, O
every O
3 O
weeks O
";" O
step O
2 O
) O
. O

A O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
";" O
topotecan O
, O
n O
= O
112 O
) O
. O

Complete B-Premise
and I-Premise
partial I-Premise
response I-Premise
rates I-Premise
to I-Premise
induction I-Premise
PE I-Premise
were I-Premise
3 I-Premise
% I-Premise
and I-Premise
32 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
";" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
402 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
9.6 I-Premise
months I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
significantly I-Premise
better I-Premise
with I-Premise
topotecan I-Premise
compared I-Premise
with I-Premise
observation I-Premise
( I-Premise
3.6 I-Premise
months I-Premise
v I-Premise
2.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

However O
, O
overall B-Premise
survival I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
observation I-Premise
and I-Premise
topotecan I-Premise
arms I-Premise
( I-Premise
8.9 I-Premise
months I-Premise
v I-Premise
9.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
occurred I-Premise
in I-Premise
50 I-Premise
% I-Premise
and I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
PE I-Premise
patients I-Premise
in I-Premise
step I-Premise
1 I-Premise
and I-Premise
60 I-Premise
% I-Premise
and I-Premise
13 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
in I-Premise
step I-Premise
2 I-Premise
. I-Premise

Grade B-Premise
4/5 I-Premise
infection I-Premise
was I-Premise
observed I-Premise
in I-Premise
4.6 I-Premise
% I-Premise
of I-Premise
PE I-Premise
patients I-Premise
and I-Premise
1.8 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
anemia I-Premise
developed I-Premise
in I-Premise
22 I-Premise
% I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
topotecan I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
topotecan I-Premise
and I-Premise
observation I-Premise
was I-Premise
observed I-Premise
at I-Premise
any I-Premise
assessment I-Premise
time I-Premise
or I-Premise
for I-Premise
any I-Premise
of I-Premise
the I-Premise
subscale I-Premise
scores I-Premise
. I-Premise

Four B-Claim
cycles I-Claim
of I-Claim
PE I-Claim
induction I-Claim
therapy I-Claim
followed I-Claim
by I-Claim
four I-Claim
cycles I-Claim
of I-Claim
topotecan I-Claim
improved I-Claim
PFS I-Claim
but I-Claim
failed I-Claim
to I-Claim
improve I-Claim
overall I-Claim
survival I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
extensive-stage I-Claim
SCLC I-Claim
. I-Claim

Four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
PE I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
extensive-stage I-Claim
SCLC I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim

Patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O

We O
randomized O
122 O
patients O
with O
lymphoma O
to O
usual O
care O
( O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
60 O
) O
. O

Our O
primary O
sleep O
endpoint O
was O
global O
sleep O
quality O
assessed O
by O
the O
Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
. O

Secondary O
endpoints O
were O
the O
PSQI O
component O
scores O
. O

Planned O
subgroup O
analyses O
were O
also O
conducted O
. O

Intention-to-treat B-Premise
analyses I-Premise
indicated I-Premise
that I-Premise
AET I-Premise
resulted I-Premise
in I-Premise
a I-Premise
nonsignificant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.16 I-Premise
) I-Premise
improvement I-Premise
in I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
[ I-Premise
mean I-Premise
group I-Premise
difference I-Premise
= I-Premise
-0.64 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
, I-Premise
-1.56 I-Premise
to I-Premise
+0.27 I-Premise
] I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
statistically I-Premise
significant I-Premise
or I-Premise
borderline I-Premise
significant I-Premise
interactions I-Premise
were I-Premise
identified I-Premise
for I-Premise
type I-Premise
of I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
, I-Premise
current I-Premise
treatment I-Premise
status I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.036 I-Premise
) I-Premise
, I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.010 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
, I-Premise
and I-Premise
baseline I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
. I-Premise

Specifically O
, O
AET B-Premise
improved I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
in I-Premise
patients I-Premise
with I-Premise
lymphoma I-Premise
who I-Premise
had I-Premise
indolent I-Premise
non-Hodgkin I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
were I-Premise
receiving I-Premise
chemotherapy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
were I-Premise
< I-Premise
2 I-Premise
years I-Premise
post-diagnosis I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
were I-Premise
obese I-Premise
( I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
, I-Premise
and I-Premise
were I-Premise
poor I-Premise
sleepers I-Premise
at I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.007 I-Premise
) I-Premise
. I-Premise

AET B-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
sleep I-Claim
quality I-Claim
in I-Claim
this I-Claim
heterogeneous I-Claim
sample I-Claim
of I-Claim
patients I-Claim
with I-Claim
lymphoma I-Claim
";" I-Claim
however B-Claim
, I-Claim
clinically I-Claim
identifiable I-Claim
subgroups I-Claim
appeared I-Claim
to I-Claim
benefit I-Claim
. I-Claim

Future O
exercise O
trials O
targeting O
these O
responsive O
subgroups O
are O
needed O
to O
confirm O
these O
findings O
. O

If O
replicated O
in O
larger O
and O
more O
focused O
trials O
, O
aerobic O
exercise O
may O
be O
an O
attractive O
option O
to O
manage O
sleep O
dysfunction O
in O
patients O
with O
cancer O
because O
of O
its O
favorable O
safety O
profile O
and O
other O
documented O
health O
benefits O
. O

In B-Claim
vivo I-Claim
data I-Claim
have I-Claim
shown I-Claim
a I-Claim
more I-Claim
potent I-Claim
antiangiogenic I-Claim
effect I-Claim
and I-Claim
a I-Claim
higher I-Claim
antitumor I-Claim
activity I-Claim
of I-Claim
low-dose I-Claim
interferon I-Claim
( I-Claim
IFN I-Claim
) I-Claim
given I-Claim
twice I-Claim
daily I-Claim
. I-Claim

In O
a O
randomized O
Phase O
II O
trial O
, O
the O
authors O
tested O
the O
hypothesis O
that O
twice-daily O
low-dose O
IFN O
is O
more O
effective O
than O
daily O
intermediate-dose O
IFN O
in O
patients O
with O
metastatic O
renal O
cell O
cancer O
( O
MRCC O
) O
. O

A O
total O
of O
118 O
patients O
( O
59 O
per O
arm O
) O
were O
randomly O
assigned O
to O
receive O
IFN O
at O
a O
dose O
of O
0.5 O
million O
units O
( O
MU O
) O
given O
subcutaneously O
twice O
daily O
( O
IFN1 O
) O
or O
IFN O
at O
a O
dose O
of O
5 O
MU O
given O
subcutaneously O
daily O
( O
IFN5 O
) O
. O

The O
primary O
endpoint O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Secondary O
endpoints O
included O
response O
rate O
( O
RR O
) O
, O
overall O
survival O
( O
OS O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
either I-Premise
PFS I-Premise
or I-Premise
OS I-Premise
between I-Premise
IFN1 I-Premise
and I-Premise
IFN5 I-Premise
( I-Premise
median I-Premise
of I-Premise
3.7 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
3.4 I-Premise
months I-Premise
PFS I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
of I-Premise
25.5 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
17.5 I-Premise
months I-Premise
OS I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
RRs I-Premise
were I-Premise
identical I-Premise
in I-Premise
the I-Premise
2 I-Premise
arms I-Premise
( I-Premise
6.7 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.8-16.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Two B-Premise
patients I-Premise
, I-Premise
1 I-Premise
in I-Premise
each I-Premise
arm I-Premise
, I-Premise
remained I-Premise
in I-Premise
complete I-Premise
remission I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
last I-Premise
follow-up I-Premise
, I-Premise
at I-Premise
45 I-Premise
and I-Premise
38 I-Premise
months I-Premise
from I-Premise
treatment I-Premise
. I-Premise

Thirty-two B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
19 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
experienced I-Premise
Grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
adverse I-Premise
events I-Premise
( I-Premise
graded I-Premise
using I-Premise
the I-Premise
National I-Premise
Cancer I-Premise
Institute I-Premise
Common I-Premise
Toxicity I-Premise
Criteria I-Premise
[ I-Premise
version I-Premise
2.0 I-Premise
] I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Eighteen B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
4 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
had I-Premise
dose I-Premise
reductions I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
depression I-Premise
associated I-Premise
with I-Premise
IFN5 I-Premise
but I-Premise
no I-Premise
change I-Premise
was I-Premise
noted I-Premise
with I-Premise
IFN1 I-Premise
. I-Premise

Compared B-Claim
with I-Claim
IFN5 I-Claim
, I-Claim
IFN1 I-Claim
is I-Claim
neither I-Claim
more I-Claim
nor I-Claim
less I-Claim
effective I-Claim
but I-Claim
is I-Claim
less I-Claim
toxic I-Claim
, I-Claim
with I-Claim
a I-Claim
better I-Claim
reported I-Claim
QOL I-Claim
. I-Claim

These B-Claim
results I-Claim
may I-Claim
have I-Claim
implications I-Claim
for I-Claim
the I-Claim
design I-Claim
of I-Claim
combination I-Claim
regimens I-Claim
incorporating I-Claim
IFN I-Claim
with I-Claim
targeted I-Claim
agents I-Claim
. I-Claim

To O
determine O
whether O
patients O
with O
locally O
advanced O
non-small O
cell O
lung O
cancer O
unsuitable O
for O
resection O
or O
radical O
radiotherapy O
, O
and O
with O
minimal O
thoracic O
symptoms O
, O
should O
be O
given O
palliative O
thoracic O
radiotherapy O
immediately O
or O
as O
needed O
to O
treat O
symptoms O
. O

Multicentre O
randomised O
controlled O
trial O
. O

23 O
centres O
in O
the O
United O
Kingdom O
, O
Ireland O
, O
and O
South O
Africa O
. O

230 O
patients O
with O
previously O
untreated O
, O
non-small O
cell O
lung O
cancer O
that O
is O
locally O
too O
advanced O
for O
resection O
or O
radical O
radiotherapy O
with O
curative O
intent O
, O
with O
minimal O
thoracic O
symptoms O
, O
and O
with O
no O
indication O
for O
immediate O
thoracic O
radiotherapy O
. O

All O
patients O
were O
given O
supportive O
treatment O
and O
were O
randomised O
to O
receive O
palliative O
thoracic O
radiotherapy O
either O
immediately O
or O
delayed O
until O
needed O
to O
treat O
symptoms O
. O

The O
recommended O
regimens O
were O
17 O
Gy O
in O
two O
fractions O
one O
week O
apart O
or O
10 O
Gy O
as O
a O
single O
dose O
. O

Primary O
-- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O

Secondary O
-- O
quality O
of O
life O
, O
adverse O
events O
, O
survival O
. O

From O
December O
1992 O
to O
May O
1999 O
, O
230 O
patients O
were O
randomised O
. O

104/115 O
of O
the O
patients O
in O
the O
immediate O
treatment O
group O
received O
thoracic O
radiotherapy O
( O
90 O
received O
one O
of O
the O
recommended O
regimens O
) O
. O

In O
the O
delayed O
treatment O
group O
, O
48/115 O
( O
42 O
% O
) O
patients O
received O
thoracic O
radiotherapy O
( O
29 O
received O
one O
of O
the O
recommended O
regimens O
) O
";" O
64 O
( O
56 O
% O
) O
died O
without O
receiving O
thoracic O
radiotherapy O
";" O
the O
remaining O
three O
( O
3 O
% O
) O
were O
alive O
at O
the O
end O
of O
the O
study O
without O
having O
received O
the O
treatment O
. O

For O
patients O
who O
received O
thoracic O
radiotherapy O
, O
the O
median O
time O
to O
start O
was O
15 O
days O
in O
the O
immediate O
treatment O
group O
and O
125 O
days O
in O
the O
delayed O
treatment O
group O
. O

The B-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
was I-Premise
achieved I-Premise
in I-Premise
28 I-Premise
% I-Premise
of I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
and I-Premise
26 I-Premise
% I-Premise
of I-Premise
patients I-Premise
from I-Premise
the I-Premise
delayed I-Premise
treatment I-Premise
group I-Premise
( I-Premise
27/97 I-Premise
and I-Premise
27/103 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
absolute I-Premise
difference I-Premise
1.6 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-10.7 I-Premise
% I-Premise
to I-Premise
13.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

No B-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
was I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
activity I-Premise
level I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
and I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
as I-Premise
recorded I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
. I-Premise

Neither B-Premise
group I-Premise
had I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.95 I-Premise
, I-Premise
0.73 I-Premise
to I-Premise
1.24 I-Premise
";" I-Premise
P=0.71 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
8.3 I-Premise
months I-Premise
and I-Premise
7.9 I-Premise
months I-Premise
, I-Premise
and O
the B-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
for I-Premise
the I-Premise
immediate I-Premise
and I-Premise
delayed I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Claim
minimally I-Claim
symptomatic I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
no I-Claim
persuasive I-Claim
evidence I-Claim
was I-Claim
found I-Claim
to I-Claim
indicate I-Claim
that I-Claim
giving I-Claim
immediate I-Claim
palliative I-Claim
thoracic I-Claim
radiotherapy I-Claim
improves I-Claim
symptom I-Claim
control I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
delaying I-Claim
until I-Claim
symptoms I-Claim
require I-Claim
treatment I-Claim
. I-Claim

To O
determine O
whether O
palliation O
of O
chest O
symptoms O
from O
a O
10 O
Gy O
single O
fraction O
( O
regimen O
1 O
) O
was O
equivalent O
to O
that O
from O
30 O
Gy O
in O
10 O
fractions O
( O
regimen O
2 O
) O
. O

Patients O
with O
cytologically O
proven O
, O
symptomatic O
lung O
cancer O
not O
amenable O
to O
curative O
therapy O
, O
with O
performance O
status O
0-3 O
, O
were O
randomised O
to O
receive O
either O
30 O
Gy O
in O
10 O
fractions O
or O
a O
10 O
Gy O
single O
fraction O
. O

Local O
symptoms O
were O
scored O
on O
a O
physician-assessed O
, O
five-point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
TSS O
) O
. O

This O
, O
performance O
status O
, O
Hospital O
Anxiety O
and O
Depression O
( O
HAD O
) O
score O
and O
Spitzer O
's O
quality-of-life O
index O
were O
noted O
before O
treatment O
, O
at O
1 O
month O
after O
treatment O
and O
every O
2 O
months O
thereafter O
. O

Palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O

Equivalence O
was O
defined O
as O
less O
than O
20 O
% O
difference O
in O
the O
number O
achieving O
an O
improvement O
in O
the O
TSS O
. O

We O
randomised O
149 O
patients O
and O
analysed O
74 O
in O
each O
arm O
. O

According O
to O
the O
design O
criteria O
, O
palliation O
was O
equivalent O
between O
the O
two O
arms O
. O

TSS B-Premise
improved I-Premise
in I-Premise
49 I-Premise
patients I-Premise
( I-Premise
77 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
57 I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
, I-Premise
a I-Premise
difference I-Premise
of I-Premise
15 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
3-28 I-Premise
) I-Premise
in I-Premise
the I-Premise
proportion I-Premise
improving I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

A B-Premise
complete I-Premise
resolution I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
three I-Premise
( I-Premise
5 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
14 I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
a I-Premise
difference I-Premise
in I-Premise
the I-Premise
proportion I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
of I-Premise
21 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
10-33 I-Premise
) I-Premise
. I-Premise

A B-Premise
significantly I-Premise
higher I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
palliation I-Premise
and I-Premise
complete I-Premise
resolution I-Premise
of I-Premise
chest I-Premise
pain I-Premise
and I-Premise
dyspnoea I-Premise
with I-Premise
regimen I-Premise
2 I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
toxicity I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
22.7 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
1 I-Premise
and I-Premise
28.3 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.197 I-Premise
) I-Premise
. I-Premise

Although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre-determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim

Few O
exercise O
trials O
in O
cancer O
patients O
have O
reported O
longer-term O
follow-up O
. O

Here O
, O
we O
report O
a O
6-month O
follow-up O
of O
exercise O
behavior O
and O
patient-rated O
outcomes O
from O
an O
exercise O
trial O
in O
breast O
cancer O
patients O
. O

Breast O
cancer O
patients O
initiating O
adjuvant O
chemotherapy O
( O
n O
= O
242 O
) O
were O
randomly O
assigned O
to O
usual O
care O
( O
n O
= O
82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
";" O
n O
= O
82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
78 O
) O
for O
the O
duration O
of O
their O
chemotherapy O
. O

At O
6-month O
follow-up O
, O
participants O
were O
mailed O
a O
questionnaire O
that O
assessed O
quality O
of O
life O
, O
self-esteem O
, O
fatigue O
, O
anxiety O
, O
depression O
, O
and O
exercise O
behavior O
. O

Two O
hundred O
one O
( O
83.1 O
% O
) O
participants O
provided O
6-month O
follow-up O
data O
. O

Adjusted B-Premise
linear I-Premise
mixed-model I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
, I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
RET I-Premise
group I-Premise
reported I-Premise
higher I-Premise
self-esteem I-Premise
[ I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.6 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
, I-Premise
0.1-3.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.032 I-Premise
] I-Premise
and I-Premise
the I-Premise
AET I-Premise
group I-Premise
reported I-Premise
lower I-Premise
anxiety I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
-4.7 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.0 I-Premise
to I-Premise
-9.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

Moreover O
, O
compared B-Premise
with I-Premise
participants I-Premise
reporting I-Premise
no I-Premise
regular I-Premise
exercise I-Premise
during I-Premise
the I-Premise
follow-up I-Premise
period I-Premise
, I-Premise
those I-Premise
reporting I-Premise
regular I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
also I-Premise
reported I-Premise
better I-Premise
patient-rated I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
9.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.2-17.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
self-esteem I-Premise
observed I-Premise
with I-Premise
RET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
were I-Premise
maintained I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
whereas O
reductions B-Premise
in I-Premise
anxiety I-Premise
not I-Premise
observed I-Premise
with I-Premise
AET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
emerged I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

Moreover O
, O
adopting B-Premise
a I-Premise
combined I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
program I-Premise
after I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
was I-Premise
associated I-Premise
with I-Premise
further I-Premise
improvements I-Premise
in I-Premise
patient-rated I-Premise
outcomes I-Premise
. I-Premise

Exercise B-Claim
training I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
may I-Claim
result I-Claim
in I-Claim
some I-Claim
longer-term I-Claim
and I-Claim
late I-Claim
effects I-Claim
for I-Claim
selected I-Claim
patient-rated I-Claim
outcomes I-Claim
. I-Claim

Two O
million O
people O
across O
the O
U.K. O
are O
living O
with O
cancer O
, O
often O
experienced O
as O
a O
long-term O
condition O
. O

They O
may O
have O
unmet O
needs O
after O
active O
treatment O
. O

Rehabilitation O
aims O
to O
address O
these O
needs O
, O
maximize O
psychological O
and O
physical O
function O
, O
and O
enable O
minimum O
dependency O
regardless O
of O
life O
expectancy O
. O

We O
aimed O
to O
test O
, O
in O
a O
randomized O
controlled O
trial O
, O
the O
clinical O
and O
cost O
effectiveness O
of O
a O
rehabilitation O
intervention O
for O
patients O
with O
advanced O
, O
recurrent O
cancer O
. O

We O
conducted O
a O
two-arm O
, O
wait-list O
control O
, O
randomized O
trial O
of O
a O
complex O
rehabilitation O
intervention O
delivered O
by O
a O
hospice-based O
multidisciplinary O
team O
vs. O
usual O
care O
for O
active O
, O
progressive O
, O
recurrent O
hematological O
and O
breast O
malignancies O
, O
with O
a O
follow-up O
at O
three O
months O
. O

The O
primary O
outcome O
was O
the O
psychological O
subscale O
of O
the O
Supportive O
Care O
Needs O
Survey O
( O
SCNS O
) O
. O

Secondary O
outcomes O
were O
other O
domains O
of O
the O
SCNS O
, O
psychological O
status O
, O
continuity O
of O
care O
, O
quality O
of O
life O
, O
and O
resource O
use O
. O

Forty-one O
participants O
were O
enrolled O
and O
36 O
completed O
the O
trial O
. O

The B-Premise
primary I-Premise
outcome I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
-16.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-28.34 I-Premise
to I-Premise
-5.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
. I-Premise

The B-Premise
SCNS I-Premise
physical I-Premise
and I-Premise
patient I-Premise
care I-Premise
subscales I-Premise
( I-Premise
-14.2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-26.2 I-Premise
to I-Premise
-2.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
and I-Premise
-7.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-13.7 I-Premise
to I-Premise
-1.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
self-reported I-Premise
health I-Premise
state I-Premise
( I-Premise
12.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.2 I-Premise
to I-Premise
22.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
also I-Premise
differed I-Premise
significantly I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
was I-Premise
19,39£ I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
. I-Premise

This B-Claim
intervention I-Claim
significantly I-Claim
reduced I-Claim
the I-Claim
unmet I-Claim
needs I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
it I-Claim
is I-Claim
likely I-Claim
that I-Claim
it I-Claim
is I-Claim
cost-effective I-Claim
. I-Claim

Despite B-Claim
small I-Claim
numbers I-Claim
, I-Claim
the I-Claim
main I-Claim
effect I-Claim
size I-Claim
was I-Claim
robust I-Claim
. I-Claim

We B-Claim
recommend I-Claim
implementation I-Claim
alongside I-Claim
evaluation I-Claim
in I-Claim
wider I-Claim
clinical I-Claim
settings I-Claim
and I-Claim
patient I-Claim
populations I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
assess O
efficacy O
and O
safety O
of O
association O
of O
duloxetine O
and O
rehabilitation O
compared O
with O
rehabilitation O
alone O
in O
men O
with O
SUI O
after O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
, O
and O
to O
compare O
continence O
rate O
even O
after O
planned O
duloxetine O
suspension O
. O

After O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
A O
) O
or O
rehabilitation O
alone O
( O
group O
B O
) O
, O
for O
16 O
wk O
. O

postprostatectomy O
SUI O
with O
daily O
incontinent O
episodes O
frequency O
( O
IEF O
) O
of O
four O
or O
greater O
. O

After O
16 O
wk O
both O
groups O
suspended O
duloxetine/placebo O
and O
continued O
rehabilitation O
. O

All O
patients O
completed O
incontinence O
quality O
of O
life O
( O
I-QoL O
) O
questionnaire O
and O
bladder O
diary O
. O

Wilcoxon O
test O
was O
used O
to O
analyse O
changes O
in O
IEF O
and O
in O
I-QoL O
score O
";" O
Fisher O
exact O
test O
was O
used O
to O
compare O
continent O
patients O
between O
the O
groups O
. O

Adverse O
events O
for O
duloxetine O
was O
15.2 O
% O
. O

102 O
men O
completed O
the O
study O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pad I-Premise
use I-Premise
in I-Premise
group I-Premise
A I-Premise
. I-Premise

After B-Premise
16 I-Premise
wk I-Premise
, I-Premise
39 I-Premise
patients I-Premise
versus I-Premise
27 I-Premise
were I-Premise
dry I-Premise
( I-Premise
p=0.007 I-Premise
) I-Premise
. I-Premise

At B-Premise
20 I-Premise
wk I-Premise
, I-Premise
4 I-Premise
wk I-Premise
after I-Premise
planned I-Premise
interruption I-Premise
of I-Premise
duloxetine I-Premise
, I-Premise
we I-Premise
observed I-Premise
a I-Premise
U-turn I-Premise
, I-Premise
23 I-Premise
patients I-Premise
were I-Premise
completely I-Premise
dry I-Premise
in I-Premise
group I-Premise
A I-Premise
versus I-Premise
38 I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
. I-Premise

Whereas B-Premise
, I-Premise
after I-Premise
24 I-Premise
wk I-Premise
, I-Premise
31 I-Premise
in I-Premise
group I-Premise
A I-Premise
versus I-Premise
41 I-Premise
in I-Premise
group I-Premise
B I-Premise
were I-Premise
dry I-Premise
( I-Premise
p=0.08 I-Premise
) I-Premise
. O

The B-Claim
decrease I-Claim
in I-Claim
IEF I-Claim
and I-Claim
improvements I-Claim
in I-Claim
I-QoL I-Claim
scores I-Claim
were I-Claim
significantly I-Claim
greater I-Claim
in I-Claim
group I-Claim
A I-Claim
for I-Claim
the I-Claim
first I-Claim
16 I-Claim
wk I-Claim
. I-Claim

The B-Claim
data I-Claim
suggest I-Claim
that I-Claim
combination I-Claim
therapy I-Claim
might I-Claim
provide I-Claim
another I-Claim
treatment I-Claim
option I-Claim
for I-Claim
SUI I-Claim
in I-Claim
men I-Claim
that I-Claim
might I-Claim
increase I-Claim
the I-Claim
percentage I-Claim
of I-Claim
early I-Claim
postsurgery I-Claim
continence I-Claim
. I-Claim

To O
pilot O
an O
investigation O
of O
individualized O
homeopathy O
for O
symptoms O
of O
estrogen O
withdrawal O
in O
breast O
cancer O
survivors O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
. O

Outpatient O
department O
of O
a O
National O
Health O
Service O
( O
NHS O
) O
homeopathic O
hospital O
. O

Fifty-seven O
( O
57 O
) O
women O
met O
inclusion O
criteria O
and O
53 O
were O
randomized O
to O
the O
study O
. O

After O
2 O
weeks O
of O
baseline O
assessment O
, O
all O
participants O
received O
a O
consultation O
plus O
either O
oral O
homeopathic O
medicine O
or O
placebo O
, O
assessed O
every O
4 O
weeks O
for O
16 O
weeks O
. O

The O
primary O
outcome O
measures O
were O
the O
activity O
score O
and O
profile O
score O
of O
the O
Measure O
Yourself O
Medical O
Outcome O
Profile O
( O
MYMOP O
) O
. O

Eighty-five O
percent O
( O
85 O
% O
) O
( O
45/53 O
) O
of O
women O
completed O
the O
study O
. O

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
either I-Premise
activity I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
=-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
CI I-Premise
-1.0 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.17 I-Premise
) I-Premise
or I-Premise
profile I-Premise
scores I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
-0.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.9 I-Premise
to I-Premise
0.1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
using I-Premise
this I-Premise
trial I-Premise
design I-Premise
, I-Premise
although B-Claim
post I-Claim
hoc I-Claim
power I-Claim
calculations I-Claim
suggests I-Claim
that I-Claim
65-175 I-Claim
would I-Claim
be I-Claim
needed I-Claim
per I-Claim
group I-Claim
to I-Claim
detect I-Claim
differences I-Claim
of I-Claim
this I-Claim
magnitude I-Claim
with I-Claim
sufficient I-Claim
precision I-Claim
. I-Claim

Clinically B-Premise
relevant I-Premise
improvements I-Premise
in I-Premise
symptoms I-Premise
and I-Premise
mood I-Premise
disturbance I-Premise
were I-Premise
seen I-Premise
for I-Premise
both I-Premise
groups I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

Improvements B-Claim
were I-Claim
seen I-Claim
for I-Claim
symptom I-Claim
scores I-Claim
over I-Claim
the I-Claim
study I-Claim
period I-Claim
. I-Claim

However B-Claim
, I-Claim
presuming I-Claim
these I-Claim
improvements I-Claim
were I-Claim
caused I-Claim
by I-Claim
the I-Claim
individualized I-Claim
homeopathic I-Claim
approach I-Claim
, I-Claim
the I-Claim
study I-Claim
failed I-Claim
to I-Claim
show I-Claim
clearly I-Claim
that I-Claim
the I-Claim
specific I-Claim
effect I-Claim
of I-Claim
the I-Claim
remedy I-Claim
added I-Claim
further I-Claim
to I-Claim
the I-Claim
nonspecific I-Claim
effects I-Claim
of I-Claim
the I-Claim
consultation I-Claim
. I-Claim

Future B-Claim
trial I-Claim
design I-Claim
must I-Claim
ensure I-Claim
adequate I-Claim
power I-Claim
to I-Claim
account I-Claim
for I-Claim
the I-Claim
nonspecific I-Claim
impact I-Claim
of I-Claim
such I-Claim
complex I-Claim
individualized I-Claim
interventions I-Claim
while I-Claim
pragmatic I-Claim
designs I-Claim
may I-Claim
more I-Claim
readily I-Claim
answer I-Claim
questions I-Claim
of I-Claim
clinical I-Claim
and I-Claim
cost I-Claim
effectiveness I-Claim
. O

A O
phase O
III O
trial O
( O
Cancer O
and O
Leukemia O
Group O
B O
CALGB-49907 O
) O
was O
conducted O
to O
test O
whether O
older O
patients O
with O
early-stage O
breast O
cancer O
would O
have O
equivalent O
relapse-free O
and O
overall O
survival O
with O
capecitabine O
compared O
with O
standard O
chemotherapy O
. O

The O
quality O
of O
life O
( O
QoL O
) O
substudy O
tested O
whether O
capecitabine O
treatment O
would O
be O
associated O
with O
a O
better O
QoL O
than O
standard O
chemotherapy O
. O

QoL O
was O
assessed O
in O
350 O
patients O
randomly O
assigned O
to O
either O
standard O
chemotherapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
CMF O
] O
or O
doxorubicin O
and O
cyclophosphamide O
[ O
AC O
] O
";" O
n O
= O
182 O
) O
or O
capecitabine O
( O
n O
= O
168 O
) O
. O

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

Compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
QoL I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Capecitabine B-Premise
treatment I-Premise
was I-Premise
associated I-Premise
with I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
constipation I-Premise
and I-Premise
with I-Premise
better I-Premise
appetite I-Premise
than I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.004 I-Premise
) I-Premise
, I-Premise
but I-Premise
worse I-Premise
hand-foot I-Premise
syndrome I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
. I-Premise

These O
differences O
all O
resolved O
by O
12 O
months O
. O

Standard B-Claim
chemotherapy I-Claim
was I-Claim
superior I-Claim
to I-Claim
capecitabine I-Claim
in I-Claim
improving I-Claim
relapse-free I-Claim
and I-Claim
overall I-Claim
survival I-Claim
for I-Claim
older I-Claim
women I-Claim
with I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Although O
capecitabine B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
QoL I-Claim
during I-Claim
treatment I-Claim
, O
QoL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
groups I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

The O
brief O
period O
of O
poorer O
QoL O
with O
standard O
treatment O
is O
a O
modest O
price O
to O
pay O
for O
a O
chance O
at O
improved O
survival O
. O

To O
assess O
whether O
the O
administration O
of O
recombinant O
human O
erythropoietin O
( O
r-HuEPO O
) O
would O
increase O
the O
hematocrit O
, O
reduce O
the O
requirement O
for O
transfusion O
, O
and O
improve O
the O
quality O
of O
life O
in O
anemic O
cancer O
patients O
receiving O
myelosuppressive O
, O
cisplatin-based O
chemotherapy O
. O

One O
hundred O
thirty-two O
anemic O
cancer O
patients O
receiving O
cyclic O
, O
cisplatin-containing O
, O
myelosuppressive O
chemotherapy O
were O
evaluated O
. O

Patients O
received O
either O
r-HuEPO O
( O
150 O
U/kg O
) O
or O
placebo O
, O
subcutaneously O
, O
three O
times O
a O
week O
for O
3 O
months O
. O

Responses O
were O
assessed O
by O
measuring O
changes O
in O
hemoglobin/hematocrit O
, O
transfusion O
requirement O
, O
and O
quality O
of O
life O
. O

The B-Premise
mean I-Premise
hematocrit I-Premise
increased I-Premise
by I-Premise
6.0 I-Premise
percentage I-Premise
points I-Premise
in I-Premise
the I-Premise
r-HuEPO I-Premise
group I-Premise
versus I-Premise
1.3 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r-HuEPO I-Premise
vs. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1.20 I-Premise
units I-Premise
r-HuEPO I-Premise
vs. I-Premise
2.02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r-HuEPO I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise

Pretreatment B-Premise
serum I-Premise
erythropoietin I-Premise
levels I-Premise
were I-Premise
lower I-Premise
in I-Premise
responders I-Premise
than I-Premise
in I-Premise
nonresponders I-Premise
( I-Premise
73.5 I-Premise
IU/L I-Premise
and I-Premise
86.3 I-Premise
IU/L I-Premise
means I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
this I-Premise
difference I-Premise
was I-Premise
not I-Premise
helpful I-Premise
in I-Premise
defining I-Premise
which I-Premise
patients I-Premise
were I-Premise
likely I-Premise
to I-Premise
respond I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
r-HuEPO-treated I-Premise
group I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
adverse I-Premise
effects I-Premise
associated I-Premise
with I-Premise
r-HuEPO I-Premise
. I-Premise

r-HuEPO B-Claim
is I-Claim
safe I-Claim
and I-Claim
can I-Claim
cause I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
the I-Claim
hematocrit I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
myelosuppressive I-Claim
, I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
. I-Claim

After B-Claim
1 I-Claim
month I-Claim
of I-Claim
r-HuEPO I-Claim
, I-Claim
there I-Claim
is I-Claim
also I-Claim
a I-Claim
reduction I-Claim
in I-Claim
transfusion I-Claim
requirement I-Claim
. I-Claim

Older O
breast O
cancer O
survivors O
( O
BCSs O
) O
are O
at O
risk O
for O
late O
and O
long-term O
treatment O
effects O
on O
quality O
of O
life O
( O
QOL O
) O
, O
including O
lower O
physical O
functioning O
and O
fear O
of O
recurrence O
. O

Two O
promising O
approaches O
to O
address O
this O
include O
dance/movement O
therapy O
and O
mindfulness O
. O

The O
purpose O
of O
this O
2-group O
randomized O
controlled O
pilot O
feasibility O
study O
was O
to O
test O
short-term O
effects O
of O
a O
12-week O
Mindful O
Movement O
Program O
( O
MMP O
) O
intervention O
combining O
mindfulness O
with O
self-directed O
movement O
on O
QOL O
and O
mindfulness O
in O
female O
BCSs O
50 O
years O
or O
older O
and O
at O
12 O
months O
or O
more O
following O
treatment O
. O

Consented O
participants O
were O
randomized O
to O
an O
experimental O
group O
( O
EG O
) O
( O
12 O
weekly O
MMP O
sessions O
) O
or O
a O
control O
group O
( O
no O
sessions O
) O
. O

All O
completed O
questionnaires O
3 O
times O
. O

The O
EG O
participants O
kept O
home O
practice O
diaries O
. O

Analysis O
was O
conducted O
after O
intervention O
for O
immediate O
effects O
on O
outcome O
variables O
and O
6 O
weeks O
later O
for O
maintenance O
of O
effects O
. O

Participants O
( O
n O
= O
49 O
) O
ranged O
in O
age O
from O
50 O
to O
90 O
years O
( O
average O
, O
65.6 O
years O
) O
and O
were O
at O
9.8 O
years O
since O
diagnosis O
( O
range O
, O
1-32 O
years O
) O
, O
and O
the O
majority O
were O
white O
, O
unpartnered O
, O
and O
retired O
. O

After B-Premise
intervention I-Premise
, I-Premise
EG I-Premise
participants I-Premise
showed I-Premise
improved I-Premise
QOL I-Premise
via I-Premise
decreased I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
increased I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
initial I-Premise
effects I-Premise
were I-Premise
retained I-Premise
. I-Premise

The B-Premise
MMP I-Premise
appears I-Premise
to I-Premise
benefit I-Premise
older I-Premise
BCSs I-Premise
by I-Premise
reducing I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
improving I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

Although B-Claim
these I-Claim
findings I-Claim
are I-Claim
promising I-Claim
, I-Claim
a I-Claim
larger I-Claim
study I-Claim
is I-Claim
needed I-Claim
to I-Claim
determine I-Claim
more I-Claim
specifically I-Claim
what I-Claim
short- I-Claim
and I-Claim
long-term I-Claim
effects I-Claim
are I-Claim
possible I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
self-directed I-Claim
movement I-Claim
and I-Claim
mindfulness I-Claim
, I-Claim
as I-Claim
tested I-Claim
here I-Claim
, I-Claim
may I-Claim
be I-Claim
a I-Claim
valuable I-Claim
tool I-Claim
for I-Claim
promoting I-Claim
health I-Claim
and I-Claim
well-being I-Claim
in I-Claim
older I-Claim
long-term I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

N O
, O
N-diethyl-2- O
[ O
-4 O
( O
phenylmethyl O
) O
phenoxy O
] O
ethanamine O
( O
DPPE O
";" O
tesmilifene O
) O
is O
a O
novel O
agent O
that O
augments O
chemotherapy O
cytotoxicity O
in O
vitro O
and O
in O
vivo O
. O

A O
phase O
II O
trial O
combining O
DPPE O
and O
doxorubicin O
( O
DOX O
) O
in O
metastatic O
breast O
carcinoma O
showed O
increased O
response O
over O
that O
expected O
with O
DOX O
. O

We O
report O
a O
phase O
III O
trial O
comparing O
DOX O
with O
DPPE O
plus O
DOX O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O

Anthracycline-naive O
women O
with O
measurable O
metastatic O
disease O
were O
randomly O
assigned O
to O
receive O
, O
every O
21 O
days O
, O
either O
DOX O
60 O
mg/m O
( O
2 O
) O
intravenously O
or O
DOX O
during O
the O
last O
20 O
minutes O
of O
an O
80-minute O
infusion O
of O
DPPE O
( O
5.3 O
mg/kg O
) O
, O
in O
both O
cases O
to O
cumulative O
DOX O
doses O
of O
450 O
mg/m O
( O
2 O
) O
. O

Patients O
receiving O
DPPE O
were O
aggressively O
premedicated O
to O
ameliorate O
toxicity O
. O

End O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
and O
response O
duration O
( O
RD O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
overall O
survival O
( O
OS O
) O
. O

A O
planned O
interim O
analysis O
failed O
to O
detect O
an O
RR O
difference O
more O
than O
5 O
% O
. O

The O
study O
was O
closed O
to O
additional O
accrual O
and O
all O
DPPE O
was O
discontinued O
. O

The O
final O
analysis O
was O
conducted O
as O
planned O
after O
256 O
progression O
events O
( O
median O
follow-up O
, O
20.5 O
months O
) O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
RR I-Premise
, I-Premise
RD I-Premise
, I-Premise
or I-Premise
PFS I-Premise
between I-Premise
arms I-Premise
. I-Premise

DPPE B-Premise
plus I-Premise
DOX I-Premise
was I-Premise
statistically I-Premise
superior I-Premise
to I-Premise
DOX I-Premise
in I-Premise
OS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.48 I-Premise
to I-Premise
0.91 I-Premise
";" I-Premise
P I-Premise
=.021 I-Premise
) I-Premise
. I-Premise

DPPE B-Premise
plus I-Premise
DOX I-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
gastrointestinal I-Premise
and I-Premise
CNS I-Premise
toxicity I-Premise
. I-Premise

No B-Premise
consistent I-Premise
influence I-Premise
on I-Premise
QOL I-Premise
was I-Premise
detected I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
RR I-Claim
, I-Claim
RD I-Claim
, I-Claim
or I-Claim
PFS I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
OS I-Claim
for I-Claim
DPPE I-Claim
plus I-Claim
DOX I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
of I-Claim
DPPE I-Claim
are I-Claim
warranted I-Claim
. I-Claim

Experimental B-Claim
and I-Claim
early I-Claim
clinical I-Claim
investigations I-Claim
have I-Claim
demonstrated I-Claim
encouraging I-Claim
results I-Claim
for I-Claim
estramustine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
malignant I-Claim
glioma I-Claim
. O

The O
present O
study O
is O
an O
open O
randomized O
clinical O
trial O
comparing O
estramustine O
phosphate O
( O
Estracyt O
) O
in O
addition O
to O
radiotherapy O
with O
radiotherapy O
alone O
as O
first O
line O
treatment O
of O
astrocytoma O
grade O
III O
and O
IV O
. O

The O
140 O
patients O
included O
were O
in O
a O
good O
clinical O
condition O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
22-87 O
) O
. O

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

Radiotherapy O
was O
delivered O
on O
weekdays O
2 O
Gy O
daily O
up O
to O
56 O
Gy O
. O

Eighteen O
patients O
were O
excluded O
due O
to O
misclassification O
, O
leaving O
122 O
patients O
eligible O
for O
evaluation O
. O

Overall B-Premise
the I-Premise
treatment I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
. O

Mild B-Premise
or I-Premise
moderate I-Premise
nausea I-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
side I-Premise
effect I-Premise
of I-Premise
estramustine I-Premise
. I-Premise

The O
minimum O
follow-up O
time O
was O
5.2 O
years O
for O
the O
surviving O
patients O
. O

For B-Premise
astrocytoma I-Premise
grade I-Premise
III I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
10.6 I-Premise
( I-Premise
1.3-92.7 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
radiotherapy I-Premise
only I-Premise
group I-Premise
and I-Premise
17.3 I-Premise
( I-Premise
0.4-96.9+ I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
estramustine I-Premise
+ I-Premise
radiotherapy I-Premise
group I-Premise
. I-Premise

In B-Premise
grade I-Premise
IV I-Premise
the I-Premise
corresponding I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
12.3 I-Premise
( I-Premise
2.1-89.2 I-Premise
) I-Premise
and I-Premise
10.3 I-Premise
( I-Premise
0.3-91.7+ I-Premise
) I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
grade I-Premise
IV I-Premise
tumours I-Premise
the I-Premise
corresponding I-Premise
figures I-Premise
were I-Premise
5.1 I-Premise
and I-Premise
3.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Although B-Premise
there I-Premise
was I-Premise
a I-Premise
tendency I-Premise
for I-Premise
improved I-Premise
survival I-Premise
in I-Premise
grade I-Premise
III I-Premise
, I-Premise
no I-Premise
statistical I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

No B-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
evident I-Premise
with I-Premise
respect I-Premise
to I-Premise
quality I-Premise
of I-Premise
life I-Premise
according I-Premise
to I-Premise
the I-Premise
EORTC I-Premise
QLQ-protocol I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
III I-Claim
glioma I-Claim
. I-Claim

In B-Claim
advanced I-Claim
not I-Claim
selected I-Claim
NSCLC I-Claim
chemotherapy I-Claim
achieved I-Claim
an I-Claim
advantage I-Claim
of I-Claim
approximately I-Claim
1-2 I-Claim
months I-Claim
on I-Claim
median I-Claim
survival I-Claim
versus I-Claim
best I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Chemotherapy B-Claim
seems I-Claim
to I-Claim
improve I-Claim
symptoms I-Claim
control I-Claim
, I-Claim
even O
if O
randomised O
studies O
with O
quality O
of O
life O
as O
first O
endpoint O
are O
lacking O
and O
often O
chemotherapy O
toxicity O
compromises O
the O
frail O
cost/benefit O
ratio O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
impact O
on O
QoL O
, O
substituting O
cisplatin O
, O
a O
pivot O
drug O
in O
NSCLC O
therapy O
, O
with O
carboplatin O
, O
an O
analogue O
with O
an O
improved O
toxicity O
profile O
. O

The O
combination O
of O
cisplatin O
with O
Mitomycin O
and O
Vinblastine O
was O
one O
of O
the O
most O
frequently O
used O
in O
the O
palliative O
setting O
at O
the O
time O
of O
design O
of O
our O
study O
. O

Patients O
were O
randomized O
to O
receive O
MVP O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Cisplatin O
100 O
mg/m2 O
d1 O
) O
or O
MVC O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Carboplatin O
300 O
mg/m2 O
d1 O
) O
every O
3 O
weeks O
. O

The O
QoL O
was O
evaluated O
by O
the O
Spitzer O
QL-Index O
and O
by O
the O
EORTC O
QLQ-C30+LC O
13 O
questionnaires O
before O
chemotherapy O
, O
after O
one O
cycle O
, O
after O
three O
cycles O
, O
and O
then O
every O
6 O
weeks O
in O
the O
first O
6 O
months O
and O
every O
3 O
months O
thenafter O
. O

From O
September O
1994 O
to O
July O
1997 O
, O
153 O
consecutive O
patients O
were O
randomized O
to O
MVP O
( O
75 O
patients O
) O
or O
MVC O
arm O
( O
78 O
patients O
) O
. O

Despite B-Premise
difficulties I-Premise
in I-Premise
carrying I-Premise
out I-Premise
and I-Premise
analysing I-Premise
QoL I-Premise
items I-Premise
in I-Premise
such I-Premise
patients I-Premise
, I-Premise
the I-Premise
global I-Premise
QoL I-Premise
evaluated I-Premise
by I-Premise
the I-Premise
Spitzer I-Premise
's I-Premise
questionnaire I-Premise
suggested I-Premise
an I-Premise
advantage I-Premise
for I-Premise
MVC I-Premise
regimen I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
and I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
global I-Premise
health I-Premise
subdomain I-Premise
( I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

The B-Premise
disease-related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise

When B-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
questionnaire I-Premise
there I-Premise
was I-Premise
significantly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P=0.0001 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
and I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
MVC I-Premise
, I-Premise
and I-Premise
a I-Premise
trend I-Premise
for I-Premise
less I-Premise
hair I-Premise
loss I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
advantage I-Premise
lasted I-Premise
for I-Premise
all I-Premise
the I-Premise
duration I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
P=0.40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise

QoL O
was O
the O
first O
endpoint O
and O
the O
statistical O
power O
was O
inadequate O
to O
assess O
other O
parameters O
. O

However O
, O
we B-Premise
reported I-Premise
a I-Premise
response I-Premise
rate I-Premise
of I-Premise
43.1 I-Premise
and I-Premise
38.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
MVP I-Premise
and I-Premise
MVC I-Premise
arm I-Premise
( I-Premise
P=0.59 I-Premise
) I-Premise
and I-Premise
a I-Premise
median I-Premise
survival I-Premise
of I-Premise
10.2 I-Premise
and I-Premise
7.2 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
cisplatin I-Premise
and I-Premise
carboplatin I-Premise
arm I-Premise
( I-Premise
P=0.39 I-Premise
) I-Premise
. I-Premise

The B-Premise
carboplatin I-Premise
containing I-Premise
regimen I-Premise
( I-Premise
MVC I-Premise
) I-Premise
has I-Premise
a I-Premise
significant I-Premise
better I-Premise
toxicity I-Premise
profile I-Premise
than I-Premise
the I-Premise
cisplatin I-Premise
containing I-Premise
( I-Premise
MVP I-Premise
) I-Premise
regimen I-Premise
as I-Premise
proven I-Premise
both I-Premise
by I-Premise
the I-Premise
EORTC I-Premise
questionnaires I-Premise
and I-Premise
by I-Premise
the I-Premise
WHO I-Premise
toxicity I-Premise
data I-Premise
reported I-Premise
by I-Premise
physicians I-Premise
. I-Premise

No B-Claim
significant I-Claim
differences I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
rate I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
were I-Claim
observed I-Claim
between I-Claim
the I-Claim
two I-Claim
regimen I-Claim
. I-Claim

The B-Claim
two I-Claim
chemotherapy I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
similar I-Claim
effectiveness I-Claim
in I-Claim
symptom I-Claim
palliation I-Claim
when I-Claim
evaluated I-Claim
with I-Claim
C30 I-Claim
addendum I-Claim
of I-Claim
EORTC I-Claim
QOL I-Claim
questionnaire I-Claim
. I-Claim

With B-Premise
the I-Premise
Spitzer I-Premise
's I-Premise
questionnaires I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
improved I-Premise
quality I-Premise
of I-Premise
life I-Premise
index I-Premise
was I-Premise
observed I-Premise
during I-Premise
treatment I-Premise
with I-Premise
the I-Premise
carboplatin I-Premise
combination I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
cisplatin I-Premise
combination I-Premise
. I-Premise

This B-Premise
difference I-Premise
, I-Premise
however I-Premise
, I-Premise
was I-Premise
not I-Premise
observed I-Premise
when I-Premise
the I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
patients I-Premise
compiled I-Premise
questionnaires I-Premise
. I-Premise

A B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
determine O
1-year O
outcomes O
of O
a O
four-component O
behavioral O
therapy O
( O
BT O
) O
sleep O
intervention O
( O
Individualized O
Sleep O
Promotion O
Plan O
[ O
ISPP O
] O
) O
versus O
a O
healthy O
eating O
control O
( O
HEC O
) O
on O
cancer-related O
fatigue O
in O
women O
receiving O
breast O
cancer O
adjuvant O
chemotherapy O
treatment O
( O
CTX O
) O
. O

A O
total O
of O
219 O
participants O
from O
12 O
oncology O
clinics O
were O
randomly O
assigned O
in O
a O
clinical O
trial O
. O

Before O
CTX O
, O
research O
nurses O
coached O
intervention O
participants O
to O
develop O
a O
BT O
plan O
including O
stimulus O
control O
, O
modified O
sleep O
restriction O
, O
relaxation O
therapy O
, O
and O
sleep O
hygiene O
. O

BT O
plans O
were O
revised O
before O
each O
CTX O
and O
30 O
, O
60 O
, O
and O
90 O
days O
after O
the O
last O
CTX O
and O
reinforced O
7 O
to O
9 O
days O
later O
. O

HEC O
participants O
received O
nutritional O
information O
and O
equal O
attention O
. O

Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
, O
Daily O
Diary O
, O
Wrist O
Actigraph O
, O
and O
Piper O
Fatigue O
Scale O
measures O
and O
Repeated O
Linear O
Mixed O
Model O
analysis O
following O
the O
Intent O
to O
Treat O
paradigm O
were O
used O
. O

Sleep B-Premise
quality I-Premise
differed I-Premise
over I-Premise
1 I-Premise
years I-Premise
time I-Premise
( I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
7.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
1,173 I-Premise
] I-Premise
= I-Premise
4.8 I-Premise
, I-Premise
P I-Premise
= I-Premise
.029 I-Premise
";" I-Premise
and I-Premise
over I-Premise
time I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
3.3 I-Premise
, I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

Pairwise B-Premise
comparisons I-Premise
revealed I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
but B-Premise
not I-Premise
at I-Premise
1 I-Premise
year I-Premise
( I-Premise
P I-Premise
= I-Premise
.052 I-Premise
) I-Premise
. I-Premise

Seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
PSQI O
) O
. O

The B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
CTX I-Premise
";" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise

The B-Claim
BT I-Claim
group I-Claim
, I-Claim
on I-Claim
average I-Claim
, I-Claim
experienced I-Claim
significant I-Claim
improvement I-Claim
on I-Claim
global I-Claim
sleep I-Claim
quality I-Claim
compared I-Claim
with I-Claim
the I-Claim
HEC I-Claim
group I-Claim
, I-Claim
but B-Claim
not I-Claim
on I-Claim
objective I-Claim
sleep I-Claim
or I-Claim
fatigue I-Claim
outcomes I-Claim
. I-Claim

To O
compare O
the O
outcomes O
of O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
with O
use O
of O
tris-acryl O
gelatin O
microspheres O
( O
TAGM O
) O
versus O
spherical O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
. O

Patients O
undergoing O
UAE O
were O
randomly O
assigned O
to O
receive O
TAGMs O
or O
PVA O
. O

Embolization O
was O
performed O
in O
a O
standardized O
manner O
. O

Outcome O
data O
were O
collected O
at O
3 O
months O
after O
embolization O
, O
including O
assessment O
of O
clinical O
symptoms O
, O
scores O
from O
a O
fibroid O
tumor-specific O
symptom O
and O
quality O
of O
life O
( O
QOL O
) O
questionnaire O
, O
and O
findings O
on O
contrast O
material-enhanced O
magnetic O
resonance O
( O
MR O
) O
imaging O
, O
including O
the O
degree O
of O
tumor O
infarction O
and O
volume O
reduction O
. O

Data O
were O
analyzed O
with O
use O
of O
t O
tests O
, O
the O
Mann-Whitney O
U O
test O
, O
and O
chi2 O
tests O
as O
appropriate O
. O

Thirty-six O
patients O
were O
treated O
. O

There O
were O
no O
differences O
in O
the O
two O
treatment O
groups O
at O
baseline O
. O

Clinical O
follow-up O
was O
obtained O
in O
35 O
patients O
. O

Among B-Premise
the I-Premise
clinical I-Premise
outcome I-Premise
measures I-Premise
, I-Premise
QOL I-Premise
score I-Premise
improvement I-Premise
was I-Premise
greater I-Premise
for I-Premise
UAE I-Premise
with I-Premise
TAGMs I-Premise
compared I-Premise
with I-Premise
PVA I-Premise
( I-Premise
49.0 I-Premise
vs I-Premise
27.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
but B-Premise
no I-Premise
other I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

Of B-Premise
the I-Premise
25 I-Premise
patients I-Premise
in I-Premise
whom I-Premise
3-month I-Premise
MR I-Premise
imaging I-Premise
follow-up I-Premise
was I-Premise
completed I-Premise
, I-Premise
those I-Premise
treated I-Premise
with I-Premise
TAGM I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
complete I-Premise
infarction I-Premise
of I-Premise
all I-Premise
leiomyomas I-Premise
( I-Premise
six I-Premise
patients I-Premise
vs I-Premise
one I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
at I-Premise
least I-Premise
90 I-Premise
% I-Premise
tumor I-Premise
infarction I-Premise
( I-Premise
eight I-Premise
patients I-Premise
vs I-Premise
four I-Premise
patients I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
had I-Premise
a I-Premise
lower I-Premise
mean I-Premise
percent I-Premise
of I-Premise
residual I-Premise
perfused I-Premise
fibroid I-Premise
tumor I-Premise
tissue I-Premise
( I-Premise
9.6 I-Premise
% I-Premise
vs I-Premise
44.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
compared I-Premise
with I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PVA I-Premise
. I-Premise

Based O
on O
these O
differences O
between O
the O
embolic O
agents O
, O
enrollment O
in O
this O
study O
was O
terminated O
. O

The B-Claim
use I-Claim
of I-Claim
spherical I-Claim
PVA I-Claim
particles I-Claim
in I-Claim
the I-Claim
manner I-Claim
described I-Claim
herein I-Claim
results I-Claim
in I-Claim
an I-Claim
unacceptably I-Claim
high I-Claim
rate I-Claim
of I-Claim
failed I-Claim
tumor I-Claim
infarction I-Claim
in I-Claim
UAE I-Claim
. I-Claim

To O
determine O
the O
efficacy O
and O
safety O
of O
a O
biweekly O
regimen O
of O
leucovorin O
( O
LV O
) O
plus O
fluorouracil O
( O
FU O
) O
alone O
or O
in O
combination O
with O
cisplatin O
or O
irinotecan O
in O
patients O
with O
previously O
untreated O
metastatic O
gastric O
adenocarcinoma O
and O
to O
select O
the O
best O
arm O
for O
a O
phase O
III O
study O
. O

One O
hundred O
thirty-six O
patients O
( O
two O
were O
ineligible O
) O
were O
enrolled O
onto O
the O
randomized O
multicenter O
phase O
II O
trial O
. O

Patients O
received O
LV O
200 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
followed O
by O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolus O
) O
and O
FU O
600 O
mg/m O
( O
2 O
) O
( O
22-hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
LV5FU2 O
";" O
arm O
A O
) O
, O
LV5FU2 O
plus O
cisplatin O
50 O
mg/m O
( O
2 O
) O
( O
1-hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
B O
) O
, O
or O
LV5FU2 O
plus O
irinotecan O
180 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
on O
day O
1 O
( O
arm O
C O
) O
. O

The B-Premise
overall I-Premise
response I-Premise
rates I-Premise
, I-Premise
which I-Premise
were I-Premise
confirmed I-Premise
by I-Premise
an I-Premise
independent I-Premise
expert I-Premise
panel I-Premise
, I-Premise
were I-Premise
13 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
% I-Premise
to I-Premise
23.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
27 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
14.1 I-Premise
% I-Premise
to I-Premise
40.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
40 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
25.7 I-Premise
% I-Premise
to I-Premise
54.3 I-Premise
% I-Premise
) I-Premise
for I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
and I-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.8 I-Premise
to I-Premise
4.6 I-Premise
months I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.6 I-Premise
to I-Premise
11.1 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
4.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.5 I-Premise
to I-Premise
6.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
9.5 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
6.9 I-Premise
to I-Premise
12.2 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-cisplatin I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
and I-Premise
6.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.5 I-Premise
to I-Premise
8.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.3 I-Premise
to I-Premise
13.3 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-irinotecan I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2-irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

LV5FU2 O
with O
high-dose O
leucovorin O
( O
LV O
) O
, O
weekly O
infusional O
5-fluorouracil O
( O
5FU O
) O
( O
AIO O
schedule O
) O
and O
raltitrexed O
have O
been O
demonstrated O
to O
be O
active O
agents O
in O
first-line O
treatment O
of O
colorectal O
cancer O
. O

We O
performed O
a O
4-arm O
randomised O
trial O
to O
compare O
( O
1 O
) O
a O
low-dose O
intravenous O
bolus O
of O
LV O
( O
20 O
mg/m2 O
) O
, O
followed O
by O
an O
intravenous O
bolus O
of O
5FU O
( O
400 O
mg/m2 O
) O
, O
followed O
by O
a O
22-hour O
continuous O
infusion O
of O
5FU O
( O
600 O
mg/m2 O
) O
on O
day O
1 O
and O
day O
2/2 O
weeks O
( O
ldLV5FU2 O
arm O
) O
, O
( O
2 O
) O
a O
weekly O
continuous O
infusion O
of O
high-dose O
5FU O
( O
2.6 O
g/m2/week O
) O
for O
6 O
weeks O
followed O
by O
a O
rest O
week O
( O
HD-FU O
arm O
) O
and O
( O
3 O
) O
raltitrexed O
( O
Tomudex O
arm O
";" O
3 O
mg/m2/3 O
weeks O
) O
to O
standard O
LV5FU2 O
. O

From O
1997 O
to O
2001 O
, O
294 O
patients O
were O
included O
. O

The O
4 O
arms O
were O
well O
balanced O
for O
sex O
ratio O
, O
age O
, O
WHO O
performance O
status O
, O
the O
primary O
tumour O
site O
and O
prior O
adjuvant O
chemotherapy O
. O

Treatment O
was O
stopped O
due O
to O
low O
accrual O
. O

Two B-Premise
toxicity-related I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
Tomudex I-Premise
arm I-Premise
. I-Premise

The B-Premise
treatments I-Premise
gave I-Premise
rise I-Premise
to I-Premise
different I-Premise
rates I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
, I-Premise
4 I-Premise
, I-Premise
11 I-Premise
and I-Premise
14 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
and I-Premise
vomiting I-Premise
. I-Premise

At B-Premise
least I-Premise
one I-Premise
episode I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
was I-Premise
observed I-Premise
in I-Premise
27 I-Premise
, I-Premise
25 I-Premise
, I-Premise
38 I-Premise
and I-Premise
47 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
. I-Premise

An B-Premise
objective I-Premise
response I-Premise
was I-Premise
observed I-Premise
in I-Premise
28 I-Premise
, I-Premise
21 I-Premise
, I-Premise
22 I-Premise
and I-Premise
10 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
Tomudex I-Premise
arm I-Premise
was I-Premise
statistically I-Premise
lower I-Premise
compared I-Premise
to I-Premise
that I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
LV5FU2 I-Premise
or I-Premise
ldLV5FU2 I-Premise
( I-Premise
combined I-Premise
group I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
Tomudex I-Claim
is I-Claim
more I-Claim
toxic I-Claim
and I-Claim
yields I-Claim
shorter I-Claim
PFS I-Claim
than I-Claim
infusional I-Claim
5FU I-Claim
. I-Claim

Despite B-Claim
the I-Claim
early I-Claim
closure I-Claim
of I-Claim
the I-Claim
study I-Claim
and I-Claim
the I-Claim
lack I-Claim
of I-Claim
power I-Claim
of I-Claim
the I-Claim
comparison I-Claim
, I-Claim
it I-Claim
seems I-Claim
that I-Claim
ldLV5FU2 I-Claim
could I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
active I-Claim
, I-Claim
easier I-Claim
and I-Claim
less I-Claim
expensive I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
compared I-Claim
to I-Claim
classic I-Claim
LV5FU2 I-Claim
or I-Claim
weekly I-Claim
HD-FU I-Claim
. I-Claim

To O
compare O
the O
outcome O
of O
treatment O
of O
mediastinoscopy-verified O
N2 O
non-small-cell O
lung O
cancer O
treated O
with O
induction O
chemotherapy O
followed O
by O
either O
surgery O
or O
radiotherapy O
( O
RT O
) O
, O
with O
both O
options O
followed O
by O
consolidation O
chemotherapy O
. O

A O
randomized O
Phase O
III O
trial O
for O
Stage O
IIIA O
( O
T1-T3N2M0 O
) O
non-small O
cell O
lung O
cancer O
was O
conducted O
by O
the O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
and O
Eastern O
Cooperative O
Oncology O
Group O
between O
April O
1990 O
and O
April O
1994 O
. O

After O
documentation O
of O
N2 O
disease O
by O
mediastinoscopy O
or O
anterior O
mediastinotomy O
, O
patients O
received O
induction O
chemotherapy O
with O
cisplatin O
, O
vinblastine O
, O
and O
mitomycin-C. O
Mitomycin-C O
was O
later O
dropped O
from O
the O
induction O
regimen O
. O

Patients O
were O
then O
randomized O
to O
surgery O
or O
RT O
( O
64 O
Gy O
in O
7 O
weeks O
) O
followed O
by O
cisplatin O
and O
vinblastine O
. O

RTOG O
89-01 O
accrued O
75 O
patients O
, O
of O
whom O
73 O
were O
eligible O
and O
analyzable O
. O

Twelve O
patients O
received O
induction O
chemotherapy O
but O
were O
not O
randomized O
to O
RT O
or O
surgery O
thereafter O
. O

Forty-five O
patients O
were O
randomized O
to O
postinduction O
RT O
or O
surgery O
. O

Of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
Karnofsky O
performance O
score O
of O
90-100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
N2 O
disease O
. O

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

The B-Premise
incidence I-Premise
of I-Premise
Grade I-Premise
4 I-Premise
toxicity I-Premise
was I-Premise
56 I-Premise
% I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
mitomycin-C I-Premise
and I-Premise
29 I-Premise
% I-Premise
in I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
. I-Premise

Only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
Grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise

No B-Premise
acute I-Premise
Grade I-Premise
4 I-Premise
radiation I-Premise
toxicity I-Premise
developed I-Premise
. I-Premise

The B-Premise
incidences I-Premise
of I-Premise
long-term I-Premise
toxicity I-Premise
were I-Premise
equivalent I-Premise
across I-Premise
the I-Premise
arms I-Premise
. I-Premise

Three B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
: I-Premise
2 I-Premise
patients I-Premise
in I-Premise
the I-Premise
surgical I-Premise
arms I-Premise
( I-Premise
one I-Premise
late I-Premise
pulmonary I-Premise
toxicity I-Premise
and I-Premise
one I-Premise
pulmonary I-Premise
embolus I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
radiation I-Premise
arm I-Premise
( I-Premise
radiation I-Premise
pneumonitis I-Premise
) I-Premise
. I-Premise

Induction B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
78 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

Complete B-Premise
resection I-Premise
was I-Premise
performed I-Premise
in I-Premise
73 I-Premise
% I-Premise
of I-Premise
26 I-Premise
patients I-Premise
undergoing I-Premise
thoracotomy I-Premise
. I-Premise

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
among I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
overall I-Premise
progression-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
the I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
( I-Premise
70 I-Premise
% I-Premise
vs. I-Premise
66 I-Premise
% I-Premise
) I-Premise
or I-Premise
median I-Premise
survival I-Premise
time I-Premise
( I-Premise
19.4 I-Premise
vs. I-Premise
17.4 I-Premise
months I-Premise
) I-Premise
between I-Premise
the I-Premise
surgery I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
induction I-Premise
chemotherapy I-Premise
only I-Premise
was I-Premise
8.9 I-Premise
months I-Premise
. I-Premise

Mitomycin-C B-Premise
had I-Premise
no I-Premise
impact I-Premise
on I-Premise
survival I-Premise
( I-Premise
p I-Premise
= I-Premise
0.75 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
time I-Premise
to I-Premise
local I-Premise
failure I-Premise
between I-Premise
the I-Premise
surgical I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

The B-Claim
patient I-Claim
accrual I-Claim
to I-Claim
this I-Claim
trial I-Claim
made I-Claim
its I-Claim
results I-Claim
inconclusive I-Claim
, I-Claim
but O
several O
observations O
are O
notable O
. O

In O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim

In O
this O
setting O
, O
local B-Claim
control I-Claim
and I-Claim
survival I-Claim
were I-Claim
essentially I-Claim
equal I-Claim
between I-Claim
the I-Claim
surgical I-Claim
and I-Claim
RT I-Claim
arms I-Claim
. I-Claim

The B-Claim
-3 I-Claim
and I-Claim
5-year I-Claim
survival I-Claim
rates I-Claim
of I-Claim
nonsurgical I-Claim
therapy I-Claim
were I-Claim
comparable I-Claim
to I-Claim
published I-Claim
surgical I-Claim
trials I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
. I-Claim

Amitriptyline B-Claim
is I-Claim
the I-Claim
most I-Claim
common I-Claim
analgesic I-Claim
adjuvant I-Claim
used I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
neuropathic I-Claim
pain I-Claim
, I-Claim
even O
though O
no B-Claim
specific I-Claim
studies I-Claim
have I-Claim
demonstrated I-Claim
a I-Claim
benefit I-Claim
. I-Claim

A O
randomized O
placebo-controlled O
, O
double-blind O
crossover O
study O
was O
designed O
to O
evidence O
the O
effects O
of O
amitriptyline O
in O
patients O
with O
neuropathic O
cancer O
pain O
. O

Sixteen O
advanced O
cancer O
patients O
with O
neuropathic O
pain O
on O
systemic O
morphine O
therapy O
, O
no O
longer O
receiving O
oncologic O
treatment O
, O
presenting O
moderate O
pain O
( O
about O
4 O
or O
more O
, O
but O
less O
than O
7 O
, O
on O
a O
numerical O
scale O
of O
0-10 O
) O
in O
the O
last O
week O
, O
and O
given O
a O
stable O
morphine O
dose O
in O
the O
last O
2 O
days O
were O
admitted O
to O
the O
study O
. O

During O
the O
first O
week O
of O
study O
, O
patients O
were O
administered O
25 O
mg O
of O
amitriptyline O
or O
equivalent O
drops O
of O
placebo O
at O
night O
for O
3 O
days O
and O
50 O
mg O
for O
the O
following O
4 O
days O
. O

Doses O
for O
patients O
aged O
more O
than O
65 O
years O
were O
15 O
mg O
( O
first O
3 O
days O
) O
and O
30 O
mg O
( O
3 O
days O
after O
) O
. O

After O
a O
week O
, O
a O
crossover O
took O
place O
for O
the O
second O
week O
, O
with O
the O
other O
treatment O
at O
an O
inverse O
sequence O
. O

Opioid O
consumption O
, O
pain O
intensity O
, O
symptoms O
and O
adverse O
effects O
, O
mood O
, O
sleep O
, O
patient O
's O
preference O
, O
quality O
of O
life O
before O
starting O
the O
study O
, O
the O
first O
week O
after O
and O
the O
second O
week O
after O
were O
recorded O
. O

No B-Premise
significant I-Premise
benefits I-Premise
in I-Premise
analgesia I-Premise
were I-Premise
found I-Premise
in I-Premise
the I-Premise
global I-Premise
pain I-Premise
intensity I-Premise
of I-Premise
the I-Premise
previous I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
the I-Premise
least I-Premise
pain I-Premise
intensity I-Premise
or I-Premise
the I-Premise
pain I-Premise
evaluated I-Premise
just I-Premise
after I-Premise
a I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
at I-Premise
the I-Premise
moment I-Premise
of I-Premise
the I-Premise
visit I-Premise
, I-Premise
when I-Premise
amitriptyline I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

A B-Premise
significant I-Premise
difference I-Premise
was I-Premise
evidenced I-Premise
for I-Premise
the I-Premise
worst I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
0.035 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
opioid I-Premise
doses I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
study I-Premise
were I-Premise
found I-Premise
. I-Premise

Drowsiness B-Premise
, I-Premise
confusion I-Premise
and I-Premise
dry I-Premise
mouth I-Premise
were I-Premise
significantly I-Premise
more I-Premise
intense I-Premise
with I-Premise
amitriptyline I-Premise
than I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.036 I-Premise
, I-Premise
0.003 I-Premise
, I-Premise
and I-Premise
0.034 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
substantial I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
Spitzer I-Premise
's I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
and I-Premise
for I-Premise
each I-Premise
item I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
preference I-Premise
for I-Premise
the I-Premise
two I-Premise
treatment I-Premise
periods I-Premise
were I-Premise
found I-Premise
. I-Premise

The B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

In O
light O
of O
the O
results O
obtained O
in O
the O
study O
, O
the B-Claim
extensive I-Claim
use I-Claim
of I-Claim
the I-Claim
drug I-Claim
for I-Claim
cancer I-Claim
pain I-Claim
should I-Claim
be I-Claim
questioned I-Claim
. I-Claim

Anemia B-Claim
, I-Claim
highly I-Claim
common I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
is I-Claim
often I-Claim
an I-Claim
underlying I-Claim
cause I-Claim
of I-Claim
cancer-related I-Claim
fatigue I-Claim
and I-Claim
other I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
deficits I-Claim
. I-Claim

Although O
randomized O
clinical O
trials O
have O
shown O
that O
treatment O
with O
epoetin O
alfa O
increases O
hemoglobin O
levels O
, O
reduces O
fatigue O
, O
lessens O
transfusion O
requirements O
, O
and O
improves O
overall O
QOL O
, O
cancer-related O
anemia O
and O
fatigue O
remain O
undertreated O
. O

This O
is O
, O
in O
part O
, O
because O
scales O
and O
measures O
of O
QOL O
are O
still O
relatively O
unfamiliar O
to O
most O
clinicians O
and O
because O
population-based O
reference O
ranges O
are O
lacking O
, O
thus O
making O
clinical O
trial O
results O
difficult O
to O
interpret O
. O

To O
aid O
in O
the O
interpretation O
of O
QOL O
results O
from O
clinical O
trials O
, O
we O
administered O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
( O
FACT-An O
) O
QOL O
instrument O
to O
a O
nationally O
representative O
sample O
of O
1,400 O
people O
using O
an O
Internet O
survey O
panel O
in O
the O
United O
States O
. O

We O
then O
compared O
the O
FACT-An O
data O
from O
the O
Internet O
survey O
with O
the O
QOL O
data O
of O
a O
375-patient O
randomized O
, O
double-blind O
clinical O
trial O
evaluating O
epoetin O
alfa O
versus O
placebo O
in O
anemic O
cancer O
patients O
. O

FACT-An O
, O
as O
administered O
to O
the O
survey O
population O
, O
displayed O
good O
psychometric O
properties O
and O
was O
able O
to O
discriminate O
between O
respondents O
with O
histories O
of O
specified O
illnesses O
, O
including O
anemia O
and O
cancer O
, O
and O
those O
without O
. O

Comparison B-Premise
of I-Premise
the I-Premise
population I-Premise
norm I-Premise
and I-Premise
clinical I-Premise
trial I-Premise
data I-Premise
showed I-Premise
that I-Premise
treatment I-Premise
with I-Premise
epoetin I-Premise
alfa I-Premise
resulted I-Premise
in I-Premise
clinically I-Premise
meaningful I-Premise
as I-Premise
well I-Premise
as I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
QOL I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Reliable O
population O
norm O
data O
are O
now O
available O
to O
aid O
in O
the O
interpretation O
of O
clinical O
trial O
results O
where O
the O
FACT-An O
questionnaire O
is O
administered O
. O

In B-Claim
the I-Claim
clinical I-Claim
trial I-Claim
, I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
overcame I-Claim
much I-Claim
of I-Claim
the I-Claim
QOL I-Claim
deficit I-Claim
seen I-Claim
in I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
compared I-Claim
with I-Claim
the I-Claim
norm I-Claim
population I-Claim
sample I-Claim
. I-Claim

A O
multicenter O
trial O
was O
conducted O
to O
determine O
the O
efficacy O
and O
toxicity O
of O
escalating O
dosages O
of O
liposomal O
tretinoin O
( O
all-trans-retinoic O
acid O
) O
administered O
once O
or O
three O
times O
weekly O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
. O

Seventy-six O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
were O
randomized O
to O
receive O
the O
study O
drug O
either O
once O
( O
n O
= O
30 O
) O
or O
3 O
times O
weekly O
( O
n O
= O
46 O
) O
. O

The O
starting O
dosage O
was O
60 O
mg/m O
( O
2 O
) O
, O
which O
was O
escalated O
to O
90 O
mg/m O
( O
2 O
) O
and O
then O
120 O
mg/m O
( O
2 O
) O
if O
the O
drug O
was O
well O
tolerated O
( O
< O
or= O
Grade O
2 O
toxicities O
[ O
according O
to O
the O
Southwest O
Oncology O
Group O
toxicity O
scale O
] O
) O
. O

Four O
weeks O
of O
therapy O
constituted O
1 O
cycle O
";" O
patients O
could O
receive O
up O
to O
8 O
cycles O
and O
those O
who O
completed O
8 O
cycles O
were O
given O
the O
option O
of O
receiving O
extended O
therapy O
. O

Clinical O
response O
was O
defined O
as O
complete O
response O
( O
CR O
) O
, O
partial O
response O
( O
PR O
) O
, O
or O
stable O
disease O
( O
SD O
) O
. O

Efficacy O
was O
assessed O
after O
the O
completion O
of O
3 O
treatment O
cycles O
";" O
28.9 O
% O
of O
patients O
( O
22 O
of O
76 O
patients O
) O
responded O
( O
no O
CRs O
, O
1 O
PR O
, O
and O
21 O
SDs O
) O
. O

Among B-Premise
the I-Premise
patients I-Premise
receiving I-Premise
treatment I-Premise
3 I-Premise
times I-Premise
weekly I-Premise
, I-Premise
16 I-Premise
of I-Premise
49 I-Premise
patients I-Premise
( I-Premise
32.7 I-Premise
% I-Premise
) I-Premise
achieved I-Premise
a I-Premise
clinical I-Premise
response I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
third I-Premise
treatment I-Premise
cycle I-Premise
( I-Premise
no I-Premise
CRs I-Premise
, I-Premise
1 I-Premise
PR I-Premise
, I-Premise
and I-Premise
15 I-Premise
SDs I-Premise
) I-Premise
. I-Premise

Concomitant B-Premise
or I-Premise
prior I-Premise
use I-Premise
of I-Premise
protease I-Premise
inhibitors I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
affect I-Premise
the I-Premise
patient I-Premise
's I-Premise
response I-Premise
to I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
0.183 I-Premise
) I-Premise
. I-Premise

Liposomal B-Premise
tretinoin I-Premise
is I-Premise
a I-Premise
new I-Premise
therapeutic I-Premise
agent I-Premise
that I-Premise
has I-Premise
been I-Premise
reported I-Premise
to I-Premise
have I-Premise
some I-Premise
clinical I-Premise
activity I-Premise
in I-Premise
patients I-Premise
with I-Premise
AIDS-associated I-Premise
Kaposi I-Premise
sarcoma I-Premise
. I-Premise

A B-Claim
three-times-per-week I-Claim
dosing I-Claim
schedule I-Claim
was I-Claim
noted I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
compared I-Claim
with I-Claim
a I-Claim
once-a-week I-Claim
schedule I-Claim
without I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
toxicity I-Claim
reported I-Claim
. I-Claim

Chronic O
gastrointestinal O
symptoms O
after O
pelvic O
radiotherapy O
are O
common O
, O
multifactorial O
in O
cause O
, O
and O
affect O
patients O
' O
quality O
of O
life O
. O

We O
assessed O
whether O
such O
patients O
could O
be O
helped O
if O
a O
practitioner O
followed O
an O
investigative O
and O
management O
algorithm O
, O
and O
whether O
outcomes O
differed O
by O
whether O
a O
nurse O
or O
a O
gastroenterologist O
led O
this O
algorithm-based O
care O
. O

For O
this O
three-arm O
randomised O
controlled O
trial O
we O
recruited O
patients O
( O
aged O
≥18 O
years O
) O
from O
clinics O
in O
London O
, O
UK O
, O
with O
new-onset O
gastrointestinal O
symptoms O
persisting O
6 O
months O
after O
pelvic O
radiotherapy O
. O

Using O
a O
computer-generated O
randomisation O
sequence O
, O
we O
randomly O
allocated O
patients O
to O
one O
of O
three O
groups O
( O
1:1:1 O
";" O
stratified O
by O
tumour O
site O
[ O
urological O
, O
gynaecological O
, O
or O
gastrointestinal O
] O
, O
and O
degree O
of O
bowel O
dysfunction O
[ O
IBDQ-B O
score O
< O
60 O
vs O
60-70 O
] O
) O
: O
usual O
care O
( O
a O
detailed O
self-help O
booklet O
) O
, O
gastroenterologist-led O
algorithm-based O
treatment O
, O
or O
nurse-led O
algorithm-based O
treatment O
. O

The O
primary O
endpoint O
was O
change O
in O
Inflammatory O
Bowel O
Disease O
Questionnaire-Bowel O
subset O
score O
( O
IBDQ-B O
) O
at O
6 O
months O
, O
analysed O
by O
intention O
to O
treat O
. O

Between O
Nov O
26 O
, O
2007 O
, O
and O
Dec O
12 O
, O
2011 O
, O
we O
enrolled O
and O
randomly O
allocated O
218 O
patients O
to O
treatment O
: O
80 O
to O
the O
nurse O
group O
, O
70 O
to O
the O
gastroenterologist O
group O
, O
and O
68 O
to O
the O
booklet O
group O
( O
figure O
) O
. O

Most O
had O
a O
baseline O
IBDQ-B O
score O
indicating O
moderate-to-severe O
symptoms O
. O

We B-Premise
recorded I-Premise
the I-Premise
following I-Premise
pair-wise I-Premise
mean I-Premise
difference I-Premise
in I-Premise
change I-Premise
in I-Premise
IBDQ-B I-Premise
score I-Premise
between I-Premise
groups I-Premise
: I-Premise
nurse I-Premise
versus I-Premise
booklet I-Premise
4·12 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·04-8·19 I-Premise
";" I-Premise
p=0·04 I-Premise
) I-Premise
, I-Premise
gastroenterologist I-Premise
versus I-Premise
booklet I-Premise
5·47 I-Premise
( I-Premise
1·14-9·81 I-Premise
";" I-Premise
p=0·01 I-Premise
) I-Premise
. I-Premise

Outcomes B-Premise
in I-Premise
the I-Premise
nurse I-Premise
group I-Premise
were I-Premise
not I-Premise
inferior I-Premise
to I-Premise
outcomes I-Premise
in I-Premise
the I-Premise
gastroenterologist I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
1·36 I-Premise
, I-Premise
one I-Premise
sided I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1·48 I-Premise
) I-Premise
. I-Premise

Patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy-induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
, I-Claim
for I-Claim
most I-Claim
patients I-Claim
, I-Claim
this I-Claim
algorithm-based I-Claim
care I-Claim
can I-Claim
be I-Claim
given I-Claim
by I-Claim
a I-Claim
trained I-Claim
nurse I-Claim
. I-Claim

The O
purpose O
of O
this O
analysis O
was O
to O
assess O
the O
impact O
of O
pretreatment O
factors O
on O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
locally O
advanced O
nonsmall O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

In O
particular O
, O
this O
study O
focused O
on O
the O
possible O
interaction O
between O
gender-specific O
baseline O
health-related O
QOL O
and O
Karnofsky O
performance O
score O
( O
KPS O
) O
in O
a O
prospective O
randomized O
lung O
cancer O
trial O
. O

QOL O
information O
, O
using O
validated O
instruments O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
[ O
FACT-L O
] O
, O
version O
2 O
, O
and O
Functional O
Living O
Index-Cancer O
[ O
FLIC O
] O
) O
, O
was O
prospectively O
collected O
in O
patients O
with O
locally O
advanced O
NSCLC O
treated O
on O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
trial O
89-01 O
. O

Between O
April O
1990 O
and O
April O
1994 O
, O
70 O
eligible O
patients O
participated O
in O
a O
phase O
III O
trial O
comparing O
a O
regimen O
containing O
sequential O
chemotherapy O
and O
radiation O
therapy O
versus O
sequential O
chemotherapy O
plus O
surgery O
. O

Of O
these O
70 O
patients O
, O
46 O
underwent O
pretreatment O
FLIC O
and O
49 O
underwent O
pretreatment O
FACT-L O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
gender I-Premise
and I-Premise
KPS I-Premise
using I-Premise
FLIC I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
, I-Premise
which I-Premise
also I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
significance I-Premise
with I-Premise
FACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
KPS-by-gender I-Premise
interactions I-Premise
were I-Premise
noted I-Premise
for I-Premise
FACT-L I-Premise
in I-Premise
the I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
additional I-Premise
concerns-lung I-Premise
subscales I-Premise
( I-Premise
P I-Premise
= I-Premise
0.012 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.0003 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
of I-Premise
both I-Premise
the I-Premise
FLIC I-Premise
and I-Premise
FACT-L I-Premise
demonstrated I-Premise
significantly I-Premise
lower I-Premise
scores I-Premise
corresponding I-Premise
to I-Premise
lower I-Premise
KPS I-Premise
values I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.016 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
QOL I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
analyzing I-Claim
QOL I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim

Understanding O
the O
interaction O
between O
gender O
and O
performance O
status O
could O
lead O
to O
better O
prognosticators O
and O
potentially O
could O
tailor O
interventions O
for O
specific O
groups O
of O
patients O
with O
lung O
cancer O
. O

This O
study O
sought O
to O
evaluate O
effectiveness O
of O
autologous O
dendritic O
cell O
vaccine O
( O
immunotherapy O
) O
for O
glioblastoma O
multiforme O
( O
GBM O
) O
. O

Patients O
14 O
to O
70 O
years O
of O
age O
with O
newly O
diagnosed O
GBM O
and O
Karnofsky O
Performance O
Scale O
( O
KPS O
) O
score O
> O
70 O
who O
were O
receiving O
initial O
treatment O
were O
enrolled O
and O
were O
randomized O
into O
2 O
groups O
during O
the O
5-year O
study O
period O
. O

Eighteen O
patients O
underwent O
conventional O
treatment O
( O
surgery O
, O
radiotherapy O
, O
and O
chemotherapy O
) O
and O
received O
adjuvant O
autologous O
dendritic O
cell O
vaccine O
, O
and O
16 O
patients O
( O
control O
group O
) O
underwent O
conventional O
treatment O
only O
. O

Administration O
of O
the O
vaccine O
was O
begun O
within O
1 O
to O
2 O
months O
postoperatively O
, O
with O
10 O
inoculations O
given O
over O
6 O
months O
. O

Outcome O
measures O
were O
overall O
survival O
( O
OS O
) O
";" O
progression-free O
survival O
( O
PFS O
) O
";" O
-1 O
, O
-2 O
, O
and O
3-year O
survival O
rates O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Follow-up O
time O
ranged O
from O
14 O
to O
56 O
months O
( O
median O
, O
33 O
months O
) O
. O

The B-Premise
-1 I-Premise
, I-Premise
-2 I-Premise
, I-Premise
and I-Premise
3-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
88.9 I-Premise
% I-Premise
, I-Premise
44.4 I-Premise
% I-Premise
, I-Premise
and I-Premise
16.7 I-Premise
% I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
75.0 I-Premise
% I-Premise
, I-Premise
18.8 I-Premise
% I-Premise
, I-Premise
and I-Premise
0 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
0.299 I-Premise
, I-Premise
0.0035 I-Premise
, I-Premise
0.0014 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
31.9 I-Premise
months I-Premise
and I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
15.0 I-Premise
months I-Premise
( I-Premise
P I-Premise
< I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
8.5 I-Premise
months I-Premise
, I-Premise
and I-Premise
8.0 I-Premise
months I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
. I-Premise

The B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
Kaplan-Meier I-Premise
analysis I-Premise
. I-Premise

Adjuvant B-Claim
immunotherapy I-Claim
with I-Claim
whole-cell I-Claim
lysate I-Claim
dendritic I-Claim
cell I-Claim
vaccine I-Claim
may I-Claim
improve I-Claim
short-term I-Claim
survival I-Claim
. I-Claim

It B-Claim
seems I-Claim
to I-Claim
be I-Claim
safe I-Claim
, I-Claim
and I-Claim
its I-Claim
long-term I-Claim
effectiveness I-Claim
is I-Claim
worthy I-Claim
of I-Claim
further I-Claim
investigation I-Claim
. I-Claim

Patients O
with O
cancer O
are O
characterized O
by O
a O
profound O
impairment O
of O
glucose O
utilization O
, O
with O
lipids O
being O
the O
preferred O
metabolic O
fuel O
. O

In O
contrast O
, O
the O
energy O
needs O
of O
malignant O
tumors O
are O
almost O
entirely O
met O
by O
glucose O
. O

We O
therefore O
studied O
the O
effects O
of O
a O
high-fat O
diet O
, O
particularly O
on O
body O
composition O
. O

Twenty-three O
moderately O
malnourished O
patients O
with O
gastrointestinal O
carcinomas O
were O
randomized O
to O
receive O
either O
a O
conventional O
diet O
supplying O
35 O
nonprotein O
kcal O
and O
1.1 O
g O
of O
protein/kg O
per O
day O
( O
group O
A O
, O
n O
= O
11 O
) O
or O
a O
fat-enriched O
artificial O
liquid O
diet O
( O
20 O
nonprotein O
kcal/kg O
per O
day O
) O
plus O
normal O
meals O
( O
group O
B O
, O
n O
= O
12 O
) O
for O
a O
period O
of O
eight O
weeks O
, O
i.e. O
, O
from O
the O
first O
to O
the O
third O
chemotherapy O
cycle O
. O

The O
fat O
content O
of O
the O
artificial O
diet O
was O
66 O
% O
of O
the O
nonprotein O
calories O
. O

The O
day O
before O
the O
nutritional O
interventions O
, O
and O
again O
after O
four O
and O
eight O
weeks O
, O
body O
compartments O
were O
determined O
using O
bioelectrical O
impedance O
analysis O
, O
lymphocyte O
subpopulations O
were O
quantified O
using O
flow O
cytometry O
, O
and O
some O
aspects O
of O
the O
quality O
of O
life O
were O
rated O
using O
four O
linear O
analog O
self-assessment O
( O
LASA O
) O
scales O
. O

The O
statistical O
calculations O
were O
done O
as O
an O
exploratory O
data O
analysis O
. O

The O
consumption O
of O
non-protein O
calories O
did O
not O
differ O
significantly O
between O
the O
two O
patient O
groups O
. O

An B-Premise
average I-Premise
weight I-Premise
gain I-Premise
in I-Premise
group I-Premise
B I-Premise
contrasted I-Premise
with I-Premise
an I-Premise
average I-Premise
weight I-Premise
loss I-Premise
in I-Premise
group I-Premise
A I-Premise
after I-Premise
four I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Fat-free B-Premise
mass I-Premise
showed I-Premise
an I-Premise
intergroup I-Premise
difference I-Premise
in I-Premise
favor I-Premise
of I-Premise
group I-Premise
B I-Premise
after I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Body B-Premise
cell I-Premise
mass I-Premise
was I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
study I-Premise
in I-Premise
group I-Premise
B I-Premise
, I-Premise
but I-Premise
declined I-Premise
significantly I-Premise
up I-Premise
to I-Premise
weeks I-Premise
4 I-Premise
and I-Premise
8 I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
intergroup I-Premise
difference I-Premise
: I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
and I-Premise
0.01 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
lymphocyte I-Premise
count I-Premise
by I-Premise
559 I-Premise
cells/mul I-Premise
occurred I-Premise
with I-Premise
the I-Premise
fat-enriched I-Premise
diet I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Several B-Premise
aspects I-Premise
of I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
rated I-Premise
to I-Premise
be I-Premise
better I-Premise
in I-Premise
group I-Premise
B I-Premise
than I-Premise
in I-Premise
group I-Premise
A I-Premise
, I-Premise
although B-Premise
not I-Premise
all I-Premise
differences I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high-fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim

However B-Claim
, I-Claim
monitoring I-Claim
the I-Claim
lymphocyte I-Claim
count I-Claim
is I-Claim
advisable I-Claim
. I-Claim

Prior O
studies O
have O
suggested O
that O
melatonin O
, O
a O
frequently O
used O
integrative O
medicine O
, O
can O
attenuate O
weight O
loss O
, O
anorexia O
, O
and O
fatigue O
in O
patients O
with O
cancer O
. O

These O
studies O
were O
limited O
by O
a O
lack O
of O
blinding O
and O
absence O
of O
placebo O
controls O
. O

The O
primary O
purpose O
of O
this O
study O
was O
to O
compare O
melatonin O
with O
placebo O
for O
appetite O
improvement O
in O
patients O
with O
cancer O
cachexia O
. O

We O
performed O
a O
randomized O
, O
double-blind O
, O
28-day O
trial O
of O
melatonin O
20 O
mg O
versus O
placebo O
in O
patients O
with O
advanced O
lung O
or O
GI O
cancer O
, O
appetite O
scores O
≥ O
4 O
on O
a O
0 O
to O
10 O
scale O
( O
10 O
= O
worst O
appetite O
) O
, O
and O
history O
of O
weight O
loss O
≥ O
5 O
% O
. O

Assessments O
included O
weight O
, O
symptoms O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
, O
and O
quality O
of O
life O
by O
the O
Functional O
Assessment O
of O
Anorexia/Cachexia O
Therapy O
( O
FAACT O
) O
questionnaire O
. O

Differences O
between O
groups O
from O
baseline O
to O
day O
28 O
were O
analyzed O
using O
one-sided O
, O
two-sample O
t O
tests O
or O
Wilcoxon O
two-sample O
tests O
. O

Interim O
analysis O
halfway O
through O
the O
trial O
had O
a O
Lan-DeMets O
monitoring O
boundary O
with O
an O
O'Brien-Fleming O
stopping O
rule O
. O

Decision O
boundaries O
were O
to O
accept O
the O
null O
hypothesis O
of O
futility O
if O
the O
test O
statistic O
z O
< O
0.39 O
( O
P O
≥ O
.348 O
) O
and O
reject O
the O
null O
hypothesis O
if O
z O
> O
2.54 O
( O
P O
≤ O
.0056 O
) O
. O

After O
interim O
analysis O
of O
48 O
patients O
, O
the O
study O
was O
closed O
for O
futility O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
for I-Premise
appetite I-Premise
( I-Premise
P I-Premise
= I-Premise
.78 I-Premise
) I-Premise
or I-Premise
other I-Premise
symptoms I-Premise
, I-Premise
weight I-Premise
( I-Premise
P I-Premise
= I-Premise
.17 I-Premise
) I-Premise
, I-Premise
FAACT I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.95 I-Premise
) I-Premise
, I-Premise
toxicity I-Premise
, I-Premise
or I-Premise
survival I-Premise
from I-Premise
baseline I-Premise
to I-Premise
day I-Premise
28 I-Premise
. I-Premise

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

Therapeutic O
protocols O
associated O
with O
appropriate O
and O
effective O
psychological O
and O
social O
support O
systems O
are O
essential O
to O
counteract O
the O
symptoms O
of O
neoplastic O
disease O
in O
incurable O
patients O
. O

A O
phase O
III O
randomized O
study O
was O
performed O
to O
establish O
the O
most O
effective O
and O
safest O
treatment O
to O
improve O
the O
key O
symptoms O
in O
advanced O
gynecological O
cancer O
patients O
, O
i.e. O
, O
lean O
body O
mass O
( O
LBM O
) O
, O
resting O
energy O
expenditure O
( O
REE O
) O
, O
fatigue O
, O
and O
QoL O
. O

In O
addition O
, O
the O
impact O
of O
the O
treatment O
arms O
on O
the O
main O
metabolic O
and O
inflammatory O
parameters O
, O
including O
C-reactive O
protein O
( O
CRP O
) O
, O
interleukin O
( O
IL O
) O
-6 O
, O
tumor O
necrosis O
factor O
( O
TNF O
) O
-α O
, O
leptin O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
and O
glutathione O
peroxidase O
, O
was O
evaluated O
. O

The O
change O
in O
the O
Glasgow O
Prognostic O
Score O
( O
GPS O
) O
during O
treatment O
was O
also O
assessed O
. O

A O
total O
of O
104 O
advanced-stage O
gynecological O
cancer O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
receive O
either O
megestrol O
acetate O
( O
MA O
) O
plus O
l-carnitine O
, O
celecoxib O
, O
and O
antioxidants O
( O
arm O
1 O
) O
or O
MA O
alone O
( O
arm O
2 O
) O
. O

The O
treatment O
duration O
was O
4 O
months O
. O

The B-Premise
combination I-Premise
arm I-Premise
was I-Premise
more I-Premise
effective I-Premise
than I-Premise
arm I-Premise
2 I-Premise
with I-Premise
respect I-Premise
to I-Premise
LBM I-Premise
, I-Premise
REE I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
global I-Premise
QoL I-Premise
. I-Premise

As B-Premise
for I-Premise
the I-Premise
secondary I-Premise
efficacy I-Premise
endpoints I-Premise
, I-Premise
patient I-Premise
appetite I-Premise
increased I-Premise
, I-Premise
and I-Premise
ECOG I-Premise
PS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
inflammation I-Premise
and I-Premise
oxidative I-Premise
stress I-Premise
parameters I-Premise
IL-6 I-Premise
, I-Premise
TNF-α I-Premise
, I-Premise
CRP I-Premise
, I-Premise
and I-Premise
ROS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
arm I-Premise
1 I-Premise
, I-Premise
while I-Premise
no I-Premise
significant I-Premise
change I-Premise
was I-Premise
observed I-Premise
in I-Premise
arm I-Premise
2 I-Premise
. I-Premise

The B-Claim
combined I-Claim
treatment I-Claim
improved I-Claim
both I-Claim
immunometabolic I-Claim
alterations I-Claim
and I-Claim
patient I-Claim
QoL I-Claim
. I-Claim

Multimodality B-Claim
therapies I-Claim
for I-Claim
cachexia I-Claim
ideally I-Claim
should I-Claim
be I-Claim
introduced I-Claim
within I-Claim
a I-Claim
context I-Claim
of I-Claim
" I-Claim
best I-Claim
supportive I-Claim
care I-Claim
" I-Claim
that I-Claim
includes I-Claim
optimal I-Claim
symptom I-Claim
management I-Claim
and I-Claim
careful I-Claim
psychosocial I-Claim
counseling I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
evaluate O
pamidronate O
for O
bone O
pain O
in O
a O
randomised O
double-blind O
trial O
and O
to O
evaluate O
the O
contribution O
of O
new O
markers O
of O
bone O
resorption O
in O
patients O
with O
bone O
metastases O
. O

Fifty-two O
patients O
with O
painful O
bone O
metastases O
were O
randomised O
to O
receive O
a O
two-hour O
infusion O
of O
pamidronate O
120 O
mg O
or O
an O
identical O
infusion O
of O
saline O
. O

Four O
weeks O
later O
, O
all O
patients O
received O
pamidronate O
120 O
mg O
. O

Bone O
resorption O
markers O
measured O
included O
urinary O
calcium O
( O
uCa O
) O
, O
hydroxyproline O
( O
Hyp O
) O
, O
and O
the O
collagen O
breakdown O
products O
: O
NTx O
, O
Crosslaps O
and O
Free O
Dpd O
. O

Symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
with I-Premise
pamidronate I-Premise
and I-Premise
deteriorated I-Premise
after I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Resorption B-Premise
markers I-Premise
did I-Premise
not I-Premise
decrease I-Premise
after I-Premise
placebo I-Premise
, I-Premise
but B-Premise
NTx I-Premise
and I-Premise
Crosslaps I-Premise
both I-Premise
decreased I-Premise
by I-Premise
70 I-Premise
% I-Premise
after I-Premise
pamidronate I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

Symptomatic B-Premise
response I-Premise
to I-Premise
pamidronate I-Premise
correlated I-Premise
closely I-Premise
with I-Premise
the I-Premise
rate I-Premise
of I-Premise
bone I-Premise
resorption I-Premise
";" I-Premise
it B-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
those I-Premise
patients I-Premise
with I-Premise
an I-Premise
initial I-Premise
NTx I-Premise
value I-Premise
of I-Premise
< I-Premise
2 I-Premise
times I-Premise
the I-Premise
upper I-Premise
limit I-Premise
of I-Premise
normal I-Premise
( I-Premise
17 I-Premise
of I-Premise
27 I-Premise
, I-Premise
62 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
where I-Premise
the I-Premise
level I-Premise
of I-Premise
Ntx I-Premise
returned I-Premise
to I-Premise
normal I-Premise
( I-Premise
19 I-Premise
of I-Premise
32 I-Premise
, I-Premise
59 I-Premise
% I-Premise
) I-Premise
, I-Premise
than I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
either I-Premise
high I-Premise
baseline I-Premise
values I-Premise
of I-Premise
NTx I-Premise
( I-Premise
> I-Premise
2 I-Premise
times I-Premise
the I-Premise
upper I-Premise
limit I-Premise
of I-Premise
normal I-Premise
) I-Premise
or I-Premise
Ntx I-Premise
levels I-Premise
which I-Premise
failed I-Premise
to I-Premise
normalise I-Premise
for I-Premise
whom I-Premise
the I-Premise
response I-Premise
frequencies I-Premise
were I-Premise
2 I-Premise
of I-Premise
16 I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0 I-Premise
of I-Premise
11 I-Premise
( I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Subjective B-Claim
benefit I-Claim
after I-Claim
intravenous I-Claim
pamidronate I-Claim
is I-Claim
confirmed I-Claim
in I-Claim
this I-Claim
placebo-controlled I-Claim
study I-Claim
. I-Claim

The B-Claim
new I-Claim
bone I-Claim
resorption I-Claim
markers I-Claim
of I-Claim
collagen I-Claim
breakdown I-Claim
were I-Claim
able I-Claim
to I-Claim
predict I-Claim
clinical I-Claim
response I-Claim
to I-Claim
pamidronate I-Claim
. I-Claim

Over O
30 O
% O
of O
patients O
with O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
develop O
brain O
metastases O
. O

If O
inoperable O
, O
optimal O
supportive O
care O
( O
OSC O
) O
, O
including O
steroids O
, O
and O
whole O
brain O
radiotherapy O
( O
WBRT O
) O
are O
generally O
considered O
to O
be O
standard O
care O
, O
although O
there O
is O
no O
randomised O
evidence O
demonstrating O
that O
the O
addition O
of O
WBRT O
to O
OSC O
improves O
survival O
or O
quality O
of O
life O
. O

QUARTZ O
is O
a O
randomised O
, O
non-inferiority O
, O
phase O
III O
trial O
comparing O
OSC O
+ O
WBRT O
versus O
OSC O
in O
patients O
with O
inoperable O
brain O
metastases O
from O
NSCLC O
. O

The O
primary O
outcome O
measure O
is O
quality-adjusted O
life O
years O
( O
QALYs O
) O
. O

QUARTZ O
was O
threatened O
with O
both O
loss O
of O
funding O
and O
early O
closure O
due O
to O
poor O
accrual O
. O

A O
lack O
of O
preliminary O
randomised O
data O
supporting O
the O
trial O
's O
hypotheses O
was O
thought O
to O
underlie O
the O
poor O
accrual O
, O
so O
, O
with O
no O
knowledge O
of O
the O
data O
, O
the O
independent O
trial O
steering O
committee O
agreed O
to O
the O
unusual O
step O
of O
releasing O
interim O
data O
. O

Between O
March O
2007 O
and O
April O
2010 O
, O
151 O
( O
of O
the O
planned O
534 O
) O
patients O
were O
randomised O
( O
75 O
OSC O
+ O
WBRT O
, O
76 O
OSC O
) O
. O

Participants O
' O
baseline O
demographics O
included O
median O
age O
67 O
years O
( O
interquartile O
range O
62-73 O
) O
, O
60 O
% O
male O
, O
50 O
% O
with O
a O
Karnofsky O
performance O
status O
< O
70 O
";" O
steroid O
usage O
was O
similar O
in O
the O
two O
groups O
";" O
64/75 O
( O
85 O
% O
) O
received O
WBRT O
( O
20 O
Gy O
in O
five O
fractions O
) O
. O

Median B-Premise
survival I-Premise
was I-Premise
: I-Premise
OSC I-Premise
+ I-Premise
WBRT I-Premise
49 I-Premise
days I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
39-61 I-Premise
) I-Premise
, I-Premise
OSC I-Premise
51 I-Premise
days I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
27-57 I-Premise
) I-Premise
- I-Premise
hazard I-Premise
ratio I-Premise
1.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0.80-1.53 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
WBRT I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
assessed I-Premise
using I-Premise
EQ-5D I-Premise
showed I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
. I-Premise

The B-Premise
estimated I-Premise
mean I-Premise
QALYs I-Premise
was I-Premise
: I-Premise
OSC I-Premise
+ I-Premise
WBRT I-Premise
31 I-Premise
days I-Premise
and I-Premise
OSC I-Premise
30 I-Premise
days I-Premise
, I-Premise
difference I-Premise
-1 I-Premise
day I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.0 I-Premise
to I-Premise
+13.2 I-Premise
days I-Premise
) I-Premise
. I-Premise

These B-Claim
interim I-Claim
data I-Claim
indicate I-Claim
no I-Claim
early I-Claim
evidence I-Claim
of I-Claim
detriment I-Claim
to I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
overall I-Claim
survival I-Claim
or I-Claim
QALYs I-Claim
for I-Claim
patients I-Claim
allocated I-Claim
to I-Claim
OSC I-Claim
alone I-Claim
. I-Claim

They O
provide O
key O
information O
for O
discussing O
the O
trial O
with O
patients O
and O
strengthen O
the O
argument O
for O
continuing O
QUARTZ O
to O
definitively O
answer O
this O
important O
clinical O
question O
. O

The O
aim O
of O
the O
study O
was O
to O
compare O
clinical O
outcomes O
and O
quality O
of O
life O
in O
patients O
undergoing O
surgery O
for O
pilonidal O
disease O
with O
unroofing O
and O
marsupialization O
( O
UM O
) O
or O
rhomboid O
excision O
and O
Limberg O
flap O
( O
RELP O
) O
procedures O
. O

One O
hundred O
forty O
consecutive O
patients O
with O
pilonidal O
sinus O
were O
randomly O
assigned O
to O
receive O
either O
UM O
or O
RELP O
procedures O
. O

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

Postoperative O
pain O
was O
assessed O
with O
a O
visual O
analog O
scale O
and O
the O
McGill O
Pain O
Questionnaire O
. O

Patients O
' O
quality O
of O
life O
was O
evaluated O
with O
the O
Cardiff O
Wound O
Impact O
Schedule O
( O
CWIS O
) O
. O

Questionnaires O
were O
administered O
by O
a O
clinician O
blinded O
to O
treatment O
. O

Compared B-Premise
with I-Premise
RELP I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
UM I-Premise
had I-Premise
significantly I-Premise
shorter I-Premise
duration I-Premise
of I-Premise
operation I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
shorter I-Premise
time I-Premise
periods I-Premise
to I-Premise
walk I-Premise
, I-Premise
return I-Premise
to I-Premise
daily I-Premise
activities I-Premise
, I-Premise
or I-Premise
sit I-Premise
without I-Premise
pain I-Premise
and I-Premise
to I-Premise
return I-Premise
to I-Premise
work I-Premise
or I-Premise
school I-Premise
, I-Premise
and I-Premise
fewer I-Premise
complications I-Premise
. I-Premise

Time B-Premise
to I-Premise
final I-Premise
healing I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
on I-Premise
the I-Premise
CWIS I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
RELP I-Premise
than I-Premise
in I-Premise
those I-Premise
receiving I-Premise
UM I-Premise
. I-Premise

Patients B-Premise
with I-Premise
UM I-Premise
had I-Premise
lower I-Premise
levels I-Premise
of I-Premise
pain I-Premise
one I-Premise
week I-Premise
after I-Premise
surgery I-Premise
. I-Premise

The B-Claim
unroofing I-Claim
and I-Claim
marsupialization I-Claim
procedure I-Claim
provides I-Claim
more I-Claim
clinical I-Claim
benefits I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
pilonidal I-Claim
disease I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Limberg I-Claim
flap I-Claim
and I-Claim
should I-Claim
be I-Claim
considered I-Claim
the I-Claim
procedure I-Claim
of I-Claim
choice I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
more I-Claim
inconvenience I-Claim
in I-Claim
wound I-Claim
care I-Claim
and I-Claim
longer I-Claim
healing I-Claim
time I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Lindberg I-Claim
flap I-Claim
. I-Claim

Maintenance O
therapy O
can O
delay O
progression O
and O
prolong O
survival O
in O
metastatic O
non-small-cell O
lung O
cancer O
( O
mNSCLC O
) O
. O

As O
treatment O
for O
mNSCLC O
is O
non-curative O
, O
its O
impact O
on O
patient O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
is O
an O
important O
consideration O
. O

SATURN O
( O
Sequential O
Tarceva O
in O
Unresectable O
NSCLC O
) O
was O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
, O
multicentre O
study O
investigating O
the O
impact O
of O
erlotinib O
maintenance O
therapy O
on O
HRQoL O
in O
patients O
with O
locally O
advanced O
or O
recurrent O
NSCLC O
. O

Eligible O
patients O
who O
had O
previously O
completed O
four O
cycles O
of O
platinum-based O
chemotherapy O
were O
randomised O
1:1 O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
until O
disease O
progression O
, O
unacceptable O
toxicity O
or O
death O
. O

Patient O
HRQoL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
questionnaire O
, O
in O
terms O
of O
time O
to O
symptom O
progression O
( O
TSP O
) O
, O
time O
to O
deterioration O
( O
TTD O
) O
in O
Trial O
Outcome O
Index O
( O
TOI O
) O
and O
TTD O
. O

Exploratory O
analysis O
was O
based O
on O
time O
to O
analgesia O
and O
appearance O
of O
key O
symptoms O
( O
pain O
, O
cough O
and O
dyspnoea O
) O
. O

Compared B-Premise
with I-Premise
placebo I-Premise
, I-Premise
erlotinib I-Premise
maintenance I-Premise
therapy I-Premise
prolonged I-Premise
progression-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
by I-Premise
41 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At O
baseline O
, O
HRQoL O
measures O
were O
comparable O
between O
the O
two O
treatment O
groups O
. O

Maintenance B-Premise
therapy I-Premise
with I-Premise
erlotinib I-Premise
did I-Premise
not I-Premise
impact I-Premise
on I-Premise
deterioration I-Premise
in I-Premise
HRQoL I-Premise
: I-Premise
TSP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
=0.91 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.74-1.12 I-Premise
] I-Premise
";" I-Premise
n=785 I-Premise
) I-Premise
, I-Premise
TTD I-Premise
in I-Premise
TOI I-Premise
( I-Premise
HR=1.06 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.87-1.31 I-Premise
] I-Premise
";" I-Premise
n=781 I-Premise
) I-Premise
and I-Premise
TTD I-Premise
in I-Premise
HRQoL I-Premise
( I-Premise
HR=0.96 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.79-1.16 I-Premise
] I-Premise
";" I-Premise
n=776 I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR=0.61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.42-0.88 I-Premise
] I-Premise
";" I-Premise
p=0.0080 I-Premise
and I-Premise
HR=0.66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.46-0.94 I-Premise
] I-Premise
";" I-Premise
p=0.0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A B-Premise
non-significant I-Premise
trend I-Premise
towards I-Premise
delayed I-Premise
time I-Premise
to I-Premise
cough I-Premise
and I-Premise
time I-Premise
to I-Premise
dyspnoea I-Premise
( I-Premise
HR=0.77 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.49-1.21 I-Premise
] I-Premise
and I-Premise
HR=0.75 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.48-1.17 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
was I-Premise
also I-Premise
observed I-Premise
. I-Premise

Erlotinib B-Claim
maintenance I-Claim
therapy I-Claim
significantly I-Claim
extends I-Claim
progression-free I-Claim
survival I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
HRQoL I-Claim
in I-Claim
comparison I-Claim
with I-Claim
placebo I-Claim
, I-Claim
with I-Claim
some I-Claim
improvement I-Claim
in I-Claim
symptoms I-Claim
. I-Claim

In O
the O
randomized O
, O
multinational O
phase O
II/III O
trial O
( O
V325 O
) O
of O
untreated O
advanced O
gastric O
cancer O
patients O
, O
the O
phase O
II O
part O
selected O
docetaxel O
, O
cisplatin O
, O
and O
fluorouracil O
( O
DCF O
) O
over O
docetaxel O
and O
cisplatin O
for O
comparison O
against O
cisplatin O
and O
fluorouracil O
( O
CF O
";" O
reference O
regimen O
) O
in O
the O
phase O
III O
part O
. O

Advanced O
gastric O
cancer O
patients O
were O
randomly O
assigned O
to O
docetaxel O
75 O
mg/m2 O
and O
cisplatin O
75 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
750 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
3 O
weeks O
or O
cisplatin O
100 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
1,000 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
4 O
weeks O
. O

The O
primary O
end O
point O
was O
time-to-progression O
( O
TTP O
) O
. O

In O
445 O
randomly O
assigned O
and O
treated O
patients O
( O
DCF O
= O
221 O
";" O
CF O
= O
224 O
) O
, O
TTP O
was O
longer O
with O
DCF O
versus O
CF O
( O
32 O
% O
risk O
reduction O
";" O
log-rank O
P O
< O
.001 O
) O
. O

Overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
with I-Premise
DCF I-Premise
versus I-Premise
CF I-Premise
( I-Premise
23 I-Premise
% I-Premise
risk I-Premise
reduction I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Two-year B-Premise
survival I-Premise
rate I-Premise
was I-Premise
18 I-Premise
% I-Premise
with I-Premise
DCF I-Premise
and I-Premise
9 I-Premise
% I-Premise
with I-Premise
CF I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rate I-Premise
was I-Premise
higher I-Premise
with I-Premise
DCF I-Premise
( I-Premise
chi2 I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
occurred I-Premise
in I-Premise
69 I-Premise
% I-Premise
( I-Premise
DCF I-Premise
) I-Premise
v I-Premise
59 I-Premise
% I-Premise
( I-Premise
CF I-Premise
) I-Premise
of I-Premise
patients I-Premise
. I-Premise

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
DCF I-Premise
than I-Premise
CF I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

Adding B-Claim
docetaxel I-Claim
to I-Claim
CF I-Claim
significantly I-Claim
improved I-Claim
TTP I-Claim
, I-Claim
survival I-Claim
, I-Claim
and I-Claim
response I-Claim
rate I-Claim
in I-Claim
gastric I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
but I-Claim
resulted I-Claim
in I-Claim
some I-Claim
increase I-Claim
in I-Claim
toxicity I-Claim
. I-Claim

Incorporation B-Claim
of I-Claim
docetaxel I-Claim
, I-Claim
as I-Claim
in I-Claim
DCF I-Claim
or I-Claim
with I-Claim
other I-Claim
active I-Claim
drug I-Claim
( I-Claim
s I-Claim
) I-Claim
, I-Claim
is I-Claim
a I-Claim
new I-Claim
therapy I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
untreated I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

Hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim

This O
study O
investigated O
differences O
between O
the O
symptoms O
associated O
with O
either O
adjuvant O
tamoxifen O
or O
exemestane O
. O

Ten O
common O
symptoms O
were O
assessed O
by O
self-report O
questionnaire O
administered O
to O
1,614 O
consecutive O
patients O
at O
baseline O
and O
every O
3 O
months O
during O
the O
first O
year O
of O
a O
double-blind O
, O
randomized O
trial O
of O
postmenopausal O
women O
with O
early O
hormone O
receptor-positive O
breast O
cancer O
. O

Symptoms O
were O
categorized O
as O
none O
, O
mild O
, O
moderate O
, O
or O
severe O
. O

A O
hot O
flash O
score O
was O
calculated O
at O
each O
time O
point O
. O

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O

Each O
time O
period O
was O
tested O
repeatedly O
against O
the O
baseline O
";" O
an O
overall O
P O
value O
was O
assigned O
for O
each O
reported O
symptom O
. O

Compliance O
was O
excellent O
, O
with O
7,286 O
questionnaires O
analyzed O
. O

Baseline O
symptom O
prevalence O
ranged O
from O
2 O
% O
( O
vaginal O
bleeding O
) O
to O
60 O
% O
to O
70 O
% O
( O
bone/muscle O
aches O
and O
low O
energy O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
vaginal I-Premise
bleeding I-Premise
, I-Premise
mood I-Premise
alteration I-Premise
, I-Premise
or I-Premise
low I-Premise
energy I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

In B-Premise
both I-Premise
groups I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
score I-Premise
peaked I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
decreased I-Premise
thereafter I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
hot I-Premise
flash I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
with I-Premise
daily I-Premise
hot I-Premise
flashes I-Premise
increasing I-Premise
from I-Premise
baseline I-Premise
by I-Premise
33 I-Premise
% I-Premise
compared I-Premise
with I-Premise
a I-Premise
7 I-Premise
% I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
with I-Premise
exemestane I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
exemestane I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
less I-Premise
vaginal I-Premise
discharge I-Premise
than I-Premise
tamoxifen I-Premise
, I-Premise
but I-Premise
with I-Premise
more I-Premise
vaginal I-Premise
dryness I-Premise
, I-Premise
bone/muscle I-Premise
aches I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
. I-Premise

Symptoms B-Claim
were I-Claim
common I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

We O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
lay-administered O
tailored O
education O
and O
coaching O
( O
TEC O
) O
intervention O
( O
aimed O
at O
reducing O
pain O
misconceptions O
and O
enhancing O
self-efficacy O
for O
communicating O
with O
physicians O
) O
on O
cancer O
pain O
severity O
, O
pain-related O
impairment O
, O
and O
quality O
of O
life O
. O

Cancer O
patients O
with O
baseline O
" O
worst O
pain O
" O
of O
≥4 O
on O
a O
0-10 O
scale O
or O
at O
least O
moderate O
functional O
impairment O
due O
to O
pain O
were O
randomly O
assigned O
to O
TEC O
or O
enhanced O
usual O
care O
( O
EUC O
) O
during O
a O
telephone O
interview O
conducted O
in O
advance O
of O
a O
planned O
oncology O
office O
visit O
( O
265 O
patients O
randomized O
to O
TEC O
or O
EUC O
";" O
258 O
completed O
at O
least O
one O
follow-up O
) O
. O

Patients O
completed O
questionnaires O
before O
and O
after O
the O
visit O
and O
were O
interviewed O
by O
telephone O
at O
2 O
, O
6 O
, O
and O
12 O
weeks O
. O

Mixed O
effects O
regressions O
were O
used O
to O
evaluate O
the O
intervention O
adjusting O
for O
patient O
, O
practice O
, O
and O
site O
characteristics O
. O

Compared B-Premise
to I-Premise
EUC I-Premise
, I-Premise
TEC I-Premise
was I-Premise
associated I-Premise
with I-Premise
increased I-Premise
pain I-Premise
communication I-Premise
self-efficacy I-Premise
after I-Premise
the I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
both B-Premise
groups I-Premise
showed I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
similar I-Premise
, I-Premise
reductions I-Premise
in I-Premise
pain I-Premise
misconceptions I-Premise
. I-Premise

At B-Premise
2 I-Premise
weeks I-Premise
, I-Premise
assignment I-Premise
to I-Premise
TEC I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvement I-Premise
in I-Premise
pain-related I-Premise
impairment I-Premise
( I-Premise
-0.25 I-Premise
points I-Premise
on I-Premise
a I-Premise
5-point I-Premise
scale I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-0.43 I-Premise
to I-Premise
-0.06 I-Premise
, I-Premise
P=.01 I-Premise
) I-Premise
but B-Premise
not I-Premise
in I-Premise
pain I-Premise
severity I-Premise
( I-Premise
-0.21 I-Premise
points I-Premise
on I-Premise
an I-Premise
11-point I-Premise
scale I-Premise
, I-Premise
-0.60 I-Premise
to I-Premise
0.17 I-Premise
, I-Premise
P=.27 I-Premise
) I-Premise
. I-Premise

The B-Premise
improvement I-Premise
in I-Premise
pain-related I-Premise
impairment I-Premise
was I-Premise
not I-Premise
sustained I-Premise
at I-Premise
6 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
intervention I-Premise
by I-Premise
subgroup I-Premise
interactions I-Premise
( I-Premise
P I-Premise
> I-Premise
.10 I-Premise
) I-Premise
. I-Premise

We B-Claim
conclude I-Claim
that I-Claim
TEC I-Claim
, I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
, I-Claim
resulted I-Claim
in I-Claim
improved I-Claim
pain I-Claim
communication I-Claim
self-efficacy I-Claim
and I-Claim
temporary I-Claim
improvement I-Claim
in I-Claim
pain-related I-Claim
impairment I-Claim
, I-Claim
but I-Claim
no I-Claim
improvement I-Claim
in I-Claim
pain I-Claim
severity I-Claim
. I-Claim

In B-Claim
phase I-Claim
II I-Claim
trials I-Claim
, I-Claim
paclitaxel I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antitumor I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

However O
, O
the O
survival O
and O
quality-of-life O
( O
QOL O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O

A O
total O
of O
157 O
patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
who O
had O
received O
no O
prior O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive O
care O
alone O
( O
78 O
patients O
) O
or O
paclitaxel O
plus O
supportive O
care O
( O
79 O
patients O
) O
. O

Paclitaxel O
was O
administered O
as O
a O
3-hour O
intravenous O
infusion O
every O
3 O
weeks O
. O

Supportive O
care O
included O
palliative O
radiotherapy O
and O
supportive O
therapy O
with O
corticosteroids O
, O
antibiotics O
, O
analgesics O
, O
antiemetics O
, O
transfusions O
, O
and O
other O
symptomatic O
therapy O
as O
required O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
survival O
. O

Time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
QOL O
were O
secondary O
end O
points O
. O

Pretreatment O
characteristics O
were O
evenly O
distributed O
between O
the O
two O
arms O
. O

Survival B-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
alone I-Premise
arm I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
( I-Premise
median I-Premise
survival I-Premise
= I-Premise
6.8 I-Premise
months I-Premise
versus I-Premise
4.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

Cox B-Premise
multivariate I-Premise
analysis I-Premise
showed I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
to I-Premise
be I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
survival I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
except B-Premise
for I-Premise
the I-Premise
functional I-Premise
activity I-Premise
score I-Premise
of I-Premise
the I-Premise
Rotterdam I-Premise
Symptom I-Premise
Checklist I-Premise
, I-Premise
where I-Premise
QOL I-Premise
data I-Premise
statistically I-Premise
significantly I-Premise
favored I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.043 I-Premise
) I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
paclitaxel I-Claim
to I-Claim
best I-Claim
supportive I-Claim
care I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
disease I-Claim
progression I-Claim
compared I-Claim
with I-Claim
best I-Claim
supportive I-Claim
care I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
may I-Claim
improve I-Claim
some I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
CO.17 O
demonstrated O
the O
antiepidermal O
growth O
factor O
receptor O
( O
anti-EGFR O
) O
monoclonal O
antibody O
cetuximab O
improves O
overall O
and O
progression-free O
survival O
in O
patients O
with O
advanced O
, O
chemotherapy-refractory O
colorectal O
cancer O
( O
CRC O
) O
, O
particularly O
in O
patients O
with O
wild-type O
KRAS O
tumors O
. O

This O
article O
reports O
the O
health-related O
quality-of-life O
( O
HRQL O
) O
outcomes O
from O
CO.17 O
. O

Patients O
( O
N O
= O
572 O
) O
with O
pretreated O
EGFR-detectable O
advanced O
CRC O
were O
randomly O
assigned O
to O
cetuximab O
and O
best O
supportive O
care O
( O
BSC O
) O
or O
to O
BSC O
alone O
. O

HRQL O
primary O
end O
points O
assessed O
by O
the O
EORTC O
QLQ-C30 O
were O
physical O
function O
( O
PF O
) O
and O
global O
health O
status O
( O
GHS O
) O
";" O
mean O
changes O
from O
baseline O
to O
8 O
and O
16 O
weeks O
were O
assessed O
. O

Post O
hoc O
analysis O
by O
KRAS O
mutation O
status O
was O
performed O
. O

Questionnaire O
compliance O
was O
94 O
% O
at O
baseline O
, O
but O
it O
declined O
differentially O
( O
67 O
% O
v O
47 O
% O
for O
cetuximab O
v O
BSC O
at O
16 O
weeks O
) O
. O

PF B-Premise
change I-Premise
scores I-Premise
were I-Premise
-3.9 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
-8.6 I-Premise
for I-Premise
BSC I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-5.9 I-Premise
and I-Premise
-12.5 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
.027 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
. I-Premise

GHS B-Premise
change I-Premise
scores I-Premise
were I-Premise
-0.5 I-Premise
and I-Premise
-7.1 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-3.6 I-Premise
and I-Premise
-15.2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
patients I-Premise
who I-Premise
had I-Premise
tumors I-Premise
with I-Premise
wild-type I-Premise
KRAS I-Premise
status I-Premise
, I-Premise
cetuximab I-Premise
resulted I-Premise
in I-Premise
less I-Premise
PF I-Premise
deterioration I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
( I-Premise
-0.7 I-Premise
v I-Premise
-7.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.11 I-Premise
) I-Premise
and I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-3.4 I-Premise
v I-Premise
-13.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
compared I-Premise
with I-Premise
BSC I-Premise
. I-Premise

Patients B-Premise
with I-Premise
wild-type I-Premise
status I-Premise
who I-Premise
received I-Premise
cetuximab I-Premise
experienced I-Premise
improved I-Premise
GHS I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
who I-Premise
received I-Premise
BSC I-Premise
alone I-Premise
deteriorated I-Premise
( I-Premise
3.2 I-Premise
v I-Premise
-7.7 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Cetuximab B-Premise
preserved I-Premise
GHS I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-0.2 I-Premise
v I-Premise
-18.1 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
study I-Premise
arms I-Premise
for I-Premise
patients I-Premise
with I-Premise
mutated I-Premise
KRAS I-Premise
tumors I-Premise
. I-Premise

Cetuximab B-Claim
offers I-Claim
important I-Claim
HRQL I-Claim
and I-Claim
survival I-Claim
benefits I-Claim
for I-Claim
pretreated I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
wild-type I-Claim
KRAS I-Claim
CRC I-Claim
. I-Claim

To O
evaluate O
the O
impact O
of O
letrozole O
compared O
with O
placebo O
after O
adjuvant O
tamoxifen O
on O
quality O
of O
life O
( O
QOL O
) O
in O
the O
MA.17 O
trial O
. O

Patients O
completed O
the O
Short O
Form O
36-item O
Health O
Survey O
( O
SF-36 O
) O
and O
the O
Menopause O
Specific O
Quality O
of O
Life O
Questionnaire O
( O
MENQOL O
) O
at O
baseline O
, O
6 O
months O
, O
and O
annually O
. O

Mean O
change O
scores O
from O
baseline O
were O
compared O
between O
groups O
for O
summary O
measures O
and O
domains O
. O

A O
response O
analysis O
compared O
the O
proportion O
of O
patients O
who O
demonstrated O
an O
important O
change O
in O
QOL O
. O

Of O
5,187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3,612 O
( O
69.9 O
% O
) O
participated O
in O
the O
QOL O
substudy O
: O
1,799 O
were O
allocated O
to O
placebo O
and O
1,813 O
were O
allocated O
to O
letrozole O
. O

No B-Premise
differences I-Premise
were I-Premise
seen I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
physical I-Premise
and I-Premise
mental I-Premise
component I-Premise
summary I-Premise
scores I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
24 I-Premise
, I-Premise
and I-Premise
36 I-Premise
months I-Premise
. I-Premise

Small B-Premise
( I-Premise
< I-Premise
0.2 I-Premise
standard I-Premise
deviations I-Premise
) I-Premise
but I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
were I-Premise
seen I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
domains I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
6 I-Premise
months I-Premise
) I-Premise
and I-Premise
vitality I-Premise
( I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
MENQOL I-Premise
vasomotor I-Premise
( I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
and I-Premise
sexual I-Premise
domains I-Premise
( I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
. I-Premise

On B-Premise
the I-Premise
response I-Premise
analysis I-Premise
, I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
the I-Premise
bodily I-Premise
pain I-Premise
domain I-Premise
( I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
reporting I-Premise
a I-Premise
worsening I-Premise
of I-Premise
QOL I-Premise
, I-Premise
47 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
51 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
vasomotor I-Premise
domain I-Premise
( I-Premise
22 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
29 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Letrozole B-Claim
did I-Claim
not I-Claim
have I-Claim
an I-Claim
adverse I-Claim
impact I-Claim
on I-Claim
overall I-Claim
QOL I-Claim
. I-Claim

Small B-Claim
effects I-Claim
were I-Claim
seen I-Claim
in I-Claim
some I-Claim
domains I-Claim
consistent I-Claim
with I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
experiencing I-Claim
changes I-Claim
in I-Claim
QOL I-Claim
compatible I-Claim
with I-Claim
a I-Claim
reduction I-Claim
in I-Claim
estrogen I-Claim
synthesis I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
interferon I-Claim
alfa I-Claim
( I-Claim
IFNalpha I-Claim
) I-Claim
and I-Claim
isotretinoin I-Claim
has I-Claim
shown I-Claim
a I-Claim
direct I-Claim
antiproliferative I-Claim
effect I-Claim
on I-Claim
human I-Claim
melanoma I-Claim
cell I-Claim
lines I-Claim
, I-Claim
but B-Claim
it I-Claim
remained I-Claim
unclear I-Claim
whether I-Claim
this I-Claim
combination I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
IFNalpha I-Claim
alone I-Claim
in I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
melanoma I-Claim
. I-Claim

We O
evaluated O
safety O
and O
efficacy O
of O
IFNalpha O
and O
isotretinoin O
compared O
with O
IFNalpha O
alone O
as O
adjuvant O
treatment O
in O
patients O
with O
primary O
malignant O
melanoma O
stage O
IIA O
and O
IIB O
. O

In O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
, O
407 O
melanoma O
patients O
in O
stage O
IIA O
( O
301 O
patients O
) O
and O
IIB O
( O
106 O
patients O
) O
were O
randomly O
assigned O
to O
either O
IFNalpha O
and O
isotretinoin O
( O
isotretinoin O
group O
";" O
206 O
patients O
) O
or O
IFNalpha O
and O
placebo O
( O
placebo O
group O
";" O
201 O
patients O
) O
after O
excision O
of O
the O
primary O
tumor O
. O

IFNalpha O
was O
administered O
three O
times O
a O
week O
at O
a O
dose O
of O
3 O
million O
units O
subcutaneously O
for O
24 O
months O
. O

Isotretinoin O
at O
a O
dose O
of O
20 O
mg O
for O
patients O
< O
or O
= O
73 O
kg O
, O
30 O
mg O
for O
patients O
greater O
than O
73 O
kg O
, O
or O
placebo O
daily O
for O
24 O
months O
. O

A B-Premise
scheduled I-Premise
interim I-Premise
analysis I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
survival I-Premise
rates I-Premise
, I-Premise
with I-Premise
the I-Premise
isotretinoin I-Premise
group I-Premise
and I-Premise
the I-Premise
placebo I-Premise
group I-Premise
showing I-Premise
5-year I-Premise
disease-free I-Premise
survival I-Premise
rates I-Premise
of I-Premise
55 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
46 I-Premise
% I-Premise
to I-Premise
65 I-Premise
% I-Premise
) I-Premise
and I-Premise
67 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
59 I-Premise
% I-Premise
to I-Premise
75 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
overall I-Premise
5-year I-Premise
survival I-Premise
rates I-Premise
of I-Premise
76 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
67 I-Premise
% I-Premise
to I-Premise
84 I-Premise
% I-Premise
) I-Premise
and I-Premise
81 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
74 I-Premise
% I-Premise
to I-Premise
88 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
trial O
was O
stopped O
for O
futility O
. O

The B-Claim
addition I-Claim
of I-Claim
isotretinoin I-Claim
to I-Claim
an I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
low-dose I-Claim
IFNalpha I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IIA I-Claim
and I-Claim
IIB I-Claim
melanoma I-Claim
had I-Claim
no I-Claim
significant I-Claim
effect I-Claim
on I-Claim
disease-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
and I-Claim
is I-Claim
therefore I-Claim
not I-Claim
recommended I-Claim
. I-Claim

A O
randomised O
controlled O
trial O
of O
radiotherapy O
alone O
versus O
radiotherapy O
with O
concomitant O
and O
adjuvant O
temozolomide O
for O
patients O
with O
glioblastoma O
showed O
that O
survival O
was O
higher O
for O
patients O
assigned O
combination O
treatment O
compared O
with O
those O
assigned O
standard O
radiotherapy O
alone O
. O

This O
paper O
reports O
the O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
the O
patients O
in O
this O
trial O
. O

573 O
patients O
with O
newly O
diagnosed O
glioblastoma O
were O
randomly O
allocated O
either O
radiotherapy O
alone O
or O
radiotherapy O
and O
temozolomide O
. O

The O
primary O
endpoint O
was O
survival O
, O
and O
HRQOL O
was O
a O
secondary O
endpoint O
. O

We O
assessed O
HRQOL O
at O
baseline O
and O
at O
every O
3 O
months O
during O
treatment O
until O
progression O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
quality O
of O
life O
questionnaire O
core-30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
brain O
cancer O
module O
( O
EORTC O
BN-20 O
) O
. O

We O
calculated O
changes O
from O
baseline O
score O
for O
seven O
predefined O
HRQOL O
measures O
( O
fatigue O
, O
overall O
health O
, O
social O
function O
, O
emotional O
function O
, O
future O
uncertainty O
, O
insomnia O
, O
and O
communication O
deficit O
) O
and O
differences O
between O
groups O
for O
these O
measures O
at O
every O
time O
point O
. O

The O
significance O
of O
, O
and O
proportions O
of O
patients O
with O
, O
improved O
HRQOL O
scores O
-- O
defined O
as O
a O
change O
of O
10 O
points O
or O
more O
-- O
were O
recorded O
. O

Baseline O
questionnaires O
were O
available O
for O
490 O
( O
86 O
% O
) O
patients O
. O

Baseline O
HRQOL O
scores O
did O
not O
differ O
between O
groups O
. O

At B-Premise
first I-Premise
follow-up I-Premise
, I-Premise
groups I-Premise
differed I-Premise
only I-Premise
in I-Premise
social I-Premise
functioning I-Premise
, I-Premise
favouring I-Premise
the I-Premise
radiotherapy-only I-Premise
group I-Premise
( I-Premise
mean I-Premise
score I-Premise
79.0 I-Premise
[ I-Premise
SD I-Premise
3.2 I-Premise
] I-Premise
for I-Premise
patients I-Premise
assigned I-Premise
radiotherapy I-Premise
vs I-Premise
67.4 I-Premise
[ I-Premise
2.7 I-Premise
] I-Premise
for I-Premise
those I-Premise
assigned I-Premise
radiotherapy I-Premise
and I-Premise
temozolomide I-Premise
";" I-Premise
difference I-Premise
between I-Premise
groups I-Premise
11.6 I-Premise
points I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.5-19.7 I-Premise
] I-Premise
, I-Premise
p=0.0052 I-Premise
) I-Premise
. I-Premise

Over B-Premise
subsequent I-Premise
assessments I-Premise
, I-Premise
HRQOL I-Premise
was I-Premise
much I-Premise
the I-Premise
same I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Addition B-Claim
of I-Claim
temozolomide I-Claim
during I-Claim
and I-Claim
after I-Claim
radiotherapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
glioblastoma I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
without I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQOL I-Claim
. I-Claim

To O
determine O
the O
feasibility O
of O
administering O
a O
flavonoid-rich O
adjunctive O
treatment O
( O
Concord O
grape O
juice O
) O
for O
the O
management O
of O
chemotherapy-induced O
nausea O
and O
vomiting O
( O
CINV O
) O
";" O
to O
evaluate O
the O
usefulness O
of O
existing O
measures O
for O
assessing O
CINV O
frequency O
and O
severity O
, O
quality O
of O
life O
, O
control O
over O
life O
events O
, O
and O
psychological O
state O
";" O
to O
identify O
any O
actual O
or O
potential O
adverse O
events O
associated O
with O
frequent O
grape O
juice O
intake O
";" O
and O
to O
provide O
preliminary O
data O
concerning O
the O
effect O
of O
Concord O
grape O
juice O
on O
CINV O
, O
quality O
of O
life O
, O
perceived O
control O
over O
life O
events O
, O
and O
psychological O
state O
. O

Double-blind O
, O
randomized O
clinical O
trial O
. O

A O
cancer O
center O
in O
an O
academic O
health O
science O
center O
in O
the O
northeastern O
United O
States O
. O

77 O
adult O
patients O
with O
cancer O
receiving O
moderately O
or O
highly O
emetogenic O
chemotherapy O
agents O
. O

Participants O
drank O
4 O
oz O
. O

of O
grape O
juice O
or O
placebo O
prior O
to O
meals O
for O
one O
week O
following O
each O
of O
four O
chemotherapy O
treatment O
cycles O
. O

They O
recorded O
frequency O
, O
duration O
, O
and O
distress O
of O
nausea O
, O
vomiting O
, O
and O
retching O
daily O
, O
beginning O
the O
evening O
of O
chemotherapy O
administration O
and O
continuing O
for O
seven O
days O
. O

Data O
were O
analyzed O
with O
generalized O
estimating O
equations O
methodology O
to O
model O
differences O
between O
groups O
over O
time O
. O

Nausea B-Premise
and I-Premise
vomiting I-Premise
frequency I-Premise
, I-Premise
duration I-Premise
, I-Premise
and I-Premise
distress I-Premise
were I-Premise
lower I-Premise
for I-Premise
experimental I-Premise
group I-Premise
members I-Premise
, I-Premise
although B-Premise
a I-Premise
high I-Premise
attrition I-Premise
rate I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
resulted I-Premise
in I-Premise
insufficient I-Premise
power I-Premise
to I-Premise
detect I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
over I-Premise
time I-Premise
. I-Premise

Greater O
levels O
of O
anxiety O
, O
depression O
, O
and O
hostility O
at O
baseline O
were O
related O
to O
nausea O
and O
vomiting O
, O
quality O
of O
life O
, O
and O
perceived O
control O
over O
decision O
making O
. O

The B-Claim
effect I-Claim
of I-Claim
grape I-Claim
juice I-Claim
flavonoids I-Claim
on I-Claim
CINV I-Claim
should I-Claim
be I-Claim
investigated I-Claim
further I-Claim
with I-Claim
a I-Claim
larger I-Claim
sample I-Claim
to I-Claim
determine I-Claim
whether I-Claim
preliminary I-Claim
findings I-Claim
are I-Claim
supported I-Claim
. I-Claim

Alterations O
to O
the O
study O
protocol O
will O
be O
necessary O
to O
decrease O
attrition O
. O

Flavonoid-rich B-Claim
fruits I-Claim
and I-Claim
vegetables I-Claim
may I-Claim
provide I-Claim
additional I-Claim
protection I-Claim
against I-Claim
CINV I-Claim
. I-Claim

If O
the O
compounds O
work O
, O
they O
would O
offer O
a O
low-cost O
, O
readily O
available O
adjunctive O
treatment O
for O
the O
management O
of O
CINV O
. O

The B-Claim
role I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
in I-Claim
postmenopausal I-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node-negative I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
controversial I-Claim
. I-Claim

After O
demonstrating O
the O
efficacy O
of O
chemotherapy O
combined O
with O
tamoxifen O
for O
postmenopausal O
patients O
with O
lymph O
node-positive O
disease O
, O
the O
International O
Breast O
Cancer O
Study O
Group O
launched O
a O
randomized O
trial O
( O
Trial O
IX O
) O
to O
evaluate O
the O
role O
of O
adjuvant O
chemotherapy O
preceding O
treatment O
with O
tamoxifen O
for O
patients O
with O
lymph O
node-negative O
disease O
. O

After O
stratification O
by O
estrogen O
receptor O
( O
ER O
) O
status O
, O
patients O
were O
randomly O
assigned O
to O
receive O
three O
28-day O
courses O
of O
" O
classical O
" O
adjuvant O
CMF O
chemotherapy O
( O
cyclophosphamide O
at O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-14 O
, O
orally O
";" O
methotrexate O
at O
40 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
";" O
and O
5-fluorouracil O
at O
600 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
) O
followed O
by O
tamoxifen O
( O
20 O
mg/day O
, O
orally O
for O
57 O
months O
) O
( O
CMF O
-- O
> O
tamoxifen O
) O
or O
to O
receive O
tamoxifen O
alone O
( O
20 O
mg/day O
, O
orally O
for O
60 O
months O
) O
. O

We O
enrolled O
1669 O
eligible O
patients O
, O
382 O
( O
23 O
% O
) O
with O
ER-negative O
tumors O
, O
1217 O
( O
73 O
% O
) O
with O
ER-positive O
tumors O
, O
and O
70 O
( O
4 O
% O
) O
with O
unknown O
ER O
status O
. O

The O
median O
follow-up O
was O
71 O
months O
. O

All O
statistical O
tests O
were O
two-sided O
. O

The B-Premise
added I-Premise
benefit I-Premise
of I-Premise
CMF I-Premise
followed I-Premise
by I-Premise
tamoxifen I-Premise
over I-Premise
tamoxifen I-Premise
alone I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
dependent I-Premise
on I-Premise
ER I-Premise
status I-Premise
( I-Premise
tests I-Premise
for I-Premise
interaction I-Premise
: I-Premise
P I-Premise
=.01 I-Premise
for I-Premise
disease-free I-Premise
survival I-Premise
[ I-Premise
DFS I-Premise
] I-Premise
and I-Premise
P I-Premise
=.07 I-Premise
for I-Premise
overall I-Premise
survival I-Premise
[ I-Premise
OS I-Premise
] I-Premise
) I-Premise
. I-Premise

For B-Premise
patients I-Premise
with I-Premise
ER-negative I-Premise
tumors I-Premise
, I-Premise
the I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
69 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
15 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
6 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
";" I-Premise
risk I-Premise
ratio I-Premise
[ I-Premise
RR I-Premise
] I-Premise
= I-Premise
0.52 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.34 I-Premise
to I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
=.003 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
89 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
81 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
8 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
% I-Premise
to I-Premise
16 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.51 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.30 I-Premise
to I-Premise
0.87 I-Premise
";" I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
for I-Premise
patients I-Premise
with I-Premise
ER-positive I-Premise
tumors I-Premise
, I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
provided I-Premise
no I-Premise
benefit I-Premise
in I-Premise
terms I-Premise
of I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
85 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-1 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-6 I-Premise
% I-Premise
to I-Premise
4 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.75 I-Premise
to I-Premise
1.30 I-Premise
";" I-Premise
P I-Premise
=.92 I-Premise
) I-Premise
or I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
95 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
93 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
2 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1 I-Premise
% I-Premise
to I-Premise
5 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.95 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.64 I-Premise
to I-Premise
1.40 I-Premise
";" I-Premise
P I-Premise
=.80 I-Premise
) I-Premise
. I-Premise

Postmenopausal B-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node-negative I-Claim
breast I-Claim
cancer I-Claim
benefited I-Claim
substantially I-Claim
from I-Claim
adjuvant I-Claim
chemotherapy I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
ER-negative I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
endocrine-nonresponsive I-Claim
) I-Claim
. I-Claim

In B-Claim
contrast I-Claim
, I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
ER-positive I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
endocrine-responsive I-Claim
) I-Claim
, I-Claim
they I-Claim
obtained I-Claim
no I-Claim
benefit I-Claim
from I-Claim
the I-Claim
combination I-Claim
treatment I-Claim
compared I-Claim
with I-Claim
tamoxifen I-Claim
alone I-Claim
. I-Claim

In O
phase O
II O
studies O
, O
irinotecan O
is O
active O
in O
metastatic O
colorectal O
cancer O
, O
but O
the O
overall O
benefit O
has O
not O
been O
assessed O
in O
a O
randomised O
clinical O
trial O
. O

Patients O
with O
proven O
metastatic O
colorectal O
cancer O
, O
which O
had O
progressed O
within O
6 O
months O
of O
treatment O
with O
fluorouracil O
, O
were O
randomly O
assigned O
either O
300-350 O
mg/m2 O
irinotecan O
every O
3 O
weeks O
with O
supportive O
care O
or O
supportive O
care O
alone O
, O
in O
a O
2:1 O
ratio O
. O

189 O
patients O
were O
allocated O
irinotecan O
and O
supportive O
care O
and O
90 O
supportive O
care O
alone O
. O

The O
mean O
age O
of O
the O
participants O
was O
58.8 O
years O
";" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O

WHO O
performance O
status O
was O
0 O
in O
79 O
( O
42 O
% O
) O
patients O
, O
1 O
in O
77 O
( O
41 O
% O
) O
patients O
, O
and O
2 O
in O
32 O
( O
17 O
% O
) O
patients O
. O

Tumour-related O
symptoms O
were O
present O
in O
134 O
( O
71 O
% O
) O
patients O
and O
weight O
loss O
of O
more O
than O
5 O
% O
was O
seen O
in O
15 O
( O
8 O
% O
) O
patients O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
13 I-Premise
months I-Premise
, I-Premise
the I-Premise
overall I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
with I-Premise
36.2 I-Premise
% I-Premise
1-year I-Premise
survival I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
versus I-Premise
13.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
supportive-care I-Premise
group I-Premise
. I-Premise

The B-Premise
survival I-Premise
benefit I-Premise
, I-Premise
adjusted I-Premise
for I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
a I-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
remained I-Premise
significant I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
. I-Premise

Survival B-Premise
without I-Premise
performance-status I-Premise
deterioration I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain-free I-Premise
survival I-Premise
( I-Premise
p=0.003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise

In B-Premise
a I-Premise
quality-of-life I-Premise
analysis I-Premise
, I-Premise
all I-Premise
significant I-Premise
differences I-Premise
, I-Premise
except I-Premise
on I-Premise
diarrhoea I-Premise
score I-Premise
, I-Premise
were I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
. I-Premise

Our B-Claim
study I-Claim
shows I-Claim
that I-Claim
despite I-Claim
the I-Claim
side-effects I-Claim
of I-Claim
treatment I-Claim
, I-Claim
patients I-Claim
who I-Claim
have I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
and I-Claim
for I-Claim
whom I-Claim
fluorouracil I-Claim
has I-Claim
failed I-Claim
, I-Claim
have I-Claim
a I-Claim
longer I-Claim
survival I-Claim
, I-Claim
fewer I-Claim
tumour-related I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
a I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
when I-Claim
treated I-Claim
with I-Claim
irinotecan I-Claim
than I-Claim
with I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
. I-Claim

The O
standard O
doublet O
, O
vinorelbine-cisplatin O
, O
was O
compared O
with O
a O
triplet O
of O
vinorelbine-ifosfamide-cisplatin O
, O
in O
terms O
of O
survival O
, O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

From O
February O
1998 O
to O
June O
1999 O
, O
259 O
chemonaïve O
patients O
entered O
the O
study O
and O
were O
randomised O
to O
receive O
either O
vinorelbine-cisplatin O
( O
NP O
";" O
vinorelbine O
30 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
and O
15 O
with O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
or O
vinorelbine-ifosfamide-cisplatin O
( O
NIP O
";" O
vinorelbine O
25 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
ifosfamide O
3 O
g/m O
( O
2 O
) O
on O
day O
1 O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
with O
both O
regimens O
being O
repeated O
every O
3 O
weeks O
. O

All O
patients O
had O
stage O
IV O
or O
relapsed O
disease O
and O
a O
performance O
score O
of O
0 O
or O
1 O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
34.6 I-Premise
% I-Premise
for I-Premise
NP I-Premise
and I-Premise
35.7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
. I-Premise

Median B-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
10.0 I-Premise
months I-Premise
and I-Premise
38.4 I-Premise
% I-Premise
for I-Premise
NP I-Premise
, I-Premise
and I-Premise
8.2 I-Premise
months I-Premise
and I-Premise
33.7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A O
median O
of O
four O
cycles O
was O
administered O
in O
each O
arm O
. O

The B-Premise
major I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
grade I-Premise
3-4 I-Premise
toxicities I-Premise
for I-Premise
NP I-Premise
and I-Premise
NIP I-Premise
, I-Premise
respectively I-Premise
, I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
20.3 I-Premise
% I-Premise
compared I-Premise
with I-Premise
9 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
anaemia I-Premise
( I-Premise
4.1 I-Premise
% I-Premise
compared I-Premise
with I-Premise
5 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
22.2 I-Premise
% I-Premise
compared I-Premise
with I-Premise
19.4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
5.6 I-Premise
% I-Premise
compared I-Premise
with I-Premise
29.8 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Four B-Premise
toxic I-Premise
deaths I-Premise
occurred I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
and I-Premise
eight I-Premise
in I-Premise
the I-Premise
NIP I-Premise
arm I-Premise
. I-Premise

The B-Premise
different I-Premise
schedules I-Premise
of I-Premise
vinorelbine I-Premise
in I-Premise
the I-Premise
two I-Premise
arms I-Premise
led I-Premise
to I-Premise
a I-Premise
greater I-Premise
survival I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
without I-Premise
impairing I-Premise
the I-Premise
tolerance I-Premise
profile I-Premise
, I-Premise
although B-Premise
this I-Premise
is I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

This B-Claim
confirms I-Claim
that I-Claim
the I-Claim
two-drug I-Claim
combination I-Claim
NP I-Claim
is I-Claim
a I-Claim
reference I-Claim
treatment I-Claim
for I-Claim
metastatic I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
role I-Claim
of I-Claim
three-drug I-Claim
combinations I-Claim
remains I-Claim
questionable I-Claim
in I-Claim
this I-Claim
subset I-Claim
of I-Claim
patients I-Claim
. I-Claim

Chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
QOL O
outcomes O
. O

Our O
purpose O
was O
to O
assess O
the O
impact O
of O
cisplatin O
( O
C O
) O
versus O
cisplatin O
plus O
paclitaxel O
( O
CP O
) O
on O
overall O
QOL O
and O
pain O
in O
cervical O
cancer O
patients O
. O

QOL O
was O
assessed O
using O
FACT-Cx O
, O
consisting O
of O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT-G O
) O
plus O
a O
cervix O
cancer-specific O
subscale O
, O
the O
Brief O
Pain O
Inventory-Short O
Form O
( O
BPI-SF O
) O
, O
and O
a O
neurotoxicity O
subscale O
. O

Time O
points O
were O
: O
baseline O
( O
prior O
to O
randomization O
) O
and O
prior O
to O
chemotherapy O
cycles O
2 O
, O
3 O
, O
and O
4 O
. O

Overall B-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
scores I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
arms I-Premise
at I-Premise
the I-Premise
fourth I-Premise
assessment I-Premise
( I-Premise
C I-Premise
= I-Premise
70.3 I-Premise
( I-Premise
19.6 I-Premise
) I-Premise
";" I-Premise
CP I-Premise
= I-Premise
72.8 I-Premise
( I-Premise
17.4 I-Premise
) I-Premise
) I-Premise
. I-Premise

Scores B-Premise
were I-Premise
stable I-Premise
over I-Premise
time I-Premise
and I-Premise
considerably I-Premise
lower I-Premise
than I-Premise
the I-Premise
general I-Premise
population I-Premise
norms I-Premise
. I-Premise

The B-Premise
BPI-SF I-Premise
revealed I-Premise
a I-Premise
decline I-Premise
in I-Premise
pain I-Premise
scores I-Premise
in I-Premise
both I-Premise
arms I-Premise
from I-Premise
the I-Premise
first I-Premise
to I-Premise
fourth I-Premise
assessments I-Premise
. I-Premise

The B-Premise
CP I-Premise
arm I-Premise
produced I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
response I-Premise
rate I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
but B-Premise
not I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
. I-Premise

Greater B-Premise
myelosuppression I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
QOL I-Premise
drop-out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
C I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
CP I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

At O
the O
fourth O
time O
point O
, O
60 O
% O
of O
living O
patients O
in O
both O
arms O
completed O
a O
QOL O
assessment O
. O

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
in I-Claim
overall I-Claim
QOL I-Claim
scores I-Claim
between I-Claim
treatment I-Claim
arms I-Claim
or I-Claim
serially I-Claim
. I-Claim

Combined B-Claim
with I-Claim
QOL I-Claim
results I-Claim
, I-Claim
the I-Claim
significant I-Claim
increase I-Claim
in I-Claim
response I-Claim
and I-Claim
PFS I-Claim
in I-Claim
the I-Claim
CP I-Claim
arm I-Claim
and I-Claim
the I-Claim
higher I-Claim
drop-out I-Claim
rate I-Claim
in I-Claim
the I-Claim
C I-Claim
arm I-Claim
suggest I-Claim
a I-Claim
better I-Claim
outcome I-Claim
for I-Claim
the I-Claim
combination I-Claim
regimen I-Claim
despite I-Claim
its I-Claim
increased I-Claim
myelosuppression I-Claim
. I-Claim

To O
compare O
the O
effects O
of O
cannabis O
extract O
( O
CE O
) O
, O
delta-9-tetrahydrocannabinol O
( O
THC O
) O
, O
and O
placebo O
( O
PL O
) O
on O
appetite O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
cancer-related O
anorexia-cachexia O
syndrome O
( O
CACS O
) O
. O

Adult O
patients O
with O
advanced O
cancer O
, O
CACS O
, O
weight O
loss O
( O
> O
or O
= O
5 O
% O
over O
6 O
months O
) O
, O
and O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
performance O
status O
( O
PS O
) O
< O
or O
= O
2 O
were O
randomly O
assigned O
( O
2:2:1 O
) O
to O
receive O
CE O
( O
standardized O
for O
2.5 O
mg O
THC O
and O
1 O
mg O
cannabidiol O
) O
or O
THC O
( O
2.5 O
mg O
) O
or O
PL O
orally O
, O
twice O
daily O
for O
6 O
weeks O
. O

Appetite O
, O
mood O
, O
and O
nausea O
were O
monitored O
daily O
with O
a O
visual O
analog O
scale O
( O
VAS O
) O
";" O
QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
composite O
score O
: O
questions O
29 O
and O
30 O
) O
. O

Cannabinoid-related O
toxicity O
was O
assessed O
every O
2 O
weeks O
. O

Of O
289 O
patients O
screened O
, O
243 O
were O
randomly O
assigned O
and O
164 O
( O
CE O
, O
66 O
of O
95 O
patients O
";" O
THC O
, O
65 O
of O
100 O
patients O
";" O
and O
PL O
, O
33 O
of O
48 O
patients O
) O
completed O
treatment O
. O

At O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
VAS O
score O
, O
31/100 O
mm O
) O
, O
and O
QOL O
( O
mean O
score O
, O
30/100 O
) O
. O

Intent-to-treat B-Premise
analysis I-Premise
showed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
three I-Premise
arms I-Premise
for I-Premise
appetite I-Premise
, I-Premise
QOL I-Premise
, I-Premise
or I-Premise
cannabinoid-related I-Premise
toxicity I-Premise
. I-Premise

Increased B-Premise
appetite I-Premise
was I-Premise
reported I-Premise
by I-Premise
73 I-Premise
% I-Premise
, I-Premise
58 I-Premise
% I-Premise
, I-Premise
and I-Premise
69 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
CE I-Premise
, I-Premise
THC I-Premise
, I-Premise
or I-Premise
PL I-Premise
, I-Premise
respectively I-Premise
. I-Premise

An O
independent O
data O
review O
board O
recommended O
termination O
of O
recruitment O
because O
of O
insufficient O
differences O
between O
study O
arms O
. O

CE B-Premise
at I-Premise
the I-Premise
oral I-Premise
dose I-Premise
administered I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
these I-Premise
patients I-Premise
with I-Premise
CACS I-Premise
. I-Premise

No B-Claim
differences I-Claim
in I-Claim
patients I-Claim
' I-Claim
appetite I-Claim
or I-Claim
QOL I-Claim
were I-Claim
found I-Claim
either I-Claim
between I-Claim
CE I-Claim
, I-Claim
THC I-Claim
, I-Claim
and I-Claim
PL I-Claim
or I-Claim
between I-Claim
CE I-Claim
and I-Claim
THC I-Claim
at I-Claim
the I-Claim
dosages I-Claim
investigated I-Claim
. I-Claim

It O
is O
well O
documented O
that O
stress O
is O
associated O
with O
negative O
health O
outcomes O
in O
cancer O
patients O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
a O
novel O
mindfulness O
intervention O
called O
mindfulness-based O
art O
therapy O
( O
MBAT O
) O
versus O
standard O
educational O
support O
, O
on O
indices O
of O
stress O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
with O
high O
stress O
levels O
. O

A O
total O
of O
191 O
women O
were O
enrolled O
, O
stratified O
by O
age O
and O
stress O
level O
, O
and O
randomized O
to O
receive O
either O
an O
8-week O
MBAT O
intervention O
or O
a O
breast O
cancer O
educational O
support O
program O
of O
equal O
time O
and O
duration O
. O

Psychosocial O
stress O
was O
measured O
using O
the O
Symptoms O
Checklist-90-Revised O
, O
and O
quality O
of O
life O
was O
measured O
using O
the O
Medical O
Outcomes O
Study O
Short-Form O
Health O
Survey O
at O
baseline O
, O
immediately O
post-intervention O
, O
and O
at O
6 O
months O
. O

Results B-Premise
showed I-Premise
overall I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
psychosocial I-Premise
stress I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
in I-Premise
both I-Premise
the I-Premise
MBAT I-Premise
and I-Premise
educational I-Premise
support I-Premise
groups I-Premise
immediately I-Premise
post-intervention I-Premise
";" I-Premise
however B-Premise
, I-Premise
participants I-Premise
with I-Premise
high I-Premise
stress I-Premise
levels I-Premise
at I-Premise
baseline I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
overall I-Premise
outcomes I-Premise
only I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
group I-Premise
, I-Premise
both I-Premise
immediately I-Premise
post-intervention I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

In O
addition O
, O
at B-Premise
6 I-Premise
months I-Premise
follow-up I-Premise
, I-Premise
participants I-Premise
attending I-Premise
five I-Premise
or I-Premise
more I-Premise
sessions I-Premise
trended I-Premise
toward I-Premise
retaining I-Premise
treatment I-Premise
effects I-Premise
better I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
MBAT I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
MBAT I-Claim
is I-Claim
associated I-Claim
with I-Claim
significant I-Claim
, I-Claim
sustained I-Claim
benefits I-Claim
across I-Claim
a I-Claim
diverse I-Claim
range I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
particularly I-Claim
those I-Claim
with I-Claim
high I-Claim
stress I-Claim
levels I-Claim
. I-Claim

This O
study O
was O
designed O
to O
evaluate O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
of O
combination O
of O
chemotherapy O
drugs O
and O
intraperitoneal O
perfusion O
of O
verapamil O
in O
the O
treatment O
of O
malignant O
ascites O
. O

Seventy-two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O

Patients O
in O
control O
group O
( O
31 O
cases O
) O
received O
conventional O
chemotherapy O
, O
whereas O
patients O
in O
the O
combined O
treatment O
group O
( O
41 O
cases O
) O
were O
given O
verapamil O
intraperitoneally O
in O
addition O
to O
chemotherapy O
drugs O
. O

Thirty O
days O
after O
the O
treatment O
, O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
were O
assessed O
in O
both O
study O
groups O
. O

The B-Premise
treatment I-Premise
of I-Premise
control I-Premise
group I-Premise
led I-Premise
to I-Premise
1 I-Premise
case I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
2 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
, I-Premise
making I-Premise
the I-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
( I-Premise
complete I-Premise
+ I-Premise
partial I-Premise
remission I-Premise
) I-Premise
of I-Premise
9.7 I-Premise
% I-Premise
. I-Premise

The B-Premise
combined I-Premise
treatment I-Premise
group I-Premise
demonstrated I-Premise
13 I-Premise
cases I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
22 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
. I-Premise

Thus O
, O
the B-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
( I-Premise
85.36 I-Premise
% I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

Using O
KPS O
scores O
, O
changes O
in O
quality O
of O
life O
were O
compared O
before O
and O
after O
the O
treatment O
. O

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
in I-Premise
control I-Premise
group I-Premise
by I-Premise
13.7 I-Premise
% I-Premise
, I-Premise
while I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
improvement I-Premise
of I-Premise
83.5 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

Further O
, O
cumulative B-Premise
survival I-Premise
rate I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
. I-Premise

Treatment B-Premise
toxicity I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
and I-Premise
intestinal I-Premise
adhesion I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
study I-Premise
groups I-Premise
. I-Premise

Intraperitoneal B-Claim
perfusion I-Claim
of I-Claim
verapamil I-Claim
enhances I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
chemotherapy I-Claim
drugs I-Claim
, I-Claim
prolongs I-Claim
survival I-Claim
, I-Claim
and I-Claim
improves I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

Impaired B-Claim
cognition I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
diminished I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
are I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
pilot O
trial O
assessed O
the O
feasibility O
of O
quantifying O
the O
effects O
of O
epoetin O
alfa O
on O
cognitive O
function O
and O
mood O
, O
and O
evaluated O
its O
effects O
on O
fatigue O
and O
QOL O
in O
patients O
with O
breast O
cancer O
treated O
with O
anthracycline-based O
adjuvant O
or O
neoadjuvant O
chemotherapy O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
40,000 O
U O
subcutaneously O
once O
weekly O
or O
placebo O
at O
the O
beginning O
of O
4 O
cycles O
of O
chemotherapy O
administered O
over O
12 O
weeks O
. O

Cognitive O
function O
was O
assessed O
by O
Executive O
Interview O
( O
EXIT25 O
) O
and O
Clock O
Drawing O
Tasks O
";" O
mood O
by O
Profile O
of O
Mood O
States O
";" O
anemia-related O
symptoms O
, O
including O
fatigue O
, O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
( O
FACT-An O
) O
subscale O
";" O
and O
QOL O
by O
Linear O
Analog O
Scale O
Assessment O
. O

Ninety-four O
patients O
were O
evaluable O
for O
efficacy O
and O
safety O
. O

Mean B-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
was I-Premise
1.3 I-Premise
+/- I-Premise
3.3 I-Premise
";" I-Premise
the B-Premise
mean I-Premise
change I-Premise
was I-Premise
0.3 I-Premise
+/- I-Premise
2.4 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
a I-Premise
negative I-Premise
change I-Premise
indicates I-Premise
improved I-Premise
executive I-Premise
function I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
score I-Premise
from I-Premise
baseline I-Premise
to I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
. I-Premise

Mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Epoetin B-Premise
alfa I-Premise
recipients I-Premise
had I-Premise
less I-Premise
of I-Premise
a I-Premise
decrease I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
and I-Premise
improvement I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
therapy I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

These B-Claim
data I-Claim
suggest I-Claim
that I-Claim
epoetin I-Claim
alfa I-Claim
may I-Claim
have I-Claim
attenuated I-Claim
the I-Claim
cognitive I-Claim
impairment I-Claim
and I-Claim
fatigue I-Claim
that I-Claim
occurred I-Claim
during I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

In O
the O
Asia-Pacific O
region O
and O
elsewhere O
, O
almost O
85 O
% O
of O
patients O
with O
hepatocellular O
carcinoma O
( O
HCC O
) O
are O
inoperable O
at O
diagnosis O
and O
have O
a O
dismal O
prognosis O
. O

Tamoxifen B-Claim
( I-Claim
TMX I-Claim
) I-Claim
is I-Claim
believed I-Claim
to I-Claim
inhibit I-Claim
HCC I-Claim
positive I-Claim
for I-Claim
estrogen I-Claim
receptor I-Claim
( I-Claim
ER I-Claim
) I-Claim
, I-Claim
but I-Claim
most I-Claim
HCCs I-Claim
are I-Claim
ER I-Claim
negative I-Claim
. I-Claim

Results B-Claim
of I-Claim
previous I-Claim
phase I-Claim
3 I-Claim
trials I-Claim
in I-Claim
inoperable I-Claim
HCC I-Claim
have I-Claim
been I-Claim
conflicting I-Claim
and I-Claim
inconclusive I-Claim
. I-Claim

At B-Claim
higher I-Claim
doses I-Claim
, I-Claim
however I-Claim
, I-Claim
TMX I-Claim
inhibits I-Claim
HCC I-Claim
through I-Claim
ER-independent I-Claim
mechanisms I-Claim
. I-Claim

A O
multicenter O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
role O
of O
high-dose O
TMX O
versus O
placebo O
( O
P O
) O
in O
the O
treatment O
of O
patients O
with O
inoperable O
HCC O
with O
respect O
to O
survival O
and O
quality O
of O
life O
( O
QoL O
) O
. O

A O
total O
of O
329 O
patients O
from O
10 O
centers O
in O
9 O
countries O
in O
the O
Asia-Pacific O
region O
enrolled O
in O
a O
double-blind O
randomized O
controlled O
trial O
of O
TMX O
120 O
mg/d O
( O
TMX120 O
) O
against O
P O
as O
a O
control O
arm O
with O
an O
intermediate O
dosage O
of O
TMX O
60 O
mg/d O
( O
TMX60 O
) O
to O
assess O
possible O
dose O
response O
. O

An O
independent O
data O
monitoring O
committee O
reviewed O
all O
aspects O
of O
the O
trial O
. O

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

Three-month B-Premise
survival I-Premise
rates I-Premise
for I-Premise
the I-Premise
P I-Premise
, I-Premise
TMX60 I-Premise
, I-Premise
and I-Premise
TMX120 I-Premise
groups I-Premise
were I-Premise
44 I-Premise
% I-Premise
, I-Premise
41 I-Premise
% I-Premise
, I-Premise
and I-Premise
35 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
trend I-Premise
difference I-Premise
in I-Premise
survival I-Premise
across I-Premise
the I-Premise
3 I-Premise
treatment I-Premise
regimens I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
risk I-Premise
of I-Premise
death I-Premise
in I-Premise
the I-Premise
TMX120 I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
P I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.39 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.07-1.81 I-Premise
) I-Premise
. I-Premise

Adverse B-Premise
drug I-Premise
reactions I-Premise
were I-Premise
reported I-Premise
in I-Premise
3 I-Premise
% I-Premise
( I-Premise
9 I-Premise
patients I-Premise
) I-Premise
, I-Premise
and O
8 B-Premise
patients I-Premise
were I-Premise
lost I-Premise
to I-Premise
follow-up I-Premise
. I-Premise

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

No B-Claim
appreciable I-Claim
advantage I-Claim
to I-Claim
QoL I-Claim
with I-Claim
TMX I-Claim
was I-Claim
observed I-Claim
. I-Claim

This O
is O
a O
randomized O
phase O
II O
study O
designed O
to O
compare O
the O
toxicity O
profile O
of O
a O
non-platinum-based O
with O
a O
platinum-based O
regimen O
in O
the O
treatment O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

Eighty-nine O
chemotherapy-naïve O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1,000 O
mg/m2 O
, O
30-min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1-14 O
";" O
GE O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg/m2 O
on O
day O
15 O
";" O
GP O
group O
) O
. O

The O
primary O
endpoint O
is O
toxicity O
, O
and O
secondary O
endpoints O
include O
response O
rate O
, O
survival O
outcome O
and O
quality O
of O
life O
( O
QOL O
) O
. O

The B-Premise
incidence I-Premise
of I-Premise
WHO I-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
anemia I-Premise
, I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
was I-Premise
29 I-Premise
, I-Premise
44 I-Premise
and I-Premise
22 I-Premise
% I-Premise
( I-Premise
GE I-Premise
group I-Premise
) I-Premise
, I-Premise
and I-Premise
28 I-Premise
, I-Premise
49 I-Premise
and I-Premise
23 I-Premise
% I-Premise
( I-Premise
GP I-Premise
group I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.75 I-Premise
, I-Premise
0.95 I-Premise
and I-Premise
0.87 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
grade I-Premise
2 I-Premise
or I-Premise
above I-Premise
nausea I-Premise
was I-Premise
numerically I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
GE I-Premise
15.5 I-Premise
% I-Premise
, I-Premise
GP I-Premise
27.7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
vomiting I-Premise
in I-Premise
the I-Premise
GE I-Premise
and I-Premise
GP I-Premise
arms I-Premise
was I-Premise
20.0 I-Premise
and I-Premise
20.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.96 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
subjective I-Premise
changes I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
on I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Other B-Premise
symptoms I-Premise
including I-Premise
sore I-Premise
mouth I-Premise
and I-Premise
hair I-Premise
loss I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
GE I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.003 I-Premise
and I-Premise
0.007 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
significant I-Premise
differences I-Premise
observed I-Premise
in I-Premise
emotional I-Premise
( I-Premise
p I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
, I-Premise
cognitive I-Premise
( I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
and I-Premise
social I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0.034 I-Premise
) I-Premise
in I-Premise
favor I-Premise
of I-Premise
GP I-Premise
. I-Premise

The B-Premise
differences I-Premise
in I-Premise
tumor I-Premise
response I-Premise
( I-Premise
35.5 I-Premise
and I-Premise
46.5 I-Premise
% I-Premise
for I-Premise
GE I-Premise
and I-Premise
GP I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
( I-Premise
33.8 I-Premise
and I-Premise
40.7 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
41.4 I-Premise
and I-Premise
57.3 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
of I-Premise
borderline I-Premise
significance I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
GP I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.055 I-Premise
) I-Premise
. I-Premise

This B-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
GE I-Claim
is I-Claim
similar I-Claim
to I-Claim
GP I-Claim
, I-Claim
but B-Claim
the I-Claim
apparent I-Claim
inferior I-Claim
efficacy I-Claim
may I-Claim
discourage I-Claim
further I-Claim
investigation I-Claim
. O

To O
evaluate O
the O
analgesic O
effect O
, O
safety O
, O
and O
cost-effectiveness O
of O
controlled-release O
oxycodone O
( O
CRO O
) O
to O
control O
postoperative O
pain O
in O
patients O
with O
liver O
cancer O
who O
are O
undergoing O
transarterial O
chemoembolization O
. O

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
prospective O
clinical O
study O
received O
institutional O
review O
board O
approval O
. O

After O
written O
informed O
consent O
was O
obtained O
, O
210 O
patients O
with O
liver O
cancer O
were O
randomized O
into O
three O
groups O
of O
70 O
patients O
. O

Group O
1 O
received O
20 O
mg O
of O
CRO O
, O
group O
2 O
received O
10 O
mg O
of O
CRO O
, O
and O
group O
3 O
received O
a O
placebo O
at O
1 O
hour O
before O
transarterial O
chemoembolization O
( O
T O
( O
0 O
) O
) O
and O
12 O
( O
T O
( O
12 O
) O
) O
and O
24 O
( O
T O
( O
24 O
) O
) O
hours O
after O
T O
( O
0 O
) O
. O

Pain O
intensity O
on O
a O
numeric O
rating O
scale O
, O
percentage O
of O
patients O
with O
each O
degree O
of O
pain O
, O
quality O
of O
life O
, O
adverse O
reactions O
, O
analgesic O
costs O
, O
and O
hospital O
stays O
were O
evaluated O
and O
compared O
among O
the O
three O
groups O
. O

Numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

When B-Premise
group I-Premise
1 I-Premise
with I-Premise
group I-Premise
2 I-Premise
were I-Premise
compared I-Premise
, I-Premise
numeric I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
group I-Premise
2 I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but B-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
at I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.68 I-Premise
) I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
) I-Premise
. I-Premise

Analgesic B-Premise
cost I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
treated I-Premise
groups I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
treated I-Premise
groups I-Premise
and I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

CRO B-Claim
is I-Claim
effective I-Claim
, I-Claim
safe I-Claim
, I-Claim
and I-Claim
cost-effective I-Claim
in I-Claim
the I-Claim
control I-Claim
of I-Claim
postoperative I-Claim
pain I-Claim
after I-Claim
transarterial I-Claim
chemoembolization I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
liver I-Claim
cancer I-Claim
. I-Claim

Health-related O
quality O
of O
life O
( O
HRQOL O
) O
, O
symptoms O
of O
depression O
, O
and O
adverse O
events O
( O
AEs O
) O
were O
compared O
between O
Japanese O
postmenopausal O
patients O
with O
hormone-sensitive O
breast O
cancer O
( O
BC O
) O
who O
received O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
in O
an O
open-labeled O
, O
randomized O
, O
multicenter O
trial O
designated O
as O
the O
National O
Surgical O
Adjuvant O
Study O
of O
Breast O
Cancer O
( O
N-SAS O
BC O
) O
4 O
substudy O
of O
the O
Tamoxifen O
Exemestane O
Adjuvant O
Multinational O
( O
TEAM O
) O
trial O
. O

During O
the O
first O
year O
of O
treatment O
, O
HRQOL O
and O
symptoms O
of O
depression O
were O
analyzed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
and O
its O
Endocrine O
Symptom O
Subscale O
( O
ES O
) O
, O
and O
the O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
( O
CES-D O
) O
, O
respectively O
. O

In O
addition O
, O
predefined O
AEs O
were O
analyzed O
. O

A O
total O
of O
166 O
eligible O
patients O
were O
randomly O
assigned O
to O
receive O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
. O

FACT-B B-Premise
scores I-Premise
increased I-Premise
after I-Premise
treatment I-Premise
began I-Premise
and I-Premise
remained I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
year I-Premise
( I-Premise
P I-Premise
= I-Premise
0.045 I-Premise
) I-Premise
. I-Premise

FACT-B B-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
and I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise

ES B-Premise
scores I-Premise
and I-Premise
CES-D I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Arthralgia B-Premise
and I-Premise
fatigue I-Premise
were I-Premise
less I-Premise
frequent I-Premise
, I-Premise
but I-Premise
vaginal I-Premise
discharge I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise

HRQOL B-Claim
was I-Claim
better I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
treated I-Claim
with I-Claim
tamoxifen I-Claim
than I-Claim
those I-Claim
treated I-Claim
with I-Claim
exemestane I-Claim
or I-Claim
anastrozole I-Claim
. I-Claim

HRQOL B-Claim
and I-Claim
AEs I-Claim
were I-Claim
similar I-Claim
with I-Claim
exemestane I-Claim
and I-Claim
anastrozole I-Claim
. I-Claim

Given B-Claim
the I-Claim
results I-Claim
of I-Claim
the I-Claim
TEAM I-Claim
trial I-Claim
, I-Claim
upfront I-Claim
use I-Claim
of I-Claim
tamoxifen I-Claim
followed I-Claim
by I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
( I-Claim
AI I-Claim
) I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
option I-Claim
for I-Claim
adjuvant I-Claim
endocrine I-Claim
therapy I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
. I-Claim

We O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal O
women O
with O
estrogen O
receptor-positive O
advanced O
breast O
cancer O
who O
experienced O
progression O
after O
prior O
endocrine O
therapy O
. O

Comparison O
of O
Faslodex O
in O
Recurrent O
or O
Metastatic O
Breast O
Cancer O
( O
CONFIRM O
) O
is O
a O
double-blind O
, O
parallel-group O
, O
multicenter O
, O
phase O
III O
study O
. O

Patients O
were O
randomly O
assigned O
to O
fulvestrant O
500 O
mg O
( O
500 O
mg O
intramuscularly O
[ O
IM O
] O
on O
day O
0 O
, O
then O
500 O
mg O
IM O
on O
days O
14 O
and O
28 O
and O
every O
28 O
days O
thereafter O
) O
or O
250 O
mg O
every O
28 O
days O
. O

Primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Secondary O
end O
points O
included O
objective O
response O
rate O
, O
clinical O
benefit O
rate O
( O
CBR O
) O
, O
duration O
of O
clinical O
benefit O
( O
DoCB O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

PFS B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
362 I-Premise
) I-Premise
than I-Premise
250 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
374 I-Premise
) I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.68 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
risk I-Premise
of I-Premise
progression I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rate I-Premise
was I-Premise
similar I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
250 I-Premise
mg I-Premise
( I-Premise
9.1 I-Premise
% I-Premise
v I-Premise
10.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

CBR B-Premise
was I-Premise
45.6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
39.6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
250 I-Premise
mg. I-Premise
DoCB B-Premise
and I-Premise
OS I-Premise
were I-Premise
16.6 I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
500-mg I-Premise
group I-Premise
, I-Premise
whereas I-Premise
DoCB I-Premise
and I-Premise
OS I-Premise
were I-Premise
13.9 I-Premise
and I-Premise
22.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
250-mg I-Premise
group I-Premise
. I-Premise

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
no I-Claim
dose-dependent I-Claim
adverse I-Claim
events I-Claim
. I-Claim

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
increase I-Claim
in I-Claim
PFS I-Claim
and I-Claim
not I-Claim
associated I-Claim
with I-Claim
increased I-Claim
toxicity I-Claim
, I-Claim
corresponding O
to O
a O
clinically O
meaningful O
improvement O
in O
benefit O
versus O
risk O
compared O
with O
fulvestrant O
250 O
mg O
. O

A O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O

To O
determine O
the O
impact O
of O
nutrition O
intervention O
compared O
with O
standard O
practice O
on O
dietary O
intake O
in O
outpatients O
receiving O
radiotherapy O
. O

Prospective O
, O
randomized O
, O
controlled O
trial O
. O

Sixty O
consecutive O
radiation O
oncology O
outpatients O
( O
51 O
men O
and O
nine O
women O
";" O
age O
61.9+/-14 O
years O
[ O
mean+/-standard O
deviation O
] O
) O
. O

Australian O
private O
radiotherapy O
facility O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n=29 O
) O
( O
nutrition O
counseling O
following O
the O
American O
Dietetic O
Association O
[ O
ADA O
] O
medical O
nutrition O
therapy O
[ O
MNT O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n=31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O

Dietary O
intake O
( O
protein O
, O
energy O
, O
fiber O
) O
assessed O
at O
baseline O
and O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
starting O
radiotherapy O
. O

Repeated-measures O
analysis O
of O
variance O
done O
on O
an O
intention O
to O
treat O
basis O
. O

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
total I-Premise
energy I-Premise
( I-Premise
P=0.029 I-Premise
) I-Premise
and I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
. I-Premise

Mean B-Premise
intake I-Premise
per I-Premise
kilogram I-Premise
of I-Premise
body I-Premise
weight I-Premise
for I-Premise
the I-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
ranged I-Premise
from I-Premise
28 I-Premise
to I-Premise
31 I-Premise
kcal/kg/day I-Premise
compared I-Premise
with I-Premise
25 I-Premise
to I-Premise
29 I-Premise
kcal/kg/day I-Premise
for I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
P=0.022 I-Premise
) I-Premise
. I-Premise

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
protein I-Premise
intake I-Premise
( I-Premise
1.1 I-Premise
to I-Premise
1.3 I-Premise
g/kg/day I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
1.1 I-Premise
g/kg/day I-Premise
) I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
change I-Premise
in I-Premise
fiber I-Premise
intake I-Premise
between I-Premise
the I-Premise
groups I-Premise
was I-Premise
not I-Premise
significant I-Premise
, I-Premise
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
in I-Premise
the I-Premise
anticipated I-Premise
direction I-Premise
( I-Premise
P=0.083 I-Premise
) I-Premise
. I-Premise

Intensive B-Claim
nutrition I-Claim
intervention I-Claim
following I-Claim
the I-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
results I-Claim
in I-Claim
improved I-Claim
dietary I-Claim
intake I-Claim
compared I-Claim
with I-Claim
standard I-Claim
practice I-Claim
and I-Claim
seems I-Claim
to I-Claim
beneficially I-Claim
impact I-Claim
nutrition-related I-Claim
outcomes I-Claim
previously I-Claim
observed I-Claim
in I-Claim
oncology I-Claim
outpatients I-Claim
receiving I-Claim
radiotherapy I-Claim
. I-Claim

The B-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
for I-Claim
radiation I-Claim
oncology I-Claim
is I-Claim
a I-Claim
useful I-Claim
guide I-Claim
to I-Claim
the I-Claim
level I-Claim
of I-Claim
nutrition I-Claim
support I-Claim
required I-Claim
. I-Claim

To O
determine O
if O
the O
type O
of O
embolic O
material O
used O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
has O
an O
impact O
on O
short-term O
recovery O
or O
the O
effectiveness O
of O
embolization O
. O

One O
hundred O
patients O
were O
randomly O
assigned O
to O
undergo O
UAE O
with O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
or O
tris-acryl O
gelatin O
microspheres O
. O

Short-term O
, O
in-hospital O
medication O
use O
and O
pain O
levels O
were O
recorded O
. O

After O
discharge O
, O
symptom O
severity O
, O
temperature O
, O
and O
medications O
used O
were O
recorded O
daily O
for O
1 O
week O
and O
symptom O
levels O
were O
measured O
for O
weeks O
2-4 O
. O

Three O
months O
after O
embolization O
, O
contrast O
material-enhanced O
magnetic O
resonance O
imaging O
examinations O
were O
evaluated O
blindly O
to O
determine O
the O
extent O
of O
leiomyoma O
infarction O
. O

Symptom O
and O
quality O
of O
life O
( O
QOL O
) O
status O
was O
determined O
with O
use O
of O
questionnaires O
. O

Analysis O
was O
completed O
with O
use O
of O
chi O
( O
2 O
) O
analysis O
, O
Fisher O
exact O
tests O
, O
Student O
t O
tests O
, O
and O
analysis O
of O
variance O
as O
appropriate O
. O

Regression O
analysis O
was O
used O
to O
analyze O
the O
impact O
on O
outcome O
of O
baseline O
factors O
( O
other O
than O
type O
of O
embolic O
agent O
) O
. O

No O
significant O
differences O
were O
noted O
at O
baseline O
between O
the O
two O
treatment O
groups O
. O

On B-Premise
average I-Premise
, I-Premise
there I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
volumes I-Premise
of I-Premise
tris-acryl I-Premise
microspheres I-Premise
used I-Premise
( I-Premise
9.0 I-Premise
mL I-Premise
vs I-Premise
3.0 I-Premise
mL I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
, I-Premise
whereas O
microcatheter B-Premise
occlusion I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
PVA I-Premise
( I-Premise
28 I-Premise
% I-Premise
vs I-Premise
4 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
pain I-Premise
severity I-Premise
, I-Premise
other I-Premise
postprocedural I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
medication I-Premise
use I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
QOL I-Premise
. I-Premise

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

Previous B-Claim
trials I-Claim
have I-Claim
suggested I-Claim
a I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
improvement I-Claim
for I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
erythropoietin I-Claim
, I-Claim
but I-Claim
few I-Claim
used I-Claim
QOL I-Claim
as I-Claim
the I-Claim
primary I-Claim
outcome I-Claim
. I-Claim

We O
designed O
a O
trial O
to O
investigate O
the O
effects O
of O
epoetin O
alfa O
therapy O
on O
the O
QOL O
of O
anemic O
patients O
with O
advanced O
non-small-cell O
carcinoma O
of O
the O
lung O
( O
NSCLC O
) O
. O

A O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O

The O
proposed O
sample O
size O
was O
300 O
patients O
. O

Eligible O
patients O
were O
required O
to O
have O
NSCLC O
unsuitable O
for O
curative O
therapy O
and O
baseline O
hemoglobin O
( O
Hgb O
) O
levels O
less O
than O
121 O
g/L O
. O

Patients O
were O
assigned O
to O
12 O
weekly O
injections O
of O
subcutaneous O
epoetin O
alpha O
or O
placebo O
, O
targeting O
Hgb O
levels O
between O
120 O
and O
140 O
g/L O
. O

The O
primary O
outcome O
was O
the O
difference O
in O
the O
change O
in O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
scores O
between O
baseline O
and O
12 O
weeks O
. O

Reports O
of O
thrombotic O
events O
in O
other O
epoetin O
trials O
prompted O
an O
unplanned O
safety O
analysis O
after O
70 O
patients O
had O
been O
randomly O
assigned O
( O
33 O
to O
the O
active O
arm O
and O
37 O
to O
the O
placebo O
arm O
) O
. O

This B-Premise
revealed I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
survival I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
patients I-Premise
on I-Premise
the I-Premise
placebo I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
( I-Premise
63 I-Premise
v I-Premise
129 I-Premise
days I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.84 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

The O
Steering O
Committee O
closed O
the O
trial O
. O

Patient B-Premise
numbers I-Premise
compromised I-Premise
the I-Premise
interpretation I-Premise
of I-Premise
the I-Premise
QOL I-Premise
analysis I-Premise
, I-Premise
but O
a B-Premise
positive I-Premise
Hgb I-Premise
response I-Premise
was I-Premise
noted I-Premise
with I-Premise
epoetin I-Premise
alfa I-Premise
treatment I-Premise
. I-Premise

An B-Claim
unplanned I-Claim
safety I-Claim
analysis I-Claim
suggested I-Claim
decreased I-Claim
overall I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
treated I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

Although O
infrequent O
, O
other O
similar O
reports O
highlight O
the O
need O
for O
ongoing O
trials O
evaluating O
erythropoietin O
receptor O
agonists O
to O
ensure O
that O
overall O
survival O
is O
monitored O
closely O
. O

We O
report O
results O
of O
a O
randomized O
prospective O
study O
that O
compared O
single O
agents O
of O
low O
toxicity O
given O
both O
as O
the O
first-line O
and O
second-line O
chemotherapy O
with O
combination O
chemotherapy O
in O
advanced O
breast O
cancer O
with O
distant O
metastases O
. O

Patients O
in O
the O
single-agent O
arm O
( O
n O
= O
153 O
) O
received O
weekly O
epirubicin O
( O
E O
) O
20 O
mg/m2 O
until O
progression O
or O
until O
the O
cumulative O
dose O
of O
1,000 O
mg/m2 O
, O
followed O
by O
mitomycin O
( O
M O
) O
8 O
mg/m2 O
every O
4 O
weeks O
, O
and O
those O
in O
the O
combination O
chemotherapy O
arm O
( O
n O
= O
150 O
) O
were O
first O
given O
cyclophosphamide O
500 O
mg/m2 O
, O
E O
60 O
mg/m2 O
, O
and O
fluorouracil O
500 O
mg/m2 O
three O
times O
per O
week O
( O
CEF O
) O
followed O
by O
M O
8 O
mg/m2 O
plus O
vinblastine O
( O
V O
) O
6 O
mg/m2 O
every O
4 O
weeks O
. O

Exclusion O
criteria O
included O
age O
greater O
than O
70 O
years O
, O
World O
Health O
Organization O
( O
WHO O
) O
performance O
status O
greater O
than O
2 O
, O
prior O
chemotherapy O
for O
metastatic O
disease O
, O
and O
presence O
of O
liver O
metastases O
in O
patients O
younger O
than O
50 O
. O

An B-Premise
objective I-Premise
response I-Premise
( I-Premise
complete I-Premise
[ I-Premise
CR I-Premise
] I-Premise
or I-Premise
partial I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
was I-Premise
obtained I-Premise
in I-Premise
55 I-Premise
% I-Premise
, I-Premise
48 I-Premise
% I-Premise
, I-Premise
16 I-Premise
% I-Premise
, I-Premise
and I-Premise
7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CEF I-Premise
, I-Premise
E I-Premise
, I-Premise
M I-Premise
, I-Premise
and I-Premise
MV I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
response I-Premise
to I-Premise
CEF I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
than I-Premise
a I-Premise
response I-Premise
to I-Premise
E I-Premise
( I-Premise
median I-Premise
, I-Premise
12 I-Premise
v I-Premise
10.5 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
and I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
or I-Premise
survival I-Premise
was I-Premise
found I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
was I-Premise
found I-Premise
when I-Premise
the I-Premise
patients I-Premise
who I-Premise
received I-Premise
both I-Premise
the I-Premise
planned I-Premise
first-and I-Premise
second-line I-Premise
treatments I-Premise
were I-Premise
compared I-Premise
or I-Premise
when I-Premise
survival I-Premise
was I-Premise
calculated I-Premise
from I-Premise
the I-Premise
beginning I-Premise
of I-Premise
the I-Premise
second-line I-Premise
therapy I-Premise
. I-Premise

Patients B-Claim
treated I-Claim
with I-Claim
single-agent I-Claim
E I-Claim
followed I-Claim
by I-Claim
single-agent I-Claim
M I-Claim
had I-Claim
similar I-Claim
survival I-Claim
, I-Claim
but I-Claim
less I-Claim
treatment-related I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QOL I-Claim
as I-Claim
compared I-Claim
with I-Claim
those I-Claim
treated I-Claim
with I-Claim
CEF I-Claim
followed I-Claim
by I-Claim
MV I-Claim
. I-Claim

Premenopausal O
women O
with O
breast O
cancer O
receiving O
adjuvant O
chemotherapy O
are O
at O
risk O
for O
amenorrhea O
. O

The O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
B-30 O
trial O
included O
menstrual O
history O
( O
MH O
) O
and O
quality-of-life O
( O
QOL O
) O
studies O
to O
compare O
treatments O
on O
these O
outcomes O
. O

Patients O
were O
randomly O
assigned O
to O
sequential O
doxorubicin O
( O
A O
) O
and O
cyclophosphamide O
( O
C O
) O
followed O
by O
docetaxel O
( O
T O
";" O
AC→T O
) O
, O
concurrent O
TAC O
, O
or O
AT O
, O
which O
varied O
in O
duration O
( O
24 O
, O
12 O
, O
12 O
weeks O
, O
respectively O
) O
, O
and O
use O
of O
C. O
Endocrine O
therapy O
was O
prescribed O
for O
women O
with O
hormone O
receptor-positive O
tumors O
. O

MH O
and O
QOL O
were O
assessed O
with O
standardized O
questionnaires O
at O
baseline O
";" O
cycle O
4 O
, O
day O
1 O
";" O
and O
every O
6 O
months O
through O
24 O
months O
. O

Prespecified O
analyses O
examined O
rates O
of O
amenorrhea O
by O
treatment O
arm O
, O
the O
relationship O
between O
amenorrhea O
and O
QOL O
, O
and O
QOL O
by O
treatment O
arm O
. O

Amenorrhea B-Premise
12 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
was I-Premise
significantly I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
: I-Premise
69.8 I-Premise
% I-Premise
for I-Premise
AC→T I-Premise
, I-Premise
57.7 I-Premise
% I-Premise
for I-Premise
TAC I-Premise
, I-Premise
and I-Premise
37.9 I-Premise
% I-Premise
for I-Premise
AT I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
AT I-Premise
group I-Premise
without I-Premise
tamoxifen I-Premise
had I-Premise
the I-Premise
lowest I-Premise
rate I-Premise
of I-Premise
amenorrhea I-Premise
. I-Premise

QOL B-Premise
was I-Premise
poorer I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
AC→T I-Premise
at I-Premise
6 I-Premise
months I-Premise
but I-Premise
similar I-Premise
to I-Premise
others I-Premise
by I-Premise
12 I-Premise
months I-Premise
. I-Premise

Post-treatment B-Premise
symptoms I-Premise
were I-Premise
increased I-Premise
above I-Premise
baseline I-Premise
for I-Premise
all I-Premise
treatments I-Premise
. I-Premise

Multivariable B-Premise
repeated I-Premise
measures I-Premise
modeling I-Premise
demonstrated I-Premise
that I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
time I-Premise
point I-Premise
, I-Premise
age I-Premise
, I-Premise
and I-Premise
tamoxifen I-Premise
use I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
symptom I-Premise
severity I-Premise
( I-Premise
all I-Premise
P I-Premise
values I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Amenorrhea B-Claim
rates I-Claim
differed I-Claim
significantly I-Claim
by I-Claim
treatment I-Claim
arm I-Claim
, I-Claim
with I-Claim
the I-Claim
AT I-Claim
arm I-Claim
having I-Claim
the I-Claim
lowest I-Claim
rate I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
longer I-Claim
duration I-Claim
therapy I-Claim
( I-Claim
AC→T I-Claim
) I-Claim
had I-Claim
greater I-Claim
symptom I-Claim
severity I-Claim
and I-Claim
poorer I-Claim
QOL I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
but I-Claim
did I-Claim
not I-Claim
differ I-Claim
from I-Claim
shorter I-Claim
duration I-Claim
treatments I-Claim
at I-Claim
12 I-Claim
months I-Claim
. I-Claim

To O
investigate O
whether O
frequent O
hospital O
follow-up O
in O
the O
first O
year O
after O
breast O
cancer O
treatment O
might O
partly O
be O
replaced O
by O
nurse-led O
telephone O
follow-up O
without O
deteriorating O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
, O
and O
whether O
a O
short O
educational O
group O
programme O
( O
EGP O
) O
would O
enhance O
HRQoL O
. O

A O
multicentre O
pragmatic O
randomised O
controlled O
trial O
( O
RCT O
) O
with O
a O
2×2 O
factorial O
design O
was O
performed O
among O
320 O
breast O
cancer O
patients O
who O
were O
treated O
with O
curative O
intent O
. O

Participants O
were O
randomised O
to O
follow-up O
care O
as O
usual O
( O
3-monthly O
outpatient O
clinic O
visits O
) O
, O
nurse-led O
telephone O
follow-up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O

The O
primary O
outcome O
for O
both O
interventions O
was O
HRQoL O
, O
measured O
by O
EORTC O
QLQ-C30 O
. O

Secondary O
outcomes O
were O
role O
and O
emotional O
functioning O
and O
feelings O
of O
control O
and O
anxiety O
. O

Data O
of O
299 O
patients O
were O
available O
for O
evaluation O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
HRQoL I-Premise
between I-Premise
nurse-led I-Premise
telephone I-Premise
and I-Premise
hospital I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
for I-Premise
difference I-Premise
: I-Premise
-1.93-4.64 I-Premise
) I-Premise
and I-Premise
neither I-Premise
between I-Premise
follow-up I-Premise
with I-Premise
or I-Premise
without I-Premise
EGP I-Premise
( I-Premise
p I-Premise
= I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
for I-Premise
difference I-Premise
: I-Premise
-3.59-3.00 I-Premise
) I-Premise
. I-Premise

Furthermore O
, O
no B-Premise
differences I-Premise
between I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
and I-Premise
their I-Premise
corresponding I-Premise
control I-Premise
groups I-Premise
were I-Premise
found I-Premise
in I-Premise
role I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
feelings I-Premise
of I-Premise
control I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
p-values I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow-up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse-led I-Claim
telephone I-Claim
follow-up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Hence O
, O
nurse-led B-Claim
telephone I-Claim
follow-up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim

An O
EGP O
does O
not O
unequivocally O
affect O
positive O
HRQoL O
outcomes O
. O

To O
investigate O
the O
impact O
of O
dietary O
counseling O
or O
nutritional O
supplements O
on O
outcomes O
in O
cancer O
patients O
: O
nutritional O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
during O
and O
3 O
months O
after O
radiotherapy O
. O

A O
total O
of O
111 O
colorectal O
cancer O
outpatients O
referred O
for O
radiotherapy O
, O
stratified O
by O
staging O
, O
were O
randomly O
assigned O
: O
group O
1 O
( O
G1 O
";" O
n O
= O
37 O
) O
, O
dietary O
counseling O
( O
regular O
foods O
) O
";" O
group O
2 O
( O
G2 O
";" O
n O
= O
37 O
) O
, O
protein O
supplements O
";" O
and O
group O
3 O
( O
G3 O
";" O
n O
= O
37 O
) O
, O
ad O
libitum O
intake O
. O

Nutritional O
intake O
( O
diet O
history O
) O
, O
status O
( O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QoL O
( O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
, O
and O
3 O
months O
after O
radiotherapy O
. O

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
more I-Premise
than I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Protein B-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.007 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
less I-Premise
than I-Premise
G2 I-Premise
( I-Premise
not I-Premise
significant I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
maintained I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
G2/G3 I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
. I-Premise

After B-Premise
radiotherapy I-Premise
and I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
rates I-Premise
of I-Premise
anorexia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
diarrhea I-Premise
were I-Premise
higher I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
in I-Premise
G1 I-Premise
all I-Premise
QoL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
adequate I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
whereas I-Premise
in I-Premise
G2 I-Premise
only I-Premise
three I-Premise
of I-Premise
six I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
G3 I-Premise
all I-Premise
scores I-Premise
worsened I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
patients I-Premise
maintained/improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single-item I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
.02 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G3 I-Premise
, I-Premise
QoL I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

In B-Premise
G1/G2 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
improvement/deterioration I-Premise
of I-Premise
QoL I-Premise
correlated I-Premise
with I-Premise
better I-Premise
or I-Premise
poorer I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

During B-Claim
radiotherapy I-Claim
, I-Claim
both I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
";" I-Claim
dietary B-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
or I-Claim
higher I-Claim
benefit I-Claim
, I-Claim
whereas I-Claim
even I-Claim
3 I-Claim
months I-Claim
after I-Claim
RT I-Claim
, I-Claim
it I-Claim
was I-Claim
the I-Claim
only I-Claim
method I-Claim
to I-Claim
sustain I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

This O
phase O
III O
study O
was O
performed O
to O
determine O
the O
superiority O
of O
doxorubicin O
( O
DOX O
) O
and O
vinorelbine O
( O
VNB O
) O
( O
arm O
1 O
) O
versus O
DOX O
alone O
( O
arm O
2 O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
for O
overall O
survival O
( O
OS O
) O
, O
time O
to O
treatment O
failure O
( O
TTF O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Three O
hundred O
three O
patients O
were O
randomized O
to O
DOX O
50 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
on O
day O
1 O
and O
VNB O
25 O
mg/m O
( O
2 O
) O
IV O
on O
days O
1 O
and O
8 O
( O
arm O
1 O
) O
or O
DOX O
70 O
mg/m O
( O
2 O
) O
IV O
on O
day O
1 O
( O
arm O
2 O
) O
. O

Both O
regimens O
were O
given O
every O
3 O
weeks O
until O
a O
cumulative O
DOX O
dose O
of O
450 O
mg/m O
( O
2 O
) O
. O

After O
16 O
of O
the O
first O
65 O
randomized O
patients O
experienced O
febrile O
neutropenia O
( O
FN O
) O
, O
the O
doses O
were O
reduced O
to O
DOX O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
VNB O
20 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
versus O
DOX O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
. O

Eligible O
patients O
were O
vinca O
alkaloid O
and O
anthracycline O
naive O
. O

Chemotherapy O
was O
first-line O
or O
second-line O
for O
MBC O
. O

Three O
patients O
were O
ineligible O
. O

Thus O
, O
300 O
patients O
were O
assessable O
for O
toxicity O
and O
to O
determine O
time O
to O
disease O
progression O
( O
TTP O
) O
, O
TTF O
, O
and O
OS O
. O

Two O
hundred O
eighty-nine O
patients O
were O
assessable O
for O
response O
, O
and O
99 O
responders O
were O
assessable O
for O
response O
duration O
( O
RD O
) O
. O

The B-Premise
response I-Premise
rates I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
median I-Premise
RD I-Premise
, I-Premise
TTP I-Premise
, I-Premise
and I-Premise
TTF I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
arms I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
13.8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14.4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
P I-Premise
=.4 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
granulocytopenia I-Premise
was I-Premise
equivalent I-Premise
in I-Premise
both I-Premise
arms I-Premise
but I-Premise
more I-Premise
grade I-Premise
3/4 I-Premise
neurotoxicity I-Premise
, I-Premise
mild I-Premise
venous I-Premise
toxicity I-Premise
, I-Premise
and I-Premise
FN I-Premise
were I-Premise
seen I-Premise
on I-Premise
arm I-Premise
1 I-Premise
. I-Premise

The B-Claim
survival I-Claim
with I-Claim
DOX I-Claim
and I-Claim
VNB I-Claim
is I-Claim
not I-Claim
superior I-Claim
to I-Claim
DOX I-Claim
alone I-Claim
in I-Claim
MBC I-Claim
. I-Claim

To O
analyze O
the O
prospectively O
collected O
health-related O
quality-of-life O
( O
HRQOL O
) O
data O
from O
patients O
enrolled O
in O
two O
Radiation O
Therapy O
Oncology O
Group O
randomized O
Phase O
III O
head O
and O
neck O
cancer O
trials O
( O
90-03 O
and O
91-11 O
) O
to O
assess O
their O
value O
as O
an O
independent O
prognostic O
factor O
for O
locoregional O
control O
( O
LRC O
) O
and/or O
overall O
survival O
( O
OS O
) O
. O

HRQOL O
questionnaires O
, O
using O
a O
validated O
instrument O
, O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-H O
& O
amp O
";" O
N O
) O
, O
version O
2 O
, O
were O
completed O
by O
patients O
before O
the O
start O
of O
treatment O
. O

OS O
and O
LRC O
were O
the O
outcome O
measures O
analyzed O
using O
a O
multivariate O
Cox O
proportional O
hazard O
model O
. O

Baseline O
FACT-H O
& O
amp O
";" O
N O
data O
were O
available O
for O
1,093 O
patients O
and O
missing O
for O
417 O
patients O
. O

No O
significant O
difference O
in O
outcome O
was O
found O
between O
the O
patients O
with O
and O
without O
baseline O
FACT-H O
& O
amp O
";" O
N O
data O
( O
p O
= O
0.58 O
) O
. O

The O
median O
follow-up O
time O
was O
27.2 O
months O
for O
all O
patients O
and O
49 O
months O
for O
surviving O
patients O
. O

Multivariate O
analyses O
were O
performed O
for O
both O
OS O
and O
LRC O
. O

Beyond B-Premise
tumor I-Premise
and I-Premise
nodal I-Premise
stage I-Premise
, I-Premise
Karnofsky I-Premise
performance I-Premise
status I-Premise
, I-Premise
primary I-Premise
site I-Premise
, I-Premise
cigarette I-Premise
use I-Premise
, I-Premise
use I-Premise
of I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
and I-Premise
altered I-Premise
fractionation I-Premise
schedules I-Premise
, I-Premise
the I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
";" I-Premise
N I-Premise
score I-Premise
was I-Premise
independently I-Premise
predictive I-Premise
of I-Premise
LRC I-Premise
( I-Premise
but I-Premise
not I-Premise
OS I-Premise
) I-Premise
, I-Premise
with I-Premise
p I-Premise
= I-Premise
0.0038 I-Premise
. I-Premise

The B-Premise
functional I-Premise
well-being I-Premise
component I-Premise
of I-Premise
the I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
";" I-Premise
N I-Premise
predicted I-Premise
most I-Premise
significantly I-Premise
for I-Premise
LRC I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0004 I-Premise
) I-Premise
. I-Premise

This B-Claim
study I-Claim
represents I-Claim
, I-Claim
to I-Claim
our I-Claim
knowledge I-Claim
, I-Claim
the I-Claim
largest I-Claim
analysis I-Claim
of I-Claim
HRQOL I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
factor I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
have I-Claim
demonstrated I-Claim
the I-Claim
importance I-Claim
of I-Claim
baseline I-Claim
HRQOL I-Claim
as I-Claim
a I-Claim
significant I-Claim
and I-Claim
independent I-Claim
predictor I-Claim
of I-Claim
LRC I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
. I-Claim

Lymphedema O
is O
an O
adverse O
effect O
of O
breast O
cancer O
surgery O
. O

Aqua O
lymphatic O
therapy O
( O
ALT O
) O
is O
a O
novel O
treatment O
for O
limb O
volume O
reduction O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
whether O
ALT O
is O
a O
safe O
method O
and O
whether O
there O
are O
differences O
in O
adherence O
, O
limb O
volume O
, O
and O
quality O
of O
life O
between O
women O
who O
perform O
only O
self-management O
treatment O
and O
women O
who O
participate O
as O
well O
in O
ALT O
. O

Design O
of O
the O
study O
was O
single-blind O
randomized O
clinical O
trial O
. O

The O
setting O
was O
in O
a O
hydrotherapy O
pool O
, O
1.2 O
m O
depth O
, O
and O
a O
temperature O
of O
32-33 O
degrees O
capital O
ES O
, O
Cyrillic O
. O

Forty-eight O
women O
( O
56 O
+/- O
10 O
years O
) O
, O
with O
a O
12.8 O
% O
lymphedema O
relative O
volume O
, O
participated O
in O
the O
study O
. O

The O
control O
group O
was O
instructed O
to O
perform O
the O
self-management O
treatment O
. O

The O
study O
group O
joined O
a O
weekly O
session O
of O
ALT O
for O
3 O
months O
in O
addition O
to O
the O
self-management O
therapy O
. O

Adherence O
was O
assessed O
by O
a O
self-reported O
diary O
, O
limb O
volume O
by O
a O
water O
displacement O
device O
, O
quality O
of O
life O
by O
the O
Upper O
Limb O
Lymphedema O
Questionnaire O
( O
ULL27 O
) O
, O
prior O
to O
, O
and O
after O
the O
intervention O
period O
. O

There B-Premise
was I-Premise
no I-Premise
episode I-Premise
of I-Premise
arm I-Premise
infection I-Premise
or I-Premise
aggravation I-Premise
in I-Premise
limb I-Premise
volume I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

ALT B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long-term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise

The B-Premise
adherence I-Premise
rate I-Premise
to I-Premise
ALT I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
the I-Premise
adherence I-Premise
to I-Premise
self-management I-Premise
therapy I-Premise
. I-Premise

QOL B-Premise
improved I-Premise
in I-Premise
the I-Premise
study I-Premise
group I-Premise
. I-Premise

ALT B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim

A B-Claim
significant I-Claim
immediate I-Claim
and I-Claim
insignificant I-Claim
long-term I-Claim
effect I-Claim
on I-Claim
limb I-Claim
volume I-Claim
was I-Claim
noted I-Claim
. I-Claim

Recombinant O
human O
TSH O
( O
rhTSH O
) O
has O
become O
the O
modality O
of O
choice O
for O
radioiodine O
remnant O
ablation O
( O
RRA O
) O
in O
low-risk O
thyroid O
cancer O
patients O
. O

The O
aims O
of O
the O
present O
prospective O
randomized O
study O
were O
to O
evaluate O
the O
impact O
of O
TSH O
stimulation O
procedure O
( O
hypothyroidism O
vs. O
rhTSH O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RRA O
and O
to O
evaluate O
efficacy O
of O
both O
procedures O
. O

L-T4 O
was O
initiated O
in O
both O
groups O
after O
thyroidectomy O
. O

After O
randomization O
, O
L-T4 O
was O
discontinued O
in O
hypothyroid O
( O
hypo O
) O
group O
and O
continued O
in O
rhTSH O
group O
. O

A O
measure O
of O
3.7 O
GBq O
of O
radioiodine O
was O
given O
to O
both O
groups O
. O

The O
functional O
assessment O
of O
chronic O
illness O
therapy-fatigue O
( O
FACIT-F O
) O
was O
administered O
from O
the O
early O
postoperative O
period O
to O
9 O
months O
. O

Socio-demographic O
parameters O
, O
anxiety O
and O
depression O
scales O
were O
also O
evaluated O
( O
CES-D O
, O
BDI O
and O
Spielberger O
state-trait O
questionnaires O
) O
. O

At O
9 O
months O
, O
patients O
underwent O
an O
rhTSH O
stimulation O
test O
, O
diagnostic O
( O
131 O
) O
I O
whole O
body O
scan O
( O
dxWBS O
) O
and O
neck O
ultrasonography O
. O

A O
total O
of O
74 O
patients O
were O
enrolled O
for O
the O
study O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
QoL I-Premise
from I-Premise
baseline I-Premise
( I-Premise
t0 I-Premise
) I-Premise
to I-Premise
t1 I-Premise
( I-Premise
RRA I-Premise
period I-Premise
) I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
with I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FACIT-F I-Premise
TOI I-Premise
( I-Premise
P I-Premise
< I-Premise
10 I-Premise
( I-Premise
-3 I-Premise
) I-Premise
) I-Premise
, I-Premise
FACT-G I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
FACIT-F I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
QoL I-Premise
was I-Premise
preserved I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
group I-Premise
. I-Premise

In O
the O
multivariate O
analysis O
, O
FACIT-TOI O
changes O
were O
only O
affected O
by O
the O
modality O
of O
TSH O
stimulation O
performed O
for O
RRA O
. O

From B-Premise
3 I-Premise
to I-Premise
9 I-Premise
months I-Premise
, I-Premise
changes I-Premise
of I-Premise
QoL I-Premise
scales I-Premise
and I-Premise
subscales I-Premise
were I-Premise
no I-Premise
longer I-Premise
statistically I-Premise
different I-Premise
in I-Premise
both I-Premise
groups I-Premise
of I-Premise
patients I-Premise
. I-Premise

Based B-Premise
on I-Premise
serum I-Premise
rhTSH-stimulated I-Premise
Tg I-Premise
alone I-Premise
( I-Premise
Tg I-Premise
< I-Premise
0.8 I-Premise
microg/l I-Premise
, I-Premise
BRAHMS I-Premise
Tg I-Premise
Kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
ablation I-Premise
success I-Premise
was I-Premise
observed I-Premise
between I-Premise
rhTSH I-Premise
and I-Premise
hypothyroidism I-Premise
groups I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
and I-Premise
97.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
higher I-Premise
rate I-Premise
of I-Premise
persistent I-Premise
thyroid I-Premise
remnants I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
arm I-Premise
, I-Premise
although B-Premise
in I-Premise
most I-Premise
cases I-Premise
uptake I-Premise
was I-Premise
< I-Premise
0.1 I-Premise
% I-Premise
and I-Premise
of I-Premise
no I-Premise
clinical I-Premise
significance I-Premise
. I-Premise

rhTSH B-Claim
preserves I-Claim
QoL I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
RRA I-Claim
with I-Claim
similar I-Claim
rates I-Claim
of I-Claim
ablation I-Claim
success I-Claim
compared I-Claim
to I-Claim
hypothyrodism I-Claim
. I-Claim

However O
, O
there O
is O
a O
wide O
heterogeneity O
in O
the O
clinical O
impact O
of O
hypothyroidism O
. O

Chemotherapy-induced O
anemia O
( O
CIA O
) O
is O
responsive O
to O
treatment O
with O
erythropoiesis-stimulating O
agents O
( O
ESAs O
) O
such O
as O
darbepoetin O
alfa O
. O

Administration O
of O
ESAs O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on-time O
chemotherapy O
delivery O
. O

This O
phase O
2 O
, O
25-week O
, O
open-label O
study O
evaluated O
the O
noninferiority O
of O
darbepoetin O
alfa O
administered O
weekly O
vs. O
as O
an O
extended O
dosing O
schedule O
( O
every O
2 O
or O
3 O
weeks O
) O
in O
patients O
with O
CIA O
. O

Patients O
were O
randomized O
1:1 O
to O
an O
extended O
dosing O
schedule O
( O
EDS O
: O
darbepoetin O
alfa O
300 O
μg O
Q2W O
if O
chemotherapy O
was O
QW O
, O
Q2W O
, O
or O
Q4W O
or O
darbepoetin O
alfa O
500 O
μg O
Q3W O
if O
chemotherapy O
was O
Q3W O
) O
or O
weekly O
( O
150 O
μg O
QW O
regardless O
of O
chemotherapy O
schedule O
) O
. O

Stratification O
factors O
included O
chemotherapy O
cycle O
length O
, O
screening O
hemoglobin O
( O
< O
10 O
g/dL O
vs. O
≥10 O
g/dL O
) O
, O
and O
tumor O
type O
( O
lung/gynecological O
vs. O
other O
nonmyeloid O
malignancies O
) O
. O

The O
primary O
endpoint O
was O
change O
in O
hemoglobin O
from O
baseline O
to O
Week O
13 O
. O

Seven O
hundred O
fifty-two O
patients O
( O
374 O
QW O
patients O
";" O
378 O
EDS O
patients O
) O
received O
≥1 O
dose O
of O
darbepoetin O
alfa O
and O
were O
included O
in O
the O
analysis O
. O

Demographics O
and O
disease O
state O
were O
similar O
between O
groups O
. O

Seventy-one B-Premise
percent I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
EDS I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
achieved I-Premise
the I-Premise
target I-Premise
hemoglobin I-Premise
of I-Premise
≥11.0 I-Premise
g/dL I-Premise
. I-Premise

There O
was O
a O
minimal O
difference O
in O
the O
primary O
endpoint O
of O
mean O
change O
in O
hemoglobin O
( O
baseline O
to O
Week O
13 O
) O
between O
the O
QW O
and O
the O
EDS O
groups O
( O
-0.04 O
g/dL O
";" O
95 O
% O
confidence O
interval O
: O
-0.26 O
, O
0.17 O
g/dL O
) O
. O

The O
upper O
limit O
of O
the O
95 O
% O
confidence O
interval O
was O
less O
than O
the O
prespecified O
limit O
of O
< O
0.75 O
g/dL O
, O
supporting O
noninferiority O
of O
the O
EDS O
dosing O
schedule O
. O

Reported B-Premise
adverse I-Premise
events I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
. I-Premise

A B-Premise
slight I-Premise
increase I-Premise
in I-Premise
transfusions I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
. I-Premise

Darbepoetin B-Claim
alfa I-Claim
, I-Claim
when I-Claim
administered I-Claim
synchronously I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
on I-Claim
an I-Claim
EDS I-Claim
appears I-Claim
to I-Claim
be I-Claim
similarly I-Claim
efficacious I-Claim
to I-Claim
darbepoetin I-Claim
alfa I-Claim
weekly I-Claim
dosing I-Claim
with I-Claim
no I-Claim
unexpected I-Claim
adverse I-Claim
events I-Claim
. I-Claim

This O
study O
provides O
prospective O
data O
on O
how O
multiple O
dosing O
regimens O
available O
with O
darbepoetin O
alfa O
can O
be O
synchronized O
with O
chemotherapy O
administered O
across O
a O
range O
of O
dosing O
schedules O
. O

This O
randomized O
phase O
II O
trial O
evaluated O
two O
docetaxel-based O
regimens O
to O
see O
which O
would O
be O
most O
promising O
according O
to O
overall O
response O
rate O
( O
ORR O
) O
for O
comparison O
in O
a O
phase O
III O
trial O
with O
epirubicin-cisplatin-fluorouracil O
( O
ECF O
) O
as O
first-line O
advanced O
gastric O
cancer O
therapy O
. O

Chemotherapy-naïve O
patients O
with O
measurable O
unresectable O
and/or O
metastatic O
gastric O
carcinoma O
, O
a O
performance O
status O
< O
or= O
1 O
, O
and O
adequate O
hematologic O
, O
hepatic O
, O
and O
renal O
function O
randomly O
received O
< O
or= O
eight O
3-weekly O
cycles O
of O
ECF O
( O
epirubicin O
50 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
cisplatin O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
, O
and O
fluorouracil O
[ O
FU O
] O
200 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
21 O
) O
, O
TC O
( O
docetaxel O
initially O
85 O
mg/m O
( O
2 O
) O
on O
day O
1 O
[ O
later O
reduced O
to O
75 O
mg/m O
( O
2 O
) O
as O
a O
result O
of O
toxicity O
] O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
or O
TCF O
( O
TC O
plus O
FU O
300 O
mg/m O
( O
2 O
) O
/d O
on O
days O
1 O
to O
14 O
) O
. O

Study O
objectives O
included O
response O
( O
primary O
) O
, O
survival O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

ORR B-Premise
was I-Premise
25.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
13 I-Premise
% I-Premise
to I-Premise
41 I-Premise
% I-Premise
) I-Premise
for I-Premise
ECF I-Premise
, I-Premise
18.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9 I-Premise
% I-Premise
to I-Premise
34 I-Premise
% I-Premise
) I-Premise
for I-Premise
TC I-Premise
, I-Premise
and I-Premise
36.6 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
23 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
for I-Premise
TCF I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
8.3 I-Premise
, I-Premise
11.0 I-Premise
, I-Premise
and I-Premise
10.4 I-Premise
months I-Premise
for I-Premise
ECF I-Premise
, I-Premise
TC I-Premise
, I-Premise
and I-Premise
TCF I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
acceptable I-Premise
, I-Premise
with I-Premise
one I-Premise
toxic I-Premise
death I-Premise
( I-Premise
TC I-Premise
arm I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
more I-Premise
treatment I-Premise
cycles I-Premise
with I-Premise
docetaxel I-Premise
( I-Premise
TC I-Premise
, I-Premise
49 I-Premise
% I-Premise
";" I-Premise
TCF I-Premise
, I-Premise
57 I-Premise
% I-Premise
";" I-Premise
ECF I-Premise
, I-Premise
34 I-Premise
% I-Premise
) I-Premise
. I-Premise

Global B-Claim
health I-Claim
status/QOL I-Claim
substantially I-Claim
improved I-Claim
with I-Claim
ECF I-Claim
and I-Claim
remained I-Claim
similar I-Claim
to I-Claim
baseline I-Claim
with I-Claim
both I-Claim
docetaxel I-Claim
regimens I-Claim
. I-Claim

Time B-Premise
to I-Premise
response I-Premise
and I-Premise
ORR I-Premise
favor I-Premise
TCF I-Premise
over I-Premise
TC I-Premise
for I-Premise
further I-Premise
evaluation I-Premise
, I-Premise
particularly I-Premise
in I-Premise
the I-Premise
neoadjuvant I-Premise
setting I-Premise
. I-Premise

A B-Premise
trend I-Premise
towards I-Premise
increased I-Premise
myelosuppression I-Premise
and I-Premise
infectious I-Premise
complications I-Premise
with I-Premise
TCF I-Premise
versus I-Premise
TC I-Premise
or I-Premise
ECF I-Premise
was I-Premise
observed I-Premise
. I-Premise

Increased O
attention O
has O
focused O
on O
exercise O
as O
a O
quality O
of O
life O
intervention O
for O
breast O
cancer O
survivors O
during O
and O
after O
adjuvant O
therapy O
. O

Our O
objective O
was O
to O
examine O
the O
effects O
of O
an O
oncologist O
's O
recommendation O
to O
exercise O
on O
self-reported O
exercise O
behavior O
in O
newly O
diagnosed O
breast O
cancer O
survivors O
attending O
their O
first O
adjuvant O
therapy O
consultation O
. O

Using O
a O
single-blinded O
, O
3-armed O
, O
randomized O
controlled O
trial O
, O
450 O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
receive O
an O
oncologist O
exercise O
recommendation O
only O
, O
an O
oncologist O
exercise O
recommendation O
plus O
referral O
to O
an O
exercise O
specialist O
, O
or O
usual O
care O
. O

The O
primary O
outcome O
was O
self-reported O
total O
exercise O
( O
in O
metabolic O
equivalent O
[ O
MET O
] O
hours O
per O
week O
) O
at O
5 O
weeks O
postconsultation O
. O

The O
follow-up O
assessment O
rate O
was O
73 O
% O
( O
329 O
of O
450 O
) O
. O

Intention-to-treat B-Premise
analysis I-Premise
based I-Premise
on I-Premise
participants I-Premise
with I-Premise
follow-up I-Premise
data I-Premise
indicated I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
total I-Premise
exercise I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
recommendation-only I-Premise
group I-Premise
over I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
3.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
0.7-6.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.011 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
recommendation-plus-referral I-Premise
group I-Premise
and I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.5 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.0 I-Premise
to I-Premise
4.0 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.244 I-Premise
) I-Premise
. I-Premise

Ancillary B-Premise
" I-Premise
on-treatment I-Premise
" I-Premise
analyzes I-Premise
showed I-Premise
that I-Premise
participants I-Premise
who I-Premise
recalled I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
total I-Premise
exercise I-Premise
than I-Premise
participants I-Premise
who I-Premise
did I-Premise
not I-Premise
recall I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
4.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.9-6.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
an I-Claim
oncologist I-Claim
recommendation I-Claim
may I-Claim
increase I-Claim
exercise I-Claim
behavior I-Claim
in I-Claim
newly I-Claim
diagnosed I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
, I-Claim
particularly I-Claim
if I-Claim
it I-Claim
is I-Claim
recalled I-Claim
1 I-Claim
week I-Claim
after I-Claim
the I-Claim
recommendation I-Claim
. I-Claim

Research O
has O
shown O
that O
self-directed O
stress O
management O
training O
improves O
mental O
well-being O
in O
patients O
undergoing O
chemotherapy O
. O

The O
present O
study O
extends O
this O
work O
by O
evaluating O
separate O
and O
combined O
effects O
of O
stress O
management O
training O
and O
home-based O
exercise O
. O

Following O
assessment O
of O
mental O
and O
physical O
well-being O
, O
depression O
, O
anxiety O
, O
exercise O
, O
and O
stress O
reduction O
activity O
before O
chemotherapy O
started O
, O
patients O
were O
randomized O
to O
stress O
management O
training O
( O
SM O
) O
, O
exercise O
( O
EX O
) O
, O
combined O
stress O
management O
and O
exercise O
( O
SMEX O
) O
, O
or O
usual O
care O
only O
( O
UCO O
) O
. O

Outcomes O
were O
reassessed O
6 O
and O
12 O
weeks O
after O
chemotherapy O
started O
. O

Significance O
testing O
of O
group-by-time O
interactions O
in O
286 O
patients O
who O
completed O
all O
assessments O
was O
used O
to O
evaluate O
intervention O
efficacy O
. O

Interaction B-Premise
effects I-Premise
for I-Premise
mental I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
scores I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Depression B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
linear I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.019 I-Premise
) I-Premise
, I-Premise
with I-Premise
decreases I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Anxiety B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
quadratic I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
, I-Premise
with I-Premise
trends I-Premise
for I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Additional B-Premise
analyses I-Premise
yielded I-Premise
quadratic I-Premise
interactions I-Premise
for I-Premise
exercise I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.022 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
, I-Premise
and I-Premise
for I-Premise
stress I-Premise
management I-Premise
activity I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SM I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
SM I-Premise
and I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Only B-Claim
the I-Claim
combined I-Claim
intervention I-Claim
yielded I-Claim
effects I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
these I-Claim
were I-Claim
limited I-Claim
to I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
. I-Claim

These B-Premise
findings I-Premise
are I-Premise
consistent I-Premise
with I-Premise
evidence I-Premise
that I-Premise
only I-Premise
the I-Premise
combined I-Premise
intervention I-Premise
yielded I-Premise
increases I-Premise
in I-Premise
both I-Premise
exercise I-Premise
and I-Premise
stress I-Premise
management I-Premise
activity I-Premise
. I-Premise

Future O
research O
should O
investigate O
ways O
to O
augment O
this O
intervention O
to O
enhance O
its O
benefits O
. O

To O
determine O
the O
long-term O
outcome O
and O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
patients O
with O
endometrial O
carcinoma O
( O
EC O
) O
treated O
with O
or O
without O
pelvic O
radiotherapy O
in O
the O
Post O
Operative O
Radiation O
Therapy O
in O
Endometrial O
Carcinoma O
1 O
( O
PORTEC-1 O
) O
trial O
. O

Between O
1990 O
and O
1997 O
, O
714 O
patients O
with O
stage O
IC O
grade O
1 O
to O
2 O
or O
IB O
grade O
2 O
to O
3 O
EC O
were O
randomly O
allocated O
to O
pelvic O
external-beam O
radiotherapy O
( O
EBRT O
) O
or O
no O
additional O
treatment O
( O
NAT O
) O
. O

HRQL O
was O
evaluated O
with O
the O
Short O
Form O
36-Item O
( O
SF-36 O
) O
questionnaire O
";" O
subscales O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
PR25 O
module O
for O
bowel O
and O
bladder O
symptoms O
and O
the O
OV28 O
and O
CX24 O
modules O
for O
sexual O
symptoms O
";" O
and O
demographic O
questions O
. O

Analysis O
was O
by O
intention-to-treat O
. O

Median O
follow-up O
was O
13.3 O
years O
. O

The B-Premise
15-year I-Premise
actuarial I-Premise
locoregional I-Premise
recurrence I-Premise
rates I-Premise
were I-Premise
5.8 I-Premise
% I-Premise
for I-Premise
EBRT I-Premise
versus I-Premise
15.5 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
15-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
versus I-Premise
60 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.14 I-Premise
) I-Premise
. I-Premise

Of O
the O
351 O
patients O
confirmed O
to O
be O
alive O
with O
correct O
address O
, O
246 O
( O
70 O
% O
) O
returned O
the O
questionnaire O
. O

Patients B-Premise
treated I-Premise
with I-Premise
EBRT I-Premise
reported I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
and I-Premise
clinically I-Premise
relevant I-Premise
higher I-Premise
rates I-Premise
of I-Premise
urinary I-Premise
incontinence I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
and I-Premise
fecal I-Premise
leakage I-Premise
leading I-Premise
to I-Premise
more I-Premise
limitations I-Premise
in I-Premise
daily I-Premise
activities I-Premise
. I-Premise

Increased B-Premise
symptoms I-Premise
were I-Premise
reflected I-Premise
by I-Premise
the I-Premise
frequent I-Premise
use I-Premise
of I-Premise
incontinence I-Premise
materials I-Premise
after I-Premise
EBRT I-Premise
( I-Premise
day I-Premise
and I-Premise
night I-Premise
use I-Premise
, I-Premise
42.9 I-Premise
% I-Premise
v I-Premise
15.2 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
EBRT I-Premise
reported I-Premise
lower I-Premise
scores I-Premise
on I-Premise
the I-Premise
SF-36 I-Premise
scales I-Premise
" I-Premise
physical I-Premise
functioning I-Premise
" I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
and I-Premise
" I-Premise
role-physical I-Premise
" I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

EBRT B-Claim
for I-Claim
endometrial I-Claim
cancer I-Claim
is I-Claim
associated I-Claim
with I-Claim
long-term I-Claim
urinary I-Claim
and I-Claim
bowel I-Claim
symptoms I-Claim
and I-Claim
lower I-Claim
physical I-Claim
and I-Claim
role-physical I-Claim
functioning I-Claim
, I-Claim
even I-Claim
15 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

Despite B-Claim
its I-Claim
efficacy I-Claim
in I-Claim
reducing I-Claim
locoregional I-Claim
recurrence I-Claim
, I-Claim
EBRT I-Claim
should I-Claim
be I-Claim
avoided I-Claim
in I-Claim
patients I-Claim
with I-Claim
low- I-Claim
and I-Claim
intermediate-risk I-Claim
EC I-Claim
. I-Claim

The O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O

A O
randomized O
controlled O
trial O
was O
conducted O
in O
cooperation O
with O
the O
Departments O
of O
General O
Surgery O
and O
Medical O
Psychology O
, O
University O
Hospital O
of O
Hamburg O
, O
Germany O
, O
from O
January O
1991 O
to O
January O
1993 O
. O

Consenting O
patients O
( O
N O
= O
271 O
) O
with O
a O
preliminary O
diagnosis O
of O
cancer O
of O
the O
esophagus O
, O
stomach O
, O
liver/gallbladder O
, O
pancreas O
, O
or O
colon/rectum O
were O
stratified O
by O
sex O
and O
randomly O
assigned O
to O
a O
control O
group O
that O
received O
standard O
care O
as O
provided O
on O
the O
surgical O
wards O
, O
or O
to O
an O
experimental O
group O
that O
received O
formal O
psychotherapeutic O
support O
in O
addition O
to O
routine O
care O
during O
the O
hospital O
stay O
. O

From O
June O
2003 O
to O
December O
2003 O
, O
the O
10-year O
follow-up O
was O
conducted O
. O

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

Kaplan-Meier B-Premise
survival I-Premise
curves I-Premise
demonstrated I-Premise
better I-Premise
survival I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
than I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

The B-Premise
unadjusted I-Premise
significance I-Premise
level I-Premise
for I-Premise
group I-Premise
differences I-Premise
was I-Premise
P I-Premise
= I-Premise
.0006 I-Premise
for I-Premise
survival I-Premise
to I-Premise
10 I-Premise
years I-Premise
. I-Premise

Cox B-Premise
regression I-Premise
models I-Premise
that I-Premise
took I-Premise
TNM I-Premise
staging I-Premise
or I-Premise
the I-Premise
residual I-Premise
tumor I-Premise
classification I-Premise
and I-Premise
tumor I-Premise
site I-Premise
into I-Premise
account I-Premise
also I-Premise
found I-Premise
significant I-Premise
differences I-Premise
at I-Premise
10 I-Premise
years I-Premise
. I-Premise

Secondary B-Premise
analyses I-Premise
found I-Premise
that I-Premise
differences I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
experimental I-Premise
group I-Premise
occurred I-Premise
in I-Premise
patients I-Premise
with I-Premise
stomach I-Premise
, I-Premise
pancreatic I-Premise
, I-Premise
primary I-Premise
liver I-Premise
, I-Premise
or I-Premise
colorectal I-Premise
cancer I-Premise
. I-Premise

The B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
indicate I-Claim
that I-Claim
patients I-Claim
with I-Claim
gastrointestinal I-Claim
cancer I-Claim
, I-Claim
who I-Claim
undergo I-Claim
surgery I-Claim
for I-Claim
stomach I-Claim
, I-Claim
pancreatic I-Claim
, I-Claim
primary I-Claim
liver I-Claim
, I-Claim
or I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
benefit I-Claim
from I-Claim
a I-Claim
formal I-Claim
program I-Claim
of I-Claim
psychotherapeutic I-Claim
support I-Claim
during I-Claim
the I-Claim
inpatient I-Claim
hospital I-Claim
stay I-Claim
in I-Claim
terms I-Claim
of I-Claim
long-term I-Claim
survival I-Claim
. I-Claim

Compared O
with O
placebo O
, O
prophylactic O
treatment O
with O
bisphosphonates O
reduces O
risk O
of O
skeletal O
events O
in O
patients O
with O
multiple O
myeloma O
. O

However O
, O
because O
of O
toxicity O
associated O
with O
long-term O
bisphosphonate O
treatment O
, O
establishing O
the O
lowest O
effective O
dose O
is O
important O
. O

This O
study O
compared O
the O
effect O
of O
two O
doses O
of O
pamidronate O
on O
health-related O
quality O
of O
life O
and O
skeletal O
morbidity O
in O
patients O
with O
newly O
diagnosed O
multiple O
myeloma O
. O

This O
double-blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
Denmark O
, O
Norway O
, O
and O
Sweden O
. O

Patients O
with O
multiple O
myeloma O
who O
were O
starting O
antimyeloma O
treatment O
were O
randomly O
assigned O
in O
a O
1:1 O
ratio O
to O
receive O
one O
of O
two O
doses O
of O
pamidronate O
( O
30 O
mg O
or O
90 O
mg O
) O
given O
by O
intravenous O
infusion O
once O
a O
month O
for O
at O
least O
3 O
years O
. O

Randomisation O
was O
done O
by O
use O
of O
a O
central O
, O
computerised O
minimisation O
system O
. O

Primary O
outcome O
was O
physical O
function O
after O
12 O
months O
estimated O
by O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
QLQ-C30 O
questionnaire O
( O
scale O
0-100 O
) O
. O

All O
patients O
who O
returned O
questionnaires O
at O
12 O
months O
and O
were O
still O
on O
study O
treatment O
were O
included O
in O
the O
analysis O
of O
the O
primary O
endpoint O
. O

From O
January O
, O
2001 O
, O
until O
August O
, O
2005 O
, O
504 O
patients O
were O
randomly O
assigned O
to O
pamidronate O
30 O
mg O
or O
90 O
mg O
( O
252 O
in O
each O
group O
) O
. O

157 O
patients O
in O
the O
90 O
mg O
group O
and O
156 O
in O
the O
30 O
mg O
group O
were O
included O
in O
the O
primary O
analysis O
. O

Mean B-Premise
physical I-Premise
function I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
66 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
62·9-70·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
68 I-Premise
points I-Premise
( I-Premise
64·6-71·4 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
of I-Premise
difference I-Premise
-6·6 I-Premise
to I-Premise
3·3 I-Premise
";" I-Premise
p=0·52 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
in I-Premise
patients I-Premise
who I-Premise
had I-Premise
such I-Premise
an I-Premise
event I-Premise
was I-Premise
9·2 I-Premise
months I-Premise
( I-Premise
8·1-10·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
10·2 I-Premise
months I-Premise
( I-Premise
7·3-14·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
p=0·63 I-Premise
) I-Premise
. I-Premise

In O
a O
retrospective O
analysis O
, O
eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
pamidronate I-Premise
90 I-Premise
mg I-Premise
group I-Premise
developed I-Premise
osteonecrosis I-Premise
of I-Premise
the I-Premise
jaw I-Premise
compared I-Premise
with I-Premise
two I-Premise
patients I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
. I-Premise

Monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim

Bone B-Claim
metastases I-Claim
are I-Claim
a I-Claim
common I-Claim
cause I-Claim
of I-Claim
morbidity I-Claim
in I-Claim
patients I-Claim
with I-Claim
prostate I-Claim
carcinoma I-Claim
. I-Claim

We O
studied O
the O
effect O
of O
a O
new O
bisphosphonate O
, O
zoledronic O
acid O
, O
which O
blocks O
bone O
destruction O
, O
on O
skeletal O
complications O
in O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

Patients O
with O
hormone-refractory O
prostate O
cancer O
and O
a O
history O
of O
bone O
metastases O
were O
randomly O
assigned O
to O
a O
double-blind O
treatment O
regimen O
of O
intravenous O
zoledronic O
acid O
at O
4 O
mg O
( O
N O
= O
214 O
) O
, O
zoledronic O
acid O
at O
8 O
mg O
( O
subsequently O
reduced O
to O
4 O
mg O
";" O
8/4 O
) O
( O
N O
= O
221 O
) O
, O
or O
placebo O
( O
N O
= O
208 O
) O
every O
3 O
weeks O
for O
15 O
months O
. O

Proportions O
of O
patients O
with O
skeletal-related O
events O
, O
time O
to O
the O
first O
skeletal-related O
event O
, O
skeletal O
morbidity O
rate O
, O
pain O
and O
analgesic O
scores O
, O
disease O
progression O
, O
and O
safety O
were O
assessed O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Approximately O
38 O
% O
of O
patients O
who O
received O
zoledronic O
acid O
at O
4 O
mg O
, O
28 O
% O
who O
received O
zoledronic O
acid O
at O
8/4 O
mg O
, O
and O
31 O
% O
who O
received O
placebo O
completed O
the O
study O
. O

A B-Premise
greater I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
had I-Premise
skeletal-related I-Premise
events I-Premise
than I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
44.2 I-Premise
% I-Premise
versus I-Premise
33.2 I-Premise
% I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-11.0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-20.3 I-Premise
% I-Premise
to I-Premise
-1.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.021 I-Premise
) I-Premise
or I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
38.5 I-Premise
% I-Premise
";" I-Premise
difference I-Premise
versus I-Premise
placebo I-Premise
= I-Premise
-5.8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-15.1 I-Premise
% I-Premise
to I-Premise
3.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.222 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
was I-Premise
321 I-Premise
days I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
was I-Premise
not I-Premise
reached I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
363 I-Premise
days I-Premise
for I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.491 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
urinary I-Premise
markers I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
urinary I-Premise
markers I-Premise
of I-Premise
bone I-Premise
resorption I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
decreased I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
either I-Premise
dose I-Premise
( I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

Pain B-Premise
and I-Premise
analgesic I-Premise
scores I-Premise
increased I-Premise
more I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
, I-Premise
but O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
disease I-Premise
progression I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
or I-Premise
quality-of-life I-Premise
scores I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

Zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
given I-Claim
as I-Claim
a I-Claim
15-minute I-Claim
infusion I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
but O
the B-Claim
8-mg I-Claim
dose I-Claim
was I-Claim
associated I-Claim
with I-Claim
renal I-Claim
function I-Claim
deterioration I-Claim
. I-Claim

Zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
reduced I-Claim
skeletal-related I-Claim
events I-Claim
in I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

For O
patients O
undergoing O
oncologic O
surgery O
, O
the O
quality O
of O
life O
( O
QoL O
) O
is O
generally O
accepted O
as O
an O
important O
outcome O
parameter O
in O
addition O
to O
long-term O
survival O
, O
mortality O
and O
complication O
rates O
. O

This O
study O
focussed O
on O
the O
QoL O
in O
patients O
after O
oesophagectomy O
for O
cancer O
, O
comparing O
the O
method O
of O
reconstruction O
( O
narrow O
gastric O
tube O
vs O
whole O
stomach O
) O
. O

In O
a O
prospective O
randomised O
single-centre O
study O
from O
2007 O
to O
2008 O
, O
104 O
patients O
underwent O
oesophagectomy O
for O
cancer O
. O

To O
assess O
the O
QoL O
, O
a O
questionnaire O
in O
reference O
to O
the O
EORTC-QLQ-C30 O
and O
the O
QLQ-OES24 O
was O
administered O
at O
3 O
weeks O
, O
6 O
months O
and O
1 O
year O
after O
surgery O
. O

Clinical O
data O
were O
collected O
prospectively O
, O
and O
follow-up O
was O
performed O
regularly O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
( I-Premise
NGT I-Premise
group I-Premise
, I-Premise
n=52 I-Premise
) I-Premise
and I-Premise
the I-Premise
whole-stomach I-Premise
group I-Premise
( I-Premise
WS I-Premise
group I-Premise
, I-Premise
n=52 I-Premise
) I-Premise
with I-Premise
regard I-Premise
to I-Premise
patient I-Premise
and I-Premise
cancer I-Premise
characteristics I-Premise
, I-Premise
operative I-Premise
procedure I-Premise
, I-Premise
postoperative I-Premise
intensive I-Premise
care I-Premise
unit I-Premise
( I-Premise
ICU I-Premise
) I-Premise
hospitalisation I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
postoperative I-Premise
complication I-Premise
, I-Premise
there I-Premise
were I-Premise
more I-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
reflux I-Premise
oesophagitis I-Premise
and I-Premise
impairment I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
in I-Premise
the I-Premise
WS I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
QoL I-Premise
investigation I-Premise
, I-Premise
the I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
dropped I-Premise
for I-Premise
all I-Premise
patients I-Premise
at I-Premise
3 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Slowly O
, O
recovery B-Premise
was I-Premise
found I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
NGT I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
better I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
. I-Premise

Patients B-Claim
who I-Claim
underwent I-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
develop I-Claim
less I-Claim
postoperative I-Claim
digestive I-Claim
tract I-Claim
complications I-Claim
, I-Claim
and I-Claim
have I-Claim
a I-Claim
quicker I-Claim
recovery I-Claim
and I-Claim
a I-Claim
better I-Claim
QoL I-Claim
during I-Claim
the I-Claim
follow-up I-Claim
period I-Claim
. I-Claim

Further O
investigation O
and O
data O
collection O
will O
allow O
the O
assessment O
of O
this O
procedure O
beyond O
1 O
year O
after O
operation O
. O

To O
carry O
out O
a O
preliminary O
trial O
evaluating O
the O
effectiveness O
of O
two O
types O
of O
homeopathy O
for O
the O
treatment O
of O
menopausal O
symptoms O
in O
breast O
cancer O
survivors O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
. O

Private O
medical O
clinic O
, O
Seattle O
, O
WA O
. O

Women O
with O
a O
history O
of O
breast O
cancer O
who O
had O
completed O
all O
surgery O
, O
chemotherapy O
, O
and O
radiation O
treatment O
and O
who O
had O
an O
average O
of O
at O
least O
three O
hot O
flashes O
per O
day O
for O
the O
previous O
month O
. O

Subjects O
were O
randomized O
to O
receive O
either O
an O
individualized O
homeopathic O
single O
remedy O
, O
a O
homeopathic O
combination O
medicine O
, O
or O
placebo O
. O

Patients O
were O
seen O
by O
homeopathic O
providers O
every O
2 O
months O
for O
1 O
year O
. O

Hot O
flash O
frequency O
and O
severity O
, O
Kupperman O
Menopausal O
Index O
( O
KMI O
) O
, O
Short O
Form O
36 O
( O
SF-36 O
) O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
found I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
severity I-Premise
score I-Premise
, I-Premise
although B-Premise
there I-Premise
was I-Premise
a I-Premise
positive I-Premise
trend I-Premise
in I-Premise
the I-Premise
single I-Premise
remedy I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
3 I-Premise
months I-Premise
of I-Premise
the I-Premise
study I-Premise
( I-Premise
p I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
general I-Premise
health I-Premise
score I-Premise
in I-Premise
both I-Premise
homeopathy I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
on I-Premise
the I-Premise
SF-36 I-Premise
after I-Premise
1 I-Premise
year I-Premise
was I-Premise
found I-Premise
. I-Premise

Evidence B-Premise
of I-Premise
a I-Premise
homeopathic I-Premise
" I-Premise
drug I-Premise
proving I-Premise
" I-Premise
in I-Premise
the I-Premise
subjects I-Premise
receiving I-Premise
the I-Premise
homeopathic I-Premise
combination I-Premise
medicine I-Premise
who I-Premise
were I-Premise
not I-Premise
taking I-Premise
tamoxifen I-Premise
also I-Premise
was I-Premise
found I-Premise
. I-Premise

Small B-Claim
sample I-Claim
size I-Claim
precludes I-Claim
definitive I-Claim
answers I-Claim
, I-Claim
but B-Claim
results I-Claim
from I-Claim
this I-Claim
preliminary I-Claim
trial I-Claim
suggest I-Claim
that I-Claim
homeopathy I-Claim
may I-Claim
be I-Claim
of I-Claim
value I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
menopausal I-Claim
symptoms I-Claim
and I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
especially I-Claim
in I-Claim
those I-Claim
women I-Claim
not I-Claim
on I-Claim
tamoxifen I-Claim
. I-Claim

Larger B-Claim
studies I-Claim
should I-Claim
be I-Claim
carried I-Claim
out I-Claim
that I-Claim
also I-Claim
include I-Claim
healthy I-Claim
women I-Claim
who I-Claim
want I-Claim
to I-Claim
avoid I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
. I-Claim

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

This O
trial O
was O
undertaken O
to O
determine O
whether O
adjuvant O
treatment O
with O
the O
metalloproteinase O
inhibitor O
marimastat O
could O
prolong O
survival O
in O
responding O
patients O
with O
SCLC O
after O
chemotherapy O
. O

SCLC O
patients O
in O
complete O
or O
partial O
remission O
were O
eligible O
. O

They O
were O
stratified O
by O
radiotherapy O
( O
early O
, O
late O
, O
or O
none O
) O
, O
stage O
( O
extensive O
or O
limited O
) O
, O
response O
( O
complete O
or O
partial O
) O
, O
and O
cooperative O
group O
( O
National O
Cancer O
Institute O
of O
Canada-Clinical O
Trials O
Group O
or O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
) O
. O

They O
were O
randomized O
to O
receive O
marimastat O
10 O
mg O
or O
placebo O
orally O
bid O
for O
up O
to O
2 O
years O
. O

There O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O

Stage O
was O
limited O
for O
279 O
patients O
( O
52 O
% O
) O
and O
extensive O
for O
253 O
( O
48 O
% O
) O
. O

Best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4.4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.81 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survivals I-Premise
for I-Premise
marimastat I-Premise
and I-Premise
placebo I-Premise
patients I-Premise
were I-Premise
9.3 I-Premise
months I-Premise
and I-Premise
9.7 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.90 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
generally I-Premise
limited I-Premise
to I-Premise
musculoskeletal I-Premise
symptoms I-Premise
( I-Premise
18 I-Premise
% I-Premise
grade I-Premise
3/4 I-Premise
for I-Premise
marimastat I-Premise
) I-Premise
. I-Premise

Dose B-Premise
modifications I-Premise
for I-Premise
musculoskeletal I-Premise
toxicity I-Premise
were I-Premise
required I-Premise
in I-Premise
90 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
on I-Premise
the I-Premise
marimastat I-Premise
arm I-Premise
, I-Premise
and I-Premise
87 I-Premise
( I-Premise
32 I-Premise
% I-Premise
) I-Premise
permanently I-Premise
stopped I-Premise
marimastat I-Premise
because I-Premise
of I-Premise
toxicity I-Premise
. I-Premise

Patients B-Premise
on I-Premise
marimastat I-Premise
had I-Premise
significantly I-Premise
poorer I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
marimastat I-Claim
after I-Claim
induction I-Claim
therapy I-Claim
for I-Claim
SCLC I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
improved I-Claim
survival I-Claim
and I-Claim
had I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Morbidity B-Claim
associated I-Claim
with I-Claim
wound I-Claim
complications I-Claim
may I-Claim
translate I-Claim
into I-Claim
disability I-Claim
and I-Claim
quality-of-life I-Claim
disadvantages I-Claim
for I-Claim
patients I-Claim
treated I-Claim
with I-Claim
radiotherapy I-Claim
( I-Claim
RT I-Claim
) I-Claim
for I-Claim
soft I-Claim
tissue I-Claim
sarcoma I-Claim
( I-Claim
STS I-Claim
) I-Claim
of I-Claim
the I-Claim
extremities I-Claim
. I-Claim

Functional O
outcome O
and O
health O
status O
of O
extremity O
STS O
patients O
randomized O
in O
a O
phase O
III O
trial O
comparing O
preoperative O
versus O
postoperative O
RT O
is O
described O
. O

One O
hundred O
ninety O
patients O
with O
extremity O
STS O
were O
randomized O
after O
stratification O
by O
tumor O
size O
dichotomized O
at O
10 O
cm O
. O

Function O
and O
quality O
of O
life O
were O
measured O
by O
the O
Musculoskeletal O
Tumor O
Society O
Rating O
Scale O
( O
MSTS O
) O
, O
the O
Toronto O
Extremity O
Salvage O
Score O
( O
TESS O
) O
, O
and O
the O
Short O
Form-36 O
( O
SF-36 O
) O
at O
randomization O
, O
6 O
weeks O
, O
and O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
months O
after O
surgery O
. O

One O
hundred O
eighty-five O
patients O
had O
function O
data O
. O

Patients B-Premise
treated I-Premise
with I-Premise
postoperative I-Premise
RT I-Premise
had I-Premise
better I-Premise
function I-Premise
with I-Premise
higher I-Premise
MSTS I-Premise
( I-Premise
25.8 I-Premise
v I-Premise
21.3 I-Premise
, I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
, I-Premise
TESS I-Premise
( I-Premise
69.8 I-Premise
v I-Premise
60.6 I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
SF-36 I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
67.7 I-Premise
v I-Premise
58.5 I-Premise
, I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
scores I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

There O
were O
no O
differences O
at O
later O
time O
points O
. O

Scores B-Premise
on I-Premise
the I-Premise
physical I-Premise
function I-Premise
, I-Premise
role-physical I-Premise
, I-Premise
and I-Premise
general I-Premise
health I-Premise
subscales I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
Canadian I-Premise
normative I-Premise
data I-Premise
at I-Premise
all I-Premise
time I-Premise
points I-Premise
. I-Premise

After O
treatment O
arm O
was O
controlled O
for O
, O
MSTS O
change O
scores O
were O
predicted O
by O
a O
lower-extremity O
tumor O
, O
a O
large O
resection O
specimen O
, O
and O
motor O
nerve O
sacrifice O
";" O
TESS O
change O
scores O
were O
predicted O
by O
lower-extremity O
tumor O
and O
prior O
incomplete O
excision O
. O

When B-Premise
wound I-Premise
complication I-Premise
was I-Premise
included I-Premise
in I-Premise
the I-Premise
model I-Premise
, I-Premise
patients I-Premise
with I-Premise
complications I-Premise
had I-Premise
lower I-Premise
MSTS I-Premise
and I-Premise
TESS I-Premise
scores I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
. I-Premise

The B-Claim
timing I-Claim
of I-Claim
RT I-Claim
has I-Claim
minimal I-Claim
impact I-Claim
on I-Claim
the I-Claim
function I-Claim
of I-Claim
STS I-Claim
patients I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
surgery I-Claim
. O

Tumor B-Claim
characteristics I-Claim
and I-Claim
wound I-Claim
complications I-Claim
have I-Claim
a I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
patient I-Claim
function I-Claim
. I-Claim

This O
randomized O
controlled O
trial O
assessed O
the O
effect O
of O
a O
SMART O
( O
Stress O
Management O
and O
Resiliency O
Training O
) O
program O
among O
25 O
women O
diagnosed O
with O
breast O
cancer O
. O

Resilience O
, O
perceived O
stress O
, O
anxiety O
, O
and O
quality O
of O
life O
improved O
at O
12 O
weeks O
in O
the O
active O
but O
not O
the O
control O
arm O
. O

A O
brief O
training O
in O
the O
SMART O
program O
can O
enhance O
resilience O
and O
quality O
of O
life O
and O
decrease O
stress O
and O
anxiety O
. O

Patients O
with O
breast O
cancer O
experience O
stress O
and O
anxiety O
related O
to O
their O
diagnosis O
, O
with O
resulting O
lower O
quality O
of O
life O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effect O
of O
a O
SMART O
( O
Stress O
Management O
and O
Resiliency O
Training O
) O
program O
for O
increasing O
resiliency O
and O
for O
decreasing O
stress O
and O
anxiety O
among O
mentors O
who O
themselves O
were O
previously O
diagnosed O
with O
breast O
cancer O
. O

The O
program O
consisted O
of O
two O
90-minute O
group O
training O
sessions O
, O
a O
brief O
individual O
session O
, O
and O
3 O
follow-up O
telephone O
calls O
. O

Twenty-four O
mentors O
at O
Mayo O
Clinic O
in O
Rochester O
, O
Minnesota O
, O
were O
randomized O
in O
a O
single-blind O
, O
wait-list O
controlled O
clinical O
trial O
to O
either O
the O
SMART O
intervention O
or O
a O
control O
group O
for O
12 O
weeks O
. O

Primary O
outcome O
measures O
assessed O
at O
baseline O
and O
at O
week O
12 O
included O
the O
Connor O
Davidson O
Resilience O
Scale O
, O
Perceived O
Stress O
Scale O
, O
Smith O
Anxiety O
Scale O
, O
and O
Linear O
Analog O
Self O
Assessment O
Scale O
. O

Twenty O
patients O
completed O
the O
study O
. O

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
resilience I-Premise
, I-Premise
perceived I-Premise
stress I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
, I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
study I-Premise
arm I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
these I-Premise
measures I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
a I-Claim
brief I-Claim
, I-Claim
predominantly I-Claim
group-based I-Claim
resilience I-Claim
training I-Claim
intervention I-Claim
is I-Claim
feasible I-Claim
in I-Claim
patients I-Claim
with I-Claim
previous I-Claim
breast I-Claim
cancer I-Claim
";" I-Claim
also I-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
efficacious I-Claim
. I-Claim

Both O
gemcitabine O
( O
GEM O
) O
and O
fluoropyrimidines O
are O
valuable O
treatment O
for O
advanced O
pancreatic O
cancer O
. O

This O
open-label O
study O
was O
designed O
to O
compare O
the O
overall O
survival O
( O
OS O
) O
of O
patients O
randomly O
assigned O
to O
GEM O
alone O
or O
GEM O
plus O
capecitabine O
( O
GEM-CAP O
) O
. O

Patients O
with O
previously O
untreated O
histologically O
or O
cytologically O
proven O
locally O
advanced O
or O
metastatic O
carcinoma O
of O
the O
pancreas O
with O
a O
performance O
status O
< O
or= O
2 O
were O
recruited O
. O

Patients O
were O
randomly O
assigned O
to O
GEM O
or O
GEM-CAP O
. O

The O
primary O
outcome O
measure O
was O
survival O
. O

Meta-analysis O
of O
published O
studies O
was O
also O
conducted O
. O

Between O
May O
2002 O
and O
January O
2005 O
, O
533 O
patients O
were O
randomly O
assigned O
to O
GEM O
( O
n O
= O
266 O
) O
and O
GEM-CAP O
( O
n O
= O
267 O
) O
arms O
. O

GEM-CAP B-Premise
significantly I-Premise
improved I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
19.1 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.78 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.66 I-Premise
to I-Premise
0.93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
OS I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.72 I-Premise
to I-Premise
1.02 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.08 I-Premise
) I-Premise
compared I-Premise
with I-Premise
GEM I-Premise
alone I-Premise
. I-Premise

This B-Premise
trend I-Premise
for I-Premise
OS I-Premise
benefit I-Premise
for I-Premise
GEM-CAP I-Premise
was I-Premise
consistent I-Premise
across I-Premise
different I-Premise
prognostic I-Premise
subgroups I-Premise
according I-Premise
to I-Premise
baseline I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
stage I-Premise
and I-Premise
performance I-Premise
status I-Premise
) I-Premise
and I-Premise
remained I-Premise
after I-Premise
adjusting I-Premise
for I-Premise
these I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
P I-Premise
= I-Premise
.077 I-Premise
) I-Premise
. I-Premise

Moreover O
, O
the B-Premise
meta-analysis I-Premise
of I-Premise
two I-Premise
additional I-Premise
studies I-Premise
involving I-Premise
935 I-Premise
patients I-Premise
showed I-Premise
a I-Premise
significant I-Premise
survival I-Premise
benefit I-Premise
in I-Premise
favor I-Premise
of I-Premise
GEM-CAP I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
0.98 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
with I-Premise
no I-Premise
intertrial I-Premise
heterogeneity I-Premise
. I-Premise

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
our I-Claim
trial I-Claim
and I-Claim
the I-Claim
meta-analysis I-Claim
, I-Claim
GEM-CAP I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
one I-Claim
of I-Claim
the I-Claim
standard I-Claim
first-line I-Claim
options I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
and I-Claim
metastatic I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

The O
World O
Health O
Organization O
( O
WHO O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first-line O
therapy O
, O
so-called O
" O
weak O
" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second-line O
therapy O
, O
and O
so-called O
" O
strong O
" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third-line O
therapy O
. O

However O
, O
these O
guidelines O
can O
be O
questioned O
with O
regard O
to O
the O
extent O
of O
efficacy O
as O
well O
as O
the O
rationale O
for O
not O
using O
strong O
opioids O
as O
first-line O
treatment O
, O
especially O
in O
terminal O
cancer O
patients O
. O

The O
purpose O
of O
this O
randomized O
study O
was O
to O
prospectively O
compare O
the O
efficacy O
and O
tolerability O
of O
strong O
opioids O
as O
first-line O
agents O
with O
the O
recommendations O
of O
the O
WHO O
in O
terminal O
cancer O
patients O
. O

One O
hundred O
patients O
with O
mild-moderate O
pain O
were O
randomized O
to O
treatment O
according O
to O
WHO O
guidelines O
or O
to O
treatment O
with O
strong O
opioids O
. O

Evaluated O
outcomes O
included O
pain O
intensity O
, O
need O
for O
change O
in O
therapy O
, O
quality O
of O
life O
, O
Karnofsky O
Performance O
Status O
, O
general O
condition O
of O
the O
patient O
, O
and O
adverse O
events O
. O

No B-Premise
between-treatment I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
changes I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
performance I-Premise
status I-Premise
, I-Premise
but O
patients B-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
had I-Premise
significantly I-Premise
better I-Premise
pain I-Premise
relief I-Premise
than I-Premise
patients I-Premise
treated I-Premise
according I-Premise
to I-Premise
WHO I-Premise
guidelines I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

Additionally B-Premise
, I-Premise
patients I-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
required I-Premise
significantly I-Premise
fewer I-Premise
changes I-Premise
in I-Premise
therapy I-Premise
, I-Premise
had I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
when I-Premise
a I-Premise
change I-Premise
was I-Premise
initiated I-Premise
, I-Premise
and I-Premise
reported I-Premise
greater I-Premise
satisfaction I-Premise
with I-Premise
treatment I-Premise
than I-Premise
the I-Premise
comparator I-Premise
group I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

Strong B-Claim
opioids I-Claim
were I-Claim
safe I-Claim
and I-Claim
well-tolerated I-Claim
, I-Claim
with I-Claim
no I-Claim
development I-Claim
of I-Claim
tolerance I-Claim
or I-Claim
serious I-Claim
adverse I-Claim
events I-Claim
. I-Claim

These B-Claim
data I-Claim
suggest I-Claim
the I-Claim
utility I-Claim
of I-Claim
strong I-Claim
opioids I-Claim
for I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
pain I-Claim
in I-Claim
patients I-Claim
with I-Claim
terminal I-Claim
cancer I-Claim
. I-Claim

It O
is O
not O
clear O
whether O
the O
administration O
of O
radioiodine O
provides O
any O
benefit O
to O
patients O
with O
low-risk O
thyroid O
cancer O
after O
a O
complete O
surgical O
resection O
. O

The O
administration O
of O
the O
smallest O
possible O
amount O
of O
radioiodine O
would O
improve O
care O
. O

In O
our O
randomized O
, O
phase O
3 O
trial O
, O
we O
compared O
two O
thyrotropin-stimulation O
methods O
( O
thyroid O
hormone O
withdrawal O
and O
use O
of O
recombinant O
human O
thyrotropin O
) O
and O
two O
radioiodine O
( O
( O
131 O
) O
I O
) O
doses O
( O
i.e. O
, O
administered O
activities O
) O
( O
1.1 O
GBq O
and O
3.7 O
GBq O
) O
in O
a O
2-by-2 O
design O
. O

Inclusion O
criteria O
were O
an O
age O
of O
18 O
years O
or O
older O
";" O
total O
thyroidectomy O
for O
differentiated O
thyroid O
carcinoma O
";" O
tumor-node-metastasis O
( O
TNM O
) O
stage O
, O
ascertained O
on O
pathological O
examination O
( O
p O
) O
of O
a O
surgical O
specimen O
, O
of O
pT1 O
( O
with O
tumor O
diameter O
≤1 O
cm O
) O
and O
N1 O
or O
Nx O
, O
pT1 O
( O
with O
tumor O
diameter O
> O
1 O
to O
2 O
cm O
) O
and O
any O
N O
stage O
, O
or O
pT2N0 O
";" O
absence O
of O
distant O
metastasis O
";" O
and O
no O
iodine O
contamination O
. O

Thyroid O
ablation O
was O
assessed O
8 O
months O
after O
radioiodine O
administration O
by O
neck O
ultrasonography O
and O
measurement O
of O
recombinant O
human O
thyrotropin-stimulated O
thyroglobulin O
. O

Comparisons O
were O
based O
on O
an O
equivalence O
framework O
. O

There O
were O
752 O
patients O
enrolled O
between O
2007 O
and O
2010 O
";" O
92 O
% O
had O
papillary O
cancer O
. O

There B-Premise
were I-Premise
no I-Premise
unexpected I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
. I-Premise

In B-Premise
the I-Premise
684 I-Premise
patients I-Premise
with I-Premise
data I-Premise
that I-Premise
could I-Premise
be I-Premise
evaluated I-Premise
, I-Premise
ultrasonography I-Premise
of I-Premise
the I-Premise
neck I-Premise
was I-Premise
normal I-Premise
in I-Premise
652 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
stimulated I-Premise
thyroglobulin I-Premise
level I-Premise
was I-Premise
1.0 I-Premise
ng I-Premise
per I-Premise
milliliter I-Premise
or I-Premise
less I-Premise
in I-Premise
621 I-Premise
of I-Premise
the I-Premise
652 I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
without I-Premise
detectable I-Premise
thyroglobulin I-Premise
antibodies I-Premise
. I-Premise

Thyroid B-Premise
ablation I-Premise
was I-Premise
complete I-Premise
in I-Premise
631 I-Premise
of I-Premise
the I-Premise
684 I-Premise
patients I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
ablation I-Premise
rate I-Premise
was I-Premise
equivalent I-Premise
between I-Premise
the I-Premise
( I-Premise
131 I-Premise
) I-Premise
I I-Premise
doses I-Premise
and I-Premise
between I-Premise
the I-Premise
thyrotropin-stimulation I-Premise
methods I-Premise
. I-Premise

The B-Claim
use I-Claim
of I-Claim
recombinant I-Claim
human I-Claim
thyrotropin I-Claim
and I-Claim
low-dose I-Claim
( I-Claim
1.1 I-Claim
GBq I-Claim
) I-Claim
postoperative I-Claim
radioiodine I-Claim
ablation I-Claim
may I-Claim
be I-Claim
sufficient I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
low-risk I-Claim
thyroid I-Claim
cancer I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
toxicity O
and O
efficacy O
of O
radiation O
therapy O
( O
RT O
) O
for O
localized O
carcinoma O
of O
the O
prostate O
, O
using O
a O
hypofractionated O
( O
55 O
Gy/20 O
fractions/4 O
weeks O
) O
vs. O
a O
conventionally O
fractionated O
( O
64 O
Gy/32 O
fractions/6.5 O
weeks O
) O
dose O
schedule O
. O

A O
total O
of O
217 O
patients O
were O
randomized O
to O
either O
the O
hypofractionated O
( O
108 O
patients O
) O
or O
the O
conventional O
( O
109 O
patients O
) O
dose O
schedule O
, O
with O
planning O
with O
two-dimensional O
( O
2D O
) O
CT O
scan O
planning O
methodology O
in O
the O
majority O
of O
cases O
. O

All O
patients O
were O
followed O
for O
a O
median O
of O
48 O
( O
6-108 O
) O
months O
. O

Gastrointestinal O
( O
GI O
) O
and O
genitourinary O
( O
GU O
) O
toxicity O
was O
evaluated O
before O
RT O
and O
after O
its O
completion O
using O
modified O
late O
effects O
of O
normal O
tissue-subjective O
, O
objective O
, O
management O
, O
analytic O
( O
LENT-SOMA O
) O
scales O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
sexual O
function O
questionnaire O
. O

Efficacy O
of O
RT O
based O
on O
clinical O
, O
radiologic O
, O
and O
prostate-specific O
antigen O
data O
were O
also O
evaluated O
at O
baseline O
and O
after O
RT O
. O

Gastrointestinal B-Premise
and I-Premise
GU I-Premise
toxicity I-Premise
persisted I-Premise
5 I-Premise
years I-Premise
after I-Premise
RT I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
dose I-Premise
schedules I-Premise
other I-Premise
than I-Premise
in I-Premise
regard I-Premise
to I-Premise
urgency I-Premise
of I-Premise
defecation I-Premise
. I-Premise

However B-Premise
, I-Premise
1-month I-Premise
GI I-Premise
toxicity I-Premise
was I-Premise
not I-Premise
only I-Premise
worse I-Premise
in I-Premise
patients I-Premise
with I-Premise
the I-Premise
hypofractionated I-Premise
RT I-Premise
schedule I-Premise
but I-Premise
also I-Premise
adversely I-Premise
affected I-Premise
daily I-Premise
activities I-Premise
. I-Premise

Nadir B-Premise
prostate-specific I-Premise
antigen I-Premise
values I-Premise
occurred I-Premise
at I-Premise
a I-Premise
median I-Premise
of I-Premise
18.0 I-Premise
( I-Premise
3.0-54.0 I-Premise
) I-Premise
months I-Premise
after I-Premise
RT I-Premise
. I-Premise

A B-Premise
total I-Premise
of I-Premise
76 I-Premise
biochemical I-Premise
relapses I-Premise
, I-Premise
with I-Premise
or I-Premise
without I-Premise
clinical I-Premise
relapses I-Premise
, I-Premise
have I-Premise
occurred I-Premise
since I-Premise
";" I-Premise
of I-Premise
these I-Premise
, I-Premise
37 I-Premise
were I-Premise
in I-Premise
the I-Premise
hypofractionated I-Premise
and I-Premise
39 I-Premise
in I-Premise
the I-Premise
conventional I-Premise
schedule I-Premise
. I-Premise

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

Radiation B-Claim
therapy I-Claim
for I-Claim
prostate I-Claim
carcinoma I-Claim
causes I-Claim
persistent I-Claim
GI I-Claim
toxicity I-Claim
that I-Claim
is I-Claim
largely I-Claim
independent I-Claim
of I-Claim
the I-Claim
two I-Claim
dose I-Claim
schedules I-Claim
. I-Claim

The B-Claim
hypofractionated I-Claim
schedule I-Claim
is I-Claim
equivalent I-Claim
in I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
conventional I-Claim
schedule I-Claim
. I-Claim

To O
assess O
the O
effectiveness O
of O
mindfulness-based O
stress O
reduction O
( O
MBSR O
) O
for O
mood O
, O
breast- O
and O
endocrine-specific O
quality O
of O
life O
, O
and O
well-being O
after O
hospital O
treatment O
in O
women O
with O
stage O
0 O
to O
III O
breast O
cancer O
. O

A O
randomized O
, O
wait-listed O
, O
controlled O
trial O
was O
carried O
out O
in O
229 O
women O
after O
surgery O
, O
chemotherapy O
, O
and O
radiotherapy O
for O
breast O
cancer O
. O

Patients O
were O
randomly O
assigned O
to O
the O
8-week O
MBSR O
program O
or O
standard O
care O
. O

Profile O
of O
Mood O
States O
( O
POMS O
";" O
primary O
outcome O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-Endocrine O
Symptoms O
( O
FACT-ES O
) O
scales O
and O
the O
WHO O
five-item O
well-being O
questionnaire O
( O
WHO-5 O
) O
evaluated O
mood O
, O
quality O
of O
life O
, O
and O
well-being O
at O
weeks O
0 O
, O
8 O
, O
and O
12 O
. O

For O
each O
outcome O
measure O
, O
a O
repeated-measures O
analysis O
of O
variance O
model O
, O
which O
incorporated O
week O
0 O
measurements O
as O
a O
covariate O
, O
was O
used O
to O
compare O
treatment O
groups O
at O
8 O
and O
12 O
weeks O
. O

There B-Premise
were I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
outcome I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
at I-Premise
both I-Premise
8 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
( I-Premise
except I-Premise
as I-Premise
indicated I-Premise
) I-Premise
for I-Premise
POMS I-Premise
total I-Premise
mood I-Premise
disturbance I-Premise
( I-Premise
and I-Premise
its I-Premise
subscales I-Premise
of I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
anger I-Premise
[ I-Premise
12 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
vigor I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
confusion I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
, I-Premise
FACT-ES I-Premise
, I-Premise
( I-Premise
and I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
subscales I-Premise
of I-Premise
physical I-Premise
, I-Premise
social I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
emotional I-Premise
, I-Premise
and I-Premise
functional I-Premise
well-being I-Premise
) I-Premise
, I-Premise
and I-Premise
WHO-5 I-Premise
. I-Premise

MSBR B-Premise
improved I-Premise
mood I-Premise
, I-Premise
breast- I-Premise
and I-Premise
endocrine-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
well-being I-Premise
more I-Premise
effectively I-Premise
than I-Premise
standard I-Premise
care I-Premise
in I-Premise
women I-Premise
with I-Premise
stage I-Premise
0 I-Premise
to I-Premise
III I-Premise
breast I-Premise
cancer I-Premise
, I-Premise
and I-Premise
these I-Premise
results I-Premise
persisted I-Premise
at I-Premise
three I-Premise
months I-Premise
. I-Premise

To B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
MBSR I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long-term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim

MBSR B-Claim
is I-Claim
recommended I-Claim
to I-Claim
support I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

This O
trial O
was O
conducted O
to O
determine O
whether O
high-dose O
fluorouracil O
( O
FU O
) O
given O
as O
a O
weekly O
24-hour O
infusion O
is O
more O
active O
than O
bolus O
FU O
+ O
leucovorin O
( O
LV O
) O
, O
and O
whether O
high-dose O
infusional O
FU O
can O
be O
modulated O
by O
LV O
. O

A O
total O
of O
497 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
were O
randomly O
assigned O
to O
receive O
bolus O
FU O
425 O
mg/m2 O
intravenously O
+ O
LV O
20 O
mg/m2 O
on O
days O
1 O
to O
5 O
and O
repeated O
on O
day O
28 O
( O
FU O
+ O
LV O
) O
, O
or O
FU O
2600 O
mg/m2 O
as O
a O
24-hour O
infusion O
alone O
( O
FU24h O
) O
or O
in O
combination O
with O
500 O
mg/m2 O
LV O
( O
FU24h O
+ O
LV O
) O
-all O
given O
weekly O
x6 O
followed O
by O
a O
2-week O
rest O
period O
. O

Survival O
was O
the O
major O
study O
end O
point O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.2 I-Premise
to I-Premise
15.0 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
13.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.4 I-Premise
to I-Premise
15.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13.7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.0 I-Premise
to I-Premise
16.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.724 I-Premise
) I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
4.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
4.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
5.0 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
5.6 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.4 I-Premise
to I-Premise
6.7 I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.029 I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rates I-Premise
in I-Premise
the I-Premise
subgroup I-Premise
of I-Premise
patients I-Premise
with I-Premise
measurable I-Premise
disease I-Premise
were I-Premise
12 I-Premise
% I-Premise
, I-Premise
10 I-Premise
% I-Premise
, I-Premise
and I-Premise
17 I-Premise
% I-Premise
for I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
FU24h I-Premise
, I-Premise
and I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
respectively I-Premise
( I-Premise
not I-Premise
significant I-Premise
) I-Premise
. I-Premise

Occurrence B-Premise
of I-Premise
grade I-Premise
3 I-Premise
and I-Premise
4 I-Premise
diarrhea I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
FU24h I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
or I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
arms I-Premise
";" I-Premise
however B-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
11 I-Premise
% I-Premise
in I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
v I-Premise
3 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
v I-Premise
5 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arms I-Premise
) I-Premise
and I-Premise
hematologic I-Premise
toxicity I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
bolus I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
. I-Premise

Global B-Claim
quality I-Claim
of I-Claim
life I-Claim
did I-Claim
not I-Claim
differ I-Claim
within I-Claim
the I-Claim
three I-Claim
arms I-Claim
. I-Claim

Neither B-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
nor I-Claim
FU24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

Leucovorin B-Claim
increases I-Claim
PFS I-Claim
if I-Claim
added I-Claim
to I-Claim
FU24h I-Claim
, I-Claim
but I-Claim
increases I-Claim
toxicity I-Claim
. I-Claim

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

The O
importance O
of O
parallel O
evaluation O
of O
survival O
and O
quality O
of O
life O
( O
QoL O
) O
has O
been O
recognized O
as O
fundamental O
and O
the O
aim O
was O
to O
assess O
QoL O
and O
quality O
adjusted O
survival O
. O

A O
longitudinal O
QoL O
study O
on O
a O
subset O
of O
ESPAC-1 O
patients O
who O
prospectively O
completed O
the O
EORTC O
QLQ O
C-30 O
questionnaire O
during O
treatment O
and O
follow-up O
. O

An O
integrated O
quality-survival O
product O
method O
was O
used O
to O
adjust O
any O
treatment O
effect O
on O
survival O
by O
a O
function O
of O
measured O
QoL O
, O
calculated O
over O
a O
restricted O
24-month-period O
( O
QALM-24 O
) O
. O

Three O
hundred O
and O
sixteen O
patients O
completed O
1,201 O
questionnaires O
. O

There O
were O
no O
differences O
between O
treatment O
groups O
in O
dimension O
scores O
at O
baseline O
( O
randomization O
) O
. O

For B-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Months I-Premise
over I-Premise
24 I-Premise
months I-Premise
( I-Premise
QALM-24 I-Premise
) I-Premise
was I-Premise
9.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
8.7 I-Premise
, I-Premise
11.2 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.6 I-Premise
, I-Premise
10.5 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise

For B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
was I-Premise
7.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
6.0 I-Premise
, I-Premise
9.0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.0 I-Premise
, I-Premise
10.0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise

The B-Claim
previously I-Claim
reported I-Claim
survival I-Claim
advantage I-Claim
supporting I-Claim
the I-Claim
use I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
is I-Claim
maintained I-Claim
when I-Claim
adjusted I-Claim
using I-Claim
quality I-Claim
adjusted I-Claim
survival I-Claim
methodology I-Claim
. I-Claim

Chemotherapy B-Claim
provided I-Claim
on I-Claim
average I-Claim
an I-Claim
additional I-Claim
1.0 I-Claim
quality-adjusted I-Claim
life I-Claim
months I-Claim
within I-Claim
a I-Claim
restricted I-Claim
2-year I-Claim
time I-Claim
period I-Claim
from I-Claim
the I-Claim
time I-Claim
of I-Claim
resection I-Claim
. I-Claim

Improvements O
can O
be O
made O
in O
the O
quality O
of O
cancer O
care O
if O
supportive O
care O
needs O
are O
addressed O
";" O
however O
, O
there O
are O
few O
trials O
of O
supportive O
care O
interventions O
to O
guide O
policy O
and O
practice O
. O

This O
study O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
nurse-delivered O
telephone O
supportive O
intervention O
( O
the O
" O
CONNECT O
" O
intervention O
) O
. O

This O
study O
was O
a O
pilot O
randomized O
controlled O
trial O
. O

Intervention O
group O
patients O
received O
5 O
calls O
from O
a O
specialist O
colorectal O
nurse O
in O
the O
6 O
months O
after O
hospital O
discharge O
. O

Each O
call O
was O
standardized O
, O
comprising O
the O
assessment O
of O
unmet O
need O
and O
the O
provision O
of O
information O
and O
emotional O
support O
. O

CONNECT O
was O
in O
addition O
to O
standard O
clinical O
follow-up O
. O

Patients O
allocated O
to O
the O
control O
group O
received O
standard O
follow-up O
only O
. O

This O
study O
took O
place O
at O
the O
Royal O
Prince O
Alfred O
Hospital O
, O
Sydney O
, O
Australia O
. O

Patients O
( O
n O
= O
75 O
) O
were O
included O
who O
had O
been O
surgically O
treated O
for O
colorectal O
cancer O
( O
any O
stage O
) O
. O

The O
main O
outcome O
measures O
were O
the O
unmet O
supportive O
care O
needs O
, O
health O
service O
utilization O
, O
and O
quality O
of O
life O
at O
1 O
, O
3 O
, O
and O
6 O
months O
postdischarge O
. O

Of O
87 O
eligible O
patients O
, O
75 O
consented O
( O
86 O
% O
consent O
rate O
) O
. O

Thirty-nine O
patients O
were O
randomly O
assigned O
to O
CONNECT O
and O
36 O
to O
usual O
care O
. O

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
1.41 I-Premise
, I-Premise
P I-Premise
= I-Premise
.23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
0.82 I-Premise
, I-Premise
P I-Premise
= I-Premise
.37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise

Nonsignificant B-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
found I-Premise
for I-Premise
all I-Premise
unmet I-Premise
supportive I-Premise
care I-Premise
need I-Premise
and I-Premise
quality-of-life I-Premise
scores I-Premise
, I-Premise
change I-Premise
scores I-Premise
, I-Premise
and I-Premise
trends I-Premise
. I-Premise

However B-Premise
, I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
total I-Premise
quality-of-life I-Premise
scores I-Premise
were I-Premise
higher I-Premise
for I-Premise
intervention I-Premise
group I-Premise
patients I-Premise
than I-Premise
controls I-Premise
( I-Premise
106.0 I-Premise
vs I-Premise
98.6 I-Premise
) I-Premise
. I-Premise

This O
difference O
( O
7.4 O
) O
was O
clinically O
relevant O
. O

Improvements B-Claim
in I-Claim
total I-Claim
quality-of-life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim

CONNECT B-Claim
has I-Claim
shown I-Claim
promising I-Claim
indications I-Claim
on I-Claim
health I-Claim
system I-Claim
and I-Claim
patient I-Claim
outcomes I-Claim
that I-Claim
warrant I-Claim
a I-Claim
larger I-Claim
study I-Claim
to I-Claim
further I-Claim
investigate I-Claim
the I-Claim
potential I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

We O
conducted O
a O
multicenter O
, O
randomized O
trial O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
quality O
of O
life O
in O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
receiving O
high-dose O
chemotherapy O
plus O
autologous O
stem-cell O
transplantation O
( O
ASCT O
";" O
HDCT O
) O
compared O
with O
standard-dose O
therapy O
. O

Between O
April O
1997 O
and O
December O
2000 O
, O
386 O
women O
with O
MBC O
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
registered O
. O

After O
initial O
response O
to O
anthracycline- O
or O
taxane-based O
induction O
chemotherapy O
, O
224 O
patients O
were O
randomly O
assigned O
: O
112 O
to O
high-dose O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
carboplatin O
chemotherapy O
and O
ASCT O
( O
HDCT O
) O
, O
and O
112 O
to O
standard O
therapy O
( O
ST O
) O
. O

Median O
age O
was O
47 O
years O
( O
range O
, O
25 O
to O
67 O
years O
) O
. O

Thirty O
two O
percent O
of O
women O
randomly O
assigned O
had O
estrogen O
and O
progesterone O
receptor-negative O
breast O
cancer O
, O
42 O
% O
had O
visceral O
metastases O
, O
and O
58 O
% O
had O
bone O
metastases O
. O

Complete O
remission O
rates O
before O
random O
assignment O
were O
11 O
% O
for O
those O
receiving O
HDCT O
and O
12 O
% O
for O
those O
receiving O
ST. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
48 I-Premise
months I-Premise
, I-Premise
79 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
and I-Premise
77 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
ST I-Premise
arm I-Premise
";" I-Premise
seven B-Premise
patients I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
died I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
toxicity I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
was I-Premise
24 I-Premise
months I-Premise
for I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
21 I-Premise
to I-Premise
35 I-Premise
months I-Premise
) I-Premise
and I-Premise
28 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
22 I-Premise
to I-Premise
33 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.9 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.6 I-Premise
to I-Premise
1.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.43 I-Premise
) I-Premise
. I-Premise

PFS B-Premise
was I-Premise
11 I-Premise
months I-Premise
for I-Premise
HDCT I-Premise
and I-Premise
9 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.6 I-Premise
in I-Premise
favor I-Premise
of I-Premise
HDCT I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.5 I-Premise
to I-Premise
0.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

HDCT B-Claim
did I-Claim
not I-Claim
improve I-Claim
OS I-Claim
in I-Claim
women I-Claim
with I-Claim
MBC I-Claim
when I-Claim
used I-Claim
as I-Claim
consolidation I-Claim
after I-Claim
response I-Claim
to I-Claim
induction I-Claim
chemotherapy I-Claim
. I-Claim

Care O
closer O
to O
home O
is O
being O
explored O
as O
a O
means O
of O
improving O
patient O
experience O
as O
well O
as O
efficiency O
in O
terms O
of O
cost O
savings O
. O

Evidence O
that O
community O
cancer O
services O
improve O
care O
quality O
and/or O
generate O
cost O
savings O
is O
currently O
limited O
. O

A O
randomised O
study O
was O
undertaken O
to O
compare O
delivery O
of O
cancer O
treatment O
in O
the O
hospital O
with O
two O
different O
community O
settings O
. O

Ninety-seven O
patients O
being O
offered O
outpatient-based O
cancer O
treatment O
were O
randomised O
to O
treatment O
delivered O
in O
a O
hospital O
day O
unit O
, O
at O
the O
patient O
's O
home O
or O
in O
local O
general O
practice O
( O
GP O
) O
surgeries O
. O

The O
primary O
outcome O
was O
patient-perceived O
benefits O
, O
using O
the O
emotional O
function O
domain O
of O
the O
EORTC O
quality O
of O
life O
( O
QOL O
) O
QLQC30 O
questionnaire O
evaluated O
after O
12 O
weeks O
. O

Secondary O
outcomes O
included O
additional O
QOL O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
QOL I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
in I-Premise
the I-Premise
combined I-Premise
community I-Premise
locations I-Premise
relative I-Premise
to I-Premise
hospital I-Premise
( I-Premise
difference I-Premise
of I-Premise
-7.2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
: I-Premise
-19·5 I-Premise
to I-Premise
+5·2 I-Premise
, I-Premise
P=0.25 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+15·2 I-Premise
, I-Premise
1·3 I-Premise
to I-Premise
29·1 I-Premise
, I-Premise
P=0.033 I-Premise
) I-Premise
. I-Premise

Hospital O
anxiety O
and O
depression O
scale O
scores O
were O
consistent O
with O
the O
primary O
outcome O
measure O
. O

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
that I-Premise
community I-Premise
treatment I-Premise
compromised I-Premise
patient I-Premise
safety I-Premise
and O
no B-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
terms I-Premise
of I-Premise
overall I-Premise
costs I-Premise
or I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Year I-Premise
. I-Premise

Seventy-eight B-Premise
percent I-Premise
of I-Premise
patients I-Premise
expressed I-Premise
satisfaction I-Premise
with I-Premise
their I-Premise
treatment I-Premise
whatever I-Premise
their I-Premise
location I-Premise
, I-Premise
whereas I-Premise
57 I-Premise
% I-Premise
of I-Premise
patients I-Premise
preferred I-Premise
future I-Premise
treatment I-Premise
to I-Premise
continue I-Premise
at I-Premise
the I-Premise
hospital I-Premise
, I-Premise
81 I-Premise
% I-Premise
at I-Premise
GP I-Premise
surgeries I-Premise
and I-Premise
90 I-Premise
% I-Premise
at I-Premise
home I-Premise
. I-Premise

Although O
initial O
pre-trial O
interviews O
revealed O
concerns O
among O
health-care O
professionals O
and O
some O
patients O
regarding O
community O
treatment O
, O
opinions O
were O
largely O
more O
favourable O
in O
post-trial O
interviews O
. O

Patient B-Claim
QOL I-Claim
favours I-Claim
delivering I-Claim
cancer I-Claim
treatment I-Claim
in I-Claim
the I-Claim
home I-Claim
rather I-Claim
than I-Claim
GP I-Claim
surgeries I-Claim
. I-Claim

Nevertheless B-Claim
, I-Claim
both I-Claim
community I-Claim
settings I-Claim
were I-Claim
acceptable I-Claim
to I-Claim
and I-Claim
preferred I-Claim
by I-Claim
patients I-Claim
compared I-Claim
with I-Claim
hospital I-Claim
, I-Claim
were I-Claim
safe I-Claim
, I-Claim
with I-Claim
no I-Claim
detrimental I-Claim
impact I-Claim
on I-Claim
overall I-Claim
health-care I-Claim
costs I-Claim
. I-Claim

Docetaxel B-Claim
has I-Claim
shown I-Claim
activity I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

This O
randomized O
phase O
III O
trial O
evaluated O
the O
efficacy O
and O
safety O
of O
docetaxel O
versus O
vinorelbine O
( O
the O
current O
standard O
treatment O
) O
in O
elderly O
patients O
. O

Chemotherapy-naïve O
patients O
age O
70 O
years O
or O
older O
with O
stage O
IIIB/IV O
NSCLC O
and O
performance O
status O
2 O
or O
lower O
were O
eligible O
. O

Patients O
randomly O
received O
docetaxel O
60 O
mg/m2 O
( O
day O
1 O
) O
or O
vinorelbine O
25 O
mg/m2 O
( O
days O
1 O
and O
8 O
) O
every O
21 O
days O
for O
four O
cycles O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Overall O
disease-related O
symptom O
improvement O
was O
assessed O
using O
an O
eight-item O
questionnaire O
. O

In O
total O
, O
182 O
patients O
were O
enrolled O
. O

Median O
age O
was O
76 O
years O
( O
range O
, O
70 O
years O
to O
86 O
years O
) O
. O

There B-Premise
was I-Premise
no I-Premise
statistical I-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
14.3 I-Premise
months I-Premise
v I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.780 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.561 I-Premise
to I-Premise
1.085 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.138 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.5 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
also I-Premise
significantly I-Premise
improved I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
22.7 I-Premise
% I-Premise
v I-Premise
9.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.019 I-Premise
) I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
82.9 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
69.2 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
";" I-Premise
P I-Premise
= I-Premise
.031 I-Premise
) I-Premise
and I-Premise
leukopenia I-Premise
( I-Premise
58.0 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
51.7 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
) I-Premise
. I-Premise

Other B-Premise
toxicities I-Premise
were I-Premise
mild I-Premise
and I-Premise
generally I-Premise
well I-Premise
tolerated I-Premise
. I-Premise

Docetaxel B-Premise
improved I-Premise
overall I-Premise
disease-related I-Premise
symptoms I-Premise
over I-Premise
vinorelbine I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
1.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.09 I-Premise
to I-Premise
3.20 I-Premise
) I-Premise
. I-Premise

Docetaxel B-Premise
improved I-Premise
progression-free I-Premise
survival I-Premise
, I-Premise
response I-Premise
rate I-Premise
, I-Premise
and I-Premise
disease-related I-Premise
symptoms I-Premise
versus I-Premise
vinorelbine I-Premise
. I-Premise

Overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim

Docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
determine O
the O
effectiveness O
of O
the O
Alleviating O
Depression O
Among O
Patients O
With O
Cancer O
( O
ADAPt-C O
) O
collaborative O
care O
management O
for O
major O
depression O
or O
dysthymia O
. O

Study O
patients O
included O
472 O
low-income O
, O
predominantly O
female O
Hispanic O
patients O
with O
cancer O
age O
> O
or= O
18 O
years O
with O
major O
depression O
( O
49 O
% O
) O
, O
dysthymia O
( O
5 O
% O
) O
, O
or O
both O
( O
46 O
% O
) O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
n O
= O
242 O
) O
or O
enhanced O
usual O
care O
( O
EUC O
";" O
n O
= O
230 O
) O
. O

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
clinical O
specialist O
( O
supervised O
by O
a O
psychiatrist O
) O
who O
offered O
education O
, O
structured O
psychotherapy O
, O
and O
maintenance/relapse O
prevention O
support O
. O

The O
psychiatrist O
prescribed O
antidepressant O
medications O
for O
patients O
preferring O
or O
assessed O
to O
require O
medication O
. O

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
63 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
from I-Premise
baseline I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
Patient I-Premise
Health I-Premise
Questionnaire-9 I-Premise
( I-Premise
PHQ-9 I-Premise
) I-Premise
depression I-Premise
scale I-Premise
compared I-Premise
with I-Premise
50 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
OR I-Premise
] I-Premise
= I-Premise
1.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.16 I-Premise
to I-Premise
3.38 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Improvement B-Premise
was I-Premise
also I-Premise
found I-Premise
for I-Premise
5-point I-Premise
decrease I-Premise
in I-Premise
PHQ-9 I-Premise
score I-Premise
among I-Premise
72.2 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
compared I-Premise
with I-Premise
59.7 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
OR I-Premise
= I-Premise
1.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.14 I-Premise
to I-Premise
3.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
rates I-Premise
of I-Premise
depression I-Premise
treatment I-Premise
( I-Premise
72.3 I-Premise
% I-Premise
v I-Premise
10.4 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
better I-Premise
quality-of-life I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
social/family I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
, I-Premise
2.7 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.22 I-Premise
to I-Premise
4.17 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
emotional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.29 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26 I-Premise
to I-Premise
2.22 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.34 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.08 I-Premise
to I-Premise
2.59 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
2.79 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.49 I-Premise
to I-Premise
5.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

ADAPt-C B-Claim
collaborative I-Claim
care I-Claim
is I-Claim
feasible I-Claim
and I-Claim
results I-Claim
in I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
, I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
lower I-Claim
pain I-Claim
levels I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
for I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
disorders I-Claim
in I-Claim
a I-Claim
low-income I-Claim
, I-Claim
predominantly I-Claim
Hispanic I-Claim
population I-Claim
in I-Claim
public I-Claim
sector I-Claim
oncology I-Claim
clinics I-Claim
. I-Claim

Depression O
is O
common O
among O
older O
cancer O
patients O
, O
but O
little O
is O
known O
about O
the O
optimal O
approach O
to O
caring O
for O
this O
population O
. O

This O
analysis O
evaluates O
the O
effectiveness O
of O
the O
Improving O
Mood-Promoting O
Access O
to O
Collaborative O
Treatment O
( O
IMPACT O
) O
program O
, O
a O
stepped O
care O
management O
program O
for O
depression O
in O
primary O
care O
patients O
who O
had O
an O
ICD-9 O
cancer O
diagnosis O
. O

Two O
hundred O
fifteen O
cancer O
patients O
were O
identified O
from O
the O
1,801 O
participants O
in O
the O
parent O
study O
. O

Subjects O
were O
60 O
years O
or O
older O
with O
major O
depression O
( O
18 O
% O
) O
, O
dysthymic O
disorder O
( O
33 O
% O
) O
, O
or O
both O
( O
49 O
% O
) O
, O
recruited O
from O
18 O
primary O
care O
clinics O
belonging O
to O
8 O
health-care O
organizations O
in O
5 O
states O
. O

Patients O
were O
randomly O
assigned O
to O
the O
IMPACT O
intervention O
( O
n O
= O
112 O
) O
or O
usual O
care O
( O
n O
= O
103 O
) O
. O

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
care O
manager O
who O
was O
supervised O
by O
a O
psychiatrist O
and O
a O
primary O
care O
provider O
and O
who O
offered O
education O
, O
care O
management O
, O
support O
of O
antidepressant O
management O
, O
and O
brief O
, O
structured O
psychosocial O
interventions O
including O
behavioral O
activation O
and O
problem-solving O
treatment O
. O

At B-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
, I-Premise
55 I-Premise
% I-Premise
and I-Premise
39 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
( I-Premise
SCL-20 I-Premise
) I-Premise
from I-Premise
baseline I-Premise
compared I-Premise
to I-Premise
34 I-Premise
% I-Premise
and I-Premise
20 I-Premise
% I-Premise
of I-Premise
usual I-Premise
care I-Premise
participants I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.029 I-Premise
) I-Premise
. I-Premise

Intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
remission I-Premise
rates I-Premise
( I-Premise
P I-Premise
= I-Premise
0.031 I-Premise
) I-Premise
, I-Premise
more I-Premise
depression-free I-Premise
days I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
less I-Premise
functional I-Premise
impairment I-Premise
( I-Premise
P I-Premise
= I-Premise
0.011 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
0.039 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
than I-Premise
usual I-Premise
care I-Premise
participants I-Premise
. I-Premise

The B-Claim
IMPACT I-Claim
collaborative I-Claim
care I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
for I-Claim
depression I-Claim
among I-Claim
older I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
diverse I-Claim
primary I-Claim
care I-Claim
settings I-Claim
. I-Claim

Sunitinib O
has O
demonstrated O
antitumor O
activity O
in O
metastatic O
renal O
cell O
carcinoma O
( O
mRCC O
) O
when O
given O
at O
50 O
mg/d O
on O
a O
4-weeks-on O
2-weeks-off O
regimen O
. O

Herein O
, O
we O
report O
results O
of O
an O
open-label O
, O
multicenter O
phase O
II O
mRCC O
study O
of O
sunitinib O
administered O
on O
a O
continuous O
once-daily O
dosing O
regimen O
. O

Eligibility O
criteria O
included O
histologically O
proven O
mRCC O
with O
measurable O
disease O
, O
failure O
of O
one O
prior O
cytokine O
regimen O
, O
and O
good O
performance O
status O
. O

Patients O
were O
randomly O
assigned O
to O
a O
sunitinib O
starting O
dose O
of O
37.5 O
mg/d O
in O
the O
morning O
( O
AM O
) O
or O
evening O
( O
PM O
) O
. O

RECIST-defined O
objective O
response O
rate O
( O
ORR O
) O
was O
the O
primary O
end O
point O
. O

Secondary O
end O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
adverse O
events O
( O
AEs O
) O
, O
and O
quality-of-life O
measures O
. O

One O
hundred O
seven O
patients O
were O
randomly O
assigned O
to O
AM O
( O
n O
= O
54 O
) O
or O
PM O
( O
n O
= O
53 O
) O
dosing O
and O
on O
study O
for O
a O
median O
8.3 O
months O
. O

Eighty-three O
patients O
discontinued O
, O
65 O
due O
to O
disease O
progression O
and O
16 O
because O
of O
AEs O
";" O
two O
patients O
withdrew O
consent O
. O

Dosing O
was O
reduced O
to O
25 O
mg/d O
in O
46 O
patients O
( O
43 O
% O
) O
due O
to O
grade O
3/4 O
AEs O
. O

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
treatment-related I-Premise
AEs I-Premise
were I-Premise
asthenia/fatigue I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hypertension I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hand-foot I-Premise
syndrome I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
anorexia I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
. I-Premise

ORR O
was O
20 O
% O
with O
a O
7.2-month O
median O
response O
duration O
. O

Median B-Premise
PFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
8.2 I-Premise
and I-Premise
19.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
26.4 I-Premise
months I-Premise
. I-Premise

Efficacy B-Premise
, I-Premise
tolerability I-Premise
, I-Premise
and I-Premise
quality-of-life I-Premise
results I-Premise
were I-Premise
similar I-Premise
between I-Premise
patients I-Premise
dosed I-Premise
in I-Premise
the I-Premise
AM I-Premise
or I-Premise
PM I-Premise
. I-Premise

Sunitinib B-Claim
37.5 I-Claim
mg I-Claim
, I-Claim
administered I-Claim
on I-Claim
a I-Claim
continuous I-Claim
once-daily I-Claim
dosing I-Claim
regimen I-Claim
, I-Claim
has I-Claim
a I-Claim
manageable I-Claim
safety I-Claim
profile I-Claim
as I-Claim
second-line I-Claim
mRCC I-Claim
therapy I-Claim
, I-Claim
providing I-Claim
flexible I-Claim
dosing I-Claim
, I-Claim
which I-Claim
can I-Claim
be I-Claim
explored I-Claim
in I-Claim
combination I-Claim
studies I-Claim
. I-Claim

Observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O

To O
test O
these O
observations O
with O
a O
large O
, O
randomized O
clinical O
trial O
, O
an O
intervention O
that O
significantly O
impacts O
physical O
activity O
in O
these O
patients O
is O
needed O
. O

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

Sedentary O
( O
engaging O
in O
< O
60 O
min O
of O
recreational O
activity/week O
) O
breast O
and O
colorectal O
cancer O
survivors O
were O
randomized O
to O
a O
telephone-based O
exercise O
intervention O
or O
usual O
care O
control O
group O
. O

The O
intervention O
was O
delivered O
through O
the O
University O
of O
California O
at O
San O
Diego O
";" O
participants O
received O
ten O
phone O
calls O
over O
the O
course O
of O
the O
16-week O
intervention O
. O

All O
participants O
underwent O
assessment O
of O
physical O
activity O
, O
fitness O
, O
physical O
functioning O
, O
fatigue O
and O
exercise O
self-efficacy O
at O
baseline O
and O
after O
the O
16-week O
intervention O
. O

One O
hundred O
and O
twenty-one O
patients O
were O
enrolled O
through O
ten O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
institutions O
";" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O

Participants B-Premise
randomized I-Premise
to I-Premise
the I-Premise
exercise I-Premise
group I-Premise
increased I-Premise
physical I-Premise
activity I-Premise
by I-Premise
more I-Premise
than I-Premise
100 I-Premise
versus I-Premise
22 I-Premise
% I-Premise
in I-Premise
controls I-Premise
( I-Premise
54.5 I-Premise
vs. I-Premise
14.6 I-Premise
min I-Premise
, I-Premise
P I-Premise
= I-Premise
0.13 I-Premise
) I-Premise
, I-Premise
and I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
fitness I-Premise
( I-Premise
increased I-Premise
6-min I-Premise
walk I-Premise
test I-Premise
distance I-Premise
by I-Premise
186.9 I-Premise
vs. I-Premise
81.9 I-Premise
feet I-Premise
, I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
7.1 I-Premise
vs. I-Premise
2.6 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Breast B-Claim
and I-Claim
colorectal I-Claim
cancer I-Claim
survivors I-Claim
enrolled I-Claim
in I-Claim
a I-Claim
multicenter I-Claim
, I-Claim
telephone-based I-Claim
physical I-Claim
activity I-Claim
intervention I-Claim
increased I-Claim
physical I-Claim
activity I-Claim
and I-Claim
experienced I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
fitness I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
. I-Claim

Lifestyle B-Claim
intervention I-Claim
research I-Claim
is I-Claim
feasible I-Claim
in I-Claim
a I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

The O
primary O
objective O
of O
this O
study O
was O
to O
compare O
the O
response O
rates O
of O
elderly O
, O
chemonaive O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
treated O
with O
daily O
oral O
erlotinib O
versus O
oral O
vinorelbine O
. O

Chemonaive O
Taiwanese O
patients O
aged O
70 O
years O
or O
older O
who O
had O
advanced O
NSCLC O
were O
randomized O
to O
receive O
either O
oral O
erlotinib O
150 O
mg O
( O
E O
) O
daily O
or O
oral O
vinorelbine O
60 O
mg/m O
( O
V O
) O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
. O

From O
February O
2007 O
to O
July O
2008 O
, O
116 O
patients O
were O
enrolled O
and O
113 O
were O
included O
in O
the O
intent-to-treat O
population O
: O
57 O
patients O
in O
the O
E O
group O
and O
56 O
patients O
in O
the O
V O
group O
. O

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
22.8 I-Premise
% I-Premise
( I-Premise
13 I-Premise
of I-Premise
57 I-Premise
) I-Premise
in I-Premise
E I-Premise
and I-Premise
8.9 I-Premise
% I-Premise
( I-Premise
5 I-Premise
of I-Premise
56 I-Premise
) I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0388 I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
4.57 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
2.53 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0287 I-Premise
) I-Premise
, I-Premise
with I-Premise
an I-Premise
80.6 I-Premise
% I-Premise
increase I-Premise
in I-Premise
median I-Premise
PFS I-Premise
for I-Premise
E I-Premise
compared I-Premise
with I-Premise
V. I-Premise
Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
11.67 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.6975 I-Premise
) I-Premise
. I-Premise

Toxicities B-Premise
were I-Premise
generally I-Premise
mild I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
longest I-Premise
for I-Premise
epidermal I-Premise
growth I-Premise
factor I-Premise
receptor I-Premise
gene I-Premise
( I-Premise
EGFR I-Premise
) I-Premise
-mutated I-Premise
patients I-Premise
in I-Premise
the I-Premise
E I-Premise
group I-Premise
, I-Premise
followed I-Premise
by I-Premise
EGFR-mutated I-Premise
patients I-Premise
in I-Premise
V I-Premise
, I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
E I-Premise
, I-Premise
and I-Premise
EGFR I-Premise
wild I-Premise
type I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0034 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
for I-Premise
EGFR-mutated I-Premise
patients I-Premise
than I-Premise
for I-Premise
EGFR I-Premise
wild-type I-Premise
patients I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

EGFR-mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
EGFR I-Claim
wild-type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim

To O
prospectively O
evaluate O
and O
compare O
health-related O
quality-of-life O
( O
QOL O
) O
outcomes O
in O
patients O
with O
head-neck O
squamous O
cell O
carcinoma O
randomized O
to O
either O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
or O
three-dimensional O
conformal O
radiotherapy O
( O
3D-CRT O
) O
and O
assess O
serial O
longitudinal O
change O
in O
QOL O
over O
time O
. O

QOL O
outcomes O
were O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
QOL O
questionnaire O
( O
QLQ-C30 O
) O
and O
Head-Neck O
module O
( O
HN-35 O
) O
at O
baseline O
( O
pre-treatment O
) O
and O
subsequently O
periodically O
on O
follow-up O
. O

Mean O
scores O
of O
individual O
domains/scales O
of O
3D-CRT O
and O
IMRT O
were O
compared O
using O
't O
' O
test O
at O
each O
time O
point O
";" O
while O
longitudinal O
change O
in O
mean O
scores O
of O
both O
groups O
over O
time O
was O
evaluated O
by O
repeated O
measurement O
analysis O
of O
variance O
. O

Fifty O
eight O
of O
the O
60 O
randomized O
patients O
who O
filled O
the O
QOL O
questionnaire O
at O
least O
at O
one O
time O
point O
were O
included O
in O
the O
analysis O
. O

Several O
general O
( O
emotional O
functioning O
, O
role O
functioning O
, O
social O
contact O
) O
as O
well O
as O
head O
and O
neck O
cancer-specific O
( O
dry O
mouth O
, O
opening O
mouth O
, O
sticky O
saliva O
, O
pain O
, O
senses O
) O
QOL O
domains O
were O
better O
preserved O
with O
IMRT O
compared O
to O
3D-CRT O
at O
different O
time O
points O
. O

Importantly O
, O
none O
of O
the O
QOL O
domains O
were O
worse O
with O
IMRT O
at O
any O
time O
point O
. O

There B-Premise
was I-Premise
substantial I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
immediate I-Premise
post-treatment I-Premise
( I-Premise
3-months I-Premise
) I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

However B-Premise
, I-Premise
QOL I-Premise
scores I-Premise
gradually I-Premise
but I-Premise
definitely I-Premise
improved I-Premise
over I-Premise
time I-Premise
for I-Premise
most I-Premise
domains I-Premise
. I-Premise

Global B-Premise
QOL I-Premise
, I-Premise
emotional/role I-Premise
functioning I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
pain I-Premise
, I-Premise
swallowing I-Premise
, I-Premise
speech I-Premise
, I-Premise
social I-Premise
contact/eating I-Premise
, I-Premise
insomnia I-Premise
showed I-Premise
rapid I-Premise
recovery I-Premise
( I-Premise
< I-Premise
6months I-Premise
) I-Premise
while I-Premise
physical/cognitive I-Premise
functioning I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
sticky I-Premise
saliva I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
senses I-Premise
showed I-Premise
delayed I-Premise
recovery I-Premise
( I-Premise
> I-Premise
6months I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
loco-regional I-Premise
or I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

There B-Claim
is I-Claim
substantial I-Claim
deterioration I-Claim
in I-Claim
QOL I-Claim
after I-Claim
curative-intent I-Claim
head-neck I-Claim
irradiation I-Claim
that I-Claim
gradually I-Claim
improves I-Claim
over I-Claim
time I-Claim
. I-Claim

IMRT B-Claim
results I-Claim
in I-Claim
clinically I-Claim
meaningful I-Claim
and I-Claim
statistically I-Claim
better I-Claim
QOL I-Claim
scores I-Claim
for I-Claim
some I-Claim
domains I-Claim
compared I-Claim
to I-Claim
3D-CRT I-Claim
at I-Claim
several I-Claim
time I-Claim
points I-Claim
with I-Claim
comparable I-Claim
disease I-Claim
outcomes I-Claim
that I-Claim
could I-Claim
support I-Claim
its I-Claim
widespread I-Claim
adoption I-Claim
in I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

In O
Lithuania O
, O
about O
400 O
cases O
of O
pancreatic O
cancer O
are O
diagnosed O
each O
year O
, O
and O
more O
than O
50 O
% O
of O
patients O
are O
diagnosed O
with O
stage O
IV O
disease O
. O

Quality B-Claim
of I-Claim
life I-Claim
is I-Claim
an I-Claim
important I-Claim
issue I-Claim
in I-Claim
pancreatic I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

A O
prospective O
randomized O
clinical O
study O
on O
the O
treatment O
of O
patients O
with O
resectable O
and O
unresectable O
pancreatic O
cancer O
was O
conducted O
at O
the O
Department O
of O
Oncology O
of O
Kaunas O
University O
of O
Medicine O
Hospital O
, O
and O
in O
this O
study O
, O
quality O
of O
life O
was O
analyzed O
. O

The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
effect O
of O
combined O
treatment O
methods O
on O
quality O
of O
life O
in O
patients O
diagnosed O
with O
pancreatic O
cancer O
. O

During O
2000-2005 O
, O
two O
concomitant O
chemoradiation O
treatment O
methods O
( O
radiotherapy O
with O
5-fluorouracil O
and O
radiotherapy O
with O
gemcitabine O
) O
were O
analyzed O
in O
the O
study O
. O

A O
total O
of O
60 O
patients O
were O
enrolled O
: O
41 O
patients O
diagnosed O
with O
resectable O
and O
19 O
patients O
diagnosed O
with O
unresectable O
pancreatic O
cancer O
. O

Quality O
of O
life O
was O
assessed O
using O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
questionnaire O
. O

Three O
main O
quality O
of O
life O
scales O
( O
general O
health O
status O
, O
functional O
, O
and O
symptom O
scales O
) O
were O
assessed O
and O
compared O
between O
two O
treatment O
groups O
. O

The B-Premise
analysis I-Premise
of I-Premise
quality I-Premise
of I-Premise
live I-Premise
assessment I-Premise
showed I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
after I-Premise
treatment I-Premise
in I-Premise
patients I-Premise
with I-Premise
resectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
and I-Premise
gemcitabine I-Premise
. I-Premise

Decreased B-Premise
quality I-Premise
of I-Premise
life I-Premise
later I-Premise
after I-Premise
treatment I-Premise
was I-Premise
also I-Premise
observed I-Premise
in I-Premise
patients I-Premise
diagnosed I-Premise
with I-Premise
unresectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
the I-Premise
same I-Premise
regimen I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
radiotherapy I-Claim
and I-Claim
5-fluorouracil I-Claim
changed I-Claim
only I-Claim
some I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
did I-Claim
not I-Claim
have I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Therapy B-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
should I-Claim
provide I-Claim
symptom I-Claim
relief I-Claim
and I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
because I-Claim
most I-Claim
patients I-Claim
are I-Claim
symptomatic I-Claim
at I-Claim
baseline I-Claim
. I-Claim

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
( O
even O
after O
completion O
of O
protocol O
treatment O
) O
as O
one O
of O
the O
secondary O
end O
points O
of O
the O
V325 O
phase O
III O
trial O
. O

Four O
hundred O
forty-five O
patients O
randomly O
received O
either O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
each O
on O
day O
1 O
plus O
fluorouracil O
750 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
3 O
weeks O
( O
DCF O
) O
or O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
plus O
fluorouracil O
1,000 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
4 O
weeks O
( O
CF O
) O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
, O
where O
available O
, O
the O
EuroQOL O
EQ-5D O
questionnaire O
were O
administered O
every O
8 O
weeks O
from O
baseline O
until O
progression O
and O
then O
every O
3 O
months O
. O

Time O
to O
definitive O
deterioration O
of O
QOL O
parameters O
was O
analyzed O
. O

The O
proportions O
of O
patients O
having O
assessable O
EORTC O
QLQ-C30 O
and O
EQ-5D O
questionnaires O
at O
baseline O
were O
86.0 O
% O
and O
78.7 O
% O
with O
DCF O
, O
respectively O
, O
and O
89.7 O
% O
and O
92.8 O
% O
with O
CF O
, O
respectively O
. O

Time B-Premise
to I-Premise
5 I-Premise
% I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
( I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
significantly I-Premise
favored I-Premise
DCF I-Premise
over I-Premise
CF I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
was I-Premise
preserved I-Premise
longer I-Premise
for I-Premise
patients I-Premise
on I-Premise
DCF I-Premise
than I-Premise
those I-Premise
on I-Premise
CF I-Premise
for I-Premise
all I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
analyses I-Premise
, I-Premise
demonstrating I-Premise
the I-Premise
statistical I-Premise
superiority I-Premise
of I-Premise
DCF I-Premise
compared I-Premise
with I-Premise
CF I-Premise
. I-Premise

V325 O
represents O
the O
largest O
trial O
with O
the O
longest O
prospectively O
controlled O
evaluations O
of O
QOL O
during O
protocol O
chemotherapy O
and O
follow-up O
in O
patients O
with O
advanced O
gastric O
or O
gastroesophageal O
junction O
cancer O
. O

In B-Claim
V325 I-Claim
, I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
DCF I-Claim
not I-Claim
only I-Claim
had I-Claim
statistically I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
tumor-progression I-Claim
, I-Claim
but I-Claim
they I-Claim
also I-Claim
had I-Claim
better I-Claim
preservation I-Claim
of I-Claim
QOL I-Claim
compared I-Claim
with I-Claim
patients I-Claim
receiving I-Claim
CF I-Claim
. I-Claim

Many O
patients O
with O
cancer O
experience O
depression O
and O
anxiety O
, O
and O
an O
associated O
decrease O
in O
quality O
of O
life O
( O
QOL O
) O
during O
radiation O
therapy O
( O
RT O
) O
. O

The O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
benefits O
of O
psychosocial O
interventions O
for O
cancer O
patients O
who O
received O
RT O
. O

Patients O
with O
cancer O
( O
n O
= O
178 O
) O
who O
agreed O
to O
participate O
in O
the O
study O
were O
randomized O
to O
the O
intervention O
arm O
( O
n O
= O
89 O
) O
or O
the O
control O
arm O
( O
n O
= O
89 O
) O
. O

Patients O
in O
the O
intervention O
group O
received O
psychosocial O
care O
during O
RT O
, O
whereas O
the O
control O
group O
received O
RT O
only O
. O

The O
benefits O
of O
the O
intervention O
were O
evaluated O
using O
the O
Zung O
Self-rating O
Depression O
Scale O
( O
SDS O
) O
to O
measure O
depression O
, O
the O
Self-rating O
Anxiety O
Scale O
( O
SAS O
) O
to O
assess O
anxiety O
, O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
to O
survey O
health-related O
QOL O
. O

The O
association O
between O
intervention O
and O
survival O
was O
also O
assessed O
. O

Patients B-Premise
randomly I-Premise
assigned I-Premise
to I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
symptoms I-Premise
of I-Premise
depression I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
health-related I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
( I-Premise
i.e I-Premise
. I-Premise
better I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
and I-Premise
physical I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
less I-Premise
insomnia I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
controls I-Premise
. I-Premise

In B-Claim
the I-Claim
subset I-Claim
analysis I-Claim
, I-Claim
female I-Claim
patients I-Claim
, I-Claim
those I-Claim
that I-Claim
received I-Claim
high I-Claim
dose I-Claim
irradiation I-Claim
, I-Claim
and I-Claim
those I-Claim
that I-Claim
underwent I-Claim
adjuvant I-Claim
chemotherapy I-Claim
could I-Claim
benefit I-Claim
more I-Claim
from I-Claim
psychosocial I-Claim
intervention I-Claim
. I-Claim

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
DFS I-Premise
79.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76.4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
OS I-Premise
83.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.925 I-Premise
) I-Premise
. I-Premise

Psychosocial B-Claim
intervention I-Claim
is I-Claim
a I-Claim
cost-effective I-Claim
approach I-Claim
that I-Claim
can I-Claim
improve I-Claim
a I-Claim
patient I-Claim
's I-Claim
mood I-Claim
and I-Claim
QOL I-Claim
both I-Claim
during I-Claim
and I-Claim
after I-Claim
RT I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
intervention I-Claim
was I-Claim
not I-Claim
found I-Claim
to I-Claim
reduce I-Claim
the I-Claim
risk I-Claim
of I-Claim
cancer I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
. I-Claim

Dignity O
therapy O
is O
a O
unique O
, O
individualised O
, O
short-term O
psychotherapy O
that O
was O
developed O
for O
patients O
( O
and O
their O
families O
) O
living O
with O
life-threatening O
or O
life-limiting O
illness O
. O

We O
investigated O
whether O
dignity O
therapy O
could O
mitigate O
distress O
or O
bolster O
the O
experience O
in O
patients O
nearing O
the O
end O
of O
their O
lives O
. O

Patients O
( O
aged O
≥18 O
years O
) O
with O
a O
terminal O
prognosis O
( O
life O
expectancy O
≤6 O
months O
) O
who O
were O
receiving O
palliative O
care O
in O
a O
hospital O
or O
community O
setting O
( O
hospice O
or O
home O
) O
in O
Canada O
, O
USA O
, O
and O
Australia O
were O
randomly O
assigned O
to O
dignity O
therapy O
, O
client-centred O
care O
, O
or O
standard O
palliative O
care O
in O
a O
1:1:1 O
ratio O
. O

Randomisation O
was O
by O
use O
of O
a O
computer-generated O
table O
of O
random O
numbers O
in O
blocks O
of O
30 O
. O

Allocation O
concealment O
was O
by O
use O
of O
opaque O
sealed O
envelopes O
. O

The O
primary O
outcomes O
-- O
reductions O
in O
various O
dimensions O
of O
distress O
before O
and O
after O
completion O
of O
the O
study O
-- O
were O
measured O
with O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Spiritual O
Well-Being O
Scale O
, O
Patient O
Dignity O
Inventory O
, O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
items O
from O
the O
Structured O
Interview O
for O
Symptoms O
and O
Concerns O
, O
Quality O
of O
Life O
Scale O
, O
and O
modified O
Edmonton O
Symptom O
Assessment O
Scale O
. O

Secondary O
outcomes O
of O
self-reported O
end-of-life O
experiences O
were O
assessed O
in O
a O
survey O
that O
was O
undertaken O
after O
the O
completion O
of O
the O
study O
. O

Outcomes O
were O
assessed O
by O
research O
staff O
with O
whom O
the O
participant O
had O
no O
previous O
contact O
to O
avoid O
any O
possible O
response O
bias O
or O
contamination O
. O

Analyses O
were O
done O
on O
all O
patients O
with O
available O
data O
at O
baseline O
and O
at O
the O
end O
of O
the O
study O
intervention O
. O

165 O
of O
441 O
patients O
were O
assigned O
to O
dignity O
therapy O
, O
140 O
standard O
palliative O
care O
, O
and O
136 O
client-centred O
care O
. O

108 O
, O
111 O
, O
and O
107 O
patients O
, O
respectively O
, O
were O
analysed O
. O

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
distress I-Premise
levels I-Premise
before I-Premise
and I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
study I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

For B-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
, I-Premise
patients I-Premise
reported I-Premise
that I-Premise
dignity I-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
than I-Premise
the I-Premise
other I-Premise
two I-Premise
interventions I-Premise
to I-Premise
have I-Premise
been I-Premise
helpful I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=35·50 I-Premise
, I-Premise
df=2 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
, I-Premise
improve I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=14·52 I-Premise
";" I-Premise
p=0·001 I-Premise
) I-Premise
, I-Premise
increase I-Premise
sense I-Premise
of I-Premise
dignity I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=12·66 I-Premise
";" I-Premise
p=0·002 I-Premise
) I-Premise
, I-Premise
change I-Premise
how I-Premise
their I-Premise
family I-Premise
saw I-Premise
and I-Premise
appreciated I-Premise
them I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=33·81 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
be I-Premise
helpful I-Premise
to I-Premise
their I-Premise
family I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=33·86 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

Dignity B-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
client-centred I-Premise
care I-Premise
in I-Premise
improving I-Premise
spiritual I-Premise
wellbeing I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=10·35 I-Premise
";" I-Premise
p=0·006 I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
in I-Premise
terms I-Premise
of I-Premise
lessening I-Premise
sadness I-Premise
or I-Premise
depression I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=9·38 I-Premise
";" I-Premise
p=0·009 I-Premise
) I-Premise
";" I-Premise
significantly B-Premise
more I-Premise
patients I-Premise
who I-Premise
had I-Premise
received I-Premise
dignity I-Premise
therapy I-Premise
reported I-Premise
that I-Premise
the I-Premise
study I-Premise
group I-Premise
had I-Premise
been I-Premise
satisfactory I-Premise
, I-Premise
compared I-Premise
with I-Premise
those I-Premise
who I-Premise
received I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=29·58 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

Although B-Claim
the I-Claim
ability I-Claim
of I-Claim
dignity I-Claim
therapy I-Claim
to I-Claim
mitigate I-Claim
outright I-Claim
distress I-Claim
, I-Claim
such I-Claim
as I-Claim
depression I-Claim
, I-Claim
desire I-Claim
for I-Claim
death I-Claim
or I-Claim
suicidality I-Claim
, I-Claim
has I-Claim
yet I-Claim
to I-Claim
be I-Claim
proven I-Claim
, I-Claim
its B-Claim
benefits I-Claim
in I-Claim
terms I-Claim
of I-Claim
self-reported I-Claim
end-of-life I-Claim
experiences I-Claim
support I-Claim
its I-Claim
clinical I-Claim
application I-Claim
for I-Claim
patients I-Claim
nearing I-Claim
death I-Claim
. I-Claim

The O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O

To O
test O
this O
hypothesis O
, O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
initiated O
the O
Breast O
Cancer O
Prevention O
Trial O
( O
P-1 O
) O
in O
1992 O
. O

Women O
( O
N=13388 O
) O
at O
increased O
risk O
for O
breast O
cancer O
because O
they O
1 O
) O
were O
60 O
years O
of O
age O
or O
older O
, O
2 O
) O
were O
35-59 O
years O
of O
age O
with O
a O
5-year O
predicted O
risk O
for O
breast O
cancer O
of O
at O
least O
1.66 O
% O
, O
or O
3 O
) O
had O
a O
history O
of O
lobular O
carcinoma O
in O
situ O
were O
randomly O
assigned O
to O
receive O
placebo O
( O
n=6707 O
) O
or O
20 O
mg/day O
tamoxifen O
( O
n=6681 O
) O
for O
5 O
years O
. O

Gail O
's O
algorithm O
, O
based O
on O
a O
multivariate O
logistic O
regression O
model O
using O
combinations O
of O
risk O
factors O
, O
was O
used O
to O
estimate O
the O
probability O
( O
risk O
) O
of O
occurrence O
of O
breast O
cancer O
over O
time O
. O

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
49 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.00001 I-Premise
) I-Premise
, I-Premise
with I-Premise
cumulative I-Premise
incidence I-Premise
through I-Premise
69 I-Premise
months I-Premise
of I-Premise
follow-up I-Premise
of I-Premise
43.4 I-Premise
versus I-Premise
22.0 I-Premise
per I-Premise
1000 I-Premise
women I-Premise
in I-Premise
the I-Premise
placebo I-Premise
and I-Premise
tamoxifen I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
decreased O
risk O
occurred O
in O
women O
aged O
49 O
years O
or O
younger O
( O
44 O
% O
) O
, O
50-59 O
years O
( O
51 O
% O
) O
, O
and O
60 O
years O
or O
older O
( O
55 O
% O
) O
";" O
risk B-Premise
was I-Premise
also I-Premise
reduced I-Premise
in I-Premise
women I-Premise
with I-Premise
a I-Premise
history I-Premise
of I-Premise
lobular I-Premise
carcinoma I-Premise
in I-Premise
situ I-Premise
( I-Premise
56 I-Premise
% I-Premise
) I-Premise
or I-Premise
atypical I-Premise
hyperplasia I-Premise
( I-Premise
86 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
with I-Premise
any I-Premise
category I-Premise
of I-Premise
predicted I-Premise
5-year I-Premise
risk I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
noninvasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
50 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor-positive I-Premise
tumors I-Premise
by I-Premise
69 I-Premise
% I-Premise
, I-Premise
but I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor-negative I-Premise
tumors I-Premise
was I-Premise
seen I-Premise
. I-Premise

Tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
";" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
Colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
endometrial I-Premise
cancer I-Premise
was I-Premise
increased I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
( I-Premise
risk I-Premise
ratio I-Premise
= I-Premise
2.53 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
1.35-4.97 I-Premise
) I-Premise
";" I-Premise
this I-Premise
increased I-Premise
risk I-Premise
occurred I-Premise
predominantly I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

All O
endometrial O
cancers O
in O
the O
tamoxifen O
group O
were O
stage O
I O
( O
localized O
disease O
) O
";" O
no B-Premise
endometrial I-Premise
cancer I-Premise
deaths I-Premise
have I-Premise
occurred I-Premise
in I-Premise
this I-Premise
group I-Premise
. I-Premise

No B-Premise
liver I-Premise
cancers I-Premise
or I-Premise
increase I-Premise
in I-Premise
colon I-Premise
, I-Premise
rectal I-Premise
, I-Premise
ovarian I-Premise
, I-Premise
or I-Premise
other I-Premise
tumors I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
. I-Premise

The B-Premise
rates I-Premise
of I-Premise
stroke I-Premise
, I-Premise
pulmonary I-Premise
embolism I-Premise
, I-Premise
and I-Premise
deep-vein I-Premise
thrombosis I-Premise
were I-Premise
elevated I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
these I-Premise
events I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Despite B-Claim
side I-Claim
effects I-Claim
resulting I-Claim
from I-Claim
administration I-Claim
of I-Claim
tamoxifen I-Claim
, I-Claim
its I-Claim
use I-Claim
as I-Claim
a I-Claim
breast I-Claim
cancer I-Claim
preventive I-Claim
agent I-Claim
is I-Claim
appropriate I-Claim
in I-Claim
many I-Claim
women I-Claim
at I-Claim
increased I-Claim
risk I-Claim
for I-Claim
the I-Claim
disease I-Claim
. I-Claim

To O
compare O
the O
efficacy O
of O
a O
standard O
anthracycline-based O
regimen O
to O
a O
dose-intensified O
anthracycline O
regimen O
in O
locally O
advanced O
breast O
cancer O
. O

Locally O
advanced O
breast O
cancer O
patients O
were O
randomly O
assigned O
onto O
a O
study O
comparing O
cyclophosphamide O
( O
C O
";" O
75 O
mg/m O
( O
2 O
) O
orally O
days O
1 O
to O
14 O
) O
, O
epirubicin O
( O
E O
";" O
60 O
mg/m O
( O
2 O
) O
intravenously O
[ O
IV O
] O
days O
1 O
, O
8 O
) O
, O
and O
fluorouracil O
( O
F O
";" O
500 O
mg/m O
( O
2 O
) O
IV O
days O
1 O
, O
8 O
) O
six O
cycles O
every O
28 O
days O
versus O
E O
( O
120 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
C O
( O
830 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
and O
granulocyte O
colony-stimulating O
factor O
( O
filgrastim O
";" O
5 O
micro O
g/kg/d O
subcutaneously O
days O
2 O
to O
13 O
) O
six O
cycles O
every O
14 O
days O
. O

The O
study O
was O
designed O
to O
detect O
a O
15 O
% O
improvement O
";" O
that O
is O
, O
from O
50 O
% O
to O
65 O
% O
in O
median O
progression-free O
survival O
( O
PFS O
) O
in O
favor O
of O
the O
dose-intensified O
regimen O
. O

A O
total O
of O
448 O
patients O
were O
enrolled O
over O
a O
period O
of O
3 O
years O
. O

The O
median O
dose O
intensity O
delivered O
for O
C O
and O
E O
reached O
, O
respectively O
, O
85 O
% O
and O
87 O
% O
of O
that O
planned O
in O
the O
CEF O
arm O
and O
96 O
% O
and O
95 O
% O
of O
that O
planned O
in O
the O
EC O
arm O
. O

The B-Premise
dose-intensified I-Premise
arm I-Premise
was I-Premise
slightly I-Premise
more I-Premise
emetogenic I-Premise
and I-Premise
generated I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
but I-Premise
less I-Premise
febrile I-Premise
neutropenia I-Premise
episodes I-Premise
. I-Premise

After O
a O
median O
follow-up O
of O
5.5 O
years O
, O
277 O
events O
have O
been O
reported O
. O

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
34 I-Premise
and I-Premise
33.7 I-Premise
months I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.68 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
5-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
and I-Premise
51 I-Premise
% I-Premise
for I-Premise
CEF I-Premise
and I-Premise
EC I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.94 I-Premise
) I-Premise
. I-Premise

Dose-intensified B-Claim
EC I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
CEF I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

To O
compare O
dose-volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
IUS/EUS O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O

Subjects O
were O
42 O
consecutive O
men O
from O
a O
prospective O
study O
of O
brachytherapy O
as O
monotherapy O
with O
( O
125 O
) O
I O
for O
intermediate-risk O
localized O
prostate O
cancer O
. O

No O
patient O
received O
hormonal O
therapy O
. O

Preplanning O
constraints O
included O
prostate O
V100 O
higher O
than O
95 O
% O
, O
V150 O
lower O
than O
60 O
% O
, O
and O
V200 O
lower O
than O
20 O
% O
and O
rectal O
R100 O
less O
than O
1cm O
( O
3 O
) O
. O

Patients O
completed O
the O
Expanded O
Prostate O
Cancer O
Index O
Composite O
quality-of-life O
questionnaire O
before O
and O
at O
1 O
, O
4 O
, O
8 O
, O
and O
12 O
months O
after O
implantation O
, O
and O
urinary O
domain O
scores O
were O
analyzed O
. O

All O
structures O
including O
the O
IUS O
and O
EUS O
were O
contoured O
on O
T2-weighted O
MRI O
at O
day O
30 O
, O
and O
doses O
received O
were O
calculated O
from O
identification O
of O
seeds O
on O
CT. O
Spearman O
's O
( O
nonparametric O
) O
rank O
correlation O
coefficient O
( O
ρ O
) O
was O
used O
for O
statistical O
analyses O
. O

Overall O
urinary O
morbidity O
was O
worst O
at O
1 O
month O
after O
the O
implant O
. O

Urinary B-Premise
function I-Premise
declined I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V285 I-Premise
was I-Premise
0.4 I-Premise
% I-Premise
( I-Premise
ρ=-0.32 I-Premise
, I-Premise
p=0.04 I-Premise
) I-Premise
";" I-Premise
bother B-Premise
worsened I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
99 I-Premise
% I-Premise
( I-Premise
ρ=-0.31 I-Premise
, I-Premise
p=0.05 I-Premise
) I-Premise
or I-Premise
the I-Premise
EUS I-Premise
V240 I-Premise
was I-Premise
63 I-Premise
% I-Premise
( I-Premise
ρ=-0.31 I-Premise
, I-Premise
p=0.05 I-Premise
) I-Premise
";" I-Premise
irritation B-Premise
increased I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
95 I-Premise
% I-Premise
( I-Premise
ρ=-0.37 I-Premise
, I-Premise
p=0.02 I-Premise
) I-Premise
and I-Premise
the I-Premise
EUS I-Premise
V265 I-Premise
was I-Premise
24 I-Premise
% I-Premise
( I-Premise
ρ=-0.32 I-Premise
, I-Premise
p=0.04 I-Premise
) I-Premise
";" I-Premise
and O
urgency B-Premise
worsened I-Premise
when I-Premise
the I-Premise
IUS I-Premise
V35 I-Premise
was I-Premise
99.5 I-Premise
% I-Premise
( I-Premise
ρ=-0.38 I-Premise
, I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

Incontinence B-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
EUS I-Premise
or I-Premise
IUS I-Premise
dose I-Premise
. I-Premise

Doses B-Claim
to I-Claim
the I-Claim
IUS I-Claim
and I-Claim
EUS I-Claim
on I-Claim
MRI/CT I-Claim
predicted I-Claim
worse I-Claim
urinary I-Claim
function I-Claim
, I-Claim
with I-Claim
greater I-Claim
bother I-Claim
, I-Claim
irritative I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
urgency I-Claim
. I-Claim

Incorporating B-Claim
MRI-based I-Claim
dose-volume I-Claim
histogram I-Claim
analysis I-Claim
into I-Claim
the I-Claim
treatment I-Claim
planning I-Claim
process I-Claim
may I-Claim
reduce I-Claim
acute I-Claim
urinary I-Claim
morbidity I-Claim
after I-Claim
brachytherapy I-Claim
. I-Claim

The B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim

The O
immune O
system O
can O
not O
identify O
and O
remove O
malignant O
and O
mutant O
cells O
, O
which O
cause O
tumor O
cells O
to O
escape O
from O
surveillance O
and O
clearance O
of O
the O
immune O
system O
. O

Immunobiological O
cancer O
therapy O
plays O
an O
important O
role O
in O
strengthening O
body O
immunological O
surveillance O
function O
and O
killing O
remaining O
tumor O
cells O
in O
the O
body O
. O

We O
investigated O
the O
role O
of O
DC/CIK O
( O
dendritic O
cell/cytokine-induced O
killer O
cells O
) O
immunobiological O
cancer O
therapy O
in O
maintenance O
therapy O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

When O
60 O
cases O
of O
non-small O
cell O
lung O
cancer O
patients O
in O
stage O
IIIb O
and O
IV O
reached O
stable O
disease O
after O
treatment O
with O
4 O
cycles O
of O
a O
two-drug O
regimen O
with O
platinum O
, O
they O
were O
randomly O
divided O
into O
two O
groups O
. O

One O
group O
was O
treated O
with O
DC/CIK O
immunobiological O
cancer O
therapy O
, O
and O
the O
other O
was O
taken O
as O
a O
control O
group O
. O

Finally O
, O
cancer O
progression O
time O
and O
toxicity O
reaction O
of O
the O
two O
groups O
were O
evaluated O
. O

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
proportion I-Premise
of I-Premise
NK I-Premise
cells I-Premise
, I-Premise
T-cell I-Premise
subgroups I-Premise
CD3+ I-Premise
, I-Premise
CD4+ I-Premise
and I-Premise
CD8+ I-Premise
had I-Premise
a I-Premise
significant I-Premise
change I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise

Liver B-Premise
and I-Premise
kidney I-Premise
function I-Premise
and I-Premise
blood I-Premise
tests I-Premise
of I-Premise
the I-Premise
treatment I-Premise
group I-Premise
were I-Premise
within I-Premise
the I-Premise
normal I-Premise
range I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
1 I-Premise
case I-Premise
suffered I-Premise
from I-Premise
chest I-Premise
distress I-Premise
, I-Premise
3 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
acratia I-Premise
, I-Premise
and I-Premise
4 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
pyrexia I-Premise
. I-Premise

DC/CIK B-Claim
treatment I-Claim
had I-Claim
potential I-Claim
benefit I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
and I-Claim
had I-Claim
no I-Claim
obvious I-Claim
side I-Claim
effects I-Claim
. I-Claim

DC/CIK B-Claim
treatment I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
method I-Claim
for I-Claim
maintenance I-Claim
therapy I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

Many O
women O
with O
breast O
cancer O
need O
psychological O
help O
to O
cope O
more O
effectively O
after O
treatment O
. O

Cognitive O
and O
behavioural O
techniques O
are O
not O
yet O
well O
established O
in O
France O
. O

A O
multi-site O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
a O
psycho-educational O
group O
intervention O
in O
this O
population O
. O

Two O
hundred O
and O
three O
patients O
, O
recruited O
after O
primary O
treatment O
, O
were O
randomly O
assigned O
either O
to O
a O
treatment O
group O
( O
psycho-educational O
intervention O
) O
or O
to O
a O
waiting-list O
control O
group O
. O

The O
8-week O
programme O
of O
2 O
h O
sessions O
comprised O
of O
thematic O
discussions O
, O
information O
and O
training O
in O
stress O
management O
techniques O
. O

Evaluation O
at O
baseline O
, O
after O
8 O
sessions O
, O
and O
1 O
month O
after O
programme O
completion O
, O
included O
evaluations O
using O
the O
STAI O
, O
POMS O
, O
MAC O
, O
EORTC O
QLQ-C30 O
and O
EORTC O
QLQ-BR23 O
breast O
module O
scales O
. O

We B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

No B-Premise
group-related I-Premise
negative I-Premise
effects I-Premise
were I-Premise
observed I-Premise
and I-Premise
the I-Premise
global I-Premise
satisfaction I-Premise
levels I-Premise
were I-Premise
very I-Premise
high I-Premise
. I-Premise

This B-Claim
study I-Claim
demonstrates I-Claim
the I-Claim
feasibility I-Claim
and I-Claim
effectiveness I-Claim
of I-Claim
a I-Claim
psycho-educational I-Claim
intervention I-Claim
, I-Claim
which I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
reduction I-Claim
of I-Claim
those I-Claim
negative I-Claim
affects I-Claim
which I-Claim
are I-Claim
present I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
treatment I-Claim
. I-Claim

It B-Claim
represents I-Claim
an I-Claim
excellent I-Claim
complement I-Claim
or I-Claim
an I-Claim
alternative I-Claim
to I-Claim
individual I-Claim
psycho-oncologic I-Claim
therapeutic I-Claim
support I-Claim
, I-Claim
widely O
proposed O
in O
France O
, O
and O
should O
now O
be O
tested O
in O
groups O
with O
other O
types O
of O
cancer O
and O
at O
other O
disease O
phases O
. O

To O
examine O
the O
effects O
of O
a O
scapula-oriented O
exercise O
on O
upper O
limb O
dysfunction O
in O
breast O
cancer O
survivors O
. O

A O
prospective O
randomized O
, O
controlled O
pilot O
trial O
with O
historical O
control O
. O

Rehabilitation O
department O
at O
a O
university O
hospital O
. O

Thirty-two O
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
scapula-oriented O
exercise O
group O
( O
n O
= O
16 O
) O
and O
general O
exercise O
group O
( O
n O
= O
16 O
) O
. O

An O
historical O
control O
group O
( O
n O
= O
18 O
) O
without O
exercise O
was O
enrolled O
from O
breast O
cancer O
survivors O
. O

The O
scapula-oriented O
exercises O
were O
designed O
focusing O
on O
scapulothoracic O
movement O
. O

The O
general O
exercise O
group O
performed O
body O
conditioning O
exercise O
. O

Exercise O
therapies O
were O
performed O
for O
one O
session O
per O
week O
for O
eight O
weeks O
. O

Pain O
and O
physical O
disabilities O
related O
to O
upper O
limb O
dysfunction O
, O
quality O
of O
life O
and O
depression O
were O
used O
as O
subjective O
outcomes O
. O

Objective O
outcome O
measures O
included O
shoulder O
range O
of O
motion O
and O
strength O
. O

Outcomes O
were O
assessed O
at O
baseline O
and O
post O
exercise O
. O

At O
baseline O
, O
no O
significant O
difference O
was O
observed O
among O
the O
three O
groups O
. O

The B-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
physical I-Premise
function I-Premise
, I-Premise
social I-Premise
function I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
, I-Premise
whereas I-Premise
the I-Premise
general I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
range I-Premise
of I-Premise
motion I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
0.067 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.33 I-Premise
) I-Premise
and I-Premise
strength I-Premise
of I-Premise
external I-Premise
rotation I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.55 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
general I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
. I-Premise

Scapula-oriented B-Claim
exercise I-Claim
had I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
pain I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
aspects I-Claim
of I-Claim
strength I-Claim
. I-Claim

The O
sample O
size O
required O
in O
a O
larger O
definitive O
study O
is O
32 O
subjects O
per O
group O
. O

The O
aim O
of O
the O
project O
was O
to O
identify O
clinical O
and O
quality O
of O
life O
( O
QL O
) O
factors O
that O
together O
predict O
survival O
and O
response O
to O
chemotherapy O
in O
advanced O
breast O
cancer O
. O

Potential O
prognostic O
factors O
were O
studied O
in O
187 O
women O
with O
baseline O
QL O
data O
from O
a O
trial O
of O
paclitaxel O
versus O
doxorubicin O
as O
first-line O
chemotherapy O
. O

Demographic O
and O
clinical O
factors O
studied O
were O
age O
, O
performance O
status O
, O
dominant O
site O
of O
disease O
and O
preceding O
disease-free O
interval O
( O
DFI O
) O
. O

Factors O
from O
the O
EORTC O
QLQ-C30 O
were O
all O
function O
scales O
, O
fatigue O
, O
nausea/vomiting O
, O
pain O
, O
dyspnoea O
, O
insomnia O
, O
loss O
of O
appetite O
and O
global O
QL O
. O

The O
proportional O
hazards O
regression O
model O
with O
stratification O
for O
treatment O
, O
and O
the O
logistic O
regression O
model O
adjusting O
for O
treatment O
arm O
were O
used O
for O
univariate O
and O
multivariate O
analyses O
of O
survival O
and O
response O
to O
treatment O
, O
respectively O
. O

For B-Premise
survival I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
, I-Premise
pain I-Premise
, I-Premise
global I-Premise
QL I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
significant I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
predicted I-Premise
poor I-Premise
survival I-Premise
with I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
, I-Premise
DFI I-Premise
< I-Premise
/=2 I-Premise
years I-Premise
( I-Premise
P=0.026 I-Premise
) I-Premise
and I-Premise
pain I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
. I-Premise

For B-Premise
response I-Premise
, I-Premise
age I-Premise
, I-Premise
dyspnoea I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
global I-Premise
QL I-Premise
were I-Premise
significant I-Premise
predictive I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
for I-Premise
response I-Premise
selected I-Premise
DFI I-Premise
( I-Premise
P=0.009 I-Premise
) I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.037 I-Premise
) I-Premise
and I-Premise
dyspnoea I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
using I-Premise
forward I-Premise
selection I-Premise
, I-Premise
but B-Premise
model I-Premise
instability I-Premise
was I-Premise
indicated I-Premise
by I-Premise
the I-Premise
inclusion I-Premise
of I-Premise
fatigue I-Premise
and I-Premise
emotional I-Premise
function I-Premise
in I-Premise
the I-Premise
final I-Premise
model I-Premise
when I-Premise
backward I-Premise
selection I-Premise
was I-Premise
used I-Premise
. I-Premise

In O
addition O
to O
known O
clinical O
factors O
, O
patient-assessed B-Claim
QL I-Claim
variables I-Claim
appear I-Claim
to I-Claim
be I-Claim
prognostic I-Claim
for I-Claim
survival I-Claim
and I-Claim
response I-Claim
to I-Claim
chemotherapy I-Claim
in I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

However B-Claim
, I-Claim
identification I-Claim
of I-Claim
prognostic I-Claim
factors I-Claim
from I-Claim
responses I-Claim
to I-Claim
questionnaires I-Claim
may I-Claim
be I-Claim
unstable I-Claim
, I-Claim
and I-Claim
their I-Claim
reliability I-Claim
and I-Claim
clinical I-Claim
utility I-Claim
should I-Claim
be I-Claim
tested I-Claim
prospectively I-Claim
. I-Claim

Everolimus O
( O
EVE O
) O
+exemestane O
( O
EXE O
";" O
n O
= O
485 O
) O
more O
than O
doubled O
median O
progression-free O
survival O
versus O
placebo O
( O
PBO O
) O
+ O
EXE O
( O
n O
= O
239 O
) O
, O
with O
a O
manageable O
safety O
profile O
and O
no O
deterioration O
in O
health-related O
quality-of-life O
( O
HRQOL O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
advanced O
breast O
cancer O
( O
ABC O
) O
who O
recurred O
or O
progressed O
on/after O
nonsteroidal O
aromatase O
inhibitor O
( O
NSAI O
) O
therapy O
. O

To O
further O
evaluate O
EVE O
+ O
EXE O
impact O
on O
disease O
burden O
, O
we O
conducted O
additional O
post-hoc O
analyses O
of O
patient-reported O
HRQOL O
. O

HRQOL O
was O
assessed O
using O
EORTC O
QLQ-C30 O
and O
QLQ-BR23 O
questionnaires O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
treatment O
discontinuation O
because O
of O
disease O
progression O
, O
toxicity O
, O
or O
consent O
withdrawal O
. O

Endpoints O
included O
the O
QLQ-C30 O
Global O
Health O
Status O
( O
QL2 O
) O
scale O
, O
the O
QLQ-BR23 O
breast O
symptom O
( O
BRBS O
) O
, O
and O
arm O
symptom O
( O
BRAS O
) O
scales O
. O

Between-group O
differences O
in O
change O
from O
baseline O
were O
assessed O
using O
linear O
mixed O
models O
with O
selected O
covariates O
. O

Sensitivity O
analysis O
using O
pattern-mixture O
models O
determined O
the O
effect O
of O
study O
discontinuation O
on/before O
week O
24 O
. O

Treatment O
arms O
were O
compared O
using O
differences O
of O
least O
squares O
mean O
( O
LSM O
) O
changes O
from O
baseline O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
at O
each O
timepoint O
and O
overall O
. O

Progression-free O
survival O
, O
survival O
, O
response O
rate O
, O
safety O
, O
and O
HRQOL O
. O

Linear B-Premise
mixed I-Premise
models I-Premise
( I-Premise
primary I-Premise
model I-Premise
) I-Premise
demonstrated I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
overall I-Premise
difference I-Premise
between I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
and I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
for I-Premise
QL2 I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-1.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-4.61 I-Premise
, I-Premise
0.78 I-Premise
) I-Premise
, I-Premise
BRBS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.18 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.98 I-Premise
, I-Premise
1.62 I-Premise
) I-Premise
, I-Premise
or I-Premise
BRAS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.94 I-Premise
, I-Premise
2.10 I-Premise
) I-Premise
. I-Premise

Based O
on O
pattern-mixture O
models O
, O
patients O
who O
dropped O
out O
early O
had O
worse O
QL2 O
decline O
on O
both O
treatments O
. O

In B-Premise
the I-Premise
expanded I-Premise
pattern-mixture I-Premise
model I-Premise
, I-Premise
EVE I-Premise
+ I-Premise
EXE-treated I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
drop I-Premise
out I-Premise
early I-Premise
had I-Premise
stable I-Premise
BRBS I-Premise
and I-Premise
BRAS I-Premise
relative I-Premise
to I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
. I-Premise

HRQOL O
data O
were O
not O
collected O
after O
disease O
progression O
. O

These B-Claim
analyses I-Claim
confirm I-Claim
that I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
provides I-Claim
clinical I-Claim
benefit I-Claim
without I-Claim
adversely I-Claim
impacting I-Claim
HRQOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
HR I-Claim
( I-Claim
+ I-Claim
) I-Claim
ABC I-Claim
who I-Claim
recurred/progressed I-Claim
on I-Claim
prior I-Claim
NSAIs I-Claim
versus I-Claim
endocrine I-Claim
therapy I-Claim
alone I-Claim
. I-Claim

To O
examine O
the O
effect O
of O
a O
progressive O
upper-body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O

Fourteen O
breast O
cancer O
survivors O
with O
unilateral O
upper O
extremity O
lymphedema O
were O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
7 O
) O
or O
control O
group O
( O
n O
= O
7 O
) O
. O

The O
exercise O
group O
followed O
a O
progressive O
, O
8-week O
upper-body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
Monark O
Rehab O
Trainer O
arm O
ergometer O
. O

Lymphedema O
was O
assessed O
by O
arm O
circumference O
and O
measurement O
of O
arm O
volume O
by O
water O
displacement O
. O

Patients O
were O
evaluated O
on O
five O
occasions O
over O
the O
experimental O
period O
. O

The O
Medical O
Outcomes O
Trust O
Short-Form O
36 O
Survey O
was O
used O
to O
measure O
quality O
of O
life O
before O
and O
after O
the O
intervention O
. O

Significance O
was O
set O
at O
alpha O
< O
or O
= O
0.01 O
. O

No B-Premise
changes I-Premise
were I-Premise
found I-Premise
in I-Premise
arm I-Premise
circumference I-Premise
or I-Premise
arm I-Premise
volume I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
exercise I-Premise
program I-Premise
. I-Premise

Three B-Premise
of I-Premise
the I-Premise
quality-of-life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
=.050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.023 I-Premise
) I-Premise
. I-Premise

Mental B-Premise
health I-Premise
increased I-Premise
, I-Premise
although I-Premise
not I-Premise
significantly I-Premise
, I-Premise
for I-Premise
all I-Premise
subjects I-Premise
( I-Premise
P I-Premise
=.019 I-Premise
) I-Premise
. I-Premise

Arm B-Premise
volume I-Premise
measured I-Premise
by I-Premise
water I-Premise
displacement I-Premise
was I-Premise
correlated I-Premise
with I-Premise
calculated I-Premise
arm I-Premise
volume I-Premise
( I-Premise
r I-Premise
=.973 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
although B-Premise
the I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
means I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Participation B-Claim
in I-Claim
an I-Claim
upper-body I-Claim
exercise I-Claim
program I-Claim
caused I-Claim
no I-Claim
changes I-Claim
in I-Claim
arm I-Claim
circumference I-Claim
or I-Claim
arm I-Claim
volume I-Claim
in I-Claim
women I-Claim
with I-Claim
lymphedema I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
and I-Claim
they I-Claim
may I-Claim
have I-Claim
experienced I-Claim
an I-Claim
increase I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
should I-Claim
be I-Claim
done I-Claim
in I-Claim
this I-Claim
area I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimum I-Claim
training I-Claim
program I-Claim
. I-Claim

Studies O
have O
shown O
that O
there O
is O
a O
high O
prevalence O
of O
depression O
in O
cancer O
patients O
. O

Women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim

A O
small O
number O
of O
randomized O
controlled O
trials O
have O
examined O
the O
efficacy O
of O
antidepressants O
compared O
to O
that O
of O
a O
placebo O
in O
cancer O
patients O
, O
but O
some O
results O
have O
been O
difficult O
to O
interpret O
due O
to O
a O
heterogeneous O
patient O
group O
. O

In O
the O
current O
investigation O
, O
we O
screened O
newly O
diagnosed O
early O
stage O
breast O
cancer O
patients O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
and O
investigated O
whether O
the O
oral O
antidepressant O
fluoxetine O
affected O
depressive O
symptoms O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
quality O
of O
life O
. O

Patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
screened O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

Patients O
with O
depressive O
symptoms O
were O
randomized O
to O
a O
daily O
oral O
fluoxetine O
or O
a O
placebo O
. O

Patients O
were O
then O
followed O
for O
6 O
months O
and O
evaluated O
for O
quality O
of O
life O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
depressive O
symptoms O
. O

A O
high O
percentage O
of O
patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
found O
to O
have O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

The B-Premise
use I-Premise
of I-Premise
fluoxetine I-Premise
for I-Premise
6 I-Premise
months I-Premise
resulted I-Premise
in I-Premise
an I-Premise
improvement I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
a I-Premise
higher I-Premise
completion I-Premise
of I-Premise
adjuvant I-Premise
treatment I-Premise
( I-Premise
chemotherapy I-Premise
, I-Premise
hormonal I-Premise
therapy I-Premise
, I-Premise
chemotherapy I-Premise
plus I-Premise
hormonal I-Premise
therapy I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
compared I-Premise
to I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
. I-Premise

An B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim

The O
second O
International O
Society O
of O
Paediatric O
Oncology O
( O
SIOP O
) O
study O
for O
rhabdomyosarcoma O
( O
MMT84 O
) O
had O
several O
goals O
. O

The O
two O
principal O
aims O
were O
: O
( O
1 O
) O
to O
improve O
the O
survival O
of O
children O
with O
rhabdomyosarcoma O
";" O
and O
( O
2 O
) O
to O
reduce O
the O
late O
effects O
from O
therapy O
by O
restricting O
the O
indications O
for O
surgery O
and/or O
radiotherapy O
after O
good O
response O
to O
initial O
chemotherapy O
. O

A O
further O
aim O
was O
to O
investigate O
the O
role O
of O
high-dose O
chemotherapy O
in O
young O
patients O
with O
parameningeal O
primary O
tumours O
. O

186 O
previously O
untreated O
eligible O
patients O
entered O
the O
study O
. O

Patients O
with O
completely O
resected O
primary O
tumour O
received O
three O
courses O
of O
IVA O
( O
ifosfamide O
, O
vincristine O
and O
actinomycin O
D O
) O
. O

Patients O
with O
incompletely O
resected O
tumour O
received O
six O
to O
10 O
courses O
of O
IVA O
according O
to O
stage O
. O

Patients O
achieving O
complete O
remission O
with O
chemotherapy O
alone O
did O
not O
usually O
receive O
radiotherapy O
or O
undergo O
extensive O
surgery O
, O
but O
patients O
remaining O
in O
partial O
remission O
received O
local O
therapy O
with O
surgery O
and/or O
radiotherapy O
. O

Only O
patients O
over O
5 O
years O
of O
age O
with O
parameningeal O
disease O
and O
patients O
over O
12 O
years O
with O
tumours O
at O
any O
site O
were O
given O
systematic O
irradiation O
. O

Complete B-Premise
remission I-Premise
was I-Premise
achieved I-Premise
in I-Premise
91 I-Premise
% I-Premise
( I-Premise
170/186 I-Premise
) I-Premise
of I-Premise
all I-Premise
patients I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
8 I-Premise
years I-Premise
, I-Premise
the I-Premise
5-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
68 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
3 I-Premise
% I-Premise
standard I-Premise
error I-Premise
of I-Premise
the I-Premise
mean I-Premise
( I-Premise
SEM I-Premise
) I-Premise
and I-Premise
the I-Premise
5-year I-Premise
event-free I-Premise
survival I-Premise
53 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
4 I-Premise
% I-Premise
SEM I-Premise
) I-Premise
. I-Premise

These B-Premise
results I-Premise
show I-Premise
an I-Premise
improvement I-Premise
over I-Premise
previous I-Premise
SIOP I-Premise
study I-Premise
( I-Premise
RMS75 I-Premise
) I-Premise
in I-Premise
which I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
and I-Premise
event-free I-Premise
survival I-Premise
was I-Premise
47 I-Premise
% I-Premise
. I-Premise

Among B-Premise
the I-Premise
54 I-Premise
patients I-Premise
who I-Premise
exhibited I-Premise
isolated I-Premise
local I-Premise
relapse I-Premise
, I-Premise
35 I-Premise
% I-Premise
( I-Premise
19/54 I-Premise
) I-Premise
survived I-Premise
in I-Premise
further I-Premise
remission I-Premise
longer I-Premise
than I-Premise
2 I-Premise
years I-Premise
after I-Premise
retreatment I-Premise
, I-Premise
including I-Premise
local I-Premise
therapy I-Premise
( I-Premise
surgery I-Premise
+/- I-Premise
radiotherapy I-Premise
) I-Premise
. I-Premise

Analysis O
of O
the O
overall O
burden O
of O
therapy O
received O
by O
all O
surviving O
children O
( O
including O
primary O
treatment O
and O
treatment O
for O
relapse O
if O
required O
) O
showed O
that O
24 O
% O
( O
28/116 O
) O
were O
treated O
by O
limited O
surgery O
followed O
by O
three O
courses O
of O
IVA O
, O
29 O
% O
( O
34/116 O
) O
were O
treated O
by O
chemotherapy O
alone O
( O
after O
initial O
biopsy O
) O
and O
13 O
% O
( O
15/116 O
) O
received O
chemotherapy O
plus O
conservative O
local O
treatment O
( O
limited O
surgery O
or O
radiotherapy O
for O
residual O
disease O
) O
. O

Only O
34 O
% O
( O
39/116 O
) O
received O
intensive O
local O
therapy O
defined O
as O
radical O
wide O
field O
radiotherapy O
or O
radical O
surgery O
or O
both O
. O

Compared B-Claim
with I-Claim
the I-Claim
results I-Claim
obtained I-Claim
in I-Claim
the I-Claim
previous I-Claim
SIOP I-Claim
study I-Claim
, I-Claim
treatment I-Claim
in I-Claim
MMT84 I-Claim
was I-Claim
based I-Claim
on I-Claim
response I-Claim
to I-Claim
initial I-Claim
chemotherapy I-Claim
and I-Claim
, I-Claim
despite I-Claim
an I-Claim
overall I-Claim
reduction I-Claim
of I-Claim
the I-Claim
use I-Claim
of I-Claim
local I-Claim
therapy I-Claim
, I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
for I-Claim
patients I-Claim
with I-Claim
non-metastatic I-Claim
disease I-Claim
. I-Claim

This B-Claim
trial I-Claim
, I-Claim
also I-Claim
for I-Claim
the I-Claim
first I-Claim
time I-Claim
, I-Claim
provides I-Claim
evidence I-Claim
that I-Claim
retreatment I-Claim
after I-Claim
local I-Claim
relapse I-Claim
can I-Claim
achieve I-Claim
long-term I-Claim
second I-Claim
remissions I-Claim
. I-Claim

DPPE B-Claim
( I-Claim
tesmilifene I-Claim
) I-Claim
plus I-Claim
doxorubicin I-Claim
( I-Claim
DOX I-Claim
) I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
survival I-Claim
versus I-Claim
DOX I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

However B-Premise
, I-Premise
DPPE I-Premise
is I-Premise
associated I-Premise
with I-Premise
unusual I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
form I-Premise
of I-Premise
hallucinations I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
which I-Premise
were I-Premise
anticipated I-Premise
to I-Premise
impact I-Premise
on I-Premise
short-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
. I-Premise

Standard O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
( O
NCIC O
CTG O
) O
approaches O
were O
applied O
as O
the O
primary O
method O
to O
analyze O
the O
QOL O
data O
from O
this O
trial O
. O

This O
includes O
cross-sectional O
comparisons O
, O
together O
with O
a O
global O
test O
for O
the O
QOL O
response O
rate O
. O

Sensitivity O
analyses O
were O
also O
performed O
for O
selected O
QOL O
domains O
and O
items O
, O
using O
other O
types O
of O
summary O
measures O
and O
statistics O
. O

Two O
hundred O
seventy O
one O
patients O
( O
89 O
% O
of O
randomized O
) O
submitted O
the O
baseline O
QOL O
questionnaires O
and O
were O
included O
in O
the O
QOL O
analysis O
. O

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
response I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
found I-Premise
for I-Premise
any I-Premise
domain I-Premise
or I-Premise
item I-Premise
except I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Cross-sectional B-Premise
comparisons I-Premise
showed I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
some I-Premise
domains/items I-Premise
at I-Premise
specific I-Premise
assessment I-Premise
times I-Premise
with I-Premise
all I-Premise
differences I-Premise
favoring I-Premise
the I-Premise
DOX I-Premise
alone I-Premise
arm I-Premise
. I-Premise

Patients B-Premise
on I-Premise
DPPE/DOX I-Premise
arm I-Premise
were I-Premise
significantly I-Premise
worse I-Premise
in I-Premise
terms I-Premise
of I-Premise
average I-Premise
and I-Premise
median I-Premise
pain I-Premise
change I-Premise
scores I-Premise
. I-Premise

Different B-Claim
analyses I-Claim
yielded I-Claim
slightly I-Claim
different I-Claim
conclusions I-Claim
but O
, O
in B-Claim
general I-Claim
, I-Claim
the I-Claim
QOL I-Claim
analyses I-Claim
were I-Claim
concordant I-Claim
and I-Claim
showed I-Claim
that I-Claim
patients I-Claim
on I-Claim
DOX I-Claim
alone I-Claim
had I-Claim
fewer I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
related I-Claim
adverse I-Claim
events I-Claim
and I-Claim
better I-Claim
QOL I-Claim
. I-Claim

Interestingly B-Claim
, I-Claim
the I-Claim
QOL I-Claim
response I-Claim
analysis I-Claim
also I-Claim
showed I-Claim
that I-Claim
aggressive I-Claim
premedication I-Claim
regimens I-Claim
appear I-Claim
to I-Claim
ameliorate I-Claim
potential I-Claim
negative I-Claim
effects I-Claim
of I-Claim
DPPE I-Claim
on I-Claim
emesis I-Claim
and I-Claim
nausea I-Claim
as I-Claim
measured I-Claim
by I-Claim
patient I-Claim
assessed I-Claim
QOL I-Claim
. I-Claim

Numerous O
studies O
have O
examined O
the O
comorbidity O
of O
depression O
with O
cancer O
, O
and O
some O
have O
indicated O
that O
depression O
may O
be O
associated O
with O
cancer O
progression O
or O
survival O
. O

However O
, O
few O
studies O
have O
assessed O
whether O
changes O
in O
depression O
symptoms O
are O
associated O
with O
survival O
. O

In O
a O
secondary O
analysis O
of O
a O
randomized O
trial O
of O
supportive-expressive O
group O
therapy O
, O
125 O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
completed O
a O
depression O
symptom O
measure O
( O
Center O
for O
Epidemiologic O
Studies-Depression O
Scale O
[ O
CES-D O
] O
) O
at O
baseline O
and O
were O
randomly O
assigned O
to O
a O
treatment O
group O
or O
to O
a O
control O
group O
that O
received O
educational O
materials O
. O

At O
baseline O
and O
three O
follow-up O
points O
, O
101 O
of O
125 O
women O
completed O
a O
depression O
symptom O
measure O
. O

We O
used O
these O
data O
in O
a O
Cox O
proportional O
hazards O
analysis O
to O
examine O
whether O
decreasing O
depression O
symptoms O
over O
the O
first O
year O
of O
the O
study O
( O
the O
length O
of O
the O
intervention O
) O
would O
be O
associated O
with O
longer O
survival O
. O

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
53.6 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
decreasing I-Premise
CES-D I-Premise
scores I-Premise
over I-Premise
1 I-Premise
year I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
increasing I-Premise
CES-D I-Premise
scores I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
change I-Premise
in I-Premise
CES-D I-Premise
over I-Premise
the I-Premise
first I-Premise
year I-Premise
on I-Premise
survival I-Premise
out I-Premise
to I-Premise
14 I-Premise
years I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
but B-Premise
no I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
treatment I-Premise
condition I-Premise
and I-Premise
CES-D I-Premise
change I-Premise
on I-Premise
survival I-Premise
. I-Premise

Neither O
demographic O
nor O
medical O
variables O
explained O
this O
association O
. O

Decreasing B-Claim
depression I-Claim
symptoms I-Claim
over I-Claim
the I-Claim
first I-Claim
year I-Claim
were I-Claim
associated I-Claim
with I-Claim
longer I-Claim
subsequent I-Claim
survival I-Claim
for I-Claim
women I-Claim
with I-Claim
MBC I-Claim
in I-Claim
this I-Claim
sample I-Claim
. I-Claim

Further B-Claim
research I-Claim
is I-Claim
necessary I-Claim
to I-Claim
confirm I-Claim
this I-Claim
hypothesis I-Claim
in I-Claim
other I-Claim
samples I-Claim
, I-Claim
and I-Claim
causation I-Claim
can I-Claim
not I-Claim
be I-Claim
assumed I-Claim
based I-Claim
on I-Claim
this I-Claim
analysis I-Claim
. I-Claim

We O
aimed O
to O
determine O
the O
effect O
of O
dietary O
counseling O
or O
oral O
supplements O
on O
outcome O
for O
patients O
with O
cancer O
, O
specifically O
, O
nutritional O
outcome O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
, O
during O
and O
3 O
months O
after O
radiotherapy O
. O

Seventy-five O
patients O
with O
head O
and O
neck O
cancer O
who O
were O
referred O
for O
radiotherapy O
( O
RT O
) O
were O
randomized O
to O
the O
following O
groups O
: O
group O
1 O
( O
n O
= O
25 O
) O
, O
patients O
who O
received O
dietary O
counseling O
with O
regular O
foods O
";" O
group O
2 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
usual O
diet O
plus O
supplements O
";" O
and O
group O
3 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
intake O
ad O
lib O
. O

Nutritional O
intake O
( O
determined O
by O
diet O
history O
) O
and O
status O
( O
determined O
by O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QOL O
( O
determined O
by O
the O
European O
Organization O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
[ O
EORTC O
QLQ-C30 O
] O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
of O
RT O
, O
and O
at O
3 O
months O
. O

Energy B-Premise
intake I-Premise
after I-Premise
RT I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Protein B-Premise
intake I-Premise
also I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Both B-Premise
energy I-Premise
and I-Premise
protein I-Premise
intake I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
intakes I-Premise
, I-Premise
whereas I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
returned I-Premise
to I-Premise
or I-Premise
below I-Premise
baseline I-Premise
levels I-Premise
. I-Premise

After B-Premise
RT I-Premise
, I-Premise
> I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
RT I-Premise
toxicity I-Premise
";" I-Premise
this B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
for I-Premise
reduced I-Premise
symptomatology I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
group I-Premise
2/group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.07 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
incidence/severity I-Premise
of I-Premise
grade I-Premise
1+2 I-Premise
anorexia I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
xerostomia I-Premise
, I-Premise
and I-Premise
dysgeusia I-Premise
was I-Premise
different I-Premise
: I-Premise
90 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
improved I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
67 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
versus I-Premise
51 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

After B-Premise
RT I-Premise
, I-Premise
QOL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
.003 I-Premise
) I-Premise
proportionally I-Premise
with I-Premise
improved I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
status I-Premise
in I-Premise
group I-Premise
1/group I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
worsened I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
overall I-Premise
QOL I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
maintained I-Premise
or I-Premise
worsened I-Premise
overall I-Premise
QOL I-Premise
. I-Premise

During B-Claim
RT I-Claim
, I-Claim
nutritional I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar/higher I-Claim
benefit I-Claim
";" I-Claim
in B-Claim
the I-Claim
medium I-Claim
term I-Claim
, I-Claim
only I-Claim
counseling I-Claim
exerted I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Pemetrexed O
maintenance O
therapy O
significantly O
improved O
overall O
survival O
and O
progression-free O
survival O
compared O
with O
placebo O
, O
and O
had O
a O
good O
safety O
profile O
in O
a O
phase O
3 O
placebo-controlled O
study O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Results O
for O
quality O
of O
life O
, O
symptom O
palliation O
, O
and O
tolerability O
are O
presented O
here O
. O

After O
four O
cycles O
of O
platinum-based O
induction O
therapy O
, O
663 O
patients O
with O
stage O
IIIB O
or O
stage O
IV O
NSCLC O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
or O
1 O
were O
randomly O
assigned O
( O
in O
a O
2:1 O
ratio O
) O
from O
March O
15 O
, O
2005 O
, O
to O
July O
20 O
, O
2007 O
, O
using O
the O
Pocock O
and O
Simon O
minimisation O
method O
to O
receive O
pemetrexed O
( O
500 O
mg/m O
( O
2 O
) O
every O
21 O
days O
";" O
n=441 O
) O
or O
placebo O
( O
n=222 O
) O
plus O
best O
supportive O
care O
until O
disease O
progression O
. O

The O
primary O
efficacy O
data O
have O
been O
reported O
previously O
. O

Patients O
completed O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post-discontinuation O
. O

Worsening O
of O
symptoms O
was O
defined O
as O
an O
increase O
of O
15 O
mm O
or O
more O
from O
baseline O
on O
a O
100 O
mm O
scale O
for O
each O
LCSS O
item O
. O

The O
primary O
outcome O
for O
these O
quality-of-life O
analyses O
was O
time O
to O
worsening O
of O
symptoms O
, O
analysed O
for O
all O
randomised O
patients O
. O

Baseline O
characteristics O
, O
including O
LCSS O
scores O
, O
were O
well O
balanced O
between O
groups O
. O

Baseline O
LCSS O
scores O
were O
low O
, O
indicating O
low O
symptom O
burden O
for O
patients O
without O
disease O
progression O
after O
completion O
of O
first-line O
treatment O
. O

Longer B-Premise
time I-Premise
to I-Premise
worsening I-Premise
was I-Premise
recorded I-Premise
for I-Premise
pain I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0·76 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·59-0·99 I-Premise
";" I-Premise
p=0·041 I-Premise
) I-Premise
and I-Premise
haemoptysis I-Premise
( I-Premise
HR I-Premise
0·58 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·34-0·97 I-Premise
";" I-Premise
p=0·038 I-Premise
) I-Premise
with I-Premise
pemetrexed I-Premise
than I-Premise
with I-Premise
placebo I-Premise
";" I-Premise
no B-Premise
other I-Premise
significant I-Premise
differences I-Premise
in I-Premise
analyses I-Premise
of I-Premise
time I-Premise
to I-Premise
worsening I-Premise
were I-Premise
noted I-Premise
. I-Premise

Additional B-Premise
longitudinal I-Premise
analyses I-Premise
showed I-Premise
a I-Premise
greater I-Premise
increase I-Premise
in I-Premise
loss I-Premise
of I-Premise
appetite I-Premise
in I-Premise
the I-Premise
pemetrexed I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
4·3 I-Premise
mm I-Premise
vs I-Premise
0·2 I-Premise
mm I-Premise
";" I-Premise
p=0·028 I-Premise
) I-Premise
. I-Premise

Rates B-Premise
of I-Premise
resource I-Premise
use I-Premise
were I-Premise
statistically I-Premise
higher I-Premise
for I-Premise
pemetrexed I-Premise
than I-Premise
for I-Premise
placebo I-Premise
: I-Premise
admissions I-Premise
to I-Premise
hospital I-Premise
for I-Premise
drug-related I-Premise
adverse I-Premise
events I-Premise
( I-Premise
19 I-Premise
[ I-Premise
4 I-Premise
% I-Premise
] I-Premise
vs I-Premise
none I-Premise
";" I-Premise
p=0·001 I-Premise
) I-Premise
, I-Premise
transfusions I-Premise
( I-Premise
42 I-Premise
[ I-Premise
10 I-Premise
% I-Premise
] I-Premise
vs I-Premise
seven I-Premise
[ I-Premise
3 I-Premise
% I-Premise
] I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
, I-Premise
and I-Premise
erythropoiesis-stimulating I-Premise
agents I-Premise
( I-Premise
26 I-Premise
[ I-Premise
6 I-Premise
% I-Premise
] I-Premise
vs I-Premise
four I-Premise
[ I-Premise
2 I-Premise
% I-Premise
] I-Premise
";" I-Premise
p=0·017 I-Premise
) I-Premise
. I-Premise

Quality B-Claim
of I-Claim
life I-Claim
during I-Claim
maintenance I-Claim
therapy I-Claim
with I-Claim
pemetrexed I-Claim
is I-Claim
similar I-Claim
to I-Claim
placebo I-Claim
, I-Claim
except B-Claim
for I-Claim
a I-Claim
small I-Claim
increase I-Claim
in I-Claim
loss I-Claim
of I-Claim
appetite I-Claim
, I-Claim
and I-Claim
significantly I-Claim
delayed I-Claim
worsening I-Claim
of I-Claim
pain I-Claim
and I-Claim
haemoptysis I-Claim
. I-Claim

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

The B-Claim
role I-Claim
of I-Claim
high-dose I-Claim
chemotherapy I-Claim
( I-Claim
HDCT I-Claim
) I-Claim
in I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
HDCT I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim

This O
study O
was O
initiated O
to O
compare O
up-front O
tandem O
HDCT O
and O
standard O
combination O
therapy O
in O
patients O
with O
metastatic O
breast O
cancer O
. O

Patients O
without O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomly O
assigned O
to O
standard O
combination O
therapy O
with O
doxorubicin O
and O
paclitaxel O
( O
AT O
) O
or O
double O
HDCT O
with O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
etoposide O
followed O
by O
peripheral-blood O
stem-cell O
transplantation O
. O

HDCT O
was O
repeated O
after O
6 O
weeks O
. O

Patients O
were O
stratified O
by O
menopausal O
and O
hormone-receptor O
status O
. O

The O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
CR O
) O
rates O
. O

A O
total O
of O
93 O
patients O
were O
enrolled O
onto O
the O
trial O
. O

Intent-to-treat B-Premise
CR I-Premise
rates I-Premise
for I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
HDCT I-Premise
and I-Premise
AT I-Premise
were I-Premise
12.5 I-Premise
% I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
66.7 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
and I-Premise
64.4 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
AT I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.82 I-Premise
) I-Premise
. I-Premise

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
10.6 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.67 I-Premise
) I-Premise
, I-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
13.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
14.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.98 I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
26.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
23.4 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.60 I-Premise
) I-Premise
. I-Premise

HDCT B-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
more I-Premise
myelosuppression I-Premise
, I-Premise
infection I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
treated I-Premise
with I-Premise
AT I-Premise
developed I-Premise
more I-Premise
neurotoxicity I-Premise
. I-Premise

This B-Claim
trial I-Claim
failed I-Claim
to I-Claim
show I-Claim
a I-Claim
benefit I-Claim
for I-Claim
up-front I-Claim
tandem I-Claim
HDCT I-Claim
compared I-Claim
with I-Claim
standard I-Claim
combination I-Claim
therapy I-Claim
. I-Claim

HDCT B-Claim
was I-Claim
associated I-Claim
with I-Claim
more I-Claim
acute I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

Standard O
guidelines O
for O
cancer O
pain O
treatment O
routinely O
recommend O
training O
patients O
to O
reduce O
barriers O
to O
pain O
relief O
, O
use O
medications O
appropriately O
, O
and O
communicate O
their O
pain-related O
needs O
. O

Methods B-Claim
are I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
professional I-Claim
time I-Claim
required I-Claim
while I-Claim
achieving I-Claim
sustained I-Claim
intervention I-Claim
effectiveness I-Claim
. I-Claim

In O
a O
multisite O
, O
randomized O
controlled O
trial O
, O
this O
study O
tested O
a O
pain O
training O
method O
versus O
a O
nutrition O
control O
. O

At O
six O
oncology O
clinics O
, O
physicians O
( O
N=22 O
) O
and O
nurses O
( O
N=23 O
) O
enrolled O
patients O
( O
N=93 O
) O
who O
were O
over O
18 O
years O
of O
age O
, O
with O
cancer O
diagnoses O
, O
pain O
, O
and O
a O
life O
expectancy O
of O
at O
least O
6 O
months O
. O

Pain O
training O
and O
control O
interventions O
were O
matched O
for O
materials O
and O
method O
. O

Patients O
watched O
a O
video O
followed O
by O
about O
20 O
min O
of O
manual-standardized O
training O
with O
an O
oncology O
nurse O
focused O
on O
reviewing O
the O
printed O
material O
and O
adapted O
to O
individual O
concerns O
of O
patients O
. O

A O
follow-up O
phone O
call O
after O
72 O
h O
addressed O
individualized O
treatment O
content O
and O
pain O
communication O
. O

Assessments O
at O
baseline O
, O
one O
, O
three O
, O
and O
6 O
months O
included O
barriers O
, O
the O
Brief O
Pain O
Inventory O
, O
opioid O
use O
, O
and O
physician O
and O
nurse O
ratings O
of O
their O
patients O
' O
pain O
. O

Trained B-Premise
versus I-Premise
control I-Premise
patients I-Premise
reported I-Premise
reduced I-Premise
barriers I-Premise
to I-Premise
pain I-Premise
relief I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
lower I-Premise
usual I-Premise
pain I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
opioid I-Premise
use I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
pain I-Premise
training I-Premise
patients I-Premise
reported I-Premise
severe I-Premise
pain I-Premise
( I-Premise
> I-Premise
6 I-Premise
on I-Premise
a I-Premise
0-10 I-Premise
scale I-Premise
) I-Premise
at I-Premise
1-month I-Premise
outcomes I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
. I-Premise

Physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
P=.04 O
and O
< O
.001 O
, O
respectively O
) O
. O

Training O
efficacy O
was O
not O
modified O
by O
patient O
characteristics O
. O

Using B-Claim
video I-Claim
and I-Claim
print I-Claim
materials I-Claim
, I-Claim
with I-Claim
brief I-Claim
individualized I-Claim
training I-Claim
, I-Claim
effectively I-Claim
improved I-Claim
pain I-Claim
management I-Claim
over I-Claim
time I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
of I-Claim
varying I-Claim
diagnostic I-Claim
and I-Claim
demographic I-Claim
groups I-Claim
. I-Claim

Sexual O
dysfunction O
represents O
a O
complex O
and O
multifactorial O
construct O
that O
can O
affect O
both O
men O
and O
women O
and O
has O
been O
noted O
to O
often O
deteriorate O
significantly O
after O
treatment O
for O
rectal O
and O
anal O
cancer O
. O

Despite O
this O
, O
it O
remains O
an O
understudied O
, O
underreported O
, O
and O
undertreated O
issue O
in O
the O
field O
of O
cancer O
survivorship O
. O

This O
study O
examined O
the O
characteristics O
of O
women O
enrolled O
in O
an O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
, O
and O
explored O
the O
relationship O
between O
sexual O
functioning O
and O
psychological O
well-being O
. O

There O
were O
70 O
female O
posttreatment O
anal O
or O
rectal O
cancer O
survivors O
assessed O
as O
part O
of O
the O
current O
study O
. O

Participants O
were O
enrolled O
in O
a O
randomized O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
and O
completed O
outcome O
measures O
prior O
to O
randomization O
. O

The O
main O
outcome O
measures O
are O
quality O
of O
life O
( O
QOL O
) O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
[ O
EORTC-QLQ-C30 O
] O
and O
Colorectal O
Cancer-Specific O
Module O
[ O
QLQ-CR38 O
] O
) O
, O
sexual O
functioning O
( O
Female O
Sexual O
Functioning O
Index O
) O
, O
and O
psychological O
well-being O
( O
Brief O
Symptom O
Inventory O
Depression/Anxiety O
, O
Impact O
of O
Events O
Scale-Revised O
, O
CR-38 O
Body O
Image O
) O
. O

Women O
enrolled O
in O
the O
study O
intervention O
were O
on O
average O
55 O
years O
old O
, O
predominantly O
Caucasian O
( O
79 O
% O
) O
, O
married O
( O
57 O
% O
) O
, O
and O
a O
median O
of O
4 O
years O
postprimary O
treatment O
. O

For O
those O
reporting O
sexual O
activity O
at O
baseline O
( O
N=41 O
) O
, O
sexual O
dysfunction O
was O
associated O
with O
a O
range O
of O
specific O
measures O
of O
psychological O
well-being O
, O
all O
in O
the O
hypothesized O
direction O
. O

The B-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
subscale I-Premise
was I-Premise
associated I-Premise
with I-Premise
all I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
( I-Premise
r=-0.45 I-Premise
to I-Premise
-0.70 I-Premise
, I-Premise
all I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Body B-Premise
image I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
cancer-specific I-Premise
posttraumatic I-Premise
distress I-Premise
were I-Premise
notable I-Premise
in I-Premise
their I-Premise
association I-Premise
with I-Premise
subscales I-Premise
of I-Premise
sexual I-Premise
functioning I-Premise
, I-Premise
while I-Premise
a I-Premise
global I-Premise
QOL I-Premise
measure I-Premise
was I-Premise
largely I-Premise
unrelated I-Premise
. I-Premise

For B-Premise
sexually I-Premise
active I-Premise
female I-Premise
rectal I-Premise
and I-Premise
anal I-Premise
cancer I-Premise
survivors I-Premise
enrolled I-Premise
in I-Premise
a I-Premise
sexual I-Premise
health I-Premise
intervention I-Premise
, I-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
and I-Premise
consistently I-Premise
associated I-Premise
with I-Premise
specific I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
, I-Premise
most I-Premise
notably I-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
. I-Premise

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
QOL I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
Sexual/Relationship I-Claim
Satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim

We O
have O
recently O
suggested O
that O
bolus O
5-fluorouracil O
( O
5-FU O
) O
may O
work O
via O
a O
RNA O
directed O
mechanism O
while O
continuous O
infusion O
5-FU O
may O
kill O
cells O
via O
a O
thymidylate O
synthase O
related O
pathway O
. O

It O
may O
thus O
be O
possible O
to O
selectively O
modulate O
each O
schedule O
biochemically O
. O

We O
have O
compared O
an O
alternating O
regimen O
of O
bolus O
and O
continuous O
infusion O
5-FU O
, O
selectively O
modulated O
for O
the O
schedule O
of O
administration O
, O
with O
modulated O
bolus O
5-FU O
in O
advanced O
colorectal O
cancer O
patients O
. O

Two O
hundred O
fourteen O
patients O
from O
nineteen O
Italian O
centers O
were O
randomized O
to O
the O
control O
arm O
consisting O
of O
biweekly O
cycles O
of O
MTX O
, O
200 O
mg/m2 O
on O
day O
1 O
, O
followed O
by O
bolus O
5-FU O
600 O
mg/m2 O
on O
day O
2 O
and O
6-S-leucovorin O
rescue O
, O
or O
to O
the O
experimental O
arm O
consisting O
of O
two O
biweekly O
cycles O
of O
the O
same O
regimen O
as O
in O
the O
control O
arm O
alternated O
to O
three O
weeks O
of O
continuous O
infusion O
5-FU O
( O
200 O
mg/m2 O
day O
) O
+ O
weekly O
bolus O
6-S-leucovorin O
, O
20 O
mg/m2 O
. O

Nine B-Premise
CR I-Premise
and I-Premise
twenty-seven I-Premise
PR I-Premise
were I-Premise
obtained I-Premise
on I-Premise
one I-Premise
hundred I-Premise
eleven I-Premise
evaluable I-Premise
patients I-Premise
treated I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
RR I-Premise
= I-Premise
32 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
: I-Premise
24 I-Premise
% I-Premise
-42 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
two I-Premise
CR I-Premise
and I-Premise
eleven I-Premise
PR I-Premise
were I-Premise
observed I-Premise
among I-Premise
one I-Premise
hundred I-Premise
three I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
control I-Premise
arm I-Premise
( I-Premise
RR I-Premise
= I-Premise
13 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7 I-Premise
% I-Premise
-21 I-Premise
% I-Premise
) I-Premise
. I-Premise

WHO B-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
occurred I-Premise
in I-Premise
13 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
of I-Premise
experimental I-Premise
arm I-Premise
and I-Premise
in I-Premise
8 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
in I-Premise
control I-Premise
arm I-Premise
. I-Premise

The B-Premise
PFS I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
6.2 I-Premise
vs. I-Premise
4.3 I-Premise
months I-Premise
, I-Premise
odds I-Premise
ratio I-Premise
0.66 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
, I-Premise
while O
the B-Premise
overall I-Premise
survival I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
14.8 I-Premise
months I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
vs. I-Premise
14.1 I-Premise
months I-Premise
in I-Premise
control I-Premise
arm I-Premise
) I-Premise
";" I-Premise
quality B-Claim
of I-Claim
life I-Claim
was I-Claim
similar I-Claim
as I-Claim
well I-Claim
. I-Claim

Eighty B-Premise
percent I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
second-line I-Premise
chemotherapy I-Premise
in I-Premise
control I-Premise
arm I-Premise
were I-Premise
treated I-Premise
with I-Premise
continuous I-Premise
infusion I-Premise
5-FU I-Premise
. I-Premise

Alternating O
, O
schedule-specific B-Claim
biochemical I-Claim
modulation I-Claim
of I-Claim
FU I-Claim
is I-Claim
more I-Claim
active I-Claim
than I-Claim
MTX I-Claim
-- I-Claim
> I-Claim
5-FU I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
overall I-Claim
survival I-Claim
was I-Claim
similar I-Claim
suggesting I-Claim
that I-Claim
alternating I-Claim
bolus I-Claim
and I-Claim
infusional I-Claim
5-FU I-Claim
upfront I-Claim
may I-Claim
be I-Claim
as I-Claim
effective I-Claim
as I-Claim
giving I-Claim
them I-Claim
in I-Claim
sequence I-Claim
as I-Claim
first- I-Claim
and I-Claim
second-line I-Claim
treatment I-Claim
. I-Claim

Gefitinib O
has O
shown O
high O
response O
rate O
and O
improved O
progression-free O
survival O
( O
PFS O
) O
in O
never-smokers O
with O
lung O
adenocarcinoma O
( O
NSLAs O
) O
. O

We O
compared O
efficacy O
of O
gefitinib O
with O
gemcitabine O
and O
cisplatin O
( O
GP O
) O
chemotherapy O
in O
this O
group O
of O
patients O
as O
first-line O
therapy O
. O

In O
this O
randomized O
phase O
III O
trial O
, O
a O
total O
of O
313 O
Korean O
never-smokers O
with O
stage O
IIIB O
or O
IV O
lung O
adenocarcinoma O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
0 O
to O
2 O
, O
and O
adequate O
organ O
function O
were O
randomly O
assigned O
to O
receive O
either O
gefitinib O
( O
250 O
mg O
daily O
) O
or O
GP O
chemotherapy O
( O
gemcitabine O
1,250 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
";" O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
, O
for O
up O
to O
nine O
courses O
) O
. O

The O
primary O
objective O
was O
to O
demonstrate O
better O
overall O
survival O
( O
OS O
) O
for O
gefitinib O
compared O
with O
GP O
in O
chemotherapy-naive O
NSLAs O
. O

Three O
hundred O
nine O
patients O
were O
analyzed O
per O
protocol O
( O
gefitinib O
arm O
, O
n O
= O
159 O
";" O
GP O
arm O
, O
n O
= O
150 O
) O
. O

Gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
OS I-Premise
compared I-Premise
with I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.932 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.716 I-Premise
to I-Premise
1.213 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.604 I-Premise
";" I-Premise
median I-Premise
OS I-Premise
, I-Premise
22.3 I-Premise
v I-Premise
22.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
1-year I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
16.7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2.8 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.198 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.944 I-Premise
to I-Premise
1.520 I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
55 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
46 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
P I-Premise
= I-Premise
.101 I-Premise
) I-Premise
. I-Premise

Myelosuppression B-Premise
, I-Premise
renal I-Premise
insufficiency I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but O
skin B-Premise
toxicities I-Premise
and I-Premise
liver I-Premise
dysfunction I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
. I-Premise

Two B-Premise
patients I-Premise
( I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
developed I-Premise
interstitial I-Premise
lung I-Premise
disease I-Premise
and I-Premise
died I-Premise
. I-Premise

Gefitinib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
superior I-Claim
OS I-Claim
compared I-Claim
with I-Claim
GP I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
for I-Claim
NSLAs I-Claim
. I-Claim

To O
compare O
survival O
in O
patients O
with O
recurrent O
or O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCCHN O
) O
treated O
with O
gefitinib O
250 O
or O
500 O
mg/day O
or O
standard O
methotrexate O
. O

Four O
hundred O
eighty-six O
patients O
with O
recurrent O
SCCHN O
were O
randomly O
assigned O
to O
oral O
gefitinib O
250 O
mg/day O
, O
gefitinib O
500 O
mg/day O
, O
or O
methotrexate O
40 O
mg/m O
( O
2 O
) O
intravenously O
weekly O
. O

Primary O
end O
point O
was O
overall O
survival O
, O
secondary O
end O
points O
were O
objective O
response O
rate O
( O
ORR O
) O
, O
safety O
, O
symptom O
improvement O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Exploratory O
end O
points O
included O
association O
of O
efficacy O
with O
epidermal O
growth O
factor O
receptor O
gene O
copy O
number O
and O
other O
biomarkers O
. O

Neither B-Premise
gefitinib I-Premise
250 I-Premise
nor I-Premise
500 I-Premise
mg/day I-Premise
improved I-Premise
overall I-Premise
survival I-Premise
compared I-Premise
with I-Premise
methotrexate I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.22 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.95 I-Premise
to I-Premise
1.57 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
";" I-Premise
and I-Premise
HR I-Premise
, I-Premise
1.12 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87 I-Premise
to I-Premise
1.43 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.39 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
5.6 I-Premise
, I-Premise
6.0 I-Premise
, I-Premise
and I-Premise
6.7 I-Premise
months I-Premise
";" I-Premise
ORRs I-Premise
( I-Premise
Response I-Premise
Evaluation I-Premise
Criteria I-Premise
in I-Premise
Solid I-Premise
Tumors I-Premise
) I-Premise
were I-Premise
2.7 I-Premise
% I-Premise
, I-Premise
7.6 I-Premise
% I-Premise
and I-Premise
3.9 I-Premise
% I-Premise
, I-Premise
with I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
either I-Premise
gefitinib I-Premise
arm I-Premise
and I-Premise
methotrexate I-Premise
. I-Premise

No B-Premise
unexpected I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
, I-Premise
except B-Premise
for I-Premise
tumor I-Premise
hemorrhage-type I-Premise
events I-Premise
with I-Premise
gefitinib I-Premise
( I-Premise
8.9 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
";" I-Premise
11.4 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
500 I-Premise
mg/day I-Premise
";" I-Premise
1.9 I-Premise
% I-Premise
, I-Premise
methotrexate I-Premise
) I-Premise
. I-Premise

QOL B-Premise
improvement I-Premise
rates I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
& I-Premise
amp I-Premise
";" I-Premise
Neck I-Premise
total I-Premise
score I-Premise
) I-Premise
were I-Premise
13.4 I-Premise
% I-Premise
, I-Premise
18.0 I-Premise
% I-Premise
, I-Premise
and I-Premise
6.0 I-Premise
% I-Premise
for I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
recurrent I-Claim
or I-Claim
metastatic I-Claim
SCCHN I-Claim
, I-Claim
while I-Claim
responses I-Claim
with I-Claim
gefitinib I-Claim
were I-Claim
seen I-Claim
, I-Claim
neither I-Claim
gefitinib I-Claim
250 I-Claim
nor I-Claim
500 I-Claim
mg/day I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
methotrexate I-Claim
. I-Claim

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage-type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

Gemcitabine O
( O
G O
) O
is O
standard O
therapy O
for O
pancreatic O
cancer O
. O

Enzastaurin O
( O
E O
) O
inhibits O
PKCβ O
and O
PI3K/AKT O
signaling O
pathways O
with O
a O
dose-dependent O
effect O
on O
growth O
of O
pancreatic O
carcinoma O
xenografts O
. O

Data B-Claim
suggest I-Claim
that I-Claim
the I-Claim
GE I-Claim
combination I-Claim
may I-Claim
improve I-Claim
clinical I-Claim
outcomes I-Claim
. I-Claim

Primary O
objective O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
objectives O
assessed O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
relationships O
between O
biomarker O
expression O
and O
clinical O
outcomes O
. O

Patients O
were O
randomly O
assigned O
( O
2:1 O
) O
to O
GE O
or O
G O
treatment O
";" O
GE O
arm O
: O
E O
500 O
mg O
p.o O
. O

daily O
";" O
loading-dose O
( O
1200 O
mg O
";" O
Day O
1 O
Cycle O
1 O
only O
) O
and O
G O
1000 O
mg/m O
( O
2 O
) O
i.v O
. O

Days O
1 O
, O
8 O
, O
and O
15 O
in O
28-day O
cycles O
";" O
G O
arm O
: O
G O
as O
in O
GE O
. O

Biomarker O
expression O
was O
assessed O
by O
immunohistochemistry O
. O

Randomization O
totaled O
130 O
patients O
( O
GE O
= O
86 O
, O
G O
= O
44 O
) O
";" O
121 O
patients O
were O
treated O
( O
GE O
= O
82 O
, O
G O
= O
39 O
) O
. O

GE/G O
median O
OS O
was O
5.6/5.1 O
months O
";" O
median O
PFS O
was O
3.4/3.0 O
months O
. O

GE O
responses O
: O
1 O
complete O
response O
( O
CR O
, O
1.2 O
% O
) O
, O
6 O
partial O
response O
( O
PR O
, O
7.4 O
% O
) O
, O
and O
33 O
stable O
disease O
( O
SD O
, O
40.7 O
% O
) O
";" O
disease O
control O
rate O
( O
DCR=CR+PR+SD O
, O
49.4 O
% O
) O
. O

G O
responses O
: O
2 O
PR O
( O
5.3 O
% O
) O
and O
16 O
SD O
( O
42.1 O
% O
) O
";" O
DCR O
( O
47.4 O
% O
) O
. O

No B-Premise
QOL I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
arms I-Premise
. I-Premise

GE/G B-Premise
Grade I-Premise
3-4 I-Premise
toxicities I-Premise
included I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
18.3 I-Premise
% I-Premise
/28.2 I-Premise
% I-Premise
) I-Premise
";" I-Premise
thrombocytopenia I-Premise
( I-Premise
14.6 I-Premise
% I-Premise
/25.6 I-Premise
% I-Premise
) I-Premise
";" I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
11.0 I-Premise
% I-Premise
/7.7 I-Premise
% I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
relationships I-Premise
between I-Premise
biomarker I-Premise
expression I-Premise
and I-Premise
outcomes I-Premise
were I-Premise
observed I-Premise
. I-Premise

However O
, O
patients B-Premise
with I-Premise
low I-Premise
expression I-Premise
of I-Premise
cytoplasmic I-Premise
pGSK-3β I-Premise
trended I-Premise
toward I-Premise
greater I-Premise
OS I-Premise
with I-Premise
GE I-Premise
treatment I-Premise
. I-Premise

OS B-Premise
, I-Premise
PFS I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
RR I-Premise
were I-Premise
comparable I-Premise
between I-Premise
arms I-Premise
. I-Premise

Adding B-Claim
E I-Claim
to I-Claim
G I-Claim
did I-Claim
not I-Claim
increase I-Claim
hematologic I-Claim
toxicities I-Claim
. I-Claim

GE O
does O
not O
warrant O
further O
investigation O
in O
unselected O
pancreatic O
cancer O
patients O
. O

To O
determine O
whether O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
on O
the O
well-being O
of O
patients O
with O
advanced O
cancer O
is O
more O
efficient O
when O
performed O
by O
a O
person O
with O
self-declared O
" O
healing O
powers O
" O
as O
compared O
to O
an O
actor O
mimicking O
the O
healer O
in O
close O
detail O
. O

A O
total O
of O
80 O
patients O
were O
registered O
to O
participate O
in O
a O
randomized O
, O
single-blind O
phase O
III O
trial O
to O
evaluate O
the O
difference O
in O
efficacy O
of O
" O
laying O
on O
of O
hands O
" O
by O
either O
a O
" O
healer O
" O
or O
an O
actor O
. O

Each O
group O
consisted O
of O
40 O
patients O
, O
scheduled O
to O
receive O
treatment O
for O
5 O
min O
, O
three O
times O
a O
week O
. O

The O
effect O
of O
treatment O
was O
measured O
using O
a O
" O
Well-Being O
scale O
" O
, O
with O
the O
difference O
of O
the O
average O
score O
of O
the O
" O
Well-Being O
scale O
" O
on O
day O
10 O
being O
defined O
as O
primary O
and O
that O
on O
day O
5 O
as O
secondary O
endpoint O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
average I-Premise
score I-Premise
values I-Premise
between I-Premise
the I-Premise
" I-Premise
healer I-Premise
" I-Premise
and I-Premise
the I-Premise
actor I-Premise
with I-Premise
regard I-Premise
to I-Premise
the I-Premise
primary I-Premise
( I-Premise
p I-Premise
= I-Premise
0.34 I-Premise
) I-Premise
or I-Premise
the I-Premise
secondary I-Premise
endpoint I-Premise
( I-Premise
p I-Premise
= I-Premise
0.94 I-Premise
) I-Premise
, I-Premise
but B-Premise
the I-Premise
comparison I-Premise
was I-Premise
limited I-Premise
due I-Premise
to I-Premise
major I-Premise
protocol I-Premise
violations I-Premise
by I-Premise
the I-Premise
" I-Premise
healer I-Premise
" I-Premise
who I-Premise
unblinded I-Premise
his I-Premise
status I-Premise
after I-Premise
the I-Premise
first I-Premise
run I-Premise
and I-Premise
quit I-Premise
the I-Premise
study I-Premise
. I-Premise

The O
study O
was O
completed O
by O
the O
actor O
as O
a O
descriptive O
, O
explorative O
study O
on O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
. O

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

" B-Claim
Laying I-Claim
on I-Claim
of I-Claim
hands I-Claim
" I-Claim
resulted I-Claim
in I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
cancer- I-Claim
or I-Claim
cancer-therapy-associated I-Claim
symptoms I-Claim
. I-Claim

The B-Claim
magnitude I-Claim
of I-Claim
improvement I-Claim
obtained I-Claim
was I-Claim
similar I-Claim
whether I-Claim
on I-Claim
a I-Claim
self-declared-healer- I-Claim
or I-Claim
an I-Claim
actor-provided I-Claim
" I-Claim
treatment I-Claim
" I-Claim
. I-Claim

To O
assess O
the O
effect O
of O
a O
multimodal O
group O
exercise O
intervention O
, O
as O
an O
adjunct O
to O
conventional O
care O
, O
on O
fatigue O
, O
physical O
capacity O
, O
general O
wellbeing O
, O
physical O
activity O
, O
and O
quality O
of O
life O
in O
patients O
with O
cancer O
who O
were O
undergoing O
adjuvant O
chemotherapy O
or O
treatment O
for O
advanced O
disease O
. O

Randomised O
controlled O
trial O
. O

Two O
university O
hospitals O
in O
Copenhagen O
, O
Denmark O
. O

269 O
patients O
with O
cancer O
";" O
73 O
men O
, O
196 O
women O
, O
mean O
age O
47 O
years O
( O
range O
20-65 O
) O
representing O
21 O
diagnoses O
. O

Main O
exclusion O
criteria O
were O
brain O
or O
bone O
metastases O
. O

235 O
patients O
completed O
follow-up O
. O

Supervised O
exercise O
comprising O
high O
intensity O
cardiovascular O
and O
resistance O
training O
, O
relaxation O
and O
body O
awareness O
training O
, O
massage O
, O
nine O
hours O
weekly O
for O
six O
weeks O
in O
addition O
to O
conventional O
care O
, O
compared O
with O
conventional O
care O
. O

The O
general O
linear O
model O
was O
used O
for O
continuous O
outcome O
while O
analysis O
of O
associates O
between O
categorical O
outcomes O
was O
performed O
as O
analysis O
of O
marginal O
homogeneity O
in O
contingency O
tables O
. O

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
effects I-Premise
were I-Premise
seen I-Premise
on I-Premise
vitality I-Premise
( I-Premise
effect I-Premise
size I-Premise
0.55 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.27 I-Premise
to I-Premise
0.82 I-Premise
) I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.09 I-Premise
to I-Premise
0.65 I-Premise
) I-Premise
, I-Premise
role I-Premise
physical I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.10 I-Premise
to I-Premise
0.64 I-Premise
) I-Premise
, I-Premise
role I-Premise
emotional I-Premise
( I-Premise
0.32 I-Premise
, I-Premise
0.05 I-Premise
to I-Premise
0.59 I-Premise
) I-Premise
, I-Premise
and I-Premise
mental I-Premise
health I-Premise
( I-Premise
0.28 I-Premise
, I-Premise
0.02 I-Premise
to I-Premise
0.56 I-Premise
) I-Premise
scores I-Premise
. I-Premise

Improvement B-Premise
was I-Premise
noted I-Premise
in I-Premise
physical I-Premise
capacity I-Premise
: I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
for I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
was I-Premise
0.16 I-Premise
l/min I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.1 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
( I-Premise
leg I-Premise
press I-Premise
) I-Premise
was I-Premise
29.7 I-Premise
kg I-Premise
( I-Premise
23.4 I-Premise
to I-Premise
34.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
on I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
. I-Premise

A B-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
including I-Claim
high I-Claim
and I-Claim
low I-Claim
intensity I-Claim
components I-Claim
was I-Claim
feasible I-Claim
and I-Claim
could I-Claim
safely I-Claim
be I-Claim
used I-Claim
in I-Claim
patients I-Claim
with I-Claim
various I-Claim
cancers I-Claim
who I-Claim
were I-Claim
receiving I-Claim
adjuvant I-Claim
chemotherapy I-Claim
or I-Claim
treatment I-Claim
for I-Claim
advanced I-Claim
disease I-Claim
. I-Claim

The B-Claim
intervention I-Claim
reduced I-Claim
fatigue I-Claim
and I-Claim
improved I-Claim
vitality I-Claim
, I-Claim
aerobic I-Claim
capacity I-Claim
, I-Claim
muscular I-Claim
strength I-Claim
, I-Claim
and I-Claim
physical I-Claim
and I-Claim
functional I-Claim
activity I-Claim
, I-Claim
and I-Claim
emotional I-Claim
wellbeing I-Claim
, I-Claim
but B-Claim
not I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

To O
determine O
whether O
weekly O
epoetin O
alfa O
could O
improve O
hemoglobin O
( O
HgB O
) O
levels O
, O
reduce O
RBC O
transfusions O
, O
and O
improve O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
advanced O
cancer O
and O
with O
anemia O
after O
receiving O
myelosuppressive O
chemotherapy O
. O

This O
double-blind O
, O
placebo-controlled O
study O
randomly O
assigned O
patients O
to O
placebo O
or O
epoetin O
alfa O
( O
Ortho O
Biotech O
, O
Bridgewater O
, O
NJ O
) O
40,000 O
U O
subcutaneous O
weekly O
for O
16 O
weeks O
. O

QOL O
, O
HgB O
, O
and O
RBC O
transfusions O
were O
measured O
pretreatment O
and O
monthly O
. O

The O
study O
accrued O
344 O
patients O
";" O
330 O
were O
assessable O
for O
efficacy O
and O
305 O
were O
assessable O
for O
QOL O
. O

Placebo-treated B-Premise
patients I-Premise
had I-Premise
a I-Premise
mean I-Premise
increase I-Premise
in I-Premise
HgB I-Premise
of I-Premise
0.9 I-Premise
g/dL I-Premise
( I-Premise
range I-Premise
, I-Premise
-3.8 I-Premise
to I-Premise
+5.3 I-Premise
) I-Premise
compared I-Premise
with I-Premise
2.8 I-Premise
g/dL I-Premise
( I-Premise
range I-Premise
, I-Premise
-2.2 I-Premise
to I-Premise
+7.5 I-Premise
) I-Premise
for I-Premise
epoetin-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

During B-Premise
the I-Premise
study I-Premise
, I-Premise
31.7 I-Premise
% I-Premise
of I-Premise
placebo-treated I-Premise
patients I-Premise
achieved I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
HgB I-Premise
increase I-Premise
compared I-Premise
with I-Premise
72.7 I-Premise
% I-Premise
of I-Premise
epoetin-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
RBC I-Premise
transfusion I-Premise
for I-Premise
placebo I-Premise
and I-Premise
epoetin I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
39.6 I-Premise
% I-Premise
and I-Premise
25.3 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The O
placebo O
group O
received O
256 O
units O
of O
RBCs O
compared O
with O
127 O
units O
in O
the O
epoetin O
group O
( O
P O
< O
.0001 O
) O
. O

The B-Premise
incidence I-Premise
of I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
groups I-Premise
was I-Premise
similar I-Premise
. I-Premise

Changes B-Premise
in I-Premise
the I-Premise
average I-Premise
QOL I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
study I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
P I-Premise
= I-Premise
not I-Premise
significant I-Premise
) I-Premise
. I-Premise

The B-Premise
HgB I-Premise
responders I-Premise
( I-Premise
irrespective I-Premise
of I-Premise
treatment I-Premise
arm I-Premise
) I-Premise
had I-Premise
a I-Premise
mean I-Premise
change I-Premise
in I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
( I-Premise
FACT I-Premise
) I-Premise
fatigue I-Premise
score I-Premise
from I-Premise
a I-Premise
baseline I-Premise
of I-Premise
+5.1 I-Premise
compared I-Premise
with I-Premise
-2.1 I-Premise
for I-Premise
the I-Premise
nonresponders I-Premise
( I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
significantly I-Claim
improved I-Claim
HgB I-Claim
and I-Claim
reduced I-Claim
transfusions I-Claim
in I-Claim
this I-Claim
patient I-Claim
population I-Claim
. I-Claim

These B-Claim
results I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
weekly I-Claim
epoetin I-Claim
alfa I-Claim
as I-Claim
an I-Claim
ameliorative I-Claim
agent I-Claim
for I-Claim
cancer-related I-Claim
anemia I-Claim
. I-Claim

Temozolomide O
( O
TMZ O
) O
is O
an O
alkylating O
agent O
licensed O
for O
treatment O
of O
high-grade O
glioma O
( O
HGG O
) O
. O

No O
prospective O
comparison O
with O
nitrosourea-based O
chemotherapy O
exists O
. O

We O
report O
, O
to O
our O
knowledge O
, O
the O
first O
randomized O
trial O
of O
procarbazine O
, O
lomustine O
, O
and O
vincristine O
( O
PCV O
) O
versus O
TMZ O
in O
chemotherapy-naive O
patients O
with O
recurrent O
HGG O
. O

Four O
hundred O
forty-seven O
patients O
were O
randomly O
assigned O
to O
PCV O
( O
224 O
patients O
) O
or O
TMZ O
( O
sub-random O
assignment O
: O
TMZ-5 O
[ O
200 O
mg/m O
( O
2 O
) O
for O
5 O
days O
, O
112 O
patients O
] O
or O
TMZ-21 O
[ O
100 O
mg/m O
( O
2 O
) O
for O
21 O
days O
, O
111 O
patients O
] O
) O
for O
up O
to O
9 O
months O
or O
until O
progression O
. O

The O
primary O
outcomes O
were O
survival O
( O
PCV O
v O
TMZ O
) O
and O
12-week O
progression-free O
survival O
( O
PFS O
";" O
TMZ-5 O
v O
TMZ-21 O
) O
. O

This O
study O
is O
registered O
as O
ISRCTN83176944 O
. O

Percentages O
of O
patients O
completing O
9 O
months O
of O
treatment O
in O
the O
PCV O
, O
TMZ-5 O
, O
and O
TMZ-21 O
arms O
were O
17 O
% O
, O
26 O
% O
, O
and O
13 O
% O
, O
respectively O
. O

Major B-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
groups I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
12 I-Premise
months I-Premise
and I-Premise
382 I-Premise
deaths I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
clear I-Premise
survival I-Premise
benefit I-Premise
when I-Premise
comparing I-Premise
PCV I-Premise
with I-Premise
TMZ I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.74 I-Premise
to I-Premise
1.11 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.350 I-Premise
) I-Premise
. I-Premise

For B-Premise
TMZ-5 I-Premise
versus I-Premise
TMZ-21 I-Premise
, I-Premise
12-week I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
63.6 I-Premise
% I-Premise
and I-Premise
65.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.745 I-Premise
) I-Premise
, I-Premise
but B-Premise
TMZ-5 I-Premise
improved I-Premise
overall I-Premise
PFS I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.38 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.05 I-Premise
to I-Premise
1.82 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.023 I-Premise
) I-Premise
, I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.32 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.99 I-Premise
to I-Premise
1.75 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.056 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
49 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
improved I-Premise
> I-Premise
10 I-Premise
points I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Although B-Claim
TMZ I-Claim
( I-Claim
both I-Claim
arms I-Claim
combined I-Claim
) I-Claim
did I-Claim
not I-Claim
show I-Claim
a I-Claim
clear I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
PCV I-Claim
, I-Claim
comparison I-Claim
of I-Claim
the I-Claim
TMZ I-Claim
schedules I-Claim
demonstrated I-Claim
that I-Claim
the I-Claim
21-day I-Claim
schedule I-Claim
was I-Claim
inferior I-Claim
to I-Claim
the I-Claim
5-day I-Claim
schedule I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

This B-Claim
challenges I-Claim
the I-Claim
current I-Claim
understanding I-Claim
of I-Claim
increasing I-Claim
TMZ I-Claim
dose-intensity I-Claim
by I-Claim
prolonged I-Claim
scheduling I-Claim
. I-Claim

Radiation-induced O
mucositis O
is O
an O
acute O
reaction O
of O
the O
mucosa O
of O
patients O
undergoing O
head O
and O
neck O
radiotherapy O
. O

It O
can O
have O
debilitating O
and O
dose-limiting O
consequences O
. O

There B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim

Misoprostol O
is O
a O
synthetic O
prostaglandin O
E1 O
analogue O
, O
with O
properties O
of O
a O
mucosal O
cytoprotectant O
. O

We O
designed O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
misoprostol O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
if O
topical O
misoprostol O
was O
effective O
in O
reducing O
the O
severity O
of O
radiation-induced O
mucositis O
in O
patients O
receiving O
radical O
dose O
radiotherapy O
. O

The O
effect O
of O
this O
intervention O
on O
a O
patient O
's O
general O
well-being O
was O
also O
investigated O
. O

The O
primary O
end-point O
of O
the O
study O
was O
the O
incidence O
of O
Radiation O
Therapy O
Oncology O
Group O
grade O
3 O
mucositis O
. O

Between O
1999 O
and O
2002 O
, O
83 O
patients O
were O
recruited O
into O
the O
study O
at O
Westmead O
and O
Nepean O
Hospitals O
, O
Sydney O
. O

Forty-two O
patients O
were O
randomized O
to O
receive O
misoprostol O
and O
41 O
to O
receive O
a O
placebo O
. O

Most O
patients O
received O
radiotherapy O
in O
the O
adjuvant O
setting O
( O
52 O
of O
the O
83 O
) O
and O
had O
either O
an O
oral O
cavity O
( O
42 O
of O
the O
83 O
) O
or O
an O
oropharyngeal O
( O
16 O
of O
the O
83 O
) O
cancer O
. O

We B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
based I-Claim
on I-Claim
whether I-Claim
patients I-Claim
were I-Claim
allocated I-Claim
to I-Claim
receive I-Claim
misoprostol I-Claim
or I-Claim
placebo I-Claim
. I-Claim

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
area I-Premise
under I-Premise
the I-Premise
mucositis I-Premise
curve I-Premise
( I-Premise
13.2 I-Premise
vs I-Premise
16.6 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7.6 I-Premise
vs I-Premise
6.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise

However B-Premise
, I-Premise
this I-Premise
difference I-Premise
did I-Premise
not I-Premise
translate I-Premise
into I-Premise
a I-Premise
worse I-Premise
feeling I-Premise
of I-Premise
general I-Premise
well-being I-Premise
as I-Premise
measured I-Premise
by I-Premise
a I-Premise
simple I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
( I-Premise
5.8 I-Premise
vs I-Premise
5.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.3 I-Premise
) I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
we I-Claim
were I-Claim
unable I-Claim
to I-Claim
identify I-Claim
a I-Claim
reduction I-Claim
in I-Claim
radiation-induced I-Claim
mucositis I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
misoprostol I-Claim
. I-Claim

There B-Claim
is I-Claim
a I-Claim
paucity I-Claim
of I-Claim
high-level I-Claim
evidence I-Claim
on I-Claim
potentially I-Claim
useful I-Claim
interventions I-Claim
and I-Claim
a I-Claim
continued I-Claim
need I-Claim
for I-Claim
new I-Claim
and I-Claim
innovative I-Claim
research I-Claim
, I-Claim
incorporating I-Claim
quality-of-life I-Claim
measurements I-Claim
, I-Claim
in I-Claim
patients I-Claim
experiencing I-Claim
radiation-induced I-Claim
mucositis I-Claim
. I-Claim

This O
randomized O
phase O
II O
study O
compared O
two O
treatment O
schedules O
of O
gemcitabine O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
and O
impaired O
Karnofsky O
performance O
status O
( O
KP O
) O
. O

Primary O
objectives O
were O
to O
record O
changes O
from O
baseline O
KP O
and O
to O
assess O
symptom O
palliation O
. O

Secondary O
objectives O
were O
overall O
survival O
, O
tumor O
response O
, O
and O
toxicity O
. O

Patients O
with O
stage O
IIIb O
and O
IV O
NSCLC O
and O
KP O
< O
/= O
70 O
were O
randomly O
assigned O
to O
receive O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
each O
28-day O
cycle O
( O
3w4 O
) O
or O
gemcitabine O
1,500 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
of O
each O
21-day O
cycle O
( O
2w3 O
) O
, O
both O
for O
up O
to O
six O
cycles O
. O

KP O
, O
toxicity O
, O
and O
SS14 O
lung O
cancer O
specific O
questions O
were O
recorded O
before O
each O
cycle O
of O
treatment O
. O

Response O
was O
evaluated O
4 O
weeks O
after O
the O
last O
cycle O
. O

One O
hundred O
seventy-four O
patients O
were O
enrolled O
. O

There B-Premise
was I-Premise
significant I-Premise
early I-Premise
attrition I-Premise
due I-Premise
to I-Premise
disease I-Premise
progression I-Premise
";" I-Premise
only I-Premise
61.5 I-Premise
% I-Premise
of I-Premise
patients I-Premise
were I-Premise
alive I-Premise
at I-Premise
2 I-Premise
months I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
KP I-Premise
from I-Premise
baseline I-Premise
to I-Premise
pre-cycle I-Premise
3 I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
3w4 I-Premise
regimen I-Premise
for I-Premise
duration I-Premise
and I-Premise
faster I-Premise
onset I-Premise
of I-Premise
improvement I-Premise
. I-Premise

Eight B-Premise
of I-Premise
the I-Premise
17 I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
variables I-Premise
assessed I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
of I-Premise
more I-Premise
than I-Premise
10 I-Premise
% I-Premise
between I-Premise
baseline I-Premise
and I-Premise
the I-Premise
start I-Premise
of I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Response B-Premise
rate I-Premise
, I-Premise
survival I-Premise
, I-Premise
and I-Premise
duration I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
schedules I-Claim
examined I-Claim
in I-Claim
terms I-Claim
of I-Claim
improvement I-Claim
in I-Claim
KP I-Claim
or I-Claim
QOL I-Claim
, I-Claim
but I-Claim
there I-Claim
seemed I-Claim
to I-Claim
be I-Claim
a I-Claim
trend I-Claim
in I-Claim
favor I-Claim
of I-Claim
the I-Claim
3w4 I-Claim
schedule I-Claim
. I-Claim

Behavioral O
symptoms O
are O
common O
in O
breast O
cancer O
survivors O
, O
including O
disturbances O
in O
energy O
, O
sleep O
, O
and O
mood O
, O
though O
few O
risk O
factors O
for O
these O
negative O
outcomes O
have O
been O
identified O
. O

Our O
study O
examined O
intrusive O
thoughts O
as O
a O
predictor O
of O
lingering O
symptoms O
in O
breast O
cancer O
survivors O
in O
the O
year O
following O
treatment O
. O

Data O
come O
from O
the O
Moving O
Beyond O
Cancer O
psychoeducational O
intervention O
trial O
, O
aimed O
at O
easing O
the O
transition O
from O
patient O
to O
survivor O
. O

Women O
( O
n O
= O
558 O
) O
completed O
psychosocial O
questionnaires O
within O
4 O
weeks O
posttreatment O
and O
again O
2 O
, O
6 O
, O
and O
12 O
months O
later O
. O

We O
examined O
intrusive O
thoughts O
about O
cancer O
at O
the O
baseline O
assessment O
as O
a O
predictor O
of O
fatigue O
, O
sleep O
problems O
, O
pain O
, O
breast O
cancer-specific O
symptoms O
, O
depressive O
symptoms O
, O
negative O
affect O
, O
and O
quality O
of O
life O
using O
growth O
curve O
modeling O
, O
controlling O
for O
study O
condition O
and O
other O
covariates O
. O

Intrusive B-Premise
thoughts I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
levels I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
and I-Premise
at I-Premise
the I-Premise
12-month I-Premise
assessment I-Premise
. I-Premise

Intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise

Intrusions B-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
fatigue I-Premise
, I-Premise
sleep I-Premise
, I-Premise
breast I-Premise
cancer-specific I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
mental I-Premise
functioning I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
remained I-Premise
worse I-Premise
over I-Premise
time I-Premise
. I-Premise

Intrusive B-Claim
thoughts I-Claim
are I-Claim
associated I-Claim
with I-Claim
enduring I-Claim
elevations I-Claim
in I-Claim
behavioral I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
the I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
and I-Claim
may I-Claim
be I-Claim
a I-Claim
risk I-Claim
factor I-Claim
for I-Claim
poor I-Claim
outcomes I-Claim
. I-Claim

On O
March O
15 O
, O
2005 O
, O
the O
US O
Food O
and O
Drug O
Administration O
approved O
temozolomide O
( O
Temodar O
capsules O
, O
Schering-Plough O
Research O
Institute O
) O
for O
the O
treatment O
of O
adult O
patients O
with O
newly O
diagnosed O
glioblastoma O
multiforme O
concomitantly O
with O
radiotherapy O
and O
then O
as O
maintenance O
treatment O
. O

Five O
hundred O
seventy-three O
glioblastoma O
multiforme O
patients O
were O
randomized O
to O
receive O
either O
temozolomide O
+ O
radiotherapy O
( O
n O
= O
287 O
) O
or O
radiotherapy O
alone O
( O
n O
= O
286 O
) O
. O

Patients O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
received O
concomitant O
temozolomide O
( O
75 O
mg/m2 O
) O
once O
daily O
for O
the O
duration O
of O
radiation O
therapy O
( O
42-49 O
days O
) O
. O

This O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg/m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O

Patients O
in O
the O
control O
arm O
received O
radiotherapy O
only O
. O

In O
both O
arms O
, O
radiotherapy O
was O
delivered O
as O
60 O
Gy/30 O
fractions O
to O
the O
tumor O
site O
with O
a O
2 O
to O
3 O
cm O
margin O
. O

Pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
Common O
Toxicity O
Criteria O
grade O
< O
1 O
) O
. O

At O
disease O
progression O
, O
temozolomide O
salvage O
treatment O
was O
given O
to O
161 O
of O
282 O
patients O
( O
57 O
% O
) O
in O
the O
radiotherapy O
alone O
arm O
, O
and O
to O
62 O
of O
277 O
patients O
( O
22 O
% O
) O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
. O

Patients B-Claim
receiving I-Claim
concomitant I-Claim
and I-Claim
maintenance I-Claim
temozolomide I-Claim
+ I-Claim
radiotherapy I-Claim
had I-Claim
significantly I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
. I-Claim

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.52-0.75 I-Premise
";" I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

Adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim

This O
study O
examined O
the O
feasibility O
and O
acceptability O
of O
an O
Individual O
Internet O
Intervention O
( O
III O
) O
embedded O
and O
integrated O
into O
an O
Internet O
Support O
Group O
( O
ISG O
) O
with O
the O
ultimate O
goal O
of O
enhancing O
adherence O
and O
learning O
, O
compared O
with O
an O
individual O
internet O
invention O
alone O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

Seventeen O
participants O
met O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
criteria O
for O
depressive O
symptoms O
( O
HADS O
≥ O
8 O
) O
. O

Among O
all O
participants O
, O
the O
mean O
number O
of O
logins O
over O
8 O
weeks O
was O
20.8 O
± O
17.7 O
logins O
for O
the O
III O
+ O
ISG O
compared O
with O
12.5 O
± O
12.5 O
in O
III-only O
( O
p O
= O
0.15 O
) O
. O

Two O
participants O
in O
the O
III O
+ O
ISG O
dropped O
out O
, O
compared O
with O
five O
in O
III O
( O
p O
= O
0.39 O
) O
. O

Among B-Premise
the I-Premise
17 I-Premise
participants I-Premise
with I-Premise
depressive I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
, I-Premise
both I-Premise
the I-Premise
Onward I-Premise
and I-Premise
the I-Premise
III-only I-Premise
condition I-Premise
showed I-Premise
large I-Premise
reductions I-Premise
in I-Premise
the I-Premise
depression I-Premise
scale I-Premise
of I-Premise
HADS I-Premise
( I-Premise
d I-Premise
= I-Premise
1.27 I-Premise
and I-Premise
0.89 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Improvement B-Premise
over I-Premise
time I-Premise
and I-Premise
time I-Premise
x I-Premise
treatment I-Premise
effects I-Premise
only I-Premise
reached I-Premise
trend I-Premise
significance I-Premise
levels I-Premise
( I-Premise
ps I-Premise
= I-Premise
0.07 I-Premise
& I-Premise
amp I-Premise
";" I-Premise
0.12 I-Premise
) I-Premise
as I-Premise
this I-Premise
pilot I-Premise
was I-Premise
not I-Premise
powered I-Premise
to I-Premise
detect I-Premise
these I-Premise
differences I-Premise
. I-Premise

Both B-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
and I-Claim
III-only I-Claim
demonstrated I-Claim
pre-post I-Claim
reductions I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
and I-Claim
high I-Claim
rates I-Claim
of I-Claim
utilization I-Claim
compared I-Claim
with I-Claim
other I-Claim
web-based I-Claim
treatments I-Claim
for I-Claim
depression I-Claim
. I-Claim

Although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
IIIs I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim

The O
optimal O
duration O
over O
which O
lung O
SBRT O
should O
be O
delivered O
is O
unknown O
. O

We O
conducted O
a O
randomized O
pilot O
study O
in O
patients O
treated O
with O
four O
fractions O
of O
lung O
SBRT O
delivered O
over O
4 O
or O
over O
11 O
days O
. O

Patients O
with O
a O
peripheral O
solitary O
lung O
tumor O
( O
NSCLC O
or O
pulmonary O
metastasis O
) O
≤ O
5 O
cm O
were O
eligible O
. O

For O
NSCLC O
lung O
tumors O
≤ O
3 O
cm O
, O
a O
dose O
of O
48 O
Gy O
in O
4 O
fractions O
was O
used O
, O
otherwise O
52 O
Gy O
in O
4 O
fractions O
was O
delivered O
. O

Patients O
were O
randomized O
to O
receive O
treatment O
over O
4 O
consecutive O
days O
or O
over O
11 O
days O
. O

The O
primary O
end-point O
was O
acute O
grade O
≥ O
2 O
toxicity O
. O

Secondary O
end-points O
included O
quality O
of O
life O
( O
QOL O
) O
assessed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-LC13 O
questionnaires O
. O

Fifty O
four O
patients O
were O
enrolled O
. O

More O
patients O
in O
the O
11 O
day O
group O
had O
respiratory O
symptoms O
at O
baseline O
. O

55.6 B-Premise
% I-Premise
patients I-Premise
treated I-Premise
over I-Premise
4 I-Premise
days I-Premise
and I-Premise
33.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
over I-Premise
11 I-Premise
days I-Premise
experienced I-Premise
acute I-Premise
grade I-Premise
≥ I-Premise
2 I-Premise
toxicity I-Premise
( I-Premise
p=0.085 I-Premise
) I-Premise
. I-Premise

Dyspnea B-Premise
, I-Premise
fatigue I-Premise
and I-Premise
coughing I-Premise
domains I-Premise
were I-Premise
worse I-Premise
in I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
at I-Premise
baseline I-Premise
. I-Premise

At B-Premise
1 I-Premise
and I-Premise
4 I-Premise
months I-Premise
, I-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
4 I-Premise
day I-Premise
group I-Premise
experienced I-Premise
a I-Premise
clinically I-Premise
meaningful I-Premise
worsening I-Premise
in I-Premise
the I-Premise
dyspnea I-Premise
QOL I-Premise
domain I-Premise
compared I-Premise
to I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
( I-Premise
44.5 I-Premise
% I-Premise
vs I-Premise
15.4 I-Premise
% I-Premise
, I-Premise
p=0.02 I-Premise
";" I-Premise
38.5 I-Premise
% I-Premise
vs I-Premise
12.0 I-Premise
% I-Premise
, I-Premise
p=0.03 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
raw I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
not I-Premise
different I-Premise
at I-Premise
these I-Premise
time-points I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Grade B-Claim
2 I-Claim
or I-Claim
higher I-Claim
acute I-Claim
toxicity I-Claim
was I-Claim
more I-Claim
common I-Claim
in I-Claim
the I-Claim
4 I-Claim
day I-Claim
group I-Claim
, I-Claim
approaching I-Claim
statistical I-Claim
significance I-Claim
. I-Claim

More B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

Larger B-Claim
studies I-Claim
are I-Claim
required I-Claim
to I-Claim
validate I-Claim
these I-Claim
results I-Claim
. I-Claim

Several O
guidelines O
on O
the O
treatment O
of O
cancer-related O
fatigue O
recommend O
optimizing O
treatment O
of O
accompanying O
symptoms O
. O

However O
, O
evidence O
for O
this O
recommendation O
from O
randomized O
clinical O
trials O
is O
lacking O
. O

We O
investigated O
whether O
monitoring O
and O
protocolized O
treatment O
of O
physical O
symptoms O
alleviates O
fatigue O
. O

In O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient-tailored O
treatment O
( O
PPT O
) O
of O
symptoms O
or O
care O
as O
usual O
. O

The O
PPT O
group O
had O
four O
appointments O
with O
a O
nurse O
who O
assessed O
nine O
symptoms O
on O
a O
0 O
to O
10 O
numeric O
rating O
scale O
( O
NRS O
) O
. O

Patients O
received O
a O
nonpharmacologic O
intervention O
for O
symptoms O
with O
a O
score O
≥ O
1 O
and O
a O
medical O
intervention O
for O
symptoms O
with O
a O
score O
≥ O
4 O
. O

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

Differences O
between O
the O
groups O
over O
time O
were O
assessed O
by O
using O
mixed O
modeling O
. O

Seventy-six O
patients O
were O
randomly O
assigned O
to O
each O
study O
arm O
. O

Mean O
age O
was O
58 O
± O
10 O
years O
, O
57 O
% O
were O
female O
, O
and O
65 O
% O
were O
given O
palliative O
chemotherapy O
. O

We B-Premise
found I-Premise
significant I-Premise
improvements I-Premise
over I-Premise
time I-Premise
in I-Premise
favor I-Premise
of I-Premise
PPT I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
with I-Premise
significant I-Premise
group I-Premise
differences I-Premise
at I-Premise
month I-Premise
1 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.26 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
and I-Premise
month I-Premise
2 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.35 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
favor I-Premise
of I-Premise
PPT I-Premise
were I-Premise
also I-Premise
found I-Premise
for I-Premise
the I-Premise
following I-Premise
secondary I-Premise
outcomes I-Premise
: I-Premise
fatigue I-Premise
dimensions I-Premise
" I-Premise
reduced I-Premise
activity I-Premise
" I-Premise
and I-Premise
" I-Premise
reduced I-Premise
motivation I-Premise
, I-Premise
" I-Premise
fatigue I-Premise
NRS I-Premise
, I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
interference I-Premise
of I-Premise
fatigue I-Premise
with I-Premise
daily I-Premise
life I-Premise
, I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
P I-Premise
≤ I-Premise
.03 I-Premise
) I-Premise
. I-Premise

In B-Claim
fatigued I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
nurse-led I-Claim
monitoring I-Claim
and I-Claim
protocolized I-Claim
treatment I-Claim
of I-Claim
physical I-Claim
symptoms I-Claim
is I-Claim
effective I-Claim
in I-Claim
alleviating I-Claim
fatigue I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
, I-Claim
increases I-Claim
survival I-Claim
when I-Claim
combined I-Claim
with I-Claim
irinotecan-based I-Claim
chemotherapy I-Claim
in I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
CRC I-Claim
) I-Claim
. I-Claim

This O
randomized O
, O
phase O
II O
trial O
compared O
bevacizumab O
plus O
fluorouracil O
and O
leucovorin O
( O
FU/LV O
) O
versus O
placebo O
plus O
FU/LV O
as O
first-line O
therapy O
in O
patients O
considered O
nonoptimal O
candidates O
for O
first-line O
irinotecan O
. O

Patients O
had O
metastatic O
CRC O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3.5 O
g/dL O
, O
or O
prior O
abdominal/pelvic O
radiotherapy O
. O

Patients O
were O
randomly O
assigned O
to O
FU/LV/placebo O
( O
n O
= O
105 O
) O
or O
FU/LV/bevacizumab O
( O
n O
= O
104 O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Secondary O
end O
points O
were O
progression-free O
survival O
, O
response O
rate O
, O
response O
duration O
, O
and O
quality O
of O
life O
. O

Safety O
was O
also O
assessed O
. O

Median B-Premise
survival I-Premise
was I-Premise
16.6 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/bevacizumab I-Premise
group I-Premise
and I-Premise
12.9 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/placebo I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.16 I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
5.5 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0002 I-Premise
. O

Response B-Premise
rates I-Premise
were I-Premise
26.0 I-Premise
% I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
";" I-Premise
duration B-Premise
of I-Premise
response I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.088 I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
hypertension I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
bevacizumab I-Premise
treatment I-Premise
( I-Premise
16 I-Premise
% I-Premise
v I-Premise
3 I-Premise
% I-Premise
) I-Premise
but B-Premise
was I-Premise
controlled I-Premise
with I-Premise
oral I-Premise
medication I-Premise
and I-Premise
did I-Premise
not I-Premise
cause I-Premise
study I-Premise
drug I-Premise
discontinuation I-Premise
. I-Premise

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU/LV I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first-line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression-free I-Claim
survival I-Claim
. I-Claim

The B-Claim
generalizability I-Claim
of I-Claim
palliative I-Claim
care I-Claim
intervention I-Claim
research I-Claim
is I-Claim
often I-Claim
limited I-Claim
by I-Claim
high I-Claim
rates I-Claim
of I-Claim
study I-Claim
attrition I-Claim
. I-Claim

This O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning-centered O
group O
psychotherapy O
( O
MCGP O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
SGP O
) O
, O
a O
standardized O
support O
group O
. O

Patients O
with O
advanced O
solid O
tumor O
cancers O
( O
n O
= O
153 O
) O
were O
randomized O
to O
eight O
sessions O
of O
either O
the O
MCGP O
or O
SGP O
. O

They O
completed O
assessments O
of O
psychosocial O
, O
spiritual O
, O
and O
physical O
well-being O
pretreatment O
, O
midtreatment O
, O
and O
2 O
months O
post-treatment O
. O

Attrition O
was O
assessed O
in O
terms O
of O
the O
percent O
of O
participants O
who O
failed O
to O
complete O
these O
assessments O
, O
and O
demographic O
, O
psychiatric O
, O
medical O
, O
and O
study-related O
correlates O
of O
attrition O
were O
examined O
for O
the O
participants O
in O
each O
of O
these O
categories O
. O

The B-Premise
rates I-Premise
of I-Premise
attrition I-Premise
at I-Premise
these I-Premise
time I-Premise
points I-Premise
were I-Premise
28.1 I-Premise
% I-Premise
, I-Premise
17.7 I-Premise
% I-Premise
, I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
43.1 I-Premise
% I-Premise
of I-Premise
the I-Premise
participants I-Premise
( I-Premise
66 I-Premise
of I-Premise
153 I-Premise
) I-Premise
completed I-Premise
the I-Premise
entire I-Premise
study I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
reason I-Premise
for I-Premise
dropout I-Premise
was I-Premise
patients I-Premise
feeling I-Premise
too I-Premise
ill I-Premise
. I-Premise

Attrition B-Premise
rates I-Premise
did I-Premise
not I-Premise
vary I-Premise
significantly I-Premise
between I-Premise
study I-Premise
arms I-Premise
. I-Premise

The O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post-treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O

There B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study-related I-Premise
variables I-Premise
. I-Premise

These B-Claim
findings I-Claim
highlight I-Claim
the I-Claim
challenge I-Claim
of I-Claim
maintaining I-Claim
advanced I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
longitudinal I-Claim
research I-Claim
and I-Claim
suggest I-Claim
the I-Claim
need I-Claim
to I-Claim
consider I-Claim
alternative I-Claim
approaches I-Claim
( I-Claim
e.g. I-Claim
, I-Claim
telemedicine I-Claim
) I-Claim
for I-Claim
patients I-Claim
who I-Claim
might I-Claim
benefit I-Claim
from I-Claim
group I-Claim
interventions I-Claim
but I-Claim
are I-Claim
too I-Claim
ill I-Claim
to I-Claim
travel I-Claim
. I-Claim

We O
evaluated O
the O
role O
of O
glutathione-related O
genotypes O
on O
overall O
survival O
, O
time O
to O
progression O
, O
adverse O
events O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
stage O
IIIB/IV O
non-small O
cell O
lung O
cancer O
patients O
who O
were O
stable O
or O
responding O
from O
initial O
treatment O
with O
platinum-based O
chemotherapy O
and O
subsequently O
randomized O
to O
receive O
daily O
oral O
carboxyaminoimidazole O
or O
a O
placebo O
. O

Of O
the O
186 O
total O
patients O
, O
113 O
had O
initial O
treatment O
with O
platinum O
therapy O
and O
DNA O
samples O
of O
whom O
46 O
also O
had O
QOL O
data O
. O

These O
samples O
were O
analyzed O
using O
six O
polymorphic O
DNA O
markers O
that O
encode O
five O
important O
enzymes O
in O
the O
glutathione O
metabolic O
pathway O
. O

Patient O
QOL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
and O
the O
UNISCALE O
QOL O
questionnaires O
. O

A O
clinically O
significant O
decline O
in O
QOL O
was O
defined O
as O
a O
10 O
% O
decrease O
from O
baseline O
to O
week-8 O
. O

Multivariate O
analyses O
were O
used O
to O
evaluate O
the O
association O
of O
the O
genotypes O
on O
the O
four O
endpoints O
. O

Patients B-Premise
carrying I-Premise
a I-Premise
GCLC I-Premise
77 I-Premise
genotype I-Premise
had I-Premise
a I-Premise
worse I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
= I-Premise
1.5 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
carrying I-Premise
the I-Premise
GPX1-CC I-Premise
genotype I-Premise
had I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
the I-Premise
UNISCALE I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
OR I-Premise
) I-Premise
: I-Premise
7.5 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
total I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
score I-Premise
( I-Premise
OR I-Premise
: I-Premise
11.0 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
physical I-Premise
( I-Premise
OR I-Premise
: I-Premise
7.1 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
OR I-Premise
: I-Premise
5.2 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
constructs I-Premise
( I-Premise
OR I-Premise
: I-Premise
23.8 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

GPX1 B-Claim
may I-Claim
be I-Claim
an I-Claim
inherited I-Claim
factor I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

Further B-Claim
investigation I-Claim
to I-Claim
define I-Claim
and I-Claim
measure I-Claim
the I-Claim
effects I-Claim
of I-Claim
these I-Claim
genes I-Claim
in I-Claim
chemotherapeutic I-Claim
regimens I-Claim
, I-Claim
drug I-Claim
toxicities I-Claim
, I-Claim
disease I-Claim
progression I-Claim
, I-Claim
and I-Claim
QOL I-Claim
are I-Claim
critical I-Claim
. I-Claim

Serum O
CA125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O

In O
the O
MRC O
OV05/EORTC O
55955 O
collaborative O
trial O
, O
we O
aimed O
to O
establish O
the O
benefits O
of O
early O
treatment O
on O
the O
basis O
of O
increased O
CA125 O
concentrations O
compared O
with O
delayed O
treatment O
on O
the O
basis O
of O
clinical O
recurrence O
. O

Women O
with O
ovarian O
cancer O
in O
complete O
remission O
after O
first-line O
platinum-based O
chemotherapy O
and O
a O
normal O
CA125 O
concentration O
were O
registered O
for O
this O
randomised O
controlled O
trial O
. O

Clinical O
examination O
and O
CA125 O
measurement O
were O
done O
every O
3 O
months O
. O

Patients O
and O
investigators O
were O
masked O
to O
CA125 O
results O
, O
which O
were O
monitored O
by O
coordinating O
centres O
. O

If O
CA125 O
concentration O
exceeded O
twice O
the O
upper O
limit O
of O
normal O
, O
patients O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
minimisation O
to O
early O
or O
delayed O
chemotherapy O
. O

Patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
CA125 O
measurement O
. O

Patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
CA125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O

All O
patients O
were O
treated O
according O
to O
standard O
local O
practice O
. O

The O
primary O
outcome O
was O
overall O
survival O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

This O
study O
is O
registered O
, O
ISRCTN87786644 O
. O

1442 O
patients O
were O
registered O
for O
the O
trial O
, O
of O
whom O
529 O
were O
randomly O
assigned O
to O
treatment O
groups O
and O
were O
included O
in O
our O
analysis O
( O
265 O
early O
, O
264 O
delayed O
) O
. O

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
56·9 I-Premise
months I-Premise
( I-Premise
IQR I-Premise
37·4-81·8 I-Premise
) I-Premise
from I-Premise
randomisation I-Premise
and I-Premise
370 I-Premise
deaths I-Premise
( I-Premise
186 I-Premise
early I-Premise
, I-Premise
184 I-Premise
delayed I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
between I-Premise
early I-Premise
and I-Premise
delayed I-Premise
treatment I-Premise
( I-Premise
HR I-Premise
0·98 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·80-1·20 I-Premise
, I-Premise
p=0·85 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23·0-27·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27·1 I-Premise
months I-Premise
( I-Premise
22·8-30·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

Our B-Claim
findings I-Claim
showed I-Claim
no I-Claim
evidence I-Claim
of I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
with I-Claim
early I-Claim
treatment I-Claim
of I-Claim
relapse I-Claim
on I-Claim
the I-Claim
basis I-Claim
of I-Claim
a I-Claim
raised I-Claim
CA125 I-Claim
concentration I-Claim
alone I-Claim
, I-Claim
and B-Claim
therefore I-Claim
the I-Claim
value I-Claim
of I-Claim
routine I-Claim
measurement I-Claim
of I-Claim
CA125 I-Claim
in I-Claim
the I-Claim
follow-up I-Claim
of I-Claim
patients I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
who I-Claim
attain I-Claim
a I-Claim
complete I-Claim
response I-Claim
after I-Claim
first-line I-Claim
treatment I-Claim
is I-Claim
not I-Claim
proven I-Claim
. I-Claim

Kaposi O
's O
sarcoma O
is O
currently O
the O
most O
common O
tumor O
in O
Zimbabwe O
. O

The O
purpose O
of O
our O
study O
is O
to O
compare O
the O
effectiveness O
of O
supportive O
care O
vs. O
3 O
intervention O
approaches O
, O
namely O
oral O
Etoposide O
, O
a O
3-drug O
combination O
, O
and O
radiotherapy O
using O
quality O
of O
life O
( O
QOL O
) O
as O
the O
primary O
measure O
of O
success O
. O

In O
addition O
, O
our O
study O
was O
to O
determine O
whether O
a O
disease-specific O
module O
has O
greater O
sensitivity O
to O
group O
differences O
than O
a O
generic O
QOL O
questionnaire O
and O
to O
determine O
the O
most O
pragmatic O
approach O
to O
treating O
epidemic O
Kaposi O
's O
sarcoma O
( O
EKS O
) O
in O
Zimbabwe O
. O

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

No O
patient O
received O
antiretroviral O
therapy O
. O

The O
primary O
outcome O
was O
QOL O
measured O
by O
the O
functional O
living O
index-cancer O
( O
FLI-C O
) O
and O
supplemented O
by O
the O
Kaposi O
's O
sarcoma O
module O
( O
KSM O
) O
. O

From O
1994-1999 O
, O
495 O
EKS O
patients O
were O
accrued O
, O
and O
470 O
were O
evaluable O
. O

Of O
these O
, O
433 O
are O
known O
to O
be O
dead O
, O
26 O
are O
lost O
to O
follow-up O
and O
11 O
are O
still O
alive O
. O

The B-Premise
group I-Premise
treated I-Premise
with I-Premise
oral I-Premise
Etoposide I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
QOL I-Premise
than I-Premise
the I-Premise
radiotherapy I-Premise
group I-Premise
for I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
plus I-Premise
standard I-Premise
error I-Premise
at I-Premise
3-months I-Premise
89 I-Premise
+/- I-Premise
3 I-Premise
vs. I-Premise
76 I-Premise
+/- I-Premise
3 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
for I-Premise
the I-Premise
hardship I-Premise
( I-Premise
11 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
9 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
";" I-Premise
social I-Premise
( I-Premise
10 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
9 I-Premise
+/- I-Premise
0.4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0.4 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
subscales I-Premise
. I-Premise

In B-Premise
addition I-Premise
, I-Premise
on I-Premise
the I-Premise
physical I-Premise
and I-Premise
psychological I-Premise
subscales I-Premise
, I-Premise
the I-Premise
Etoposide I-Premise
group I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
QOL I-Premise
than I-Premise
the I-Premise
other I-Premise
3 I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

The B-Premise
3-drug I-Premise
combination I-Premise
, I-Premise
supportive I-Premise
care I-Premise
and I-Premise
radiotherapy I-Premise
groups I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
from I-Premise
each I-Premise
other I-Premise
with I-Premise
respect I-Premise
to I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
or I-Premise
its I-Premise
subscales I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
group I-Premise
differences I-Premise
with I-Premise
respect I-Premise
to I-Premise
survival I-Premise
. I-Premise

Oral B-Claim
Etoposide I-Claim
therapy I-Claim
resulted I-Claim
in I-Claim
better I-Claim
total I-Claim
FLI-C I-Claim
QOL I-Claim
score I-Claim
than I-Claim
radiotherapy I-Claim
. I-Claim

As O
well O
, O
Etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3-drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Thus B-Claim
, I-Claim
funds I-Claim
permitting I-Claim
, I-Claim
oral I-Claim
Etoposide I-Claim
is I-Claim
a I-Claim
pragmatic I-Claim
approach I-Claim
to I-Claim
treating I-Claim
EKS I-Claim
in I-Claim
an I-Claim
environment I-Claim
where I-Claim
antiretroviral I-Claim
drugs I-Claim
are I-Claim
not I-Claim
universally I-Claim
available I-Claim
. I-Claim

The B-Claim
study I-Claim
underscores I-Claim
the I-Claim
value I-Claim
of I-Claim
undertaking I-Claim
studies I-Claim
in I-Claim
areas I-Claim
of I-Claim
disease I-Claim
prevalence I-Claim
and I-Claim
the I-Claim
necessity I-Claim
of I-Claim
selecting I-Claim
appropriate I-Claim
outcome I-Claim
measures I-Claim
. I-Claim

To O
determine O
functional O
and O
psychological O
benefits O
of O
a O
12 O
week O
supervised O
group O
exercise O
programme O
during O
treatment O
for O
early O
stage O
breast O
cancer O
, O
with O
six O
month O
follow-up O
. O

Pragmatic O
randomised O
controlled O
prospective O
open O
trial O
. O

Three O
National O
Health O
Service O
oncology O
clinics O
in O
Scotland O
and O
community O
exercise O
facilities O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

Supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O

Functional O
assessment O
of O
cancer O
therapy O
( O
FACT O
) O
questionnaire O
, O
Beck O
depression O
inventory O
, O
positive O
and O
negative O
affect O
scale O
, O
body O
mass O
index O
, O
seven O
day O
recall O
of O
physical O
activity O
, O
12 O
minute O
walk O
test O
, O
and O
assessment O
of O
shoulder O
mobility O
. O

Mixed B-Premise
effects I-Premise
models I-Premise
with I-Premise
adjustment I-Premise
for I-Premise
baseline I-Premise
values I-Premise
, I-Premise
study I-Premise
site I-Premise
, I-Premise
treatment I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
age I-Premise
gave I-Premise
intervention I-Premise
effect I-Premise
estimates I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
control I-Premise
) I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
of I-Premise
129 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
83 I-Premise
to I-Premise
176 I-Premise
) I-Premise
for I-Premise
metres I-Premise
walked I-Premise
in I-Premise
12 I-Premise
minutes I-Premise
, I-Premise
182 I-Premise
( I-Premise
75 I-Premise
to I-Premise
289 I-Premise
) I-Premise
for I-Premise
minutes I-Premise
of I-Premise
moderate I-Premise
intensity I-Premise
activity I-Premise
reported I-Premise
in I-Premise
a I-Premise
week I-Premise
, I-Premise
2.6 I-Premise
( I-Premise
1.6 I-Premise
to I-Premise
3.7 I-Premise
) I-Premise
for I-Premise
shoulder I-Premise
mobility I-Premise
, I-Premise
2.5 I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
3.9 I-Premise
) I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
subscale I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
4.0 I-Premise
( I-Premise
1.8 I-Premise
to I-Premise
6.3 I-Premise
) I-Premise
for I-Premise
positive I-Premise
mood I-Premise
. I-Premise

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
for I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
, I-Premise
which I-Premise
was I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise

At B-Premise
the I-Premise
six I-Premise
month I-Premise
follow-up I-Premise
, I-Premise
most I-Premise
of I-Premise
these I-Premise
effects I-Premise
were I-Premise
maintained I-Premise
and I-Premise
an I-Premise
intervention I-Premise
effect I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
quality I-Premise
of I-Premise
life I-Premise
emerged I-Premise
. I-Premise

No B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise

Supervised B-Claim
group I-Claim
exercise I-Claim
provided I-Claim
functional I-Claim
and I-Claim
psychological I-Claim
benefit I-Claim
after I-Claim
a I-Claim
12 I-Claim
week I-Claim
intervention I-Claim
and I-Claim
six I-Claim
months I-Claim
later I-Claim
. I-Claim

Clinicians B-Claim
should I-Claim
encourage I-Claim
activity I-Claim
for I-Claim
their I-Claim
patients I-Claim
. I-Claim

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

The O
purpose O
of O
this O
study O
is O
to O
compare O
the O
treatment O
and O
retention O
effects O
between O
standard O
decongestive O
lymphatic O
therapy O
( O
DLT O
) O
combined O
with O
pneumatic O
compression O
( O
PC O
) O
and O
modified O
DLT O
, O
in O
which O
the O
use O
of O
a O
short-stretch O
bandage O
is O
replaced O
with O
the O
use O
of O
Kinesio O
tape O
( O
K-tape O
) O
combined O
with O
PC O
. O

Forty-one O
patients O
with O
unilateral O
breast-cancer-related O
lymphedema O
for O
at O
least O
3 O
months O
were O
randomly O
grouped O
into O
the O
DLT O
group O
( O
bandage O
group O
, O
N O
= O
21 O
) O
or O
the O
modified O
DLT O
group O
( O
K-tape O
group O
, O
N O
= O
20 O
) O
. O

Skin O
care O
, O
30-min O
manual O
lymphatic O
drainage O
, O
1-h O
pneumatic O
compression O
therapy O
, O
application O
of O
a O
short-stretch O
bandage O
or O
K-tape O
for O
each O
group O
, O
and O
a O
20-min O
physical O
therapy O
exercise O
were O
given O
during O
every O
treatment O
session O
. O

Patient O
evaluation O
items O
included O
physical O
therapy O
assessment O
, O
limb O
size O
, O
water O
composition O
of O
the O
upper O
extremity O
, O
lymphedema-related O
symptoms O
, O
quality O
of O
life O
, O
and O
patients O
' O
acceptance O
to O
the O
bandage O
or O
tape O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
all I-Premise
outcome I-Premise
variables I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
through I-Premise
the I-Premise
whole I-Premise
study I-Premise
period I-Premise
. I-Premise

Excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
";" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise

The B-Premise
acceptance I-Premise
of I-Premise
K-tape I-Premise
was I-Premise
better I-Premise
than I-Premise
the I-Premise
bandage I-Premise
, I-Premise
and I-Premise
benefits I-Premise
included I-Premise
longer I-Premise
wearing I-Premise
time I-Premise
, I-Premise
less I-Premise
difficulty I-Premise
in I-Premise
usage I-Premise
, I-Premise
and I-Premise
increased I-Premise
comfort I-Premise
and I-Premise
convenience I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

If O
the O
intervention O
period O
was O
prolonged O
, O
we O
might O
get O
different O
conclusion O
. O

Moreover O
, O
these B-Claim
two I-Claim
treatment I-Claim
protocols I-Claim
are I-Claim
inefficient I-Claim
and I-Claim
cost I-Claim
time I-Claim
in I-Claim
application I-Claim
. I-Claim

More B-Claim
efficient I-Claim
treatment I-Claim
protocol I-Claim
is I-Claim
needed I-Claim
for I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

To O
study O
the O
effects O
of O
Fuzheng O
Jianpi O
Decoction O
( O
FJD O
) O
combined O
chemotherapy O
on O
the O
quality O
of O
life O
( O
QOL O
) O
and O
the O
survival O
time O
of O
children O
with O
solid O
tumor O
. O

Recruited O
were O
167 O
solid O
tumor O
children O
patients O
at O
Department O
of O
Tumor O
, O
Beijing O
Children O
's O
Hospital O
. O

They O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
83 O
cases O
) O
and O
the O
control O
group O
( O
84 O
cases O
) O
according O
to O
the O
random O
digit O
table O
. O

All O
had O
chemotherapy O
. O

Those O
in O
the O
treatment O
group O
additionally O
took O
FJD O
, O
50 O
-100 O
mL O
each O
time O
, O
twice O
daily O
. O

After O
chemotherapy O
those O
in O
the O
treatment O
group O
took O
modified O
FJD O
. O

The O
WBC O
, O
Hb O
, O
and O
PLT O
were O
detected O
in O
all O
patients O
before O
treatment O
, O
6 O
months O
after O
treatment O
, O
and O
1 O
year O
after O
treatment O
. O

The O
-1 O
, O
-2 O
, O
and O
3-year O
QOL O
, O
3-year O
survival O
rate O
, O
and O
the O
survival O
life O
of O
dead O
children O
patients O
were O
observed O
. O

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
6-month I-Premise
and I-Premise
1-year I-Premise
WBC I-Premise
and I-Premise
Hb I-Premise
increased I-Premise
, I-Premise
the I-Premise
1-year I-Premise
PLT I-Premise
increased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
1-year I-Premise
treatment I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
somatic I-Premise
functions I-Premise
, I-Premise
psychological I-Premise
functions I-Premise
, I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
2-year I-Premise
somatic I-Premise
functions I-Premise
and I-Premise
psychological I-Premise
functions I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
all I-Premise
with I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
death I-Premise
number I-Premise
decreased I-Premise
, I-Premise
the I-Premise
survival I-Premise
rate I-Premise
increased I-Premise
, I-Premise
the I-Premise
life I-Premise
span I-Premise
of I-Premise
dead I-Premise
children I-Premise
was I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

FJD B-Claim
combined I-Claim
chemotherapy I-Claim
could I-Claim
effectively I-Claim
improve I-Claim
the I-Claim
QOL I-Claim
of I-Claim
solid I-Claim
tumor I-Claim
children I-Claim
patients I-Claim
, I-Claim
elevate I-Claim
their I-Claim
survival I-Claim
rate I-Claim
, I-Claim
and I-Claim
prolong I-Claim
their I-Claim
life I-Claim
spans I-Claim
. I-Claim

This O
study O
examined O
whether O
changes O
in O
self-efficacy O
explain O
the O
effects O
of O
a O
mailed O
print O
intervention O
on O
long-term O
dietary O
practices O
of O
breast O
and O
prostate O
cancer O
survivors O
. O

The O
relationship O
between O
change O
in O
self-efficacy O
and O
long-term O
physical O
activity O
( O
PA O
) O
also O
was O
examined O
. O

Breast O
and O
prostate O
cancer O
survivors O
( O
N O
= O
543 O
) O
from O
39 O
US O
states O
and O
two O
Canadian O
provinces O
participated O
in O
the O
FRESH O
START O
intervention O
trial O
. O

Participants O
were O
randomly O
assigned O
to O
receive O
a O
10-month O
program O
of O
mailed O
print O
materials O
on O
diet O
and O
PA O
available O
in O
the O
public O
domain O
or O
a O
10-month O
program O
of O
tailored O
materials O
designed O
to O
increase O
fruit O
and O
vegetable O
( O
F O
& O
V O
) O
intake O
, O
decrease O
fat O
intake O
, O
and/or O
increase O
PA. O
Changes O
in O
self-efficacy O
for O
F O
& O
V O
intake O
and O
fat O
restriction O
were O
analyzed O
as O
potential O
mediators O
of O
the O
intervention O
's O
effects O
on O
diet O
at O
2-year O
follow-up O
. O

Because O
we O
previously O
found O
that O
change O
in O
self-efficacy O
for O
PA O
did O
not O
vary O
by O
group O
assignment O
, O
the O
relationship O
between O
change O
in O
self-efficacy O
and O
PA O
at O
2-year O
follow-up O
was O
examined O
across O
study O
conditions O
. O

Results B-Claim
suggest I-Claim
that I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
fat I-Claim
restriction I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
fat I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
-0.28 I-Claim
) I-Claim
, I-Claim
and I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
F I-Claim
& I-Claim
V I-Claim
consumption I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
daily I-Claim
F I-Claim
& I-Claim
V I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
.11 I-Claim
) I-Claim
. I-Claim

Change B-Premise
in I-Premise
self-efficacy I-Premise
for I-Premise
fat I-Premise
restriction I-Premise
partially I-Premise
accounted I-Premise
for I-Premise
the I-Premise
intervention I-Premise
's I-Premise
impact I-Premise
on I-Premise
overall I-Premise
diet I-Premise
quality I-Premise
among I-Premise
men I-Premise
only I-Premise
( I-Premise
mean I-Premise
indirect I-Premise
effect I-Premise
= I-Premise
0.60 I-Premise
) I-Premise
. I-Premise

Finally O
, O
change O
in O
self-efficacy O
for O
PA O
predicted O
PA O
at O
2-year O
follow-up O
. O

Findings B-Claim
suggest I-Claim
that I-Claim
self-efficacy I-Claim
may I-Claim
influence I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Patients O
experience O
reductions O
in O
quality O
of O
life O
( O
QOL O
) O
while O
receiving O
cancer O
treatment O
and O
several O
approaches O
have O
been O
proposed O
to O
address O
QOL O
issues O
. O

In O
this O
project O
, O
the O
QOL O
differences O
between O
older O
adult O
( O
age O
65 O
) O
and O
younger O
adult O
( O
age O
18-64 O
) O
advanced O
cancer O
patients O
in O
response O
to O
a O
multidisciplinary O
intervention O
designed O
to O
improve O
QOL O
were O
examined O
. O

This O
study O
was O
registered O
on O
ClinicalTrials.gov O
. O

Newly O
diagnosed O
advanced O
cancer O
patients O
undergoing O
radiation O
therapy O
were O
randomized O
to O
active O
QOL O
intervention O
or O
control O
groups O
. O

Those O
in O
the O
intervention O
group O
received O
six O
multidisciplinary O
90-minute O
sessions O
designed O
to O
address O
the O
five O
major O
domains O
of O
QOL O
. O

Outcomes O
measured O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
included O
QOL O
( O
Linear O
Analogue O
Self-Assessment O
( O
LASA O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
( O
FACT-G O
) O
) O
and O
mood O
( O
Profile O
of O
Mood O
States O
( O
POMS O
) O
) O
. O

Kruskall-Wallis O
methodology O
was O
used O
to O
compare O
scores O
between O
older O
and O
younger O
adult O
patients O
randomized O
to O
the O
intervention O
. O

Of O
131 O
patients O
in O
the O
larger O
randomized O
controlled O
study O
, O
we O
report O
data O
on O
54 O
evaluable O
patients O
( O
16 O
older O
adults O
and O
38 O
younger O
adults O
) O
randomized O
to O
the O
intervention O
. O

Older B-Premise
adult I-Premise
patients I-Premise
reported I-Premise
better I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
LASA I-Premise
74.4 I-Premise
vs. I-Premise
62.9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.040 I-Premise
) I-Premise
, I-Premise
higher I-Premise
social I-Premise
well-being I-Premise
( I-Premise
FACT-G I-Premise
91.1 I-Premise
vs. I-Premise
83.3 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.045 I-Premise
) I-Premise
, I-Premise
and I-Premise
fewer I-Premise
problems I-Premise
with I-Premise
anger I-Premise
( I-Premise
POMS I-Premise
anger-hostility I-Premise
95.0 I-Premise
vs. I-Premise
86.4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
. I-Premise

Long-term B-Premise
benefits I-Premise
for I-Premise
older I-Premise
patients I-Premise
were I-Premise
seen I-Premise
in I-Premise
the I-Premise
anger-hostility I-Premise
scale I-Premise
at I-Premise
week I-Premise
27 I-Premise
( I-Premise
92.2 I-Premise
vs. I-Premise
84.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.027 I-Premise
) I-Premise
and I-Premise
week I-Premise
52 I-Premise
( I-Premise
96.3 I-Premise
vs. I-Premise
85.9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
. I-Premise

Older B-Claim
adult I-Claim
patients I-Claim
who I-Claim
received I-Claim
a I-Claim
multidisciplinary I-Claim
intervention I-Claim
to I-Claim
improve I-Claim
QOL I-Claim
while I-Claim
undergoing I-Claim
advanced I-Claim
cancer I-Claim
treatments I-Claim
benefited I-Claim
differently I-Claim
in I-Claim
some I-Claim
QOL I-Claim
domains I-Claim
, I-Claim
compared I-Claim
to I-Claim
younger I-Claim
adult I-Claim
patients I-Claim
. I-Claim

Future O
studies O
can O
provide O
further O
insight O
on O
how O
to O
tailor O
QOL O
interventions O
for O
these O
age O
groups O
. O

The O
objective O
of O
this O
study O
is O
to O
explore O
the O
inflammatory O
modulation O
effect O
of O
glutamine-enriched O
total O
parenteral O
nutrition O
( O
TPN O
) O
by O
investigating O
the O
alterations O
of O
inflammation-related O
cytokines O
in O
gastrointestinal O
( O
GI O
) O
cancer O
patients O
postoperatively O
. O

Fifty O
GI O
cancer O
patients O
received O
postoperative O
7 O
days O
of O
isocaloric O
and O
isonitrogenous O
TPN O
after O
operation O
. O

They O
were O
randomly O
divided O
to O
receive O
either O
glutamine-enriched O
TPN O
or O
standard O
TPN O
. O

The O
inflammation-related O
cytokines O
including O
interleukin-6 O
, O
interleukin-10 O
, O
and O
tumor O
necrosis O
factor-α O
were O
also O
determined O
. O

Records O
of O
nutritional O
assessments O
, O
inflammatory O
status O
, O
and O
postoperative O
complications O
were O
compared O
between O
the O
two O
groups O
. O

Of O
50 O
enrolled O
patients O
, O
25 O
patients O
were O
classified O
as O
the O
intervention O
group O
, O
and O
the O
control O
group O
also O
comprised O
25 O
patients O
. O

The O
differences O
of O
gender O
, O
age O
, O
primary O
GI O
malignancies O
, O
and O
hematological O
and O
biochemical O
data O
between O
the O
two O
compared O
groups O
were O
not O
statistically O
significant O
( O
all O
P O
> O
0.05 O
) O
. O

Compared B-Premise
with I-Premise
standard I-Premise
TPN I-Premise
, I-Premise
a I-Premise
higher I-Premise
serum I-Premise
prealbumin I-Premise
level I-Premise
and I-Premise
better I-Premise
nitrogen I-Premise
balance I-Premise
were I-Premise
observed I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.039 I-Premise
and I-Premise
0.048 I-Premise
respectively I-Premise
) I-Premise
. I-Premise

A B-Premise
significantly I-Premise
lower I-Premise
serum I-Premise
interleukin-6 I-Premise
level I-Premise
was I-Premise
found I-Premise
in I-Premise
comparing I-Premise
glutamine-enriched I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
in I-Premise
interleukin-10 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.374 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
levels I-Premise
( I-Premise
P I-Premise
= I-Premise
0.653 I-Premise
) I-Premise
. I-Premise

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C-reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

Indeed O
, O
four B-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
but I-Premise
no I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
interventional I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

Our B-Claim
present I-Claim
study I-Claim
shows I-Claim
that I-Claim
glutamine-enriched I-Claim
TPN I-Claim
may I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
the I-Claim
inflammatory I-Claim
status I-Claim
and I-Claim
decreasing I-Claim
the I-Claim
infectious I-Claim
morbidity I-Claim
in I-Claim
postoperative I-Claim
GI I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

This O
study O
was O
designed O
to O
evaluate O
the O
impact O
of O
laparoscopic O
rectal O
resection O
on O
short-term O
postoperative O
morbidity O
and O
costs O
. O

A O
total O
of O
168 O
patients O
with O
rectal O
cancer O
were O
randomly O
assigned O
to O
laparoscopic O
( O
n O
= O
83 O
) O
or O
open O
( O
n O
= O
85 O
) O
resection O
. O

Outcome O
parameters O
were O
: O
postoperative O
morbidity O
, O
length O
of O
hospital O
stay O
, O
quality O
of O
life O
, O
long-term O
survival O
, O
and O
local O
recurrences O
. O

The O
mean O
follow-up O
period O
was O
53.6 O
months O
. O

Cost-benefit O
analysis O
was O
based O
on O
hospital O
costs O
. O

Operative B-Premise
time I-Premise
was I-Premise
53 I-Premise
minutes I-Premise
longer I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28.9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
was I-Premise
10 I-Premise
( I-Premise
4.9 I-Premise
) I-Premise
days I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
and I-Premise
13.6 I-Premise
( I-Premise
10 I-Premise
) I-Premise
days I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

Local B-Premise
recurrence I-Premise
rate I-Premise
and I-Premise
five-year I-Premise
survival I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
";" I-Premise
however B-Claim
, I-Claim
the I-Claim
limited I-Claim
number I-Claim
of I-Claim
patients I-Claim
does I-Claim
not I-Claim
allow I-Claim
firm I-Claim
conclusions I-Claim
. I-Claim

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
better I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
only I-Premise
in I-Premise
the I-Premise
first I-Premise
year I-Premise
after I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
additional I-Premise
charge I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,748 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
1,194 I-Premise
the I-Premise
result I-Premise
of I-Premise
surgical I-Premise
instruments I-Premise
and I-Premise
$ I-Premise
554 I-Premise
the I-Premise
result I-Premise
of I-Premise
longer I-Premise
operative I-Premise
time I-Premise
) I-Premise
. I-Premise

The B-Premise
saving I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,396 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
647 I-Premise
the I-Premise
result I-Premise
of I-Premise
shorter I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
and I-Premise
$ I-Premise
749 I-Premise
the I-Premise
result I-Premise
of I-Premise
the I-Premise
lower I-Premise
cost I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
) I-Premise
. I-Premise

The B-Premise
net I-Premise
balance I-Premise
resulted I-Premise
in I-Premise
$ I-Premise
351 I-Premise
extra I-Premise
cost I-Premise
per I-Premise
patient I-Premise
randomly I-Premise
allocated I-Premise
to I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
. I-Premise

Short-term B-Claim
postoperative I-Claim
morbidity I-Claim
was I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

Laparoscopic B-Claim
resection I-Claim
reduced I-Claim
length I-Claim
of I-Claim
hospital I-Claim
stay I-Claim
, I-Claim
improved I-Claim
first-year I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
slightly I-Claim
increased I-Claim
hospital I-Claim
costs I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
specialized O
supportive O
enteral O
and O
parenteral O
feeding O
have O
superior O
effects O
compared O
to O
oral O
nutrition O
on O
recovery O
during O
long-term O
postoperative O
treatment O
of O
cancer O
patients O
with O
preoperative O
weight O
loss O
and O
reduced O
maximum O
exercise O
capacity O
. O

One O
hundred O
twenty-six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O

Included O
patients O
( O
n O
= O
80 O
) O
received O
supportive O
enteral O
or O
parenteral O
nutrition O
postoperatively O
at O
home O
corresponding O
to O
1000 O
kcal/d O
until O
the O
patients O
did O
not O
wish O
to O
continue O
with O
artificial O
nutrition O
for O
any O
reason O
. O

Patients O
randomized O
to O
oral O
nutrition O
only O
served O
as O
control O
subjects O
. O

Caloric O
intake O
, O
body O
composition O
( O
dual-energy O
x-ray O
absorptiometry O
) O
, O
and O
respiratory O
gas O
exchanges O
at O
rest O
and O
during O
exercise O
were O
measured O
including O
health-related O
quality O
of O
life O
. O

Survival B-Premise
and I-Premise
hospital I-Premise
stay I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
groups I-Premise
, I-Premise
whereas I-Premise
overall I-Premise
complications I-Premise
were I-Premise
higher I-Premise
on I-Premise
artificial I-Premise
nutrition I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Changes B-Premise
in I-Premise
resting I-Premise
energy I-Premise
expenditure I-Premise
and I-Premise
biochemical I-Premise
tests I-Premise
did I-Premise
not I-Premise
differ I-Premise
during I-Premise
follow-up I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

Body B-Premise
weight I-Premise
and I-Premise
whole I-Premise
body I-Premise
fat I-Premise
declined I-Premise
similarly I-Premise
over I-Premise
time I-Premise
in I-Premise
all I-Premise
groups I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
, I-Premise
whereas O
lean B-Premise
body I-Premise
mass I-Premise
was I-Premise
unchanged I-Premise
during I-Premise
follow-up I-Premise
compared I-Premise
to I-Premise
preoperative I-Premise
values I-Premise
. I-Premise

Maximum B-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
were I-Premise
normalized I-Premise
within I-Premise
6 I-Premise
months I-Premise
postoperatively I-Premise
in I-Premise
all I-Premise
groups I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
recovery I-Premise
of I-Premise
food I-Premise
intake I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

Parenteral B-Claim
feeding I-Claim
was I-Claim
associated I-Claim
with I-Claim
the I-Claim
highest I-Claim
rate I-Claim
of I-Claim
nutrition-related I-Claim
complications I-Claim
, I-Claim
whereas O
enteral B-Claim
feeding I-Claim
reduced I-Claim
quality I-Claim
of I-Claim
life I-Claim
most I-Claim
extensively I-Claim
. I-Claim

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

To O
analyze O
and O
compare O
radiologic O
lung O
expansion O
after O
talc O
pleurodesis O
performed O
either O
by O
videothoracoscopy O
or O
chest O
tube O
and O
correlate O
it O
with O
clinical O
outcome O
. O

Secondary O
end O
points O
evaluated O
were O
as O
follows O
: O
clinical O
efficacy O
";" O
quality O
of O
life O
";" O
safety O
";" O
and O
survival O
. O

Prospective O
randomized O
study O
that O
included O
60 O
patients O
( O
45 O
women O
, O
15 O
men O
";" O
mean O
age O
, O
55.2 O
years O
) O
with O
recurrent O
malignant O
pleural O
effusion O
between O
January O
2005 O
and O
January O
2008 O
. O

They O
were O
randomized O
into O
the O
following O
two O
groups O
: O
video-assisted O
thoracic O
surgery O
( O
VATS O
) O
talc O
poudrage O
";" O
and O
talc O
slurry O
( O
TS O
) O
administered O
through O
a O
chest O
tube O
. O

Lung O
expansion O
was O
evaluated O
through O
chest O
CT O
scans O
obtained O
0 O
, O
1 O
, O
3 O
and O
6 O
months O
after O
pleurodesis O
. O

Complications O
, O
drainage O
time O
, O
hospital O
stay O
, O
and O
quality O
of O
life O
( O
Medical O
Outcomes O
Study O
36-item O
short O
form O
and O
World O
Health O
Organization O
quality-of-life O
questionnaires O
) O
were O
also O
analyzed O
. O

There O
were O
no O
significant O
differences O
in O
preprocedure O
clinical O
and O
pathologic O
variables O
between O
groups O
. O

The O
immediate O
total O
( O
ie O
, O
> O
90 O
% O
) O
lung O
expansion O
was O
observed O
in O
27 O
patients O
( O
45 O
% O
) O
and O
was O
more O
frequent O
in O
the O
VATS O
group O
( O
60 O
% O
vs O
30 O
% O
, O
respectively O
";" O
p O
= O
0.027 O
) O
. O

During B-Premise
follow-up I-Premise
, I-Premise
71 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
showed I-Premise
unaltered I-Premise
or I-Premise
improved I-Premise
lung I-Premise
expansion I-Premise
and I-Premise
9 I-Premise
patients I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
needed I-Premise
new I-Premise
pleural I-Premise
procedures I-Premise
( I-Premise
VATS I-Premise
group I-Premise
, I-Premise
5 I-Premise
recurrences I-Premise
";" I-Premise
TS I-Premise
group I-Premise
, I-Premise
4 I-Premise
recurrences I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.999 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
complications I-Premise
, I-Premise
drainage I-Premise
time I-Premise
, I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
survival I-Premise
. I-Premise

Immediate B-Premise
lung I-Premise
expansion I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
radiologic I-Premise
recurrence I-Premise
, I-Premise
clinical I-Premise
recurrence I-Premise
, I-Premise
or I-Premise
complications I-Premise
( I-Premise
p I-Premise
= I-Premise
0.60 I-Premise
, I-Premise
0.15 I-Premise
, I-Premise
and I-Premise
0.20 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Immediate B-Premise
partial I-Premise
lung I-Premise
expansion I-Premise
was I-Premise
a I-Premise
frequent I-Premise
finding I-Premise
and I-Premise
was I-Premise
more I-Premise
frequent I-Premise
after I-Premise
TS I-Premise
. I-Premise

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

Psychological B-Claim
interventions I-Claim
are I-Claim
efficacious I-Claim
in I-Claim
reducing I-Claim
emotional I-Claim
distress I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
is I-Claim
not I-Claim
clear I-Claim
whether I-Claim
psychological I-Claim
improvements I-Claim
are I-Claim
, I-Claim
in I-Claim
turn I-Claim
, I-Claim
related I-Claim
to I-Claim
improved I-Claim
health I-Claim
. I-Claim

A O
clinical O
trial O
tests O
whether O
a O
psychological O
intervention O
for O
cancer O
patients O
can O
do O
so O
, O
and O
also O
tests O
two O
routes O
to O
achieve O
better O
health O
: O
( O
a O
) O
reducing O
patients O
' O
Emotional O
Distress O
, O
and/or O
( O
b O
) O
enhancing O
their O
functional O
immunity O
. O

Post-surgery O
, O
227 O
breast O
cancer O
patients O
were O
randomized O
to O
intervention O
or O
assessment O
only O
Study O
Arms O
. O

Conducted O
in O
small O
groups O
, O
intervention O
sessions O
were O
offered O
weekly O
for O
4 O
months O
and O
followed O
by O
monthly O
sessions O
for O
8 O
months O
. O

Measures O
included O
psychological O
( O
distress O
) O
, O
biological O
( O
immune O
) O
, O
and O
health O
outcomes O
( O
performance O
status O
and O
evaluations O
of O
patient O
's O
symptomatology O
, O
including O
toxicity O
from O
cancer O
treatment O
, O
lab O
values O
) O
collected O
at O
baseline O
, O
4 O
months O
, O
and O
12 O
months O
. O

A B-Premise
path I-Premise
model I-Premise
revealed I-Premise
that I-Premise
intervention I-Premise
participation I-Premise
directly I-Premise
improved I-Premise
health I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
. I-Premise

These B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
mechanisms I-Premise
for I-Premise
achieving I-Premise
better I-Premise
health I-Premise
, I-Premise
support I-Premise
was I-Premise
found I-Premise
for I-Premise
an I-Premise
indirect I-Premise
effect I-Premise
of I-Premise
distress I-Premise
reduction I-Premise
. I-Premise

That B-Premise
is I-Premise
, I-Premise
by I-Premise
specifically I-Premise
lowering I-Premise
intervention I-Premise
patients I-Premise
' I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
, I-Premise
their I-Premise
health I-Premise
was I-Premise
improved I-Premise
at I-Premise
12 I-Premise
months I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
intervention I-Premise
simultaneously I-Premise
improved I-Premise
patients I-Premise
' I-Premise
T-cell I-Premise
blastogenesis I-Premise
in I-Premise
response I-Premise
to I-Premise
phytohemagglutinin I-Premise
( I-Premise
PHA I-Premise
) I-Premise
, I-Premise
the B-Premise
latter I-Premise
increases I-Premise
were I-Premise
unrelated I-Premise
to I-Premise
improved I-Premise
health I-Premise
. I-Premise

A B-Premise
convergence I-Premise
of I-Premise
biobehavioral I-Premise
effects I-Premise
and I-Premise
health I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
. I-Premise

Behavioral B-Claim
change I-Claim
, I-Claim
rather I-Claim
than I-Claim
immunity I-Claim
change I-Claim
, I-Claim
was I-Claim
influential I-Claim
in I-Claim
achieving I-Claim
lower I-Claim
levels I-Claim
of I-Claim
symptomatology I-Claim
and I-Claim
higher I-Claim
functional I-Claim
status I-Claim
. I-Claim

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

To O
compare O
directly O
the O
effect O
of O
intensity-modulated O
radiotherapy O
( O
IMRT O
) O
vs. O
conventional O
radiotherapy O
( O
CRT O
) O
on O
salivary O
flow O
and O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
early-stage O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
. O

Fifty-one O
patients O
with O
T2 O
, O
N0/N1 O
, O
M0 O
NPC O
took O
part O
in O
a O
randomized O
controlled O
clinical O
study O
and O
received O
IMRT O
or O
CRT O
. O

Stimulated O
whole O
( O
SWS O
) O
and O
parotid O
( O
SPS O
) O
saliva O
flow O
were O
measured O
and O
Medical O
Outcomes O
Short O
Form O
36 O
( O
SF-36 O
) O
, O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
core O
quetionnaire O
, O
and O
EORTC O
head-and-neck O
module O
( O
QLQ-H O
& O
amp O
";" O
N35 O
) O
were O
completed O
at O
baseline O
and O
2 O
, O
6 O
, O
and O
12 O
months O
after O
radiotherapy O
. O

Forty-six B-Premise
patients I-Premise
( I-Premise
88 I-Premise
% I-Premise
) I-Premise
were I-Premise
in I-Premise
disease I-Premise
remission I-Premise
12 I-Premise
months I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
, I-Premise
12 I-Premise
( I-Premise
50.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
20 I-Premise
patients I-Premise
( I-Premise
83.3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IMRT I-Premise
group I-Premise
had I-Premise
recovered I-Premise
at I-Premise
least I-Premise
25 I-Premise
% I-Premise
of I-Premise
preradiotherapy I-Premise
SWS I-Premise
and I-Premise
SPS I-Premise
flow I-Premise
respectively I-Premise
, I-Premise
compared I-Premise
with I-Premise
1 I-Premise
( I-Premise
4.8 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
patients I-Premise
( I-Premise
9.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
. I-Premise

Global B-Premise
health I-Premise
scores I-Premise
showed I-Premise
continuous I-Premise
improvement I-Premise
in I-Premise
QoL I-Premise
after I-Premise
both I-Premise
treatments I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
after I-Premise
12 I-Premise
months I-Premise
subscale I-Premise
scores I-Premise
for I-Premise
role-physical I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
, I-Premise
and I-Premise
physical I-Premise
function I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
indicating I-Premise
a I-Premise
better I-Premise
condition I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Dry B-Premise
mouth I-Premise
and I-Premise
sticky I-Premise
saliva I-Premise
were I-Premise
problems I-Premise
in I-Premise
both I-Premise
groups I-Premise
2 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
. I-Premise

In B-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
there I-Premise
was I-Premise
consistent I-Premise
improvement I-Premise
over I-Premise
time I-Premise
with I-Premise
xerostomia-related I-Premise
symptoms I-Premise
significantly I-Premise
less I-Premise
common I-Premise
than I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
. I-Premise

IMRT B-Claim
was I-Claim
significantly I-Claim
better I-Claim
than I-Claim
CRT I-Claim
in I-Claim
terms I-Claim
of I-Claim
parotid I-Claim
sparing I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
for I-Claim
early-stage I-Claim
disease I-Claim
. I-Claim

The B-Claim
findings I-Claim
support I-Claim
the I-Claim
case I-Claim
for I-Claim
assessment I-Claim
of I-Claim
health-related I-Claim
QoL I-Claim
in I-Claim
relation I-Claim
to I-Claim
head-and-neck I-Claim
cancer I-Claim
using I-Claim
a I-Claim
site-specific I-Claim
approach I-Claim
. O

A O
dramatic O
rise O
in O
incidence O
, O
an O
aging O
population O
, O
and O
expensive O
palliative O
treatments O
have O
led O
to O
an O
escalating O
burden O
on O
clinicians O
managing O
inoperable O
esophageal O
cancer O
with O
only O
limited O
evidence O
of O
effectiveness O
. O

This O
study O
compares O
the O
clinical O
effectiveness O
and O
cost-effectiveness O
of O
self-expanding O
metal O
stents O
( O
SEMSs O
) O
with O
other O
palliative O
therapies O
to O
aid O
clinicians O
in O
making O
an O
evidence-based O
treatment O
choice O
. O

We O
conducted O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
controlled O
, O
clinical O
trial O
with O
215 O
patients O
followed O
until O
death O
or O
study O
closure O
. O

The O
primary O
outcome O
measures O
were O
dysphagia O
, O
quality O
of O
life O
( O
QL O
) O
6 O
weeks O
following O
treatment O
, O
and O
total O
cost O
of O
treatment O
. O

Secondary O
outcome O
measures O
included O
treatment-associated O
morbidity O
, O
mortality O
, O
survival O
, O
and O
cost-effectiveness O
. O

An O
intention-to-treat O
analysis O
was O
carried O
out O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
mean I-Premise
dysphagia I-Premise
grade I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
( I-Premise
P=0.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
worse I-Premise
swallowing I-Premise
reported I-Premise
by I-Premise
rigid I-Premise
stent-treated I-Premise
patients I-Premise
( I-Premise
mean I-Premise
dysphagia I-Premise
score I-Premise
difference=-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-0.10 I-Premise
to I-Premise
-0.89 I-Premise
, I-Premise
P=0.014 I-Premise
) I-Premise
. I-Premise

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

These B-Premise
findings I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
post-procedure I-Premise
pain I-Premise
scores I-Premise
in I-Premise
the I-Premise
SEMS I-Premise
patient I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
of I-Premise
the I-Premise
European I-Premise
Organisation I-Premise
for I-Premise
Research I-Premise
and I-Premise
Treatment I-Premise
of I-Premise
Cancer I-Premise
QLQ I-Premise
C-30 I-Premise
pain I-Premise
symptom I-Premise
score I-Premise
at I-Premise
week I-Premise
1=11.13 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
2.89-19.4 I-Premise
";" I-Premise
P=0.01 I-Premise
) I-Premise
. I-Premise

Although B-Premise
mean I-Premise
EQ-5D I-Premise
QL I-Premise
values I-Premise
differed I-Premise
between I-Premise
the I-Premise
treatments I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
this I-Premise
difference I-Premise
dissipated I-Premise
following I-Premise
generation I-Premise
of I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
values I-Premise
. I-Premise

Total O
costs O
varied O
between O
treatment O
arms O
but O
these O
findings O
canceled O
out O
when O
SEMSs O
were O
compared O
with O
non-SEMS O
therapies O
( O
95 O
% O
CI O
-845.15-1,332.62 O
) O
. O

These O
results O
were O
robust O
to O
sensitivity O
analysis O
. O

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
in-hospital I-Premise
mortality I-Premise
or I-Premise
early I-Premise
complication I-Premise
rates I-Premise
, I-Premise
but B-Premise
late I-Premise
complications I-Premise
were I-Premise
more I-Premise
frequent I-Premise
after I-Premise
rigid I-Premise
stenting I-Premise
( I-Premise
risk I-Premise
ratio=2.47 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.88-3.04 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
non-stent-treated I-Premise
patients I-Premise
( I-Premise
log-rank I-Premise
statistic=4.21 I-Premise
, I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non-stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine-artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim

We O
conducted O
a O
randomized O
trial O
comparing O
uterine-artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O

The O
primary O
outcome O
was O
quality O
of O
life O
at O
1 O
year O
of O
follow-up O
, O
as O
measured O
by O
the O
Medical O
Outcomes O
Study O
36-Item O
Short-Form O
General O
Health O
Survey O
( O
SF-36 O
) O
. O

Patients O
were O
randomly O
assigned O
in O
a O
2:1 O
ratio O
to O
undergo O
either O
uterine-artery O
embolization O
or O
surgery O
, O
with O
106 O
patients O
undergoing O
embolization O
and O
51 O
undergoing O
surgery O
( O
43 O
hysterectomies O
and O
8 O
myomectomies O
) O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
eight I-Premise
components I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
scores I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

The B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs. I-Premise
5 I-Premise
days I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
1 I-Premise
year I-Premise
, I-Premise
symptom I-Premise
scores I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
. I-Premise

During B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
there I-Premise
were I-Premise
13 I-Premise
major I-Premise
adverse I-Premise
events I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
and I-Premise
10 I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
( I-Premise
P=0.22 I-Premise
) I-Premise
, I-Premise
mostly I-Premise
related I-Premise
to I-Premise
the I-Premise
intervention I-Premise
. I-Premise

Ten B-Premise
patients I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
required I-Premise
repeated I-Premise
embolization I-Premise
or I-Premise
hysterectomy I-Premise
for I-Premise
inadequate I-Premise
symptom I-Premise
control I-Premise
. I-Premise

After B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
14 I-Premise
women I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
required I-Premise
hospitalization I-Premise
, I-Premise
3 I-Premise
of I-Premise
them I-Premise
for I-Premise
major I-Premise
adverse I-Premise
events I-Premise
and I-Premise
11 I-Premise
for I-Premise
reintervention I-Premise
for I-Premise
treatment I-Premise
failure I-Premise
. I-Premise

In B-Claim
women I-Claim
with I-Claim
symptomatic I-Claim
fibroids I-Claim
, I-Claim
the I-Claim
faster I-Claim
recovery I-Claim
after I-Claim
embolization I-Claim
must I-Claim
be I-Claim
weighed I-Claim
against I-Claim
the I-Claim
need I-Claim
for I-Claim
further I-Claim
treatment I-Claim
in I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
. I-Claim

Pain O
is O
1 O
of O
the O
most O
common O
symptoms O
that O
a O
cancer O
patient O
would O
experience O
. O

A O
significant O
barrier O
to O
positive O
pain O
management O
is O
patients O
' O
misconceptions O
regarding O
analgesics O
and O
inadequate O
use O
of O
nonpharmacological O
strategies O
as O
pain O
relief O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effectiveness O
of O
a O
pain O
management O
program O
( O
PMP O
) O
on O
pain O
intensity O
, O
use O
of O
PRN O
drugs O
and O
nonpharmacological O
strategies O
as O
pain O
relief O
, O
and O
barriers O
to O
managing O
pain O
in O
cancer O
patients O
. O

The O
study O
was O
conducted O
in O
the O
palliative O
care O
and O
hospice O
ward O
of O
a O
public O
hospital O
in O
Hong O
Kong O
. O

Patients O
were O
randomized O
to O
either O
an O
experimental O
group O
( O
receiving O
the O
PMP O
) O
or O
a O
control O
group O
( O
routine O
care O
) O
. O

There O
were O
38 O
hospitalized O
patients O
, O
with O
20 O
( O
13 O
males O
and O
7 O
females O
) O
in O
the O
experimental O
group O
and O
18 O
( O
11 O
males O
and O
7 O
females O
) O
in O
the O
control O
group O
";" O
mean O
age O
was O
61.95 O
years O
( O
experimental O
group O
) O
to O
63.94 O
years O
( O
control O
group O
) O
. O

Upon B-Premise
the I-Premise
completion I-Premise
of I-Premise
PMP I-Premise
, I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
yet B-Premise
patients I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
use I-Premise
of I-Premise
PRN I-Premise
analgesics I-Premise
and I-Premise
nonpharmacological I-Premise
strategies I-Premise
to I-Premise
relieve I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
reduce I-Premise
barriers I-Premise
to I-Premise
managing I-Premise
their I-Premise
cancer I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Cancer B-Claim
patients I-Claim
should I-Claim
be I-Claim
empowered I-Claim
with I-Claim
pain I-Claim
management I-Claim
education I-Claim
to I-Claim
gain I-Claim
knowledge I-Claim
and I-Claim
correct I-Claim
misconceptions I-Claim
in I-Claim
managing I-Claim
their I-Claim
cancer I-Claim
pain I-Claim
. I-Claim

Integration B-Claim
of I-Claim
the I-Claim
PMP I-Claim
into I-Claim
routine I-Claim
clinical I-Claim
work I-Claim
may I-Claim
help I-Claim
to I-Claim
improve I-Claim
the I-Claim
standard I-Claim
of I-Claim
care I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

It O
is O
recommended O
to O
provide O
pain O
management O
education O
to O
all O
cancer O
patients O
. O

This O
phase O
III O
trial O
was O
conducted O
to O
test O
whether O
the O
novel O
vascular O
disrupting O
agent O
ASA404 O
( O
vadimezan O
) O
, O
when O
combined O
with O
first-line O
platinum-based O
chemotherapy O
, O
improves O
survival O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
versus O
chemotherapy O
alone O
. O

Patients O
with O
advanced O
stage O
IIIB O
or O
IV O
NSCLC O
, O
stratified O
by O
sex O
and O
tumor O
histology O
, O
were O
randomly O
assigned O
1:1 O
to O
paclitaxel O
( O
200 O
mg/m O
( O
2 O
) O
) O
and O
carboplatin O
( O
area O
under O
the O
curve O
, O
6.0 O
) O
with O
or O
without O
ASA404 O
( O
1,800 O
mg O
m O
( O
2 O
) O
) O
, O
given O
intravenously O
once O
every O
3 O
weeks O
for O
six O
cycles O
followed O
by O
maintenance O
ASA404 O
or O
placebo O
. O

Primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
end O
points O
included O
overall O
response O
rate O
( O
ORR O
) O
and O
progression-free O
survival O
( O
PFS O
) O
. O

One O
thousand O
two O
hundred O
ninety-nine O
patients O
were O
randomly O
assigned O
. O

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

At O
final O
analysis O
, O
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
OS I-Premise
seen I-Premise
between I-Premise
ASA404 I-Premise
( I-Premise
n I-Premise
= I-Premise
649 I-Premise
) I-Premise
and I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
650 I-Premise
) I-Premise
arms I-Premise
: I-Premise
median I-Premise
OS I-Premise
was I-Premise
13.4 I-Premise
and I-Premise
12.7 I-Premise
months I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.85 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.535 I-Premise
) I-Premise
. I-Premise

Similarly O
, O
no B-Premise
OS I-Premise
difference I-Premise
was I-Premise
seen I-Premise
in I-Premise
the I-Premise
histologic I-Premise
( I-Premise
squamous I-Premise
or I-Premise
nonsquamous I-Premise
) I-Premise
and I-Premise
sex I-Premise
( I-Premise
male I-Premise
or I-Premise
female I-Premise
) I-Premise
strata I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
5.5 I-Premise
months I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.04 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.727 I-Premise
) I-Premise
, I-Premise
while I-Premise
ORR I-Premise
was I-Premise
25 I-Premise
% I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AEs I-Premise
) I-Premise
was I-Premise
comparable I-Premise
between I-Premise
the I-Premise
ASA404 I-Premise
and I-Premise
placebo I-Premise
arms I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
27 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
infusion I-Premise
site I-Premise
pain I-Premise
( I-Premise
10 I-Premise
% I-Premise
v I-Premise
0.5 I-Premise
% I-Premise
) I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
ASA404 I-Premise
arm I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
ASA404 I-Claim
to I-Claim
carboplatin I-Claim
and I-Claim
paclitaxel I-Claim
, I-Claim
although I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
failed I-Claim
to I-Claim
improve I-Claim
frontline I-Claim
efficacy I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
postoperative I-Claim
clinical I-Claim
superiority I-Claim
of I-Claim
the I-Claim
interposition I-Claim
of I-Claim
jejunum I-Claim
reconstruction I-Claim
( I-Claim
INT I-Claim
) I-Claim
to I-Claim
Roux-en-Y I-Claim
reconstruction I-Claim
( I-Claim
RY I-Claim
) I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
has I-Claim
not I-Claim
been I-Claim
clarified I-Claim
. I-Claim

Postoperative O
quality O
of O
life O
( O
QOL O
) O
was O
evaluated O
between O
the O
2 O
methods O
by O
a O
multi-institutional O
prospective O
randomized O
trial O
. O

A O
total O
of O
103 O
patients O
with O
gastric O
cancer O
were O
prospectively O
randomly O
divided O
into O
groups O
for O
RY O
( O
n O
= O
51 O
) O
or O
INT O
reconstruction O
( O
n O
= O
52 O
) O
after O
total O
gastrectomy O
. O

They O
were O
stratified O
by O
sex O
, O
age O
, O
institute O
, O
histology O
, O
and O
degree O
of O
lymph O
node O
dissection O
. O

Postoperatively O
, O
body O
mass O
index O
( O
BMI O
) O
and O
nutritional O
conditions O
were O
measured O
serially O
, O
and O
QOL O
and O
postoperative O
squalor O
scores O
were O
evaluated O
at O
3 O
, O
12 O
, O
and O
60 O
months O
and O
compared O
between O
the O
2 O
groups O
. O

After O
removing O
patients O
who O
did O
not O
complete O
the O
follow-up O
survey O
or O
censured O
cases O
, O
24 O
patients O
in O
the O
RY O
group O
and O
18 O
patients O
in O
the O
INT O
group O
were O
clinically O
available O
and O
their O
postoperative O
status O
was O
assessed O
. O

QOL B-Premise
scores I-Premise
were I-Premise
increased I-Premise
and I-Premise
complication I-Premise
scores I-Premise
were I-Premise
improved I-Premise
in I-Premise
the I-Premise
postoperative I-Premise
periods I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
BMI I-Premise
significantly I-Premise
deteriorated I-Premise
compared I-Premise
with I-Premise
preoperative I-Premise
BMI I-Premise
in I-Premise
each I-Premise
group I-Premise
. I-Premise

The B-Premise
postoperative I-Premise
QOL I-Premise
and I-Premise
complication I-Premise
scores I-Premise
at I-Premise
60 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
were I-Premise
significantly I-Premise
better I-Premise
than I-Premise
those I-Premise
at I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
in I-Premise
each I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
of I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
postoperative I-Premise
complication I-Premise
scores I-Premise
between I-Premise
the I-Premise
2 I-Premise
reconstruction I-Premise
groups I-Premise
. I-Premise

The B-Premise
nutritional I-Premise
condition I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
was I-Premise
nearly I-Premise
the I-Premise
same I-Premise
as I-Premise
that I-Premise
in I-Premise
the I-Premise
RY I-Premise
group I-Premise
. I-Premise

Although B-Premise
our I-Premise
patient I-Premise
sample I-Premise
was I-Premise
small I-Premise
and I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
complete I-Premise
the I-Premise
follow-up I-Premise
survey I-Premise
were I-Premise
present I-Premise
, I-Premise
we B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
clinical I-Claim
difference I-Claim
between I-Claim
INT I-Claim
and I-Claim
RY I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
60 I-Claim
months I-Claim
after I-Claim
surgery I-Claim
. I-Claim

The B-Claim
safer I-Claim
and I-Claim
simpler I-Claim
RY I-Claim
method I-Claim
may I-Claim
be I-Claim
a I-Claim
more I-Claim
suitable I-Claim
reconstruction I-Claim
method I-Claim
than I-Claim
INT I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
. I-Claim

Approximately O
30 O
% O
of O
lung O
cancer O
cases O
are O
diagnosed O
in O
patients O
> O
70 O
years O
of O
age O
. O

Standard B-Claim
chemotherapy I-Claim
regimens I-Claim
are I-Claim
generally I-Claim
considered I-Claim
too I-Claim
toxic I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
. I-Claim

We O
conducted O
a O
multicenter O
phase O
II O
trial O
to O
determine O
the O
efficacy O
and O
safety O
of O
carboplatin O
combined O
with O
vinorelbine O
every O
4 O
weeks O
as O
first-line O
treatment O
for O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
in O
elderly O
patients O
. O

Patients O
were O
eligible O
if O
they O
were O
aged O
> O
OR= O
70 O
years O
, O
had O
stage O
IIIB O
( O
with O
pleural O
effusion O
) O
or O
stage O
IV O
NSCLC O
, O
had O
a O
performance O
status O
of O
0/1 O
, O
had O
not O
previously O
received O
chemotherapy O
, O
and O
had O
normal O
organ O
function O
. O

Forty O
patients O
( O
31 O
men O
and O
9 O
women O
) O
were O
enrolled O
and O
received O
3-5 O
courses O
of O
treatment O
. O

Median O
age O
was O
72 O
years O
( O
range O
, O
70-82 O
years O
) O
. O

Eighty O
percent O
of O
patients O
had O
stage O
IV O
NSCLC O
, O
with O
squamous O
cell O
( O
n=21 O
) O
, O
adenocarcinoma O
( O
n=12 O
) O
, O
and O
undifferentiated O
( O
n=7 O
) O
histologies O
. O

Forty O
patients O
were O
assessable O
for O
toxicity O
and O
32 O
for O
treatment O
response O
. O

Among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent-to-treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
0.2-13.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
in I-Premise
27 I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
grade I-Premise
3/4 I-Premise
anemia I-Premise
was I-Premise
seen I-Premise
in I-Premise
5 I-Premise
patients I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
. I-Premise

One B-Premise
patient I-Premise
died I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
during I-Premise
treatment I-Premise
. I-Premise

The B-Premise
main I-Premise
nonhematologic I-Premise
adverse I-Premise
effect I-Premise
was I-Premise
fatigue I-Premise
( I-Premise
grade I-Premise
3/4 I-Premise
in I-Premise
18 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Carboplatin/vinorelbine B-Claim
is I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
extensive-stage I-Claim
NSCLC I-Claim
. I-Claim

Efficacy B-Claim
is I-Claim
low I-Claim
but I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
other I-Claim
treatments I-Claim
used I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

The O
purpose O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
a O
combined O
cardiorespiratory O
and O
resistance O
exercise O
training O
program O
of O
short O
duration O
on O
the O
cardiorespiratory O
fitness O
, O
strength O
endurance O
, O
task O
specific O
functional O
muscle O
capacity O
, O
body O
composition O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
breast O
cancer O
survivors O
. O

Sixteen O
subjects O
were O
randomly O
assigned O
to O
either O
a O
training O
( O
n O
= O
8 O
";" O
age O
: O
50 O
+/- O
5 O
yrs O
) O
or O
control O
non-exercising O
group O
( O
n O
= O
8 O
";" O
age O
: O
51 O
+/- O
10 O
yrs O
) O
. O

The O
training O
group O
followed O
an O
8-week O
exercise O
program O
consisting O
of O
3 O
weekly O
sessions O
of O
90-min O
duration O
, O
supervised O
by O
an O
experienced O
investigator O
and O
divided O
into O
resistance O
exercises O
and O
aerobic O
training O
. O

Before O
and O
after O
the O
intervention O
period O
, O
all O
of O
the O
subjects O
performed O
a O
cardiorespiratory O
test O
to O
measure O
peak O
oxygen O
uptake O
( O
VO2peak O
) O
, O
a O
dynamic O
strength O
endurance O
test O
( O
maximum O
number O
of O
repetitions O
for O
chest O
and O
leg O
press O
exercise O
at O
30 O
- O
35 O
% O
and O
100 O
- O
110 O
% O
of O
body O
mass O
, O
respectively O
) O
and O
a O
sit-stand O
test O
. O

Quality O
of O
life O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
( O
EORTC-C30 O
) O
questionnaire O
. O

In B-Premise
response I-Premise
to I-Premise
training I-Premise
, I-Premise
QOL I-Premise
, I-Premise
VO2peak I-Premise
( I-Premise
mean I-Premise
3.9 I-Premise
ml/kg/min I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
, I-Premise
6.90 I-Premise
) I-Premise
performance I-Premise
in I-Premise
leg I-Premise
press I-Premise
( I-Premise
17.9 I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.8 I-Premise
, I-Premise
22.4 I-Premise
) I-Premise
and I-Premise
sit-stand I-Premise
test I-Premise
( I-Premise
- I-Premise
0.67 I-Premise
s I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0.52 I-Premise
, I-Premise
- I-Premise
1.2 I-Premise
) I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

We B-Premise
observed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Combined B-Claim
cardiorespiratory I-Claim
and I-Claim
resistance I-Claim
training I-Claim
, I-Claim
even I-Claim
of I-Claim
very I-Claim
brief I-Claim
duration I-Claim
, I-Claim
improves I-Claim
the I-Claim
QOL I-Claim
and I-Claim
the I-Claim
overall I-Claim
physical I-Claim
fitness I-Claim
of I-Claim
women I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Phase O
III O
EGF104900 O
data O
demonstrated O
that O
lapatinib O
plus O
trastuzumab O
significantly O
improved O
progression-free O
survival O
( O
PFS O
) O
and O
clinical O
benefit O
rate O
versus O
lapatinib O
monotherapy O
, O
offering O
a O
chemotherapy-free O
option O
for O
patients O
with O
heavily O
pretreated O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

Final O
planned O
overall O
survival O
( O
OS O
) O
analysis O
from O
EGF104900 O
is O
reported O
here O
. O

Patients O
with O
HER2-positive O
MBC O
whose O
disease O
progressed O
during O
prior O
trastuzumab-based O
therapies O
were O
randomly O
assigned O
to O
receive O
lapatinib O
monotherapy O
or O
lapatinib O
in O
combination O
with O
trastuzumab O
. O

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

Subgroup O
analyses O
were O
conducted O
to O
identify O
characteristics O
of O
patients O
deriving O
the O
greatest O
clinical O
benefit O
. O

In B-Premise
this I-Premise
updated I-Premise
final I-Premise
analysis I-Premise
of I-Premise
all I-Premise
patients I-Premise
randomly I-Premise
assigned I-Premise
with I-Premise
strata I-Premise
( I-Premise
n I-Premise
= I-Premise
291 I-Premise
) I-Premise
, I-Premise
lapatinib I-Premise
plus I-Premise
trastuzumab I-Premise
continued I-Premise
to I-Premise
show I-Premise
superiority I-Premise
to I-Premise
lapatinib I-Premise
monotherapy I-Premise
in I-Premise
PFS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.58 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.011 I-Premise
) I-Premise
and I-Premise
offered I-Premise
significant I-Premise
OS I-Premise
benefit I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.57 I-Premise
to I-Premise
0.97 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.026 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
absolute I-Premise
OS I-Premise
rates I-Premise
were I-Premise
10 I-Premise
% I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
15 I-Premise
% I-Premise
at I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
monotherapy I-Premise
arm I-Premise
. I-Premise

Multiple B-Premise
baseline I-Premise
factors I-Premise
, I-Premise
including I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
of I-Premise
0 I-Premise
, I-Premise
nonvisceral I-Premise
disease I-Premise
, I-Premise
< I-Premise
three I-Premise
metastatic I-Premise
sites I-Premise
, I-Premise
and I-Premise
less I-Premise
time I-Premise
from I-Premise
initial I-Premise
diagnosis I-Premise
until I-Premise
random I-Premise
assignment I-Premise
, I-Premise
were I-Premise
associated I-Premise
with I-Premise
improved I-Premise
OS I-Premise
. I-Premise

Incidence B-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
consistent I-Premise
with I-Premise
previously I-Premise
reported I-Premise
rates I-Premise
. I-Premise

These B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4.5-month I-Claim
median I-Claim
OS I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
HER2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
HER2-positive I-Claim
MBC I-Claim
. I-Claim

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
chemotherapy O
on O
the O
quality O
of O
life O
and O
survival O
of O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
( O
stage O
IIIB O
or O
IV O
) O
. O

In O
a O
controlled O
multicentre O
trial O
, O
patients O
were O
randomised O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
chemotherapy O
. O

Chemotherapy O
consisted O
of O
intravenous O
( O
i.v O
. O
) O

carboplatin O
300 O
mg/m2 O
on O
day O
1 O
and O
etoposide O
120 O
mg/m2 O
orally O
on O
days O
1-5 O
every O
4 O
weeks O
for O
a O
maximum O
of O
eight O
courses O
. O

Quality O
of O
life O
was O
measured O
at O
randomisation O
and O
prior O
to O
each O
treatment O
course O
and O
at O
corresponding O
4-week O
intervals O
in O
the O
control O
arm O
, O
using O
the O
EORTC O
QLQ-C30 O
+ O
LC13 O
questionnaire O
. O

48 O
patients O
were O
randomised O
( O
supportive O
care O
26 O
, O
chemotherapy O
22 O
) O
, O
being O
eligible O
for O
comparative O
analyses O
. O

Another O
102 O
patients O
, O
97 O
of O
which O
received O
chemotherapy O
, O
were O
subsequently O
included O
in O
the O
study O
on O
an O
individual O
treatment O
preference O
basis O
. O

Data O
from O
these O
patients O
were O
used O
for O
confirmative O
purposes O
. O

Patients B-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
reported I-Premise
better I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
symptom I-Premise
control I-Premise
compared I-Premise
with I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
. I-Premise

Group B-Premise
differences I-Premise
were I-Premise
smaller I-Premise
within I-Premise
the I-Premise
psychosocial I-Premise
domain I-Premise
, I-Premise
although B-Premise
trends I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
except B-Premise
for I-Premise
hair I-Premise
loss I-Premise
. I-Premise

Median B-Premise
survival I-Premise
times I-Premise
were I-Premise
29 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
versus I-Premise
11 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
28 I-Premise
% I-Premise
versus I-Premise
8 I-Premise
% I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
and I-Premise
survival I-Premise
outcomes I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
randomised I-Premise
and I-Premise
non-randomised I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

No B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
treatment I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
etoposide I-Claim
can I-Claim
improve I-Claim
both I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
the I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

To O
assess O
the O
efficacy O
of O
prophylactic O
swallowing O
exercises O
on O
swallowing O
function O
in O
patients O
undergoing O
chemoradiation O
therapy O
( O
CRT O
) O
for O
head O
and O
neck O
cancer O
. O

Randomized O
controlled O
trial O
. O

Tertiary O
care O
, O
academic O
medical O
center O
. O

Twenty-six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
CRT O
. O

Patients O
performed O
5 O
targeted O
swallowing O
exercises O
throughout O
their O
CRT O
and O
participated O
in O
weekly O
swallowing O
therapy O
sessions O
to O
promote O
adherence O
and O
accurate O
technique O
. O

Controls O
had O
no O
prophylactic O
exercises O
and O
were O
referred O
for O
swallowing O
treatment O
after O
completion O
of O
CRT O
if O
indicated O
. O

Swallowing O
function O
was O
assessed O
with O
the O
Functional O
Oral O
Intake O
Scale O
( O
FOIS O
) O
and O
the O
Performance O
Status O
Scale O
for O
Head O
and O
Neck O
Cancer O
Patients O
( O
PSS-H O
& O
N O
) O
at O
baseline O
, O
immediately O
after O
CRT O
, O
and O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
CRT O
. O

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FOIS I-Premise
scores I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
( I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
: I-Premise
intervention I-Premise
group I-Premise
median I-Premise
score I-Premise
, I-Premise
3 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
4 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-6 I-Premise
] I-Premise
( I-Premise
P I-Premise
= I-Premise
.88 I-Premise
) I-Premise
. I-Premise

However O
, O
intervention B-Premise
patients I-Premise
had I-Premise
significantly I-Premise
better I-Premise
scores I-Premise
at I-Premise
months I-Premise
3 I-Premise
and I-Premise
6 I-Premise
( I-Premise
median I-Premise
3-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
5-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
5 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
";" I-Premise
median I-Premise
6-month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
6-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
6 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.009 I-Premise
] I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
scores I-Premise
at I-Premise
months I-Premise
9 I-Premise
and I-Premise
12 I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
and I-Premise
P I-Premise
= I-Premise
.93 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
same I-Premise
pattern I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
was I-Premise
observed I-Premise
for I-Premise
scores I-Premise
on I-Premise
the I-Premise
PSS-H I-Premise
& I-Premise
N I-Premise
. I-Premise

Patients B-Claim
who I-Claim
performed I-Claim
prophylactic I-Claim
swallowing I-Claim
exercises I-Claim
had I-Claim
improved I-Claim
swallowing I-Claim
function I-Claim
at I-Claim
3 I-Claim
and I-Claim
6 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
but I-Claim
not I-Claim
immediately I-Claim
after I-Claim
CRT I-Claim
or I-Claim
at I-Claim
9 I-Claim
and I-Claim
12 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
. I-Claim

The B-Claim
small I-Claim
sample I-Claim
size I-Claim
may I-Claim
have I-Claim
limited I-Claim
our I-Claim
ability I-Claim
to I-Claim
detect I-Claim
significant I-Claim
differences I-Claim
beyond I-Claim
6 I-Claim
months I-Claim
of I-Claim
observation I-Claim
as I-Claim
well I-Claim
as I-Claim
additional I-Claim
significant I-Claim
differences I-Claim
in I-Claim
our I-Claim
study I-Claim
. I-Claim

To O
prospectively O
evaluate O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
outcomes O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
and O
hysterectomy O
up O
to O
24 O
months O
after O
the O
intervention O
in O
terms O
of O
mental O
and O
physical O
health O
, O
urinary O
and O
defecatory O
function O
, O
and O
overall O
patient O
satisfaction O
. O

Ethics O
committee O
approval O
and O
informed O
consent O
were O
obtained O
for O
the O
Embolisation O
versus O
Hysterectomy O
Trial O
. O

Women O
( O
n O
= O
177 O
) O
with O
uterine O
fibroids O
and O
heavy O
menstrual O
bleeding O
who O
were O
scheduled O
to O
undergo O
hysterectomy O
were O
randomly O
assigned O
to O
undergo O
UAE O
( O
n O
= O
88 O
) O
or O
hysterectomy O
( O
n O
= O
89 O
) O
. O

HRQOL O
was O
measured O
six O
times O
during O
a O
24-month O
follow-up O
period O
with O
the O
following O
validated O
questionnaires O
: O
Medical O
Outcome O
Study O
Short O
Form O
36 O
( O
SF-36 O
) O
mental O
component O
summary O
( O
MCS O
) O
and O
physical O
component O
summary O
( O
PCS O
) O
, O
Health O
Utilities O
Index O
Mark O
3 O
, O
EuroQol O
5D O
, O
urogenital O
distress O
inventory O
( O
UDI O
) O
, O
incontinence O
impact O
questionnaire O
, O
and O
defecation O
distress O
inventory O
( O
DDI O
) O
. O

Satisfaction O
was O
assessed O
with O
a O
seven-point O
Likert O
scale O
. O

Repeated O
measurement O
analysis O
was O
performed O
for O
between-group O
analysis O
. O

Paired O
t O
tests O
were O
performed O
for O
within-group O
analysis O
. O

Satisfaction O
was O
analyzed O
with O
the O
Fisher O
exact O
test O
. O

The B-Premise
SF-36 I-Premise
MCS I-Premise
and I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
and I-Premise
UDI I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The O
DDI O
score O
was O
improved O
significantly O
in O
only O
the O
UAE O
group O
at O
6 O
months O
and O
afterward O
( O
P O
< O
.05 O
) O
. O

No O
differences O
between O
groups O
were O
observed O
, O
with O
the O
exception O
of O
PCS O
scores O
at O
6-week O
follow-up O
: O
Patients O
in O
the O
UAE O
group O
had O
significantly O
better O
scores O
than O
did O
patients O
in O
the O
hysterectomy O
group O
( O
P O
< O
.001 O
) O
. O

Improvement O
in O
PCS O
score O
at O
24-month O
follow-up O
was O
significantly O
higher O
for O
patients O
who O
were O
employed O
at O
baseline O
( O
P O
= O
.035 O
) O
. O

At B-Premise
24-month I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
hysterectomy I-Premise
group I-Premise
were I-Premise
significantly I-Premise
more I-Premise
satisfied I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Both B-Claim
UAE I-Claim
and I-Claim
hysterectomy I-Claim
improved I-Claim
HRQOL I-Claim
. I-Claim

No B-Claim
differences I-Claim
were I-Claim
observed I-Claim
between I-Claim
groups I-Claim
regarding I-Claim
HRQOL I-Claim
at I-Claim
24-month I-Claim
follow-up I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
HRQOL I-Claim
results I-Claim
, I-Claim
the I-Claim
authors I-Claim
determined I-Claim
that I-Claim
UAE I-Claim
is I-Claim
a I-Claim
good I-Claim
alternative I-Claim
to I-Claim
hysterectomy I-Claim
. I-Claim

There O
are O
no O
known O
effective O
treatments O
for O
painful O
chemotherapy-induced O
peripheral O
neuropathy O
. O

To O
determine O
the O
effect O
of O
duloxetine O
, O
60 O
mg O
daily O
, O
on O
average O
pain O
severity O
. O

Randomized O
, O
double-blind O
, O
placebo-controlled O
crossover O
trial O
at O
8 O
National O
Cancer O
Institute O
( O
NCI O
) O
-funded O
cooperative O
research O
networks O
that O
enrolled O
231 O
patients O
who O
were O
25 O
years O
or O
older O
being O
treated O
at O
community O
and O
academic O
settings O
between O
April O
2008 O
and O
March O
2011 O
. O

Study O
follow-up O
was O
completed O
July O
2012 O
. O

Stratified O
by O
chemotherapeutic O
drug O
and O
comorbid O
pain O
risk O
, O
patients O
were O
randomized O
to O
receive O
either O
duloxetine O
followed O
by O
placebo O
or O
placebo O
followed O
by O
duloxetine O
. O

Eligibility O
required O
that O
patients O
have O
grade O
1 O
or O
higher O
sensory O
neuropathy O
according O
to O
the O
NCI O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
and O
at O
least O
4 O
on O
a O
scale O
of O
0 O
to O
10 O
, O
representing O
average O
chemotherapy-induced O
pain O
, O
after O
paclitaxel O
, O
other O
taxane O
, O
or O
oxaliplatin O
treatment O
. O

The O
initial O
treatment O
consisted O
of O
taking O
1 O
capsule O
daily O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
for O
the O
first O
week O
and O
2 O
capsules O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
daily O
for O
4 O
additional O
weeks O
. O

The O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy-induced O
peripheral O
neuropathic O
pain O
. O

Pain O
severity O
was O
assessed O
using O
the O
Brief O
Pain O
Inventory-Short O
Form O
" O
average O
pain O
" O
item O
with O
0 O
representing O
no O
pain O
and O
10 O
representing O
as O
bad O
as O
can O
be O
imagined O
. O

Individuals B-Premise
receiving I-Premise
duloxetine I-Premise
as I-Premise
their I-Premise
initial I-Premise
5-week I-Premise
treatment I-Premise
reported I-Premise
a I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
average I-Premise
pain I-Premise
of I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.72-1.40 I-Premise
) I-Premise
vs I-Premise
0.34 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.01-0.66 I-Premise
) I-Premise
among I-Premise
those I-Premise
who I-Premise
received I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.513 I-Premise
) I-Premise
. I-Premise

The B-Premise
observed I-Premise
mean I-Premise
difference I-Premise
in I-Premise
the I-Premise
average I-Premise
pain I-Premise
score I-Premise
between I-Premise
duloxetine I-Premise
and I-Premise
placebo I-Premise
was I-Premise
0.73 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26-1.20 I-Premise
) I-Premise
. I-Premise

Fifty-nine B-Premise
percent I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
duloxetine I-Premise
vs I-Premise
38 I-Premise
% I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
placebo I-Premise
reported I-Premise
decreased I-Premise
pain I-Premise
of I-Premise
any I-Premise
amount I-Premise
. I-Premise

Among B-Claim
patients I-Claim
with I-Claim
painful I-Claim
chemotherapy-induced I-Claim
peripheral I-Claim
neuropathy I-Claim
, I-Claim
the I-Claim
use I-Claim
of I-Claim
duloxetine I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
for I-Claim
5 I-Claim
weeks I-Claim
resulted I-Claim
in I-Claim
a I-Claim
greater I-Claim
reduction I-Claim
in I-Claim
pain I-Claim
. I-Claim

The O
majority O
of O
prostate O
carcinoma O
survivors O
experience O
enduring O
sexual O
difficulties O
and O
associated O
distress O
in O
the O
years O
after O
definitive O
treatment O
. O

A O
counseling O
intervention O
aimed O
at O
improving O
levels O
of O
sexual O
satisfaction O
and O
increasing O
successful O
utilization O
of O
medical O
treatment O
for O
erectile O
dysfunction O
( O
ED O
) O
was O
developed O
and O
pilot-tested O
for O
both O
the O
survivor O
of O
prostate O
carcinoma O
and O
his O
partner O
. O

All O
male O
participants O
were O
3-month O
to O
5-year O
survivors O
of O
localized O
prostate O
carcinoma O
who O
had O
been O
treated O
with O
radical O
prostatectomy O
or O
radiation O
therapy O
, O
and O
were O
married O
or O
in O
a O
committed O
relationship O
. O

Couples O
were O
randomized O
to O
attend O
four O
sessions O
of O
counseling O
together O
or O
to O
have O
the O
man O
attend O
alone O
. O

In O
both O
groups O
, O
partners O
completed O
behavioral O
homework O
. O

The O
sessions O
included O
education O
on O
prostate O
carcinoma O
and O
sexual O
function O
and O
options O
to O
treat O
ED O
as O
well O
as O
sexual O
communication O
and O
stimulation O
skills O
. O

Standardized O
questionnaires O
at O
baseline O
, O
posttreatment O
, O
and O
at O
3-month O
and O
6-month O
follow-up O
assessed O
sexual O
function O
, O
marital O
adjustment O
, O
psychologic O
distress O
, O
and O
utilization O
of O
treatments O
for O
ED O
. O

Fifty-one O
of O
84 O
couples O
randomized O
to O
treatment O
completed O
the O
intervention O
( O
61 O
% O
) O
. O

Attendance O
by O
the O
partner O
did O
not O
affect O
outcomes O
. O

Participants B-Premise
completing I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
improvement I-Premise
in I-Premise
male I-Premise
overall I-Premise
distress I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
male I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
female I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
, I-Premise
but B-Premise
regression I-Premise
toward I-Premise
baseline I-Premise
was I-Premise
noted I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

However B-Premise
, I-Premise
utilization I-Premise
of I-Premise
ED I-Premise
treatments I-Premise
increased I-Premise
from I-Premise
31 I-Premise
% I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
to I-Premise
49 I-Premise
% I-Premise
at I-Premise
the I-Premise
6-month I-Premise
follow-up I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

However B-Claim
, I-Claim
modifications I-Claim
are I-Claim
needed I-Claim
in I-Claim
future I-Claim
randomized I-Claim
trials I-Claim
to I-Claim
reduce I-Claim
the I-Claim
rate I-Claim
of I-Claim
premature I-Claim
termination I-Claim
and I-Claim
to I-Claim
improve I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
gains I-Claim
. I-Claim

The O
aim O
of O
this O
prospective O
controlled O
study O
was O
to O
assess O
the O
efficacy O
of O
two O
different O
combination O
treatment O
modalities O
of O
lymphedema O
( O
LE O
) O
. O

Manual O
lymphatic O
drainage O
( O
MLD O
) O
and O
compression O
bandage O
combination O
( O
complex O
decongestive O
therapy O
) O
have O
been O
compared O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
plus O
self-lymphatic O
drainage O
( O
SLD O
) O
. O

Both O
MLD O
with O
compression O
bandage O
( O
complex O
decongestive O
therapy O
) O
group O
( O
Group O
I O
, O
n=15 O
) O
and O
IPC O
with O
SLD O
group O
( O
Group O
II O
, O
n=15 O
) O
received O
treatment O
for O
LE O
3 O
days O
in O
a O
week O
and O
every O
other O
day O
for O
6 O
weeks O
. O

Arm O
circumferences O
were O
measured O
before O
and O
the O
1st O
, O
3rd O
, O
and O
6th O
weeks O
of O
the O
treatment O
. O

EORTC-QLQ O
and O
ASES-tests O
were O
performed O
to O
assess O
the O
quality O
of O
life O
before O
and O
after O
6 O
week-treatment O
. O

Patients O
in O
both O
groups O
had O
similar O
demographic O
and O
clinical O
characteristics O
. O

Even O
though O
both B-Premise
treatment I-Premise
modalities I-Premise
resulted I-Premise
in I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
arm I-Premise
volume I-Premise
( I-Premise
12.2 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
II I-Premise
and I-Premise
14.9 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
I I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
no B-Premise
significant I-Premise
difference I-Premise
( I-Premise
p=0.582 I-Premise
) I-Premise
was I-Premise
found I-Premise
between I-Premise
those I-Premise
two I-Premise
groups I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
ASES I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
Group I-Premise
I I-Premise
and I-Premise
II I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

While B-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
functional I-Premise
and I-Premise
cognitive I-Premise
functioning I-Premise
scores I-Premise
appeared I-Premise
to I-Premise
be I-Premise
improved I-Premise
only I-Premise
in I-Premise
patients I-Premise
of I-Premise
group I-Premise
I I-Premise
. I-Premise

Different B-Claim
treatment I-Claim
modalities I-Claim
consisting I-Claim
of I-Claim
MLD I-Claim
and I-Claim
compression I-Claim
bandage I-Claim
( I-Claim
complex I-Claim
decongestive I-Claim
therapy I-Claim
) I-Claim
or I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
appear I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
LE I-Claim
with I-Claim
similar I-Claim
therapeutic I-Claim
efficacy I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

However B-Claim
, I-Claim
combination I-Claim
modalities I-Claim
including I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
may I-Claim
be I-Claim
the I-Claim
preferred I-Claim
choices I-Claim
for I-Claim
their I-Claim
applicability I-Claim
at I-Claim
home I-Claim
. I-Claim

This O
randomized O
, O
multicenter O
, O
phase O
III O
study O
compared O
doxorubicin O
and O
docetaxel O
( O
AT O
) O
with O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
as O
first-line O
chemotherapy O
( O
CT O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

Patients O
( O
n O
= O
429 O
) O
were O
randomly O
assigned O
to O
receive O
doxorubicin O
50 O
mg/m O
( O
2 O
) O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
( O
n O
= O
214 O
) O
or O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
( O
n O
= O
215 O
) O
on O
day O
1 O
, O
every O
3 O
weeks O
for O
up O
to O
eight O
cycles O
. O

Time B-Premise
to I-Premise
progression I-Premise
( I-Premise
TTP I-Premise
";" I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
TTF I-Premise
) I-Premise
were I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
AT I-Premise
than I-Premise
AC I-Premise
( I-Premise
median I-Premise
TTP I-Premise
, I-Premise
37.3 I-Premise
v I-Premise
31.9 I-Premise
weeks I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.014 I-Premise
";" I-Premise
median I-Premise
TTF I-Premise
, I-Premise
25.6 I-Premise
v I-Premise
23.7 I-Premise
weeks I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
59 I-Premise
% I-Premise
, I-Premise
with I-Premise
10 I-Premise
% I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
49 I-Premise
% I-Premise
partial I-Premise
response I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
than I-Premise
for I-Premise
those I-Premise
taking I-Premise
AC I-Premise
( I-Premise
47 I-Premise
% I-Premise
, I-Premise
with I-Premise
7 I-Premise
% I-Premise
CR I-Premise
, I-Premise
39 I-Premise
% I-Premise
PR I-Premise
) I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
. I-Premise

The B-Premise
ORR I-Premise
was I-Premise
also I-Premise
higher I-Premise
with I-Premise
AT I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
involvement I-Premise
( I-Premise
58 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
";" I-Premise
liver I-Premise
, I-Premise
62 I-Premise
% I-Premise
v I-Premise
42 I-Premise
% I-Premise
";" I-Premise
lung I-Premise
, I-Premise
58 I-Premise
% I-Premise
v I-Premise
35 I-Premise
% I-Premise
) I-Premise
, I-Premise
three I-Premise
or I-Premise
more I-Premise
organs I-Premise
involved I-Premise
( I-Premise
59 I-Premise
% I-Premise
v I-Premise
40 I-Premise
% I-Premise
) I-Premise
, I-Premise
or I-Premise
prior I-Premise
adjuvant I-Premise
CT I-Premise
( I-Premise
53 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
) I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
was I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
was I-Premise
frequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
febrile I-Premise
neutropenia I-Premise
and I-Premise
infections I-Premise
were I-Premise
more I-Premise
frequent I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
respectively I-Premise
, I-Premise
33 I-Premise
% I-Premise
v I-Premise
10 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
8 I-Premise
% I-Premise
v I-Premise
2 I-Premise
% I-Premise
, I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

Severe B-Premise
nonhematologic I-Premise
toxicity I-Premise
was I-Premise
infrequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
including I-Premise
grade I-Premise
3/4 I-Premise
cardiac I-Premise
events I-Premise
( I-Premise
AT I-Premise
, I-Premise
3 I-Premise
% I-Premise
";" I-Premise
AC I-Premise
, I-Premise
4 I-Premise
% I-Premise
) I-Premise
. I-Premise

AT B-Claim
significantly I-Claim
improves I-Claim
TTP I-Claim
and I-Claim
ORR I-Claim
compared I-Claim
with I-Claim
AC I-Claim
in I-Claim
patients I-Claim
with I-Claim
MBC I-Claim
, I-Claim
but B-Claim
there I-Claim
is I-Claim
no I-Claim
difference I-Claim
in I-Claim
OS I-Claim
. I-Claim

AT B-Claim
represents I-Claim
a I-Claim
valid I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
MBC I-Claim
. I-Claim

Few O
intervention O
studies O
have O
been O
conducted O
to O
help O
couples O
manage O
the O
effects O
of O
prostate O
cancer O
and O
maintain O
their O
quality O
of O
life O
. O

The O
objective O
of O
this O
study O
was O
to O
determine O
whether O
a O
family-based O
intervention O
could O
improve O
appraisal O
variables O
( O
appraisal O
of O
illness O
or O
caregiving O
, O
uncertainty O
, O
hopelessness O
) O
, O
coping O
resources O
( O
coping O
strategies O
, O
self-efficacy O
, O
communication O
) O
, O
symptom O
distress O
, O
and O
quality O
of O
life O
in O
men O
with O
prostate O
cancer O
and O
their O
spouses O
. O

For O
this O
clinical O
trial O
, O
263 O
patient-spouse O
dyads O
were O
stratified O
by O
research O
site O
, O
phase O
of O
illness O
, O
and O
treatment O
";" O
then O
, O
they O
were O
randomized O
to O
the O
control O
group O
( O
standard O
care O
) O
or O
the O
experimental O
group O
( O
standard O
care O
plus O
a O
5-session O
family O
intervention O
) O
. O

The O
intervention O
targeted O
couples O
' O
communication O
, O
hope O
, O
coping O
, O
uncertainty O
, O
and O
symptom O
management O
. O

The O
final O
sample O
consisted O
of O
235 O
couples O
: O
123 O
couples O
in O
the O
control O
group O
and O
112 O
couples O
in O
the O
experimental O
group O
. O

Data O
collection O
occurred O
at O
baseline O
before O
randomization O
and O
at O
4 O
months O
, O
8 O
months O
, O
and O
12 O
months O
. O

At B-Premise
4-month I-Premise
follow-up I-Premise
, I-Premise
intervention I-Premise
patients I-Premise
reported I-Premise
less I-Premise
uncertainty I-Premise
and I-Premise
better I-Premise
communication I-Premise
with I-Premise
spouses I-Premise
than I-Premise
control I-Premise
patients I-Premise
, I-Premise
but B-Premise
they I-Premise
reported I-Premise
no I-Premise
other I-Premise
effects I-Premise
. I-Premise

Intervention B-Premise
spouses I-Premise
reported I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
more I-Premise
self-efficacy I-Premise
, I-Premise
better I-Premise
communication I-Premise
, I-Premise
and I-Premise
less I-Premise
negative I-Premise
appraisal I-Premise
of I-Premise
caregiving I-Premise
, I-Premise
uncertainty I-Premise
, I-Premise
hopelessness I-Premise
, I-Premise
and I-Premise
symptom I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
compared I-Premise
with I-Premise
controls I-Premise
, I-Premise
and I-Premise
some I-Premise
effects I-Premise
were I-Premise
sustained I-Premise
to I-Premise
8 I-Premise
months I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

Men B-Premise
with I-Premise
prostate I-Premise
cancer I-Premise
and I-Premise
their I-Premise
spouses I-Premise
reported I-Premise
positive I-Premise
outcomes I-Premise
from I-Premise
a I-Premise
family I-Premise
intervention I-Premise
that I-Premise
offered I-Premise
them I-Premise
information I-Premise
and I-Premise
support I-Premise
. I-Premise

Programs B-Claim
of I-Claim
care I-Claim
need I-Claim
to I-Claim
be I-Claim
extended I-Claim
to I-Claim
spouses I-Claim
who I-Claim
likely I-Claim
will I-Claim
experience I-Claim
multiple I-Claim
benefits I-Claim
from I-Claim
intervention I-Claim
. I-Claim

Exercise O
training O
improves O
supportive O
care O
outcomes O
in O
patients O
with O
breast O
cancer O
who O
are O
receiving O
adjuvant O
therapy O
, O
but O
the O
responses O
are O
heterogeneous O
. O

In O
this O
study O
, O
the O
authors O
examined O
personal O
and O
clinical O
factors O
that O
may O
predict O
exercise O
training O
responses O
. O

Breast O
cancer O
patients O
who O
were O
initiating O
adjuvant O
chemotherapy O
( O
N=242 O
) O
were O
assigned O
randomly O
to O
receive O
usual O
care O
( O
UC O
) O
( O
n=82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
) O
( O
n=82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
) O
( O
n=78 O
) O
for O
the O
duration O
of O
chemotherapy O
. O

Endpoints O
were O
quality O
of O
life O
( O
QoL O
) O
, O
aerobic O
fitness O
, O
muscular O
strength O
, O
lean O
body O
mass O
, O
and O
body O
fat O
. O

Moderators O
were O
patient O
preference O
for O
group O
assignment O
, O
marital O
status O
, O
age O
, O
disease O
stage O
, O
and O
chemotherapy O
regimen O
. O

Adjusted O
linear O
mixed-model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
QoL O
response O
( O
P= O
.005 O
) O
. O

Patients B-Premise
who I-Premise
preferred I-Premise
RET I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
RET I-Premise
compared I-Premise
with I-Premise
UC I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4.3-28.7 I-Premise
";" I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
or I-Premise
AET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.1-23.4 I-Premise
";" I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
had I-Premise
no I-Premise
preference I-Premise
had I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
AET I-Premise
compared I-Premise
with I-Premise
RET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
23 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.9-41 I-Premise
";" I-Premise
P= I-Premise
.014 I-Premise
) I-Premise
. I-Premise

Marital B-Premise
status I-Premise
also I-Premise
moderated I-Premise
QoL I-Premise
response I-Premise
( I-Premise
P= I-Premise
.026 I-Premise
) I-Premise
, I-Premise
age I-Premise
moderated I-Premise
aerobic I-Premise
fitness I-Premise
response I-Premise
( I-Premise
P= I-Premise
.029 I-Premise
) I-Premise
, I-Premise
chemotherapy I-Premise
regimen I-Premise
moderated I-Premise
strength I-Premise
gain I-Premise
( I-Premise
P= I-Premise
.009 I-Premise
) I-Premise
, I-Premise
and I-Premise
disease I-Premise
stage I-Premise
moderated I-Premise
both I-Premise
lean I-Premise
body I-Premise
mass I-Premise
gain I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
fat I-Premise
loss I-Premise
( I-Premise
P= I-Premise
.059 I-Premise
) I-Premise
. I-Premise

Unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane-based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise

The O
findings O
were O
not O
explained O
by O
differences O
in O
adherence O
. O

Patient B-Claim
preference I-Claim
, I-Claim
demographic I-Claim
variables I-Claim
, I-Claim
and I-Claim
medical I-Claim
variables I-Claim
moderated I-Claim
the I-Claim
effects I-Claim
of I-Claim
exercise I-Claim
training I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
were I-Claim
receiving I-Claim
chemotherapy I-Claim
. I-Claim

If O
replicated O
, O
these O
results O
may O
inform O
clinical O
practice O
. O

To O
compare O
short- O
and O
long-term O
effects O
of O
adjuvant O
treatment O
versus O
observation O
after O
surgery O
on O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
prostate O
cancer O
patients O
. O

The O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
intergroup O
trial O
compared O
radical O
prostatectomy O
( O
RP O
) O
plus O
observation O
versus O
RP O
plus O
adjuvant O
radiation O
therapy O
( O
RT O
) O
. O

Two-hundred O
seventeen O
of O
425 O
therapeutic O
trial O
patients O
were O
eligible O
and O
registered O
to O
the O
HRQL O
study O
. O

Patients O
completed O
the O
SWOG O
Quality O
of O
Life O
Questionnaire O
( O
emotional O
, O
physical O
, O
social O
, O
and O
role O
function O
";" O
general O
symptom O
status O
";" O
treatment/disease-specific O
symptoms O
";" O
and O
global O
HRQL O
[ O
GHRQL O
] O
) O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
annually O
for O
5 O
years O
. O

Prespecified O
outcomes O
were O
three O
genitourinary O
symptoms O
( O
bowel O
function O
tenderness O
, O
frequent O
urination O
, O
and O
erectile O
dysfunction O
[ O
ED O
] O
) O
and O
measures O
of O
physical O
and O
emotional O
function O
. O

Adjustments O
were O
made O
for O
the O
baseline O
score O
. O

Patients O
receiving O
adjuvant O
RT O
reported O
worse O
bowel O
function O
( O
through O
approximately O
2 O
years O
) O
and O
worse O
urinary O
function O
. O

There O
were O
no O
statistically O
significant O
differences O
for O
ED O
. O

GHRQL B-Premise
was I-Premise
initially I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
but I-Premise
improved I-Premise
over I-Premise
time I-Premise
and I-Premise
was I-Premise
better I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
period I-Premise
than I-Premise
the I-Premise
GHRQL I-Premise
reported I-Premise
for I-Premise
RP I-Premise
alone I-Premise
( I-Premise
treatment I-Premise
arm I-Premise
x I-Premise
time I-Premise
interaction I-Premise
, I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
. I-Premise

Symptom B-Premise
distress I-Premise
was I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
RP I-Premise
alone I-Premise
arm I-Premise
, O
but B-Premise
the I-Premise
treatment I-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
with I-Premise
respect I-Premise
to I-Premise
other I-Premise
general I-Premise
measures I-Premise
of I-Premise
HRQL I-Premise
. I-Premise

The B-Premise
addition I-Premise
of I-Premise
RT I-Premise
to I-Premise
surgery I-Premise
resulted I-Premise
in I-Premise
more I-Premise
frequent I-Premise
urination I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
early I-Premise
report I-Premise
of I-Premise
more I-Premise
bowel I-Premise
dysfunction I-Premise
, O
although B-Premise
bowel I-Premise
function I-Premise
differences I-Premise
disappeared I-Premise
over I-Premise
the I-Premise
5-year I-Premise
period I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
RT I-Claim
did I-Claim
not I-Claim
negatively I-Claim
impact I-Claim
ED I-Claim
. I-Claim

Evidence B-Claim
suggests I-Claim
that I-Claim
the I-Claim
re-entry I-Claim
phase I-Claim
( I-Claim
ie I-Claim
, I-Claim
early I-Claim
period I-Claim
after I-Claim
medical I-Claim
treatment I-Claim
completion I-Claim
) I-Claim
presents I-Claim
distinct I-Claim
challenges I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

To O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
Moving O
Beyond O
Cancer O
( O
MBC O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O

Breast O
cancer O
patients O
were O
registered O
within O
6 O
weeks O
after O
surgery O
. O

After O
medical O
treatment O
, O
they O
completed O
baseline O
measures O
and O
were O
randomly O
assigned O
to O
standard O
National O
Cancer O
Institute O
print O
material O
( O
CTL O
) O
";" O
standard O
print O
material O
and O
peer-modeling O
videotape O
( O
VID O
) O
";" O
or O
standard O
print O
material O
, O
videotape O
, O
two O
sessions O
with O
a O
trained O
cancer O
educator O
, O
and O
informational O
workbook O
( O
EDU O
) O
. O

Two O
primary O
end O
points O
were O
examined O
: O
energy/fatigue O
and O
cancer-specific O
distress O
. O

Secondary O
end O
points O
were O
depressive O
symptoms O
and O
post-traumatic O
growth O
. O

Perceived O
preparedness O
for O
re-entry O
was O
analyzed O
as O
a O
moderator O
of O
effects O
. O

Of O
558 O
women O
randomly O
assigned O
to O
treatment O
, O
418 O
completed O
the O
6-month O
assessment O
and O
399 O
completed O
the O
12-month O
assessment O
. O

In B-Premise
analyses I-Premise
controlling I-Premise
for I-Premise
study I-Premise
site I-Premise
and I-Premise
baseline I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
VID I-Premise
produced I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
energy/fatigue I-Premise
at I-Premise
6 I-Premise
months I-Premise
relative I-Premise
to I-Premise
CTL I-Premise
, I-Premise
particularly I-Premise
among I-Premise
women I-Premise
who I-Premise
felt I-Premise
less I-Premise
prepared I-Premise
for I-Premise
re-entry I-Premise
at I-Premise
baseline I-Premise
. I-Premise

No B-Premise
significant I-Premise
main I-Premise
effect I-Premise
of I-Premise
the I-Premise
interventions I-Premise
emerged I-Premise
on I-Premise
cancer-specific I-Premise
distress I-Premise
, I-Premise
but B-Premise
EDU I-Premise
prompted I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
this I-Premise
outcome I-Premise
relative I-Premise
to I-Premise
CTL I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
patients I-Premise
who I-Premise
felt I-Premise
more I-Premise
prepared I-Premise
for I-Premise
re-entry I-Premise
. I-Premise

Between-group B-Premise
differences I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
were I-Premise
not I-Premise
significant I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
and B-Premise
no I-Premise
significant I-Premise
effects I-Premise
emerged I-Premise
on I-Premise
the I-Premise
secondary I-Premise
end I-Premise
points I-Premise
. I-Premise

A B-Claim
peer-modeling I-Claim
videotape I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
recovery I-Claim
of I-Claim
energy I-Claim
during I-Claim
the I-Claim
re-entry I-Claim
phase I-Claim
in I-Claim
women I-Claim
treated I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
particularly I-Claim
among I-Claim
those I-Claim
who I-Claim
feel I-Claim
less I-Claim
prepared I-Claim
for I-Claim
re-entry I-Claim
. I-Claim

Sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
in I-Claim
women I-Claim
with I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
routinely I-Claim
used I-Claim
in I-Claim
some I-Claim
countries I-Claim
for I-Claim
staging I-Claim
the I-Claim
axilla I-Claim
despite I-Claim
limited I-Claim
data I-Claim
from I-Claim
randomized I-Claim
trials I-Claim
on I-Claim
morbidity I-Claim
and I-Claim
mortality I-Claim
outcomes I-Claim
. I-Claim

We O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
quality-of-life O
outcomes O
between O
patients O
with O
clinically O
node-negative O
invasive O
breast O
cancer O
who O
received O
sentinel O
lymph O
node O
biopsy O
and O
patients O
who O
received O
standard O
axillary O
treatment O
. O

The O
primary O
outcome O
measures O
were O
arm O
and O
shoulder O
morbidity O
and O
quality O
of O
life O
. O

From O
November O
1999 O
to O
October O
2003 O
, O
1031 O
patients O
were O
randomly O
assigned O
to O
undergo O
sentinel O
lymph O
node O
biopsy O
( O
n O
= O
515 O
) O
or O
standard O
axillary O
surgery O
( O
n O
= O
516 O
) O
. O

Patients O
with O
sentinel O
lymph O
node O
metastases O
proceeded O
to O
delayed O
axillary O
clearance O
or O
received O
axillary O
radiotherapy O
( O
depending O
on O
the O
protocol O
at O
the O
treating O
institution O
) O
. O

Intention-to-treat O
analyses O
of O
data O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
are O
presented O
. O

All O
statistical O
tests O
were O
two-sided O
. O

The B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.23 I-Premise
to I-Premise
0.60 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.27 I-Premise
to I-Premise
0.50 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Drain B-Premise
usage I-Premise
, I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
resumption I-Premise
of I-Premise
normal I-Premise
day-to-day I-Premise
activities I-Premise
after I-Premise
surgery I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
axillary I-Premise
operative I-Premise
time I-Premise
was I-Premise
reduced I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
patient-recorded I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
arm I-Premise
functioning I-Premise
scores I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
throughout I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

These B-Premise
benefits I-Premise
were I-Premise
seen I-Premise
with I-Premise
no I-Premise
increase I-Premise
in I-Premise
anxiety I-Premise
levels I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
P I-Premise
> I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
is I-Claim
associated I-Claim
with I-Claim
reduced I-Claim
arm I-Claim
morbidity I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
than I-Claim
standard I-Claim
axillary I-Claim
treatment I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
patients I-Claim
who I-Claim
have I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
with I-Claim
clinically I-Claim
negative I-Claim
nodes I-Claim
. I-Claim

To O
determine O
the O
immediate O
and O
long-term O
effects O
of O
TRUE O
acupuncture O
versus O
sham O
acupuncture O
on O
hot O
flash O
frequency O
in O
women O
with O
breast O
cancer O
. O

Seventy-two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
TRUE O
or O
sham O
acupuncture O
. O

Interventions O
were O
given O
twice O
weekly O
for O
4 O
consecutive O
weeks O
. O

Hot O
flash O
frequency O
was O
evaluated O
at O
baseline O
, O
at O
6 O
weeks O
, O
and O
at O
6 O
months O
after O
initiation O
of O
treatment O
. O

Patients O
initially O
randomly O
assigned O
to O
the O
sham O
group O
were O
crossed O
over O
to O
TRUE O
acupuncture O
starting O
at O
week O
7 O
. O

The O
mean O
number O
of O
hot O
flashes O
per O
day O
was O
reduced O
from O
8.7 O
( O
standard O
deviation O
[ O
SD O
] O
, O
3.9 O
) O
to O
6.2 O
( O
SD O
, O
4.2 O
) O
in O
the O
TRUE O
acupuncture O
group O
and O
from O
10.0 O
( O
SD O
, O
6.1 O
) O
to O
7.6 O
( O
SD O
, O
5.7 O
) O
in O
the O
sham O
group O
. O

TRUE B-Premise
acupuncture I-Premise
was I-Premise
associated I-Premise
with I-Premise
0.8 I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
per I-Premise
day I-Premise
than I-Premise
sham I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
, O
but B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.7 I-Premise
to I-Premise
2.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.3 I-Premise
) I-Premise
. I-Premise

When B-Premise
participants I-Premise
in I-Premise
the I-Premise
sham I-Premise
acupuncture I-Premise
group I-Premise
were I-Premise
crossed I-Premise
over I-Premise
to I-Premise
TRUE I-Premise
acupuncture I-Premise
, I-Premise
a I-Premise
further I-Premise
reduction I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
was I-Premise
seen I-Premise
. I-Premise

This O
reduction O
in O
hot O
flash O
frequency O
persisted O
for O
up O
to O
6 O
months O
after O
the O
completion O
of O
treatment O
. O

Hot B-Claim
flash I-Claim
frequency I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
was I-Claim
reduced I-Claim
following I-Claim
acupuncture I-Claim
. I-Claim

However O
, O
when B-Premise
compared I-Premise
with I-Premise
sham I-Premise
acupuncture I-Premise
, I-Premise
the I-Premise
reduction I-Premise
by I-Premise
the I-Premise
acupuncture I-Premise
regimen I-Premise
as I-Premise
provided I-Premise
in I-Premise
the I-Premise
current I-Premise
study I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

We B-Claim
can I-Claim
not I-Claim
exclude I-Claim
the I-Claim
possibility I-Claim
that I-Claim
a I-Claim
longer I-Claim
and I-Claim
more I-Claim
intense I-Claim
acupuncture I-Claim
intervention I-Claim
could I-Claim
produce I-Claim
a I-Claim
larger I-Claim
reduction I-Claim
of I-Claim
these I-Claim
symptoms I-Claim
. I-Claim

Single-agent O
therapy O
with O
bicalutamide O
, O
a O
nonsteroidal O
antiandrogen O
, O
was O
compared O
with O
castration O
, O
either O
surgical O
or O
medical O
, O
in O
patients O
with O
untreated O
Stage O
D2 O
prostate O
cancer O
. O

In O
an O
open O
, O
randomized O
, O
multicenter O
trial O
, O
patients O
were O
randomized O
to O
treatment O
with O
50 O
mg O
bicalutamide O
( O
n O
= O
243 O
) O
once O
daily O
or O
to O
castration O
( O
n O
= O
243 O
) O
, O
either O
orchiectomy O
or O
depot O
injection O
of O
goserelin O
acetate O
every O
28 O
days O
. O

Primary O
efficacy O
endpoints O
were O
times O
to O
treatment O
failure O
and O
objective O
disease O
progression O
and O
survival O
. O

Assessments O
included O
review O
of O
measurable O
metastases O
, O
prostate O
dimensions O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
pain O
, O
analgesic O
requirements O
, O
and O
quality O
of O
life O
responses O
. O

The O
median O
duration O
of O
therapy O
was O
39 O
weeks O
for O
bicalutamide-treated O
patients O
and O
42 O
weeks O
for O
castrated O
patients O
";" O
treatment O
failure O
occurred O
in O
53 O
% O
and O
42 O
% O
and O
disease O
progression O
in O
43 O
% O
and O
33 O
% O
, O
respectively O
. O

Treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1.54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
to I-Premise
2.00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.19 I-Premise
to I-Premise
2.15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise

From B-Premise
the I-Premise
1-year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1.29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.96 I-Premise
to I-Premise
1.72 I-Premise
) I-Premise
. I-Premise

Thus B-Premise
far I-Premise
, I-Premise
with I-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
86 I-Premise
weeks I-Premise
, I-Premise
median I-Premise
survival I-Premise
has I-Premise
not I-Premise
been I-Premise
reached I-Premise
in I-Premise
either I-Premise
group I-Premise
. I-Premise

Changes B-Premise
from I-Premise
baseline I-Premise
in I-Premise
several I-Premise
quality I-Premise
of I-Premise
life I-Premise
variables I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
periodically I-Premise
from I-Premise
months I-Premise
1 I-Premise
to I-Premise
6 I-Premise
, I-Premise
and I-Premise
all I-Premise
favored I-Premise
bicalutamide I-Premise
. I-Premise

Overall B-Premise
, I-Premise
the I-Premise
antiandrogen I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
compared I-Premise
with I-Premise
castration I-Premise
";" I-Premise
with B-Premise
bicalutamide I-Premise
, I-Premise
hot I-Premise
flushes I-Premise
occurred I-Premise
less I-Premise
often I-Premise
and I-Premise
breast I-Premise
tenderness I-Premise
and I-Premise
gynecomastia I-Premise
more I-Premise
often I-Premise
. I-Premise

Although B-Premise
a I-Premise
dosage I-Premise
of I-Premise
50 I-Premise
mg I-Premise
of I-Premise
bicalutamide I-Premise
once I-Premise
daily I-Premise
was I-Premise
not I-Premise
as I-Premise
effective I-Premise
as I-Premise
castration I-Premise
, I-Premise
the B-Claim
favorable I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
and I-Claim
the I-Claim
low I-Claim
incidence I-Claim
of I-Claim
nonhormonal I-Claim
adverse I-Claim
events I-Claim
provide I-Claim
reasons I-Claim
to I-Claim
evaluate I-Claim
bicalutamide I-Claim
, I-Claim
as I-Claim
a I-Claim
single I-Claim
therapeutic I-Claim
agent I-Claim
, I-Claim
at I-Claim
higher I-Claim
doses I-Claim
. I-Claim

To O
test O
the O
equivalence O
of O
three O
versus O
four O
cycles O
of O
bleomycin O
, O
etoposide O
, O
and O
cisplatin O
( O
BEP O
) O
and O
of O
the O
5-day O
schedule O
versus O
3 O
days O
per O
cycle O
in O
good-prognosis O
germ O
cell O
cancer O
. O

The O
study O
was O
designed O
as O
a O
2 O
x O
2 O
factorial O
trial O
. O

The O
aim O
was O
to O
rule O
out O
a O
5 O
% O
decrease O
in O
the O
2-year O
progression-free O
survival O
( O
PFS O
) O
rate O
. O

The O
study O
included O
the O
assessment O
of O
patient O
quality O
of O
life O
. O

A O
cycle O
of O
BEP O
consisted O
of O
etoposide O
500 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
100 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
165 O
mg/m O
( O
2 O
) O
days O
1 O
through O
3 O
, O
cisplatin O
100 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
20 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
50 O
mg/m O
( O
2 O
) O
days O
1 O
and O
2 O
. O

Bleomycin O
30 O
mg O
was O
administered O
on O
days O
1 O
, O
8 O
, O
and O
15 O
during O
cycles O
1 O
through O
3 O
. O

The O
randomization O
procedure O
allowed O
some O
investigators O
to O
participate O
only O
in O
the O
comparison O
of O
three O
versus O
four O
cycles O
. O

From O
March O
1995 O
until O
April O
1998 O
, O
812 O
patients O
were O
randomly O
assigned O
to O
receive O
three O
or O
four O
cycles O
: O
of O
these O
, O
681 O
were O
also O
randomly O
assigned O
to O
the O
5-day O
or O
the O
3-day O
schedule O
. O

Histology O
, O
marker O
values O
, O
and O
disease O
extent O
are O
well O
balanced O
in O
the O
treatment O
arms O
of O
the O
two O
comparisons O
. O

The B-Premise
projected I-Premise
2-year I-Premise
PFS I-Premise
is I-Premise
90.4 I-Premise
% I-Premise
on I-Premise
three I-Premise
cycles I-Premise
and I-Premise
89.4 I-Premise
% I-Premise
on I-Premise
four I-Premise
cycles I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

Equivalence B-Claim
for I-Claim
three I-Claim
versus I-Claim
four I-Claim
cycles I-Claim
is I-Claim
claimed I-Claim
because I-Claim
both I-Claim
the I-Claim
upper I-Claim
and I-Claim
lower I-Claim
bounds I-Claim
of I-Claim
the I-Claim
80 I-Claim
% I-Claim
CL I-Claim
are I-Claim
less I-Claim
than I-Claim
5 I-Claim
% I-Claim
. I-Claim

In B-Premise
the I-Premise
-5 I-Premise
versus I-Premise
3-day I-Premise
comparison I-Premise
, I-Premise
the I-Premise
projected I-Premise
2-year I-Premise
PFS I-Premise
is I-Premise
88.8 I-Premise
% I-Premise
and I-Premise
89.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
difference I-Premise
, I-Premise
-0.9 I-Premise
% I-Premise
, I-Premise
( I-Premise
80 I-Premise
% I-Premise
CL I-Premise
, I-Premise
-4.1 I-Premise
% I-Premise
, I-Premise
+2.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Hence O
, O
equivalence B-Claim
is I-Claim
claimed I-Claim
in I-Claim
this I-Claim
comparison I-Claim
also I-Claim
. I-Claim

Frequencies B-Premise
of I-Premise
hematologic I-Premise
and I-Premise
nonhematologic I-Premise
toxicities I-Premise
were I-Premise
essentially I-Premise
similar I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
";" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise

We O
conclude O
that O
three B-Claim
cycles I-Claim
of I-Claim
BEP I-Claim
, I-Claim
with I-Claim
etoposide I-Claim
at I-Claim
500 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
is I-Claim
sufficient I-Claim
therapy I-Claim
in I-Claim
good-prognosis I-Claim
germ I-Claim
cell I-Claim
cancer I-Claim
and O
that O
the B-Claim
administration I-Claim
of I-Claim
the I-Claim
chemotherapy I-Claim
in I-Claim
3 I-Claim
days I-Claim
has I-Claim
no I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
the I-Claim
effectiveness I-Claim
of I-Claim
the I-Claim
BEP I-Claim
regimen I-Claim
. I-Claim

The O
effectiveness O
of O
a O
Pain O
Education O
Program O
in O
cancer O
patients O
with O
chronic O
pain O
offered O
by O
nurses O
was O
investigated O
in O
a O
randomized O
controlled O
clinical O
trial O
. O

A O
multi-method O
approach O
was O
used O
in O
which O
verbal O
instruction O
, O
written O
material O
, O
an O
audio O
cassette O
tape O
, O
and O
the O
use O
of O
a O
pain O
diary O
were O
combined O
to O
inform O
and O
instruct O
patients O
about O
pain O
and O
pain O
management O
. O

The O
Pain O
Education O
Program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
";" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
";" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O

Following O
pretesting O
in O
313 O
patients O
, O
patients O
who O
needed O
district O
nursing O
and O
who O
did O
not O
need O
district O
nursing O
at O
home O
were O
randomly O
assigned O
to O
a O
control O
or O
intervention O
group O
. O

Intervention O
group O
patients O
received O
the O
Pain O
Education O
Program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
";" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O

Follow-up O
assessments O
were O
at O
2 O
, O
4 O
and O
8 O
weeks O
postdischarge O
. O

Results O
of O
the O
pretest O
showed O
that O
many O
patients O
lacked O
knowledge O
about O
pain O
and O
pain O
management O
. O

The O
majority O
of O
pain O
topics O
had O
to O
be O
discussed O
. O

The B-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
proved I-Claim
to I-Claim
be I-Claim
feasible I-Claim
: I-Claim
75.0 B-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
had I-Premise
read I-Premise
the I-Premise
entire I-Premise
pain I-Premise
brochure I-Premise
, I-Premise
55.7 I-Premise
% I-Premise
had I-Premise
listened I-Premise
to I-Premise
the I-Premise
audio I-Premise
cassette I-Premise
, I-Premise
and I-Premise
85.6 I-Premise
% I-Premise
of I-Premise
pain I-Premise
scores I-Premise
were I-Premise
completed I-Premise
in I-Premise
the I-Premise
pain I-Premise
diary I-Premise
. I-Premise

Results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim

However B-Premise
, I-Premise
pain I-Premise
relief I-Premise
was I-Premise
mainly I-Premise
found I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
patients I-Premise
without I-Premise
district I-Premise
nursing I-Premise
. I-Premise

It B-Claim
can I-Claim
be I-Claim
concluded I-Claim
that I-Claim
the I-Claim
tailored I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
is I-Claim
effective I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
chronic I-Claim
pain I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
by I-Claim
nurses I-Claim
should I-Claim
be I-Claim
seriously I-Claim
considered I-Claim
on I-Claim
oncology I-Claim
units I-Claim
. I-Claim

Proinflammatory O
cytokines O
, O
especially O
tumour O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
, O
play O
a O
prominent O
role O
in O
the O
pathogenesis O
of O
cancer O
cachexia O
. O

Thalidomide B-Claim
, I-Claim
which I-Claim
is I-Claim
an I-Claim
inhibitor I-Claim
of I-Claim
TNF-alpha I-Claim
synthesis I-Claim
, I-Claim
may I-Claim
represent I-Claim
a I-Claim
novel I-Claim
and I-Claim
rational I-Claim
approach I-Claim
to I-Claim
the I-Claim
treatment I-Claim
of I-Claim
cancer I-Claim
cachexia I-Claim
. I-Claim

To O
assess O
the O
safety O
and O
efficacy O
of O
thalidomide O
in O
attenuating O
weight O
loss O
in O
patients O
with O
cachexia O
secondary O
to O
advanced O
pancreatic O
cancer O
. O

Fifty O
patients O
with O
advanced O
pancreatic O
cancer O
who O
had O
lost O
at O
least O
10 O
% O
of O
their O
body O
weight O
were O
randomised O
to O
receive O
thalidomide O
200 O
mg O
daily O
or O
placebo O
for O
24 O
weeks O
in O
a O
single O
centre O
, O
double O
blind O
, O
randomised O
controlled O
trial O
. O

The O
primary O
outcome O
was O
change O
in O
weight O
and O
nutritional O
status O
. O

Thirty O
three O
patients O
( O
16 O
control O
, O
17 O
thalidomide O
) O
were O
evaluated O
at O
four O
weeks O
, O
and O
20 O
patients O
( O
eight O
control O
, O
12 O
thalidomide O
) O
at O
eight O
weeks O
. O

At B-Premise
four I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
thalidomide I-Premise
had I-Premise
gained I-Premise
on I-Premise
average I-Premise
0.37 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
1.0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
arm I-Premise
muscle I-Premise
mass I-Premise
( I-Premise
AMA I-Premise
) I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
2.21 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-2.59 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-4.3 I-Premise
to I-Premise
-0.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
4.46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-5.6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-8.9 I-Premise
to I-Premise
-2.2 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

At B-Premise
eight I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
lost I-Premise
0.06 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
0.5 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
AMA I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
3.62 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-3.57 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.8 I-Premise
to I-Premise
-0.3 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.034 I-Premise
) I-Premise
and I-Premise
8.4 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-7.9 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-14.0 I-Premise
to I-Premise
-1.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Improvement B-Premise
in I-Premise
physical I-Premise
functioning I-Premise
correlated I-Premise
positively I-Premise
with I-Premise
weight I-Premise
gain I-Premise
( I-Premise
r I-Premise
= I-Premise
0.56 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Thalidomide B-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
at I-Claim
attenuating I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
lean I-Claim
body I-Claim
mass I-Claim
in I-Claim
patients I-Claim
with I-Claim
cachexia I-Claim
due I-Claim
to I-Claim
advanced I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

The O
purpose O
of O
our O
study O
was O
to O
evaluate O
the O
effect O
of O
cognitive O
behavioral O
therapy O
( O
CBT O
) O
, O
physical O
exercise O
( O
PE O
) O
, O
and O
of O
these O
two O
interventions O
combined O
( O
CBT/PE O
) O
on O
menopausal O
symptoms O
( O
primary O
outcome O
) O
, O
body O
image O
, O
sexual O
functioning O
, O
psychological O
well-being O
, O
and O
health-related O
quality O
of O
life O
( O
secondary O
outcomes O
) O
in O
patients O
with O
breast O
cancer O
experiencing O
treatment-induced O
menopause O
. O

Patients O
with O
breast O
cancer O
reporting O
treatment-induced O
menopausal O
symptoms O
( O
N=422 O
) O
were O
randomly O
assigned O
to O
CBT O
( O
n=109 O
) O
, O
PE O
( O
n=104 O
) O
, O
CBT/PE O
( O
n=106 O
) O
, O
or O
to O
a O
waiting O
list O
control O
group O
( O
n=103 O
) O
. O

Self-report O
questionnaires O
were O
completed O
at O
baseline O
, O
12 O
weeks O
, O
and O
6 O
months O
. O

Multilevel O
procedures O
were O
used O
to O
compare O
the O
intervention O
groups O
with O
the O
control O
group O
over O
time O
. O

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
had I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
levels I-Premise
of I-Premise
endocrine I-Premise
symptoms I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Endocrine I-Premise
Symptoms I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.31-0.52 I-Premise
) I-Premise
and I-Premise
urinary I-Premise
symptoms I-Premise
( I-Premise
Bristol I-Premise
Female I-Premise
Lower I-Premise
Urinary I-Premise
Tract I-Premise
Symptoms I-Premise
Questionnaire I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.29-0.33 I-Premise
) I-Premise
, I-Premise
and I-Premise
they I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
36-Item I-Premise
Short I-Premise
Form I-Premise
Health I-Premise
Survey I-Premise
physical I-Premise
functioning I-Premise
subscale I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.37-0.46 I-Premise
) I-Premise
. I-Premise

The B-Premise
groups I-Premise
that I-Premise
included I-Premise
CBT I-Premise
also I-Premise
showed I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
perceived I-Premise
burden I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
night I-Premise
sweats I-Premise
( I-Premise
problem I-Premise
rating I-Premise
scale I-Premise
of I-Premise
the I-Premise
Hot I-Premise
Flush I-Premise
Rating I-Premise
Scale I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.39-0.56 I-Premise
) I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
sexual I-Premise
activity I-Premise
( I-Premise
Sexual I-Premise
Activity I-Premise
Questionnaire I-Premise
habit I-Premise
subscale I-Premise
";" I-Premise
P=.027 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

Most O
of O
these O
effects O
were O
observed O
at O
both O
the O
12-week O
and O
6-month O
follow-ups O
. O

CBT B-Claim
and I-Claim
PE I-Claim
can I-Claim
have I-Claim
salutary I-Claim
effects I-Claim
on I-Claim
endocrine I-Claim
symptoms I-Claim
and I-Claim
, I-Claim
to I-Claim
a I-Claim
lesser I-Claim
degree I-Claim
, I-Claim
on I-Claim
sexuality I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
of I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
experiencing I-Claim
treatment-induced I-Claim
menopause I-Claim
. I-Claim

Future B-Claim
work I-Claim
is I-Claim
needed I-Claim
to I-Claim
improve I-Claim
the I-Claim
design I-Claim
and I-Claim
the I-Claim
planning I-Claim
of I-Claim
these I-Claim
interventions I-Claim
to I-Claim
improve I-Claim
program I-Claim
adherence I-Claim
. I-Claim

Randomized B-Claim
trials I-Claim
in I-Claim
fluorouracil I-Claim
( I-Claim
FU I-Claim
) I-Claim
-refractory I-Claim
colorectal I-Claim
cancer I-Claim
demonstrate I-Claim
significant I-Claim
survival I-Claim
advantages I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
irinotecan I-Claim
. I-Claim

We O
prospectively O
compared O
the O
efficacy O
and O
tolerability O
of O
two O
irinotecan O
regimens O
( O
once O
a O
week O
for O
4 O
weeks O
followed O
by O
a O
2-week O
rest O
period O
[ O
weekly O
] O
v O
once O
every O
3 O
weeks O
) O
in O
such O
patients O
. O

This O
multicenter O
, O
open-label O
, O
phase O
III O
study O
randomly O
assigned O
patients O
in O
a O
1:2 O
ratio O
to O
irinotecan O
given O
either O
weekly O
( O
125 O
mg/m O
( O
2 O
) O
) O
or O
once O
every O
3 O
weeks O
( O
350 O
mg/m O
( O
2 O
) O
, O
or O
300 O
mg/m O
( O
2 O
) O
in O
patients O
who O
were O
> O
/= O
70 O
years O
of O
age O
, O
who O
had O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
equal O
to O
2 O
, O
or O
who O
had O
prior O
pelvic O
irradiation O
) O
. O

With B-Premise
median I-Premise
follow-up I-Premise
of I-Premise
15.8 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
1-year I-Premise
survival I-Premise
( I-Premise
46 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.42 I-Premise
) I-Premise
, I-Premise
median I-Premise
survival I-Premise
( I-Premise
9.9 I-Premise
v I-Premise
9.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
, I-Premise
or I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
4.0 I-Premise
v I-Premise
3.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.54 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
diarrhea I-Premise
occurred I-Premise
in I-Premise
36 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
in I-Premise
19 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
29 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
34 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.35 I-Premise
) I-Premise
. I-Premise

Treatment-related B-Premise
mortality I-Premise
occurred I-Premise
in I-Premise
five I-Premise
patients I-Premise
( I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
receiving I-Premise
irinotecan I-Premise
weekly I-Premise
and I-Premise
three I-Premise
patients I-Premise
( I-Premise
1.6 I-Premise
% I-Premise
) I-Premise
given I-Premise
therapy I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.12 I-Premise
) I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
not I-Premise
statistically I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Irinotecan B-Claim
schedules I-Claim
of I-Claim
weekly I-Claim
and I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
demonstrated I-Claim
similar I-Claim
efficacy I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
FU-refractory I-Claim
, I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

The B-Claim
regimen I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
significantly I-Claim
lower I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
diarrhea I-Claim
. I-Claim

Gefitinib O
and O
Pemetrexed O
are O
drugs O
used O
as O
second-line O
therapy O
for O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
, O
although O
studies O
comparing O
the O
two O
drugs O
are O
limited O
. O

The O
aim O
of O
this O
study O
is O
to O
explore O
the O
effects O
, O
safety O
, O
and O
quality O
of O
life O
( O
QoL O
) O
of O
Gefitinib O
and O
Pemetrexed O
on O
patients O
with O
advanced O
non-squamous O
NSCLC O
. O

Forty-six O
advanced O
non-squamous O
NSCLC O
patients O
who O
failed O
to O
first-line O
therapy O
were O
randomly O
divided O
into O
two O
groups O
with O
23 O
patients O
each O
, O
one O
using O
oral O
Gefitinib O
( O
Gefitinib O
group O
) O
and O
the O
other O
using O
intravenous O
injection O
Pemetrexed O
( O
Pemetrexed O
group O
) O
. O

The O
effects O
, O
safety O
, O
and O
QoL O
were O
determined O
and O
analyzed O
. O

For B-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
13.0 I-Premise
% I-Premise
( I-Premise
3/23 I-Premise
) I-Premise
, I-Premise
disease I-Premise
control I-Premise
rate I-Premise
( I-Premise
DCR I-Premise
) I-Premise
was I-Premise
30.4 I-Premise
% I-Premise
( I-Premise
7/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
mPFS I-Premise
) I-Premise
was I-Premise
3.1 I-Premise
months I-Premise
. I-Premise

In B-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
, I-Premise
ORR I-Premise
was I-Premise
17.3 I-Premise
% I-Premise
( I-Premise
4/23 I-Premise
) I-Premise
, I-Premise
DCR I-Premise
was I-Premise
39.1 I-Premise
% I-Premise
( I-Premise
9/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
was I-Premise
4.4 I-Premise
months I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
the I-Premise
ORR I-Premise
, I-Premise
DCR I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
exhibited I-Premise
no I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Furthermore O
, O
the B-Premise
most I-Premise
common I-Premise
toxicities I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
n=9 I-Premise
, I-Premise
39.13 I-Premise
% I-Premise
) I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
, I-Premise
whereas I-Premise
those I-Premise
in I-Premise
the I-Premise
in I-Premise
Gefitinib I-Premise
group I-Premise
were I-Premise
skin I-Premise
rash I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
n=4 I-Premise
, I-Premise
17.39 I-Premise
% I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
QoL I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise

Likewise O
, O
emotional B-Premise
, I-Premise
functional I-Premise
well-being I-Premise
, I-Premise
and I-Premise
QoL I-Premise
aspects I-Premise
specifically I-Premise
related I-Premise
to I-Premise
lung I-Premise
cancer I-Premise
were I-Premise
better I-Premise
improved I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Claim
effects I-Claim
of I-Claim
Pemetrexed I-Claim
and I-Claim
Gefitinib I-Claim
as I-Claim
second I-Claim
line I-Claim
therapy I-Claim
were I-Claim
similar I-Claim
, I-Claim
although B-Premise
with I-Premise
different I-Premise
AEs I-Premise
. I-Premise

Both B-Claim
drugs I-Claim
could I-Claim
improve I-Claim
the I-Claim
QoL I-Claim
, I-Claim
but O
Gefitinib B-Claim
showed I-Claim
better I-Claim
overall I-Claim
results I-Claim
than I-Claim
Pemetrexed I-Claim
. I-Claim

Patients B-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
do I-Claim
not I-Claim
have I-Claim
curative I-Claim
treatment I-Claim
options I-Claim
";" I-Claim
therefore O
, O
treatments O
should O
prolong O
survival O
and O
improve O
quality O
of O
life O
( O
QoL O
) O
. O

We O
compared O
the O
effect O
on O
QoL O
of O
two O
docetaxel-platinum O
regimens O
with O
vinorelbine-cisplatin O
. O

QoL O
was O
assessed O
by O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
and O
the O
general O
EuroQol O
five-dimensional O
questionnaire O
( O
EQ-5D O
) O
in O
926 O
chemotherapy-naïve O
patients O
with O
stages O
IIIB O
to O
IV O
NSCLC O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
: O
docetaxel O
75 O
mg/m2 O
plus O
cisplatin O
75 O
mg/m2 O
, O
every O
3 O
weeks O
( O
DC O
) O
";" O
docetaxel O
75 O
mg/m2 O
and O
carboplatin O
6 O
mg/ml O
min O
, O
every O
3 O
weeks O
( O
DCb O
) O
";" O
or O
vinorelbine O
25 O
mg/m2/week O
plus O
cisplatin O
100 O
mg/m2 O
, O
every O
4 O
weeks O
( O
VC O
) O
. O

Overall B-Premise
, I-Premise
patients I-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel-containing I-Premise
regimen I-Premise
had I-Premise
better I-Premise
QoL I-Premise
than I-Premise
VC-treated I-Premise
patients I-Premise
( I-Premise
LCSS I-Premise
global I-Premise
item I-Premise
" I-Premise
QoL I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.064 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P=0.016 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
";" I-Premise
EQ-5D I-Premise
global I-Premise
item I-Premise
" I-Premise
health I-Premise
state I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.016 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

DC-treated B-Premise
patients I-Premise
experienced I-Premise
improved I-Premise
pain I-Premise
relief I-Premise
compared I-Premise
with I-Premise
VC I-Premise
( I-Premise
P=0.033 I-Premise
) I-Premise
, I-Premise
whereas O
pain B-Premise
relief I-Premise
with I-Premise
DCb I-Premise
and I-Premise
VC I-Premise
was I-Premise
similar I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
regimen I-Premise
had I-Premise
more I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
performance I-Premise
status I-Premise
( I-Premise
P=0.065 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
and I-Premise
mean I-Premise
weight I-Premise
loss I-Premise
( I-Premise
0.06 I-Premise
kg I-Premise
, I-Premise
gain I-Premise
of I-Premise
0.08 I-Premise
kg I-Premise
, I-Premise
and I-Premise
2.27 I-Premise
kg I-Premise
for I-Premise
DC I-Premise
, I-Premise
DCb I-Premise
, I-Premise
and I-Premise
VC I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
both I-Premise
DC I-Premise
versus I-Premise
VC I-Premise
and I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

The B-Claim
TAX I-Claim
326 I-Claim
study I-Claim
shows I-Claim
that I-Claim
docetaxel-platinum I-Claim
regimens I-Claim
relieve I-Claim
symptoms I-Claim
and I-Claim
improve I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

DCb B-Claim
and I-Claim
DC I-Claim
were I-Claim
superior I-Claim
to I-Claim
VC I-Claim
in I-Claim
all I-Claim
QoL I-Claim
outcomes I-Claim
assessed I-Claim
except I-Claim
for I-Claim
the I-Claim
difference I-Claim
between I-Claim
DC I-Claim
and I-Claim
VC I-Claim
in I-Claim
LCSS I-Claim
" I-Claim
QoL I-Claim
today I-Claim
" I-Claim
, I-Claim
which I-Claim
was I-Claim
not I-Claim
significant I-Claim
. I-Claim

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Third-generation O
aromatase O
inhibitors O
, O
such O
as O
letrozole O
, O
provide O
a O
new O
option O
for O
extended O
adjuvant O
hormonal O
therapy O
after O
5 O
years O
of O
tamoxifen O
. O

MA.17 O
was O
conducted O
to O
determine O
whether O
letrozole O
improves O
outcome O
after O
discontinuation O
of O
tamoxifen O
. O

Postmenopausal O
women O
with O
hormone O
receptor-positive O
breast O
cancer O
( O
N=5,187 O
) O
were O
randomized O
to O
letrozole O
2.5 O
mg O
or O
placebo O
once O
daily O
for O
5 O
years O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
30 I-Premise
months I-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
the I-Premise
primary I-Premise
end I-Premise
point I-Premise
, I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
for I-Premise
recurrence I-Premise
or I-Premise
contralateral I-Premise
breast I-Premise
cancer I-Premise
0.58 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
0.45 I-Premise
, I-Premise
0.76 I-Premise
] I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Furthermore B-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
distant I-Premise
DFS I-Premise
( I-Premise
HR=0.60 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.43 I-Premise
, I-Premise
0.84 I-Premise
";" I-Premise
P=0.002 I-Premise
) I-Premise
and I-Premise
, I-Premise
in I-Premise
women I-Premise
with I-Premise
node-positive I-Premise
tumors I-Premise
, I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR=0.61 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.38 I-Premise
, I-Premise
0.98 I-Premise
";" I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Clinical B-Premise
benefits I-Premise
, I-Premise
including I-Premise
an I-Premise
overall I-Premise
survival I-Premise
advantage I-Premise
, I-Premise
were I-Premise
also I-Premise
seen I-Premise
in I-Premise
women I-Premise
who I-Premise
crossed I-Premise
over I-Premise
from I-Premise
placebo I-Premise
to I-Premise
letrozole I-Premise
after I-Premise
unblinding I-Premise
, I-Premise
indicating I-Premise
that I-Premise
tumors I-Premise
remain I-Premise
sensitive I-Premise
to I-Premise
hormone I-Premise
therapy I-Premise
despite I-Premise
a I-Premise
prolonged I-Premise
period I-Premise
since I-Premise
discontinuation I-Premise
of I-Premise
tamoxifen I-Premise
. I-Premise

The O
efficacy O
and O
safety O
of O
letrozole O
therapy O
beyond O
5 O
years O
is O
being O
assessed O
in O
a O
re-randomization O
study O
, O
following O
the O
emergence O
of O
new O
data O
suggesting O
that O
clinical O
benefit O
correlates O
with O
the O
duration O
of O
letrozole O
. O

MA.17 B-Claim
showed I-Claim
that I-Claim
letrozole I-Claim
is I-Claim
extremely I-Claim
well-tolerated I-Claim
relative I-Claim
to I-Claim
placebo I-Claim
. I-Claim

Letrozole B-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
women I-Claim
completing I-Claim
tamoxifen I-Claim
";" I-Claim
new B-Claim
results I-Claim
from I-Claim
the I-Claim
post-unblinding I-Claim
analysis I-Claim
suggest I-Claim
that I-Claim
letrozole I-Claim
treatment I-Claim
should I-Claim
also I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
disease-free I-Claim
women I-Claim
for I-Claim
periods I-Claim
up I-Claim
to I-Claim
5 I-Claim
years I-Claim
following I-Claim
completion I-Claim
of I-Claim
adjuvant I-Claim
tamoxifen I-Claim
. I-Claim

Lung O
cancer O
is O
one O
of O
the O
most O
common O
cancers O
in O
the O
United O
States O
and O
is O
associated O
with O
high O
levels O
of O
symptoms O
, O
including O
pain O
, O
fatigue O
, O
shortness O
of O
breath O
, O
and O
psychological O
distress O
. O

Caregivers O
and O
patients O
are O
adversely O
affected O
. O

However O
, O
previous O
studies O
of O
coping O
skills O
training O
( O
CST O
) O
interventions O
have O
not O
been O
tested O
in O
patients O
with O
lung O
cancer O
nor O
have O
systematically O
included O
caregivers O
. O

This O
study O
tested O
the O
efficacy O
of O
a O
caregiver-assisted O
CST O
protocol O
in O
a O
sample O
of O
patients O
with O
lung O
cancer O
. O

Two O
hundred O
thirty-three O
lung O
cancer O
patients O
and O
their O
caregivers O
were O
randomly O
assigned O
to O
receive O
14 O
telephone-based O
sessions O
of O
either O
caregiver-assisted O
CST O
or O
education/support O
involving O
the O
caregiver O
. O

Patients O
completed O
measures O
assessing O
pain O
, O
psychological O
distress O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
self-efficacy O
for O
symptom O
management O
";" O
caregivers O
completed O
measures O
assessing O
psychological O
distress O
, O
caregiver O
strain O
, O
and O
self-efficacy O
for O
helping O
the O
patient O
manage O
symptoms O
. O

Patients B-Premise
in I-Premise
both I-Premise
treatment I-Premise
conditions I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
depression I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
self-efficacy I-Premise
, I-Premise
and I-Premise
caregivers I-Premise
in I-Premise
both I-Premise
conditions I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
anxiety I-Premise
and I-Premise
self-efficacy I-Premise
from I-Premise
baseline I-Premise
to I-Premise
four-month I-Premise
follow-up I-Premise
. I-Premise

Results B-Premise
of I-Premise
exploratory I-Premise
analyses I-Premise
suggested I-Premise
that I-Premise
the I-Premise
CST I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients/caregivers I-Premise
with I-Premise
Stage I-Premise
II I-Premise
and I-Premise
III I-Premise
cancers I-Premise
, I-Premise
whereas O
the B-Premise
education/support I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients/caregivers I-Premise
with I-Premise
Stage I-Premise
I I-Premise
cancer I-Premise
. I-Premise

Taken B-Premise
together I-Premise
with I-Premise
the I-Premise
broader I-Premise
literature I-Premise
in I-Premise
this I-Premise
area I-Premise
, I-Premise
results B-Claim
from I-Claim
this I-Claim
study I-Claim
suggest I-Claim
that I-Claim
psychosocial I-Claim
interventions I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
a I-Claim
range I-Claim
of I-Claim
outcomes I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Suggestions O
for O
future O
studies O
include O
the O
use O
of O
three-group O
designs O
( O
e.g. O
, O
comparing O
two O
active O
interventions O
with O
a O
standard-care O
control O
) O
and O
examining O
mechanisms O
of O
change O
. O

El B-Claim
hirsutismo I-Claim
facial I-Claim
es I-Claim
uno I-Claim
de I-Claim
los I-Claim
rasgos I-Claim
característicos I-Claim
del I-Claim
síndrome I-Claim
de I-Claim
ovario I-Claim
poliquístico I-Claim
( I-Claim
SOP I-Claim
) I-Claim
, I-Claim
y I-Claim
esto I-Claim
puede I-Claim
conducir I-Claim
a I-Claim
altos I-Claim
niveles I-Claim
de I-Claim
depresión I-Claim
y I-Claim
ansiedad I-Claim
. I-Claim

Evaluar O
el O
impacto O
del O
tratamiento O
con O
láser O
en O
la O
gravedad O
del O
hirsutismo O
facial O
y O
en O
la O
morbilidad O
psicológica O
de O
las O
mujeres O
con O
SOP. O

Se O
realizó O
un O
ensayo O
controlado O
aleatorio O
de O
cinco O
tratamientos O
de O
alta O
influencia O
( O
intervención O
) O
frente O
a O
cinco O
tratamientos O
de O
baja O
influencia O
( O
control O
) O
durante O
6 O
meses O
en O
un O
hospital O
universitario O
del O
Servicio O
Nacional O
de O
Salud O
. O

Los O
sujetos O
fueron O
88 O
mujeres O
con O
hirsutismo O
facial O
debido O
al O
síndrome O
de O
ovario O
poliquístico O
reclutadas O
en O
las O
clínicas O
ambulatorias O
de O
los O
hospitales O
y O
en O
un O
grupo O
de O
apoyo O
a O
pacientes O
en O
2001-2002. O

Los O
resultados O
principales O
fueron O
la O
gravedad O
del O
vello O
facial O
autodeclarada O
(medida O
en O
una O
escala O
del O
1 O
al O
10), O
la O
depresión, O
la O
ansiedad O
(medida O
en O
la O
Escala O
de O
Ansiedad O
y O
Depresión O
Hospitalaria) O
y O
la O
calidad O
de O
vida O
(medida O
en O
el O
WHOQOL-BREF). O

La B-Premise
gravedad I-Premise
del I-Premise
vello I-Premise
facial I-Premise
autodeclarada I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
se I-Premise
redujo I-Premise
de I-Premise
7,3 I-Premise
a I-Premise
3,6 I-Premise
durante I-Premise
el I-Premise
periodo I-Premise
de I-Premise
estudio I-Premise
de I-Premise
6 I-Premise
meses I-Premise
; I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
las I-Premise
puntuaciones I-Premise
correspondientes I-Premise
fueron I-Premise
de I-Premise
7,1 I-Premise
y I-Premise
6,1 I-Premise
. I-Premise

El B-Premise
cambio I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
[ I-Premise
ancova I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
24,5 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
] I-Premise
. I-Premise

El B-Premise
tiempo I-Premise
autodeclarado I-Premise
dedicado I-Premise
a I-Premise
la I-Premise
depilación I-Premise
disminuyó I-Premise
de I-Premise
112 I-Premise
a I-Premise
21 I-Premise
minutos I-Premise
por I-Premise
semana I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
y I-Premise
de I-Premise
92 I-Premise
a I-Premise
56 I-Premise
minutos I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,80 I-Premise
) I-Premise
) I-Premise
= I-Premise
10,2 I-Premise
, I-Premise
P I-Premise
< I-Premise
/= I-Premise
0,05 I-Premise
] I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
medias I-Premise
de I-Premise
depresión I-Premise
disminuyeron I-Premise
de I-Premise
6,7 I-Premise
a I-Premise
3,6 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
6,1 I-Premise
a I-Premise
5,4 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
14,7 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
] I-Premise
. I-Premise

Se B-Premise
observó I-Premise
un I-Premise
cambio I-Premise
similar I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
medias I-Premise
de I-Premise
ansiedad: I-Premise
intervención I-Premise
11,1 I-Premise
a I-Premise
8,2 I-Premise
, I-Premise
control I-Premise
9,6 I-Premise
a I-Premise
9,3 I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
17,8 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
] I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
psicológica I-Premise
también I-Premise
mejoró I-Premise
más I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
, I-Premise
de I-Premise
49,6 I-Premise
a I-Premise
61,2 I-Premise
frente I-Premise
a I-Premise
50,1 I-Premise
a I-Premise
51,5 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10,9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
] I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
láser I-Claim
pareció I-Claim
reducir I-Claim
la I-Claim
gravedad I-Claim
del I-Claim
vello I-Claim
facial I-Claim
y I-Claim
el I-Claim
tiempo I-Claim
dedicado I-Claim
a I-Claim
la I-Claim
depilación, I-Claim
además I-Claim
de I-Claim
aliviar I-Claim
la I-Claim
depresión I-Claim
y I-Claim
la I-Claim
ansiedad I-Claim
en I-Claim
las I-Claim
mujeres I-Claim
con I-Claim
SOP. I-Claim

Estos B-Claim
resultados I-Claim
sugieren I-Claim
que I-Claim
se I-Claim
debería I-Claim
estudiar I-Claim
la I-Claim
forma I-Claim
de I-Claim
hacer I-Claim
más I-Claim
accesible I-Claim
este I-Claim
método I-Claim
de I-Claim
depilación I-Claim
a I-Claim
las I-Claim
mujeres I-Claim
con I-Claim
hirsutismo I-Claim
facial. I-Claim

A B-Claim
pesar I-Claim
de I-Claim
la I-Claim
considerable I-Claim
mejora I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
avanzado, I-Claim
la I-Claim
optimización I-Claim
de I-Claim
la I-Claim
eficacia I-Claim
y I-Claim
la I-Claim
tolerabilidad I-Claim
sigue I-Claim
siendo I-Claim
una I-Claim
cuestión I-Claim
importante. I-Claim

Por O
lo O
tanto, O
realizamos O
un O
ensayo O
aleatorio O
de O
fase O
III O
de O
no O
inferioridad O
que O
comparaba O
paclitaxel O
más O
cisplatino O
( O
PT O
) O
con O
paclitaxel O
más O
carboplatino O
( O
TC O
) O
en O
pacientes O
con O
cáncer O
de O
ovario O
avanzado O
. O

Un O
total O
de O
798 O
pacientes O
con O
estadio O
IIB-IV O
de O
la O
Federación O
Internacional O
de O
Ginecología O
y O
Obstetricia O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
seis O
cursos O
de O
PT O
o O
TC O
a O
intervalos O
de O
3 O
semanas O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
proporción O
de O
pacientes O
sin O
progresión O
a O
los O
2 O
años. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
toxicidad, O
la O
respuesta O
al O
tratamiento, O
la O
calidad O
de O
vida O
y O
el O
tiempo O
de O
supervivencia O
global O
y O
sin O
progresión. O

La O
calidad O
de O
vida O
se O
evaluó O
mediante O
el O
cuestionario O
de O
calidad O
de O
vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
QLQ O
) O
-C30 O
, O
versión O
2.0 O
. O

Las O
curvas O
de O
supervivencia O
se O
calcularon O
mediante O
el O
método O
de O
Kaplan-Meier O
y O
las O
razones O
de O
riesgo O
se O
estimaron O
mediante O
el O
modelo O
de O
riesgos O
proporcionales O
de O
Cox. O

La B-Premise
proporción I-Premise
de I-Premise
pacientes I-Premise
sin I-Premise
progresión I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
no I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
desde I-Premise
el I-Premise
punto I-Premise
de I-Premise
vista I-Premise
estadístico I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
40,0 I-Premise
% I-Premise
para I-Premise
PT I-Premise
frente I-Premise
a I-Premise
37,5 I-Premise
% I-Premise
para I-Premise
TC I-Premise
, I-Premise
diferencia I-Premise
= I-Premise
2,5 I-Premise
% I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
unilateral I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinito I-Premise
a I-Premise
8,2 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
CT I-Premise
( I-Premise
17,2 I-Premise
meses I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
15,2 I-Premise
a I-Premise
19,3 I-Premise
meses I-Premise
) I-Premise
y I-Premise
el I-Premise
brazo I-Premise
de I-Premise
PT I-Premise
( I-Premise
19,1 I-Premise
meses I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
16,7 I-Premise
a I-Premise
21,5 I-Premise
meses I-Premise
) I-Premise
tampoco I-Premise
fueron I-Premise
estadísticamente I-Premise
significativos I-Premise
; O
lo B-Premise
mismo I-Premise
ocurrió I-Premise
con I-Premise
la I-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
43,3 I-Premise
meses I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
37,2 I-Premise
a I-Premise
47,8 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
44,1 I-Premise
meses I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
40,2 I-Premise
a I-Premise
49,4 I-Premise
meses I-Premise
, I-Premise
para I-Premise
los I-Premise
brazos I-Premise
de I-Premise
CT I-Premise
y I-Premise
PT I-Premise
, I-Premise
respectivamente I-Premise
) O
. O

El B-Premise
régimen I-Premise
TC I-Premise
se I-Premise
asoció I-Premise
con I-Premise
una I-Premise
mayor I-Premise
frecuencia I-Premise
de I-Premise
toxicidad I-Premise
hematológica I-Premise
, O
pero B-Premise
una I-Premise
menor I-Premise
frecuencia I-Premise
de I-Premise
toxicidad I-Premise
gastrointestinal I-Premise
y I-Premise
neurológica I-Premise
, I-Premise
que I-Premise
el I-Premise
régimen I-Premise
PT I-Premise
. O

Las B-Premise
puntuaciones I-Premise
medias I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
al I-Premise
final I-Premise
del I-Premise
tratamiento I-Premise
fueron I-Premise
significativamente I-Premise
mejores I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
CT I-Premise
que I-Premise
en I-Premise
el I-Premise
de I-Premise
PT I-Premise
( I-Premise
65,25 I-Premise
frente I-Premise
a I-Premise
51,97 I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
diferencia I-Premise
= I-Premise
-13,28 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
-18,88 I-Premise
a I-Premise
-7,68 I-Premise
) I-Premise
. I-Premise

El B-Claim
régimen I-Claim
TC I-Claim
logró I-Claim
una I-Claim
eficacia I-Claim
comparable I-Claim
a I-Claim
la I-Claim
del I-Claim
régimen I-Claim
PT, I-Claim
pero I-Claim
se I-Claim
asoció I-Claim
con I-Claim
una I-Claim
mejor I-Claim
tolerabilidad I-Claim
y I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
, I-Claim
y I-Claim
debería I-Claim
, I-Claim
por I-Claim
lo I-Claim
tanto I-Claim
, I-Claim
ser I-Claim
considerado I-Claim
como I-Claim
una I-Claim
alternativa I-Claim
importante I-Claim
para I-Claim
la I-Claim
quimioterapia I-Claim
estándar I-Claim
de I-Claim
primera I-Claim
línea I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
avanzado I-Claim
. I-Claim

El O
objetivo O
de O
este O
estudio O
fue O
comparar O
el O
rendimiento O
funcional O
y O
la O
calidad O
de O
vida O
a O
los O
dos O
años O
en O
pacientes O
con O
carcinoma O
escamocelular O
operable O
de O
esófago O
, O
que O
han O
recibido O
cirugía O
o O
quimiorradiación O
definitiva O
( O
CRT O
) O
. O

Los O
resultados O
funcionales O
y O
la O
calidad O
de O
vida O
de O
los O
pacientes O
que O
reciben O
una O
esofagectomía O
o O
una O
TRC O
definitiva O
son O
inciertos. O

Los O
datos O
se O
extrajeron O
de O
la O
base O
de O
datos O
de O
un O
ensayo O
controlado O
aleatorio O
prospectivo O
que O
incluía O
a O
pacientes O
con O
cánceres O
de O
esófago O
torácicos O
medios O
o O
bajos O
resecables. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
la O
esofagectomía O
estándar O
o O
a O
la O
TRC O
definitiva. O

Las O
evaluaciones O
de O
la O
calidad O
de O
vida O
se O
realizaron O
mediante O
los O
módulos O
EORTC O
QLQ-C30 O
y O
QLQ-OES24 O
. O

Otras O
evaluaciones O
funcionales O
incluyeron O
las O
funciones O
pulmonar O
y O
alimentaria O
. O

Desde O
julio O
de O
2000 O
hasta O
diciembre O
de O
2004, O
se O
inscribieron O
en O
el O
estudio O
un O
total O
de O
81 O
pacientes. O

No B-Premise
se I-Premise
detectaron I-Premise
cambios I-Premise
longitudinales I-Premise
significativos I-Premise
en I-Premise
el I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
tras I-Premise
el I-Premise
seguimiento I-Premise
disponible I-Premise
. I-Premise

La B-Premise
cirugía I-Premise
se I-Premise
asoció I-Premise
con I-Premise
un I-Premise
empeoramiento I-Premise
del I-Premise
funcionamiento I-Premise
físico I-Premise
y I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
de I-Premise
fatiga I-Premise
hasta I-Premise
6 I-Premise
meses I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
y I-Premise
P I-Premise
= I-Premise
0,021 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
y I-Premise
estas I-Premise
escalas I-Premise
mejoraron I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
función I-Premise
pulmonar I-Premise
, I-Premise
los I-Premise
síntomas I-Premise
de I-Premise
disnea I-Premise
y I-Premise
tos I-Premise
empeoraron I-Premise
significativamente I-Premise
3 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
cirugía I-Premise
( I-Premise
P I-Premise
= I-Premise
0,024 I-Premise
y I-Premise
P I-Premise
= I-Premise
0,036 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
mientras I-Premise
que I-Premise
los I-Premise
síntomas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
TRC I-Premise
se I-Premise
deterioraron I-Premise
progresivamente I-Premise
con I-Premise
el I-Premise
tiempo I-Premise
. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
función I-Premise
alimentaria, I-Premise
ambos I-Premise
grupos I-Premise
presentaron I-Premise
mejoras I-Premise
en I-Premise
la I-Premise
disfagia, I-Premise
pero I-Premise
fue I-Premise
frecuente I-Premise
la I-Premise
necesidad I-Premise
de I-Premise
una I-Premise
intervención I-Premise
endoscópica. I-Premise

Ni B-Premise
la I-Premise
cirugía I-Premise
ni I-Premise
la I-Premise
TRC I-Premise
definitiva I-Premise
deterioraron I-Premise
significativamente I-Premise
el I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
. I-Premise

La B-Claim
cirugía I-Claim
se I-Claim
asoció I-Claim
con I-Claim
un I-Claim
impacto I-Claim
negativo I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
en I-Claim
algunos I-Claim
aspectos I-Claim
de I-Claim
las I-Claim
evaluaciones I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
salud, I-Claim
pero I-Claim
estos I-Claim
cambios I-Claim
se I-Claim
volvieron I-Claim
insignificantes I-Claim
2 I-Claim
años I-Claim
después I-Claim
del I-Claim
tratamiento I-Claim
. O

Sin O
embargo, O
la O
TRC B-Claim
se I-Claim
asoció I-Claim
a I-Claim
un I-Claim
deterioro I-Claim
progresivo I-Claim
de I-Claim
la I-Claim
función I-Claim
pulmonar I-Claim
a I-Claim
largo I-Claim
plazo. I-Claim

Observar O
el O
efecto O
de O
la O
terapia O
de O
MTC O
para O
eliminar O
la O
sustancia O
tóxica O
y O
desbloquear O
los O
meridianos O
en O
la O
calidad O
de O
vida O
posterior O
a O
la O
radiación O
( O
QOF O
) O
en O
55 O
pacientes O
con O
cáncer O
de O
pulmón O
. O

Todos O
los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
dos O
grupos O
, O
los O
55 O
pacientes O
del O
grupo O
tratado O
fueron O
tratados O
con O
radioterapia O
combinada O
con O
la O
terapia O
de O
MTC O
, O
y O
los O
53 O
del O
grupo O
de O
control O
recibieron O
sólo O
radioterapia O
. O

La O
eficacia O
clínica O
se O
evaluó O
mediante O
índices O
que O
incluían O
las O
puntuaciones O
KPS O
, O
el O
cuestionario O
QLQ-C30 O
, O
la O
escala O
LC13 O
específica O
para O
el O
cáncer O
de O
pulmón O
, O
los O
criterios O
de O
evaluación O
de O
la O
eficacia O
de O
la O
MTC O
, O
la O
distancia O
de O
marcha O
de O
6 O
minutos O
y O
el O
peso O
corporal O
, O
etc O
. O

La B-Premise
puntuación I-Premise
KPS I-Premise
en I-Premise
el I-Premise
grupo I-Premise
tratado I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
mejoró I-Premise
en I-Premise
13 I-Premise
pacientes I-Premise
( I-Premise
23,6 I-Premise
% I-Premise
) I-Premise
, I-Premise
se I-Premise
estabilizó I-Premise
en I-Premise
27 I-Premise
( I-Premise
49,6 I-Premise
% I-Premise
) I-Premise
y I-Premise
disminuyó I-Premise
en I-Premise
15 I-Premise
( I-Premise
27,3 I-Premise
% I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
, I-Premise
mejoró I-Premise
en I-Premise
7 I-Premise
( I-Premise
13,2 I-Premise
% I-Premise
) I-Premise
, I-Premise
se I-Premise
estabilizó I-Premise
en I-Premise
21 I-Premise
( I-Premise
39,6 I-Premise
% I-Premise
) I-Premise
y I-Premise
disminuyó I-Premise
en I-Premise
25 I-Premise
( I-Premise
47,2 I-Premise
% I-Premise
) I-Premise
, I-Premise
la I-Premise
diferencia I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
fue I-Premise
significativa I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Premise
resultados I-Premise
de I-Premise
la I-Premise
evaluación I-Premise
con I-Premise
el I-Premise
cuestionario I-Premise
QLQ-C30 I-Premise
y I-Premise
la I-Premise
escala I-Premise
LC30 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
tratado I-Premise
también I-Premise
fueron I-Premise
superiores I-Premise
a I-Premise
los I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
eficacia I-Premise
de I-Premise
la I-Premise
MTC I-Premise
( I-Premise
24,52 I-Premise
+/- I-Premise
8,98 I-Premise
frente I-Premise
a I-Premise
29,76 I-Premise
+/- I-Premise
7,09 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
la I-Premise
distancia I-Premise
de I-Premise
marcha I-Premise
de I-Premise
6 I-Premise
minutos I-Premise
( I-Premise
233,4 I-Premise
+/- I-Premise
29,2 I-Premise
m I-Premise
frente I-Premise
a I-Premise
205,8 I-Premise
+/- I-Premise
31,9 I-Premise
m I-Premise
, I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
fueron I-Premise
mejores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
tratado I-Premise
. I-Premise

Después B-Premise
del I-Premise
tratamiento I-Premise
en I-Premise
el I-Premise
grupo I-Premise
tratado I-Premise
, I-Premise
el I-Premise
peso I-Premise
corporal I-Premise
aumentó I-Premise
en I-Premise
11 I-Premise
pacientes I-Premise
( I-Premise
20,0 I-Premise
% I-Premise
) I-Premise
, I-Premise
se I-Premise
estabilizó I-Premise
en I-Premise
28 I-Premise
( I-Premise
50,9 I-Premise
% I-Premise
) I-Premise
y I-Premise
disminuyó I-Premise
en I-Premise
16 I-Premise
( I-Premise
29,1 I-Premise
% I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
aumentó I-Premise
en I-Premise
5 I-Premise
( I-Premise
9,4 I-Premise
% I-Premise
) I-Premise
, I-Premise
se I-Premise
estabilizó I-Premise
en I-Premise
26 I-Premise
( I-Premise
49,1 I-Premise
% I-Premise
) I-Premise
y I-Premise
disminuyó I-Premise
en I-Premise
22 I-Premise
( I-Premise
41,5 I-Premise
% I-Premise
) I-Premise
, I-Premise
la I-Premise
diferencia I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
fue I-Premise
significativa I-Premise
, I-Premise
también I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Claim
terapia I-Claim
de I-Claim
MTC I-Claim
para I-Claim
eliminar I-Claim
las I-Claim
sustancias I-Claim
tóxicas I-Claim
y I-Claim
desbloquear I-Claim
los I-Claim
meridianos I-Claim
puede I-Claim
mejorar I-Claim
en I-Claim
cierta I-Claim
medida I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
tras I-Claim
la I-Claim
radiación. I-Claim

El O
ensayo O
AVEREL O
[ O
Estudio O
de O
Avastin O
( O
Bevacizumab O
) O
en O
combinación O
con O
Herceptin O
( O
Trastuzumab O
) O
/Docetaxel O
en O
pacientes O
con O
cáncer O
de O
mama O
metastásico O
HER2 O
positivo O
] O
evaluó O
el O
tratamiento O
de O
primera O
línea O
con O
bevacizumab O
para O
el O
cáncer O
de O
mama O
localmente O
recurrente/metastásico O
( O
LR/MBC O
) O
positivo O
al O
receptor O
del O
factor O
de O
crecimiento O
epidérmico O
humano O
2 O
( O
HER2 O
) O
. O

Las O
pacientes O
con O
LR/MBC O
medible/evaluable O
HER2-positivo O
que O
no O
habían O
recibido O
trastuzumab O
o O
quimioterapia O
para O
LR/MBC O
fueron O
estratificadas O
por O
trastuzumab O
adyuvante O
previo O
, O
taxano O
adyuvante O
( O
neo O
) O
previo O
, O
estado O
de O
los O
receptores O
hormonales O
y O
enfermedad O
medible O
y O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
docetaxel O
100 O
mg/m O
( O
2 O
) O
más O
trastuzumab O
8 O
mg/kg O
de O
dosis O
de O
carga O
seguido O
de O
6 O
mg/kg O
ya O
sea O
con O
bevacizumab O
15 O
mg/kg O
o O
sin O
bevacizumab O
, O
todos O
administrados O
cada O
3 O
semanas O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
supervivencia O
sin O
progresión O
( O
PFS O
) O
. O

Otros O
criterios O
de O
valoración O
fueron O
la O
supervivencia O
global, O
la O
tasa O
de O
respuesta O
(TR), O
la O
seguridad, O
la O
calidad O
de O
vida O
y O
la O
investigación O
traslacional. O

Resultados O
Las O
características O
basales O
de O
los O
424 O
pacientes O
estaban O
equilibradas O
entre O
los O
brazos O
de O
tratamiento. O

La O
mayoría O
de O
los O
pacientes O
tenían O
metástasis O
viscerales, O
el O
43% O
tenía O
un O
intervalo O
libre O
de O
enfermedad O
inferior O
a O
12 O
meses O
y O
el O
85% O
tenía O
enfermedad O
medible. O

La O
mediana O
de O
seguimiento O
fue O
de O
26 O
meses. O

El B-Premise
cociente I-Premise
de I-Premise
riesgo I-Premise
para I-Premise
la I-Premise
SLP I-Premise
evaluada I-Premise
por I-Premise
el I-Premise
investigador I-Premise
fue I-Premise
de I-Premise
0,82 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
0,65 I-Premise
a I-Premise
1,02; I-Premise
P I-Premise
= I-Premise
0,0775; I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP, I-Premise
13,7 I-Premise
frente I-Premise
a I-Premise
16,5 I-Premise
meses I-Premise
en I-Premise
los I-Premise
brazos I-Premise
sin I-Premise
bevacizumab I-Premise
y I-Premise
con I-Premise
bevacizumab, I-Premise
respectivamente; I-Premise
eventos I-Premise
de I-Premise
SLP I-Premise
en I-Premise
el I-Premise
72 I-Premise
%). I-Premise

La B-Premise
razón I-Premise
de I-Premise
riesgo I-Premise
de I-Premise
la I-Premise
SLP I-Premise
evaluada I-Premise
por I-Premise
el I-Premise
Comité I-Premise
de I-Premise
Revisión I-Premise
Independiente I-Premise
fue I-Premise
de I-Premise
0,72 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
0,54 I-Premise
a I-Premise
0,94; I-Premise
P I-Premise
= I-Premise
0,0162; I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP, I-Premise
13,9 I-Premise
frente I-Premise
a I-Premise
16,8 I-Premise
meses, I-Premise
respectivamente; I-Premise
eventos I-Premise
de I-Premise
SLP I-Premise
en I-Premise
el I-Premise
53%). I-Premise

El B-Premise
RR I-Premise
fue I-Premise
del I-Premise
70% I-Premise
frente I-Premise
al I-Premise
74% I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
= I-Premise
.3492 I-Premise
) I-Premise
. I-Premise

La B-Claim
neutropenia I-Claim
febril I-Claim
de I-Claim
grado I-Claim
≥ I-Claim
3 I-Claim
y I-Claim
la I-Claim
hipertensión I-Claim
fueron I-Claim
más I-Claim
frecuentes I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
que I-Claim
contiene I-Claim
bevacizumab I-Claim
. I-Claim

Unas B-Premise
concentraciones I-Premise
plasmáticas I-Premise
elevadas I-Premise
del I-Premise
factor I-Premise
de I-Premise
crecimiento I-Premise
endotelial I-Premise
vascular I-Premise
A I-Premise
( I-Premise
VEGF-A I-Premise
) I-Premise
se I-Premise
asociaron I-Premise
a I-Premise
un I-Premise
mayor I-Premise
beneficio I-Premise
del I-Premise
bevacizumab I-Premise
( I-Premise
no I-Premise
significativo I-Premise
estadísticamente I-Premise
) I-Premise
. I-Premise

La B-Claim
combinación I-Claim
de I-Claim
bevacizumab I-Claim
con I-Claim
docetaxel I-Claim
y I-Claim
trastuzumab I-Claim
no I-Claim
mejoró I-Claim
significativamente I-Claim
la I-Claim
SLP I-Claim
evaluada I-Claim
por I-Claim
los I-Claim
investigadores. I-Claim

El O
potencial O
valor O
predictivo O
del O
VEGF-A O
en O
plasma O
es O
consistente O
con O
los O
hallazgos O
en O
LR/MBC O
negativo O
para O
HER2, O
lo O
que O
justifica O
una O
evaluación O
prospectiva. O

La B-Claim
vinorelbina I-Claim
prolonga I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
mejora I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
pacientes I-Claim
de I-Claim
edad I-Claim
avanzada I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
no I-Claim
microcítico I-Claim
( I-Claim
CPNM I-Claim
) I-Claim
avanzado. I-Claim

Algunos B-Claim
estudios I-Claim
también I-Claim
han I-Claim
sugerido I-Claim
que I-Claim
la I-Claim
gemcitabina I-Claim
se I-Claim
tolera I-Claim
bien I-Claim
y I-Claim
es I-Claim
eficaz I-Claim
en I-Claim
estos I-Claim
pacientes. I-Claim

Se O
comparó O
la O
eficacia O
y O
la O
toxicidad O
de O
la O
combinación O
de O
vinorelbina O
más O
gemcitabina O
con O
las O
de O
cada O
fármaco O
administrado O
por O
separado O
en O
un O
ensayo O
de O
fase O
III O
abierto O
y O
aleatorizado O
en O
pacientes O
ancianos O
con O
CPNM O
avanzado. O

Los O
pacientes O
de O
70 O
años O
o O
más O
, O
inscritos O
entre O
diciembre O
de O
1997 O
y O
noviembre O
de O
2000 O
, O
fueron O
asignados O
aleatoriamente O
a O
recibir O
vinorelbina O
intravenosa O
( O
30 O
mg/m O
( O
2 O
) O
de O
superficie O
corporal O
) O
, O
gemcitabina O
( O
1200 O
mg/m O
( O
2 O
) O
) O
o O
vinorelbina O
( O
25 O
mg/m O
( O
2 O
) O
) O
más O
gemcitabina O
( O
1000 O
mg/m O
( O
2 O
) O
) O
. O

Todos O
los O
tratamientos O
se O
administraron O
los O
días O
1 O
y O
8 O
cada O
3 O
semanas O
durante O
un O
máximo O
de O
seis O
ciclos. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia. O

Las O
curvas O
de O
supervivencia O
se O
trazaron O
con O
el O
método O
de O
Kaplan-Meier O
y O
se O
analizaron O
mediante O
la O
prueba O
de O
Mantel-Haenszel. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
calidad O
de O
vida O
y O
la O
toxicidad. O

De O
los O
698 O
pacientes O
disponibles O
para O
el O
análisis O
por O
intención O
de O
tratar, O
233 O
fueron O
asignados O
a O
recibir O
vinorelbina, O
233 O
a O
gemcitabina O
y O
232 O
a O
vinorelbina O
más O
gemcitabina. O

En B-Premise
comparación I-Premise
con I-Premise
cada I-Premise
fármaco I-Premise
por I-Premise
separado, I-Premise
el I-Premise
tratamiento I-Premise
combinado I-Premise
no I-Premise
mejoró I-Premise
la I-Premise
supervivencia. I-Premise

La B-Premise
razón I-Premise
de I-Premise
riesgo I-Premise
de I-Premise
muerte I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
el I-Premise
tratamiento I-Premise
combinado I-Premise
fue I-Premise
de I-Premise
1,17 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0,95 I-Premise
a I-Premise
1,44 I-Premise
) I-Premise
la I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
vinorelbina I-Premise
y I-Premise
de I-Premise
1,06 I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,86 I-Premise
a I-Premise
1,29 I-Premise
) I-Premise
la I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
gemcitabina I-Premise
. I-Premise

Aunque B-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fue I-Premise
similar I-Premise
en I-Premise
los I-Premise
tres I-Premise
brazos I-Premise
de I-Premise
tratamiento, I-Premise
el I-Premise
tratamiento I-Premise
combinado I-Premise
fue I-Premise
más I-Premise
tóxico I-Premise
que I-Premise
los I-Premise
dos I-Premise
fármacos I-Premise
administrados I-Premise
por I-Premise
separado. I-Premise

La B-Claim
combinación I-Claim
de I-Claim
vinorelbina I-Claim
más I-Claim
gemcitabina I-Claim
no I-Claim
es I-Claim
más I-Claim
eficaz I-Claim
que I-Claim
la I-Claim
vinorelbina I-Claim
o I-Claim
la I-Claim
gemcitabina I-Claim
como I-Claim
agente I-Claim
único I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
pacientes I-Claim
ancianos I-Claim
con I-Claim
CPNM I-Claim
avanzado. I-Claim

Evaluar O
la O
eficacia O
de O
una O
intervención O
psicoeducativa O
para O
mejorar O
la O
fatiga O
relacionada O
con O
el O
cáncer O
. O

En O
este O
ensayo O
controlado O
aleatorio O
participaron O
109 O
mujeres O
que O
iniciaron O
la O
quimioterapia O
adyuvante O
para O
el O
cáncer O
de O
mama O
en O
estadio O
I O
o O
II O
en O
cinco O
centros O
de O
tratamiento O
de O
quimioterapia O
. O

Los O
pacientes O
del O
grupo O
de O
intervención O
recibieron O
un O
programa O
individualizado O
de O
educación O
y O
apoyo O
a O
la O
fatiga O
que O
se O
impartió O
en O
la O
clínica O
y O
por O
teléfono O
en O
tres O
sesiones O
de O
10 O
a O
20 O
minutos O
con O
una O
semana O
de O
diferencia. O

Los O
instrumentos O
incluían O
una O
escala O
de O
valoración O
numérica O
que O
evaluaba O
la O
confianza O
en O
el O
manejo O
de O
la O
fatiga; O
escalas O
de O
valoración O
numérica O
de O
11 O
puntos O
que O
medían O
la O
fatiga O
en O
el O
peor O
momento, O
en O
el O
promedio O
y O
en O
el O
mejor O
momento; O
las O
escalas O
de O
evaluación O
funcional O
de O
la O
terapia O
del O
cáncer O
y O
de O
la O
fatiga O
de O
Piper; O
la O
escala O
de O
autoeficacia O
para O
el O
cáncer; O
el O
cuestionario O
C30 O
de O
calidad O
de O
vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer; O
y O
la O
escala O
de O
ansiedad O
y O
depresión O
hospitalaria. O

Para O
cada O
resultado, O
se O
realizaron O
análisis O
separados O
de O
covarianza O
de O
las O
puntuaciones O
de O
cambio O
entre O
la O
línea O
de O
base O
( O
T1 O
) O
y O
los O
tres O
puntos O
temporales O
de O
seguimiento O
( O
T2 O
, O
T3 O
y O
T4 O
), O
controlando O
el O
valor O
correspondiente O
de O
la O
línea O
de O
base O
de O
la O
variable. O

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
diferencia I-Premise
media I-Premise
entre I-Premise
las I-Premise
evaluaciones I-Premise
de I-Premise
referencia I-Premise
( I-Premise
T1 I-Premise
) I-Premise
e I-Premise
inmediatamente I-Premise
después I-Premise
de I-Premise
la I-Premise
prueba I-Premise
( I-Premise
T2 I-Premise
) I-Premise
aumentaron I-Premise
significativamente I-Premise
más I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
para I-Premise
la I-Premise
peor I-Premise
y I-Premise
la I-Premise
media I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
, I-Premise
la I-Premise
Evaluación I-Premise
Funcional I-Premise
de I-Premise
la I-Premise
Terapia I-Premise
del I-Premise
Cáncer-Fatiga I-Premise
, I-Premise
y I-Premise
las I-Premise
medidas I-Premise
de I-Premise
gravedad I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
de I-Premise
Piper I-Premise
y I-Premise
de I-Premise
interferencia I-Premise
. I-Premise

Estas B-Premise
diferencias I-Premise
no I-Premise
se I-Premise
observaron I-Premise
entre I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
y I-Premise
las I-Premise
evaluaciones I-Premise
de I-Premise
T3 I-Premise
y I-Premise
T4 I-Premise
. I-Premise

No B-Premise
se I-Premise
identificaron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
ninguna I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
cambio I-Premise
antes I-Premise
o I-Premise
después I-Premise
de I-Premise
la I-Premise
prueba I-Premise
para I-Premise
la I-Premise
confianza I-Premise
en I-Premise
el I-Premise
manejo I-Premise
de I-Premise
la I-Premise
fatiga, I-Premise
la I-Premise
autoeficacia I-Premise
del I-Premise
cáncer, I-Premise
la I-Premise
ansiedad, I-Premise
la I-Premise
depresión I-Premise
o I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida. I-Premise

La B-Claim
educación I-Claim
y I-Claim
el I-Claim
apoyo I-Claim
preparatorios I-Claim
tienen I-Claim
el I-Claim
potencial I-Claim
de I-Claim
ayudar I-Claim
a I-Claim
las I-Claim
mujeres I-Claim
a I-Claim
hacer I-Claim
frente I-Claim
a I-Claim
la I-Claim
fatiga I-Claim
relacionada I-Claim
con I-Claim
el I-Claim
cáncer I-Claim
a I-Claim
corto I-Claim
plazo. I-Claim

Sin B-Claim
embargo, I-Claim
se I-Claim
necesita I-Claim
más I-Claim
investigación I-Claim
para I-Claim
identificar I-Claim
formas I-Claim
de I-Claim
mejorar I-Claim
la I-Claim
potencia I-Claim
y I-Claim
la I-Claim
sostenibilidad I-Claim
de I-Claim
las I-Claim
intervenciones I-Claim
psicoeducativas I-Claim
para I-Claim
el I-Claim
manejo I-Claim
de I-Claim
la I-Claim
fatiga I-Claim
relacionada I-Claim
con I-Claim
el I-Claim
cáncer. I-Claim

Evaluar O
la O
incidencia O
y O
la O
resolución O
temporal O
de O
la O
disuria O
después O
de O
la O
braquiterapia O
permanente O
de O
próstata O
, O
e O
identificar O
los O
factores O
predictivos O
de O
la O
disuria O
relacionada O
con O
la O
braquiterapia O
. O

El O
estudio O
incluyó O
a O
130 O
pacientes O
sin O
antecedentes O
de O
resección O
transuretral O
de O
la O
próstata O
antes O
del O
tratamiento O
, O
que O
se O
sometieron O
a O
braquiterapia O
en O
uno O
de O
los O
dos O
ensayos O
prospectivos O
aleatorios O
, O
con O
técnicas O
de O
preservación O
de O
la O
uretra O
explícitamente O
planificadas O
y O
ejecutadas O
( O
100-150 O
% O
de O
dosis O
mínima O
periférica O
) O
utilizando O
103Pd O
o O
125I O
para O
el O
cáncer O
de O
próstata O
clínico O
T1c-T2c O
. O

La O
mediana O
de O
seguimiento O
fue O
de O
22,6 O
meses. O

Se O
inició O
un O
alfabloqueante O
de O
forma O
profiláctica O
2 O
semanas O
antes O
de O
la O
implantación O
y O
se O
continuó O
al O
menos O
hasta O
que O
la O
Puntuación O
Internacional O
de O
Síntomas O
de O
la O
Próstata O
( O
IPSS O
) O
volviera O
a O
la O
normalidad O
, O
o O
se O
retuvo O
hasta O
la O
aparición O
de O
una O
morbilidad O
urinaria O
significativa O
relacionada O
con O
la O
braquiterapia O
. O

La O
disuria O
se O
evaluó O
en O
una O
escala O
de O
0 O
a O
10, O
antes O
de O
la O
braquiterapia O
y O
después O
a O
los O
1, O
3, O
6 O
y O
12 O
meses, O
con O
una O
media O
de O
cuatro O
cuestionarios O
de O
disuria O
por O
paciente. O

Las O
variables O
clínicas, O
de O
tratamiento O
y O
dosimétricas O
evaluadas O
fueron O
el O
alfabloqueante, O
la O
edad, O
el O
IPSS O
antes O
y O
el O
máximo O
después O
del O
tratamiento, O
el O
volumen O
de O
la O
próstata O
en O
la O
ecografía, O
el O
estado O
hormonal, O
la O
radioterapia O
suplementaria, O
el O
isótopo, O
la O
dosis O
uretral, O
el O
V O
( O
100/200 O
), O
el O
D90 O
y O
el O
tiempo O
hasta O
obtener O
un O
IPSS O
normal. O

La O
incidencia O
máxima O
de O
disuria O
fue O
del O
85% O
al O
mes O
de O
la O
braquiterapia, O
con O
una O
resolución O
posterior O
en O
el O
tiempo. O

El B-Premise
uso I-Premise
de I-Premise
tamsulosina I-Premise
profiláctica I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
una I-Premise
puntuación I-Premise
de I-Premise
gravedad I-Premise
de I-Premise
la I-Premise
disuria I-Premise
estadísticamente I-Premise
más I-Premise
baja I-Premise
( I-Premise
diferencia I-Premise
de I-Premise
2,7 I-Premise
frente I-Premise
a I-Premise
4,2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,005 I-Premise
) I-Premise
a I-Premise
1 I-Premise
mes I-Premise
, I-Premise
sin I-Premise
diferencias I-Premise
discernibles I-Premise
a I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
y I-Premise
18 I-Premise
meses I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
disuria I-Premise
tenían I-Premise
un I-Premise
IPSS I-Premise
estadísticamente I-Premise
más I-Premise
alto. I-Premise

La B-Premise
disuria I-Premise
se I-Premise
resolvió I-Premise
más I-Premise
rápidamente I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
implantados I-Premise
con I-Premise
103Pd, I-Premise
pero B-Premise
no I-Premise
se I-Premise
vio I-Premise
afectada I-Premise
por I-Premise
el I-Premise
uso I-Premise
de I-Premise
radioterapia I-Premise
suplementaria I-Premise
y/o I-Premise
terapia I-Premise
de I-Premise
privación I-Premise
de I-Premise
andrógenos. I-Premise

En B-Premise
el I-Premise
análisis I-Premise
multivariante I-Premise
, I-Premise
los I-Premise
alfabloqueantes I-Premise
profilácticos I-Premise
dieron I-Premise
lugar I-Premise
a I-Premise
puntuaciones I-Premise
máximas I-Premise
de I-Premise
disuria I-Premise
estadísticamente I-Premise
inferiores I-Premise
, O
mientras B-Premise
que I-Premise
el I-Premise
IPSS I-Premise
máximo I-Premise
tras I-Premise
la I-Premise
implantación I-Premise
y I-Premise
el I-Premise
tipo I-Premise
de I-Premise
isótopo I-Premise
( I-Premise
pero I-Premise
sólo I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
) I-Premise
fueron I-Premise
los I-Premise
mejores I-Premise
predictores I-Premise
de I-Premise
la I-Premise
resolución I-Premise
de I-Premise
la I-Premise
disuria I-Premise
. O

La B-Claim
disuria I-Claim
es I-Claim
común I-Claim
después I-Claim
de I-Claim
la I-Claim
braquiterapia, I-Claim
pero I-Claim
suele I-Claim
ser I-Claim
leve. I-Claim

Los B-Claim
alfabloqueantes I-Claim
profilácticos I-Claim
dieron I-Claim
puntuaciones I-Claim
máximas I-Claim
de I-Claim
disuria I-Claim
significativamente I-Claim
más I-Claim
bajas, I-Claim
pero B-Claim
no I-Claim
afectaron I-Claim
al I-Claim
tiempo I-Claim
de I-Claim
resolución I-Claim
de I-Claim
la I-Claim
disuria I-Claim
. O

El B-Claim
IPSS I-Claim
máximo I-Claim
tras I-Claim
el I-Claim
implante I-Claim
fue I-Claim
el I-Claim
mejor I-Claim
predictor I-Claim
de I-Claim
la I-Claim
resolución I-Claim
de I-Claim
la I-Claim
disuria I-Claim
. I-Claim

La B-Claim
adición I-Claim
de I-Claim
bevacizumab I-Claim
a I-Claim
paclitaxel I-Claim
mejoró I-Claim
la I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
( I-Claim
PFS I-Claim
) I-Claim
de I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
metastásico I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim

Examinamos O
la O
eficacia O
y O
seguridad O
de O
añadir O
gemcitabina O
a O
paclitaxel/bevacizumab O
( O
PB O
) O
. O

En O
este O
ensayo O
multicéntrico, O
abierto O
y O
aleatorizado O
de O
fase O
II, O
las O
mujeres O
con O
cáncer O
de O
mama O
o O
localmente O
avanzado O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
paclitaxel O
90 O
mg/m O
( O
2 O
) O
( O
días O
1 O
, O
8 O
, O
15 O
) O
y O
bevacizumab O
10 O
mg/kg O
( O
días O
1 O
, O
15 O
) O
con O
o O
sin O
gemcitabina O
1500 O
mg/m O
( O
2 O
) O
( O
días O
1 O
, O
15 O
) O
en O
ciclos O
de O
28 O
días O
. O

Los O
pacientes O
con O
tratamiento O
citotóxico O
previo O
para O
el O
CMB O
no O
fueron O
elegibles. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
tasa O
de O
respuesta O
global O
( O
ORR O
) O
evaluada O
por O
el O
investigador; O
los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
SLP O
, O
la O
supervivencia O
global O
( O
SG O
) O
, O
la O
seguridad O
y O
la O
calidad O
de O
vida O
. O

Noventa O
y O
cuatro O
pacientes O
recibieron O
PB O
, O
y O
93 O
recibieron O
paclitaxel/bevacizumab/gemcitabina O
( O
PB+G O
) O
. O

Las B-Premise
ORR I-Premise
fueron I-Premise
del I-Premise
48,9 I-Premise
% I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
38,5 I-Premise
% I-Premise
-59,5 I-Premise
% I-Premise
) I-Premise
y I-Premise
del I-Premise
58,7 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
47,9 I-Premise
% I-Premise
-68,9 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
.117 I-Premise
) I-Premise
con I-Premise
PB I-Premise
y I-Premise
PB+G I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
de I-Premise
8,8 I-Premise
meses I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
8,1-10,4 I-Premise
meses) I-Premise
y I-Premise
11,3 I-Premise
meses I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
9,7-12,7 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,247; I-Premise
cociente I-Premise
de I-Premise
riesgos, I-Premise
0,82); I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SG I-Premise
fue I-Premise
de I-Premise
25,0 I-Premise
meses I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
18,8 I-Premise
meses I-Premise
no I-Premise
evaluables) I-Premise
y I-Premise
24,3 I-Premise
meses I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
20,3 I-Premise
meses I-Premise
N/A; I-Premise
P I-Premise
= I-Premise
0,475; I-Premise
cociente I-Premise
de I-Premise
riesgos, I-Premise
0,84), I-Premise
con I-Premise
PB I-Premise
y I-Premise
PB+G, I-Premise
respectivamente. I-Premise

Hubo B-Premise
significativamente I-Premise
más I-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
disnea I-Premise
( I-Premise
P I-Premise
= I-Premise
0,014 I-Premise
) I-Premise
con I-Premise
PB+G I-Premise
. I-Premise

Las B-Premise
pacientes I-Premise
tratadas I-Premise
con I-Premise
PB I-Premise
experimentaron I-Premise
una I-Premise
mayor I-Premise
mejora I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
totales I-Premise
de I-Premise
FACT-B I-Premise
( I-Premise
Evaluación I-Premise
Funcional I-Premise
de I-Premise
la I-Premise
Terapia I-Premise
del I-Premise
Cáncer-Mama I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
0,021 I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
Bienestar I-Premise
Social/Familiar I-Premise
( I-Premise
P I-Premise
= I-Premise
0,041 I-Premise
) I-Premise
y I-Premise
Cáncer I-Premise
de I-Premise
Mama-Preocupaciones I-Premise
Adicionales I-Premise
( I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
) I-Premise
que I-Premise
las I-Premise
pacientes I-Premise
tratadas I-Premise
con I-Premise
PB+G I-Premise
. I-Premise

La B-Claim
adición I-Claim
de I-Claim
gemcitabina I-Claim
a I-Claim
PB I-Claim
no I-Claim
se I-Claim
asoció I-Claim
a I-Claim
una I-Claim
mejora I-Claim
estadísticamente I-Claim
significativa I-Claim
de I-Claim
la I-Claim
ORR I-Claim
. I-Claim

El B-Claim
tratamiento I-Claim
con I-Claim
PB+G I-Claim
aumentó I-Claim
la I-Claim
incidencia I-Claim
de I-Claim
neutropenia I-Claim
grave I-Claim
y I-Claim
disnea, I-Claim
aunque B-Claim
el I-Claim
régimen I-Claim
fue I-Claim
generalmente I-Claim
bien I-Claim
tolerado. I-Claim

El O
tratamiento O
de O
mantenimiento, O
iniciado O
inmediatamente O
después O
de O
la O
finalización O
de O
la O
quimioterapia O
de O
primera O
línea, O
es O
una O
estrategia O
prometedora O
para O
mejorar O
los O
resultados O
del O
tratamiento O
en O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
( O
CPNM O
) O
. O

El O
estudio O
global O
de O
fase O
III O
SequentiAl O
Tarceva O
in O
UnResectable O
NSCLC O
( O
SATURN O
) O
evaluó O
la O
eficacia O
y O
seguridad O
del O
inhibidor O
de O
la O
tirosina-cinasa O
del O
receptor O
del O
factor O
de O
crecimiento O
epidérmico O
( O
EGFR O
) O
erlotinib O
como O
tratamiento O
de O
mantenimiento O
en O
pacientes O
con O
CPNM O
sin O
progresión O
después O
de O
la O
quimioterapia O
de O
primera O
línea O
. O

Informamos O
de O
un O
subanálisis O
retrospectivo O
de O
pacientes O
asiáticos O
inscritos O
en O
SATURN O
. O

Los O
pacientes O
con O
CPNM O
avanzado O
sin O
evidencia O
de O
progresión O
después O
de O
cuatro O
ciclos O
de O
quimioterapia O
fueron O
aleatorizados O
para O
recibir O
erlotinib O
150 O
mg/día O
o O
placebo O
, O
hasta O
la O
enfermedad O
progresiva O
o O
toxicidad O
limitante O
. O

Los O
criterios O
de O
valoración O
coprincipales O
de O
SATURN O
fueron O
la O
supervivencia O
libre O
de O
progresión O
(SLP) O
en O
todos O
los O
pacientes O
y O
en O
aquellos O
con O
estado O
de O
inmunohistoquímica O
(IHC) O
positiva O
para O
el O
EGFR. O

Los O
criterios O
de O
valoración O
secundarios O
incluían O
la O
supervivencia O
global O
( O
SG O
) O
, O
la O
tasa O
de O
control O
de O
la O
enfermedad O
, O
la O
seguridad O
, O
la O
calidad O
de O
vida O
( O
QoL O
) O
y O
los O
análisis O
de O
biomarcadores O
. O

En O
total, O
se O
asignaron O
al O
azar O
126 O
pacientes O
de O
centros O
de O
Asia O
oriental O
y O
sudoriental O
(el O
14% O
de O
la O
población O
con O
intención O
de O
tratamiento): O
88 O
de O
Corea, O
28 O
de O
China O
y O
10 O
de O
Malasia; O
un O
paciente O
fue O
excluido O
de O
este O
análisis O
debido O
a O
su O
origen O
étnico O
indio. O

La B-Premise
SLP I-Premise
se I-Premise
prolongó I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
tratamiento I-Premise
con I-Premise
erlotinib I-Premise
, I-Premise
tanto I-Premise
en I-Premise
general I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
: I-Premise
0,57 I-Premise
; I-Premise
p=0,0067 I-Premise
) I-Premise
como I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
enfermedad I-Premise
EGFR I-Premise
IHC-positiva I-Premise
( I-Premise
HR=0,50 I-Premise
; I-Premise
p=0,0057 I-Premise
) I-Premise
. I-Premise

Hubo B-Premise
una I-Premise
tendencia I-Premise
hacia I-Premise
un I-Premise
aumento I-Premise
de I-Premise
la I-Premise
SG I-Premise
, I-Premise
que I-Premise
alcanzó I-Premise
significación I-Premise
estadística I-Premise
en I-Premise
el I-Premise
subgrupo I-Premise
positivo I-Premise
para I-Premise
el I-Premise
EGFR I-Premise
IHC I-Premise
( I-Premise
p=0,0233 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
global I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
con I-Premise
erlotinib I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
frente I-Premise
a I-Premise
5 I-Premise
% I-Premise
; I-Premise
p=0,0025 I-Premise
) I-Premise
. I-Premise

El B-Claim
erlotinib I-Claim
fue I-Claim
generalmente I-Claim
bien I-Claim
tolerado I-Claim
y I-Claim
no I-Claim
tuvo I-Claim
un I-Claim
impacto I-Claim
negativo I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
esta I-Claim
subpoblación. I-Claim

Los B-Premise
efectos I-Premise
adversos I-Premise
más I-Premise
frecuentes I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
fueron I-Premise
erupción I-Premise
cutánea, I-Premise
diarrea I-Premise
y I-Premise
prurito. I-Premise

El B-Claim
erlotinib I-Claim
fue I-Claim
eficaz I-Claim
y I-Claim
bien I-Claim
tolerado I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
asiáticos, I-Claim
produciendo I-Claim
beneficios I-Claim
consistentes I-Claim
con I-Claim
los I-Claim
observados I-Claim
en I-Claim
la I-Claim
población I-Claim
general I-Claim
de I-Claim
SATURN. I-Claim

El B-Claim
tratamiento I-Claim
de I-Claim
mantenimiento I-Claim
con I-Claim
erlotinib I-Claim
parece I-Claim
ser I-Claim
una I-Claim
opción I-Claim
útil I-Claim
para I-Claim
el I-Claim
manejo I-Claim
de I-Claim
pacientes I-Claim
asiáticos I-Claim
con I-Claim
CPNM I-Claim
avanzado I-Claim
sin I-Claim
progresión I-Claim
después I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
de I-Claim
primera I-Claim
línea I-Claim
. I-Claim

Evaluar O
la O
seguridad O
y O
eficacia O
de O
abatacept O
durante O
2 O
años O
del O
ensayo O
ATTAIN O
( O
Abatacept O
Trial O
in O
Treatment O
of O
Anti-TNF O
INadequate O
responders O
) O
en O
pacientes O
con O
artritis O
reumatoide O
. O

Los O
pacientes O
que O
completaron O
el O
período O
de O
6 O
meses O
, O
doble O
ciego, O
fueron O
elegibles O
para O
entrar O
en O
la O
extensión O
a O
largo O
plazo O
; O
los O
pacientes O
recibieron O
abatacept O
aproximadamente O
10 O
mg O
/ O
kg O
, O
además O
de O
medicamentos O
antirreumáticos O
modificadores O
de O
la O
enfermedad O
. O

Se O
evaluaron O
la O
seguridad O
y O
la O
eficacia O
( O
respuestas O
a O
los O
criterios O
del O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
, O
DAS28 O
( O
proteína O
C O
reactiva O
) O
, O
HAQ-DI O
, O
SF-36 O
, O
Medical O
Outcomes O
Study O
Sleep O
Problems O
Index O
, O
fatiga O
VAS O
) O
hasta O
los O
2 O
años O
. O

317 O
pacientes O
( O
218 O
del O
grupo O
de O
abatacept O
y O
99 O
del O
grupo O
de O
placebo O
) O
entraron O
y O
222 O
( O
70 O
% O
) O
completaron O
18 O
meses O
de O
tratamiento O
de O
extensión O
a O
largo O
plazo O
. O

La B-Premise
incidencia I-Premise
y I-Premise
el I-Premise
tipo I-Premise
de I-Premise
eventos I-Premise
adversos I-Premise
fueron I-Premise
consistentes I-Premise
entre I-Premise
los I-Premise
períodos I-Premise
doble I-Premise
ciego I-Premise
y I-Premise
acumulativo I-Premise
( I-Premise
doble I-Premise
ciego I-Premise
más I-Premise
extensión I-Premise
a I-Premise
largo I-Premise
plazo I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
acontecimientos I-Premise
adversos I-Premise
graves I-Premise
fueron I-Premise
de I-Premise
25,6 I-Premise
y I-Premise
23,4 I-Premise
por I-Premise
cada I-Premise
100 I-Premise
pacientes-año I-Premise
en I-Premise
el I-Premise
periodo I-Premise
doble I-Premise
ciego I-Premise
frente I-Premise
al I-Premise
acumulativo I-Premise
. I-Premise

A B-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
, I-Premise
utilizando I-Premise
análisis I-Premise
de I-Premise
no I-Premise
respuesta I-Premise
, I-Premise
las I-Premise
respuestas I-Premise
ACR I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
abatacept I-Premise
fueron I-Premise
: I-Premise
ACR I-Premise
20 I-Premise
, I-Premise
59,4 I-Premise
% I-Premise
y I-Premise
56,2 I-Premise
% I-Premise
; I-Premise
ACR I-Premise
50 I-Premise
, I-Premise
23,5 I-Premise
% I-Premise
y I-Premise
33,2 I-Premise
% I-Premise
; I-Premise
ACR I-Premise
70 I-Premise
, I-Premise
11,5 I-Premise
% I-Premise
y I-Premise
16,1 I-Premise
% I-Premise
; I-Premise
las I-Premise
respuestas I-Premise
del I-Premise
HAQ-DI I-Premise
fueron I-Premise
del I-Premise
54,4 I-Premise
% I-Premise
y I-Premise
47,9 I-Premise
% I-Premise
. I-Premise

A B-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
, I-Premise
utilizando I-Premise
análisis I-Premise
post-hoc I-Premise
as-observados I-Premise
, I-Premise
el I-Premise
porcentaje I-Premise
de I-Premise
pacientes I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
) I-Premise
que I-Premise
alcanzó I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
actividad I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
DAS28 I-Premise
( I-Premise
proteína I-Premise
C I-Premise
reactiva I-Premise
) I-Premise
baja I-Premise
( I-Premise
< I-Premise
o I-Premise
= I-Premise
3,2 I-Premise
) I-Premise
y I-Premise
la I-Premise
remisión I-Premise
definida I-Premise
por I-Premise
DAS28 I-Premise
( I-Premise
proteína I-Premise
C I-Premise
reactiva I-Premise
) I-Premise
( I-Premise
< I-Premise
2,6 I-Premise
) I-Premise
aumentó I-Premise
del I-Premise
18,3 I-Premise
% I-Premise
( I-Premise
13,0 I-Premise
, I-Premise
23,5 I-Premise
) I-Premise
al I-Premise
32,0 I-Premise
% I-Premise
( I-Premise
24,6 I-Premise
, I-Premise
39,4 I-Premise
) I-Premise
y I-Premise
del I-Premise
11,1 I-Premise
% I-Premise
( I-Premise
6,8 I-Premise
, I-Premise
15,3 I-Premise
) I-Premise
al I-Premise
20,3 I-Premise
% I-Premise
( I-Premise
13,9 I-Premise
, I-Premise
26,6 I-Premise
) I-Premise
. I-Premise

Las B-Premise
mejoras I-Premise
clínicamente I-Premise
significativas I-Premise
en I-Premise
la I-Premise
SF-36 I-Premise
, I-Premise
el I-Premise
dolor I-Premise
, I-Premise
la I-Premise
fatiga I-Premise
y I-Premise
los I-Premise
problemas I-Premise
de I-Premise
sueño I-Premise
también I-Premise
se I-Premise
mantuvieron I-Premise
a I-Premise
lo I-Premise
largo I-Premise
de I-Premise
los I-Premise
2 I-Premise
años I-Premise
de I-Premise
tratamiento I-Premise
con I-Premise
abatacept I-Premise
. I-Premise

No B-Premise
se I-Premise
han I-Premise
notificado I-Premise
observaciones I-Premise
de I-Premise
seguridad I-Premise
únicas I-Premise
durante I-Premise
la I-Premise
exposición I-Premise
en I-Premise
abierto. I-Premise

Las B-Premise
mejoras I-Premise
en I-Premise
los I-Premise
signos I-Premise
y I-Premise
síntomas I-Premise
de I-Premise
la I-Premise
artritis I-Premise
reumatoide, I-Premise
la I-Premise
función I-Premise
física I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
relacionada I-Premise
con I-Premise
la I-Premise
salud I-Premise
observadas I-Premise
después I-Premise
de I-Premise
6 I-Premise
meses, I-Premise
se I-Premise
mantuvieron I-Premise
a I-Premise
lo I-Premise
largo I-Premise
de I-Premise
los I-Premise
2 I-Premise
años I-Premise
en I-Premise
esta I-Premise
población I-Premise
con I-Premise
enfermedad I-Premise
difícil I-Premise
de I-Premise
tratar. I-Premise

La O
gemcitabina O
para O
el O
cáncer O
de O
páncreas O
avanzado O
( O
CPA O
) O
es O
paliativa O
y O
el O
pronóstico O
es O
malo O
, O
por O
lo O
que O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
CVRS O
) O
es O
particularmente O
importante O
. O

Se O
evaluó O
la O
CVRS O
con O
el O
EuroQol O
( O
EQ-5D™ O
) O
en O
pacientes O
con O
CCA O
que O
participaban O
en O
el O
Grupo O
B O
80303 O
de O
Cáncer O
y O
Leucemia O
, O
un O
ensayo O
multicéntrico O
, O
doble O
ciego O
, O
aleatorizado O
que O
comparaba O
la O
supervivencia O
global O
( O
SG O
) O
entre O
dos O
brazos O
de O
tratamiento O
: O
gemcitabina O
con O
bevacizumab O
o O
gemcitabina O
con O
placebo O
. O

Se O
invitó O
a O
una O
submuestra O
consecutiva O
de O
pacientes O
a O
completar O
las O
encuestas O
EQ-5D O
. O

Dado O
que O
ni O
los O
resultados O
clínicos O
ni O
los O
de O
la O
CVRS O
difirieron O
en O
función O
del O
brazo O
del O
estudio, O
se O
agruparon O
los O
análisis. O

Se O
evaluaron O
los O
cambios O
en O
las O
puntuaciones O
medias O
desde O
el O
inicio O
hasta O
las O
ocho O
semanas O
y O
el O
valor O
pronóstico O
del O
EQ-5D. O

Las B-Premise
puntuaciones I-Premise
medias I-Premise
del I-Premise
índice I-Premise
se I-Premise
mantuvieron I-Premise
estables I-Premise
( I-Premise
0,78 I-Premise
al I-Premise
inicio I-Premise
[ I-Premise
n=267 I-Premise
] I-Premise
, I-Premise
0,79 I-Premise
a I-Premise
las I-Premise
ocho I-Premise
semanas I-Premise
[ I-Premise
n=186 I-Premise
] I-Premise
, I-Premise
P=0,34 I-Premise
, I-Premise
prueba I-Premise
de I-Premise
rango I-Premise
con I-Premise
signo I-Premise
de I-Premise
Wilcoxon I-Premise
) I-Premise
, I-Premise
atribuibles I-Premise
a I-Premise
un I-Premise
modesto I-Premise
deterioro I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
dominio I-Premise
de I-Premise
la I-Premise
función I-Premise
física I-Premise
coincidente I-Premise
con I-Premise
pequeñas I-Premise
mejoras I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
dolor I-Premise
y I-Premise
la I-Premise
ansiedad/depresión I-Premise
. I-Premise

Se B-Premise
observó I-Premise
un I-Premise
pequeño I-Premise
descenso I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
escala I-Premise
visual I-Premise
analógica I-Premise
( I-Premise
70,7 I-Premise
frente I-Premise
a I-Premise
68,2 I-Premise
, I-Premise
P=0,026 I-Premise
) I-Premise
. I-Premise

Los B-Premise
cambios I-Premise
en I-Premise
la I-Premise
CVRS I-Premise
dentro I-Premise
de I-Premise
los I-Premise
estratos I-Premise
de I-Premise
respuesta I-Premise
a I-Premise
la I-Premise
quimioterapia I-Premise
revelaron I-Premise
puntuaciones I-Premise
de I-Premise
índice I-Premise
estables, I-Premise
pero I-Premise
una I-Premise
tendencia I-Premise
de I-Premise
empeoramiento I-Premise
de I-Premise
la I-Premise
función I-Premise
física I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
progresión I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
en I-Premise
comparación I-Premise
con I-Premise
aquellos I-Premise
con I-Premise
enfermedad I-Premise
estable I-Premise
o I-Premise
mejorada I-Premise
. O

Las B-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
escala I-Premise
visual I-Premise
analógica I-Premise
tendieron I-Premise
a I-Premise
disminuir I-Premise
con I-Premise
el I-Premise
tiempo, I-Premise
independientemente I-Premise
del I-Premise
estado I-Premise
de I-Premise
respuesta I-Premise
a I-Premise
la I-Premise
quimioterapia I-Premise
, I-Premise
con I-Premise
un I-Premise
deterioro I-Premise
estadísticamente I-Premise
significativo I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
progresaron I-Premise
( I-Premise
68,9 I-Premise
frente I-Premise
a I-Premise
64,4 I-Premise
, I-Premise
P=0,029 I-Premise
) I-Premise
. I-Premise

Las O
puntuaciones O
iniciales O
de O
ambas O
escalas O
EQ-5D O
fueron O
predictores O
significativos O
de O
la O
SG O
en O
los O
modelos O
de O
riesgos O
proporcionales O
de O
Cox. O

La B-Claim
respuesta I-Claim
al I-Claim
tratamiento I-Claim
con I-Claim
gemcitabina I-Claim
en I-Claim
APC I-Claim
no I-Claim
se I-Claim
asocia I-Claim
a I-Claim
una I-Claim
mejora I-Claim
apreciable I-Claim
de I-Claim
la I-Claim
CVRS I-Claim
global. I-Claim

Se O
observan O
pequeñas O
mejoras O
en O
el O
dolor O
y O
el O
estado O
de O
ánimo O
a O
pesar O
del O
progresivo O
deterioro O
funcional O
. O

Los B-Claim
que I-Claim
responden I-Claim
a I-Claim
la I-Claim
gemcitabina I-Claim
pueden I-Claim
experimentar I-Claim
una I-Claim
ligera I-Claim
ralentización I-Claim
del I-Claim
deterioro I-Claim
funcional I-Claim
. I-Claim

El O
dolor O
óseo-cáncer O
es O
un O
dolor O
oncológico O
común O
y O
refractario O
. O

Los O
opiáceos, O
por O
sí O
solos, O
no O
controlan O
lo O
suficientemente O
bien O
este O
tipo O
de O
dolor, O
y O
son O
necesarios O
los O
coanalgésicos. O

Los O
pacientes O
con O
dolor O
relacionado O
con O
las O
metástasis O
óseas O
en O
la O
escala O
de O
calificación O
numérica O
≥4 O
se O
inscribieron O
en O
este O
ensayo O
aleatorio O
controlado O
con O
placebo O
. O

También O
habían O
recibido O
morfina O
o O
parches O
transdérmicos O
de O
fentanilo O
durante O
al O
menos O
una O
semana. O

Durante O
la O
fase O
de O
eficacia O
de O
3 O
días O
, O
los O
pacientes O
recibieron O
placebo O
o O
1-3 O
comprimidos O
de O
oxicodona/paracetamol O
( O
5/325 O
mg O
) O
, O
cuatro O
veces O
al O
día O
durante O
3 O
días O
. O

Todos O
los O
pacientes O
llevaban O
un O
diario O
del O
dolor. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
diferencia O
de O
intensidad O
del O
dolor O
(DIP). O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
los O
casos O
de O
dolor O
irruptivo O
y O
el O
consumo O
de O
morfina O
de O
rescate. O

Los O
análisis O
adicionales O
incluyeron O
la O
escala O
de O
calidad O
de O
vida O
Short O
Form-6 O
Dimensions O
( O
SF-6D O
) O
y O
una O
impresión O
general O
( O
GI O
) O
de O
la O
satisfacción O
del O
paciente O
con O
el O
tratamiento O
al O
final O
de O
la O
fase O
. O

De O
los O
246 O
pacientes O
del O
conjunto O
de O
intención O
de O
tratamiento, O
el O
89-4% O
completó O
la O
fase O
de O
eficacia O
de O
3 O
días. O

Las B-Premise
EPIs I-Premise
fueron I-Premise
de I-Premise
0-9 I-Premise
y I-Premise
0-3 I-Premise
en I-Premise
los I-Premise
grupos I-Premise
de I-Premise
oxicodona/paracetamol I-Premise
y I-Premise
placebo I-Premise
respectivamente I-Premise
, I-Premise
en I-Premise
el I-Premise
día I-Premise
1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0-001 I-Premise
) I-Premise
, I-Premise
y I-Premise
de I-Premise
1-5 I-Premise
y I-Premise
0-3 I-Premise
respectivamente I-Premise
en I-Premise
el I-Premise
día I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0-001 I-Premise
) I-Premise
. I-Premise

Treinta B-Premise
y I-Premise
ocho I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
tratamiento, I-Premise
y I-Premise
58 I-Premise
del I-Premise
grupo I-Premise
de I-Premise
placebo, I-Premise
sufrieron I-Premise
dolor I-Premise
irruptivo I-Premise
el I-Premise
día I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0-001 I-Premise
) I-Premise
. I-Premise

La B-Premise
puntuación I-Premise
del I-Premise
SF-6D I-Premise
disminuyó I-Premise
a I-Premise
21-2 I-Premise
± I-Premise
2-5 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
oxicodona/paracetamol I-Premise
al I-Premise
final I-Premise
de I-Premise
la I-Premise
fase I-Premise
( I-Premise
P I-Premise
= I-Premise
0-001 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
oxicodona/paracetamol, I-Premise
el I-Premise
67% I-Premise
calificó I-Premise
el I-Premise
IG I-Premise
como I-Premise
bueno, I-Premise
muy I-Premise
bueno I-Premise
o I-Premise
excelente. I-Premise

Los B-Claim
pacientes I-Claim
con I-Claim
dolor I-Claim
por I-Claim
cáncer I-Claim
óseo, I-Claim
que I-Claim
ya I-Claim
toman I-Claim
opioides, I-Claim
obtienen I-Claim
un I-Claim
control I-Claim
del I-Claim
dolor I-Claim
adicional I-Claim
clínicamente I-Claim
importante, I-Claim
con I-Claim
una I-Claim
dosis I-Claim
regular I-Claim
de I-Claim
oxicodona/paracetamol. I-Claim

Examinar O
los O
efectos O
de O
un O
programa O
de O
ejercicio O
sentado O
sobre O
la O
fatiga O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
en O
mujeres O
con O
cáncer O
de O
mama O
metastásico O
. O

Ensayo O
aleatorio, O
controlado O
y O
longitudinal. O

Clínica O
ambulatoria O
de O
un O
centro O
oncológico O
integral O
. O

Muestra O
de O
conveniencia O
de O
38 O
mujeres O
que O
iniciaban O
quimioterapia O
ambulatoria O
. O

Los O
sujetos O
fueron O
asignados O
aleatoriamente O
a O
un O
grupo O
de O
control O
o O
de O
intervención; O
la O
intervención O
consistió O
en O
la O
realización O
de O
un O
programa O
de O
ejercicios O
en O
posición O
sentada O
utilizando O
una O
cinta O
de O
vídeo O
casera O
tres O
veces O
por O
semana O
durante O
cuatro O
ciclos O
de O
quimioterapia O
. O

Todos O
los O
sujetos O
completaron O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
de O
Enfermedades O
Crónicas O
Versión O
IV O
( O
FACIT O
F O
) O
en O
la O
línea O
de O
base O
y O
en O
el O
momento O
de O
los O
tres O
ciclos O
siguientes O
. O

Se O
pidió O
a O
los O
sujetos O
que O
documentaran O
la O
frecuencia, O
la O
duración O
y O
la O
intensidad O
de O
toda O
la O
participación O
en O
el O
ejercicio O
en O
calendarios O
mensuales. O

Ejercicio, O
fatiga O
y O
calidad O
de O
vida. O

32 O
sujetos, O
16 O
por O
grupo, O
completaron O
el O
seguimiento O
del O
estudio. O

Con B-Premise
un I-Premise
enfoque I-Premise
de I-Premise
modelos I-Premise
mixtos, I-Premise
las I-Premise
puntuaciones I-Premise
totales I-Premise
de I-Premise
FACIT I-Premise
para I-Premise
toda I-Premise
la I-Premise
muestra I-Premise
disminuyeron I-Premise
a I-Premise
un I-Premise
ritmo I-Premise
significativo I-Premise
( I-Premise
p I-Premise
= I-Premise
0,003 I-Premise
) I-Premise
a I-Premise
partir I-Premise
del I-Premise
ciclo I-Premise
3, I-Premise
pero I-Premise
a I-Premise
un I-Premise
ritmo I-Premise
más I-Premise
lento I-Premise
para I-Premise
el I-Premise
grupo I-Premise
experimental I-Premise
( I-Premise
p I-Premise
= I-Premise
0,02 I-Premise
) O
. O

Las B-Premise
puntuaciones I-Premise
de I-Premise
fatiga I-Premise
indicaron I-Premise
un I-Premise
menor I-Premise
aumento I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
subescala I-Premise
de I-Premise
bienestar I-Premise
físico I-Premise
mostraron I-Premise
un I-Premise
menor I-Premise
descenso I-Premise
para I-Premise
el I-Premise
grupo I-Premise
experimental I-Premise
( I-Premise
p I-Premise
= I-Premise
0,008 I-Premise
y I-Premise
p I-Premise
= I-Premise
0,02 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Las B-Premise
mujeres I-Premise
con I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
avanzado I-Premise
asignadas I-Premise
al I-Premise
azar I-Premise
a I-Premise
la I-Premise
intervención I-Premise
de I-Premise
ejercicio I-Premise
sentado I-Premise
tuvieron I-Premise
un I-Premise
descenso I-Premise
más I-Premise
lento I-Premise
del I-Premise
bienestar I-Premise
total I-Premise
y I-Premise
físico I-Premise
y I-Premise
un I-Premise
menor I-Premise
aumento I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
fatiga I-Premise
a I-Premise
partir I-Premise
del I-Premise
tercer I-Premise
ciclo I-Premise
de I-Premise
quimioterapia I-Premise
. I-Premise

El B-Claim
ejercicio I-Claim
sentado I-Claim
puede I-Claim
ser I-Claim
un I-Claim
programa I-Claim
de I-Claim
ejercicio I-Claim
factible I-Claim
para I-Claim
las I-Claim
mujeres I-Claim
con I-Claim
cáncer I-Claim
avanzado I-Claim
para I-Claim
controlar I-Claim
la I-Claim
fatiga I-Claim
y I-Claim
mejorar I-Claim
el I-Claim
bienestar I-Claim
físico I-Claim
. I-Claim

Pocos O
programas O
de O
intervención O
ayudan O
a O
los O
pacientes O
y O
a O
sus O
familiares O
cuidadores O
a O
manejar O
el O
cáncer O
avanzado O
y O
a O
mantener O
su O
calidad O
de O
vida O
( O
QOL O
) O
. O

Este O
estudio O
examinó O
( O
i O
) O
si O
las O
díadas O
paciente-cuidador O
( O
es O
decir, O
las O
parejas O
) O
asignadas O
al O
azar O
a O
una O
intervención O
diádica O
breve O
o O
extensa O
( O
el O
Programa O
FOCUS O
) O
tenían O
mejores O
resultados O
que O
las O
díadas O
asignadas O
al O
azar O
a O
la O
atención O
habitual O
y O
( O
ii O
) O
si O
el O
riesgo O
de O
angustia O
de O
los O
pacientes O
y O
otros O
factores O
moderaban O
el O
efecto O
del O
programa O
breve O
o O
extenso O
en O
los O
resultados O
. O

Los O
pacientes O
con O
cáncer O
avanzado O
y O
sus O
cuidadores O
( O
N O
= O
484 O
díadas O
) O
fueron O
estratificados O
por O
el O
riesgo O
de O
base O
de O
los O
pacientes O
para O
la O
angustia O
( O
alto O
versus O
bajo O
) O
, O
el O
tipo O
de O
cáncer O
( O
pulmón O
, O
colorrectal O
, O
de O
mama O
o O
de O
próstata O
) O
, O
y O
luego O
asignados O
al O
azar O
a O
una O
breve O
( O
tres O
sesiones O
) O
o O
extensa O
( O
seis O
sesiones O
) O
intervención O
o O
control O
. O

Las O
intervenciones O
ofrecieron O
a O
las O
díadas O
información O
y O
apoyo. O

Los O
resultados O
intermedios O
fueron O
las O
valoraciones O
( O
es O
decir, O
la O
valoración O
de O
la O
enfermedad/la O
atención, O
la O
incertidumbre O
y O
la O
desesperanza) O
y O
los O
recursos O
( O
es O
decir, O
el O
afrontamiento, O
las O
relaciones O
interpersonales O
y O
la O
autoeficacia) O
. O

El O
resultado O
primario O
fue O
la O
calidad O
de O
vida. O

Los O
datos O
se O
recogieron O
antes O
de O
la O
intervención O
y O
después O
de O
la O
misma O
( O
3 O
y O
6 O
meses O
desde O
la O
línea O
de O
base O
) O
. O

La O
muestra O
final O
fue O
de O
302 O
díadas. O

Se O
utilizó O
un O
MANCOVA O
de O
medidas O
repetidas O
para O
evaluar O
los O
resultados. O

Las B-Premise
interacciones I-Premise
significativas I-Premise
entre I-Premise
el I-Premise
grupo I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
mostraron I-Premise
que I-Premise
había I-Premise
una I-Premise
mejora I-Premise
en I-Premise
el I-Premise
afrontamiento I-Premise
de I-Premise
las I-Premise
díadas I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
la I-Premise
autoeficacia I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
CdV I-Premise
social I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
y I-Premise
en I-Premise
la I-Premise
CdV I-Premise
emocional I-Premise
de I-Premise
los I-Premise
cuidadores I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los O
efectos O
variaron O
según O
la O
dosis O
de O
intervención O
. O

La O
mayoría O
de O
los O
efectos O
se O
encontraron O
sólo O
a O
los O
3 O
meses. O

El B-Premise
riesgo I-Premise
de I-Premise
angustia I-Premise
representó I-Premise
muy I-Premise
pocos I-Premise
efectos I-Premise
de I-Premise
moderación I-Premise
. I-Premise

Tanto B-Premise
los I-Premise
programas I-Premise
breves I-Premise
como I-Premise
los I-Premise
extensos I-Premise
tuvieron I-Premise
resultados I-Premise
positivos I-Premise
para I-Premise
las I-Premise
díadas I-Premise
paciente-cuidador I-Premise
, O
pero B-Premise
pocos I-Premise
efectos I-Premise
sostenidos I-Premise
. O

Las B-Claim
díadas I-Claim
paciente-cuidador I-Claim
se I-Claim
benefician I-Claim
cuando I-Claim
se I-Claim
consideran I-Claim
como I-Claim
la I-Claim
"unidad I-Claim
de I-Claim
cuidados". I-Claim

Observar O
la O
eficacia O
clínica O
de O
la O
inyección O
de O
Shenqi O
Fuzheng O
( O
SFI O
) O
combinada O
con O
quimioterapia O
en O
el O
tratamiento O
de O
pacientes O
con O
cáncer O
de O
mama O
avanzado O
. O

Sesenta O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
dos O
grupos O
por O
tabla O
digital O
, O
el O
grupo O
de O
control O
y O
el O
grupo O
de O
tratamiento O
, O
30 O
en O
cada O
grupo O
. O

Todos O
los O
pacientes O
fueron O
tratados O
con O
el O
mismo O
régimen O
de O
quimioterapia O
CTF O
durante O
21 O
días O
como O
un O
ciclo O
terapéutico O
, O
mientras O
que O
los O
del O
grupo O
de O
tratamiento O
recibieron O
SFI O
adicionalmente O
en O
el O
medio O
blanco O
. O

La O
eficacia O
terapéutica O
se O
evaluó O
después O
de O
2 O
ciclos O
de O
tratamiento O
mediante O
la O
observación O
de O
los O
cambios O
de O
la O
eficacia O
a O
corto O
plazo O
, O
el O
síndrome O
TCM O
, O
la O
calidad O
de O
vida O
y O
la O
función O
inmune O
, O
así O
como O
la O
reacción O
adversa O
. O

La B-Premise
tasa I-Premise
de I-Premise
remisión I-Premise
total I-Premise
a I-Premise
corto I-Premise
plazo, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
mejora I-Premise
del I-Premise
síndrome I-Premise
clínico I-Premise
y I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fue I-Premise
del I-Premise
50,0 I-Premise
%, I-Premise
70,0 I-Premise
% I-Premise
y I-Premise
76,7 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento, I-Premise
y I-Premise
del I-Premise
43,3 I-Premise
%, I-Premise
46,7 I-Premise
% I-Premise
y I-Premise
50,0 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
respectivamente, I-Premise
lo I-Premise
que I-Premise
muestra I-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
( I-Premise
todos I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
aparición I-Premise
de I-Premise
reacciones I-Premise
adversas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
fue I-Premise
menor I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

El B-Premise
nivel I-Premise
de I-Premise
CD3+ I-Premise
CD4+ I-Premise
y I-Premise
la I-Premise
relación I-Premise
CD4+/CD8+ I-Premise
aumentaron I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
los I-Premise
CD8+ I-Premise
disminuyeron I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
mostraron I-Premise
un I-Premise
cambio I-Premise
insignificante I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
. I-Premise

Para B-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
avanzado, I-Claim
SFI I-Claim
puede I-Claim
aliviar I-Claim
la I-Claim
inhibición I-Claim
de I-Claim
la I-Claim
médula I-Claim
ósea I-Claim
causada I-Claim
por I-Claim
la I-Claim
quimioterapia, I-Claim
mejorar I-Claim
los I-Claim
síntomas I-Claim
clínicos I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
prolongar I-Claim
el I-Claim
período I-Claim
de I-Claim
supervivencia I-Claim
mediante I-Claim
la I-Claim
regulación I-Claim
de I-Claim
la I-Claim
función I-Claim
inmune I-Claim
celular I-Claim
de I-Claim
los I-Claim
pacientes, I-Claim
a I-Claim
fin I-Claim
de I-Claim
mejorar I-Claim
el I-Claim
efecto I-Claim
terapéutico I-Claim
de I-Claim
la I-Claim
quimioterapia. I-Claim

El O
ensayo O
de O
fase O
III O
del O
Grupo O
de O
Oncología O
del O
Colegio O
Americano O
de O
Cirujanos O
sobre O
la O
prostatectomía O
quirúrgica O
frente O
a O
la O
intervención O
de O
radiación O
intersticial, O
que O
comparaba O
la O
prostatectomía O
radical O
( O
RP O
) O
y O
la O
braquiterapia O
( O
BT O
), O
se O
cerró O
después O
de O
2 O
años O
debido O
a O
la O
escasa O
participación. O

Informamos O
sobre O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
a O
una O
media O
de O
5,3 O
años O
para O
168 O
hombres O
elegibles O
para O
el O
ensayo O
que O
eligieron O
o O
fueron O
asignados O
al O
azar O
a O
RP O
o O
BT O
después O
de O
una O
sesión O
educativa O
multidisciplinar O
. O

Tras O
la O
falta O
de O
participación O
inicial, O
se O
introdujo O
una O
sesión O
educativa O
multidisciplinar O
para O
los O
pacientes O
elegibles. O

En O
total, O
263 O
hombres O
asistieron O
a O
47 O
sesiones. O

De O
ellos, O
34 O
aceptaron O
la O
asignación O
aleatoria, O
62 O
eligieron O
el O
RP O
y O
94 O
el O
BT. O

Cinco O
años O
más O
tarde, O
estos O
190 O
hombres O
se O
sometieron O
a O
una O
evaluación O
de O
la O
CVRS O
utilizando O
el O
Índice O
Compuesto O
Expandido O
de O
Cáncer O
de O
Próstata O
de O
50 O
ítems O
específico O
para O
el O
cáncer, O
el O
Short O
Form O
12 O
Physical O
Component O
Score O
y O
el O
Short O
Form O
12 O
Mental O
Component O
Score. O

La O
tasa O
de O
respuesta O
fue O
del O
88,4%. O

Se O
utilizó O
la O
prueba O
de O
suma O
de O
rangos O
de O
Wilcoxon O
para O
comparar O
las O
puntuaciones O
de O
resumen O
entre O
las O
dos O
intervenciones O
. O

De O
los O
168 O
encuestados, O
el O
60,7% O
tenía O
BT O
(9,5% O
asignados O
al O
azar) O
y O
el O
39,3% O
tenía O
RP O
(9,5% O
asignados O
al O
azar). O

La O
mediana O
de O
edad O
fue O
de O
61,4 O
años O
para O
el O
BT O
y O
de O
59,4 O
para O
el O
RP O
( O
P O
= O
0,05 O
) O
. O

La O
mediana O
de O
seguimiento O
fue O
de O
5,2 O
años O
( O
rango O
, O
3,2 O
a O
6,5 O
años O
) O
. O

En B-Premise
el I-Premise
caso I-Premise
de I-Premise
la I-Premise
BT I-Premise
frente I-Premise
a I-Premise
la I-Premise
RP I-Premise
, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
los I-Premise
dominios I-Premise
intestinales I-Premise
u I-Premise
hormonales I-Premise
, O
pero O
los B-Premise
hombres I-Premise
tratados I-Premise
con I-Premise
BT I-Premise
obtuvieron I-Premise
mejores I-Premise
puntuaciones I-Premise
en I-Premise
los I-Premise
dominios I-Premise
urinario I-Premise
( I-Premise
91,8 I-Premise
frente I-Premise
a I-Premise
88,1 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
y I-Premise
sexual I-Premise
( I-Premise
52,5 I-Premise
frente I-Premise
a I-Premise
39,2 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
y I-Premise
en I-Premise
la I-Premise
satisfacción I-Premise
del I-Premise
paciente I-Premise
( I-Premise
93,6 I-Premise
frente I-Premise
a I-Premise
76,9 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) O
. O

Aunque O
la O
asignación O
del O
tratamiento O
fue O
aleatoria O
sólo O
en O
el O
19% O
, O
todos O
los O
pacientes O
recibieron O
idéntica O
información O
en O
un O
entorno O
multidisciplinar O
antes O
de O
seleccionar O
la O
RP O
, O
la O
BT O
, O
o O
la O
asignación O
aleatoria O
. O

La B-Claim
CVRS I-Claim
evaluada I-Claim
entre I-Claim
3,2 I-Claim
y I-Claim
6,5 I-Claim
años I-Claim
después I-Claim
del I-Claim
tratamiento I-Claim
mostró I-Claim
una I-Claim
ventaja I-Claim
para I-Claim
el I-Claim
BT I-Claim
en I-Claim
los I-Claim
dominios I-Claim
urinario I-Claim
y I-Claim
sexual I-Claim
y I-Claim
en I-Claim
la I-Claim
satisfacción I-Claim
del I-Claim
paciente I-Claim
. I-Claim

Se O
desarrolló O
un O
programa O
de O
rehabilitación O
multidimensional O
para O
los O
supervivientes O
de O
cáncer O
con O
el O
fin O
de O
superar O
los O
problemas O
relacionados O
con O
el O
cáncer O
y O
mejorar O
la O
calidad O
de O
vida O
. O

Los O
dos O
propósitos O
del O
estudio O
eran O
describir O
la O
eficacia O
del O
programa O
y O
obtener O
información O
sobre O
las O
preferencias O
de O
los O
pacientes O
por O
los O
programas O
de O
rehabilitación O
multi O
o O
monodimensionales O
. O

supervivientes O
de O
cáncer O
con O
diferentes O
diagnósticos, O
y O
problemas O
físicos O
y O
psicosociales O
relacionados O
con O
el O
cáncer. O

un O
programa O
de O
rehabilitación O
de O
15 O
semanas O
que O
incluye O
ejercicios O
individuales, O
deportes, O
psicoeducación O
e O
información. O

La O
aleatorización O
por O
grupos O
se O
llevó O
a O
cabo O
asignando O
a O
la O
mitad O
de O
los O
pacientes O
el O
programa O
completo, O
mientras O
que O
a O
la O
otra O
mitad O
se O
le O
permitió O
elegir O
los O
componentes O
del O
programa O
que O
consideraban O
pertinentes. O

Calidad O
de O
vida O
relacionada O
con O
la O
salud O
[ O
RAND-36 O
y O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
capacidad O
de O
ejercicio O
( O
ergometría O
en O
bicicleta O
limitada O
por O
los O
síntomas O
) O
, O
fuerza O
muscular O
( O
dinamometría O
manual O
) O
y O
preferencias O
del O
paciente O
. O

Las O
mediciones O
se O
realizaron O
antes O
( O
T0 O
) O
y O
después O
del O
programa O
de O
rehabilitación O
( O
T1 O
) O
, O
y O
en O
un O
seguimiento O
de O
3 O
meses O
( O
T2 O
) O
. O

Tras B-Premise
el I-Premise
programa I-Premise
de I-Premise
rehabilitación, I-Premise
los I-Premise
supervivientes I-Premise
de I-Premise
cáncer I-Premise
( I-Premise
n=63 I-Premise
) I-Premise
mostraron I-Premise
mejoras I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
relacionada I-Premise
con I-Premise
la I-Premise
salud, I-Premise
con I-Premise
tamaños I-Premise
del I-Premise
efecto I-Premise
( I-Premise
ES I-Premise
) I-Premise
que I-Premise
variaban I-Premise
de I-Premise
0,38 I-Premise
a I-Premise
0,99 I-Premise
( I-Premise
RAND-36 I-Premise
) I-Premise
y I-Premise
de I-Premise
-0,34 I-Premise
a I-Premise
-0,57 I-Premise
( I-Premise
RSCL I-Premise
) I-Premise
, I-Premise
más I-Premise
persistentes I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses I-Premise
de I-Premise
seguimiento I-Premise
. I-Premise

Además, B-Premise
después I-Premise
de I-Premise
la I-Premise
rehabilitación I-Premise
se I-Premise
observaron I-Premise
mejoras I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
la I-Premise
capacidad I-Premise
de I-Premise
ejercicio I-Premise
y I-Premise
la I-Premise
fuerza I-Premise
muscular I-Premise
de I-Premise
las I-Premise
extremidades I-Premise
superiores I-Premise
e I-Premise
inferiores. I-Premise

Si B-Premise
se I-Premise
les I-Premise
ofrecía I-Premise
la I-Premise
posibilidad I-Premise
de I-Premise
elegir, I-Premise
el I-Premise
80% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
antes I-Premise
de I-Premise
empezar I-Premise
y I-Premise
el I-Premise
58% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
después I-Premise
de I-Premise
terminar I-Premise
el I-Premise
programa I-Premise
indicaron I-Premise
que I-Premise
preferían I-Premise
el I-Premise
programa I-Premise
multidimensional I-Premise
completo. I-Premise

Un B-Claim
programa I-Claim
de I-Claim
rehabilitación I-Claim
multidimensional I-Claim
tiene I-Claim
efectos I-Claim
beneficiosos I-Claim
estadística I-Claim
y I-Claim
clínicamente I-Claim
relevantes I-Claim
sobre I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
salud I-Claim
, I-Claim
la I-Claim
capacidad I-Claim
de I-Claim
ejercicio I-Claim
y I-Claim
la I-Claim
fuerza I-Claim
muscular I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
con I-Claim
diferentes I-Claim
diagnósticos I-Claim
. I-Claim

Además, O
si B-Claim
se I-Claim
les I-Claim
ofrece I-Claim
la I-Claim
posibilidad I-Claim
de I-Claim
elegir, I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
parecen I-Claim
preferir I-Claim
los I-Claim
programas I-Claim
multidimensionales I-Claim
a I-Claim
los I-Claim
que I-Claim
sólo I-Claim
tienen I-Claim
un I-Claim
componente. I-Claim

La O
cirugía O
y O
la O
radioterapia O
suelen O
causar O
problemas O
musculoesqueléticos O
adversos, O
en O
particular O
la O
pérdida O
de O
fuerza O
y O
amplitud O
de O
movimiento, O
en O
el O
cuadrante O
superior O
de O
las O
pacientes O
con O
cáncer O
de O
mama. O

Pocos O
estudios O
bien O
diseñados O
han O
investigado O
si O
estas O
deficiencias O
pueden O
prevenirse. O

Los B-Claim
estiramientos I-Claim
son I-Claim
una I-Claim
técnica I-Claim
eficaz I-Claim
para I-Claim
aumentar I-Claim
la I-Claim
amplitud I-Claim
de I-Claim
movimiento, I-Claim
por O
lo O
que O
el O
objetivo O
de O
este O
estudio O
era O
investigar O
si O
un O
programa O
de O
estiramientos O
reducía O
las O
alteraciones O
musculoesqueléticas O
agudas O
en O
pacientes O
sometidas O
a O
radioterapia O
por O
cáncer O
de O
mama. O

Se O
reclutaron O
sesenta O
y O
cuatro O
mujeres O
antes O
del O
inicio O
de O
la O
radioterapia O
tras O
la O
cirugía O
de O
cáncer O
de O
mama O
. O

Los O
participantes O
fueron O
asignados O
al O
azar O
a O
un O
grupo O
de O
control O
o O
de O
estiramiento. O

Los O
participantes O
de O
ambos O
grupos O
fueron O
revisados O
por O
el O
fisioterapeuta O
semanalmente O
durante O
aproximadamente O
6 O
semanas O
, O
y O
recibieron O
información O
general O
sobre O
el O
cuidado O
de O
la O
piel O
y O
el O
linfedema O
. O

El O
grupo O
de O
control O
no O
recibió O
ningún O
consejo O
sobre O
el O
ejercicio. O

El O
grupo O
de O
estiramiento O
recibió O
instrucciones O
sobre O
estiramientos O
pectorales O
prolongados O
y O
de O
baja O
carga, O
que O
debían O
realizarse O
diariamente O
y O
se O
controlaban O
en O
las O
visitas O
semanales. O

Se O
tomaron O
mediciones O
de O
la O
amplitud O
de O
movimiento O
del O
hombro, O
la O
fuerza, O
la O
circunferencia O
del O
brazo O
y O
la O
calidad O
de O
vida O
antes O
de O
la O
radioterapia, O
al O
finalizarla O
y O
a O
los O
7 O
meses O
de O
la O
misma. O

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
ningún I-Premise
resultado I-Premise
entre I-Premise
los I-Premise
grupos. I-Premise

Los B-Premise
síntomas I-Premise
mamarios I-Premise
aumentaron I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
durante I-Premise
la I-Premise
radioterapia I-Premise
, I-Premise
sin I-Premise
pérdida I-Premise
de I-Premise
fuerza I-Premise
o I-Premise
amplitud I-Premise
de I-Premise
movimiento I-Premise
. I-Premise

La B-Premise
incidencia I-Premise
de I-Premise
linfedema I-Premise
durante I-Premise
el I-Premise
estudio I-Premise
fue I-Premise
baja I-Premise
para I-Premise
ambos I-Premise
grupos I-Premise
y I-Premise
no I-Premise
difirió I-Premise
entre I-Premise
ellos. I-Premise

El B-Premise
programa I-Premise
de I-Premise
estiramiento I-Premise
de I-Premise
los I-Premise
pectorales I-Premise
no I-Premise
influyó I-Premise
en I-Premise
los I-Premise
resultados I-Premise
medidos, I-Premise
ya I-Premise
que I-Premise
los I-Premise
síntomas I-Premise
declarados I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
no I-Premise
eran I-Premise
consecuencia I-Premise
de I-Premise
la I-Premise
contractura I-Premise
. I-Premise

Los B-Claim
resultados I-Claim
postoperatorios I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
sometidos I-Claim
a I-Claim
colectomía I-Claim
asistida I-Claim
por I-Claim
laparoscopia I-Claim
( I-Claim
LAC I-Claim
) I-Claim
han I-Claim
mostrado I-Claim
modestas I-Claim
mejoras I-Claim
en I-Claim
la I-Claim
recuperación, I-Claim
pero I-Claim
sólo I-Claim
diferencias I-Claim
mínimas I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
colectomía I-Claim
abierta I-Claim
. I-Claim

Por O
lo O
tanto, O
se O
trató O
de O
evaluar O
el O
efecto O
de O
la O
LAC O
en O
la O
CdV O
a O
corto O
y O
largo O
plazo, O
utilizando O
el O
análisis O
de O
ítems O
individuales O
de O
las O
evaluaciones O
de O
la O
CdV O
de O
múltiples O
ítems. O

Se O
analizaron O
las O
variables O
de O
CdV O
en O
449 O
pacientes O
aleatorizados O
del O
ensayo O
COST O
93-46-53 O
( O
INT O
0146 O
) O
. O

Tanto O
las O
evaluaciones O
transversales O
en O
un O
solo O
momento O
como O
los O
cambios O
con O
respecto O
a O
la O
línea O
de O
base O
se O
llevaron O
a O
cabo O
en O
el O
día O
2, O
la O
semana O
2, O
el O
mes O
2 O
y O
el O
mes O
18 O
del O
postoperatorio O
en O
un O
análisis O
por O
intención O
de O
tratar O
utilizando O
las O
pruebas O
de O
suma O
de O
rangos O
de O
Wilcoxon. O

Se O
utilizaron O
modelos O
de O
regresión O
por O
pasos O
para O
determinar O
los O
predictores O
de O
la O
CdV O
. O

De O
449 O
pacientes O
con O
cáncer O
de O
colon, O
230 O
fueron O
sometidos O
a O
LAC O
y O
219 O
a O
colectomía O
abierta. O

El B-Premise
análisis I-Premise
de I-Premise
subdominios I-Premise
reveló I-Premise
una I-Premise
mejora I-Premise
clínicamente I-Premise
moderada I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
para I-Premise
LAC I-Premise
en I-Premise
el I-Premise
índice I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
total I-Premise
a I-Premise
los I-Premise
18 I-Premise
meses I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
), I-Premise
así I-Premise
como I-Premise
otras I-Premise
pequeñas I-Premise
mejoras I-Premise
sintomáticas I-Premise
. I-Premise

La O
mala O
calidad O
de O
vida O
preoperatoria, O
indicada O
por O
una O
escala O
de O
valoración O
de O
≤ O
50, O
fue O
un O
predictor O
independiente O
de O
mala O
calidad O
de O
vida O
a O
los O
2 O
meses O
del O
postoperatorio O
. O

Las O
variables O
de O
calidad O
de O
vida O
relacionadas O
con O
la O
supervivencia O
fueron O
el O
apoyo O
inicial O
( O
P O
= O
0,001 O
) O
y O
la O
perspectiva O
inicial O
( O
P O
= O
0,01 O
) O
. O

Dieciocho B-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
cirugía, I-Premise
cualquier I-Premise
diferencia I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
al I-Premise
azar I-Premise
a I-Premise
LAC I-Premise
o I-Premise
colectomía I-Premise
abierta I-Premise
favoreció I-Premise
a I-Premise
LAC I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
la I-Premise
magnitud I-Premise
de I-Premise
los I-Premise
beneficios I-Premise
fue I-Premise
pequeña. I-Premise

Los B-Claim
pacientes I-Claim
con I-Claim
una I-Claim
mala I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
preoperatoria I-Claim
parecen I-Claim
tener I-Claim
un I-Claim
mayor I-Claim
riesgo I-Claim
de I-Claim
sufrir I-Claim
un I-Claim
postoperatorio I-Claim
difícil I-Claim
y I-Claim
pueden I-Claim
ser I-Claim
candidatos I-Claim
a I-Claim
recibir I-Claim
servicios I-Claim
auxiliares I-Claim
mejorados I-Claim
para I-Claim
atender I-Claim
sus I-Claim
necesidades I-Claim
particulares. I-Claim

El O
objetivo O
de O
este O
estudio O
fue O
evaluar O
el O
impacto O
de O
la O
neuronavegación O
en O
el O
tratamiento O
citorreductor O
de O
los O
tumores O
intracerebrales O
solitarios O
con O
contraste O
y O
los O
resultados O
de O
este O
tratamiento O
en O
los O
casos O
en O
los O
que O
la O
neuronavegación O
se O
consideró O
redundante O
en O
el O
preoperatorio. O

Los O
autores O
llevaron O
a O
cabo O
un O
estudio O
prospectivo O
aleatorio O
en O
el O
que O
45 O
pacientes, O
cada O
uno O
de O
los O
cuales O
albergaba O
un O
tumor O
intracerebral O
solitario O
con O
realce O
de O
contraste, O
fueron O
asignados O
al O
azar O
para O
ser O
operados O
con O
o O
sin O
neuronavegación. O

Los O
parámetros O
peri O
y O
postoperatorios O
que O
se O
investigaron O
fueron O
los O
siguientes: O
la O
duración O
de O
la O
intervención, O
la O
estimación O
del O
cirujano O
sobre O
la O
utilidad O
de O
la O
neuronavegación, O
la O
cuantificación O
de O
la O
extensión O
de O
la O
resección, O
determinada O
mediante O
resonancia O
magnética, O
y O
la O
evolución O
postoperatoria, O
evaluada O
mediante O
exámenes O
neurológicos, O
la O
autoevaluación O
de O
la O
calidad O
de O
vida O
del O
paciente, O
la O
aplicación O
del O
índice O
de O
Barthel O
y O
la O
puntuación O
de O
la O
escala O
de O
rendimiento O
de O
Karnofsky, O
y O
el O
momento O
de O
la O
muerte O
del O
paciente. O

La B-Premise
cantidad I-Premise
media I-Premise
de I-Premise
tejido I-Premise
tumoral I-Premise
residual I-Premise
fue I-Premise
del I-Premise
28,9% I-Premise
para I-Premise
la I-Premise
cirugía I-Premise
estándar I-Premise
( I-Premise
SS I-Premise
) I-Premise
y I-Premise
del I-Premise
13,8% I-Premise
para I-Premise
la I-Premise
cirugía I-Premise
con I-Premise
neuronavegación I-Premise
( I-Premise
SN I-Premise
) I-Premise
. I-Premise

Las B-Premise
cantidades I-Premise
medias I-Premise
correspondientes I-Premise
de I-Premise
tejido I-Premise
tumoral I-Premise
residual I-Premise
con I-Premise
contraste I-Premise
fueron I-Premise
del I-Premise
29,2 I-Premise
y I-Premise
24,4 I-Premise
% I-Premise
, I-Premise
respectivamente. I-Premise

Estas B-Premise
diferencias I-Premise
no I-Premise
fueron I-Premise
significativas. I-Premise

La B-Premise
extirpación I-Premise
total I-Premise
bruta I-Premise
( I-Premise
GTR I-Premise
) I-Premise
se I-Premise
logró I-Premise
en I-Premise
cinco I-Premise
pacientes I-Premise
que I-Premise
se I-Premise
sometieron I-Premise
a I-Premise
SS I-Premise
y I-Premise
en I-Premise
tres I-Premise
que I-Premise
se I-Premise
sometieron I-Premise
a I-Premise
SN I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
significativamente I-Premise
más I-Premise
corta I-Premise
en I-Premise
el I-Premise
grupo I-Premise
SN I-Premise
( I-Premise
5,6 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
9 I-Premise
meses I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
no I-Premise
ajustado I-Premise
= I-Premise
1,6 I-Premise
) O
; O
sin B-Premise
embargo I-Premise
, I-Premise
esta I-Premise
diferencia I-Premise
puede I-Premise
ser I-Premise
atribuible I-Premise
a I-Premise
la I-Premise
muerte I-Premise
temprana I-Premise
coincidente I-Premise
de I-Premise
tres I-Premise
pacientes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
SN I-Premise
. O

No B-Premise
se I-Premise
identificó I-Premise
ningún I-Premise
efecto I-Premise
importante I-Premise
discernible I-Premise
en I-Premise
la I-Premise
evolución I-Premise
postoperatoria I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses. I-Premise

No B-Claim
existe I-Claim
ninguna I-Claim
justificación I-Claim
para I-Claim
el I-Claim
uso I-Claim
rutinario I-Claim
de I-Claim
la I-Claim
neuronavegación I-Claim
con I-Claim
el I-Claim
fin I-Claim
de I-Claim
mejorar I-Claim
la I-Claim
extensión I-Claim
de I-Claim
la I-Claim
resección I-Claim
del I-Claim
tumor I-Claim
y I-Claim
el I-Claim
pronóstico I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
albergan I-Claim
una I-Claim
lesión I-Claim
intracerebral I-Claim
solitaria I-Claim
potenciadora I-Claim
cuando I-Claim
la I-Claim
neuronavegación I-Claim
no I-Claim
se I-Claim
considera I-Claim
ya I-Claim
ventajosa I-Claim
por I-Claim
el I-Claim
tamaño I-Claim
o I-Claim
la I-Claim
localización I-Claim
de I-Claim
la I-Claim
lesión I-Claim
. I-Claim

Probar O
la O
capacidad O
del O
citoprotector O
, O
amifostina O
, O
para O
reducir O
la O
esofagitis O
inducida O
por O
la O
quimioterapia O
y O
evaluar O
su O
influencia O
en O
la O
calidad O
de O
vida O
( O
QOL O
) O
y O
los O
síntomas O
de O
la O
deglución O
. O

Un O
total O
de O
243 O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
en O
estadio O
II O
a O
IIIA/B O
recibieron O
paclitaxel O
de O
inducción O
225 O
mg/m O
( O
2 O
) O
por O
vía O
intravenosa O
( O
IV O
) O
los O
días O
1 O
y O
22 O
y O
área O
bajo O
la O
curva O
( O
AUC O
) O
de O
carboplatino O
los O
días O
1 O
y O
22 O
, O
seguidos O
de O
paclitaxel O
( O
50 O
mg/m O
( O
2 O
) O
IV O
) O
y O
carboplatino O
( O
AUC O
2 O
) O
concurrentes O
, O
y O
radioterapia O
hiperfraccionada O
( O
69,6 O
Gy O
a O
1,2 O
Gy O
bid O
) O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
en O
el O
momento O
del O
registro O
a O
amifostina O
( O
AM O
) O
500 O
mg O
IV O
cuatro O
veces O
por O
semana O
o O
a O
no O
AM O
durante O
la O
quimiorradioterapia O
. O

Además O
de O
los O
puntos O
finales O
de O
toxicidad O
estándar, O
también O
se O
recogieron O
los O
registros O
de O
disfagia O
del O
médico O
( O
PDL O
), O
los O
diarios O
de O
deglución O
del O
paciente O
y O
la O
calidad O
de O
vida O
( O
EORTC O
QLQ-C30/LC-13 O
). O

Los O
análisis O
del O
AUC O
de O
la O
deglución O
se O
calcularon O
a O
partir O
de O
los O
diarios O
de O
los O
pacientes O
y O
de O
los O
PDL. O

Un O
total O
de O
120 O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
AM O
, O
y O
122 O
, O
a O
no O
recibir O
AM O
( O
un O
paciente O
no O
fue O
elegible O
) O
; O
el O
72 O
% O
recibió O
AM O
según O
el O
protocolo O
o O
con O
una O
desviación O
menor O
. O

El B-Premise
AM I-Premise
se I-Premise
asoció I-Premise
con I-Premise
tasas I-Premise
más I-Premise
altas I-Premise
de I-Premise
náuseas I-Premise
agudas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
vómitos I-Premise
( I-Premise
P I-Premise
= I-Premise
0,007 I-Premise
) I-Premise
, I-Premise
toxicidad I-Premise
cardiovascular I-Premise
( I-Premise
P I-Premise
= I-Premise
0,0001 I-Premise
) I-Premise
, I-Premise
e I-Premise
infección I-Premise
o I-Premise
neutropenia I-Premise
febril I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
esofagitis I-Premise
> I-Premise
/= I-Premise
grado I-Premise
3 I-Premise
fue I-Premise
del I-Premise
30% I-Premise
con I-Premise
AM I-Premise
frente I-Premise
al I-Premise
34% I-Premise
sin I-Premise
AM I-Premise
( I-Premise
P I-Premise
= I-Premise
0,9 I-Premise
) I-Premise
. I-Premise

Los B-Premise
diarios I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
demostraron I-Premise
un I-Premise
menor I-Premise
AUC I-Premise
de I-Premise
la I-Premise
disfunción I-Premise
de I-Premise
la I-Premise
deglución I-Premise
con I-Premise
amifostina I-Premise
( I-Premise
prueba I-Premise
z I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
no I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos, I-Premise
excepto I-Premise
en I-Premise
el I-Premise
caso I-Premise
del I-Premise
dolor, I-Premise
que I-Premise
mostró I-Premise
una I-Premise
mejoría I-Premise
más I-Premise
significativa I-Premise
desde I-Premise
el I-Premise
punto I-Premise
de I-Premise
vista I-Premise
clínico I-Premise
y I-Premise
un I-Premise
menor I-Premise
deterioro I-Premise
a I-Premise
las I-Premise
6 I-Premise
semanas I-Premise
de I-Premise
seguimiento I-Premise
(en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
pretratamiento) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
AM I-Premise
(p I-Premise
= I-Premise
0,003). I-Premise

La B-Premise
mediana I-Premise
de I-Premise
las I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
ambos I-Premise
brazos I-Premise
fue I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17,3 I-Premise
frente I-Premise
a I-Premise
no I-Premise
AM I-Premise
, I-Premise
17,9 I-Premise
meses I-Premise
; I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

El B-Claim
AM I-Claim
no I-Claim
redujo I-Claim
significativamente I-Claim
la I-Claim
esofagitis I-Claim
> I-Claim
/= I-Claim
grado I-Claim
3 I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
radioterapia I-Claim
hiperfraccionada I-Claim
y I-Claim
quimioterapia I-Claim
. I-Claim

Sin B-Claim
embargo, I-Claim
las I-Claim
autoevaluaciones I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
sugirieron I-Claim
una I-Claim
posible I-Claim
ventaja I-Claim
de I-Claim
la I-Claim
AM I-Claim
que I-Claim
se I-Claim
está I-Claim
explorando I-Claim
con I-Claim
estrategias I-Claim
de I-Claim
vías I-Claim
de I-Claim
dosificación I-Claim
modificadas. I-Claim

El O
impacto O
de O
los O
efectos O
secundarios O
del O
acetato O
de O
megestrol O
en O
la O
calidad O
de O
vida O
de O
las O
mujeres O
no O
caquécticas O
con O
cáncer O
de O
mama O
avanzado O
se O
estudió O
en O
un O
ensayo O
clínico O
dosis-respuesta O
del O
Grupo O
B O
de O
Cáncer O
y O
Leucemia O
( O
CALGB O
8741 O
) O
. O

Se O
predijo O
que O
los O
efectos O
secundarios O
del O
aumento O
del O
apetito O
y O
el O
aumento O
de O
peso O
a O
dosis O
más O
altas O
tendrían O
un O
efecto O
negativo O
en O
la O
calidad O
de O
vida O
. O

Las O
pacientes O
con O
cáncer O
de O
mama O
en O
estadio O
IV O
fueron O
aleatorizadas O
para O
recibir O
160, O
800 O
o O
1.600 O
mg/día O
de O
acetato O
de O
megestrol. O

La O
calidad O
de O
vida O
se O
evaluó O
en O
131 O
pacientes O
al O
inicio O
del O
ensayo O
y O
a O
los O
1 O
y O
3 O
meses O
mientras O
estaban O
en O
tratamiento O
, O
mediante O
entrevista O
telefónica O
, O
utilizando O
las O
siguientes O
medidas O
: O
el O
Índice O
de O
Vida O
Funcional-Cáncer O
( O
FLIC O
) O
, O
la O
Escala O
de O
Limitaciones O
Funcionales O
de O
Rand O
, O
el O
Inventario O
de O
Salud O
Mental O
de O
Rand O
( O
MHI O
) O
, O
la O
Subescala O
de O
Imagen O
Corporal O
, O
y O
escalas O
analógicas O
lineales O
de O
efectos O
secundarios O
de O
los O
medicamentos O
. O

A B-Premise
los I-Premise
3 I-Premise
meses, I-Premise
las I-Premise
mujeres I-Premise
tratadas I-Premise
con I-Premise
160 I-Premise
mg/d I-Premise
informaron I-Premise
de I-Premise
menos I-Premise
efectos I-Premise
secundarios I-Premise
graves I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0005 I-Premise
) I-Premise
, I-Premise
mejor I-Premise
funcionamiento I-Premise
físico I-Premise
( I-Premise
FLS I-Premise
, I-Premise
P I-Premise
< I-Premise
0,0005 I-Premise
) I-Premise
, I-Premise
menos I-Premise
angustia I-Premise
psicológica I-Premise
( I-Premise
MHI I-Premise
, I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
) I-Premise
y I-Premise
una I-Premise
mejora I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
( I-Premise
FLIC I-Premise
, I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
) I-Premise
desde I-Premise
el I-Premise
momento I-Premise
de I-Premise
entrada I-Premise
en I-Premise
el I-Premise
estudio I-Premise
en I-Premise
comparación I-Premise
con I-Premise
las I-Premise
tratadas I-Premise
con I-Premise
1.600 I-Premise
mg/d I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
la I-Premise
dosis I-Premise
de I-Premise
800 I-Premise
mg/día I-Premise
se I-Premise
situaron I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
dosis I-Premise
baja I-Premise
y I-Premise
alta I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
intensidad I-Premise
de I-Premise
los I-Premise
efectos I-Premise
secundarios I-Premise
del I-Premise
fármaco, I-Premise
pero I-Premise
respondieron I-Premise
de I-Premise
forma I-Premise
similar I-Premise
a I-Premise
los I-Premise
del I-Premise
grupo I-Premise
de I-Premise
160 I-Premise
mg/día I-Premise
en I-Premise
términos I-Premise
de I-Premise
funcionamiento I-Premise
físico, I-Premise
malestar I-Premise
psicológico I-Premise
y I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general. I-Premise

A B-Claim
menos I-Claim
que I-Claim
los I-Claim
datos I-Claim
de I-Claim
seguimiento I-Claim
adicionales I-Claim
demuestren I-Claim
una I-Claim
ventaja I-Claim
de I-Claim
supervivencia I-Claim
con I-Claim
dosis I-Claim
más I-Claim
altas I-Claim
, I-Claim
la I-Claim
dosis I-Claim
de I-Claim
160 I-Claim
mg/día I-Claim
es I-Claim
la I-Claim
óptima I-Claim
, I-Claim
logrando I-Claim
el I-Claim
máximo I-Claim
efecto I-Claim
del I-Claim
tratamiento I-Claim
con I-Claim
el I-Claim
menor I-Claim
número I-Claim
de I-Claim
efectos I-Claim
secundarios I-Claim
y I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
. I-Claim

Tipo O
de O
estudio O
-- O
Terapia O
( O
RCT O
) O
Nivel O
de O
evidencia O
1b O
. O

¿Qué O
se O
sabe O
sobre O
el O
tema? O

y O
¿Qué O
añade O
el O
estudio? O

La O
terapia O
de O
privación O
de O
andrógenos O
( O
ADT O
) O
se O
utiliza O
habitualmente O
como O
tratamiento O
primario O
para O
los O
pacientes O
con O
cáncer O
de O
próstata O
( O
PCa O
) O
que O
no O
son O
elegibles O
para O
las O
opciones O
de O
tratamiento O
radical O
. O

La O
TAD O
también O
se O
utiliza O
en O
pacientes O
con O
CaP O
como O
terapia O
hormonal O
neoadyuvante O
para O
reducir O
el O
volumen O
de O
la O
próstata O
y O
reducir O
el O
estadio O
de O
la O
enfermedad O
antes O
de O
la O
radioterapia O
con O
intención O
curativa. O

El O
presente O
estudio O
demostró O
que O
la O
TAD O
con O
el O
antagonista O
de O
la O
hormona O
liberadora O
de O
gonadotropina O
( O
GhRH O
) O
degarelix O
no O
es O
inferior O
al O
tratamiento O
combinado O
con O
el O
agonista O
de O
la O
LHRH O
goserelina O
y O
bicalutamida O
en O
cuanto O
a O
la O
reducción O
del O
volumen O
de O
la O
próstata O
durante O
el O
período O
de O
tratamiento O
de O
3 O
meses O
. O

Sin O
embargo, O
el O
tratamiento O
con O
Degarelix O
produce O
un O
alivio O
significativamente O
mayor O
de O
los O
síntomas O
del O
tracto O
urinario O
inferior O
en O
los O
pacientes O
con O
problemas O
de O
vaciado O
moderados O
y O
graves. O

Evaluar O
la O
eficacia O
del O
tratamiento O
mensual O
con O
degarelix O
para O
la O
reducción O
del O
volumen O
total O
de O
la O
próstata O
( O
TPV O
) O
, O
el O
alivio O
de O
los O
síntomas O
del O
tracto O
urinario O
inferior O
( O
LUTS O
) O
y O
la O
mejora O
de O
la O
calidad O
de O
vida O
( O
QoL O
) O
en O
pacientes O
con O
cáncer O
de O
próstata O
( O
PCa O
) O
utilizando O
goserelina O
mensual O
como O
control O
activo O
. O

Se O
trata O
de O
un O
ensayo O
multicéntrico, O
aleatorizado, O
de O
brazos O
paralelos, O
con O
control O
activo O
y O
abierto, O
en O
el O
que O
se O
trató O
a O
182 O
pacientes O
con O
degarelix O
mensual O
( O
240/80 O
mg O
) O
o O
goserelina O
( O
3,6 O
mg O
) O
durante O
12 O
semanas. O

Para O
la O
protección O
contra O
el O
brote, O
los O
pacientes O
tratados O
con O
goserelina O
también O
recibieron O
bicalutamida O
diaria O
( O
50 O
mg O
) O
durante O
los O
28 O
días O
iniciales. O

Las O
variables O
clave O
del O
ensayo O
que O
se O
controlaron O
mensualmente O
fueron O
la O
VPT O
(criterio O
de O
valoración O
primario), O
la O
testosterona O
sérica, O
el O
antígeno O
prostático O
específico O
(PSA), O
la O
puntuación O
internacional O
de O
los O
síntomas O
prostáticos O
(IPSS) O
y O
el O
índice O
de O
impacto O
de O
la O
hiperplasia O
prostática O
benigna. O

En O
total, O
175 O
pacientes O
completaron O
el O
ensayo O
( O
96,1 O
% O
) O
. O

En B-Premise
la I-Premise
semana I-Premise
12, I-Premise
los I-Premise
cambios I-Premise
en I-Premise
el I-Premise
VPT I-Premise
de I-Premise
degarelix I-Premise
y I-Premise
goserelina I-Premise
fueron I-Premise
similares I-Premise
( I-Premise
-37,2 I-Premise
% I-Premise
frente I-Premise
a I-Premise
-39,0 I-Premise
% I-Premise
) I-Premise
y I-Premise
cumplieron I-Premise
el I-Premise
criterio I-Premise
de I-Premise
no I-Premise
inferioridad I-Premise
predefinido. I-Premise

Los B-Premise
descensos I-Premise
del I-Premise
IPSS I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
degarelix I-Premise
que I-Premise
con I-Premise
goserelina I-Premise
, I-Premise
siendo I-Premise
las I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
IPSS I-Premise
basal I-Premise
> I-Premise
13 I-Premise
( I-Premise
-6,7 I-Premise
± I-Premise
1,8 I-Premise
vs I-Premise
-4,0 I-Premise
± I-Premise
1,0 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

El B-Premise
número I-Premise
de I-Premise
pacientes I-Premise
con I-Premise
un I-Premise
cambio I-Premise
en I-Premise
la I-Premise
IPSS I-Premise
de I-Premise
≥ I-Premise
3 I-Premise
con I-Premise
respecto I-Premise
al I-Premise
valor I-Premise
inicial I-Premise
también I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
degarelix I-Premise
( I-Premise
61,0 I-Premise
frente I-Premise
a I-Premise
44,3 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

Ambos B-Claim
tratamientos I-Claim
fueron I-Claim
seguros I-Claim
y I-Claim
bien I-Claim
tolerados. I-Claim

La B-Claim
castración I-Claim
médica I-Claim
reduce I-Claim
el I-Claim
TPV I-Claim
y I-Claim
también I-Claim
podría I-Claim
mejorar I-Claim
los I-Claim
STUI I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CaP I-Claim
. I-Claim

Mientras O
que O
la B-Claim
eficacia I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
de I-Claim
degarelix I-Claim
y I-Claim
goserelina I-Claim
+ I-Claim
bicalutamida I-Claim
fue I-Claim
la I-Claim
misma I-Claim
en I-Claim
términos I-Claim
de I-Claim
reducción I-Claim
de I-Claim
la I-Claim
VPT I-Claim
, O
degarelix B-Claim
mostró I-Claim
superioridad I-Claim
en I-Claim
el I-Claim
alivio I-Claim
de I-Claim
los I-Claim
STUI I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
sintomáticos I-Claim
, I-Claim
lo I-Claim
que I-Claim
podría I-Claim
poner I-Claim
de I-Claim
manifiesto I-Claim
las I-Claim
diferentes I-Claim
acciones I-Claim
de I-Claim
estos I-Claim
fármacos I-Claim
sobre I-Claim
los I-Claim
receptores I-Claim
extrapituitarios I-Claim
de I-Claim
la I-Claim
hormona I-Claim
liberadora I-Claim
de I-Claim
gonadotrofina I-Claim
( I-Claim
GnRH I-Claim
) I-Claim
en I-Claim
la I-Claim
vejiga I-Claim
y/o I-Claim
la I-Claim
próstata I-Claim
. O

Evaluar O
si O
la O
omisión O
de O
la O
radioterapia O
postoperatoria O
en O
mujeres O
con O
cáncer O
de O
mama O
de O
"bajo O
riesgo" O
con O
ganglios O
axilares O
negativos O
( O
T0-2 O
) O
tratadas O
mediante O
cirugía O
conservadora O
de O
la O
mama O
y O
tratamiento O
endocrino O
mejora O
la O
calidad O
de O
vida O
y O
es O
más O
rentable O
. O

Se O
realizó O
un O
ensayo O
clínico O
controlado O
y O
aleatorio O
, O
utilizando O
un O
método O
de O
minimización O
equilibrado O
por O
centro O
, O
grado O
de O
cáncer O
, O
edad O
, O
invasión O
linfática/vascular O
y O
terapia O
endocrina O
preoperatoria O
. O

También O
se O
reclutó O
una O
cohorte O
no O
aleatoria, O
para O
completar O
un O
estudio O
de O
cohortes O
exhaustivo. O

El O
escenario O
fueron O
las O
clínicas O
de O
cáncer O
de O
mama O
de O
los O
centros O
oncológicos O
del O
Reino O
Unido. O

Las O
pacientes O
de O
65 O
años O
o O
más O
eran O
elegibles O
siempre O
que O
sus O
cánceres O
se O
consideraran O
de O
bajo O
riesgo O
de O
recidiva O
local O
, O
fueran O
adecuados O
para O
la O
cirugía O
de O
conservación O
de O
la O
mama O
, O
estuvieran O
recibiendo O
terapia O
endocrina O
y O
pudieran O
y O
quisieran O
dar O
su O
consentimiento O
informado O
. O

El O
tratamiento O
estándar O
de O
irradiación O
mamaria O
postoperatoria O
o O
la O
omisión O
de O
la O
radioterapia O
. O

La O
calidad O
de O
vida O
fue O
la O
principal O
medida O
de O
resultado, O
junto O
con O
la O
ansiedad O
y O
la O
depresión O
y O
la O
rentabilidad. O

Las O
medidas O
de O
resultado O
secundarias O
fueron O
las O
tasas O
de O
recidiva, O
el O
estado O
funcional, O
la O
morbilidad O
relacionada O
con O
el O
tratamiento O
y O
la O
cosmética. O

El O
principal O
método O
de O
recogida O
de O
datos O
fue O
un O
cuestionario, O
que O
se O
rellenó O
en O
casa O
con O
una O
enfermera O
de O
investigación O
en O
cuatro O
ocasiones O
a O
lo O
largo O
de O
15 O
meses. O

La B-Claim
hipotética I-Claim
mejora I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
general I-Claim
con I-Claim
la I-Claim
omisión I-Claim
de I-Claim
la I-Claim
radioterapia I-Claim
no I-Claim
se I-Claim
observó I-Claim
en I-Claim
la I-Claim
evaluación I-Claim
EuroQol I-Claim
ni I-Claim
en I-Claim
los I-Claim
dominios I-Claim
de I-Claim
resumen I-Claim
de I-Claim
funcionalidad I-Claim
y I-Claim
síntomas I-Claim
de I-Claim
las I-Claim
escalas I-Claim
de I-Claim
la I-Claim
Organización I-Claim
Europea I-Claim
para I-Claim
la I-Claim
Investigación I-Claim
en I-Claim
el I-Claim
Tratamiento I-Claim
del I-Claim
Cáncer I-Claim
( I-Claim
EORTC I-Claim
) I-Claim
. I-Claim

Se O
observaron O
algunas O
diferencias O
dentro O
de O
las O
subescalas O
de O
los O
cuestionarios O
de O
la O
EORTC, O
y O
los O
datos O
cualitativos O
obtenidos O
mediante O
preguntas O
abiertas O
también O
aportaron O
información O
sobre O
el O
impacto O
del O
tratamiento. O

Las B-Premise
diferencias I-Premise
fueron I-Premise
más I-Premise
evidentes I-Premise
poco I-Premise
después I-Premise
de I-Premise
la I-Premise
finalización I-Premise
de I-Premise
la I-Premise
radioterapia. I-Premise

La B-Claim
radioterapia I-Claim
se I-Claim
asoció I-Claim
entonces I-Claim
con I-Claim
un I-Claim
aumento I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
mamarios I-Claim
y I-Claim
con I-Claim
una I-Claim
mayor I-Claim
fatiga, I-Claim
pero I-Claim
con I-Claim
menos I-Claim
insomnio I-Claim
y I-Claim
efectos I-Claim
secundarios I-Claim
endocrinos I-Claim
. I-Claim

Los B-Premise
pacientes I-Premise
mostraron I-Premise
una I-Premise
gran I-Premise
preocupación I-Premise
por I-Premise
la I-Premise
prestación I-Premise
de I-Premise
servicios I-Premise
de I-Premise
radioterapia, I-Premise
como I-Premise
el I-Premise
transporte, I-Premise
el I-Premise
alojamiento I-Premise
y I-Premise
los I-Premise
costes I-Premise
de I-Premise
viaje I-Premise
asociados I-Premise
a I-Premise
la I-Premise
recepción I-Premise
de I-Premise
la I-Premise
radioterapia. I-Premise

Al B-Premise
final I-Premise
del I-Premise
seguimiento, I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
radioterapia I-Premise
expresaban I-Premise
menos I-Premise
ansiedad I-Premise
por I-Premise
la I-Premise
recidiva I-Premise
que I-Premise
los I-Premise
que I-Premise
no I-Premise
habían I-Premise
recibido I-Premise
radioterapia. I-Premise

La B-Premise
funcionalidad I-Premise
no I-Premise
se I-Premise
vio I-Premise
muy I-Premise
afectada I-Premise
por I-Premise
el I-Premise
tratamiento. I-Premise

En B-Premise
el I-Premise
ensayo I-Premise
controlado I-Premise
aleatorio, I-Premise
el I-Premise
índice I-Premise
de I-Premise
Barthel I-Premise
demostró I-Premise
una I-Premise
pequeña I-Premise
pero I-Premise
significativa I-Premise
disminución I-Premise
de I-Premise
la I-Premise
funcionalidad I-Premise
con I-Premise
la I-Premise
radioterapia I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
brazo I-Premise
sin I-Premise
radioterapia I-Premise
del I-Premise
ensayo. I-Premise

Sin B-Premise
embargo, I-Premise
los I-Premise
resultados I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
no I-Premise
aleatorizados I-Premise
no I-Premise
confirmaron I-Premise
este I-Premise
efecto. I-Premise

Los B-Premise
resultados I-Premise
cosméticos I-Premise
fueron I-Premise
mejores I-Premise
en I-Premise
los I-Premise
que I-Premise
no I-Premise
recibieron I-Premise
radioterapia, I-Premise
pero B-Premise
esto I-Premise
no I-Premise
pareció I-Premise
ser I-Premise
un I-Premise
problema I-Premise
importante I-Premise
para I-Premise
los I-Premise
pacientes. I-Premise

El B-Claim
uso I-Claim
de I-Claim
evaluaciones I-Claim
a I-Claim
domicilio I-Claim
por I-Claim
parte I-Claim
de I-Claim
una I-Claim
enfermera I-Claim
de I-Claim
investigación I-Claim
demostró I-Claim
ser I-Claim
una I-Claim
forma I-Claim
eficaz I-Claim
de I-Claim
obtener I-Claim
datos I-Claim
de I-Claim
alta I-Claim
calidad I-Claim
. I-Claim

Se O
calculó O
que O
los O
costes O
para O
el O
NHS O
asociados O
a O
la O
radioterapia O
postoperatoria O
eran O
del O
orden O
de O
2.000 O
libras O
por O
paciente. O

En B-Premise
el I-Premise
seguimiento I-Premise
de I-Premise
este I-Premise
estudio I-Premise
, I-Premise
no I-Premise
hubo I-Premise
recidivas I-Premise
, I-Premise
y I-Premise
las I-Premise
utilidades I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
del I-Premise
EuroQol I-Premise
fueron I-Premise
casi I-Premise
idénticas I-Premise
. I-Premise

Aunque B-Premise
no I-Premise
hay I-Premise
diferencias I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
globales I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
y I-Premise
sin I-Premise
radioterapia I-Premise
, I-Premise
hay I-Premise
varias I-Premise
dimensiones I-Premise
que I-Premise
muestran I-Premise
una I-Premise
ventaja I-Premise
significativa I-Premise
a I-Premise
la I-Premise
omisión I-Premise
de I-Premise
la I-Premise
irradiación I-Premise
. I-Premise

Durante B-Premise
los I-Premise
primeros I-Premise
15 I-Premise
meses, I-Premise
la I-Premise
radioterapia I-Premise
para I-Premise
esta I-Premise
población I-Premise
no I-Premise
es I-Premise
un I-Premise
tratamiento I-Premise
rentable. I-Premise

Sin O
embargo, O
los O
resultados B-Claim
postoperatorios I-Claim
tempranos I-Claim
no I-Claim
ofrecen I-Claim
una I-Claim
respuesta I-Claim
completa I-Claim
y O
la B-Claim
rentabilidad I-Claim
final I-Claim
sólo I-Claim
quedará I-Claim
clara I-Claim
tras I-Claim
un I-Claim
seguimiento I-Claim
a I-Claim
largo I-Claim
plazo. I-Claim

Las B-Claim
extrapolaciones I-Claim
de I-Claim
estos I-Claim
datos I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
radioterapia I-Claim
puede I-Claim
no I-Claim
ser I-Claim
un I-Claim
tratamiento I-Claim
rentable I-Claim
a I-Claim
menos I-Claim
que I-Claim
dé I-Claim
lugar I-Claim
a I-Claim
una I-Claim
tasa I-Claim
de I-Claim
recurrencia I-Claim
que I-Claim
sea I-Claim
al I-Claim
menos I-Claim
un I-Claim
5 I-Claim
% I-Claim
inferior I-Claim
en I-Claim
términos I-Claim
absolutos I-Claim
a I-Claim
la I-Claim
de I-Claim
los I-Claim
tratados I-Claim
sin I-Claim
radioterapia I-Claim
. I-Claim

Es B-Claim
necesario I-Claim
seguir I-Claim
investigando I-Claim
en I-Claim
una I-Claim
serie I-Claim
de I-Claim
ámbitos, I-Claim
como I-Claim
los I-Claim
aspectos I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida, I-Claim
los I-Claim
resultados I-Claim
clínicos, I-Claim
los I-Claim
costes I-Claim
y I-Claim
las I-Claim
consecuencias I-Claim
de I-Claim
omitir I-Claim
la I-Claim
radioterapia. I-Claim

Se O
realizó O
un O
ensayo O
controlado O
aleatorio O
para O
evaluar O
el O
resultado O
de O
la O
alimentación O
oral O
postoperatoria O
temprana O
( O
EOF O
) O
en O
comparación O
con O
la O
alimentación O
oral O
tradicional O
( O
TOF O
) O
en O
pacientes O
de O
oncología O
ginecológica O
sometidas O
a O
una O
laparotomía O
compleja O
, O
incluida O
la O
cirugía O
abdominal O
superior O
. O

Las O
pacientes O
de O
entre O
18 O
y O
75 O
años, O
sometidas O
a O
una O
laparotomía O
electiva O
y O
con O
una O
sospecha O
preoperatoria O
de O
neoplasia O
ginecológica, O
fueron O
elegibles. O

Los O
criterios O
de O
exclusión O
incluían O
afecciones O
infecciosas, O
obstrucción O
intestinal, O
desnutrición O
grave, O
puntuación O
C4 O
de O
la O
Sociedad O
Americana O
de O
Anestesiólogos, O
resección O
intestinal O
y O
estancia O
postoperatoria O
en O
la O
unidad O
de O
cuidados O
intensivos O
de O
24 O
horas. O

Los O
pacientes O
recibieron O
el O
esquema O
de O
alimentación O
tradicional O
hasta O
la O
resolución O
del O
íleo O
postoperatorio O
para O
iniciar O
la O
dieta O
líquida O
. O

El O
criterio O
de O
valoración O
principal O
del O
ensayo O
fue O
la O
duración O
de O
la O
estancia O
hospitalaria. O

Entre O
el O
1 O
de O
enero O
de O
2007 O
y O
el O
17 O
de O
noviembre O
de O
2007, O
un O
total O
de O
143 O
pacientes O
fueron O
asignados O
aleatoriamente O
para O
recibir O
EOF O
o O
TOF. O

La B-Premise
estancia I-Premise
hospitalaria I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
EOF I-Premise
( I-Premise
n=71 I-Premise
) I-Premise
fue I-Premise
de I-Premise
4,7 I-Premise
frente I-Premise
a I-Premise
5,8 I-Premise
días I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
TOF I-Premise
( I-Premise
n=72 I-Premise
) I-Premise
( I-Premise
P=0,006 I-Premise
) I-Premise
. I-Premise

El B-Premise
nivel I-Premise
medio I-Premise
de I-Premise
satisfacción I-Premise
postoperatoria I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
EOF I-Premise
( I-Premise
82,8 I-Premise
frente I-Premise
a I-Premise
71,7 I-Premise
mm I-Premise
, I-Premise
P I-Premise
B I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
el I-Premise
esquema I-Premise
TOF I-Premise
tuvieron I-Premise
complicaciones I-Premise
postoperatorias I-Premise
generales I-Premise
significativamente I-Premise
mayores I-Premise
( I-Premise
39 I-Premise
frente I-Premise
al I-Premise
17 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
EOF I-Premise
, I-Premise
P=0,003 I-Premise
) I-Premise
y I-Premise
complicaciones I-Premise
infecciosas I-Premise
( I-Premise
14 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
TOF I-Premise
frente I-Premise
al I-Premise
3 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
EOF I-Premise
, I-Premise
P=0,017 I-Premise
) I-Premise
. I-Premise

Variables B-Premise
como I-Premise
las I-Premise
náuseas I-Premise
y I-Premise
los I-Premise
vómitos, I-Premise
la I-Premise
necesidad I-Premise
de I-Premise
analgésicos I-Premise
y I-Premise
antieméticos, I-Premise
así I-Premise
como I-Premise
el I-Premise
nivel I-Premise
de I-Premise
dolor I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
no I-Premise
fueron I-Premise
diferentes I-Premise
entre I-Premise
los I-Premise
grupos. I-Premise

Sobre B-Claim
la I-Claim
base I-Claim
de I-Claim
estos I-Claim
resultados, I-Claim
la I-Claim
política I-Claim
de I-Claim
EOF I-Claim
debe I-Claim
utilizarse I-Claim
después I-Claim
de I-Claim
una I-Claim
laparotomía I-Claim
ginecológica I-Claim
compleja. I-Claim

El B-Claim
insomnio I-Claim
es I-Claim
una I-Claim
queja I-Claim
común I-Claim
entre I-Claim
los I-Claim
supervivientes I-Claim
de I-Claim
cáncer. I-Claim

Afortunadamente O
, O
la O
terapia O
cognitivo-conductual O
para O
el O
insomnio O
( O
TCC-I O
) O
ha O
demostrado O
ser O
un O
tratamiento O
eficaz O
en O
esta O
población O
. O

Sin O
embargo, O
rara O
vez O
se O
aplica, O
dada O
su O
limitada O
disponibilidad. O

Para O
abordar O
esta O
barrera O
, O
se O
examinó O
la O
capacidad O
de O
un O
programa O
de O
TCC-I O
de O
fácil O
acceso O
en O
línea O
para O
mejorar O
los O
síntomas O
de O
insomnio O
en O
los O
sobrevivientes O
de O
cáncer O
. O

Veintiocho O
supervivientes O
de O
cáncer O
con O
insomnio O
fueron O
asignados O
aleatoriamente O
a O
una O
intervención O
de O
insomnio O
por O
Internet O
( O
n O
= O
14 O
) O
o O
a O
un O
grupo O
de O
control O
de O
lista O
de O
espera O
( O
n O
= O
14 O
) O
. O

El O
programa O
online O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
ofrece O
los O
componentes O
principales O
de O
la O
TCC-I O
( O
restricción O
del O
sueño O
, O
control O
de O
estímulos O
, O
reestructuración O
cognitiva O
, O
higiene O
del O
sueño O
y O
prevención O
de O
recaídas O
) O
. O

Los O
datos O
anteriores O
y O
posteriores O
a O
la O
evaluación O
se O
recogieron O
mediante O
cuestionarios O
en O
línea O
y O
diarios O
de O
sueño. O

Los B-Premise
participantes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
Internet I-Premise
mostraron I-Premise
mejoras I-Premise
significativas I-Premise
en I-Premise
la I-Premise
evaluación I-Premise
posterior I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
gravedad I-Premise
general I-Premise
del I-Premise
insomnio I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
22,8 I-Premise
; I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
la I-Premise
eficiencia I-Premise
del I-Premise
sueño I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11,45 I-Premise
; I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
la I-Premise
latencia I-Premise
de I-Premise
inicio I-Premise
del I-Premise
sueño I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
5,18 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
la I-Premise
solidez I-Premise
del I-Premise
sueño I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
9,34 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,005 I-Premise
) I-Premise
, I-Premise
la I-Premise
sensación I-Premise
de I-Premise
restablecimiento I-Premise
al I-Premise
despertar I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11,95 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
general I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
13,88 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Aunque B-Premise
otras I-Premise
interacciones I-Premise
grupo I-Premise
× I-Premise
tiempo I-Premise
no I-Premise
fueron I-Premise
significativas, I-Premise
los I-Premise
tamaños I-Premise
del I-Premise
efecto I-Premise
general I-Premise
ajustado I-Premise
para I-Premise
todas I-Premise
las I-Premise
variables I-Premise
del I-Premise
sueño, I-Premise
así I-Premise
como I-Premise
para I-Premise
la I-Premise
fatiga, I-Premise
la I-Premise
depresión, I-Premise
la I-Premise
ansiedad I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
oscilaron I-Premise
entre I-Premise
pequeños I-Premise
y I-Premise
grandes. I-Premise

La B-Claim
TCC-I I-Claim
administrada I-Claim
a I-Claim
través I-Claim
de I-Claim
una I-Claim
intervención I-Claim
interactiva I-Claim
e I-Claim
individualizada I-Claim
por I-Claim
Internet I-Claim
puede I-Claim
ser I-Claim
una I-Claim
opción I-Claim
de I-Claim
tratamiento I-Claim
viable I-Claim
para I-Claim
los I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
que I-Claim
sufren I-Claim
insomnio. I-Claim

Comparar O
la O
eficacia O
y O
la O
tolerabilidad O
de O
gemcitabina O
más O
cisplatino O
con O
gemcitabina O
como O
agente O
único O
de O
quimioterapia O
de O
primera O
línea O
para O
el O
cáncer O
de O
páncreas O
localmente O
avanzado O
o O
metastásico. O

Los O
pacientes O
con O
adenocarcinoma O
de O
páncreas O
avanzado O
fueron O
asignados O
aleatoriamente O
a O
recibir O
gemcitabina O
1.000 O
mg/m2 O
y O
cisplatino O
50 O
mg/m2 O
administrados O
los O
días O
1 O
y O
15 O
de O
un O
ciclo O
de O
4 O
semanas O
( O
brazo O
GemCis O
) O
o O
gemcitabina O
sola O
a O
una O
dosis O
de O
1.000 O
mg/m2 O
los O
días O
1 O
, O
8 O
y O
15 O
de O
un O
régimen O
de O
4 O
semanas O
( O
brazo O
Gem O
) O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia O
global; O
los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
supervivencia O
sin O
progresión, O
la O
tasa O
de O
respuesta, O
la O
seguridad O
y O
la O
calidad O
de O
vida. O

Se O
inscribieron O
ciento O
noventa O
y O
cinco O
pacientes O
y O
las O
características O
basales O
estaban O
bien O
equilibradas O
entre O
los O
brazos O
de O
tratamiento. O

El B-Premise
tratamiento I-Premise
combinado I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
GemCis I-Premise
se I-Premise
asoció I-Premise
con I-Premise
una I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
prolongada I-Premise
( I-Premise
5,3 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
3,1 I-Premise
meses I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0,75 I-Premise
; I-Premise
P I-Premise
= I-Premise
.053 I-Premise
) I-Premise
. I-Premise

Además, B-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
superior I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
en I-Premise
el I-Premise
brazo I-Premise
GemCis I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
brazo I-Premise
Gem I-Premise
( I-Premise
7,5 I-Premise
frente I-Premise
a I-Premise
6,0 I-Premise
meses I-Premise
), O
una B-Premise
ventaja I-Premise
que, I-Premise
sin I-Premise
embargo, I-Premise
no I-Premise
alcanzó I-Premise
significación I-Premise
estadística I-Premise
( I-Premise
HR I-Premise
= I-Premise
0,80 I-Premise
; I-Premise
P I-Premise
= I-Premise
.15 I-Premise
) O
. O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
tumoral I-Premise
fueron I-Premise
comparables I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
10,2 I-Premise
% I-Premise
frente I-Premise
a I-Premise
8,2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
enfermedad I-Premise
estable I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
la I-Premise
combinación I-Premise
( I-Premise
60,2% I-Premise
frente I-Premise
a I-Premise
40,2%; I-Premise
P I-Premise
<0,001 I-Premise
) O
. O

La B-Premise
toxicidad I-Premise
hematológica I-Premise
de I-Premise
grado I-Premise
3 I-Premise
a I-Premise
4 I-Premise
no I-Premise
superó I-Premise
el I-Premise
15 I-Premise
% I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
de I-Premise
tratamiento. I-Premise

Estos B-Claim
resultados I-Claim
apoyan I-Claim
la I-Claim
eficacia I-Claim
y I-Claim
seguridad I-Claim
de I-Claim
un I-Claim
tratamiento I-Claim
cada I-Claim
2 I-Claim
semanas I-Claim
con I-Claim
gemcitabina I-Claim
más I-Claim
cisplatino I-Claim
. I-Claim

La B-Claim
mediana I-Claim
de I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
y I-Claim
la I-Claim
supervivencia I-Claim
sin I-Claim
progresión I-Claim
fueron I-Claim
más I-Claim
favorables I-Claim
en I-Claim
el I-Claim
brazo I-Claim
de I-Claim
la I-Claim
combinación I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
gemcitabina I-Claim
sola, I-Claim
aunque B-Premise
la I-Premise
diferencia I-Premise
no I-Premise
alcanzó I-Premise
significación I-Premise
estadística. I-Premise

El O
adenosín O
5'-trifosfato O
extracelular O
( O
ATP O
) O
está O
implicado O
en O
la O
regulación O
de O
una O
variedad O
de O
procesos O
biológicos O
, O
incluyendo O
la O
neurotransmisión O
, O
la O
contracción O
muscular O
, O
y O
el O
metabolismo O
de O
la O
glucosa O
en O
el O
hígado O
, O
a O
través O
de O
los O
receptores O
purinérgicos O
. O

En B-Claim
estudios I-Claim
no I-Claim
aleatorios I-Claim
con I-Claim
pacientes I-Claim
de I-Claim
diferentes I-Claim
tipos I-Claim
de I-Claim
tumores, I-Claim
incluido I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
no I-Claim
microcítico I-Claim
( I-Claim
CPNM I-Claim
), I-Claim
la I-Claim
infusión I-Claim
de I-Claim
ATP I-Claim
pareció I-Claim
inhibir I-Claim
la I-Claim
pérdida I-Claim
de I-Claim
peso I-Claim
y I-Claim
el I-Claim
deterioro I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
y I-Claim
el I-Claim
estado I-Claim
de I-Claim
rendimiento I-Claim
. I-Claim

Realizamos O
un O
ensayo O
clínico O
aleatorio O
para O
evaluar O
los O
efectos O
del O
ATP O
en O
pacientes O
con O
CPNM O
avanzado O
( O
estadio O
IIIB O
o O
IV O
) O
. O

Se O
asignó O
aleatoriamente O
a O
58 O
pacientes O
para O
que O
recibieran O
10 O
infusiones O
intravenosas O
de O
30 O
horas O
de O
ATP O
, O
con O
las O
infusiones O
administradas O
a O
intervalos O
de O
2 O
a O
4 O
semanas, O
o O
sin O
ATP O
. O

Los O
parámetros O
de O
resultado O
se O
evaluaron O
cada O
4 O
semanas O
hasta O
las O
28 O
semanas. O

La O
significación O
estadística O
de O
las O
diferencias O
entre O
grupos O
se O
comprobó O
mediante O
un O
análisis O
de O
medidas O
repetidas, O
y O
los O
valores O
P O
indicados O
son O
de O
dos O
caras. O

Veintiocho O
pacientes O
fueron O
asignados O
a O
recibir O
tratamiento O
con O
ATP O
y O
30 O
no O
recibieron O
ATP O
. O

Los B-Premise
cambios I-Premise
medios I-Premise
de I-Premise
peso I-Premise
por I-Premise
período I-Premise
de I-Premise
4 I-Premise
semanas I-Premise
fueron I-Premise
de I-Premise
-1,0 I-Premise
kg I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-1,5 I-Premise
a I-Premise
-0,5 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
y I-Premise
de I-Premise
0,2 I-Premise
kg I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
-0,2 I-Premise
a I-Premise
+0,6 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
ATP I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

La B-Premise
concentración I-Premise
de I-Premise
albúmina I-Premise
sérica I-Premise
disminuyó I-Premise
en I-Premise
-1,2 I-Premise
g/L I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-2,0 I-Premise
a I-Premise
-0,4 I-Premise
) I-Premise
por I-Premise
4 I-Premise
semanas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
pero I-Premise
se I-Premise
mantuvo I-Premise
estable I-Premise
( I-Premise
0,0 I-Premise
g/L I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-0,3 I-Premise
a I-Premise
+0,3 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
ATP I-Premise
( I-Premise
P I-Premise
= I-Premise
0,006 I-Premise
) I-Premise
. I-Premise

La B-Premise
fuerza I-Premise
de I-Premise
los I-Premise
músculos I-Premise
flexores I-Premise
del I-Premise
codo I-Premise
disminuyó I-Premise
en I-Premise
un I-Premise
-5,5 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-9,6 I-Premise
% I-Premise
a I-Premise
-1 I-Premise
.4 I-Premise
% I-Premise
) I-Premise
por I-Premise
4 I-Premise
semanas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
pero I-Premise
se I-Premise
mantuvo I-Premise
estable I-Premise
( I-Premise
0,0 I-Premise
% I-Premise
; I-Premise
IC I-Premise
95 I-Premise
%= I-Premise
-1,4 I-Premise
% I-Premise
a I-Premise
+1,4 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
ATP I-Premise
( I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

Se B-Premise
observó I-Premise
un I-Premise
patrón I-Premise
similar I-Premise
para I-Premise
los I-Premise
músculos I-Premise
extensores I-Premise
de I-Premise
la I-Premise
rodilla I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

Los B-Premise
efectos I-Premise
del I-Premise
ATP I-Premise
sobre I-Premise
el I-Premise
peso I-Premise
corporal, I-Premise
la I-Premise
fuerza I-Premise
muscular I-Premise
y I-Premise
la I-Premise
concentración I-Premise
de I-Premise
albúmina I-Premise
fueron I-Premise
especialmente I-Premise
marcados I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
caquécticos I-Premise
( I-Premise
P I-Premise
= I-Premise
0,0002 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,0001 I-Premise
y I-Premise
P I-Premise
= I-Premise
0,0001 I-Premise
, I-Premise
respectivamente, I-Premise
para I-Premise
el I-Premise
ATP I-Premise
frente I-Premise
al I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

Los B-Premise
cambios I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
CdV I-Premise
por I-Premise
período I-Premise
de I-Premise
4 I-Premise
semanas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
ATP I-Premise
mostraron I-Premise
en I-Premise
general I-Premise
un I-Premise
menor I-Premise
deterioro I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control: I-Premise
puntuaciones I-Premise
físicas I-Premise
( I-Premise
-0,2 I-Premise
% I-Premise
frente I-Premise
a I-Premise
-2,4 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,0002 I-Premise
) I-Premise
; I-Premise
puntuaciones I-Premise
funcionales I-Premise
( I-Premise
+0,4 I-Premise
% I-Premise
frente I-Premise
a I-Premise
-5,5 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
; I-Premise
puntuaciones I-Premise
psicológicas I-Premise
( I-Premise
-0,7 I-Premise
% I-Premise
frente I-Premise
a I-Premise
-2,4 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,11 I-Premise
) I-Premise
; I-Premise
puntuación I-Premise
general I-Premise
de I-Premise
CdV I-Premise
( I-Premise
+0,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
-3,5 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

Este O
ensayo O
aleatorio O
demuestra O
que O
el B-Claim
ATP I-Claim
tiene I-Claim
efectos I-Claim
beneficiosos I-Claim
sobre I-Claim
el I-Claim
peso, I-Claim
la I-Claim
fuerza I-Claim
muscular I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
avanzado. I-Claim

El B-Claim
acetato I-Claim
de I-Claim
abiraterona I-Claim
más I-Claim
prednisona I-Claim
mejora I-Claim
significativamente I-Claim
la I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
radiográfica I-Claim
en I-Claim
pacientes I-Claim
asintomáticos I-Claim
o I-Claim
ligeramente I-Claim
sintomáticos, I-Claim
sin I-Claim
quimioterapia, I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
metastásico I-Claim
resistente I-Claim
a I-Claim
la I-Claim
castración, I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
prednisona I-Claim
sola. I-Claim

Se O
describen O
los O
análisis O
de O
los O
datos O
sobre O
el O
dolor O
y O
el O
estado O
funcional O
notificados O
por O
los O
pacientes O
en O
un O
análisis O
intermedio O
preplanificado O
de O
un O
ensayo O
de O
fase O
3 O
. O

Entre O
el O
28 O
de O
abril O
de O
2009 O
y O
el O
23 O
de O
junio O
de O
2010, O
se O
inscribieron O
pacientes O
con O
cáncer O
de O
próstata O
progresivo O
y O
resistente O
a O
la O
castración O
en O
un O
ensayo O
multinacional, O
doble O
ciego O
y O
controlado O
con O
placebo. O

Los O
pacientes O
eran O
elegibles O
si O
estaban O
asintomáticos O
( O
puntuación O
de O
0 O
o O
1 O
en O
el O
punto O
tres O
del O
cuestionario O
Brief O
Pain O
Inventory O
Short O
Form O
[ O
BPI-SF O
] O
) O
o O
ligeramente O
sintomáticos O
( O
puntuación O
de O
2 O
o O
3 O
) O
y O
no O
habían O
recibido O
quimioterapia O
previamente O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
( O
1:1 O
) O
a O
recibir O
abiraterona O
oral O
( O
1 O
g O
diario O
) O
más O
prednisona O
( O
5 O
mg O
dos O
veces O
al O
día O
) O
o O
placebo O
más O
prednisona O
en O
ciclos O
continuos O
de O
4 O
semanas O
. O

El O
dolor O
se O
evaluó O
con O
el O
cuestionario O
BPI-SF O
, O
y O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQoL O
) O
con O
el O
cuestionario O
Functional O
Assessment O
of O
Cancer O
Therapy-Prostate O
( O
FACT-P O
) O
. O

Se O
analizaron O
los O
datos O
con O
criterios O
preespecificados O
de O
progresión O
del O
dolor O
y O
deterioro O
de O
la O
CVRS O
clínicamente O
significativos. O

Todos O
los O
pacientes O
que O
se O
sometieron O
a O
la O
aleatorización O
se O
incluyeron O
en O
los O
análisis O
. O

Se O
aleatorizaron O
1088 O
pacientes: O
546 O
fueron O
asignados O
a O
abiraterona O
más O
prednisona O
y O
542 O
a O
placebo O
más O
prednisona O
. O

En O
el O
momento O
del O
segundo O
análisis O
intermedio O
preespecificado, O
la O
mediana O
de O
seguimiento O
era O
de O
22-2 O
meses O
( O
IQR O
20-2-24-8 O
) O
. O

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
de I-Premise
la I-Premise
intensidad I-Premise
media I-Premise
del I-Premise
dolor I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
a I-Premise
abiraterona I-Premise
más I-Premise
prednisona I-Premise
( I-Premise
26-7 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
19-3-no I-Premise
estimable I-Premise
] I-Premise
) I-Premise
que I-Premise
en I-Premise
los I-Premise
asignados I-Premise
a I-Premise
placebo I-Premise
más I-Premise
prednisona I-Premise
( I-Premise
18-4 I-Premise
meses I-Premise
[ I-Premise
14-9-no I-Premise
estimable I-Premise
] I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0-82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-67-1-00 I-Premise
; I-Premise
p=0-0490 I-Premise
) I-Premise
, I-Premise
al I-Premise
igual I-Premise
que I-Premise
la I-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
de I-Premise
la I-Premise
interferencia I-Premise
del I-Premise
dolor I-Premise
con I-Premise
las I-Premise
actividades I-Premise
diarias I-Premise
( I-Premise
10-3 I-Premise
meses I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
9-3-13-0 I-Premise
] I-Premise
vs I-Premise
7-4 I-Premise
meses I-Premise
[ I-Premise
6-4-8-6 I-Premise
] I-Premise
; I-Premise
HR I-Premise
0-79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-67-0-93 I-Premise
; I-Premise
p=0-005 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
del I-Premise
peor I-Premise
dolor I-Premise
también I-Premise
fue I-Premise
más I-Premise
larga I-Premise
con I-Premise
abiraterona I-Premise
más I-Premise
prednisona I-Premise
( I-Premise
26-7 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
19-4-no I-Premise
estimable I-Premise
] I-Premise
) I-Premise
que I-Premise
con I-Premise
placebo I-Premise
más I-Premise
prednisona I-Premise
( I-Premise
19-4 I-Premise
meses I-Premise
[ I-Premise
16-6-no I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
pero I-Premise
la I-Premise
diferencia I-Premise
no I-Premise
fue I-Premise
significativa I-Premise
( I-Premise
HR I-Premise
0-85 I-Premise
, I-Premise
IC I-Premise
95 I-Premise
% I-Premise
0-69-1-04 I-Premise
; I-Premise
p=0-109 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
deterioro I-Premise
de I-Premise
la I-Premise
CVRS I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
a I-Premise
abiraterona I-Premise
más I-Premise
prednisona I-Premise
que I-Premise
en I-Premise
los I-Premise
asignados I-Premise
a I-Premise
placebo I-Premise
más I-Premise
prednisona, I-Premise
según I-Premise
la I-Premise
puntuación I-Premise
total I-Premise
de I-Premise
la I-Premise
FACT-P I-Premise
( I-Premise
12-7 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
11-1-14-0 I-Premise
] I-Premise
frente I-Premise
a I-Premise
8-3 I-Premise
meses I-Premise
[ I-Premise
7-4-10-6 I-Premise
] I-Premise
; I-Premise
HR I-Premise
0-78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-66-0-92 I-Premise
; I-Premise
p=0-003 I-Premise
) I-Premise
y I-Premise
por I-Premise
la I-Premise
puntuación I-Premise
en I-Premise
su I-Premise
subescala I-Premise
específica I-Premise
de I-Premise
cáncer I-Premise
de I-Premise
próstata I-Premise
( I-Premise
11-1 I-Premise
meses I-Premise
[ I-Premise
8-6-13-8 I-Premise
] I-Premise
vs I-Premise
5-8 I-Premise
meses I-Premise
[ I-Premise
5-5-8-3 I-Premise
] I-Premise
; I-Premise
HR I-Premise
0-70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-60-0-83 I-Premise
; I-Premise
p I-Premise
< I-Premise
0-0001 I-Premise
) I-Premise
. I-Premise

La B-Claim
abiraterona I-Claim
más I-Claim
la I-Claim
prednisona I-Claim
retrasa I-Claim
la I-Claim
progresión I-Claim
del I-Claim
dolor I-Claim
y I-Claim
el I-Claim
deterioro I-Claim
de I-Claim
la I-Claim
CVRS I-Claim
en I-Claim
pacientes I-Claim
sin I-Claim
quimioterapia I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
metastásico I-Claim
resistente I-Claim
a I-Claim
la I-Claim
castración. I-Claim

Estos B-Claim
resultados I-Claim
proporcionan I-Claim
un I-Claim
apoyo I-Claim
adicional I-Claim
a I-Claim
la I-Claim
eficacia I-Claim
de I-Claim
la I-Claim
abiraterona I-Claim
en I-Claim
esta I-Claim
población. I-Claim

El B-Claim
tratamiento I-Claim
adyuvante I-Claim
postoperatorio I-Claim
con I-Claim
quimiorradiación I-Claim
tras I-Claim
la I-Claim
resección I-Claim
curativa I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
recto I-Claim
era I-Claim
necesario I-Claim
para I-Claim
reducir I-Claim
la I-Claim
recidiva I-Claim
y I-Claim
mejorar I-Claim
la I-Claim
tasa I-Claim
de I-Claim
supervivencia. I-Claim

El B-Claim
5-fluorouracilo I-Claim
( I-Claim
5-FU I-Claim
) I-Claim
intravenoso I-Claim
y I-Claim
la I-Claim
leucovorina I-Claim
han I-Claim
sido I-Claim
un I-Claim
pilar I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
, O
pero O
los O
derivados B-Claim
orales I-Claim
del I-Claim
5-FU I-Claim
han I-Claim
demostrado I-Claim
una I-Claim
actividad I-Claim
antitumoral I-Claim
comparable I-Claim
. O

Se O
compararon O
el O
5-FU O
intravenoso O
y O
la O
doxifluridina O
oral O
con O
respecto O
a O
la O
eficacia O
terapéutica, O
la O
toxicidad O
del O
fármaco O
y O
la O
calidad O
de O
vida. O

Un O
total O
de O
166 O
pacientes O
fueron O
aleatorizados O
para O
recibir O
5-FU O
intravenoso O
( O
450 O
mg/m2/día O
) O
o O
doxifluridina O
oral O
( O
900 O
mg/m2/día O
) O
en O
combinación O
con O
leucovorina O
( O
20 O
mg/m2/día O
) O
para O
pacientes O
en O
profundidad O
de O
invasión O
, O
estado O
ganglionar O
, O
metástasis O
( O
TNM O
) O
en O
estadio O
II O
y O
III O
entre O
octubre O
de O
1997 O
y O
febrero O
de O
1999 O
. O

Infusión O
intravenosa O
diaria O
consecutiva O
durante O
5 O
días O
por O
cada O
mes O
para O
un O
total O
de O
12 O
ciclos O
( O
brazo O
IV O
, O
n O
= O
74 O
) O
y O
doxifluridina O
oral O
diaria O
durante O
3 O
semanas O
y O
1 O
semana O
de O
descanso O
para O
un O
total O
de O
12 O
ciclos O
( O
brazo O
oral O
, O
n O
= O
92 O
) O
. O

Se O
observó O
la O
toxicidad O
de O
los O
fármacos O
y O
la O
calidad O
de O
vida. O

La O
calidad O
de O
vida O
se O
puntuó O
según O
22 O
ítems O
de O
actividad O
diaria O
( O
buena O
, O
> O
o O
=71 O
; O
regular O
, O
< O
70 O
; O
mala O
, O
< O
52 O
) O
. O

No O
hubo O
diferencias O
de O
sexo O
entre O
los O
dos O
grupos O
( O
brazo O
IV O
: O
hombre/mujer O
= O
45/29 O
, O
brazo O
oral O
: O
hombre/mujer O
= O
59/33 O
) O
. O

La O
edad O
media O
fue O
de O
52,3 O
frente O
a O
59,5 O
años, O
respectivamente. O

Tampoco O
hubo O
diferencias O
en O
la O
distribución O
del O
estadio O
TNM O
ni O
en O
el O
tipo O
de O
operación O
entre O
los O
grupos O
( O
P O
> O
.05 O
) O
. O

El B-Premise
número I-Premise
medio I-Premise
de I-Premise
ciclos I-Premise
de I-Premise
quimioterapia I-Premise
fue I-Premise
de I-Premise
6,5+/-3,7 I-Premise
(brazo I-Premise
IV) I-Premise
frente I-Premise
a I-Premise
7,2+/-4,3 I-Premise
(brazo I-Premise
oral), I-Premise
respectivamente. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
recurrencia I-Premise
fue I-Premise
de I-Premise
9/74 I-Premise
( I-Premise
12,1 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
IV I-Premise
y I-Premise
de I-Premise
6/92 I-Premise
( I-Premise
6,5 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
oral I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
= I-Premise
0,937 I-Premise
) I-Premise
. I-Premise

La B-Premise
recidiva I-Premise
local I-Premise
fue I-Premise
de I-Premise
2/74 I-Premise
(estadio I-Premise
III; I-Premise
2,7%) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
IV I-Premise
y I-Premise
de I-Premise
1/92 I-Premise
(estadio I-Premise
II; I-Premise
1,1%) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
oral, I-Premise
respectivamente. I-Premise

La B-Premise
recurrencia I-Premise
sistémica I-Premise
fue I-Premise
de I-Premise
7/74 I-Premise
(estadio I-Premise
III; I-Premise
9,4 I-Premise
%) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
IV I-Premise
y I-Premise
de I-Premise
5/92 I-Premise
(estadio I-Premise
III; I-Premise
5,4 I-Premise
%) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
oral, I-Premise
respectivamente. I-Premise

El B-Premise
sitio I-Premise
más I-Premise
común I-Premise
de I-Premise
recurrencia I-Premise
sistémica I-Premise
fue I-Premise
el I-Premise
hígado I-Premise
. I-Premise

El B-Premise
perfil I-Premise
de I-Premise
toxicidad I-Premise
fue I-Premise
el I-Premise
siguiente: I-Premise
la I-Premise
leucopenia I-Premise
( I-Premise
30/74 I-Premise
frente I-Premise
a I-Premise
17/92 I-Premise
) I-Premise
y I-Premise
la I-Premise
alopecia I-Premise
( I-Premise
21/74 I-Premise
frente I-Premise
a I-Premise
13/92 I-Premise
) I-Premise
fueron I-Premise
estadísticamente I-Premise
más I-Premise
frecuentes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
IV I-Premise
. I-Premise

La B-Premise
diarrea I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
en I-Premise
el I-Premise
brazo I-Premise
oral. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
mala I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
al I-Premise
mes I-Premise
( I-Premise
23,9 I-Premise
% I-Premise
frente I-Premise
al I-Premise
13 I-Premise
% I-Premise
) I-Premise
y I-Premise
a I-Premise
los I-Premise
dos I-Premise
meses I-Premise
( I-Premise
15,8 I-Premise
% I-Premise
frente I-Premise
al I-Premise
3,7 I-Premise
% I-Premise
) I-Premise
después I-Premise
de I-Premise
la I-Premise
quimioterapia I-Premise
. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
buena I-Premise
puntuación I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
al I-Premise
mes I-Premise
( I-Premise
19,5% I-Premise
frente I-Premise
al I-Premise
49% I-Premise
) I-Premise
y I-Premise
a I-Premise
los I-Premise
dos I-Premise
meses I-Premise
( I-Premise
47% I-Premise
frente I-Premise
al I-Premise
72% I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Claim
doxifluridina I-Claim
oral I-Claim
con I-Claim
leucovorina I-Claim
muestra I-Claim
una I-Claim
eficacia I-Claim
terapéutica I-Claim
comparable I-Claim
a I-Claim
la I-Claim
del I-Claim
régimen I-Claim
de I-Claim
5-FU I-Claim
intravenoso I-Claim
con I-Claim
una I-Claim
alta I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
como I-Claim
terapia I-Claim
adyuvante I-Claim
postoperatoria I-Claim
. I-Claim

El B-Claim
régimen I-Claim
oral I-Claim
también I-Claim
puede I-Claim
administrarse I-Claim
de I-Claim
forma I-Claim
segura I-Claim
con I-Claim
una I-Claim
toxicidad I-Claim
y I-Claim
tolerabilidad I-Claim
adecuadas. I-Claim

Este O
ensayo O
aleatorizado O
de O
fase O
III O
comparó O
dos O
regímenes O
de O
quimioterapia O
, O
gemcitabina O
más O
carboplatino O
y O
mitomicina O
, O
ifosfamida O
y O
cisplatino O
, O
en O
pacientes O
no O
tratados O
con O
quimioterapia O
con O
cáncer O
de O
pulmón O
no O
microcítico O
avanzado O
( O
CPNM O
) O
. O

Los O
regímenes O
se O
compararon O
con O
respecto O
a O
los O
efectos O
sobre O
la O
supervivencia, O
las O
tasas O
de O
respuesta, O
la O
toxicidad O
y O
la O
calidad O
de O
vida. O

Los O
pacientes O
elegibles O
tenían O
un O
CPNM O
en O
estadio O
IIIB O
o O
IV O
no O
tratado O
previamente O
y O
apto O
para O
la O
quimioterapia O
con O
cisplatino. O

Los O
pacientes O
asignados O
al O
azar O
debían O
recibir O
cuatro O
ciclos O
, O
cada O
uno O
a O
intervalos O
de O
3 O
semanas O
, O
de O
carboplatino O
área O
bajo O
la O
curva O
de O
5 O
en O
el O
día O
1 O
más O
gemcitabina O
1.200 O
mg/m O
( O
2 O
) O
en O
los O
días O
1 O
y O
8 O
( O
GCa O
) O
o O
mitomicina O
6 O
mg/m O
( O
2 O
) O
, O
ifosfamida O
3g/m O
( O
2 O
) O
y O
cisplatino O
50 O
mg/m O
( O
2 O
) O
en O
el O
día O
1 O
( O
MIC O
) O
. O

Entre O
febrero O
de O
1999 O
y O
agosto O
de O
2001, O
se O
asignaron O
aleatoriamente O
422 O
pacientes O
( O
GCa O
, O
n O
= O
212 O
; O
MIC O
, O
n O
= O
210 O
) O
en O
el O
Reino O
Unido O
. O

La O
mayoría O
de O
los O
pacientes O
recibieron O
los O
cuatro O
ciclos O
previstos O
( O
GCa O
, O
64 O
% O
; O
MIC O
, O
61 O
% O
) O
. O

Hubo B-Premise
una I-Premise
ventaja I-Premise
de I-Premise
supervivencia I-Premise
significativa I-Premise
para I-Premise
el I-Premise
GCa I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0,76 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,61 I-Premise
a I-Premise
0 I-Premise
.93 I-Premise
; I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
10 I-Premise
meses I-Premise
con I-Premise
GCa I-Premise
y I-Premise
7,6 I-Premise
meses I-Premise
con I-Premise
MIC I-Premise
( I-Premise
diferencia I-Premise
, I-Premise
2,4 I-Premise
meses I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
1,0 I-Premise
a I-Premise
4,0 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
fue I-Premise
del I-Premise
40 I-Premise
% I-Premise
con I-Premise
GCa I-Premise
y I-Premise
del I-Premise
30 I-Premise
% I-Premise
con I-Premise
MIC I-Premise
( I-Premise
diferencia I-Premise
, I-Premise
10 I-Premise
% I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
3 I-Premise
% I-Premise
a I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
global I-Premise
fueron I-Premise
similares I-Premise
( I-Premise
42% I-Premise
para I-Premise
GCa I-Premise
frente I-Premise
a I-Premise
41% I-Premise
para I-Premise
MIC I-Premise
; I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

Se B-Premise
produjo I-Premise
más I-Premise
trombocitopenia I-Premise
con I-Premise
el I-Premise
GCa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) O
, O
pero B-Premise
esto I-Premise
no I-Premise
se I-Premise
asoció I-Premise
con I-Premise
un I-Premise
mayor I-Premise
ingreso I-Premise
hospitalario I-Premise
o I-Premise
fatalidad I-Premise
. O

La B-Premise
GCa I-Premise
causó I-Premise
menos I-Premise
náuseas, I-Premise
vómitos, I-Premise
estreñimiento I-Premise
y I-Premise
alopecia I-Premise
y I-Premise
se I-Premise
asoció I-Premise
a I-Premise
menos I-Premise
ingresos I-Premise
para I-Premise
su I-Premise
administración I-Premise
y I-Premise
a I-Premise
una I-Premise
mejor I-Premise
calidad I-Premise
de I-Premise
vida. I-Premise

En B-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
avanzado, I-Claim
la I-Claim
quimioterapia I-Claim
con I-Claim
GCa I-Claim
demostró I-Claim
ser I-Claim
un I-Claim
tratamiento I-Claim
mejor I-Claim
tolerado I-Claim
que I-Claim
confería I-Claim
una I-Claim
ventaja I-Claim
de I-Claim
supervivencia I-Claim
sobre I-Claim
la I-Claim
MIC. I-Claim

Realizar O
un O
ensayo O
aleatorio O
que O
compare O
la O
radioterapia O
de O
70 O
y O
80 O
Gy O
para O
el O
cáncer O
de O
próstata O
. O

Un O
total O
de O
306 O
pacientes O
con O
cáncer O
de O
próstata O
localizado O
fueron O
aleatorizados O
. O

No O
se O
permitió O
la O
privación O
de O
andrógenos O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
recaída O
bioquímica O
según O
las O
definiciones O
modificadas O
de O
1997 O
de O
la O
Sociedad O
Americana O
de O
Radiología O
y O
Oncología O
Terapéuticas O
y O
de O
Phoenix. O

La O
toxicidad O
se O
calificó O
utilizando O
los O
criterios O
del O
Grupo O
de O
Oncología O
Radioterápica O
de O
1991 O
y O
las O
escalas O
de O
efectos O
tardíos O
en O
los O
tejidos O
normales-subjetiva O
, O
objetiva O
, O
de O
gestión O
, O
analítica O
( O
LENT-SOMA O
) O
. O

La O
calidad O
de O
vida O
de O
los O
pacientes O
se O
puntuó O
mediante O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer, O
de O
30 O
ítems O
específicos O
para O
el O
cáncer O
y O
de O
25 O
ítems O
específicos O
para O
la O
próstata. O

La O
mediana O
de O
seguimiento O
fue O
de O
61 O
meses. O

Según O
la O
definición O
de O
la O
Sociedad O
Americana O
de O
Radiología O
Terapéutica O
y O
Oncología O
de O
1997, O
la O
tasa O
de O
recaída O
bioquímica O
a O
los O
5 O
años O
fue O
del O
39% O
y O
del O
28% O
en O
los O
brazos O
de O
70 O
y O
80 O
Gy, O
respectivamente O
( O
p O
= O
.036 O
) O
. O

Utilizando O
la O
definición O
de O
Phoenix O
, O
la O
tasa O
de O
recaída O
bioquímica O
a O
los O
5 O
años O
fue O
del O
32% O
y O
del O
23,5% O
, O
respectivamente O
( O
p O
= O
.09 O
) O
. O

El O
análisis O
de O
subgrupos O
mostró O
un O
mejor O
resultado O
bioquímico O
para O
el O
grupo O
de O
dosis O
más O
altas O
con O
un O
nivel O
inicial O
de O
antígeno O
prostático O
específico O
> O
15 O
ng/mL O
. O

En O
la O
última O
fecha O
de O
seguimiento, O
26 O
pacientes O
habían O
fallecido, O
10 O
por O
su O
enfermedad O
y O
ninguno O
por O
toxicidad, O
sin O
que O
hubiera O
diferencias O
entre O
los O
dos O
brazos. O

Según B-Premise
la I-Premise
escala I-Premise
del I-Premise
Grupo I-Premise
de I-Premise
Radioterapia I-Premise
Oncológica, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
toxicidad I-Premise
rectal I-Premise
de I-Premise
grado I-Premise
2 I-Premise
o I-Premise
superior I-Premise
fue I-Premise
del I-Premise
14 I-Premise
% I-Premise
y I-Premise
del I-Premise
19,5 I-Premise
% I-Premise
para I-Premise
los I-Premise
brazos I-Premise
de I-Premise
70 I-Premise
y I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
0,22 I-Premise
) I-Premise
, I-Premise
respectivamente. I-Premise

La B-Premise
toxicidad I-Premise
urinaria I-Premise
de I-Premise
grado I-Premise
2 I-Premise
o I-Premise
superior I-Premise
fue I-Premise
del I-Premise
10 I-Premise
% I-Premise
con I-Premise
70 I-Premise
Gy I-Premise
y I-Premise
del I-Premise
17,5 I-Premise
% I-Premise
con I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
0,046 I-Premise
) I-Premise
. I-Premise

Se B-Premise
observaron I-Premise
resultados I-Premise
similares I-Premise
utilizando I-Premise
la I-Premise
escala I-Premise
LENT-SOMA I-Premise
. I-Premise

La B-Premise
toxicidad I-Premise
vesical I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
con I-Premise
80 I-Premise
Gy I-Premise
que I-Premise
con I-Premise
70 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
0,039 I-Premise
) I-Premise
. I-Premise

Los B-Premise
resultados I-Premise
del I-Premise
cuestionario I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
antes I-Premise
y I-Premise
5 I-Premise
años I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
estaban I-Premise
disponibles I-Premise
para I-Premise
103 I-Premise
pacientes I-Premise
y I-Premise
no I-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
70 I-Premise
y I-Premise
80 I-Premise
Gy I-Premise
. I-Premise

La B-Claim
radioterapia I-Claim
de I-Claim
alta I-Claim
dosis I-Claim
proporcionó I-Claim
un I-Claim
mejor I-Claim
resultado I-Claim
bioquímico I-Claim
a I-Claim
5 I-Claim
años I-Claim
con I-Claim
una I-Claim
toxicidad I-Claim
ligeramente I-Claim
mayor I-Claim
. I-Claim

Se O
ha O
informado O
de O
la O
utilidad O
de O
varios O
regímenes O
multicomponentes O
en O
el O
cáncer O
de O
próstata O
avanzado O
e O
independiente O
de O
los O
andrógenos. O

Se O
utilizó O
un O
diseño O
aleatorio O
de O
fase O
II O
para O
evaluar O
y O
comparar O
dos O
de O
estos O
regímenes. O

Los O
pacientes O
se O
acumularon O
principalmente O
en O
el O
ámbito O
comunitario. O

Los O
pacientes O
con O
cáncer O
de O
próstata O
progresivo O
e O
independiente O
de O
los O
andrógenos O
fueron O
asignados O
aleatoriamente O
a O
uno O
de O
los O
dos O
tratamientos: O
ketoconazol/doxorrubicina O
alternado O
con O
vinblastina/estramustina O
( O
KA/VE O
) O
o O
paclitaxel O
, O
estramustina O
y O
etopósido O
oral O
( O
TEE O
) O
. O

Los O
pacientes O
fueron O
estratificados O
prospectivamente O
en O
función O
del O
volumen O
de O
la O
enfermedad. O

Los O
criterios O
de O
valoración O
primarios O
fueron O
la O
respuesta O
y O
el O
tiempo O
de O
supervivencia O
global. O

Se O
registraron O
un O
total O
de O
75 O
pacientes; O
71 O
están O
incluidos O
en O
el O
análisis. O

Según O
el O
criterio O
de O
una O
reducción O
del O
80 O
% O
del O
antígeno O
específico O
de O
la O
próstata O
mantenida O
durante O
al O
menos O
8 O
semanas O
, O
11 O
( O
30 O
% O
) O
de O
37 O
pacientes O
del O
brazo O
de O
ETE O
respondieron O
, O
mientras O
que O
11 O
( O
32 O
% O
) O
de O
34 O
asignados O
a O
KA/VE O
respondieron O
. O

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
16,9 I-Premise
meses I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
10,5 I-Premise
a I-Premise
21,2 I-Premise
meses I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
ETE I-Premise
y I-Premise
de I-Premise
23,4 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
12,9 I-Premise
a I-Premise
30,6 I-Premise
meses I-Premise
) I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
KA/VE I-Premise
. I-Premise

Muchos B-Premise
pacientes I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
no I-Premise
lograron I-Premise
completar I-Premise
al I-Premise
menos I-Premise
6 I-Premise
semanas I-Premise
de I-Premise
terapia I-Premise
, I-Premise
incluyendo I-Premise
cinco I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
muertes I-Premise
tempranas I-Premise
relacionadas I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
. I-Premise

Cada B-Claim
uno I-Claim
de I-Claim
estos I-Claim
regímenes I-Claim
produjo I-Claim
respuestas I-Claim
clínicamente I-Claim
significativas I-Claim
, O
y O
la B-Claim
mediana I-Claim
de I-Claim
supervivencia I-Claim
observada I-Claim
( I-Claim
18,9 I-Claim
meses I-Claim
para I-Claim
los I-Claim
71 I-Claim
pacientes I-Claim
) I-Claim
se I-Claim
compara I-Claim
favorablemente I-Claim
con I-Claim
los I-Claim
resultados I-Claim
publicados I-Claim
anteriormente I-Claim
, I-Claim
especialmente I-Claim
en I-Claim
el I-Claim
entorno I-Claim
comunitario I-Claim
. O

No B-Claim
obstante, I-Claim
es I-Claim
evidente I-Claim
que I-Claim
estos I-Claim
regímenes I-Claim
de I-Claim
primera I-Claim
generación I-Claim
deben I-Claim
aplicarse I-Claim
con I-Claim
criterio I-Claim
y, I-Claim
por I-Claim
lo I-Claim
tanto, I-Claim
consideramos I-Claim
que I-Claim
los I-Claim
esfuerzos I-Claim
para I-Claim
mejorar I-Claim
la I-Claim
selección I-Claim
de I-Claim
pacientes I-Claim
y I-Claim
el I-Claim
desarrollo I-Claim
de I-Claim
terapias I-Claim
más I-Claim
tolerables I-Claim
son I-Claim
más I-Claim
prioritarios I-Claim
que I-Claim
llevar I-Claim
cualquiera I-Claim
de I-Claim
estos I-Claim
regímenes I-Claim
a I-Claim
la I-Claim
evaluación I-Claim
de I-Claim
fase I-Claim
III I-Claim
en I-Claim
el I-Claim
marco I-Claim
del I-Claim
grupo I-Claim
cooperativo. I-Claim

La B-Claim
evaluación I-Claim
sistemática I-Claim
es I-Claim
vital I-Claim
para I-Claim
los I-Claim
cuidados I-Claim
paliativos, I-Claim
pero O
la O
documentación O
que O
confirma O
la O
realización O
de O
la O
evaluación O
sistemática O
en O
los O
centros O
de O
cuidados O
paliativos O
es O
a O
menudo O
inadecuada O
o O
inexistente. O

El O
objetivo O
del O
estudio O
fue O
determinar O
la O
eficacia O
de O
la O
retroalimentación O
sistemática O
de O
las O
herramientas O
de O
evaluación O
estandarizadas O
para O
las O
díadas O
de O
pacientes O
y O
cuidadores O
de O
hospicios O
en O
la O
mejora O
de O
los O
resultados O
de O
los O
hospicios O
en O
comparación O
con O
la O
práctica O
clínica O
habitual O
. O

La O
muestra O
de O
pacientes O
( O
n O
= O
709 O
) O
recién O
ingresados O
en O
los O
cuidados O
domiciliarios O
de O
2 O
hospicios O
tenían O
cuidadores O
familiares O
designados O
. O

Los O
equipos O
interdisciplinarios O
( O
IDT O
) O
que O
atendían O
a O
estas O
díadas O
fueron O
asignados O
aleatoriamente O
a O
condiciones O
experimentales O
( O
n O
= O
338 O
) O
o O
de O
control O
( O
n O
= O
371 O
) O
. O

Se O
recogieron O
datos O
de O
ambos O
grupos O
de O
díadas O
utilizando O
evaluaciones O
estandarizadas O
al O
ingreso O
y O
una O
semana O
después O
de O
cada O
una O
de O
las O
dos O
primeras O
reuniones O
del O
IDT O
en O
las O
que O
se O
habló O
de O
estas O
díadas O
. O

La O
intervención O
experimental O
consistió O
en O
comunicar O
los O
datos O
de O
las O
evaluaciones O
estandarizadas O
a O
los O
IDT. O

Los B-Premise
resultados I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
de I-Premise
la I-Premise
depresión I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
como I-Premise
resultado I-Premise
de I-Premise
la I-Premise
intervención I-Premise
y I-Premise
una I-Premise
mejora I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Ningún B-Premise
otro I-Premise
resultado I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
( I-Premise
malestar I-Premise
por I-Premise
los I-Premise
síntomas I-Premise
, I-Premise
necesidades I-Premise
espirituales I-Premise
) I-Premise
o I-Premise
de I-Premise
los I-Premise
cuidadores I-Premise
( I-Premise
depresión I-Premise
, I-Premise
apoyo I-Premise
, I-Premise
necesidades I-Premise
espirituales I-Premise
) I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
. I-Premise

La O
evaluación O
de O
la O
depresión O
añadida O
a O
los O
cuidados O
habituales O
probablemente O
tuvo O
un O
efecto O
porque O
normalmente O
no O
es O
objeto O
de O
atención O
por O
parte O
del O
personal O
de O
los O
hospicios O
. O

Los B-Premise
cuidados I-Premise
paliativos I-Premise
fueron I-Premise
tan I-Premise
buenos I-Premise
durante I-Premise
el I-Premise
estudio I-Premise
que I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
mejoró I-Premise
como I-Premise
resultado I-Premise
de I-Premise
los I-Premise
cuidados I-Premise
estándar I-Premise
y I-Premise
dejó I-Premise
poco I-Premise
margen I-Premise
de I-Premise
mejora I-Premise
en I-Premise
otras I-Premise
variables I-Premise
. I-Premise

Se B-Claim
necesita I-Claim
una I-Claim
evaluación I-Claim
sistemática I-Claim
de I-Claim
la I-Claim
depresión I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
cuidados I-Claim
paliativos I-Claim
. I-Claim

Ninguna O
variable O
de O
los O
cuidadores O
cambió O
, O
lo O
que O
puede O
indicar O
la O
necesidad O
de O
centrarse O
en O
los O
cuidadores O
. O

Este O
estudio O
tiene O
como O
objetivo O
examinar O
la O
eficacia O
de O
un O
programa O
multimodal O
de O
autogestión O
de O
estrategias O
de O
afrontamiento O
( O
CCSP O
) O
en O
la O
calidad O
de O
vida O
( O
QOL O
) O
entre O
los O
pacientes O
con O
cáncer O
de O
mama O
1 O
año O
después O
del O
tratamiento O
. O

Las O
pacientes O
( O
n O
= O
110 O
) O
con O
cáncer O
de O
mama O
en O
estadio O
II O
, O
III O
o O
IV O
programadas O
para O
recibir O
altas O
dosis O
de O
quimioterapia O
y O
trasplante O
autólogo O
de O
células O
madre O
hematopoyéticas O
fueron O
asignadas O
aleatoriamente O
al O
tratamiento O
CCSP O
o O
al O
grupo O
de O
control O
. O

La O
intervención O
del O
CCSP O
se O
enseñó O
2 O
semanas O
antes O
del O
ingreso O
en O
el O
hospital O
con O
refuerzos O
en O
momentos O
específicos O
durante O
el O
tratamiento O
y O
3 O
meses O
después O
del O
alta. O

Los O
componentes O
del O
CCSP O
incluían O
información O
educativa, O
reestructuración O
cognitiva, O
mejora O
de O
las O
habilidades O
de O
afrontamiento O
y O
relajación O
con O
imágenes O
guiadas. O

Los O
instrumentos O
administrados O
en O
la O
línea O
de O
base O
incluyeron O
los O
siguientes O
: O
Índice O
de O
Calidad O
de O
Vida-Versión O
Cáncer O
( O
QOLI-CV O
) O
, O
Inventario O
de O
Ansiedad O
Estado-Rasgo O
, O
Inventario O
de O
Depresión O
de O
Beck O
, O
y O
Cuestionario O
de O
Estrategias O
de O
Afrontamiento O
. O

Al O
año O
de O
seguimiento, O
los O
pacientes O
( O
n O
= O
73 O
) O
completaron O
y O
devolvieron O
el O
QOLI-CV O
de O
seguimiento. O

Las O
pacientes O
eran O
principalmente O
≥ O
40 O
años O
de O
edad O
, O
casadas O
, O
caucásicas O
, O
y O
diagnosticadas O
de O
cáncer O
de O
mama O
avanzado O
. O

Un B-Premise
modelo I-Premise
que I-Premise
midió I-Premise
la I-Premise
eficacia I-Premise
del I-Premise
CCSP I-Premise
en I-Premise
la I-Premise
CdV I-Premise
( I-Premise
total I-Premise
y I-Premise
subescala I-Premise
) I-Premise
en I-Premise
el I-Premise
seguimiento I-Premise
de I-Premise
1 I-Premise
año I-Premise
mostró I-Premise
que I-Premise
el I-Premise
grupo I-Premise
CCSP I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
tuvo I-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
en I-Premise
la I-Premise
CdV I-Premise
general I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
la I-Premise
salud I-Premise
y I-Premise
el I-Premise
funcionamiento I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
y I-Premise
el I-Premise
bienestar I-Premise
socioeconómico I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
psicológico/espiritual I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
CCSP I-Premise
utilizaron I-Premise
con I-Premise
frecuencia I-Premise
el I-Premise
CCSP I-Premise
para I-Premise
gestionar I-Premise
problemas I-Premise
psicológicos I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
y I-Premise
de I-Premise
sueño I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
. I-Premise

El B-Premise
CCSP I-Premise
mejoró I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
al I-Premise
año I-Premise
de I-Premise
seguimiento. I-Premise

Los B-Premise
pacientes I-Premise
informaron I-Premise
mayoritariamente I-Premise
de I-Premise
que I-Premise
el I-Premise
CCSP I-Premise
era I-Premise
beneficioso. I-Premise

El B-Claim
CCSP, I-Claim
como I-Claim
intervención I-Claim
de I-Claim
afrontamiento I-Claim
eficaz, I-Claim
tiene I-Claim
potencial I-Claim
como I-Claim
programa I-Claim
de I-Claim
autogestión I-Claim
para I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

La B-Claim
combinación I-Claim
de I-Claim
etopósido I-Claim
más I-Claim
cisplatino I-Claim
( I-Claim
EP I-Claim
) I-Claim
se I-Claim
considera I-Claim
la I-Claim
terapia I-Claim
estándar I-Claim
para I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
pequeñas I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

Para O
determinar O
si O
la O
intensificación O
de O
los O
fármacos O
mejora O
la O
supervivencia O
de O
los O
pacientes O
con O
CPCP O
extenso O
, O
se O
comparó O
este O
tratamiento O
con O
un O
régimen O
de O
cuatro O
fármacos O
que O
contiene O
EP O
más O
ciclofosfamida O
y O
4'-epidoxorrubicina O
( O
PCDE O
) O
. O

En O
un O
ensayo O
clínico O
de O
fase O
III O
organizado O
por O
la O
Federación O
Francesa O
de O
Institutos O
del O
Cáncer O
, O
los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
EP O
( O
n O
= O
109 O
; O
etopósido O
a O
una O
dosis O
de O
100 O
mg/m O
( O
2 O
) O
en O
los O
días O
1-3 O
más O
cisplatino O
a O
100 O
mg/m O
( O
2 O
) O
en O
el O
día O
2 O
) O
o O
PCDE O
( O
n O
= O
117 O
; O
etopósido O
y O
cisplatino O
administrados O
como O
en O
EP O
más O
ciclofosfamida O
a O
400 O
mg/m O
( O
2 O
) O
en O
los O
días O
1-3 O
y O
4'-epidoxorrubicina O
a O
40 O
mg/m O
( O
2 O
) O
en O
el O
día O
1 O
) O
cada O
4 O
semanas O
. O

Ambos O
grupos O
recibieron O
un O
total O
de O
seis O
ciclos. O

Las O
diferencias O
de O
supervivencia O
se O
analizaron O
mediante O
las O
pruebas O
de O
Wilcoxon O
y O
log-rank O
. O

Las O
asociaciones O
del O
grupo O
de O
tratamiento O
y O
las O
variables O
pronósticas O
putativas O
con O
la O
supervivencia O
se O
probaron O
en O
el O
modelo O
de O
riesgos O
proporcionales O
de O
Cox O
. O

La O
calidad O
de O
vida O
se O
evaluó O
a O
partir O
de O
las O
respuestas O
al O
cuestionario O
de O
calidad O
de O
vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
C30 O
, O
estado O
de O
salud O
y O
módulo O
de O
cáncer O
de O
pulmón O
13 O
) O
. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

Los B-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
PCDE I-Premise
tuvieron I-Premise
una I-Premise
frecuencia I-Premise
estadísticamente I-Premise
significativa I-Premise
más I-Premise
alta I-Premise
de I-Premise
respuestas I-Premise
completas I-Premise
y I-Premise
parciales I-Premise
combinadas I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
del I-Premise
brazo I-Premise
EP I-Premise
( I-Premise
21 I-Premise
% I-Premise
más I-Premise
55 I-Premise
% I-Premise
frente I-Premise
a I-Premise
13 I-Premise
% I-Premise
más I-Premise
48 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
para I-Premise
la I-Premise
diferencia I-Premise
en I-Premise
las I-Premise
respuestas I-Premise
objetivas I-Premise
combinadas I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
PCDE I-Premise
sobrevivieron I-Premise
más I-Premise
tiempo I-Premise
que I-Premise
los I-Premise
del I-Premise
brazo I-Premise
EP I-Premise
( I-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
: I-Premise
40 I-Premise
% I-Premise
y I-Premise
29 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
: I-Premise
10,5 I-Premise
y I-Premise
9,3 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
log-rank I-Premise
P I-Premise
=.0067 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
modelo I-Premise
de I-Premise
Cox, I-Premise
el I-Premise
riesgo I-Premise
relativo I-Premise
de I-Premise
muerte I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
PCDE I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
del I-Premise
brazo I-Premise
EP I-Premise
fue I-Premise
de I-Premise
0,70 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,51 I-Premise
a I-Premise
0,95 I-Premise
) O
; O
la B-Premise
enfermedad I-Premise
también I-Premise
progresó I-Premise
más I-Premise
lentamente I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
PCDE I-Premise
. O

La B-Premise
toxicidad I-Premise
hematológica I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
PCDE I-Premise
( I-Premise
22% I-Premise
con I-Premise
infecciones I-Premise
documentadas I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
8% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
EP I-Premise
; I-Premise
P I-Premise
=.0038 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
tasa I-Premise
de I-Premise
mortalidad I-Premise
relacionada I-Premise
con I-Premise
la I-Premise
toxicidad I-Premise
fue I-Premise
del I-Premise
9% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
PCDE I-Premise
frente I-Premise
al I-Premise
5,5% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
EP I-Premise
( I-Premise
P I-Premise
=.22 I-Premise
) O
. O

El B-Claim
estado I-Claim
de I-Claim
salud I-Claim
global I-Claim
mostró I-Claim
una I-Claim
mejora I-Claim
similar I-Claim
en I-Claim
ambos I-Claim
brazos I-Claim
durante I-Claim
el I-Claim
tratamiento I-Claim
. I-Claim

En B-Claim
comparación I-Claim
con I-Claim
el I-Claim
régimen I-Claim
EP I-Claim
, I-Claim
el I-Claim
régimen I-Claim
PCDE I-Claim
produjo I-Claim
mayores I-Claim
tasas I-Claim
de I-Claim
respuesta I-Claim
y I-Claim
mejores I-Claim
tasas I-Claim
de I-Claim
supervivencia I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CPCP I-Claim
extenso I-Claim
sin I-Claim
afectar I-Claim
a I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
durante I-Claim
la I-Claim
quimioterapia I-Claim
. I-Claim

Aunque O
se O
han O
propuesto O
muchas O
terapias O
de O
combinación O
de O
fármacos, O
no B-Claim
existe I-Claim
una I-Claim
terapia I-Claim
estándar I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
carcinoma I-Claim
gástrico I-Claim
avanzado. I-Claim

No B-Claim
se I-Claim
ha I-Claim
demostrado I-Claim
de I-Claim
forma I-Claim
convincente I-Claim
la I-Claim
superioridad I-Claim
de I-Claim
la I-Claim
terapia I-Claim
combinada I-Claim
sobre I-Claim
la I-Claim
monoquimioterapia. I-Claim

Para O
explorar O
el O
papel O
de O
la O
monoquimioterapia O
, O
los O
autores O
evaluaron O
el O
5-fluorouracilo O
( O
5-FU O
) O
, O
modulado O
por O
6S-leucovorina O
( O
6S-LV O
) O
y O
un O
régimen O
que O
contenía O
cisplatino O
, O
que O
estaba O
compuesto O
por O
epirubicina O
, O
etopósido O
y O
cisplatino O
con O
la O
adición O
del O
agente O
de O
reversión O
lonidamina O
( O
EEP-L O
) O
. O

Después O
de O
la O
estratificación O
según O
el O
estado O
de O
rendimiento O
( O
PS O
) O
y O
la O
resección O
del O
tumor O
primario O
, O
72 O
pacientes O
con O
carcinoma O
gástrico O
avanzado O
fueron O
asignados O
al O
azar O
a O
2 O
ensayos O
paralelos O
de O
fase O
II O
con O
5-FU/6S-LV O
y O
EEP-L O
, O
respectivamente O
. O

Treinta O
y O
seis O
pacientes O
del O
estudio O
A O
recibieron O
un O
bolo O
de O
6S-LV O
, O
100 O
mg/m2 O
, O
seguido O
de O
un O
bolo O
de O
5-FU O
, O
370 O
mg/m2 O
, O
los O
días O
1 O
a O
5, O
y O
otros O
36 O
del O
estudio O
B O
recibieron O
epirubicina O
, O
30 O
mg/m2 O
, O
los O
días O
1 O
y O
5 O
; O
etopósido O
, O
100 O
mg/m2 O
, O
los O
días O
1 O
, O
3 O
y O
5 O
; O
cisplatino O
, O
30 O
mg/m2 O
, O
los O
días O
2 O
y O
4 O
; O
y O
lonidamina O
, O
150 O
mg/día O
. O

Hubo O
6 O
respuestas O
parciales O
( O
18,2 O
% O
) O
( O
intervalo O
de O
confianza O
del O
95 O
% O
[ O
CI O
] O
+/- O
13,2 O
) O
en O
el O
estudio O
A O
y O
7 O
respuestas O
parciales O
( O
21,9 O
% O
) O
( O
95 O
% O
CI O
+/- O
14,3 O
) O
en O
el O
estudio O
B O
. O

Las O
respuestas O
parciales O
fueron O
más O
frecuentes O
en O
pacientes O
con O
tumores O
resecados O
o O
con O
un O
PS O
del O
Eastern O
Cooperative O
Oncology O
Group O
de O
0-1 O
. O

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
respuesta I-Premise
fue I-Premise
de I-Premise
8,8 I-Premise
y I-Premise
8,3 I-Premise
meses, I-Premise
respectivamente, I-Premise
en I-Premise
el I-Premise
Estudio I-Premise
A I-Premise
y I-Premise
el I-Premise
Estudio I-Premise
B. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
alcanzó I-Premise
los I-Premise
8 I-Premise
meses I-Premise
en I-Premise
el I-Premise
Estudio I-Premise
A I-Premise
y I-Premise
los I-Premise
9 I-Premise
meses I-Premise
en I-Premise
el I-Premise
Estudio I-Premise
B I-Premise
. I-Premise

En B-Premise
toda I-Premise
la I-Premise
población I-Premise
de I-Premise
pacientes I-Premise
la I-Premise
supervivencia I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
un I-Premise
PS I-Premise
de I-Premise
0-1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
un I-Premise
PS I-Premise
de I-Premise
0-1 I-Premise
y I-Premise
un I-Premise
tumor I-Premise
resecado I-Premise
tuvieron I-Premise
la I-Premise
supervivencia I-Premise
significativamente I-Premise
más I-Premise
larga I-Premise
tanto I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
EEP-L I-Premise
como I-Premise
en I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
evaluables I-Premise
en I-Premise
los I-Premise
dos I-Premise
estudios I-Premise
. I-Premise

Los B-Premise
efectos I-Premise
tóxicos I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
de I-Premise
la I-Premise
Organización I-Premise
Mundial I-Premise
de I-Premise
la I-Premise
Salud I-Premise
más I-Premise
frecuentes I-Premise
fueron I-Premise
los I-Premise
gastrointestinales I-Premise
en I-Premise
el I-Premise
estudio I-Premise
A I-Premise
y I-Premise
los I-Premise
hematológicos I-Premise
en I-Premise
el I-Premise
estudio I-Premise
B. I-Premise

No B-Premise
se I-Premise
observó I-Premise
ninguna I-Premise
muerte I-Premise
relacionada I-Premise
con I-Premise
el I-Premise
tratamiento. I-Premise

La B-Claim
eficacia I-Claim
de I-Claim
5-FU I-Claim
, I-Claim
modulada I-Claim
con I-Claim
6S-LV I-Claim
, I-Claim
es I-Claim
moderada I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
carcinoma I-Claim
gástrico I-Claim
avanzado I-Claim
, I-Claim
similar I-Claim
a I-Claim
los I-Claim
regímenes I-Claim
que I-Claim
contienen I-Claim
cisplatino I-Claim
. I-Claim

La B-Claim
PS I-Claim
y I-Claim
otros I-Claim
factores I-Claim
pronósticos I-Claim
podrían I-Claim
influir I-Claim
en I-Claim
la I-Claim
tasa I-Claim
de I-Claim
respuesta I-Claim
, I-Claim
que I-Claim
no I-Claim
parece I-Claim
ser I-Claim
un I-Claim
parámetro I-Claim
fiable I-Claim
para I-Claim
evaluar I-Claim
el I-Claim
resultado I-Claim
de I-Claim
los I-Claim
ensayos I-Claim
de I-Claim
quimioterapia I-Claim
. I-Claim

Evaluar O
los O
efectos O
de O
una O
intervención O
de O
escritura O
expresiva O
( O
EW O
) O
sobre O
las O
percepciones O
de O
apoyo O
emocional O
en O
las O
mujeres O
que O
completan O
el O
tratamiento O
del O
cáncer O
de O
mama O
en O
fase O
inicial O
. O

Las O
mujeres O
fueron O
reclutadas O
para O
el O
estudio O
durante O
su O
última O
semana O
de O
tratamiento. O

De O
260 O
pacientes O
elegibles, O
104 O
( O
40% O
) O
aceptaron O
participar O
y O
93 O
fueron O
asignados O
al O
azar. O

Las O
mujeres O
del O
grupo O
de O
escritura O
escribieron O
durante O
20 O
minutos O
en O
cuatro O
días O
consecutivos. O

El O
grupo O
de O
control O
recibió O
los O
cuidados O
normales. O

Las O
percepciones O
de O
las O
mujeres O
sobre O
el O
apoyo O
emocional, O
la O
calidad O
de O
vida O
( O
QOL O
), O
el O
estado O
de O
ánimo O
y O
la O
utilización O
de O
la O
atención O
sanitaria O
se O
evaluaron O
en O
la O
línea O
de O
base O
, O
1 O
mes O
, O
3 O
meses O
y O
6 O
meses O
. O

Se O
realizaron O
entrevistas O
para O
explorar O
la O
experiencia O
de O
las O
mujeres O
con O
la O
escritura. O

Ochenta O
participantes O
completaron O
todos O
los O
seguimientos. O

Hubo B-Premise
un I-Premise
efecto I-Premise
significativo I-Premise
del I-Premise
grupo I-Premise
en I-Premise
la I-Premise
percepción I-Premise
de I-Premise
las I-Premise
mujeres I-Premise
sobre I-Premise
el I-Premise
apoyo I-Premise
social; I-Premise
las I-Premise
del I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
estaban I-Premise
más I-Premise
satisfechas I-Premise
con I-Premise
el I-Premise
apoyo I-Premise
emocional I-Premise
que I-Premise
recibían I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
satisfacción I-Premise
con I-Premise
el I-Premise
apoyo I-Premise
emocional I-Premise
se I-Premise
correlacionó I-Premise
negativamente I-Premise
con I-Premise
la I-Premise
depresión/el I-Premise
rechazo I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
la I-Premise
ira/hostilidad I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
positivamente I-Premise
con I-Premise
el I-Premise
bienestar I-Premise
social I-Premise
y I-Premise
familiar I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
6 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
intervención I-Premise
. I-Premise

No B-Premise
hubo I-Premise
efectos I-Premise
significativos I-Premise
de I-Premise
la I-Premise
intervención I-Premise
sobre I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
o I-Premise
la I-Premise
utilización I-Premise
de I-Premise
la I-Premise
asistencia I-Premise
sanitaria. I-Premise

La B-Premise
mayoría I-Premise
de I-Premise
los I-Premise
participantes I-Premise
consideraron I-Premise
que I-Premise
la I-Premise
escritura I-Premise
era I-Premise
valiosa I-Premise
y I-Premise
no I-Premise
informaron I-Premise
de I-Premise
ningún I-Premise
efecto I-Premise
negativo I-Premise
a I-Premise
largo I-Premise
plazo. I-Premise

El B-Claim
EW I-Claim
se I-Claim
asoció I-Claim
con I-Claim
un I-Claim
mayor I-Claim
nivel I-Claim
de I-Claim
satisfacción I-Claim
con I-Claim
el I-Claim
apoyo I-Claim
emocional I-Claim
en I-Claim
comparación I-Claim
con I-Claim
los I-Claim
controles I-Claim
. I-Claim

Dada O
la O
evidencia O
existente O
que O
apoya O
la O
importancia O
del O
apoyo O
social O
en O
la O
adaptación O
al O
cáncer O
de O
mama O
, O
parece B-Claim
factible I-Claim
sugerir I-Claim
que I-Claim
la I-Claim
VM I-Claim
puede I-Claim
ser I-Claim
un I-Claim
tratamiento I-Claim
accesible I-Claim
y I-Claim
rentable I-Claim
que I-Claim
podría I-Claim
incorporarse I-Claim
a I-Claim
la I-Claim
atención I-Claim
continua I-Claim
de I-Claim
las I-Claim
mujeres I-Claim
. O

Este O
estudio O
probó O
el O
oxígeno O
hiperbárico O
( O
OHB O
) O
como O
complemento O
de O
la O
cirugía O
y O
los O
antibióticos O
en O
el O
tratamiento O
de O
la O
osteonecrosis O
de O
la O
mandíbula O
( O
ONM O
) O
relacionada O
con O
los O
bifosfonatos O
y O
evaluó O
sus O
efectos O
en O
la O
curación O
gingival O
, O
el O
dolor O
y O
la O
calidad O
de O
vida O
. O

Los O
investigadores O
implementaron O
un O
ensayo O
controlado O
aleatorio O
e O
inscribieron O
una O
muestra O
compuesta O
por O
pacientes O
con O
ONM O
, O
donde O
la O
variable O
predictora O
fue O
la O
OHB O
administrada O
a O
2 O
atm O
dos O
veces O
al O
día O
durante O
40 O
tratamientos O
como O
complemento O
a O
la O
terapia O
convencional O
de O
cirugía O
y O
antibióticos O
frente O
a O
la O
terapia O
convencional O
sola O
. O

A O
lo O
largo O
de O
los O
24 O
meses O
siguientes, O
se O
evaluaron O
el O
tamaño O
y O
el O
número O
de O
lesiones O
orales, O
el O
dolor O
y O
la O
calidad O
de O
vida. O

Cuarenta O
y O
seis O
pacientes O
(edad O
media, O
66 O
años; O
57% O
mujeres) O
aportaron O
datos O
al O
ensayo. O

No O
hubo O
diferencias O
estadísticamente O
significativas O
en O
la O
distribución O
de O
las O
variables O
utilizadas O
para O
evaluar O
el O
éxito O
de O
la O
aleatorización O
entre O
los O
grupos O
de O
OHB O
y O
de O
tratamiento O
estándar O
. O

Diecisiete B-Premise
de I-Premise
los I-Premise
25 I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
OHB I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
mejoraron I-Premise
frente I-Premise
a I-Premise
8 I-Premise
de I-Premise
los I-Premise
21 I-Premise
controles I-Premise
( I-Premise
38,1 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,043 I-Premise
, I-Premise
prueba I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
) I-Premise
. I-Premise

El B-Premise
tiempo I-Premise
medio I-Premise
de I-Premise
mejora I-Premise
fue I-Premise
de I-Premise
39,7 I-Premise
semanas I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
IC I-Premise
] I-Premise
, I-Premise
22,4 I-Premise
a I-Premise
57,0 I-Premise
semanas I-Premise
) I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
OHB I-Premise
frente I-Premise
a I-Premise
67,9 I-Premise
semanas I-Premise
( I-Premise
IC I-Premise
95 I-Premise
, I-Premise
48,4 I-Premise
a I-Premise
87,5 I-Premise
semanas I-Premise
) I-Premise
para I-Premise
los I-Premise
controles I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
, I-Premise
prueba I-Premise
de I-Premise
rango I-Premise
logarítmico I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
la I-Premise
cicatrización I-Premise
gingival I-Premise
completa I-Premise
sólo I-Premise
se I-Premise
produjo I-Premise
en I-Premise
14 I-Premise
de I-Premise
los I-Premise
25 I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
OHB I-Premise
( I-Premise
52 I-Premise
% I-Premise
) I-Premise
frente I-Premise
a I-Premise
7 I-Premise
de I-Premise
los I-Premise
21 I-Premise
controles I-Premise
( I-Premise
33,3 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,203 I-Premise
, I-Premise
prueba I-Premise
de I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
) I-Premise
, I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
cicatrización I-Premise
fue I-Premise
de I-Premise
59 I-Premise
semanas I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
42,8 I-Premise
% I-Premise
a I-Premise
75,8 I-Premise
% I-Premise
) I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
OHB I-Premise
frente I-Premise
a I-Premise
70 I-Premise
semanas I-Premise
( I-Premise
IC I-Premise
95 I-Premise
, I-Premise
52,2 I-Premise
% I-Premise
a I-Premise
88,36 I-Premise
% I-Premise
) I-Premise
para I-Premise
los I-Premise
controles I-Premise
( I-Premise
P I-Premise
= I-Premise
0,32 I-Premise
, I-Premise
prueba I-Premise
de I-Premise
log-rank I-Premise
) I-Premise
. I-Premise

El B-Premise
dolor I-Premise
disminuyó I-Premise
más I-Premise
rápidamente I-Premise
en I-Premise
los I-Premise
sujetos I-Premise
tratados I-Premise
con I-Premise
OHB I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
, I-Premise
regresión I-Premise
lineal I-Premise
) I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
para I-Premise
la I-Premise
salud I-Premise
física I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
y I-Premise
la I-Premise
salud I-Premise
percibida I-Premise
( I-Premise
P I-Premise
= I-Premise
0,043 I-Premise
) I-Premise
disminuyeron I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
pero I-Premise
no I-Premise
para I-Premise
el I-Premise
grupo I-Premise
HBO I-Premise
. I-Premise

La B-Claim
ONM I-Claim
es I-Claim
multifactorial I-Claim
y I-Claim
ninguna I-Claim
modalidad I-Claim
de I-Claim
tratamiento I-Claim
puede I-Claim
revertirla; I-Claim
sin B-Claim
embargo, I-Claim
es I-Claim
tratable I-Claim
e I-Claim
incluso I-Claim
las I-Claim
presentaciones I-Claim
avanzadas I-Claim
pueden I-Claim
mejorar I-Claim
con I-Claim
una I-Claim
terapia I-Claim
multimodal I-Claim
intensiva. I-Claim

Desde B-Claim
el I-Claim
punto I-Claim
de I-Claim
vista I-Claim
clínico, I-Claim
la I-Claim
OHB I-Claim
parece I-Claim
ser I-Claim
un I-Claim
complemento I-Claim
útil I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
la I-Claim
ONM, I-Claim
sobre I-Claim
todo I-Claim
en I-Claim
los I-Claim
casos I-Claim
más I-Claim
graves, I-Claim
aunque I-Claim
este I-Claim
estudio I-Claim
no I-Claim
tenía I-Claim
la I-Claim
potencia I-Claim
suficiente I-Claim
para I-Claim
respaldar I-Claim
plenamente I-Claim
esta I-Claim
afirmación. I-Claim

La O
terapia O
para O
el O
hígado O
poliquístico O
es O
invasiva, O
cara O
y O
tiene O
resultados O
decepcionantes O
a O
largo O
plazo. O

El O
tratamiento O
con O
análogos O
de O
la O
somatostatina O
ralentizó O
el O
crecimiento O
del O
riñón O
en O
pacientes O
con O
poliquistosis O
renal O
( O
PKD O
) O
y O
redujo O
el O
volumen O
del O
hígado O
y O
del O
riñón O
en O
un O
modelo O
de O
roedor O
con O
PKD O
. O

Se O
evaluaron O
los O
efectos O
de O
la O
lanreotida O
, O
un O
análogo O
de O
la O
somatostatina O
, O
en O
pacientes O
con O
hígado O
poliquístico O
debido O
a O
la O
PKD O
autosómica O
dominante O
( O
AD O
) O
o O
a O
la O
poliquistosis O
hepática O
autosómica O
dominante O
( O
PCLD O
) O
. O

Se O
realizó O
un O
ensayo O
aleatorio, O
doble O
ciego O
y O
controlado O
con O
placebo O
en O
2 O
centros O
de O
referencia O
terciarios. O

Los O
pacientes O
con O
hígado O
poliquístico O
( O
n O
= O
54 O
) O
fueron O
asignados O
aleatoriamente O
a O
grupos O
que O
recibieron O
lanreotida O
( O
120 O
mg O
) O
o O
placebo O
, O
administrados O
cada O
28 O
días O
durante O
24 O
semanas O
. O

El O
punto O
final O
primario O
fue O
la O
diferencia O
en O
el O
volumen O
total O
del O
hígado O
, O
medido O
por O
tomografía O
computarizada O
en O
las O
semanas O
0 O
y O
24 O
. O

Los O
análisis O
se O
realizaron O
por O
intención O
de O
tratar. O

Las B-Premise
características I-Premise
iniciales I-Premise
fueron I-Premise
comparables I-Premise
para I-Premise
ambos I-Premise
grupos, I-Premise
excepto B-Premise
que I-Premise
se I-Premise
asignaron I-Premise
más I-Premise
pacientes I-Premise
con I-Premise
PQRAD I-Premise
al I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
). O

El B-Premise
volumen I-Premise
medio I-Premise
del I-Premise
hígado I-Premise
se I-Premise
redujo I-Premise
en I-Premise
un I-Premise
2,9%, I-Premise
de I-Premise
4606 I-Premise
mL I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
( I-Premise
IC I-Premise
) I-Premise
del I-Premise
95% I-Premise
: I-Premise
547-8665 I-Premise
) I-Premise
a I-Premise
4471 I-Premise
mL I-Premise
( I-Premise
IC I-Premise
del I-Premise
95% I-Premise
: I-Premise
542-8401 I-Premise
mL I-Premise
) I-Premise
, I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
lanreotida I-Premise
. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo, I-Premise
el I-Premise
volumen I-Premise
medio I-Premise
del I-Premise
hígado I-Premise
aumentó I-Premise
un I-Premise
1,6 I-Premise
%, I-Premise
pasando I-Premise
de I-Premise
4689 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
613-8765 I-Premise
mL I-Premise
) I-Premise
a I-Premise
4895 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
739-9053 I-Premise
mL I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

La B-Premise
estratificación I-Premise
post I-Premise
hoc I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
PQRAD I-Premise
o I-Premise
EPOC I-Premise
reveló I-Premise
cambios I-Premise
similares I-Premise
en I-Premise
el I-Premise
volumen I-Premise
del I-Premise
hígado, I-Premise
con I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
a I-Premise
los I-Premise
que I-Premise
se I-Premise
les I-Premise
administró I-Premise
lanreotida I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
para I-Premise
ambas I-Premise
enfermedades I-Premise
) I-Premise
. I-Premise

En B-Claim
pacientes I-Claim
con I-Claim
hígado I-Claim
poliquístico, I-Claim
6 I-Claim
meses I-Claim
de I-Claim
tratamiento I-Claim
con I-Claim
lanreotida I-Claim
reducen I-Claim
el I-Claim
volumen I-Claim
del I-Claim
hígado. I-Claim

Una B-Claim
combinación I-Claim
de I-Claim
mitoxantrona I-Claim
más I-Claim
prednisona I-Claim
es I-Claim
preferible I-Claim
a I-Claim
la I-Claim
prednisona I-Claim
sola I-Claim
para I-Claim
la I-Claim
reducción I-Claim
del I-Claim
dolor I-Claim
en I-Claim
hombres I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
metastásico, I-Claim
resistente I-Claim
a I-Claim
las I-Claim
hormonas. I-Claim

El O
objetivo O
de O
este O
estudio O
era O
evaluar O
los O
efectos O
de O
estos O
tratamientos O
en O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HQL O
) O
. O

Los O
hombres O
con O
cáncer O
de O
próstata O
metastásico O
( O
n O
= O
161 O
) O
fueron O
aleatorizados O
para O
recibir O
prednisona O
diaria O
sola O
o O
mitoxantrona O
( O
cada O
3 O
semanas O
) O
más O
prednisona O
. O

A O
los O
que O
recibieron O
sólo O
prednisona O
se O
les O
podía O
añadir O
mitoxantrona O
al O
cabo O
de O
6 O
semanas O
si O
no O
mejoraba O
el O
dolor. O

La O
CV O
se O
evaluó O
antes O
de O
iniciar O
el O
tratamiento O
y O
luego O
cada O
3 O
semanas O
utilizando O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
QLQ-C30 O
) O
y O
el O
Módulo O
de O
Calidad O
de O
Vida-Prostata O
14 O
( O
QOLM-P14 O
) O
, O
un O
módulo O
específico O
del O
ensayo O
desarrollado O
para O
este O
estudio O
. O

Se O
utilizó O
un O
análisis O
por O
intención O
de O
tratar O
para O
determinar O
la O
duración O
media O
de O
la O
mejora O
de O
la O
CVH O
y O
las O
diferencias O
en O
la O
duración O
de O
la O
mejora O
entre O
los O
grupos O
de O
pacientes. O

Después B-Premise
de I-Premise
6 I-Premise
semanas, I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
tomaron I-Premise
prednisona I-Premise
no I-Premise
mostraron I-Premise
ninguna I-Premise
mejora I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
CVH, I-Premise
mientras I-Premise
que I-Premise
los I-Premise
que I-Premise
tomaron I-Premise
mitoxantrona I-Premise
más I-Premise
prednisona I-Premise
mostraron I-Premise
mejoras I-Premise
significativas I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
( I-Premise
P I-Premise
= I-Premise
0,009 I-Premise
), I-Premise
en I-Premise
cuatro I-Premise
dominios I-Premise
de I-Premise
funcionamiento I-Premise
y I-Premise
en I-Premise
nueve I-Premise
síntomas I-Premise
( I-Premise
0,001 I-Premise
< I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
), I-Premise
y I-Premise
la I-Premise
mejora I-Premise
( I-Premise
> I-Premise
10 I-Premise
unidades I-Premise
en I-Premise
una I-Premise
escala I-Premise
de I-Premise
0 I-Premise
a I-Premise
100 I-Premise
) I-Premise
duró I-Premise
más I-Premise
tiempo I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
prednisona I-Premise
sola I-Premise
( O
0,004 O
< O
P O
< O
0,05 O
). O

Después B-Premise
de I-Premise
6 I-Premise
semanas, I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
tomaron I-Premise
prednisona I-Premise
no I-Premise
mostraron I-Premise
ninguna I-Premise
mejora I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
CVH, I-Premise
mientras I-Premise
que I-Premise
los I-Premise
que I-Premise
tomaron I-Premise
mitoxantrona I-Premise
más I-Premise
prednisona I-Premise
mostraron I-Premise
mejoras I-Premise
significativas I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
( I-Premise
P I-Premise
= I-Premise
0,009 I-Premise
), I-Premise
en I-Premise
cuatro I-Premise
dominios I-Premise
de I-Premise
funcionamiento I-Premise
y I-Premise
en I-Premise
nueve I-Premise
síntomas I-Premise
( I-Premise
0,001 I-Premise
< I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) O
, O
y O
la B-Premise
mejora I-Premise
( I-Premise
> I-Premise
10 I-Premise
unidades I-Premise
en I-Premise
una I-Premise
escala I-Premise
de I-Premise
0 I-Premise
a I-Premise
100 I-Premise
) I-Premise
duró I-Premise
más I-Premise
tiempo I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
prednisona I-Premise
sola I-Premise
( I-Premise
.004 I-Premise
< I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) O
. O

La B-Premise
adición I-Premise
de I-Premise
mitoxantrona I-Premise
a I-Premise
la I-Premise
prednisona I-Premise
tras I-Premise
el I-Premise
fracaso I-Premise
de I-Premise
la I-Premise
prednisona I-Premise
sola I-Premise
se I-Premise
asoció I-Premise
con I-Premise
mejoras I-Premise
en I-Premise
el I-Premise
dolor I-Premise
, I-Premise
el I-Premise
impacto I-Premise
del I-Premise
dolor I-Premise
, I-Premise
el I-Premise
alivio I-Premise
del I-Premise
dolor I-Premise
, I-Premise
el I-Premise
insomnio I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
mitoxantrona I-Claim
más I-Claim
prednisona I-Claim
se I-Claim
asoció I-Claim
a I-Claim
una I-Claim
mejora I-Claim
mayor I-Claim
y I-Claim
más I-Claim
duradera I-Claim
en I-Claim
varios I-Claim
dominios I-Claim
y I-Claim
síntomas I-Claim
de I-Claim
la I-Claim
CVH I-Claim
que I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
prednisona I-Claim
sola I-Claim
. I-Claim

Los O
estudios O
sobre O
la O
calidad O
de O
vida O
( O
QOL O
) O
entre O
las O
mujeres O
con O
cáncer O
de O
endometrio O
han O
demostrado O
que O
las O
pacientes O
que O
se O
someten O
a O
radioterapia O
pélvica O
informan O
de O
un O
menor O
funcionamiento O
de O
su O
papel O
y O
más O
diarrea O
y O
fatiga O
. O

En O
el O
ensayo O
de O
radioterapia O
postoperatoria O
en O
el O
cáncer O
de O
endometrio O
( O
PORTEC O
) O
, O
las O
pacientes O
con O
carcinoma O
de O
endometrio O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
radioterapia O
de O
haz O
externo O
( O
EBRT O
) O
o O
braquiterapia O
vaginal O
( O
VBT O
) O
. O

La O
CdV O
se O
evaluó O
mediante O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
y O
subescalas O
del O
módulo O
de O
cáncer O
de O
próstata O
, O
PR-25 O
, O
y O
del O
módulo O
de O
cáncer O
de O
ovario O
, O
OV-28 O
. O

PORTEC-2 O
reclutó O
a O
427 O
pacientes O
entre O
2002 O
y O
2006 O
, O
de O
los O
cuales O
214 O
fueron O
asignados O
aleatoriamente O
a O
EBRT O
, O
y O
213 O
fueron O
asignados O
aleatoriamente O
a O
VBT O
. O

Trescientos O
cuarenta O
y O
ocho O
pacientes O
( O
81% O
) O
fueron O
evaluables O
para O
la O
CdV O
. O

Los O
resultados O
de O
la O
calidad O
de O
vida O
se O
analizaron O
en O
una O
mediana O
de O
seguimiento O
de O
2 O
años. O

En O
la O
línea O
de O
base O
después O
de O
la O
cirugía O
, O
el O
funcionamiento O
del O
paciente O
estaba O
en O
el O
nivel O
más O
bajo O
, O
y O
aumentó O
durante O
y O
después O
de O
la O
radioterapia O
para O
alcanzar O
una O
meseta O
después O
de O
12 O
meses O
. O

Los B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
la I-Premise
terapia I-Premise
de I-Premise
reemplazo I-Premise
intestinal I-Premise
informaron I-Premise
de I-Premise
un I-Premise
mejor I-Premise
funcionamiento I-Premise
social I-Premise
( I-Premise
P I-Premise
< I-Premise
0,002 I-Premise
) I-Premise
y I-Premise
menores I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
de I-Premise
diarrea, I-Premise
pérdidas I-Premise
fecales, I-Premise
necesidad I-Premise
de I-Premise
permanecer I-Premise
cerca I-Premise
del I-Premise
retrete I-Premise
y I-Premise
limitación I-Premise
de I-Premise
las I-Premise
actividades I-Premise
diarias I-Premise
a I-Premise
causa I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
intestinales I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
). I-Premise

En O
el O
momento O
inicial, O
el O
15% O
de O
los O
pacientes O
eran O
sexualmente O
activos; O
esta O
cifra O
aumentó O
significativamente O
hasta O
el O
39% O
durante O
el O
primer O
año O
( O
P O
< O
0,001 O
) O
. O

El B-Premise
funcionamiento I-Premise
sexual I-Premise
y I-Premise
los I-Premise
síntomas I-Premise
no I-Premise
difirieron I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
EBRT I-Premise
reportaron I-Premise
niveles I-Premise
significativamente I-Premise
más I-Premise
altos I-Premise
de I-Premise
diarrea I-Premise
y I-Premise
síntomas I-Premise
intestinales I-Premise
. I-Premise

Esto O
dio O
lugar O
a O
una O
mayor O
necesidad O
de O
permanecer O
cerca O
de O
un O
retrete O
y, O
como O
consecuencia, O
a O
una O
mayor O
limitación O
de O
las O
actividades O
diarias O
debido O
a O
los O
síntomas O
intestinales O
y O
a O
una O
disminución O
del O
funcionamiento O
social. O

La B-Claim
braquiterapia I-Claim
vaginal I-Claim
proporciona I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida, I-Claim
y I-Claim
debería I-Claim
ser I-Claim
el I-Claim
tratamiento I-Claim
preferido I-Claim
desde I-Claim
la I-Claim
perspectiva I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Evaluar O
la O
seguridad O
y O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
de O
la O
terapia O
de O
reemplazo O
hormonal O
combinada O
continua O
( O
ccHRT O
) O
con O
valerato O
de O
estradiol/acetato O
de O
medroxiprogesterona O
( O
E O
( O
2 O
) O
V/MPA O
) O
durante O
nueve O
años O
y O
en O
el O
seguimiento O
un O
año O
después O
de O
la O
interrupción O
. O

Un O
total O
de O
419 O
mujeres O
fueron O
asignadas O
al O
azar O
a O
uno O
de O
los O
cuatro O
tratamientos: O
1 O
mg O
de O
E2V/2,5 O
mg O
de O
MPA O
una O
vez O
al O
día O
( O
grupo O
1 O
+ O
2,5 O
) O
; O
1 O
mg O
de O
E2V/5 O
mg O
de O
MPA O
al O
día O
( O
grupo O
1 O
+ O
5 O
) O
; O
2 O
mg O
de O
E2V/2,5 O
mg O
de O
MPA O
al O
día O
( O
grupo O
2 O
+ O
2,5 O
) O
; O
2 O
mg O
de O
E2V/5 O
mg O
de O
MPA O
al O
día O
( O
grupo O
2 O
+ O
5 O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

Durante O
los O
últimos O
seis O
meses, O
todos O
recibieron O
la O
dosis O
de O
1 O
+ O
2,5. O

La O
dosis O
de O
2 O
+ O
2,5 O
se O
interrumpió O
al O
final O
del O
séptimo O
año. O

Un O
total O
de O
198 O
mujeres O
continuaron O
después O
del O
séptimo O
año. O

Las O
tasas O
porcentuales O
anualizadas O
de O
eventos O
cardiovasculares O
[ O
corregidas O
] O
y O
de O
cánceres O
de O
endometrio O
[ O
corregidas O
] O
se O
situaron O
por O
debajo O
de O
las O
tasas O
nacionales O
de O
Finlandia O
y O
de O
las O
comunicadas O
por O
la O
Women O
's O
Health O
Initiative O
. O

No B-Premise
se I-Premise
produjeron I-Premise
acontecimientos I-Premise
graves I-Premise
con I-Premise
la I-Premise
dosis I-Premise
de I-Premise
1 I-Premise
+ I-Premise
2,5 I-Premise
ni I-Premise
tras I-Premise
la I-Premise
interrupción I-Premise
de I-Premise
la I-Premise
THC. I-Premise

Los B-Premise
síntomas I-Premise
del I-Premise
climaterio I-Premise
se I-Premise
mantuvieron I-Premise
significativamente I-Premise
por I-Premise
debajo I-Premise
de I-Premise
los I-Premise
valores I-Premise
iniciales I-Premise
tras I-Premise
la I-Premise
reducción I-Premise
de I-Premise
la I-Premise
dosis; I-Premise
algunos I-Premise
síntomas I-Premise
reaparecieron I-Premise
tras I-Premise
la I-Premise
interrupción I-Premise
de I-Premise
la I-Premise
TRCH. I-Premise

Los B-Premise
índices I-Premise
de I-Premise
CVRS I-Premise
mejoraron I-Premise
con I-Premise
la I-Premise
TRCH, I-Premise
independientemente I-Premise
de I-Premise
la I-Premise
dosis, I-Premise
incluyendo I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
depresivo, I-Premise
la I-Premise
ansiedad, I-Premise
la I-Premise
percepción I-Premise
de I-Premise
la I-Premise
salud I-Premise
y I-Premise
el I-Premise
interés I-Premise
sexual. I-Premise

Las B-Premise
puntuaciones I-Premise
en I-Premise
una I-Premise
escala I-Premise
que I-Premise
evalúa I-Premise
el I-Premise
funcionamiento I-Premise
y I-Premise
el I-Premise
disfrute I-Premise
diarios I-Premise
( I-Premise
Q-LES-Q I-Premise
) I-Premise
mejoraron I-Premise
desde I-Premise
el I-Premise
séptimo I-Premise
al I-Premise
noveno I-Premise
año. I-Premise

Se B-Premise
deterioraron I-Premise
durante I-Premise
el I-Premise
seguimiento I-Premise
en I-Premise
las I-Premise
mujeres I-Premise
que I-Premise
no I-Premise
continuaron I-Premise
con I-Premise
la I-Premise
TRCH. I-Premise

Las B-Claim
dosis I-Claim
más I-Claim
bajas I-Claim
de I-Claim
THS I-Claim
fueron I-Claim
tan I-Claim
efectivas I-Claim
como I-Claim
las I-Claim
más I-Claim
altas I-Claim
en I-Claim
la I-Claim
mejora I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
climatéricos I-Claim
y I-Claim
las I-Claim
calificaciones I-Claim
de I-Claim
la I-Claim
CVRS I-Claim
y I-Claim
tuvieron I-Claim
menos I-Claim
problemas I-Claim
de I-Claim
seguridad. I-Claim

Tras B-Premise
la I-Premise
interrupción I-Premise
de I-Premise
la I-Premise
THC, I-Premise
la I-Premise
satisfacción I-Premise
de I-Premise
las I-Premise
pacientes I-Premise
fue I-Premise
variable, I-Premise
ya I-Premise
que I-Premise
el I-Premise
15 I-Premise
% I-Premise
decidió I-Premise
continuar I-Premise
o I-Premise
reiniciar I-Premise
la I-Premise
THC I-Premise
y I-Premise
el I-Premise
7 I-Premise
% I-Premise
la I-Premise
reanudó I-Premise
durante I-Premise
el I-Premise
seguimiento. I-Premise

Esto B-Claim
apoya I-Claim
la I-Claim
necesidad I-Claim
de I-Claim
un I-Claim
enfoque I-Claim
individualizado I-Claim
de I-Claim
las I-Claim
recomendaciones I-Claim
terapéuticas I-Claim
. I-Claim

Pocos O
ensayos O
aleatorios O
han O
comparado O
el O
beneficio O
de O
supervivencia O
del O
interferón-alfa O
sobre O
los O
controles O
en O
el O
carcinoma O
de O
células O
renales O
metastásico O
, O
y O
ninguno O
se O
ha O
realizado O
con O
interleucina-2 O
. O

El O
ensayo O
Programme O
Etude O
Rein O
Cytokines O
( O
PERCY O
) O
Quattro O
fue O
diseñado O
para O
evaluar O
ambas O
citoquinas O
por O
su O
beneficio O
en O
la O
supervivencia O
de O
los O
pacientes O
de O
pronóstico O
intermedio O
, O
que O
representan O
la O
mayoría O
de O
los O
candidatos O
a O
estos O
tratamientos O
. O

Las O
pacientes O
fueron O
asignadas O
al O
azar O
en O
un O
diseño O
factorial O
de O
2 O
por O
2 O
a O
acetato O
de O
medroxiprogesterona O
200 O
mg O
diarios, O
interferón O
alfa O
9 O
millones O
de O
UI O
3 O
veces O
por O
semana, O
interleucina O
2 O
subcutánea O
9 O
millones O
de O
UI O
diarios O
o O
una O
combinación O
de O
ambas O
citoquinas. O

La O
respuesta O
del O
tumor O
se O
evaluó O
en O
la O
semana O
12 O
y O
en O
el O
mes O
6; O
los O
pacientes O
sin O
progresión O
recibieron O
un O
tratamiento O
idéntico O
durante O
un O
máximo O
de O
3 O
meses O
adicionales. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia O
global; O
los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
supervivencia O
sin O
enfermedad, O
la O
tasa O
de O
respuesta, O
la O
toxicidad O
y O
la O
calidad O
de O
vida. O

La O
supervivencia O
se O
analizó O
por O
intención O
de O
tratar. O

Entre O
enero O
de O
2000 O
y O
julio O
de O
2004, O
se O
inscribieron O
492 O
pacientes. O

El O
análisis O
se O
realizó O
tras O
una O
mediana O
de O
seguimiento O
de O
29,2 O
meses O
( O
rango O
, O
0 O
meses O
a O
54,6 O
meses O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
de I-Premise
supervivencia I-Premise
entre I-Premise
los I-Premise
244 I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
interferón-alfa I-Premise
y I-Premise
los I-Premise
248 I-Premise
pacientes I-Premise
sin I-Premise
interferón-alfa I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1,00 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,81-1,24 I-Premise
) I-Premise
o I-Premise
entre I-Premise
los I-Premise
247 I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
interleucina-2 I-Premise
y I-Premise
245 I-Premise
sin I-Premise
interleucina-2 I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1,07 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,87-1,33 I-Premise
; I-Premise
log I-Premise
rank I-Premise
, I-Premise
0,99 I-Premise
y I-Premise
0,52 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Las B-Premise
toxicidades I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
fueron I-Premise
significativamente I-Premise
más I-Premise
frecuentes I-Premise
en I-Premise
las I-Premise
pacientes I-Premise
tratadas I-Premise
con I-Premise
citoquinas I-Premise
que I-Premise
en I-Premise
las I-Premise
tratadas I-Premise
con I-Premise
medroxiprogesterona I-Premise
. I-Premise

La B-Claim
interleucina-2 I-Claim
y/o I-Claim
el I-Claim
interferón-alfa I-Claim
subcutáneos I-Claim
no I-Claim
aportan I-Claim
ningún I-Claim
beneficio I-Claim
de I-Claim
supervivencia I-Claim
en I-Claim
los I-Claim
cánceres I-Claim
renales I-Claim
metastásicos I-Claim
de I-Claim
pronóstico I-Claim
intermedio, I-Claim
e I-Claim
inducen I-Claim
un I-Claim
riesgo I-Claim
significativo I-Claim
de I-Claim
toxicidad. I-Claim

Los B-Claim
nuevos I-Claim
inhibidores I-Claim
de I-Claim
la I-Claim
angiogénesis I-Claim
disponibles I-Claim
deben I-Claim
ser I-Claim
preferidos I-Claim
para I-Claim
estos I-Claim
pacientes I-Claim
. I-Claim

Investigar O
si O
el O
efecto O
de O
la O
radioterapia O
torácica O
hipofraccionada O
( O
TRT O
) O
es O
comparable O
al O
de O
la O
radioterapia O
fraccionada O
( O
RT O
) O
más O
estándar O
en O
el O
cáncer O
de O
pulmón O
no O
microcítico O
( O
CPNM O
) O
avanzado. O

Se O
incluyó O
a O
un O
total O
de O
421 O
pacientes O
con O
tumores O
de O
CPNM O
localmente O
avanzados O
en O
estadio O
III O
o O
estadio O
IV. O

Los O
criterios O
de O
inclusión O
fueron: O
inoperable, O
enfermedad O
demasiado O
avanzada O
para O
la O
radioterapia O
curativa O
y O
síntomas O
torácicos O
o O
tumor O
central O
que O
amenace O
las O
vías O
respiratorias. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
tres O
brazos O
: O
A O
, O
17 O
Gy O
por O
dos O
fracciones O
( O
n O
= O
146 O
) O
; O
B O
, O
42 O
Gy O
por O
15 O
fracciones O
( O
n O
= O
145 O
) O
; O
y O
C O
, O
50 O
Gy O
por O
25 O
fracciones O
( O
n O
= O
130 O
) O
. O

Cuatrocientos O
siete O
pacientes O
fueron O
elegibles O
para O
el O
estudio; O
395 O
pacientes O
( O
97% O
) O
participaron O
en O
el O
estudio O
de O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
. O

Para O
investigar O
el O
alivio O
de O
los O
síntomas O
de O
las O
vías O
respiratorias O
y O
los O
cambios O
en O
la O
CVRS O
se O
utilizaron O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
( O
QLQ O
) O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
-C30 O
y O
el O
módulo O
específico O
de O
cáncer O
de O
pulmón O
( O
LC13 O
) O
de O
la O
EORTC. O

Las O
evaluaciones O
se O
realizaron O
antes O
de O
la O
TRT O
y O
hasta O
la O
semana O
54 O
. O

Las O
evaluaciones O
de O
los O
médicos O
sobre O
la O
mejora O
de O
los O
síntomas O
se O
realizaron O
a O
las O
2, O
6 O
y O
14 O
semanas O
después O
de O
la O
finalización O
de O
la O
TRT. O

Los O
pacientes O
fueron O
observados O
durante O
un O
mínimo O
de O
3 O
años. O

Resultados O
Los O
datos O
pronósticos O
iniciales O
se O
distribuyeron O
por O
igual O
en O
los O
grupos O
de O
tratamiento. O

El O
cumplimiento O
de O
los O
pacientes O
con O
respecto O
a O
la O
investigación O
de O
la O
CVRS O
fue O
de O
un O
mínimo O
del O
74%. O

La B-Premise
CVRS I-Premise
y I-Premise
el I-Premise
alivio I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
fueron I-Premise
equivalentes I-Premise
en I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
A, I-Premise
B I-Premise
y I-Premise
C, I-Premise
con I-Premise
una I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
8,2, I-Premise
7,0 I-Premise
y I-Premise
6,8 I-Premise
meses, I-Premise
respectivamente. I-Premise

Nuestros B-Claim
datos I-Claim
indican I-Claim
que I-Claim
la I-Claim
TRT I-Claim
paliativa I-Claim
prolongada I-Claim
no I-Claim
aporta I-Claim
ninguna I-Claim
mejora I-Claim
en I-Claim
el I-Claim
alivio I-Claim
de I-Claim
los I-Claim
síntomas, I-Claim
la I-Claim
CVRS I-Claim
o I-Claim
la I-Claim
supervivencia I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
hipofraccionado I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
en I-Claim
el I-Claim
CPNM I-Claim
avanzado. I-Claim

El B-Claim
cisplatino I-Claim
reduce I-Claim
los I-Claim
niveles I-Claim
de I-Claim
grelina I-Claim
en I-Claim
plasma I-Claim
a I-Claim
través I-Claim
del I-Claim
receptor I-Claim
de I-Claim
la I-Claim
5-hidroxitriptamina I-Claim
( I-Claim
5-HT I-Claim
) I-Claim
. I-Claim

Esto O
puede O
provocar O
trastornos O
gastrointestinales O
inducidos O
por O
el O
cisplatino O
y O
dificultar O
la O
continuación O
de O
la O
quimioterapia O
. O

Los O
autores O
de O
este O
informe O
realizaron O
un O
ensayo O
prospectivo O
y O
aleatorizado O
de O
fase O
2 O
para O
evaluar O
los O
efectos O
de O
la O
grelina O
exógena O
durante O
la O
quimioterapia O
basada O
en O
cisplatino. O

Cuarenta O
y O
dos O
pacientes O
con O
cáncer O
de O
esófago O
que O
estaban O
recibiendo O
quimioterapia O
neoadyuvante O
basada O
en O
cisplatino O
fueron O
asignados O
a O
un O
grupo O
de O
grelina O
( O
n O
= O
21 O
) O
o O
a O
un O
grupo O
de O
placebo O
( O
n O
= O
21 O
) O
. O

Recibieron O
infusiones O
intravenosas O
de O
ghrelina O
humana O
sintética O
( O
3 O
μg/kg O
) O
o O
solución O
salina O
dos O
veces O
al O
día O
durante O
1 O
semana O
con O
la O
administración O
de O
cisplatino O
. O

El O
criterio O
de O
valoración O
primario O
fue O
los O
cambios O
en O
la O
ingesta O
de O
calorías O
por O
vía O
oral O
, O
y O
los O
criterios O
de O
valoración O
secundarios O
fueron O
los O
acontecimientos O
adversos O
relacionados O
con O
la O
quimioterapia O
; O
las O
puntuaciones O
de O
la O
escala O
analógica O
visual O
( O
EVA O
) O
del O
apetito O
; O
los O
cambios O
en O
las O
hormonas O
gastrointestinales O
y O
el O
estado O
nutricional O
, O
incluyendo O
las O
proteínas O
de O
recambio O
rápido O
, O
y O
la O
calidad O
de O
vida O
( O
QoL O
) O
estimada O
con O
el O
cuestionario O
central O
de O
QoL O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
QLQ-C30 O
) O
. O

Dos O
pacientes O
fueron O
excluidos O
del O
análisis O
final: O
un O
paciente O
suspendió O
la O
administración O
de O
grelina O
debido O
a O
una O
diaforesis O
excesiva, O
y O
otro O
paciente O
del O
grupo O
de O
placebo O
no O
cumplió O
con O
el O
autocuestionario. O

La B-Premise
ingesta I-Premise
de I-Premise
alimentos I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
EVA I-Premise
del I-Premise
apetito I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
grelina I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
( I-Premise
18,2 I-Premise
± I-Premise
5,2 I-Premise
kcal/kg/día I-Premise
frente I-Premise
a I-Premise
12,7 I-Premise
± I-Premise
3,4 I-Premise
kcal/kg/día I-Premise
[ I-Premise
P I-Premise
= I-Premise
.001 I-Premise
] I-Premise
y I-Premise
6,2 I-Premise
± I-Premise
0,9 I-Premise
frente I-Premise
a I-Premise
4,1 I-Premise
± I-Premise
0,9 I-Premise
[ I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
] I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
la I-Premise
grelina I-Premise
tuvieron I-Premise
menos I-Premise
acontecimientos I-Premise
adversos I-Premise
durante I-Premise
la I-Premise
quimioterapia I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
anorexia I-Premise
y I-Premise
las I-Premise
náuseas I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
. I-Premise

Después B-Premise
de I-Premise
la I-Premise
quimioterapia I-Premise
se I-Premise
observó I-Premise
un I-Premise
deterioro I-Premise
significativo I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
CdV, I-Premise
el I-Premise
apetito, I-Premise
las I-Premise
náuseas I-Premise
y I-Premise
los I-Premise
vómitos, I-Premise
y I-Premise
el I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global. I-Premise

La B-Claim
administración I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
de I-Claim
grelina I-Claim
exógena I-Claim
al I-Claim
inicio I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
con I-Claim
cisplatino I-Claim
estimuló I-Claim
la I-Claim
ingesta I-Claim
de I-Claim
alimentos I-Claim
y I-Claim
minimizó I-Claim
los I-Claim
efectos I-Claim
adversos. I-Claim

La O
mucositis O
oral O
inducida O
por O
la O
quimioterapia O
( O
CRT O
) O
afecta O
negativamente O
a O
las O
funciones O
orales O
del O
paciente O
y O
a O
su O
calidad O
de O
vida O
( O
QOL O
) O
. O

La O
terapia O
con O
láser O
de O
bajo O
nivel O
( O
LLLT O
) O
mostró O
algunos O
efectos O
preventivos O
y O
curativos O
frente O
a O
las O
medidas O
objetivas O
de O
la O
OM O
reportadas O
clínicamente O
en O
pocos O
ensayos, O
incluyendo O
nuestro O
estudio O
recientemente O
publicado O
. O

Existen O
pocas O
pruebas O
sobre O
los O
efectos O
de O
la O
TLV O
en O
la O
experiencia O
subjetiva O
de O
los O
pacientes O
con O
la O
OM O
y O
la O
CdV. O

Por O
lo O
tanto, O
realizamos O
este O
estudio O
para O
evaluar O
los O
efectos O
de O
la O
LLLT O
en O
las O
medidas O
informadas O
por O
el O
paciente O
sobre O
la O
OM O
y O
la O
QOL O
en O
pacientes O
con O
cáncer O
de O
cabeza O
y O
cuello O
( O
HNC O
) O
que O
reciben O
CRT O
. O

Este O
estudio O
triplemente O
ciego O
aleatorizó O
a O
220 O
pacientes O
de O
HNC O
programados O
para O
CRT O
( O
tres O
semanas O
de O
Cisplatino O
+ O
RT O
= O
66 O
Gray O
( O
2 O
Gy/sesión O
) O
, O
cinco O
fracciones/semana O
durante O
6,5 O
semanas O
, O
total O
33 O
fracciones O
) O
en O
grupos O
de O
láser O
( O
110 O
) O
y O
placebo O
( O
110 O
) O
. O

El O
grupo O
de O
láser O
recibió O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He-Ne O
, O
λ O
= O
632,8 O
nm O
, O
densidad O
de O
potencia O
= O
24 O
mW/cm O
( O
2 O
) O
, O
dosis O
= O
3,0 O
J O
en O
cada O
punto O
, O
dosis O
total/sesión O
= O
36-40 O
J O
, O
tamaño O
del O
punto O
1 O
cm O
( O
2 O
) O
, O
tiempo O
de O
irradiación/punto O
125 O
s O
) O
antes O
de O
cada O
sesión O
de O
radiación O
, O
mientras O
que O
el O
grupo O
de O
placebo O
no O
recibió O
terapia O
láser O
. O

La O
metodología O
fue O
similar O
a O
la O
de O
nuestro O
estudio O
recientemente O
publicado O
( O
Gautam O
et O
al O
. O

Radiother O
Oncol O
104:349-354 O
, O
2012 O
) O
. O

En O
esta O
parte O
de O
nuestro O
estudio, O
un O
evaluador O
cegado O
recogió O
los O
resultados O
subjetivos O
de O
las O
medidas O
de O
la O
OM O
comunicadas O
por O
el O
paciente O
mediante O
el O
Cuestionario O
Semanal O
de O
Mucositis O
Oral-Cabeza O
y O
Cuello O
(OMWQ-HN) O
y O
la O
CdV O
mediante O
el O
Cuestionario O
de O
Evaluación O
Funcional O
del O
Tratamiento O
del O
Cáncer-Cabeza O
y O
Cuello O
(FACT-HN). O

Los O
datos O
se O
analizaron O
mediante O
ANOVA O
de O
medidas O
repetidas O
a O
través O
de O
un O
modelo O
lineal O
general. O

La O
significación O
estadística O
se O
mantuvo O
en O
p O
< O
0,05 O
. O

El B-Premise
análisis I-Premise
de I-Premise
los I-Premise
resultados I-Premise
reveló I-Premise
que I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
OMWQ-HN I-Premise
( I-Premise
F I-Premise
= I-Premise
12,199 I-Premise
, I-Premise
df I-Premise
= I-Premise
6,1314 I-Premise
, I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
del I-Premise
FACT-HN I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
fueron I-Premise
significativamente I-Premise
menores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
LLLT I-Premise
que I-Premise
en I-Premise
los I-Premise
del I-Premise
grupo I-Premise
placebo I-Premise
. I-Premise

También O
se O
observó B-Premise
una I-Premise
reducción I-Premise
significativa I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
de I-Premise
la I-Premise
incidencia I-Premise
de I-Premise
la I-Premise
OM I-Premise
grave, I-Premise
la I-Premise
necesidad I-Premise
de I-Premise
analgésicos I-Premise
opiáceos I-Premise
y I-Premise
la I-Premise
nutrición I-Premise
parenteral I-Premise
total. I-Premise

La B-Claim
LLLT I-Claim
fue I-Claim
eficaz I-Claim
en I-Claim
la I-Claim
mejora I-Claim
de I-Claim
la I-Claim
experiencia I-Claim
subjetiva I-Claim
del I-Claim
paciente I-Claim
de I-Claim
la I-Claim
OM I-Claim
y I-Claim
la I-Claim
QOL I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
HNC I-Claim
que I-Claim
reciben I-Claim
CRT I-Claim
. I-Claim

Debido O
a O
la O
preocupación O
por O
las O
fracturas O
por O
fragilidad, O
el O
ejercicio O
es O
una O
contraindicación O
para O
los O
pacientes O
con O
cáncer O
de O
próstata O
con O
metástasis O
óseas. O

Estos O
pacientes O
experimentan O
un O
importante O
deterioro O
funcional O
y O
atrofia O
muscular, O
lo O
que O
puede O
conducir O
a O
una O
mayor O
probabilidad O
de O
complicaciones O
esqueléticas O
(es O
decir, O
fractura O
patológica, O
dolor O
óseo) O
y/o O
caídas. O

La O
prescripción O
de O
ejercicios O
de O
resistencia O
seguros O
puede O
contrarrestar O
este O
efecto O
. O

El O
objetivo O
de O
este O
ensayo O
de O
viabilidad O
era O
determinar O
la O
seguridad O
y O
la O
eficacia O
del O
ejercicio O
de O
resistencia O
por O
parte O
de O
los O
supervivientes O
de O
cáncer O
de O
próstata O
con O
enfermedad O
metastásica O
ósea O
. O

Veinte O
hombres O
con O
metástasis O
óseas O
establecidas O
secundarias O
al O
cáncer O
de O
próstata O
fueron O
asignados O
aleatoriamente O
a O
un O
programa O
de O
ejercicios O
de O
resistencia O
de O
12 O
semanas O
en O
el O
que O
la O
prescripción O
de O
ejercicios O
se O
basó O
en O
la O
localización O
de O
las O
lesiones O
óseas O
( O
n=10 O
) O
o O
a O
la O
atención O
habitual O
( O
n=10 O
) O
. O

Los O
resultados O
incluyeron O
la O
seguridad O
y O
la O
tolerancia O
del O
programa O
de O
ejercicios, O
la O
función O
física, O
el O
nivel O
de O
actividad O
física, O
la O
composición O
corporal, O
la O
fatiga, O
la O
calidad O
de O
vida O
y O
el O
malestar O
psicológico. O

Los O
resultados O
se O
compararon O
entre O
los O
grupos O
mediante O
un O
análisis O
de O
covarianza O
ajustado O
a O
los O
valores O
iniciales. O

Los O
participantes O
tenían O
una O
carga O
de O
enfermedad O
significativa, O
con O
un O
65% O
de O
participantes O
que O
presentaban O
dos O
o O
más O
regiones O
afectadas O
por O
metástasis O
óseas O
y O
una O
puntuación O
media O
de O
Gleason O
de O
8,2±0,9 O
. O

Cinco O
participantes O
( O
ejercicio=2 O
; O
atención O
habitual=3 O
) O
no O
completaron O
la O
intervención O
, O
tres O
de O
los O
cuales O
se O
debieron O
al O
avance O
de O
la O
enfermedad O
( O
ejercicio=2 O
; O
atención O
habitual=1 O
) O
. O

No B-Premise
se I-Premise
produjeron I-Premise
acontecimientos I-Premise
adversos I-Premise
ni I-Premise
complicaciones I-Premise
esqueléticas I-Premise
durante I-Premise
las I-Premise
sesiones I-Premise
de I-Premise
ejercicio I-Premise
supervisado I-Premise
. I-Premise

El B-Premise
programa I-Premise
de I-Premise
ejercicios I-Premise
fue I-Premise
bien I-Premise
tolerado, I-Premise
como I-Premise
lo I-Premise
demuestran I-Premise
las I-Premise
elevadas I-Premise
tasas I-Premise
de I-Premise
asistencia I-Premise
( I-Premise
83% I-Premise
) I-Premise
y I-Premise
de I-Premise
cumplimiento I-Premise
( I-Premise
93% I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
capacidad I-Premise
de I-Premise
los I-Premise
participantes I-Premise
de I-Premise
ejercitarse I-Premise
a I-Premise
una I-Premise
intensidad I-Premise
dentro I-Premise
del I-Premise
rango I-Premise
objetivo I-Premise
para I-Premise
los I-Premise
supervivientes I-Premise
de I-Premise
cáncer I-Premise
( I-Premise
índice I-Premise
de I-Premise
esfuerzo I-Premise
percibido I-Premise
=13,8±1,5 I-Premise
) I-Premise
. I-Premise

El B-Premise
cambio I-Premise
en I-Premise
la I-Premise
función I-Premise
física I-Premise
( I-Premise
fuerza I-Premise
muscular I-Premise
∼11 I-Premise
% I-Premise
; I-Premise
capacidad I-Premise
de I-Premise
ejercicio I-Premise
aeróbico I-Premise
submáximo I-Premise
∼5 I-Premise
% I-Premise
y I-Premise
deambulación I-Premise
∼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
el I-Premise
nivel I-Premise
de I-Premise
actividad I-Premise
física I-Premise
( I-Premise
∼24 I-Premise
% I-Premise
) I-Premise
y I-Premise
la I-Premise
masa I-Premise
magra I-Premise
( I-Premise
∼3 I-Premise
% I-Premise
) I-Premise
difirieron I-Premise
significativamente I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
tras I-Premise
la I-Premise
intervención I-Premise
, I-Premise
con I-Premise
cambios I-Premise
favorables I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
ejercicio I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
atención I-Premise
habitual I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
fatiga, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
o I-Premise
el I-Premise
malestar I-Premise
psicológico. I-Premise

Esta B-Claim
evidencia I-Claim
inicial I-Claim
que I-Claim
incluye I-Claim
un I-Claim
tamaño I-Claim
de I-Claim
muestra I-Claim
pequeño I-Claim
sugiere I-Claim
que I-Claim
el I-Claim
ejercicio I-Claim
de I-Claim
resistencia I-Claim
adecuadamente I-Claim
diseñado I-Claim
y I-Claim
supervisado I-Claim
puede I-Claim
ser I-Claim
seguro I-Claim
y I-Claim
bien I-Claim
tolerado I-Claim
por I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
con I-Claim
enfermedad I-Claim
metastásica I-Claim
ósea I-Claim
y I-Claim
puede I-Claim
conducir I-Claim
a I-Claim
mejoras I-Claim
en I-Claim
la I-Claim
función I-Claim
física I-Claim
, I-Claim
los I-Claim
niveles I-Claim
de I-Claim
actividad I-Claim
física I-Claim
y I-Claim
la I-Claim
masa I-Claim
magra I-Claim
. I-Claim

Para B-Claim
ampliar I-Claim
estos I-Claim
resultados I-Claim
preliminares, I-Claim
se I-Claim
necesitan I-Claim
ensayos I-Claim
futuros I-Claim
con I-Claim
muestras I-Claim
de I-Claim
mayor I-Claim
tamaño. I-Claim

Un O
reciente O
ensayo O
aleatorio O
para O
comparar O
la O
radioterapia O
de O
haz O
externo O
( O
EBRT O
) O
con O
la O
crioablación O
para O
la O
enfermedad O
localizada O
demostró O
que O
la O
crioablación O
no O
es O
inferior O
a O
la O
EBRT O
de O
haz O
externo O
en O
cuanto O
a O
la O
progresión O
de O
la O
enfermedad O
y O
la O
supervivencia O
global O
y O
específica O
de O
la O
enfermedad O
. O

Informamos O
sobre O
los O
resultados O
de O
calidad O
de O
vida O
( O
QOL O
) O
de O
este O
ensayo O
. O

Desde O
diciembre O
de O
1997 O
hasta O
febrero O
de O
2003, O
244 O
hombres O
con O
cáncer O
de O
próstata O
localizado O
de O
reciente O
diagnóstico O
fueron O
asignados O
aleatoriamente O
a O
crioablación O
o O
EBRT O
( O
dosis O
media O
de O
68 O
Gy O
) O
. O

Todos O
los O
pacientes O
recibieron O
una O
terapia O
antiandrogénica O
neoadyuvante. O

Los O
pacientes O
completaron O
el O
EORTC O
QLQ O
C30 O
y O
el O
Índice O
de O
Cáncer O
de O
Próstata O
( O
PCI O
) O
antes O
del O
tratamiento O
y O
a O
los O
1,5 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
y O
36 O
meses O
después O
del O
mismo. O

Independientemente B-Premise
del I-Premise
brazo I-Premise
de I-Premise
tratamiento, I-Premise
los I-Premise
participantes I-Premise
informaron I-Premise
de I-Premise
niveles I-Premise
elevados I-Premise
de I-Premise
CdV, I-Premise
con I-Premise
pocas I-Premise
excepciones. I-Premise

La B-Premise
crioablación I-Premise
se I-Premise
asoció I-Premise
a I-Premise
una I-Premise
mayor I-Premise
disfunción I-Premise
urinaria I-Premise
aguda I-Premise
( I-Premise
media I-Premise
de I-Premise
la I-Premise
función I-Premise
urinaria I-Premise
PCI I-Premise
crioablación=69,4 I-Premise
; I-Premise
media I-Premise
EBRT=90,7 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
que I-Premise
se I-Premise
resolvió I-Premise
con I-Premise
el I-Premise
tiempo I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
problemas I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
de I-Premise
última I-Premise
hora. I-Premise

Tanto B-Premise
los I-Premise
participantes I-Premise
de I-Premise
la I-Premise
EBRT I-Premise
como I-Premise
los I-Premise
de I-Premise
la I-Premise
crioablación I-Premise
informaron I-Premise
de I-Premise
una I-Premise
disminución I-Premise
de I-Premise
la I-Premise
función I-Premise
sexual I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses, I-Premise
y I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
crioablación I-Premise
informaron I-Premise
de I-Premise
un I-Premise
peor I-Premise
funcionamiento I-Premise
( I-Premise
media I-Premise
de I-Premise
la I-Premise
crioablación=7,2 I-Premise
: I-Premise
media I-Premise
de I-Premise
la I-Premise
EBRT=32,9 I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

La B-Premise
puntuación I-Premise
media I-Premise
de I-Premise
la I-Premise
función I-Premise
sexual I-Premise
fue I-Premise
15 I-Premise
puntos I-Premise
inferior I-Premise
a I-Premise
los I-Premise
3 I-Premise
años I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
crioablación I-Premise
y I-Premise
un I-Premise
13% I-Premise
más I-Premise
de I-Premise
los I-Premise
hombres I-Premise
sometidos I-Premise
a I-Premise
crioablación I-Premise
dijeron I-Premise
que I-Premise
la I-Premise
sexualidad I-Premise
era I-Premise
un I-Premise
problema I-Premise
moderado I-Premise
o I-Premise
grande. I-Premise

En B-Claim
este I-Claim
ensayo I-Claim
aleatorio, I-Claim
no I-Claim
se I-Claim
observó I-Claim
ninguna I-Claim
ventaja I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
para I-Claim
ninguno I-Claim
de I-Claim
los I-Claim
dos I-Claim
tratamientos, I-Claim
con I-Claim
la I-Claim
excepción I-Claim
de I-Claim
una I-Claim
peor I-Claim
función I-Claim
sexual I-Claim
comunicada I-Claim
por I-Claim
los I-Claim
tratados I-Claim
con I-Claim
crioablación. I-Claim

A O
los O
hombres O
que O
deseen O
aumentar O
sus O
probabilidades O
de O
conservar O
la O
función O
sexual O
se O
les O
puede O
aconsejar O
que O
elijan O
la O
EBRT O
en O
lugar O
de O
la O
crioablación O
. O

Se B-Claim
ha I-Claim
demostrado I-Claim
que I-Claim
las I-Claim
intervenciones I-Claim
no I-Claim
farmacológicas I-Claim
son I-Claim
técnicas I-Claim
de I-Claim
gestión I-Claim
eficaces I-Claim
para I-Claim
la I-Claim
fatiga I-Claim
relacionada I-Claim
con I-Claim
el I-Claim
cáncer I-Claim
( I-Claim
CRF I-Claim
) I-Claim
en I-Claim
los I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
. I-Claim

Sin O
embargo, O
pocos O
estudios O
han O
investigado O
su O
eficacia O
en O
pacientes O
que O
reciben O
quimioterapia. O

En O
este O
estudio, O
los O
autores O
probaron O
la O
eficacia O
de O
una O
intervención O
breve O
orientada O
al O
comportamiento O
para O
reducir O
el O
FRC O
y O
mejorar O
la O
función O
física O
y O
la O
angustia O
asociada O
en O
individuos O
que O
estaban O
recibiendo O
quimioterapia. O

Para O
este O
ensayo O
controlado O
aleatorio, O
se O
reclutaron O
60 O
pacientes O
con O
cáncer O
que O
recibieron O
la O
atención O
habitual O
o O
la O
intervención. O

La O
intervención O
se O
llevó O
a O
cabo O
de O
forma O
individual O
en O
3 O
ocasiones O
durante O
un O
período O
de O
9 O
a O
12 O
semanas, O
y O
el O
objetivo O
de O
la O
intervención O
era O
modificar O
los O
pensamientos O
y O
el O
comportamiento O
relacionados O
con O
la O
fatiga. O

Los O
resultados O
primarios O
se O
evaluaron O
de O
la O
siguiente O
manera O
: O
El O
FRC O
utilizando O
la O
Escala O
Visual O
Analógica-Fatiga O
Global; O
el O
funcionamiento O
físico O
utilizando O
el O
Cuestionario O
Básico O
30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer; O
y O
la O
angustia O
asociada O
al O
FRC O
utilizando O
la O
Medida O
del O
Resultado O
de O
la O
Fatiga. O

Las O
evaluaciones O
se O
realizaron O
en O
4 O
ocasiones: O
al O
inicio O
( O
T0 O
) O
, O
al O
final O
de O
la O
quimioterapia O
( O
T1 O
) O
, O
1 O
mes O
después O
de O
la O
quimioterapia O
( O
T2 O
) O
, O
y O
9 O
meses O
después O
del O
reclutamiento O
( O
T3 O
) O
. O

Los O
datos O
con O
distribución O
normal O
se O
analizaron O
mediante O
pruebas O
t O
y O
modelos O
mixtos O
de O
pendiente O
aleatoria O
e O
intercepción O
aleatoria. O

La B-Premise
intervención I-Premise
demostró I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
la I-Premise
mejora I-Premise
de I-Premise
la I-Premise
FRC, I-Premise
aunque B-Premise
este I-Premise
efecto I-Premise
se I-Premise
redujo I-Premise
una I-Premise
vez I-Premise
que I-Premise
se I-Premise
controlaron I-Premise
estadísticamente I-Premise
los I-Premise
factores I-Premise
de I-Premise
confusión. I-Premise

Hubo B-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
en I-Premise
el I-Premise
funcionamiento I-Premise
físico I-Premise
( I-Premise
coeficiente I-Premise
, I-Premise
10,0 I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
2,5-17,5 I-Premise
; I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
, I-Premise
y I-Premise
este I-Premise
efecto I-Premise
se I-Premise
mantuvo I-Premise
una I-Premise
vez I-Premise
que I-Premise
se I-Premise
controlaron I-Premise
estadísticamente I-Premise
los I-Premise
efectos I-Premise
de I-Premise
confusión I-Premise
de I-Premise
los I-Premise
trastornos I-Premise
del I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
y I-Premise
los I-Premise
trastornos I-Premise
comórbidos I-Premise
. I-Premise

No B-Premise
se I-Premise
detectó I-Premise
ninguna I-Premise
disminución I-Premise
de I-Premise
la I-Premise
angustia I-Premise
relacionada I-Premise
con I-Premise
la I-Premise
fatiga. I-Premise

La B-Claim
intervención I-Claim
orientada I-Claim
a I-Claim
la I-Claim
conducta I-Claim
produjo I-Claim
mejoras I-Claim
significativas I-Claim
en I-Claim
el I-Claim
funcionamiento I-Claim
físico I-Claim
, I-Claim
indicó I-Claim
una I-Claim
tendencia I-Claim
hacia I-Claim
la I-Claim
mejora I-Claim
del I-Claim
CRF I-Claim
, I-Claim
pero I-Claim
no I-Claim
detectó I-Claim
ningún I-Claim
efecto I-Claim
para I-Claim
la I-Claim
angustia I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
fatiga I-Claim
. I-Claim

La B-Claim
radioterapia I-Claim
es I-Claim
un I-Claim
tratamiento I-Claim
paliativo I-Claim
eficaz I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
cáncer I-Claim
con I-Claim
metástasis I-Claim
óseas I-Claim
dolorosas. I-Claim

Aunque O
se O
cree O
que O
la O
radioterapia O
de O
una O
o O
varias O
fracciones O
proporciona O
la O
misma O
paliación, O
se O
desconoce O
qué O
esquema O
de O
tratamiento O
ofrece O
una O
mejor O
relación O
calidad-precio. O

Se O
comparó O
la O
esperanza O
de O
vida O
ajustada O
a O
la O
calidad O
( O
la O
valoración O
global O
de O
la O
salud O
de O
los O
pacientes O
) O
y O
los O
costes O
sociales O
de O
los O
pacientes O
que O
recibieron O
radioterapia O
de O
una O
o O
varias O
fracciones O
. O

Se O
realizó O
un O
análisis O
de O
coste-utilidad O
en O
un O
ensayo O
holandés O
aleatorizado O
y O
controlado O
de O
1.157 O
pacientes O
con O
metástasis O
óseas O
dolorosas, O
en O
el O
que O
se O
compararon O
las O
respuestas O
al O
dolor O
y O
la O
calidad O
de O
vida O
de O
un O
programa O
de O
tratamiento O
de O
una O
sola O
fracción O
de O
8 O
Gy O
con O
un O
programa O
de O
tratamiento O
de O
seis O
fracciones O
de O
4 O
Gy O
cada O
una. O

Los O
valores O
sociales O
de O
las O
expectativas O
de O
vida O
se O
evaluaron O
con O
el O
cuestionario O
del O
sistema O
de O
clasificación O
EuroQol O
( O
EQ-5D O
) O
. O

Un O
subgrupo O
de O
166 O
pacientes O
también O
respondió O
a O
cuestionarios O
adicionales O
para O
estimar O
los O
costes O
no O
relacionados O
con O
la O
radioterapia O
y O
la O
medicina. O

Las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

Al B-Premise
comparar I-Premise
los I-Premise
esquemas I-Premise
de I-Premise
radioterapia I-Premise
de I-Premise
una I-Premise
y I-Premise
múltiples I-Premise
fracciones I-Premise
, I-Premise
no I-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
esperanza I-Premise
de I-Premise
vida I-Premise
( I-Premise
43,0 I-Premise
frente I-Premise
a I-Premise
40,4 I-Premise
semanas I-Premise
, I-Premise
P I-Premise
=0,20 I-Premise
) I-Premise
ni I-Premise
en I-Premise
la I-Premise
esperanza I-Premise
de I-Premise
vida I-Premise
ajustada I-Premise
a I-Premise
la I-Premise
calidad I-Premise
( I-Premise
17,7 I-Premise
frente I-Premise
a I-Premise
16,0 I-Premise
semanas I-Premise
, I-Premise
P I-Premise
=0,21 I-Premise
) I-Premise
. I-Premise

El B-Premise
coste I-Premise
estimado I-Premise
de I-Premise
la I-Premise
radioterapia, I-Premise
incluidos I-Premise
los I-Premise
retratamientos I-Premise
y I-Premise
los I-Premise
costes I-Premise
no I-Premise
médicos, I-Premise
fue I-Premise
significativamente I-Premise
inferior I-Premise
desde I-Premise
el I-Premise
punto I-Premise
de I-Premise
vista I-Premise
estadístico I-Premise
para I-Premise
el I-Premise
programa I-Premise
de I-Premise
una I-Premise
sola I-Premise
fracción I-Premise
que I-Premise
para I-Premise
el I-Premise
programa I-Premise
de I-Premise
múltiples I-Premise
fracciones I-Premise
( I-Premise
2.438 I-Premise
dólares I-Premise
frente I-Premise
a I-Premise
3.311 I-Premise
dólares, I-Premise
diferencia I-Premise
= I-Premise
873 I-Premise
dólares, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[IC] I-Premise
sobre I-Premise
la I-Premise
diferencia I-Premise
= I-Premise
449 I-Premise
dólares I-Premise
a I-Premise
1.297 I-Premise
dólares; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
). I-Premise

La B-Premise
diferencia I-Premise
estimada I-Premise
en I-Premise
los I-Premise
costes I-Premise
sociales I-Premise
totales I-Premise
fue I-Premise
mayor, I-Premise
también I-Premise
a I-Premise
favor I-Premise
del I-Premise
esquema I-Premise
de I-Premise
una I-Premise
sola I-Premise
fracción, I-Premise
pero B-Premise
no I-Premise
fue I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
4700 I-Premise
$ I-Premise
frente I-Premise
a I-Premise
6453 I-Premise
$ I-Premise
, I-Premise
diferencia I-Premise
= I-Premise
1753 I-Premise
$ I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
de I-Premise
la I-Premise
diferencia I-Premise
= I-Premise
- I-Premise
99 I-Premise
$ I-Premise
a I-Premise
3604 I-Premise
$ I-Premise
; I-Premise
P I-Premise
=.06 I-Premise
) O
. O

Para B-Premise
la I-Premise
disposición I-Premise
a I-Premise
pagar I-Premise
entre I-Premise
5.000 I-Premise
y I-Premise
40.000 I-Premise
dólares I-Premise
por I-Premise
año I-Premise
de I-Premise
vida I-Premise
ajustado I-Premise
a I-Premise
la I-Premise
calidad, I-Premise
el I-Premise
esquema I-Premise
de I-Premise
una I-Premise
sola I-Premise
fracción I-Premise
fue I-Premise
estadísticamente I-Premise
más I-Premise
rentable I-Premise
que I-Premise
el I-Premise
esquema I-Premise
de I-Premise
múltiples I-Premise
fracciones I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

En B-Claim
comparación I-Claim
con I-Claim
la I-Claim
radioterapia I-Claim
de I-Claim
fracciones I-Claim
múltiples I-Claim
, I-Claim
la I-Claim
radioterapia I-Claim
de I-Claim
fracción I-Claim
única I-Claim
proporciona I-Claim
igual I-Claim
paliación I-Claim
y I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
tiene I-Claim
menores I-Claim
costes I-Claim
médicos I-Claim
y I-Claim
sociales I-Claim
, I-Claim
al I-Claim
menos I-Claim
en I-Claim
los I-Claim
Países I-Claim
Bajos I-Claim
. I-Claim

Por B-Claim
lo I-Claim
tanto, I-Claim
la I-Claim
radioterapia I-Claim
de I-Claim
fracción I-Claim
única I-Claim
debe I-Claim
considerarse I-Claim
el I-Claim
tratamiento I-Claim
paliativo I-Claim
de I-Claim
elección I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
con I-Claim
metástasis I-Claim
óseas I-Claim
dolorosas. I-Claim

Para B-Claim
los I-Claim
pacientes I-Claim
con I-Claim
mesotelioma I-Claim
pleural I-Claim
maligno I-Claim
( I-Claim
MPM I-Claim
) I-Claim
con I-Claim
mal I-Claim
pronóstico, I-Claim
es I-Claim
importante I-Claim
mantener I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
salud I-Claim
( I-Claim
HRQOL I-Claim
). I-Claim

Este O
artículo O
compara O
el O
impacto O
en O
la O
CVRS O
del O
tratamiento O
de O
primera O
línea O
con O
cisplatino O
frente O
a O
raltitrexed O
y O
cisplatino O
. O

Los O
pacientes O
con O
MPM O
no O
resecable O
histológicamente O
probado, O
no O
pretratados O
con O
quimioterapia, O
fueron O
asignados O
aleatoriamente O
a O
recibir O
cisplatino O
80 O
mg/m2 O
por O
vía O
intravenosa O
el O
día O
1, O
con O
o O
sin O
infusión O
precedente O
de O
raltitrexed O
3 O
mg/m2. O

La O
CVRS O
se O
evaluó O
con O
las O
herramientas O
del O
Cuestionario O
Central O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
QLQ-C30 O
) O
y O
del O
Módulo O
de O
Cáncer O
de O
Pulmón O
de O
la O
EORTC O
( O
QLQ-LC13 O
) O
. O

Las O
evaluaciones O
se O
realizaron O
al O
inicio, O
inmediatamente O
antes O
de O
cada O
ciclo O
de O
tratamiento, O
al O
final O
del O
tratamiento O
y O
cada O
seis O
semanas O
durante O
12 O
meses. O

Doscientos O
cincuenta O
pacientes O
fueron O
asignados O
al O
azar O
, O
el O
80 O
% O
eran O
hombres O
con O
una O
edad O
media O
de O
58 O
años O
, O
el O
estado O
de O
rendimiento O
de O
la O
OMS O
0 O
, O
1 O
, O
y O
2 O
, O
en O
el O
25 O
% O
, O
62 O
% O
, O
y O
13 O
% O
de O
los O
casos O
. O

Los B-Premise
resultados I-Premise
clínicos I-Premise
determinaron I-Premise
que I-Premise
el I-Premise
raltitrexed I-Premise
y I-Premise
el I-Premise
cisplatino I-Premise
eran I-Premise
superiores I-Premise
al I-Premise
cisplatino I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
P I-Premise
= I-Premise
0,048 I-Premise
) I-Premise
. I-Premise

La B-Premise
escala I-Premise
global I-Premise
de I-Premise
CVRS I-Premise
fue I-Premise
comparable I-Premise
en I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
= I-Premise
0,848 I-Premise
); O
en B-Premise
ningún I-Premise
momento I-Premise
se I-Premise
apreciaron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
este I-Premise
punto I-Premise
final. I-Premise

Ambos B-Premise
tratamientos I-Premise
condujeron I-Premise
a I-Premise
una I-Premise
mejora, I-Premise
con I-Premise
el I-Premise
tiempo, I-Premise
de I-Premise
la I-Premise
disnea. I-Premise

Este B-Claim
efecto I-Claim
es I-Claim
una I-Claim
importante I-Claim
reducción I-Claim
clínicamente I-Claim
significativa I-Claim
desde I-Claim
el I-Claim
punto I-Claim
de I-Claim
partida I-Claim
en I-Claim
el I-Claim
brazo I-Claim
de I-Claim
cisplatino/raltitrexed I-Claim
. I-Claim

Sin B-Premise
embargo, I-Premise
la I-Premise
mayoría I-Premise
de I-Premise
las I-Premise
escalas I-Premise
del I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
o I-Premise
LC13 I-Premise
mostraron I-Premise
una I-Premise
estabilización I-Premise
de I-Premise
la I-Premise
CVRS I-Premise
con I-Premise
pocas I-Premise
diferencias I-Premise
clínicamente I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento. I-Premise

Este B-Claim
estudio I-Claim
proporciona I-Claim
información I-Claim
importante I-Claim
sobre I-Claim
la I-Claim
CVRS I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
MPM I-Claim
tratados I-Claim
con I-Claim
quimioterapia. I-Claim

El O
estrés O
fisiológico O
y O
psicológico O
que O
sufren O
los O
pacientes O
con O
tumores O
cerebrales O
durante O
toda O
la O
experiencia O
quirúrgica O
puede O
afectar O
considerablemente O
a O
varios O
aspectos O
de O
su O
hospitalización O
. O

El O
propósito O
de O
este O
estudio O
fue O
examinar O
los O
efectos O
de O
la O
musicoterapia O
en O
vivo O
sobre O
los O
indicadores O
de O
calidad O
de O
vida, O
la O
cantidad O
de O
medicamentos O
administrados O
y O
la O
duración O
de O
la O
estancia O
de O
las O
personas O
que O
reciben O
procedimientos O
quirúrgicos O
electivos O
del O
cerebro. O

Los O
sujetos O
( O
N O
= O
27 O
) O
eran O
pacientes O
ingresados O
por O
algún O
tipo O
de O
procedimiento O
quirúrgico O
del O
cerebro O
. O

Los O
sujetos O
fueron O
asignados O
aleatoriamente O
al O
grupo O
de O
control O
que O
no O
recibió O
ninguna O
intervención O
musical O
( O
n O
= O
13 O
) O
o O
al O
grupo O
experimental O
que O
recibió O
sesiones O
de O
musicoterapia O
en O
vivo O
antes O
y O
después O
de O
la O
operación O
( O
n O
= O
14 O
) O
. O

La O
ansiedad, O
el O
estado O
de O
ánimo, O
el O
dolor, O
la O
percepción O
de O
la O
hospitalización O
o O
el O
procedimiento, O
la O
relajación O
y O
el O
estrés O
se O
midieron O
mediante O
una O
escala O
visual O
analógica O
(EVA) O
de O
autoinforme O
para O
cada O
una O
de O
las O
variables. O

También O
se O
comparó O
la O
administración O
documentada O
de O
analgésicos O
postoperatorios; O
la O
frecuencia, O
la O
dosis, O
el O
tipo O
y O
la O
forma O
de O
administración O
entre O
los O
grupos. O

Sujetos O
experimentales O
viven O
y O
sesiones O
de O
musicoterapia O
interactiva O
, O
incluyendo O
una O
sesión O
preoperatoria O
y O
continuando O
con O
sesiones O
diarias O
hasta O
que O
el O
paciente O
fue O
dado O
de O
alta O
a O
casa O
. O

Los O
sujetos O
de O
control O
recibieron O
atención O
hospitalaria O
rutinaria O
sin O
ninguna O
intervención O
de O
musicoterapia O
. O

Las O
diferencias O
en O
las O
puntuaciones O
experimentales O
del O
pretest O
y O
el O
postest O
se O
analizaron O
mediante O
una O
prueba O
de O
Wilcoxon O
de O
pares O
con O
signo. O

Los B-Premise
resultados I-Premise
indicaron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
para I-Premise
4 I-Premise
de I-Premise
las I-Premise
6 I-Premise
medidas I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida: I-Premise
ansiedad I-Premise
( I-Premise
p I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
percepción I-Premise
de I-Premise
la I-Premise
hospitalización I-Premise
( I-Premise
p I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
relajación I-Premise
( I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
estrés I-Premise
( I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
los I-Premise
niveles I-Premise
de I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
( I-Premise
p I-Premise
> I-Premise
0,05 I-Premise
) I-Premise
o I-Premise
de I-Premise
dolor I-Premise
( I-Premise
p I-Premise
> I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Las O
cantidades O
de O
administración O
de O
los O
medicamentos O
para O
las O
náuseas O
y O
el O
dolor O
se O
compararon O
con O
un O
ANOVA O
de O
dos O
vías O
con O
una O
medida O
repetida, O
lo O
que O
dio O
como O
resultado O
que O
no O
había O
diferencias O
significativas O
entre O
los O
grupos O
y O
los O
medicamentos, O
F O
( O
1 O
, O
51 O
) O
= O
0,03 O
; O
p O
> O
.05 O
. O

Los O
resultados O
indican O
que O
no O
hay O
diferencias O
significativas O
entre O
los O
grupos O
en O
cuanto O
a O
la O
duración O
de O
la O
estancia O
( O
t O
= O
0,97 O
, O
df O
= O
25 O
, O
p O
> O
0,05 O
) O
. O

Este B-Claim
estudio I-Claim
de I-Claim
investigación I-Claim
indica I-Claim
que I-Claim
la I-Claim
musicoterapia I-Claim
en I-Claim
vivo I-Claim
con I-Claim
música I-Claim
preferida I-Claim
por I-Claim
el I-Claim
paciente I-Claim
puede I-Claim
ser I-Claim
beneficiosa I-Claim
para I-Claim
mejorar I-Claim
los I-Claim
indicadores I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
como I-Claim
la I-Claim
ansiedad I-Claim
, I-Claim
la I-Claim
percepción I-Claim
de I-Claim
la I-Claim
hospitalización I-Claim
o I-Claim
el I-Claim
procedimiento I-Claim
, I-Claim
la I-Claim
relajación I-Claim
y I-Claim
el I-Claim
estrés I-Claim
en I-Claim
pacientes I-Claim
sometidos I-Claim
a I-Claim
procedimientos I-Claim
quirúrgicos I-Claim
del I-Claim
cerebro I-Claim
. I-Claim

El O
bienestar O
espiritual O
y O
el O
sentido O
de O
la O
vida O
son O
preocupaciones O
importantes O
para O
los O
médicos O
que O
atienden O
a O
pacientes O
con O
cáncer. O

Desarrollamos O
la O
Psicoterapia O
Individual O
Centrada O
en O
el O
Significado O
(PICS) O
para O
abordar O
la O
necesidad O
de O
intervenciones O
breves O
dirigidas O
al O
bienestar O
espiritual O
y O
al O
significado O
para O
pacientes O
con O
cáncer O
avanzado. O

Los O
pacientes O
con O
cáncer O
en O
estadio O
III O
o O
IV O
( O
N O
= O
120 O
) O
fueron O
asignados O
aleatoriamente O
a O
siete O
sesiones O
de O
PCIM O
o O
de O
masaje O
terapéutico O
( O
TM O
) O
. O

Los O
pacientes O
fueron O
evaluados O
antes O
y O
después O
de O
completar O
la O
intervención O
y O
2 O
meses O
después O
de O
la O
misma. O

Las O
medidas O
de O
resultado O
primarias O
evaluaron O
el O
bienestar O
espiritual O
y O
la O
calidad O
de O
vida; O
las O
medidas O
de O
resultado O
secundarias O
incluyeron O
la O
ansiedad, O
la O
depresión, O
la O
desesperanza, O
la O
carga O
de O
los O
síntomas O
y O
la O
angustia O
relacionada O
con O
los O
síntomas. O

De O
los O
120 O
participantes O
asignados O
al O
azar, O
78 O
( O
65 O
% O
) O
completaron O
la O
evaluación O
posterior O
al O
tratamiento O
y O
67 O
( O
56 O
% O
) O
completaron O
el O
seguimiento O
de O
2 O
meses O
. O

En B-Premise
la I-Premise
evaluación I-Premise
posterior I-Premise
al I-Premise
tratamiento, I-Premise
los I-Premise
participantes I-Premise
del I-Premise
IMCP I-Premise
demostraron I-Premise
una I-Premise
mejora I-Premise
significativamente I-Premise
mayor I-Premise
que I-Premise
la I-Premise
condición I-Premise
de I-Premise
control I-Premise
en I-Premise
los I-Premise
resultados I-Premise
primarios I-Premise
de I-Premise
bienestar I-Premise
espiritual I-Premise
( I-Premise
b I-Premise
= I-Premise
0,39 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
, I-Premise
incluyendo I-Premise
ambos I-Premise
componentes I-Premise
del I-Premise
bienestar I-Premise
espiritual I-Premise
( I-Premise
sentido I-Premise
de I-Premise
significado I-Premise
: I-Premise
b I-Premise
= I-Premise
0,34 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
y I-Premise
fe I-Premise
: I-Premise
b I-Premise
= I-Premise
0,42 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
y I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
b I-Premise
= I-Premise
0,76 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,013 I-Premise
) I-Premise
. I-Premise

También B-Premise
se I-Premise
observaron I-Premise
mejoras I-Premise
significativamente I-Premise
mayores I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
IMCP I-Premise
en I-Premise
los I-Premise
resultados I-Premise
secundarios I-Premise
de I-Premise
carga I-Premise
de I-Premise
síntomas I-Premise
( I-Premise
b I-Premise
= I-Premise
-6,56 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
angustia I-Premise
relacionada I-Premise
con I-Premise
los I-Premise
síntomas I-Premise
( I-Premise
b I-Premise
= I-Premise
-0,47 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
), I-Premise
pero I-Premise
no I-Premise
para I-Premise
la I-Premise
ansiedad, I-Premise
la I-Premise
depresión I-Premise
o I-Premise
la I-Premise
desesperanza I-Premise
. I-Premise

En B-Premise
la I-Premise
evaluación I-Premise
de I-Premise
seguimiento I-Premise
a I-Premise
los I-Premise
2 I-Premise
meses, I-Premise
las I-Premise
mejoras I-Premise
observadas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
IMCP I-Premise
ya I-Premise
no I-Premise
eran I-Premise
significativamente I-Premise
mayores I-Premise
que I-Premise
las I-Premise
observadas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
TM. I-Premise

La B-Claim
PCIM I-Claim
tiene I-Claim
claros I-Claim
beneficios I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
para I-Claim
el I-Claim
sufrimiento I-Claim
espiritual I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
avanzado I-Claim
. I-Claim

Los O
clínicos O
que O
trabajan O
con O
pacientes O
que O
tienen O
cáncer O
avanzado O
deberían O
considerar O
la O
PCIM O
como O
un O
enfoque O
para O
mejorar O
la O
calidad O
de O
vida O
y O
el O
bienestar O
espiritual O
. O

Recientemente, B-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
gástrico I-Claim
avanzado I-Claim
mediante I-Claim
infusión I-Claim
continua I-Claim
de I-Claim
5-fluorouracilo I-Claim
( I-Claim
5-FU I-Claim
) I-Claim
con I-Claim
dosis I-Claim
bajas I-Claim
de I-Claim
cisplatino I-Claim
( I-Claim
CDDP I-Claim
) I-Claim
ha I-Claim
mejorado I-Claim
la I-Claim
eficacia I-Claim
sin I-Claim
toxicidades I-Claim
graves I-Claim
. I-Claim

La B-Claim
posible I-Claim
eficacia I-Claim
de I-Claim
5-FU+dosis I-Claim
baja I-Claim
de I-Claim
CDDP I-Claim
para I-Claim
el I-Claim
cáncer I-Claim
colorrectal I-Claim
( I-Claim
CCR I-Claim
) I-Claim
es I-Claim
intrigante I-Claim
. I-Claim

Ciento O
cincuenta O
y O
cinco O
pacientes O
con O
CCR O
muy O
avanzado O
que O
incluían O
al O
menos O
una O
lesión O
medible O
se O
inscribieron O
en O
un O
ensayo O
clínico O
prospectivo O
aleatorio O
financiado O
por O
la O
Fundación O
Japonesa O
para O
el O
Tratamiento O
Multidisciplinar O
del O
Cáncer. O

Estos O
pacientes O
fueron O
asignados O
a O
los O
dos O
brazos O
para O
evaluar O
el O
valor O
de O
la O
dosis O
baja O
de O
CDDP O
cuando O
se O
añade O
a O
una O
infusión O
intravenosa O
continua O
de O
5-FU O
a O
una O
dosis O
de O
300 O
mg/m O
( O
2 O
) O
/24 O
horas O
en O
un O
ciclo O
de O
una O
semana O
que O
consiste O
en O
5 O
días O
de O
tratamiento O
y O
2 O
días O
de O
descanso O
durante O
al O
menos O
12 O
semanas O
. O

La O
CD-DP O
se O
administró O
por O
vía O
intravenosa O
a O
una O
dosis O
de O
3 O
mg/m O
( O
2 O
) O
los O
días O
1-5 O
y O
8-12 O
, O
y O
luego O
a O
una O
dosis O
de O
7 O
mg/m O
( O
2 O
) O
dos O
veces O
por O
semana O
. O

Tres O
pacientes O
fueron O
excluidos O
del O
ensayo. O

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
5-FU+dosis I-Premise
baja I-Premise
de I-Premise
CDDP I-Premise
( I-Premise
n=75 I-Premise
) I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
que I-Premise
la I-Premise
del I-Premise
brazo I-Premise
de I-Premise
5-FU I-Premise
( I-Premise
n=77 I-Premise
) I-Premise
( I-Premise
25,3 I-Premise
% I-Premise
frente I-Premise
a I-Premise
11,7 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,037 I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
entre I-Premise
el I-Premise
brazo I-Premise
de I-Premise
5-FU+dosis I-Premise
baja I-Premise
de I-Premise
CDDP I-Premise
y I-Premise
el I-Premise
brazo I-Premise
de I-Premise
5-FU I-Premise
( I-Premise
479 I-Premise
y I-Premise
491 I-Premise
días I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Las B-Premise
toxicidades I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
se I-Premise
produjeron I-Premise
con I-Premise
poca I-Premise
frecuencia I-Premise
en I-Premise
ambos I-Premise
brazos. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fue I-Premise
casi I-Premise
la I-Premise
misma I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
. O

Las B-Claim
dosis I-Claim
bajas I-Claim
de I-Claim
CDDP I-Claim
mejoraron I-Claim
la I-Claim
tasa I-Claim
de I-Claim
respuesta I-Claim
manteniendo I-Claim
las I-Claim
toxicidades I-Claim
dentro I-Claim
de I-Claim
los I-Claim
límites I-Claim
clínicamente I-Claim
aceptables. I-Claim

Sin B-Claim
embargo, I-Claim
este I-Claim
tratamiento I-Claim
combinado I-Claim
no I-Claim
confirió I-Claim
una I-Claim
ventaja I-Claim
de I-Claim
supervivencia I-Claim
sobre I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
infusión I-Claim
continua I-Claim
de I-Claim
5-FU I-Claim
solo I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CCR I-Claim
muy I-Claim
avanzado; I-Claim
eso I-Claim
podría I-Claim
ser I-Claim
atribuible I-Claim
a I-Claim
la I-Claim
corta I-Claim
duración I-Claim
de I-Claim
la I-Claim
administración I-Claim
de I-Claim
CDDP I-Claim
de I-Claim
12 I-Claim
semanas. I-Claim

Estudios B-Claim
recientes I-Claim
han I-Claim
demostrado I-Claim
que I-Claim
la I-Claim
administración I-Claim
del I-Claim
inhibidor I-Claim
de I-Claim
la I-Claim
aromatasa I-Claim
exemestano I-Claim
tras I-Claim
2-3 I-Claim
años I-Claim
de I-Claim
tratamiento I-Claim
con I-Claim
tamoxifeno I-Claim
mejora I-Claim
significativamente I-Claim
la I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
enfermedad I-Claim
en I-Claim
mujeres I-Claim
posmenopáusicas I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
primario I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
estándar I-Claim
con I-Claim
tamoxifeno I-Claim
durante I-Claim
5 I-Claim
años I-Claim
. I-Claim

Aunque O
se O
han O
analizado O
muchos O
de O
los O
efectos O
adversos O
asociados O
al O
exemestano O
y O
al O
tamoxifeno, O
no O
existen O
datos O
comparativos O
sobre O
el O
peso O
y O
la O
composición O
corporal. O

El O
objetivo O
de O
este O
estudio O
aleatorio O
fue O
evaluar O
los O
cambios O
longitudinales O
en O
la O
composición O
corporal O
y O
los O
perfiles O
lipídicos O
en O
mujeres O
posmenopáusicas O
a O
las O
que O
se O
les O
cambió O
el O
tamoxifeno O
por O
el O
exemestano O
. O

En O
total, O
se O
inscribieron O
60 O
pacientes O
posmenopáusicas O
con O
sobrepeso O
u O
obesidad. O

Se O
evaluaron O
los O
datos O
antropométricos, O
la O
composición O
corporal, O
incluida O
la O
masa O
grasa O
(MG) O
y O
la O
masa O
libre O
de O
grasa O
(MLG), O
y O
los O
perfiles O
lipídicos, O
la O
ingesta O
calórica O
y O
la O
actividad O
física O
una O
semana O
antes O
de O
la O
aleatorización, O
y O
6 O
y O
12 O
meses O
después. O

En O
total, O
55 O
pacientes O
( O
27 O
con O
tamoxifeno O
y O
28 O
con O
exemestano O
) O
completaron O
el O
periodo O
de O
estudio O
de O
1 O
año. O

La B-Premise
masa I-Premise
grasa I-Premise
había I-Premise
disminuido I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
mes I-Premise
12 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
exemestano, I-Premise
pero I-Premise
no I-Premise
en I-Premise
el I-Premise
de I-Premise
tamoxifeno; I-Premise
la B-Premise
diferencia I-Premise
entre I-Premise
grupos I-Premise
fue I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) O
. O

La B-Premise
relación I-Premise
FFM/FM I-Premise
había I-Premise
aumentado I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
exemestano, I-Premise
pero I-Premise
no I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tamoxifeno; I-Premise
la B-Premise
diferencia I-Premise
entre I-Premise
grupos I-Premise
fue I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) O
. O

Los B-Premise
triglicéridos I-Premise
y I-Premise
el I-Premise
colesterol I-Premise
de I-Premise
lipoproteínas I-Premise
de I-Premise
alta I-Premise
densidad I-Premise
disminuyeron I-Premise
significativamente I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) O
, O
y O
el O
colesterol B-Premise
de I-Premise
lipoproteínas I-Premise
de I-Premise
baja I-Premise
densidad I-Premise
aumentó I-Premise
significativamente I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
exemestano I-Premise
al I-Premise
final I-Premise
del I-Premise
período I-Premise
de I-Premise
estudio I-Premise
de I-Premise
1 I-Premise
año I-Premise
. O

Nuestros B-Claim
resultados I-Claim
sugieren I-Claim
que I-Claim
el I-Claim
cambio I-Claim
de I-Claim
las I-Claim
pacientes I-Claim
al I-Claim
tratamiento I-Claim
adyuvante I-Claim
con I-Claim
exemestano I-Claim
después I-Claim
de I-Claim
al I-Claim
menos I-Claim
2 I-Claim
años I-Claim
de I-Claim
terapia I-Claim
con I-Claim
tamoxifeno I-Claim
puede I-Claim
estar I-Claim
asociado I-Claim
con I-Claim
una I-Claim
ventaja I-Claim
sobre I-Claim
la I-Claim
continuación I-Claim
del I-Claim
tratamiento I-Claim
adyuvante I-Claim
con I-Claim
tamoxifeno I-Claim
en I-Claim
términos I-Claim
de I-Claim
composición I-Claim
corporal I-Claim
. I-Claim

La B-Claim
terapia I-Claim
antiaromatasa I-Claim
es I-Claim
importante I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
en I-Claim
mujeres I-Claim
posmenopáusicas, I-Claim
pero O
tienen O
efectos O
sobre O
la O
densidad O
mineral O
ósea O
( O
DMO O
) O
y O
la O
osteoporosis O
. O

Los B-Claim
inhibidores I-Claim
de I-Claim
la I-Claim
ciclooxigenasa-2 I-Claim
( I-Claim
COX-2 I-Claim
) I-Claim
han I-Claim
demostrado I-Claim
su I-Claim
eficacia I-Claim
en I-Claim
la I-Claim
quimioprevención I-Claim
en I-Claim
estudios I-Claim
animales I-Claim
y I-Claim
clínicos I-Claim
. I-Claim

Se O
realizó O
un O
estudio O
de O
prueba O
de O
principio O
para O
investigar O
la O
eficacia O
de O
combinar O
la O
terapia O
antiaromatasa O
( O
exemestano O
) O
y O
los O
inhibidores O
de O
la O
COX-2 O
de O
forma O
neoadyuvante O
. O

Los O
cambios O
en O
la O
DMO O
, O
las O
proteínas O
de O
recambio O
óseo O
y O
la O
calidad O
de O
vida O
( O
QoL O
) O
fueron O
analizados O
y O
presentados O
aquí O
. O

Se O
incluyeron O
82 O
pacientes O
posmenopáusicas O
con O
cánceres O
de O
mama O
invasivos O
hormonosensibles O
confirmados O
histológicamente O
para O
la O
terapia O
neoadyuvante O
( O
NHT O
) O
. O

30 O
pacientes O
recibieron O
exemestano O
( O
EXE O
) O
25 O
mg O
diarios O
y O
celecoxib O
( O
CXB O
) O
400 O
mg O
dos O
veces O
al O
día O
( O
grupo O
A O
) O
, O
24 O
pacientes O
recibieron O
EXE O
25 O
mg O
diarios O
( O
grupo O
B O
) O
y O
28 O
pacientes O
recibieron O
letrozol O
( O
LET O
) O
2,5 O
mg O
diarios O
( O
grupo O
C O
) O
. O

El O
mismo O
tratamiento O
asignado O
debía O
continuar O
durante O
2 O
años O
para O
estudiar O
los O
cambios O
en O
el O
metabolismo O
óseo O
. O

Se O
analizó O
la O
DMO O
de O
48 O
pacientes; O
23 O
pertenecen O
al O
grupo O
A, O
10 O
al O
grupo O
B O
y O
15 O
al O
grupo O
C. O
Las O
proteínas O
séricas O
de O
recambio O
óseo O
fosfatasa O
alcalina O
específica O
del O
hueso O
( O
BAP O
) O
y O
telopéptido O
carboxiterminal O
reticulado O
del O
colágeno O
tipo O
I O
( O
ICTP O
) O
, O
se O
midieron O
con O
kits O
de O
prueba O
disponibles O
en O
el O
mercado O
antes O
del O
tratamiento O
, O
3 O
meses O
y O
15 O
meses O
después O
del O
tratamiento O
. O

El O
cuestionario O
básico O
de O
Evaluación O
Funcional O
de O
la O
Terapia O
contra O
el O
Cáncer O
( O
FACT-G O
) O
con O
su O
subescala O
adicional O
de O
cáncer O
de O
mama O
se O
realizó O
en O
la O
línea O
de O
base O
, O
4 O
, O
8 O
y O
12 O
semanas O
después O
de O
la O
NHT O
. O

La B-Premise
diferencia I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
( I-Premise
p=0,007 I-Premise
) I-Premise
para I-Premise
la I-Premise
DMO I-Premise
en I-Premise
el I-Premise
fémur I-Premise
fue I-Premise
significativa I-Premise
. I-Premise

Los B-Premise
cambios I-Premise
de I-Premise
la I-Premise
DMO I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
B I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
que I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
A I-Premise
( I-Premise
p=0,011 I-Premise
, I-Premise
CI=0,063-0,437 I-Premise
) I-Premise
, I-Premise
y I-Premise
del I-Premise
grupo I-Premise
C I-Premise
( I-Premise
p=0,003 I-Premise
, I-Premise
CI=0,146-0,620 I-Premise
) I-Premise
. I-Premise

La B-Premise
media I-Premise
de I-Premise
BAP I-Premise
aumentó I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
B, I-Premise
pero I-Premise
disminuyó I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
C I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses I-Premise
y I-Premise
a I-Premise
los I-Premise
15 I-Premise
meses. I-Premise

No B-Premise
se I-Premise
encontró I-Premise
significación I-Premise
estadística I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
FACT-G I-Premise
y I-Premise
FACT-B I-Premise
entre I-Premise
los I-Premise
diferentes I-Premise
grupos I-Premise
al I-Premise
inicio, I-Premise
en I-Premise
la I-Premise
semana I-Premise
4, I-Premise
en I-Premise
la I-Premise
semana I-Premise
8 I-Premise
y I-Premise
en I-Premise
la I-Premise
semana I-Premise
12 I-Premise
después I-Premise
de I-Premise
la I-Premise
NHT. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
subescala I-Premise
de I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
en I-Premise
las I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
A I-Premise
fueron I-Premise
significativamente I-Premise
más I-Premise
altas I-Premise
que I-Premise
las I-Premise
del I-Premise
grupo I-Premise
C I-Premise
( I-Premise
p=0,021 I-Premise
) I-Premise
. I-Premise

Después B-Premise
de I-Premise
4 I-Premise
semanas I-Premise
de I-Premise
NHT I-Premise
, I-Premise
se I-Premise
encontraron I-Premise
cambios I-Premise
negativos I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
FACT-B I-Premise
y I-Premise
FACT-G I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
B I-Premise
y I-Premise
C I-Premise
, O
pero B-Premise
hubo I-Premise
cambios I-Premise
positivos I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
A I-Premise
. O

Se B-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
FACT-B I-Premise
( I-Premise
p=0,008 I-Premise
) I-Premise
y I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
FACT-G I-Premise
( I-Premise
p=0,019 I-Premise
) I-Premise
en I-Premise
ese I-Premise
momento. I-Premise

Artículo O
del O
número O
especial O
sobre O
Inhibidores O
Dirigidos O
. O

Los O
sofocos O
y O
los O
sudores O
nocturnos O
( O
HFNS O
) O
afectan O
al O
65-85 O
% O
de O
las O
mujeres O
después O
del O
tratamiento O
del O
cáncer O
de O
mama O
; O
son O
angustiosos O
, O
causan O
problemas O
de O
sueño O
y O
disminuyen O
la O
calidad O
de O
vida O
. O

La B-Claim
terapia I-Claim
hormonal I-Claim
sustitutiva I-Claim
suele I-Claim
ser I-Claim
indeseable I-Claim
o I-Claim
estar I-Claim
contraindicada. I-Claim

Se B-Claim
necesitan I-Claim
tratamientos I-Claim
no I-Claim
hormonales I-Claim
seguros I-Claim
y I-Claim
eficaces. I-Claim

Se O
investigó O
si O
la O
terapia O
cognitivo-conductual O
( O
TCC O
) O
puede O
ayudar O
a O
las O
supervivientes O
de O
cáncer O
de O
mama O
a O
manejar O
eficazmente O
la O
HFNS O
. O

En O
este O
ensayo O
controlado O
aleatorio O
, O
se O
reclutaron O
mujeres O
de O
clínicas O
de O
mama O
en O
Londres O
, O
Reino O
Unido O
, O
que O
tenían O
HFNS O
problemático O
( O
mínimo O
diez O
episodios O
problemáticos O
a O
la O
semana O
) O
después O
del O
tratamiento O
del O
cáncer O
de O
mama O
. O

Los O
participantes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
la O
atención O
habitual O
o O
la O
atención O
habitual O
más O
la O
TCC O
de O
grupo O
( O
1:1 O
) O
. O

La O
aleatorización O
se O
hizo O
en O
bloques O
de O
12-20 O
participantes O
, O
estratificando O
por O
edad O
( O
menores O
de O
50 O
años O
, O
50 O
años O
o O
más O
) O
, O
y O
se O
hizo O
con O
una O
secuencia O
generada O
por O
ordenador O
. O

El O
estadístico O
del O
ensayo O
y O
los O
investigadores O
que O
recogían O
las O
medidas O
de O
resultado O
no O
conocían O
la O
asignación O
de O
los O
grupos. O

La O
TCC O
grupal O
comprendía O
una O
sesión O
de O
90 O
minutos O
a O
la O
semana O
durante O
6 O
semanas O
, O
e O
incluía O
psicoeducación O
, O
respiración O
acompasada O
, O
y O
estrategias O
cognitivas O
y O
conductuales O
para O
manejar O
el O
HFNS O
. O

Las O
evaluaciones O
se O
realizaron O
al O
inicio, O
a O
las O
9 O
semanas O
y O
a O
las O
26 O
semanas O
después O
de O
la O
aleatorización. O

El O
resultado O
primario O
fue O
la O
diferencia O
media O
ajustada O
en O
la O
calificación O
de O
problemas O
de O
HFNS O
( O
1-10 O
) O
entre O
los O
grupos O
de O
TCC O
y O
de O
atención O
habitual O
a O
las O
9 O
semanas O
después O
de O
la O
aleatorización O
. O

El O
análisis O
del O
criterio O
de O
valoración O
primario O
se O
realizó O
por O
intención O
de O
tratar O
modificada. O

El O
ensayo O
está O
registrado, O
ISRCTN13771934, O
y O
se O
cerró O
el O
15 O
de O
marzo O
de O
2011. O

Entre O
el O
5 O
de O
mayo O
de O
2009 O
y O
el O
27 O
de O
agosto O
de O
2010, O
96 O
mujeres O
fueron O
asignadas O
aleatoriamente O
a O
la O
TCC O
grupal O
( O
n=47 O
) O
o O
a O
la O
atención O
habitual O
( O
n=49 O
) O
. O

La B-Premise
TCC I-Premise
grupal I-Premise
redujo I-Premise
significativamente I-Premise
el I-Premise
índice I-Premise
de I-Premise
problemas I-Premise
de I-Premise
HFNS I-Premise
a I-Premise
las I-Premise
9 I-Premise
semanas I-Premise
de I-Premise
la I-Premise
aleatorización I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
atención I-Premise
habitual I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
-1-67 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
-2-43 I-Premise
a I-Premise
-0-91 I-Premise
; I-Premise
p I-Premise
< I-Premise
0-0001 I-Premise
) I-Premise
y I-Premise
las I-Premise
mejoras I-Premise
se I-Premise
mantuvieron I-Premise
a I-Premise
las I-Premise
26 I-Premise
semanas I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
-1-76 I-Premise
, I-Premise
-2-54 I-Premise
a I-Premise
-0-99 I-Premise
; I-Premise
p I-Premise
< I-Premise
0-0001 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
registraron I-Premise
eventos I-Premise
adversos I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
TCC. I-Premise

La B-Claim
TCC I-Claim
grupal I-Claim
parece I-Claim
ser I-Claim
un I-Claim
tratamiento I-Claim
seguro I-Claim
y I-Claim
eficaz I-Claim
para I-Claim
las I-Claim
mujeres I-Claim
que I-Claim
tienen I-Claim
HFNS I-Claim
problemáticas I-Claim
después I-Claim
del I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama, I-Claim
con I-Claim
beneficios I-Claim
adicionales I-Claim
para I-Claim
el I-Claim
estado I-Claim
de I-Claim
ánimo, I-Claim
el I-Claim
sueño I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

El O
tratamiento O
podría O
incorporarse O
a O
los O
programas O
de O
supervivencia O
al O
cáncer O
de O
mama O
y O
ser O
administrado O
por O
enfermeras O
formadas O
en O
la O
materia. O

La B-Claim
mayoría I-Claim
de I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
avanzado I-Claim
desarrollan I-Claim
una I-Claim
enfermedad I-Claim
recurrente. I-Claim

Para B-Claim
aquellos I-Claim
pacientes I-Claim
que I-Claim
recurren I-Claim
al I-Claim
menos I-Claim
6 I-Claim
meses I-Claim
después I-Claim
de I-Claim
la I-Claim
terapia I-Claim
inicial I-Claim
, I-Claim
el I-Claim
platino I-Claim
paclitaxel I-Claim
ha I-Claim
mostrado I-Claim
una I-Claim
modesta I-Claim
ventaja I-Claim
de I-Claim
supervivencia I-Claim
sobre I-Claim
el I-Claim
platino I-Claim
sin I-Claim
paclitaxel I-Claim
; O
sin B-Premise
embargo I-Premise
, I-Premise
muchos I-Premise
pacientes I-Premise
desarrollan I-Premise
neurotoxicidad I-Premise
clínicamente I-Premise
relevante I-Premise
, I-Premise
lo I-Premise
que I-Premise
frecuentemente I-Premise
resulta I-Premise
en I-Premise
la I-Premise
interrupción I-Premise
del I-Premise
tratamiento I-Premise
. O

Así, O
se O
evaluó O
un O
régimen O
alternativo O
sin O
neurotoxicidad O
significativa O
comparando O
gemcitabina O
más O
carboplatino O
con O
carboplatino O
como O
agente O
único O
en O
pacientes O
con O
cáncer O
de O
ovario O
recurrente O
sensibles O
al O
platino. O

Las O
pacientes O
con O
cáncer O
de O
ovario O
recurrente O
sensible O
al O
platino O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
gemcitabina O
más O
carboplatino O
o O
carboplatino O
solo, O
cada O
21 O
días. O

El O
objetivo O
primario O
fue O
comparar O
la O
supervivencia O
libre O
de O
progresión O
( O
SSP O
) O
. O

Se O
asignaron O
aleatoriamente O
356 O
pacientes O
( O
178 O
gemcitabina O
más O
carboplatino O
; O
178 O
carboplatino O
). O

Los O
pacientes O
recibieron O
una O
mediana O
de O
seis O
ciclos O
en O
ambos O
brazos. O

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
17 I-Premise
meses I-Premise
, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
de I-Premise
8,6 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
7,9 I-Premise
a I-Premise
9,7 I-Premise
meses I-Premise
) I-Premise
para I-Premise
la I-Premise
gemcitabina I-Premise
más I-Premise
carboplatino I-Premise
y I-Premise
de I-Premise
5,8 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
5,2 I-Premise
a I-Premise
7,1 I-Premise
meses I-Premise
) I-Premise
para I-Premise
el I-Premise
carboplatino I-Premise
. I-Premise

La B-Premise
razón I-Premise
de I-Premise
riesgo I-Premise
( I-Premise
HR I-Premise
) I-Premise
para I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
de I-Premise
0,72 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,58 I-Premise
a I-Premise
0,90 I-Premise
; I-Premise
P I-Premise
= I-Premise
.0031 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
fue I-Premise
del I-Premise
47,2 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
39,9 I-Premise
% I-Premise
a I-Premise
54,5 I-Premise
% I-Premise
) I-Premise
para I-Premise
la I-Premise
gemcitabina I-Premise
más I-Premise
carboplatino I-Premise
y I-Premise
del I-Premise
30,9 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
24,1 I-Premise
% I-Premise
a I-Premise
37,7 I-Premise
% I-Premise
) I-Premise
para I-Premise
el I-Premise
carboplatino I-Premise
( I-Premise
P I-Premise
= I-Premise
.0016 I-Premise
) I-Premise
. I-Premise

El B-Premise
CRI I-Premise
para I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
0,96 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,75 I-Premise
a1,23 I-Premise
; I-Premise
P I-Premise
= I-Premise
.7349 I-Premise
) I-Premise
. I-Premise

Aunque B-Premise
la I-Premise
mielosupresión I-Premise
fue I-Premise
significativamente I-Premise
más I-Premise
frecuente I-Premise
en I-Premise
la I-Premise
combinación, I-Premise
las I-Premise
secuelas I-Premise
como I-Premise
la I-Premise
neutropenia I-Premise
febril I-Premise
o I-Premise
las I-Premise
infecciones I-Premise
fueron I-Premise
poco I-Premise
frecuentes. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
los I-Premise
brazos. I-Premise

Gemcitabina B-Claim
más I-Claim
carboplatino I-Claim
mejora I-Claim
significativamente I-Claim
la I-Claim
SLP I-Claim
y I-Claim
la I-Claim
tasa I-Claim
de I-Claim
respuesta I-Claim
sin I-Claim
empeorar I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
recurrente I-Claim
sensible I-Claim
al I-Claim
platino I-Claim
. I-Claim

Hay O
muy O
pocos O
estudios O
controlados O
aleatorios O
sobre O
el O
ejercicio O
en O
pacientes O
con O
cáncer. O

En O
consecuencia, O
no O
se O
dispone O
de O
directrices O
sobre O
los O
ejercicios O
que O
pueden O
recomendarse O
y O
en O
la O
práctica O
clínica O
surgen O
dificultades O
para O
determinar O
qué O
ejercicio O
es O
el O
más O
adecuado O
para O
los O
pacientes. O

El O
propósito O
de O
este O
estudio O
fue O
investigar O
el O
impacto O
de O
los O
ejercicios O
de O
pilates O
en O
el O
rendimiento O
físico O
, O
la O
flexibilidad O
, O
la O
fatiga O
, O
la O
depresión O
y O
la O
calidad O
de O
vida O
en O
las O
mujeres O
que O
habían O
sido O
tratadas O
de O
cáncer O
de O
mama O
. O

Ensayo O
controlado O
aleatorio O
. O

Grupo O
de O
pacientes O
externos O
, O
Departamento O
de O
Medicina O
Física O
y O
Rehabilitación O
y O
Departamento O
de O
Oncología O
Médica O
, O
Hospital O
Universitario O
. O

Cincuenta O
y O
dos O
pacientes O
con O
cáncer O
de O
mama O
se O
dividieron O
en O
ejercicios O
de O
pilates O
( O
grupo O
1 O
) O
y O
grupo O
de O
control O
( O
grupo O
2 O
) O
. O

Los O
pacientes O
del O
grupo O
1 O
realizaron O
pilates O
y O
ejercicios O
en O
casa O
y O
los O
del O
grupo O
2 O
sólo O
ejercicios O
en O
casa O
. O

Se O
realizaron O
sesiones O
de O
ejercicios O
de O
Pilates O
tres O
veces O
por O
semana O
durante O
un O
período O
de O
ocho O
semanas O
en O
la O
unidad O
de O
rehabilitación O
. O

Los O
sujetos O
fueron O
evaluados O
antes O
y O
después O
del O
programa O
de O
rehabilitación, O
con O
respecto O
a O
, O
la O
prueba O
de O
caminata O
de O
6 O
minutos O
( O
6MWT O
) O
, O
la O
prueba O
de O
sentarse O
y O
alcanzar O
, O
el O
Inventario O
Breve O
de O
Fatiga O
( O
BFI O
) O
, O
el O
Índice O
de O
Depresión O
de O
Beck O
( O
BDI O
) O
y O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
Calidad O
de O
Vida O
C30 O
( O
EORTC O
QLQ-C30 O
) O
y O
EORTC O
QLQ O
BR23 O
. O

Tras B-Premise
el I-Premise
programa I-Premise
de I-Premise
ejercicios, I-Premise
se I-Premise
observaron I-Premise
mejoras I-Premise
en I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
prueba I-Premise
de I-Premise
marcha I-Premise
de I-Premise
6 I-Premise
minutos, I-Premise
el I-Premise
BDI, I-Premise
el I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
funcional I-Premise
y I-Premise
el I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
BR23 I-Premise
funcional I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

En O
cambio, O
no B-Premise
se I-Premise
observó I-Premise
ninguna I-Premise
mejora I-Premise
significativa I-Premise
en I-Premise
el I-Premise
Grupo I-Premise
2 I-Premise
después I-Premise
del I-Premise
programa I-Premise
de I-Premise
ejercicios I-Premise
en I-Premise
ninguno I-Premise
de I-Premise
los I-Premise
parámetros I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
período I-Premise
anterior I-Premise
al I-Premise
ejercicio I-Premise
( I-Premise
P I-Premise
> I-Premise
0,05 I-Premise
) O
. O

Cuando B-Premise
se I-Premise
compararon I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
de I-Premise
ejercicio, I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
el I-Premise
6MWT I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
pilates-ejercicio I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Claim
ejercicios I-Claim
de I-Claim
Pilates I-Claim
son I-Claim
eficaces I-Claim
y I-Claim
seguros I-Claim
en I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

Es B-Claim
necesario I-Claim
realizar I-Claim
más I-Claim
estudios I-Claim
para I-Claim
poder I-Claim
confirmar I-Claim
su I-Claim
efecto. I-Claim

Este O
estudio O
aborda O
los O
efectos O
del O
ejercicio O
de O
pilates O
, O
como O
un O
nuevo O
enfoque O
, O
sobre O
la O
capacidad O
funcional O
, O
la O
fatiga O
, O
la O
depresión O
y O
la O
calidad O
de O
vida O
en O
pacientes O
con O
cáncer O
de O
mama O
en O
las O
que O
existen O
dudas O
sobre O
la O
eficacia O
y O
utilidad O
del O
ejercicio O
. O

El O
linfedema O
de O
brazo O
inducido O
por O
el O
tratamiento O
es O
una O
complicación O
común O
y O
angustiosa O
de O
la O
cirugía O
curativa O
y O
la O
radioterapia O
para O
el O
cáncer O
de O
mama O
temprano O
. O

Varios O
estudios O
que O
prueban O
el O
alfa-tocoferol O
( O
vitamina O
E O
) O
y O
la O
pentoxifilina O
sugieren O
evidencias O
de O
regresión O
clínica O
de O
la O
fibrosis O
superficial O
inducida O
por O
la O
radiación, O
pero O
sólo O
hay O
pruebas O
muy O
limitadas O
de O
ensayos O
aleatorios O
. O

En O
el O
presente O
estudio O
se O
ha O
utilizado O
el O
linfedema O
del O
brazo O
después O
de O
la O
radioterapia O
linfática O
y O
la O
cirugía O
como O
sistema O
clínico O
para O
probar O
estos O
fármacos O
en O
un O
ensayo O
aleatorio O
de O
fase O
II, O
doble O
ciego O
y O
controlado O
con O
placebo. O

Sesenta O
y O
ocho O
voluntarios O
de O
investigación O
elegibles O
con O
un O
aumento O
mínimo O
del O
20% O
en O
el O
volumen O
del O
brazo O
en O
una O
mediana O
de O
15,5 O
años O
( O
rango O
2-41 O
) O
después O
de O
la O
radioterapia O
axilar/supraclavicular O
( O
más O
cirugía O
axilar O
en O
51/68 O
( O
75% O
) O
casos O
) O
fueron O
asignados O
al O
azar O
a O
los O
fármacos O
activos O
o O
al O
placebo O
. O

Todos O
los O
voluntarios O
recibieron O
acetato O
de O
dl-alfa O
tocoferilo O
500 O
mg O
dos O
veces O
al O
día O
por O
vía O
oral O
más O
pentoxifilina O
400 O
mg O
dos O
veces O
al O
día O
por O
vía O
oral O
, O
o O
los O
correspondientes O
placebos O
, O
durante O
6 O
meses O
. O

El O
criterio O
de O
valoración O
principal O
fue O
el O
volumen O
de O
la O
extremidad O
ipsilateral O
medido O
optoelectrónicamente O
con O
un O
perómetro O
y O
expresado O
como O
porcentaje O
del O
volumen O
de O
la O
extremidad O
contralateral. O

A B-Premise
los I-Premise
12 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
aleatorización, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
y I-Premise
de I-Premise
control I-Premise
en I-Premise
cuanto I-Premise
al I-Premise
volumen I-Premise
del I-Premise
brazo. I-Premise

El B-Premise
cambio I-Premise
absoluto I-Premise
en I-Premise
el I-Premise
volumen I-Premise
del I-Premise
brazo I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
fue I-Premise
del I-Premise
2,5 I-Premise
% I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-0,40 I-Premise
a I-Premise
5,3) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
1,2 I-Premise
% I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-2,8 I-Premise
a I-Premise
5,1) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo. I-Premise

La B-Premise
diferencia I-Premise
en I-Premise
el I-Premise
cambio I-Premise
de I-Premise
volumen I-Premise
medio I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
aleatorización I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
no I-Premise
fue I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,6 I-Premise
) I-Premise
, I-Premise
-1,3 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
-6,1 I-Premise
a I-Premise
3,5 I-Premise
) I-Premise
, I-Premise
ni I-Premise
tampoco I-Premise
hubo I-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
en I-Premise
la I-Premise
respuesta I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
( I-Premise
P I-Premise
= I-Premise
0,7 I-Premise
) I-Premise
, I-Premise
donde I-Premise
el I-Premise
cambio I-Premise
medio I-Premise
en I-Premise
el I-Premise
volumen I-Premise
del I-Premise
brazo I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
en I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
y I-Premise
placebo I-Premise
fue I-Premise
de I-Premise
-2,3 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
-7,9 I-Premise
a I-Premise
3,4 I-Premise
) I-Premise
y I-Premise
-1,1 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
-3,9 I-Premise
a I-Premise
1,7 I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
aleatorizados I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
los I-Premise
criterios I-Premise
de I-Premise
valoración I-Premise
secundarios, I-Premise
incluida I-Premise
la I-Premise
induración I-Premise
tisular I-Premise
( I-Premise
fibrosis I-Premise
) I-Premise
en I-Premise
la I-Premise
mama I-Premise
o I-Premise
la I-Premise
pared I-Premise
torácica I-Premise
irradiada, I-Premise
el I-Premise
pliegue I-Premise
pectoral I-Premise
o I-Premise
la I-Premise
fosa I-Premise
supraclavicular, I-Premise
el I-Premise
cambio I-Premise
en I-Premise
el I-Premise
aspecto I-Premise
fotográfico I-Premise
de I-Premise
la I-Premise
mama I-Premise
o I-Premise
la I-Premise
pared I-Premise
torácica I-Premise
o I-Premise
la I-Premise
autoevaluación I-Premise
de I-Premise
la I-Premise
función I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
por I-Premise
parte I-Premise
de I-Premise
las I-Premise
pacientes I-Premise
a I-Premise
los I-Premise
6 I-Premise
o I-Premise
12 I-Premise
meses. I-Premise

El B-Claim
estudio I-Claim
no I-Claim
demuestra I-Claim
la I-Claim
eficacia I-Claim
del I-Claim
acetato I-Claim
de I-Claim
dl-alfa I-Claim
tocoferilo I-Claim
más I-Claim
la I-Claim
pentoxifilina I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
linfedema I-Claim
de I-Claim
brazo I-Claim
después I-Claim
de I-Claim
la I-Claim
cirugía I-Claim
axilar I-Claim
y I-Claim
la I-Claim
radioterapia I-Claim
linfática I-Claim
, I-Claim
ni I-Claim
sugiere I-Claim
ningún I-Claim
beneficio I-Claim
de I-Claim
estos I-Claim
fármacos I-Claim
en I-Claim
la I-Claim
induración I-Claim
inducida I-Claim
por I-Claim
la I-Claim
radiación I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
en I-Claim
la I-Claim
mama I-Claim
, I-Claim
la I-Claim
pared I-Claim
torácica I-Claim
, I-Claim
el I-Claim
pliegue I-Claim
pectoral I-Claim
, I-Claim
la I-Claim
axila I-Claim
o I-Claim
la I-Claim
fosa I-Claim
supraclavicular I-Claim
. I-Claim

Muchas O
pacientes O
con O
cáncer O
de O
ovario O
avanzado O
desarrollarán O
una O
enfermedad O
recurrente. O

Para B-Premise
aquellos I-Premise
pacientes I-Premise
que I-Premise
presentan I-Premise
recurrencia I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
al I-Premise
menos I-Premise
6 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
terapia I-Premise
inicial I-Premise
, I-Premise
la I-Premise
combinación I-Premise
paclitaxel-platino I-Premise
ha I-Premise
demostrado I-Premise
ser I-Premise
un I-Premise
tratamiento I-Premise
superior I-Premise
a I-Premise
la I-Premise
monoterapia I-Premise
con I-Premise
platino I-Premise
. I-Premise

Sin B-Claim
embargo, I-Claim
muchos I-Claim
pacientes I-Claim
desarrollan I-Claim
una I-Claim
neurotoxicidad I-Claim
clínicamente I-Claim
relevante, I-Claim
que I-Claim
a I-Claim
menudo I-Claim
provoca I-Claim
la I-Claim
interrupción I-Claim
del I-Claim
tratamiento. I-Claim

La O
eficacia O
y O
seguridad O
de O
un O
régimen O
alternativo O
que O
no O
muestra O
neurotoxicidad O
significativa O
se O
evaluó O
comparando O
gemcitabina-carboplatino O
con O
carboplatino O
en O
pacientes O
con O
cáncer O
de O
ovario O
recurrente O
sensible O
al O
platino O
en O
un O
ensayo O
del O
InterGroup O
Gynecologic O
Cancer O
del O
Arbeitsgemeinschaft O
Gynakologische O
Onkologie O
Ovarian O
Cancer O
Study O
Group O
, O
el O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
y O
el O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Gynaecological O
Cancer O
Group O
. O

Las O
participantes O
con O
cáncer O
de O
ovario O
recurrente O
sensible O
al O
platino O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
gemcitabina-carboplatino O
o O
carboplatino O
cada O
21 O
días O
. O

El O
objetivo O
primario O
era O
comparar O
la O
supervivencia O
libre O
de O
progresión O
(SLP) O
entre O
los O
grupos. O

Desde O
septiembre O
de O
1999 O
hasta O
abril O
de O
2002, O
356 O
pacientes O
( O
178 O
participantes O
recibieron O
gemcitabina-carboplatino O
, O
178 O
recibieron O
sólo O
carboplatino O
) O
fueron O
aleatorizados O
al O
tratamiento O
. O

Los O
pacientes O
recibieron O
seis O
ciclos O
de O
gemcitabina-carboplatino O
o O
de O
carboplatino. O

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
17 I-Premise
meses, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
de I-Premise
8,6 I-Premise
meses I-Premise
para I-Premise
la I-Premise
gemcitabina-carboplatino I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
IC I-Premise
] I-Premise
7,9-9,7 I-Premise
meses I-Premise
) I-Premise
y I-Premise
de I-Premise
5,8 I-Premise
meses I-Premise
para I-Premise
el I-Premise
carboplatino I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
5,2-7,1 I-Premise
meses I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0,72 I-Premise
[ I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
0,58-0,90 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,0032 I-Premise
] I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
gemcitabina-carboplatino I-Premise
fue I-Premise
del I-Premise
47,2% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
39,9-54,5% I-Premise
) I-Premise
y I-Premise
del I-Premise
30,9% I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
carboplatino I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
24,1-37,7% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,0016 I-Premise
) I-Premise
. I-Premise

El B-Premise
CRI I-Premise
para I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
0,96 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
0,75-1,23 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,7349 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
gemcitabina-carboplatino I-Premise
informaron I-Premise
de I-Premise
una I-Premise
paliación I-Premise
significativamente I-Premise
más I-Premise
rápida I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
abdominales I-Premise
y I-Premise
una I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
significativamente I-Premise
mejorada I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
gemcitabina-carboplatino I-Claim
mejora I-Claim
significativamente I-Claim
la I-Claim
SLP I-Claim
de I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
recurrente I-Claim
sensible I-Claim
al I-Claim
platino. I-Claim

La O
combinación O
de O
cisplatino O
y O
etopósido O
( O
PE O
) O
ha O
sido O
un O
tratamiento O
estándar O
para O
los O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
pequeñas O
( O
SCLC O
) O
de O
mal O
pronóstico O
. O

Este O
ensayo O
de O
diseño O
de O
no O
inferioridad O
tenía O
como O
objetivo O
determinar O
si O
la O
combinación O
de O
gemcitabina O
y O
carboplatino O
( O
GC O
) O
da O
lugar O
a O
una O
supervivencia O
similar O
pero O
es O
menos O
tóxica O
y O
con O
mejor O
calidad O
de O
vida O
. O

Los O
pacientes O
con O
CPCP O
sin O
tratamiento O
previo O
con O
enfermedad O
extensa O
o O
estadio O
limitado O
con O
factores O
de O
mal O
pronóstico O
fueron O
asignados O
aleatoriamente O
a O
seis O
ciclos O
de O
3 O
semanas O
de O
GC O
o O
PE O
. O

Se O
reclutaron O
241 O
pacientes O
( O
121 O
GC O
, O
120 O
PE O
) O
, O
de O
los O
cuales O
216 O
( O
90 O
% O
) O
habían O
fallecido O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
HR I-Premise
1,01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,77 I-Premise
a I-Premise
1,32 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
con I-Premise
GC I-Premise
y I-Premise
PE I-Premise
fue I-Premise
de I-Premise
8,0 I-Premise
y I-Premise
8,1 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
5,9 I-Premise
meses I-Premise
con I-Premise
GC I-Premise
y I-Premise
de I-Premise
6,3 I-Premise
meses I-Premise
con I-Premise
PE I-Premise
. I-Premise

Las B-Premise
mielosupresiones I-Premise
de I-Premise
grado I-Premise
3 I-Premise
ó I-Premise
4 I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
con I-Premise
la I-Premise
CG I-Premise
( I-Premise
anemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
CG I-Premise
frente I-Premise
a I-Premise
2 I-Premise
% I-Premise
EP I-Premise
; I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
CG I-Premise
frente I-Premise
a I-Premise
13 I-Premise
% I-Premise
EP I-Premise
; I-Premise
trombocitopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
CG I-Premise
frente I-Premise
a I-Premise
4 I-Premise
% I-Premise
EP I-Premise
) I-Premise
, I-Premise
pero I-Premise
no I-Premise
se I-Premise
asociaron I-Premise
a I-Premise
un I-Premise
aumento I-Premise
de I-Premise
los I-Premise
ingresos I-Premise
hospitalarios I-Premise
, I-Premise
infecciones I-Premise
o I-Premise
fallecimientos I-Premise
. O

La B-Premise
alopecia I-Premise
de I-Premise
grado I-Premise
2-3 I-Premise
( I-Premise
68 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
17 I-Premise
% I-Premise
GC I-Premise
) I-Premise
y I-Premise
las I-Premise
náuseas I-Premise
( I-Premise
43 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
26 I-Premise
% I-Premise
GC I-Premise
) I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
con I-Premise
PE I-Premise
. I-Premise

Los O
pacientes O
a O
los O
que O
se O
les O
administró O
GC O
recibieron O
más O
quimioterapia O
en O
régimen O
ambulatorio O
( O
89 O
% O
GC O
frente O
al O
66 O
% O
PE O
de O
los O
ciclos O
de O
tratamiento O
) O
. O

En B-Premise
los I-Premise
cuestionarios I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
un I-Premise
mayor I-Premise
número I-Premise
de I-Premise
pacientes I-Premise
que I-Premise
recibían I-Premise
PE I-Premise
declararon I-Premise
estar I-Premise
molestos I-Premise
por I-Premise
la I-Premise
caída I-Premise
del I-Premise
cabello I-Premise
( I-Premise
p I-Premise
= I-Premise
0,004 I-Premise
) I-Premise
y I-Premise
por I-Premise
el I-Premise
deterioro I-Premise
del I-Premise
funcionamiento I-Premise
cognitivo I-Premise
( I-Premise
p I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
. I-Premise

El B-Claim
GC I-Claim
es I-Claim
tan I-Claim
eficaz I-Claim
como I-Claim
el I-Claim
PE I-Claim
en I-Claim
términos I-Claim
de I-Claim
supervivencia I-Claim
global I-Claim
y I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
y I-Claim
tiene I-Claim
un I-Claim
perfil I-Claim
de I-Claim
toxicidad I-Claim
más I-Claim
aceptable I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
. I-Claim

Evaluar O
la O
eficacia O
de O
un O
nuevo O
diseño O
de O
bolsa O
colónica O
de O
coloplastia O
para O
optimizar O
la O
función O
intestinal O
tras O
una O
resección O
anterior O
ultrabaja. O

Una B-Claim
bolsa I-Claim
colónica I-Claim
en I-Claim
J I-Claim
puede I-Claim
reducir I-Claim
la I-Claim
excesiva I-Claim
frecuencia I-Claim
de I-Claim
las I-Claim
deposiciones I-Claim
y I-Claim
la I-Claim
incontinencia I-Claim
después I-Claim
de I-Claim
la I-Claim
resección I-Claim
anterior I-Claim
, I-Claim
pero I-Claim
con I-Claim
el I-Claim
riesgo I-Claim
de I-Claim
problemas I-Claim
de I-Claim
evacuación I-Claim
. I-Claim

La O
cirugía B-Claim
experimental I-Claim
en I-Claim
cerdos I-Claim
ha I-Claim
sugerido I-Claim
que I-Claim
una I-Claim
bolsa I-Claim
de I-Claim
coloplastia I-Claim
( I-Claim
CP I-Claim
) I-Claim
puede I-Claim
ser I-Claim
una I-Claim
alternativa I-Claim
útil I-Claim
. O

Aunque O
recientemente O
se O
ha O
demostrado O
que O
la O
CP O
es O
factible O
en O
los O
pacientes O
, O
no O
existe O
ningún O
ensayo O
controlado O
aleatorio O
que O
compare O
la O
función O
intestinal O
con O
la O
bolsa O
en O
J O
. O

Tras O
la O
resección O
anterior O
por O
cáncer O
, O
los O
pacientes O
fueron O
asignados O
a O
anastomosis O
en O
J O
o O
CP-anal O
. O

La O
puntuación O
de O
la O
continencia, O
la O
manometría O
anorrectal O
y O
la O
ecografía O
endoanal O
se O
realizaron O
antes O
de O
la O
cirugía. O

Se O
registraron O
todas O
las O
complicaciones, O
y O
estas O
evaluaciones O
preoperatorias O
se O
repitieron O
a O
los O
4 O
meses. O

Las O
evaluaciones O
se O
repitieron O
de O
nuevo O
al O
año, O
y O
se O
añadió O
un O
cuestionario O
de O
calidad O
de O
vida. O

Se O
reclutaron O
88 O
pacientes O
entre O
octubre O
de O
1998 O
y O
abril O
de O
2000. O

Ambos O
grupos O
estaban O
bien O
emparejados O
en O
cuanto O
a O
la O
edad, O
el O
sexo, O
el O
estadio, O
la O
terapia O
adyuvante O
y O
el O
seguimiento O
medio. O

No O
hubo O
diferencias O
en O
el O
tiempo O
intraoperatorio O
ni O
en O
la O
estancia O
hospitalaria. O

El B-Premise
CP I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
más I-Premise
fugas I-Premise
anastomóticas I-Premise
. I-Premise

A B-Premise
los I-Premise
4 I-Premise
meses, I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
J-pouch I-Premise
presentaban I-Premise
un I-Premise
10,3% I-Premise
menos I-Premise
de I-Premise
fragmentación I-Premise
de I-Premise
las I-Premise
heces, I-Premise
pero I-Premise
un I-Premise
peor I-Premise
aplazamiento I-Premise
de I-Premise
las I-Premise
mismas I-Premise
y I-Premise
más I-Premise
fugas I-Premise
nocturnas. I-Premise

Sin O
embargo, O
no B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
función I-Premise
intestinal, I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
continencia I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
al I-Premise
año. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
los I-Premise
resultados I-Premise
de I-Premise
la I-Premise
manometría I-Premise
anorrectal I-Premise
y I-Premise
la I-Premise
ecografía I-Premise
endoanal. I-Premise

Las B-Claim
bolsas I-Claim
de I-Claim
coloplastia I-Claim
dieron I-Claim
lugar I-Claim
a I-Claim
más I-Claim
fugas I-Claim
anastomóticas I-Claim
y I-Claim
a I-Claim
diferencias I-Claim
mínimas I-Claim
en I-Claim
la I-Claim
función I-Claim
intestinal I-Claim
. I-Claim

En O
la O
actualidad, O
la B-Claim
bolsa I-Claim
en I-Claim
J I-Claim
sigue I-Claim
siendo I-Claim
el I-Claim
punto I-Claim
de I-Claim
referencia I-Claim
para I-Claim
la I-Claim
práctica I-Claim
clínica I-Claim
rutinaria, I-Claim
y O
se B-Claim
debe I-Claim
prestar I-Claim
la I-Claim
debida I-Claim
atención I-Claim
( I-Claim
incluyendo I-Claim
la I-Claim
defunción I-Claim
del I-Claim
estoma) I-Claim
en I-Claim
las I-Claim
situaciones I-Claim
que I-Claim
requieran I-Claim
CP I-Claim
. O

Entre O
1984 O
y O
1989, O
el O
Grupo O
Suizo O
para O
la O
Investigación O
Clínica O
del O
Cáncer O
( O
SAKK O
) O
realizó O
un O
ensayo O
aleatorio O
de O
fase O
III O
en O
el O
que O
se O
comparaba O
la O
quimioterapia O
alternada O
temprana O
frente O
a O
la O
tardía O
en O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
pequeñas O
. O

Se O
incluyeron O
en O
el O
ensayo O
406 O
pacientes O
elegibles. O

El O
régimen O
A O
consistió O
en O
PAV O
( O
cisPlatino O
, O
Adriamicina O
, O
VP O
16-213 O
, O
y O
el O
régimen O
B O
en O
CyMOC O
( O
Ciclofosfamida O
, O
Metotrexato O
, O
Oncovin O
, O
CCNU O
) O
. O

Los O
ciclos O
se O
repitieron O
con O
la O
mayor O
rapidez O
posible. O

Los O
pacientes O
fueron O
aleatorizados O
para O
recibir O
ABABAB O
( O
quimioterapia O
alternante O
temprana O
) O
o O
AAABBB O
( O
quimioterapia O
alternante O
tardía O
) O
. O

Después O
de O
seis O
ciclos, O
los O
pacientes O
con O
enfermedad O
limitada O
en O
remisión O
completa O
o O
parcial O
y O
aquellos O
con O
enfermedad O
extensa O
en O
remisión O
completa O
recibieron O
irradiación O
en O
el O
primario O
( O
45 O
Gy O
) O
y O
en O
el O
SNC O
( O
36 O
Gy O
) O
. O

La B-Premise
tasa I-Premise
de I-Premise
remisión I-Premise
global I-Premise
fue I-Premise
del I-Premise
87%, I-Premise
con I-Premise
un I-Premise
31% I-Premise
de I-Premise
remisiones I-Premise
completas. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
los I-Premise
406 I-Premise
pacientes I-Premise
elegibles I-Premise
fue I-Premise
de I-Premise
346 I-Premise
días, I-Premise
con I-Premise
un I-Premise
15% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
vivos I-Premise
a I-Premise
los I-Premise
dos I-Premise
años. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
remisión I-Premise
global, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
remisión I-Premise
completa, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
y I-Premise
la I-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
largo I-Premise
plazo I-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
en I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
de I-Premise
tratamiento. I-Premise

En B-Premise
la I-Premise
enfermedad I-Premise
limitada, I-Premise
los I-Premise
porcentajes I-Premise
estimados I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
fueron I-Premise
del I-Premise
33% I-Premise
en I-Premise
los I-Premise
brazos I-Premise
de I-Premise
quimioterapia I-Premise
temprana I-Premise
y I-Premise
del I-Premise
24% I-Premise
en I-Premise
los I-Premise
tardíos. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
enfermedad I-Premise
extensa I-Premise
sobrevivieron I-Premise
significativamente I-Premise
más I-Premise
tiempo I-Premise
con I-Premise
la I-Premise
quimioterapia I-Premise
de I-Premise
alternancia I-Premise
tardía I-Premise
que I-Premise
con I-Premise
el I-Premise
régimen I-Premise
de I-Premise
alternancia I-Premise
temprana I-Premise
( I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
336 I-Premise
días I-Premise
frente I-Premise
a I-Premise
301 I-Premise
días I-Premise
, I-Premise
p I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

En B-Premise
estos I-Premise
últimos I-Premise
pacientes, I-Premise
las I-Premise
intensidades I-Premise
de I-Premise
dosis I-Premise
recibidas I-Premise
( I-Premise
RDI I-Premise
) I-Premise
de I-Premise
cisplatino I-Premise
, I-Premise
adriamicina I-Premise
y I-Premise
etopósido I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
alternancia I-Premise
tardía I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
quimioterapia I-Premise
alternante I-Premise
temprana I-Premise
valoraron I-Premise
significativamente I-Premise
mejor I-Premise
sus I-Premise
síntomas I-Premise
tumorales, I-Premise
estados I-Premise
funcionales, I-Premise
fatiga/malestar I-Premise
y I-Premise
restricción I-Premise
de I-Premise
la I-Premise
actividad I-Premise
social, I-Premise
lo I-Premise
que I-Premise
refleja I-Premise
una I-Premise
mejor I-Premise
adaptación I-Premise
subjetiva. I-Premise

La B-Claim
alternancia I-Claim
de I-Claim
quimioterapia I-Claim
con I-Claim
PAV-CyMOC I-Claim
más I-Claim
radioterapia I-Claim
de I-Claim
consolidación I-Claim
es I-Claim
un I-Claim
tratamiento I-Claim
factible I-Claim
y I-Claim
eficaz I-Claim
para I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
pequeñas I-Claim
, I-Claim
con I-Claim
una I-Claim
toxicidad I-Claim
aceptable I-Claim
. I-Claim

Mientras O
que O
los B-Claim
pacientes I-Claim
con I-Claim
quimioterapia I-Claim
alternante I-Claim
temprana I-Claim
logran I-Claim
un I-Claim
mejor I-Claim
ajuste I-Claim
subjetivo I-Claim
, O
la B-Claim
quimioterapia I-Claim
alternante I-Claim
tardía I-Claim
permite I-Claim
una I-Claim
mayor I-Claim
IDR I-Claim
de I-Claim
cisplatino I-Claim
, I-Claim
adriamicina I-Claim
y I-Claim
etopósido I-Claim
, I-Claim
lo I-Claim
que I-Claim
se I-Claim
traduce I-Claim
en I-Claim
una I-Claim
mediana I-Claim
de I-Claim
supervivencia I-Claim
significativamente I-Claim
mayor I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
enfermedad I-Claim
extensa I-Claim
. O

Evaluar O
la O
toxicidad O
y O
la O
eficacia O
de O
las O
combinaciones O
de O
doblete O
de O
cisplatino O
( O
Cis O
) O
en O
el O
carcinoma O
cervical O
avanzado O
y O
recurrente O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
paclitaxel O
135 O
mg/m O
( O
2 O
) O
durante O
24 O
horas O
más O
Cis O
50 O
mg/m O
( O
2 O
) O
día O
2 O
cada O
3 O
semanas O
( O
PC O
, O
brazo O
de O
referencia O
) O
; O
vinorelbina O
30 O
mg/m O
( O
2 O
) O
días O
1 O
y O
8 O
más O
Cis O
50 O
mg/m O
( O
2 O
) O
día O
1 O
cada O
3 O
semanas O
( O
VC O
) O
; O
gemcitabina O
1.000 O
mg/m O
( O
2 O
) O
día O
1 O
y O
8 O
más O
Cis O
50 O
mg/m O
( O
2 O
) O
día O
1 O
cada O
3 O
semanas O
( O
GC O
) O
; O
o O
topotecan O
0. O
75 O
mg/m O
( O
2 O
) O
días O
1 O
, O
2 O
y O
3 O
más O
Cis O
50 O
mg/m O
( O
2 O
) O
día O
1 O
cada O
3 O
semanas O
( O
TC O
) O
.75 O
mg/m O
( O
2 O
) O
días O
1, O
2 O
y O
3 O
más O
Cis O
50 O
mg/m O
( O
2 O
) O
día O
1 O
cada O
3 O
semanas O
( O
TC O
) O
. O

La O
supervivencia O
fue O
el O
punto O
final O
primario, O
con O
una O
mejora O
del O
33 O
% O
en O
relación O
con O
el O
CP O
considerada O
importante O
( O
potencia O
del O
85 O
% O
, O
alfa O
= O
5 O
% O
) O
. O

Los O
datos O
sobre O
la O
calidad O
de O
vida O
se O
recogieron O
de O
forma O
prospectiva. O

Un O
total O
de O
513 O
pacientes O
fueron O
inscritos O
cuando O
un O
análisis O
intermedio O
planificado O
recomendó O
el O
cierre O
temprano O
por O
futilidad O
. O

Los B-Premise
cocientes I-Premise
de I-Premise
riesgo I-Premise
de I-Premise
muerte I-Premise
entre I-Premise
el I-Premise
experimento I-Premise
y I-Premise
el I-Premise
CV I-Premise
fueron I-Premise
de I-Premise
1,15 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
de I-Premise
0,79 I-Premise
a I-Premise
1,67) I-Premise
para I-Premise
el I-Premise
CV, I-Premise
de I-Premise
1,32 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
de I-Premise
0,91 I-Premise
a I-Premise
1,92) I-Premise
para I-Premise
el I-Premise
GC I-Premise
y I-Premise
de I-Premise
1,26 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
de I-Premise
0,86 I-Premise
a I-Premise
1,82) I-Premise
para I-Premise
el I-Premise
CT. I-Premise

Los B-Premise
cocientes I-Premise
de I-Premise
riesgo I-Premise
para I-Premise
la I-Premise
supervivencia I-Premise
sin I-Premise
progresión I-Premise
(SSP) I-Premise
fueron I-Premise
de I-Premise
1,36 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
de I-Premise
0,97 I-Premise
a I-Premise
1,90) I-Premise
para I-Premise
la I-Premise
CV, I-Premise
de I-Premise
1,39 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
de I-Premise
0,99 I-Premise
a I-Premise
1,96) I-Premise
para I-Premise
la I-Premise
GC I-Premise
y I-Premise
de I-Premise
1,27 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
de I-Premise
0,90 I-Premise
a I-Premise
1,78) I-Premise
para I-Premise
la I-Premise
CT. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
( I-Premise
RR I-Premise
) I-Premise
para I-Premise
PC I-Premise
, I-Premise
VC I-Premise
, I-Premise
GC I-Premise
y I-Premise
TC I-Premise
fueron I-Premise
del I-Premise
29,1 I-Premise
% I-Premise
, I-Premise
25,9 I-Premise
% I-Premise
, I-Premise
22,3 I-Premise
% I-Premise
y I-Premise
23,4 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

Los B-Premise
brazos I-Premise
fueron I-Premise
comparables I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
toxicidad, I-Premise
excepto I-Premise
la I-Premise
leucopenia I-Premise
, I-Premise
la I-Premise
neutropenia I-Premise
, I-Premise
la I-Premise
infección I-Premise
y I-Premise
la I-Premise
alopecia I-Premise
. I-Premise

La B-Claim
CV, I-Claim
la I-Claim
CG I-Claim
y I-Claim
la I-Claim
CT I-Claim
no I-Claim
son I-Claim
superiores I-Claim
a I-Claim
la I-Claim
CP I-Claim
en I-Claim
términos I-Claim
de I-Claim
supervivencia I-Claim
global I-Claim
(SG). I-Claim

Sin B-Claim
embargo, I-Claim
la I-Claim
tendencia I-Claim
del I-Claim
RR, I-Claim
la I-Claim
SLP I-Claim
y I-Claim
la I-Claim
SG I-Claim
es I-Claim
favorable I-Claim
a I-Claim
la I-Claim
CP. I-Claim

Las B-Claim
diferencias I-Claim
en I-Claim
la I-Claim
programación I-Claim
de I-Claim
la I-Claim
quimioterapia, I-Claim
la I-Claim
morbilidad I-Claim
preexistente I-Claim
y I-Claim
la I-Claim
toxicidad I-Claim
son I-Claim
importantes I-Claim
para I-Claim
individualizar I-Claim
el I-Claim
tratamiento. I-Claim

Informar O
sobre O
los O
resultados O
de O
la O
resonancia O
magnética O
con O
contraste O
a O
los O
5 O
años O
de O
los O
reclutas O
del O
ensayo O
REST O
que O
se O
sometieron O
a O
la O
embolización O
de O
la O
arteria O
uterina O
( O
EAU O
) O
o O
a O
la O
miomectomía O
. O

Un O
total O
de O
157 O
pacientes O
fueron O
aleatorizadas O
a O
EAU O
o O
a O
cirugía O
( O
histerectomía O
o O
miomectomía O
) O
. O

Se O
analizaron O
99 O
pacientes O
a O
los O
que O
se O
les O
practicó O
la O
EAU O
y O
8 O
pacientes O
a O
los O
que O
se O
les O
practicó O
la O
miomectomía. O

Dos O
radiólogos O
interpretaron O
de O
forma O
independiente O
las O
imágenes O
de O
resonancia O
magnética O
al O
inicio, O
a O
los O
6 O
meses O
y O
a O
los O
5 O
años. O

El O
diámetro O
del O
mioma O
dominante O
, O
el O
volumen O
uterino O
, O
el O
infarto O
total O
del O
mioma O
( O
completo O
100 O
% O
, O
casi O
completo O
90-99 O
% O
, O
parcial O
< O
90 O
% O
) O
y O
la O
formación O
de O
nuevos O
miomas O
fueron O
los O
principales O
parámetros O
evaluados O
y O
relacionados O
con O
la O
necesidad O
de O
reintervención O
. O

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
EAU, I-Premise
el I-Premise
volumen I-Premise
uterino I-Premise
medio I-Premise
± I-Premise
desviación I-Premise
estándar I-Premise
fue I-Premise
de I-Premise
670 I-Premise
± I-Premise
503, I-Premise
422 I-Premise
± I-Premise
353 I-Premise
y I-Premise
292 I-Premise
± I-Premise
287 I-Premise
mL I-Premise
al I-Premise
inicio, I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
a I-Premise
los I-Premise
5 I-Premise
años, I-Premise
respectivamente. I-Premise

El B-Premise
diámetro I-Premise
medio I-Premise
de I-Premise
los I-Premise
miomas I-Premise
dominantes I-Premise
fue I-Premise
de I-Premise
7,6 I-Premise
± I-Premise
3,0 I-Premise
, I-Premise
5,8 I-Premise
± I-Premise
2,9 I-Premise
y I-Premise
5 I-Premise
± I-Premise
2,9 I-Premise
cm I-Premise
al I-Premise
inicio, I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
a I-Premise
los I-Premise
5 I-Premise
años. I-Premise

El B-Premise
infarto I-Premise
de I-Premise
miocardio I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
fue I-Premise
completo I-Premise
en I-Premise
el I-Premise
35% I-Premise
de I-Premise
las I-Premise
mujeres, I-Premise
casi I-Premise
completo I-Premise
en I-Premise
el I-Premise
29% I-Premise
y I-Premise
parcial I-Premise
en I-Premise
el I-Premise
36%. I-Premise

La B-Premise
necesidad I-Premise
de I-Premise
reintervención I-Premise
fue I-Premise
del I-Premise
19, I-Premise
10 I-Premise
y I-Premise
33% I-Premise
en I-Premise
estos I-Premise
grupos, I-Premise
respectivamente I-Premise
( I-Premise
p I-Premise
= I-Premise
0,123 I-Premise
) I-Premise
. I-Premise

Ningún B-Premise
caso I-Premise
de I-Premise
miomectomía I-Premise
tuvo I-Premise
una I-Premise
intervención I-Premise
posterior I-Premise
. I-Premise

A B-Premise
los I-Premise
5 I-Premise
años, I-Premise
la I-Premise
prevalencia I-Premise
de I-Premise
nuevos I-Premise
miomas I-Premise
fue I-Premise
del I-Premise
60% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
miomectomía I-Premise
y I-Premise
del I-Premise
7% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
EAU I-Premise
( I-Premise
p I-Premise
= I-Premise
0,008 I-Premise
) I-Premise
. I-Premise

Hay B-Premise
una I-Premise
reducción I-Premise
significativa I-Premise
adicional I-Premise
tanto I-Premise
del I-Premise
volumen I-Premise
uterino I-Premise
como I-Premise
del I-Premise
diámetro I-Premise
del I-Premise
fibroma I-Premise
dominante I-Premise
entre I-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
los I-Premise
5 I-Premise
años I-Premise
después I-Premise
de I-Premise
la I-Premise
EAU. I-Premise

El B-Claim
infarto I-Claim
completo I-Claim
del I-Claim
fibroma I-Claim
no I-Claim
se I-Claim
traduce I-Claim
en I-Claim
la I-Claim
ausencia I-Claim
total I-Claim
de I-Claim
una I-Claim
reintervención I-Claim
posterior. I-Claim

La B-Claim
formación I-Claim
de I-Claim
nuevos I-Claim
fibroides I-Claim
es I-Claim
significativamente I-Claim
mayor I-Claim
después I-Claim
de I-Claim
la I-Claim
miomectomía I-Claim
. I-Claim

El O
presente O
estudio O
examinó O
el O
efecto O
de O
la O
desoxirribonucleasa O
humana O
recombinante O
( O
rhDNase O
) O
sobre O
las O
medidas O
de O
calidad O
de O
vida O
( O
QOL O
) O
, O
la O
mejora O
clínica O
y O
el O
contenido O
de O
ADN O
de O
las O
secreciones O
orofaríngeas O
espesas O
( O
OPS O
) O
en O
pacientes O
con O
cánceres O
de O
cabeza O
y O
cuello O
( O
H O
& O
N O
) O
. O

Treinta O
y O
seis O
pacientes O
con O
cáncer O
H O
& O
amp O
; O
N O
avanzado O
local-regional O
que O
reciben O
quimiorradioterapia O
( O
CRT O
) O
fueron O
asignados O
al O
azar O
para O
recibir O
placebo O
o O
rhDNase O
. O

Los O
criterios O
de O
valoración O
incluyeron O
las O
puntuaciones O
del O
MD O
Anderson O
Symptom O
Inventory-Head O
and O
Neck O
( O
MDASI-HN O
) O
y O
la O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-NH O
) O
, O
junto O
con O
la O
evaluación O
clínica O
y O
la O
concentración O
de O
ADN O
del O
OPS O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
los I-Premise
resultados I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
durante I-Premise
el I-Premise
período I-Premise
de I-Premise
estudio. I-Premise

Ambos B-Premise
grupos I-Premise
mostraron I-Premise
un I-Premise
aumento I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
y I-Premise
la I-Premise
interferencia I-Premise
, O
aunque O
los O
pacientes B-Premise
del I-Premise
grupo I-Premise
de I-Premise
rhDNase I-Premise
mostraron I-Premise
un I-Premise
mayor I-Premise
descenso I-Premise
en I-Premise
ambas I-Premise
puntuaciones I-Premise
durante I-Premise
los I-Premise
3 I-Premise
meses I-Premise
posteriores I-Premise
al I-Premise
tratamiento I-Premise
. O

Del B-Premise
mismo I-Premise
modo, I-Premise
ambos I-Premise
grupos I-Premise
mostraron I-Premise
una I-Premise
disminución I-Premise
del I-Premise
bienestar I-Premise
físico I-Premise
y I-Premise
funcional, I-Premise
pero I-Premise
se I-Premise
recuperaron I-Premise
en I-Premise
el I-Premise
seguimiento I-Premise
de I-Premise
3 I-Premise
meses I-Premise
después I-Premise
del I-Premise
tratamiento, I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
rhDNase I-Premise
mostrando I-Premise
una I-Premise
recuperación I-Premise
más I-Premise
rápida. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
rhDNase I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
clínica I-Premise
significativa I-Premise
en I-Premise
la I-Premise
OPS I-Premise
, I-Premise
evaluada I-Premise
ciegamente I-Premise
por I-Premise
un I-Premise
médico, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
( I-Premise
67 I-Premise
% I-Premise
frente I-Premise
a I-Premise
27 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P=.046 I-Premise
) I-Premise
. I-Premise

El B-Premise
grupo I-Premise
de I-Premise
rhDNase I-Premise
no I-Premise
mostró I-Premise
ningún I-Premise
cambio I-Premise
en I-Premise
la I-Premise
concentración I-Premise
de I-Premise
OPS-ADN I-Premise
, O
aunque O
el B-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
mostró I-Premise
un I-Premise
aumento I-Premise
significativo I-Premise
de I-Premise
la I-Premise
concentración I-Premise
de I-Premise
ADN I-Premise
durante I-Premise
el I-Premise
ensayo I-Premise
del I-Premise
fármaco I-Premise
( I-Premise
P=.045 I-Premise
) O
. O

No B-Claim
hubo I-Claim
diferencias I-Claim
en I-Claim
las I-Claim
toxicidades I-Claim
agudas I-Claim
entre I-Claim
los I-Claim
2 I-Claim
grupos. I-Claim

Nuestros B-Claim
datos I-Claim
preliminares I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
rhDNase I-Claim
no I-Claim
mejoró I-Claim
significativamente I-Claim
los I-Claim
criterios I-Claim
de I-Claim
valoración I-Claim
primarios I-Claim
del I-Claim
estudio I-Claim
de I-Claim
las I-Claim
medidas I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
grupo I-Claim
de I-Claim
placebo. I-Claim

Sin O
embargo, O
hubo B-Claim
una I-Claim
mejora I-Claim
significativa I-Claim
en I-Claim
los I-Claim
criterios I-Claim
de I-Claim
valoración I-Claim
secundarios I-Claim
de I-Claim
la I-Claim
OPS I-Claim
evaluada I-Claim
clínicamente I-Claim
y I-Claim
la I-Claim
concentración I-Claim
de I-Claim
ADN I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
placebo I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
H I-Claim
y I-Claim
N I-Claim
tratados I-Claim
con I-Claim
TRC. I-Claim

Se O
justifica O
la O
realización O
de O
más O
investigaciones O
en O
un O
mayor O
número O
de O
pacientes. O

La O
talidomida O
con O
melfalán/prednisona O
( O
MPT O
) O
se O
definió O
como O
tratamiento O
estándar O
en O
pacientes O
de O
edad O
avanzada O
con O
mieloma O
múltiple O
( O
MM O
) O
sobre O
la O
base O
de O
cinco O
ensayos O
aleatorios O
. O

En O
uno O
de O
estos O
ensayos, O
HOVON49 O
, O
se O
inició O
un O
estudio O
prospectivo O
sobre O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQoL O
) O
para O
evaluar O
el O
impacto O
de O
la O
talidomida O
en O
la O
QoL O
. O

Los O
pacientes O
de O
más O
de O
65 O
años O
con O
MM O
recién O
diagnosticado O
fueron O
aleatorizados O
para O
recibir O
melfalán O
más O
prednisona O
( O
MP O
) O
o O
MPT O
, O
seguido O
de O
mantenimiento O
con O
talidomida O
en O
el O
brazo O
MPT O
. O

Doscientos O
ochenta O
y O
cuatro O
pacientes O
fueron O
incluidos O
en O
este O
estudio O
lateral O
( O
MP O
, O
n=149 O
; O
MPT O
n=135 O
) O
. O

La O
CVRS O
se O
evaluó O
con O
el O
Cuestionario O
Básico O
de O
CV O
de O
la O
EORTC O
( O
QLQ-C30 O
) O
y O
el O
módulo O
específico O
de O
mieloma O
( O
QLQ-MY24 O
) O
al O
inicio O
y O
a O
intervalos O
predeterminados O
durante O
el O
tratamiento O
. O

Las B-Premise
subescalas I-Premise
QLQ-C30 I-Premise
función I-Premise
física I-Premise
( I-Premise
P=0,044 I-Premise
) I-Premise
y I-Premise
estreñimiento I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
durante I-Premise
la I-Premise
inducción I-Premise
a I-Premise
favor I-Premise
del I-Premise
brazo I-Premise
MP I-Premise
. I-Premise

Durante B-Premise
el I-Premise
mantenimiento I-Premise
con I-Premise
talidomida, I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
QLQ-MY24 I-Premise
sobre I-Premise
la I-Premise
parestesia I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
MPT I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Las B-Premise
subescalas I-Premise
de I-Premise
dolor I-Premise
del I-Premise
QLQ-C30 I-Premise
( I-Premise
P=0,12 I-Premise
) I-Premise
, I-Premise
insomnio I-Premise
( I-Premise
P=0,068 I-Premise
) I-Premise
, I-Premise
pérdida I-Premise
de I-Premise
apetito I-Premise
( I-Premise
P=0,074 I-Premise
) I-Premise
y I-Premise
el I-Premise
ítem I-Premise
de I-Premise
enfermedad I-Premise
del I-Premise
QLQ-MY24 I-Premise
( I-Premise
P=0,086 I-Premise
) I-Premise
obtuvieron I-Premise
una I-Premise
puntuación I-Premise
marginalmente I-Premise
mejor I-Premise
durante I-Premise
el I-Premise
mantenimiento I-Premise
con I-Premise
talidomida I-Premise
. I-Premise

La B-Premise
escala I-Premise
global I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
QLQ-C30-HRQoL I-Premise
mostró I-Premise
una I-Premise
tendencia I-Premise
temporal I-Premise
significativa I-Premise
hacia I-Premise
valores I-Premise
medios I-Premise
más I-Premise
favorables I-Premise
durante I-Premise
el I-Premise
tratamiento I-Premise
del I-Premise
protocolo, I-Premise
sin I-Premise
diferencias I-Premise
entre I-Premise
MP I-Premise
y I-Premise
MPT I-Premise
. I-Premise

Para B-Premise
las I-Premise
subescalas I-Premise
del I-Premise
QLQ-C30, I-Premise
función I-Premise
emocional I-Premise
y I-Premise
perspectivas I-Premise
de I-Premise
futuro, I-Premise
se I-Premise
observó I-Premise
una I-Premise
diferencia I-Premise
a I-Premise
favor I-Premise
del I-Premise
brazo I-Premise
de I-Premise
MPT I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
P=0,018 I-Premise
y I-Premise
P=0,045 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
sin I-Premise
una I-Premise
interacción I-Premise
significativa I-Premise
"tiempo I-Premise
× I-Premise
brazo", I-Premise
lo I-Premise
que I-Premise
indica I-Premise
una I-Premise
mejor I-Premise
perspectiva I-Premise
persistente I-Premise
del I-Premise
paciente I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
de I-Premise
MPT I-Premise
. I-Premise

Este B-Claim
estudio I-Claim
muestra I-Claim
que I-Claim
la I-Claim
mayor I-Claim
frecuencia I-Claim
de I-Claim
toxicidad I-Claim
asociada I-Claim
al I-Claim
MPT I-Claim
no I-Claim
se I-Claim
traduce I-Claim
en I-Claim
un I-Claim
efecto I-Claim
negativo I-Claim
sobre I-Claim
la I-Claim
CVRS I-Claim
y I-Claim
que I-Claim
el I-Claim
MPT I-Claim
tiene I-Claim
una I-Claim
mejor I-Claim
perspectiva I-Claim
para I-Claim
el I-Claim
paciente I-Claim
. I-Claim

El O
paclitaxel O
y O
la O
doxorrubicina O
liposomal O
pegilada O
( O
PLD O
) O
son O
agentes O
citotóxicos O
activos O
para O
el O
tratamiento O
del O
sarcoma O
de O
Kaposi O
( O
KS O
) O
asociado O
al O
virus O
de O
la O
inmunodeficiencia O
humana O
( O
VIH O
) O
. O

Se O
llevó O
a O
cabo O
un O
ensayo O
aleatorio O
en O
el O
que O
se O
comparó O
la O
eficacia O
y O
la O
toxicidad O
de O
paclitaxel O
y O
PLD, O
y O
se O
determinaron O
los O
efectos O
de O
la O
terapia O
en O
la O
paliación O
de O
los O
síntomas O
y O
la O
calidad O
de O
vida. O

Los O
pacientes O
con O
SK O
avanzado O
asociado O
al O
VIH O
fueron O
asignados O
aleatoriamente O
a O
recibir O
paclitaxel O
a O
una O
dosis O
de O
100 O
mg/m2 O
por O
vía O
intravenosa O
( O
iv O
) O
cada O
2 O
semanas O
o O
PLD O
a O
una O
dosis O
de O
20 O
mg/m2 O
iv O
cada O
3 O
semanas O
. O

Se O
utilizó O
el O
instrumento O
de O
calidad O
de O
vida O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
antes O
y O
después O
de O
cada O
dos O
ciclos O
de O
tratamiento O
. O

El O
estudio O
incluyó O
a O
73 O
pacientes O
analizables O
inscritos O
entre O
1998 O
y O
2002 O
, O
incluyendo O
36 O
en O
el O
brazo O
de O
paclitaxel O
y O
37 O
en O
el O
brazo O
de O
PLD O
; O
el O
73% O
de O
los O
pacientes O
recibió O
terapia O
antirretroviral O
altamente O
activa O
( O
HAART O
) O
y O
el O
32% O
tenía O
una O
carga O
viral O
indetectable O
( O
< O
400 O
copias/mL O
) O
. O

El B-Premise
tratamiento I-Premise
se I-Premise
asoció I-Premise
a I-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
del I-Premise
dolor I-Premise
( I-Premise
P=0,024 I-Premise
) I-Premise
y I-Premise
de I-Premise
la I-Premise
inflamación I-Premise
( I-Premise
P I-Premise
<0,001 I-Premise
) I-Premise
. I-Premise

De B-Premise
los I-Premise
36 I-Premise
pacientes I-Premise
que I-Premise
declararon I-Premise
que I-Premise
el I-Premise
dolor I-Premise
interfería I-Premise
con I-Premise
su I-Premise
trabajo I-Premise
o I-Premise
actividades I-Premise
normales I-Premise
al I-Premise
inicio, I-Premise
25 I-Premise
( I-Premise
69 I-Premise
% I-Premise
) I-Premise
mejoraron. I-Premise

De B-Premise
los I-Premise
41 I-Premise
pacientes I-Premise
que I-Premise
informaron I-Premise
de I-Premise
hinchazón I-Premise
al I-Premise
inicio, I-Premise
38 I-Premise
( I-Premise
93% I-Premise
) I-Premise
mejoraron. I-Premise

La B-Premise
comparación I-Premise
de I-Premise
los I-Premise
brazos I-Premise
de I-Premise
paclitaxel I-Premise
y I-Premise
PLD I-Premise
reveló I-Premise
unas I-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
comparables I-Premise
( I-Premise
56 I-Premise
% I-Premise
frente I-Premise
a I-Premise
46 I-Premise
% I-Premise
; I-Premise
P=0,49 I-Premise
) I-Premise
, I-Premise
una I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
( I-Premise
17,5 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
12,2 I-Premise
meses I-Premise
; I-Premise
P=0,66 I-Premise
) I-Premise
y I-Premise
unas I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
dos I-Premise
años I-Premise
( I-Premise
79 I-Premise
% I-Premise
frente I-Premise
a I-Premise
78 I-Premise
% I-Premise
; I-Premise
P=0,75 I-Premise
) I-Premise
, I-Premise
pero I-Premise
una I-Premise
toxicidad I-Premise
algo I-Premise
mayor I-Premise
de I-Premise
grado I-Premise
3 I-Premise
a I-Premise
5 I-Premise
para I-Premise
el I-Premise
paclitaxel I-Premise
( I-Premise
84 I-Premise
% I-Premise
frente I-Premise
a I-Premise
66 I-Premise
% I-Premise
; I-Premise
P=0,077 I-Premise
) O
. O

El B-Claim
tratamiento I-Claim
con I-Claim
paclitaxel I-Claim
o I-Claim
PLD I-Claim
parece I-Claim
producir I-Claim
mejoras I-Claim
significativas I-Claim
del I-Claim
dolor I-Claim
y I-Claim
la I-Claim
inflamación I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
SK I-Claim
avanzado, I-Claim
sintomático I-Claim
y I-Claim
asociado I-Claim
al I-Claim
VIH I-Claim
tratados I-Claim
en I-Claim
la I-Claim
era I-Claim
TARGA. I-Claim

El O
estudio O
de O
fase O
3 O
VISTA O
en O
pacientes O
con O
mieloma O
elegibles O
para O
trasplante O
demostró O
una O
eficacia O
superior O
con O
bortezomib-melfalán-prednisona O
( O
VMP O
; O
nueve O
ciclos O
de O
6 O
semanas O
) O
frente O
a O
melfalán-prednisona O
( O
MP O
) O
pero O
también O
una O
mayor O
toxicidad O
. O

La O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQoL O
; O
criterio O
de O
valoración O
exploratorio O
) O
se O
evaluó O
mediante O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
( O
QLQ-C30 O
) O
. O

El O
estudio O
de O
fase O
3 O
VISTA O
en O
pacientes O
con O
mieloma O
elegibles O
para O
trasplante O
demostró O
una O
eficacia O
superior O
con O
bortezomib-melfalán-prednisona O
( O
VMP O
; O
nueve O
ciclos O
de O
6 O
semanas O
) O
frente O
a O
melfalán-prednisona O
( O
MP O
) O
pero O
también O
una O
mayor O
toxicidad O
. O

La O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQoL O
; O
criterio O
de O
valoración O
exploratorio O
) O
se O
evaluó O
mediante O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
( O
QLQ-C30 O
) O
. O

El O
EORTC O
QLQ-C30 O
se O
administró O
en O
el O
momento O
del O
cribado, O
el O
día O
1 O
de O
cada O
ciclo, O
en O
la O
visita O
de O
fin O
de O
tratamiento O
y O
cada O
8 O
semanas O
hasta O
la O
progresión. O

Se O
evaluaron O
las O
puntuaciones O
del O
EORTC O
QLQ-C30 O
entre O
los O
pacientes O
con O
una O
línea O
de O
base O
válida O
y O
al O
menos O
una O
evaluación O
de O
la O
CVRS O
posterior O
a O
la O
línea O
de O
base. O

En O
la O
línea O
de O
base, O
las O
puntuaciones O
de O
los O
dominios O
fueron O
similares O
entre O
los O
brazos. O

En B-Premise
el I-Premise
ciclo I-Premise
4, I-Premise
las I-Premise
diferencias I-Premise
medias I-Premise
eran I-Premise
clínicamente I-Premise
significativas I-Premise
para I-Premise
la I-Premise
mayoría I-Premise
de I-Premise
los I-Premise
dominios, I-Premise
lo I-Premise
que I-Premise
indica I-Premise
un I-Premise
peor I-Premise
estado I-Premise
de I-Premise
salud I-Premise
con I-Premise
el I-Premise
PMV. I-Premise

A B-Premise
partir I-Premise
del I-Premise
ciclo I-Premise
5, I-Premise
se I-Premise
observaron I-Premise
mejoras I-Premise
respecto I-Premise
a I-Premise
la I-Premise
línea I-Premise
de I-Premise
base/MP I-Premise
en I-Premise
todos I-Premise
los I-Premise
ámbitos I-Premise
con I-Premise
VMP. I-Premise

Las B-Premise
puntuaciones I-Premise
medias I-Premise
mejoraron I-Premise
en I-Premise
general I-Premise
en I-Premise
la I-Premise
evaluación I-Premise
del I-Premise
final I-Premise
del I-Premise
tratamiento I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
inicio I-Premise
en I-Premise
ambos I-Premise
brazos. I-Premise

Entre B-Premise
los I-Premise
pacientes I-Premise
que I-Premise
respondieron, I-Premise
las I-Premise
puntuaciones I-Premise
medias I-Premise
mejoraron I-Premise
en I-Premise
general I-Premise
desde I-Premise
el I-Premise
momento I-Premise
de I-Premise
la I-Premise
respuesta I-Premise
hasta I-Premise
la I-Premise
evaluación I-Premise
del I-Premise
final I-Premise
del I-Premise
tratamiento, I-Premise
impulsadas I-Premise
sustancialmente I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
lograron I-Premise
una I-Premise
respuesta I-Premise
completa I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

El B-Premise
análisis I-Premise
multivariante I-Premise
mostró I-Premise
un I-Premise
impacto I-Premise
significativo I-Premise
de I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
respuesta/RC I-Premise
en I-Premise
la I-Premise
mejora I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global, I-Premise
el I-Premise
dolor I-Premise
y I-Premise
la I-Premise
pérdida I-Premise
de I-Premise
apetito. I-Premise

Los B-Claim
análisis I-Claim
según I-Claim
la I-Claim
intensidad I-Claim
de I-Claim
la I-Claim
dosis I-Claim
de I-Claim
bortezomib I-Claim
indicaron I-Claim
una I-Claim
mejor I-Claim
CVRS I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
una I-Claim
menor I-Claim
intensidad I-Claim
de I-Claim
dosis I-Claim
. I-Claim

Estos B-Claim
hallazgos I-Claim
demuestran I-Claim
disminuciones I-Claim
de I-Claim
la I-Claim
CVRS I-Claim
clínicamente I-Claim
significativas I-Claim
y I-Claim
transitorias I-Claim
con I-Claim
el I-Claim
VMP I-Claim
y I-Claim
una I-Claim
CVRS I-Claim
relativamente I-Claim
menor I-Claim
frente I-Claim
al I-Claim
MP I-Claim
durante I-Claim
los I-Claim
primeros I-Claim
ciclos I-Claim
de I-Claim
tratamiento, I-Claim
asociados I-Claim
a I-Claim
las I-Claim
toxicidades I-Claim
adicionales I-Claim
esperadas. I-Claim

Sin B-Claim
embargo, I-Claim
la I-Claim
CVRS I-Claim
no I-Claim
se I-Claim
ve I-Claim
comprometida I-Claim
a I-Claim
largo I-Claim
plazo, I-Claim
recuperándose I-Claim
en I-Claim
la I-Claim
visita I-Claim
de I-Claim
fin I-Claim
de I-Claim
tratamiento I-Claim
para I-Claim
ser I-Claim
comparable I-Claim
frente I-Claim
a I-Claim
MP. I-Claim

La B-Claim
quimioterapia I-Claim
prolonga I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
mejora I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
buen I-Claim
estado I-Claim
funcional I-Claim
( I-Claim
PS I-Claim
) I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
no I-Claim
pequeñas I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
avanzado I-Claim
. I-Claim

Las B-Claim
terapias I-Claim
dirigidas I-Claim
pueden I-Claim
mejorar I-Claim
la I-Claim
eficacia I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
sin I-Claim
empeorar I-Claim
la I-Claim
toxicidad I-Claim
. I-Claim

SGN-15 O
es O
un O
conjugado O
anticuerpo-fármaco O
( O
ADC O
) O
, O
que O
consiste O
en O
un O
anticuerpo O
monoclonal O
murino O
quimérico O
que O
reconoce O
el O
antígeno O
Lewis O
Y O
( O
Le O
( O
y O
) O
) O
, O
conjugado O
con O
doxorrubicina O
. O

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
es I-Claim
un I-Claim
objetivo I-Claim
atractivo I-Claim
ya I-Claim
que I-Claim
se I-Claim
expresa I-Claim
en I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
CPNM I-Claim
. I-Claim

SGN-15 B-Premise
fue I-Premise
activo I-Premise
contra I-Premise
tumores I-Premise
Le I-Premise
( I-Premise
y I-Premise
) I-Premise
-positivos I-Premise
en I-Premise
ensayos I-Premise
clínicos I-Premise
de I-Premise
fase I-Premise
temprana I-Premise
y I-Premise
fue I-Premise
sinérgico I-Premise
con I-Premise
docetaxel I-Premise
en I-Premise
experimentos I-Premise
preclínicos I-Premise
. I-Premise

Este O
estudio O
de O
fase O
II, O
abierto, O
se O
realizó O
para O
confirmar O
la O
actividad O
de O
SGN-15 O
más O
docetaxel O
en O
pacientes O
con O
CPNM O
previamente O
tratados. O

Sesenta O
y O
dos O
pacientes O
con O
CPNM O
recurrente O
o O
metastásico O
que O
expresaban O
Le O
( O
y O
) O
, O
uno O
o O
dos O
regímenes O
de O
quimioterapia O
previos O
y O
PS O
< O
o O
=2 O
fueron O
aleatorizados O
2:1 O
para O
recibir O
SGN-15 O
200 O
mg/m2/semana O
con O
docetaxel O
35 O
mg/m2/semana O
( O
Brazo O
A O
) O
o O
docetaxel O
35 O
mg/m2/semana O
solo O
( O
Brazo O
B O
) O
durante O
6 O
de O
8 O
semanas O
. O

En O
la O
segunda O
mitad O
del O
estudio O
se O
permitió O
el O
aumento O
de O
la O
dosis O
de O
SGN-15 O
a O
350 O
mg/m2. O

Los O
criterios O
de O
valoración O
fueron O
la O
supervivencia, O
la O
seguridad, O
la O
eficacia O
y O
la O
calidad O
de O
vida. O

Cuarenta O
pacientes O
del O
brazo O
A O
y O
19 O
del O
brazo O
B O
recibieron O
al O
menos O
un O
tratamiento. O

Los B-Premise
pacientes I-Premise
de I-Premise
los I-Premise
brazos I-Premise
A I-Premise
y I-Premise
B I-Premise
tuvieron I-Premise
una I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
31,4 I-Premise
y I-Premise
25,3 I-Premise
semanas, I-Premise
una I-Premise
supervivencia I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
del I-Premise
29% I-Premise
y I-Premise
el I-Premise
24%, I-Premise
y I-Premise
una I-Premise
supervivencia I-Premise
a I-Premise
los I-Premise
18 I-Premise
meses I-Premise
del I-Premise
18% I-Premise
y I-Premise
el I-Premise
8%, I-Premise
respectivamente. I-Premise

La B-Premise
toxicidad I-Premise
fue I-Premise
leve I-Premise
en I-Premise
ambos I-Premise
brazos. I-Premise

Los B-Premise
análisis I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
favorecieron I-Premise
el I-Premise
brazo I-Premise
A. I-Premise
SGN-15 B-Claim
más I-Claim
docetaxel I-Claim
es I-Claim
un I-Claim
tratamiento I-Claim
de I-Claim
segunda I-Claim
y I-Claim
tercera I-Claim
línea I-Claim
bien I-Claim
tolerado I-Claim
y I-Claim
activo I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPNM. I-Claim

Los O
estudios O
en O
curso O
están O
explorando O
esquemas O
alternativos O
para O
maximizar O
la O
sinergia O
entre O
estos O
agentes O
. O

La O
combinación O
de O
radioterapia O
más O
supresión O
médica O
de O
andrógenos O
a O
largo O
plazo O
( O
> O
o O
= O
2 O
años O
) O
mejora O
la O
supervivencia O
global O
en O
pacientes O
con O
cáncer O
de O
próstata O
localmente O
avanzado O
. O

Se O
comparó O
el O
uso O
de O
radioterapia O
más O
supresión O
androgénica O
a O
corto O
plazo O
con O
el O
uso O
de O
radioterapia O
más O
supresión O
androgénica O
a O
largo O
plazo O
en O
el O
tratamiento O
del O
cáncer O
de O
próstata O
localmente O
avanzado O
. O

Se O
asignaron O
aleatoriamente O
pacientes O
con O
cáncer O
de O
próstata O
localmente O
avanzado O
que O
habían O
recibido O
radioterapia O
de O
haz O
externo O
más O
6 O
meses O
de O
supresión O
androgénica O
a O
dos O
grupos O
, O
uno O
para O
no O
recibir O
más O
tratamiento O
( O
supresión O
a O
corto O
plazo O
) O
y O
el O
otro O
para O
recibir O
2,5 O
años O
de O
tratamiento O
adicional O
con O
un O
agonista O
de O
la O
hormona O
liberadora O
de O
hormona O
luteinizante O
( O
supresión O
a O
largo O
plazo O
) O
. O

Un O
resultado O
de O
no O
inferioridad O
de O
la O
supresión O
androgénica O
a O
corto O
plazo O
en O
comparación O
con O
la O
supresión O
a O
largo O
plazo O
requería O
un O
cociente O
de O
riesgo O
de O
más O
de O
1,35 O
para O
la O
supervivencia O
global O
, O
con O
un O
nivel O
alfa O
unilateral O
de O
0,05 O
. O

Un O
análisis O
intermedio O
mostró O
futilidad O
, O
y O
los O
resultados O
se O
presentan O
con O
un O
nivel O
alfa O
unilateral O
ajustado O
de O
0,0429 O
. O

Se O
registraron O
1113 O
hombres, O
de O
los O
cuales O
970 O
fueron O
asignados O
al O
azar, O
483 O
a O
la O
supresión O
a O
corto O
plazo O
y O
487 O
a O
la O
supresión O
a O
largo O
plazo. O

Tras B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
6,4 I-Premise
años, I-Premise
132 I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
a I-Premise
corto I-Premise
plazo I-Premise
y I-Premise
98 I-Premise
del I-Premise
grupo I-Premise
a I-Premise
largo I-Premise
plazo I-Premise
habían I-Premise
fallecido; I-Premise
el B-Premise
número I-Premise
de I-Premise
muertes I-Premise
por I-Premise
cáncer I-Premise
de I-Premise
próstata I-Premise
fue I-Premise
de I-Premise
47 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
a I-Premise
corto I-Premise
plazo I-Premise
y I-Premise
de I-Premise
29 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
a I-Premise
largo I-Premise
plazo. I-Premise

La B-Premise
mortalidad I-Premise
global I-Premise
a I-Premise
los I-Premise
5 I-Premise
años I-Premise
para I-Premise
la I-Premise
supresión I-Premise
a I-Premise
corto I-Premise
y I-Premise
largo I-Premise
plazo I-Premise
fue I-Premise
del I-Premise
19,0 I-Premise
% I-Premise
y I-Premise
del I-Premise
15,2 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; O
la O
razón O
de O
riesgo O
observada O
fue O
de O
1,42 O
( O
límite O
superior O
de O
confianza O
del O
95,71 O
% O
, O
1,79 O
; O
P=0,65 O
para O
la O
no O
inferioridad O
) O
. O

Los B-Premise
eventos I-Premise
adversos I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
incluyeron I-Premise
fatiga, I-Premise
disminución I-Premise
de I-Premise
la I-Premise
función I-Premise
sexual I-Premise
y I-Premise
sofocos. I-Premise

La B-Claim
combinación I-Claim
de I-Claim
radioterapia I-Claim
más I-Claim
6 I-Claim
meses I-Claim
de I-Claim
supresión I-Claim
androgénica I-Claim
proporciona I-Claim
una I-Claim
supervivencia I-Claim
inferior I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
radioterapia I-Claim
más I-Claim
3 I-Claim
años I-Claim
de I-Claim
supresión I-Claim
androgénica I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
localmente I-Claim
avanzado I-Claim
. I-Claim

La O
caquexia O
por O
cáncer O
es O
un O
problema O
común O
entre O
los O
pacientes O
con O
cáncer O
avanzado O
. O

Una O
mezcla O
de O
beta-hidroxil O
beta-metil O
butirato O
, O
glutamina O
y O
arginina O
( O
HMB/Arg/Gln O
) O
mostró O
previamente O
actividad O
para O
aumentar O
la O
masa O
corporal O
magra O
( O
LBM O
) O
entre O
los O
pacientes O
con O
caquexia O
por O
cáncer O
. O

Por O
lo O
tanto, O
se O
llevó O
a O
cabo O
un O
ensayo O
de O
fase O
III O
para O
confirmar O
esta O
actividad. O

Cuatrocientos O
setenta O
y O
dos O
pacientes O
con O
cáncer O
avanzado O
con O
una O
pérdida O
de O
peso O
de O
entre O
el O
2 O
% O
y O
el O
10 O
% O
fueron O
asignados O
al O
azar O
a O
una O
mezcla O
de O
beta-hidroxil O
beta-metilbutirato O
, O
glutamina O
y O
arginina O
o O
a O
una O
mezcla O
de O
control O
isonitrogenada O
e O
isocalórica O
tomada O
dos O
veces O
al O
día O
durante O
8 O
semanas O
. O

La O
masa O
corporal O
magra O
se O
estimó O
mediante O
mediciones O
de O
bioimpedancia O
y O
pliegues O
cutáneos O
. O

Se O
utilizó O
la O
pletismografía O
corporal O
cuando O
estaba O
disponible. O

También O
se O
midieron O
el O
peso, O
la O
escala O
de O
fatiga O
de O
Schwartz O
y O
la O
escala O
de O
calidad O
de O
vida O
de O
Spitzer. O

Sólo O
el O
37% O
de O
los O
pacientes O
completó O
el O
tratamiento O
del O
protocolo. O

La O
mayor O
parte O
de O
la O
pérdida O
de O
pacientes O
se O
debió O
a O
la O
preferencia O
de O
los O
mismos O
( O
45% O
de O
los O
pacientes O
inscritos O
) O
. O

Sin O
embargo, O
la O
pérdida O
de O
potencia O
no O
fue O
un O
problema O
debido O
al O
gran O
tamaño O
de O
la O
muestra O
prevista. O

Según O
un O
análisis O
por O
intención O
de O
tratar, O
no O
hubo O
diferencias O
estadísticamente O
significativas O
en O
la O
masa O
corporal O
magra O
a O
las O
8 O
semanas O
entre O
los O
dos O
brazos. O

Los O
criterios O
de O
valoración O
secundarios O
tampoco O
fueron O
significativamente O
diferentes O
entre O
los O
brazos. O

Según B-Premise
los I-Premise
resultados I-Premise
del I-Premise
análisis I-Premise
del I-Premise
área I-Premise
bajo I-Premise
la I-Premise
curva I-Premise
(AUC), I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
HMB/Arg/Gln I-Premise
presentaron I-Premise
una I-Premise
fuerte I-Premise
tendencia I-Premise
a I-Premise
un I-Premise
mayor I-Premise
LBM I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
estudio, I-Premise
medido I-Premise
tanto I-Premise
por I-Premise
la I-Premise
bioimpedancia I-Premise
( I-Premise
p I-Premise
= I-Premise
0,08 I-Premise
) I-Premise
como I-Premise
por I-Premise
las I-Premise
mediciones I-Premise
del I-Premise
pliegue I-Premise
cutáneo I-Premise
( I-Premise
p I-Premise
= I-Premise
0,08 I-Premise
) I-Premise
. I-Premise

Entre B-Premise
el I-Premise
subconjunto I-Premise
de I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
quimioterapia I-Premise
simultánea, I-Premise
tampoco I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
los I-Premise
criterios I-Premise
de I-Premise
valoración. I-Premise

Los O
criterios O
de O
valoración O
secundarios O
tampoco O
fueron O
significativamente O
diferentes O
entre O
los O
brazos. O

Este B-Claim
ensayo I-Claim
no I-Claim
pudo I-Claim
probar I-Claim
adecuadamente I-Claim
la I-Claim
capacidad I-Claim
del I-Claim
beta-hidroxi-beta-metilbutirato I-Claim
, I-Claim
la I-Claim
glutamina I-Claim
y I-Claim
la I-Claim
arginina I-Claim
para I-Claim
revertir I-Claim
o I-Claim
prevenir I-Claim
el I-Claim
desgaste I-Claim
de I-Claim
la I-Claim
masa I-Claim
corporal I-Claim
magra I-Claim
entre I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
. I-Claim

Los O
posibles O
factores O
que O
contribuyeron, O
más O
allá O
de O
la O
eficacia O
de O
la O
intervención, O
fueron O
la O
incapacidad O
de O
los O
pacientes O
para O
completar O
un O
curso O
de O
8 O
semanas O
de O
tratamiento O
y O
volver O
a O
tiempo O
para O
la O
evaluación O
de O
seguimiento O
, O
y O
porque O
los O
pacientes O
sólo O
pueden O
haber O
tenido O
una O
posible O
pérdida O
de O
peso O
no O
relacionada O
con O
la O
caquexia O
, O
sino O
con O
otras O
causas O
de O
pérdida O
de O
peso O
, O
como O
la O
disminución O
del O
apetito O
. O

Sin O
embargo, O
hubo O
una O
fuerte O
tendencia O
hacia O
un O
aumento O
de O
la O
masa O
corporal O
entre O
los O
pacientes O
que O
tomaron O
el O
compuesto O
Juven O
utilizando O
el O
criterio O
de O
valoración O
secundario O
del O
AUC. O

Evaluar O
la O
seguridad, O
la O
tolerabilidad O
y O
la O
eficacia O
de O
abatacept O
en O
pacientes O
con O
artritis O
reumatoide O
(AR) O
a O
los O
que O
les O
ha O
fallado O
el O
tratamiento O
contra O
el O
factor O
de O
necrosis O
tumoral O
(TNF) O
y O
a O
los O
que O
se O
les O
cambió O
a O
abatacept O
directamente O
o O
después O
de O
completar O
el O
lavado. O

En O
este O
ensayo O
internacional, O
de O
6 O
meses O
de O
duración O
y O
de O
etiqueta O
abierta, O
los O
pacientes O
tenían O
AR O
activa, O
una O
respuesta O
inadecuada O
al O
tratamiento O
con O
anti-TNF O
durante O
3 O
meses O
o O
más O
y O
una O
puntuación O
de O
actividad O
de O
la O
enfermedad O
en O
28 O
articulaciones O
( O
DAS28 O
) O
de O
5,1 O
o O
más. O

Los O
pacientes O
de O
"lavado" O
interrumpieron O
la O
terapia O
anti-TNF O
2 O
meses O
o O
más O
antes O
de O
la O
selección; O
los O
pacientes O
de O
"cambio O
directo" O
comenzaron O
a O
tomar O
abatacept O
(aproximadamente O
10 O
mg/kg) O
en O
su O
siguiente O
dosis O
programada O
de O
terapia O
anti-TNF. O

Se O
trataron O
1046 O
pacientes O
( O
449 O
de O
lavado, O
597 O
de O
cambio O
directo; O
las O
características O
basales O
fueron O
similares O
entre O
los O
grupos O
) O
. O

A B-Premise
los I-Premise
6 I-Premise
meses, I-Premise
los I-Premise
acontecimientos I-Premise
adversos I-Premise
(EA; I-Premise
78,0 I-Premise
% I-Premise
frente I-Premise
a I-Premise
79,2 I-Premise
%), I-Premise
los I-Premise
EA I-Premise
graves I-Premise
(11,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
9,9 I-Premise
%) I-Premise
y I-Premise
las I-Premise
interrupciones I-Premise
debidas I-Premise
a I-Premise
EA I-Premise
(3,8 I-Premise
% I-Premise
frente I-Premise
a I-Premise
4,0 I-Premise
%) I-Premise
y I-Premise
a I-Premise
EA I-Premise
graves I-Premise
(2,0 I-Premise
% I-Premise
frente I-Premise
a I-Premise
1,3 I-Premise
%) I-Premise
fueron I-Premise
comparables I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
lavado I-Premise
frente I-Premise
a I-Premise
los I-Premise
de I-Premise
cambio I-Premise
directo. I-Premise

No B-Premise
hubo I-Premise
infecciones I-Premise
oportunistas. I-Premise

A B-Premise
los I-Premise
6 I-Premise
meses, I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
lavado I-Premise
frente I-Premise
a I-Premise
los I-Premise
de I-Premise
cambio I-Premise
directo, I-Premise
se I-Premise
observaron I-Premise
mejoras I-Premise
clínicamente I-Premise
significativas I-Premise
similares I-Premise
en I-Premise
la I-Premise
DAS28 I-Premise
( I-Premise
PCR I-Premise
) I-Premise
( I-Premise
mejora I-Premise
de I-Premise
> I-Premise
o I-Premise
=1,2 I-Premise
unidades I-Premise
, I-Premise
59,5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
53,6 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
estado I-Premise
de I-Premise
baja I-Premise
actividad I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
, I-Premise
22,5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
22,3 I-Premise
% I-Premise
; I-Premise
remisión I-Premise
definida I-Premise
por I-Premise
la I-Premise
DAS28 I-Premise
, I-Premise
12,0 I-Premise
% I-Premise
frente I-Premise
a I-Premise
13.7 I-Premise
% I-Premise
) I-Premise
, I-Premise
la I-Premise
función I-Premise
física I-Premise
( I-Premise
índice I-Premise
de I-Premise
discapacidad I-Premise
del I-Premise
cuestionario I-Premise
de I-Premise
evaluación I-Premise
de I-Premise
la I-Premise
salud I-Premise
> I-Premise
o I-Premise
=0,22 I-Premise
de I-Premise
mejora I-Premise
; I-Premise
46,3 I-Premise
% I-Premise
vs I-Premise
47,1 I-Premise
% I-Premise
) I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
relacionada I-Premise
con I-Premise
la I-Premise
salud I-Premise
( I-Premise
cambio I-Premise
medio I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
formulario I-Premise
corto I-Premise
36 I-Premise
: I-Premise
resumen I-Premise
del I-Premise
componente I-Premise
físico I-Premise
, I-Premise
5,5 I-Premise
vs I-Premise
6,1 I-Premise
; I-Premise
resumen I-Premise
del I-Premise
componente I-Premise
mental I-Premise
, I-Premise
4,8 I-Premise
vs I-Premise
5,4 I-Premise
) I-Premise
. I-Premise

Abatacept B-Claim
demostró I-Claim
una I-Claim
seguridad I-Claim
y I-Claim
tolerabilidad I-Claim
aceptables I-Claim
y I-Claim
una I-Claim
eficacia I-Claim
clínicamente I-Claim
significativa I-Claim
durante I-Claim
6 I-Claim
meses I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
una I-Claim
respuesta I-Claim
inadecuada I-Claim
a I-Claim
la I-Claim
terapia I-Claim
anti-TNF I-Claim
. I-Claim

Los B-Claim
resultados I-Claim
fueron I-Claim
comparables I-Claim
con I-Claim
o I-Claim
sin I-Claim
lavado I-Claim
, I-Claim
apoyando I-Claim
el I-Claim
cambio I-Claim
directo I-Claim
de I-Claim
la I-Claim
terapia I-Claim
anti-TNF I-Claim
a I-Claim
abatacept I-Claim
como I-Claim
una I-Claim
opción I-Claim
en I-Claim
la I-Claim
práctica I-Claim
clínica I-Claim
. I-Claim

Evaluar O
la O
calidad O
de O
vida O
específica O
del O
cáncer O
de O
próstata O
informada O
por O
los O
pacientes O
2 O
y O
3 O
años O
después O
de O
la O
radioterapia O
de O
la O
próstata O
en O
un O
ensayo O
aleatorio O
de O
escalada O
de O
dosis O
de O
70 O
frente O
a O
78 O
Gy O
realizado O
entre O
1993 O
y O
1998. O

Dos O
años O
después O
de O
finalizar O
la O
radioterapia, O
se O
envió O
a O
301 O
pacientes O
del O
estudio O
un O
cuestionario O
que O
evaluaba O
la O
función O
vesical, O
rectal O
y O
sexual. O

Tres O
años O
después O
del O
tratamiento, O
se O
envió O
un O
segundo O
cuestionario O
a O
los O
175 O
pacientes O
con O
un O
seguimiento O
adecuado. O

Tres B-Premise
años I-Premise
después I-Premise
de I-Premise
la I-Premise
radioterapia, I-Premise
el I-Premise
35% I-Premise
de I-Premise
las I-Premise
pacientes I-Premise
declararon I-Premise
incontinencia I-Premise
urinaria, I-Premise
pero I-Premise
sólo I-Premise
el I-Premise
6% I-Premise
necesitó I-Premise
el I-Premise
uso I-Premise
de I-Premise
una I-Premise
compresa I-Premise
u I-Premise
otro I-Premise
dispositivo I-Premise
de I-Premise
protección. I-Premise

Las B-Premise
pacientes I-Premise
declararon I-Premise
un I-Premise
aumento I-Premise
de I-Premise
las I-Premise
pérdidas I-Premise
con I-Premise
la I-Premise
vejiga I-Premise
llena I-Premise
( I-Premise
incontinencia I-Premise
de I-Premise
urgencia I-Premise
) I-Premise
entre I-Premise
los I-Premise
cuestionarios I-Premise
de I-Premise
2 I-Premise
y I-Premise
3 I-Premise
años I-Premise
( I-Premise
42 I-Premise
% I-Premise
frente I-Premise
a I-Premise
50 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
. I-Premise

A B-Premise
los I-Premise
3 I-Premise
años, I-Premise
el I-Premise
33% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
declararon I-Premise
una I-Premise
hemorragia I-Premise
rectal, I-Premise
frente I-Premise
al I-Premise
47% I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
( I-Premise
P I-Premise
= I-Premise
0,006 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
78 I-Premise
Gy I-Premise
informaron I-Premise
de I-Premise
movimientos I-Premise
intestinales I-Premise
más I-Premise
frecuentes I-Premise
a I-Premise
los I-Premise
3 I-Premise
años I-Premise
y I-Premise
menos I-Premise
cambios I-Premise
en I-Premise
la I-Premise
función I-Premise
intestinal I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
70 I-Premise
Gy I-Premise
. I-Premise

Antes B-Premise
de I-Premise
la I-Premise
radioterapia, I-Premise
el I-Premise
84% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
declararon I-Premise
haber I-Premise
tenido I-Premise
erecciones I-Premise
adecuadas I-Premise
para I-Premise
el I-Premise
coito I-Premise
al I-Premise
menos I-Premise
un I-Premise
par I-Premise
de I-Premise
veces I-Premise
durante I-Premise
el I-Premise
año I-Premise
anterior. I-Premise

Al B-Premise
cabo I-Premise
de I-Premise
2 I-Premise
y I-Premise
3 I-Premise
años, I-Premise
este I-Premise
porcentaje I-Premise
había I-Premise
disminuido I-Premise
al I-Premise
49% I-Premise
y I-Premise
al I-Premise
41%, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
< I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

Según B-Claim
el I-Claim
cuestionario I-Claim
informado I-Claim
por I-Claim
los I-Claim
pacientes, I-Claim
78 I-Claim
Gy I-Claim
produjeron I-Claim
un I-Claim
aumento I-Claim
de I-Claim
la I-Claim
frecuencia I-Claim
de I-Claim
los I-Claim
movimientos I-Claim
intestinales I-Claim
y I-Claim
ningún I-Claim
aumento I-Claim
de I-Claim
los I-Claim
efectos I-Claim
secundarios I-Claim
vesicales I-Claim
o I-Claim
sexuales I-Claim
a I-Claim
los I-Claim
3 I-Claim
años, I-Claim
en I-Claim
comparación I-Claim
con I-Claim
70 I-Claim
Gy. I-Claim

Comparando B-Claim
los I-Claim
resultados I-Claim
2 I-Claim
y I-Claim
3 I-Claim
años I-Claim
después I-Claim
de I-Claim
la I-Claim
radioterapia I-Claim
, I-Claim
los I-Claim
síntomas I-Claim
de I-Claim
sangrado I-Claim
rectal I-Claim
habían I-Claim
mejorado I-Claim
, I-Claim
la I-Claim
función I-Claim
eréctil I-Claim
había I-Claim
disminuido I-Claim
, I-Claim
y I-Claim
la I-Claim
incontinencia I-Claim
urinaria I-Claim
de I-Claim
urgencia I-Claim
había I-Claim
aumentado I-Claim
. I-Claim

Debido O
a O
las O
diversas O
diferencias O
interindividuales O
en O
las O
características O
biológicas O
de O
las O
células O
tumorales O
, O
así O
como O
las O
cuestiones O
sobre O
la O
eficacia O
, O
las O
reacciones O
adversas O
, O
y O
los O
defectos O
de O
los O
fármacos O
existentes O
, O
se O
comparó O
la O
eficacia O
clínica O
y O
la O
toxicidad O
de O
pemetrexed O
y O
gemcitabina O
combinada O
con O
cisplatino O
para O
el O
tratamiento O
del O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
avanzado O
( O
NSCLC O
) O
no O
tratado O
previamente O
. O

251 O
pacientes O
fueron O
divididos O
aleatoriamente O
en O
el O
grupo O
de O
pemetrexed O
combinado O
con O
cisplatino O
( O
grupo O
PP O
) O
con O
127 O
casos O
y O
el O
grupo O
de O
gemcitabina O
combinado O
con O
cisplatino O
( O
grupo O
GP O
) O
con O
124 O
casos O
. O

El O
grupo O
PP O
recibió O
pemetrexed O
500 O
mg/m² O
iv O
en O
infusión O
d1 O
y O
cisplatino O
75 O
mg/m² O
iv O
en O
infusión O
d1 O
, O
mientras O
que O
el O
grupo O
GP O
recibió O
gemcitabina O
1.000 O
mg/m² O
iv O
en O
infusión O
d1,8 O
y O
cisplatino O
75 O
mg/m² O
iv O
en O
infusión O
d1 O
. O

El O
ciclo O
de O
tratamiento O
era O
una O
vez O
cada O
tres O
semanas. O

Además, O
se O
administró O
ácido O
fólico, O
vitamina O
B12 O
y O
dexametasona O
en O
ambos O
grupos. O

Las B-Premise
tasas I-Premise
clínicas I-Premise
efectivas I-Premise
totales I-Premise
en I-Premise
el I-Premise
grupo I-Premise
PP I-Premise
y I-Premise
en I-Premise
el I-Premise
grupo I-Premise
GP I-Premise
fueron I-Premise
del I-Premise
25,20% I-Premise
y I-Premise
del I-Premise
17,74% I-Premise
, I-Premise
respectivamente. I-Premise

Las B-Premise
eficacias I-Premise
totales I-Premise
del I-Premise
carcinoma I-Premise
de I-Premise
células I-Premise
no I-Premise
escamosas I-Premise
fueron I-Premise
del I-Premise
27,62 I-Premise
% I-Premise
y I-Premise
del I-Premise
16,00 I-Premise
% I-Premise
. I-Premise

La B-Premise
duración I-Premise
de I-Premise
la I-Premise
progresión I-Premise
del I-Premise
tumor I-Premise
en I-Premise
estos I-Premise
dos I-Premise
grupos I-Premise
fue I-Premise
de I-Premise
6,5 I-Premise
y I-Premise
5,6 I-Premise
meses, I-Premise
respectivamente. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
en I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
fue I-Premise
de I-Premise
16,9 I-Premise
y I-Premise
17,0 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
con I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
del I-Premise
59,62 I-Premise
% I-Premise
y I-Premise
65,87 I-Premise
% I-Premise
de I-Premise
1 I-Premise
año I-Premise
y I-Premise
del I-Premise
27,28 I-Premise
% I-Premise
y I-Premise
27,93 I-Premise
% I-Premise
de I-Premise
2 I-Premise
años I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

La B-Premise
eficacia I-Premise
total I-Premise
del I-Premise
carcinoma I-Premise
de I-Premise
células I-Premise
no I-Premise
escamosas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
PP I-Premise
fue I-Premise
significativamente I-Premise
superior I-Premise
a I-Premise
la I-Premise
del I-Premise
grupo I-Premise
GP I-Premise
. I-Premise

Los B-Premise
resultados I-Premise
fueron I-Premise
estadísticamente I-Premise
significativos. I-Premise

Sin O
embargo O
, O
no O
hubo O
diferencias O
significativas O
en O
las O
tasas O
de O
respuesta O
total O
, O
la O
duración O
de O
la O
progresión O
del O
tumor O
, O
y O
las O
tasas O
de O
supervivencia O
media O
de O
1 O
y O
2 O
años O
. O

La B-Premise
tasa I-Premise
de I-Premise
reacciones I-Premise
adversas I-Premise
, I-Premise
incluyendo I-Premise
la I-Premise
reducción I-Premise
de I-Premise
los I-Premise
glóbulos I-Premise
blancos I-Premise
, I-Premise
la I-Premise
disminución I-Premise
del I-Premise
recuento I-Premise
de I-Premise
plaquetas I-Premise
, I-Premise
la I-Premise
disminución I-Premise
de I-Premise
la I-Premise
hemoglobina I-Premise
, I-Premise
y I-Premise
la I-Premise
pérdida I-Premise
de I-Premise
cabello I-Premise
en I-Premise
el I-Premise
grupo I-Premise
PP I-Premise
fue I-Premise
significativamente I-Premise
menor I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
GP I-Premise
. I-Premise

Los O
resultados O
fueron O
estadísticamente O
significativos. O

La B-Claim
eficacia I-Claim
clínica I-Claim
del I-Claim
pemetrexed I-Claim
y I-Claim
la I-Claim
gemcitabina I-Claim
combinada I-Claim
con I-Claim
cisplatino I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
CPNM I-Claim
avanzado I-Claim
no I-Claim
tratado I-Claim
previamente I-Claim
fue I-Claim
aproximadamente I-Claim
la I-Claim
misma, I-Claim
pero B-Claim
las I-Claim
reacciones I-Claim
adversas I-Claim
disminuyeron I-Claim
significativamente I-Claim
en I-Claim
el I-Claim
grupo I-Claim
de I-Claim
PP I-Claim
en I-Claim
comparación I-Claim
con I-Claim
las I-Claim
del I-Claim
grupo I-Claim
de I-Claim
GP. I-Claim

Por B-Claim
lo I-Claim
tanto, I-Claim
el I-Claim
pemetrexed I-Claim
combinado I-Claim
con I-Claim
cisplatino I-Claim
puede I-Claim
utilizarse I-Claim
como I-Claim
un I-Claim
fármaco I-Claim
seguro I-Claim
y I-Claim
eficaz I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
clínico I-Claim
de I-Claim
primera I-Claim
línea I-Claim
del I-Claim
CPNM I-Claim
no I-Claim
tratado I-Claim
previamente. I-Claim

Este O
ensayo O
multicéntrico O
aleatorio O
se O
realizó O
para O
establecer O
la O
duración O
óptima O
de O
la O
quimioterapia O
paliativa O
en O
el O
cáncer O
de O
pulmón O
no O
microcítico O
avanzado O
( O
CPNM O
) O
. O

Se O
comparó O
una O
política O
de O
tres O
frente O
a O
seis O
cursos O
de O
quimioterapia O
combinada O
basada O
en O
platino O
de O
nueva O
generación O
con O
respecto O
a O
los O
efectos O
sobre O
la O
calidad O
de O
vida O
( O
QoL O
) O
y O
la O
supervivencia O
. O

Los O
pacientes O
con O
CPNM O
en O
estadio O
IIIB O
o O
IV O
y O
estado O
de O
rendimiento O
( O
PS O
) O
0-2 O
de O
la O
OMS O
fueron O
aleatorizados O
para O
recibir O
tres O
( O
C3 O
) O
o O
seis O
( O
C6 O
) O
ciclos O
de O
carboplatino O
( O
área O
bajo O
la O
curva O
( O
AUC O
) O
4 O
, O
fórmula O
de O
Chatelut O
, O
equivalente O
al O
AUC O
5 O
de O
Calvert O
) O
el O
día O
1 O
y O
vinorelbina O
25 O
mg O
m O
( O
-2 O
) O
los O
días O
1 O
y O
8 O
de O
un O
ciclo O
de O
3 O
semanas O
. O

Los O
criterios O
de O
valoración O
clave O
fueron O
la O
calidad O
de O
vida O
a O
las O
18 O
semanas, O
medida O
con O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
( O
QLQ O
) O
-C30 O
y O
el O
QLQ-LC13 O
de O
la O
EORTC, O
y O
la O
supervivencia O
global. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
supervivencia O
sin O
progresión O
y O
la O
necesidad O
de O
radioterapia O
paliativa. O

Se O
asignaron O
al O
azar O
297 O
pacientes O
( O
C3 O
150 O
, O
C6 O
147 O
) O
. O

La O
mediana O
de O
edad O
era O
de O
65 O
años, O
el O
30% O
tenía O
PS O
2 O
y O
el O
76% O
estaba O
en O
estadio O
IV. O

El O
78 O
y O
el O
54% O
de O
los O
pacientes O
C3 O
y O
C6 O
, O
respectivamente, O
completaron O
todos O
los O
cursos O
de O
quimioterapia O
programados. O

El O
cumplimiento O
de O
los O
cuestionarios O
de O
calidad O
de O
vida O
fue O
del O
88%. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global, I-Premise
el I-Premise
dolor I-Premise
o I-Premise
la I-Premise
fatiga I-Premise
hasta I-Premise
las I-Premise
26 I-Premise
semanas. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
paliación I-Premise
de I-Premise
la I-Premise
disnea I-Premise
fue I-Premise
menor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
C3 I-Premise
a I-Premise
las I-Premise
18 I-Premise
y I-Premise
26 I-Premise
semanas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) O
, O
pero B-Premise
este I-Premise
hallazgo I-Premise
fue I-Premise
inconsistente I-Premise
en I-Premise
los I-Premise
diferentes I-Premise
métodos I-Premise
de I-Premise
análisis I-Premise
. O

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
en I-Premise
el I-Premise
grupo I-Premise
C3 I-Premise
fue I-Premise
de I-Premise
28 I-Premise
frente I-Premise
a I-Premise
32 I-Premise
semanas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
C6 I-Premise
( I-Premise
P=0,75 I-Premise
, I-Premise
HR I-Premise
1,04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,82-1,31 I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
uno I-Premise
y I-Premise
dos I-Premise
años I-Premise
fueron I-Premise
del I-Premise
25 I-Premise
y I-Premise
9 I-Premise
% I-Premise
frente I-Premise
al I-Premise
25 I-Premise
y I-Premise
5 I-Premise
% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
C3 I-Premise
y I-Premise
C6 I-Premise
, I-Premise
respectivamente. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
16 I-Premise
y I-Premise
21 I-Premise
semanas I-Premise
en I-Premise
los I-Premise
grupos I-Premise
C3 I-Premise
y I-Premise
C6 I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
P=0,21 I-Premise
, I-Premise
HR I-Premise
0,86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,68-1,08 I-Premise
) I-Premise
. I-Premise

En B-Claim
conclusión, I-Claim
la I-Claim
quimioterapia I-Claim
paliativa I-Claim
con I-Claim
carboplatino I-Claim
y I-Claim
vinorelbina I-Claim
más I-Claim
allá I-Claim
de I-Claim
tres I-Claim
ciclos I-Claim
no I-Claim
aporta I-Claim
beneficios I-Claim
de I-Claim
supervivencia I-Claim
ni I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
consistentes I-Claim
en I-Claim
el I-Claim
CPNM I-Claim
avanzado. I-Claim

Determinar O
la O
eficacia, O
el O
impacto O
en O
la O
calidad O
de O
vida O
( O
QoL O
) O
y O
la O
tolerabilidad O
de O
dos O
esquemas O
diferentes O
de O
administración O
de O
irinotecán O
en O
combinación O
con O
capecitabina O
como O
tratamiento O
de O
primera O
línea O
del O
cáncer O
colorrectal O
metastásico O
. O

Llevamos O
a O
cabo O
un O
ensayo O
aleatorio O
de O
fase O
II O
para O
seleccionar O
uno O
de O
los O
siguientes O
regímenes O
de O
tratamiento O
para O
su O
posterior O
investigación: O
irinotecán O
semanal O
a O
una O
dosis O
de O
70 O
mg/m O
( O
2 O
) O
días O
1 O
, O
8 O
, O
15 O
, O
22 O
, O
29 O
( O
brazo O
A O
) O
o O
irinotecán O
de O
3 O
semanas O
a O
una O
dosis O
de O
300/240 O
mg/m O
( O
2 O
) O
día O
1 O
y O
días O
22 O
( O
brazo O
B O
) O
en O
combinación O
con O
capecitabina O
1000 O
mg/m O
( O
2 O
) O
dos O
veces O
al O
día O
días O
1-14 O
y O
días O
22-35 O
cada O
6 O
semanas O
. O

Setenta O
y O
cinco O
pacientes O
con O
buen O
estado O
funcional O
entraron O
en O
el O
ensayo. O

Los O
dos O
brazos O
estaban O
bien O
equilibrados O
en O
cuanto O
a O
las O
características O
relevantes O
de O
los O
pacientes O
y O
de O
la O
enfermedad. O

Los B-Premise
efectos I-Premise
tóxicos I-Premise
más I-Premise
frecuentes I-Premise
fueron I-Premise
diarrea I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
( I-Premise
brazo I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
y I-Premise
alopecia I-Premise
de I-Premise
grado I-Premise
2/3 I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

Otros B-Premise
efectos I-Premise
tóxicos I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
fueron I-Premise
raros I-Premise
( I-Premise
< I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
fueron I-Premise
del I-Premise
34 I-Premise
% I-Premise
[intervalo I-Premise
de I-Premise
confianza I-Premise
( I-Premise
IC I-Premise
) I-Premise
del I-Premise
95 I-Premise
% I-Premise
al I-Premise
51 I-Premise
% I-Premise
] I-Premise
en I-Premise
el I-Premise
brazo I-Premise
A I-Premise
y I-Premise
del I-Premise
35 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
: I-Premise
20 I-Premise
% I-Premise
al I-Premise
53 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
B I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
6,9 I-Premise
( I-Premise
4,6-10,1 I-Premise
) I-Premise
y I-Premise
9,2 I-Premise
( I-Premise
7,9-11,5 I-Premise
) I-Premise
meses I-Premise
y I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
17,4 I-Premise
( I-Premise
12,6-23,0+ I-Premise
) I-Premise
y I-Premise
24,7 I-Premise
( I-Premise
16,3-26,4+ I-Premise
) I-Premise
meses I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
una I-Premise
respuesta I-Premise
tumoral I-Premise
objetiva I-Premise
informaron I-Premise
de I-Premise
un I-Premise
mejor I-Premise
bienestar I-Premise
físico I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
rendimiento I-Premise
funcional I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
menor I-Premise
esfuerzo I-Premise
de I-Premise
afrontamiento I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
no I-Premise
respondedores I-Premise
y I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
enfermedad I-Premise
estable I-Premise
. I-Premise

El O
criterio O
de O
valoración O
principal O
de O
este O
estudio O
fue O
la O
tasa O
de O
respuesta O
objetiva O
y, O
basándose O
en O
el O
diseño O
estadístico O
del O
ensayo, O
se O
seleccionó O
el O
esquema O
de O
irinotecán O
de O
3 O
semanas O
en O
lugar O
de O
la O
administración O
semanal O
de O
irinotecán. O

La B-Claim
pauta I-Claim
de I-Claim
irinotecán I-Claim
de I-Claim
3 I-Claim
semanas I-Claim
también I-Claim
parecía I-Claim
ventajosa I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
diarrea I-Claim
de I-Claim
grado I-Claim
3/4, I-Claim
el I-Claim
tiempo I-Claim
hasta I-Claim
la I-Claim
progresión, I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
y I-Claim
la I-Claim
comodidad I-Claim
de I-Claim
los I-Claim
pacientes, I-Claim
pero B-Claim
el I-Claim
estudio I-Claim
no I-Claim
estaba I-Claim
diseñado I-Claim
para I-Claim
detectar I-Claim
diferencias I-Claim
en I-Claim
estos I-Claim
parámetros. I-Claim

Además, O
se B-Claim
demostró I-Claim
que I-Claim
la I-Claim
respuesta I-Claim
tumoral I-Claim
tiene I-Claim
un I-Claim
efecto I-Claim
beneficioso I-Claim
sobre I-Claim
los I-Claim
indicadores I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Comparar O
la O
infusión O
venosa O
prolongada O
( O
PVI O
) O
de O
5-fluorouracilo O
( O
5-FU O
) O
con O
y O
sin O
mitomicina O
C O
( O
MMC O
) O
en O
un O
estudio O
prospectivo O
aleatorio O
y O
analizar O
la O
respuesta O
tumoral O
, O
la O
supervivencia O
, O
la O
toxicidad O
y O
la O
calidad O
de O
vida O
( O
QL O
) O
. O

Doscientos O
pacientes O
con O
cáncer O
colorrectal O
avanzado O
recibieron O
PVI O
5-FU O
300 O
mg/m2/día O
durante O
un O
máximo O
de O
24 O
semanas O
y O
fueron O
aleatorizados O
a O
PVI O
5-FU O
solo O
o O
PVI O
5-FU O
+ O
MMC O
10 O
mg/m2 O
( O
7 O
mg/m2 O
a O
partir O
de O
junio O
de O
1995) O
6 O
veces O
por O
semana O
durante O
4 O
cursos O
. O

La B-Premise
respuesta I-Premise
global I-Premise
fue I-Premise
del I-Premise
54 I-Premise
% I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
IC I-Premise
] I-Premise
44,1 I-Premise
% I-Premise
-63,9 I-Premise
% I-Premise
) I-Premise
con I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
38 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
: I-Premise
28,3 I-Premise
% I-Premise
-47,7 I-Premise
% I-Premise
) I-Premise
para I-Premise
PVI I-Premise
5-FU I-Premise
solo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,024 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
fracaso I-Premise
fue I-Premise
de I-Premise
7,9 I-Premise
meses I-Premise
en I-Premise
PVI I-Premise
5-FU I-Premise
más I-Premise
MMC I-Premise
y I-Premise
de I-Premise
5,4 I-Premise
meses I-Premise
con I-Premise
PVI I-Premise
5-FU I-Premise
solo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,033 I-Premise
) I-Premise
y I-Premise
al I-Premise
año I-Premise
del I-Premise
31,9% I-Premise
para I-Premise
la I-Premise
combinación I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
17,7% I-Premise
para I-Premise
PVI I-Premise
5-FU I-Premise
solo I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
14 I-Premise
meses I-Premise
con I-Premise
MMC I-Premise
y I-Premise
de I-Premise
15 I-Premise
meses I-Premise
con I-Premise
5-FU I-Premise
solo; I-Premise
la I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
fue I-Premise
del I-Premise
51,7% I-Premise
frente I-Premise
al I-Premise
57,2%. I-Premise

El B-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
causó I-Premise
más I-Premise
toxicidad I-Premise
hematológica I-Premise
global, I-Premise
pero I-Premise
los I-Premise
grados I-Premise
3/4 I-Premise
del I-Premise
CTC I-Premise
sólo I-Premise
aumentaron I-Premise
para I-Premise
la I-Premise
trombocitopenia. I-Premise

Dos B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
una I-Premise
dosis I-Premise
acumulada I-Premise
de I-Premise
MMC I-Premise
de I-Premise
40 I-Premise
mg/m2 I-Premise
desarrollaron I-Premise
un I-Premise
síndrome I-Premise
urémico I-Premise
hemolítico I-Premise
que I-Premise
justificó I-Premise
la I-Premise
reducción I-Premise
de I-Premise
la I-Premise
dosis I-Premise
acumulada I-Premise
de I-Premise
MMC I-Premise
a I-Premise
28 I-Premise
mg/m2. I-Premise

Las B-Premise
puntuaciones I-Premise
globales I-Premise
de I-Premise
la I-Premise
CV I-Premise
fueron I-Premise
mejores I-Premise
para I-Premise
el I-Premise
brazo I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
a I-Premise
las I-Premise
24 I-Premise
semanas I-Premise
, O
pero B-Premise
el I-Premise
resto I-Premise
de I-Premise
los I-Premise
datos I-Premise
de I-Premise
la I-Premise
CV I-Premise
no I-Premise
mostraron I-Premise
diferencias I-Premise
. O

PVI B-Claim
5-FU I-Claim
+ I-Claim
MMC I-Claim
da I-Claim
lugar I-Claim
a I-Claim
una I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
fracasos I-Claim
y I-Claim
una I-Claim
ventaja I-Claim
de I-Claim
respuesta, I-Claim
una I-Claim
toxicidad I-Claim
tolerable I-Claim
y I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
comparación I-Claim
con I-Claim
PVI I-Claim
5-FU I-Claim
solo, I-Claim
pero I-Claim
no I-Claim
hay I-Claim
ventaja I-Claim
de I-Claim
supervivencia I-Claim
global. I-Claim

No B-Premise
hay I-Premise
toxicidad I-Premise
irreversible I-Premise
con I-Premise
la I-Premise
MMC I-Premise
a I-Premise
una I-Premise
dosis I-Premise
acumulada I-Premise
de I-Premise
28 I-Premise
mg/m2. I-Premise

Comparar O
en O
un O
estudio O
de O
fase O
III O
la O
seguridad O
y O
eficacia O
de O
la O
fludarabina O
con O
la O
de O
la O
ciclofosfamida O
, O
vincristina O
y O
prednisona O
( O
CVP O
) O
en O
el O
linfoma O
no O
Hodgkin O
de O
bajo O
grado O
recurrente O
después O
de O
una O
respuesta O
previa O
al O
tratamiento O
sistémico O
. O

Los O
pacientes O
fueron O
asignados O
al O
azar O
a O
fludarabina O
( O
25 O
mg/m O
( O
2 O
) O
por O
vía O
intravenosa O
los O
días O
1 O
a O
5 O
, O
cada O
28 O
días O
) O
o O
CVP O
( O
ciclofosfamida O
750 O
mg/m O
( O
2 O
) O
y O
vincristina O
1,2 O
mg/m O
( O
2 O
) O
ambos O
por O
vía O
intravenosa O
el O
día O
1 O
y O
prednisona O
40 O
mg/m O
( O
2 O
) O
por O
vía O
oral O
los O
días O
1 O
a O
5 O
, O
cada O
21 O
días O
) O
. O

El O
resultado O
primario O
evaluado O
fue O
la O
supervivencia O
libre O
de O
progresión O
(SLP); O
los O
resultados O
secundarios O
incluyeron O
la O
supervivencia O
libre O
de O
tratamiento O
(SLT), O
la O
supervivencia O
global O
(SG), O
la O
toxicidad O
relacionada O
con O
el O
tratamiento O
y O
la O
calidad O
de O
vida O
(CdV) O
según O
el O
instrumento O
del O
Cuestionario O
de O
Calidad O
de O
Vida O
C-30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer, O
versión O
1.0. O

Se O
asignaron O
al O
azar O
91 O
pacientes, O
47 O
a O
fludarabina O
y O
44 O
a O
CVP. O

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
las I-Premise
tasas I-Premise
de I-Premise
respuesta, I-Premise
con I-Premise
un I-Premise
64 I-Premise
% I-Premise
( I-Premise
respuesta I-Premise
completa I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
9 I-Premise
% I-Premise
) I-Premise
para I-Premise
la I-Premise
fludarabina I-Premise
frente I-Premise
al I-Premise
52 I-Premise
% I-Premise
( I-Premise
CR I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
para I-Premise
la I-Premise
CVP I-Premise
( I-Premise
P I-Premise
= I-Premise
0,72 I-Premise
) I-Premise
. I-Premise

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
42 I-Premise
meses, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
( I-Premise
11 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
9,1 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
y I-Premise
la I-Premise
SLP I-Premise
( I-Premise
15 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
11 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
fueron I-Premise
superiores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
fludarabina. I-Premise

No B-Premise
se I-Premise
detectaron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
57 I-Premise
meses I-Premise
para I-Premise
la I-Premise
fludarabina I-Premise
frente I-Premise
a I-Premise
44 I-Premise
meses I-Premise
para I-Premise
la I-Premise
CVP I-Premise
; I-Premise
P I-Premise
=,95 I-Premise
) I-Premise
. I-Premise

Tres B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
fludarabina I-Premise
murieron I-Premise
por I-Premise
toxicidad I-Premise
relacionada I-Premise
con I-Premise
el I-Premise
tratamiento, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
ninguno I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
CVP I-Premise
. I-Premise

La B-Premise
neuropatía I-Premise
periférica I-Premise
y I-Premise
la I-Premise
alopecia I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
con I-Premise
la I-Premise
CVP I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
fludarabina I-Premise
obtuvieron I-Premise
puntuaciones I-Premise
más I-Premise
altas I-Premise
en I-Premise
la I-Premise
función I-Premise
social I-Premise
( I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
); O
no B-Premise
se I-Premise
detectaron I-Premise
otras I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
CdV. I-Premise

En B-Claim
el I-Claim
linfoma I-Claim
de I-Claim
bajo I-Claim
grado I-Claim
recurrente, I-Claim
la I-Claim
fludarabina I-Claim
mejora I-Claim
la I-Claim
SLP, I-Claim
la I-Claim
SLT I-Claim
y I-Claim
las I-Claim
puntuaciones I-Claim
de I-Claim
la I-Claim
función I-Claim
social I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
CVP, I-Claim
pero I-Claim
no I-Claim
mejora I-Claim
la I-Claim
SG. I-Claim

En B-Claim
las I-Claim
pacientes I-Claim
con I-Claim
carcinoma I-Claim
de I-Claim
mama I-Claim
metastásico I-Claim
tratado I-Claim
con I-Claim
antraciclinas, I-Claim
la I-Claim
capecitabina I-Claim
más I-Claim
docetaxel I-Claim
aumentó I-Claim
significativamente I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
docetaxel I-Claim
solo. I-Claim

El O
presente O
estudio O
evaluó O
la O
relación O
coste-eficacia O
de O
la O
combinación O
capecitabina/docetaxel O
frente O
a O
la O
monoterapia O
con O
docetaxel O
, O
comparando O
la O
ganancia O
de O
supervivencia O
ajustada O
a O
la O
calidad O
con O
los O
costes O
sanitarios O
asociados. O

Los O
pacientes O
fueron O
aleatorizados O
para O
recibir O
ciclos O
de O
21 O
días O
de O
capecitabina O
oral O
1250 O
mg/m2 O
dos O
veces O
al O
día O
, O
en O
los O
días O
1-14 O
, O
más O
docetaxel O
75 O
mg/m2 O
el O
día O
1 O
( O
n O
= O
255 O
) O
, O
o O
docetaxel O
100 O
mg/m2 O
el O
día O
1 O
( O
n O
= O
256 O
) O
. O

Se O
compararon O
los O
resultados O
sanitarios O
y O
económicos O
de O
los O
dos O
brazos O
y O
se O
calculó O
la O
relación O
coste-eficacia. O

En O
el O
ensayo O
se O
recogieron O
prospectivamente O
datos O
sobre O
el O
tiempo O
de O
supervivencia O
y O
el O
uso O
de O
recursos O
de O
atención O
médica. O

Los O
costes O
asociados O
al O
uso O
de O
recursos O
de O
atención O
médica O
y O
a O
los O
ajustes O
de O
la O
calidad O
de O
vida O
se O
obtuvieron O
de O
la O
literatura O
publicada O
. O

La O
relación O
coste-eficacia O
incremental O
se O
calculó O
como O
el O
coste O
por O
año O
de O
vida O
ajustado O
a O
la O
calidad O
(AVAC) O
ganado. O

La B-Premise
capecitabina/docetaxel I-Premise
aumentó I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
en I-Premise
3 I-Premise
meses I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
docetaxel I-Premise
solo I-Premise
( I-Premise
14,5 I-Premise
frente I-Premise
a I-Premise
11,5 I-Premise
meses I-Premise
) I-Premise
. I-Premise

La B-Premise
media I-Premise
de I-Premise
supervivencia I-Premise
ajustada I-Premise
a I-Premise
la I-Premise
calidad I-Premise
aumentó I-Premise
en I-Premise
1,8 I-Premise
meses I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
capecitabina/docetaxel. I-Premise

El B-Premise
coste I-Premise
total I-Premise
de I-Premise
utilización I-Premise
de I-Premise
recursos I-Premise
médicos I-Premise
por I-Premise
paciente I-Premise
fue I-Premise
un I-Premise
8,9% I-Premise
mayor I-Premise
con I-Premise
la I-Premise
combinación: I-Premise
24.475 I-Premise
dólares I-Premise
para I-Premise
la I-Premise
terapia I-Premise
combinada I-Premise
frente I-Premise
a I-Premise
22.477 I-Premise
dólares I-Premise
para I-Premise
el I-Premise
docetaxel I-Premise
como I-Premise
agente I-Premise
único. I-Premise

El B-Premise
coste I-Premise
medio I-Premise
por I-Premise
QALY I-Premise
ganado I-Premise
con I-Premise
la I-Premise
terapia I-Premise
combinada I-Premise
fue I-Premise
de I-Premise
13.558 I-Premise
dólares I-Premise
( I-Premise
desviación I-Premise
estándar I-Premise
, I-Premise
6742 I-Premise
dólares I-Premise
) I-Premise
. I-Premise

El B-Premise
ahorro I-Premise
de I-Premise
costes I-Premise
debido I-Premise
a I-Premise
la I-Premise
reducción I-Premise
de I-Premise
la I-Premise
dosis I-Premise
de I-Premise
docetaxel I-Premise
y I-Premise
el I-Premise
uso I-Premise
del I-Premise
hospital I-Premise
fueron I-Premise
las I-Premise
principales I-Premise
compensaciones I-Premise
de I-Premise
costes I-Premise
con I-Premise
la I-Premise
combinación I-Premise
. I-Premise

Los B-Premise
análisis I-Premise
de I-Premise
sensibilidad I-Premise
mostraron I-Premise
que I-Premise
la I-Premise
variación I-Premise
del I-Premise
coste I-Premise
medio I-Premise
del I-Premise
hospital I-Premise
por I-Premise
día I-Premise
entre I-Premise
el I-Premise
percentil I-Premise
5 I-Premise
y I-Premise
el I-Premise
95 I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
relaciones I-Premise
coste-utilidad I-Premise
que I-Premise
oscilaban I-Premise
entre I-Premise
los I-Premise
20.326 I-Premise
dólares I-Premise
y I-Premise
los I-Premise
6.360 I-Premise
dólares. I-Premise

La B-Claim
capecitabina/docetaxel I-Claim
fue I-Claim
un I-Claim
tratamiento I-Claim
rentable I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
carcinoma I-Claim
de I-Claim
mama I-Claim
avanzado I-Claim
tratado I-Claim
con I-Claim
antraciclinas I-Claim
, I-Claim
y I-Claim
tuvo I-Claim
una I-Claim
relación I-Claim
coste-efectividad I-Claim
incremental I-Claim
que I-Claim
se I-Claim
compara I-Claim
muy I-Claim
favorablemente I-Claim
con I-Claim
la I-Claim
de I-Claim
muchas I-Claim
otras I-Claim
terapias I-Claim
oncológicas I-Claim
. I-Claim

La B-Claim
epoetina I-Claim
alfa I-Claim
administrada I-Claim
a I-Claim
40.000 I-Claim
U I-Claim
una I-Claim
vez I-Claim
a I-Claim
la I-Claim
semana I-Claim
( I-Claim
qw I-Claim
) I-Claim
a I-Claim
pacientes I-Claim
anémicos I-Claim
con I-Claim
cáncer I-Claim
que I-Claim
reciben I-Claim
quimioterapia I-Claim
aumenta I-Claim
los I-Claim
niveles I-Claim
de I-Claim
hemoglobina I-Claim
, I-Claim
mejora I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
y I-Claim
reduce I-Claim
las I-Claim
transfusiones I-Claim
. I-Claim

No O
se O
ha O
evaluado O
el O
beneficio O
de O
la O
epoetina O
alfa O
en O
el O
mantenimiento O
de O
los O
niveles O
de O
hemoglobina O
en O
pacientes O
con O
cáncer O
con O
una O
hemoglobina O
inferior O
a O
12 O
g/dl. O

Las O
pacientes O
con O
cáncer O
de O
mama O
( O
N O
= O
354 O
) O
que O
recibían O
quimioterapia O
fueron O
asignadas O
aleatoriamente O
en O
proporción O
1:1 O
a O
epoetina O
alfa O
( O
40.000 O
U O
qw O
) O
o O
al O
tratamiento O
estándar O
( O
SOC O
) O
. O

La O
calidad O
de O
vida O
se O
evaluó O
al O
inicio O
y O
en O
la O
semana O
12. O

Se O
midieron O
las O
respuestas O
de O
hemoglobina O
, O
las O
necesidades O
de O
transfusión O
y O
los O
factores O
pronósticos O
de O
las O
respuestas O
. O

En B-Premise
la I-Premise
semana I-Premise
12, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
cambio I-Premise
de I-Premise
la I-Premise
Evaluación I-Premise
Funcional I-Premise
de I-Premise
la I-Premise
Terapia I-Premise
del I-Premise
Cáncer-Anemia I-Premise
( I-Premise
FACT-An I-Premise
; I-Premise
media I-Premise
, I-Premise
2,16 I-Premise
+/- I-Premise
12,84 I-Premise
para I-Premise
la I-Premise
epoetina I-Premise
alfa I-Premise
frente I-Premise
a I-Premise
-4,43 I-Premise
+/- I-Premise
13,42 I-Premise
para I-Premise
el I-Premise
SOC I-Premise
) I-Premise
y I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
FACT-An I-Premise
( I-Premise
media I-Premise
, I-Premise
1,85 I-Premise
+/- I-Premise
10,52 I-Premise
para I-Premise
la I-Premise
epoetina I-Premise
alfa I-Premise
frente I-Premise
a I-Premise
-3,55 I-Premise
+/- I-Premise
11,14 I-Premise
para I-Premise
el I-Premise
SOC I-Premise
) I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
epoetina I-Premise
alfa I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Las B-Premise
respuestas I-Premise
de I-Premise
la I-Premise
hemoglobina, I-Premise
definidas I-Premise
como I-Premise
una I-Premise
hemoglobina I-Premise
media I-Premise
> I-Premise
o I-Premise
= I-Premise
12 I-Premise
g/dl I-Premise
o I-Premise
un I-Premise
aumento I-Premise
> I-Premise
o I-Premise
= I-Premise
2 I-Premise
g/dl I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
valor I-Premise
inicial, I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
epoetina I-Premise
alfa I-Premise
frente I-Premise
al I-Premise
SOC: I-Premise
52,0 I-Premise
% I-Premise
frente I-Premise
a I-Premise
5,1 I-Premise
% I-Premise
y I-Premise
65,7 I-Premise
% I-Premise
frente I-Premise
a I-Premise
6,3 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
para I-Premise
ambas I-Premise
comparaciones I-Premise
) I-Premise
. I-Premise

El B-Premise
porcentaje I-Premise
de I-Premise
transfusiones I-Premise
fue I-Premise
significativamente I-Premise
menor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
epoetina I-Premise
alfa I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
SOC I-Premise
( I-Premise
8,6 I-Premise
% I-Premise
frente I-Premise
a I-Premise
22,9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Más B-Premise
del I-Premise
90% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
no I-Premise
necesitaron I-Premise
un I-Premise
aumento I-Premise
de I-Premise
la I-Premise
dosis I-Premise
y I-Premise
el I-Premise
28,7% I-Premise
tuvieron I-Premise
una I-Premise
reducción I-Premise
de I-Premise
la I-Premise
misma. I-Premise

La B-Claim
epoetina I-Claim
alfa I-Claim
administrada I-Claim
a I-Claim
40.000 I-Claim
U I-Claim
qw I-Claim
es I-Claim
eficaz I-Claim
para I-Claim
mejorar I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida, I-Claim
mantener I-Claim
el I-Claim
nivel I-Claim
de I-Claim
hemoglobina I-Claim
y I-Claim
reducir I-Claim
las I-Claim
necesidades I-Claim
de I-Claim
transfusión I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama. I-Claim

La B-Claim
alta I-Claim
eficacia I-Claim
observada I-Claim
podría I-Claim
atribuirse I-Claim
en I-Claim
parte I-Claim
al I-Claim
tratamiento I-Claim
temprano I-Claim
con I-Claim
epoetina I-Claim
alfa I-Claim
. I-Claim

Durante B-Premise
la I-Premise
última I-Premise
década, I-Premise
las I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
del I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
han I-Premise
aumentado I-Premise
como I-Premise
resultado I-Premise
de I-Premise
una I-Premise
detección I-Premise
más I-Premise
temprana I-Premise
y I-Premise
un I-Premise
mayor I-Premise
uso I-Premise
de I-Premise
la I-Premise
terapia I-Premise
adyuvante. I-Premise

Existen O
pocos O
datos O
sobre O
los O
aspectos O
psicosociales O
del O
periodo O
de O
transición O
entre O
el O
final O
del O
tratamiento O
primario O
y O
la O
supervivencia. O

Se O
investigó O
el O
estado O
psicosocial O
de O
referencia O
de O
las O
mujeres O
inscritas O
en O
un O
ensayo O
aleatorio O
que O
probaba O
dos O
intervenciones O
psicosociales O
para O
mujeres O
al O
final O
del O
tratamiento O
primario O
. O

Los O
participantes O
, O
identificados O
en O
el O
plazo O
de O
un O
mes O
después O
de O
la O
cirugía O
( O
registro O
) O
, O
proporcionaron O
información O
demográfica O
y O
medidas O
limitadas O
de O
calidad O
de O
vida O
. O

Se O
les O
hizo O
un O
seguimiento O
hasta O
que O
terminaron O
el O
tratamiento O
primario O
("inscripción") O
, O
momento O
en O
el O
que O
completaron O
una O
encuesta O
de O
referencia O
enviada O
por O
correo O
que O
incluía O
medidas O
estandarizadas O
de O
calidad O
de O
vida O
( O
incluyendo O
escalas O
estandarizadas O
de O
funcionamiento O
físico O
y O
emocional) O
, O
estado O
de O
ánimo O
, O
síntomas O
y O
funcionamiento O
sexual O
. O

Entre O
el O
1 O
de O
julio O
de O
1999 O
y O
el O
30 O
de O
junio O
de O
2002 O
se O
inscribieron O
en O
el O
estudio O
558 O
pacientes O
(edad O
media O
= O
56,9 O
años). O

Se O
examinaron O
los O
resultados O
de O
salud O
según O
el O
tratamiento O
recibido: O
mastectomía O
con O
y O
sin O
quimioterapia O
, O
y O
tumorectomía O
con O
y O
sin O
quimioterapia O
. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

Entre B-Premise
todos I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento, I-Premise
las I-Premise
pacientes I-Premise
que I-Premise
se I-Premise
sometieron I-Premise
a I-Premise
una I-Premise
mastectomía I-Premise
tenían I-Premise
el I-Premise
peor I-Premise
funcionamiento I-Premise
físico I-Premise
en I-Premise
el I-Premise
momento I-Premise
del I-Premise
registro I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
en I-Premise
el I-Premise
momento I-Premise
de I-Premise
la I-Premise
inscripción I-Premise
( I-Premise
P I-Premise
= I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
momento I-Premise
de I-Premise
la I-Premise
inscripción, I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
y I-Premise
el I-Premise
funcionamiento I-Premise
emocional I-Premise
eran I-Premise
similares I-Premise
entre I-Premise
todos I-Premise
los I-Premise
pacientes, I-Premise
sin I-Premise
diferencias I-Premise
por I-Premise
el I-Premise
tipo I-Premise
de I-Premise
tratamiento I-Premise
recibido. I-Premise

En B-Premise
el I-Premise
momento I-Premise
de I-Premise
la I-Premise
inscripción, I-Premise
los I-Premise
síntomas, I-Premise
como I-Premise
la I-Premise
rigidez I-Premise
muscular, I-Premise
la I-Premise
sensibilidad I-Premise
mamaria, I-Premise
los I-Premise
dolores, I-Premise
la I-Premise
tendencia I-Premise
a I-Premise
las I-Premise
siestas I-Premise
y I-Premise
la I-Premise
dificultad I-Premise
para I-Premise
concentrarse, I-Premise
fueron I-Premise
comunes I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
todos I-Premise
los I-Premise
grupos I-Premise
y I-Premise
se I-Premise
asociaron I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
con I-Premise
un I-Premise
funcionamiento I-Premise
físico I-Premise
y I-Premise
un I-Premise
bienestar I-Premise
emocional I-Premise
deficientes. I-Premise

El B-Premise
funcionamiento I-Premise
sexual I-Premise
fue I-Premise
peor I-Premise
en I-Premise
las I-Premise
mujeres I-Premise
que I-Premise
recibieron I-Premise
quimioterapia I-Premise
que I-Premise
en I-Premise
las I-Premise
que I-Premise
no I-Premise
la I-Premise
recibieron, I-Premise
independientemente I-Premise
del I-Premise
tipo I-Premise
de I-Premise
cirugía I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Al B-Claim
final I-Claim
del I-Claim
tratamiento I-Claim
primario I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama, I-Claim
las I-Claim
mujeres I-Claim
de I-Claim
todos I-Claim
los I-Claim
grupos I-Claim
de I-Claim
tratamiento I-Claim
informan I-Claim
de I-Claim
un I-Claim
buen I-Claim
funcionamiento I-Claim
emocional, I-Claim
pero I-Claim
informan I-Claim
de I-Claim
una I-Claim
disminución I-Claim
del I-Claim
funcionamiento I-Claim
físico, I-Claim
especialmente I-Claim
entre I-Claim
las I-Claim
mujeres I-Claim
que I-Claim
se I-Claim
someten I-Claim
a I-Claim
una I-Claim
mastectomía I-Claim
o I-Claim
reciben I-Claim
quimioterapia. I-Claim

Las B-Claim
intervenciones I-Claim
clínicas I-Claim
para I-Claim
abordar I-Claim
los I-Claim
síntomas I-Claim
comunes I-Claim
asociados I-Claim
al I-Claim
tratamiento I-Claim
deben I-Claim
considerarse I-Claim
para I-Claim
mejorar I-Claim
el I-Claim
funcionamiento I-Claim
físico I-Claim
y I-Claim
emocional I-Claim
al I-Claim
final I-Claim
del I-Claim
tratamiento I-Claim
primario I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

En B-Premise
un I-Premise
ensayo I-Premise
multinacional I-Premise
de I-Premise
pacientes I-Premise
anémicos I-Premise
con I-Premise
cáncer I-Premise
que I-Premise
recibían I-Premise
quimioterapia I-Premise
sin I-Premise
platino, I-Premise
la I-Premise
epoetina-alfa I-Premise
aumentó I-Premise
eficazmente I-Premise
los I-Premise
niveles I-Premise
de I-Premise
hemoglobina, I-Premise
redujo I-Premise
las I-Premise
necesidades I-Premise
de I-Premise
transfusión I-Premise
de I-Premise
glóbulos I-Premise
rojos I-Premise
y I-Premise
mejoró I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida. I-Premise

Aunque O
el O
estudio O
no O
se O
diseñó O
ni O
se O
potenció O
para O
evaluar O
la O
supervivencia, O
se O
observó B-Premise
una I-Premise
tendencia I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
favor I-Premise
de I-Premise
la I-Premise
epoetina-alfa I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
17 I-Premise
frente I-Premise
a I-Premise
11 I-Premise
meses I-Premise
[ I-Premise
p I-Premise
= I-Premise
0,126 I-Premise
] O
) O
. O

Determinar O
la O
utilidad O
del O
coste O
incremental O
de O
la O
epoetina-alfa O
frente O
al O
placebo O
en O
pacientes O
anémicas O
con O
cáncer O
de O
mama O
en O
estadio O
IV O
desde O
la O
perspectiva O
del O
Servicio O
Nacional O
de O
Salud O
del O
Reino O
Unido. O

Se O
registraron O
los O
datos O
de O
los O
pacientes O
relativos O
a O
las O
transfusiones, O
el O
uso O
de O
epoetina O
alfa, O
los O
ciclos O
de O
tratamiento O
de O
quimioterapia O
y O
los O
acontecimientos O
adversos, O
con O
un O
seguimiento O
de O
la O
supervivencia O
durante O
12-36 O
meses O
después O
del O
estudio. O

Los O
costes O
de O
la O
terapia O
del O
cáncer O
de O
mama O
en O
estadio O
IV O
se O
recogieron O
mediante O
una O
encuesta O
a O
oncólogos O
del O
Reino O
Unido, O
y O
las O
utilidades O
de O
los O
estados O
de O
salud O
asociados O
procedían O
de O
fuentes O
publicadas. O

Los O
costes O
se O
expresan O
en O
libras O
esterlinas O
y O
en O
valores O
del O
año O
2000. O

Los O
costes O
y O
beneficios O
se O
determinaron O
conjuntamente O
para O
el O
subgrupo O
de O
cáncer O
de O
mama O
en O
estadio O
IV O
( O
n O
= O
55 O
) O
. O

Las O
relaciones O
coste-utilidad O
incrementales O
( O
ICUR O
) O
se O
calcularon O
asumiendo O
una O
tasa O
de O
descuento O
anual O
del O
6% O
para O
los O
costes O
y O
una O
tasa O
de O
descuento O
anual O
del O
1,5% O
para O
los O
beneficios O
. O

Se O
realizaron O
simulaciones O
Bootstrap O
( O
10.000 O
iteraciones O
) O
para O
tener O
en O
cuenta O
la O
incertidumbre O
, O
y O
se O
realizaron O
análisis O
de O
sensibilidad O
para O
establecer O
la O
robustez O
. O

El B-Premise
ICUR I-Premise
para I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
epoetina-alfa I-Premise
fue I-Premise
de I-Premise
8.851 I-Premise
libras I-Premise
por I-Premise
QALY I-Premise
, I-Premise
con I-Premise
una I-Premise
probabilidad I-Premise
del I-Premise
99% I-Premise
de I-Premise
un I-Premise
beneficio I-Premise
neto I-Premise
positivo I-Premise
en I-Premise
QALYs I-Premise
( I-Premise
beneficio I-Premise
neto I-Premise
= I-Premise
0,4805 I-Premise
años I-Premise
de I-Premise
vida I-Premise
perfecta I-Premise
) I-Premise
y I-Premise
una I-Premise
probabilidad I-Premise
del I-Premise
94% I-Premise
de I-Premise
ser I-Premise
aceptable I-Premise
utilizando I-Premise
un I-Premise
ICUR I-Premise
umbral I-Premise
de I-Premise
30.000 I-Premise
libras/QALY I-Premise
. I-Premise

Los B-Premise
principales I-Premise
factores I-Premise
de I-Premise
coste I-Premise
que I-Premise
distinguen I-Premise
a I-Premise
la I-Premise
epoetina-alfa I-Premise
del I-Premise
placebo I-Premise
fueron I-Premise
los I-Premise
costes I-Premise
del I-Premise
fármaco I-Premise
y I-Premise
de I-Premise
la I-Premise
atención I-Premise
al I-Premise
paciente I-Premise
debido I-Premise
al I-Premise
aumento I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
. I-Premise

Los B-Claim
datos I-Claim
disponibles I-Claim
sugieren I-Claim
una I-Claim
alta I-Claim
probabilidad I-Claim
de I-Claim
resultados I-Claim
favorables I-Claim
en I-Claim
términos I-Claim
de I-Claim
coste-utilidad I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
epoetina-alfa I-Claim
para I-Claim
la I-Claim
anemia I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
en I-Claim
estadio I-Claim
IV I-Claim
que I-Claim
reciben I-Claim
quimioterapia I-Claim
que I-Claim
no I-Claim
contiene I-Claim
platino I-Claim
. I-Claim

Se B-Claim
justifica I-Claim
la I-Claim
realización I-Claim
de I-Claim
estudios I-Claim
adicionales. I-Claim

El O
EORTC O
24971/TAX O
323 O
, O
un O
estudio O
de O
fase O
III O
de O
358 O
pacientes O
con O
carcinoma O
de O
células O
escamosas O
locorregionalmente O
avanzado O
no O
resecable O
de O
cabeza O
y O
cuello O
, O
mostró O
una O
mejora O
de O
la O
supervivencia O
libre O
de O
progresión O
y O
global O
( O
SG O
) O
con O
menos O
toxicidad O
cuando O
se O
añadió O
docetaxel O
( O
T O
) O
al O
cisplatino O
y O
5-fluorouracilo O
( O
PF O
) O
para O
la O
inducción O
y O
se O
administró O
antes O
de O
la O
radioterapia O
( O
RT O
) O
. O

Se O
investigó O
el O
impacto O
de O
la O
adición O
de O
docetaxel O
en O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
y O
los O
síntomas O
de O
los O
pacientes. O

La O
CVRS O
se O
evaluó O
en O
la O
línea O
de O
base O
, O
al O
final O
del O
ciclo O
2 O
, O
y O
4 O
, O
6 O
y O
9 O
meses O
después O
de O
la O
finalización O
de O
la O
RT O
utilizando O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
( O
QLQ-C30 O
) O
y O
el O
módulo O
específico O
de O
cáncer O
de O
cabeza O
y O
cuello O
EORTC O
QLQ-H O
& O
amp O
; O
N35 O
) O
. O

La O
escala O
primaria O
de O
CVRS O
fue O
la O
CVRS O
global O
según O
el O
protocolo. O

El O
cumplimiento O
de O
las O
evaluaciones O
de O
CVRS O
fue O
del O
97% O
al O
inicio, O
pero O
descendió O
al O
54% O
a O
los O
6 O
meses. O

Los O
datos O
se O
analizaron O
hasta O
los O
6 O
meses. O

Hubo B-Premise
una I-Premise
tendencia I-Premise
a I-Premise
la I-Premise
mejora I-Premise
de I-Premise
la I-Premise
CVRS I-Premise
global I-Premise
durante I-Premise
el I-Premise
periodo I-Premise
de I-Premise
tratamiento. I-Premise

A B-Premise
los I-Premise
6 I-Premise
meses I-Premise
de I-Premise
finalizar I-Premise
la I-Premise
RT I-Premise
, I-Premise
la I-Premise
CVRS I-Premise
global I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
TPF I-Premise
que I-Premise
en I-Premise
el I-Premise
brazo I-Premise
PF I-Premise
, O
pero B-Premise
el I-Premise
bajo I-Premise
cumplimiento I-Premise
no I-Premise
permite I-Premise
sacar I-Premise
conclusiones I-Premise
definitivas I-Premise
. O

Los B-Premise
problemas I-Premise
de I-Premise
deglución I-Premise
y I-Premise
tos I-Premise
disminuyeron I-Premise
más I-Premise
en I-Premise
el I-Premise
brazo I-Premise
TPF I-Premise
que I-Premise
en I-Premise
el I-Premise
brazo I-Premise
PF I-Premise
al I-Premise
final I-Premise
del I-Premise
ciclo I-Premise
2 I-Premise
, O
pero B-Premise
en I-Premise
una I-Premise
medida I-Premise
limitada I-Premise
. O

La B-Claim
quimioterapia I-Claim
de I-Claim
inducción I-Claim
con I-Claim
TPF I-Claim
antes I-Claim
de I-Claim
la I-Claim
RT I-Claim
no I-Claim
sólo I-Claim
mejora I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
reduce I-Claim
la I-Claim
toxicidad I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
PF, I-Claim
sino I-Claim
que I-Claim
también I-Claim
parece I-Claim
mejorar I-Claim
la I-Claim
CVRS I-Claim
global I-Claim
de I-Claim
forma I-Claim
más I-Claim
sostenible I-Claim
. I-Claim

Un O
ensayo O
controlado O
aleatorio O
( O
ECA O
) O
demostró O
que O
la O
terapia O
cognitivo-conductual O
( O
TCC O
) O
para O
la O
fatiga O
durante O
el O
tratamiento O
curativo O
del O
cáncer O
fue O
eficaz O
poco O
después O
del O
tratamiento O
del O
cáncer O
. O

El O
objetivo O
de O
este O
estudio O
es O
identificar O
qué O
características O
de O
los O
pacientes O
predicen O
la O
mejora O
de O
la O
fatiga O
tras O
la O
TCC. O

Además, O
se O
investigó O
la O
eficacia O
a O
largo O
plazo. O

En O
el O
ECA O
participaron O
pacientes O
con O
diversas O
neoplasias O
( O
n O
= O
210 O
) O
. O

Los O
participantes O
fueron O
evaluados O
antes O
del O
tratamiento O
del O
cáncer O
( O
T1 O
) O
, O
después O
de O
la O
intervención O
( O
T2 O
) O
, O
que O
fue O
al O
menos O
2 O
meses O
después O
del O
tratamiento O
del O
cáncer O
, O
y O
después O
de O
un O
año O
de O
seguimiento O
( O
T3 O
) O
. O

Se O
realizaron O
evaluaciones O
mensuales O
de O
la O
fatiga O
entre O
T2 O
y O
T3. O

Se O
realizó O
un O
análisis O
de O
regresión O
con O
interacciones O
para O
determinar O
si O
los O
dominios O
de O
calidad O
de O
vida O
( O
EORTC-QLQ-C30 O
) O
funcionamiento O
( O
Health O
Survey O
Short O
Form-36 O
) O
o O
malestar O
psicológico O
( O
Symptom O
Checklist-90 O
) O
moderaban O
el O
efecto O
de O
la O
TCC O
sobre O
la O
fatiga O
. O

Se O
utilizaron O
análisis O
de O
covarianza O
para O
estudiar O
la O
eficacia O
a O
largo O
plazo O
de O
la O
TCC. O

La B-Premise
fatiga I-Premise
en I-Premise
T2 I-Premise
se I-Premise
predijo I-Premise
mediante I-Premise
una I-Premise
interacción I-Premise
significativa I-Premise
entre I-Premise
el I-Premise
funcionamiento I-Premise
cognitivo I-Premise
autodeclarado I-Premise
y I-Premise
la I-Premise
TCC. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
interacciones I-Premise
entre I-Premise
otros I-Premise
dominios I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
, I-Premise
funcionamiento I-Premise
, I-Premise
malestar I-Premise
psicológico I-Premise
y I-Premise
TCC I-Premise
. I-Premise

En B-Premise
T3 I-Premise
, I-Premise
no I-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
significativas I-Premise
sobre I-Premise
la I-Premise
fatiga I-Premise
entre I-Premise
la I-Premise
TCC I-Premise
y I-Premise
la I-Premise
atención I-Premise
habitual I-Premise
. I-Premise

Los B-Premise
análisis I-Premise
exploratorios I-Premise
mostraron I-Premise
que I-Premise
la I-Premise
diferencia I-Premise
casi I-Premise
alcanzó I-Premise
la I-Premise
significación I-Premise
hasta I-Premise
los I-Premise
7 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
intervención. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
experimentaron I-Premise
más I-Premise
problemas I-Premise
de I-Premise
concentración I-Premise
y I-Premise
memoria I-Premise
en I-Premise
T1 I-Premise
se I-Premise
beneficiaron I-Premise
más I-Premise
de I-Premise
la I-Premise
TCC I-Premise
para I-Premise
la I-Premise
fatiga I-Premise
y I-Premise
son I-Premise
indicadores I-Premise
. I-Premise

Después B-Premise
de I-Premise
un I-Premise
año I-Premise
de I-Premise
seguimiento, I-Premise
ya I-Premise
no I-Premise
se I-Premise
observó I-Premise
el I-Premise
efecto I-Premise
de I-Premise
la I-Premise
TCC I-Premise
para I-Premise
la I-Premise
fatiga, I-Premise
y I-Premise
el I-Premise
efecto I-Premise
sobre I-Premise
la I-Premise
fatiga I-Premise
pareció I-Premise
disminuir I-Premise
7 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
intervención. I-Premise

La B-Claim
implicación I-Claim
es I-Claim
que I-Claim
la I-Claim
TCC I-Claim
para I-Claim
la I-Claim
fatiga I-Claim
debe I-Claim
ofrecerse I-Claim
a I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
con I-Claim
la I-Claim
mayor I-Claim
probabilidad I-Claim
de I-Claim
beneficiarse I-Claim
. I-Claim

Se O
llevó O
a O
cabo O
un O
ensayo O
aleatorio O
de O
fase O
III O
para O
comparar O
dos O
esquemas O
del O
régimen O
de O
vinorelbina O
( O
VNR O
) O
-cisplatino O
( O
CDDP O
) O
en O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
localmente O
avanzado O
e O
irresecable O
de O
mal O
pronóstico O
en O
estadio O
IIIB O
o O
metastásico O
en O
estadio O
IV O
. O

Los O
criterios O
de O
valoración O
primarios O
fueron O
la O
supervivencia O
global O
( O
SG O
) O
y O
el O
análisis O
de O
la O
toxicidad O
, O
mientras O
que O
los O
criterios O
de O
valoración O
secundarios O
incluyeron O
las O
tasas O
de O
respuesta O
, O
el O
tiempo O
hasta O
la O
progresión O
( O
TTP O
) O
y O
la O
calidad O
de O
vida O
( O
QoL O
) O
. O

Los O
pacientes O
elegibles O
fueron O
asignados O
al O
azar O
para O
recibir O
: O
( O
a O
) O
VNR O
25mg/m O
( O
2 O
) O
el O
día O
1 O
, O
8 O
y O
15 O
más O
CDDP O
100mg/m O
( O
2 O
) O
el O
día O
1 O
cada O
4 O
semanas O
o O
( O
b O
) O
VNR O
30 O
mg/m O
( O
2 O
) O
el O
día O
1 O
y O
8 O
más O
CDDP O
80 O
mg/m O
( O
2 O
) O
el O
día O
1 O
cada O
3 O
semanas O
. O

Todos O
los O
pacientes O
no O
habían O
recibido O
quimioterapia O
y O
tenían O
un O
estado O
de O
rendimiento O
ECOG O
( O
PS O
) O
de O
0 O
a O
1 O
. O

En O
total, O
se O
inscribieron O
278 O
pacientes O
en O
el O
ensayo. O

La O
tasa O
de O
respuesta O
global O
fue O
del O
34 O
% O
( O
95 O
% O
CL O
26-42 O
% O
) O
en O
el O
brazo O
de O
VNR/CDDP O
semanal O
, O
y O
del O
32 O
% O
( O
95 O
% O
CL O
24-40 O
% O
) O
en O
los O
pacientes O
tratados O
con O
VNR/CDDP O
del O
día O
1 O
al O
8 O
sin O
ninguna O
diferencia O
estadísticamente O
significativa O
. O

La B-Premise
mediana I-Premise
del I-Premise
TTP I-Premise
fue I-Premise
de I-Premise
4,5 I-Premise
y I-Premise
4,6 I-Premise
meses I-Premise
respectivamente I-Premise
para I-Premise
el I-Premise
brazo I-Premise
de I-Premise
VNR/CDDP I-Premise
semanal I-Premise
y I-Premise
el I-Premise
de I-Premise
VNR/CDDP I-Premise
del I-Premise
día I-Premise
1 I-Premise
al I-Premise
8. I-Premise

Esta B-Premise
diferencia I-Premise
no I-Premise
fue I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
prueba I-Premise
de I-Premise
rango I-Premise
logarítmico I-Premise
, I-Premise
p=0,818 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SG I-Premise
fue I-Premise
de I-Premise
9,45 I-Premise
y I-Premise
10 I-Premise
meses, I-Premise
respectivamente, I-Premise
para I-Premise
el I-Premise
brazo I-Premise
de I-Premise
VNR/CDDP I-Premise
semanal I-Premise
y I-Premise
el I-Premise
de I-Premise
VNR/CDDP I-Premise
del I-Premise
día I-Premise
1 I-Premise
al I-Premise
8, I-Premise
sin I-Premise
que I-Premise
hubiera I-Premise
una I-Premise
diferencia I-Premise
estadísticamente I-Premise
significativa I-Premise
(prueba I-Premise
de I-Premise
rango I-Premise
logarítmico, I-Premise
p=0,259). I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
1 I-Premise
y I-Premise
2 I-Premise
años I-Premise
fueron I-Premise
del I-Premise
31 I-Premise
y I-Premise
36 I-Premise
% I-Premise
, I-Premise
y I-Premise
del I-Premise
10 I-Premise
y I-Premise
11 I-Premise
% I-Premise
respectivamente I-Premise
. I-Premise

La B-Premise
incidencia I-Premise
de I-Premise
neutropenia I-Premise
grave I-Premise
( I-Premise
34 I-Premise
% I-Premise
frente I-Premise
a I-Premise
68 I-Premise
% I-Premise
; I-Premise
p=0,0001 I-Premise
) I-Premise
y I-Premise
de I-Premise
neutropenia I-Premise
febril I-Premise
( I-Premise
5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
12 I-Premise
% I-Premise
; I-Premise
p=0,026 I-Premise
) I-Premise
, I-Premise
así I-Premise
como I-Premise
la I-Premise
tasa I-Premise
de I-Premise
omisiones I-Premise
terapéuticas I-Premise
( I-Premise
10 I-Premise
% I-Premise
frente I-Premise
a I-Premise
24 I-Premise
% I-Premise
; I-Premise
p=0,0037 I-Premise
) I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
VNR/CDDP I-Premise
semanal I-Premise
que I-Premise
en I-Premise
el I-Premise
de I-Premise
VNR/CDDP I-Premise
día I-Premise
1 I-Premise
a I-Premise
8 I-Premise
. I-Premise

El B-Premise
régimen I-Premise
semanal I-Premise
de I-Premise
VNR/CDDP I-Premise
se I-Premise
asoció I-Premise
con I-Premise
una I-Premise
menor I-Premise
intensidad I-Premise
de I-Premise
dosis I-Premise
recibida I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
9 I-Premise
% I-Premise
frente I-Premise
a I-Premise
22 I-Premise
% I-Premise
; I-Premise
p=0,0001 I-Premise
) I-Premise
y I-Premise
con I-Premise
una I-Premise
menor I-Premise
puntuación I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
no I-Premise
estadísticamente I-Premise
significativa I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
régimen I-Premise
de I-Premise
VNR/CDDP I-Premise
del I-Premise
día I-Premise
1 I-Premise
al I-Premise
8 I-Premise
. I-Premise

La B-Claim
combinación I-Claim
de I-Claim
VNR I-Claim
día I-Claim
1-8 I-Claim
más I-Claim
CDDP I-Claim
cada I-Claim
3 I-Claim
semanas I-Claim
es I-Claim
menos I-Claim
tóxica I-Claim
y I-Claim
mejor I-Claim
tolerada I-Claim
que I-Claim
el I-Claim
régimen I-Claim
de I-Claim
VNR I-Claim
semanal I-Claim
más I-Claim
CDDP I-Claim
cada I-Claim
4 I-Claim
semanas I-Claim
. I-Claim

Los B-Claim
dos I-Claim
esquemas I-Claim
son I-Claim
equivalentes I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
tasa I-Claim
de I-Claim
respuesta I-Claim
global, I-Claim
la I-Claim
mediana I-Claim
del I-Claim
tiempo I-Claim
hasta I-Claim
la I-Claim
progresión I-Claim
y I-Claim
la I-Claim
supervivencia I-Claim
global. I-Claim

La B-Claim
combinación I-Claim
de I-Claim
VNR I-Claim
en I-Claim
el I-Claim
día I-Claim
1-8 I-Claim
más I-Claim
CDDP I-Claim
cada I-Claim
3 I-Claim
semanas I-Claim
puede I-Claim
considerarse I-Claim
como I-Claim
un I-Claim
régimen I-Claim
de I-Claim
referencia I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
enfermedad I-Claim
avanzada I-Claim
y I-Claim
los I-Claim
que I-Claim
merecen I-Claim
una I-Claim
terapia I-Claim
postoperatoria I-Claim
, I-Claim
y I-Claim
para I-Claim
futuros I-Claim
estudios I-Claim
. I-Claim

La O
fatiga O
relacionada O
con O
el O
cáncer O
( O
CRF O
) O
es O
un O
problema O
común O
para O
los O
pacientes O
de O
cáncer O
a O
través O
de O
los O
diagnósticos O
durante O
la O
quimioterapia O
y O
se O
asocia O
con O
la O
inactividad O
física O
, O
menor O
nivel O
funcional O
y O
la O
falta O
de O
energía O
. O

Pocos O
estudios O
de O
intervención O
con O
ejercicios O
de O
ECA O
han O
incluido O
a O
pacientes O
con O
cáncer O
sometidos O
a O
quimioterapia O
. O

El O
objetivo O
de O
este O
estudio O
es O
evaluar O
si O
una O
intervención O
de O
ejercicio O
multimodal O
supervisada O
de O
seis O
semanas, O
complementaria O
a O
la O
quimioterapia O
y O
al O
tratamiento O
estándar, O
puede O
reducir O
el O
nivel O
de O
FRC O
del O
paciente. O

Los O
datos O
se O
basan O
en O
los O
análisis O
de O
un O
ensayo O
prospectivo O
controlado O
y O
aleatorio O
"The O
Body O
Cancer O
Trial". O

213 O
pacientes O
de O
cáncer O
con O
diferentes O
diagnósticos O
fueron O
asignados O
al O
azar O
a O
un O
grupo O
de O
intervención O
o O
a O
un O
grupo O
de O
control O
en O
lista O
de O
espera. O

El O
resultado O
primario O
, O
la O
puntuación O
de O
la O
fatiga O
( O
CRF O
) O
, O
se O
evaluó O
mediante O
el O
Cuestionario O
de O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-An- O
( O
FACT-An- O
) O
( O
puntuación O
FACT-G O
y O
subescala O
FACT-An O
Anemia O
) O
. O

Ejercicio O
supervisado O
, O
que O
comprende O
entrenamiento O
cardiovascular O
de O
alta O
intensidad O
y O
de O
resistencia O
pesada O
, O
entrenamiento O
de O
relajación O
y O
conciencia O
corporal O
y O
masaje O
, O
9 O
h O
semanales O
durante O
6 O
semanas O
. O

El B-Premise
FRC I-Premise
se I-Premise
redujo I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención, I-Premise
lo I-Premise
que I-Premise
corresponde I-Premise
a I-Premise
una I-Premise
reducción I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
de I-Premise
3,04 I-Premise
(tamaño I-Premise
del I-Premise
efecto I-Premise
de I-Premise
0,44, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
0,17-0,72) I-Premise
(p I-Premise
= I-Premise
0,002), I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
FACT-An I-Premise
de I-Premise
5,40 I-Premise
(p I-Premise
= I-Premise
0,015), I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
FACT-An I-Premise
Toi I-Premise
de I-Premise
5,22 I-Premise
(p I-Premise
= I-Premise
0,009) I-Premise
y I-Premise
de I-Premise
la I-Premise
anemia-ANS I-Premise
de I-Premise
3,76 I-Premise
(p I-Premise
= I-Premise
0,002). I-Premise

No B-Premise
hubo I-Premise
ningún I-Premise
efecto I-Premise
estadísticamente I-Premise
significativo I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
ni I-Premise
en I-Premise
ninguna I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
bienestar I-Premise
individual; I-Premise
físico I-Premise
( I-Premise
P I-Premise
= I-Premise
.13 I-Premise
) I-Premise
, I-Premise
emocional I-Premise
( I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
, I-Premise
social I-Premise
( I-Premise
P I-Premise
= I-Premise
.83 I-Premise
) I-Premise
y I-Premise
funcional I-Premise
( I-Premise
P I-Premise
= I-Premise
.26 I-Premise
) I-Premise
. I-Premise

En B-Claim
resumen, I-Claim
esta I-Claim
intervención I-Claim
de I-Claim
ejercicio I-Claim
multimodal I-Claim
supervisado I-Claim
de I-Claim
seis I-Claim
semanas I-Claim
de I-Claim
duración I-Claim
puede I-Claim
conducir I-Claim
a I-Claim
una I-Claim
reducción I-Claim
significativa I-Claim
de I-Claim
los I-Claim
FRCV I-Claim
autodeclarados I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
sometidos I-Claim
a I-Claim
quimioterapia. I-Claim

La O
quimioterapia O
con O
un O
agente O
de O
platino O
y O
un O
taxano O
( O
paclitaxel O
) O
se O
considera O
el O
estándar O
de O
atención O
para O
el O
tratamiento O
del O
carcinoma O
de O
ovario O
. O

Se O
comparó O
la O
combinación O
de O
docetaxel-carboplatino O
con O
la O
combinación O
de O
paclitaxel-carboplatino O
como O
quimioterapia O
de O
primera O
línea O
para O
el O
cáncer O
epitelial O
de O
ovario O
o O
peritoneal O
primario O
en O
estadio O
Ic-IV O
. O

Se O
asignaron O
aleatoriamente O
1077 O
pacientes O
para O
recibir O
docetaxel O
a O
75 O
mg/m2 O
de O
superficie O
corporal O
( O
infusión O
intravenosa O
de O
1 O
hora O
) O
o O
paclitaxel O
a O
175 O
mg/m2 O
( O
infusión O
intravenosa O
de O
3 O
horas O
) O
. O

Ambos O
tratamientos O
fueron O
seguidos O
de O
carboplatino O
hasta O
un O
área O
bajo O
la O
curva O
de O
concentración O
plasmática-tiempo O
de O
5 O
. O

Los O
tratamientos O
se O
repitieron O
cada O
3 O
semanas O
durante O
seis O
ciclos; O
en O
los O
pacientes O
que O
respondieron, O
se O
permitieron O
tres O
ciclos O
adicionales O
de O
carboplatino O
como O
agente O
único. O

Las O
curvas O
de O
supervivencia O
se O
calcularon O
mediante O
el O
método O
de O
Kaplan-Meier, O
y O
las O
razones O
de O
riesgo O
se O
estimaron O
con O
el O
modelo O
de O
riesgos O
proporcionales O
de O
Cox. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

Tras B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
23 I-Premise
meses, I-Premise
ambos I-Premise
grupos I-Premise
tuvieron I-Premise
una I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
similar I-Premise
( I-Premise
medianas I-Premise
de I-Premise
15,0 I-Premise
meses I-Premise
para I-Premise
docetaxel-carboplatino I-Premise
y I-Premise
14,8 I-Premise
meses I-Premise
para I-Premise
paclitaxel-carboplatino I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
0,97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0,83 I-Premise
a I-Premise
1,13 I-Premise
; I-Premise
P I-Premise
= I-Premise
.707 I-Premise
) I-Premise
, I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
( I-Premise
64,2 I-Premise
% I-Premise
y I-Premise
68.9 I-Premise
% I-Premise
, I-Premise
respectivamente; I-Premise
HR I-Premise
= I-Premise
1,13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0,92 I-Premise
a I-Premise
1,39 I-Premise
; I-Premise
P I-Premise
= I-Premise
.238 I-Premise
) I-Premise
, I-Premise
y I-Premise
tumor I-Premise
objetivo I-Premise
( I-Premise
58,7 I-Premise
% I-Premise
y I-Premise
59,5 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
diferencia I-Premise
entre I-Premise
docetaxel I-Premise
y I-Premise
paclitaxel I-Premise
= I-Premise
-0.8 I-Premise
% I-Premise
, I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-8,6 I-Premise
% I-Premise
a I-Premise
7,1 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
.868 I-Premise
) I-Premise
y I-Premise
CA-125 I-Premise
( I-Premise
75,8 I-Premise
% I-Premise
y I-Premise
76,8 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
diferencia I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
-1,0 I-Premise
% I-Premise
, I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-7,2 I-Premise
% I-Premise
a I-Premise
5,1 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
.794 I-Premise
) I-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
docetaxel-carboplatino I-Premise
se I-Premise
asoció I-Premise
con I-Premise
una I-Premise
neurotoxicidad I-Premise
general I-Premise
y I-Premise
de I-Premise
grado I-Premise
2 I-Premise
o I-Premise
superior I-Premise
sustancialmente I-Premise
menor I-Premise
que I-Premise
paclitaxel-carboplatino I-Premise
( I-Premise
toxicidad I-Premise
neurosensorial I-Premise
de I-Premise
grado I-Premise
> I-Premise
o I-Premise
=2 I-Premise
en I-Premise
el I-Premise
11 I-Premise
% I-Premise
frente I-Premise
al I-Premise
30 I-Premise
% I-Premise
, I-Premise
diferencia I-Premise
= I-Premise
19 I-Premise
% I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
15 I-Premise
% I-Premise
a I-Premise
24 I-Premise
% I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
; I-Premise
toxicidad I-Premise
neuromotora I-Premise
de I-Premise
grado I-Premise
> I-Premise
o I-Premise
=2 I-Premise
en I-Premise
el I-Premise
3 I-Premise
% I-Premise
frente I-Premise
al I-Premise
7 I-Premise
% I-Premise
, I-Premise
diferencia I-Premise
= I-Premise
4 I-Premise
% I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
1 I-Premise
% I-Premise
a I-Premise
7 I-Premise
% I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

El B-Premise
tratamiento I-Premise
con I-Premise
docetaxel-carboplatino I-Premise
se I-Premise
asoció I-Premise
con I-Premise
un I-Premise
número I-Premise
estadísticamente I-Premise
significativo I-Premise
de I-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
( I-Premise
94 I-Premise
% I-Premise
frente I-Premise
a I-Premise
84 I-Premise
% I-Premise
, I-Premise
diferencia I-Premise
= I-Premise
11 I-Premise
% I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
7 I-Premise
% I-Premise
a I-Premise
14 I-Premise
% I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
de I-Premise
complicaciones I-Premise
neutropénicas I-Premise
que I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
paclitaxel-carboplatino I-Premise
, O
aunque B-Premise
la I-Premise
mielosupresión I-Premise
no I-Premise
influyó I-Premise
en I-Premise
la I-Premise
administración I-Premise
de I-Premise
dosis I-Premise
ni I-Premise
en I-Premise
la I-Premise
seguridad I-Premise
del I-Premise
paciente I-Premise
. O

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
fue I-Premise
similar I-Premise
en I-Premise
ambos I-Premise
brazos, I-Premise
pero B-Premise
las I-Premise
diferencias I-Premise
sustanciales I-Premise
en I-Premise
muchas I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
favorecieron I-Premise
al I-Premise
docetaxel. I-Premise

Docetaxel-carboplatino B-Claim
parece I-Claim
ser I-Claim
similar I-Claim
a I-Claim
paclitaxel-carboplatino I-Claim
en I-Claim
términos I-Claim
de I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
y I-Claim
respuesta I-Claim
, O
aunque B-Claim
se I-Claim
requiere I-Claim
un I-Claim
seguimiento I-Claim
más I-Claim
largo I-Claim
para I-Claim
una I-Claim
declaración I-Claim
definitiva I-Claim
sobre I-Claim
la I-Claim
supervivencia I-Claim
. O

Por B-Claim
lo I-Claim
tanto, I-Claim
docetaxel-carboplatino I-Claim
representa I-Claim
un I-Claim
régimen I-Claim
alternativo I-Claim
de I-Claim
quimioterapia I-Claim
de I-Claim
primera I-Claim
línea I-Claim
para I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
recién I-Claim
diagnosticado. I-Claim

El O
ejercicio O
para O
la O
salud O
fue O
un O
ensayo O
aleatorio O
y O
controlado O
diseñado O
para O
evaluar O
dos O
modos O
de O
entrega O
( O
cara O
a O
cara O
[ O
FtF O
] O
y O
por O
teléfono O
[ O
Tel O
] O
) O
una O
intervención O
de O
ejercicio O
traslacional O
de O
8 O
meses, O
comenzando O
6 O
semanas O
después O
de O
la O
cirugía O
de O
cáncer O
de O
mama O
( O
PS O
) O
. O

Los O
resultados O
incluyeron O
la O
calidad O
de O
vida O
( O
QoL O
) O
, O
la O
función O
( O
fitness O
y O
parte O
superior O
del O
cuerpo O
) O
y O
los O
efectos O
secundarios O
relacionados O
con O
el O
tratamiento O
( O
fatiga O
, O
linfedema O
, O
índice O
de O
masa O
corporal O
, O
síntomas O
de O
la O
menopausia O
, O
ansiedad O
, O
depresión O
y O
dolor O
) O
. O

La O
modelización O
de O
ecuaciones O
de O
estimación O
generalizada O
determinó O
el O
tiempo O
( O
línea O
de O
base O
[ O
5 O
semanas O
PS O
] O
, O
mitad O
de O
la O
intervención O
[ O
6 O
meses O
PS O
] O
, O
post-intervención O
[ O
12 O
meses O
PS O
] O
) O
, O
el O
grupo O
( O
FtF O
, O
Tel O
, O
Atención O
habitual O
[ O
UC O
] O
) O
y O
los O
efectos O
de O
tiempo O
por O
grupo O
. O

194 O
mujeres O
representativas O
de O
la O
población O
con O
cáncer O
de O
mama O
fueron O
asignadas O
al O
azar O
a O
los O
grupos O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
y O
UC O
( O
n O
= O
60 O
) O
. O

Hubo B-Premise
efectos I-Premise
de I-Premise
interacción I-Premise
significativos I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
sobre I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
, I-Premise
el I-Premise
estado I-Premise
físico I-Premise
y I-Premise
la I-Premise
fatiga, I-Premise
observándose I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
y I-Premise
el I-Premise
grupo I-Premise
de I-Premise
CU I-Premise
. I-Premise

Las B-Premise
tendencias I-Premise
observadas I-Premise
en I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
fueron I-Premise
similares. I-Premise

Los B-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
informaron I-Premise
de I-Premise
una I-Premise
mejora I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
la I-Premise
forma I-Premise
física I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo, I-Premise
y I-Premise
los I-Premise
cambios I-Premise
observados I-Premise
entre I-Premise
el I-Premise
inicio I-Premise
y I-Premise
el I-Premise
final I-Premise
de I-Premise
la I-Premise
intervención I-Premise
fueron I-Premise
clínicamente I-Premise
relevantes. I-Premise

En B-Premise
cambio, I-Premise
el I-Premise
grupo I-Premise
de I-Premise
CU I-Premise
no I-Premise
experimentó I-Premise
ningún I-Premise
cambio, I-Premise
o I-Premise
empeoró I-Premise
su I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
su I-Premise
estado I-Premise
físico I-Premise
y I-Premise
su I-Premise
fatiga, I-Premise
a I-Premise
mitad I-Premise
de I-Premise
la I-Premise
intervención. I-Premise

Aunque B-Premise
se I-Premise
produjeron I-Premise
mejoras I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
CU I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
de I-Premise
la I-Premise
cirugía, I-Premise
el I-Premise
cambio I-Premise
no I-Premise
alcanzó I-Premise
el I-Premise
umbral I-Premise
clínicamente I-Premise
relevante. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
otros I-Premise
efectos I-Premise
secundarios I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
entre I-Premise
los I-Premise
grupos. I-Premise

Este B-Claim
ensayo I-Claim
de I-Claim
intervención I-Claim
traslacional I-Claim
, I-Claim
entregado I-Claim
FtF I-Claim
o I-Claim
Tel I-Claim
, I-Claim
apoya I-Claim
el I-Claim
ejercicio I-Claim
como I-Claim
una I-Claim
forma I-Claim
de I-Claim
terapia I-Claim
adyuvante I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
que I-Claim
puede I-Claim
prevenir I-Claim
la I-Claim
disminución I-Claim
de I-Claim
la I-Claim
aptitud I-Claim
y I-Claim
la I-Claim
función I-Claim
durante I-Claim
el I-Claim
tratamiento I-Claim
y I-Claim
optimizar I-Claim
la I-Claim
recuperación I-Claim
después I-Claim
del I-Claim
tratamiento I-Claim
. I-Claim

El B-Claim
derrame I-Claim
pleural I-Claim
maligno I-Claim
(EPM) I-Claim
es I-Claim
una I-Claim
complicación I-Claim
común I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
no I-Claim
pequeñas I-Claim
avanzado I-Claim
(CPNM). I-Claim

El B-Claim
bevacizumab I-Claim
, I-Claim
un I-Claim
anticuerpo I-Claim
monoclonal I-Claim
humanizado I-Claim
contra I-Claim
el I-Claim
factor I-Claim
de I-Claim
crecimiento I-Claim
endotelial I-Claim
vascular I-Claim
( I-Claim
VEGF I-Claim
) I-Claim
, I-Claim
ha I-Claim
demostrado I-Claim
ser I-Claim
eficaz I-Claim
para I-Claim
suprimir I-Claim
la I-Claim
acumulación I-Claim
de I-Claim
líquido I-Claim
pleural I-Claim
. I-Claim

Sin O
embargo, O
aún O
se O
desconoce O
si O
la O
administración O
intrapleural O
de O
bevacizumab O
puede O
utilizarse O
para O
tratar O
el O
MPE. O

El O
objetivo O
del O
presente O
estudio O
fue O
evaluar O
la O
eficacia O
y O
la O
seguridad O
de O
la O
terapia O
intrapleural O
combinada O
con O
bevacizumab O
y O
cisplatino O
, O
un O
agente O
antineoplásico O
, O
en O
el O
control O
del O
MPE O
. O

Un O
total O
de O
72 O
sujetos O
del O
estudio O
de O
CPNM O
con O
MPE O
fueron O
asignados O
aleatoriamente O
a O
uno O
de O
los O
dos O
grupos O
. O

El O
primer O
grupo O
recibió O
bevacizumab O
intrapleural O
( O
300 O
mg O
) O
con O
terapia O
de O
cisplatino O
( O
30 O
mg O
) O
y O
el O
segundo O
grupo O
recibió O
terapia O
de O
cisplatino O
intrapleural O
( O
30 O
mg O
) O
sola O
. O

Se O
recogió O
líquido O
pleural O
de O
ambos O
grupos O
antes O
y O
después O
del O
tratamiento. O

Los O
niveles O
de O
VEGF O
y O
antígeno O
carcinoembrionario O
( O
CEA O
) O
en O
el O
líquido O
pleural O
se O
determinaron O
mediante O
ELISA O
. O

En B-Premise
70 I-Premise
sujetos I-Premise
de I-Premise
estudio I-Premise
evaluables I-Premise
, I-Premise
la I-Premise
eficacia I-Premise
curativa I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
bevacizumab I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
que I-Premise
la I-Premise
encontrada I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
cisplatino I-Premise
( I-Premise
83,33 I-Premise
frente I-Premise
a I-Premise
50,00 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
terapia I-Premise
con I-Premise
bevacizumab I-Premise
combinado I-Premise
más I-Premise
cisplatino I-Premise
redujo I-Premise
significativamente I-Premise
los I-Premise
niveles I-Premise
de I-Premise
VEGF I-Premise
en I-Premise
el I-Premise
líquido I-Premise
pleural I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
bevacizumab I-Premise
, I-Premise
los I-Premise
niveles I-Premise
de I-Premise
VEGF I-Premise
en I-Premise
el I-Premise
líquido I-Premise
pleural I-Premise
fueron I-Premise
significativamente I-Premise
menores I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
del I-Premise
grupo I-Premise
de I-Premise
cisplatino I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
, I-Premise
lo I-Premise
que I-Premise
demostró I-Premise
una I-Premise
mayor I-Premise
eficacia I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

Además B-Premise
, I-Premise
la I-Premise
terapia I-Premise
combinada I-Premise
mostró I-Premise
una I-Premise
mayor I-Premise
eficacia I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
altos I-Premise
niveles I-Premise
de I-Premise
expresión I-Premise
de I-Premise
VEGF I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
los I-Premise
efectos I-Premise
adversos I-Premise
de I-Premise
grado I-Premise
III/IV I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos. I-Premise

Todos B-Premise
los I-Premise
procedimientos I-Premise
fueron I-Premise
bien I-Premise
tolerados I-Premise
por I-Premise
los I-Premise
pacientes. I-Premise

La B-Claim
terapia I-Claim
intrapleural I-Claim
combinada I-Claim
con I-Claim
bevacizumab I-Claim
y I-Claim
cisplatino I-Claim
fue I-Claim
eficaz I-Claim
y I-Claim
segura I-Claim
en I-Claim
el I-Claim
manejo I-Claim
del I-Claim
MPE I-Claim
mediado I-Claim
por I-Claim
CPNM I-Claim
. I-Claim

Proponemos B-Claim
que I-Claim
los I-Claim
niveles I-Claim
de I-Claim
expresión I-Claim
de I-Claim
VEGF I-Claim
en I-Claim
el I-Claim
MPE I-Claim
podrían I-Claim
servir I-Claim
como I-Claim
marcador I-Claim
pronóstico I-Claim
para I-Claim
la I-Claim
terapia I-Claim
con I-Claim
bevacizumab I-Claim
. I-Claim

En B-Claim
los I-Claim
ensayos I-Claim
de I-Claim
terapia I-Claim
endocrina I-Claim
en I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
avanzado I-Claim
, I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
respuesta I-Claim
( I-Claim
respuesta I-Claim
completa/respuesta I-Claim
parcial I-Claim
[ I-Claim
CR/PR I-Claim
] I-Claim
) I-Claim
y I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
enfermedad I-Claim
estable I-Claim
durante I-Claim
al I-Claim
menos I-Claim
6 I-Claim
meses I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
han I-Claim
mostrado I-Claim
una I-Claim
supervivencia I-Claim
similar I-Claim
y, I-Claim
por I-Claim
lo I-Claim
tanto, I-Claim
a I-Claim
menudo I-Claim
se I-Claim
definen I-Claim
como I-Claim
una I-Claim
población I-Claim
con I-Claim
beneficio I-Claim
clínico I-Claim
( I-Claim
pacientes I-Claim
con I-Claim
CR/PR I-Claim
o I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

Se O
evaluó O
el O
impacto O
de O
la O
respuesta O
y/o O
el O
beneficio O
clínico O
en O
la O
calidad O
de O
vida O
( O
QL O
) O
en O
pacientes O
posmenopáusicas O
bajo O
tratamiento O
endocrino O
de O
segunda O
línea O
tras O
el O
fracaso O
del O
tamoxifeno O
. O

Se O
analizaron O
ciento O
veintiocho O
de O
177 O
pacientes O
elegibles O
de O
un O
ensayo O
aleatorio O
( O
Grupo O
Suizo O
para O
la O
Investigación O
Clínica O
del O
Cáncer O
20/90 O
) O
que O
recibieron O
formestano O
( O
250 O
mg O
por O
vía O
intramuscular O
quincenal O
) O
o O
acetato O
de O
megestrol O
( O
160 O
mg O
por O
vía O
oral O
diariamente O
) O
. O

Las O
características O
basales O
( O
a O
excepción O
del O
lugar O
de O
las O
metástasis O
) O
estaban O
equilibradas O
entre O
los O
pacientes O
con O
RC/PR O
, O
SD O
( O
6m O
) O
y O
enfermedad O
progresiva O
( O
PD O
) O
. O

Los O
pacientes O
completaron O
los O
indicadores O
de O
calidad O
de O
vida O
al O
inicio O
y O
a O
los O
1, O
3, O
5, O
7, O
9 O
y O
11 O
meses. O

Los O
pacientes O
que O
respondieron O
se O
compararon O
por O
separado O
con O
los O
que O
no O
respondieron O
( O
pacientes O
con O
SD O
( O
6m O
) O
o O
PD O
) O
y O
con O
los O
pacientes O
con O
SD O
( O
6m O
) O
, O
y O
los O
pacientes O
con O
beneficio O
clínico O
se O
compararon O
con O
los O
pacientes O
con O
PD O
mediante O
un O
análisis O
de O
covarianza O
con O
ajuste O
por O
las O
puntuaciones O
iniciales O
. O

En O
total, O
se O
recibió O
el O
88% O
( O
557 O
de O
634 O
) O
de O
los O
formularios O
QL O
previstos. O

En O
la O
comparación O
de O
los O
respondedores O
frente O
a O
los O
pacientes O
con O
SD O
( O
6m O
) O
y O
PD O
, O
los B-Premise
respondedores I-Premise
indicaron I-Premise
un I-Premise
mejor I-Premise
bienestar I-Premise
físico I-Premise
( I-Premise
P I-Premise
= I-Premise
0,004 I-Premise
) I-Premise
y I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
en I-Premise
el I-Premise
mes I-Premise
3 I-Premise
. O

Comparados B-Premise
sólo I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
, I-Premise
los I-Premise
respondedores I-Premise
no I-Premise
mostraron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
CV I-Premise
de I-Premise
partida I-Premise
ni I-Premise
en I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
fracaso I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
328,5 I-Premise
frente I-Premise
a I-Premise
340 I-Premise
días I-Premise
) I-Premise
. I-Premise

Mientras B-Premise
estaban I-Premise
bajo I-Premise
tratamiento I-Premise
, I-Premise
los I-Premise
respondedores I-Premise
informaron I-Premise
de I-Premise
un I-Premise
bienestar I-Premise
físico I-Premise
significativamente I-Premise
mejor I-Premise
( I-Premise
meses I-Premise
3 I-Premise
a I-Premise
11 I-Premise
) I-Premise
, I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
( I-Premise
meses I-Premise
5 I-Premise
a I-Premise
11 I-Premise
) I-Premise
, I-Premise
el I-Premise
afrontamiento I-Premise
( I-Premise
meses I-Premise
5 I-Premise
a I-Premise
9 I-Premise
) I-Premise
y I-Premise
el I-Premise
apetito I-Premise
( I-Premise
meses I-Premise
7 I-Premise
a I-Premise
11 I-Premise
) I-Premise
y I-Premise
menos I-Premise
mareos I-Premise
( I-Premise
mes I-Premise
9 I-Premise
) I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Los B-Premise
cambios I-Premise
entre I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
y I-Premise
los I-Premise
meses I-Premise
5 I-Premise
y I-Premise
7 I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
indicaron I-Premise
una I-Premise
mejora I-Premise
en I-Premise
los I-Premise
respondedores I-Premise
pero I-Premise
patrones I-Premise
heterogéneos I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Aunque B-Premise
los I-Premise
grupos I-Premise
CR/PR I-Premise
y I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
tuvieron I-Premise
tiempos I-Premise
similares I-Premise
hasta I-Premise
el I-Premise
fracaso I-Premise
del I-Premise
tratamiento I-Premise
, O
los B-Claim
pacientes I-Claim
con I-Claim
CR/PR I-Claim
informaron I-Claim
de I-Claim
una I-Claim
mejor I-Claim
QL I-Claim
, I-Claim
lo I-Claim
que I-Claim
sugiere I-Claim
una I-Claim
respuesta I-Claim
más I-Claim
beneficiosa I-Claim
al I-Claim
tratamiento I-Claim
endocrino I-Claim
de I-Claim
segunda I-Claim
línea I-Claim
. O

La O
perspectiva O
subjetiva O
de O
los O
pacientes O
debe O
tenerse O
en O
cuenta O
en O
este O
entorno O
principalmente O
paliativo. O

Los O
ensayos O
futuros O
deberían O
diseñarse O
de O
manera O
que O
los O
grupos O
CR/PR O
y O
SD O
( O
6m O
) O
se O
investiguen O
por O
separado O
. O

Describir O
la O
revisión O
y O
aprobación O
por O
parte O
de O
la O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
de O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
para O
el O
tratamiento O
de O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
( O
NSCLC O
) O
localmente O
avanzado O
o O
metastásico O
tras O
el O
fracaso O
de O
al O
menos O
un O
régimen O
de O
quimioterapia O
previo O
. O

La O
FDA O
revisó O
los O
datos O
brutos O
en O
formato O
electrónico O
de O
un O
ensayo O
clínico O
controlado O
y O
aleatorizado O
que O
comparaba O
erlotinib O
con O
placebo O
en O
pacientes O
con O
CPNM O
localmente O
avanzado O
o O
metastásico O
tras O
el O
fracaso O
de O
al O
menos O
un O
régimen O
de O
quimioterapia O
previo O
. O

Los O
pacientes O
fueron O
aleatorizados O
en O
una O
proporción O
2:1 O
( O
erlotinib O
, O
n O
= O
488 O
y O
placebo O
, O
n O
= O
243 O
) O
. O

El B-Claim
erlotinib I-Claim
fue I-Claim
superior I-Claim
al I-Claim
placebo I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
supervivencia, I-Claim
la I-Claim
supervivencia I-Claim
sin I-Claim
progresión I-Claim
y I-Claim
la I-Claim
tasa I-Claim
de I-Claim
respuesta I-Claim
tumoral. I-Claim

Los B-Claim
análisis I-Claim
exploratorios I-Claim
indican I-Claim
que I-Claim
el I-Claim
estado I-Claim
del I-Claim
receptor I-Claim
del I-Claim
factor I-Claim
de I-Claim
crecimiento I-Claim
epidérmico I-Claim
puede I-Claim
ser I-Claim
un I-Claim
importante I-Claim
predictor I-Claim
del I-Claim
efecto I-Claim
de I-Claim
supervivencia I-Claim
del I-Claim
erlotinib I-Claim
. I-Claim

Los B-Premise
acontecimientos I-Premise
adversos I-Premise
más I-Premise
frecuentes I-Premise
fueron I-Premise
la I-Premise
erupción I-Premise
cutánea I-Premise
(75 I-Premise
% I-Premise
frente I-Premise
al I-Premise
17 I-Premise
%) I-Premise
y I-Premise
la I-Premise
diarrea I-Premise
(54 I-Premise
% I-Premise
frente I-Premise
al I-Premise
18 I-Premise
%) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
erlotnib I-Premise
y I-Premise
en I-Premise
el I-Premise
de I-Premise
placebo, I-Premise
respectivamente. I-Premise

En B-Premise
el I-Premise
9% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
erlotinib I-Premise
se I-Premise
produjo I-Premise
una I-Premise
erupción I-Premise
cutánea I-Premise
grave I-Premise
y I-Premise
en I-Premise
el I-Premise
6% I-Premise
una I-Premise
diarrea I-Premise
grave, I-Premise
y I-Premise
cada I-Premise
una I-Premise
de I-Premise
ellas I-Premise
provocó I-Premise
la I-Premise
interrupción I-Premise
del I-Premise
estudio I-Premise
en I-Premise
el I-Premise
1% I-Premise
de I-Premise
los I-Premise
pacientes. I-Premise

Fue B-Premise
necesario I-Premise
reducir I-Premise
la I-Premise
dosis I-Premise
en I-Premise
el I-Premise
10% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
erupción I-Premise
cutánea I-Premise
y I-Premise
en I-Premise
el I-Premise
4% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
diarrea. I-Premise

El O
18 O
de O
noviembre O
de O
2004, O
la O
FDA O
concedió O
la O
aprobación O
ordinaria O
del O
erlotinib O
para O
el O
tratamiento O
de O
pacientes O
con O
CPNM O
localmente O
avanzado O
o O
metastásico O
tras O
el O
fracaso O
de O
al O
menos O
un O
régimen O
de O
quimioterapia O
previo. O

El O
solicitante O
se O
ha O
comprometido O
a O
realizar O
ensayos O
clínicos O
posteriores O
a O
la O
comercialización O
para O
evaluar O
más O
el O
efecto O
de O
la O
expresión O
del O
receptor O
del O
factor O
de O
crecimiento O
epidérmico O
, O
medido O
con O
tinción O
inmunohistoquímica O
, O
sobre O
el O
efecto O
del O
tratamiento O
con O
erlotinib O
. O

La O
gastroyeyunostomía O
( O
GJJ O
) O
y O
la O
colocación O
de O
stents O
son O
los O
tratamientos O
paliativos O
más O
utilizados O
para O
la O
obstrucción O
maligna O
de O
la O
salida O
gástrica O
( O
GOO O
) O
. O

En O
un O
ensayo O
aleatorio O
reciente, O
se O
prefirió O
la O
colocación O
de O
un O
stent O
en O
los O
pacientes O
con O
una O
supervivencia O
relativamente O
corta O
y O
la O
JG O
en O
los O
pacientes O
con O
una O
supervivencia O
más O
larga. O

Dado O
que O
los O
aspectos O
económicos O
de O
la O
salud O
sólo O
se O
han O
estudiado O
en O
términos O
generales, O
hemos O
calculado O
el O
coste O
de O
la O
GJJ O
y O
el O
de O
la O
colocación O
del O
stent O
en O
estos O
pacientes. O

En O
el O
estudio O
SUSTENT O
, O
los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
GJJ O
( O
n O
= O
18 O
) O
o O
a O
la O
colocación O
de O
un O
stent O
( O
n O
= O
21 O
) O
. O

El O
cáncer O
de O
páncreas O
fue O
la O
causa O
más O
común O
de O
GOO O
. O

Se O
compararon O
los O
costes O
iniciales O
y O
los O
costes O
durante O
el O
seguimiento. O

Para O
la O
relación O
coste-eficacia, O
se O
calculó O
la O
relación O
coste-eficacia O
incremental. O

La B-Premise
ingesta I-Premise
de I-Premise
alimentos I-Premise
mejoró I-Premise
más I-Premise
rápidamente I-Premise
después I-Premise
de I-Premise
la I-Premise
colocación I-Premise
de I-Premise
la I-Premise
endoprótesis I-Premise
que I-Premise
después I-Premise
de I-Premise
la I-Premise
GJJ I-Premise
, O
pero B-Premise
el I-Premise
alivio I-Premise
a I-Premise
largo I-Premise
plazo I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
obstructivos I-Premise
fue I-Premise
mejor I-Premise
después I-Premise
de I-Premise
la I-Premise
GJJ I-Premise
. O

Se B-Premise
produjeron I-Premise
más I-Premise
complicaciones I-Premise
importantes I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
y I-Premise
se I-Premise
realizaron I-Premise
más I-Premise
reintervenciones I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
después I-Premise
de I-Premise
la I-Premise
colocación I-Premise
del I-Premise
stent I-Premise
que I-Premise
después I-Premise
de I-Premise
la I-Premise
GJJ I-Premise
. I-Premise

Los B-Premise
costes I-Premise
iniciales I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
el I-Premise
caso I-Premise
de I-Premise
la I-Premise
GJJ I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
colocación I-Premise
de I-Premise
un I-Premise
stent I-Premise
( I-Premise
8315 I-Premise
euros I-Premise
frente I-Premise
a I-Premise
4820 I-Premise
euros I-Premise
, I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

No B-Premise
encontramos I-Premise
diferencias I-Premise
en I-Premise
los I-Premise
costes I-Premise
de I-Premise
seguimiento. I-Premise

Los B-Premise
costes I-Premise
totales I-Premise
por I-Premise
paciente I-Premise
fueron I-Premise
más I-Premise
elevados I-Premise
en I-Premise
el I-Premise
caso I-Premise
de I-Premise
la I-Premise
GJJ I-Premise
que I-Premise
en I-Premise
el I-Premise
de I-Premise
la I-Premise
colocación I-Premise
de I-Premise
un I-Premise
stent I-Premise
(12433 I-Premise
euros I-Premise
frente I-Premise
a I-Premise
8819 I-Premise
euros, I-Premise
p I-Premise
= I-Premise
0,049). I-Premise

La B-Premise
relación I-Premise
coste-eficacia I-Premise
incremental I-Premise
de I-Premise
la I-Premise
GJJ I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
colocación I-Premise
de I-Premise
un I-Premise
stent I-Premise
fue I-Premise
de I-Premise
164 I-Premise
euros I-Premise
por I-Premise
día I-Premise
adicional I-Premise
con I-Premise
un I-Premise
sistema I-Premise
de I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
obstrucción I-Premise
de I-Premise
la I-Premise
salida I-Premise
gástrica I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
o=2 I-Premise
ajustado I-Premise
a I-Premise
la I-Premise
supervivencia I-Premise
. I-Premise

Los O
efectos B-Claim
médicos I-Claim
fueron I-Claim
mejores I-Claim
después I-Claim
de I-Claim
la I-Claim
GJJ I-Claim
, O
aunque B-Claim
la I-Claim
GJJ I-Claim
tuvo I-Claim
mayores I-Claim
costes I-Claim
totales. I-Claim

Dado B-Claim
que I-Claim
la I-Claim
diferencia I-Claim
de I-Claim
costes I-Claim
entre I-Claim
los I-Claim
dos I-Claim
tratamientos I-Claim
fue I-Claim
escasa, I-Claim
el I-Claim
coste B-Claim
no I-Claim
debería I-Claim
desempeñar I-Claim
un I-Claim
papel I-Claim
predominante I-Claim
a I-Claim
la I-Claim
hora I-Claim
de I-Claim
decidir I-Claim
el I-Claim
tipo I-Claim
de I-Claim
tratamiento I-Claim
asignado I-Claim
a I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
GOO I-Claim
maligno. I-Claim

Se O
llevó O
a O
cabo O
un O
ensayo O
clínico O
prospectivo, O
aleatorizado O
y O
multicéntrico O
para O
comparar O
los O
efectos O
y O
los O
costes O
del O
GM-CSF O
como O
complemento O
de O
la O
quimioterapia O
intensiva O
en O
pacientes O
de O
edad O
avanzada O
con O
leucemia O
mieloide O
aguda O
(LMA). O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
daunomicina-arabinósido O
de O
citosina O
( O
brazo O
de O
control O
: O
n O
= O
161 O
) O
o O
daunomicina-arabinósido O
de O
citosina O
con O
GM-CSF O
( O
brazo O
GM-CSF O
: O
n O
= O
157 O
) O
. O

El O
criterio O
de O
valoración O
principal O
fue O
el O
efecto O
del O
GM-CSF O
en O
el O
porcentaje O
de O
remisiones O
completas O
( O
CR O
) O
. O

Se O
evaluaron O
por O
separado O
la O
duración O
de O
la O
supervivencia, O
la O
supervivencia O
sin O
enfermedad, O
la O
calidad O
de O
vida O
y O
los O
costes. O

La B-Premise
RC I-Premise
tras I-Premise
el I-Premise
tratamiento I-Premise
de I-Premise
inducción I-Premise
de I-Premise
la I-Premise
remisión I-Premise
se I-Premise
alcanzó I-Premise
en I-Premise
el I-Premise
55% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
y I-Premise
en I-Premise
el I-Premise
56% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
GM-CSF I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

La B-Premise
duración I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
enfermedad I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
de I-Premise
la I-Premise
aleatorización I-Premise
se I-Premise
estimaron I-Premise
en I-Premise
un I-Premise
22 I-Premise
% I-Premise
y I-Premise
un I-Premise
19 I-Premise
% I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
y I-Premise
un I-Premise
22 I-Premise
% I-Premise
y I-Premise
un I-Premise
14 I-Premise
% I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
GM-CSF I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
a I-Premise
corto I-Premise
plazo, I-Premise
la I-Premise
administración I-Premise
de I-Premise
GM-CSF I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
más I-Premise
problemas I-Premise
en I-Premise
relación I-Premise
con I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
deprimido, I-Premise
la I-Premise
diarrea I-Premise
y I-Premise
el I-Premise
sarpullido/eczema. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
a I-Premise
largo I-Premise
plazo, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos. I-Premise

Los B-Premise
costes I-Premise
medios I-Premise
del I-Premise
tratamiento I-Premise
primario I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
GM-CSF I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
es I-Premise
decir, I-Premise
40782 I-Premise
dólares I-Premise
y I-Premise
34465 I-Premise
dólares, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

Los B-Premise
costes I-Premise
durante I-Premise
el I-Premise
periodo I-Premise
de I-Premise
seguimiento I-Premise
no I-Premise
difieren I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos. I-Premise

Los B-Claim
resultados I-Claim
de I-Claim
este I-Claim
ensayo I-Claim
clínico I-Claim
aleatorio I-Claim
indican I-Claim
que I-Claim
la I-Claim
daunomicina-arabinósido I-Claim
de I-Claim
citosina I-Claim
más I-Claim
GM-CSF I-Claim
no I-Claim
es I-Claim
una I-Claim
estrategia I-Claim
de I-Claim
tratamiento I-Claim
rentable I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
daunomicina-arabinósido I-Claim
de I-Claim
citosina I-Claim
sola. I-Claim

El O
tratamiento O
con O
andrógenos O
para O
el O
cáncer O
de O
próstata O
puede O
afectar O
negativamente O
a O
los O
dominios O
funcionales O
de O
la O
calidad O
de O
vida O
. O

El O
objetivo O
fue O
evaluar O
la O
calidad O
de O
vida O
en O
hombres O
con O
cáncer O
de O
próstata O
localmente O
avanzado O
en O
una O
comparación O
aleatoria O
de O
fase O
III O
abierta O
entre O
el O
tratamiento O
endocrino O
de O
por O
vida O
con O
y O
sin O
radioterapia O
. O

Se O
obtuvo O
información O
sobre O
la O
calidad O
de O
vida O
de O
872 O
( O
99 O
% O
) O
de O
875 O
hombres O
elegibles O
con O
cáncer O
de O
próstata O
localmente O
avanzado O
( O
T3 O
; O
78 O
% O
) O
que O
fueron O
asignados O
aleatoriamente O
, O
entre O
1996 O
y O
2002 O
, O
a O
3 O
meses O
de O
bloqueo O
total O
de O
andrógenos O
seguido O
de O
tratamiento O
endocrino O
continuo O
( O
439 O
pacientes O
) O
o O
al O
mismo O
tratamiento O
hormonal O
con O
radioterapia O
3 O
meses O
después O
de O
la O
aleatorización O
( O
436 O
pacientes O
) O
. O

Los O
resultados O
prospectivos O
incluyeron O
los O
síntomas O
notificados O
por O
los O
pacientes O
y O
la O
calidad O
de O
vida O
evaluada O
con O
cuestionarios O
desde O
el O
inicio O
hasta O
4 O
años O
después O
de O
la O
aleatorización O
. O

El O
análisis O
fue O
por O
intención O
de O
tratar O
. O

Este O
estudio O
está O
registrado O
como O
un O
ensayo O
controlado O
aleatorio O
estándar O
internacional, O
número O
ISRCTN01534787. O

438 O
de O
los O
439 O
hombres O
asignados O
a O
tratamiento O
endocrino O
y O
434 O
de O
los O
436 O
asignados O
a O
endocrino O
más O
radioterapia O
completaron O
al O
menos O
un O
cuestionario O
. O

Los O
datos O
que O
faltaban O
en O
la O
línea O
de O
base O
y O
durante O
el O
seguimiento O
se O
distribuyeron O
por O
igual O
entre O
los O
grupos O
. O

A B-Premise
los I-Premise
4 I-Premise
años, I-Premise
64 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
de I-Premise
353 I-Premise
pacientes I-Premise
en I-Premise
tratamiento I-Premise
combinado I-Premise
y I-Premise
39 I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
de I-Premise
337 I-Premise
en I-Premise
tratamiento I-Premise
endocrino I-Premise
solo I-Premise
tenían I-Premise
molestias I-Premise
urinarias I-Premise
de I-Premise
moderadas I-Premise
a I-Premise
graves I-Premise
( I-Premise
p=0,005 I-Premise
) I-Premise
, I-Premise
y I-Premise
16 I-Premise
( I-Premise
4 I-Premise
% I-Premise
) I-Premise
de I-Premise
355 I-Premise
en I-Premise
tratamiento I-Premise
combinado I-Premise
y I-Premise
cinco I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
de I-Premise
338 I-Premise
en I-Premise
tratamiento I-Premise
endocrino I-Premise
solo I-Premise
tenían I-Premise
dolor I-Premise
al I-Premise
orinar I-Premise
( I-Premise
p=0,024 I-Premise
) I-Premise
. I-Premise

37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
de I-Premise
350 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
combinado I-Premise
y I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
de I-Premise
35 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
sólo I-Premise
endocrinos I-Premise
tuvieron I-Premise
molestias I-Premise
generales I-Premise
de I-Premise
todos I-Premise
los I-Premise
síntomas I-Premise
intestinales I-Premise
( I-Premise
p=0.022 I-Premise
) I-Premise
. I-Premise

281 B-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
de I-Premise
332 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
combinado I-Premise
y I-Premise
227 I-Premise
( I-Premise
72 I-Premise
% I-Premise
) I-Premise
de I-Premise
313 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
sólo I-Premise
endocrinos I-Premise
tenían I-Premise
disfunción I-Premise
eréctil I-Premise
( I-Premise
p=0,0002 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
a I-Premise
los I-Premise
4 I-Premise
años I-Premise
fue I-Premise
similar, I-Premise
con I-Premise
la I-Premise
excepción I-Premise
de I-Premise
la I-Premise
disminución I-Premise
de I-Premise
la I-Premise
función I-Premise
social I-Premise
en I-Premise
las I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
tratamiento I-Premise
endocrino I-Premise
más I-Premise
radioterapia. I-Premise

Aunque B-Claim
la I-Claim
adición I-Claim
de I-Claim
la I-Claim
radioterapia I-Claim
al I-Claim
tratamiento I-Claim
endocrino I-Claim
aumentó I-Claim
significativamente I-Claim
algunos I-Claim
síntomas I-Claim
relacionados I-Claim
con I-Claim
el I-Claim
tratamiento, I-Claim
ninguno I-Claim
fue I-Claim
grave. I-Claim

Dado O
el O
sustancial O
beneficio O
de O
supervivencia O
del O
tratamiento O
combinado O
, O
el B-Claim
aumento I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
parece I-Claim
aceptable I-Claim
y I-Claim
tiene I-Claim
poco I-Claim
efecto I-Claim
adicional I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
después I-Claim
de I-Claim
4 I-Claim
años I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
endocrino I-Claim
solo I-Claim
. O

El O
objetivo O
de O
este O
ensayo O
aleatorio O
fue O
evaluar O
la O
actividad O
y O
toxicidad O
de O
un O
régimen O
quincenal O
que O
incluye O
5-fluorouracilo O
modulado O
con O
6S-leucovorina O
( O
LFA-5-FU O
) O
, O
combinado O
con O
irinotecán O
( O
CPT-11 O
+ O
LFA O
5-FU O
) O
o O
raltitrexed O
( O
Tomudex O
) O
( O
TOM O
+ O
LFA-5-FU O
) O
, O
en O
pacientes O
con O
cáncer O
colorrectal O
avanzado O
, O
y O
hacer O
una O
comparación O
preliminar O
de O
estos O
dos O
regímenes O
experimentales O
con O
una O
administración O
quincenal O
de O
LFA-5-FU O
modulada O
por O
metotrexato O
( O
MTX O
+ O
LFA-5-FU O
) O
. O

Ciento O
cincuenta O
y O
nueve O
pacientes O
con O
carcinoma O
colorrectal O
avanzado O
no O
tratados O
previamente O
para O
la O
enfermedad O
metastásica O
( O
34 O
de O
ellos O
expuestos O
previamente O
a O
5-FU O
adyuvante O
) O
fueron O
asignados O
aleatoriamente O
para O
recibir O
: O
CPT-11 O
, O
200 O
mg/m2 O
i.v O
. O

el O
día O
1 O
, O
seguido O
el O
día O
2 O
por O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

infusión O
y O
5-FU O
, O
850 O
mg/m2 O
s O
i.v O
. O

bolo O
( O
brazo O
A O
) O
; O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

el O
día O
1 O
, O
seguido O
el O
día O
2 O
por O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

infusión O
y O
5-FU O
, O
1050 O
mg/m2 O
i.v O
. O

bolo O
( O
brazo O
B O
) O
; O
o O
MTX O
, O
750 O
mg/m2 O
i.v O
. O

el O
día O
1 O
, O
seguido O
el O
día O
2 O
por O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

infusión O
y O
5-FU O
, O
800 O
mg/m2 O
i.v O
. O

bolo O
( O
brazo O
C O
) O
. O

Los O
cursos O
se O
repitieron O
cada O
dos O
semanas O
en O
todos O
los O
brazos O
del O
ensayo. O

La O
tasa O
de O
respuesta O
( O
RR O
) O
se O
evaluó O
después O
de O
cada O
cuatro O
cursos O
. O

El O
tamaño O
de O
la O
muestra O
se O
definió O
para O
tener O
una O
potencia O
del O
80 O
% O
para O
detectar O
un O
RR O
del O
35 O
% O
para O
cada O
tratamiento O
experimental O
, O
y O
para O
mostrar O
una O
diferencia O
de O
al O
menos O
el O
4 O
% O
en O
el O
RR O
con O
el O
tratamiento O
estándar O
si O
la O
diferencia O
verdadera O
es O
del O
15 O
% O
o O
más O
. O

Los O
RR O
fueron: O
34 O
% O
( O
intervalo O
de O
confianza O
del O
95 O
% O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
-48 O
% O
) O
en O
el O
brazo O
A O
, O
incluyendo O
3 O
respuestas O
completas O
( O
RC O
) O
y O
15 O
respuestas O
parciales O
( O
RP O
) O
, O
24 O
% O
( O
IC O
del O
95 O
% O
: O
14 O
% O
-38 O
% O
) O
en O
el O
brazo O
B O
, O
incluyendo O
2 O
RC O
y O
11 O
RP O
, O
y O
24 O
% O
( O
IC O
del O
95 O
% O
: O
14 O
% O
-38 O
% O
) O
, O
con O
2 O
RC O
y O
11 O
RP O
, O
en O
el O
brazo O
C. O
Después B-Premise
de I-Premise
una I-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
62 I-Premise
( I-Premise
rango I-Premise
18-108 I-Premise
) I-Premise
semanas I-Premise
, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
38 I-Premise
, I-Premise
25 I-Premise
y I-Premise
27 I-Premise
semanas I-Premise
para I-Premise
el I-Premise
brazo I-Premise
A I-Premise
, I-Premise
B I-Premise
y I-Premise
C I-Premise
, I-Premise
respectivamente I-Premise
. O

Con B-Premise
94 I-Premise
pacientes I-Premise
aún I-Premise
vivos, I-Premise
la I-Premise
probabilidad I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
fue I-Premise
del I-Premise
61 I-Premise
%, I-Premise
54 I-Premise
% I-Premise
y I-Premise
59 I-Premise
%, I-Premise
respectivamente. I-Premise

La B-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3 I-Premise
ó I-Premise
4 I-Premise
de I-Premise
la I-Premise
OMS I-Premise
y I-Premise
la I-Premise
diarrea I-Premise
afectaron I-Premise
al I-Premise
46% I-Premise
y I-Premise
al I-Premise
16% I-Premise
, I-Premise
respectivamente, I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
CPT-11 I-Premise
+ I-Premise
LFA I-Premise
5-FU I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
intensidad I-Premise
de I-Premise
la I-Premise
dosis I-Premise
relativa I-Premise
a I-Premise
lo I-Premise
largo I-Premise
de I-Premise
ocho I-Premise
ciclos I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
fue I-Premise
del I-Premise
78 I-Premise
% I-Premise
para I-Premise
el I-Premise
CPT-11 I-Premise
y I-Premise
del I-Premise
82 I-Premise
% I-Premise
para I-Premise
el I-Premise
5-FU I-Premise
. I-Premise

Las B-Premise
toxicidades I-Premise
graves I-Premise
de I-Premise
TOM I-Premise
+ I-Premise
LFA-5-FU I-Premise
fueron I-Premise
la I-Premise
neutropenia I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
y I-Premise
la I-Premise
diarrea I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
pero I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
DI8 I-Premise
relativa I-Premise
fue I-Premise
del I-Premise
93 I-Premise
% I-Premise
para I-Premise
TOM I-Premise
, I-Premise
y I-Premise
del I-Premise
82 I-Premise
% I-Premise
para I-Premise
5-FU I-Premise
. I-Premise

CPT-11 B-Premise
+ I-Premise
LFA-5-FU I-Premise
se I-Premise
compara I-Premise
favorablemente I-Premise
en I-Premise
términos I-Premise
de I-Premise
actividad I-Premise
y I-Premise
toxicidad I-Premise
con I-Premise
otros I-Premise
regímenes I-Premise
combinados I-Premise
que I-Premise
incluyen I-Premise
CPT-11 I-Premise
y I-Premise
5-FU I-Premise
en I-Premise
infusión I-Premise
continua. I-Premise

La B-Claim
hipótesis I-Claim
de I-Claim
un I-Claim
RR I-Claim
un I-Claim
15 I-Claim
% I-Claim
superior I-Claim
al I-Claim
del I-Claim
tratamiento I-Claim
MTX I-Claim
+ I-Claim
LFA-5-FU I-Claim
no I-Claim
puede I-Claim
descartarse I-Claim
tras I-Claim
este I-Claim
análisis I-Claim
intermedio I-Claim
. I-Claim

El B-Claim
régimen I-Claim
TOM I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
mostró I-Claim
un I-Claim
RR I-Claim
y I-Claim
un I-Claim
perfil I-Claim
de I-Claim
toxicidad I-Claim
muy I-Claim
cercano I-Claim
al I-Claim
de I-Claim
la I-Claim
combinación I-Claim
MTX I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
, I-Claim
y I-Claim
no I-Claim
merece I-Claim
más I-Claim
evaluación I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
colorrectal I-Claim
avanzado I-Claim
. I-Claim

La O
quimioterapia O
adyuvante O
para O
el O
cáncer O
de O
pulmón O
no O
microcítico O
(CPNM) O
en O
fase O
inicial O
es O
actualmente O
el O
tratamiento O
estándar, O
pero O
hay O
poca O
información O
sobre O
su O
impacto O
en O
la O
calidad O
de O
vida O
(CdV). O

Informamos O
de O
los O
resultados O
de O
la O
calidad O
de O
vida O
del O
JBR.10, O
un O
ensayo O
norteamericano, O
intergrupal O
y O
aleatorizado O
de O
cisplatino O
y O
vinorelbina O
adyuvantes O
en O
comparación O
con O
la O
observación O
en O
pacientes O
con O
CPNM O
completamente O
resecado, O
en O
estadios O
IB O
a O
II. O

La O
CdV O
se O
evaluó O
con O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
y O
con O
una O
lista O
de O
comprobación O
específica O
del O
ensayo O
al O
inicio O
y O
en O
las O
semanas O
5 O
y O
9 O
para O
los O
que O
recibieron O
quimioterapia O
y O
en O
los O
meses O
de O
seguimiento O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
y O
36 O
. O

Un O
cambio O
de O
10 O
puntos O
en O
las O
puntuaciones O
de O
la O
CdV O
con O
respecto O
al O
inicio O
se O
consideró O
clínicamente O
significativo. O

Cuatrocientos O
ochenta O
y O
dos O
pacientes O
fueron O
asignados O
al O
azar O
en O
JBR.10 O
. O

Un O
total O
de O
173 O
pacientes O
(el O
82% O
de O
los O
previstos) O
en O
el O
brazo O
de O
observación O
y O
186 O
(el O
85% O
de O
los O
previstos) O
en O
el O
brazo O
de O
quimioterapia O
completaron O
las O
evaluaciones O
iniciales O
de O
la O
calidad O
de O
vida. O

Los B-Premise
dos I-Premise
grupos I-Premise
eran I-Premise
comparables, I-Premise
con I-Premise
puntuaciones I-Premise
globales I-Premise
de I-Premise
CdV I-Premise
bajas I-Premise
y I-Premise
una I-Premise
carga I-Premise
sintomática I-Premise
significativa, I-Premise
especialmente I-Premise
dolor I-Premise
y I-Premise
fatiga, I-Premise
tras I-Premise
la I-Premise
toracotomía. I-Premise

Los O
cambios O
en O
la O
CdV O
durante O
la O
quimioterapia O
fueron O
relativamente O
modestos; O
la O
fatiga, B-Premise
las I-Premise
náuseas I-Premise
y I-Premise
los I-Premise
vómitos I-Premise
empeoraron, I-Premise
pero B-Premise
hubo I-Premise
una I-Premise
reducción I-Premise
del I-Premise
dolor I-Premise
y I-Premise
ningún I-Premise
cambio I-Premise
en I-Premise
la I-Premise
CdV I-Premise
global. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
de I-Premise
observación I-Premise
mostraron I-Premise
mejoras I-Premise
considerables I-Premise
en I-Premise
la I-Premise
CdV I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
excepto I-Premise
los I-Premise
síntomas I-Premise
de I-Premise
neuropatía I-Premise
sensorial I-Premise
y I-Premise
pérdida I-Premise
de I-Premise
audición, I-Premise
en I-Premise
los I-Premise
tratados I-Premise
con I-Premise
quimioterapia I-Premise
volvió I-Premise
a I-Premise
ser I-Premise
la I-Premise
misma I-Premise
que I-Premise
en I-Premise
los I-Premise
primeros I-Premise
9 I-Premise
meses. I-Premise

Los B-Claim
resultados I-Claim
de I-Claim
este I-Claim
ensayo I-Claim
indican I-Claim
que I-Claim
los I-Claim
efectos I-Claim
negativos I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
adyuvante I-Claim
sobre I-Claim
la I-Claim
CdV I-Claim
parecen I-Claim
ser I-Claim
temporales I-Claim
, I-Claim
y I-Claim
que I-Claim
es I-Claim
probable I-Claim
que I-Claim
se I-Claim
produzcan I-Claim
mejoras I-Claim
( I-Claim
con I-Claim
un I-Claim
retorno I-Claim
a I-Claim
la I-Claim
función I-Claim
de I-Claim
base I-Claim
) I-Claim
en I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
. I-Claim

Los O
resultados O
prometedores O
en O
un O
ensayo O
aleatorio O
de O
fase O
II O
con O
la O
citotoxina O
hipóxica O
tirapazamina O
( O
TPZ O
) O
combinada O
con O
cisplatino O
( O
CIS O
) O
y O
radiación O
llevaron O
a O
este O
ensayo O
de O
fase O
III O
. O

Los O
pacientes O
con O
carcinoma O
de O
células O
escamosas O
de O
la O
cavidad O
oral, O
la O
orofaringe, O
la O
hipofaringe O
o O
la O
laringe O
en O
estadio O
III O
o O
IV O
( O
excluyendo O
T1-2N1 O
y O
M1 O
) O
no O
tratados O
previamente O
fueron O
asignados O
al O
azar O
para O
recibir O
radioterapia O
definitiva O
( O
70 O
Gy O
en O
7 O
semanas O
) O
simultáneamente O
con O
CIS O
( O
100 O
mg/m O
( O
2 O
) O
) O
el O
día O
1 O
de O
las O
semanas O
1 O
, O
4 O
y O
7 O
o O
CIS O
( O
75 O
mg/m O
( O
2 O
) O
) O
más O
TPZ O
( O
290 O
mg/m O
( O
2 O
) O
/d O
) O
el O
día O
1 O
de O
las O
semanas O
1, O
4 O
y O
7 O
y O
TPZ O
solo O
( O
160 O
mg/m O
( O
2 O
) O
/d O
) O
los O
días O
1, O
3 O
y O
5 O
de O
las O
semanas O
2 O
y O
3 O
( O
TPZ/CIS O
) O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
supervivencia O
global O
(SG). O

El O
tamaño O
de O
la O
muestra O
previsto O
era O
de O
850, O
con O
un O
resultado O
estimado O
de O
334 O
muertes, O
lo O
que O
proporcionaría O
una O
potencia O
del O
90 O
% O
para O
detectar O
una O
diferencia O
en O
las O
tasas O
de O
supervivencia O
a O
los O
2 O
años O
del O
60 O
% O
frente O
al O
70 O
% O
en O
el O
caso O
del O
SIC O
frente O
al O
TPZ/CIS, O
respectivamente O
( O
cociente O
de O
riesgos O
= O
0,69 O
) O
. O

Se O
registraron O
860 O
pacientes O
en O
89 O
centros O
de O
16 O
países. O

En B-Premise
un I-Premise
análisis I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar, I-Premise
las I-Premise
tasas I-Premise
de I-Premise
SG I-Premise
a I-Premise
dos I-Premise
años I-Premise
fueron I-Premise
del I-Premise
65,7% I-Premise
para I-Premise
el I-Premise
SIC I-Premise
y I-Premise
del I-Premise
66,2% I-Premise
para I-Premise
el I-Premise
TPZ/CIS I-Premise
( I-Premise
TPZ/CIS I-Premise
-- I-Premise
CIS I-Premise
: I-Premise
IC I-Premise
del I-Premise
95% I-Premise
, I-Premise
-5,9% I-Premise
a I-Premise
6,9% I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
fracasos, I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
fracaso I-Premise
locorregional I-Premise
o I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
medida I-Premise
por I-Premise
la I-Premise
Evaluación I-Premise
Funcional I-Premise
de I-Premise
la I-Premise
Terapia I-Premise
del I-Premise
Cáncer-Cabeza I-Premise
y I-Premise
Cuello. I-Premise

No B-Claim
se I-Claim
encontraron I-Claim
pruebas I-Claim
de I-Claim
que I-Claim
la I-Claim
adición I-Claim
de I-Claim
TPZ I-Claim
a I-Claim
la I-Claim
quimiorradioterapia I-Claim
, I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
cabeza I-Claim
y I-Claim
cuello I-Claim
avanzado I-Claim
no I-Claim
seleccionados I-Claim
por I-Claim
la I-Claim
presencia I-Claim
de I-Claim
hipoxia I-Claim
, I-Claim
mejore I-Claim
la I-Claim
SG I-Claim
. I-Claim

La O
combinación O
de O
carboplatino O
y O
paclitaxel O
es O
el O
tratamiento O
estándar O
para O
el O
cáncer O
de O
ovario, O
pero O
las O
tasas O
de O
recurrencia O
y O
muerte O
siguen O
siendo O
altas. O

Realizamos O
un O
estudio O
prospectivo O
aleatorio O
de O
fase O
III O
para O
examinar O
si O
la O
administración O
secuencial O
de O
topotecán O
puede O
mejorar O
la O
eficacia O
del O
carboplatino O
y O
el O
paclitaxel O
en O
el O
tratamiento O
de O
primera O
línea O
del O
cáncer O
de O
ovario O
epitelial O
avanzado O
. O

Un O
total O
de O
1308 O
pacientes O
con O
cáncer O
de O
ovario O
no O
tratado O
previamente O
(estadios O
IIB-IV O
de O
la O
Federación O
Internacional O
de O
Ginecología O
y O
Obstetricia) O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
seis O
ciclos O
de O
paclitaxel O
y O
carboplatino O
seguidos O
de O
cuatro O
ciclos O
de O
topotecán O
( O
TC-Top O
; O
658 O
pacientes O
) O
o O
de O
vigilancia O
( O
TC O
; O
650 O
pacientes O
) O
en O
un O
esquema O
de O
3 O
semanas O
por O
ciclo O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
supervivencia O
global, O
y O
los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
supervivencia O
sin O
progresión, O
la O
tasa O
de O
respuesta, O
la O
toxicidad O
y O
la O
calidad O
de O
vida. O

Los O
datos O
de O
tiempo O
hasta O
el O
acontecimiento O
se O
analizaron O
mediante O
el O
método O
de O
Kaplan-Meier, O
y O
se O
utilizó O
una O
prueba O
de O
rango O
logarítmico O
estratificada O
para O
comparar O
las O
distribuciones O
entre O
los O
grupos O
de O
tratamiento. O

Se O
estimaron O
los O
cocientes O
de O
riesgos O
(HR) O
con O
intervalos O
de O
confianza O
(CI) O
del O
95 O
% O
mediante O
un O
modelo O
de O
riesgos O
proporcionales O
de O
Cox. O

Los O
datos O
categóricos O
se O
compararon O
mediante O
una O
prueba O
estratificada O
de O
Cochran-Mantel-Haenszel. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
18,2 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
TC-Top I-Premise
frente I-Premise
a I-Premise
18,5 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
TC I-Premise
( I-Premise
HR I-Premise
ajustado I-Premise
por I-Premise
estrato I-Premise
= I-Premise
0,97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0,85 I-Premise
a I-Premise
1,10 I-Premise
] I-Premise
; I-Premise
P I-Premise
= I-Premise
.688 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
43,1 I-Premise
meses I-Premise
para I-Premise
el I-Premise
brazo I-Premise
TC-Top I-Premise
frente I-Premise
a I-Premise
44,5 I-Premise
meses I-Premise
para I-Premise
el I-Premise
brazo I-Premise
TC I-Premise
( I-Premise
HR I-Premise
ajustado I-Premise
por I-Premise
estrato I-Premise
= I-Premise
1,01 I-Premise
[ I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,86 I-Premise
a I-Premise
1,18 I-Premise
] I-Premise
; I-Premise
P I-Premise
= I-Premise
.885 I-Premise
) I-Premise
. I-Premise

A B-Premise
los I-Premise
3 I-Premise
años, I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
fue I-Premise
del I-Premise
57% I-Premise
( I-Premise
58,5% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
TC I-Premise
y I-Premise
55,7% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
TC-Top I-Premise
) I-Premise
. I-Premise

En B-Premise
comparación I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
TC, I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
TC-Top I-Premise
tuvieron I-Premise
más I-Premise
efectos I-Premise
tóxicos I-Premise
hematológicos I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
( I-Premise
que I-Premise
requirieron I-Premise
más I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
) I-Premise
y I-Premise
más I-Premise
infecciones I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
( I-Premise
5,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
2,7 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,034 I-Premise
) I-Premise
pero I-Premise
no I-Premise
tuvieron I-Premise
un I-Premise
aumento I-Premise
estadísticamente I-Premise
significativo I-Premise
de I-Premise
la I-Premise
neutropenia I-Premise
febril I-Premise
( I-Premise
3,3 I-Premise
% I-Premise
frente I-Premise
a I-Premise
3,1 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,80 I-Premise
) I-Premise
. I-Premise

Entre B-Premise
los I-Premise
pacientes I-Premise
que I-Premise
tenían I-Premise
enfermedad I-Premise
medible I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
; I-Premise
TC-Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
la I-Premise
respuesta I-Premise
global I-Premise
( I-Premise
es I-Premise
decir, I-Premise
completa I-Premise
o I-Premise
parcial I-Premise
) I-Premise
fue I-Premise
del I-Premise
69,0 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
61,4 I-Premise
% I-Premise
a I-Premise
76,5 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
TC-Top I-Premise
y I-Premise
del I-Premise
76,2 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
69,3 I-Premise
% I-Premise
a I-Premise
83,1 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
TC I-Premise
( I-Premise
P I-Premise
= I-Premise
.166 I-Premise
) I-Premise
. I-Premise

La B-Claim
adición I-Claim
secuencial I-Claim
de I-Claim
topotecán I-Claim
a I-Claim
carboplatino-paclitaxel I-Claim
no I-Claim
dio I-Claim
lugar I-Claim
a I-Claim
una I-Claim
respuesta I-Claim
global I-Claim
superior I-Claim
ni I-Claim
a I-Claim
una I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
o I-Claim
global. I-Claim

Por B-Claim
lo I-Claim
tanto, I-Claim
este I-Claim
régimen I-Claim
no I-Claim
se I-Claim
recomienda I-Claim
como I-Claim
tratamiento I-Claim
estándar I-Claim
para I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
ovario. I-Claim

Para O
examinar O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
, O
se O
investigó O
el O
efecto O
de O
los O
regímenes O
de O
quimioterapia O
adyuvante O
en O
las O
puntuaciones O
de O
utilidad O
evaluadas O
por O
el O
instrumento O
EuroQoL-5D O
( O
EQ-5D O
) O
en O
un O
ensayo O
aleatorio O
y O
controlado O
para O
pacientes O
con O
cáncer O
de O
mama O
después O
de O
la O
cirugía O
. O

También O
se O
investigó O
la O
relación O
entre O
las O
puntuaciones O
de O
la O
escala O
de O
Evaluación O
Funcional O
del O
Tratamiento O
del O
Cáncer O
( O
FACT O
) O
y O
las O
utilidades O
del O
EQ-5D O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
los O
siguientes O
cuatro O
regímenes O
de O
quimioterapia: O
cuatro O
ciclos O
de O
antraciclina O
seguidos O
de O
paclitaxel O
( O
ACP O
) O
, O
cuatro O
ciclos O
de O
regímenes O
que O
contienen O
antraciclina O
seguidos O
de O
docetaxel O
( O
ACD O
) O
, O
ocho O
ciclos O
de O
paclitaxel O
( O
PTX O
) O
y O
ocho O
ciclos O
de O
docetaxel O
( O
DTX O
) O
. O

De O
los O
1060 O
registrados, O
los O
primeros O
300 O
pacientes O
consecutivos O
se O
incluyeron O
en O
el O
presente O
estudio O
de O
utilidad. O

Las O
puntuaciones O
de O
utilidad O
se O
evaluaron O
mediante O
el O
instrumento O
EQ-5D O
al O
inicio, O
en O
los O
ciclos O
3, O
5 O
y O
7, O
a O
los O
7 O
meses O
y O
al O
año. O

También O
evaluamos O
la O
correlación O
entre O
estas O
puntuaciones O
y O
las O
puntuaciones O
de O
FACT-G O
, O
-B O
y O
-Taxane O
en O
cada O
punto O
temporal. O

Las B-Premise
puntuaciones I-Premise
de I-Premise
utilidad I-Premise
fueron I-Premise
significativamente I-Premise
menores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
DTX I-Premise
que I-Premise
en I-Premise
los I-Premise
grupos I-Premise
ACP I-Premise
y I-Premise
ACD I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
medias I-Premise
de I-Premise
utilidad I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
DTX I-Premise
fueron I-Premise
las I-Premise
más I-Premise
bajas I-Premise
a I-Premise
los I-Premise
7 I-Premise
meses I-Premise
y I-Premise
tendieron I-Premise
a I-Premise
mantenerse I-Premise
bajas I-Premise
durante I-Premise
mucho I-Premise
tiempo. I-Premise

El B-Premise
grupo I-Premise
de I-Premise
antraciclina I-Premise
combinada I-Premise
seguida I-Premise
de I-Premise
taxano I-Premise
tuvo I-Premise
puntuaciones I-Premise
de I-Premise
utilidad I-Premise
significativamente I-Premise
más I-Premise
altas I-Premise
que I-Premise
el I-Premise
grupo I-Premise
de I-Premise
taxano I-Premise
solo I-Premise
, I-Premise
sin I-Premise
diferencias I-Premise
significativas I-Premise
según I-Premise
el I-Premise
tipo I-Premise
de I-Premise
taxano I-Premise
. I-Premise

Sólo B-Premise
la I-Premise
subescala I-Premise
de I-Premise
bienestar I-Premise
social/familiar I-Premise
del I-Premise
FACT-G I-Premise
no I-Premise
tuvo I-Premise
relación I-Premise
con I-Premise
las I-Premise
respuestas I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
utilidad I-Premise
del I-Premise
EQ-5D. I-Premise

Aunque B-Claim
los I-Claim
regímenes I-Claim
de I-Claim
este I-Claim
estudio I-Claim
eran I-Claim
similares I-Claim
en I-Claim
el I-Claim
sentido I-Claim
de I-Claim
que I-Claim
incluían I-Claim
taxanos, I-Claim
las I-Claim
puntuaciones I-Claim
medias I-Claim
de I-Claim
utilidad I-Claim
y I-Claim
los I-Claim
patrones I-Claim
longitudinales I-Claim
de I-Claim
las I-Claim
puntuaciones I-Claim
de I-Claim
utilidad I-Claim
eran I-Claim
diferentes I-Claim
entre I-Claim
los I-Claim
regímenes. I-Claim

La O
terapia O
fotodinámica O
tópica O
( O
TFD O
) O
con O
ácido O
aminolevulínico O
( O
ALA O
) O
y O
la O
crema O
de O
imiquimod O
al O
5 O
% O
son O
terapias O
eficaces O
para O
el O
tratamiento O
de O
las O
queratosis O
actínicas O
( O
QA O
) O
, O
pero O
en O
la O
literatura O
no O
hay O
estudios O
de O
cara O
dividida O
que O
comparen O
directamente O
estas O
opciones O
de O
tratamiento O
. O

Comparar O
la O
eficacia O
y O
la O
tolerabilidad O
de O
ALA-PDT O
y O
de O
la O
crema O
de O
imiquimod O
5 O
% O
para O
el O
tratamiento O
de O
las O
QA. O

Se O
inscribieron O
61 O
pacientes O
del O
Salt O
Lake O
City O
Veterans O
Affairs O
Hospital; O
51 O
completaron O
el O
estudio O
y O
se O
incluyeron O
en O
el O
análisis. O

Todos O
los O
pacientes O
fueron O
asignados O
al O
azar O
para O
recibir O
la O
mitad O
de O
un O
sobre O
de O
crema O
de O
imiquimod O
al O
5 O
% O
dos O
veces O
por O
semana O
en O
la O
mitad O
de O
la O
cara O
y O
dos O
sesiones O
de O
TFD O
con O
una O
solución O
de O
ALA O
al O
20 O
% O
aplicada O
durante O
1 O
hora O
en O
el O
otro O
lado O
de O
la O
cara O
. O

La B-Premise
tasa I-Premise
de I-Premise
eliminación I-Premise
del I-Premise
75% I-Premise
de I-Premise
la I-Premise
AK I-Premise
fue I-Premise
del I-Premise
34,6% I-Premise
para I-Premise
el I-Premise
ALA-PDT I-Premise
y I-Premise
del I-Premise
25% I-Premise
para I-Premise
la I-Premise
crema I-Premise
de I-Premise
imiquimod I-Premise
al I-Premise
5% I-Premise
( I-Premise
p I-Premise
= I-Premise
0,30 I-Premise
) I-Premise
. I-Premise

La B-Premise
reducción I-Premise
media I-Premise
del I-Premise
recuento I-Premise
de I-Premise
QA I-Premise
fue I-Premise
del I-Premise
59,2 I-Premise
% I-Premise
para I-Premise
el I-Premise
ALA-PDT I-Premise
y I-Premise
del I-Premise
41,4 I-Premise
% I-Premise
para I-Premise
la I-Premise
crema I-Premise
de I-Premise
imiquimod I-Premise
al I-Premise
5 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
del I-Premise
Índice I-Premise
de I-Premise
Calidad I-Premise
de I-Premise
Vida I-Premise
Dermatológica I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
se I-Premise
evaluaron I-Premise
para I-Premise
cada I-Premise
modalidad I-Premise
de I-Premise
tratamiento I-Premise
en I-Premise
la I-Premise
semana I-Premise
4 I-Premise
y I-Premise
fueron I-Premise
de I-Premise
1,95 I-Premise
y I-Premise
1,38 I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
p I-Premise
= I-Premise
0,20 I-Premise
) I-Premise
. I-Premise

El B-Premise
tamaño I-Premise
de I-Premise
la I-Premise
muestra I-Premise
era I-Premise
pequeño, I-Premise
y I-Premise
los I-Premise
pacientes I-Premise
se I-Premise
aplicaron I-Premise
una I-Premise
pequeña I-Premise
cantidad I-Premise
de I-Premise
crema I-Premise
de I-Premise
imiquimod I-Premise
al I-Premise
5% I-Premise
( I-Premise
medio I-Premise
sobre I-Premise
) I-Premise
en I-Premise
una I-Premise
gran I-Premise
superficie. I-Premise

No B-Claim
hubo I-Claim
diferencias I-Claim
estadísticamente I-Claim
significativas I-Claim
en I-Claim
la I-Claim
respuesta I-Claim
al I-Claim
tratamiento I-Claim
cuando I-Claim
se I-Claim
utilizó I-Claim
la I-Claim
tasa I-Claim
de I-Claim
eliminación I-Claim
del I-Claim
100 I-Claim
% I-Claim
o I-Claim
del I-Claim
75 I-Claim
%, O
pero B-Claim
nuestro I-Claim
resultado I-Claim
secundario I-Claim
sugiere I-Claim
que I-Claim
dos I-Claim
sesiones I-Claim
de I-Claim
ALA-PDT I-Claim
son I-Claim
superiores I-Claim
a I-Claim
la I-Claim
crema I-Claim
de I-Claim
imiquimod I-Claim
al I-Claim
5 I-Claim
% I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
las I-Claim
QA. I-Claim

No B-Claim
hubo I-Claim
diferencias I-Claim
estadísticamente I-Claim
significativas I-Claim
en I-Claim
el I-Claim
efecto I-Claim
sobre I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
evaluada I-Claim
mediante I-Claim
el I-Claim
DLQI I-Claim
. I-Claim

El O
objetivo O
fue O
investigar O
la O
eficacia, O
la O
tolerabilidad O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
de O
la O
gemcitabina O
( O
GEM O
) O
en O
comparación O
con O
la O
doxorrubicina O
liposomal O
pegilada O
( O
PLD O
) O
en O
el O
tratamiento O
de O
rescate O
del O
cáncer O
de O
ovario O
recurrente O
. O

Se O
planificó O
un O
ensayo O
multicéntrico O
aleatorizado O
de O
fase O
III O
para O
comparar O
GEM O
( O
1.000 O
mg/m O
( O
2 O
) O
en O
los O
días O
1 O
, O
8 O
y O
15 O
cada O
28 O
días O
) O
con O
PLD O
( O
40 O
mg/m O
( O
2 O
) O
cada O
28 O
días O
) O
en O
pacientes O
con O
cáncer O
de O
ovario O
que O
experimentaron O
el O
fracaso O
del O
tratamiento O
con O
un O
solo O
régimen O
de O
platino/paclitaxel O
y O
que O
experimentaron O
recurrencia O
o O
progresión O
dentro O
de O
los O
12 O
meses O
posteriores O
a O
la O
finalización O
del O
tratamiento O
primario O
. O

Ciento O
cincuenta O
y O
tres O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
PLD O
( O
n O
= O
76 O
) O
o O
GEM O
( O
n O
= O
77 O
) O
. O

Los O
brazos O
de O
tratamiento O
estaban O
bien O
equilibrados O
en O
cuanto O
a O
las O
características O
clinicopatológicas. O

La O
neutropenia O
de O
grado O
3 O
ó O
4 O
fue O
más O
frecuente O
en O
los O
pacientes O
tratados O
con O
GEM O
que O
en O
los O
tratados O
con O
PLD O
( O
P O
= O
.007 O
) O
. O

La O
eritrodisestesia O
palmo-plantar O
de O
grado O
3 O
o O
4 O
se O
documentó O
en O
una O
proporción O
mayor O
de O
pacientes O
con O
PLD O
( O
6 O
% O
) O
frente O
a O
los O
pacientes O
con O
GEM O
( O
0 O
% O
; O
P O
= O
.061 O
) O
. O

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
global I-Premise
fue I-Premise
del I-Premise
16% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
PLD, I-Premise
frente I-Premise
al I-Premise
29% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
GEM I-Premise
( I-Premise
P I-Premise
= I-Premise
.056 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
documentaron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
las I-Premise
curvas I-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
( I-Premise
TTP I-Premise
) I-Premise
según I-Premise
la I-Premise
asignación I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
= I-Premise
.411 I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
se I-Premise
documentó I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
una I-Premise
supervivencia I-Premise
global I-Premise
más I-Premise
favorable I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
PLD I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
brazo I-Premise
de I-Premise
GEM, I-Premise
aunque B-Premise
el I-Premise
valor I-Premise
P I-Premise
fue I-Premise
de I-Premise
significación I-Premise
estadística I-Premise
límite I-Premise
( I-Premise
P I-Premise
= I-Premise
0,048 I-Premise
) O
. O

Las B-Premise
puntuaciones I-Premise
globales I-Premise
de I-Premise
la I-Premise
CdV I-Premise
fueron I-Premise
significativamente I-Premise
más I-Premise
altas I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
PLD I-Premise
en I-Premise
la I-Premise
primera I-Premise
y I-Premise
segunda I-Premise
evaluación I-Premise
de I-Premise
la I-Premise
CdV. I-Premise

El B-Claim
GEM I-Claim
no I-Claim
proporciona I-Claim
una I-Claim
ventaja I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
PLD I-Claim
en I-Claim
términos I-Claim
de I-Claim
TTP I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
que I-Claim
experimentan I-Claim
una I-Claim
recurrencia I-Claim
dentro I-Claim
de I-Claim
los I-Claim
12 I-Claim
meses I-Claim
posteriores I-Claim
al I-Claim
tratamiento I-Claim
primario, I-Claim
pero I-Claim
debería I-Claim
considerarse I-Claim
en I-Claim
el I-Claim
espectro I-Claim
de I-Claim
fármacos I-Claim
que I-Claim
posiblemente I-Claim
se I-Claim
utilicen I-Claim
en I-Claim
el I-Claim
entorno I-Claim
de I-Claim
rescate I-Claim
. I-Claim

El O
objetivo O
de O
este O
ensayo O
aleatorio O
multicéntrico O
fue O
evaluar O
la O
eficacia O
y O
la O
seguridad O
de O
la O
biopsia O
del O
ganglio O
linfático O
centinela O
( O
SLN O
) O
en O
comparación O
con O
la O
disección O
de O
los O
ganglios O
linfáticos O
axilares O
( O
ALND O
) O
. O

Todos O
los O
estudios O
sobre O
la O
biopsia O
de O
GLC O
en O
el O
cáncer O
de O
mama O
informan O
de O
una O
tasa O
variable O
de O
falsos O
negativos, O
cuyas O
consecuencias O
pronósticas O
aún O
no O
están O
claras. O

Desde O
mayo O
de O
1999 O
hasta O
diciembre O
de O
2004, O
las O
pacientes O
con O
cáncer O
de O
mama O
< O
o O
=3 O
cm O
fueron O
asignadas O
aleatoriamente O
para O
recibir O
una O
biopsia O
de O
GLC O
asociada O
a O
la O
DGLA O
( O
brazo O
de O
DGLA O
) O
o O
una O
biopsia O
de O
GLC O
seguida O
de O
DGLA O
sólo O
si O
el O
GLC O
era O
metastásico O
( O
brazo O
de O
DGLA O
) O
. O

El O
objetivo O
principal O
era O
la O
comparación O
de O
la O
supervivencia O
libre O
de O
enfermedad O
en O
los O
dos O
brazos. O

Un O
total O
de O
749 O
pacientes O
fueron O
aleatorizados O
y O
697 O
estaban O
disponibles O
para O
el O
análisis. O

Se O
identificaron O
GLCs O
en O
662 O
de O
697 O
pacientes O
( O
95 O
% O
) O
y O
se O
encontraron O
GLCs O
positivos O
en O
189 O
de O
662 O
pacientes O
( O
28,5 O
% O
) O
. O

En O
el O
grupo O
de O
ALND O
, O
se O
encontraron O
NPS O
positivos O
en O
18 O
pacientes O
con O
NPS O
negativos O
, O
lo O
que O
supone O
una O
tasa O
de O
falsos O
negativos O
del O
16,7% O
( O
18 O
de O
108 O
) O
. O

Los B-Premise
efectos I-Premise
secundarios I-Premise
postoperatorios I-Premise
fueron I-Premise
significativamente I-Premise
menores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
SLN I-Premise
y I-Premise
no I-Premise
hubo I-Premise
ningún I-Premise
impacto I-Premise
negativo I-Premise
del I-Premise
procedimiento I-Premise
de I-Premise
SLN I-Premise
en I-Premise
el I-Premise
bienestar I-Premise
psicológico. I-Premise

En O
una O
mediana O
de O
seguimiento O
de O
56 O
meses, O
hubo O
más O
recidivas O
locorregionales O
en O
el O
brazo O
de O
SLN, O
y O
la O
supervivencia O
libre O
de O
enfermedad O
a O
5 O
años O
fue O
del O
89,9% O
en O
el O
brazo O
de O
ALND O
y O
del O
87,6% O
en O
el O
brazo O
de O
SLN, O
con O
una O
diferencia O
del O
2,3% O
( O
intervalo O
de O
confianza O
del O
95%: O
-3,1% O
a O
7,6% O
) O
. O

Sin B-Premise
embargo, I-Premise
el I-Premise
número I-Premise
de I-Premise
pacientes I-Premise
inscritos I-Premise
no I-Premise
fue I-Premise
suficiente I-Premise
para I-Premise
sacar I-Premise
conclusiones I-Premise
definitivas. I-Premise

La B-Claim
biopsia I-Claim
del I-Claim
GLC I-Claim
es I-Claim
un I-Claim
procedimiento I-Claim
eficaz I-Claim
y I-Claim
bien I-Claim
tolerado. I-Claim

Sin B-Claim
embargo, I-Claim
su I-Claim
seguridad I-Claim
debe I-Claim
ser I-Claim
confirmada I-Claim
por I-Claim
los I-Claim
resultados I-Claim
de I-Claim
ensayos I-Claim
aleatorios I-Claim
y I-Claim
meta-análisis I-Claim
más I-Claim
amplios. I-Claim

La O
administración O
nocturna O
de O
gránulos O
de O
aminoácidos O
de O
cadena O
ramificada O
( O
BCAA O
) O
mejora O
los O
niveles O
de O
albúmina O
sérica O
en O
pacientes O
con O
cirrosis O
. O

Sin O
embargo, O
no O
está O
claro O
si O
este O
método O
de O
administración O
puede O
mejorar O
la O
calidad O
de O
vida O
(QOL) O
de O
los O
pacientes. O

En O
este O
estudio, O
nos O
propusimos O
investigar O
la O
eficacia O
de O
los O
gránulos O
de O
BCAA, O
administrados O
por O
la O
noche, O
para O
mejorar O
la O
calidad O
de O
vida O
de O
estos O
pacientes. O

Se O
realizó O
un O
ensayo O
controlado O
aleatorio O
multicéntrico O
que O
examinó O
los O
efectos O
comparativos O
de O
los O
gránulos O
de O
BCAA O
administrados O
por O
vía O
oral O
durante O
3 O
meses O
con O
administración O
diurna O
o O
nocturna O
en O
pacientes O
con O
cirrosis O
compensada. O

La O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
se O
midió O
mediante O
una O
versión O
japonesa O
del O
cuestionario O
sobre O
síntomas O
subjetivos O
y O
objetivos O
, O
y O
el O
cuestionario O
Short O
Form-8 O
( O
SF-8 O
) O
. O

Veintiún O
pacientes O
recibieron O
gránulos O
de O
BCAA O
tres O
veces O
al O
día O
( O
un O
sobre O
después O
de O
cada O
comida O
: O
el O
grupo O
diurno O
) O
, O
y O
16 O
pacientes O
recibieron O
los O
gránulos O
dos O
veces O
al O
día O
( O
un O
sobre O
después O
del O
desayuno O
, O
y O
dos O
sobres O
antes O
de O
acostarse O
: O
el O
grupo O
nocturno O
) O
. O

Las O
características O
iniciales O
no O
difirieron O
entre O
los O
grupos O
( O
cohorte O
completa O
: O
grado O
A/B O
de O
Child-Pugh O
, O
21/16 O
; O
edad O
media O
, O
68,2 O
años O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
ninguno I-Premise
de I-Premise
los I-Premise
sujetos I-Premise
reveladas I-Premise
por I-Premise
el I-Premise
cuestionario I-Premise
relativo I-Premise
a I-Premise
los I-Premise
síntomas I-Premise
subjetivos I-Premise
u I-Premise
objetivos I-Premise
, I-Premise
o I-Premise
por I-Premise
el I-Premise
SF-8 I-Premise
entre I-Premise
el I-Premise
grupo I-Premise
diurno I-Premise
y I-Premise
el I-Premise
grupo I-Premise
nocturno I-Premise
después I-Premise
de I-Premise
3 I-Premise
meses I-Premise
de I-Premise
tratamiento I-Premise
. I-Premise

El B-Premise
grupo I-Premise
diurno I-Premise
mostró I-Premise
un I-Premise
efecto I-Premise
significativo I-Premise
en I-Premise
la I-Premise
salud I-Premise
general, I-Premise
la I-Premise
vitalidad, I-Premise
el I-Premise
funcionamiento I-Premise
social, I-Premise
la I-Premise
salud I-Premise
mental I-Premise
y I-Premise
el I-Premise
rol I-Premise
emocional, I-Premise
tal I-Premise
y I-Premise
como I-Premise
revela I-Premise
el I-Premise
SF-8. I-Premise

Por B-Premise
el I-Premise
contrario, I-Premise
el I-Premise
grupo I-Premise
nocturno I-Premise
mostró I-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
en I-Premise
la I-Premise
aparición I-Premise
de I-Premise
calambres I-Premise
musculares I-Premise
en I-Premise
las I-Premise
piernas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,014 I-Premise
) I-Premise
y I-Premise
mejoró I-Premise
significativamente I-Premise
la I-Premise
relación I-Premise
de I-Premise
Fisher I-Premise
después I-Premise
de I-Premise
3 I-Premise
meses I-Premise
( I-Premise
P I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
. I-Premise

La B-Claim
administración I-Claim
nocturna I-Claim
de I-Claim
gránulos I-Claim
de I-Claim
BCAA I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cirrosis I-Claim
redujo I-Claim
la I-Claim
aparición I-Claim
de I-Claim
calambres I-Claim
musculares I-Claim
en I-Claim
las I-Claim
piernas, I-Claim
pero I-Claim
no I-Claim
mejoró I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes. I-Claim

El O
tratamiento O
de O
los O
pacientes O
con O
adenocarcinoma O
esofagogástrico O
avanzado O
o O
metastásico O
no O
sólo O
debe O
prolongar O
la O
vida, O
sino O
también O
proporcionar O
alivio O
de O
los O
síntomas O
y O
mejorar O
la O
calidad O
de O
vida O
( O
QOL O
) O
. O

El O
adenocarcinoma O
esofagogástrico O
se O
da O
principalmente O
en O
pacientes O
de O
edad O
avanzada, O
pero O
están O
infrarrepresentados O
en O
la O
mayoría O
de O
los O
ensayos O
clínicos O
y O
a O
menudo O
no O
reciben O
una O
quimioterapia O
combinada O
eficaz, O
muy O
probablemente O
por O
miedo O
a O
la O
intolerancia. O

Utilizando O
instrumentos O
validados O
, O
evaluamos O
prospectivamente O
la O
CdV O
dentro O
del O
ensayo O
aleatorio O
de O
fase O
II O
FLOT65+ O
. O

Dentro O
del O
ensayo O
FLOT65+ O
, O
un O
total O
de O
143 O
pacientes O
de O
edad O
≥65 O
años O
fueron O
asignados O
aleatoriamente O
a O
recibir O
oxaliplatino O
quincenal O
más O
infusión O
continua O
de O
5-fluorouracilo O
( O
5-FU O
) O
y O
ácido O
folínico O
( O
FLO O
) O
o O
el O
mismo O
régimen O
en O
combinación O
con O
docetaxel O
50 O
mg/m O
( O
2 O
) O
( O
FLOT O
) O
. O

El O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
QLQ-C30 O
) O
y O
el O
módulo O
gástrico O
STO22 O
se O
administraron O
cada O
8 O
semanas O
hasta O
la O
progresión O
. O

Se O
analizó O
el O
tiempo O
hasta O
el O
deterioro O
definitivo O
de O
los O
parámetros O
de O
la O
CdV O
y O
se O
comparó O
dentro O
de O
los O
brazos O
de O
tratamiento O
. O

La O
edad O
media O
de O
los O
pacientes O
era O
de O
70 O
años. O

Los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
FLOT I-Premise
mostraron I-Premise
mayores I-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
y I-Premise
tuvieron I-Premise
una I-Premise
mejor I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
enfermedad I-Premise
y I-Premise
de I-Premise
progresión I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

Las O
proporciones O
de O
pacientes O
con O
cuestionarios O
EORTC O
QLQ-C30 O
y O
STO22 O
evaluables O
al O
inicio O
del O
estudio O
estaban O
equilibradas O
( O
83 O
% O
en O
FLOT O
y O
89 O
% O
en O
FLO O
) O
. O

Considerando O
los O
pacientes O
evaluables O
con O
cuestionarios O
evaluables O
( O
n O
= O
123 O
) O
, O
ni O
los O
parámetros O
de O
funcionamiento O
ni O
los O
de O
síntomas O
difirieron O
significativamente O
a O
favor O
de O
uno O
de O
los O
dos O
grupos O
de O
tratamiento O
. O

En O
particular, O
no B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
con I-Premise
respecto I-Premise
al I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
deterioro I-Premise
definitivo I-Premise
del I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global/calidad I-Premise
de I-Premise
vida I-Premise
desde I-Premise
el I-Premise
punto I-Premise
de I-Premise
partida I-Premise
( I-Premise
punto I-Premise
final I-Premise
primario O
) O
. O

En O
particular, O
los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
FLO I-Premise
o I-Premise
FLOT I-Premise
como I-Premise
tratamiento I-Premise
paliativo I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
obtuvieron I-Premise
resultados I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
comparables. I-Premise

Aunque B-Premise
la I-Premise
toxicidad I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
FLOT, I-Premise
no B-Premise
se I-Premise
pudo I-Premise
demostrar I-Premise
ningún I-Premise
impacto I-Premise
negativo I-Premise
de I-Premise
la I-Premise
adición I-Premise
de I-Premise
docetaxel I-Premise
en I-Premise
los I-Premise
parámetros I-Premise
de I-Premise
la I-Premise
CdV. I-Premise

Así O
pues, O
los B-Claim
pacientes I-Claim
de I-Claim
edad I-Claim
avanzada I-Claim
que I-Claim
necesiten I-Claim
una I-Claim
quimioterapia I-Claim
intensificada I-Claim
pueden I-Claim
recibir I-Claim
FLOT I-Claim
sin I-Claim
que I-Claim
se I-Claim
vean I-Claim
comprometidos I-Claim
los I-Claim
parámetros I-Claim
de I-Claim
resultados I-Claim
comunicados I-Claim
por I-Claim
los I-Claim
pacientes. I-Claim

Comparar O
las O
toxicidades, O
el O
control O
del O
tumor, O
la O
supervivencia O
y O
la O
calidad O
de O
vida O
de O
los O
pacientes O
con O
cáncer O
nasofaríngeo O
( O
CNP O
) O
tratados O
con O
quimioterapia O
neoadyuvante O
secuencial O
seguida O
de O
cisplatino-radioterapia O
( O
CRT O
) O
concurrente O
o O
CRT O
sola O
. O

Los O
CPN O
en O
estadio O
III O
a O
IVB O
no O
tratados O
previamente O
fueron O
asignados O
aleatoriamente O
a O
( O
1 O
) O
docetaxel O
neoadyuvante O
75 O
mg/m O
( O
2 O
) O
y O
cisplatino O
75 O
mg/m O
( O
2 O
) O
cada O
3 O
semanas O
durante O
dos O
ciclos O
, O
seguido O
de O
cisplatino O
40 O
mg/m O
( O
2 O
) O
/semana O
concurrente O
con O
radioterapia O
, O
o O
( O
2 O
) O
CRT O
solo O
. O

El O
número O
de O
pacientes O
previsto O
era O
de O
30 O
por O
brazo O
para O
detectar O
una O
diferencia O
del O
20% O
de O
las O
toxicidades O
según O
los O
IC O
del O
95%. O

De O
noviembre O
de O
2002 O
a O
noviembre O
de O
2004 O
, O
65 O
pacientes O
elegibles O
fueron O
asignados O
aleatoriamente O
a O
quimioterapia O
neoadyuvante O
seguida O
de O
TRC O
( O
n O
= O
34 O
) O
o O
TRC O
sola O
( O
n O
= O
31 O
) O
. O

Hubo B-Premise
una I-Premise
alta I-Premise
tasa I-Premise
de I-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
( I-Premise
97 I-Premise
% I-Premise
) I-Premise
pero I-Premise
no I-Premise
de I-Premise
fiebre I-Premise
neutropénica I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
durante I-Premise
la I-Premise
quimioterapia I-Premise
neoadyuvante I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
las I-Premise
tasas I-Premise
de I-Premise
toxicidades I-Premise
agudas I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
durante I-Premise
la I-Premise
TRC I-Premise
. I-Premise

Las B-Premise
intensidades I-Premise
de I-Premise
dosis I-Premise
de I-Premise
cisplatino I-Premise
concurrente, I-Premise
las I-Premise
toxicidades I-Premise
tardías I-Premise
de I-Premise
la I-Premise
RT I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fueron I-Premise
comparables I-Premise
en I-Premise
ambos I-Premise
brazos. I-Premise

La B-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
a I-Premise
3 I-Premise
años I-Premise
para I-Premise
el I-Premise
brazo I-Premise
neoadyuvante I-Premise
frente I-Premise
al I-Premise
brazo I-Premise
de I-Premise
control I-Premise
fue I-Premise
del I-Premise
88,2% I-Premise
y I-Premise
del I-Premise
59,5% I-Premise
( I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
= I-Premise
0,49 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95% I-Premise
, I-Premise
0,20 I-Premise
a I-Premise
1,19 I-Premise
; I-Premise
P I-Premise
= I-Premise
.12 I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
global I-Premise
a I-Premise
tres I-Premise
años I-Premise
del I-Premise
brazo I-Premise
neoadyuvante I-Premise
frente I-Premise
al I-Premise
brazo I-Premise
de I-Premise
control I-Premise
fue I-Premise
del I-Premise
94,1% I-Premise
y I-Premise
del I-Premise
67,7% I-Premise
( I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
= I-Premise
0,24; I-Premise
IC I-Premise
del I-Premise
95%, I-Premise
0,078 I-Premise
a I-Premise
0,73; I-Premise
P I-Premise
= I-Premise
0,012 I-Premise
) I-Premise
. I-Premise

La B-Claim
neoadyuvancia I-Claim
de I-Claim
docetaxel-cisplatino I-Claim
seguida I-Claim
de I-Claim
TRC I-Claim
fue I-Claim
bien I-Claim
tolerada I-Claim
con I-Claim
un I-Claim
perfil I-Claim
de I-Claim
toxicidad I-Claim
manejable I-Claim
que I-Claim
permitió I-Claim
la I-Claim
posterior I-Claim
administración I-Claim
de I-Claim
dosis I-Claim
completas I-Claim
de I-Claim
TRC I-Claim
. I-Claim

Los B-Claim
resultados I-Claim
preliminares I-Claim
sugieren I-Claim
un I-Claim
impacto I-Claim
positivo I-Claim
en I-Claim
la I-Claim
supervivencia. I-Claim

Se O
justifica O
un O
estudio O
de O
fase O
III O
para O
probar O
definitivamente O
esta O
estrategia O
neoadyuvante-concurrente. O

La O
fatiga O
es O
un O
problema O
frecuente O
después O
del O
tratamiento O
quirúrgico O
de O
los O
tumores O
sólidos O
. O

Se B-Claim
ha I-Claim
demostrado I-Claim
que I-Claim
el I-Claim
ejercicio I-Claim
aeróbico I-Claim
y I-Claim
las I-Claim
intervenciones I-Claim
psicosociales I-Claim
reducen I-Claim
la I-Claim
gravedad I-Claim
de I-Claim
este I-Claim
síntoma I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer. I-Claim

Por O
lo O
tanto, O
se O
comparó O
el O
efecto O
de O
las O
dos O
terapias O
sobre O
la O
fatiga O
en O
un O
estudio O
controlado O
aleatorio. O

Setenta O
y O
dos O
pacientes O
operados O
de O
tumores O
pulmonares O
( O
n=27 O
) O
o O
gastrointestinales O
( O
n=42 O
) O
fueron O
asignados O
a O
un O
grupo O
de O
ejercicio O
aeróbico O
( O
bicicleta O
estática O
30 O
min O
cinco O
veces O
por O
semana O
) O
o O
a O
un O
grupo O
de O
entrenamiento O
de O
relajación O
progresiva O
( O
45 O
min O
tres O
veces O
por O
semana O
) O
. O

Ambas O
intervenciones O
se O
llevaron O
a O
cabo O
durante O
3 O
semanas. O

Al O
principio O
y O
al O
final O
del O
estudio, O
se O
evaluó O
el O
estado O
físico, O
cognitivo O
y O
emocional O
y O
las O
quejas O
somáticas O
con O
el O
cuestionario O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
(EORTC-QLQ-30), O
y O
el O
rendimiento O
físico O
máximo O
con O
una O
prueba O
de O
esfuerzo O
ergométrica. O

El B-Premise
rendimiento I-Premise
físico I-Premise
del I-Premise
grupo I-Premise
de I-Premise
entrenamiento I-Premise
mejoró I-Premise
significativamente I-Premise
durante I-Premise
el I-Premise
programa I-Premise
( I-Premise
9,4+/-20 I-Premise
vatios I-Premise
, I-Premise
p=0,01 I-Premise
) I-Premise
pero I-Premise
se I-Premise
mantuvo I-Premise
sin I-Premise
cambios I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
relajación I-Premise
( I-Premise
1,5+/-14,8 I-Premise
vatios I-Premise
, I-Premise
p=0,37 I-Premise
) I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
fatiga I-Premise
y I-Premise
salud I-Premise
global I-Premise
mejoraron I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
durante I-Premise
la I-Premise
intervención I-Premise
( I-Premise
fatiga I-Premise
: I-Premise
grupo I-Premise
de I-Premise
entrenamiento I-Premise
21 I-Premise
% I-Premise
, I-Premise
grupo I-Premise
de I-Premise
relajación I-Premise
19 I-Premise
% I-Premise
; I-Premise
salud I-Premise
global I-Premise
de I-Premise
ambos I-Premise
grupos I-Premise
19 I-Premise
% I-Premise
, I-Premise
p I-Premise
para I-Premise
todos I-Premise
< I-Premise
o I-Premise
=0,01 I-Premise
) O
; O
sin O
embargo B-Premise
, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
cambios I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
ambos I-Premise
grupos I-Premise
( I-Premise
p=0,67 I-Premise
) O
. O

Concluimos B-Claim
que I-Claim
un I-Claim
programa I-Claim
de I-Claim
entrenamiento I-Claim
aeróbico I-Claim
estructurado I-Claim
mejora I-Claim
el I-Claim
rendimiento I-Claim
físico I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
se I-Claim
recuperan I-Claim
de I-Claim
la I-Claim
cirugía I-Claim
de I-Claim
tumores I-Claim
sólidos I-Claim
. I-Claim

Sin B-Claim
embargo, I-Claim
el I-Claim
ejercicio I-Claim
no I-Claim
es I-Claim
mejor I-Claim
que I-Claim
el I-Claim
entrenamiento I-Claim
de I-Claim
relajación I-Claim
progresiva I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
la I-Claim
fatiga I-Claim
en I-Claim
este I-Claim
contexto. I-Claim

El O
ensayo O
aleatorizado O
y O
controlado O
BOLERO-2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
demostró O
una O
mejora O
significativa O
de O
la O
supervivencia O
libre O
de O
progresión O
con O
el O
uso O
de O
everolimus O
más O
exemestano O
( O
EVE O
+ O
EXE O
) O
frente O
a O
placebo O
más O
exemestano O
( O
PBO O
+ O
EXE O
) O
en O
pacientes O
con O
cáncer O
de O
mama O
avanzado O
que O
desarrollaron O
progresión O
de O
la O
enfermedad O
tras O
el O
tratamiento O
con O
inhibidores O
de O
la O
aromatasa O
no O
esteroideos O
. O

Este O
análisis O
investigó O
los O
efectos O
del O
tratamiento O
en O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
. O

Mediante O
el O
cuestionario O
de O
calidad O
de O
vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
(EORTC O
QLQ-C30), O
se O
evaluó O
la O
CVRS O
al O
inicio O
y O
cada O
6 O
semanas O
hasta O
la O
progresión O
de O
la O
enfermedad O
o O
la O
interrupción O
del O
tratamiento. O

Los O
30 O
ítems O
de O
las O
15 O
subescalas O
del O
QLQ-C30 O
incluyen O
el O
estado O
de O
salud O
global, O
en O
el O
que O
las O
puntuaciones O
más O
altas O
( O
rango O
, O
0-100 O
) O
indican O
una O
mejor O
CVRS O
. O

Este O
análisis O
incluyó O
un O
análisis O
del O
tiempo O
hasta O
el O
deterioro O
definitivo O
( O
TDD O
) O
especificado O
por O
el O
protocolo O
en O
una O
disminución O
del O
5 O
% O
de O
la O
CVRS O
frente O
al O
valor O
inicial O
, O
sin O
que O
se O
produzca O
un O
aumento O
posterior O
por O
encima O
de O
este O
umbral O
. O

Los O
autores O
informan O
de O
análisis O
de O
sensibilidad O
adicionales O
utilizando O
disminuciones O
de O
10 O
puntos O
de O
diferencia O
mínima O
importante O
en O
la O
puntuación O
del O
estado O
de O
salud O
global O
frente O
a O
la O
línea O
de O
base O
. O

Los O
brazos O
de O
tratamiento O
se O
compararon O
mediante O
la O
prueba O
de O
rangos O
logarítmicos O
estratificada O
y O
el O
modelo O
de O
riesgos O
proporcionales O
de O
Cox O
ajustado O
por O
el O
estrato O
del O
ensayo O
( O
metástasis O
viscerales O
, O
sensibilidad O
hormonal O
previa O
) O
, O
la O
edad O
, O
el O
sexo O
, O
la O
raza O
, O
la O
puntuación O
del O
estado O
de O
salud O
global O
inicial O
y O
el O
estado O
de O
rendimiento O
del O
Eastern O
Cooperative O
Oncology O
Group O
, O
los O
factores O
de O
riesgo O
pronóstico O
y O
los O
antecedentes O
de O
tratamiento O
. O

Las O
puntuaciones O
iniciales O
del O
estado O
de O
salud O
global O
fueron O
similares O
entre O
los O
grupos O
de O
tratamiento O
( O
64,7 O
frente O
a O
65,3 O
) O
. O

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
TDD I-Premise
en I-Premise
la I-Premise
CVRS I-Premise
fue I-Premise
de I-Premise
8,3 I-Premise
meses I-Premise
con I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
frente I-Premise
a I-Premise
5,8 I-Premise
meses I-Premise
con I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0,74 I-Premise
; I-Premise
P I-Premise
= I-Premise
.0084 I-Premise
) I-Premise
. I-Premise

En B-Premise
la I-Premise
diferencia I-Premise
mínima I-Premise
importante I-Premise
de I-Premise
10 I-Premise
puntos I-Premise
, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
TDD I-Premise
con I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
fue I-Premise
de I-Premise
11,7 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
8,4 I-Premise
meses I-Premise
con I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0,80 I-Premise
; I-Premise
P I-Premise
= I-Premise
.1017 I-Premise
) I-Premise
. I-Premise

En B-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
avanzado I-Claim
que I-Claim
desarrollan I-Claim
progresión I-Claim
de I-Claim
la I-Claim
enfermedad I-Claim
tras I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
inhibidores I-Claim
de I-Claim
la I-Claim
aromatasa I-Claim
no I-Claim
esteroideos I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
se I-Claim
asoció I-Claim
con I-Claim
una I-Claim
mayor I-Claim
TDD I-Claim
en I-Claim
la I-Claim
CVRS I-Claim
global I-Claim
frente I-Claim
a I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

La B-Premise
mucositis I-Premise
se I-Premise
produce I-Premise
en I-Premise
casi I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
radioterapia I-Premise
para I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
cabeza I-Premise
y I-Premise
cuello. I-Premise

El O
objetivo O
de O
este O
ensayo O
multicéntrico, O
doble O
ciego, O
prospectivo O
y O
aleatorizado O
fue O
evaluar O
la O
eficacia O
clínica O
de O
una O
pastilla O
antimicrobiana O
económicamente O
viable O
( O
bacitracina, O
clotrimazol O
y O
gentamicina O
[ O
BcoG O
] O
) O
en O
el O
alivio O
de O
la O
mucositis O
inducida O
por O
la O
radiación O
en O
pacientes O
con O
cáncer O
de O
cabeza O
y O
cuello O
. O

Ciento O
treinta O
y O
siete O
pacientes O
elegibles O
fueron O
asignados O
aleatoriamente O
al O
tratamiento O
con O
pastillas O
antimicrobianas O
( O
69 O
pacientes O
) O
o O
con O
pastillas O
de O
placebo O
( O
68 O
pacientes O
) O
. O

El O
criterio O
de O
valoración O
principal O
del O
estudio O
fue O
el O
tiempo O
transcurrido O
hasta O
el O
desarrollo O
de O
mucositis O
grave O
desde O
el O
inicio O
de O
la O
radioterapia. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
gravedad O
y O
la O
duración O
de O
la O
mucositis, O
la O
medición O
del O
dolor, O
la O
interrupción O
de O
la O
radioterapia O
y O
la O
calidad O
de O
vida. O

La O
mucositis O
se O
puntuó O
mediante O
un O
sistema O
de O
puntuación O
de O
mucositis O
validado. O

Los B-Premise
perfiles I-Premise
de I-Premise
toxicidad I-Premise
fueron I-Premise
similares I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
del I-Premise
estudio. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
desarrollo I-Premise
de I-Premise
mucositis I-Premise
grave I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
de I-Premise
la I-Premise
radioterapia I-Premise
fue I-Premise
de I-Premise
3,61 I-Premise
semanas I-Premise
con I-Premise
BCoG I-Premise
y I-Premise
de I-Premise
3,96 I-Premise
semanas I-Premise
con I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,61 I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
en I-Premise
la I-Premise
extensión I-Premise
de I-Premise
la I-Premise
mucositis I-Premise
grave I-Premise
medida I-Premise
por I-Premise
el I-Premise
médico, I-Premise
en I-Premise
las I-Premise
toxicidades I-Premise
orales I-Premise
registradas I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
o I-Premise
en I-Premise
los I-Premise
retrasos I-Premise
de I-Premise
la I-Premise
radioterapia. I-Premise

Este O
estudio O
se O
llevó O
a O
cabo O
sobre O
la O
base O
de O
un O
estudio O
piloto O
que O
demostró O
que O
las O
pastillas O
de O
BCoG O
eran O
tolerables O
y O
microbiológicamente O
eficaces. O

Se O
utilizó O
un O
sistema O
de O
puntuación O
de O
la O
mucositis O
validado. O

Sin O
embargo, O
en B-Claim
este I-Claim
grupo I-Claim
de I-Claim
pacientes I-Claim
tratados I-Claim
con I-Claim
radioterapia I-Claim
convencional, I-Claim
la I-Claim
pastilla I-Claim
no I-Claim
tuvo I-Claim
un I-Claim
impacto I-Claim
significativo I-Claim
en I-Claim
la I-Claim
gravedad I-Claim
de I-Claim
la I-Claim
mucositis. I-Claim

Se B-Claim
desconoce I-Claim
si I-Claim
una I-Claim
pastilla I-Claim
de I-Claim
este I-Claim
tipo I-Claim
sería I-Claim
beneficiosa I-Claim
en I-Claim
situaciones I-Claim
de I-Claim
tratamiento I-Claim
en I-Claim
las I-Claim
que I-Claim
la I-Claim
tasa I-Claim
de I-Claim
mucositis I-Claim
grave I-Claim
es I-Claim
mayor I-Claim
( I-Claim
es I-Claim
decir, I-Claim
en I-Claim
pacientes I-Claim
tratados I-Claim
con I-Claim
fraccionamiento I-Claim
no I-Claim
convencional I-Claim
o I-Claim
con I-Claim
quimioterapia I-Claim
concomitante I-Claim
). I-Claim

Para B-Claim
los I-Claim
hombres I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
localizado, I-Claim
la I-Claim
cirugía I-Claim
proporciona I-Claim
un I-Claim
beneficio I-Claim
de I-Claim
supervivencia I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
espera I-Claim
vigilante. I-Claim

Los O
tratamientos O
están O
asociados O
a O
la O
morbilidad O
. O

Los O
resultados O
de O
los O
resultados O
funcionales O
y O
de O
la O
calidad O
de O
vida O
rara O
vez O
se O
comunican O
más O
allá O
de O
los O
10 O
años O
y O
se O
carece O
de O
ellos O
en O
contextos O
aleatorios. O

Informamos O
de O
los O
resultados O
de O
la O
calidad O
de O
vida O
de O
los O
hombres O
del O
Estudio O
Número O
4 O
del O
Grupo O
Escandinavo O
de O
Cáncer O
de O
Próstata O
( O
SPCG-4 O
) O
tras O
un O
seguimiento O
medio O
de O
más O
de O
12 O
años O
. O

En O
nuestro O
análisis O
se O
incluyeron O
todos O
los O
hombres O
suecos O
y O
finlandeses O
vivos O
( O
400 O
de O
695 O
) O
asignados O
aleatoriamente O
a O
la O
prostatectomía O
radical O
o O
a O
la O
espera O
vigilante O
en O
el O
SPCG-4 O
desde O
1989 O
hasta O
1999. O

Se O
incluyeron O
otros O
281 O
hombres O
en O
un O
grupo O
de O
control O
basado O
en O
la O
población O
y O
emparejado O
por O
región O
y O
edad. O

Se O
evaluaron O
los O
síntomas O
físicos, O
el O
estrés O
inducido O
por O
los O
síntomas O
y O
la O
calidad O
de O
vida O
autoevaluada O
con O
un O
cuestionario O
específico O
del O
estudio. O

Se O
disponía O
de O
datos O
longitudinales O
de O
166 O
hombres O
suecos O
que O
habían O
respondido O
a O
cuestionarios O
de O
calidad O
de O
vida O
en O
un O
momento O
anterior. O

182 O
( O
88 O
% O
) O
de O
208 O
hombres O
del O
grupo O
de O
prostatectomía O
radical O
, O
167 O
( O
87 O
% O
) O
de O
192 O
hombres O
del O
grupo O
de O
espera O
vigilante O
y O
214 O
( O
76 O
% O
) O
de O
281 O
hombres O
del O
grupo O
de O
control O
basado O
en O
la O
población O
respondieron O
al O
cuestionario O
. O

Los O
hombres O
del O
SPCG-4 O
tuvieron O
una O
mediana O
de O
seguimiento O
de O
12-2 O
años O
( O
rango O
7-17 O
) O
y O
una O
mediana O
de O
edad O
de O
77-0 O
años O
( O
rango O
61-88 O
) O
. O

El B-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
de I-Premise
los I-Premise
179 I-Premise
hombres I-Premise
asignados I-Premise
a I-Premise
la I-Premise
prostatectomía I-Premise
radical, I-Premise
el I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
de I-Premise
los I-Premise
160 I-Premise
hombres I-Premise
asignados I-Premise
a I-Premise
la I-Premise
espera I-Premise
vigilante I-Premise
y I-Premise
el I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
de I-Premise
los I-Premise
208 I-Premise
hombres I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
informaron I-Premise
de I-Premise
una I-Premise
alta I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
autoevaluada. I-Premise

La B-Premise
ansiedad I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
los I-Premise
grupos I-Premise
de I-Premise
SPCG-4 I-Premise
( I-Premise
77 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
de I-Premise
178 I-Premise
y I-Premise
69 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
de I-Premise
161 I-Premise
hombres I-Premise
) I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
( I-Premise
68 I-Premise
[ I-Premise
33 I-Premise
% I-Premise
] I-Premise
de I-Premise
208 I-Premise
hombres I-Premise
; I-Premise
riesgo I-Premise
relativo I-Premise
1-42 I-Premise
, I-Premise
IC I-Premise
95 I-Premise
% I-Premise
1-07-1-88 I-Premise
) I-Premise
. I-Premise

La B-Premise
prevalencia I-Premise
de I-Premise
la I-Premise
disfunción I-Premise
eréctil I-Premise
fue I-Premise
del I-Premise
84% I-Premise
( I-Premise
146 I-Premise
de I-Premise
173 I-Premise
hombres I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
prostatectomía I-Premise
radical, I-Premise
del I-Premise
80% I-Premise
( I-Premise
122 I-Premise
de I-Premise
153 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
espera I-Premise
vigilante I-Premise
y I-Premise
del I-Premise
46% I-Premise
( I-Premise
95 I-Premise
de I-Premise
208 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
y I-Premise
la I-Premise
prevalencia I-Premise
de I-Premise
las I-Premise
pérdidas I-Premise
de I-Premise
orina I-Premise
fue I-Premise
del I-Premise
41% I-Premise
( I-Premise
71 I-Premise
de I-Premise
173 I-Premise
), I-Premise
del I-Premise
11% I-Premise
( I-Premise
18 I-Premise
de I-Premise
164 I-Premise
) I-Premise
y I-Premise
del I-Premise
3% I-Premise
( I-Premise
seis I-Premise
de I-Premise
209 I-Premise
), I-Premise
respectivamente. I-Premise

Los B-Premise
hombres I-Premise
a I-Premise
los I-Premise
que I-Premise
se I-Premise
les I-Premise
asignó I-Premise
la I-Premise
prostatectomía I-Premise
radical I-Premise
manifestaron I-Premise
con I-Premise
mucha I-Premise
más I-Premise
frecuencia I-Premise
la I-Premise
angustia I-Premise
causada I-Premise
por I-Premise
estos I-Premise
síntomas I-Premise
que I-Premise
los I-Premise
hombres I-Premise
asignados I-Premise
a I-Premise
la I-Premise
espera I-Premise
vigilante. I-Premise

En B-Premise
un I-Premise
análisis I-Premise
longitudinal I-Premise
de I-Premise
los I-Premise
hombres I-Premise
del I-Premise
SPCG-4 I-Premise
que I-Premise
proporcionaron I-Premise
información I-Premise
en I-Premise
dos I-Premise
puntos I-Premise
de I-Premise
seguimiento I-Premise
con I-Premise
9 I-Premise
años I-Premise
de I-Premise
diferencia I-Premise
, I-Premise
el I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
de I-Premise
85 I-Premise
hombres I-Premise
a I-Premise
los I-Premise
que I-Premise
se I-Premise
les I-Premise
asignó I-Premise
la I-Premise
prostatectomía I-Premise
radical I-Premise
y I-Premise
el I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
de I-Premise
80 I-Premise
hombres I-Premise
a I-Premise
los I-Premise
que I-Premise
se I-Premise
les I-Premise
asignó I-Premise
la I-Premise
espera I-Premise
vigilante I-Premise
informaron I-Premise
de I-Premise
un I-Premise
aumento I-Premise
del I-Premise
número I-Premise
de I-Premise
síntomas I-Premise
físicos I-Premise
; I-Premise
el I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
de I-Premise
82 I-Premise
y I-Premise
el I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
de I-Premise
74 I-Premise
hombres I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
informaron I-Premise
de I-Premise
una I-Premise
reducción I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
. I-Premise

En B-Premise
el I-Premise
caso I-Premise
de I-Premise
los I-Premise
hombres I-Premise
del I-Premise
SPCG-4 I-Premise
, I-Premise
los I-Premise
efectos I-Premise
secundarios I-Premise
negativos I-Premise
fueron I-Premise
frecuentes I-Premise
y I-Premise
añadieron I-Premise
más I-Premise
estrés I-Premise
que I-Premise
el I-Premise
registrado I-Premise
en I-Premise
la I-Premise
población I-Premise
de I-Premise
control. I-Premise

En B-Claim
el I-Claim
grupo I-Claim
de I-Claim
prostatectomía I-Claim
radical, I-Claim
la I-Claim
disfunción I-Claim
eréctil I-Claim
y I-Claim
las I-Claim
pérdidas I-Claim
de I-Claim
orina I-Claim
fueron I-Claim
a I-Claim
menudo I-Claim
consecuencias I-Claim
de I-Claim
la I-Claim
cirugía. I-Claim

En B-Claim
el I-Claim
grupo I-Claim
de I-Claim
espera I-Claim
vigilante, I-Claim
los I-Claim
efectos I-Claim
secundarios I-Claim
pueden I-Claim
deberse I-Claim
a I-Claim
la I-Claim
progresión I-Claim
del I-Claim
tumor. I-Claim

El B-Claim
número I-Claim
y I-Claim
la I-Claim
gravedad I-Claim
de I-Claim
los I-Claim
efectos I-Claim
secundarios I-Claim
cambian I-Claim
con I-Claim
el I-Claim
tiempo I-Claim
a I-Claim
un I-Claim
ritmo I-Claim
mayor I-Claim
que I-Claim
el I-Claim
causado I-Claim
por I-Claim
el I-Claim
envejecimiento I-Claim
normal I-Claim
y I-Claim
la I-Claim
pérdida I-Claim
de I-Claim
capacidad I-Claim
sexual I-Claim
es I-Claim
un I-Claim
problema I-Claim
psicológico I-Claim
persistente I-Claim
para I-Claim
ambas I-Claim
intervenciones I-Claim
. I-Claim

La O
comprensión O
de O
los O
patrones O
de O
los O
efectos O
secundarios O
y O
la O
dimensión O
temporal O
de O
su O
aparición O
para O
cada O
tratamiento O
es O
importante O
para O
la O
información O
completa O
del O
paciente O
. O

En B-Claim
el I-Claim
caso I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
metastásico, I-Claim
el I-Claim
tratamiento I-Claim
es I-Claim
fundamentalmente I-Claim
paliativo, I-Claim
y I-Claim
se I-Claim
basa I-Claim
principalmente I-Claim
en I-Claim
la I-Claim
supresión I-Claim
de I-Claim
los I-Claim
niveles I-Claim
hormonales I-Claim
de I-Claim
andrógenos I-Claim
sistémicos. I-Claim

Para O
ayudar O
a O
documentar O
el O
logro O
de O
la O
paliación O
y O
caracterizar O
los O
efectos O
positivos O
y O
negativos O
del O
tratamiento O
, O
se O
evaluaron O
parámetros O
de O
calidad O
de O
vida O
( O
QOL O
) O
en O
pacientes O
con O
cáncer O
de O
próstata O
metastásico O
que O
fueron O
asignados O
al O
azar O
a O
dos O
métodos O
de O
privación O
de O
andrógenos O
. O

Los O
pacientes O
( O
n O
= O
739 O
) O
con O
cáncer O
de O
próstata O
en O
estadio O
M1 O
( O
metástasis O
en O
huesos O
o O
tejidos O
blandos O
) O
se O
inscribieron O
en O
un O
protocolo O
de O
QOL O
que O
acompañaba O
al O
Southwest O
Oncology O
Group O
INT-0105 O
, O
un O
ensayo O
aleatorio O
doble O
ciego O
que O
comparaba O
el O
tratamiento O
con O
orquiectomía O
bilateral O
( O
castración O
quirúrgica O
) O
más O
flutamida O
o O
placebo O
. O

Los O
pacientes O
completaron O
una O
batería O
completa O
de O
cuestionarios O
de O
calidad O
de O
vida O
en O
el O
momento O
de O
la O
asignación O
aleatoria O
al O
tratamiento O
y O
a O
los O
1, O
3 O
y O
6 O
meses O
después. O

Se O
recogieron O
datos O
sobre O
tres O
síntomas O
específicos O
del O
tratamiento O
( O
diarrea O
, O
dolor O
por O
gases O
e O
imagen O
corporal O
) O
, O
sobre O
el O
funcionamiento O
físico O
y O
sobre O
el O
funcionamiento O
emocional O
. O

Todos O
los O
valores O
P O
son O
de O
dos O
caras. O

Las O
tasas O
de O
devolución O
de O
los O
cuestionarios O
de O
este O
estudio O
nunca O
fueron O
inferiores O
al O
80 O
%; O
sólo O
el O
2 O
% O
de O
los O
pacientes O
no O
presentaron O
las O
evaluaciones O
iniciales O
de O
la O
calidad O
de O
vida. O

Los B-Premise
análisis I-Premise
transversales I-Premise
( I-Premise
corregidos I-Premise
para I-Premise
pruebas I-Premise
múltiples I-Premise
) I-Premise
identificaron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
que I-Premise
favorecieron I-Premise
la I-Premise
orquiectomía I-Premise
más I-Premise
el I-Premise
placebo I-Premise
para I-Premise
dos I-Premise
de I-Premise
los I-Premise
cinco I-Premise
parámetros I-Premise
primarios I-Premise
de I-Premise
CdV I-Premise
como I-Premise
sigue: I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
flutamida I-Premise
informaron I-Premise
de I-Premise
más I-Premise
diarrea I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses I-Premise
( I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
peor I-Premise
funcionamiento I-Premise
emocional I-Premise
a I-Premise
los I-Premise
3 I-Premise
y I-Premise
6 I-Premise
meses I-Premise
( I-Premise
ambos I-Premise
P I-Premise
< I-Premise
0,003 I-Premise
) I-Premise
. I-Premise

Los B-Premise
análisis I-Premise
longitudinales I-Premise
han I-Premise
confirmado I-Premise
estos I-Premise
resultados. I-Premise

Otros B-Premise
parámetros I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
analizados I-Premise
favorecieron I-Premise
al I-Premise
grupo I-Premise
que I-Premise
recibió I-Premise
placebo, I-Premise
pero B-Premise
no I-Premise
fueron I-Premise
estadísticamente I-Premise
significativos I-Premise
tras I-Premise
el I-Premise
ajuste I-Premise
por I-Premise
pruebas I-Premise
múltiples. I-Premise

Se B-Claim
encontró I-Claim
un I-Claim
patrón I-Claim
consistente I-Claim
de I-Claim
mejores I-Claim
resultados I-Claim
de I-Claim
CdV I-Claim
en I-Claim
cada I-Claim
evaluación I-Claim
de I-Claim
seguimiento I-Claim
durante I-Claim
los I-Claim
primeros I-Claim
6 I-Claim
meses I-Claim
de I-Claim
tratamiento I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
orquiectomizados I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
metastásico I-Claim
que I-Claim
recibieron I-Claim
placebo I-Claim
versus I-Claim
flutamida I-Claim
. I-Claim

La B-Claim
mejora I-Claim
a I-Claim
lo I-Claim
largo I-Claim
del I-Claim
tiempo I-Claim
fue I-Claim
evidente I-Claim
en I-Claim
ambos I-Claim
grupos I-Claim
de I-Claim
tratamiento, I-Claim
pero I-Claim
más I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
placebo I-Claim
. I-Claim

La O
recopilación O
periódica O
de O
resultados O
comunicados O
por O
los O
pacientes O
(PRO) O
sobre O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud, O
con O
información O
para O
los O
oncólogos, O
puede O
ayudar O
a O
obtener O
y O
supervisar O
los O
problemas O
de O
los O
pacientes O
durante O
el O
tratamiento O
del O
cáncer. O

Este O
estudio O
examinó O
el O
impacto O
de O
la O
retroalimentación O
de O
los O
PRO O
en O
la O
comunicación O
médico-paciente O
a O
lo O
largo O
del O
tiempo O
para O
comprender O
mejor O
cómo O
puede O
influir O
en O
la O
atención O
al O
paciente. O

Se O
realizaron O
análisis O
exploratorios O
con O
un O
conjunto O
de O
datos O
de O
un O
estudio O
anterior. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
la O
intervención O
( O
cumplimentación O
periódica O
del O
Cuestionario O
de O
Calidad O
de O
Vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer-Core O
30 O
y O
de O
la O
Escala O
de O
Ansiedad O
y O
Depresión O
Hospitalaria O
con O
retroalimentación O
a O
los O
oncólogos O
) O
, O
atención-control O
( O
cumplimentación O
de O
los O
mismos O
cuestionarios O
sin O
retroalimentación O
) O
y O
brazos O
de O
control O
( O
atención O
estándar O
) O
. O

Se O
analizó O
el O
contenido O
de O
las O
grabaciones O
de O
audio O
de O
las O
consultas O
entre O
28 O
oncólogos O
y O
198 O
pacientes O
durante O
cuatro O
visitas O
consecutivas O
( O
792 O
consultas O
). O

Se O
utilizaron O
modelos O
de O
efectos O
mixtos O
y O
regresiones O
multivariantes O
para O
examinar O
el O
impacto O
longitudinal O
de O
la O
intervención O
en O
la O
comunicación O
médico-paciente O
, O
la O
dinámica O
de O
la O
interacción O
médico-paciente O
y O
la O
asociación O
entre O
los O
PRO O
y O
el O
contenido O
de O
la O
discusión O
clínica O
. O

Los B-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
de I-Premise
intervención I-Premise
comentaron I-Premise
más I-Premise
síntomas I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
los I-Premise
brazos I-Premise
de I-Premise
atención-control I-Premise
( I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
) I-Premise
y I-Premise
control I-Premise
( I-Premise
P I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
observó I-Premise
ningún I-Premise
efecto I-Premise
del I-Premise
brazo I-Premise
de I-Premise
estudio I-Premise
para I-Premise
las I-Premise
discusiones I-Premise
sobre I-Premise
la I-Premise
función I-Premise
. I-Premise

Los O
temas O
de O
discusión O
fueron O
planteados O
predominantemente O
por O
los O
pacientes/familiares, O
independientemente O
de O
la O
asignación O
del O
brazo. O

Las B-Premise
discusiones I-Premise
clínicas I-Premise
se I-Premise
asociaron I-Premise
con I-Premise
la I-Premise
gravedad I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
declarados I-Premise
por I-Premise
los I-Premise
pacientes, I-Premise
pero I-Premise
no I-Premise
con I-Premise
las I-Premise
preocupaciones I-Premise
funcionales I-Premise
declaradas I-Premise
por I-Premise
los I-Premise
pacientes. I-Premise

Se B-Premise
observó I-Premise
un I-Premise
impacto I-Premise
longitudinal I-Premise
positivo I-Premise
de I-Premise
la I-Premise
intervención I-Premise
en I-Premise
la I-Premise
discusión I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
, O
pero B-Premise
no I-Premise
para I-Premise
la I-Premise
discusión I-Premise
de I-Premise
las I-Premise
funciones I-Premise
, I-Premise
lo I-Premise
que I-Premise
sugiere I-Premise
que I-Premise
los I-Premise
problemas I-Premise
potencialmente I-Premise
graves I-Premise
pueden I-Premise
quedar I-Premise
sin I-Premise
tratar I-Premise
. O

La B-Claim
formación I-Claim
de I-Claim
los I-Claim
oncólogos I-Claim
para I-Claim
responder I-Claim
a I-Claim
las I-Claim
preocupaciones I-Claim
funcionales I-Claim
comunicadas I-Claim
por I-Claim
los I-Claim
pacientes I-Claim
puede I-Claim
aumentar I-Claim
el I-Claim
impacto I-Claim
de I-Claim
esta I-Claim
intervención. I-Claim

La B-Claim
anemia I-Claim
es I-Claim
una I-Claim
consecuencia I-Claim
esperada I-Claim
de I-Claim
los I-Claim
regímenes I-Claim
intensivos I-Claim
de I-Claim
quimioterapia I-Claim
administrados I-Claim
a I-Claim
pacientes I-Claim
con I-Claim
leucemia I-Claim
aguda I-Claim
. I-Claim

Este O
estudio O
se O
diseñó O
para O
determinar O
si O
la O
epoetina O
alfa O
disminuiría O
el O
número O
de O
eventos O
de O
transfusión O
y O
las O
unidades O
de O
eritrocitos O
empaquetados O
( O
PRBCs O
) O
transfundidos O
, O
y O
el O
objetivo O
secundario O
fue O
estudiar O
los O
efectos O
de O
la O
epoetina O
alfa O
en O
la O
calidad O
de O
vida O
( O
QOL O
) O
y O
las O
tasas O
de O
remisión O
completa O
( O
CR O
) O
. O

Los O
pacientes O
con O
leucemia O
linfoblástica O
aguda O
( O
LLA O
) O
, O
linfoma O
linfoblástico O
( O
LL O
) O
o O
linfoma O
de O
Burkitt O
( O
BL O
) O
que O
estaban O
recibiendo O
quimioterapia O
mielosupresora O
de O
primera O
línea O
fueron O
aleatorizados O
para O
recibir O
epoetina O
alfa O
o O
no O
epoetina O
durante O
los O
primeros O
6 O
ciclos O
de O
su O
quimioterapia O
planificada O
. O

La O
calidad O
de O
vida O
se O
evaluó O
mediante O
los O
cuestionarios O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
y O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Anemia O
. O

Cincuenta O
y O
cinco O
pacientes O
fueron O
aleatorizados O
para O
recibir O
epoetina O
alfa O
, O
y O
54 O
pacientes O
no O
recibieron O
epoetina O
. O

Se O
dispuso O
de O
datos O
de O
transfusión O
para O
79 O
de O
los O
81 O
pacientes O
evaluables O
( O
98% O
) O
que O
completaron O
el O
periodo O
de O
tratamiento/observación O
. O

El B-Premise
ensayo I-Premise
se I-Premise
interrumpió I-Premise
de I-Premise
forma I-Premise
prematura I-Premise
debido I-Premise
a I-Premise
la I-Premise
escasa I-Premise
participación I-Premise
antes I-Premise
de I-Premise
que I-Premise
se I-Premise
alcanzara I-Premise
el I-Premise
objetivo I-Premise
de I-Premise
123 I-Premise
pacientes I-Premise
evaluables. I-Premise

Se B-Premise
administró I-Premise
una I-Premise
media I-Premise
de I-Premise
10,6 I-Premise
unidades I-Premise
de I-Premise
glóbulos I-Premise
rojos I-Premise
durante I-Premise
5 I-Premise
meses I-Premise
a I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
epoetina I-Premise
alfa, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
13 I-Premise
unidades I-Premise
para I-Premise
los I-Premise
que I-Premise
no I-Premise
recibieron I-Premise
epoetina I-Premise
( I-Premise
P I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
CdV I-Premise
evaluada I-Premise
por I-Premise
los I-Premise
instrumentos I-Premise
FACT-Anemia I-Premise
o I-Premise
ESAS I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
RC I-Premise
y I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
RC I-Premise
a I-Premise
3 I-Premise
años I-Premise
no I-Premise
se I-Premise
vieron I-Premise
afectadas I-Premise
negativamente I-Premise
por I-Premise
el I-Premise
uso I-Premise
de I-Premise
epoetina I-Premise
alfa I-Premise
. I-Premise

La B-Claim
epoetina I-Claim
alfa I-Claim
redujo I-Claim
el I-Claim
número I-Claim
de I-Claim
transfusiones I-Claim
de I-Claim
glóbulos I-Claim
rojos I-Claim
y I-Claim
no I-Claim
pareció I-Claim
tener I-Claim
un I-Claim
impacto I-Claim
negativo I-Claim
en I-Claim
la I-Claim
duración I-Claim
de I-Claim
la I-Claim
remisión. I-Claim

No B-Claim
se I-Claim
observaron I-Claim
diferencias I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Se O
comparó O
una O
escala O
de O
autoevaluación O
analógica O
lineal O
de O
un O
solo O
ítem O
para O
el O
estado O
de O
ánimo O
con O
una O
lista O
de O
verificación O
adjetiva O
de O
28 O
ítems O
para O
el O
bienestar O
emocional O
. O

Para O
confirmar O
su O
validez O
concurrente O
y O
su O
capacidad O
de O
respuesta O
al O
tratamiento O
y O
a O
la O
recidiva O
en O
pacientes O
con O
cáncer O
de O
mama O
, O
se O
evaluó O
el O
bienestar O
emocional O
cada O
3 O
meses O
durante O
2 O
años O
y O
a O
1 O
y O
6 O
meses O
después O
de O
la O
recidiva O
en O
1.169 O
pacientes O
premenopáusicas O
y O
960 O
pacientes O
posmenopáusicas O
. O

Estas O
pacientes O
se O
inscribieron O
en O
dos O
ensayos O
clínicos O
aleatorios O
del O
International O
Breast O
Cancer O
Study O
Group O
en O
cáncer O
de O
mama O
operable O
realizados O
entre O
1986 O
y O
1993 O
. O

Para O
evaluar O
la O
validez O
concurrente, O
se O
calculó O
la O
correlación O
de O
Pearson O
entre O
la O
escala O
de O
autoevaluación O
analógica O
lineal O
y O
la O
lista O
de O
comprobación O
adjetiva O
para O
cada O
punto O
temporal O
dentro O
de O
cada O
grupo O
de O
tratamiento O
y O
para O
las O
dos O
evaluaciones O
después O
de O
la O
recidiva. O

La O
capacidad O
de O
respuesta O
al O
tratamiento O
y O
la O
recurrencia O
se O
analizaron O
mediante O
pruebas O
t O
emparejadas O
y O
el O
cociente O
al O
cuadrado O
de O
estas O
pruebas O
t O
, O
una O
estimación O
de O
la O
eficacia O
relativa O
. O

La O
validez O
concurrente O
de O
la O
autoevaluación O
analógica O
lineal O
del O
estado O
de O
ánimo O
se O
confirmó O
de O
forma O
consistente O
en O
los O
cuatro O
grupos O
lingüísticos. O

Ambas B-Claim
medidas I-Claim
respondieron; I-Claim
de B-Premise
24 I-Premise
cambios I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
, I-Premise
19 I-Premise
fueron I-Premise
en I-Premise
la I-Premise
dirección I-Premise
esperada I-Premise
para I-Premise
la I-Premise
escala I-Premise
de I-Premise
autoevaluación I-Premise
analógica I-Premise
lineal I-Premise
( I-Premise
p I-Premise
< I-Premise
o I-Premise
= I-Premise
0,05 I-Premise
para I-Premise
9 I-Premise
de I-Premise
19 I-Premise
) I-Premise
y I-Premise
17 I-Premise
para I-Premise
la I-Premise
lista I-Premise
de I-Premise
verificación I-Premise
de I-Premise
adjetivos I-Premise
( I-Premise
p I-Premise
< I-Premise
o I-Premise
= I-Premise
0,05 I-Premise
para I-Premise
10 I-Premise
de I-Premise
17 I-Premise
) O
. O

La B-Premise
escala I-Premise
de I-Premise
autoevaluación I-Premise
lineal I-Premise
analógica I-Premise
fue I-Premise
menos I-Premise
pero I-Premise
significativamente I-Premise
eficiente I-Premise
para I-Premise
la I-Premise
detección I-Premise
de I-Premise
los I-Premise
efectos I-Premise
del I-Premise
tratamiento I-Premise
, I-Premise
con I-Premise
estimaciones I-Premise
de I-Premise
eficiencia I-Premise
relativa I-Premise
que I-Premise
oscilaron I-Premise
entre I-Premise
0,16 I-Premise
y I-Premise
2,45 I-Premise
y I-Premise
una I-Premise
mediana I-Premise
de I-Premise
0,66 I-Premise
entre I-Premise
las I-Premise
comparaciones I-Premise
con I-Premise
estimaciones I-Premise
relativamente I-Premise
estables I-Premise
( I-Premise
/t/ I-Premise
> I-Premise
o I-Premise
= I-Premise
1,0 I-Premise
) I-Premise
y I-Premise
más I-Premise
eficiente I-Premise
para I-Premise
la I-Premise
recurrencia I-Premise
que I-Premise
la I-Premise
lista I-Premise
de I-Premise
verificación I-Premise
adjetiva I-Premise
. I-Premise

La B-Claim
escala I-Claim
de I-Claim
autoevaluación I-Claim
analógica I-Claim
lineal I-Claim
del I-Claim
estado I-Claim
de I-Claim
ánimo I-Claim
es I-Claim
un I-Claim
indicador I-Claim
válido I-Claim
del I-Claim
bienestar I-Claim
emocional I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
en I-Claim
grandes I-Claim
ensayos I-Claim
multicéntricos I-Claim
y I-Claim
multiculturales I-Claim
en I-Claim
los I-Claim
que I-Claim
las I-Claim
escalas I-Claim
globales I-Claim
son I-Claim
menos I-Claim
factibles. I-Claim

Esta B-Claim
investigación I-Claim
respalda I-Claim
la I-Claim
relevancia I-Claim
clínica I-Claim
de I-Claim
las I-Claim
escalas I-Claim
de I-Claim
autoevaluación I-Claim
analógica I-Claim
lineal I-Claim
como I-Claim
indicadores I-Claim
de I-Claim
los I-Claim
componentes I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
los I-Claim
ensayos I-Claim
clínicos I-Claim
sobre I-Claim
el I-Claim
cáncer I-Claim
. I-Claim

Analizar O
el O
valor O
predictivo O
del O
PSA O
para O
la O
progresión O
y O
el O
papel O
de O
la O
testosterona O
para O
la O
calidad O
de O
vida O
( O
QOL O
) O
en O
pacientes O
con O
terapia O
de O
privación O
de O
andrógenos O
( O
ADT O
) O
para O
el O
cáncer O
de O
próstata O
metastásico O
. O

Se O
utilizaron O
los O
datos O
de O
PSA O
y O
testosterona O
de O
un O
ensayo O
de O
fase O
III O
en O
el O
que O
se O
aleatorizó O
a O
los O
pacientes O
sin O
progresión O
y O
con O
PSA O
< O
4 O
ng/ml O
( O
n O
= O
193 O
) O
, O
después O
de O
6 O
meses O
de O
curso O
de O
inducción O
, O
entre O
ADT O
continua O
( O
CAD O
) O
( O
n O
= O
96 O
) O
e O
intermitente O
( O
IAD O
) O
( O
n O
= O
97 O
) O
. O

El O
riesgo O
de O
progresión O
a O
los O
2 O
años O
se O
calculó O
en O
función O
del O
PSA O
basal, O
el O
descenso O
"rápido" O
y O
"lento" O
del O
PSA O
a O
< O
4 O
ng/ml O
(punto O
de O
corte O
de O
60 O
días), O
el O
nadir O
del O
PSA, O
el O
estado O
funcional O
y O
el O
dolor. O

También O
se O
evaluó O
la O
cinética O
de O
la O
testosterona O
y O
la O
calidad O
de O
vida. O

Se O
utilizó O
el O
análisis O
de O
supervivencia O
univariante O
de O
Kaplan O
Meier O
y O
las O
pruebas O
de O
rango O
logarítmico O
para O
comparar O
el O
riesgo O
de O
progresión. O

Para O
el O
análisis O
de O
la O
progresión, O
se O
disponía O
de O
los O
datos O
de O
173 O
pacientes. O

El O
riesgo O
de O
progresión O
a O
2 O
años O
para O
el O
PSA O
basal O
< O
50 O
ng/ml O
, O
50 O
a O
< O
500 O
ng/ml O
, O
y O
≥ O
500 O
ng/ml O
fue O
del O
25 O
% O
, O
55 O
% O
y O
76 O
% O
( O
P O
= O
0,03 O
) O
en O
la O
EAC O
, O
y O
del O
38 O
% O
, O
64 O
% O
y O
85 O
% O
( O
P O
= O
0,006 O
) O
en O
la O
DAI O
, O
respectivamente O
. O

El B-Premise
riesgo I-Premise
de I-Premise
progresión I-Premise
a I-Premise
2 I-Premise
años I-Premise
para I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0,2 I-Premise
ng/ml I-Premise
, I-Premise
y I-Premise
> I-Premise
0,2 I-Premise
a I-Premise
4 I-Premise
ng/ml I-Premise
en I-Premise
EAC I-Premise
fue I-Premise
del I-Premise
31 I-Premise
% I-Premise
y I-Premise
del I-Premise
70 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
DAI, I-Premise
se I-Premise
observó I-Premise
una I-Premise
tendencia I-Premise
similar. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0,2 I-Premise
ng/ml I-Premise
, I-Premise
sin I-Premise
embargo, I-Premise
tenían I-Premise
un I-Premise
riesgo I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
progresión I-Premise
a I-Premise
los I-Premise
dos I-Premise
años I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
EAC I-Premise
( I-Premise
53 I-Premise
% I-Premise
frente I-Premise
al I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

El O
descenso O
del O
PSA O
no O
mostró O
ningún O
valor O
predictivo O
. O

Los B-Premise
pacientes I-Premise
sin I-Premise
dolor I-Premise
tenían I-Premise
un I-Premise
riesgo I-Premise
de I-Premise
progresión I-Premise
a I-Premise
los I-Premise
dos I-Premise
años I-Premise
significativamente I-Premise
menor I-Premise
en I-Premise
ambos I-Premise
grupos. I-Premise

Sin B-Premise
ADT I-Premise
la I-Premise
testosterona I-Premise
se I-Premise
mantuvo I-Premise
en I-Premise
el I-Premise
nivel I-Premise
de I-Premise
castrado I-Premise
durante I-Premise
4 I-Premise
meses I-Premise
. I-Premise

Después O
del O
primer O
y O
segundo O
ciclo O
de O
DAI, O
el O
92% O
y O
el O
46% O
, O
respectivamente, O
tenían O
una O
testosterona O
normalizada. O

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
aunque I-Premise
se I-Premise
produjeron I-Premise
más I-Premise
efectos I-Premise
secundarios I-Premise
en I-Premise
la I-Premise
EAC. I-Premise

Los B-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
metastásico I-Claim
con I-Claim
PSA I-Claim
basal I-Claim
elevado, I-Claim
dolor I-Claim
y I-Claim
nadir I-Claim
de I-Claim
PSA I-Claim
elevado I-Claim
tienen I-Claim
un I-Claim
mal I-Claim
pronóstico I-Claim
con I-Claim
ADT. I-Claim

Los B-Claim
pacientes I-Claim
con I-Claim
un I-Claim
nadir I-Claim
de I-Claim
PSA I-Claim
bajo I-Claim
obtienen I-Claim
resultados I-Claim
significativamente I-Claim
peores I-Claim
con I-Claim
la I-Claim
DAI I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
EAC I-Claim
. I-Claim

La O
baja O
testosterona O
después O
de O
la O
ADT O
y O
la O
recuperación O
incompleta O
de O
la O
testosterona O
pueden O
explicar O
una O
CdV O
similar. O

Por O
lo O
tanto, O
la O
DAI B-Claim
no I-Claim
es I-Claim
una I-Claim
buena I-Claim
opción I-Claim
de I-Claim
tratamiento I-Claim
para I-Claim
muchos I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
metastásico. I-Claim

Comparar O
la O
eficacia O
de O
la O
electroterapia O
de O
baja O
frecuencia O
y O
baja O
intensidad O
y O
el O
drenaje O
linfático O
manual O
en O
el O
tratamiento O
del O
linfedema O
crónico O
relacionado O
con O
el O
cáncer O
de O
mama O
en O
las O
extremidades O
superiores. O

Ensayo O
clínico O
cruzado, O
aleatorio O
y O
a O
ciegas. O

Servicio O
de O
rehabilitación O
. O

Treinta O
y O
seis O
mujeres O
con O
linfedema O
crónico O
relacionado O
con O
el O
cáncer O
de O
mama O
en O
las O
extremidades O
superiores O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
someterse O
a O
10 O
sesiones O
de O
drenaje O
linfático O
manual O
seguidas O
de O
10 O
sesiones O
de O
electroterapia O
de O
baja O
frecuencia O
y O
baja O
intensidad O
o O
a O
someterse O
primero O
a O
electroterapia O
de O
baja O
frecuencia O
y O
baja O
intensidad O
seguida O
de O
drenaje O
linfático O
manual. O

Hubo O
un O
mes O
de O
lavado O
entre O
los O
tratamientos. O

Cada O
paciente O
fue O
examinado O
justo O
antes O
y O
después O
de O
cada O
tratamiento. O

Los O
investigadores O
y O
los O
evaluadores O
de O
resultados O
estaban O
cegados O
para O
el O
tratamiento O
asignado O
. O

Los O
resultados O
fueron O
el O
volumen O
del O
linfedema, O
el O
dolor, O
la O
pesadez O
y O
la O
tirantez, O
y O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud, O
medida O
con O
el O
Cuestionario O
de O
Evaluación O
Funcional O
del O
Tratamiento O
del O
Cáncer O
de O
Mama O
versión O
4 O
( O
FACT-B+4 O
) O
. O

Se O
analizaron O
los O
efectos O
del O
arrastre, O
del O
periodo O
y O
del O
tratamiento. O

El O
efecto O
del O
tratamiento O
se O
evaluó O
mediante O
una O
prueba O
t O
emparejada. O

Treinta O
pacientes O
finalizaron O
el O
tratamiento. O

Si B-Premise
se I-Premise
comparan I-Premise
los I-Premise
cambios I-Premise
de I-Premise
la I-Premise
electroterapia I-Premise
de I-Premise
baja I-Premise
frecuencia I-Premise
y I-Premise
baja I-Premise
intensidad I-Premise
con I-Premise
los I-Premise
cambios I-Premise
del I-Premise
drenaje I-Premise
linfático I-Premise
manual, I-Premise
no I-Premise
hay I-Premise
diferencias I-Premise
significativas. I-Premise

La B-Premise
electroterapia I-Premise
de I-Premise
baja I-Premise
frecuencia I-Premise
y I-Premise
baja I-Premise
intensidad I-Premise
no I-Premise
redujo I-Premise
el I-Premise
volumen I-Premise
del I-Premise
linfedema I-Premise
( I-Premise
media I-Premise
de I-Premise
cambio I-Premise
= I-Premise
19,77 I-Premise
mL I-Premise
, I-Premise
p I-Premise
= I-Premise
0,36 I-Premise
) O
, O
pero O
se B-Premise
observaron I-Premise
reducciones I-Premise
significativas I-Premise
del I-Premise
dolor I-Premise
, I-Premise
la I-Premise
pesadez I-Premise
y I-Premise
la I-Premise
tirantez I-Premise
( I-Premise
media I-Premise
de I-Premise
cambio I-Premise
= I-Premise
13,1 I-Premise
, I-Premise
16,2 I-Premise
y I-Premise
6,4 I-Premise
mm I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
, I-Premise
y I-Premise
los I-Premise
resúmenes I-Premise
del I-Premise
FACT-B+4 I-Premise
mejoraron I-Premise
significativamente I-Premise
( I-Premise
media I-Premise
de I-Premise
cambio I-Premise
del I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
= I-Premise
5,4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,015 I-Premise
) O
. O

El B-Premise
drenaje I-Premise
linfático I-Premise
manual I-Premise
no I-Premise
mostró I-Premise
cambios I-Premise
significativos I-Premise
en I-Premise
ninguno I-Premise
de I-Premise
los I-Premise
resultados. I-Premise

Aunque B-Claim
no I-Claim
hay I-Claim
diferencias I-Claim
significativas I-Claim
entre I-Claim
los I-Claim
cambios I-Claim
de I-Claim
tratamiento I-Claim
, I-Claim
la I-Claim
tendencia I-Claim
observada I-Claim
hacia I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
salud I-Claim
es I-Claim
notable I-Claim
en I-Claim
la I-Claim
electroterapia I-Claim
de I-Claim
baja I-Claim
frecuencia I-Claim
y I-Claim
baja I-Claim
intensidad I-Claim
. O

No O
se O
han O
establecido O
marcadores O
moleculares O
para O
predecir O
la O
respuesta O
al O
tratamiento O
con O
5-fluorouracilo O
( O
FU O
) O
del O
cáncer O
colorrectal O
recurrente O
o O
con O
metástasis O
( O
mCRC O
). O

El O
objetivo O
de O
este O
ensayo O
fue O
determinar O
el O
valor O
de O
la O
timidilato O
sintasa O
( O
TS O
) O
, O
una O
enzima O
clave O
de O
la O
síntesis O
del O
ADN O
y O
objetivo O
del O
5-FU O
, O
para O
predecir O
la O
respuesta O
a O
la O
quimioterapia O
del O
mCRC O
. O

Se O
obtuvo O
tejido O
tumoral O
de O
168 O
pacientes O
con O
CCRm O
para O
la O
cuantificación O
relativa O
del O
ARNm O
de O
la O
timidilato O
sintasa O
( O
TS O
) O
. O

Los O
pacientes O
fueron O
aleatorizados O
para O
recibir O
5-FU/ácido O
folínico O
( O
FA O
, O
FUFA O
) O
solo O
o O
en O
combinación O
con O
irinotecán O
5-fluorouracilo/ácido O
folínico O
e O
irinotecán O
( O
FOLFIRI O
) O
estratificado O
por O
TS O
( O
bajo O
versus O
alto O
) O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
respuesta O
global O
al O
tratamiento O
de O
primera O
línea O
entre O
los O
pacientes O
con O
TS O
alta O
. O

Todas O
las O
partes, O
excepto O
el O
centro O
de O
aleatorización, O
fueron O
cegadas O
para O
el O
estado O
de O
la O
ST. O

Las O
biopsias O
( O
n=168 O
) O
se O
tomaron O
sin O
complicaciones O
. O

Se O
disponía O
de O
los O
niveles O
de O
ST O
en O
147 O
pacientes O
( O
87,5 O
% O
) O
. O

El B-Premise
análisis I-Premise
de I-Premise
la I-Premise
respuesta I-Premise
al I-Premise
FUFA I-Premise
y I-Premise
al I-Premise
FOLFIRI I-Premise
en I-Premise
el I-Premise
conjunto I-Premise
por I-Premise
protocolo I-Premise
( I-Premise
n=119 I-Premise
) I-Premise
después I-Premise
de I-Premise
desenmascarar I-Premise
la I-Premise
ST I-Premise
en I-Premise
la I-Premise
base I-Premise
de I-Premise
datos I-Premise
reveló I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
una I-Premise
mejor I-Premise
respuesta I-Premise
global I-Premise
al I-Premise
FOLFIRI I-Premise
( I-Premise
9/19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
en I-Premise
la I-Premise
ST I-Premise
alta I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
FUFA I-Premise
( I-Premise
5/23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p=0,077 I-Premise
) I-Premise
. I-Premise

En B-Premise
los I-Premise
pacientes I-Premise
con I-Premise
biopsias I-Premise
tomadas I-Premise
de I-Premise
lesiones I-Premise
hepáticas I-Premise
( I-Premise
n=91 I-Premise
) I-Premise
la I-Premise
respuesta I-Premise
global I-Premise
a I-Premise
FOLFIRI I-Premise
y I-Premise
FUFA I-Premise
en I-Premise
TS I-Premise
alta I-Premise
fue I-Premise
del I-Premise
53% I-Premise
( I-Premise
9/17 I-Premise
) I-Premise
y I-Premise
del I-Premise
18% I-Premise
( I-Premise
3/17 I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
p=0,035 I-Premise
) I-Premise
. I-Premise

En B-Premise
los I-Premise
pacientes I-Premise
con I-Premise
TS I-Premise
baja, I-Premise
no I-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
notables I-Premise
en I-Premise
la I-Premise
respuesta I-Premise
global I-Premise
a I-Premise
FOLFIRI I-Premise
y I-Premise
FUFA. I-Premise

La B-Claim
toma I-Claim
de I-Claim
una I-Claim
biopsia I-Claim
previa I-Claim
al I-Claim
tratamiento I-Claim
es I-Claim
un I-Claim
procedimiento I-Claim
seguro I-Claim
y I-Claim
factible I-Claim
en I-Claim
el I-Claim
CCRm. I-Claim

Tras B-Claim
la I-Claim
validación I-Claim
de I-Claim
nuestros I-Claim
datos I-Claim
en I-Claim
un I-Claim
grupo I-Claim
más I-Claim
amplio, I-Claim
la I-Claim
determinación I-Claim
de I-Claim
la I-Claim
ST I-Claim
puede I-Claim
tener I-Claim
el I-Claim
potencial I-Claim
de I-Claim
ayudar I-Claim
a I-Claim
dirigir I-Claim
mejor I-Claim
el I-Claim
tratamiento I-Claim
sistémico I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CCRm I-Claim
principalmente I-Claim
no I-Claim
resecable. I-Claim

No O
se O
sabe O
si O
el O
yodo O
radioactivo O
en O
dosis O
bajas O
( O
1,1 O
GBq O
[ O
30 O
mCi O
] O
) O
es O
tan O
eficaz O
como O
el O
yodo O
radioactivo O
en O
dosis O
altas O
( O
3,7 O
GBq O
[ O
100 O
mCi O
] O
) O
para O
el O
tratamiento O
de O
pacientes O
con O
cáncer O
de O
tiroides O
diferenciado O
o O
si O
los O
efectos O
del O
yodo O
radioactivo O
( O
especialmente O
en O
dosis O
bajas O
) O
se O
ven O
influidos O
por O
el O
uso O
de O
tirotropina O
humana O
recombinante O
( O
tirotropina O
alfa O
) O
o O
la O
retirada O
de O
la O
hormona O
tiroidea O
. O

En O
29 O
centros O
del O
Reino O
Unido, O
realizamos O
un O
ensayo O
aleatorio O
de O
no O
inferioridad O
que O
comparaba O
dosis O
bajas O
y O
altas O
de O
yodo O
radiactivo, O
cada O
una O
de O
ellas O
en O
combinación O
con O
tirotropina O
alfa O
o O
con O
la O
retirada O
de O
la O
hormona O
tiroidea O
antes O
de O
la O
ablación. O

Los O
pacientes O
( O
rango O
de O
edad O
, O
16 O
a O
80 O
años O
) O
tenían O
un O
estadio O
tumoral O
T1 O
a O
T3 O
, O
con O
posible O
diseminación O
a O
los O
ganglios O
linfáticos O
cercanos O
pero O
sin O
metástasis O
. O

Los O
puntos O
finales O
fueron O
la O
tasa O
de O
éxito O
de O
la O
ablación O
entre O
6 O
y O
9 O
meses, O
los O
acontecimientos O
adversos, O
la O
calidad O
de O
vida O
y O
la O
duración O
de O
la O
estancia O
hospitalaria. O

Un O
total O
de O
438 O
pacientes O
se O
sometieron O
a O
la O
aleatorización; O
se O
pudieron O
analizar O
los O
datos O
de O
421 O
. O

Las B-Premise
tasas I-Premise
de I-Premise
éxito I-Premise
de I-Premise
la I-Premise
ablación I-Premise
fueron I-Premise
del I-Premise
85,0 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
que I-Premise
recibió I-Premise
dosis I-Premise
bajas I-Premise
de I-Premise
yodo I-Premise
radiactivo I-Premise
frente I-Premise
al I-Premise
88,9 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
que I-Premise
recibió I-Premise
la I-Premise
dosis I-Premise
alta, I-Premise
y I-Premise
del I-Premise
87,1 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tirotropina I-Premise
alfa I-Premise
frente I-Premise
al I-Premise
86,7 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
que I-Premise
se I-Premise
sometió I-Premise
a I-Premise
la I-Premise
retirada I-Premise
de I-Premise
la I-Premise
hormona I-Premise
tiroidea I-Premise
. I-Premise

Todos B-Premise
los I-Premise
intervalos I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
para I-Premise
las I-Premise
diferencias I-Premise
estaban I-Premise
dentro I-Premise
de I-Premise
±10 I-Premise
puntos I-Premise
porcentuales I-Premise
, I-Premise
lo I-Premise
que I-Premise
indica I-Premise
que I-Premise
no I-Premise
hay I-Premise
inferioridad. I-Premise

Se B-Premise
encontraron I-Premise
resultados I-Premise
similares I-Premise
para I-Premise
dosis I-Premise
bajas I-Premise
de I-Premise
yodo I-Premise
radiactivo I-Premise
más I-Premise
tirotropina I-Premise
alfa I-Premise
( I-Premise
84,3 I-Premise
% I-Premise
) I-Premise
frente I-Premise
a I-Premise
dosis I-Premise
altas I-Premise
de I-Premise
yodo I-Premise
radiactivo I-Premise
más I-Premise
retirada I-Premise
de I-Premise
hormona I-Premise
tiroidea I-Premise
( I-Premise
87,6 I-Premise
% I-Premise
) I-Premise
o I-Premise
dosis I-Premise
altas I-Premise
de I-Premise
yodo I-Premise
radiactivo I-Premise
más I-Premise
tirotropina I-Premise
alfa I-Premise
( I-Premise
90,2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Hubo B-Premise
más I-Premise
pacientes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
dosis I-Premise
altas I-Premise
que I-Premise
en I-Premise
el I-Premise
de I-Premise
dosis I-Premise
bajas I-Premise
que I-Premise
fueron I-Premise
hospitalizados I-Premise
durante I-Premise
al I-Premise
menos I-Premise
3 I-Premise
días I-Premise
( I-Premise
36,3 I-Premise
% I-Premise
frente I-Premise
a I-Premise
13,0 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Las B-Premise
proporciones I-Premise
de I-Premise
pacientes I-Premise
con I-Premise
acontecimientos I-Premise
adversos I-Premise
fueron I-Premise
del I-Premise
21 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
dosis I-Premise
bajas I-Premise
frente I-Premise
al I-Premise
33 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
dosis I-Premise
altas I-Premise
( I-Premise
P=0,007 I-Premise
) I-Premise
y I-Premise
del I-Premise
23 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tirotropina I-Premise
alfa I-Premise
frente I-Premise
al I-Premise
30 I-Premise
% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
al I-Premise
que I-Premise
se I-Premise
le I-Premise
retiró I-Premise
la I-Premise
hormona I-Premise
tiroidea I-Premise
( I-Premise
P=0,11 I-Premise
) I-Premise
. I-Premise

La B-Claim
dosis I-Claim
baja I-Claim
de I-Claim
yodo I-Claim
radiactivo I-Claim
más I-Claim
tirotropina I-Claim
alfa I-Claim
fue I-Claim
tan I-Claim
eficaz I-Claim
como I-Claim
la I-Claim
dosis I-Claim
alta I-Claim
de I-Claim
yodo I-Claim
radiactivo, I-Claim
con I-Claim
una I-Claim
tasa I-Claim
menor I-Claim
de I-Claim
acontecimientos I-Claim
adversos. I-Claim

Aunque O
se O
han O
explorado O
numerosas O
modalidades O
de O
tratamiento O
en O
pacientes O
con O
CHC O
avanzado, O
las O
opciones O
terapéuticas O
siguen O
siendo O
limitadas. O

Se B-Claim
ha I-Claim
demostrado I-Claim
que I-Claim
la I-Claim
somatostatina I-Claim
tiene I-Claim
actividad I-Claim
antimitótica I-Claim
en I-Claim
los I-Claim
tumores I-Claim
endocrinos I-Claim
y I-Claim
en I-Claim
una I-Claim
variedad I-Claim
de I-Claim
tumores I-Claim
no I-Claim
endocrinos. I-Claim

La B-Premise
expresión I-Premise
de I-Premise
los I-Premise
receptores I-Premise
de I-Premise
somatostatina I-Premise
se I-Premise
encuentra I-Premise
en I-Premise
los I-Premise
CHC, I-Premise
pero O
la B-Claim
eficacia I-Claim
del I-Claim
análogo I-Claim
de I-Claim
la I-Claim
somatostatina I-Claim
octreotida I-Claim
sigue I-Claim
siendo I-Claim
controvertida. I-Claim

Por O
lo O
tanto, O
se O
realizó O
un O
ensayo O
multicéntrico O
aleatorizado, O
doble O
ciego O
y O
controlado O
con O
placebo O
para O
evaluar O
la O
eficacia O
de O
la O
octreotida O
de O
acción O
prolongada O
para O
el O
tratamiento O
del O
CHC O
avanzado. O

Ciento O
veinte O
pacientes O
no O
tratados O
con O
CHC O
histológicamente O
confirmado O
fueron O
aleatorizados O
para O
recibir O
octreotida O
de O
acción O
prolongada O
( O
Sandostation O
LAR O
30 O
mg O
) O
por O
vía O
intramuscular O
cada O
4 O
semanas O
o O
placebo O
. O

Los O
grupos O
del O
estudio O
eran O
comparables O
en O
cuanto O
a O
las O
características O
clínicas. O

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
acumulada. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
4,7 I-Premise
meses I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
octreotida, I-Premise
frente I-Premise
a I-Premise
5,3 I-Premise
meses I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
los I-Premise
seis I-Premise
meses I-Premise
fueron I-Premise
del I-Premise
41% I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
octreotida I-Premise
y I-Premise
del I-Premise
42% I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
control, I-Premise
respectivamente. I-Premise

El B-Premise
riesgo I-Premise
relativo I-Premise
no I-Premise
ajustado I-Premise
de I-Premise
mortalidad I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
octreotida I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
fue I-Premise
de I-Premise
1,11 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
0,76-1,63; I-Premise
p I-Premise
= I-Premise
0,59). I-Premise

Cuando B-Premise
se I-Premise
ajustó I-Premise
por I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
Okuda I-Premise
, I-Premise
CTP I-Premise
y I-Premise
el I-Premise
Programa I-Premise
Italiano I-Premise
de I-Premise
Cáncer I-Premise
de I-Premise
Hígado I-Premise
( I-Premise
CLIP I-Premise
) I-Premise
, I-Premise
el I-Premise
riesgo I-Premise
relativo I-Premise
para I-Premise
la I-Premise
octreotida I-Premise
no I-Premise
cambió I-Premise
notablemente I-Premise
y I-Premise
fue I-Premise
de I-Premise
1,05 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
0,71-1,55 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,83 I-Premise
) I-Premise
. I-Premise

La B-Claim
puntuación I-Claim
CLIP I-Claim
parece I-Claim
predecir I-Claim
mejor I-Claim
la I-Claim
supervivencia I-Claim
que I-Claim
la I-Claim
puntuación I-Claim
Okuda I-Claim
y I-Claim
la I-Claim
CTP. I-Claim

El B-Claim
ensayo I-Claim
aleatorizado, I-Claim
controlado I-Claim
y I-Claim
a I-Claim
doble I-Claim
ciego I-Claim
HECTOR I-Claim
no I-Claim
mostró I-Claim
ningún I-Claim
beneficio I-Claim
en I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CHC I-Claim
tratados I-Claim
con I-Claim
octreotida I-Claim
de I-Claim
acción I-Claim
prolongada I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
placebo I-Claim
. I-Claim

Se O
investigó O
el O
papel O
del O
tamoxifeno O
y O
la O
radioterapia O
( O
RT O
) O
para O
la O
prevención O
y O
el O
tratamiento O
de O
la O
ginecomastia O
y O
el O
dolor O
de O
mama O
durante O
la O
monoterapia O
adyuvante O
con O
bicalutamida O
después O
de O
la O
prostatectomía O
radical O
( O
RP O
) O
en O
pacientes O
con O
cáncer O
de O
próstata O
. O

Además, O
se O
evaluaron O
sus O
efectos O
sobre O
el O
estado O
hormonal O
del O
paciente, O
la O
calidad O
de O
vida O
(QOL), O
la O
función O
sexual O
y O
la O
supervivencia O
libre O
de O
recaída O
del O
antígeno O
específico O
de O
la O
próstata. O

Se O
trata O
de O
un O
ensayo O
prospectivo O
multicéntrico. O

De O
enero O
de O
2002 O
a O
febrero O
de O
2004, O
se O
reclutaron O
102 O
pacientes O
que O
se O
habían O
sometido O
a O
RP O
por O
cáncer O
de O
próstata O
localizado O
o O
localmente O
avanzado O
y O
se O
asignaron O
al O
azar O
a O
3 O
grupos, O
a O
saber, O
el O
grupo O
1, O
que O
recibió O
sólo O
150 O
mg O
de O
bicalutamida O
como O
terapia O
hormonal O
adyuvante, O
el O
grupo O
2, O
que O
recibió O
bicalutamida O
y O
10 O
mg O
de O
tamoxifeno, O
y O
el O
grupo O
3, O
que O
recibió O
bicalutamida O
y O
RT. O

Las O
pacientes O
del O
grupo O
1 O
en O
las O
que O
se O
desarrolló O
la O
ginecomastia O
o O
el O
dolor O
mamario O
fueron O
aleatorizadas O
posteriormente O
para O
recibir O
tamoxifeno O
o O
RT O
poco O
después O
del O
inicio O
de O
los O
síntomas O
. O

Se O
evaluaron O
la O
ginecomastia, O
el O
dolor O
mamario, O
el O
antígeno O
prostático O
específico, O
la O
calidad O
de O
vida, O
la O
función O
sexual O
y O
los O
niveles O
hormonales. O

El O
seguimiento O
mínimo O
fue O
de O
12 O
meses. O

El B-Premise
67% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
1 I-Premise
tenían I-Premise
ginecomastia, I-Premise
frente I-Premise
al I-Premise
8% I-Premise
del I-Premise
grupo I-Premise
2 I-Premise
y I-Premise
el I-Premise
34% I-Premise
del I-Premise
grupo I-Premise
3. I-Premise

El B-Premise
dolor I-Premise
mamario I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
en I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
que I-Premise
en I-Premise
los I-Premise
grupos I-Premise
2 I-Premise
y I-Premise
3 I-Premise
( I-Premise
58 I-Premise
% I-Premise
frente I-Premise
a I-Premise
7 I-Premise
% I-Premise
y I-Premise
30 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Las B-Premise
diferencias I-Premise
fueron I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
1 I-Premise
y I-Premise
2 I-Premise
( I-Premise
OR I-Premise
0,12 I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
y I-Premise
los I-Premise
grupos I-Premise
1 I-Premise
y I-Premise
3 I-Premise
( I-Premise
OR I-Premise
0,52 I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

En B-Premise
las I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
1 I-Premise
que I-Premise
presentaban I-Premise
ginecomastia I-Premise
o I-Premise
dolor I-Premise
mamario I-Premise
se I-Premise
produjo I-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
en I-Premise
las I-Premise
que I-Premise
recibieron I-Premise
tamoxifeno I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Premise
tratamientos I-Premise
fueron I-Premise
bien I-Premise
tolerados I-Premise
en I-Premise
los I-Premise
3 I-Premise
grupos. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
CdV I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
2 I-Premise
y I-Premise
3 I-Premise
. I-Premise

En B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
26 I-Premise
meses, I-Premise
observamos I-Premise
12 I-Premise
recaídas I-Premise
bioquímicas. I-Premise

La B-Claim
ginecomastia I-Claim
y I-Claim
el I-Claim
dolor I-Claim
mamario I-Claim
inducidos I-Claim
por I-Claim
la I-Claim
monoterapia I-Claim
con I-Claim
bicalutamida I-Claim
después I-Claim
de I-Claim
la I-Claim
RP I-Claim
pueden I-Claim
prevenirse I-Claim
y I-Claim
tratarse I-Claim
. I-Claim

El B-Claim
tamoxifeno I-Claim
ha I-Claim
demostrado I-Claim
ser I-Claim
más I-Claim
eficaz I-Claim
y I-Claim
seguro I-Claim
que I-Claim
la I-Claim
RT I-Claim
en I-Claim
este I-Claim
contexto. I-Claim

La B-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
la I-Claim
función I-Claim
sexual I-Claim
no I-Claim
se I-Claim
ven I-Claim
influidas I-Claim
negativamente I-Claim
por I-Claim
estas I-Claim
dos I-Claim
opciones I-Claim
de I-Claim
tratamiento. I-Claim

Probar O
la O
hipótesis O
de O
que O
la O
modulación O
de O
Bcl-2 O
con O
ácido O
retinoico O
13-cis O
( O
CRA O
) O
/interferón-alfa2b O
( O
IFN O
) O
con O
paclitaxel O
( O
TAX O
) O
, O
o O
mitoxantrona O
, O
estramustina O
y O
vinorelbina O
( O
MEV O
) O
tendrá O
actividad O
clínica O
en O
hombres O
con O
cáncer O
de O
próstata O
resistente O
a O
la O
castración O
( O
CRPC O
) O
metastásico O
. O

70 O
pacientes O
fueron O
tratados O
con O
MEV O
( O
Brazo O
A O
) O
en O
un O
ciclo O
de O
3 O
semanas O
o O
CRA/IFN/TAX O
con O
un O
ciclo O
de O
8 O
semanas O
( O
Brazo O
B O
) O
. O

Se O
evaluó O
la O
respuesta, O
la O
toxicidad, O
la O
calidad O
de O
vida O
(QOL) O
y O
el O
efecto O
del O
tratamiento O
en O
los O
niveles O
de O
Bcl-2 O
en O
las O
células O
mononucleares O
de O
sangre O
periférica O
(PBMC). O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
del I-Premise
PSA I-Premise
fueron I-Premise
del I-Premise
50 I-Premise
% I-Premise
y I-Premise
el I-Premise
23 I-Premise
%, I-Premise
las I-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
medible I-Premise
( I-Premise
CR+PR I-Premise
) I-Premise
del I-Premise
14 I-Premise
% I-Premise
y I-Premise
el I-Premise
15 I-Premise
%, I-Premise
y I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
de I-Premise
19,4 I-Premise
meses I-Premise
y I-Premise
13,9 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
A I-Premise
y I-Premise
el I-Premise
brazo I-Premise
B, I-Premise
respectivamente. I-Premise

Se B-Premise
produjeron I-Premise
neutropenias I-Premise
transitorias I-Premise
de I-Premise
grado I-Premise
4 I-Premise
en I-Premise
18 I-Premise
y I-Premise
2 I-Premise
pacientes I-Premise
, I-Premise
y I-Premise
trombosis I-Premise
de I-Premise
grado I-Premise
3 I-Premise
a I-Premise
4 I-Premise
en I-Premise
7 I-Premise
pacientes I-Premise
y I-Premise
1 I-Premise
paciente I-Premise
en I-Premise
el I-Premise
brazo I-Premise
A I-Premise
y I-Premise
el I-Premise
brazo I-Premise
B I-Premise
respectivamente I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
B I-Premise
informaron I-Premise
de I-Premise
un I-Premise
descenso I-Premise
clínicamente I-Premise
significativo I-Premise
de I-Premise
la I-Premise
CdV I-Premise
entre I-Premise
el I-Premise
inicio I-Premise
y I-Premise
la I-Premise
semana I-Premise
9/10 I-Premise
(.71 I-Premise
s.d I-Premise
.) I-Premise
, I-Premise
y I-Premise
un I-Premise
nivel I-Premise
de I-Premise
QOL I-Premise
significativamente I-Premise
inferior I-Premise
al I-Premise
del I-Premise
Brazo I-Premise
A I-Premise
( I-Premise
p I-Premise
= I-Premise
0,01 I-Premise
) O
. O

Tal B-Premise
y I-Premise
como I-Premise
se I-Premise
hipotetizó, I-Premise
los I-Premise
niveles I-Premise
de I-Premise
Bcl-2 I-Premise
disminuyeron I-Premise
con I-Premise
la I-Premise
terapia I-Premise
CRA/IFN I-Premise
sólo I-Premise
en I-Premise
el I-Premise
brazo I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
MEV I-Claim
fue I-Claim
bien I-Claim
tolerado I-Claim
y I-Claim
demostró I-Claim
actividad I-Claim
clínica I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CPRC I-Claim
. I-Claim

Dado B-Claim
el I-Claim
efecto I-Claim
adverso I-Claim
de I-Claim
CRA/IFN/TAX I-Claim
sobre I-Claim
la I-Claim
CdV, I-Claim
se I-Claim
justifica I-Claim
el I-Claim
estudio I-Claim
de I-Claim
otros I-Claim
agentes I-Claim
novedosos I-Claim
dirigidos I-Claim
a I-Claim
las I-Claim
proteínas I-Claim
de I-Claim
la I-Claim
familia I-Claim
Bcl-2. I-Claim

La O
viabilidad O
de O
la O
medición O
de O
la O
proteína O
Bcl-2 O
en O
un O
entorno O
de O
grupo O
cooperativo O
es O
generadora O
de O
hipótesis O
y O
apoya O
la O
realización O
de O
más O
estudios O
como O
marcador O
para O
la O
terapia O
dirigida O
a O
Bcl-2 O
. O

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
; I-Premise
Bristol-Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
es I-Premise
un I-Premise
nuevo I-Premise
agente I-Premise
anticancerígeno I-Premise
con I-Premise
actividad I-Premise
en I-Premise
una I-Premise
serie I-Premise
de I-Premise
tumores I-Premise
humanos I-Premise
, I-Premise
incluyendo I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
ovario I-Premise
epitelial I-Premise
. I-Premise

En O
ensayos O
no O
aleatorios, O
las O
dosis O
estudiadas O
han O
oscilado O
entre O
135 O
mg/m2 O
y O
250 O
mg/m2 O
administrados O
durante O
24 O
horas O
con O
premedicación O
para O
evitar O
reacciones O
de O
hipersensibilidad O
( O
RHS O
) O
. O

Este O
estudio O
aborda O
dos O
cuestiones: O
la O
relación O
dosis-respuesta O
de O
Taxol O
en O
el O
cáncer O
de O
ovario O
recidivante O
y O
la O
seguridad O
de O
una O
infusión O
corta O
administrada O
con O
premedicación O
. O

Las O
mujeres O
con O
cáncer O
de O
ovario O
epitelial O
tratado O
con O
platino O
y O
enfermedad O
recurrente O
medible O
fueron O
aleatorizadas O
en O
un O
diseño O
bifactorial O
para O
recibir O
175 O
o O
135 O
mg/m2 O
de O
Taxol O
en O
24 O
o O
3 O
horas. O

Los O
principales O
criterios O
de O
valoración O
fueron O
la O
frecuencia O
de O
HSR O
significativas O
y O
la O
tasa O
de O
respuesta O
objetiva. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
supervivencia O
libre O
de O
progresión O
y O
la O
supervivencia O
global. O

De O
los O
407 O
pacientes O
aleatorizados, O
391 O
fueron O
elegibles O
y O
382 O
evaluables O
para O
la O
respuesta. O

El O
análisis O
se O
realizó O
según O
el O
diseño O
bifactorial O
. O

Las B-Premise
reacciones I-Premise
adversas I-Premise
graves I-Premise
fueron I-Premise
poco I-Premise
frecuentes I-Premise
(1,5% I-Premise
de I-Premise
los I-Premise
pacientes) I-Premise
y I-Premise
no I-Premise
se I-Premise
vieron I-Premise
afectadas I-Premise
ni I-Premise
por I-Premise
la I-Premise
dosis I-Premise
ni I-Premise
por I-Premise
el I-Premise
programa. I-Premise

La B-Premise
respuesta I-Premise
fue I-Premise
ligeramente I-Premise
mayor I-Premise
con I-Premise
la I-Premise
dosis I-Premise
de I-Premise
175 I-Premise
mg/m2 I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
que I-Premise
con I-Premise
la I-Premise
de I-Premise
135 I-Premise
mg/m2 I-Premise
( I-Premise
15 I-Premise
% O
) O
, O
pero B-Premise
esto I-Premise
no I-Premise
fue I-Premise
estadísticamente I-Premise
significativo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,2 I-Premise
) O
. O

Sin B-Premise
embargo, I-Premise
la I-Premise
supervivencia I-Premise
sin I-Premise
progresión I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
dosis I-Premise
altas I-Premise
( I-Premise
19 I-Premise
frente I-Premise
a I-Premise
14 I-Premise
semanas; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
). I-Premise

Se B-Premise
observó I-Premise
una I-Premise
neutropenia I-Premise
significativamente I-Premise
mayor I-Premise
cuando I-Premise
el I-Premise
Taxol I-Premise
se I-Premise
administró I-Premise
en I-Premise
infusión I-Premise
de I-Premise
24 I-Premise
horas. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
los I-Premise
grupos I-Premise
de I-Premise
24 I-Premise
y I-Premise
3 I-Premise
horas I-Premise
( I-Premise
19 I-Premise
% I-Premise
y I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
= I-Premise
.6 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
de I-Premise
supervivencia. I-Premise

La B-Claim
infusión I-Claim
de I-Claim
3 I-Claim
horas I-Claim
de I-Claim
Taxol I-Claim
es I-Claim
segura I-Claim
cuando I-Claim
se I-Claim
administra I-Claim
con I-Claim
premedicación I-Claim
y I-Claim
se I-Claim
asocia I-Claim
con I-Claim
menos I-Claim
neutropenia I-Claim
. I-Claim

Existe O
un O
modesto O
efecto O
de O
la O
dosis O
con O
un O
mayor O
tiempo O
hasta O
la O
progresión O
con O
175 O
mg/m2. O

La B-Claim
observación I-Claim
de I-Claim
que I-Claim
una I-Claim
infusión I-Claim
más I-Claim
prolongada I-Claim
produce I-Claim
una I-Claim
mayor I-Claim
mielosupresión, I-Claim
pero I-Claim
no I-Claim
produce I-Claim
mayores I-Claim
tasas I-Claim
de I-Claim
respuesta, I-Claim
debería I-Claim
dar I-Claim
lugar I-Claim
a I-Claim
nuevos I-Claim
estudios I-Claim
para I-Claim
determinar I-Claim
la I-Claim
dosis I-Claim
y I-Claim
el I-Claim
calendario I-Claim
óptimos I-Claim
de I-Claim
este I-Claim
interesante I-Claim
nuevo I-Claim
agente. I-Claim

La O
anemia O
es O
común O
en O
los O
pacientes O
que O
reciben O
quimioterapia O
, O
causando O
síntomas O
que O
tienen O
un O
gran O
impacto O
en O
la O
calidad O
de O
vida O
( O
QoL O
) O
. O

La O
epoetina O
beta O
aumenta O
rápidamente O
los O
niveles O
de O
hemoglobina O
( O
Hb O
) O
y O
mejora O
la O
calidad O
de O
vida O
de O
los O
pacientes O
anémicos O
con O
diversos O
tumores O
. O

Se O
trata O
de O
un O
estudio O
aleatorizado, O
doble O
ciego, O
de O
grupos O
paralelos O
y O
de O
búsqueda O
de O
dosis O
que O
evalúa O
la O
eficacia O
y O
la O
seguridad O
de O
la O
epoetina O
beta O
una O
vez O
a O
la O
semana O
en O
pacientes O
con O
tumores O
sólidos O
que O
reciben O
quimioterapia. O

Los O
pacientes O
adultos O
con O
anemia O
( O
Hb O
< O
11 O
g/dL O
) O
fueron O
aleatorizados O
para O
recibir O
epoetina O
beta O
30.000 O
UI O
o O
20.000 O
UI O
una O
vez O
por O
semana O
durante O
12 O
semanas O
. O

Todos O
los O
pacientes O
recibieron O
suplementos O
de O
hierro O
por O
vía O
oral. O

Se O
evaluaron O
a O
intervalos O
regulares O
los O
niveles O
de O
hemoglobina, O
la O
necesidad O
de O
transfusiones O
y O
la O
calidad O
de O
vida O
[puntuación O
de O
la O
subescala O
de O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-Fatiga O
(FACT-F)]. O

Se O
aleatorizó O
a O
50 O
pacientes; O
30 O
recibieron O
epoetina O
beta O
30.000 O
UI O
una O
vez O
por O
semana O
y O
20 O
recibieron O
20.000 O
UI O
una O
vez O
por O
semana. O

El B-Premise
aumento I-Premise
medio I-Premise
( I-Premise
+/- I-Premise
SD I-Premise
) I-Premise
de I-Premise
la I-Premise
Hb I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
la I-Premise
semana I-Premise
12 I-Premise
fue I-Premise
de I-Premise
1,75 I-Premise
+/- I-Premise
2,15 I-Premise
g/dL I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
30.000 I-Premise
UI I-Premise
( I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
frente I-Premise
al I-Premise
inicio I-Premise
) I-Premise
y I-Premise
de I-Premise
1,04 I-Premise
+/- I-Premise
1,75 I-Premise
g/dL I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
20.000 I-Premise
UI I-Premise
( I-Premise
no I-Premise
significativo I-Premise
) I-Premise
. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
respuesta I-Premise
de I-Premise
la I-Premise
hemoglobina I-Premise
( I-Premise
aumento I-Premise
de I-Premise
la I-Premise
Hb I-Premise
> I-Premise
o=2 I-Premise
g/dL I-Premise
con I-Premise
respecto I-Premise
al I-Premise
valor I-Premise
inicial I-Premise
) I-Premise
en I-Premise
el I-Premise
78,3 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
epoetina I-Premise
beta I-Premise
30.000 I-Premise
UI I-Premise
y I-Premise
en I-Premise
el I-Premise
66,7 I-Premise
% I-Premise
que I-Premise
recibieron I-Premise
epoetina I-Premise
beta I-Premise
20.000 I-Premise
UI I-Premise
. I-Premise

Las O
mejoras O
en O
la O
puntuación O
de O
la O
subescala O
FACT-F O
se O
correlacionaron O
significativamente O
( O
P O
< O
0,001 O
) O
con O
los O
aumentos O
del O
nivel O
de O
Hb O
. O

El O
uso O
de O
transfusiones O
fue O
bajo O
durante O
el O
estudio O
en O
ambos O
grupos. O

Ambos B-Premise
regímenes I-Premise
de I-Premise
epoetina I-Premise
beta I-Premise
fueron I-Premise
bien I-Premise
tolerados I-Premise
y I-Premise
no I-Premise
hubo I-Premise
acontecimientos I-Premise
adversos I-Premise
dependientes I-Premise
de I-Premise
la I-Premise
dosis. I-Premise

La B-Claim
epoetina I-Claim
beta I-Claim
30.000 I-Claim
UI I-Claim
una I-Claim
vez I-Claim
por I-Claim
semana I-Claim
es I-Claim
un I-Claim
tratamiento I-Claim
eficaz I-Claim
y I-Claim
bien I-Claim
tolerado I-Claim
de I-Claim
la I-Claim
anemia I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
tumores I-Claim
sólidos I-Claim
. I-Claim

Ante O
el O
conocimiento O
de O
que O
5 O
años O
de O
tamoxifeno O
adyuvante O
es O
menos O
eficaz O
que O
2 O
a O
3 O
años O
de O
tamoxifeno O
seguidos O
de O
2 O
a O
3 O
años O
de O
anastrozol/exemestano O
, O
diseñamos O
un O
ensayo O
controlado O
aleatorio O
multicéntrico O
a O
doble O
ciego O
en O
mujeres O
que O
tomaban O
tamoxifeno O
con O
un O
endometrio O
engrosado O
para O
comparar O
los O
parámetros O
uterinos O
y O
de O
calidad O
de O
vida O
entre O
las O
que O
cambiaban O
a O
anastrozol O
y O
las O
que O
continuaban O
con O
tamoxifeno O
. O

Las O
mujeres O
posmenopáusicas O
asintomáticas O
que O
tomaron O
tamoxifeno O
adyuvante O
durante O
2 O
a O
3 O
años O
por O
un O
cáncer O
de O
mama O
operable O
con O
un O
doble O
grosor O
endometrial O
superior O
a O
7 O
mm O
fueron O
aleatorizadas O
a O
20 O
mg O
de O
tamoxifeno O
o O
1 O
mg O
de O
anastrozol O
durante O
el O
tiempo O
restante O
, O
en O
total O
5 O
años O
. O

Los O
comprimidos O
eran O
irreconocibles O
para O
la O
asignación O
del O
fármaco O
. O

Los O
criterios O
de O
valoración O
primarios O
fueron O
las O
diferencias O
en O
el O
grosor O
doble O
del O
endometrio O
y O
el O
volumen O
uterino O
al O
cabo O
de O
un O
año. O

Los O
datos O
uterinos O
y O
de O
calidad O
de O
vida O
se O
analizaron O
mediante O
métodos O
de O
regresión, O
y O
los O
valores O
perdidos O
se O
trataron O
mediante O
imputación O
múltiple. O

Setenta O
y O
dos O
mujeres O
(edad O
media, O
60 O
años) O
fueron O
asignadas O
al O
azar O
en O
cinco O
hospitales. O

En B-Premise
comparación I-Premise
con I-Premise
las I-Premise
mujeres I-Premise
que I-Premise
continuaron I-Premise
con I-Premise
el I-Premise
tamoxifeno, I-Premise
las I-Premise
mujeres I-Premise
que I-Premise
cambiaron I-Premise
a I-Premise
anastrozol I-Premise
experimentaron I-Premise
una I-Premise
disminución I-Premise
del I-Premise
53 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
41 I-Premise
% I-Premise
-63 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
grosor I-Premise
doble I-Premise
del I-Premise
endometrio I-Premise
y I-Premise
una I-Premise
disminución I-Premise
del I-Premise
51 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
39 I-Premise
% I-Premise
-60 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
volumen I-Premise
uterino I-Premise
. I-Premise

La B-Premise
sequedad I-Premise
vaginal I-Premise
( I-Premise
b I-Premise
= I-Premise
0,064 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,016-0,112 I-Premise
) I-Premise
y I-Premise
los I-Premise
problemas I-Premise
sexuales I-Premise
( I-Premise
b I-Premise
= I-Premise
0,054 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,007-0,102 I-Premise
) I-Premise
aumentaron I-Premise
en I-Premise
las I-Premise
mujeres I-Premise
que I-Premise
tomaban I-Premise
anastrozol I-Premise
en I-Premise
comparación I-Premise
con I-Premise
las I-Premise
que I-Premise
tomaban I-Premise
tamoxifeno I-Premise
. I-Premise

Los B-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
no I-Premise
difirieron I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
tasa I-Premise
de I-Premise
retirada I-Premise
y I-Premise
la I-Premise
experiencia I-Premise
de I-Premise
eventos I-Premise
adversos I-Premise
( I-Premise
graves I-Premise
) I-Premise
. I-Premise

A O
pesar O
del O
cierre O
prematuro O
del O
ensayo, O
nuestros O
datos O
proporcionaron O
información O
valiosa. O

El B-Claim
cambio I-Claim
a I-Claim
anastrozol I-Claim
disminuyó I-Claim
fuertemente I-Claim
el I-Claim
grosor I-Claim
endometrial I-Claim
y I-Claim
el I-Claim
volumen I-Claim
uterino, I-Claim
pero I-Claim
aumentó I-Claim
los I-Claim
trastornos I-Claim
sexuales I-Claim
. I-Claim

Se B-Claim
necesitan I-Claim
intervenciones I-Claim
seguras I-Claim
y I-Claim
eficaces I-Claim
para I-Claim
aliviar I-Claim
la I-Claim
disfunción I-Claim
sexual I-Claim
. I-Claim

La B-Claim
depresión, I-Claim
la I-Claim
ansiedad, I-Claim
la I-Claim
fatiga I-Claim
y I-Claim
el I-Claim
deterioro I-Claim
del I-Claim
bienestar I-Claim
son I-Claim
comunes, I-Claim
importantes I-Claim
y I-Claim
están I-Claim
estrechamente I-Claim
relacionados I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
avanzado. I-Claim

El O
objetivo O
era O
identificar O
los O
efectos O
de O
un O
antidepresivo O
establecido O
sobre O
estos O
síntomas O
y O
la O
supervivencia O
en O
pacientes O
con O
cáncer O
avanzado O
que O
no O
tenían O
depresión O
mayor O
según O
la O
evaluación O
de O
los O
médicos O
. O

Entre O
julio O
de O
2001 O
y O
febrero O
de O
2006, O
189 O
pacientes O
con O
cáncer O
avanzado O
fueron O
asignados O
aleatoriamente O
a O
sertralina O
50 O
mg O
( O
n=95 O
) O
, O
o O
placebo O
( O
n=94 O
) O
, O
una O
vez O
al O
día O
. O

El O
resultado O
primario O
fue O
la O
depresión, O
evaluada O
por O
la O
escala O
de O
depresión O
del O
Centro O
de O
Estudios O
Epidemiológicos O
(CES-D); O
los O
principales O
resultados O
secundarios O
fueron: O
la O
ansiedad, O
evaluada O
por O
las O
Escalas O
Hospitalarias O
de O
Ansiedad O
y O
Depresión O
(HADS-A); O
la O
calidad O
de O
vida O
general O
y O
la O
fatiga, O
evaluadas O
por O
las O
escalas O
de O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer O
General O
y O
de O
Fatiga O
(FACT-G O
y O
FACT-F, O
respectivamente); O
y O
las O
calificaciones O
de O
los O
médicos O
sobre O
la O
calidad O
de O
vida O
mediante O
el O
Índice O
de O
Calidad O
de O
Vida O
de O
Spizter O
(SQLI). O

Se O
utilizaron O
múltiples O
medidas O
para O
corroborar O
los O
resultados O
más O
importantes O
. O

Los O
análisis O
primarios O
se O
realizaron O
por O
intención O
de O
tratar O
y O
se O
basaron O
en O
las O
puntuaciones O
de O
la O
escala O
a O
las O
4 O
y O
8 O
semanas. O

Los O
beneficios O
de O
la O
sertralina O
en O
comparación O
con O
el O
placebo O
se O
expresan O
en O
un O
rango O
de O
+100 O
( O
es O
decir, O
el O
máximo O
beneficio O
) O
a O
-100 O
( O
es O
decir, O
el O
máximo O
daño O
) O
; O
una O
diferencia O
de O
10 O
se O
consideró O
clínicamente O
significativa O
. O

Este O
ensayo O
clínico O
está O
registrado O
en O
el O
sitio O
web O
de O
Current O
Controlled O
Trials O
http O
: O
//www.controlled-trials.com/ISRCTN72466475 O
. O

La B-Premise
sertralina I-Premise
no I-Premise
tuvo I-Premise
un I-Premise
efecto I-Premise
significativo I-Premise
( I-Premise
escala I-Premise
, I-Premise
beneficio I-Premise
sobre I-Premise
el I-Premise
placebo I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
] I-Premise
) I-Premise
sobre I-Premise
la I-Premise
depresión I-Premise
( I-Premise
CES-D I-Premise
0,4 I-Premise
[ I-Premise
-2,6 I-Premise
a I-Premise
3,4 I-Premise
] I-Premise
) I-Premise
, I-Premise
la I-Premise
ansiedad I-Premise
( I-Premise
HADS-A I-Premise
2,0 I-Premise
[ I-Premise
-1,5 I-Premise
a I-Premise
5,5 I-Premise
] I-Premise
) I-Premise
, I-Premise
la I-Premise
fatiga I-Premise
( I-Premise
FACT-F I-Premise
0,3 I-Premise
[ I-Premise
-4,3 I-Premise
a I-Premise
4.9 I-Premise
) I-Premise
, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
( I-Premise
FACT-G I-Premise
1,7 I-Premise
[ I-Premise
-1,3 I-Premise
a I-Premise
4,7 I-Premise
] I-Premise
) I-Premise
, I-Premise
o I-Premise
las I-Premise
calificaciones I-Premise
de I-Premise
los I-Premise
médicos I-Premise
( I-Premise
SQLI I-Premise
2,0 I-Premise
[ I-Premise
-2,5 I-Premise
a I-Premise
6,5 I-Premise
] I-Premise
) I-Premise
, I-Premise
y I-Premise
el I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
descartó I-Premise
un I-Premise
beneficio I-Premise
clínicamente I-Premise
significativo I-Premise
para I-Premise
todos I-Premise
los I-Premise
resultados I-Premise
principales I-Premise
. I-Premise

La B-Premise
sertralina I-Premise
se I-Premise
interrumpió I-Premise
con I-Premise
más I-Premise
frecuencia I-Premise
y I-Premise
antes I-Premise
que I-Premise
el I-Premise
placebo I-Premise
( I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
1,46 I-Premise
[ I-Premise
1,03-2,06 I-Premise
] I-Premise
, I-Premise
p=0,03 I-Premise
) I-Premise
. I-Premise

El O
reclutamiento O
se O
detuvo O
después O
de O
que O
el B-Premise
primer I-Premise
análisis I-Premise
intermedio I-Premise
planificado I-Premise
en I-Premise
febrero I-Premise
de I-Premise
2006 I-Premise
( I-Premise
n=150 I-Premise
) I-Premise
mostrara I-Premise
que I-Premise
la I-Premise
supervivencia I-Premise
era I-Premise
mayor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
a I-Premise
placebo I-Premise
que I-Premise
en I-Premise
los I-Premise
asignados I-Premise
a I-Premise
sertralina I-Premise
( I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
no I-Premise
ajustado I-Premise
1,60 I-Premise
[ I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
1,04-2,45 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0,04 I-Premise
; I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
ajustado I-Premise
1,62 I-Premise
[ I-Premise
1,06-2,41 I-Premise
] I-Premise
, I-Premise
modelo I-Premise
de I-Premise
Cox I-Premise
p=0,02 I-Premise
) O
. O

Sin B-Premise
embargo, I-Premise
en I-Premise
el I-Premise
análisis I-Premise
final I-Premise
de I-Premise
julio I-Premise
de I-Premise
2006 I-Premise
de I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
( I-Premise
n=189 I-Premise
) I-Premise
y I-Premise
con I-Premise
un I-Premise
seguimiento I-Premise
más I-Premise
largo, I-Premise
la I-Premise
supervivencia I-Premise
no I-Premise
difirió I-Premise
significativamente I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
no I-Premise
ajustado I-Premise
1,35 I-Premise
[ I-Premise
0,95-1,91 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0,09 I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
ajustado I-Premise
1,27 I-Premise
[ I-Premise
0,87-1,84 I-Premise
] I-Premise
, I-Premise
modelo I-Premise
de I-Premise
Cox I-Premise
p=0,20 I-Premise
) I-Premise
. I-Premise

El O
ensayo O
se O
cerró O
porque O
había O
descartado O
un O
beneficio O
significativo O
de O
la O
sertralina O
. O

La B-Claim
sertralina I-Claim
no I-Claim
mejoró I-Claim
los I-Claim
síntomas I-Claim
, I-Claim
el I-Claim
bienestar I-Claim
o I-Claim
la I-Claim
supervivencia I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
avanzado I-Claim
que I-Claim
no I-Claim
tienen I-Claim
depresión I-Claim
mayor I-Claim
, I-Claim
y I-Claim
debe I-Claim
reservarse I-Claim
para I-Claim
aquellos I-Claim
con I-Claim
una I-Claim
indicación I-Claim
probada I-Claim
. I-Claim

Este O
ensayo O
aleatorio O
doble O
ciego O
de O
fase O
II O
examinó O
si O
el O
vandetanib O
, O
un O
inhibidor O
de O
los O
receptores O
del O
factor O
de O
crecimiento O
endotelial O
vascular O
y O
epidérmico, O
podía O
prolongar O
la O
supervivencia O
sin O
progresión O
en O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
pequeñas O
que O
respondían O
al O
tratamiento. O

Los O
pacientes O
elegibles O
con O
respuesta O
completa O
( O
CR O
) O
o O
respuesta O
parcial O
( O
PR O
) O
a O
la O
quimioterapia O
combinada O
( O
+/- O
radiación O
torácica O
o O
craneal O
profiláctica O
) O
recibieron O
vandetanib O
oral O
300 O
mg/d O
o O
placebo O
emparejado O
. O

Con O
100 O
pacientes O
y O
77 O
eventos, O
el O
estudio O
tenía O
un O
poder O
del O
80 O
% O
para O
detectar O
una O
mejora O
en O
la O
mediana O
de O
la O
supervivencia O
libre O
de O
progresión O
de O
4 O
a O
6,5 O
meses O
(prueba O
unilateral, O
nivel O
del O
10 O
%). O

Entre O
mayo O
de O
2003 O
y O
marzo O
de O
2006, O
se O
registraron O
107 O
pacientes, O
46 O
con O
enfermedad O
limitada O
y O
61 O
con O
enfermedad O
extensa. O

Hubo O
menos O
pacientes O
con O
un O
estado O
de O
rendimiento O
de O
0 O
( O
n O
= O
11 O
frente O
a O
20 O
) O
, O
y O
menos O
tenían O
CR O
a O
la O
terapia O
inicial O
( O
n O
= O
4 O
frente O
a O
8 O
) O
en O
el O
brazo O
de O
vandetanib O
. O

Los B-Premise
pacientes I-Premise
de I-Premise
Vandetanib I-Premise
tuvieron I-Premise
más I-Premise
toxicidad I-Premise
y I-Premise
requirieron I-Premise
más I-Premise
modificaciones I-Premise
de I-Premise
dosis I-Premise
por I-Premise
toxicidad I-Premise
gastrointestinal I-Premise
y I-Premise
erupción I-Premise
cutánea I-Premise
. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
prolongación I-Premise
asintomática I-Premise
del I-Premise
intervalo I-Premise
QT I-Premise
corregido I-Premise
( I-Premise
QTC I-Premise
) I-Premise
en I-Premise
ocho I-Premise
pacientes I-Premise
con I-Premise
vandetanib I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
para I-Premise
vandetanib I-Premise
y I-Premise
placebo I-Premise
fue I-Premise
de I-Premise
2,7 I-Premise
y I-Premise
2,8 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1,01 I-Premise
; I-Premise
80 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,75 I-Premise
a I-Premise
1,36 I-Premise
; I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.51 I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
global I-Premise
de I-Premise
vandetanib I-Premise
fue I-Premise
de I-Premise
10,6 I-Premise
frente I-Premise
a I-Premise
11,9 I-Premise
meses I-Premise
de I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
1,43 I-Premise
; I-Premise
IC I-Premise
del I-Premise
80 I-Premise
% I-Premise
, I-Premise
1,00 I-Premise
a I-Premise
2,05 I-Premise
; I-Premise
P I-Premise
unilateral I-Premise
= I-Premise
0,9 I-Premise
) I-Premise
. I-Premise

En B-Premise
los I-Premise
análisis I-Premise
de I-Premise
subgrupos I-Premise
planificados, I-Premise
se I-Premise
observó I-Premise
una I-Premise
interacción I-Premise
significativa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
): I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
vandetanib I-Premise
en I-Premise
estadio I-Premise
limitado I-Premise
tuvieron I-Premise
una I-Premise
mayor I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
HR I-Premise
, I-Premise
0,45 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,07 I-Premise
) I-Premise
y I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
vandetanib I-Premise
en I-Premise
estadio I-Premise
extenso I-Premise
una I-Premise
menor I-Premise
supervivencia I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
2,27 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,996 I-Premise
) I-Premise
. I-Premise

El B-Claim
vandetanib I-Claim
no I-Claim
demostró I-Claim
su I-Claim
eficacia I-Claim
como I-Claim
terapia I-Claim
de I-Claim
mantenimiento I-Claim
para I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
pequeñas. I-Claim

Las O
células O
cancerosas O
dependen O
de O
la O
angiogénesis O
para O
crecer O
y O
diseminarse, O
y O
el O
cáncer O
de O
pulmón O
de O
células O
pequeñas O
(CPCP) O
es O
un O
tumor O
altamente O
angiogénico. O

Se O
evaluó O
la O
talidomida O
, O
un O
agente O
antiangiogénico O
, O
cuando O
se O
combina O
con O
la O
quimioterapia O
y O
como O
tratamiento O
de O
mantenimiento O
. O

Un O
total O
de O
724 O
pacientes O
( O
51 O
% O
con O
enfermedad O
limitada O
y O
49 O
% O
con O
enfermedad O
extensa O
) O
fueron O
asignados O
aleatoriamente O
a O
recibir O
placebo O
o O
cápsulas O
de O
talidomida O
, O
100-200 O
mg O
diarios O
durante O
un O
máximo O
de O
2 O
años O
. O

Todos O
los O
pacientes O
recibieron O
etopósido O
y O
carboplatino O
cada O
3 O
semanas O
durante O
un O
máximo O
de O
seis O
ciclos. O

Los O
criterios O
de O
valoración O
fueron O
la O
supervivencia O
global O
, O
la O
supervivencia O
sin O
progresión O
, O
la O
tasa O
de O
respuesta O
tumoral O
, O
la O
toxicidad O
y O
la O
calidad O
de O
vida O
( O
QoL O
) O
. O

Los O
cocientes O
de O
riesgos O
( O
HR O
) O
para O
comparar O
la O
talidomida O
con O
el O
placebo O
se O
estimaron O
mediante O
un O
modelo O
de O
regresión O
de O
Cox O
. O

Las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
10,5 I-Premise
meses I-Premise
( I-Premise
placebo I-Premise
) I-Premise
y I-Premise
10,1 I-Premise
meses I-Premise
( I-Premise
talidomida I-Premise
) I-Premise
( I-Premise
HR I-Premise
para I-Premise
la I-Premise
muerte I-Premise
= I-Premise
1,09 I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0,93 I-Premise
a I-Premise
1,27 I-Premise
; I-Premise
P I-Premise
= I-Premise
.28 I-Premise
) I-Premise
. I-Premise

Entre B-Premise
los I-Premise
pacientes I-Premise
con I-Premise
enfermedad I-Premise
en I-Premise
estadio I-Premise
limitado I-Premise
, I-Premise
no I-Premise
hubo I-Premise
evidencia I-Premise
de I-Premise
una I-Premise
diferencia I-Premise
de I-Premise
supervivencia I-Premise
( I-Premise
HR I-Premise
para I-Premise
la I-Premise
muerte I-Premise
= I-Premise
0,91 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0,73 I-Premise
a I-Premise
1,15 I-Premise
) O
, O
pero B-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
enfermedad I-Premise
extensa I-Premise
, I-Premise
la I-Premise
supervivencia I-Premise
fue I-Premise
peor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
talidomida I-Premise
( I-Premise
HR I-Premise
para I-Premise
la I-Premise
muerte I-Premise
= I-Premise
1,36 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1,10 I-Premise
a I-Premise
1,68 I-Premise
) O
. O

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
sin I-Premise
progresión I-Premise
también I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
( I-Premise
HR I-Premise
= I-Premise
1,07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0,92 I-Premise
a I-Premise
1,24 I-Premise
) I-Premise
. I-Premise

La B-Premise
talidomida I-Premise
se I-Premise
asoció I-Premise
con I-Premise
un I-Premise
mayor I-Premise
riesgo I-Premise
de I-Premise
sufrir I-Premise
un I-Premise
evento I-Premise
trombótico, I-Premise
principalmente I-Premise
una I-Premise
embolia I-Premise
pulmonar I-Premise
y I-Premise
una I-Premise
trombosis I-Premise
venosa I-Premise
profunda I-Premise
( I-Premise
19% I-Premise
de I-Premise
talidomida I-Premise
frente I-Premise
al I-Premise
10% I-Premise
de I-Premise
placebo; I-Premise
HR I-Premise
= I-Premise
2,13; I-Premise
IC I-Premise
del I-Premise
95% I-Premise
= I-Premise
1,41 I-Premise
a I-Premise
3,20; I-Premise
P I-Premise
<0,001 I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
tratamientos I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
los I-Premise
efectos I-Premise
tóxicos I-Premise
hematológicos I-Premise
y I-Premise
no I-Premise
hematológicos I-Premise
, O
excepto B-Premise
que I-Premise
un I-Premise
mayor I-Premise
número I-Premise
de I-Premise
pacientes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
talidomida I-Premise
presentó I-Premise
erupción I-Premise
cutánea I-Premise
, I-Premise
estreñimiento I-Premise
o I-Premise
neuropatía I-Premise
. O

En O
general, O
las O
puntuaciones B-Claim
de I-Claim
la I-Claim
CdV I-Claim
fueron I-Claim
similares I-Claim
en I-Claim
los I-Claim
dos I-Claim
grupos I-Claim
de I-Claim
tratamiento, I-Claim
pero B-Claim
la I-Claim
talidomida I-Claim
se I-Claim
asoció I-Claim
con I-Claim
menos I-Claim
insomnio I-Claim
y I-Claim
diarrea I-Claim
y I-Claim
más I-Claim
estreñimiento I-Claim
y I-Claim
neuropatía I-Claim
periférica. I-Claim

En O
este O
gran O
ensayo O
aleatorio, O
la B-Claim
talidomida I-Claim
en I-Claim
combinación I-Claim
con I-Claim
la I-Claim
quimioterapia I-Claim
no I-Claim
mejoró I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPCP, I-Claim
pero I-Claim
se I-Claim
asoció I-Claim
con I-Claim
un I-Claim
mayor I-Claim
riesgo I-Claim
de I-Claim
eventos I-Claim
trombóticos. I-Claim

La B-Claim
vinorelbina I-Claim
, I-Claim
un I-Claim
alcaloide I-Claim
de I-Claim
la I-Claim
vinca I-Claim
semisintético, I-Claim
representa I-Claim
un I-Claim
tratamiento I-Claim
bien I-Claim
tolerado I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
edad I-Claim
avanzada I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
no I-Claim
microcítico I-Claim
( I-Claim
CPNM I-Claim
) I-Claim
avanzado. I-Claim

Se O
exploró O
la O
calidad O
de O
vida O
( O
QoL O
) O
de O
tales O
pacientes O
en O
un O
ensayo O
aleatorio O
multicéntrico O
que O
comparó O
el O
tratamiento O
con O
vinorelbina O
con O
el O
cuidado O
de O
apoyo O
solo O
. O

Los O
pacientes O
elegibles O
tenían O
70 O
años O
o O
más O
, O
tenían O
un O
CPNM O
en O
estadio O
IV O
o O
IIIB O
que O
no O
era O
elegible O
para O
la O
radioterapia O
, O
y O
tenían O
un O
estado O
de O
rendimiento O
de O
0-2 O
( O
un O
estado O
de O
totalmente O
activo O
a O
un O
estado O
de O
capaz O
de O
todo O
el O
cuidado O
de O
sí O
mismo O
pero O
incapaz O
de O
trabajar O
) O
. O

La O
vinorelbina O
se O
administró O
por O
vía O
intravenosa O
los O
días O
1 O
y O
8 O
de O
un O
ciclo O
de O
tratamiento O
de O
21 O
días, O
para O
un O
total O
de O
seis O
ciclos. O

La O
calidad O
de O
vida O
se O
evaluó O
con O
los O
cuestionarios O
QLQ-C30 O
y O
QLQ-LC13 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer, O
y O
los O
datos O
de O
calidad O
de O
vida O
se O
analizaron O
ajustando O
un O
modelo O
lineal O
mixto O
para O
cada O
escala O
de O
calidad O
de O
vida. O

Se O
trazaron O
curvas O
de O
supervivencia O
y O
se O
compararon O
con O
la O
prueba O
de O
Mantel-Haenszel. O

Los O
riesgos O
relativos O
de O
muerte O
y O
los O
intervalos O
de O
confianza O
( O
IC O
) O
del O
95 O
% O
se O
estimaron O
mediante O
el O
modelo O
de O
Cox O
. O

Los O
investigadores, O
que O
no O
conocían O
los O
resultados, O
interrumpieron O
el O
ensayo O
antes O
de O
tiempo O
debido O
a O
la O
baja O
tasa O
de O
inscripción. O

( O
De O
abril O
de O
1996 O
a O
noviembre O
de O
1997, O
se O
asignaron O
aleatoriamente O
191 O
de O
los O
350 O
pacientes O
previstos. O
) O

Se O
han O
analizado O
los O
datos O
de O
161 O
pacientes. O

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
vinorelbina I-Premise
obtuvieron I-Premise
mejores I-Premise
puntuaciones I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
control I-Premise
en I-Premise
las I-Premise
escalas I-Premise
de I-Premise
funcionamiento I-Premise
de I-Premise
la I-Premise
CdV I-Premise
, I-Premise
y I-Premise
manifestaron I-Premise
menos I-Premise
síntomas I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
pulmón, I-Premise
pero I-Premise
informaron I-Premise
de I-Premise
peores I-Premise
síntomas I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
toxicidad I-Premise
. I-Premise

Hubo B-Premise
una I-Premise
ventaja I-Premise
de I-Premise
supervivencia I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03) I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
vinorelbina; I-Premise
la O
mediana B-Premise
de I-Premise
supervivencia I-Premise
aumentó I-Premise
de I-Premise
21 I-Premise
a I-Premise
28 I-Premise
semanas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
tratado I-Premise
con I-Premise
vinorelbina. I-Premise

El B-Premise
riesgo I-Premise
relativo I-Premise
de I-Premise
muerte I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
vinorelbina I-Premise
fue I-Premise
de I-Premise
0,65 I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,45-0,93 I-Premise
) I-Premise
. I-Premise

La B-Claim
vinorelbina I-Claim
mejora I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
ancianos I-Claim
con I-Claim
CPNM I-Claim
avanzado I-Claim
y I-Claim
posiblemente I-Claim
mejore I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
general. I-Claim

El O
tratamiento O
del O
síndrome O
de O
anorexia/caquexia O
relacionado O
con O
el O
cáncer O
( O
CACS O
) O
es O
un O
gran O
reto O
en O
la O
práctica O
clínica O
. O

Hasta O
la O
fecha, O
se O
carece O
de O
guías O
de O
práctica O
para O
la O
prevención O
y O
el O
tratamiento O
del O
CACS. O

Los O
autores O
llevaron O
a O
cabo O
un O
estudio O
aleatorio O
para O
confirmar O
la O
eficacia O
y O
la O
seguridad O
del O
tratamiento O
del O
CACS O
utilizando O
acetato O
de O
megestrol O
( O
MA O
) O
más O
talidomida O
. O

Ciento O
dos O
candidatos O
con O
CACS O
fueron O
asignados O
aleatoriamente O
a O
dos O
grupos O
de O
tratamiento O
( O
grupo O
de O
prueba O
y O
grupo O
de O
control O
) O
: O
el O
grupo O
de O
prueba O
recibió O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
más O
talidomida O
( O
50 O
mg O
po O
, O
bid O
) O
, O
mientras O
que O
el O
grupo O
de O
control O
recibió O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
solo O
. O

La O
duración O
del O
tratamiento O
fue O
de O
8 O
semanas. O

El B-Premise
análisis I-Premise
del I-Premise
grupo I-Premise
de I-Premise
ensayo I-Premise
demostró I-Premise
un I-Premise
aumento I-Premise
significativo I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
en I-Premise
el I-Premise
peso I-Premise
corporal I-Premise
( I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
p I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
el I-Premise
apetito I-Premise
( I-Premise
p I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
y I-Premise
la I-Premise
fuerza I-Premise
de I-Premise
agarre I-Premise
( I-Premise
p I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
y I-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
, I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
pronóstico I-Premise
de I-Premise
Glasgow I-Premise
( I-Premise
p I-Premise
= I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
el I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
del I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
( I-Premise
p I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
la I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
y I-Premise
el I-Premise
factor I-Premise
de I-Premise
necrosis I-Premise
tumoral-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

En B-Premise
cambio, I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
los I-Premise
criterios I-Premise
de I-Premise
valoración I-Premise
con I-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
incluyeron I-Premise
el I-Premise
peso I-Premise
corporal I-Premise
( I-Premise
p I-Premise
< I-Premise
0,02 I-Premise
) I-Premise
y I-Premise
el I-Premise
apetito I-Premise
( I-Premise
p I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

Los B-Premise
cambios I-Premise
medios I-Premise
en I-Premise
los I-Premise
criterios I-Premise
de I-Premise
valoración I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
en I-Premise
el I-Premise
grupo I-Premise
del I-Premise
ensayo I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control: I-Premise
en I-Premise
los I-Premise
criterios I-Premise
de I-Premise
valoración I-Premise
primarios I-Premise
, I-Premise
peso I-Premise
corporal I-Premise
( I-Premise
p I-Premise
= I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
fatiga I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
y I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
y I-Premise
en I-Premise
los I-Premise
criterios I-Premise
de I-Premise
valoración I-Premise
secundarios I-Premise
, I-Premise
la I-Premise
fuerza I-Premise
de I-Premise
agarre I-Premise
( I-Premise
p I-Premise
= I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
pronóstico I-Premise
de I-Premise
Glasgow I-Premise
( I-Premise
p I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
el I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
del I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
( I-Premise
p I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
la I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
y I-Premise
el I-Premise
factor I-Premise
de I-Premise
necrosis I-Premise
tumoral-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

La B-Premise
toxicidad I-Premise
fue I-Premise
relativamente I-Premise
insignificante I-Premise
en I-Premise
ambos I-Premise
grupos. I-Premise

Un B-Claim
régimen I-Claim
combinado I-Claim
de I-Claim
AM I-Claim
y I-Claim
talidomida I-Claim
es I-Claim
más I-Claim
eficaz I-Claim
que I-Claim
la I-Claim
AM I-Claim
sola I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
CACS I-Claim
. I-Claim

Este O
ensayo O
aleatorio O
de O
no O
inferioridad O
se O
diseñó O
para O
evaluar O
si O
la O
radiocirugía O
más O
la O
radioterapia O
adyuvante O
de O
todo O
el O
cerebro O
( O
RS O
+ O
WBRT O
) O
es O
tan O
eficaz O
como O
la O
cirugía O
más O
la O
radioterapia O
de O
todo O
el O
cerebro O
( O
S O
+ O
WBRT O
) O
para O
los O
pacientes O
con O
cáncer O
con O
una O
metástasis O
cerebral O
solitaria O
, O
con O
respecto O
a O
la O
supervivencia O
global O
y O
la O
calidad O
de O
vida O
. O

Los O
principales O
criterios O
de O
inclusión O
fueron O
un O
historial O
de O
cáncer O
sistémico O
en O
los O
últimos O
5 O
años O
y O
una O
metástasis O
cerebral O
solitaria O
confirmada O
por O
resonancia O
magnética, O
adecuada O
tanto O
para O
la O
radiocirugía O
como O
para O
la O
cirugía. O

Todos O
los O
pacientes O
iban O
a O
recibir O
WBRT O
( O
30 O
Gy O
en O
10 O
fracciones O
) O
. O

Entre O
febrero O
de O
2003 O
y O
abril O
de O
2009 O
, O
40 O
pacientes O
fueron O
considerados O
elegibles O
, O
22 O
consintieron O
la O
aleatorización O
y O
21 O
fueron O
analizados O
( O
11 O
RS O
+ O
WBRT O
, O
10 O
S O
+ O
WBRT O
) O
. O

El O
ensayo O
se O
cerró O
antes O
de O
tiempo O
debido O
a O
la O
lentitud O
de O
la O
acumulación. O

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
estimada I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
y I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
fue I-Premise
de I-Premise
6,2 I-Premise
y I-Premise
2,8 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0,53 I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
0,20-1,43 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,20 I-Premise
) I-Premise
. I-Premise

Las B-Premise
correspondientes I-Premise
medianas I-Premise
de I-Premise
supervivencia I-Premise
sin I-Premise
fallos I-Premise
fueron I-Premise
de I-Premise
3,1 I-Premise
y I-Premise
1,7 I-Premise
meses I-Premise
( I-Premise
P I-Premise
= I-Premise
0,20 I-Premise
) I-Premise
. I-Premise

Para B-Premise
19 I-Premise
pacientes I-Premise
"por I-Premise
protocolo", I-Premise
2/10 I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
tuvieron I-Premise
fallo I-Premise
intracraneal I-Premise
a I-Premise
distancia I-Premise
( I-Premise
uno I-Premise
también I-Premise
tuvo I-Premise
fallo I-Premise
local I-Premise
) I-Premise
y I-Premise
3/9 I-Premise
pacientes I-Premise
de I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
tuvieron I-Premise
fallo I-Premise
intracraneal I-Premise
a I-Premise
distancia I-Premise
( I-Premise
no I-Premise
hubo I-Premise
fallos I-Premise
locales I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
toxicidades I-Premise
tardías I-Premise
por I-Premise
radiación I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
. I-Premise

Dos B-Claim
meses I-Claim
después I-Claim
de I-Claim
iniciar I-Claim
el I-Claim
tratamiento I-Claim
no I-Claim
hubo I-Claim
diferencias I-Claim
significativas I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
entre I-Claim
los I-Claim
brazos I-Claim
. I-Claim

Este B-Claim
ensayo I-Claim
aleatorio I-Claim
se I-Claim
enfrentó I-Claim
a I-Claim
las I-Claim
dificultades I-Claim
de I-Claim
adhesión I-Claim
y I-Claim
a I-Claim
la I-Claim
consiguiente I-Claim
escasa I-Claim
potencia I-Claim
estadística I-Claim
que I-Claim
se I-Claim
suele I-Claim
asociar I-Claim
a I-Claim
los I-Claim
estudios I-Claim
interdisciplinares I-Claim
basados I-Claim
en I-Claim
una I-Claim
pequeña I-Claim
población I-Claim
elegible, I-Claim
pero O
puede O
contribuir O
a O
futuras O
revisiones O
del O
tratamiento O
de O
las O
metástasis O
cerebrales O
solitarias. O

El B-Claim
impacto I-Claim
del I-Claim
tratamiento I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
salud I-Claim
( I-Claim
HRQoL I-Claim
) I-Claim
es I-Claim
una I-Claim
consideración I-Claim
importante I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
adyuvante I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
operable I-Claim
. I-Claim

Aquí O
informamos O
de O
los O
resultados O
maduros O
de O
la O
CVRS O
del O
ensayo O
ATAC, O
que O
compara O
el O
anastrozol O
con O
el O
tamoxifeno O
como O
tratamiento O
adyuvante O
primario O
para O
mujeres O
posmenopáusicas O
con O
cáncer O
de O
mama O
localizado. O

Las O
pacientes O
completaron O
el O
cuestionario O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
más O
la O
subescala O
endocrina O
( O
ES O
) O
al O
inicio O
del O
estudio, O
a O
los O
3 O
y O
6 O
meses, O
y O
cada O
6 O
meses O
a O
partir O
de O
entonces. O

Las O
características O
basales O
en O
el O
subprotocolo O
de O
CVRS O
estaban O
bien O
equilibradas O
entre O
los O
grupos O
de O
anastrozol O
( O
n O
= O
335 O
) O
y O
tamoxifeno O
( O
n O
= O
347 O
) O
en O
la O
población O
del O
análisis O
primario O
. O

Al B-Premise
igual I-Premise
que I-Premise
los I-Premise
resultados I-Premise
publicados I-Premise
anteriormente I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
el I-Premise
índice I-Premise
de I-Premise
resultados I-Premise
del I-Premise
ensayo I-Premise
de I-Premise
la I-Premise
FACT-B I-Premise
, I-Premise
el I-Premise
criterio I-Premise
de I-Premise
valoración I-Premise
principal I-Premise
del I-Premise
estudio, I-Premise
entre I-Premise
los I-Premise
tratamientos I-Premise
a I-Premise
los I-Premise
5 I-Premise
años I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
totales I-Premise
de I-Premise
ES I-Premise
. I-Premise

En O
consonancia O
con O
el O
análisis O
de O
2 O
años, O
hubo B-Claim
diferencias I-Claim
entre I-Claim
los I-Claim
grupos I-Claim
de I-Claim
tratamiento I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
los I-Claim
efectos I-Claim
secundarios I-Claim
notificados I-Claim
por I-Claim
las I-Claim
pacientes: I-Claim
la B-Premise
diarrea I-Premise
( I-Premise
anastrozol I-Premise
3,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
tamoxifeno I-Premise
1,3 I-Premise
% I-Premise
) I-Premise
, I-Premise
la I-Premise
sequedad I-Premise
vaginal I-Premise
( I-Premise
18,5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
9,1 I-Premise
% I-Premise
) I-Premise
, I-Premise
la I-Premise
disminución I-Premise
de I-Premise
la I-Premise
libido I-Premise
( I-Premise
34,0 I-Premise
% I-Premise
frente I-Premise
a I-Premise
26,1 I-Premise
% I-Premise
) I-Premise
y I-Premise
la I-Premise
dispareunia I-Premise
( I-Premise
17,3 I-Premise
% I-Premise
frente I-Premise
a I-Premise
8,1 I-Premise
% I-Premise
) I-Premise
fueron I-Premise
significativamente I-Premise
más I-Premise
frecuentes I-Premise
con I-Premise
anastrozol I-Premise
en I-Premise
comparación I-Premise
con I-Premise
tamoxifeno I-Premise
. O

Los B-Premise
mareos I-Premise
( I-Premise
3,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
5,4 I-Premise
% I-Premise
) I-Premise
y I-Premise
el I-Premise
flujo I-Premise
vaginal I-Premise
( I-Premise
1,2 I-Premise
% I-Premise
frente I-Premise
a I-Premise
5,2 I-Premise
% I-Premise
) I-Premise
fueron I-Premise
significativamente I-Premise
menos I-Premise
frecuentes I-Premise
con I-Premise
anastrozol I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
tamoxifeno I-Premise
. I-Premise

En B-Claim
este, I-Claim
el I-Claim
primer I-Claim
informe I-Claim
sobre I-Claim
la I-Claim
CVRS I-Claim
a I-Claim
lo I-Claim
largo I-Claim
de I-Claim
5 I-Claim
años I-Claim
de I-Claim
tratamiento I-Claim
adyuvante I-Claim
inicial I-Claim
con I-Claim
un I-Claim
inhibidor I-Claim
de I-Claim
la I-Claim
aromatasa, I-Claim
concluimos I-Claim
que I-Claim
el I-Claim
anastrozol I-Claim
y I-Claim
el I-Claim
tamoxifeno I-Claim
tuvieron I-Claim
impactos I-Claim
similares I-Claim
en I-Claim
la I-Claim
CVRS, I-Claim
que I-Claim
se I-Claim
mantuvo I-Claim
o I-Claim
mejoró I-Claim
ligeramente I-Claim
durante I-Claim
el I-Claim
período I-Claim
de I-Claim
tratamiento I-Claim
para I-Claim
ambos I-Claim
grupos. I-Claim

El B-Claim
vaciado I-Claim
axilar I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
precoz I-Claim
tiene I-Claim
como I-Claim
objetivo I-Claim
mejorar I-Claim
el I-Claim
control I-Claim
locorregional I-Claim
y I-Claim
proporcionar I-Claim
información I-Claim
sobre I-Claim
la I-Claim
estadificación, I-Claim
pero O
se O
asocia O
a O
una O
morbilidad O
indeseable O
. O

Por O
lo O
tanto, O
se O
investigó O
si O
evitar O
la O
cirugía O
axilar O
en O
las O
mujeres O
mayores O
daría O
lugar O
a O
una O
mejor O
calidad O
de O
vida O
( O
QL O
) O
con O
una O
supervivencia O
libre O
de O
enfermedad O
( O
DFS O
) O
y O
una O
supervivencia O
global O
( O
OS O
) O
similares. O

Entre O
1993 O
y O
2002 O
, O
las O
mujeres O
> O
o O
= O
60 O
años O
con O
cáncer O
de O
mama O
operable O
con O
ganglios O
negativos O
clínicamente O
en O
las O
que O
se O
consideró O
indicado O
el O
tamoxifeno O
adyuvante O
independientemente O
del O
estado O
ganglionar O
patológico O
fueron O
asignadas O
aleatoriamente O
a O
cirugía O
primaria O
más O
vaciado O
axilar O
( O
Sx O
+ O
Ax O
) O
seguido O
de O
tamoxifeno O
( O
Tam O
) O
frente O
a O
Sx O
sin O
Ax O
seguido O
de O
Tam O
durante O
5 O
años O
consecutivos O
. O

El O
punto O
final O
primario O
fue O
la O
calidad O
de O
vida O
informada O
por O
el O
paciente O
y O
por O
la O
evaluación O
del O
médico. O

Un O
total O
de O
473 O
pacientes O
( O
234 O
a O
Sx O
+ O
Ax O
, O
239 O
a O
Sx O
) O
fueron O
asignados O
aleatoriamente O
. O

La O
mediana O
de O
edad O
era O
de O
74 O
años; O
el O
80% O
tenía O
enfermedad O
con O
receptores O
de O
estrógeno O
positivos. O

Tanto B-Premise
en I-Premise
la I-Premise
evaluación I-Premise
subjetiva I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
como I-Premise
en I-Premise
la I-Premise
percepción I-Premise
de I-Premise
los I-Premise
médicos I-Premise
de I-Premise
la I-Premise
CV I-Premise
de I-Premise
los I-Premise
pacientes, I-Premise
los I-Premise
mayores I-Premise
efectos I-Premise
adversos I-Premise
de I-Premise
la I-Premise
CV I-Premise
de I-Premise
Ax I-Premise
se I-Premise
observaron I-Premise
desde I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
hasta I-Premise
la I-Premise
primera I-Premise
evaluación I-Premise
postoperatoria, I-Premise
pero B-Premise
las I-Premise
diferencias I-Premise
tendieron I-Premise
a I-Premise
desaparecer I-Premise
en I-Premise
6 I-Premise
a I-Premise
12 I-Premise
meses. I-Premise

En B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
6,6 I-Premise
años, I-Premise
los I-Premise
resultados I-Premise
de I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
y I-Premise
Sx I-Premise
arrojaron I-Premise
una I-Premise
SSE I-Premise
similar I-Premise
( I-Premise
SSE I-Premise
a I-Premise
6 I-Premise
años I-Premise
, I-Premise
67 I-Premise
% I-Premise
frente I-Premise
a I-Premise
66 I-Premise
% I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1,06 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,79 I-Premise
a I-Premise
1,42 I-Premise
; I-Premise
P I-Premise
= I-Premise
.69 I-Premise
) I-Premise
y I-Premise
una I-Premise
SG I-Premise
( I-Premise
SSE I-Premise
a I-Premise
6 I-Premise
años I-Premise
, I-Premise
75 I-Premise
% I-Premise
frente I-Premise
a I-Premise
73 I-Premise
% I-Premise
; I-Premise
HR I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1,05 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,76 I-Premise
a I-Premise
1,46 I-Premise
; I-Premise
P I-Premise
= I-Premise
.77 I-Premise
) I-Premise
. I-Premise

Evitar B-Claim
el I-Claim
vaciado I-Claim
axilar I-Claim
en I-Claim
las I-Claim
mujeres I-Claim
de I-Claim
más I-Claim
de I-Claim
60 I-Claim
años I-Claim
que I-Claim
tienen I-Claim
una I-Claim
enfermedad I-Claim
con I-Claim
ganglios I-Claim
negativos I-Claim
y I-Claim
que I-Claim
reciben I-Claim
Tam I-Claim
para I-Claim
la I-Claim
enfermedad I-Claim
que I-Claim
responde I-Claim
al I-Claim
tratamiento I-Claim
endocrino I-Claim
tiene I-Claim
una I-Claim
eficacia I-Claim
similar I-Claim
y I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

La B-Claim
quimioterapia I-Claim
es I-Claim
moderadamente I-Claim
eficaz I-Claim
como I-Claim
tratamiento I-Claim
del I-Claim
adenocarcinoma I-Claim
de I-Claim
páncreas, I-Claim
pero B-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
han I-Claim
mejorado I-Claim
con I-Claim
esta I-Claim
modalidad I-Claim
en I-Claim
algunos I-Claim
ensayos. I-Claim

En O
un O
ensayo O
previo O
de O
fase O
II O
, O
el O
5-fluorouracilo O
( O
5-FU O
) O
más O
cisplatino O
( O
FUP O
) O
produjo O
una O
tasa O
de O
respuesta O
del O
26,5 O
% O
y O
una O
tasa O
de O
supervivencia O
del O
29 O
% O
a O
1 O
año O
. O

El O
presente O
estudio O
tenía O
como O
objetivo O
comparar O
la O
FUP O
con O
el O
5-FU O
solo, O
que O
era O
el O
brazo O
de O
control O
en O
los O
anteriores O
ensayos O
de O
la O
Clínica O
Mayo. O

Los O
pacientes O
con O
adenocarcinoma O
de O
páncreas O
metastásico O
o O
localmente O
avanzado O
no O
tratado O
y O
comprobado O
citológica O
o O
histológicamente O
se O
consideraron O
medibles O
o O
evaluables O
. O

Los O
regímenes O
de O
quimioterapia O
consistieron O
en O
un O
brazo O
de O
control O
de O
FU O
( O
5-FU O
500 O
mg/m O
( O
2 O
) O
/día O
durante O
5 O
días O
) O
y O
el O
brazo O
de O
investigación O
de O
FUP O
( O
5-FU O
1000 O
mg/m O
( O
2 O
) O
/día O
continuo O
durante O
5 O
días O
más O
cisplatino O
100 O
mg/m O
( O
2 O
) O
en O
el O
día O
1 O
o O
el O
día O
2 O
) O
. O

En O
ambos O
brazos, O
la O
quimioterapia O
se O
repitió O
el O
día O
29. O

Se O
asignaron O
al O
azar O
200 O
pacientes O
de O
18 O
centros: O
103 O
en O
el O
brazo O
de O
FU O
y O
104 O
en O
el O
de O
FUP. O

Los O
brazos O
de O
tratamiento O
estaban O
equilibrados O
con O
respecto O
al O
estado O
de O
rendimiento O
de O
grado O
0-1 O
( O
83 O
% O
frente O
a O
86 O
% O
, O
respectivamente O
) O
y O
la O
presencia O
de O
metástasis O
( O
92 O
% O
frente O
a O
89 O
% O
, O
respectivamente O
) O
. O

La O
mediana O
del O
número O
de O
ciclos O
administrados O
fue O
de O
dos O
en O
ambos O
brazos O
( O
rango O
0-14 O
) O
. O

Cinco O
pacientes O
no O
recibieron O
ningún O
tipo O
de O
quimioterapia O
y O
45 O
sólo O
recibieron O
un O
ciclo. O

La B-Premise
toxicidad I-Premise
( I-Premise
grado I-Premise
3-4 I-Premise
de I-Premise
la I-Premise
OMS I-Premise
) I-Premise
fue I-Premise
menor I-Premise
con I-Premise
el I-Premise
FU I-Premise
que I-Premise
con I-Premise
el I-Premise
FUP I-Premise
( I-Premise
20 I-Premise
% I-Premise
frente I-Premise
a I-Premise
48 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
al I-Premise
igual I-Premise
que I-Premise
la I-Premise
neutropenia I-Premise
( I-Premise
6 I-Premise
% I-Premise
frente I-Premise
a I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
los I-Premise
vómitos I-Premise
( I-Premise
4 I-Premise
% I-Premise
frente I-Premise
a I-Premise
17 I-Premise
% I-Premise
) I-Premise
y I-Premise
las I-Premise
muertes I-Premise
relacionadas I-Premise
con I-Premise
la I-Premise
toxicidad I-Premise
( I-Premise
una I-Premise
frente I-Premise
a I-Premise
cuatro I-Premise
al I-Premise
principio I-Premise
del I-Premise
ensayo I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
fue I-Premise
baja I-Premise
en I-Premise
ambos I-Premise
brazos, I-Premise
pero I-Premise
superior I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
FUP: I-Premise
12% I-Premise
frente I-Premise
a I-Premise
0% I-Premise
(análisis I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar, I-Premise
P I-Premise
< I-Premise
0,01). I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
fueron I-Premise
del I-Premise
28% I-Premise
y I-Premise
el I-Premise
38% I-Premise
para I-Premise
los I-Premise
brazos I-Premise
de I-Premise
FU I-Premise
y I-Premise
FUP I-Premise
, I-Premise
respectivamente, I-Premise
y I-Premise
las I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
fueron I-Premise
del I-Premise
9% I-Premise
y I-Premise
el I-Premise
17% I-Premise
( I-Premise
prueba I-Premise
de I-Premise
rango I-Premise
logarítmico I-Premise
, I-Premise
P I-Premise
= I-Premise
0,10 I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
a I-Premise
un I-Premise
año I-Premise
fue I-Premise
del I-Premise
0% I-Premise
con I-Premise
la I-Premise
FU I-Premise
frente I-Premise
al I-Premise
10% I-Premise
con I-Premise
la I-Premise
FUP I-Premise
( I-Premise
prueba I-Premise
de I-Premise
rango I-Premise
logarítmico I-Premise
, I-Premise
P I-Premise
= I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

En B-Claim
los I-Claim
carcinomas I-Claim
pancreáticos I-Claim
avanzados I-Claim
con I-Claim
mal I-Claim
pronóstico, I-Claim
la I-Claim
FUP I-Claim
fue I-Claim
superior I-Claim
al I-Claim
FU I-Claim
en I-Claim
términos I-Claim
de I-Claim
respuesta I-Claim
y I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión, I-Claim
pero I-Claim
no I-Claim
en I-Claim
términos I-Claim
de I-Claim
supervivencia I-Claim
global. I-Claim

La O
baja O
tasa O
de O
respuesta O
está O
en O
parte O
relacionada O
con O
el O
número O
de O
pacientes O
que O
recibieron O
sólo O
un O
ciclo O
de O
quimioterapia O
. O

Se B-Claim
necesita I-Claim
una I-Claim
versión I-Claim
más I-Claim
eficaz I-Claim
y I-Claim
mejor I-Claim
tolerada I-Claim
de I-Claim
esta I-Claim
combinación I-Claim
de I-Claim
FUP. I-Claim

Tras O
la O
cirugía O
del O
carcinoma O
diferenciado O
de O
tiroides O
, O
muchos O
pacientes O
son O
tratados O
con O
radioyodo O
para O
ablacionar O
el O
tejido O
tiroideo O
remanente O
. O

Este B-Claim
procedimiento I-Claim
se I-Claim
ha I-Claim
realizado I-Claim
con I-Claim
el I-Claim
paciente I-Claim
en I-Claim
estado I-Claim
de I-Claim
hipotiroidismo I-Claim
para I-Claim
promover I-Claim
la I-Claim
estimulación I-Claim
endógena I-Claim
de I-Claim
la I-Claim
TSH I-Claim
y I-Claim
suele I-Claim
asociarse I-Claim
con I-Claim
síntomas I-Claim
de I-Claim
hipotiroidismo I-Claim
y I-Claim
deterioro I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
. I-Claim

Este O
ensayo O
internacional, O
aleatorizado, O
controlado O
y O
multicéntrico O
tuvo O
como O
objetivo O
comparar O
la O
eficacia O
y O
seguridad O
de O
la O
TSH O
humana O
recombinante O
( O
rhTSH O
) O
para O
preparar O
a O
los O
pacientes O
eutiroideos O
en O
tratamiento O
con O
L-tiroxina O
( O
grupo O
eutiroideo O
) O
para O
la O
ablación O
del O
tejido O
tiroideo O
remanente O
con O
3,7 O
GBq O
( O
100 O
mCi O
) O
131I O
, O
en O
comparación O
con O
la O
ablación O
remanente O
convencional O
realizada O
en O
el O
estado O
hipotiroideo O
( O
grupo O
hipotiroideo O
) O
. O

La O
calidad O
de O
vida O
se O
determinó O
en O
el O
momento O
de O
la O
aleatorización O
y O
de O
la O
ablación O
. O

Después O
de O
la O
administración O
de O
la O
dosis O
de O
131-I O
, O
se O
midió O
la O
tasa O
de O
eliminación O
de O
la O
radiación O
de O
la O
sangre O
, O
el O
remanente O
de O
la O
tiroides O
, O
y O
todo O
el O
cuerpo O
. O

El O
criterio O
primario O
predefinido O
para O
el O
éxito O
de O
la O
ablación O
fue O
"la O
ausencia O
de O
captación O
visible O
en O
el O
lecho O
tiroideo O
o, O
si O
era O
visible, O
una O
captación O
fraccional O
inferior O
al O
0,1%" O
en O
las O
exploraciones O
del O
cuello O
realizadas O
8 O
meses O
después O
del O
tratamiento, O
y O
se O
cumplió O
en O
el O
100% O
de O
los O
pacientes O
de O
ambos O
grupos. O

Un O
criterio O
secundario O
para O
la O
ablación O
, O
una O
concentración O
de O
tiroglobulina O
sérica O
estimulada O
por O
rhTSH O
inferior O
a O
2 O
ng/ml O
, O
fue O
cumplido O
por O
23 O
de O
24 O
( O
96 O
% O
) O
pacientes O
eutiroideos O
y O
18 O
de O
21 O
( O
86 O
% O
) O
pacientes O
hipotiroideos O
( O
P O
= O
0,2341 O
) O
. O

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
estaba I-Premise
bien I-Premise
conservada I-Premise
en I-Premise
el I-Premise
grupo I-Premise
eutiroideo, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
hipotiroideo, I-Premise
como I-Premise
demuestran I-Premise
sus I-Premise
puntuaciones I-Premise
más I-Premise
bajas I-Premise
antes I-Premise
del I-Premise
tratamiento I-Premise
en I-Premise
la I-Premise
escala I-Premise
de I-Premise
Billewicz I-Premise
para I-Premise
los I-Premise
signos I-Premise
y I-Premise
síntomas I-Premise
del I-Premise
hipotiroidismo, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
frente I-Premise
a I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
y I-Premise
sus I-Premise
puntuaciones I-Premise
significativamente I-Premise
más I-Premise
altas I-Premise
en I-Premise
la I-Premise
escala I-Premise
de I-Premise
evaluación I-Premise
de I-Premise
la I-Premise
salud I-Premise
Short I-Premise
Form-36 I-Premise
en I-Premise
cinco I-Premise
de I-Premise
las I-Premise
ocho I-Premise
categorías I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
eutiroideos I-Premise
tuvieron I-Premise
una I-Premise
dosis I-Premise
de I-Premise
radiación I-Premise
en I-Premise
sangre I-Premise
estadísticamente I-Premise
significativa, I-Premise
un I-Premise
tercio I-Premise
menor, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
hipotiroideo. I-Premise

Este B-Claim
estudio I-Claim
demuestra I-Claim
tasas I-Claim
de I-Claim
ablación I-Claim
de I-Claim
remanentes I-Claim
comparables I-Claim
en I-Claim
pacientes I-Claim
preparados I-Claim
para I-Claim
la I-Claim
ablación I-Claim
de I-Claim
remanentes I-Claim
con I-Claim
131I I-Claim
con I-Claim
3,7 I-Claim
GBq I-Claim
ya I-Claim
sea I-Claim
administrando I-Claim
rhTSH I-Claim
o I-Claim
reteniendo I-Claim
la I-Claim
hormona I-Claim
tiroidea I-Claim
. I-Claim

Los B-Claim
pacientes I-Claim
preparados I-Claim
con I-Claim
rhTSH I-Claim
mantuvieron I-Claim
una I-Claim
mayor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
recibieron I-Claim
menos I-Claim
exposición I-Claim
a I-Claim
la I-Claim
radiación I-Claim
en I-Claim
la I-Claim
sangre I-Claim
. I-Claim

A O
medida O
que O
los O
pacientes O
con O
cáncer O
de O
páncreas O
y O
periampular O
( O
PPC O
) O
experimentan O
una O
mejora O
de O
las O
tasas O
de O
supervivencia O
y O
de O
la O
longevidad O
, O
el O
enfoque O
se O
desplaza O
hacia O
vivir O
la O
vida O
mientras O
se O
sobrevive O
al O
cáncer O
. O

La O
fatiga O
es O
el O
síntoma O
más O
comúnmente O
reportado O
en O
todos O
los O
pacientes O
con O
cáncer O
. O

Se O
ha O
comprobado O
que O
el O
ejercicio O
disminuye O
eficazmente O
los O
niveles O
de O
fatiga O
y O
mejora O
el O
funcionamiento O
físico O
de O
los O
pacientes O
con O
cáncer. O

Ciento O
dos O
pacientes O
con O
PPC O
resecado O
consintieron O
en O
participar O
en O
este O
estudio O
y O
fueron O
aleatorizados O
a O
un O
grupo O
de O
intervención O
( O
IG O
) O
o O
a O
un O
grupo O
de O
atención O
habitual O
( O
UCG O
) O
. O

Los O
sujetos O
completaron O
las O
escalas O
analógicas O
visuales O
, O
la O
escala O
FACIT-Fatiga O
y O
el O
Short O
Form-36v2 O
después O
de O
la O
cirugía O
y O
de O
nuevo O
entre O
3 O
y O
6 O
meses O
después O
del O
alta O
hospitalaria O
. O

Los O
pacientes O
del O
GI O
y O
del O
UCG O
eran O
comparables O
en O
cuanto O
a O
datos O
demográficos, O
comorbilidades, O
tipo O
de O
cáncer O
y O
estadiaje, O
tipo O
de O
resección, O
niveles O
de O
fatiga O
y O
dolor O
preoperatorios, O
tratamiento O
adyuvante O
y O
distancia O
de O
marcha O
inicial. O

Los B-Premise
pacientes I-Premise
del I-Premise
GI I-Premise
obtuvieron I-Premise
puntuaciones I-Premise
significativamente I-Premise
mejores I-Premise
en I-Premise
la I-Premise
escala I-Premise
FACIT-Fatiga I-Premise
al I-Premise
finalizar I-Premise
el I-Premise
estudio I-Premise
, I-Premise
mejoraron I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
fatiga I-Premise
y I-Premise
dolor I-Premise
, I-Premise
así I-Premise
como I-Premise
las I-Premise
puntuaciones I-Premise
compuestas I-Premise
de I-Premise
funcionamiento I-Premise
físico I-Premise
general I-Premise
y I-Premise
salud I-Premise
mental I-Premise
. I-Premise

Al B-Premise
finalizar I-Premise
el I-Premise
estudio, I-Premise
los I-Premise
participantes I-Premise
del I-Premise
GI I-Premise
caminaban I-Premise
el I-Premise
doble I-Premise
de I-Premise
distancia I-Premise
y I-Premise
eran I-Premise
significativamente I-Premise
más I-Premise
propensos I-Premise
a I-Premise
seguir I-Premise
caminando I-Premise
o I-Premise
haciendo I-Premise
otra I-Premise
forma I-Premise
de I-Premise
ejercicio I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
UCG. I-Premise

Mediante O
un O
análisis O
jerárquico O
de O
conglomerados, O
se O
identificaron O
3 O
agrupaciones O
de O
síntomas O
mutuamente O
excluyentes O
en O
la O
cohorte. O

El B-Premise
análisis I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
Kaplan-Meier I-Premise
no I-Premise
indicó I-Premise
un I-Premise
beneficio I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
para I-Premise
el I-Premise
GI I-Premise
. I-Premise

Este B-Claim
es I-Claim
el I-Claim
primer I-Claim
ensayo I-Claim
prospectivo, I-Claim
aleatorio I-Claim
y I-Claim
controlado I-Claim
que I-Claim
informa I-Claim
de I-Claim
que I-Claim
la I-Claim
participación I-Claim
en I-Claim
un I-Claim
programa I-Claim
de I-Claim
caminatas I-Claim
a I-Claim
domicilio I-Claim
confiere I-Claim
un I-Claim
beneficio I-Claim
significativo I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CPP I-Claim
resecado I-Claim
en I-Claim
lo I-Claim
que I-Claim
respecta I-Claim
a I-Claim
los I-Claim
niveles I-Claim
de I-Claim
fatiga, I-Claim
el I-Claim
funcionamiento I-Claim
físico I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
salud. I-Claim

El B-Claim
tratamiento I-Claim
con I-Claim
quimioterapia I-Claim
a I-Claim
base I-Claim
de I-Claim
cisplatino I-Claim
proporciona I-Claim
una I-Claim
modesta I-Claim
ventaja I-Claim
de I-Claim
supervivencia I-Claim
frente I-Claim
a I-Claim
los I-Claim
cuidados I-Claim
de I-Claim
apoyo I-Claim
únicamente I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
no I-Claim
microcítico I-Claim
avanzado I-Claim
( I-Claim
CPNM I-Claim
) I-Claim
. I-Claim

Para O
determinar O
si O
un O
nuevo O
agente, O
el O
paclitaxel, O
mejoraría O
aún O
más O
la O
supervivencia O
en O
el O
CPNM, O
el O
Grupo O
de O
Oncología O
Cooperativa O
del O
Este O
llevó O
a O
cabo O
un O
ensayo O
aleatorio O
en O
el O
que O
se O
comparaba O
el O
paclitaxel O
más O
el O
cisplatino O
con O
un O
régimen O
de O
quimioterapia O
estándar O
consistente O
en O
cisplatino O
y O
etopósido. O

El O
estudio O
fue O
llevado O
a O
cabo O
por O
un O
grupo O
cooperativo O
multiinstitucional O
en O
pacientes O
con O
CPNM O
en O
estadio O
IIIB O
a O
IV O
que O
no O
recibieron O
quimioterapia O
y O
que O
fueron O
aleatorizados O
para O
recibir O
paclitaxel O
más O
cisplatino O
o O
etopósido O
más O
cisplatino. O

Se O
administró O
paclitaxel O
a O
dos O
niveles O
de O
dosis O
diferentes O
( O
135 O
mg/m O
( O
2 O
) O
y O
250 O
mg/m O
( O
2 O
) O
) O
y O
el O
etopósido O
se O
administró O
a O
una O
dosis O
de O
100 O
mg/m O
( O
2 O
) O
diarios O
en O
los O
días O
1 O
a O
3 O
. O

Cada O
régimen O
se O
repitió O
cada O
21 O
días O
y O
cada O
uno O
incluía O
cisplatino O
( O
75 O
mg/m O
( O
2 O
) O
) O
. O

Las O
características O
de O
los O
599 O
pacientes O
estaban O
bien O
equilibradas O
en O
los O
tres O
grupos O
de O
tratamiento. O

Se B-Premise
observó I-Premise
una I-Premise
mayor I-Premise
supervivencia I-Premise
con I-Premise
los I-Premise
regímenes I-Premise
combinados I-Premise
de I-Premise
paclitaxel I-Premise
( I-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
, I-Premise
9,9 I-Premise
meses I-Premise
; I-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
, I-Premise
38,9 I-Premise
% I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
etopósido I-Premise
más I-Premise
cisplatino I-Premise
( I-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
, I-Premise
7,6 I-Premise
meses I-Premise
; I-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
, I-Premise
31,8 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

La B-Premise
comparación I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
para I-Premise
los I-Premise
dos I-Premise
niveles I-Premise
de I-Premise
dosis I-Premise
de I-Premise
paclitaxel I-Premise
no I-Premise
reveló I-Premise
ninguna I-Premise
diferencia I-Premise
significativa. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
para I-Premise
el I-Premise
subgrupo I-Premise
de I-Premise
estadio I-Premise
IIIB I-Premise
fue I-Premise
de I-Premise
7,9 I-Premise
meses I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
etopósido I-Premise
más I-Premise
cisplatino I-Premise
frente I-Premise
a I-Premise
13,1 I-Premise
meses I-Premise
para I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
paclitaxel I-Premise
( I-Premise
P I-Premise
= I-Premise
0,152 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
subgrupo I-Premise
de I-Premise
estadio I-Premise
IV, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
del I-Premise
etopósido I-Premise
más I-Premise
cisplatino I-Premise
fue I-Premise
de I-Premise
7,6 I-Premise
meses, I-Premise
frente I-Premise
a I-Premise
los I-Premise
8,9 I-Premise
meses I-Premise
del I-Premise
paclitaxel I-Premise
( I-Premise
P I-Premise
= I-Premise
0,246 I-Premise
) I-Premise
. I-Premise

Con B-Premise
la I-Premise
excepción I-Premise
de I-Premise
un I-Premise
aumento I-Premise
de I-Premise
la I-Premise
granulocitopenia I-Premise
en I-Premise
el I-Premise
régimen I-Premise
de I-Premise
dosis I-Premise
bajas I-Premise
de I-Premise
paclitaxel I-Premise
y I-Premise
un I-Premise
aumento I-Premise
de I-Premise
las I-Premise
mialgias, I-Premise
la I-Premise
neurotoxicidad I-Premise
y, I-Premise
posiblemente, I-Premise
un I-Premise
aumento I-Premise
de I-Premise
los I-Premise
eventos I-Premise
cardíacos I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
dosis I-Premise
altas I-Premise
de I-Premise
paclitaxel, I-Premise
la I-Premise
toxicidad I-Premise
fue I-Premise
similar I-Premise
en I-Premise
los I-Premise
tres I-Premise
brazos. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
QOL I-Premise
) I-Premise
disminuyó I-Premise
significativamente I-Premise
durante I-Premise
los I-Premise
6 I-Premise
meses I-Premise
. I-Premise

Sin O
embargo, O
las O
puntuaciones B-Claim
de I-Claim
la I-Claim
CdV I-Claim
no I-Claim
fueron I-Claim
significativamente I-Claim
diferentes I-Claim
entre I-Claim
los I-Claim
regímenes. I-Claim

Como O
resultado O
de O
estas O
observaciones, O
el O
paclitaxel B-Claim
( I-Claim
135 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
) I-Claim
combinado I-Claim
con I-Claim
cisplatino I-Claim
ha I-Claim
sustituido I-Claim
al I-Claim
etopósido I-Claim
más I-Claim
cisplatino I-Claim
como I-Claim
régimen I-Claim
de I-Claim
referencia I-Claim
en I-Claim
nuestro I-Claim
ensayo I-Claim
de I-Claim
fase I-Claim
III I-Claim
recientemente I-Claim
finalizado. I-Claim

Evaluar O
los O
riesgos O
y O
beneficios O
a O
largo O
plazo O
de O
la O
terapia O
hormonal O
sustitutiva O
( O
terapia O
hormonal O
combinada O
frente O
a O
placebo O
, O
y O
estrógeno O
solo O
frente O
a O
terapia O
hormonal O
combinada O
) O
. O

Ensayo O
multicéntrico, O
aleatorizado, O
controlado O
con O
placebo O
y O
a O
doble O
ciego. O

Consultas O
generales O
en O
el O
Reino O
Unido O
( O
384 O
) O
, O
Australia O
( O
91 O
) O
y O
Nueva O
Zelanda O
( O
24 O
) O
.s O

Mujeres O
posmenopáusicas O
de O
50-69 O
años O
en O
el O
momento O
de O
la O
aleatorización O
. O

Al O
cierre O
anticipado O
del O
ensayo, O
56.583 O
personas O
habían O
sido O
seleccionadas, O
8.980 O
entraron O
en O
el O
periodo O
de O
rodaje O
y O
5.692 O
(el O
26% O
del O
objetivo O
de O
22.300) O
iniciaron O
el O
tratamiento. O

Terapia O
con O
estrógenos O
solamente O
( O
estrógenos O
equinos O
conjugados O
0,625 O
mg O
por O
vía O
oral O
diariamente O
) O
o O
terapia O
hormonal O
combinada O
( O
estrógenos O
equinos O
conjugados O
más O
acetato O
de O
medroxiprogesterona O
2,5/5,0 O
mg O
por O
vía O
oral O
diariamente O
) O
. O

Diez O
años O
de O
tratamiento O
previstos O
. O

enfermedades O
cardiovasculares O
graves, O
fracturas O
osteoporóticas O
y O
cáncer O
de O
mama. O

otros O
cánceres O
, O
muerte O
por O
todas O
las O
causas O
, O
tromboembolismo O
venoso O
, O
enfermedad O
cerebrovascular O
, O
demencia O
y O
calidad O
de O
vida O
. O

El O
ensayo O
se O
cerró O
prematuramente O
durante O
el O
reclutamiento, O
después O
de O
una O
mediana O
de O
seguimiento O
de O
11,9 O
meses O
(rango O
intercuartil O
7,1-19,6, O
total O
de O
6498 O
mujeres O
años) O
en O
las O
inscritas, O
tras O
la O
publicación O
de O
los O
primeros O
resultados O
del O
estudio O
Women's O
Health O
Initiative. O

La O
edad O
media O
de O
las O
mujeres O
asignadas O
al O
azar O
era O
de O
62,8 O
( O
SD O
4,8 O
) O
años O
. O

Cuando B-Premise
la I-Premise
terapia I-Premise
hormonal I-Premise
combinada I-Premise
( I-Premise
n=2196 I-Premise
) I-Premise
se I-Premise
comparó I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
n=2189 I-Premise
) I-Premise
, I-Premise
hubo I-Premise
un I-Premise
aumento I-Premise
significativo I-Premise
del I-Premise
número I-Premise
de I-Premise
eventos I-Premise
cardiovasculares I-Premise
mayores I-Premise
( I-Premise
7 I-Premise
v I-Premise
0 I-Premise
, I-Premise
P=0,016 I-Premise
) I-Premise
y I-Premise
de I-Premise
tromboembolismos I-Premise
venosos I-Premise
( I-Premise
22 I-Premise
v I-Premise
3 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
7,36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
2,20 I-Premise
a I-Premise
24,60 I-Premise
) I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
el I-Premise
número I-Premise
de I-Premise
cánceres I-Premise
de I-Premise
mama I-Premise
o I-Premise
de I-Premise
otro I-Premise
tipo I-Premise
( I-Premise
22 I-Premise
frente I-Premise
a I-Premise
25 I-Premise
, I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
0,88 I-Premise
( I-Premise
0,49 I-Premise
a I-Premise
1,56 I-Premise
) I-Premise
) I-Premise
, I-Premise
eventos I-Premise
cerebrovasculares I-Premise
( I-Premise
14 I-Premise
frente I-Premise
a I-Premise
19 I-Premise
, I-Premise
0,73 I-Premise
( I-Premise
0,37 I-Premise
a I-Premise
1,46 I-Premise
) I-Premise
) I-Premise
fracturas I-Premise
( I-Premise
40 I-Premise
frente I-Premise
a I-Premise
58 I-Premise
, I-Premise
0,69 I-Premise
( I-Premise
0,46 I-Premise
a I-Premise
1,03 I-Premise
) I-Premise
) I-Premise
y I-Premise
muertes I-Premise
en I-Premise
general I-Premise
( I-Premise
8 I-Premise
frente I-Premise
a I-Premise
5 I-Premise
, I-Premise
1,60 I-Premise
( I-Premise
0,52 I-Premise
a I-Premise
4,89 I-Premise
) I-Premise
) I-Premise
. I-Premise

La B-Premise
comparación I-Premise
de I-Premise
los I-Premise
resultados I-Premise
de I-Premise
la I-Premise
terapia I-Premise
hormonal I-Premise
combinada I-Premise
( I-Premise
n=815 I-Premise
) I-Premise
frente I-Premise
a I-Premise
la I-Premise
terapia I-Premise
estrogénica I-Premise
( I-Premise
n=826 I-Premise
) I-Premise
no I-Premise
reveló I-Premise
diferencias I-Premise
significativas I-Premise
. I-Premise

La B-Claim
terapia I-Claim
hormonal I-Claim
sustitutiva I-Claim
aumenta I-Claim
el I-Claim
riesgo I-Claim
cardiovascular I-Claim
y I-Claim
tromboembólico I-Claim
cuando I-Claim
se I-Claim
inicia I-Claim
muchos I-Claim
años I-Claim
después I-Claim
de I-Claim
la I-Claim
menopausia I-Claim
. I-Claim

Los B-Claim
resultados I-Claim
son I-Claim
coherentes I-Claim
con I-Claim
las I-Claim
conclusiones I-Claim
del I-Claim
estudio I-Claim
de I-Claim
la I-Claim
iniciativa I-Claim
de I-Claim
salud I-Claim
de I-Claim
la I-Claim
mujer I-Claim
y I-Claim
los I-Claim
estudios I-Claim
de I-Claim
prevención I-Claim
secundaria. I-Claim

Es B-Claim
necesario I-Claim
investigar I-Claim
para I-Claim
evaluar I-Claim
los I-Claim
riesgos I-Claim
y I-Claim
beneficios I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
de I-Claim
iniciar I-Claim
la I-Claim
terapia I-Claim
hormonal I-Claim
sustitutiva I-Claim
cerca I-Claim
de I-Claim
la I-Claim
menopausia I-Claim
, I-Claim
cuando I-Claim
el I-Claim
efecto I-Claim
puede I-Claim
ser I-Claim
diferente I-Claim
. I-Claim

El O
imatinib O
es O
el O
tratamiento O
estándar O
de O
los O
tumores O
del O
estroma O
gastrointestinal O
avanzados O
(GIST). O

No B-Claim
se I-Claim
sabe I-Claim
si I-Claim
el I-Claim
imatinib I-Claim
se I-Claim
puede I-Claim
suspender I-Claim
en I-Claim
pacientes I-Claim
en I-Claim
los I-Claim
que I-Claim
la I-Claim
enfermedad I-Claim
está I-Claim
controlada I-Claim
. I-Claim

Este O
estudio O
prospectivo, O
aleatorio O
y O
multicéntrico O
de O
fase O
III O
fue O
diseñado O
para O
comparar O
el O
imatinib O
continuo O
( O
CONT O
) O
en O
comparación O
con O
el O
interrumpido O
( O
INT O
) O
más O
allá O
de O
1 O
año O
de O
tratamiento O
en O
pacientes O
con O
GIST O
avanzado O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia O
sin O
progresión. O

Los O
criterios O
de O
valoración O
secundarios O
incluían O
la O
supervivencia O
global, O
la O
tasa O
de O
respuesta O
tras O
el O
reinicio O
del O
imatinib O
y O
la O
calidad O
de O
vida. O

Se O
definieron O
reglas O
de O
interrupción O
temprana O
en O
casos O
de O
rápida O
progresión O
de O
la O
enfermedad, O
con O
análisis O
intermedios O
planificados O
de O
antemano. O

Entre O
mayo O
de O
2002 O
y O
abril O
de O
2004, O
se O
inscribieron O
182 O
pacientes O
con O
GIST O
avanzado. O

Entre O
mayo O
de O
2003 O
y O
abril O
de O
2004 O
, O
98 O
pacientes O
en O
respuesta O
o O
con O
enfermedad O
estable O
bajo O
imatinib O
alcanzaron O
más O
de O
1 O
año O
de O
seguimiento O
. O

Cuarenta O
no O
fueron O
elegibles O
para O
la O
aleatorización O
, O
y O
58 O
pacientes O
fueron O
asignados O
al O
azar O
, O
32 O
y O
26 O
pacientes O
en O
los O
brazos O
INT O
y O
CONT O
, O
respectivamente O
. O

Al B-Premise
15 I-Premise
de I-Premise
octubre I-Premise
de I-Premise
2005, I-Premise
ocho I-Premise
de I-Premise
26 I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
CONT I-Premise
y I-Premise
26 I-Premise
de I-Premise
32 I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
INT I-Premise
habían I-Premise
documentado I-Premise
una I-Premise
progresión I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
). I-Premise

Veinticuatro B-Premise
de I-Premise
26 I-Premise
pacientes I-Premise
con I-Premise
progresión I-Premise
documentada I-Premise
en I-Premise
el I-Premise
brazo I-Premise
INT I-Premise
respondieron I-Premise
a I-Premise
la I-Premise
reintroducción I-Premise
de I-Premise
imatinib I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
ni I-Premise
en I-Premise
la I-Premise
resistencia I-Premise
al I-Premise
imatinib I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
evaluada I-Premise
6 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
asignación I-Premise
aleatoria I-Premise
mediante I-Premise
el I-Premise
Cuestionario I-Premise
de I-Premise
Calidad I-Premise
de I-Premise
Vida I-Premise
de I-Premise
30 I-Premise
ítems I-Premise
no I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
de I-Premise
pacientes I-Premise
asignados I-Premise
al I-Premise
azar I-Premise
. I-Premise

La B-Claim
interrupción I-Claim
del I-Claim
imatinib I-Claim
provoca I-Claim
una I-Claim
rápida I-Claim
progresión I-Claim
en I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
GIST I-Claim
avanzado, I-Claim
y I-Claim
no I-Claim
puede I-Claim
recomendarse I-Claim
en I-Claim
la I-Claim
práctica I-Claim
rutinaria I-Claim
a I-Claim
menos I-Claim
que I-Claim
el I-Claim
paciente I-Claim
experimente I-Claim
una I-Claim
toxicidad I-Claim
significativa. I-Claim

Este O
informe O
describe O
los O
resultados O
de O
calidad O
de O
vida O
( O
QOL O
) O
de O
un O
estudio O
aleatorio O
controlado O
con O
placebo O
de O
erlotinib O
, O
un O
inhibidor O
del O
receptor O
del O
factor O
de O
crecimiento O
epidérmico O
, O
en O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
( O
NSCLC O
) O
. O

Este O
ensayo O
doble O
ciego O
de O
fase O
III O
asignó O
aleatoriamente O
a O
731 O
pacientes O
con O
CPNM O
que O
habían O
progresado O
después O
de O
la O
quimioterapia O
previa O
a O
erlotinib O
150 O
mg O
diarios O
o O
a O
placebo O
, O
con O
la O
supervivencia O
como O
resultado O
primario O
del O
estudio. O

La O
CdV O
se O
evaluó O
mediante O
el O
QLQ-C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
y O
el O
módulo O
de O
cáncer O
de O
pulmón O
QLQ-LC13 O
. O

Los O
puntos O
finales O
primarios O
para O
el O
análisis O
de O
la O
calidad O
de O
vida O
fueron O
el O
tiempo O
hasta O
el O
deterioro O
de O
tres O
síntomas O
comunes O
del O
cáncer O
de O
pulmón: O
tos, O
disnea O
y O
dolor. O

La B-Premise
supervivencia I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0,70 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
erlotinib I-Premise
. I-Premise

El B-Premise
cumplimiento I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fue I-Premise
del I-Premise
87% I-Premise
al I-Premise
inicio I-Premise
y I-Premise
de I-Premise
más I-Premise
del I-Premise
70% I-Premise
durante I-Premise
el I-Premise
tratamiento. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
erlotinib I-Premise
tuvieron I-Premise
una I-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
deterioro I-Premise
significativamente I-Premise
más I-Premise
larga I-Premise
para I-Premise
los I-Premise
tres I-Premise
síntomas I-Premise
( I-Premise
4,9 I-Premise
frente I-Premise
a I-Premise
3,7 I-Premise
meses I-Premise
para I-Premise
la I-Premise
tos I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
; I-Premise
4,7 I-Premise
frente I-Premise
a I-Premise
2,9 I-Premise
meses I-Premise
para I-Premise
la I-Premise
disnea I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
, I-Premise
y I-Premise
2,8 I-Premise
frente I-Premise
a I-Premise
1,9 I-Premise
meses I-Premise
para I-Premise
el I-Premise
dolor I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
) I-Premise
. I-Premise

Los B-Premise
análisis I-Premise
de I-Premise
respuesta I-Premise
de I-Premise
la I-Premise
CdV I-Premise
mostraron I-Premise
que I-Premise
el I-Premise
44%, I-Premise
el I-Premise
34% I-Premise
y I-Premise
el I-Premise
42% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
erlotinib I-Premise
tuvieron I-Premise
una I-Premise
mejora I-Premise
en I-Premise
estos I-Premise
tres I-Premise
síntomas, I-Premise
respectivamente. I-Premise

Esto B-Premise
se I-Premise
acompañó I-Premise
de I-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
de I-Premise
la I-Premise
función I-Premise
física I-Premise
( I-Premise
31 I-Premise
% I-Premise
de I-Premise
erlotinib I-Premise
frente I-Premise
a I-Premise
19 I-Premise
% I-Premise
de I-Premise
placebo I-Premise
, I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
y I-Premise
de I-Premise
la I-Premise
CdV I-Premise
global I-Premise
( I-Premise
35 I-Premise
% I-Premise
frente I-Premise
a I-Premise
26 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
respuesta I-Premise
completa I-Premise
o I-Premise
parcial I-Premise
fueron I-Premise
más I-Premise
propensos I-Premise
a I-Premise
tener I-Premise
una I-Premise
mejora I-Premise
en I-Premise
la I-Premise
respuesta I-Premise
de I-Premise
la I-Premise
CdV I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
enfermedad I-Premise
estable I-Premise
o I-Premise
progresiva I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

El B-Claim
erlotinib I-Claim
no I-Claim
sólo I-Claim
mejora I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
previamente I-Claim
tratados, I-Claim
sino I-Claim
que I-Claim
también I-Claim
mejora I-Claim
los I-Claim
síntomas I-Claim
relacionados I-Claim
con I-Claim
el I-Claim
tumor I-Claim
y I-Claim
aspectos I-Claim
importantes I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Los B-Claim
síntomas I-Claim
de I-Claim
la I-Claim
menopausia I-Claim
( I-Claim
por I-Claim
ejemplo, I-Claim
sofocos, I-Claim
sequedad I-Claim
vaginal I-Claim
e I-Claim
incontinencia I-Claim
urinaria I-Claim
de I-Claim
esfuerzo I-Claim
) I-Claim
son I-Claim
muy I-Claim
comunes I-Claim
en I-Claim
las I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
y I-Claim
no I-Claim
pueden I-Claim
ser I-Claim
tratados I-Claim
con I-Claim
la I-Claim
terapia I-Claim
de I-Claim
sustitución I-Claim
de I-Claim
estrógenos I-Claim
( I-Claim
TRE I-Claim
) I-Claim
estándar I-Claim
en I-Claim
estas I-Claim
pacientes I-Claim
. I-Claim

El O
propósito O
de O
este O
estudio O
fue O
probar O
la O
eficacia O
de O
un O
programa O
de O
intervención O
de O
evaluación O
integral O
de O
la O
menopausia O
( O
CMA O
) O
para O
lograr O
el O
alivio O
de O
los O
síntomas O
, O
la O
mejora O
de O
la O
calidad O
de O
vida O
( O
QOL O
) O
, O
y O
el O
funcionamiento O
sexual O
en O
los O
sobrevivientes O
de O
cáncer O
de O
mama O
. O

Utilizando O
un O
diseño O
controlado O
aleatorio O
de O
dos O
grupos, O
asignamos O
a O
76 O
supervivientes O
de O
cáncer O
de O
mama O
posmenopáusicas O
con O
al O
menos O
un O
síntoma O
objetivo O
grave O
al O
grupo O
de O
intervención O
o O
al O
grupo O
de O
atención O
habitual. O

Setenta O
y O
dos O
mujeres O
fueron O
evaluadas O
al O
final O
del O
período O
de O
estudio. O

La O
intervención O
de O
la O
CMA, O
llevada O
a O
cabo O
por O
un O
profesional O
de O
enfermería, O
se O
centró O
en O
la O
evaluación O
de O
los O
síntomas, O
la O
educación, O
el O
asesoramiento O
y, O
en O
su O
caso, O
las O
intervenciones O
farmacológicas O
y O
conductuales O
específicas O
para O
cada O
uno O
de O
los O
tres O
síntomas O
objetivo. O

Los O
síntomas O
psicosociales O
se O
evaluaron O
con O
un O
instrumento O
de O
cribado O
de O
autoinforme, O
y O
las O
mujeres O
con O
problemas O
fueron O
remitidas O
para O
recibir O
asesoramiento O
si O
lo O
necesitaban. O

La O
intervención O
se O
llevó O
a O
cabo O
durante O
un O
periodo O
de O
4 O
meses. O

Los O
resultados O
medidos O
fueron O
las O
puntuaciones O
en O
una O
escala O
compuesta O
de O
síntomas O
de O
la O
menopausia, O
la O
Escala O
de O
Vitalidad O
de O
la O
Encuesta O
Breve O
de O
Salud O
RAND O
y O
la O
Escala O
de O
Funcionamiento O
Sexual O
del O
Sistema O
de O
Evaluación O
de O
la O
Rehabilitación O
del O
Cáncer O
(CARES) O
al O
inicio O
y O
a O
los O
4 O
meses O
de O
seguimiento. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras O
y O
se O
realizaron O
con O
el O
valor O
alfa O
= O
. O

05 O
significance O
level O
. O

Las B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
la I-Premise
intervención I-Premise
demostraron I-Premise
una I-Premise
mejora I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,0004 I-Premise
) I-Premise
en I-Premise
los I-Premise
síntomas I-Premise
de I-Premise
la I-Premise
menopausia, I-Premise
pero I-Premise
ningún I-Premise
cambio I-Premise
significativo I-Premise
en I-Premise
la I-Premise
vitalidad I-Premise
( I-Premise
P I-Premise
= I-Premise
0,77 I-Premise
) I-Premise
. I-Premise

El B-Premise
funcionamiento I-Premise
sexual I-Premise
mejoró I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
atención I-Premise
habitual. I-Premise

Un B-Claim
programa I-Claim
de I-Claim
evaluación I-Claim
e I-Claim
intervención I-Claim
clínica I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
de I-Claim
la I-Claim
menopausia I-Claim
en I-Claim
las I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
es I-Claim
factible I-Claim
y I-Claim
aceptable I-Claim
para I-Claim
las I-Claim
pacientes I-Claim
, I-Claim
lo I-Claim
que I-Claim
conduce I-Claim
a I-Claim
la I-Claim
reducción I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
y I-Claim
la I-Claim
mejora I-Claim
del I-Claim
funcionamiento I-Claim
sexual I-Claim
. I-Claim

No B-Claim
se I-Claim
demostró I-Claim
una I-Claim
mejora I-Claim
medible I-Claim
en I-Claim
una I-Claim
medida I-Claim
general I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Este O
estudio O
es O
el O
primer O
gran O
ECA O
prospectivo O
de O
la O
biopsia O
del O
ganglio O
centinela O
( O
SNB O
) O
en O
comparación O
con O
el O
tratamiento O
axilar O
estándar O
( O
disección O
de O
los O
ganglios O
linfáticos O
axilares O
de O
nivel O
I-III O
o O
muestreo O
de O
cuatro O
ganglios O
) O
, O
que O
incluye O
evaluaciones O
completas O
y O
repetidas O
de O
la O
calidad O
de O
vida O
( O
QOL O
) O
durante O
18 O
meses O
. O

Las O
pacientes O
( O
n O
= O
829 O
) O
completaron O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
contra O
el O
Cáncer O
- O
Mama O
( O
FACT-B+4 O
) O
y O
el O
Inventario O
de O
Ansiedad O
Estado/Rasgo O
de O
Spielberger O
( O
STAI O
) O
al O
inicio O
( O
antes O
de O
la O
cirugía O
) O
y O
a O
los O
1 O
, O
3 O
, O
6 O
, O
12 O
y O
18 O
meses O
después O
de O
la O
cirugía O
. O

Hubo B-Claim
diferencias I-Claim
significativas I-Claim
entre I-Claim
los I-Claim
grupos I-Claim
de I-Claim
tratamiento I-Claim
que I-Claim
favorecieron I-Claim
al I-Claim
grupo I-Claim
de I-Claim
SNB I-Claim
a I-Claim
lo I-Claim
largo I-Claim
de I-Claim
la I-Claim
evaluación I-Claim
de I-Claim
18 I-Claim
meses. I-Claim

Las B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
estándar I-Premise
mostraron I-Premise
un I-Premise
mayor I-Premise
descenso I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
Índice I-Premise
de I-Premise
Resultados I-Premise
del I-Premise
Ensayo I-Premise
( I-Premise
TOI I-Premise
) I-Premise
( I-Premise
subescalas I-Premise
de I-Premise
bienestar I-Premise
físico I-Premise
, I-Premise
bienestar I-Premise
funcional I-Premise
y I-Premise
preocupaciones I-Premise
por I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
en I-Premise
FACT-B+4 I-Premise
) I-Premise
y I-Premise
se I-Premise
recuperaron I-Premise
más I-Premise
lentamente I-Premise
que I-Premise
las I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
SNB I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

El B-Premise
cambio I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
totales I-Premise
de I-Premise
la I-Premise
FACT-B+4 I-Premise
( I-Premise
que I-Premise
mide I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
) I-Premise
se I-Premise
asemejó I-Premise
mucho I-Premise
a I-Premise
los I-Premise
resultados I-Premise
de I-Premise
la I-Premise
TOI I-Premise
. I-Premise

A B-Premise
los I-Premise
18 I-Premise
meses I-Premise
del I-Premise
postoperatorio, I-Premise
aproximadamente I-Premise
el I-Premise
doble I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
estándar, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
SNB, I-Premise
informaron I-Premise
de I-Premise
una I-Premise
hinchazón I-Premise
sustancial I-Premise
del I-Premise
brazo I-Premise
( I-Premise
14 I-Premise
% I-Premise
frente I-Premise
al I-Premise
7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
o I-Premise
de I-Premise
entumecimiento I-Premise
( I-Premise
19 I-Premise
% I-Premise
frente I-Premise
al I-Premise
8,7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

A O
pesar O
de O
la O
incertidumbre O
de O
someterse O
a O
un O
procedimiento O
relativamente O
nuevo O
y O
de O
la O
posible O
necesidad O
de O
una O
nueva O
intervención O
quirúrgica, O
no B-Premise
se I-Premise
observó I-Premise
un I-Premise
aumento I-Premise
de I-Premise
la I-Premise
ansiedad I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
al I-Premise
azar I-Premise
a I-Premise
la I-Premise
CN I-Premise
( I-Premise
p I-Premise
> I-Premise
0,05 I-Premise
) O
. O

En B-Premise
el I-Premise
postoperatorio I-Premise
de I-Premise
6 I-Premise
meses, I-Premise
los I-Premise
pacientes I-Premise
más I-Premise
jóvenes I-Premise
informaron I-Premise
de I-Premise
puntuaciones I-Premise
de I-Premise
CdV I-Premise
menos I-Premise
favorables I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
de I-Premise
mayores I-Premise
niveles I-Premise
de I-Premise
ansiedad I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

En B-Claim
vista I-Claim
de I-Claim
los I-Claim
beneficios I-Claim
en I-Claim
cuanto I-Claim
al I-Claim
funcionamiento I-Claim
del I-Claim
brazo I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
, I-Claim
los I-Claim
datos I-Claim
de I-Claim
este I-Claim
estudio I-Claim
aleatorio I-Claim
apoyan I-Claim
el I-Claim
uso I-Claim
de I-Claim
la I-Claim
CN I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
clínicamente I-Claim
negativo I-Claim
. I-Claim

El O
treosulfán, O
un O
agente O
alquilante, O
ha O
demostrado O
su O
actividad O
en O
el O
carcinoma O
de O
ovario O
recurrente. O

Es O
igual O
de O
efectivo O
que O
el O
oral O
( O
p.o O
. O
) O

y O
por O
vía O
intravenosa O
( O
i.v O
. O
) O

formulación O
. O

Explorar O
la O
preferencia O
y O
el O
cumplimiento O
de O
los O
pacientes O
de O
edad O
avanzada O
con O
respecto O
a O
la O
p.o O
. O

o O
i.v O
. O

treosulfán O
para O
el O
tratamiento O
del O
carcinoma O
de O
ovario O
recidivante O
, O
se O
incluyeron O
en O
este O
estudio O
prospectivo O
multicéntrico O
mujeres O
de O
65 O
años O
o O
más. O

Dado O
que O
los O
pacientes O
de O
edad O
avanzada O
suelen O
tener O
varias O
enfermedades O
concomitantes O
y O
experimentan O
más O
toxicidad O
en O
el O
tratamiento, O
se O
planificó O
un O
análisis O
provisional O
de O
seguridad O
que O
se O
realizó O
después O
de O
que O
25 O
pacientes O
terminaran O
la O
terapia O
para O
evaluar O
la O
tolerabilidad O
de O
los O
regímenes O
de O
tratamiento. O

Los O
pacientes O
pudieron O
elegir O
libremente O
el O
treosulfán O
i.v. O

( O
7.000 O
mg/m O
( O
2 O
) O
día O
1 O
de O
un O
ciclo O
de O
28 O
días O
) O
o O
p.o O
. O

( O
600 O
mg/m O
( O
2 O
) O
día O
1-28 O
de O
un O
ciclo O
de O
56 O
días O
) O
durante O
un O
máximo O
de O
12 O
ciclos O
( O
i.v O
. O
) O

o O
12 O
meses O
( O
p.o O
. O
) O
. O

Los O
pacientes O
indecisos O
fueron O
asignados O
al O
azar. O

La O
toxicidad O
se O
evaluó O
según O
el O
NCI-CTC O
versión O
2.0 O
. O

Veinticinco O
de O
los O
51 O
pacientes O
reclutados O
completaron O
la O
terapia O
en O
el O
momento O
del O
análisis O
intermedio O
previsto O
( O
mediana O
de O
edad O
, O
75 O
años O
; O
rango O
, O
70-82 O
) O
. O

La O
mediana O
de O
ECOG O
fue O
de O
1 O
, O
y O
la O
mediana O
de O
regímenes O
de O
quimioterapia O
previos O
fue O
de O
2 O
. O

Se O
administró O
una O
mediana O
de O
4 O
ciclos O
( O
rango O
, O
1-12 O
) O
por O
paciente O
. O

La B-Premise
anemia I-Premise
fue I-Premise
la I-Premise
toxicidad I-Premise
hematológica I-Premise
más I-Premise
común I-Premise
( I-Premise
88% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
) I-Premise
. I-Premise

Las B-Premise
toxicidades I-Premise
no I-Premise
hematológicas I-Premise
más I-Premise
frecuentes I-Premise
fueron I-Premise
las I-Premise
náuseas I-Premise
( I-Premise
76 I-Premise
% I-Premise
) I-Premise
, I-Premise
el I-Premise
estreñimiento I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
. I-Premise

En B-Claim
general, I-Claim
el I-Claim
tratamiento I-Claim
fue I-Claim
bien I-Claim
tolerado I-Claim
a I-Claim
pesar I-Claim
de I-Claim
que I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
sufrían I-Claim
múltiples I-Claim
comorbilidades I-Claim
y I-Claim
estaban I-Claim
muy I-Claim
pretratados. I-Claim

No B-Claim
hubo I-Claim
toxicidades I-Claim
hematológicas I-Claim
o I-Claim
no I-Claim
hematológicas I-Claim
inesperadas. I-Claim

Sobre O
la O
base O
de O
este O
análisis O
de O
seguridad, O
se O
continuó O
con O
el O
siguiente O
paso O
de O
reclutamiento O
del O
estudio. O

El O
propósito O
de O
este O
artículo O
es O
comparar O
la O
calidad O
de O
vida O
( O
QOL O
) O
y O
los O
síntomas O
de O
la O
menopausia O
entre O
las O
pacientes O
premenopáusicas O
con O
cáncer O
de O
mama O
con O
ganglios O
linfáticos O
negativos O
que O
reciben O
quimioterapia O
, O
goserelina O
, O
o O
su O
combinación O
secuencial O
, O
y O
para O
investigar O
los O
efectos O
diferenciales O
por O
edad O
. O

Se O
evaluaron O
los O
datos O
de O
calidad O
de O
vida O
de O
874 O
mujeres O
pre O
y O
perimenopáusicas O
con O
cáncer O
de O
mama O
con O
ganglios O
linfáticos O
negativos O
que O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
seis O
ciclos O
de O
quimioterapia O
clásica O
con O
ciclofosfamida, O
metotrexato O
y O
fluorouracilo O
(CMF), O
supresión O
ovárica O
con O
goserelina O
durante O
24 O
meses O
o O
seis O
ciclos O
de O
CMF O
clásica O
seguidos O
de O
18 O
meses O
de O
goserelina. O

Informamos O
de O
los O
datos O
de O
calidad O
de O
vida O
recogidos O
durante O
3 O
años O
después O
de O
la O
asignación O
aleatoria O
en O
pacientes O
sin O
recurrencia O
de O
la O
enfermedad O
. O

En B-Premise
general, I-Premise
las I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
goserelina I-Premise
sola I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
notable I-Premise
o I-Premise
un I-Premise
menor I-Premise
deterioro I-Premise
de I-Premise
las I-Premise
medidas I-Premise
de I-Premise
CdV I-Premise
durante I-Premise
los I-Premise
primeros I-Premise
6 I-Premise
meses I-Premise
que I-Premise
las I-Premise
pacientes I-Premise
tratadas I-Premise
con I-Premise
CMF. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
a I-Premise
los I-Premise
3 I-Premise
años I-Premise
de I-Premise
la I-Premise
asignación I-Premise
aleatoria I-Premise
según I-Premise
el I-Premise
tratamiento, I-Premise
excepto I-Premise
en I-Premise
lo I-Premise
que I-Premise
respecta I-Premise
a I-Premise
los I-Premise
sofocos. I-Premise

Como B-Premise
se I-Premise
refleja I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
sofocos, I-Premise
las I-Premise
pacientes I-Premise
de I-Premise
los I-Premise
tres I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
experimentaron I-Premise
amenorrea I-Premise
inducida, I-Premise
pero B-Premise
el I-Premise
inicio I-Premise
de I-Premise
la I-Premise
supresión I-Premise
de I-Premise
la I-Premise
función I-Premise
ovárica I-Premise
se I-Premise
retrasó I-Premise
ligeramente I-Premise
en I-Premise
las I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
quimioterapia. I-Premise

Las B-Premise
pacientes I-Premise
más I-Premise
jóvenes I-Premise
( I-Premise
< I-Premise
40 I-Premise
años I-Premise
) I-Premise
que I-Premise
recibieron I-Premise
goserelina I-Premise
sola I-Premise
volvieron I-Premise
a I-Premise
su I-Premise
estado I-Premise
premenopáusico I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
de I-Premise
haber I-Premise
dejado I-Premise
la I-Premise
terapia I-Premise
, I-Premise
mientras I-Premise
que I-Premise
las I-Premise
que I-Premise
recibieron I-Premise
CMF I-Premise
mostraron I-Premise
cambios I-Premise
marginales I-Premise
respecto I-Premise
a I-Premise
sus I-Premise
puntuaciones I-Premise
iniciales I-Premise
de I-Premise
sofocos I-Premise
. I-Premise

Los B-Claim
perfiles I-Claim
de I-Claim
riesgo I-Claim
ajustados I-Claim
a I-Claim
la I-Claim
edad I-Claim
que I-Claim
tienen I-Claim
en I-Claim
cuenta I-Claim
los I-Claim
resultados I-Claim
comunicados I-Claim
por I-Claim
las I-Claim
pacientes I-Claim
permiten I-Claim
que I-Claim
éstas I-Claim
se I-Claim
adapten I-Claim
a I-Claim
su I-Claim
enfermedad I-Claim
y I-Claim
a I-Claim
su I-Claim
tratamiento I-Claim
, I-Claim
como I-Claim
por I-Claim
ejemplo I-Claim
considerar I-Claim
las I-Claim
compensaciones I-Claim
entre I-Claim
los I-Claim
síntomas I-Claim
endocrinos I-Claim
retardados I-Claim
, I-Claim
pero I-Claim
el I-Claim
mayor I-Claim
riesgo I-Claim
de I-Claim
menopausia I-Claim
permanente I-Claim
con I-Claim
la I-Claim
quimioterapia I-Claim
, I-Claim
y I-Claim
los I-Claim
síntomas I-Claim
endocrinos I-Claim
inmediatos I-Claim
pero I-Claim
reversibles I-Claim
con I-Claim
la I-Claim
goserelina I-Claim
, I-Claim
en I-Claim
las I-Claim
pacientes I-Claim
premenopáusicas I-Claim
más I-Claim
jóvenes I-Claim
. I-Claim

Con O
la O
adopción O
de O
la O
recuperación O
mejorada O
y O
las O
nuevas O
modalidades O
emergentes O
de O
analgesia O
después O
de O
la O
resección O
colorrectal O
laparoscópica O
( O
LCR O
) O
, O
el O
papel O
de O
la O
analgesia O
epidural O
ha O
sido O
cuestionado O
. O

Este O
ensayo O
piloto O
evaluó O
la O
viabilidad O
de O
un O
ensayo O
controlado O
aleatorio O
( O
ECA O
) O
que O
comparó O
la O
analgesia O
epidural O
y O
el O
uso O
de O
un O
catéter O
de O
infusión O
de O
anestesia O
local O
( O
WIC O
) O
después O
de O
la O
LCR O
. O

Entre O
abril O
de O
2010 O
y O
mayo O
de O
2011 O
, O
los O
pacientes O
sometidos O
a O
LCR O
electiva O
en O
dos O
centros O
fueron O
aleatorizados O
a O
analgesia O
vía O
epidural O
o O
WIC O
. O

Se O
utilizaron O
procedimientos O
simulados O
para O
cegar O
a O
los O
cirujanos, O
los O
pacientes O
y O
los O
evaluadores O
de O
resultados. O

El O
resultado O
primario O
fue O
la O
viabilidad O
de O
un O
gran O
ECA O
, O
y O
se O
probaron O
todos O
los O
resultados O
de O
un O
ensayo O
definitivo. O

El O
éxito O
del O
cegamiento O
se O
evaluó O
mediante O
un O
enfoque O
de O
métodos O
mixtos. O

Cuarenta O
y O
cinco O
pacientes O
fueron O
elegibles O
, O
de O
los O
cuales O
34 O
fueron O
aleatorizados O
( O
media O
( O
s.d. O
) O
edad O
de O
70 O
( O
11-8 O
) O
años O
) O
. O

El O
seguimiento O
de O
los O
pacientes O
se O
realizó O
según O
el O
protocolo; O
no O
hubo O
ninguna O
muerte, O
y O
cinco O
pacientes O
tuvieron O
un O
total O
de O
seis O
complicaciones. O

Se O
identificaron O
y O
resolvieron O
los O
problemas O
de O
captación O
de O
datos O
sobre O
el O
dolor. O

Las B-Premise
puntuaciones I-Premise
medias I-Premise
( I-Premise
s.d. I-Premise
) I-Premise
del I-Premise
dolor I-Premise
el I-Premise
día I-Premise
del I-Premise
alta I-Premise
fueron I-Premise
de I-Premise
1-9 I-Premise
( I-Premise
3-1 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
epidural I-Premise
y I-Premise
de I-Premise
0-7 I-Premise
( I-Premise
0-7 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
del I-Premise
WIC I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
estancia I-Premise
fue I-Premise
de I-Premise
4 I-Premise
( I-Premise
rango I-Premise
2-35 I-Premise
, I-Premise
rango I-Premise
intercuartil I-Premise
3-5 I-Premise
) I-Premise
días I-Premise
. I-Premise

La B-Premise
media I-Premise
de I-Premise
uso I-Premise
de I-Premise
analgesia I-Premise
adicional I-Premise
( I-Premise
equivalentes I-Premise
de I-Premise
morfina I-Premise
intravenosa I-Premise
) I-Premise
fue I-Premise
de I-Premise
12 I-Premise
mg I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
WIC I-Premise
y I-Premise
de I-Premise
9 I-Premise
mg I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
epidural I-Premise
. I-Premise

El O
cegamiento O
de O
los O
pacientes O
fue O
exitoso O
en O
ambos O
brazos O
. O

Las B-Claim
entrevistas I-Claim
cualitativas I-Claim
sugirieron I-Claim
que I-Claim
los I-Claim
pacientes I-Claim
consideraron I-Claim
aceptable I-Claim
su I-Claim
participación I-Claim
en I-Claim
el I-Claim
ensayo I-Claim
y I-Claim
que I-Claim
se I-Claim
plantearían I-Claim
participar I-Claim
en I-Claim
un I-Claim
futuro I-Claim
ensayo. I-Claim

Es B-Claim
factible I-Claim
realizar I-Claim
un I-Claim
ECA I-Claim
ciego I-Claim
que I-Claim
investigue I-Claim
el I-Claim
papel I-Claim
de I-Claim
la I-Claim
administración I-Claim
de I-Claim
la I-Claim
epidural I-Claim
y I-Claim
la I-Claim
WIC I-Claim
para I-Claim
la I-Claim
analgesia I-Claim
postoperatoria I-Claim
tras I-Claim
la I-Claim
LCR. I-Claim

Se B-Claim
necesitan I-Claim
procedimientos I-Claim
operativos I-Claim
estándar I-Claim
rigurosos I-Claim
para I-Claim
la I-Claim
recogida I-Claim
de I-Claim
datos. I-Claim

En O
un O
estudio O
anterior O
sobre O
el O
tratamiento O
del O
cáncer O
colorrectal O
avanzado, O
el O
régimen O
LV5FU2 O
, O
que O
comprende O
leucovorina O
( O
LV O
) O
más O
bolo O
y O
fluorouracilo O
( O
5FU O
) O
en O
infusión O
cada O
2 O
semanas, O
fue O
superior O
al O
régimen O
estándar O
del O
North O
Central O
Cancer O
Treatment O
Group/Mayo O
Clinic O
de O
5 O
días O
en O
bolo O
de O
5FU/LV O
. O

Este O
estudio O
de O
fase O
III O
investigó O
el O
efecto O
de O
la O
combinación O
de O
oxaliplatino O
con O
LV5FU2 O
, O
con O
la O
supervivencia O
libre O
de O
progresión O
como O
punto O
final O
primario. O

Cuatrocientos O
veinte O
pacientes O
no O
tratados O
previamente O
con O
enfermedad O
medible O
fueron O
aleatorizados O
para O
recibir O
una O
infusión O
de O
2 O
horas O
de O
LV O
( O
200 O
mg/m O
( O
2 O
) O
/d O
) O
seguida O
de O
un O
bolo O
de O
5FU O
( O
400 O
mg/m O
( O
2 O
) O
/d O
) O
y O
una O
infusión O
de O
22 O
horas O
( O
600 O
mg/m O
( O
2 O
) O
/d O
) O
durante O
2 O
días O
consecutivos O
cada O
2 O
semanas O
, O
ya O
sea O
solo O
o O
junto O
con O
oxaliplatino O
85 O
mg/m O
( O
2 O
) O
como O
infusión O
de O
2 O
horas O
el O
día O
1 O
. O

Los B-Premise
pacientes I-Premise
asignados I-Premise
a I-Premise
oxaliplatino I-Premise
más I-Premise
LV5FU2 I-Premise
tuvieron I-Premise
una I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
significativamente I-Premise
más I-Premise
larga I-Premise
( I-Premise
mediana, I-Premise
9,0 I-Premise
frente I-Premise
a I-Premise
6,2 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,0003 I-Premise
) I-Premise
y I-Premise
una I-Premise
mejor I-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
( I-Premise
50,7% I-Premise
frente I-Premise
a I-Premise
22,3%; I-Premise
P I-Premise
= I-Premise
0,0001 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
brazo I-Premise
de I-Premise
control. I-Premise

La B-Premise
mejora I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
no I-Premise
alcanzó I-Premise
la I-Premise
significación I-Premise
( I-Premise
mediana I-Premise
, I-Premise
16,2 I-Premise
frente I-Premise
a I-Premise
14,7 I-Premise
meses I-Premise
; I-Premise
P I-Premise
= I-Premise
.12 I-Premise
) I-Premise
. I-Premise

LV5FU2 B-Premise
más I-Premise
oxaliplatino I-Premise
dio I-Premise
mayores I-Premise
frecuencias I-Premise
de I-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
de I-Premise
los I-Premise
criterios I-Premise
comunes I-Premise
de I-Premise
toxicidad I-Premise
del I-Premise
Instituto I-Premise
Nacional I-Premise
del I-Premise
Cáncer I-Premise
( I-Premise
41,7 I-Premise
% I-Premise
frente I-Premise
a I-Premise
5,3 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
) I-Premise
, I-Premise
diarrea I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
( I-Premise
11,9 I-Premise
% I-Premise
frente I-Premise
a I-Premise
5,3 I-Premise
% I-Premise
) I-Premise
y I-Premise
toxicidad I-Premise
neurosensorial I-Premise
de I-Premise
grado I-Premise
3 I-Premise
( I-Premise
18,2 I-Premise
% I-Premise
frente I-Premise
a I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
pero I-Premise
esto I-Premise
no I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
un I-Premise
deterioro I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
QoL I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
sin I-Premise
progresión I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
ni I-Premise
deterioro I-Premise
del I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
al I-Premise
tratamiento I-Premise
con I-Premise
oxaliplatino I-Premise
( I-Premise
P I-Premise
= I-Premise
0,004 I-Premise
) I-Premise
. I-Premise

La B-Claim
combinación I-Claim
LV5FU2-oxaliplatino I-Claim
parece I-Claim
beneficiosa I-Claim
como I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
colorrectal I-Claim
avanzado I-Claim
, I-Claim
demostrando I-Claim
una I-Claim
prolongada I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
con I-Claim
una I-Claim
aceptable I-Claim
tolerabilidad I-Claim
y I-Claim
mantenimiento I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
. I-Claim

Pocos O
informes O
han O
examinado O
el O
uso O
de O
la O
hormona O
estimulante O
de O
la O
tiroides O
humana O
recombinante O
( O
rhTSH O
) O
para O
la O
ablación O
de O
los O
remanentes O
tiroideos O
posquirúrgicos O
después O
de O
la O
terapia O
de O
yodo O
radiactivo O
( O
RI O
) O
en O
dosis O
bajas O
, O
en O
comparación O
con O
la O
retirada O
convencional O
de O
la O
hormona O
tiroidea O
. O

Se O
investigó O
si O
la O
preparación O
de O
los O
pacientes O
mediante O
rhTSH O
era O
comparable O
a O
la O
retirada O
convencional O
de O
la O
hormona O
tiroidea O
con O
respecto O
a O
la O
eficacia O
de O
la O
ablación O
de O
remanentes O
posquirúrgica O
en O
pacientes O
de O
bajo O
riesgo O
que O
recibieron O
una O
RI O
de O
30 O
mCi O
. O

Además O
, O
también O
se O
evaluó O
el O
impacto O
de O
rhTSH O
( O
rhTSH O
frente O
a O
la O
retirada O
de O
la O
hormona O
tiroidea O
convencional O
) O
en O
la O
calidad O
de O
vida O
( O
QoL O
) O
de O
los O
pacientes O
con O
cáncer O
de O
tiroides O
sometidos O
a O
la O
ablación O
RI O
. O

Este O
estudio O
incluyó O
tres O
grupos O
de O
pacientes, O
inscritos O
consecutivamente. O

De O
febrero O
de O
2006 O
a O
marzo O
de O
2007, O
291 O
pacientes O
fueron O
reclutados O
y O
asignados O
al O
azar, O
después O
de O
la O
tiroidectomía O
total: O
( O
1 O
) O
retirada O
de O
levotiroxina O
( O
LT4 O
) O
durante O
4 O
semanas O
( O
Grupo O
T4-WD O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
retirada O
de O
LT4 O
durante O
4 O
semanas O
más O
2 O
semanas O
en O
y O
luego O
2 O
semanas O
fuera O
de O
lothyronine O
( O
LT3 O
) O
( O
Grupo O
T3-WD O
, O
n O
= O
133 O
) O
, O
y O
( O
3 O
) O
administración O
de O
rhTSH O
( O
Grupo O
rhTSH O
, O
n O
= O
69 O
) O
. O

La O
calidad O
de O
vida O
se O
determinó O
en O
el O
momento O
de O
la O
ablación. O

Los O
pacientes O
de O
los O
tres O
grupos O
no O
difirieron O
significativamente O
en O
cuanto O
a O
las O
características O
iniciales O
o O
la O
estadificación O
del O
tumor, O
los O
ganglios O
y O
las O
metástasis O
(TNM). O

En B-Premise
todos I-Premise
los I-Premise
grupos I-Premise
del I-Premise
estudio I-Premise
, I-Premise
los I-Premise
niveles I-Premise
séricos I-Premise
de I-Premise
TSH I-Premise
mostraron I-Premise
una I-Premise
muy I-Premise
buena I-Premise
estimulación I-Premise
( I-Premise
media I-Premise
, I-Premise
82,24 I-Premise
+/- I-Premise
18,21 I-Premise
mU/L I-Premise
) I-Premise
, I-Premise
sin I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
grupos I-Premise
( I-Premise
p I-Premise
= I-Premise
0,5213 I-Premise
) I-Premise
. I-Premise

Se O
realizaron O
exámenes O
de O
seguimiento O
12 O
meses O
después O
de O
la O
ablación O
para O
evaluar O
el O
resultado O
de O
la O
ablación O
en O
cada O
grupo O
mediante O
131 O
gammagrafías O
de O
cuerpo O
entero O
( O
WBS O
) O
, O
la O
medición O
de O
tiroglobulina O
sérica O
después O
de O
la O
estimulación O
de O
TSH O
, O
y O
la O
ecografía O
del O
cuello O
. O

La B-Premise
tasa I-Premise
de I-Premise
éxito I-Premise
de I-Premise
la I-Premise
ablación I-Premise
fue I-Premise
del I-Premise
91,0% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
T4-WD, I-Premise
del I-Premise
91,7% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
T3-WD I-Premise
y I-Premise
del I-Premise
91,3% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
rhTSH, I-Premise
sin I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
preparaciones I-Premise
( I-Premise
p I-Premise
= I-Premise
0,2061 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
se I-Premise
conservó I-Premise
mejor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
rhTSH I-Premise
que I-Premise
en I-Premise
los I-Premise
grupos I-Premise
T4-WD I-Premise
y I-Premise
T3-WD I-Premise
( I-Premise
p I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
en I-Premise
el I-Premise
momento I-Premise
de I-Premise
la I-Premise
ablación I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
T4-WD I-Premise
y I-Premise
T3-WD. I-Premise

Nuestro B-Claim
estudio I-Claim
indica I-Claim
que I-Claim
el I-Claim
uso I-Claim
de I-Claim
rhTSH I-Claim
preserva I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
sometidos I-Claim
a I-Claim
ablación I-Claim
de I-Claim
la I-Claim
RI I-Claim
y I-Claim
ofrece I-Claim
una I-Claim
tasa I-Claim
de I-Claim
éxito I-Claim
de I-Claim
la I-Claim
ablación I-Claim
comparable I-Claim
a I-Claim
la I-Claim
observada I-Claim
tras I-Claim
la I-Claim
retirada I-Claim
de I-Claim
la I-Claim
hormona I-Claim
tiroidea I-Claim
. I-Claim

En O
particular, O
la O
preparación O
para O
la O
ablación O
mediante O
la O
retirada O
de O
LT3 O
durante O
2 O
semanas O
no O
impidió O
el O
desarrollo O
de O
hipotiroidismo O
profundo, O
como O
también O
ocurrió O
cuando O
se O
retiró O
LT4 O
solo O
durante O
4 O
semanas. O

Determinar O
si O
un O
programa B-Claim
de I-Claim
educación I-Claim
a I-Claim
medida I-Claim
basado I-Claim
en I-Claim
Internet I-Claim
es I-Claim
eficaz I-Claim
para I-Claim
los I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
libres I-Claim
de I-Claim
enfermedad I-Claim
con I-Claim
fatiga I-Claim
relacionada I-Claim
con I-Claim
el I-Claim
cáncer I-Claim
( I-Claim
CRF I-Claim
) O
. O

Se O
asignaron O
al O
azar O
pacientes O
que O
habían O
completado O
el O
tratamiento O
primario O
del O
cáncer O
en O
los O
últimos O
24 O
meses O
en O
cualquiera O
de O
los O
cuatro O
hospitales O
coreanos O
y O
que O
habían O
reportado O
fatiga O
moderada O
a O
severa O
durante O
al O
menos O
1 O
semana O
para O
participar O
en O
un O
programa O
de O
educación O
sobre O
CRF O
de O
12 O
semanas, O
basado O
en O
Internet O
y O
adaptado O
individualmente, O
o O
para O
recibir O
atención O
rutinaria. O

Hemos O
basado O
el O
programa O
en O
las O
directrices O
del O
CRF O
de O
la O
National O
Comprehensive O
Cancer O
Network O
( O
NCCN O
) O
y O
hemos O
incorporado O
el O
modelo O
transteórico O
( O
TTM O
) O
. O

Al O
inicio O
y O
a O
las O
12 O
semanas, O
se O
utilizaron O
el O
Inventario O
Breve O
de O
Fatiga O
( O
BFI O
) O
y O
la O
Escala O
de O
Gravedad O
de O
la O
Fatiga O
( O
FSS O
) O
como O
resultados O
primarios O
y O
la O
Escala O
de O
Ansiedad O
y O
Depresión O
Hospitalaria O
( O
HADS O
) O
y O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
QLQ-C30 O
) O
como O
resultados O
secundarios O
. O

Se O
reclutaron O
273 O
participantes O
y O
se O
asignaron O
aleatoriamente O
136 O
al O
grupo O
de O
intervención. O

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
experimentó I-Premise
una I-Premise
mejora I-Premise
de I-Premise
la I-Premise
fatiga, I-Premise
tal I-Premise
y I-Premise
como I-Premise
demostró I-Premise
una I-Premise
disminución I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
global I-Premise
del I-Premise
BFI I-Premise
(-0,66 I-Premise
puntos; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-1,04 I-Premise
a I-Premise
-0,27) I-Premise
y I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
total I-Premise
del I-Premise
FSS I-Premise
(-0,49; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-0,78 I-Premise
a I-Premise
-0,21). I-Premise

En B-Premise
los I-Premise
resultados I-Premise
secundarios, I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
experimentó I-Premise
una I-Premise
disminución I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
ansiedad I-Premise
de I-Premise
la I-Premise
HADS I-Premise
( I-Premise
-0,90 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
-1,51 I-Premise
a I-Premise
-0,29 I-Premise
), I-Premise
así I-Premise
como I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
( I-Premise
5,22 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,93 I-Premise
a I-Premise
9,50 I-Premise
) I-Premise
y I-Premise
de I-Premise
varias I-Premise
puntuaciones I-Premise
de I-Premise
funcionamiento I-Premise
del I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
. I-Premise

Un B-Claim
programa I-Claim
de I-Claim
educación I-Claim
por I-Claim
Internet I-Claim
basado I-Claim
en I-Claim
las I-Claim
directrices I-Claim
de I-Claim
la I-Claim
NCCN I-Claim
y I-Claim
el I-Claim
TTM I-Claim
puede I-Claim
ayudar I-Claim
a I-Claim
los I-Claim
pacientes I-Claim
a I-Claim
controlar I-Claim
el I-Claim
CRF I-Claim
. I-Claim

El O
objetivo O
de O
este O
estudio O
fue O
comparar O
la O
calidad O
de O
vida O
( O
QOL O
) O
de O
las O
pacientes O
con O
cáncer O
de O
mama O
de O
alto O
riesgo O
incluidas O
en O
un O
ensayo O
clínico O
aleatorio O
( O
PEGASE O
01 O
) O
que O
comparaba O
la O
quimioterapia O
convencional O
frente O
a O
la O
adición O
de O
un O
ciclo O
adicional O
de O
quimioterapia O
de O
alta O
dosis O
( O
HDC O
) O
con O
apoyo O
de O
células O
madre O
sanguíneas O
. O

Un O
total O
de O
314 O
pacientes O
fueron O
incluidos O
en O
el O
ensayo O
clínico. O

Se O
disponía O
de O
evaluaciones O
de O
la O
calidad O
de O
vida O
de O
199 O
pacientes. O

La O
calidad O
de O
vida O
se O
evaluó O
durante O
un O
período O
de O
seguimiento O
de O
1 O
año, O
utilizando O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
C-30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer. O

Los O
resultados O
se O
analizaron O
mediante O
un O
modelo O
lineal O
de O
efectos O
mixtos. O

La B-Premise
toxicidad I-Premise
de I-Premise
la I-Premise
HDC I-Premise
tiene I-Premise
un I-Premise
fuerte I-Premise
impacto I-Premise
negativo I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
durante I-Premise
la I-Premise
fase I-Premise
de I-Premise
tratamiento. I-Premise

Este B-Premise
impacto I-Premise
negativo I-Premise
tendió I-Premise
a I-Premise
durar I-Premise
más I-Premise
tiempo I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
HDC I-Premise
, I-Premise
ya I-Premise
que I-Premise
para I-Premise
la I-Premise
mayoría I-Premise
de I-Premise
las I-Premise
escalas I-Premise
del I-Premise
QLQ-C30 I-Premise
, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
QOL I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
HDC I-Premise
tienden I-Premise
a I-Premise
mejorar I-Premise
a I-Premise
un I-Premise
ritmo I-Premise
más I-Premise
lento I-Premise
que I-Premise
el I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
reciben I-Premise
quimioterapia I-Premise
estándar I-Premise
. I-Premise

En O
particular, O
el B-Premise
funcionamiento I-Premise
físico I-Premise
sigue I-Premise
deteriorado I-Premise
1 I-Premise
año I-Premise
después I-Premise
de I-Premise
la I-Premise
inclusión I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
HDC I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
quimioterapia I-Premise
convencional I-Premise
( I-Premise
85,99 I-Premise
frente I-Premise
a I-Premise
76,65 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,021 I-Premise
) O
, O
y B-Premise
la I-Premise
puntuación I-Premise
del I-Premise
dolor I-Premise
seguía I-Premise
siendo I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
HDC I-Premise
en I-Premise
ese I-Premise
momento I-Premise
( I-Premise
28,32 I-Premise
frente I-Premise
a I-Premise
15,97 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,004 I-Premise
) O
. O

La B-Claim
HDC I-Claim
tiene I-Claim
un I-Claim
impacto I-Claim
negativo I-Claim
en I-Claim
la I-Claim
CdV I-Claim
incluso I-Claim
después I-Claim
de I-Claim
la I-Claim
fase I-Claim
de I-Claim
tratamiento I-Claim
. I-Claim

En O
ausencia O
de O
un O
beneficio O
de O
supervivencia O
global O
del O
uso O
de O
HDC O
para O
pacientes O
con O
cáncer O
de O
mama O
de O
alto O
riesgo O
, O
los O
estudios O
de O
QOL O
con O
un O
seguimiento O
más O
largo O
juegan O
un O
papel O
importante O
en O
la O
información O
de O
la O
compleja O
compensación O
que O
implica O
el O
HDC O
entre O
una O
mayor O
toxicidad O
, O
la O
reducción O
del O
riesgo O
de O
recaída O
, O
y O
la O
disminución O
de O
QOL O
después O
de O
la O
fase O
activa O
del O
tratamiento O
. O

El O
objetivo O
de O
este O
estudio O
fue O
comparar O
los O
efectos O
analgésicos O
y O
adversos O
, O
las O
dosis O
, O
así O
como O
el O
coste O
de O
los O
fármacos O
opiáceos O
, O
el O
tratamiento O
farmacológico O
de O
apoyo O
y O
otros O
fármacos O
analgésicos O
en O
pacientes O
tratados O
con O
morfina O
oral O
de O
liberación O
sostenida O
, O
fentanilo O
transdérmico O
, O
y O
metadona O
oral O
. O

Ciento O
ocho O
pacientes O
con O
cáncer O
, O
que O
ya O
no O
responden O
a O
los O
opioides O
para O
el O
dolor O
moderado O
, O
fueron O
seleccionados O
para O
recibir O
al O
azar O
dosis O
diarias O
iniciales O
de O
60 O
mg O
de O
morfina O
oral O
de O
liberación O
sostenida O
, O
15 O
mg O
de O
metadona O
oral O
, O
o O
0,6 O
mg O
( O
25 O
microg/h O
) O
de O
fentanilo O
transdérmico O
. O

La O
morfina O
oral O
se O
utilizó O
como O
medicación O
para O
el O
dolor O
irruptivo O
durante O
la O
titulación O
de O
opioides O
. O

Las O
dosis O
de O
opioides O
, O
la O
intensidad O
del O
dolor O
, O
los O
efectos O
adversos O
, O
los O
medicamentos O
sintomáticos O
, O
se O
registraron O
a O
intervalos O
de O
una O
semana O
durante O
4 O
semanas O
. O

También O
se O
evaluaron O
los O
costes O
de O
la O
terapia O
con O
opioides, O
los O
medicamentos O
de O
apoyo O
y O
otros O
fármacos O
analgésicos. O

Setenta O
pacientes O
completaron O
el O
período O
de O
4 O
semanas O
de O
estudio. O

Cinco, O
cinco O
y O
cuatro O
pacientes, O
tratados O
con O
morfina O
oral, O
fentanilo O
transdérmico O
y O
metadona O
oral, O
respectivamente, O
necesitaron O
cambiar O
de O
opioide. O

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
el I-Premise
dolor I-Premise
y I-Premise
la I-Premise
intensidad I-Premise
de I-Premise
los I-Premise
síntomas. I-Premise

El B-Premise
índice I-Premise
de I-Premise
escalada I-Premise
de I-Premise
opioides I-Premise
fue I-Premise
significativamente I-Premise
menor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
metadona I-Premise
( I-Premise
p I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
, I-Premise
aunque I-Premise
requirieron I-Premise
cambios I-Premise
de I-Premise
dosis I-Premise
hacia I-Premise
arriba I-Premise
y I-Premise
hacia I-Premise
abajo I-Premise
. I-Premise

En B-Premise
las I-Premise
dosis I-Premise
utilizadas, I-Premise
la I-Premise
metadona I-Premise
fue I-Premise
significativamente I-Premise
menos I-Premise
costosa I-Premise
( I-Premise
p I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
el I-Premise
uso I-Premise
y I-Premise
los I-Premise
costes I-Premise
de I-Premise
los I-Premise
medicamentos I-Premise
de I-Premise
apoyo I-Premise
y I-Premise
otros I-Premise
analgésicos I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
los I-Premise
tres I-Premise
grupos I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
relevantes I-Premise
en I-Premise
los I-Premise
efectos I-Premise
adversos I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
ni I-Premise
durante I-Premise
la I-Premise
fase I-Premise
de I-Premise
titulación I-Premise
ni I-Premise
durante I-Premise
el I-Premise
tratamiento I-Premise
crónico. I-Premise

Los B-Claim
tres I-Claim
opioides I-Claim
utilizados I-Claim
como I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
fueron I-Claim
eficaces, I-Claim
bien I-Claim
tolerados I-Claim
y I-Claim
requirieron I-Claim
cantidades I-Claim
similares I-Claim
de I-Claim
fármacos I-Claim
sintomáticos I-Claim
o I-Claim
coanalgésicos. I-Claim

La B-Claim
metadona I-Claim
fue I-Claim
significativamente I-Claim
menos I-Claim
costosa, I-Claim
pero I-Claim
requirió I-Claim
más I-Claim
cambios, I-Claim
hacia I-Claim
arriba I-Claim
y I-Claim
hacia I-Claim
abajo, I-Claim
de I-Claim
las I-Claim
dosis, I-Claim
lo I-Claim
que I-Claim
sugiere I-Claim
que I-Claim
la I-Claim
titulación I-Claim
de I-Claim
la I-Claim
dosis I-Claim
de I-Claim
este I-Claim
fármaco I-Claim
requiere I-Claim
una I-Claim
gran I-Claim
experiencia I-Claim
clínica. I-Claim

Se O
buscó O
el O
grado O
de O
reducción O
de O
la O
morbilidad O
en O
el O
brazo O
mediante O
el O
manejo O
basado O
en O
el O
ganglio O
centinela O
en O
mujeres O
con O
cáncer O
de O
mama O
temprano O
clínicamente O
negativo. O

Mil O
ochenta O
y O
ocho O
mujeres O
fueron O
asignadas O
aleatoriamente O
a O
la O
biopsia O
del O
ganglio O
centinela O
seguida O
de O
vaciado O
axilar O
si O
el O
ganglio O
centinela O
era O
positivo O
o O
no O
se O
detectaba O
( O
SNBM O
) O
o O
al O
vaciado O
axilar O
rutinario O
( O
RAC O
, O
biopsia O
del O
ganglio O
centinela O
seguida O
inmediatamente O
de O
vaciado O
axilar O
) O
. O

Los O
ganglios O
centinela O
se O
localizaron O
con O
colorante O
azul, O
solo O
o O
con O
coloide O
de O
sulfuro O
de O
antimonio O
marcado O
con O
tecnecio. O

El O
criterio O
de O
valoración O
principal O
fue O
el O
aumento O
del O
volumen O
del O
brazo O
desde O
el O
inicio O
hasta O
la O
media O
de O
las O
mediciones O
a O
los O
6 O
y O
12 O
meses. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
las O
proporciones O
de O
mujeres O
con O
al O
menos O
un O
15 O
% O
de O
aumento O
del O
volumen O
del O
brazo O
o O
de O
morbilidad O
axilar O
precoz, O
y O
las O
puntuaciones O
medias O
de O
los O
síntomas, O
disfunciones O
y O
discapacidades O
del O
brazo O
evaluadas O
a O
los O
6 O
y O
12 O
meses O
por O
las O
pacientes O
con O
las O
escalas O
específicas O
del O
estudio O
SNAC O
y O
otros O
instrumentos O
de O
calidad O
de O
vida. O

Se O
estimaron O
la O
sensibilidad, O
las O
tasas O
de O
falsos O
negativos O
y O
los O
valores O
predictivos O
negativos O
de O
la O
biopsia O
del O
ganglio O
centinela O
en O
el O
grupo O
RAC. O

El B-Premise
aumento I-Premise
medio I-Premise
del I-Premise
volumen I-Premise
del I-Premise
brazo I-Premise
fue I-Premise
del I-Premise
2,8% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
SNBM I-Premise
y I-Premise
del I-Premise
4,2% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
RAC I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
SNBM I-Premise
dieron I-Premise
valoraciones I-Premise
más I-Premise
bajas I-Premise
para I-Premise
la I-Premise
hinchazón I-Premise
del I-Premise
brazo I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
los I-Premise
síntomas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
las I-Premise
disfunciones I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
pero I-Premise
no I-Premise
las I-Premise
discapacidades I-Premise
( I-Premise
P I-Premise
= I-Premise
0,5 I-Premise
) I-Premise
. I-Premise

Se B-Premise
encontraron I-Premise
ganglios I-Premise
centinelas I-Premise
en I-Premise
el I-Premise
95 I-Premise
% I-Premise
del I-Premise
grupo I-Premise
SNBM I-Premise
( I-Premise
29 I-Premise
% I-Premise
positivos I-Premise
) I-Premise
y I-Premise
en I-Premise
el I-Premise
93 I-Premise
% I-Premise
del I-Premise
grupo I-Premise
RAC I-Premise
( I-Premise
25 I-Premise
% I-Premise
positivos I-Premise
) I-Premise
. I-Premise

La O
SNB O
tenía O
una O
sensibilidad O
del O
94,5%, O
una O
tasa O
de O
falsos O
negativos O
del O
5,5% O
y O
un O
valor O
predictivo O
negativo O
del O
98%. O

La B-Claim
SNBM I-Claim
se I-Claim
llevó I-Claim
a I-Claim
cabo I-Claim
con I-Claim
éxito I-Claim
en I-Claim
una I-Claim
amplia I-Claim
gama I-Claim
de I-Claim
centros I-Claim
quirúrgicos I-Claim
y I-Claim
causó I-Claim
una I-Claim
morbilidad I-Claim
significativamente I-Claim
menor I-Claim
que I-Claim
la I-Claim
RAC I-Claim
. I-Claim

Este O
estudio O
de O
fase O
III, O
doble O
ciego, O
aleatorizado O
y O
multicéntrico, O
evaluó O
la O
eficacia, O
la O
farmacodinámica O
y O
la O
seguridad O
del O
inactivador O
de O
la O
aromatasa O
oral O
exemestano O
( O
EXE O
) O
frente O
al O
acetato O
de O
megestrol O
( O
MA O
) O
en O
mujeres O
posmenopáusicas O
con O
cáncer O
de O
mama O
avanzado O
y O
progresivo O
que O
experimentaron O
el O
fracaso O
del O
tamoxifeno. O

Un O
total O
de O
769 O
pacientes O
fueron O
aleatorizados O
a O
EXE O
25 O
mg/día O
( O
n O
= O
366 O
) O
o O
MA O
( O
n O
= O
403 O
) O
40 O
mg O
cuatro O
veces O
al O
día O
. O

Se O
evaluaron O
la O
respuesta O
tumoral, O
la O
duración O
del O
control O
del O
tumor, O
los O
signos O
y O
síntomas O
relacionados O
con O
el O
tumor O
( O
TRSS O
), O
la O
calidad O
de O
vida O
( O
QOL O
), O
la O
supervivencia O
y O
la O
tolerabilidad. O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
objetiva I-Premise
global I-Premise
( I-Premise
OR I-Premise
) I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
EXE I-Premise
que I-Premise
en I-Premise
los I-Premise
tratados I-Premise
con I-Premise
MA I-Premise
( I-Premise
15,0 I-Premise
% I-Premise
frente I-Premise
a I-Premise
12,4 I-Premise
% I-Premise
) I-Premise
; I-Premise
se I-Premise
observó B-Premise
una I-Premise
tendencia I-Premise
similar I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
metástasis I-Premise
viscerales I-Premise
( I-Premise
13,5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
10,5 I-Premise
% O
) O
. O

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
con I-Premise
EXE I-Premise
( I-Premise
mediana I-Premise
no I-Premise
alcanzada I-Premise
) I-Premise
que I-Premise
con I-Premise
MA I-Premise
( I-Premise
123,4 I-Premise
semanas I-Premise
; I-Premise
P I-Premise
=,039 I-Premise
) I-Premise
, I-Premise
al I-Premise
igual I-Premise
que I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
duración I-Premise
del I-Premise
éxito I-Premise
global I-Premise
( I-Premise
O I-Premise
o I-Premise
enfermedad I-Premise
estable I-Premise
> I-Premise
o I-Premise
= I-Premise
24 I-Premise
semanas I-Premise
; I-Premise
60,1 I-Premise
frente I-Premise
a I-Premise
49,1 I-Premise
semanas I-Premise
; I-Premise
P I-Premise
=,025 I-Premise
) I-Premise
, I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
del I-Premise
tumor I-Premise
( I-Premise
20,3 I-Premise
frente I-Premise
a I-Premise
16,6 I-Premise
semanas I-Premise
; I-Premise
P I-Premise
=,037 I-Premise
) I-Premise
, I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
fracaso I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
16,3 I-Premise
frente I-Premise
a I-Premise
15,7 I-Premise
semanas I-Premise
; I-Premise
P I-Premise
=,042 I-Premise
) I-Premise
. I-Premise

En B-Premise
comparación I-Premise
con I-Premise
la I-Premise
AM, I-Premise
hubo I-Premise
mejoras I-Premise
similares I-Premise
o I-Premise
mayores I-Premise
en I-Premise
el I-Premise
dolor, I-Premise
la I-Premise
TRSS I-Premise
y I-Premise
la I-Premise
CdV I-Premise
con I-Premise
la I-Premise
EXE. I-Premise

Ambos B-Claim
fármacos I-Claim
fueron I-Claim
bien I-Claim
tolerados. I-Claim

Los B-Premise
cambios I-Premise
de I-Premise
peso I-Premise
de I-Premise
grado I-Premise
3 I-Premise
o I-Premise
4 I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
con I-Premise
la I-Premise
AM I-Premise
( I-Premise
17,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
7,6 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

EXE B-Claim
prolonga I-Claim
el I-Claim
tiempo I-Claim
de I-Claim
supervivencia, I-Claim
el I-Claim
tiempo I-Claim
hasta I-Claim
la I-Claim
progresión I-Claim
del I-Claim
tumor I-Claim
y I-Claim
el I-Claim
tiempo I-Claim
hasta I-Claim
el I-Claim
fracaso I-Claim
del I-Claim
tratamiento I-Claim
en I-Claim
comparación I-Claim
con I-Claim
MA I-Claim
y I-Claim
ofrece I-Claim
una I-Claim
opción I-Claim
de I-Claim
tratamiento I-Claim
bien I-Claim
tolerada I-Claim
para I-Claim
las I-Claim
mujeres I-Claim
posmenopáusicas I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
avanzado I-Claim
progresivo I-Claim
que I-Claim
experimentaron I-Claim
el I-Claim
fracaso I-Claim
del I-Claim
tamoxifeno I-Claim
. I-Claim

Se O
llevó O
a O
cabo O
un O
ensayo O
aleatorio O
de O
fase O
III O
para O
determinar O
si O
el O
tratamiento O
combinado O
con O
ácido O
13-cis-retinoico O
( O
13-CRA O
) O
más O
interferón O
alfa-2a O
( O
IFNalpha2a O
) O
es O
superior O
al O
IFNalpha2a O
solo O
en O
pacientes O
con O
carcinoma O
de O
células O
renales O
( O
CCR O
) O
avanzado. O

Doscientos O
ochenta O
y O
cuatro O
pacientes O
fueron O
asignados O
aleatoriamente O
al O
tratamiento O
con O
IFNalpha2a O
más O
13-CRA O
o O
al O
tratamiento O
con O
IFNalpha2a O
solo. O

El O
IFNalfa2a O
se O
administró O
diariamente O
por O
vía O
subcutánea, O
comenzando O
con O
una O
dosis O
de O
3 O
millones O
de O
unidades O
( O
MU O
) O
. O

La O
dosis O
se O
incrementó O
cada O
7 O
días O
de O
3 O
a O
9 O
MU O
( O
por O
incrementos O
de O
3 O
MU O
) O
, O
a O
menos O
que O
se O
produjera O
una O
toxicidad O
> O
/= O
grado O
2 O
, O
en O
cuyo O
caso O
se O
detuvo O
la O
escalada O
de O
dosis O
. O

Los O
pacientes O
asignados O
al O
azar O
a O
la O
terapia O
combinada O
recibieron O
13-CRA O
por O
vía O
oral O
1 O
mg/kg/d O
más O
IFNalpha2a O
. O

Se O
evaluó O
la O
calidad O
de O
vida O
( O
QOL O
). O

El B-Premise
12% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
IFNalpha2a I-Premise
más I-Premise
13-CRA I-Premise
y I-Premise
el I-Premise
6% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
IFNalpha2a I-Premise
lograron I-Premise
respuestas I-Premise
completas I-Premise
o I-Premise
parciales I-Premise
( I-Premise
P I-Premise
= I-Premise
0,14 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
respuesta I-Premise
( I-Premise
completa I-Premise
y I-Premise
parcial I-Premise
combinada I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
tratado I-Premise
con I-Premise
la I-Premise
combinación I-Premise
fue I-Premise
de I-Premise
33 I-Premise
meses I-Premise
( I-Premise
rango I-Premise
, I-Premise
9 I-Premise
a I-Premise
50 I-Premise
meses I-Premise
) I-Premise
, I-Premise
frente I-Premise
a I-Premise
los I-Premise
22 I-Premise
meses I-Premise
( I-Premise
rango I-Premise
, I-Premise
5 I-Premise
a I-Premise
38 I-Premise
meses I-Premise
) I-Premise
del I-Premise
segundo I-Premise
grupo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
. I-Premise

El B-Premise
19% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
IFNalpha2a I-Premise
más I-Premise
13-CRA I-Premise
estaban I-Premise
libres I-Premise
de I-Premise
progresión I-Premise
a I-Premise
los I-Premise
24 I-Premise
meses I-Premise
, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
10% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
sólo I-Premise
con I-Premise
IFNalpha2a I-Premise
( I-Premise
P I-Premise
= I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
fue I-Premise
de I-Premise
15 I-Premise
meses, I-Premise
sin I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
= I-Premise
0,26 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
disminuyó I-Premise
durante I-Premise
las I-Premise
primeras I-Premise
8 I-Premise
semanas I-Premise
de I-Premise
tratamiento, I-Premise
a I-Premise
las I-Premise
que I-Premise
siguió I-Premise
una I-Premise
recuperación I-Premise
parcial. I-Premise

Las B-Premise
puntuaciones I-Premise
más I-Premise
bajas I-Premise
se I-Premise
asociaron I-Premise
a I-Premise
la I-Premise
terapia I-Premise
combinada I-Premise
. I-Premise

La B-Claim
proporción I-Claim
de I-Claim
respuesta I-Claim
y I-Claim
la I-Claim
supervivencia I-Claim
no I-Claim
mejoraron I-Claim
significativamente I-Claim
con I-Claim
la I-Claim
adición I-Claim
de I-Claim
13-CRA I-Claim
al I-Claim
tratamiento I-Claim
con I-Claim
IFNalpha2a I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CCR I-Claim
avanzado. I-Claim

El B-Claim
13-CRA I-Claim
puede I-Claim
prolongar I-Claim
la I-Claim
respuesta I-Claim
al I-Claim
tratamiento I-Claim
con I-Claim
IFNalpha2a I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
tumores I-Claim
sensibles I-Claim
a I-Claim
este I-Claim
último. I-Claim

El B-Claim
tratamiento, I-Claim
en I-Claim
particular I-Claim
la I-Claim
terapia I-Claim
combinada, I-Claim
se I-Claim
asoció I-Claim
con I-Claim
una I-Claim
disminución I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

La O
esofagectomía O
transtorácica O
y O
transhiatal O
son O
dos O
procedimientos O
habituales O
para O
la O
resección O
del O
cáncer O
de O
esófago. O

Los O
estudios O
prospectivos O
que O
comparan O
los O
dos O
métodos O
en O
personas O
asiáticas O
son O
escasos O
. O

Además, O
faltan O
datos O
que O
comparen O
sus O
efectos O
sobre O
la O
calidad O
de O
vida. O

Se O
realizó O
un O
estudio O
prospectivo O
y O
aleatorio O
a O
partir O
de O
enero O
de O
2003. O

Los O
pacientes O
con O
cáncer O
de O
esófago O
resecable O
en O
un O
estadio O
comparable O
fueron O
asignados O
para O
someterse O
al O
procedimiento O
transtorácico O
o O
transhiatal O
por O
turnos. O

Todos O
ellos O
fueron O
reconstruidos O
con O
interposición O
de O
estómago O
por O
vía O
retroesternal O
. O

Los O
pacientes O
dados O
de O
alta O
fueron O
seguidos O
en O
la O
consulta O
externa. O

Se O
les O
interrogó O
sobre O
los O
temas O
de O
( O
i O
) O
gravedad O
del O
dolor O
, O
( O
ii O
) O
facilidad O
para O
tragar O
, O
( O
iii O
) O
satisfacción O
de O
las O
actividades O
diarias O
, O
( O
iv O
) O
dependencia O
de O
los O
medicamentos O
, O
( O
v O
) O
capacidad O
de O
trabajo O
, O
( O
vi O
) O
fatiga O
, O
( O
vii O
) O
apetito O
, O
( O
viii O
) O
socialidad O
, O
( O
ix O
) O
felicidad O
y O
( O
x O
) O
autoestima O
, O
en O
el O
tercer O
, O
sexto O
y O
duodécimo O
mes O
. O

También O
se O
registraron O
los O
datos O
demográficos, O
los O
resultados O
operativos O
y O
la O
supervivencia. O

Hasta O
diciembre O
de O
2006, O
se O
inscribieron O
ochenta O
y O
siete O
pacientes O
de O
los O
estadios O
II O
y O
III, O
incluyendo O
71 O
pacientes O
de O
lesiones O
del O
tercio O
medio O
y O
16 O
de O
lesiones O
del O
tercio O
inferior. O

El B-Premise
tiempo I-Premise
de I-Premise
la I-Premise
operación I-Premise
fue I-Premise
significativamente I-Premise
más I-Premise
largo I-Premise
y I-Premise
la I-Premise
tasa I-Premise
de I-Premise
fuga I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
transtorácico I-Premise
(prueba I-Premise
t I-Premise
de I-Premise
Student I-Premise
y I-Premise
prueba I-Premise
exacta I-Premise
de I-Premise
Fischer, I-Premise
respectivamente). I-Premise

Sin O
embargo, O
la O
pérdida B-Premise
de I-Premise
sangre I-Premise
intraoperatoria I-Premise
y I-Premise
la I-Premise
estancia I-Premise
hospitalaria I-Premise
postoperatoria I-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
(prueba I-Premise
t I-Premise
de I-Premise
Student). I-Premise

Además, O
las B-Premise
curvas I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
Kaplan-Meier I-Premise
de I-Premise
estos I-Premise
dos I-Premise
grupos I-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
mediante I-Premise
la I-Premise
prueba I-Premise
de I-Premise
log-rank I-Premise
( I-Premise
p=0,286 I-Premise
) O
. O

La B-Premise
puntuación I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
transhiáticos I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
que I-Premise
la I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
transtorácicos I-Premise
en I-Premise
el I-Premise
tercer, I-Premise
sexto I-Premise
y I-Premise
duodécimo I-Premise
mes. I-Premise

La B-Claim
esofagectomía I-Claim
transhiatal I-Claim
es I-Claim
un I-Claim
procedimiento I-Claim
seguro I-Claim
y I-Claim
rápido. I-Claim

La B-Claim
supervivencia I-Claim
fue I-Claim
similar I-Claim
a I-Claim
la I-Claim
del I-Claim
abordaje I-Claim
transtorácico. I-Claim

Su B-Claim
índice I-Claim
de I-Claim
fugas I-Claim
era I-Claim
menor I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
era I-Claim
mejor. I-Claim

Los B-Claim
sofocos I-Claim
son I-Claim
un I-Claim
problema I-Claim
importante I-Claim
para I-Claim
muchas I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

Los B-Claim
sofocos I-Claim
pueden I-Claim
provocar I-Claim
malestar, I-Claim
interrupción I-Claim
del I-Claim
sueño, I-Claim
ansiedad I-Claim
y I-Claim
disminución I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Un O
tratamiento O
mente-cuerpo O
bien O
tolerado O
y O
eficaz O
para O
los O
sofocos O
sería O
de O
gran O
valor O
. O

Sobre O
la O
base O
de O
estudios O
de O
casos O
anteriores O
, O
este O
estudio O
se O
desarrolló O
para O
evaluar O
el O
efecto O
de O
una O
intervención O
de O
hipnosis O
para O
los O
sofocos O
. O

Sesenta O
mujeres O
supervivientes O
de O
cáncer O
de O
mama O
con O
sofocos O
fueron O
asignadas O
al O
azar O
para O
recibir O
una O
intervención O
de O
hipnosis O
( O
cinco O
sesiones O
semanales O
) O
o O
ningún O
tratamiento O
. O

Las O
pacientes O
elegibles O
debían O
tener O
antecedentes O
de O
cáncer O
de O
mama O
primario O
sin O
evidencia O
de O
enfermedad O
detectable O
y O
14 O
o O
más O
sofocos O
semanales O
durante O
al O
menos O
1 O
mes O
. O

La O
principal O
medida O
de O
resultado O
fue O
un O
constructo O
bivariable O
que O
representaba O
la O
frecuencia O
de O
sofocos O
y O
la O
puntuación O
de O
sofocos O
, O
que O
se O
analizó O
mediante O
una O
comparación O
clásica O
de O
sumas O
y O
diferencias O
. O

Las O
medidas O
de O
resultado O
secundarias O
fueron O
los O
autoinformes O
sobre O
la O
interferencia O
de O
los O
sofocos O
en O
las O
actividades O
diarias. O

Cincuenta O
y O
una O
mujeres O
asignadas O
al O
azar O
completaron O
el O
estudio. O

Al B-Premise
final I-Premise
del I-Premise
período I-Premise
de I-Premise
tratamiento, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
sofocos I-Premise
(frecuencia I-Premise
x I-Premise
gravedad I-Premise
media) I-Premise
disminuyeron I-Premise
un I-Premise
68% I-Premise
desde I-Premise
el I-Premise
punto I-Premise
de I-Premise
partida I-Premise
hasta I-Premise
el I-Premise
punto I-Premise
final I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
la I-Premise
hipnosis I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Se B-Premise
observaron I-Premise
mejoras I-Premise
significativas I-Premise
en I-Premise
la I-Premise
ansiedad I-Premise
autodeclarada, I-Premise
la I-Premise
depresión, I-Premise
la I-Premise
interferencia I-Premise
de I-Premise
los I-Premise
sofocos I-Premise
en I-Premise
las I-Premise
actividades I-Premise
diarias I-Premise
y I-Premise
el I-Premise
sueño I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
la I-Premise
intervención I-Premise
de I-Premise
hipnosis I-Premise
( I-Premise
P I-Premise
< I-Premise
0,005 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
sin I-Premise
tratamiento. I-Premise

La B-Claim
hipnosis I-Claim
parece I-Claim
reducir I-Claim
los I-Claim
sofocos I-Claim
percibidos I-Claim
en I-Claim
las I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
y I-Claim
puede I-Claim
tener I-Claim
beneficios I-Claim
adicionales I-Claim
como I-Claim
la I-Claim
reducción I-Claim
de I-Claim
la I-Claim
ansiedad I-Claim
y I-Claim
la I-Claim
depresión I-Claim
, I-Claim
y I-Claim
la I-Claim
mejora I-Claim
del I-Claim
sueño I-Claim
. I-Claim

El O
estudio O
TAX O
327 O
comparó O
el O
docetaxel O
administrado O
cada O
3 O
semanas O
( O
D3 O
) O
, O
el O
docetaxel O
semanal O
( O
D1 O
) O
y O
la O
mitoxantrona O
( O
M O
) O
, O
cada O
uno O
de O
ellos O
con O
prednisona O
( O
P O
) O
, O
en O
1.006 O
hombres O
con O
cáncer O
de O
próstata O
metastásico O
resistente O
a O
las O
hormonas O
( O
HRPC O
) O
. O

El O
análisis O
original, O
realizado O
en O
agosto O
de O
2003 O
cuando O
se O
habían O
producido O
557 O
muertes, O
mostró O
una O
supervivencia O
y O
unas O
tasas O
de O
respuesta O
significativamente O
mejores O
para O
el O
dolor, O
el O
antígeno O
prostático O
específico O
( O
PSA O
) O
y O
la O
calidad O
de O
vida O
para O
el O
D3P O
en O
comparación O
con O
el O
MP O
. O

En O
este O
caso, O
presentamos O
un O
análisis O
actualizado O
de O
la O
supervivencia. O

Se O
pidió O
a O
los O
investigadores O
que O
facilitaran O
la O
fecha O
de O
fallecimiento O
o O
de O
último O
seguimiento O
de O
todos O
los O
participantes O
que O
estaban O
vivos O
en O
agosto O
de O
2003. O

En O
marzo O
de O
2007, O
se O
obtuvieron O
datos O
de O
310 O
muertes O
adicionales O
( O
total O
= O
867 O
muertes O
) O
. O

El B-Premise
beneficio I-Premise
de I-Premise
supervivencia I-Premise
del I-Premise
D3P I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
MP I-Premise
ha I-Premise
persistido I-Premise
con I-Premise
un I-Premise
seguimiento I-Premise
prolongado I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
. I-Premise

La O
mediana O
de O
supervivencia O
fue O
de O
19,2 O
meses O
(IC O
del O
95 O
%, O
17,5 O
a O
21,3 O
meses) O
en O
el O
brazo O
D3P, O
17,8 O
meses O
(IC O
del O
95 O
%, O
16,2 O
a O
19,2 O
meses) O
en O
el O
brazo O
D1P O
y O
16,3 O
meses O
(IC O
del O
95 O
%, O
14,3 O
a O
17,9 O
meses) O
en O
el O
brazo O
MP. O

Más B-Premise
pacientes I-Premise
sobrevivieron I-Premise
> I-Premise
/= I-Premise
3 I-Premise
años I-Premise
en I-Premise
los I-Premise
brazos I-Premise
D3P I-Premise
y I-Premise
D1P I-Premise
( I-Premise
18,6 I-Premise
% I-Premise
y I-Premise
16,6 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
brazo I-Premise
MP I-Premise
( I-Premise
13,5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Se B-Premise
observaron I-Premise
tendencias I-Premise
similares I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
para I-Premise
los I-Premise
hombres I-Premise
mayores I-Premise
y I-Premise
menores I-Premise
de I-Premise
65 I-Premise
años, I-Premise
para I-Premise
los I-Premise
que I-Premise
tenían I-Premise
y I-Premise
no I-Premise
tenían I-Premise
dolor I-Premise
al I-Premise
inicio, I-Premise
y I-Premise
para I-Premise
los I-Premise
que I-Premise
tenían I-Premise
un I-Premise
PSA I-Premise
inicial I-Premise
mayor I-Premise
y I-Premise
menor I-Premise
que I-Premise
el I-Premise
valor I-Premise
medio I-Premise
de I-Premise
115 I-Premise
ng/mL. I-Premise

El B-Claim
presente I-Claim
análisis I-Claim
confirma I-Claim
que I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
hombres I-Claim
con I-Claim
CPDH I-Claim
metastásico I-Claim
es I-Claim
significativamente I-Claim
mayor I-Claim
tras I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
D3P I-Claim
que I-Claim
con I-Claim
MP I-Claim
. I-Claim

Se O
observan O
resultados O
consistentes O
en O
todos O
los O
subgrupos O
de O
pacientes O
. O

Tanto O
la O
gastroyeyunostomía O
( O
GJJ O
) O
como O
la O
colocación O
de O
stents O
son O
tratamientos O
paliativos O
comúnmente O
utilizados O
para O
los O
síntomas O
obstructivos O
causados O
por O
la O
obstrucción O
maligna O
de O
la O
salida O
gástrica O
( O
GOO O
) O
. O

Comparar O
la O
GJJ O
y O
la O
colocación O
de O
un O
stent O
. O

Ensayo O
multicéntrico O
y O
aleatorizado. O

Veintiún O
centros O
en O
los O
Países O
Bajos O
. O

Pacientes O
con O
GOO O
. O

GJJ O
y O
colocación O
de O
stent O
. O

Los O
resultados O
fueron O
los O
efectos O
médicos, O
la O
calidad O
de O
vida O
y O
los O
costes. O

El O
análisis O
fue O
por O
intención O
de O
tratar O
. O

Dieciocho O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
la O
GJJ O
y O
21 O
a O
la O
colocación O
de O
un O
stent O
. O

La B-Premise
ingesta I-Premise
de I-Premise
alimentos I-Premise
mejoró I-Premise
más I-Premise
rápidamente I-Premise
después I-Premise
de I-Premise
la I-Premise
colocación I-Premise
de I-Premise
la I-Premise
endoprótesis I-Premise
que I-Premise
después I-Premise
de I-Premise
la I-Premise
JCG I-Premise
( I-Premise
puntuación I-Premise
del I-Premise
Sistema I-Premise
de I-Premise
Puntuación I-Premise
de I-Premise
GOO I-Premise
> I-Premise
o I-Premise
= I-Premise
2 I-Premise
: I-Premise
mediana I-Premise
de I-Premise
5 I-Premise
frente I-Premise
a I-Premise
8 I-Premise
días I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) O
pero B-Premise
el I-Premise
alivio I-Premise
a I-Premise
largo I-Premise
plazo I-Premise
fue I-Premise
mejor I-Premise
después I-Premise
de I-Premise
la I-Premise
JCG I-Premise
, I-Premise
con I-Premise
más I-Premise
pacientes I-Premise
que I-Premise
vivieron I-Premise
más I-Premise
días I-Premise
con I-Premise
una I-Premise
puntuación I-Premise
del I-Premise
Sistema I-Premise
de I-Premise
Puntuación I-Premise
de I-Premise
GOO I-Premise
de I-Premise
2 I-Premise
o I-Premise
más I-Premise
que I-Premise
después I-Premise
de I-Premise
la I-Premise
colocación I-Premise
de I-Premise
la I-Premise
endoprótesis I-Premise
( I-Premise
72 I-Premise
frente I-Premise
a I-Premise
50 I-Premise
días I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
= I-Premise
0,05 I-Premise
) O
. O

Se B-Premise
observaron I-Premise
más I-Premise
complicaciones I-Premise
mayores I-Premise
( I-Premise
stent I-Premise
: I-Premise
6 I-Premise
en I-Premise
4 I-Premise
pacientes I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
0 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
síntomas I-Premise
obstructivos I-Premise
recurrentes I-Premise
( I-Premise
stent I-Premise
: I-Premise
8 I-Premise
en I-Premise
5 I-Premise
pacientes I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
1 I-Premise
en I-Premise
1 I-Premise
paciente I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
y I-Premise
reintervenciones I-Premise
( I-Premise
stent I-Premise
: I-Premise
10 I-Premise
en I-Premise
7 I-Premise
pacientes I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
2 I-Premise
en I-Premise
2 I-Premise
pacientes I-Premise
; I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
después I-Premise
de I-Premise
la I-Premise
colocación I-Premise
del I-Premise
stent I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
GJJ I-Premise
. I-Premise

Cuando B-Premise
la I-Premise
obstrucción I-Premise
del I-Premise
stent I-Premise
no I-Premise
se I-Premise
consideró I-Premise
una I-Premise
complicación I-Premise
importante, I-Premise
no I-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
en I-Premise
las I-Premise
complicaciones I-Premise
( I-Premise
P I-Premise
= I-Premise
0,4 I-Premise
) I-Premise
. I-Premise

Tampoco B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
( I-Premise
stent I-Premise
: I-Premise
56 I-Premise
días I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
78 I-Premise
días I-Premise
) I-Premise
ni I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
. I-Premise

La B-Premise
media I-Premise
de I-Premise
los I-Premise
costes I-Premise
totales I-Premise
de I-Premise
la I-Premise
GJJ I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
colocación I-Premise
de I-Premise
un I-Premise
stent I-Premise
( I-Premise
16.535 I-Premise
$ I-Premise
frente I-Premise
a I-Premise
11.720 I-Premise
$ I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
= I-Premise
0,049 I-Premise
[ I-Premise
comparando I-Premise
las I-Premise
medianas I-Premise
] I-Premise
) I-Premise
. I-Premise

Debido O
al O
reducido O
número O
de O
participantes O
en O
el O
estudio, O
sólo O
los O
costes O
hospitalarios O
iniciales O
habrían O
sido O
estadísticamente O
significativos O
si O
se O
hubiera O
aplicado O
la O
corrección O
de O
Bonferroni O
para O
pruebas O
múltiples. O

Población O
de O
pacientes O
relativamente O
pequeña O
. O

A B-Premise
pesar I-Premise
de I-Premise
la I-Premise
lenta I-Premise
mejoría I-Premise
inicial I-Premise
de I-Premise
los I-Premise
síntomas, I-Premise
la B-Claim
inyección I-Claim
de I-Claim
jeringuillas I-Claim
se I-Claim
asoció I-Claim
con I-Claim
mejores I-Claim
resultados I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
y, I-Claim
por I-Claim
lo I-Claim
tanto, I-Claim
es I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
elección I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
una I-Claim
esperanza I-Claim
de I-Claim
vida I-Claim
de I-Claim
2 I-Claim
meses I-Claim
o I-Claim
más. I-Claim

Dado B-Claim
que I-Claim
la I-Claim
colocación I-Claim
de I-Claim
un I-Claim
stent I-Claim
se I-Claim
asoció I-Claim
con I-Claim
mejores I-Claim
resultados I-Claim
a I-Claim
corto I-Claim
plazo, I-Claim
este B-Claim
tratamiento I-Claim
es I-Claim
preferible I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
se I-Claim
espera I-Claim
que I-Claim
vivan I-Claim
menos I-Claim
de I-Claim
dos I-Claim
meses. I-Claim

Los O
síntomas O
vasomotores O
son O
efectos O
adversos O
comunes O
del O
tratamiento O
hormonal O
antiestrogénico O
en O
la O
atención O
convencional O
del O
cáncer O
de O
mama O
. O

La O
terapia O
hormonal O
sustitutiva O
está O
contraindicada O
en O
pacientes O
con O
cáncer O
de O
mama O
. O

La O
venlafaxina O
( O
Effexor O
) O
, O
la O
terapia O
de O
elección O
para O
estos O
síntomas O
, O
tiene O
numerosos O
efectos O
adversos O
. O

Estudios O
recientes O
sugieren O
que O
la O
acupuntura O
puede O
ser O
eficaz O
para O
reducir O
los O
síntomas O
vasomotores O
en O
las O
mujeres O
menopáusicas O
. O

Este O
ensayo O
controlado O
aleatorio O
probó O
si O
la O
acupuntura O
reduce O
los O
síntomas O
vasomotores O
y O
produce O
menos O
efectos O
adversos O
que O
la O
venlafaxina O
. O

Cincuenta O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
12 O
semanas O
de O
tratamiento O
con O
acupuntura O
( O
n O
= O
25 O
) O
o O
con O
venlafaxina O
( O
n O
= O
25 O
) O
. O

Los O
resultados O
de O
salud O
se O
midieron O
hasta O
un O
año O
después O
del O
tratamiento. O

Ambos B-Premise
grupos I-Premise
mostraron I-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
de I-Premise
los I-Premise
sofocos, I-Premise
los I-Premise
síntomas I-Premise
depresivos I-Premise
y I-Premise
otros I-Premise
síntomas I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
incluyendo I-Premise
mejoras I-Premise
significativas I-Premise
en I-Premise
la I-Premise
salud I-Premise
mental I-Premise
desde I-Premise
antes I-Premise
hasta I-Premise
después I-Premise
del I-Premise
tratamiento. I-Premise

Estos B-Premise
cambios I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
ambos I-Premise
grupos, I-Premise
lo I-Premise
que I-Premise
indica I-Premise
que I-Premise
la I-Premise
acupuntura I-Premise
fue I-Premise
tan I-Premise
eficaz I-Premise
como I-Premise
la I-Premise
venlafaxina. I-Premise

A B-Premise
las I-Premise
dos I-Premise
semanas I-Premise
del I-Premise
tratamiento, I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
venlafaxina I-Premise
experimentó I-Premise
un I-Premise
aumento I-Premise
significativo I-Premise
de I-Premise
los I-Premise
sofocos, I-Premise
mientras I-Premise
que I-Premise
los I-Premise
del I-Premise
grupo I-Premise
de I-Premise
la I-Premise
acupuntura I-Premise
se I-Premise
mantuvieron I-Premise
en I-Premise
niveles I-Premise
bajos. I-Premise

El B-Premise
grupo I-Premise
de I-Premise
venlafaxina I-Premise
experimentó I-Premise
18 I-Premise
incidencias I-Premise
de I-Premise
efectos I-Premise
adversos I-Premise
( I-Premise
por I-Premise
ejemplo, I-Premise
náuseas, I-Premise
sequedad I-Premise
de I-Premise
boca, I-Premise
mareos, I-Premise
ansiedad I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
el I-Premise
grupo I-Premise
de I-Premise
acupuntura I-Premise
no I-Premise
experimentó I-Premise
ningún I-Premise
efecto I-Premise
adverso I-Premise
negativo I-Premise
. I-Premise

La B-Premise
acupuntura I-Premise
tuvo I-Premise
el I-Premise
beneficio I-Premise
adicional I-Premise
de I-Premise
aumentar I-Premise
el I-Premise
deseo I-Premise
sexual I-Premise
en I-Premise
algunas I-Premise
mujeres, I-Premise
y I-Premise
la I-Premise
mayoría I-Premise
informó I-Premise
de I-Premise
una I-Premise
mejora I-Premise
en I-Premise
su I-Premise
energía, I-Premise
claridad I-Premise
de I-Premise
pensamiento I-Premise
y I-Premise
sensación I-Premise
de I-Premise
bienestar. I-Premise

La B-Claim
acupuntura I-Claim
parece I-Claim
ser I-Claim
equivalente I-Claim
al I-Claim
tratamiento I-Claim
farmacológico I-Claim
en I-Claim
estos I-Claim
pacientes I-Claim
. I-Claim

Es B-Claim
un I-Claim
tratamiento I-Claim
seguro, I-Claim
eficaz I-Claim
y I-Claim
duradero I-Claim
para I-Claim
los I-Claim
síntomas I-Claim
vasomotores I-Claim
secundarios I-Claim
al I-Claim
uso I-Claim
prolongado I-Claim
de I-Claim
hormonas I-Claim
antiestrogénicas I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama. I-Claim

La O
resección O
quirúrgica O
se O
considera O
la O
única O
opción O
curativa O
para O
el O
cáncer O
de O
esófago O
resecable, O
pero O
las O
complicaciones O
pulmonares O
que O
se O
producen O
en O
más O
de O
la O
mitad O
de O
los O
pacientes O
tras O
la O
esofagectomía O
abierta O
son O
una O
gran O
preocupación. O

Se O
evaluó O
si O
la O
esofagectomía O
mínimamente O
invasiva O
reduce O
la O
morbilidad O
en O
comparación O
con O
la O
esofagectomía O
abierta O
. O

Se O
realizó O
un O
ensayo O
controlado O
aleatorio, O
abierto O
y O
multicéntrico O
en O
cinco O
centros O
de O
estudio O
de O
tres O
países O
entre O
el O
1 O
de O
junio O
de O
2009 O
y O
el O
31 O
de O
marzo O
de O
2011. O

Los O
pacientes O
de O
entre O
18 O
y O
75 O
años O
con O
cáncer O
resecable O
de O
esófago O
o O
de O
la O
unión O
gastroesofágica O
fueron O
asignados O
aleatoriamente O
mediante O
una O
secuencia O
de O
aleatorización O
generada O
por O
ordenador O
para O
recibir O
una O
esofagectomía O
transtorácica O
abierta O
o O
una O
esofagectomía O
transtorácica O
mínimamente O
invasiva. O

La O
aleatorización O
se O
estratificó O
por O
centro. O

Los O
pacientes O
y O
los O
investigadores O
que O
realizaban O
las O
intervenciones, O
evaluaban O
los O
resultados O
y O
analizaban O
los O
datos O
no O
estaban O
enmascarados O
respecto O
a O
la O
asignación O
de O
grupos. O

El O
resultado O
primario O
fue O
la O
infección O
pulmonar O
en O
las O
dos O
primeras O
semanas O
tras O
la O
cirugía O
y O
durante O
toda O
la O
estancia O
en O
el O
hospital. O

El O
análisis O
fue O
por O
intención O
de O
tratar O
. O

Este O
ensayo O
está O
registrado O
en O
el O
Registro O
de O
Ensayos O
de O
los O
Países O
Bajos, O
NTR O
TC O
2452. O

Se O
asignaron O
aleatoriamente O
56 O
pacientes O
al O
grupo O
de O
esofagectomía O
abierta O
y O
59 O
al O
grupo O
de O
esofagectomía O
mínimamente O
invasiva O
. O

16 B-Premise
( I-Premise
29 I-Premise
% I-Premise
) I-Premise
pacientes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
esofagectomía I-Premise
abierta I-Premise
tuvieron I-Premise
infección I-Premise
pulmonar I-Premise
en I-Premise
las I-Premise
primeras I-Premise
2 I-Premise
semanas I-Premise
en I-Premise
comparación I-Premise
con I-Premise
cinco I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
mínimamente I-Premise
invasivo I-Premise
( I-Premise
riesgo I-Premise
relativo I-Premise
[ I-Premise
RR I-Premise
] I-Premise
0-30 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
0-12-0-76 I-Premise
; I-Premise
p=0-005 I-Premise
) I-Premise
. I-Premise

19 B-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
pacientes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
esofagectomía I-Premise
abierta I-Premise
tuvieron I-Premise
infección I-Premise
pulmonar I-Premise
en I-Premise
el I-Premise
hospital I-Premise
en I-Premise
comparación I-Premise
con I-Premise
siete I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
mínimamente I-Premise
invasivo I-Premise
( I-Premise
0-35 I-Premise
, I-Premise
0-16-0-78 I-Premise
; I-Premise
p=0-005 I-Premise
) I-Premise
. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
mortalidad I-Premise
intrahospitalaria, I-Premise
un I-Premise
paciente I-Premise
del I-Premise
grupo I-Premise
de I-Premise
esofagectomía I-Premise
abierta I-Premise
murió I-Premise
por I-Premise
fuga I-Premise
anastomótica I-Premise
y I-Premise
dos I-Premise
del I-Premise
grupo I-Premise
mínimamente I-Premise
invasivo I-Premise
por I-Premise
aspiración I-Premise
y I-Premise
mediastinitis I-Premise
tras I-Premise
la I-Premise
fuga I-Premise
anastomótica. I-Premise

Estos B-Claim
resultados I-Claim
proporcionan I-Claim
pruebas I-Claim
de I-Claim
los I-Claim
beneficios I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
de I-Claim
la I-Claim
esofagectomía I-Claim
mínimamente I-Claim
invasiva I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
esófago I-Claim
resecable I-Claim
. I-Claim

El O
objetivo O
es O
evaluar O
la O
eficacia O
de O
la O
acupuntura O
para O
la O
fatiga O
relacionada O
con O
el O
cáncer O
( O
CRF O
) O
en O
pacientes O
con O
cáncer O
de O
mama O
. O

Se O
realizó O
un O
ensayo O
controlado O
aleatorio O
pragmático O
que O
comparó O
la O
acupuntura O
con O
la O
atención O
habitual O
mejorada. O

Participaron O
32 O
pacientes O
ambulatorios O
con O
cáncer O
de O
mama. O

Se O
asignaron O
aleatoriamente O
75 O
pacientes O
a O
la O
atención O
habitual O
y O
227 O
pacientes O
a O
la O
acupuntura O
más O
la O
atención O
habitual O
( O
asignación O
aleatoria O
de O
1:3 O
respectivamente O
) O
con O
una O
minimización O
que O
controla O
la O
fatiga O
general O
de O
base O
y O
el O
tratamiento O
de O
mantenimiento O
. O

El O
tratamiento O
fue O
administrado O
por O
acupuntores O
una O
vez O
a O
la O
semana O
durante O
6 O
semanas O
mediante O
la O
aplicación O
de O
agujas O
en O
tres O
pares O
de O
acupuntos. O

El O
grupo O
de O
atención O
habitual O
recibió O
un O
folleto O
con O
información O
sobre O
la O
fatiga O
y O
su O
tratamiento. O

El O
resultado O
primario O
fue O
la O
fatiga O
general O
a O
las O
6 O
semanas O
, O
medida O
con O
el O
Inventario O
Multidimensional O
de O
Fatiga O
( O
MFI O
) O
. O

Otras O
mediciones O
incluyeron O
la O
Escala O
de O
Ansiedad O
y O
Depresión O
Hospitalaria O
, O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-Escala O
de O
Calidad O
de O
Vida O
General O
, O
y O
la O
expectativa O
del O
efecto O
de O
la O
acupuntura O
. O

Los O
análisis O
fueron O
por O
intención O
de O
tratar. O

Doscientos O
cuarenta O
y O
seis O
de O
los O
302 O
pacientes O
asignados O
al O
azar O
proporcionaron O
datos O
completos O
a O
las O
6 O
semanas O
. O

La B-Premise
diferencia I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
media I-Premise
de I-Premise
Fatiga I-Premise
General I-Premise
, I-Premise
entre I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
la I-Premise
intervención I-Premise
y I-Premise
los I-Premise
que I-Premise
no, I-Premise
fue I-Premise
de I-Premise
-3,11 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
-3,97 I-Premise
a I-Premise
-2,25 I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

La B-Premise
intervención I-Premise
también I-Premise
mejoró I-Premise
todos I-Premise
los I-Premise
demás I-Premise
aspectos I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
medidos I-Premise
por I-Premise
el I-Premise
MFI I-Premise
, I-Premise
incluyendo I-Premise
la I-Premise
fatiga I-Premise
física I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
mental I-Premise
( I-Premise
efecto I-Premise
de I-Premise
la I-Premise
acupuntura I-Premise
, I-Premise
-2,36 I-Premise
y I-Premise
-1,94 I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
ambos I-Premise
con I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
la I-Premise
ansiedad I-Premise
y I-Premise
la I-Premise
depresión I-Premise
( I-Premise
efecto I-Premise
de I-Premise
la I-Premise
acupuntura I-Premise
, I-Premise
-1,83 I-Premise
y I-Premise
-2.13 I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
ambos I-Premise
a I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
y I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
efecto I-Premise
de I-Premise
Bienestar I-Premise
Físico I-Premise
, I-Premise
3,30 I-Premise
; I-Premise
efecto I-Premise
de I-Premise
Bienestar I-Premise
Funcional I-Premise
, I-Premise
3,57 I-Premise
; I-Premise
ambos I-Premise
a I-Premise
P I-Premise
< I-Premise
.001 I-Premise
; I-Premise
efecto I-Premise
de I-Premise
Bienestar I-Premise
Emocional I-Premise
, I-Premise
1,93 I-Premise
; I-Premise
P I-Premise
= I-Premise
.001 I-Premise
; I-Premise
y I-Premise
efecto I-Premise
de I-Premise
Bienestar I-Premise
de I-Premise
Funcionamiento I-Premise
Social I-Premise
, I-Premise
1,05 I-Premise
; I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

La B-Claim
acupuntura I-Claim
es I-Claim
una I-Claim
intervención I-Claim
eficaz I-Claim
para I-Claim
controlar I-Claim
los I-Claim
síntomas I-Claim
del I-Claim
CRF I-Claim
y I-Claim
mejorar I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes. I-Claim

El O
Intergroup O
llevó O
a O
cabo O
este O
ensayo O
adyuvante O
de O
cáncer O
de O
mama O
para O
comparar O
un O
régimen O
de O
investigación O
de O
16 O
semanas O
con O
ciclofosfamida O
, O
doxorrubicina O
y O
fluorouracilo O
( O
5-FU O
; O
CAF O
) O
. O

El O
régimen O
de O
16 O
semanas O
presenta O
una O
mayor O
intensidad O
de O
dosis O
de O
doxorrubicina O
y O
5-FU O
que O
el O
CAF O
y O
una O
mejor O
programación O
de O
los O
antimetabolitos O
con O
metotrexato O
y O
5-FU O
secuenciales, O
así O
como O
5-FU O
en O
infusión. O

Un O
total O
de O
646 O
pacientes O
con O
ganglios O
positivos O
y O
receptores O
negativos O
fueron O
asignados O
aleatoriamente O
para O
recibir O
el O
régimen O
de O
1 O
6 O
semanas O
o O
seis O
ciclos O
de O
CAF. O

Los O
resultados O
del O
cáncer O
de O
mama O
incluyeron O
la O
recidiva, O
así O
como O
la O
supervivencia O
libre O
de O
enfermedad O
y O
la O
supervivencia O
global. O

La O
toxicidad O
se O
evaluó O
mediante O
los O
Criterios O
Comunes O
de O
Toxicidad O
( O
CTC O
) O
. O

La O
calidad O
de O
vida O
relacionada O
con O
el O
tratamiento O
se O
evaluó O
mediante O
el O
Cuestionario O
de O
Quimioterapia O
Mamaria O
( O
BCQ O
) O
antes O
, O
durante O
y O
4 O
meses O
después O
del O
tratamiento O
en O
163 O
pacientes O
. O

El O
ensayo O
se O
diseñó O
para O
utilizar O
pruebas O
de O
significación O
unilaterales O
para O
el O
cálculo O
de O
la O
potencia, O
pero O
ahora O
se O
presenta O
con O
pruebas O
de O
significación O
unilaterales O
y O
bilaterales. O

En B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
3,9 I-Premise
años, I-Premise
la I-Premise
tasa I-Premise
estimada I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
recidiva I-Premise
a I-Premise
los I-Premise
4 I-Premise
años I-Premise
fue I-Premise
del I-Premise
67,5% I-Premise
con I-Premise
el I-Premise
régimen I-Premise
de I-Premise
16 I-Premise
semanas I-Premise
frente I-Premise
al I-Premise
62,7% I-Premise
con I-Premise
el I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
0,19 I-Premise
, I-Premise
de I-Premise
dos I-Premise
caras I-Premise
; I-Premise
P I-Premise
= I-Premise
0,095 I-Premise
, I-Premise
de I-Premise
una I-Premise
cara I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
estimada I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
4 I-Premise
años I-Premise
fue I-Premise
del I-Premise
78,1% I-Premise
con I-Premise
el I-Premise
régimen I-Premise
de I-Premise
16 I-Premise
semanas I-Premise
frente I-Premise
al I-Premise
71,4% I-Premise
con I-Premise
el I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
0,10 I-Premise
, I-Premise
de I-Premise
dos I-Premise
caras I-Premise
; I-Premise
P I-Premise
= I-Premise
0,05 I-Premise
, I-Premise
de I-Premise
una I-Premise
cara I-Premise
) I-Premise
. I-Premise

El B-Premise
CAF I-Premise
produjo I-Premise
grados I-Premise
significativamente I-Premise
mayores I-Premise
de I-Premise
leucopenia I-Premise
, I-Premise
granulocitopenia I-Premise
y I-Premise
trombocitopenia I-Premise
, I-Premise
así I-Premise
como I-Premise
toxicidad I-Premise
hepática I-Premise
y I-Premise
cardíaca I-Premise
, O
mientras O
que O
el B-Premise
régimen I-Premise
de I-Premise
16 I-Premise
semanas I-Premise
produjo I-Premise
grados I-Premise
significativamente I-Premise
mayores I-Premise
de I-Premise
anemia I-Premise
, I-Premise
náuseas I-Premise
, I-Premise
estomatitis I-Premise
y I-Premise
pérdida I-Premise
de I-Premise
peso I-Premise
, I-Premise
así I-Premise
como I-Premise
neurotoxicidad I-Premise
cutánea O
. O

Hubo B-Premise
tres I-Premise
muertes I-Premise
relacionadas I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
el I-Premise
CAF, I-Premise
pero B-Premise
ninguna I-Premise
con I-Premise
el I-Premise
régimen I-Premise
de I-Premise
16 I-Premise
semanas. I-Premise

Durante B-Premise
el I-Premise
tratamiento, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
disminuyó I-Premise
significativamente I-Premise
más I-Premise
con I-Premise
el I-Premise
régimen I-Premise
de I-Premise
16 I-Premise
semanas I-Premise
que I-Premise
con I-Premise
el I-Premise
CAF, I-Premise
pero I-Premise
a I-Premise
los I-Premise
4 I-Premise
meses I-Premise
del I-Premise
tratamiento I-Premise
no I-Premise
hubo I-Premise
diferencias. I-Premise

El B-Premise
régimen I-Premise
de I-Premise
16 I-Premise
semanas I-Premise
produjo I-Premise
resultados I-Premise
marginalmente I-Premise
mejores I-Premise
para I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
que I-Premise
el I-Premise
CAF, I-Premise
con I-Premise
una I-Premise
toxicidad I-Premise
similar I-Premise
pero I-Premise
una I-Premise
mayor I-Premise
reducción I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
durante I-Premise
el I-Premise
tratamiento I-Premise
. I-Premise

El B-Claim
régimen I-Claim
de I-Claim
16 I-Claim
semanas I-Claim
no I-Claim
debe I-Claim
utilizarse I-Claim
en I-Claim
lugar I-Claim
de I-Claim
un I-Claim
régimen I-Claim
de I-Claim
dosis I-Claim
estándar I-Claim
sin I-Claim
considerar I-Claim
cuidadosamente I-Claim
los I-Claim
pros I-Claim
y I-Claim
los I-Claim
contras I-Claim
del I-Claim
régimen I-Claim
de I-Claim
16 I-Claim
semanas, I-Claim
que I-Claim
incluyen I-Claim
su I-Claim
complicado I-Claim
calendario. I-Claim

Probablemente B-Claim
no I-Claim
debería I-Claim
probarse I-Claim
más I-Claim
, O
pero B-Claim
sus I-Claim
esquemas I-Claim
de I-Claim
antimetabolitos I-Claim
y I-Claim
la I-Claim
administración I-Claim
frecuente I-Claim
del I-Claim
fármaco I-Claim
( I-Claim
es I-Claim
decir, I-Claim
la I-Claim
densidad I-Claim
de I-Claim
dosis I-Claim
) I-Claim
deberían I-Claim
considerarse I-Claim
en I-Claim
el I-Claim
desarrollo I-Claim
de I-Claim
nuevos I-Claim
regímenes I-Claim
. O

El O
objetivo O
del O
estudio O
es O
demostrar O
que O
el O
escalado O
de O
dosis O
intrapaciente O
de O
carboplatino O
mejoraría O
el O
resultado O
en O
el O
cáncer O
de O
ovario O
en O
comparación O
con O
la O
dosis O
plana O
. O

Las O
pacientes O
con O
cáncer O
de O
ovario O
en O
estadio O
IC-IV O
no O
tratado O
recibieron O
seis O
ciclos O
de O
área O
bajo O
la O
curva O
de O
carboplatino O
6 O
( O
AUC O
6 O
) O
3 O
semanales, O
bien O
sin O
modificación O
de O
la O
dosis, O
excepto O
por O
la O
toxicidad O
( O
Brazo O
A O
) O
o O
con O
escalada O
de O
dosis O
en O
los O
ciclos O
2-6 O
en O
función O
de O
los O
recuentos O
nadir O
de O
neutrófilos O
y O
plaquetas O
( O
Brazo O
B O
) O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
supervivencia O
sin O
progresión O
( O
PFS O
) O
. O

Se O
reclutaron O
novecientos O
sesenta O
y O
cuatro O
pacientes O
de O
71 O
centros. O

La O
escalada O
de O
dosis O
se O
logró O
en O
el O
77 O
% O
de O
los O
pacientes O
que O
tenían O
≥1 O
ciclo O
. O

La B-Premise
mediana I-Premise
de I-Premise
las I-Premise
AUC I-Premise
( I-Premise
ciclo I-Premise
2-6 I-Premise
) I-Premise
recibidas I-Premise
fue I-Premise
de I-Premise
6,0 I-Premise
( I-Premise
Brazo I-Premise
A I-Premise
) I-Premise
y I-Premise
7,2 I-Premise
( I-Premise
Brazo I-Premise
B I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

La B-Premise
toxicidad I-Premise
no I-Premise
hematológica I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
B I-Premise
( I-Premise
31% I-Premise
frente I-Premise
al I-Premise
22% I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
de I-Premise
12,1 I-Premise
meses I-Premise
en I-Premise
los I-Premise
brazos I-Premise
A I-Premise
y I-Premise
B I-Premise
[ I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
0,99 I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
( I-Premise
CI I-Premise
) I-Premise
del I-Premise
95 I-Premise
% I-Premise
0,85-1,15 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,93 I-Premise
] I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
SG I-Premise
) I-Premise
fue I-Premise
de I-Premise
34,1 I-Premise
y I-Premise
30,7 I-Premise
meses I-Premise
en I-Premise
los I-Premise
brazos I-Premise
A I-Premise
y I-Premise
B I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
HR I-Premise
0,98 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,81-1,18 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,82 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
análisis I-Premise
multivariante, I-Premise
el I-Premise
recuento I-Premise
inicial I-Premise
de I-Premise
neutrófilos I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
el I-Premise
recuento I-Premise
inicial I-Premise
de I-Premise
plaquetas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
la I-Premise
diferencia I-Premise
entre I-Premise
el I-Premise
recuento I-Premise
de I-Premise
glóbulos I-Premise
blancos I-Premise
( I-Premise
WBC I-Premise
) I-Premise
y I-Premise
el I-Premise
de I-Premise
neutrófilos I-Premise
( I-Premise
P I-Premise
= I-Premise
0,009 I-Premise
) I-Premise
tuvieron I-Premise
un I-Premise
valor I-Premise
pronóstico I-Premise
adverso I-Premise
significativo I-Premise
. I-Premise

El B-Claim
escalado I-Claim
de I-Claim
dosis I-Claim
intrapaciente I-Claim
de I-Claim
carboplatino I-Claim
basado I-Claim
en I-Claim
los I-Claim
recuentos I-Claim
sanguíneos I-Claim
nadir I-Claim
es I-Claim
factible I-Claim
y I-Claim
seguro. I-Claim

Sin B-Claim
embargo I-Claim
, I-Claim
no I-Claim
proporcionó I-Claim
ninguna I-Claim
mejora I-Claim
en I-Claim
la I-Claim
SLP I-Claim
o I-Claim
la I-Claim
SG I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
dosis I-Claim
plana I-Claim
. I-Claim

Los O
neutrófilos O
basales O
superan O
a O
los O
recuentos O
nadir O
en O
cuanto O
a O
su O
importancia O
pronóstica. O

Estos O
datos O
pueden O
tener O
implicaciones O
más O
amplias, O
especialmente O
en O
lo O
que O
respecta O
al O
tratamiento O
de O
la O
neutropenia O
inducida O
por O
la O
quimioterapia. O

Los O
pacientes O
con O
linfoma O
suelen O
experimentar O
un O
deterioro O
de O
su O
funcionamiento O
físico O
y O
de O
su O
calidad O
de O
vida O
( O
QoL O
) O
que O
puede O
revertirse O
con O
el O
entrenamiento O
de O
ejercicios O
. O

Se O
llevó O
a O
cabo O
un O
ensayo O
controlado O
aleatorio O
en O
Edmonton, O
Alberta, O
Canadá, O
entre O
2005 O
y O
2008 O
que O
estratificó O
a O
122 O
pacientes O
con O
linfoma O
por O
tipo O
de O
enfermedad O
principal O
y O
estado O
de O
tratamiento O
actual O
y O
los O
asignó O
aleatoriamente O
a O
la O
atención O
habitual O
( O
UC O
; O
n O
= O
62 O
) O
o O
a O
12 O
semanas O
de O
entrenamiento O
con O
ejercicios O
aeróbicos O
supervisados O
( O
AET O
; O
n O
= O
60 O
) O
. O

Nuestro O
criterio O
de O
valoración O
principal O
fue O
el O
funcionamiento O
físico O
evaluado O
por O
el O
Trial O
Outcome O
Index-Anemia. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
calidad O
de O
vida O
general, O
el O
funcionamiento O
psicosocial, O
el O
estado O
físico O
cardiovascular O
y O
la O
composición O
corporal. O

La O
evaluación O
de O
seguimiento O
para O
nuestro O
punto O
final O
primario O
fue O
del O
96% O
( O
117 O
de O
122 O
) O
en O
la O
fase O
posterior O
a O
la O
intervención O
y O
del O
90% O
( O
110 O
de O
122 O
) O
a O
los O
6 O
meses O
de O
seguimiento O
. O

La O
mediana O
de O
adherencia O
al O
programa O
de O
ejercicio O
supervisado O
fue O
del O
92%. O

Tras B-Premise
la I-Premise
intervención, I-Premise
la I-Premise
TEA I-Premise
fue I-Premise
superior I-Premise
a I-Premise
la I-Premise
CU I-Premise
en I-Premise
cuanto I-Premise
al I-Premise
funcionamiento I-Premise
físico I-Premise
calificado I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
(diferencia I-Premise
media I-Premise
del I-Premise
grupo, I-Premise
+9,0; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
2,0 I-Premise
a I-Premise
16,0; I-Premise
p I-Premise
= I-Premise
0,012), I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
(p I-Premise
= I-Premise
0,021), I-Premise
la I-Premise
fatiga I-Premise
(p I-Premise
= I-Premise
0,013), I-Premise
la I-Premise
felicidad I-Premise
(p I-Premise
= I-Premise
0,004), I-Premise
la I-Premise
depresión I-Premise
(p I-Premise
= I-Premise
0,005), I-Premise
la I-Premise
salud I-Premise
general I-Premise
(p I-Premise
< I-Premise
0,001), I-Premise
el I-Premise
estado I-Premise
físico I-Premise
cardiovascular I-Premise
(p I-Premise
< I-Premise
0,001) I-Premise
y I-Premise
la I-Premise
masa I-Premise
corporal I-Premise
magra I-Premise
(p I-Premise
= I-Premise
0,008). I-Premise

El O
cambio O
en O
la O
aptitud O
cardiovascular O
máxima O
medió O
el O
cambio O
en O
el O
funcionamiento O
físico O
calificado O
por O
los O
pacientes O
. O

La B-Premise
TEA I-Premise
no I-Premise
interfirió I-Premise
en I-Premise
la I-Premise
tasa I-Premise
de I-Premise
finalización I-Premise
de I-Premise
la I-Premise
quimioterapia I-Premise
ni I-Premise
en I-Premise
la I-Premise
respuesta I-Premise
al I-Premise
tratamiento. I-Premise

A B-Premise
los I-Premise
6 I-Premise
meses I-Premise
de I-Premise
seguimiento, I-Premise
la I-Premise
TEA I-Premise
seguía I-Premise
siendo I-Premise
marginal I-Premise
o I-Premise
significativamente I-Premise
superior I-Premise
a I-Premise
la I-Premise
CU I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
( I-Premise
P I-Premise
= I-Premise
0,054 I-Premise
), I-Premise
la I-Premise
felicidad I-Premise
( I-Premise
P I-Premise
= I-Premise
0,034 I-Premise
) I-Premise
y I-Premise
la I-Premise
depresión I-Premise
( I-Premise
P I-Premise
= I-Premise
0,009 I-Premise
) I-Premise
sin I-Premise
un I-Premise
mayor I-Premise
riesgo I-Premise
de I-Premise
recurrencia/progresión I-Premise
de I-Premise
la I-Premise
enfermedad. I-Premise

La B-Claim
TEA I-Claim
mejoró I-Claim
significativamente I-Claim
los I-Claim
resultados I-Claim
calificados I-Claim
por I-Claim
los I-Claim
pacientes I-Claim
y I-Claim
el I-Claim
funcionamiento I-Claim
físico I-Claim
objetivo I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
linfoma I-Claim
sin I-Claim
interferir I-Claim
con I-Claim
los I-Claim
tratamientos I-Claim
médicos I-Claim
o I-Claim
la I-Claim
respuesta I-Claim
. I-Claim

En B-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
linfoma I-Claim
debe I-Claim
considerarse I-Claim
la I-Claim
posibilidad I-Claim
de I-Claim
realizar I-Claim
ejercicios I-Claim
para I-Claim
mejorar I-Claim
la I-Claim
aptitud I-Claim
cardiovascular. I-Claim

El O
propósito O
de O
este O
ensayo O
clínico O
ciego O
y O
aleatorizado O
fue O
comparar O
dos O
agentes O
tópicos O
(crema O
de O
caléndula O
Weleda O
frente O
a O
crema O
Essex) O
para O
reducir O
el O
riesgo O
de O
reacciones O
cutáneas O
agudas O
graves O
a O
la O
radiación O
(RSA) O
en O
relación O
con O
la O
radioterapia O
adyuvante O
(RT) O
para O
el O
cáncer O
de O
mama. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
diferencia O
en O
la O
proporción O
de O
pacientes O
con O
RSA, O
evaluada O
con O
los O
criterios O
de O
puntuación O
de O
la O
morbilidad O
por O
radiación O
aguda O
del O
Grupo O
de O
Radioterapia O
Oncológica/Organización O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
(escala O
RTOG/EORTC) O
durante O
el O
seguimiento. O

Los O
criterios O
de O
valoración O
secundarios O
incluyeron O
medidas O
de O
resultado O
comunicadas O
por O
los O
pacientes; O
Cuestionario O
de O
Calidad O
de O
Vida O
( O
QLQ-C30 O
) O
, O
Alteraciones O
del O
sueño O
( O
cuestionario O
MOS-sueño O
) O
y O
síntomas O
de O
la O
zona O
irradiada O
( O
escala O
visual O
analógica O
) O
. O

También O
se O
evaluaron O
las O
experiencias O
de O
los O
pacientes O
y O
la O
adherencia O
a O
los O
agentes O
tópicos. O

Se O
aleatorizaron O
420 O
pacientes O
y O
se O
analizaron O
411. O

A O
excepción O
de O
la O
quimioterapia O
previa, O
los O
grupos O
de O
tratamiento O
estaban O
bien O
equilibrados, O
tanto O
en O
lo O
que O
respecta O
a O
los O
factores O
relacionados O
con O
el O
tratamiento O
como O
con O
los O
pacientes. O

La B-Premise
incidencia I-Premise
de I-Premise
RSA I-Premise
grave I-Premise
( I-Premise
grado I-Premise
RTOG/EORTC I-Premise
≤2 I-Premise
) I-Premise
en I-Premise
la I-Premise
visita I-Premise
de I-Premise
seguimiento I-Premise
fue I-Premise
del I-Premise
23 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
45 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
Caléndula I-Premise
y I-Premise
del I-Premise
19 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
Essex I-Premise
. I-Premise

No B-Premise
encontramos I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
RSA I-Premise
severa I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
ningún I-Premise
momento I-Premise
de I-Premise
la I-Premise
evaluación I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
informaron I-Premise
de I-Premise
bajos I-Premise
niveles I-Premise
de I-Premise
síntomas I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
piel I-Premise
y I-Premise
no I-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos. I-Premise

No B-Claim
se I-Claim
encontraron I-Claim
diferencias I-Claim
en I-Claim
la I-Claim
RSA I-Claim
entre I-Claim
los I-Claim
pacientes I-Claim
asignados I-Claim
al I-Claim
azar I-Claim
a I-Claim
la I-Claim
crema I-Claim
de I-Claim
caléndula I-Claim
o I-Claim
a I-Claim
la I-Claim
de I-Claim
Essex. I-Claim

La B-Claim
RSA I-Claim
parece I-Claim
ser I-Claim
un I-Claim
problema I-Claim
relativamente I-Claim
limitado, I-Claim
probablemente I-Claim
más I-Claim
influenciado I-Claim
por I-Claim
factores I-Claim
relacionados I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
que I-Claim
por I-Claim
la I-Claim
elección I-Claim
de I-Claim
productos I-Claim
para I-Claim
el I-Claim
cuidado I-Claim
de I-Claim
la I-Claim
piel I-Claim
en I-Claim
este I-Claim
grupo I-Claim
de I-Claim
pacientes. I-Claim

Se O
realizó O
un O
estudio O
abierto O
y O
aleatorio O
para O
evaluar O
los O
efectos O
del O
tratamiento O
de O
apoyo O
con O
pamidronato O
en O
la O
morbilidad O
de O
las O
metástasis O
óseas O
en O
pacientes O
con O
cáncer O
de O
mama. O

Se O
controlaron O
81 O
pacientes O
con O
pamidronato O
y O
80 O
pacientes O
de O
control O
durante O
una O
mediana O
de O
18 O
y O
21 O
meses, O
respectivamente, O
para O
detectar O
eventos O
de O
morbilidad O
esquelética O
y O
la O
evolución O
radiológica O
de O
la O
enfermedad O
ósea O
metastásica. O

La O
dosis O
de O
pamidronato O
oral O
fue O
de O
600 O
mg/día O
( O
dosis O
alta O
[ O
HD O
] O
) O
durante O
los O
primeros O
años O
del O
estudio O
, O
luego O
se O
cambió O
a O
300 O
mg/día O
( O
dosis O
baja O
[ O
LD O
] O
) O
debido O
a O
la O
toxicidad O
gastrointestinal O
. O

Veintinueve O
de O
los O
81 O
pacientes O
con O
pamidronato O
( O
HD/LD O
) O
recibieron O
primero O
600 O
mg/día O
y O
luego O
fueron O
cambiados O
a O
300 O
mg/día O
; O
52 O
de O
los O
81 O
pacientes O
con O
pamidronato O
LD O
recibieron O
300 O
mg/día O
durante O
todo O
el O
estudio O
. O

El O
tratamiento O
de O
los O
tumores O
no O
estaba O
restringido. O

Se O
realizó O
un O
análisis O
global O
por O
intención O
de O
tratar. O

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
pamidronato, I-Premise
la I-Premise
aparición I-Premise
de I-Premise
hipercalcemia, I-Premise
dolor I-Premise
óseo I-Premise
severo I-Premise
y I-Premise
fracturas I-Premise
sintomáticas I-Premise
inminentes I-Premise
disminuyó I-Premise
en I-Premise
un I-Premise
65%, I-Premise
30% I-Premise
y I-Premise
50%, I-Premise
respectivamente; I-Premise
las I-Premise
tasas I-Premise
de I-Premise
eventos I-Premise
de I-Premise
tratamiento I-Premise
sistémico I-Premise
y I-Premise
radioterapia I-Premise
disminuyeron I-Premise
en I-Premise
un I-Premise
35% I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

El B-Premise
período I-Premise
libre I-Premise
de I-Premise
eventos I-Premise
(PLE), I-Premise
la I-Premise
evolución I-Premise
radiológica I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
no I-Premise
mejoraron. I-Premise

Los B-Claim
análisis I-Claim
de I-Claim
subgrupos I-Claim
sugieren I-Claim
un I-Claim
efecto I-Claim
del I-Claim
tratamiento I-Claim
dependiente I-Claim
de I-Claim
la I-Claim
dosis. I-Claim

En B-Premise
comparación I-Premise
con I-Premise
sus I-Premise
controles, I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
HD/LD I-Premise
con I-Premise
pamidronato, I-Premise
los I-Premise
eventos I-Premise
se I-Premise
produjeron I-Premise
con I-Premise
una I-Premise
frecuencia I-Premise
entre I-Premise
un I-Premise
60 I-Premise
% I-Premise
y I-Premise
un I-Premise
90 I-Premise
% I-Premise
menor I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
y I-Premise
la I-Premise
PEF I-Premise
se I-Premise
prolongó I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

En B-Premise
los I-Premise
pacientes I-Premise
con I-Premise
LD I-Premise
de I-Premise
pamidronato, I-Premise
las I-Premise
tasas I-Premise
de I-Premise
eventos I-Premise
disminuyeron I-Premise
entre I-Premise
un I-Premise
15 I-Premise
% I-Premise
y I-Premise
un I-Premise
45 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

La B-Premise
toxicidad I-Premise
gastrointestinal I-Premise
del I-Premise
pamidronato I-Premise
causó I-Premise
una I-Premise
tasa I-Premise
de I-Premise
abandono I-Premise
del I-Premise
23% I-Premise
, O
pero B-Claim
otros I-Claim
factores I-Claim
asociados I-Claim
al I-Claim
cáncer I-Claim
parecían I-Claim
contribuir I-Claim
a I-Claim
esta I-Claim
toxicidad I-Claim
. O

El B-Claim
tratamiento I-Claim
con I-Claim
pamidronato I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
redujo I-Claim
eficazmente I-Claim
la I-Claim
morbilidad I-Claim
esquelética I-Claim
. I-Claim

El B-Claim
efecto I-Claim
parecía I-Claim
depender I-Claim
de I-Claim
la I-Claim
dosis. I-Claim

Es B-Claim
obligatorio I-Claim
seguir I-Claim
investigando I-Claim
sobre I-Claim
la I-Claim
dosis I-Claim
y I-Claim
el I-Claim
modo I-Claim
de I-Claim
tratamiento. I-Claim

La B-Claim
dermatitis I-Claim
es I-Claim
un I-Claim
efecto I-Claim
adverso I-Claim
frecuente I-Claim
de I-Claim
la I-Claim
radioterapia I-Claim
mamaria I-Claim
adyuvante I-Claim
. I-Claim

Es B-Claim
más I-Claim
probable I-Claim
en I-Claim
mujeres I-Claim
con I-Claim
mucho I-Claim
pecho I-Claim
y I-Claim
cuando I-Claim
la I-Claim
radiación I-Claim
se I-Claim
distribuye I-Claim
de I-Claim
forma I-Claim
no I-Claim
homogénea I-Claim
en I-Claim
la I-Claim
mama I-Claim
. I-Claim

La O
radioterapia O
de O
intensidad O
modulada O
de O
la O
mama O
( O
IMRT O
) O
es O
una O
técnica O
que O
garantiza O
una O
distribución O
de O
dosis O
más O
homogénea O
. O

Se O
realizó O
un O
ensayo O
clínico O
multicéntrico, O
doble O
ciego O
y O
aleatorizado O
para O
comprobar O
si O
la O
IMRT O
de O
mama O
reduciría O
la O
tasa O
de O
reacciones O
cutáneas O
agudas O
( O
en O
particular O
la O
descamación O
húmeda O
), O
disminuiría O
el O
dolor O
y O
mejoraría O
la O
calidad O
de O
vida O
en O
comparación O
con O
la O
radioterapia O
estándar O
con O
cuñas O
. O

Los O
pacientes O
fueron O
evaluados O
cada O
semana O
durante O
y O
hasta O
6 O
semanas O
después O
de O
la O
radioterapia O
. O

Un O
total O
de O
358 O
pacientes O
fueron O
asignados O
al O
azar O
entre O
julio O
de O
2003 O
y O
marzo O
de O
2005 O
en O
dos O
centros O
canadienses, O
y O
331 O
fueron O
incluidos O
en O
el O
análisis. O

La B-Premise
IMRT I-Premise
de I-Premise
mama I-Premise
mejoró I-Premise
significativamente I-Premise
la I-Premise
distribución I-Premise
de I-Premise
la I-Premise
dosis I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
radiación I-Premise
estándar. I-Premise

Esto B-Premise
se I-Premise
tradujo I-Premise
en I-Premise
una I-Premise
menor I-Premise
proporción I-Premise
de I-Premise
pacientes I-Premise
que I-Premise
experimentaron I-Premise
descamación I-Premise
húmeda I-Premise
durante I-Premise
o I-Premise
hasta I-Premise
6 I-Premise
semanas I-Premise
después I-Premise
de I-Premise
su I-Premise
tratamiento I-Premise
de I-Premise
radiación; I-Premise
31,2 I-Premise
% I-Premise
con I-Premise
IMRT I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
47,8 I-Premise
% I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
estándar I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Un B-Premise
análisis I-Premise
multivariado I-Premise
encontró I-Premise
que I-Premise
el I-Premise
uso I-Premise
de I-Premise
IMRT I-Premise
de I-Premise
mama I-Premise
( I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
) I-Premise
y I-Premise
un I-Premise
tamaño I-Premise
de I-Premise
mama I-Premise
más I-Premise
pequeño I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
se I-Premise
asociaron I-Premise
significativamente I-Premise
con I-Premise
un I-Premise
menor I-Premise
riesgo I-Premise
de I-Premise
descamación I-Premise
húmeda I-Premise
. I-Premise

El B-Premise
uso I-Premise
de I-Premise
la I-Premise
RIM I-Premise
no I-Premise
se I-Premise
correlacionó I-Premise
con I-Premise
el I-Premise
dolor I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
pero O
la B-Premise
presencia I-Premise
de I-Premise
descamación I-Premise
húmeda I-Premise
sí I-Premise
se I-Premise
correlacionó I-Premise
significativamente I-Premise
con I-Premise
el I-Premise
dolor I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
y I-Premise
con I-Premise
una I-Premise
menor I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
) O
. O

La B-Claim
IMRT I-Claim
de I-Claim
mama I-Claim
redujo I-Claim
significativamente I-Claim
la I-Claim
aparición I-Claim
de I-Claim
descamación I-Claim
húmeda I-Claim
en I-Claim
comparación I-Claim
con I-Claim
una I-Claim
técnica I-Claim
estándar I-Claim
en I-Claim
cuña I-Claim
. I-Claim

La B-Claim
descamación I-Claim
húmeda I-Claim
se I-Claim
correlacionó I-Claim
con I-Claim
el I-Claim
aumento I-Claim
del I-Claim
dolor I-Claim
y I-Claim
la I-Claim
reducción I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
. I-Claim

El O
objetivo O
de O
este O
estudio O
es O
comparar O
la O
calidad O
de O
vida O
( O
QOL O
) O
, O
el O
resultado O
funcional O
, O
la O
imagen O
corporal O
y O
la O
cosmética O
después O
de O
la O
laparoscopia O
asistida O
por O
la O
mano O
( O
LRP O
) O
frente O
a O
la O
proctocolectomía O
restauradora O
abierta O
( O
ORP O
) O
. O

Las O
posibles O
ventajas O
a O
largo O
plazo O
de O
la O
PRL O
sobre O
la O
PRL O
están O
por O
determinar. O

La O
ventaja O
más O
probable O
de O
la O
PRL O
es O
el O
resultado O
cosmético O
superior. O

Sin O
embargo, O
no O
está O
claro O
si O
el O
tamaño O
y O
la O
ubicación O
de O
las O
incisiones O
afectan O
a O
la O
imagen O
corporal O
y O
a O
la O
calidad O
de O
vida. O

En O
un O
ensayo O
aleatorio O
realizado O
previamente O
que O
comparaba O
la O
PRL O
con O
la O
PRL, O
se O
evaluaron O
prospectivamente O
60 O
pacientes. O

Los O
puntos O
finales O
primarios O
fueron O
la O
imagen O
corporal O
y O
la O
cosmética. O

Los O
puntos O
finales O
secundarios O
fueron O
la O
morbilidad, O
la O
calidad O
de O
vida O
y O
el O
resultado O
funcional. O

Se O
utilizó O
un O
cuestionario O
de O
imagen O
corporal O
para O
evaluar O
la O
imagen O
corporal O
y O
la O
cosmética. O

Para O
evaluar O
la O
calidad O
de O
vida O
se O
utilizaron O
el O
Short O
Form-36 O
Health O
Survey O
y O
el O
Gastrointestinal O
Quality O
of O
Life O
Inventory O
. O

La O
imagen O
corporal O
y O
la O
calidad O
de O
vida O
también O
se O
evaluaron O
antes O
de O
la O
operación. O

Un O
total O
de O
53 O
pacientes O
completaron O
los O
cuestionarios O
de O
calidad O
de O
vida O
y O
de O
resultados O
funcionales. O

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
los I-Premise
resultados I-Premise
funcionales, I-Premise
la I-Premise
morbilidad I-Premise
o I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
la I-Premise
PRL I-Premise
y I-Premise
la I-Premise
PRL. I-Premise

En O
una O
mediana O
de O
2,7 O
años O
después O
de O
la O
cirugía, O
46 O
pacientes O
devolvieron O
los O
cuestionarios O
relativos O
a O
la O
imagen O
corporal, O
la O
cosmética O
y O
la O
morbilidad. O

Las B-Premise
puntuaciones I-Premise
de I-Premise
imagen I-Premise
corporal I-Premise
y I-Premise
cosmesis I-Premise
de I-Premise
las I-Premise
pacientes I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
PRL I-Premise
que I-Premise
en I-Premise
el I-Premise
de I-Premise
PRL I-Premise
( I-Premise
imagen I-Premise
corporal I-Premise
, I-Premise
17,4 I-Premise
frente I-Premise
a I-Premise
14,9 I-Premise
; I-Premise
cosmesis I-Premise
, I-Premise
19,1 I-Premise
frente I-Premise
a I-Premise
13,0 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Las B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
PRL I-Premise
tenían I-Premise
puntuaciones I-Premise
de I-Premise
imagen I-Premise
corporal I-Premise
significativamente I-Premise
más I-Premise
bajas I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
masculinos I-Premise
( I-Premise
14,9 I-Premise
frente I-Premise
a I-Premise
18,3 I-Premise
) I-Premise
. I-Premise

Este B-Claim
estudio I-Claim
es I-Claim
el I-Claim
primero I-Claim
que I-Claim
demuestra I-Claim
que I-Claim
la I-Claim
PRL I-Claim
tiene I-Claim
un I-Claim
impacto I-Claim
negativo I-Claim
en I-Claim
la I-Claim
imagen I-Claim
corporal I-Claim
y I-Claim
la I-Claim
cosmética I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
PRL. I-Claim

Los B-Claim
resultados I-Claim
funcionales, I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
la I-Claim
morbilidad I-Claim
son I-Claim
similares I-Claim
para I-Claim
los I-Claim
dos I-Claim
enfoques. I-Claim

Las B-Claim
ventajas I-Claim
de I-Claim
una I-Claim
mejora I-Claim
duradera I-Claim
de I-Claim
la I-Claim
imagen I-Claim
corporal I-Claim
y I-Claim
de I-Claim
la I-Claim
cosmética I-Claim
para I-Claim
esta I-Claim
población I-Claim
de I-Claim
pacientes I-Claim
relativamente I-Claim
jóvenes I-Claim
pueden I-Claim
compensar I-Claim
los I-Claim
tiempos I-Claim
de I-Claim
operación I-Claim
más I-Claim
largos I-Claim
y I-Claim
los I-Claim
costes I-Claim
más I-Claim
elevados, I-Claim
especialmente I-Claim
para I-Claim
las I-Claim
mujeres. I-Claim

Hay O
pocos O
ensayos O
controlados O
aleatorios O
sobre O
la O
eficacia O
de O
las O
intervenciones O
de O
cuidados O
paliativos O
para O
mejorar O
la O
atención O
de O
los O
pacientes O
con O
cáncer O
avanzado O
. O

Determinar O
el O
efecto O
de O
una O
intervención O
dirigida O
por O
enfermería O
sobre O
la O
calidad O
de O
vida, O
la O
intensidad O
de O
los O
síntomas, O
el O
estado O
de O
ánimo O
y O
el O
uso O
de O
recursos O
en O
pacientes O
con O
cáncer O
avanzado. O

Ensayo O
controlado O
aleatorio O
realizado O
entre O
noviembre O
de O
2003 O
y O
mayo O
de O
2008 O
con O
322 O
pacientes O
con O
cáncer O
avanzado O
en O
un O
centro O
oncológico O
integral O
rural O
designado O
por O
el O
Instituto O
Nacional O
del O
Cáncer O
en O
New O
Hampshire O
y O
clínicas O
de O
extensión O
afiliadas O
y O
un O
centro O
médico O
de O
veteranos O
en O
Vermont. O

Una O
intervención O
psicoeducativa O
multicomponente O
( O
Project O
ENABLE O
[ O
Educate O
, O
Nurture O
, O
Advise O
, O
Before O
Life O
Ends O
] O
) O
llevada O
a O
cabo O
por O
enfermeras O
de O
práctica O
avanzada O
que O
consistía O
en O
4 O
sesiones O
educativas O
semanales O
y O
sesiones O
de O
seguimiento O
mensuales O
hasta O
la O
muerte O
o O
la O
finalización O
del O
estudio O
( O
n O
= O
161 O
) O
frente O
a O
la O
atención O
habitual O
( O
n O
= O
161 O
) O
. O

La O
calidad O
de O
vida O
se O
midió O
mediante O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
de O
Enfermedades O
Crónicas O
para O
Cuidados O
Paliativos O
( O
rango O
de O
puntuación O
, O
0-184 O
) O
. O

La O
intensidad O
de O
los O
síntomas O
se O
midió O
con O
la O
Escala O
de O
Evaluación O
de O
Síntomas O
de O
Edmonton O
( O
rango O
de O
puntuación O
, O
0-900 O
) O
. O

El O
estado O
de O
ánimo O
se O
midió O
con O
la O
escala O
de O
depresión O
del O
Centro O
de O
Estudios O
Epidemiológicos O
( O
rango O
, O
0-60 O
) O
. O

Estas O
medidas O
se O
evaluaron O
al O
inicio, O
al O
mes O
y O
cada O
tres O
meses O
hasta O
la O
muerte O
o O
la O
finalización O
del O
estudio. O

La O
intensidad O
del O
servicio O
se O
midió O
como O
el O
número O
de O
días O
en O
el O
hospital O
y O
en O
la O
unidad O
de O
cuidados O
intensivos O
( O
UCI O
) O
y O
el O
número O
de O
visitas O
a O
urgencias O
registradas O
en O
la O
historia O
clínica O
electrónica O
. O

Un O
total O
de O
322 O
participantes O
con O
cáncer O
del O
tracto O
gastrointestinal O
( O
41 O
% O
; O
67 O
en O
el O
grupo O
de O
atención O
habitual O
frente O
a O
66 O
en O
el O
grupo O
de O
intervención O
) O
, O
de O
pulmón O
( O
36 O
% O
; O
58 O
frente O
a O
59 O
) O
, O
del O
tracto O
genitourinario O
( O
12 O
% O
; O
20 O
frente O
a O
19 O
) O
y O
de O
mama O
( O
10 O
% O
; O
16 O
frente O
a O
17 O
) O
fueron O
asignados O
al O
azar O
. O

Los B-Premise
efectos I-Premise
estimados I-Premise
del I-Premise
tratamiento I-Premise
(intervención I-Premise
menos I-Premise
atención I-Premise
habitual) I-Premise
para I-Premise
todos I-Premise
los I-Premise
participantes I-Premise
fueron I-Premise
una I-Premise
media I-Premise
( I-Premise
SE I-Premise
) I-Premise
de I-Premise
4,6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
para I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
-27,8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
para I-Premise
la I-Premise
intensidad I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,06 I-Premise
) I-Premise
y I-Premise
-1,8 I-Premise
( I-Premise
0,81 I-Premise
) I-Premise
para I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
deprimido I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

Los B-Premise
efectos I-Premise
estimados I-Premise
del I-Premise
tratamiento I-Premise
en I-Premise
los I-Premise
participantes I-Premise
que I-Premise
murieron I-Premise
durante I-Premise
el I-Premise
estudio I-Premise
fueron I-Premise
una I-Premise
media I-Premise
( I-Premise
SE I-Premise
) I-Premise
de I-Premise
8,6 I-Premise
( I-Premise
3,6 I-Premise
) I-Premise
para I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
-24,2 I-Premise
( I-Premise
20,5 I-Premise
) I-Premise
para I-Premise
la I-Premise
intensidad I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,24 I-Premise
) I-Premise
y I-Premise
-2,7 I-Premise
( I-Premise
1,2 I-Premise
) I-Premise
para I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
deprimido I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
. I-Premise

La O
intensidad O
del O
servicio O
no O
difiere O
entre O
los O
dos O
grupos. O

En B-Claim
comparación I-Claim
con I-Claim
los I-Claim
participantes I-Claim
que I-Claim
recibieron I-Claim
la I-Claim
atención I-Claim
oncológica I-Claim
habitual, I-Claim
los I-Claim
que I-Claim
recibieron I-Claim
una I-Claim
intervención I-Claim
centrada I-Claim
en I-Claim
los I-Claim
cuidados I-Claim
paliativos I-Claim
dirigida I-Claim
por I-Claim
enfermeras I-Claim
y I-Claim
que I-Claim
abordaba I-Claim
la I-Claim
coordinación I-Claim
física, I-Claim
psicosocial I-Claim
y I-Claim
de I-Claim
los I-Claim
cuidados, I-Claim
proporcionada I-Claim
simultáneamente I-Claim
con I-Claim
la I-Claim
atención I-Claim
oncológica, I-Claim
obtuvieron I-Claim
puntuaciones I-Claim
más I-Claim
altas I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
el I-Claim
estado I-Claim
de I-Claim
ánimo, I-Claim
pero B-Claim
no I-Claim
presentaron I-Claim
mejoras I-Claim
en I-Claim
las I-Claim
puntuaciones I-Claim
de I-Claim
la I-Claim
intensidad I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
ni I-Claim
redujeron I-Claim
los I-Claim
días I-Claim
de I-Claim
estancia I-Claim
en I-Claim
el I-Claim
hospital I-Claim
o I-Claim
las I-Claim
visitas I-Claim
a I-Claim
la I-Claim
UCI I-Claim
o I-Claim
al I-Claim
servicio I-Claim
de I-Claim
urgencias. I-Claim

Para O
determinar O
la O
eficacia O
del O
topotecán O
en O
combinación O
con O
la O
quimioterapia O
estándar O
en O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
pequeñas O
( O
CPCP O
) O
en O
estadio O
extenso O
no O
tratados O
previamente, O
el O
Grupo O
de O
Oncología O
Cooperativa O
del O
Este O
( O
ECOG O
) O
realizó O
un O
ensayo O
de O
fase O
III O
. O

Los O
pacientes O
elegibles O
tenían O
una O
enfermedad O
medible O
o O
evaluable O
y O
un O
estado O
de O
rendimiento O
ECOG O
de O
0 O
a O
2; O
se O
permitían O
las O
metástasis O
cerebrales O
estables. O

Todos O
los O
pacientes O
recibieron O
cuatro O
ciclos O
de O
cisplatino O
y O
etopósido O
cada O
3 O
semanas O
( O
paso O
1 O
; O
PE O
) O
. O

A O
continuación, O
los O
pacientes O
con O
enfermedad O
estable O
o O
que O
respondía O
fueron O
asignados O
al O
azar O
a O
observación O
o O
a O
cuatro O
ciclos O
de O
topotecán O
( O
1,5 O
mg/m O
( O
2 O
) O
/d O
durante O
5 O
días O
, O
cada O
3 O
semanas O
; O
paso O
2 O
) O
. O

Un O
total O
de O
402 O
pacientes O
elegibles O
se O
registraron O
en O
el O
paso O
1 O
, O
y O
223 O
pacientes O
elegibles O
se O
registraron O
en O
el O
paso O
2 O
( O
observación O
, O
n O
= O
111 O
; O
topotecan O
, O
n O
= O
112 O
) O
. O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
completa I-Premise
y I-Premise
parcial I-Premise
a I-Premise
la I-Premise
EP I-Premise
de I-Premise
inducción I-Premise
fueron I-Premise
del I-Premise
3 I-Premise
% I-Premise
y I-Premise
del I-Premise
32 I-Premise
% I-Premise
, I-Premise
respectivamente. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
del I-Premise
7 I-Premise
% I-Premise
con I-Premise
topotecán I-Premise
( I-Premise
respuesta I-Premise
completa I-Premise
, I-Premise
2 I-Premise
% I-Premise
; I-Premise
respuesta I-Premise
parcial I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
los I-Premise
402 I-Premise
pacientes I-Premise
elegibles I-Premise
fue I-Premise
de I-Premise
9,6 I-Premise
meses. I-Premise

La B-Premise
supervivencia I-Premise
sin I-Premise
progresión I-Premise
(SSP) I-Premise
desde I-Premise
la I-Premise
fecha I-Premise
de I-Premise
aleatorización I-Premise
en I-Premise
el I-Premise
paso I-Premise
2 I-Premise
fue I-Premise
significativamente I-Premise
mejor I-Premise
con I-Premise
topotecán I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
observación I-Premise
( I-Premise
3,6 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
2,3 I-Premise
meses I-Premise
; I-Premise
P I-Premise
<0,001 I-Premise
) I-Premise
. I-Premise

Sin O
embargo, O
la B-Premise
supervivencia I-Premise
global I-Premise
desde I-Premise
la I-Premise
fecha I-Premise
de I-Premise
aleatorización I-Premise
en I-Premise
el I-Premise
paso I-Premise
2 I-Premise
no I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
observación I-Premise
y I-Premise
de I-Premise
topotecán I-Premise
( I-Premise
8,9 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
9,3 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,43 I-Premise
) O
. O

La B-Premise
neutropenia I-Premise
y I-Premise
la I-Premise
trombocitopenia I-Premise
de I-Premise
grado I-Premise
4 I-Premise
se I-Premise
produjeron I-Premise
en I-Premise
el I-Premise
50 I-Premise
% I-Premise
y I-Premise
el I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectivamente, I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
PE I-Premise
en I-Premise
el I-Premise
paso I-Premise
1 I-Premise
y I-Premise
en I-Premise
el I-Premise
60 I-Premise
% I-Premise
y I-Premise
el I-Premise
13 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
topotecán I-Premise
en I-Premise
el I-Premise
paso I-Premise
2 I-Premise
. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
infección I-Premise
de I-Premise
grado I-Premise
4/5 I-Premise
en I-Premise
el I-Premise
4,6% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
EP I-Premise
y I-Premise
en I-Premise
el I-Premise
1,8% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
topotecán. I-Premise

La B-Premise
anemia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
se I-Premise
desarrolló I-Premise
en I-Premise
el I-Premise
22% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
topotecán. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
el I-Premise
topotecán I-Premise
y I-Premise
la I-Premise
observación I-Premise
en I-Premise
ningún I-Premise
momento I-Premise
de I-Premise
la I-Premise
evaluación I-Premise
ni I-Premise
en I-Premise
ninguna I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
las I-Premise
subescalas. I-Premise

Cuatro B-Claim
ciclos I-Claim
de I-Claim
tratamiento I-Claim
de I-Claim
inducción I-Claim
con I-Claim
PE I-Claim
seguidos I-Claim
de I-Claim
cuatro I-Claim
ciclos I-Claim
de I-Claim
topotecán I-Claim
mejoraron I-Claim
la I-Claim
SLP I-Claim
pero I-Claim
no I-Claim
mejoraron I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
ni I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
el I-Claim
CPCP I-Claim
en I-Claim
estadio I-Claim
extenso. I-Claim

Cuatro B-Claim
ciclos I-Claim
de I-Claim
EP I-Claim
estándar I-Claim
siguen I-Claim
siendo I-Claim
un I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
adecuado I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPCP I-Claim
en I-Claim
estadio I-Claim
extenso I-Claim
con I-Claim
buen I-Claim
estado I-Claim
de I-Claim
rendimiento I-Claim
. I-Claim

Los O
pacientes O
con O
linfoma O
experimentan O
problemas O
de O
sueño O
que O
pueden O
controlarse O
con O
el O
ejercicio O
aeróbico, O
pero O
ningún O
estudio O
anterior O
ha O
examinado O
esta O
cuestión. O

Se O
asignaron O
al O
azar O
122 O
pacientes O
con O
linfoma O
a O
la O
atención O
habitual O
( O
n O
= O
62 O
) O
o O
a O
12 O
semanas O
de O
entrenamiento O
de O
ejercicio O
aeróbico O
supervisado O
( O
AET O
; O
n O
= O
60 O
) O
. O

Nuestro O
criterio O
de O
valoración O
principal O
fue O
la O
calidad O
global O
del O
sueño O
evaluada O
por O
el O
Índice O
de O
Calidad O
del O
Sueño O
de O
Pittsburgh O
( O
PSQI O
) O
. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
las O
puntuaciones O
de O
los O
componentes O
del O
PSQI O
. O

También O
se O
realizaron O
análisis O
de O
subgrupos O
planificados. O

Los B-Premise
análisis I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar I-Premise
indicaron I-Premise
que I-Premise
la I-Premise
TEA I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
una I-Premise
mejora I-Premise
no I-Premise
significativa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,16 I-Premise
) I-Premise
de I-Premise
la I-Premise
calidad I-Premise
global I-Premise
del I-Premise
sueño I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
atención I-Premise
habitual I-Premise
[ I-Premise
diferencia I-Premise
media I-Premise
del I-Premise
grupo I-Premise
= I-Premise
-0,64 I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
( I-Premise
IC I-Premise
) I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
-1,56 I-Premise
a I-Premise
+0,27 I-Premise
] I-Premise
. I-Premise

En B-Premise
los I-Premise
análisis I-Premise
de I-Premise
subgrupos I-Premise
planificados, I-Premise
se I-Premise
identificaron I-Premise
interacciones I-Premise
estadísticamente I-Premise
significativas I-Premise
o I-Premise
casi I-Premise
significativas I-Premise
para I-Premise
el I-Premise
tipo I-Premise
de I-Premise
linfoma I-Premise
( I-Premise
P I-Premise
( I-Premise
interacción I-Premise
) I-Premise
= I-Premise
0,006 I-Premise
) I-Premise
, I-Premise
el I-Premise
estado I-Premise
de I-Premise
tratamiento I-Premise
actual I-Premise
( I-Premise
P I-Premise
( I-Premise
interacción I-Premise
) I-Premise
= I-Premise
0,036 I-Premise
) I-Premise
, I-Premise
el I-Premise
tiempo I-Premise
transcurrido I-Premise
desde I-Premise
el I-Premise
diagnóstico I-Premise
( I-Premise
P I-Premise
( I-Premise
interacción I-Premise
) I-Premise
= I-Premise
0,010 I-Premise
) I-Premise
, I-Premise
el I-Premise
índice I-Premise
de I-Premise
masa I-Premise
corporal I-Premise
( I-Premise
P I-Premise
( I-Premise
interacción I-Premise
) I-Premise
= I-Premise
0,075 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
calidad I-Premise
del I-Premise
sueño I-Premise
inicial I-Premise
( I-Premise
P I-Premise
( I-Premise
interacción I-Premise
) I-Premise
= I-Premise
0,041 I-Premise
) I-Premise
. I-Premise

En O
concreto, O
la O
TEA B-Premise
mejoró I-Premise
la I-Premise
calidad I-Premise
global I-Premise
del I-Premise
sueño I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
linfoma I-Premise
que I-Premise
padecían I-Premise
un I-Premise
linfoma I-Premise
no I-Premise
Hodgkin I-Premise
indolente I-Premise
( I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
que I-Premise
recibían I-Premise
quimioterapia I-Premise
( I-Premise
P I-Premise
= I-Premise
0,013 I-Premise
) I-Premise
, I-Premise
que I-Premise
tenían I-Premise
menos I-Premise
de I-Premise
2 I-Premise
años I-Premise
de I-Premise
antigüedad I-Premise
tras I-Premise
el I-Premise
diagnóstico I-Premise
( I-Premise
P I-Premise
= I-Premise
0,005 I-Premise
) I-Premise
, I-Premise
que I-Premise
eran I-Premise
obesos I-Premise
( I-Premise
P I-Premise
= I-Premise
0,025 I-Premise
) I-Premise
y I-Premise
que I-Premise
tenían I-Premise
un I-Premise
sueño I-Premise
deficiente I-Premise
al I-Premise
inicio I-Premise
( I-Premise
P I-Premise
= I-Premise
0,007 I-Premise
) O
. O

La B-Claim
TEA I-Claim
no I-Claim
mejoró I-Claim
significativamente I-Claim
la I-Claim
calidad I-Claim
del I-Claim
sueño I-Claim
en I-Claim
esta I-Claim
muestra I-Claim
heterogénea I-Claim
de I-Claim
pacientes I-Claim
con I-Claim
linfoma; I-Claim
sin B-Claim
embargo, I-Claim
los I-Claim
subgrupos I-Claim
clínicamente I-Claim
identificables I-Claim
parecieron I-Claim
beneficiarse. I-Claim

Se O
necesitan O
futuros O
ensayos O
de O
ejercicio O
dirigidos O
a O
estos O
subgrupos O
receptivos O
para O
confirmar O
estos O
hallazgos O
. O

Si O
se O
reproduce O
en O
ensayos O
más O
amplios O
y O
específicos, O
el O
ejercicio O
aeróbico O
puede O
ser O
una O
opción O
atractiva O
para O
controlar O
la O
disfunción O
del O
sueño O
en O
pacientes O
con O
cáncer O
debido O
a O
su O
perfil O
de O
seguridad O
favorable O
y O
a O
otros O
beneficios O
para O
la O
salud O
documentados. O

Los B-Claim
datos I-Claim
in I-Claim
vivo I-Claim
han I-Claim
demostrado I-Claim
un I-Claim
efecto I-Claim
antiangiogénico I-Claim
más I-Claim
potente I-Claim
y I-Claim
una I-Claim
mayor I-Claim
actividad I-Claim
antitumoral I-Claim
de I-Claim
las I-Claim
dosis I-Claim
bajas I-Claim
de I-Claim
interferón I-Claim
( I-Claim
IFN I-Claim
) I-Claim
administradas I-Claim
dos I-Claim
veces I-Claim
al I-Claim
día I-Claim
. I-Claim

En O
un O
ensayo O
aleatorio O
de O
fase O
II O
, O
los O
autores O
probaron O
la O
hipótesis O
de O
que O
el O
IFN O
en O
dosis O
bajas O
dos O
veces O
al O
día O
es O
más O
eficaz O
que O
el O
IFN O
en O
dosis O
intermedias O
diarias O
en O
pacientes O
con O
cáncer O
de O
células O
renales O
metastásico O
( O
MRCC O
) O
. O

Un O
total O
de O
118 O
pacientes O
( O
59 O
por O
brazo O
) O
fueron O
asignados O
aleatoriamente O
a O
recibir O
IFN O
a O
una O
dosis O
de O
0,5 O
millones O
de O
unidades O
( O
MU O
) O
administrada O
por O
vía O
subcutánea O
dos O
veces O
al O
día O
( O
IFN1 O
) O
o O
IFN O
a O
una O
dosis O
de O
5 O
MU O
administrada O
por O
vía O
subcutánea O
diariamente O
( O
IFN5 O
) O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
supervivencia O
sin O
progresión O
( O
PFS O
) O
. O

Los O
criterios O
de O
valoración O
secundarios O
incluían O
la O
tasa O
de O
respuesta O
( O
RR O
) O
, O
la O
supervivencia O
global O
( O
SG O
) O
, O
la O
toxicidad O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
ni I-Premise
en I-Premise
la I-Premise
SLP I-Premise
ni I-Premise
en I-Premise
la I-Premise
SG I-Premise
entre I-Premise
el I-Premise
IFN1 I-Premise
y I-Premise
el I-Premise
IFN5 I-Premise
( I-Premise
mediana I-Premise
de I-Premise
3,7 I-Premise
meses I-Premise
y I-Premise
mediana I-Premise
de I-Premise
3,4 I-Premise
meses I-Premise
de I-Premise
SLP I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
mediana I-Premise
de I-Premise
25,5 I-Premise
meses I-Premise
y I-Premise
mediana I-Premise
de I-Premise
17,5 I-Premise
meses I-Premise
de I-Premise
SG I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Los B-Premise
RR I-Premise
fueron I-Premise
idénticos I-Premise
en I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
( I-Premise
6,7 I-Premise
% I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
1,8-16,5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Dos B-Premise
pacientes I-Premise
, I-Premise
1 I-Premise
en I-Premise
cada I-Premise
brazo I-Premise
, I-Premise
seguían I-Premise
en I-Premise
remisión I-Premise
completa I-Premise
en I-Premise
el I-Premise
momento I-Premise
del I-Premise
último I-Premise
seguimiento I-Premise
, I-Premise
a I-Premise
los I-Premise
45+ I-Premise
y I-Premise
38+ I-Premise
meses I-Premise
del I-Premise
tratamiento I-Premise
. I-Premise

Treinta B-Premise
y I-Premise
dos I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
IFN5 I-Premise
y I-Premise
19 I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
IFN1 I-Premise
experimentaron I-Premise
efectos I-Premise
adversos I-Premise
de I-Premise
grado I-Premise
3 I-Premise
o I-Premise
superior I-Premise
( I-Premise
calificados I-Premise
según I-Premise
los I-Premise
Criterios I-Premise
de I-Premise
Toxicidad I-Premise
Comunes I-Premise
del I-Premise
Instituto I-Premise
Nacional I-Premise
del I-Premise
Cáncer I-Premise
[ I-Premise
versión I-Premise
2.0 I-Premise
] I-Premise
). I-Premise
( I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Dieciocho B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
IFN5 I-Premise
y I-Premise
4 I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
IFN1 I-Premise
tuvieron I-Premise
reducciones I-Premise
de I-Premise
dosis I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

Hubo B-Premise
un I-Premise
deterioro I-Premise
significativo I-Premise
de I-Premise
la I-Premise
CdV I-Premise
y I-Premise
un I-Premise
aumento I-Premise
de I-Premise
la I-Premise
depresión I-Premise
asociados I-Premise
al I-Premise
IFN5, I-Premise
pero I-Premise
no I-Premise
se I-Premise
observaron I-Premise
cambios I-Premise
con I-Premise
el I-Premise
IFN1. I-Premise

En B-Claim
comparación I-Claim
con I-Claim
el I-Claim
IFN5, I-Claim
el I-Claim
IFN1 I-Claim
no I-Claim
es I-Claim
ni I-Claim
más I-Claim
ni I-Claim
menos I-Claim
eficaz, I-Claim
pero I-Claim
es I-Claim
menos I-Claim
tóxico, I-Claim
con I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Estos B-Claim
resultados I-Claim
pueden I-Claim
tener I-Claim
implicaciones I-Claim
para I-Claim
el I-Claim
diseño I-Claim
de I-Claim
regímenes I-Claim
combinados I-Claim
que I-Claim
incorporen I-Claim
IFN I-Claim
con I-Claim
agentes I-Claim
dirigidos I-Claim
. I-Claim

Determinar O
si O
los O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
localmente O
avanzado O
no O
aptos O
para O
la O
resección O
o O
la O
radioterapia O
radical O
, O
y O
con O
síntomas O
torácicos O
mínimos, O
deben O
recibir O
radioterapia O
torácica O
paliativa O
inmediatamente O
o O
según O
sea O
necesario O
para O
tratar O
los O
síntomas O
. O

Ensayo O
controlado O
aleatorio O
multicéntrico O
. O

23 O
centros O
en O
el O
Reino O
Unido, O
Irlanda O
y O
Sudáfrica. O

230 O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
no O
tratado O
previamente, O
localmente O
demasiado O
avanzado O
para O
la O
resección O
o O
la O
radioterapia O
radical O
con O
intención O
curativa, O
con O
síntomas O
torácicos O
mínimos O
y O
sin O
indicación O
de O
radioterapia O
torácica O
inmediata. O

Todos O
los O
pacientes O
recibieron O
tratamiento O
de O
apoyo O
y O
fueron O
asignados O
aleatoriamente O
a O
recibir O
radioterapia O
torácica O
paliativa O
de O
forma O
inmediata O
o O
retrasada O
hasta O
que O
fuera O
necesaria O
para O
tratar O
los O
síntomas O
. O

Los O
regímenes O
recomendados O
eran O
17 O
Gy O
en O
dos O
fracciones O
con O
una O
semana O
de O
diferencia O
o O
10 O
Gy O
en O
una O
sola O
dosis. O

Primario: O
pacientes O
vivos O
y O
sin O
tos O
moderada O
o O
grave, O
dolor O
torácico, O
hemoptisis O
o O
disnea O
a O
los O
seis O
meses O
de O
la O
aleatorización, O
según O
los O
registros O
de O
los O
médicos. O

Secundario: O
calidad O
de O
vida, O
eventos O
adversos, O
supervivencia. O

De O
diciembre O
de O
1992 O
a O
mayo O
de O
1999, O
se O
asignaron O
al O
azar O
230 O
pacientes. O

104/115 O
de O
los O
pacientes O
del O
grupo O
de O
tratamiento O
inmediato O
recibieron O
radioterapia O
torácica O
( O
90 O
recibieron O
uno O
de O
los O
regímenes O
recomendados O
) O
. O

En O
el O
grupo O
de O
tratamiento O
diferido, O
48/115 O
( O
42 O
% O
) O
pacientes O
recibieron O
radioterapia O
torácica O
( O
29 O
recibieron O
uno O
de O
los O
regímenes O
recomendados O
) O
; O
64 O
( O
56 O
% O
) O
murieron O
sin O
recibir O
radioterapia O
torácica O
; O
los O
tres O
( O
3 O
% O
) O
restantes O
estaban O
vivos O
al O
final O
del O
estudio O
sin O
haber O
recibido O
el O
tratamiento O
. O

En O
el O
caso O
de O
los O
pacientes O
que O
recibieron O
radioterapia O
torácica, O
la O
mediana O
del O
tiempo O
de O
inicio O
fue O
de O
15 O
días O
en O
el O
grupo O
de O
tratamiento O
inmediato O
y O
de O
125 O
días O
en O
el O
grupo O
de O
tratamiento O
diferido. O

La B-Premise
medida I-Premise
de I-Premise
resultado I-Premise
primaria I-Premise
se I-Premise
alcanzó I-Premise
en I-Premise
el I-Premise
28% I-Premise
del I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
inmediato I-Premise
y I-Premise
en I-Premise
el I-Premise
26% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
diferido I-Premise
( I-Premise
27/97 I-Premise
y I-Premise
27/103 I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
diferencia I-Premise
absoluta I-Premise
1,6 I-Premise
% I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
-10,7 I-Premise
% I-Premise
a I-Premise
13,9 I-Premise
% I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
observó I-Premise
ninguna I-Premise
diferencia I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
en I-Premise
cuanto I-Premise
al I-Premise
nivel I-Premise
de I-Premise
actividad, I-Premise
la I-Premise
ansiedad, I-Premise
la I-Premise
depresión I-Premise
y I-Premise
el I-Premise
malestar I-Premise
psicológico, I-Premise
según I-Premise
lo I-Premise
registrado I-Premise
por I-Premise
los I-Premise
pacientes. I-Premise

Los B-Premise
acontecimientos I-Premise
adversos I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
inmediato. I-Premise

Ninguno B-Premise
de I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
presentó I-Premise
una I-Premise
ventaja I-Premise
de I-Premise
supervivencia I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0,95 I-Premise
, I-Premise
0,73 I-Premise
a I-Premise
1,24 I-Premise
; I-Premise
P=0,71 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
8,3 I-Premise
meses I-Premise
y I-Premise
7,9 I-Premise
meses I-Premise
, O
y O
las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
fueron I-Premise
del I-Premise
31% I-Premise
y I-Premise
el I-Premise
29% I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
, I-Premise
para I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
inmediato I-Premise
y I-Premise
diferido I-Premise
, I-Premise
respectivamente I-Premise
. O

En B-Claim
los I-Claim
pacientes I-Claim
mínimamente I-Claim
sintomáticos I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
no I-Claim
pequeñas I-Claim
localmente I-Claim
avanzado, I-Claim
no I-Claim
se I-Claim
encontraron I-Claim
pruebas I-Claim
convincentes I-Claim
que I-Claim
indiquen I-Claim
que I-Claim
la I-Claim
administración I-Claim
de I-Claim
radioterapia I-Claim
torácica I-Claim
paliativa I-Claim
inmediata I-Claim
mejore I-Claim
el I-Claim
control I-Claim
de I-Claim
los I-Claim
síntomas, I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
o I-Claim
la I-Claim
supervivencia I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
retraso I-Claim
hasta I-Claim
que I-Claim
los I-Claim
síntomas I-Claim
requieran I-Claim
tratamiento. I-Claim

Determinar O
si O
la O
paliación O
de O
los O
síntomas O
torácicos O
de O
una O
fracción O
única O
de O
10 O
Gy O
( O
régimen O
1 O
) O
era O
equivalente O
a O
la O
de O
30 O
Gy O
en O
10 O
fracciones O
( O
régimen O
2 O
) O
. O

Los O
pacientes O
con O
cáncer O
de O
pulmón O
sintomático, O
comprobado O
citológicamente O
y O
no O
susceptible O
de O
tratamiento O
curativo, O
con O
un O
estado O
de O
rendimiento O
de O
0 O
a O
3, O
fueron O
asignados O
al O
azar O
para O
recibir O
30 O
Gy O
en O
10 O
fracciones O
o O
una O
sola O
fracción O
de O
10 O
Gy. O

Los O
síntomas O
locales O
se O
puntuaron O
en O
una O
escala O
categórica O
de O
cinco O
puntos O
evaluada O
por O
el O
médico O
y O
se O
sumaron O
para O
obtener O
una O
puntuación O
total O
de O
los O
síntomas O
(TSS). O

Se O
anotaron O
el O
estado O
de O
rendimiento, O
la O
puntuación O
de O
ansiedad O
y O
depresión O
hospitalaria O
(HAD) O
y O
el O
índice O
de O
calidad O
de O
vida O
de O
Spitzer O
antes O
del O
tratamiento, O
al O
mes O
de O
éste O
y O
cada O
dos O
meses O
a O
partir O
de O
entonces. O

La O
paliación O
se O
definió O
como O
una O
mejora O
de O
un O
punto O
o O
más O
en O
la O
escala O
categórica O
. O

La O
equivalencia O
se O
definió O
como O
una O
diferencia O
inferior O
al O
20 O
% O
en O
el O
número O
que O
lograba O
una O
mejora O
en O
la O
SST. O

Se O
aleatorizaron O
149 O
pacientes O
y O
se O
analizaron O
74 O
en O
cada O
brazo. O

Según O
los O
criterios O
de O
diseño, O
la O
paliación O
fue O
equivalente O
entre O
los O
dos O
brazos. O

La B-Premise
SST I-Premise
mejoró I-Premise
en I-Premise
49 I-Premise
pacientes I-Premise
( I-Premise
77 I-Premise
% I-Premise
) I-Premise
con I-Premise
el I-Premise
régimen I-Premise
1 I-Premise
, I-Premise
y I-Premise
en I-Premise
57 I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
con I-Premise
el I-Premise
régimen I-Premise
2 I-Premise
, I-Premise
una I-Premise
diferencia I-Premise
del I-Premise
15 I-Premise
% I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
IC I-Premise
] I-Premise
3-28 I-Premise
) I-Premise
en I-Premise
la I-Premise
proporción I-Premise
de I-Premise
mejora I-Premise
entre I-Premise
los I-Premise
dos I-Premise
regímenes I-Premise
. I-Premise

Se B-Premise
logró I-Premise
una I-Premise
resolución I-Premise
completa I-Premise
de I-Premise
todos I-Premise
los I-Premise
síntomas I-Premise
en I-Premise
tres I-Premise
( I-Premise
5 I-Premise
% I-Premise
) I-Premise
con I-Premise
el I-Premise
régimen I-Premise
1 I-Premise
, I-Premise
y I-Premise
en I-Premise
14 I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
pacientes I-Premise
con I-Premise
el I-Premise
régimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
una I-Premise
diferencia I-Premise
en I-Premise
la I-Premise
proporción I-Premise
entre I-Premise
los I-Premise
dos I-Premise
regímenes I-Premise
del I-Premise
21 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
IC I-Premise
10-33 I-Premise
) I-Premise
. I-Premise

Una B-Premise
proporción I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
pacientes I-Premise
experimentó I-Premise
paliación I-Premise
y I-Premise
resolución I-Premise
completa I-Premise
del I-Premise
dolor I-Premise
torácico I-Premise
y I-Premise
la I-Premise
disnea I-Premise
con I-Premise
el I-Premise
régimen I-Premise
2 I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
toxicidad. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
22,7 I-Premise
semanas I-Premise
para I-Premise
el I-Premise
régimen I-Premise
1 I-Premise
y I-Premise
de I-Premise
28,3 I-Premise
semanas I-Premise
para I-Premise
el I-Premise
régimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,197 I-Premise
) I-Premise
. I-Premise

Aunque B-Claim
este I-Claim
ensayo I-Claim
cumplió I-Claim
los I-Claim
criterios I-Claim
predeterminados I-Claim
de I-Claim
equivalencia I-Claim
entre I-Claim
los I-Claim
dos I-Claim
regímenes I-Claim
paliativos I-Claim
, O
un B-Claim
número I-Claim
significativamente I-Claim
mayor I-Claim
de I-Claim
pacientes I-Claim
logró I-Claim
la I-Claim
resolución I-Claim
completa I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
y I-Claim
la I-Claim
paliación I-Claim
del I-Claim
dolor I-Claim
torácico I-Claim
y I-Claim
la I-Claim
disnea I-Claim
con I-Claim
el I-Claim
régimen I-Claim
fraccionado I-Claim
. O

Pocos O
ensayos O
de O
ejercicio O
en O
pacientes O
con O
cáncer O
han O
informado O
de O
un O
seguimiento O
a O
largo O
plazo O
. O

Aquí, O
informamos O
de O
un O
seguimiento O
de O
6 O
meses O
de O
la O
conducta O
de O
ejercicio O
y O
los O
resultados O
calificados O
por O
los O
pacientes O
de O
un O
ensayo O
de O
ejercicio O
en O
pacientes O
con O
cáncer O
de O
mama O
. O

Las O
pacientes O
con O
cáncer O
de O
mama O
que O
iniciaban O
la O
quimioterapia O
adyuvante O
( O
n O
= O
242 O
) O
fueron O
asignadas O
aleatoriamente O
a O
la O
atención O
habitual O
( O
n O
= O
82 O
) O
, O
al O
entrenamiento O
con O
ejercicios O
de O
resistencia O
( O
RET O
; O
n O
= O
82 O
) O
, O
o O
al O
entrenamiento O
con O
ejercicios O
aeróbicos O
( O
AET O
; O
n O
= O
78 O
) O
durante O
la O
duración O
de O
su O
quimioterapia O
. O

A O
los O
6 O
meses O
de O
seguimiento, O
se O
envió O
a O
los O
participantes O
un O
cuestionario O
que O
evaluaba O
la O
calidad O
de O
vida, O
la O
autoestima, O
la O
fatiga, O
la O
ansiedad, O
la O
depresión O
y O
la O
conducta O
de O
ejercicio. O

Doscientos O
un O
( O
83,1 O
% O
) O
participantes O
proporcionaron O
datos O
de O
seguimiento O
a O
los O
6 O
meses O
. O

Los B-Premise
análisis I-Premise
lineales I-Premise
ajustados I-Premise
de I-Premise
modelos I-Premise
mixtos I-Premise
mostraron I-Premise
que, I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
de I-Premise
seguimiento, I-Premise
el I-Premise
grupo I-Premise
RET I-Premise
informó I-Premise
de I-Premise
una I-Premise
mayor I-Premise
autoestima I-Premise
[diferencia I-Premise
media I-Premise
ajustada, I-Premise
1,6; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%), I-Premise
0,1 I-Premise
a I-Premise
3,2; I-Premise
p I-Premise
= I-Premise
0,032] I-Premise
y I-Premise
el I-Premise
grupo I-Premise
AET I-Premise
informó I-Premise
de I-Premise
una I-Premise
menor I-Premise
ansiedad I-Premise
(diferencia I-Premise
media I-Premise
ajustada, I-Premise
-4,7; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
-0,0 I-Premise
a I-Premise
-9,3; I-Premise
p I-Premise
= I-Premise
0,049) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
atención I-Premise
habitual. I-Premise

Además, O
en B-Premise
comparación I-Premise
con I-Premise
los I-Premise
participantes I-Premise
que I-Premise
no I-Premise
informaron I-Premise
de I-Premise
ningún I-Premise
ejercicio I-Premise
regular I-Premise
durante I-Premise
el I-Premise
período I-Premise
de I-Premise
seguimiento, I-Premise
los I-Premise
que I-Premise
informaron I-Premise
de I-Premise
ejercicios I-Premise
aeróbicos I-Premise
y I-Premise
de I-Premise
resistencia I-Premise
regulares I-Premise
también I-Premise
informaron I-Premise
de I-Premise
mejores I-Premise
resultados I-Premise
calificados I-Premise
por I-Premise
los I-Premise
pacientes, I-Premise
incluida I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
diferencia I-Premise
de I-Premise
medias I-Premise
ajustada, I-Premise
9,5; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
1,2-17,8; I-Premise
P I-Premise
= I-Premise
0,025 I-Premise
) O
. O

Las B-Premise
mejoras I-Premise
en I-Premise
la I-Premise
autoestima I-Premise
observadas I-Premise
con I-Premise
RET I-Premise
durante I-Premise
la I-Premise
quimioterapia I-Premise
del I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
se I-Premise
mantuvieron I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
de I-Premise
seguimiento, I-Premise
mientras O
que O
las O
reducciones B-Premise
en I-Premise
la I-Premise
ansiedad I-Premise
no I-Premise
observadas I-Premise
con I-Premise
AET I-Premise
durante I-Premise
la I-Premise
quimioterapia I-Premise
del I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
surgieron I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
de I-Premise
seguimiento I-Premise
. O

Además, O
la B-Premise
adopción I-Premise
de I-Premise
un I-Premise
programa I-Premise
combinado I-Premise
de I-Premise
ejercicios I-Premise
aeróbicos I-Premise
y I-Premise
de I-Premise
resistencia I-Premise
después I-Premise
de I-Premise
la I-Premise
quimioterapia I-Premise
contra I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
se I-Premise
asoció I-Premise
con I-Premise
mejoras I-Premise
adicionales I-Premise
en I-Premise
los I-Premise
resultados I-Premise
calificados I-Premise
por I-Premise
las I-Premise
pacientes. I-Premise

El B-Claim
entrenamiento I-Claim
con I-Claim
ejercicios I-Claim
durante I-Claim
la I-Claim
quimioterapia I-Claim
para I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
puede I-Claim
producir I-Claim
algunos I-Claim
efectos I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
y I-Claim
tardíos I-Claim
para I-Claim
determinados I-Claim
resultados I-Claim
calificados I-Claim
por I-Claim
los I-Claim
pacientes I-Claim
. I-Claim

Dos O
millones O
de O
personas O
en O
todo O
el O
Reino O
Unido O
viven O
con O
cáncer, O
a O
menudo O
una O
enfermedad O
de O
larga O
duración. O

Pueden O
tener O
necesidades O
insatisfechas O
después O
del O
tratamiento O
activo O
. O

La O
rehabilitación O
tiene O
como O
objetivo O
abordar O
estas O
necesidades O
, O
maximizar O
la O
función O
psicológica O
y O
física O
, O
y O
permitir O
una O
dependencia O
mínima O
independientemente O
de O
la O
esperanza O
de O
vida O
. O

El O
objetivo O
era O
probar, O
en O
un O
ensayo O
controlado O
aleatorio, O
la O
eficacia O
clínica O
y O
económica O
de O
una O
intervención O
de O
rehabilitación O
para O
pacientes O
con O
cáncer O
avanzado O
y O
recurrente. O

Se O
llevó O
a O
cabo O
un O
ensayo O
aleatorio O
de O
dos O
brazos, O
con O
lista O
de O
espera, O
de O
una O
intervención O
de O
rehabilitación O
compleja O
realizada O
por O
un O
equipo O
multidisciplinario O
basado O
en O
un O
hospicio O
frente O
a O
la O
atención O
habitual O
para O
neoplasias O
hematológicas O
y O
de O
mama O
activas, O
progresivas O
y O
recurrentes, O
con O
un O
seguimiento O
a O
los O
tres O
meses. O

El O
resultado O
primario O
fue O
la O
subescala O
psicológica O
de O
la O
Encuesta O
de O
Necesidades O
de O
Cuidados O
de O
Apoyo O
( O
SCNS O
) O
. O

Los O
resultados O
secundarios O
fueron O
otros O
dominios O
del O
SCNS, O
el O
estado O
psicológico, O
la O
continuidad O
de O
la O
atención, O
la O
calidad O
de O
vida O
y O
el O
uso O
de O
recursos. O

Se O
inscribieron O
41 O
participantes O
y O
36 O
completaron O
el O
ensayo. O

El B-Premise
resultado I-Premise
primario I-Premise
fue I-Premise
significativamente I-Premise
menor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
intervención I-Premise
( I-Premise
diferencia I-Premise
ajustada I-Premise
-16,8 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
-28,34 I-Premise
a I-Premise
-5,3 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,006 I-Premise
) I-Premise
. I-Premise

Las B-Premise
subescalas I-Premise
SCNS I-Premise
física I-Premise
y I-Premise
de I-Premise
atención I-Premise
al I-Premise
paciente I-Premise
( I-Premise
-14,2 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-26,2 I-Premise
a I-Premise
-2,2 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
y I-Premise
-7,4 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-13,7 I-Premise
a I-Premise
-1,1 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
y I-Premise
el I-Premise
estado I-Premise
de I-Premise
salud I-Premise
autodeclarado I-Premise
( I-Premise
12,8 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
3,2 I-Premise
a I-Premise
22,4 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
también I-Premise
difirieron I-Premise
significativamente I-Premise
. I-Premise

La B-Premise
relación I-Premise
coste-eficacia I-Premise
incremental I-Premise
fue I-Premise
de I-Premise
19.390 I-Premise
libras I-Premise
por I-Premise
año I-Premise
de I-Premise
vida I-Premise
ajustado I-Premise
a I-Premise
la I-Premise
calidad. I-Premise

Esta B-Claim
intervención I-Claim
redujo I-Claim
significativamente I-Claim
las I-Claim
necesidades I-Claim
insatisfechas I-Claim
de I-Claim
los I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
y I-Claim
es I-Claim
probable I-Claim
que I-Claim
sea I-Claim
rentable I-Claim
. I-Claim

A B-Claim
pesar I-Claim
de I-Claim
su I-Claim
reducido I-Claim
número, I-Claim
el I-Claim
tamaño I-Claim
del I-Claim
efecto I-Claim
principal I-Claim
fue I-Claim
robusto. I-Claim

Recomendamos B-Claim
su I-Claim
aplicación I-Claim
junto I-Claim
con I-Claim
la I-Claim
evaluación I-Claim
en I-Claim
entornos I-Claim
clínicos I-Claim
y I-Claim
poblaciones I-Claim
de I-Claim
pacientes I-Claim
más I-Claim
amplios. I-Claim

El O
objetivo O
de O
este O
estudio O
fue O
evaluar O
la O
eficacia O
y O
la O
seguridad O
de O
la O
asociación O
de O
duloxetina O
y O
rehabilitación O
en O
comparación O
con O
la O
rehabilitación O
sola O
en O
hombres O
con O
IUE O
después O
de O
la O
prostatectomía O
retropúbica O
radical O
( O
PRR O
) O
, O
y O
comparar O
la O
tasa O
de O
continencia O
incluso O
después O
de O
la O
suspensión O
planificada O
de O
duloxetina O
. O

Tras O
la O
retirada O
del O
catéter, O
112 O
pacientes O
fueron O
aleatorizados O
para O
recibir O
rehabilitación O
y O
duloxetina O
( O
grupo O
A O
) O
o O
rehabilitación O
sola O
( O
grupo O
B O
) O
, O
durante O
16 O
semanas O
. O

IUE O
postprostatectomía O
con O
una O
frecuencia O
de O
episodios O
de O
incontinencia O
diaria O
( O
IEF O
) O
de O
cuatro O
o O
más. O

Después O
de O
16 O
semanas, O
ambos O
grupos O
suspendieron O
la O
duloxetina/placebo O
y O
continuaron O
la O
rehabilitación. O

Todas O
las O
pacientes O
rellenaron O
el O
cuestionario O
de O
calidad O
de O
vida O
sobre O
incontinencia O
(I-QoL) O
y O
el O
diario O
de O
la O
vejiga. O

Se O
utilizó O
la O
prueba O
de O
Wilcoxon O
para O
analizar O
los O
cambios O
en O
el O
IEF O
y O
en O
la O
puntuación O
de O
I-QoL; O
se O
utilizó O
la O
prueba O
exacta O
de O
Fisher O
para O
comparar O
los O
pacientes O
continentales O
entre O
los O
grupos. O

Los O
efectos O
adversos O
de O
la O
duloxetina O
fueron O
del O
15,2%. O

102 O
hombres O
completaron O
el O
estudio. O

Hubo B-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
del I-Premise
uso I-Premise
de I-Premise
compresas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
A I-Premise
. I-Premise

Tras B-Premise
16 I-Premise
semanas, I-Premise
39 I-Premise
pacientes I-Premise
frente I-Premise
a I-Premise
27 I-Premise
estaban I-Premise
secos I-Premise
( I-Premise
p=0,007 I-Premise
) I-Premise
. I-Premise

A B-Premise
las I-Premise
20 I-Premise
semanas, I-Premise
4 I-Premise
semanas I-Premise
después I-Premise
de I-Premise
la I-Premise
interrupción I-Premise
planificada I-Premise
de I-Premise
la I-Premise
duloxetina, I-Premise
observamos I-Premise
un I-Premise
giro I-Premise
en I-Premise
U, I-Premise
23 I-Premise
pacientes I-Premise
estaban I-Premise
completamente I-Premise
secos I-Premise
en I-Premise
el I-Premise
grupo I-Premise
A I-Premise
frente I-Premise
a I-Premise
38 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
B I-Premise
( I-Premise
p=0,008 I-Premise
) I-Premise
. I-Premise

Mientras B-Premise
que, I-Premise
después I-Premise
de I-Premise
24 I-Premise
semanas, I-Premise
31 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
A I-Premise
frente I-Premise
a I-Premise
41 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
B I-Premise
estaban I-Premise
secos I-Premise
( I-Premise
p=0,08 I-Premise
) O
. O

La B-Claim
disminución I-Claim
del I-Claim
IEF I-Claim
y I-Claim
las I-Claim
mejoras I-Claim
en I-Claim
las I-Claim
puntuaciones I-Claim
de I-Claim
I-QoL I-Claim
fueron I-Claim
significativamente I-Claim
mayores I-Claim
en I-Claim
el I-Claim
grupo I-Claim
A I-Claim
durante I-Claim
las I-Claim
primeras I-Claim
16 I-Claim
semanas. I-Claim

Los B-Claim
datos I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
terapia I-Claim
combinada I-Claim
podría I-Claim
proporcionar I-Claim
otra I-Claim
opción I-Claim
de I-Claim
tratamiento I-Claim
para I-Claim
la I-Claim
IUE I-Claim
en I-Claim
los I-Claim
hombres I-Claim
que I-Claim
podría I-Claim
aumentar I-Claim
el I-Claim
porcentaje I-Claim
de I-Claim
continencia I-Claim
postoperatoria I-Claim
temprana I-Claim
. I-Claim

Dirigir O
una O
investigación O
de O
homeopatía O
individualizada O
para O
los O
síntomas O
de O
abstinencia O
de O
estrógenos O
en O
supervivientes O
de O
cáncer O
de O
mama O
. O

Ensayo O
aleatorio, O
doble O
ciego, O
controlado O
con O
placebo. O

Departamento O
de O
consultas O
externas O
de O
un O
hospital O
homeopático O
del O
Servicio O
Nacional O
de O
Salud O
( O
NHS O
) O
. O

Cincuenta O
y O
siete O
( O
57 O
) O
mujeres O
cumplieron O
los O
criterios O
de O
inclusión O
y O
53 O
fueron O
asignadas O
al O
azar O
al O
estudio O
. O

Tras O
2 O
semanas O
de O
evaluación O
inicial, O
todos O
los O
participantes O
recibieron O
una O
consulta O
más O
un O
medicamento O
homeopático O
oral O
o O
un O
placebo, O
evaluados O
cada O
4 O
semanas O
durante O
16 O
semanas. O

Las O
medidas O
de O
resultado O
primarias O
fueron O
la O
puntuación O
de O
actividad O
y O
la O
puntuación O
del O
perfil O
del O
Measure O
Yourself O
Medical O
Outcome O
Profile O
( O
MYMOP O
) O
. O

El O
85% O
( O
45/53 O
) O
de O
las O
mujeres O
completaron O
el O
estudio. O

No B-Premise
hubo I-Premise
pruebas I-Premise
de I-Premise
que I-Premise
se I-Premise
observaran I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
ni I-Premise
para I-Premise
la I-Premise
actividad I-Premise
( I-Premise
diferencia I-Premise
ajustada I-Premise
=-0,4 I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-1,0 I-Premise
a I-Premise
0,2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,17 I-Premise
) I-Premise
ni I-Premise
para I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
perfil I-Premise
( I-Premise
diferencia I-Premise
ajustada I-Premise
= I-Premise
-0,4 I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-0,9 I-Premise
a I-Premise
0,1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,13 I-Premise
) I-Premise
utilizando I-Premise
este I-Premise
diseño I-Premise
de I-Premise
ensayo I-Premise
, O
aunque B-Claim
los I-Claim
cálculos I-Claim
de I-Claim
potencia I-Claim
post I-Claim
hoc I-Claim
sugieren I-Claim
que I-Claim
se I-Claim
necesitarían I-Claim
entre I-Claim
65 I-Claim
y I-Claim
175 I-Claim
por I-Claim
grupo I-Claim
para I-Claim
detectar I-Claim
diferencias I-Claim
de I-Claim
esta I-Claim
magnitud I-Claim
con I-Claim
suficiente I-Claim
precisión I-Claim
. O

Se B-Premise
observaron I-Premise
mejoras I-Premise
clínicamente I-Premise
relevantes I-Premise
en I-Premise
los I-Premise
síntomas I-Premise
y I-Premise
en I-Premise
las I-Premise
alteraciones I-Premise
del I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
durante I-Premise
el I-Premise
periodo I-Premise
de I-Premise
estudio. I-Premise

Se B-Claim
observaron I-Claim
mejoras I-Claim
en I-Claim
las I-Claim
puntuaciones I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
durante I-Claim
el I-Claim
periodo I-Claim
de I-Claim
estudio. I-Claim

Sin B-Claim
embargo I-Claim
, I-Claim
suponiendo I-Claim
que I-Claim
estas I-Claim
mejoras I-Claim
fueran I-Claim
causadas I-Claim
por I-Claim
el I-Claim
enfoque I-Claim
homeopático I-Claim
individualizado I-Claim
, I-Claim
el I-Claim
estudio I-Claim
no I-Claim
pudo I-Claim
mostrar I-Claim
claramente I-Claim
que I-Claim
el I-Claim
efecto I-Claim
específico I-Claim
del I-Claim
remedio I-Claim
se I-Claim
sumara I-Claim
a I-Claim
los I-Claim
efectos I-Claim
no I-Claim
específicos I-Claim
de I-Claim
la I-Claim
consulta I-Claim
. I-Claim

El B-Claim
diseño I-Claim
de I-Claim
los I-Claim
ensayos I-Claim
futuros I-Claim
debe I-Claim
garantizar I-Claim
una I-Claim
potencia I-Claim
adecuada I-Claim
para I-Claim
tener I-Claim
en I-Claim
cuenta I-Claim
el I-Claim
impacto I-Claim
inespecífico I-Claim
de I-Claim
estas I-Claim
complejas I-Claim
intervenciones I-Claim
individualizadas, I-Claim
mientras I-Claim
que I-Claim
los I-Claim
diseños I-Claim
pragmáticos I-Claim
pueden I-Claim
responder I-Claim
más I-Claim
fácilmente I-Claim
a I-Claim
las I-Claim
cuestiones I-Claim
de I-Claim
eficacia I-Claim
clínica I-Claim
y I-Claim
de I-Claim
costes. I-Claim

Se O
llevó O
a O
cabo O
un O
ensayo O
de O
fase O
III O
( O
Cancer O
and O
Leukemia O
Group O
B O
CALGB-49907 O
) O
para O
comprobar O
si O
las O
pacientes O
de O
mayor O
edad O
con O
cáncer O
de O
mama O
en O
fase O
inicial O
tendrían O
una O
supervivencia O
libre O
de O
recaídas O
y O
global O
equivalente O
con O
capecitabina O
en O
comparación O
con O
la O
quimioterapia O
estándar O
. O

El O
subestudio O
de O
calidad O
de O
vida O
( O
QoL O
) O
probó O
si O
el O
tratamiento O
con O
capecitabina O
se O
asociaría O
con O
una O
mejor O
QoL O
que O
la O
quimioterapia O
estándar O
. O

Se O
evaluó O
la O
calidad O
de O
vida O
de O
350 O
pacientes O
asignados O
aleatoriamente O
a O
quimioterapia O
estándar O
( O
ciclofosfamida O
, O
metotrexato O
y O
fluorouracilo O
[ O
CMF O
] O
o O
doxorrubicina O
y O
ciclofosfamida O
[ O
AC O
] O
; O
n O
= O
182 O
) O
o O
capecitabina O
( O
n O
= O
168 O
) O
. O

Se O
entrevistó O
a O
los O
pacientes O
por O
teléfono O
antes O
del O
tratamiento O
( O
línea O
de O
base O
) O
, O
a O
mitad O
del O
tratamiento O
, O
en O
el O
plazo O
de O
1 O
mes O
después O
del O
tratamiento O
, O
y O
a O
los O
12 O
, O
18 O
y O
24 O
meses O
después O
de O
la O
línea O
de O
base O
mediante O
cuestionarios O
del O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
QLQ-C30 O
) O
, O
una O
escala O
de O
efectos O
adversos O
sistémicos O
de O
la O
mama O
( O
EORTC O
BR23 O
) O
, O
y O
la O
Escala O
de O
Ansiedad O
y O
Depresión O
del O
Hospital O
( O
HADS O
) O
. O

En B-Premise
comparación I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
fueron I-Premise
tratados I-Premise
con I-Premise
quimioterapia I-Premise
estándar I-Premise
, I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
fueron I-Premise
tratados I-Premise
con I-Premise
capecitabina I-Premise
tenían I-Premise
significativamente I-Premise
mejor I-Premise
QoL I-Premise
, I-Premise
función I-Premise
de I-Premise
rol I-Premise
y I-Premise
función I-Premise
social I-Premise
, I-Premise
menos I-Premise
efectos I-Premise
adversos I-Premise
sistémicos I-Premise
, I-Premise
menos I-Premise
angustia I-Premise
psicológica I-Premise
y I-Premise
menos I-Premise
fatiga I-Premise
durante I-Premise
y I-Premise
al I-Premise
final I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

El B-Premise
tratamiento I-Premise
con I-Premise
capecitabina I-Premise
se I-Premise
asoció I-Premise
con I-Premise
menos I-Premise
náuseas I-Premise
, I-Premise
vómitos I-Premise
y I-Premise
estreñimiento I-Premise
y I-Premise
con I-Premise
mejor I-Premise
apetito I-Premise
que I-Premise
el I-Premise
tratamiento I-Premise
estándar I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.004 I-Premise
) I-Premise
, I-Premise
pero I-Premise
con I-Premise
peor I-Premise
síndrome I-Premise
mano-pie I-Premise
y I-Premise
diarrea I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Todas O
estas O
diferencias O
se O
resolvieron O
a O
los O
12 O
meses. O

La B-Claim
quimioterapia I-Claim
estándar I-Claim
fue I-Claim
superior I-Claim
a I-Claim
la I-Claim
capecitabina I-Claim
en I-Claim
la I-Claim
mejora I-Claim
de I-Claim
la I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
recaídas I-Claim
y I-Claim
global I-Claim
de I-Claim
las I-Claim
mujeres I-Claim
mayores I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
en I-Claim
fase I-Claim
inicial I-Claim
. I-Claim

Aunque O
la B-Claim
capecitabina I-Claim
se I-Claim
asoció I-Claim
con I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
durante I-Claim
el I-Claim
tratamiento, I-Claim
la O
calidad B-Premise
de I-Premise
vida I-Premise
fue I-Premise
similar I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
al I-Premise
año. I-Premise

El O
breve O
periodo O
de O
peor O
calidad O
de O
vida O
con O
el O
tratamiento O
estándar O
es O
un O
precio O
modesto O
a O
pagar O
por O
una O
oportunidad O
de O
mejorar O
la O
supervivencia. O

Evaluar O
si O
la O
administración O
de O
eritropoyetina O
humana O
recombinante O
( O
r-HuEPO O
) O
aumentaría O
el O
hematocrito O
, O
reduciría O
la O
necesidad O
de O
transfusión O
y O
mejoraría O
la O
calidad O
de O
vida O
en O
pacientes O
anémicos O
con O
cáncer O
que O
reciben O
quimioterapia O
mielosupresora O
basada O
en O
cisplatino O
. O

Se O
evaluaron O
ciento O
treinta O
y O
dos O
pacientes O
con O
cáncer O
anémico O
que O
recibían O
quimioterapia O
cíclica, O
con O
cisplatino O
y O
mielosupresora. O

Los O
pacientes O
recibieron O
r-HuEPO O
( O
150 O
U/kg O
) O
o O
placebo O
, O
por O
vía O
subcutánea O
, O
tres O
veces O
por O
semana O
durante O
3 O
meses O
. O

Las O
respuestas O
se O
evaluaron O
midiendo O
los O
cambios O
en O
la O
hemoglobina/hematocrito O
, O
la O
necesidad O
de O
transfusiones O
y O
la O
calidad O
de O
vida O
. O

El B-Premise
hematocrito I-Premise
medio I-Premise
aumentó I-Premise
en I-Premise
6,0 I-Premise
puntos I-Premise
porcentuales I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
r-HuEPO I-Premise
frente I-Premise
a I-Premise
1,3 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
. I-Premise

La B-Premise
disminución I-Premise
de I-Premise
la I-Premise
necesidad I-Premise
de I-Premise
transfusión I-Premise
no I-Premise
alcanzó I-Premise
la I-Premise
significación I-Premise
en I-Premise
los I-Premise
3 I-Premise
meses I-Premise
, I-Premise
pero I-Premise
hubo I-Premise
una I-Premise
reducción I-Premise
significativa I-Premise
en I-Premise
el I-Premise
porcentaje I-Premise
de I-Premise
pacientes I-Premise
transfundidos I-Premise
en I-Premise
el I-Premise
segundo I-Premise
y I-Premise
tercer I-Premise
mes I-Premise
( I-Premise
27 I-Premise
% I-Premise
de I-Premise
r-HuEPO I-Premise
frente I-Premise
al I-Premise
56 I-Premise
% I-Premise
de I-Premise
placebo I-Premise
) I-Premise
y I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
la I-Premise
reducción I-Premise
del I-Premise
número I-Premise
total I-Premise
medio I-Premise
de I-Premise
unidades I-Premise
transfundidas I-Premise
( I-Premise
1,20 I-Premise
unidades I-Premise
de I-Premise
r-HuEPO I-Premise
frente I-Premise
a I-Premise
2,02 I-Premise
unidades I-Premise
de I-Premise
placebo I-Premise
) I-Premise
, I-Premise
lo I-Premise
que I-Premise
sugiere I-Premise
un I-Premise
desfase I-Premise
de I-Premise
1 I-Premise
mes I-Premise
antes I-Premise
de I-Premise
que I-Premise
la I-Premise
r-HuEPO I-Premise
pueda I-Premise
afectar I-Premise
a I-Premise
la I-Premise
necesidad I-Premise
de I-Premise
transfusión I-Premise
. I-Premise

Los B-Premise
niveles I-Premise
de I-Premise
eritropoyetina I-Premise
sérica I-Premise
antes I-Premise
del I-Premise
tratamiento I-Premise
fueron I-Premise
más I-Premise
bajos I-Premise
en I-Premise
los I-Premise
respondedores I-Premise
que I-Premise
en I-Premise
los I-Premise
no I-Premise
respondedores I-Premise
( I-Premise
73,5 I-Premise
UI/L I-Premise
y I-Premise
86,3 I-Premise
UI/L I-Premise
de I-Premise
media, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
la I-Premise
magnitud I-Premise
de I-Premise
esta I-Premise
diferencia I-Premise
no I-Premise
sirvió I-Premise
para I-Premise
definir I-Premise
qué I-Premise
pacientes I-Premise
tenían I-Premise
más I-Premise
probabilidades I-Premise
de I-Premise
responder. I-Premise

Hubo B-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
a I-Premise
favor I-Premise
del I-Premise
grupo I-Premise
tratado I-Premise
con I-Premise
r-HuEPO I-Premise
. I-Premise

No B-Premise
hubo I-Premise
efectos I-Premise
adversos I-Premise
significativos I-Premise
asociados I-Premise
a I-Premise
la I-Premise
r-HuEPO I-Premise
. I-Premise

La B-Claim
r-HuEPO I-Claim
es I-Claim
segura I-Claim
y I-Claim
puede I-Claim
mejorar I-Claim
significativamente I-Claim
el I-Claim
hematocrito I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
anémicos I-Claim
con I-Claim
cáncer I-Claim
que I-Claim
reciben I-Claim
quimioterapia I-Claim
mielosupresora I-Claim
basada I-Claim
en I-Claim
cisplatino. I-Claim

Después B-Claim
de I-Claim
1 I-Claim
mes I-Claim
de I-Claim
r-HuEPO I-Claim
, I-Claim
también I-Claim
hay I-Claim
una I-Claim
reducción I-Claim
en I-Claim
la I-Claim
necesidad I-Claim
de I-Claim
transfusión I-Claim
. I-Claim

Las O
supervivientes O
de O
cáncer O
de O
mama O
de O
edad O
avanzada O
( O
BCS O
) O
corren O
el O
riesgo O
de O
sufrir O
efectos O
tardíos O
y O
a O
largo O
plazo O
del O
tratamiento O
sobre O
la O
calidad O
de O
vida O
( O
QOL O
) O
, O
incluyendo O
un O
menor O
funcionamiento O
físico O
y O
el O
miedo O
a O
la O
recurrencia O
. O

Dos O
enfoques O
prometedores O
para O
abordar O
esta O
cuestión O
son O
la O
terapia O
de O
danza/movimiento O
y O
la O
atención O
plena. O

El O
propósito O
de O
este O
estudio O
piloto O
de O
viabilidad O
controlado O
y O
aleatorizado O
de O
2 O
grupos O
fue O
probar O
los O
efectos O
a O
corto O
plazo O
de O
una O
intervención O
de O
12 O
semanas O
del O
Programa O
de O
Movimiento O
Consciente O
( O
MMP O
) O
que O
combina O
la O
atención O
plena O
con O
el O
movimiento O
autodirigido O
en O
la O
CdV O
y O
la O
atención O
plena O
en O
mujeres O
de O
50 O
años O
o O
más O
y O
a O
los O
12 O
meses O
o O
más O
después O
del O
tratamiento O
. O

Los O
participantes O
consentidos O
fueron O
asignados O
al O
azar O
a O
un O
grupo O
experimental O
( O
EG O
) O
( O
12 O
sesiones O
semanales O
de O
MMP O
) O
o O
a O
un O
grupo O
de O
control O
( O
sin O
sesiones O
) O
. O

Todos O
completaron O
los O
cuestionarios O
3 O
veces. O

Los O
participantes O
del O
Grupo O
de O
Expertos O
llevaban O
un O
diario O
de O
prácticas O
en O
casa. O

El O
análisis O
se O
realizó O
después O
de O
la O
intervención O
para O
comprobar O
los O
efectos O
inmediatos O
en O
las O
variables O
de O
resultado O
y O
6 O
semanas O
después O
para O
comprobar O
el O
mantenimiento O
de O
los O
efectos O
. O

Los O
participantes O
( O
n O
= O
49 O
) O
tenían O
edades O
comprendidas O
entre O
los O
50 O
y O
los O
90 O
años O
( O
media O
, O
65,6 O
años O
) O
y O
llevaban O
9,8 O
años O
desde O
el O
diagnóstico O
( O
rango O
, O
1-32 O
años O
) O
, O
y O
la O
mayoría O
eran O
blancos O
, O
sin O
pareja O
y O
jubilados O
. O

Después B-Premise
de I-Premise
la I-Premise
intervención, I-Premise
los I-Premise
participantes I-Premise
del I-Premise
GE I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
gracias I-Premise
a I-Premise
la I-Premise
disminución I-Premise
del I-Premise
miedo I-Premise
a I-Premise
la I-Premise
recurrencia I-Premise
y I-Premise
al I-Premise
aumento I-Premise
de I-Premise
la I-Premise
actitud I-Premise
de I-Premise
atención I-Premise
plena. I-Premise

A B-Premise
las I-Premise
6 I-Premise
semanas, I-Premise
los I-Premise
efectos I-Premise
iniciales I-Premise
se I-Premise
mantuvieron. I-Premise

El B-Premise
MMP I-Premise
parece I-Premise
beneficiar I-Premise
a I-Premise
los I-Premise
ancianos I-Premise
de I-Premise
la I-Premise
BCS I-Premise
al I-Premise
reducir I-Premise
el I-Premise
miedo I-Premise
a I-Premise
la I-Premise
recurrencia I-Premise
y I-Premise
mejorar I-Premise
la I-Premise
actitud I-Premise
de I-Premise
conciencia I-Premise
. I-Premise

Aunque B-Claim
estos I-Claim
resultados I-Claim
son I-Claim
prometedores, I-Claim
se I-Claim
necesita I-Claim
un I-Claim
estudio I-Claim
más I-Claim
amplio I-Claim
para I-Claim
determinar I-Claim
de I-Claim
forma I-Claim
más I-Claim
específica I-Claim
los I-Claim
posibles I-Claim
efectos I-Claim
a I-Claim
corto I-Claim
y I-Claim
largo I-Claim
plazo. I-Claim

La B-Claim
combinación I-Claim
de I-Claim
movimiento I-Claim
autodirigido I-Claim
y I-Claim
mindfulness I-Claim
, I-Claim
tal I-Claim
y I-Claim
como I-Claim
se I-Claim
ha I-Claim
probado I-Claim
aquí, I-Claim
puede I-Claim
ser I-Claim
una I-Claim
herramienta I-Claim
valiosa I-Claim
para I-Claim
promover I-Claim
la I-Claim
salud I-Claim
y I-Claim
el I-Claim
bienestar I-Claim
de I-Claim
las I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
de I-Claim
edad I-Claim
avanzada. I-Claim

El O
N O
, O
N-diethyl-2- O
[ O
4- O
( O
phenylmethyl O
) O
phenoxy O
] O
ethanamine O
( O
DPPE O
; O
tesmilifene O
) O
es O
un O
nuevo O
agente O
que O
aumenta O
la O
citotoxicidad O
de O
la O
quimioterapia O
in O
vitro O
e O
in O
vivo O
. O

Un O
ensayo O
de O
fase O
II O
en O
el O
que O
se O
combinó O
DPPE O
y O
doxorubicina O
( O
DOX O
) O
en O
el O
carcinoma O
de O
mama O
metastásico O
mostró O
una O
mayor O
respuesta O
que O
la O
esperada O
con O
DOX O
. O

Informamos O
de O
un O
ensayo O
de O
fase O
III O
que O
compara O
el O
DOX O
con O
el O
DPPE O
más O
el O
DOX O
en O
el O
cáncer O
de O
mama O
metastásico O
o O
recurrente. O

Las O
mujeres O
sin O
antraciclina O
con O
enfermedad O
metastásica O
medible O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
, O
cada O
21 O
días, O
60 O
mg/m O
( O
2 O
) O
de O
DOX O
por O
vía O
intravenosa O
o O
DOX O
durante O
los O
últimos O
20 O
minutos O
de O
una O
infusión O
de O
80 O
minutos O
de O
DPPE O
( O
5,3 O
mg/kg O
) O
, O
en O
ambos O
casos O
hasta O
dosis O
acumuladas O
de O
DOX O
de O
450 O
mg/m O
( O
2 O
) O
. O

Los O
pacientes O
que O
recibieron O
DPPE O
fueron O
premedicados O
de O
forma O
agresiva O
para O
mejorar O
la O
toxicidad. O

Los O
puntos O
finales O
incluyeron O
la O
supervivencia O
libre O
de O
progresión O
( O
PFS O
) O
, O
la O
tasa O
de O
respuesta O
( O
RR O
) O
y O
la O
duración O
de O
la O
respuesta O
( O
RD O
) O
, O
la O
calidad O
de O
vida O
( O
QOL O
) O
, O
la O
toxicidad O
y O
la O
supervivencia O
global O
( O
OS O
) O
. O

Un O
análisis O
intermedio O
planificado O
no O
pudo O
detectar O
una O
diferencia O
de O
RR O
superior O
al O
5 O
% O
. O

El O
estudio O
se O
cerró O
a O
la O
acumulación O
adicional O
y O
se O
suspendió O
todo O
el O
DPPE O
. O

El O
análisis O
final O
se O
realizó O
según O
lo O
previsto O
después O
de O
256 O
eventos O
de O
progresión O
( O
mediana O
de O
seguimiento O
, O
20,5 O
meses O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
el I-Premise
RR, I-Premise
la I-Premise
DR I-Premise
o I-Premise
la I-Premise
SLP I-Premise
entre I-Premise
los I-Premise
brazos. I-Premise

DPPE B-Premise
más I-Premise
DOX I-Premise
fue I-Premise
estadísticamente I-Premise
superior I-Premise
a I-Premise
DOX I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
SG I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0,66 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,48 I-Premise
a I-Premise
0,91 I-Premise
; I-Premise
P I-Premise
=.021 I-Premise
) I-Premise
. I-Premise

DPPE B-Premise
más I-Premise
DOX I-Premise
se I-Premise
asoció I-Premise
con I-Premise
más I-Premise
toxicidad I-Premise
gastrointestinal I-Premise
y I-Premise
del I-Premise
SNC I-Premise
. I-Premise

No B-Premise
se I-Premise
detectó I-Premise
una I-Premise
influencia I-Premise
consistente I-Premise
en I-Premise
la I-Premise
CdV. I-Premise

Este B-Claim
estudio I-Claim
no I-Claim
demostró I-Claim
ninguna I-Claim
ventaja I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
RR, I-Claim
RD I-Claim
o I-Claim
SSP, I-Claim
pero I-Claim
sí I-Claim
una I-Claim
SG I-Claim
significativamente I-Claim
superior I-Claim
para I-Claim
DPPE I-Claim
más I-Claim
DOX. I-Claim

Se B-Claim
justifica I-Claim
la I-Claim
realización I-Claim
de I-Claim
más I-Claim
estudios I-Claim
sobre I-Claim
el I-Claim
DPPE. I-Claim

Las B-Claim
investigaciones I-Claim
experimentales I-Claim
y I-Claim
las I-Claim
primeras I-Claim
clínicas I-Claim
han I-Claim
demostrado I-Claim
resultados I-Claim
alentadores I-Claim
de I-Claim
la I-Claim
estramustina I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
glioma I-Claim
maligno. I-Claim

El O
presente O
estudio O
es O
un O
ensayo O
clínico O
aleatorio O
abierto O
que O
compara O
el O
fosfato O
de O
estramustina O
( O
Estracyt O
) O
además O
de O
la O
radioterapia O
con O
la O
radioterapia O
sola O
como O
tratamiento O
de O
primera O
línea O
del O
astrocitoma O
de O
grado O
III O
y O
IV O
. O

Los O
140 O
pacientes O
incluidos O
se O
encontraban O
en O
buen O
estado O
clínico, O
con O
una O
media O
de O
edad O
de O
55 O
años O
( O
rango O
22-87 O
) O
. O

La O
estramustina O
se O
administró O
por O
vía O
oral, O
280 O
mg O
dos O
veces O
al O
día, O
tan O
pronto O
como O
se O
estableció O
el O
diagnóstico, O
durante O
y O
después O
de O
la O
radioterapia O
durante O
un O
período O
total O
de O
3 O
meses. O

La O
radioterapia O
se O
administró O
en O
días O
laborables O
2 O
Gy O
diarios O
hasta O
56 O
Gy O
. O

Se O
excluyeron O
18 O
pacientes O
debido O
a O
una O
clasificación O
errónea, O
lo O
que O
dejó O
a O
122 O
pacientes O
elegibles O
para O
la O
evaluación. O

En O
general, B-Premise
el I-Premise
tratamiento I-Premise
fue I-Premise
bien I-Premise
tolerado. I-Premise

Las B-Premise
náuseas I-Premise
leves I-Premise
o I-Premise
moderadas I-Premise
fueron I-Premise
el I-Premise
efecto I-Premise
secundario I-Premise
más I-Premise
frecuente I-Premise
de I-Premise
la I-Premise
estramustina. I-Premise

El O
tiempo O
mínimo O
de O
seguimiento O
fue O
de O
5,2 O
años O
para O
los O
pacientes O
supervivientes. O

En B-Premise
el I-Premise
caso I-Premise
del I-Premise
astrocitoma I-Premise
de I-Premise
grado I-Premise
III, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
10,6 I-Premise
( I-Premise
1,3-92,7 I-Premise
) I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
sólo I-Premise
radioterapia I-Premise
y I-Premise
de I-Premise
17,3 I-Premise
( I-Premise
0,4-96,9+ I-Premise
) I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
estramustina I-Premise
+ I-Premise
radioterapia I-Premise
. I-Premise

En B-Premise
el I-Premise
grado I-Premise
IV I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
correspondiente I-Premise
fue I-Premise
de I-Premise
12,3 I-Premise
( I-Premise
2,1-89,2 I-Premise
) I-Premise
y I-Premise
10,3 I-Premise
( I-Premise
0,3-91,7+ I-Premise
) I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
evolución I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
sólo I-Premise
radioterapia I-Premise
y I-Premise
el I-Premise
de I-Premise
radioterapia I-Premise
y I-Premise
estramustina I-Premise
en I-Premise
los I-Premise
tumores I-Premise
de I-Premise
grado I-Premise
III I-Premise
fue I-Premise
de I-Premise
6,5 I-Premise
y I-Premise
10,1 I-Premise
meses, I-Premise
respectivamente. I-Premise

En B-Premise
los I-Premise
tumores I-Premise
de I-Premise
grado I-Premise
IV, I-Premise
las I-Premise
cifras I-Premise
correspondientes I-Premise
fueron I-Premise
de I-Premise
5,1 I-Premise
y I-Premise
3,3 I-Premise
meses, I-Premise
respectivamente. I-Premise

Aunque B-Premise
hubo I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
mejorar I-Premise
la I-Premise
supervivencia I-Premise
en I-Premise
el I-Premise
grado I-Premise
III, I-Premise
no I-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
según I-Premise
el I-Premise
protocolo I-Premise
EORTC I-Premise
QLQ I-Premise
. I-Premise

En B-Claim
conclusión I-Claim
, I-Claim
este I-Claim
primer I-Claim
estudio I-Claim
aleatorio I-Claim
no I-Claim
demostró I-Claim
ninguna I-Claim
mejora I-Claim
significativa I-Claim
del I-Claim
uso I-Claim
de I-Claim
estramustina I-Claim
además I-Claim
de I-Claim
la I-Claim
radioterapia I-Claim
convencional I-Claim
, O
sin B-Claim
embargo I-Claim
, I-Claim
se I-Claim
encontró I-Claim
una I-Claim
tendencia I-Claim
de I-Claim
respuesta I-Claim
positiva I-Claim
para I-Claim
el I-Claim
grupo I-Claim
de I-Claim
estramustina I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
glioma I-Claim
de I-Claim
grado I-Claim
III I-Claim
. O

En B-Claim
el I-Claim
CPNM I-Claim
avanzado I-Claim
no I-Claim
seleccionado, I-Claim
la I-Claim
quimioterapia I-Claim
logró I-Claim
una I-Claim
ventaja I-Claim
de I-Claim
aproximadamente I-Claim
1-2 I-Claim
meses I-Claim
en I-Claim
la I-Claim
mediana I-Claim
de I-Claim
supervivencia I-Claim
frente I-Claim
al I-Claim
mejor I-Claim
tratamiento I-Claim
de I-Claim
apoyo I-Claim
. I-Claim

La B-Claim
quimioterapia I-Claim
parece I-Claim
mejorar I-Claim
el I-Claim
control I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
, O
aunque O
faltan O
estudios O
aleatorios O
con O
la O
calidad O
de O
vida O
como O
primer O
criterio O
de O
valoración O
y O
a O
menudo O
la O
toxicidad O
de O
la O
quimioterapia O
compromete O
la O
frágil O
relación O
coste/beneficio O
. O

El O
objetivo O
del O
presente O
estudio O
es O
evaluar O
el O
impacto O
en O
la O
CdV O
, O
sustituyendo O
el O
cisplatino O
, O
un O
fármaco O
pivote O
en O
la O
terapia O
del O
CPNM O
, O
por O
carboplatino O
, O
un O
análogo O
con O
un O
perfil O
de O
toxicidad O
mejorado O
. O

La O
combinación O
de O
cisplatino O
con O
mitomicina O
y O
vinblastina O
era O
una O
de O
las O
más O
utilizadas O
en O
el O
ámbito O
paliativo O
en O
el O
momento O
del O
diseño O
de O
nuestro O
estudio O
. O

Los O
pacientes O
fueron O
aleatorizados O
para O
recibir O
el O
régimen O
MVP O
( O
Mitomicina-C O
8 O
mg/m2 O
d1 O
, O
Vinblastina O
4 O
mg/m2 O
d O
1-8 O
, O
Cisplatino O
100 O
mg/m2 O
d1 O
) O
o O
el O
régimen O
MVC O
( O
Mitomicina-C O
8 O
mg/m2 O
d1 O
, O
Vinblastina O
4 O
mg/m2 O
d O
1-8 O
, O
Carboplatino O
300 O
mg/m2 O
d1 O
) O
cada O
3 O
semanas O
. O

La O
calidad O
de O
vida O
se O
evaluó O
mediante O
el O
Spitzer O
QL-Index O
y O
los O
cuestionarios O
EORTC O
QLQ-C30+LC O
13 O
antes O
de O
la O
quimioterapia, O
después O
de O
un O
ciclo, O
después O
de O
tres O
ciclos, O
y O
luego O
cada O
6 O
semanas O
en O
los O
primeros O
6 O
meses O
y O
cada O
3 O
meses O
después. O

Desde O
septiembre O
de O
1994 O
hasta O
julio O
de O
1997, O
153 O
pacientes O
consecutivos O
fueron O
asignados O
al O
azar O
al O
brazo O
MVP O
( O
75 O
pacientes O
) O
o O
al O
brazo O
MVC O
( O
78 O
pacientes O
) O
. O

A B-Premise
pesar I-Premise
de I-Premise
las I-Premise
dificultades I-Premise
para I-Premise
realizar I-Premise
y I-Premise
analizar I-Premise
los I-Premise
ítems I-Premise
de I-Premise
QoL I-Premise
en I-Premise
estos I-Premise
pacientes, I-Premise
la I-Premise
QoL I-Premise
global I-Premise
evaluada I-Premise
por I-Premise
el I-Premise
cuestionario I-Premise
de I-Premise
Spitzer I-Premise
sugirió I-Premise
una I-Premise
ventaja I-Premise
para I-Premise
el I-Premise
régimen I-Premise
MVC I-Premise
( I-Premise
P=0,05 I-Premise
) I-Premise
y I-Premise
se I-Premise
observó I-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
en I-Premise
el I-Premise
subdominio I-Premise
de I-Premise
salud I-Premise
global I-Premise
( I-Premise
P=0,04 I-Premise
) I-Premise
. I-Premise

Los B-Premise
síntomas I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
enfermedad I-Premise
mejoraron I-Premise
con I-Premise
el I-Premise
tiempo, I-Premise
y O
los B-Premise
beneficios I-Premise
se I-Premise
mantuvieron I-Premise
durante I-Premise
todo I-Premise
el I-Premise
periodo I-Premise
de I-Premise
tratamiento. I-Premise

Cuando B-Premise
se I-Premise
evaluó I-Premise
con I-Premise
el I-Premise
cuestionario I-Premise
de I-Premise
la I-Premise
EORTC I-Premise
hubo I-Premise
significativamente I-Premise
menos I-Premise
náuseas I-Premise
y I-Premise
vómitos I-Premise
( I-Premise
P=0,0001 I-Premise
) I-Premise
, I-Premise
pérdida I-Premise
de I-Premise
apetito I-Premise
( I-Premise
P=0,01 I-Premise
) I-Premise
, I-Premise
insomnio I-Premise
( I-Premise
P=0,03 I-Premise
) I-Premise
, I-Premise
estreñimiento I-Premise
( I-Premise
P=0,01 I-Premise
) I-Premise
y I-Premise
neuropatía I-Premise
periférica I-Premise
( I-Premise
P=0,01 I-Premise
) I-Premise
a I-Premise
favor I-Premise
de I-Premise
la I-Premise
MVC I-Premise
, I-Premise
y I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
una I-Premise
menor I-Premise
pérdida I-Premise
de I-Premise
cabello I-Premise
( I-Premise
P=0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
ventaja I-Premise
duró I-Premise
toda I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
quimioterapia I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
el I-Premise
subdominio I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
( I-Premise
P=0,40 I-Premise
) I-Premise
entre I-Premise
los I-Premise
dos I-Premise
regímenes I-Premise
. I-Premise

La O
calidad O
de O
vida O
fue O
el O
primer O
criterio O
de O
valoración O
y O
la O
potencia O
estadística O
fue O
inadecuada O
para O
evaluar O
otros O
parámetros. O

Sin O
embargo, O
informamos B-Premise
de I-Premise
una I-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
del I-Premise
43,1 I-Premise
y I-Premise
el I-Premise
38,6%, I-Premise
respectivamente, I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
MVP I-Premise
y I-Premise
MVC I-Premise
( I-Premise
P I-Premise
= I-Premise
0,59 I-Premise
) I-Premise
y I-Premise
una I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
10,2 I-Premise
y I-Premise
7,2 I-Premise
meses, I-Premise
respectivamente, I-Premise
para I-Premise
el I-Premise
brazo I-Premise
de I-Premise
cisplatino I-Premise
y I-Premise
carboplatino I-Premise
( I-Premise
P I-Premise
= I-Premise
0,39 I-Premise
) O
. O

El B-Premise
régimen I-Premise
que I-Premise
contiene I-Premise
carboplatino I-Premise
( I-Premise
MVC I-Premise
) I-Premise
tiene I-Premise
un I-Premise
perfil I-Premise
de I-Premise
toxicidad I-Premise
significativamente I-Premise
mejor I-Premise
que I-Premise
el I-Premise
régimen I-Premise
que I-Premise
contiene I-Premise
cisplatino I-Premise
( I-Premise
MVP I-Premise
), I-Premise
como I-Premise
se I-Premise
ha I-Premise
demostrado I-Premise
tanto I-Premise
en I-Premise
los I-Premise
cuestionarios I-Premise
de I-Premise
la I-Premise
EORTC I-Premise
como I-Premise
en I-Premise
los I-Premise
datos I-Premise
de I-Premise
toxicidad I-Premise
de I-Premise
la I-Premise
OMS I-Premise
comunicados I-Premise
por I-Premise
los I-Premise
médicos I-Premise
. I-Premise

No B-Claim
se I-Claim
observaron I-Claim
diferencias I-Claim
significativas I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
tasa I-Claim
de I-Claim
respuesta, I-Claim
el I-Claim
tiempo I-Claim
hasta I-Claim
la I-Claim
progresión I-Claim
y I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
entre I-Claim
los I-Claim
dos I-Claim
regímenes. I-Claim

Los B-Claim
dos I-Claim
regímenes I-Claim
de I-Claim
quimioterapia I-Claim
mostraron I-Claim
una I-Claim
eficacia I-Claim
similar I-Claim
en I-Claim
la I-Claim
paliación I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
cuando I-Claim
se I-Claim
evaluaron I-Claim
con I-Claim
el I-Claim
apéndice I-Claim
C30 I-Claim
del I-Claim
cuestionario I-Claim
EORTC I-Claim
QOL I-Claim
. I-Claim

Con B-Premise
los I-Premise
cuestionarios I-Premise
de I-Premise
Spitzer I-Premise
se I-Premise
observó I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
mejorar I-Premise
el I-Premise
índice I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
durante I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
la I-Premise
combinación I-Premise
de I-Premise
carboplatino I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
combinación I-Premise
de I-Premise
cisplatino. I-Premise

Esta B-Premise
diferencia, I-Premise
sin I-Premise
embargo, I-Premise
no I-Premise
se I-Premise
observó I-Premise
cuando I-Premise
se I-Premise
evaluó I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
con I-Premise
los I-Premise
cuestionarios I-Premise
compilados I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
EORTC. I-Premise

Un B-Claim
régimen I-Claim
que I-Claim
contenga I-Claim
carboplatino I-Claim
con I-Claim
un I-Claim
mejor I-Claim
perfil I-Claim
de I-Claim
toxicidad I-Claim
y I-Claim
una I-Claim
potencialidad I-Claim
similar I-Claim
para I-Claim
el I-Claim
control I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
ofrece I-Claim
una I-Claim
opción I-Claim
en I-Claim
comparación I-Claim
con I-Claim
combinaciones I-Claim
similares I-Claim
que I-Claim
contengan I-Claim
cisplatino I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
paliativo I-Claim
del I-Claim
CPNM I-Claim
avanzado I-Claim
. I-Claim

Determinar O
los O
resultados O
a O
un O
año O
de O
una O
intervención O
de O
terapia O
conductual O
( O
BT O
) O
de O
cuatro O
componentes O
sobre O
el O
sueño O
( O
Plan O
Individualizado O
de O
Promoción O
del O
Sueño O
[ O
ISPP O
] O
) O
frente O
a O
un O
control O
de O
alimentación O
saludable O
( O
HEC O
) O
sobre O
la O
fatiga O
relacionada O
con O
el O
cáncer O
en O
mujeres O
que O
reciben O
tratamiento O
de O
quimioterapia O
adyuvante O
( O
CTX O
) O
para O
el O
cáncer O
de O
mama. O

Un O
total O
de O
219 O
participantes O
de O
12 O
clínicas O
de O
oncología O
fueron O
asignados O
al O
azar O
en O
un O
ensayo O
clínico O
. O

Antes O
de O
la O
CTX O
, O
las O
enfermeras O
de O
la O
investigación O
entrenaron O
a O
los O
participantes O
de O
la O
intervención O
para O
desarrollar O
un O
plan O
de O
BT O
que O
incluyera O
el O
control O
de O
estímulos O
, O
la O
restricción O
modificada O
del O
sueño O
, O
la O
terapia O
de O
relajación O
y O
la O
higiene O
del O
sueño O
. O

Los O
planes O
de O
BT O
se O
revisaron O
antes O
de O
cada O
CTX O
y O
30, O
60 O
y O
90 O
días O
después O
del O
último O
CTX O
y O
se O
reforzaron O
entre O
7 O
y O
9 O
días O
después. O

Los O
participantes O
en O
el O
CEH O
recibieron O
información O
nutricional O
y O
la O
misma O
atención O
. O

Se O
utilizaron O
las O
medidas O
del O
Índice O
de O
Calidad O
del O
Sueño O
de O
Pittsburgh O
( O
PSQI O
) O
, O
el O
Diario O
, O
el O
Actigraph O
de O
Muñeca O
y O
la O
Escala O
de O
Fatiga O
de O
Piper O
y O
el O
análisis O
del O
Modelo O
Lineal O
Mixto O
Repetido O
siguiendo O
el O
paradigma O
de O
Intención O
de O
Tratamiento O
. O

La B-Premise
calidad I-Premise
del I-Premise
sueño I-Premise
difiere I-Premise
a I-Premise
lo I-Premise
largo I-Premise
de I-Premise
1 I-Premise
año I-Premise
( I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
7,7 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
; I-Premise
por I-Premise
grupo I-Premise
, I-Premise
F I-Premise
[ I-Premise
1,173 I-Premise
] I-Premise
= I-Premise
4,8 I-Premise
, I-Premise
P I-Premise
= I-Premise
.029 I-Premise
; I-Premise
y I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
por I-Premise
grupo I-Premise
, I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
3,3 I-Premise
, I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

Las B-Premise
comparaciones I-Premise
por I-Premise
pares I-Premise
revelaron I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
a I-Premise
los I-Premise
90 I-Premise
días I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
pero I-Premise
no I-Premise
al I-Premise
año I-Premise
( I-Premise
P I-Premise
= I-Premise
0,052 I-Premise
) O
. O

Los O
datos O
del O
diario O
y O
la O
actigrafía O
de O
siete O
días O
no O
corroboraron O
las O
reflexiones O
mensuales O
( O
PSQI O
) O
. O

El B-Premise
patrón I-Premise
de I-Premise
despertares I-Premise
nocturnos I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
por I-Premise
grupo I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
sin I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
a I-Premise
los I-Premise
90 I-Premise
días I-Premise
o I-Premise
al I-Premise
año I-Premise
. I-Premise

La B-Premise
fatiga I-Premise
era I-Premise
menor I-Premise
al I-Premise
año I-Premise
que I-Premise
antes I-Premise
de I-Premise
la I-Premise
CTX; I-Premise
no B-Premise
se I-Premise
encontraron I-Premise
efectos I-Premise
de I-Premise
grupo. I-Premise

El B-Claim
grupo I-Claim
de I-Claim
BT I-Claim
, I-Claim
en I-Claim
promedio, I-Claim
experimentó I-Claim
una I-Claim
mejora I-Claim
significativa I-Claim
en I-Claim
la I-Claim
calidad I-Claim
global I-Claim
del I-Claim
sueño I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
grupo I-Claim
de I-Claim
HEC I-Claim
, O
pero B-Claim
no I-Claim
en I-Claim
los I-Claim
resultados I-Claim
objetivos I-Claim
del I-Claim
sueño I-Claim
o I-Claim
la I-Claim
fatiga I-Claim
. O

Comparar O
los O
resultados O
de O
la O
embolización O
de O
la O
arteria O
uterina O
( O
EAU O
) O
para O
los O
leiomiomas O
con O
el O
uso O
de O
microesferas O
de O
gelatina O
de O
tris-acrilo O
( O
TAGM O
) O
frente O
a O
partículas O
esféricas O
de O
alcohol O
polivinílico O
( O
PVA O
) O
. O

Los O
pacientes O
sometidos O
a O
EAU O
fueron O
asignados O
aleatoriamente O
a O
recibir O
TAGMs O
o O
PVA O
. O

La O
embolización O
se O
realizó O
de O
forma O
estandarizada. O

Los O
datos O
de O
resultados O
se O
recogieron O
a O
los O
3 O
meses O
después O
de O
la O
embolización, O
incluyendo O
la O
evaluación O
de O
los O
síntomas O
clínicos, O
las O
puntuaciones O
de O
un O
cuestionario O
de O
síntomas O
y O
calidad O
de O
vida O
( O
QOL O
) O
específicos O
del O
tumor O
fibroide, O
y O
los O
hallazgos O
en O
las O
imágenes O
de O
resonancia O
magnética O
( O
MR O
) O
mejoradas O
con O
material O
de O
contraste, O
incluyendo O
el O
grado O
de O
infarto O
del O
tumor O
y O
la O
reducción O
del O
volumen O
. O

Los O
datos O
se O
analizaron O
con O
el O
uso O
de O
las O
pruebas O
t, O
la O
prueba O
U O
de O
Mann-Whitney O
y O
las O
pruebas O
chi2, O
según O
el O
caso. O

Treinta O
y O
seis O
pacientes O
fueron O
tratados. O

No O
hubo O
diferencias O
en O
los O
dos O
grupos O
de O
tratamiento O
al O
inicio. O

Se O
obtuvo O
un O
seguimiento O
clínico O
en O
35 O
pacientes. O

Entre B-Premise
las I-Premise
medidas I-Premise
de I-Premise
resultado I-Premise
clínico, I-Premise
la I-Premise
mejora I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
CdV I-Premise
fue I-Premise
mayor I-Premise
para I-Premise
la I-Premise
EAU I-Premise
con I-Premise
TAGM I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
PVA I-Premise
( I-Premise
49,0 I-Premise
frente I-Premise
a I-Premise
27,9 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) O
, O
pero B-Premise
no I-Premise
se I-Premise
observaron I-Premise
otras I-Premise
diferencias I-Premise
. O

De B-Premise
las I-Premise
25 I-Premise
pacientes I-Premise
en I-Premise
las I-Premise
que I-Premise
se I-Premise
completó I-Premise
el I-Premise
seguimiento I-Premise
con I-Premise
imágenes I-Premise
de I-Premise
RMN I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses, I-Premise
las I-Premise
tratadas I-Premise
con I-Premise
TAGM I-Premise
tenían I-Premise
una I-Premise
probabilidad I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
presentar I-Premise
una I-Premise
infartación I-Premise
completa I-Premise
de I-Premise
todos I-Premise
los I-Premise
leiomiomas I-Premise
( I-Premise
seis I-Premise
pacientes I-Premise
frente I-Premise
a I-Premise
una I-Premise
paciente; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
, I-Premise
tenían I-Premise
más I-Premise
probabilidades I-Premise
de I-Premise
presentar I-Premise
una I-Premise
infartación I-Premise
tumoral I-Premise
de I-Premise
al I-Premise
menos I-Premise
el I-Premise
90 I-Premise
% I-Premise
( I-Premise
ocho I-Premise
pacientes I-Premise
frente I-Premise
a I-Premise
cuatro I-Premise
pacientes; I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
y I-Premise
tenían I-Premise
un I-Premise
porcentaje I-Premise
medio I-Premise
menor I-Premise
de I-Premise
tejido I-Premise
tumoral I-Premise
fibroso I-Premise
residual I-Premise
perfundido I-Premise
( I-Premise
9,6 I-Premise
% I-Premise
frente I-Premise
a I-Premise
44,3 I-Premise
%; I-Premise
P I-Premise
= I-Premise
0,004 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
las I-Premise
pacientes I-Premise
tratadas I-Premise
con I-Premise
PVA I-Premise
. I-Premise

Basándose O
en O
estas O
diferencias O
entre O
los O
agentes O
embólicos O
, O
la O
inscripción O
en O
este O
estudio O
se O
dio O
por O
terminada O
. O

El B-Claim
uso I-Claim
de I-Claim
partículas I-Claim
esféricas I-Claim
de I-Claim
PVA I-Claim
en I-Claim
la I-Claim
forma I-Claim
descrita I-Claim
en I-Claim
el I-Claim
presente I-Claim
documento I-Claim
da I-Claim
lugar I-Claim
a I-Claim
una I-Claim
tasa I-Claim
inaceptablemente I-Claim
alta I-Claim
de I-Claim
infarto I-Claim
tumoral I-Claim
fallido I-Claim
en I-Claim
la I-Claim
EAU I-Claim
. I-Claim

Determinar O
la O
eficacia O
y O
seguridad O
de O
un O
régimen O
bisemanal O
de O
leucovorina O
( O
LV O
) O
más O
fluorouracilo O
( O
FU O
) O
solo O
o O
en O
combinación O
con O
cisplatino O
o O
irinotecán O
en O
pacientes O
con O
adenocarcinoma O
gástrico O
metastásico O
no O
tratado O
previamente O
y O
seleccionar O
el O
mejor O
brazo O
para O
un O
estudio O
de O
fase O
III O
. O

Ciento O
treinta O
y O
seis O
pacientes O
(dos O
no O
fueron O
elegibles) O
se O
inscribieron O
en O
el O
ensayo O
aleatorio O
multicéntrico O
de O
fase O
II. O

Los O
pacientes O
recibieron O
LV O
200 O
mg/m O
( O
2 O
) O
( O
infusión O
de O
2 O
horas O
) O
seguido O
de O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolo O
) O
y O
FU O
600 O
mg/m O
( O
2 O
) O
( O
infusión O
continua O
de O
22 O
horas O
) O
los O
días O
1 O
y O
2 O
cada O
14 O
días O
( O
LV5FU2 O
; O
brazo O
A O
) O
, O
LV5FU2 O
más O
cisplatino O
50 O
mg/m O
( O
2 O
) O
( O
infusión O
de O
1 O
hora O
) O
el O
día O
1 O
o O
2 O
( O
brazo O
B O
) O
, O
o O
LV5FU2 O
más O
irinotecán O
180 O
mg/m O
( O
2 O
) O
( O
infusión O
de O
2 O
horas O
) O
el O
día O
1 O
( O
brazo O
C O
) O
. O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
global I-Premise
, I-Premise
que I-Premise
fueron I-Premise
confirmadas I-Premise
por I-Premise
un I-Premise
panel I-Premise
de I-Premise
expertos I-Premise
independientes I-Premise
, I-Premise
fueron I-Premise
del I-Premise
13 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
3,4 I-Premise
% I-Premise
a I-Premise
23,3 I-Premise
% I-Premise
) I-Premise
, I-Premise
27 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
14,1 I-Premise
% I-Premise
a I-Premise
40,4 I-Premise
% I-Premise
) I-Premise
y I-Premise
40 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
25,7 I-Premise
% I-Premise
a I-Premise
54,3 I-Premise
% I-Premise
) I-Premise
para I-Premise
los I-Premise
brazos I-Premise
A I-Premise
, I-Premise
B I-Premise
y I-Premise
C I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
y I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
3,2 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
1,8 I-Premise
a I-Premise
4,6 I-Premise
meses I-Premise
) I-Premise
y I-Premise
6,8 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
2,6 I-Premise
a I-Premise
11,1 I-Premise
meses I-Premise
) I-Premise
con I-Premise
LV5FU2 I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
4,9 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
3,5 I-Premise
a I-Premise
6.3 I-Premise
meses I-Premise
) I-Premise
y I-Premise
9,5 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
6,9 I-Premise
a I-Premise
12,2 I-Premise
meses I-Premise
) I-Premise
con I-Premise
LV5FU2-cisplatino I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
y I-Premise
6,9 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
5,5 I-Premise
a I-Premise
8,3 I-Premise
meses I-Premise
) I-Premise
y I-Premise
11,3 I-Premise
meses I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
9,3 I-Premise
a I-Premise
13,3 I-Premise
meses I-Premise
) I-Premise
con I-Premise
LV5FU2-irinotecan I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

De B-Claim
los I-Claim
tres I-Claim
regímenes I-Claim
probados, I-Claim
la I-Claim
combinación I-Claim
de I-Claim
LV5FU2-irinotecan I-Claim
es I-Claim
la I-Claim
más I-Claim
prometedora I-Claim
y I-Claim
se I-Claim
evaluará I-Claim
en I-Claim
un I-Claim
ensayo I-Claim
de I-Claim
fase I-Claim
III. I-Claim

LV5FU2 O
con O
altas O
dosis O
de O
leucovorina O
( O
LV O
) O
, O
infusión O
semanal O
de O
5-fluorouracilo O
( O
5FU O
) O
( O
esquema O
AIO O
) O
y O
raltitrexed O
han O
demostrado O
ser O
agentes O
activos O
en O
el O
tratamiento O
de O
primera O
línea O
del O
cáncer O
colorrectal O
. O

Se O
realizó O
un O
ensayo O
aleatorio O
de O
4 O
brazos O
para O
comparar O
( O
1 O
) O
un O
bolo O
intravenoso O
de O
baja O
dosis O
de O
LV O
( O
20 O
mg/m2 O
) O
, O
seguido O
de O
un O
bolo O
intravenoso O
de O
5FU O
( O
400 O
mg/m2 O
) O
, O
seguido O
de O
una O
infusión O
continua O
de O
22 O
horas O
de O
5FU O
( O
600 O
mg/m2 O
) O
el O
día O
1 O
y O
el O
día O
2/2 O
semanas O
( O
brazo O
ldLV5FU2 O
) O
, O
( O
2 O
) O
una O
infusión O
continua O
semanal O
de O
alta O
dosis O
de O
5FU O
( O
2.6 O
g/m2/semana O
) O
durante O
6 O
semanas O
seguido O
de O
una O
semana O
de O
descanso O
( O
brazo O
HD-FU O
) O
y O
( O
3 O
) O
raltitrexed O
( O
brazo O
Tomudex O
; O
3 O
mg/m2/3 O
semanas O
) O
a O
LV5FU2 O
estándar. O

De O
1997 O
a O
2001, O
se O
incluyeron O
294 O
pacientes. O

Los O
4 O
brazos O
estaban O
bien O
equilibrados O
en O
cuanto O
a O
la O
proporción O
de O
sexos, O
la O
edad, O
el O
estado O
funcional O
de O
la O
OMS, O
la O
localización O
del O
tumor O
primario O
y O
la O
quimioterapia O
adyuvante O
previa. O

El O
tratamiento O
se O
detuvo O
debido O
a O
la O
baja O
acumulación O
. O

Se B-Premise
observaron I-Premise
dos I-Premise
muertes I-Premise
relacionadas I-Premise
con I-Premise
la I-Premise
toxicidad I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
Tomudex I-Premise
. I-Premise

Los B-Premise
tratamientos I-Premise
dieron I-Premise
lugar I-Premise
a I-Premise
diferentes I-Premise
tasas I-Premise
de I-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
( I-Premise
3 I-Premise
, I-Premise
4 I-Premise
, I-Premise
11 I-Premise
y I-Premise
14 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
en I-Premise
los I-Premise
brazos I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
y I-Premise
Tomudex I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
p I-Premise
= I-Premise
0,028 I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
y I-Premise
vómitos I-Premise
. I-Premise

Se B-Premise
observó I-Premise
al I-Premise
menos I-Premise
un I-Premise
episodio I-Premise
de I-Premise
toxicidad I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
en I-Premise
el I-Premise
27 I-Premise
, I-Premise
25 I-Premise
, I-Premise
38 I-Premise
y I-Premise
47 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
los I-Premise
brazos I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
y I-Premise
Tomudex I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
p I-Premise
= I-Premise
0,016 I-Premise
) I-Premise
. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
respuesta I-Premise
objetiva I-Premise
en I-Premise
el I-Premise
28, I-Premise
21, I-Premise
22 I-Premise
y I-Premise
10 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
los I-Premise
brazos I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
y I-Premise
Tomudex I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
p I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
(SLP) I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
de I-Premise
Tomudex I-Premise
fue I-Premise
estadísticamente I-Premise
inferior I-Premise
a I-Premise
la I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
LV5FU2 I-Premise
o I-Premise
ldLV5FU2 I-Premise
( I-Premise
grupo I-Premise
combinado I-Premise
; I-Premise
p I-Premise
= I-Premise
0,013 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

En B-Claim
conclusión, I-Claim
Tomudex I-Claim
es I-Claim
más I-Claim
tóxico I-Claim
y I-Claim
produce I-Claim
una I-Claim
SLP I-Claim
más I-Claim
corta I-Claim
que I-Claim
el I-Claim
5FU I-Claim
en I-Claim
infusión. I-Claim

A B-Claim
pesar I-Claim
del I-Claim
cierre I-Claim
prematuro I-Claim
del I-Claim
estudio I-Claim
y I-Claim
de I-Claim
la I-Claim
falta I-Claim
de I-Claim
potencia I-Claim
de I-Claim
la I-Claim
comparación, I-Claim
parece I-Claim
que I-Claim
ldLV5FU2 I-Claim
podría I-Claim
considerarse I-Claim
una I-Claim
opción I-Claim
activa, I-Claim
más I-Claim
fácil I-Claim
y I-Claim
menos I-Claim
costosa I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
colorrectal I-Claim
metastásico I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
LV5FU2 I-Claim
clásico I-Claim
o I-Claim
el I-Claim
HD-FU I-Claim
semanal. I-Claim

Comparar O
el O
resultado O
del O
tratamiento O
del O
cáncer O
de O
pulmón O
no O
microcítico O
N2 O
verificado O
por O
mediastinoscopia, O
tratado O
con O
quimioterapia O
de O
inducción O
seguida O
de O
cirugía O
o O
radioterapia O
( O
RT O
) O
, O
con O
ambas O
opciones O
seguidas O
de O
quimioterapia O
de O
consolidación O
. O

El O
Grupo O
de O
Oncología O
de O
Radioterapia O
( O
RTOG O
) O
y O
el O
Grupo O
de O
Oncología O
Cooperativa O
del O
Este O
realizaron O
un O
ensayo O
aleatorio O
de O
fase O
III O
para O
el O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
en O
estadio O
IIIA O
( O
T1-T3N2M0 O
) O
entre O
abril O
de O
1990 O
y O
abril O
de O
1994 O
. O

Tras O
la O
documentación O
de O
la O
enfermedad O
N2 O
mediante O
mediastinoscopia O
o O
mediastinotomía O
anterior, O
los O
pacientes O
recibieron O
quimioterapia O
de O
inducción O
con O
cisplatino, O
vinblastina O
y O
mitomicina-C. O
La O
mitomicina-C O
se O
eliminó O
posteriormente O
del O
régimen O
de O
inducción. O

A O
continuación, O
los O
pacientes O
fueron O
asignados O
al O
azar O
a O
la O
cirugía O
o O
a O
la O
RT O
( O
64 O
Gy O
en O
7 O
semanas O
) O
seguida O
de O
cisplatino O
y O
vinblastina O
. O

El O
RTOG O
89-01 O
reclutó O
a O
75 O
pacientes, O
de O
los O
cuales O
73 O
fueron O
elegibles O
y O
analizables. O

Doce O
pacientes O
recibieron O
quimioterapia O
de O
inducción, O
pero O
no O
fueron O
asignados O
al O
azar O
a O
la O
RT O
o O
a O
la O
cirugía. O

Cuarenta O
y O
cinco O
pacientes O
fueron O
asignados O
al O
azar O
a O
la O
RT O
postinducción O
o O
a O
la O
cirugía O
. O

De O
los O
pacientes O
analizables O
, O
el O
90 O
% O
tenía O
una O
puntuación O
de O
rendimiento O
de O
Karnofsky O
de O
90-100 O
, O
el O
18 O
% O
tenía O
una O
pérdida O
de O
peso O
> O
5 O
% O
, O
el O
37 O
% O
tenía O
características O
histológicas O
de O
células O
escamosas O
, O
y O
el O
54 O
% O
tenía O
enfermedad O
N2 O
voluminosa O
. O

La O
distribución O
de O
la O
enfermedad O
N2 O
voluminosa O
fue O
uniforme O
entre O
los O
brazos O
de O
tratamiento. O

La B-Premise
incidencia I-Premise
de I-Premise
toxicidad I-Premise
de I-Premise
grado I-Premise
4 I-Premise
fue I-Premise
del I-Premise
56% I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
mitomicina-C I-Premise
y I-Premise
del I-Premise
29% I-Premise
en I-Premise
los I-Premise
que I-Premise
no I-Premise
la I-Premise
recibieron. I-Premise

Sólo B-Premise
1 I-Premise
paciente I-Premise
de I-Premise
cada I-Premise
grupo I-Premise
tuvo I-Premise
una I-Premise
toxicidad I-Premise
aguda I-Premise
no I-Premise
hematológica I-Premise
superior I-Premise
al I-Premise
grado I-Premise
3 I-Premise
( I-Premise
náuseas I-Premise
y I-Premise
vómitos I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
desarrolló I-Premise
ninguna I-Premise
toxicidad I-Premise
aguda I-Premise
de I-Premise
grado I-Premise
4 I-Premise
por I-Premise
radiación. I-Premise

Las B-Premise
incidencias I-Premise
de I-Premise
toxicidad I-Premise
a I-Premise
largo I-Premise
plazo I-Premise
fueron I-Premise
equivalentes I-Premise
en I-Premise
todos I-Premise
los I-Premise
brazos. I-Premise

Se B-Premise
produjeron I-Premise
tres I-Premise
muertes I-Premise
relacionadas I-Premise
con I-Premise
el I-Premise
tratamiento: I-Premise
2 I-Premise
pacientes I-Premise
en I-Premise
los I-Premise
brazos I-Premise
quirúrgicos I-Premise
( I-Premise
una I-Premise
toxicidad I-Premise
pulmonar I-Premise
tardía I-Premise
y I-Premise
una I-Premise
embolia I-Premise
pulmonar I-Premise
) I-Premise
, I-Premise
y I-Premise
1 I-Premise
paciente I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
radiación I-Premise
( I-Premise
neumonitis I-Premise
por I-Premise
radiación I-Premise
) I-Premise
. I-Premise

La B-Premise
quimioterapia I-Premise
de I-Premise
inducción I-Premise
se I-Premise
completó I-Premise
en I-Premise
el I-Premise
78% I-Premise
de I-Premise
los I-Premise
pacientes. I-Premise

La B-Premise
resección I-Premise
completa I-Premise
se I-Premise
realizó I-Premise
en I-Premise
el I-Premise
73% I-Premise
de I-Premise
los I-Premise
26 I-Premise
pacientes I-Premise
sometidos I-Premise
a I-Premise
toracotomía I-Premise
. I-Premise

La B-Premise
quimioterapia I-Premise
de I-Premise
consolidación I-Premise
se I-Premise
completó I-Premise
en I-Premise
el I-Premise
75% I-Premise
de I-Premise
los I-Premise
pacientes. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
fue I-Premise
del I-Premise
53% I-Premise
a I-Premise
1 I-Premise
año I-Premise
y I-Premise
del I-Premise
17% I-Premise
a I-Premise
3 I-Premise
años. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
14 I-Premise
meses. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
( I-Premise
70 I-Premise
% I-Premise
frente I-Premise
a I-Premise
66 I-Premise
% I-Premise
) I-Premise
ni I-Premise
en I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
( I-Premise
19,4 I-Premise
frente I-Premise
a I-Premise
17,4 I-Premise
meses I-Premise
) I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
cirugía I-Premise
y I-Premise
RT I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
sólo I-Premise
recibieron I-Premise
quimioterapia I-Premise
de I-Premise
inducción I-Premise
fue I-Premise
de I-Premise
8,9 I-Premise
meses. I-Premise

La B-Premise
mitomicina-C I-Premise
no I-Premise
tuvo I-Premise
ningún I-Premise
impacto I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
( I-Premise
p I-Premise
= I-Premise
0,75 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
fracaso I-Premise
local I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
quirúrgicos I-Premise
y I-Premise
de I-Premise
RT I-Premise
. I-Premise

El B-Claim
número I-Claim
de I-Claim
pacientes I-Claim
que I-Claim
participaron I-Claim
en I-Claim
este I-Claim
ensayo I-Claim
hizo I-Claim
que I-Claim
sus I-Claim
resultados I-Claim
no I-Claim
fueran I-Claim
concluyentes, I-Claim
pero O
hay O
varias O
observaciones O
notables. O

En O
este O
ensayo, O
la B-Claim
confirmación I-Claim
histológica I-Claim
de I-Claim
la I-Claim
enfermedad I-Claim
N2 I-Claim
en I-Claim
los I-Claim
brazos I-Claim
quirúrgicos I-Claim
y I-Claim
no I-Claim
quirúrgicos I-Claim
eliminó I-Claim
los I-Claim
sesgos I-Claim
habituales I-Claim
de I-Claim
la I-Claim
estadificación I-Claim
clínica. I-Claim

En O
este O
contexto, O
el O
control B-Claim
local I-Claim
y I-Claim
la I-Claim
supervivencia I-Claim
fueron I-Claim
esencialmente I-Claim
iguales I-Claim
entre I-Claim
los I-Claim
brazos I-Claim
quirúrgicos I-Claim
y I-Claim
de I-Claim
RT. I-Claim

Las B-Claim
tasas I-Claim
de I-Claim
supervivencia I-Claim
a I-Claim
3 I-Claim
y I-Claim
5 I-Claim
años I-Claim
del I-Claim
tratamiento I-Claim
no I-Claim
quirúrgico I-Claim
fueron I-Claim
comparables I-Claim
a I-Claim
las I-Claim
de I-Claim
los I-Claim
ensayos I-Claim
quirúrgicos I-Claim
publicados I-Claim
sobre I-Claim
la I-Claim
enfermedad I-Claim
N2 I-Claim
. I-Claim

La B-Claim
amitriptilina I-Claim
es I-Claim
el I-Claim
adyuvante I-Claim
analgésico I-Claim
más I-Claim
comúnmente I-Claim
utilizado I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
con I-Claim
dolor I-Claim
neuropático I-Claim
, O
a O
pesar O
de O
que O
ningún B-Claim
estudio I-Claim
específico I-Claim
ha I-Claim
demostrado I-Claim
un I-Claim
beneficio I-Claim
. O

Se O
diseñó O
un O
estudio O
cruzado O
aleatorizado O
y O
controlado O
con O
placebo, O
a O
doble O
ciego, O
para O
evidenciar O
los O
efectos O
de O
la O
amitriptilina O
en O
pacientes O
con O
dolor O
neuropático O
por O
cáncer. O

Se O
admitieron O
en O
el O
estudio O
16 O
pacientes O
con O
cáncer O
avanzado O
con O
dolor O
neuropático O
en O
tratamiento O
con O
morfina O
sistémica, O
que O
ya O
no O
recibían O
tratamiento O
oncológico, O
que O
presentaban O
un O
dolor O
moderado O
(alrededor O
de O
4 O
o O
más, O
pero O
menos O
de O
7, O
en O
una O
escala O
numérica O
de O
0 O
a O
10) O
en O
la O
última O
semana, O
y O
a O
los O
que O
se O
había O
administrado O
una O
dosis O
estable O
de O
morfina O
en O
los O
últimos O
2 O
días. O

Durante O
la O
primera O
semana O
del O
estudio, O
los O
pacientes O
recibieron O
25 O
mg O
de O
amitriptilina O
o O
gotas O
equivalentes O
de O
placebo O
por O
la O
noche O
durante O
3 O
días O
y O
50 O
mg O
durante O
los O
4 O
días O
siguientes. O

Las O
dosis O
para O
los O
pacientes O
de O
más O
de O
65 O
años O
fueron O
de O
15 O
mg O
( O
primeros O
3 O
días O
) O
y O
30 O
mg O
( O
3 O
días O
después O
) O
. O

Después O
de O
una O
semana O
, O
se O
realizó O
un O
cruce O
para O
la O
segunda O
semana O
, O
con O
el O
otro O
tratamiento O
en O
una O
secuencia O
inversa O
. O

Se O
registraron O
el O
consumo O
de O
opiáceos, O
la O
intensidad O
del O
dolor, O
los O
síntomas O
y O
los O
efectos O
adversos, O
el O
estado O
de O
ánimo, O
el O
sueño, O
las O
preferencias O
del O
paciente O
y O
la O
calidad O
de O
vida O
antes O
de O
iniciar O
el O
estudio, O
la O
primera O
semana O
después O
y O
la O
segunda O
semana O
después. O

No B-Premise
se I-Premise
encontraron I-Premise
beneficios I-Premise
significativos I-Premise
en I-Premise
la I-Premise
analgesia I-Premise
en I-Premise
la I-Premise
intensidad I-Premise
global I-Premise
del I-Premise
dolor I-Premise
de I-Premise
la I-Premise
semana I-Premise
anterior I-Premise
de I-Premise
tratamiento I-Premise
, I-Premise
la I-Premise
menor I-Premise
intensidad I-Premise
del I-Premise
dolor I-Premise
o I-Premise
el I-Premise
dolor I-Premise
evaluado I-Premise
justo I-Premise
después I-Premise
de I-Premise
una I-Premise
semana I-Premise
de I-Premise
tratamiento I-Premise
, I-Premise
en I-Premise
el I-Premise
momento I-Premise
de I-Premise
la I-Premise
visita I-Premise
, I-Premise
cuando I-Premise
se I-Premise
comparó I-Premise
amitriptilina I-Premise
con I-Premise
placebo I-Premise
. I-Premise

Se B-Premise
evidenció I-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
para I-Premise
el I-Premise
peor I-Premise
dolor I-Premise
( I-Premise
P I-Premise
< I-Premise
0,035 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
en I-Premise
las I-Premise
dosis I-Premise
de I-Premise
opioides I-Premise
durante I-Premise
el I-Premise
periodo I-Premise
de I-Premise
estudio. I-Premise

La B-Premise
somnolencia, I-Premise
la I-Premise
confusión I-Premise
y I-Premise
la I-Premise
sequedad I-Premise
de I-Premise
boca I-Premise
fueron I-Premise
significativamente I-Premise
más I-Premise
intensas I-Premise
con I-Premise
la I-Premise
amitriptilina I-Premise
que I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0,036 I-Premise
, I-Premise
0,003 I-Premise
y I-Premise
0,034 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
sustanciales I-Premise
entre I-Premise
los I-Premise
dos I-Premise
tratamientos I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
de I-Premise
Spitzer I-Premise
y I-Premise
para I-Premise
cada I-Premise
ítem I-Premise
. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
preferencia I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
por I-Premise
los I-Premise
dos I-Premise
periodos I-Premise
de I-Premise
tratamiento. I-Premise

Los B-Claim
efectos I-Claim
analgésicos I-Claim
de I-Claim
la I-Claim
amitriptilina I-Claim
fueron I-Claim
leves I-Claim
y I-Claim
se I-Claim
asociaron I-Claim
a I-Claim
efectos I-Claim
adversos I-Claim
. I-Claim

A O
la O
luz O
de O
los O
resultados O
obtenidos O
en O
el O
estudio, O
debería B-Claim
cuestionarse I-Claim
el I-Claim
uso I-Claim
extensivo I-Claim
del I-Claim
fármaco I-Claim
para I-Claim
el I-Claim
dolor I-Claim
oncológico. I-Claim

La B-Claim
anemia, I-Claim
muy I-Claim
común I-Claim
entre I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer, I-Claim
es I-Claim
a I-Claim
menudo I-Claim
una I-Claim
causa I-Claim
subyacente I-Claim
de I-Claim
la I-Claim
fatiga I-Claim
relacionada I-Claim
con I-Claim
el I-Claim
cáncer I-Claim
y I-Claim
otros I-Claim
déficits I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
. I-Claim

Aunque O
los O
ensayos O
clínicos O
aleatorios O
han O
demostrado O
que O
el O
tratamiento O
con O
epoetina O
alfa O
aumenta O
los O
niveles O
de O
hemoglobina, O
reduce O
la O
fatiga, O
disminuye O
la O
necesidad O
de O
transfusiones O
y O
mejora O
la O
calidad O
de O
vida O
en O
general, O
la O
anemia O
y O
la O
fatiga O
relacionadas O
con O
el O
cáncer O
siguen O
estando O
infratratadas. O

Esto O
se O
debe, O
en O
parte, O
a O
que O
las O
escalas O
y O
las O
medidas O
de O
la O
calidad O
de O
vida O
siguen O
siendo O
relativamente O
desconocidas O
para O
la O
mayoría O
de O
los O
médicos O
y O
a O
que O
se O
carece O
de O
rangos O
de O
referencia O
basados O
en O
la O
población, O
lo O
que O
dificulta O
la O
interpretación O
de O
los O
resultados O
de O
los O
ensayos O
clínicos. O

Para O
ayudar O
a O
la O
interpretación O
de O
los O
resultados O
de O
la O
CdV O
de O
los O
ensayos O
clínicos O
, O
administramos O
el O
instrumento O
de O
CdV O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-Anemia O
( O
FACT-An O
) O
a O
una O
muestra O
representativa O
a O
nivel O
nacional O
de O
1.400 O
personas O
utilizando O
un O
panel O
de O
encuestas O
por O
Internet O
en O
los O
Estados O
Unidos O
. O

A O
continuación, O
se O
compararon O
los O
datos O
de O
FACT-An O
de O
la O
encuesta O
de O
Internet O
con O
los O
datos O
de O
calidad O
de O
vida O
de O
un O
ensayo O
clínico O
aleatorio O
y O
doble O
ciego O
de O
375 O
pacientes O
que O
evaluaba O
la O
epoetina O
alfa O
frente O
al O
placebo O
en O
pacientes O
anémicos O
con O
cáncer. O

La O
encuesta O
FACT-An, O
administrada O
a O
la O
población O
encuestada, O
mostró O
buenas O
propiedades O
psicométricas O
y O
fue O
capaz O
de O
discriminar O
entre O
los O
encuestados O
con O
antecedentes O
de O
enfermedades O
específicas, O
incluyendo O
anemia O
y O
cáncer, O
y O
los O
que O
no. O

La B-Premise
comparación I-Premise
de I-Premise
los I-Premise
datos I-Premise
de I-Premise
la I-Premise
norma I-Premise
poblacional I-Premise
y I-Premise
de I-Premise
los I-Premise
ensayos I-Premise
clínicos I-Premise
mostró I-Premise
que I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
epoetina I-Premise
alfa I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
mejoras I-Premise
clínicamente I-Premise
significativas, I-Premise
así I-Premise
como I-Premise
estadísticamente, I-Premise
en I-Premise
la I-Premise
CdV I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

Ahora O
se O
dispone O
de O
datos O
normativos O
poblacionales O
fiables O
que O
ayudan O
a O
interpretar O
los O
resultados O
de O
los O
ensayos O
clínicos O
en O
los O
que O
se O
administra O
el O
cuestionario O
FACT-An O
. O

En B-Claim
el I-Claim
ensayo I-Claim
clínico, I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
epoetina I-Claim
alfa I-Claim
superó I-Claim
gran I-Claim
parte I-Claim
del I-Claim
déficit I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
observado I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
anémicos I-Claim
con I-Claim
cáncer I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
muestra I-Claim
de I-Claim
población I-Claim
normal. I-Claim

Se O
llevó O
a O
cabo O
un O
ensayo O
multicéntrico O
para O
determinar O
la O
eficacia O
y O
la O
toxicidad O
de O
dosis O
crecientes O
de O
tretinoína O
liposomal O
(ácido O
todo-trans-retinoico) O
administrada O
una O
o O
tres O
veces O
por O
semana O
en O
pacientes O
con O
sarcoma O
de O
Kaposi O
asociado O
al O
síndrome O
de O
inmunodeficiencia O
adquirida O
(SIDA). O

Setenta O
y O
seis O
pacientes O
con O
sarcoma O
de O
Kaposi O
asociado O
al O
síndrome O
de O
inmunodeficiencia O
adquirida O
(SIDA) O
fueron O
aleatorizados O
para O
recibir O
el O
fármaco O
del O
estudio O
una O
vez O
( O
n O
= O
30 O
) O
o O
tres O
veces O
por O
semana O
( O
n O
= O
46 O
) O
. O

La O
dosis O
inicial O
fue O
de O
60 O
mg/m O
( O
2 O
) O
, O
que O
se O
escaló O
a O
90 O
mg/m O
( O
2 O
) O
y O
luego O
a O
120 O
mg/m O
( O
2 O
) O
si O
el O
fármaco O
era O
bien O
tolerado O
( O
< O
o= O
Grado O
2 O
de O
toxicidad O
[ O
según O
la O
escala O
de O
toxicidad O
del O
Southwest O
Oncology O
Group O
] O
) O
. O

Cuatro O
semanas O
de O
terapia O
constituyeron O
1 O
ciclo; O
los O
pacientes O
podían O
recibir O
hasta O
8 O
ciclos O
y O
a O
los O
que O
completaron O
8 O
ciclos O
se O
les O
dio O
la O
opción O
de O
recibir O
una O
terapia O
extendida O
. O

La O
respuesta O
clínica O
se O
definió O
como O
respuesta O
completa O
( O
CR O
) O
, O
respuesta O
parcial O
( O
PR O
) O
o O
enfermedad O
estable O
( O
SD O
) O
. O

La O
eficacia O
se O
evaluó O
tras O
la O
finalización O
de O
3 O
ciclos O
de O
tratamiento; O
el O
28,9% O
de O
los O
pacientes O
( O
22 O
de O
76 O
pacientes O
) O
respondieron O
( O
ninguna O
RC O
, O
1 O
RP O
y O
21 O
DS O
) O
. O

Entre B-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
tratamiento I-Premise
3 I-Premise
veces I-Premise
por I-Premise
semana I-Premise
, I-Premise
16 I-Premise
de I-Premise
49 I-Premise
pacientes I-Premise
( I-Premise
32,7 I-Premise
% I-Premise
) I-Premise
lograron I-Premise
una I-Premise
respuesta I-Premise
clínica I-Premise
al I-Premise
final I-Premise
del I-Premise
tercer I-Premise
ciclo I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
ninguna I-Premise
RC I-Premise
, I-Premise
1 I-Premise
RP I-Premise
y I-Premise
15 I-Premise
DS I-Premise
) I-Premise
. I-Premise

El B-Premise
uso I-Premise
concomitante I-Premise
o I-Premise
previo I-Premise
de I-Premise
inhibidores I-Premise
de I-Premise
la I-Premise
proteasa I-Premise
no I-Premise
pareció I-Premise
afectar I-Premise
a I-Premise
la I-Premise
respuesta I-Premise
del I-Premise
paciente I-Premise
al I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
= I-Premise
0,183 I-Premise
) I-Premise
. I-Premise

La B-Premise
tretinoína I-Premise
liposomal I-Premise
es I-Premise
un I-Premise
nuevo I-Premise
agente I-Premise
terapéutico I-Premise
del I-Premise
que I-Premise
se I-Premise
ha I-Premise
informado I-Premise
que I-Premise
tiene I-Premise
cierta I-Premise
actividad I-Premise
clínica I-Premise
en I-Premise
pacientes I-Premise
con I-Premise
sarcoma I-Premise
de I-Premise
Kaposi I-Premise
asociado I-Premise
al I-Premise
SIDA I-Premise
. I-Premise

Se B-Claim
observó I-Claim
que I-Claim
una I-Claim
pauta I-Claim
de I-Claim
dosificación I-Claim
de I-Claim
tres I-Claim
veces I-Claim
a I-Claim
la I-Claim
semana I-Claim
era I-Claim
más I-Claim
eficaz I-Claim
en I-Claim
comparación I-Claim
con I-Claim
una I-Claim
pauta I-Claim
de I-Claim
una I-Claim
vez I-Claim
a I-Claim
la I-Claim
semana, I-Claim
sin I-Claim
que I-Claim
se I-Claim
observaran I-Claim
diferencias I-Claim
significativas I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
toxicidad. I-Claim

Los O
síntomas O
gastrointestinales O
crónicos O
después O
de O
la O
radioterapia O
pélvica O
son O
frecuentes, O
tienen O
una O
causa O
multifactorial O
y O
afectan O
a O
la O
calidad O
de O
vida O
de O
los O
pacientes. O

Se O
evaluó O
si O
se O
podía O
ayudar O
a O
estos O
pacientes O
si O
un O
profesional O
seguía O
un O
algoritmo O
de O
investigación O
y O
tratamiento, O
y O
si O
los O
resultados O
diferían O
según O
si O
era O
una O
enfermera O
o O
un O
gastroenterólogo O
quien O
dirigía O
esta O
atención O
basada O
en O
el O
algoritmo. O

Para O
este O
ensayo O
controlado O
aleatorio O
de O
tres O
brazos O
se O
reclutaron O
pacientes O
( O
de O
edad O
≥18 O
años) O
de O
clínicas O
de O
Londres O
, O
Reino O
Unido, O
con O
síntomas O
gastrointestinales O
de O
nueva O
aparición O
que O
persisten O
6 O
meses O
después O
de O
la O
radioterapia O
pélvica O
. O

Mediante O
una O
secuencia O
de O
aleatorización O
generada O
por O
ordenador, O
se O
asignó O
aleatoriamente O
a O
los O
pacientes O
a O
uno O
de O
los O
tres O
grupos O
( O
1:1:1 O
; O
estratificado O
por O
la O
localización O
del O
tumor O
[ O
urológico, O
ginecológico O
o O
gastrointestinal O
], O
y O
el O
grado O
de O
disfunción O
intestinal O
[ O
puntuación O
IBDQ-B O
< O
60 O
frente O
a O
60-70 O
] O
) O
: O
atención O
habitual O
( O
un O
folleto O
de O
autoayuda O
detallado O
) O
, O
tratamiento O
basado O
en O
algoritmos O
dirigido O
por O
gastroenterólogos O
, O
o O
tratamiento O
basado O
en O
algoritmos O
dirigido O
por O
enfermeras O
. O

El O
criterio O
de O
valoración O
primario O
fue O
el O
cambio O
en O
la O
puntuación O
del O
subconjunto O
del O
Cuestionario O
de O
Enfermedad O
Inflamatoria O
Intestinal O
( O
IBDQ-B O
) O
a O
los O
6 O
meses O
, O
analizado O
por O
intención O
de O
tratar O
. O

Entre O
el O
26 O
de O
noviembre O
de O
2007 O
y O
el O
12 O
de O
diciembre O
de O
2011, O
se O
inscribieron O
y O
asignaron O
aleatoriamente O
218 O
pacientes O
al O
tratamiento: O
80 O
al O
grupo O
de O
enfermeras, O
70 O
al O
grupo O
de O
gastroenterólogos O
y O
68 O
al O
grupo O
de O
folletos O
( O
figura O
) O
. O

La O
mayoría O
tenía O
una O
puntuación O
inicial O
del O
IBDQ-B O
que O
indicaba O
síntomas O
de O
moderados O
a O
graves. O

Se B-Premise
registró I-Premise
la I-Premise
siguiente I-Premise
diferencia I-Premise
media I-Premise
por I-Premise
pares I-Premise
en I-Premise
el I-Premise
cambio I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
del I-Premise
IBDQ-B I-Premise
entre I-Premise
los I-Premise
grupos: I-Premise
enfermera I-Premise
frente I-Premise
a I-Premise
folleto I-Premise
4-12 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-04-8-19 I-Premise
; I-Premise
p=0-04 I-Premise
) I-Premise
, I-Premise
gastroenterólogo I-Premise
frente I-Premise
a I-Premise
folleto I-Premise
5-47 I-Premise
( I-Premise
1-14-9-81 I-Premise
; I-Premise
p=0-01 I-Premise
) I-Premise
. I-Premise

Los B-Premise
resultados I-Premise
del I-Premise
grupo I-Premise
de I-Premise
enfermeras I-Premise
no I-Premise
fueron I-Premise
inferiores I-Premise
a I-Premise
los I-Premise
del I-Premise
grupo I-Premise
de I-Premise
gastroenterólogos I-Premise
( I-Premise
diferencia I-Premise
de I-Premise
medias I-Premise
1-36 I-Premise
, I-Premise
IC I-Premise
95 I-Premise
% I-Premise
unilateral I-Premise
-1-48 I-Premise
) I-Premise
. I-Premise

Los B-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
una I-Claim
intervención I-Claim
dirigida I-Claim
siguiendo I-Claim
un I-Claim
algoritmo I-Claim
clínico I-Claim
detallado I-Claim
tuvieron I-Claim
mejores I-Claim
mejoras I-Claim
en I-Claim
los I-Claim
síntomas I-Claim
gastrointestinales I-Claim
inducidos I-Claim
por I-Claim
la I-Claim
radioterapia I-Claim
que I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
la I-Claim
atención I-Claim
habitual I-Claim
. I-Claim

Nuestros B-Claim
resultados I-Claim
sugieren I-Claim
que, I-Claim
para I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
pacientes, I-Claim
esta I-Claim
atención I-Claim
basada I-Claim
en I-Claim
algoritmos I-Claim
puede I-Claim
ser I-Claim
prestada I-Claim
por I-Claim
una I-Claim
enfermera I-Claim
capacitada. I-Claim

El O
propósito O
de O
este O
análisis O
fue O
evaluar O
el O
impacto O
de O
los O
factores O
previos O
al O
tratamiento O
en O
la O
calidad O
de O
vida O
( O
QOL O
) O
en O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
localmente O
avanzado O
( O
NSCLC O
) O
. O

En O
particular, O
este O
estudio O
se O
centró O
en O
la O
posible O
interacción O
entre O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
según O
el O
género O
y O
la O
puntuación O
de O
rendimiento O
de O
Karnofsky O
(KPS) O
en O
un O
ensayo O
prospectivo O
aleatorio O
sobre O
el O
cáncer O
de O
pulmón. O

La O
información O
sobre O
la O
calidad O
de O
vida, O
utilizando O
instrumentos O
validados O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
[ O
FACT-L O
] O
, O
versión O
2 O
, O
y O
Functional O
Living O
Index-Cancer O
[ O
FLIC O
] O
) O
se O
recogió O
de O
forma O
prospectiva O
en O
pacientes O
con O
CPNM O
localmente O
avanzado O
tratados O
en O
el O
ensayo O
89-01 O
del O
Grupo O
de O
Radioterapia O
Oncológica O
(RTOG). O

Entre O
abril O
de O
1990 O
y O
abril O
de O
1994 O
, O
70 O
pacientes O
elegibles O
participaron O
en O
un O
ensayo O
de O
fase O
III O
que O
comparaba O
un O
régimen O
que O
contenía O
quimioterapia O
secuencial O
y O
radioterapia O
frente O
a O
quimioterapia O
secuencial O
más O
cirugía O
. O

De O
estos O
70 O
pacientes, O
46 O
se O
sometieron O
a O
un O
tratamiento O
previo O
de O
FLIC O
y O
49 O
a O
un O
tratamiento O
previo O
de O
FACT-L. O

Hubo B-Premise
una I-Premise
interacción I-Premise
significativa I-Premise
entre I-Premise
el I-Premise
género I-Premise
y I-Premise
el I-Premise
KPS I-Premise
utilizando I-Premise
FLIC I-Premise
( I-Premise
P I-Premise
= I-Premise
0,009 I-Premise
) I-Premise
, I-Premise
que I-Premise
también I-Premise
mostró I-Premise
una I-Premise
tendencia I-Premise
hacia I-Premise
la I-Premise
significación I-Premise
con I-Premise
FACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0,09 I-Premise
) I-Premise
. I-Premise

Se B-Premise
observaron I-Premise
interacciones I-Premise
significativas I-Premise
de I-Premise
KPS I-Premise
por I-Premise
género I-Premise
para I-Premise
FACT-L I-Premise
en I-Premise
las I-Premise
subescalas I-Premise
de I-Premise
bienestar I-Premise
físico I-Premise
y I-Premise
preocupaciones I-Premise
adicionales-pulmón I-Premise
( I-Premise
P I-Premise
= I-Premise
0,012 I-Premise
y I-Premise
P I-Premise
= I-Premise
0,0003 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Los B-Premise
resultados I-Premise
tanto I-Premise
del I-Premise
FLIC I-Premise
como I-Premise
del I-Premise
FACT-L I-Premise
demostraron I-Premise
puntuaciones I-Premise
significativamente I-Premise
más I-Premise
bajas I-Premise
correspondientes I-Premise
a I-Premise
valores I-Premise
más I-Premise
bajos I-Premise
del I-Premise
KPS I-Premise
( I-Premise
P I-Premise
= I-Premise
0,009 I-Premise
y I-Premise
P I-Premise
= I-Premise
0,016 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Los B-Claim
resultados I-Claim
de I-Claim
este I-Claim
estudio I-Claim
aleatorio I-Claim
que I-Claim
incorpora I-Claim
mediciones I-Claim
prospectivas I-Claim
de I-Claim
la I-Claim
CdV I-Claim
sugieren I-Claim
que, I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
localmente I-Claim
avanzado, I-Claim
el I-Claim
análisis I-Claim
de I-Claim
los I-Claim
datos I-Claim
de I-Claim
la I-Claim
CdV I-Claim
según I-Claim
el I-Claim
sexo I-Claim
o I-Claim
el I-Claim
estado I-Claim
funcional I-Claim
por I-Claim
sí I-Claim
solos I-Claim
puede I-Claim
no I-Claim
reflejar I-Claim
con I-Claim
exactitud I-Claim
el I-Claim
modo I-Claim
en I-Claim
que I-Claim
estos I-Claim
factores I-Claim
dependen I-Claim
unos I-Claim
de I-Claim
otros. I-Claim

La O
comprensión O
de O
la O
interacción O
entre O
el O
género O
y O
el O
estado O
funcional O
podría O
conducir O
a O
mejores O
pronósticos O
y O
potencialmente O
podría O
adaptar O
las O
intervenciones O
para O
grupos O
específicos O
de O
pacientes O
con O
cáncer O
de O
pulmón O
. O

Este O
estudio O
pretendía O
evaluar O
la O
eficacia O
de O
la O
vacuna O
de O
células O
dendríticas O
autólogas O
( O
inmunoterapia O
) O
para O
el O
glioblastoma O
multiforme O
( O
GBM O
) O
. O

Se O
inscribieron O
pacientes O
de O
14 O
a O
70 O
años O
de O
edad O
con O
GBM O
recién O
diagnosticado O
y O
con O
una O
puntuación O
de O
la O
Escala O
de O
Rendimiento O
de O
Karnofsky O
( O
KPS O
) O
> O
70 O
que O
estaban O
recibiendo O
tratamiento O
inicial O
y O
fueron O
asignados O
al O
azar O
en O
2 O
grupos O
durante O
el O
período O
de O
estudio O
de O
5 O
años O
. O

Dieciocho O
pacientes O
fueron O
sometidos O
a O
tratamiento O
convencional O
( O
cirugía O
, O
radioterapia O
y O
quimioterapia O
) O
y O
recibieron O
la O
vacuna O
adyuvante O
de O
células O
dendríticas O
autólogas O
, O
y O
16 O
pacientes O
( O
grupo O
de O
control O
) O
fueron O
sometidos O
sólo O
a O
tratamiento O
convencional O
. O

La O
administración O
de O
la O
vacuna O
se O
inició O
entre O
1 O
y O
2 O
meses O
después O
de O
la O
operación, O
con O
10 O
inoculaciones O
en O
6 O
meses. O

Las O
medidas O
de O
resultado O
fueron O
la O
supervivencia O
global O
(SG), O
la O
supervivencia O
sin O
progresión O
(SLP), O
las O
tasas O
de O
supervivencia O
a O
1, O
2 O
y O
3 O
años O
y O
la O
calidad O
de O
vida O
(CV). O

El O
tiempo O
de O
seguimiento O
osciló O
entre O
14 O
y O
56 O
meses O
( O
mediana O
, O
33 O
meses O
) O
. O

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
1, I-Premise
2 I-Premise
y I-Premise
3 I-Premise
años I-Premise
fueron I-Premise
del I-Premise
88,9 I-Premise
%, I-Premise
44,4 I-Premise
% I-Premise
y I-Premise
16,7 I-Premise
% I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
vacuna, I-Premise
respectivamente, I-Premise
y I-Premise
del I-Premise
75,0 I-Premise
%, I-Premise
18,8 I-Premise
% I-Premise
y I-Premise
0 I-Premise
%, I-Premise
respectivamente, I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
( I-Premise
P I-Premise
= I-Premise
0,299 I-Premise
, I-Premise
0,0035 I-Premise
, I-Premise
0,0014 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SG I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
vacuna I-Premise
fue I-Premise
de I-Premise
31,9 I-Premise
meses I-Premise
y I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
fue I-Premise
de I-Premise
15,0 I-Premise
meses I-Premise
( I-Premise
P I-Premise
< I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
(SLP) I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
vacuna I-Premise
fue I-Premise
de I-Premise
8,5 I-Premise
meses, I-Premise
y I-Premise
de I-Premise
8,0 I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
( I-Premise
P I-Premise
= I-Premise
0,075 I-Premise
) I-Premise
. I-Premise

La B-Premise
fracción I-Premise
superviviente I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
vacuna I-Premise
según I-Premise
el I-Premise
análisis I-Premise
de I-Premise
Kaplan-Meier. I-Premise

La B-Claim
inmunoterapia I-Claim
adyuvante I-Claim
con I-Claim
una I-Claim
vacuna I-Claim
de I-Claim
células I-Claim
dendríticas I-Claim
lisadas I-Claim
de I-Claim
células I-Claim
enteras I-Claim
puede I-Claim
mejorar I-Claim
la I-Claim
supervivencia I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
. I-Claim

Parece B-Claim
ser I-Claim
seguro, I-Claim
y I-Claim
su I-Claim
eficacia I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
merece I-Claim
ser I-Claim
investigada. I-Claim

Los O
pacientes O
con O
cáncer O
se O
caracterizan O
por O
un O
profundo O
deterioro O
de O
la O
utilización O
de O
la O
glucosa O
, O
siendo O
los O
lípidos O
el O
combustible O
metabólico O
preferido O
. O

En O
cambio, O
las O
necesidades O
energéticas O
de O
los O
tumores O
malignos O
se O
cubren O
casi O
por O
completo O
con O
glucosa. O

Por O
lo O
tanto, O
estudiamos O
los O
efectos O
de O
una O
dieta O
alta O
en O
grasas, O
especialmente O
en O
la O
composición O
corporal. O

Veintitrés O
pacientes O
moderadamente O
desnutridos O
con O
carcinomas O
gastrointestinales O
fueron O
asignados O
al O
azar O
para O
recibir O
una O
dieta O
convencional O
con O
35 O
kcal O
no O
proteicas O
y O
1,1 O
g O
de O
proteína/kg O
por O
día O
( O
grupo O
A O
, O
n O
= O
11 O
) O
o O
una O
dieta O
líquida O
artificial O
enriquecida O
con O
grasa O
( O
20 O
kcal O
no O
proteicas/kg O
por O
día O
) O
más O
comidas O
normales O
( O
grupo O
B O
, O
n O
= O
12 O
) O
durante O
un O
período O
de O
ocho O
semanas O
, O
es O
decir, O
del O
primer O
al O
tercer O
ciclo O
de O
quimioterapia O
. O

El O
contenido O
de O
grasa O
de O
la O
dieta O
artificial O
era O
del O
66% O
de O
las O
calorías O
no O
proteicas. O

El O
día O
antes O
de O
las O
intervenciones O
nutricionales, O
y O
de O
nuevo O
después O
de O
cuatro O
y O
ocho O
semanas, O
se O
determinaron O
los O
compartimentos O
corporales O
mediante O
análisis O
de O
impedancia O
bioeléctrica, O
se O
cuantificaron O
las O
subpoblaciones O
de O
linfocitos O
mediante O
citometría O
de O
flujo O
y O
se O
calificaron O
algunos O
aspectos O
de O
la O
calidad O
de O
vida O
mediante O
cuatro O
escalas O
de O
autoevaluación O
analógica O
lineal O
( O
LASA O
). O

Los O
cálculos O
estadísticos O
se O
realizaron O
como O
un O
análisis O
exploratorio O
de O
datos. O

El O
consumo O
de O
calorías O
no O
proteicas O
no O
difirió O
significativamente O
entre O
los O
dos O
grupos O
de O
pacientes O
. O

Un B-Premise
aumento I-Premise
de I-Premise
peso I-Premise
medio I-Premise
en I-Premise
el I-Premise
grupo I-Premise
B I-Premise
contrastó I-Premise
con I-Premise
una I-Premise
pérdida I-Premise
de I-Premise
peso I-Premise
media I-Premise
en I-Premise
el I-Premise
grupo I-Premise
A I-Premise
después I-Premise
de I-Premise
cuatro I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
y I-Premise
ocho I-Premise
semanas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
masa I-Premise
libre I-Premise
de I-Premise
grasa I-Premise
mostró I-Premise
una I-Premise
diferencia I-Premise
intergrupal I-Premise
a I-Premise
favor I-Premise
del I-Premise
grupo I-Premise
B I-Premise
después I-Premise
de I-Premise
ocho I-Premise
semanas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
masa I-Premise
celular I-Premise
corporal I-Premise
se I-Premise
mantuvo I-Premise
durante I-Premise
todo I-Premise
el I-Premise
estudio I-Premise
en I-Premise
el I-Premise
grupo I-Premise
B I-Premise
, I-Premise
pero I-Premise
disminuyó I-Premise
significativamente I-Premise
hasta I-Premise
las I-Premise
semanas I-Premise
4 I-Premise
y I-Premise
8 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
A I-Premise
( I-Premise
diferencia I-Premise
entre I-Premise
grupos I-Premise
: I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
y I-Premise
0,01 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Se B-Premise
produjo I-Premise
una I-Premise
disminución I-Premise
del I-Premise
recuento I-Premise
total I-Premise
de I-Premise
linfocitos I-Premise
en I-Premise
559 I-Premise
células/mul I-Premise
con I-Premise
la I-Premise
dieta I-Premise
enriquecida I-Premise
en I-Premise
grasas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Varios B-Premise
aspectos I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fueron I-Premise
calificados I-Premise
como I-Premise
mejores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
B I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
A I-Premise
, O
aunque B-Premise
no I-Premise
todas I-Premise
las I-Premise
diferencias I-Premise
alcanzaron I-Premise
significación I-Premise
estadística I-Premise
. O

En B-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer, I-Claim
una I-Claim
dieta I-Claim
rica I-Claim
en I-Claim
grasas I-Claim
puede I-Claim
ayudar I-Claim
a I-Claim
mantener I-Claim
tanto I-Claim
el I-Claim
peso I-Claim
como I-Claim
la I-Claim
masa I-Claim
celular I-Claim
corporal. I-Claim

Sin B-Claim
embargo, I-Claim
es I-Claim
aconsejable I-Claim
controlar I-Claim
el I-Claim
recuento I-Claim
de I-Claim
linfocitos. I-Claim

Estudios O
anteriores O
han O
sugerido O
que O
la O
melatonina O
, O
una O
medicina O
integrativa O
de O
uso O
frecuente, O
puede O
atenuar O
la O
pérdida O
de O
peso, O
la O
anorexia O
y O
la O
fatiga O
en O
pacientes O
con O
cáncer. O

Estos O
estudios O
estaban O
limitados O
por O
la O
falta O
de O
cegamiento O
y O
la O
ausencia O
de O
controles O
con O
placebo. O

El O
objetivo O
principal O
de O
este O
estudio O
fue O
comparar O
la O
melatonina O
con O
el O
placebo O
para O
mejorar O
el O
apetito O
en O
pacientes O
con O
caquexia O
por O
cáncer. O

Se O
realizó O
un O
ensayo O
aleatorizado O
, O
doble O
ciego O
, O
de O
28 O
días O
de O
melatonina O
20 O
mg O
frente O
a O
placebo O
en O
pacientes O
con O
cáncer O
de O
pulmón O
o O
GI O
avanzado O
, O
puntuaciones O
de O
apetito O
≥ O
4 O
en O
una O
escala O
de O
0 O
a O
10 O
( O
10 O
= O
peor O
apetito O
) O
, O
y O
antecedentes O
de O
pérdida O
de O
peso O
≥ O
5 O
% O
. O

Las O
evaluaciones O
incluyeron O
el O
peso O
, O
los O
síntomas O
mediante O
la O
Escala O
de O
Evaluación O
de O
Síntomas O
de O
Edmonton O
, O
y O
la O
calidad O
de O
vida O
mediante O
el O
cuestionario O
de O
Evaluación O
Funcional O
de O
la O
Terapia O
de O
Anorexia/Cachexia O
( O
FAACT O
) O
. O

Las O
diferencias O
entre O
los O
grupos O
desde O
el O
inicio O
hasta O
el O
día O
28 O
se O
analizaron O
mediante O
pruebas O
t O
unilaterales O
de O
dos O
muestras O
o O
pruebas O
de O
Wilcoxon O
de O
dos O
muestras. O

El O
análisis O
intermedio O
a O
mitad O
del O
ensayo O
tenía O
un O
límite O
de O
seguimiento O
de O
Lan-DeMets O
con O
una O
regla O
de O
parada O
de O
O'Brien-Fleming O
. O

Los O
límites O
de O
decisión O
fueron O
aceptar O
la O
hipótesis O
nula O
de O
inutilidad O
si O
el O
estadístico O
de O
prueba O
z O
< O
0,39 O
( O
P O
≥ O
.348 O
) O
y O
rechazar O
la O
hipótesis O
nula O
si O
z O
> O
2,54 O
( O
P O
≤ O
.0056 O
) O
. O

Tras O
el O
análisis O
intermedio O
de O
48 O
pacientes, O
el O
estudio O
se O
cerró O
por O
inutilidad. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
cuanto I-Premise
al I-Premise
apetito I-Premise
( I-Premise
P I-Premise
= I-Premise
0,78 I-Premise
) I-Premise
u I-Premise
otros I-Premise
síntomas, I-Premise
el I-Premise
peso I-Premise
( I-Premise
P I-Premise
= I-Premise
0,17 I-Premise
), I-Premise
la I-Premise
puntuación I-Premise
FAACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0,95 I-Premise
), I-Premise
la I-Premise
toxicidad I-Premise
o I-Premise
la I-Premise
supervivencia I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
el I-Premise
día I-Premise
28 I-Premise
. I-Premise

En B-Claim
pacientes I-Claim
caquécticos I-Claim
con I-Claim
cáncer I-Claim
avanzado, I-Claim
la I-Claim
melatonina I-Claim
oral I-Claim
de I-Claim
20 I-Claim
mg I-Claim
por I-Claim
la I-Claim
noche I-Claim
no I-Claim
mejoró I-Claim
el I-Claim
apetito, I-Claim
el I-Claim
peso I-Claim
o I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
placebo. I-Claim

La O
progresión O
de O
la O
enfermedad O
neoplásica O
ginecológica O
se O
caracteriza O
por O
alteraciones O
específicas O
del O
metabolismo O
energético O
y O
por O
síntomas O
como O
la O
fatiga, O
la O
anorexia, O
las O
náuseas, O
la O
anemia O
y O
la O
inmunodepresión, O
que O
dan O
lugar O
a O
un O
síndrome O
de O
caquexia O
y O
a O
una O
marcada O
disminución O
de O
la O
calidad O
de O
vida O
( O
QoL O
) O
de O
la O
paciente. O

Los O
protocolos O
terapéuticos O
asociados O
a O
sistemas O
de O
apoyo O
psicológico O
y O
social O
adecuados O
y O
eficaces O
son O
esenciales O
para O
contrarrestar O
los O
síntomas O
de O
la O
enfermedad O
neoplásica O
en O
pacientes O
incurables O
. O

Se O
realizó O
un O
estudio O
aleatorio O
de O
fase O
III O
para O
establecer O
el O
tratamiento O
más O
eficaz O
y O
seguro O
para O
mejorar O
los O
síntomas O
clave O
en O
pacientes O
con O
cáncer O
ginecológico O
avanzado, O
es O
decir, O
la O
masa O
corporal O
magra O
( O
LBM O
) O
, O
el O
gasto O
energético O
en O
reposo O
( O
REE O
) O
, O
la O
fatiga O
y O
la O
calidad O
de O
vida O
. O

Además, O
se O
evaluó O
el O
impacto O
de O
los O
brazos O
de O
tratamiento O
en O
los O
principales O
parámetros O
metabólicos O
e O
inflamatorios, O
incluyendo O
la O
proteína O
C O
reactiva O
( O
CRP O
) O
, O
la O
interleucina O
( O
IL O
) O
-6 O
, O
el O
factor O
de O
necrosis O
tumoral O
( O
TNF O
) O
-α O
, O
la O
leptina O
, O
las O
especies O
reactivas O
del O
oxígeno O
( O
ROS O
) O
y O
la O
glutatión O
peroxidasa O
. O

También O
se O
evaluó O
el O
cambio O
en O
el O
Glasgow O
Prognostic O
Score O
( O
GPS O
) O
durante O
el O
tratamiento O
. O

Un O
total O
de O
104 O
pacientes O
con O
cáncer O
ginecológico O
en O
fase O
avanzada O
fueron O
inscritas O
y O
asignadas O
aleatoriamente O
a O
recibir O
acetato O
de O
megestrol O
( O
MA O
) O
más O
l-carnitina O
, O
celecoxib O
, O
y O
antioxidantes O
( O
brazo O
1 O
) O
o O
MA O
solo O
( O
brazo O
2 O
) O
. O

La O
duración O
del O
tratamiento O
fue O
de O
4 O
meses. O

El B-Premise
brazo I-Premise
combinado I-Premise
fue I-Premise
más I-Premise
eficaz I-Premise
que I-Premise
el I-Premise
brazo I-Premise
2 I-Premise
con I-Premise
respecto I-Premise
a I-Premise
LBM I-Premise
, I-Premise
REE I-Premise
, I-Premise
fatiga I-Premise
y I-Premise
QoL I-Premise
global I-Premise
. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
los I-Premise
criterios I-Premise
de I-Premise
valoración I-Premise
secundarios I-Premise
de I-Premise
la I-Premise
eficacia, I-Premise
el I-Premise
apetito I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
aumentó I-Premise
y I-Premise
la I-Premise
puntuación I-Premise
ECOG I-Premise
disminuyó I-Premise
significativamente I-Premise
en I-Premise
ambos I-Premise
brazos. I-Premise

Los B-Premise
parámetros I-Premise
de I-Premise
inflamación I-Premise
y I-Premise
estrés I-Premise
oxidativo I-Premise
IL-6 I-Premise
, I-Premise
TNF-α I-Premise
, I-Premise
CRP I-Premise
y I-Premise
ROS I-Premise
disminuyeron I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
brazo I-Premise
1 I-Premise
, I-Premise
mientras I-Premise
que I-Premise
no I-Premise
se I-Premise
observaron I-Premise
cambios I-Premise
significativos I-Premise
en I-Premise
el I-Premise
brazo I-Premise
2 I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
combinado I-Claim
mejoró I-Claim
tanto I-Claim
las I-Claim
alteraciones I-Claim
inmunometabólicas I-Claim
como I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes. I-Claim

Lo B-Claim
ideal I-Claim
es I-Claim
que I-Claim
las I-Claim
terapias I-Claim
multimodales I-Claim
para I-Claim
la I-Claim
caquexia I-Claim
se I-Claim
introduzcan I-Claim
en I-Claim
un I-Claim
contexto I-Claim
de I-Claim
"mejores I-Claim
cuidados I-Claim
de I-Claim
apoyo" I-Claim
que I-Claim
incluya I-Claim
un I-Claim
manejo I-Claim
óptimo I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
y I-Claim
un I-Claim
cuidadoso I-Claim
asesoramiento I-Claim
psicosocial. I-Claim

El O
objetivo O
de O
este O
estudio O
fue O
evaluar O
el O
pamidronato O
para O
el O
dolor O
óseo O
en O
un O
ensayo O
aleatorio O
doble O
ciego O
y O
evaluar O
la O
contribución O
de O
nuevos O
marcadores O
de O
resorción O
ósea O
en O
pacientes O
con O
metástasis O
óseas O
. O

Cincuenta O
y O
dos O
pacientes O
con O
metástasis O
óseas O
dolorosas O
fueron O
aleatorizados O
para O
recibir O
una O
infusión O
de O
dos O
horas O
de O
pamidronato O
120 O
mg O
o O
una O
infusión O
idéntica O
de O
solución O
salina O
. O

Cuatro O
semanas O
después, O
todos O
los O
pacientes O
recibieron O
pamidronato O
120 O
mg. O

Los O
marcadores O
de O
resorción O
ósea O
medidos O
incluyeron O
el O
calcio O
urinario O
( O
uCa O
) O
, O
la O
hidroxiprolina O
( O
Hyp O
) O
, O
y O
los O
productos O
de O
descomposición O
del O
colágeno O
: O
NTx O
, O
Crosslaps O
y O
Dpd O
libre O
. O

Se B-Premise
observó I-Premise
una I-Premise
respuesta I-Premise
sintomática I-Premise
durante I-Premise
las I-Premise
primeras I-Premise
cuatro I-Premise
semanas I-Premise
después I-Premise
del I-Premise
pamidronato I-Premise
, I-Premise
pero I-Premise
no I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
se I-Premise
mantuvo I-Premise
con I-Premise
pamidronato I-Premise
y I-Premise
se I-Premise
deterioró I-Premise
con I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Premise
marcadores I-Premise
de I-Premise
reabsorción I-Premise
no I-Premise
disminuyeron I-Premise
después I-Premise
del I-Premise
placebo, I-Premise
pero B-Premise
NTx I-Premise
y I-Premise
Crosslaps I-Premise
disminuyeron I-Premise
en I-Premise
un I-Premise
70% I-Premise
después I-Premise
del I-Premise
pamidronato I-Premise
( I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) O
. O

Una B-Premise
segunda I-Premise
infusión I-Premise
de I-Premise
pamidronato I-Premise
no I-Premise
redujo I-Premise
más I-Premise
la I-Premise
resorción, I-Premise
pero B-Premise
mantuvo I-Premise
la I-Premise
supresión I-Premise
de I-Premise
la I-Premise
resorción I-Premise
en I-Premise
niveles I-Premise
similares I-Premise
durante I-Premise
otras I-Premise
cuatro I-Premise
semanas. I-Premise

La B-Premise
respuesta I-Premise
sintomática I-Premise
al I-Premise
pamidronato I-Premise
se I-Premise
correlacionó I-Premise
estrechamente I-Premise
con I-Premise
la I-Premise
tasa I-Premise
de I-Premise
resorción I-Premise
ósea; I-Premise
fue B-Premise
más I-Premise
frecuente I-Premise
en I-Premise
aquellos I-Premise
pacientes I-Premise
con I-Premise
un I-Premise
valor I-Premise
inicial I-Premise
de I-Premise
NTx I-Premise
< I-Premise
2 I-Premise
veces I-Premise
el I-Premise
límite I-Premise
superior I-Premise
de I-Premise
la I-Premise
normalidad I-Premise
( I-Premise
17 I-Premise
de I-Premise
27 I-Premise
, I-Premise
62 I-Premise
% I-Premise
) I-Premise
y I-Premise
en I-Premise
aquellos I-Premise
en I-Premise
los I-Premise
que I-Premise
el I-Premise
nivel I-Premise
de I-Premise
Ntx I-Premise
volvió I-Premise
a I-Premise
la I-Premise
normalidad I-Premise
( I-Premise
19 I-Premise
de I-Premise
32 I-Premise
, I-Premise
59 I-Premise
% I-Premise
) I-Premise
, I-Premise
que I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
valores I-Premise
basales I-Premise
elevados I-Premise
de I-Premise
NTx I-Premise
( I-Premise
> I-Premise
2 I-Premise
veces I-Premise
el I-Premise
límite I-Premise
superior I-Premise
de I-Premise
la I-Premise
normalidad I-Premise
) I-Premise
o I-Premise
con I-Premise
niveles I-Premise
de I-Premise
Ntx I-Premise
que I-Premise
no I-Premise
se I-Premise
normalizaron I-Premise
para I-Premise
los I-Premise
que I-Premise
las I-Premise
frecuencias I-Premise
de I-Premise
respuesta I-Premise
fueron I-Premise
2 I-Premise
de I-Premise
16 I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
y I-Premise
0 I-Premise
de I-Premise
11 I-Premise
( O
0 O
% O
) O
, O
respectivamente O
. O

El B-Claim
beneficio I-Claim
subjetivo I-Claim
tras I-Claim
el I-Claim
pamidronato I-Claim
intravenoso I-Claim
se I-Claim
confirma I-Claim
en I-Claim
este I-Claim
estudio I-Claim
controlado I-Claim
con I-Claim
placebo I-Claim
. I-Claim

Los B-Claim
nuevos I-Claim
marcadores I-Claim
de I-Claim
resorción I-Claim
ósea I-Claim
de I-Claim
la I-Claim
descomposición I-Claim
del I-Claim
colágeno I-Claim
fueron I-Claim
capaces I-Claim
de I-Claim
predecir I-Claim
la I-Claim
respuesta I-Claim
clínica I-Claim
al I-Claim
pamidronato I-Claim
. I-Claim

Más O
del O
30% O
de O
los O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
( O
CPNM O
) O
desarrollan O
metástasis O
cerebrales O
. O

Si O
no O
se O
puede O
operar, O
los O
cuidados O
de O
apoyo O
óptimos O
(OSC), O
incluidos O
los O
esteroides, O
y O
la O
radioterapia O
de O
todo O
el O
cerebro O
(WBRT) O
se O
consideran O
generalmente O
como O
cuidados O
estándar, O
aunque O
no O
hay O
pruebas O
aleatorias O
que O
demuestren O
que O
la O
adición O
de O
WBRT O
a O
OSC O
mejore O
la O
supervivencia O
o O
la O
calidad O
de O
vida. O

QUARTZ O
es O
un O
ensayo O
aleatorio, O
de O
no O
inferioridad, O
de O
fase O
III O
que O
compara O
OSC O
+ O
WBRT O
frente O
a O
OSC O
en O
pacientes O
con O
metástasis O
cerebrales O
inoperables O
de O
CPNM. O

La O
medida O
de O
resultado O
principal O
son O
los O
años O
de O
vida O
ajustados O
a O
la O
calidad O
(AVAC). O

QUARTZ O
se O
vio O
amenazado O
por O
la O
pérdida O
de O
financiación O
y O
el O
cierre O
anticipado O
debido O
a O
la O
escasa O
acumulación O
de O
fondos. O

Se O
pensó O
que O
la O
falta O
de O
datos O
aleatorios O
preliminares O
que O
respaldaran O
las O
hipótesis O
del O
ensayo O
era O
la O
causa O
de O
la O
escasa O
adhesión, O
por O
lo O
que, O
sin O
conocer O
los O
datos, O
el O
comité O
directivo O
independiente O
del O
ensayo O
acordó O
la O
inusual O
medida O
de O
publicar O
los O
datos O
provisionales. O

Entre O
marzo O
de O
2007 O
y O
abril O
de O
2010, O
se O
aleatorizaron O
151 O
( O
de O
los O
534 O
previstos) O
pacientes O
( O
75 O
OSC O
+ O
WBRT O
, O
76 O
OSC O
) O
. O

Los O
datos O
demográficos O
de O
partida O
de O
los O
participantes O
incluían O
una O
mediana O
de O
edad O
de O
67 O
años O
( O
rango O
intercuartil O
62-73 O
) O
, O
un O
60% O
de O
hombres O
, O
un O
50% O
con O
un O
estado O
de O
rendimiento O
de O
Karnofsky O
< O
70 O
; O
el O
uso O
de O
esteroides O
fue O
similar O
en O
los O
dos O
grupos O
; O
64/75 O
( O
85% O
) O
recibieron O
WBRT O
( O
20 O
Gy O
en O
cinco O
fracciones O
) O
. O

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
: I-Premise
OSC I-Premise
+ I-Premise
WBRT I-Premise
49 I-Premise
días I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
39-61 I-Premise
) I-Premise
, I-Premise
OSC I-Premise
51 I-Premise
días I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
27-57 I-Premise
) I-Premise
- I-Premise
hazard I-Premise
ratio I-Premise
1,11 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
0,80-1,53 I-Premise
) I-Premise
a I-Premise
favor I-Premise
de I-Premise
WBRT I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
evaluada I-Premise
mediante I-Premise
el I-Premise
EQ-5D I-Premise
no I-Premise
mostró I-Premise
ninguna I-Premise
evidencia I-Premise
de I-Premise
diferencia I-Premise
. I-Premise

La B-Premise
media I-Premise
estimada I-Premise
de I-Premise
AVAC I-Premise
fue I-Premise
de I-Premise
: I-Premise
OSC I-Premise
+ I-Premise
WBRT I-Premise
31 I-Premise
días I-Premise
y I-Premise
OSC I-Premise
30 I-Premise
días I-Premise
, I-Premise
diferencia I-Premise
-1 I-Premise
día I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
-12,0 I-Premise
a I-Premise
+13,2 I-Premise
días I-Premise
) I-Premise
. I-Premise

Estos B-Claim
datos I-Claim
provisionales I-Claim
no I-Claim
indican I-Claim
ninguna I-Claim
evidencia I-Claim
temprana I-Claim
de I-Claim
detrimento I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
, I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
o I-Claim
los I-Claim
QALYs I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
asignados I-Claim
a I-Claim
OSC I-Claim
solo I-Claim
. I-Claim

Proporcionan O
información O
clave O
para O
discutir O
el O
ensayo O
con O
los O
pacientes O
y O
refuerzan O
el O
argumento O
para O
continuar O
con O
QUARTZ O
para O
responder O
definitivamente O
a O
esta O
importante O
pregunta O
clínica O
. O

El O
objetivo O
del O
estudio O
fue O
comparar O
los O
resultados O
clínicos O
y O
la O
calidad O
de O
vida O
de O
los O
pacientes O
sometidos O
a O
cirugía O
para O
la O
enfermedad O
pilonidal O
con O
procedimientos O
de O
desoperculación O
y O
marsupialización O
( O
UM O
) O
o O
de O
escisión O
romboidal O
y O
colgajo O
de O
Limberg O
( O
RELP O
) O
. O

Ciento O
cuarenta O
pacientes O
consecutivos O
con O
seno O
pilonidal O
fueron O
asignados O
al O
azar O
para O
recibir O
procedimientos O
de O
UM O
o O
RELP O
. O

Se O
administró O
un O
cuestionario O
específicamente O
diseñado O
a O
los O
tres O
meses O
para O
evaluar O
el O
tiempo O
transcurrido O
desde O
la O
operación O
hasta O
que O
el O
paciente O
fue O
capaz O
de O
caminar, O
volver O
a O
las O
actividades O
diarias O
o O
sentarse O
sin O
dolor, O
el O
tiempo O
para O
volver O
al O
trabajo O
o O
a O
la O
escuela O
y O
el O
tiempo O
de O
curación. O

El O
dolor O
postoperatorio O
se O
evaluó O
con O
una O
escala O
analógica O
visual O
y O
el O
Cuestionario O
del O
Dolor O
de O
McGill. O

La O
calidad O
de O
vida O
de O
los O
pacientes O
se O
evaluó O
con O
el O
Programa O
de O
Impacto O
de O
las O
Heridas O
de O
Cardiff O
(CWIS). O

Los O
cuestionarios O
fueron O
administrados O
por O
un O
clínico O
ciego O
al O
tratamiento. O

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
RELP I-Premise
, I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
UM I-Premise
tuvieron I-Premise
una I-Premise
duración I-Premise
significativamente I-Premise
menor I-Premise
de I-Premise
la I-Premise
operación I-Premise
y I-Premise
de I-Premise
la I-Premise
estancia I-Premise
en I-Premise
el I-Premise
hospital, I-Premise
períodos I-Premise
más I-Premise
cortos I-Premise
para I-Premise
caminar, I-Premise
volver I-Premise
a I-Premise
las I-Premise
actividades I-Premise
diarias I-Premise
o I-Premise
sentarse I-Premise
sin I-Premise
dolor I-Premise
y I-Premise
volver I-Premise
al I-Premise
trabajo I-Premise
o I-Premise
a I-Premise
la I-Premise
escuela, I-Premise
y I-Premise
menos I-Premise
complicaciones. I-Premise

El B-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
curación I-Premise
final I-Premise
fue I-Premise
significativamente I-Premise
más I-Premise
corto I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
en I-Premise
el I-Premise
CWIS I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
RELP I-Premise
que I-Premise
en I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
UM I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
UM I-Premise
tenían I-Premise
niveles I-Premise
de I-Premise
dolor I-Premise
más I-Premise
bajos I-Premise
una I-Premise
semana I-Premise
después I-Premise
de I-Premise
la I-Premise
cirugía. I-Premise

El B-Claim
procedimiento I-Claim
de I-Claim
desobstrucción I-Claim
y I-Claim
marsupialización I-Claim
proporciona I-Claim
más I-Claim
beneficios I-Claim
clínicos I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
la I-Claim
enfermedad I-Claim
pilonidal I-Claim
que I-Claim
la I-Claim
escisión I-Claim
romboidea I-Claim
y I-Claim
el I-Claim
colgajo I-Claim
de I-Claim
Limberg I-Claim
y I-Claim
debería I-Claim
considerarse I-Claim
el I-Claim
procedimiento I-Claim
de I-Claim
elección I-Claim
. I-Claim

Sin B-Claim
embargo, I-Claim
puede I-Claim
asociarse I-Claim
a I-Claim
más I-Claim
inconvenientes I-Claim
en I-Claim
el I-Claim
cuidado I-Claim
de I-Claim
la I-Claim
herida I-Claim
y I-Claim
a I-Claim
un I-Claim
mayor I-Claim
tiempo I-Claim
de I-Claim
curación I-Claim
que I-Claim
la I-Claim
escisión I-Claim
romboidal I-Claim
y I-Claim
el I-Claim
colgajo I-Claim
de I-Claim
Lindberg. I-Claim

El O
tratamiento O
de O
mantenimiento O
puede O
retrasar O
la O
progresión O
y O
prolongar O
la O
supervivencia O
en O
el O
cáncer O
de O
pulmón O
no O
microcítico O
metastásico O
( O
mNSCLC O
) O
. O

Dado O
que O
el O
tratamiento O
del O
CPNMm O
no O
es O
curativo, O
su O
impacto O
en O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
(CVRS) O
del O
paciente O
es O
una O
consideración O
importante. O

SATURN O
("Sequential O
Tarceva O
in O
Unresectable O
NSCLC") O
fue O
un O
estudio O
aleatorio, O
doble O
ciego, O
controlado O
con O
placebo O
y O
multicéntrico O
que O
investigó O
el O
impacto O
del O
tratamiento O
de O
mantenimiento O
con O
erlotinib O
en O
la O
CVRS O
de O
pacientes O
con O
CPNM O
localmente O
avanzado O
o O
recurrente. O

Los O
pacientes O
elegibles O
que O
habían O
completado O
previamente O
cuatro O
ciclos O
de O
quimioterapia O
basada O
en O
platino O
fueron O
aleatorizados O
1:1 O
para O
recibir O
erlotinib O
150 O
mg/día O
o O
placebo O
hasta O
la O
progresión O
de O
la O
enfermedad O
, O
toxicidad O
inaceptable O
o O
muerte O
. O

La O
CVRS O
de O
los O
pacientes O
se O
evaluó O
mediante O
el O
cuestionario O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
, O
en O
términos O
de O
tiempo O
hasta O
la O
progresión O
de O
los O
síntomas O
( O
TSP O
) O
, O
tiempo O
hasta O
el O
deterioro O
( O
TTD O
) O
en O
el O
Trial O
Outcome O
Index O
( O
TOI O
) O
y O
TTD O
. O

El O
análisis O
exploratorio O
se O
basó O
en O
el O
tiempo O
hasta O
la O
analgesia O
y O
la O
aparición O
de O
síntomas O
clave O
( O
dolor O
, O
tos O
y O
disnea O
) O
. O

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
placebo, I-Premise
el I-Premise
tratamiento I-Premise
de I-Premise
mantenimiento I-Premise
con I-Premise
erlotinib I-Premise
prolongó I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
en I-Premise
un I-Premise
41% I-Premise
y I-Premise
un I-Premise
23%, I-Premise
respectivamente. I-Premise

Al O
inicio, O
las O
medidas O
de O
CVRS O
eran O
comparables O
entre O
los O
dos O
grupos O
de O
tratamiento. O

El B-Premise
tratamiento I-Premise
de I-Premise
mantenimiento I-Premise
con I-Premise
erlotinib I-Premise
no I-Premise
repercutió I-Premise
en I-Premise
el I-Premise
deterioro I-Premise
de I-Premise
la I-Premise
CVRS I-Premise
: I-Premise
TSP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
=0,91 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
( I-Premise
CI I-Premise
) I-Premise
0,74-1,12 I-Premise
] I-Premise
; I-Premise
n=785 I-Premise
) I-Premise
, I-Premise
TTD I-Premise
en I-Premise
TOI I-Premise
( I-Premise
HR=1,06 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,87-1,31 I-Premise
] I-Premise
; I-Premise
n=781 I-Premise
) I-Premise
y I-Premise
TTD I-Premise
en I-Premise
CVRS I-Premise
( I-Premise
HR=0,96 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,79-1,16 I-Premise
] I-Premise
; I-Premise
n=776 I-Premise
) I-Premise
. I-Premise

El B-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
dolor I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
uso I-Premise
de I-Premise
analgésicos I-Premise
se I-Premise
retrasaron I-Premise
significativamente I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
erlotinib I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
HR=0,61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,42-0,88 I-Premise
] I-Premise
; I-Premise
p=0,0080 I-Premise
y I-Premise
HR=0,66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,46-0,94 I-Premise
] I-Premise
; I-Premise
p=0,0199 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

También B-Premise
se I-Premise
observó I-Premise
una I-Premise
tendencia I-Premise
no I-Premise
significativa I-Premise
a I-Premise
retrasar I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
tos I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
disnea I-Premise
( I-Premise
HR=0,77 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,49-1,21 I-Premise
] I-Premise
y I-Premise
HR=0,75 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,48-1,17 I-Premise
] I-Premise
, I-Premise
respectivamente I-Premise
). I-Premise

El B-Claim
tratamiento I-Claim
de I-Claim
mantenimiento I-Claim
con I-Claim
erlotinib I-Claim
prolonga I-Claim
significativamente I-Claim
la I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
sin I-Claim
comprometer I-Claim
la I-Claim
CVRS I-Claim
del I-Claim
paciente I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
placebo I-Claim
, I-Claim
con I-Claim
cierta I-Claim
mejora I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
. I-Claim

En O
el O
ensayo O
multinacional O
aleatorizado O
de O
fase O
II/III O
( O
V325 O
) O
de O
pacientes O
con O
cáncer O
gástrico O
avanzado O
no O
tratados, O
la O
parte O
de O
fase O
II O
seleccionó O
docetaxel O
, O
cisplatino O
y O
fluorouracilo O
( O
DCF O
) O
sobre O
docetaxel O
y O
cisplatino O
para O
compararlo O
con O
cisplatino O
y O
fluorouracilo O
( O
CF O
; O
régimen O
de O
referencia O
) O
en O
la O
parte O
de O
fase O
III O
. O

Los O
pacientes O
con O
cáncer O
gástrico O
avanzado O
fueron O
asignados O
aleatoriamente O
a O
docetaxel O
75 O
mg/m2 O
y O
cisplatino O
75 O
mg/m2 O
( O
día O
1 O
) O
más O
fluorouracilo O
750 O
mg/m2/d O
( O
días O
1 O
a O
5 O
) O
cada O
3 O
semanas O
o O
cisplatino O
100 O
mg/m2 O
( O
día O
1 O
) O
más O
fluorouracilo O
1.000 O
mg/m2/d O
( O
días O
1 O
a O
5 O
) O
cada O
4 O
semanas O
. O

El O
criterio O
de O
valoración O
principal O
fue O
el O
tiempo O
hasta O
la O
progresión O
( O
TTP O
) O
. O

En O
445 O
pacientes O
asignados O
al O
azar O
y O
tratados O
( O
DCF O
= O
221 O
; O
CF O
= O
224 O
) O
, O
el O
TTP O
fue O
más O
largo O
con O
DCF O
frente O
a O
CF O
( O
reducción O
del O
riesgo O
del O
32 O
% O
; O
log-rank O
P O
< O
.001 O
) O
. O

La B-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
mayor I-Premise
con I-Premise
el I-Premise
DCF I-Premise
frente I-Premise
a I-Premise
la I-Premise
CF I-Premise
( I-Premise
reducción I-Premise
del I-Premise
riesgo I-Premise
del I-Premise
23% I-Premise
; I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
los I-Premise
dos I-Premise
años I-Premise
fue I-Premise
del I-Premise
18% I-Premise
con I-Premise
la I-Premise
DCF I-Premise
y I-Premise
del I-Premise
9% I-Premise
con I-Premise
la I-Premise
CF I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
global I-Premise
fue I-Premise
mayor I-Premise
con I-Premise
el I-Premise
DCF I-Premise
( I-Premise
chi2 I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Se B-Premise
produjeron I-Premise
acontecimientos I-Premise
adversos I-Premise
de I-Premise
grado I-Premise
3 I-Premise
a I-Premise
4 I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
en I-Premise
el I-Premise
69% I-Premise
( I-Premise
DCF I-Premise
) I-Premise
frente I-Premise
al I-Premise
59% I-Premise
( I-Premise
CF I-Premise
) I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
. I-Premise

Las B-Premise
toxicidades I-Premise
de I-Premise
grado I-Premise
3 I-Premise
a I-Premise
4 I-Premise
más I-Premise
frecuentes I-Premise
para I-Premise
el I-Premise
DCF I-Premise
frente I-Premise
a I-Premise
la I-Premise
FC I-Premise
fueron: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
frente I-Premise
a I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
estomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
frente I-Premise
a I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrea I-Premise
( I-Premise
19 I-Premise
% I-Premise
frente I-Premise
a I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
letargo I-Premise
( I-Premise
19 I-Premise
% I-Premise
frente I-Premise
a I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Premise
neutropenia I-Premise
complicada I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
con I-Premise
la I-Premise
FCD I-Premise
que I-Premise
con I-Premise
la I-Premise
FQ I-Premise
( I-Premise
29 I-Premise
% I-Premise
frente I-Premise
a I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Claim
adición I-Claim
de I-Claim
docetaxel I-Claim
a I-Claim
la I-Claim
CF I-Claim
mejoró I-Claim
significativamente I-Claim
el I-Claim
TTP I-Claim
, I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
la I-Claim
tasa I-Claim
de I-Claim
respuesta I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
gástrico I-Claim
, I-Claim
pero I-Claim
dio I-Claim
lugar I-Claim
a I-Claim
un I-Claim
cierto I-Claim
aumento I-Claim
de I-Claim
la I-Claim
toxicidad I-Claim
. I-Claim

La B-Claim
incorporación I-Claim
de I-Claim
docetaxel I-Claim
, I-Claim
como I-Claim
en I-Claim
el I-Claim
DCF I-Claim
o I-Claim
con I-Claim
otro(s) I-Claim
fármaco(s) I-Claim
activo(s) I-Claim
, I-Claim
es I-Claim
una I-Claim
nueva I-Claim
opción I-Claim
terapéutica I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
gástrico I-Claim
avanzado I-Claim
no I-Claim
tratado I-Claim
. I-Claim

El B-Claim
tratamiento I-Claim
hormonal I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
aumenta I-Claim
los I-Claim
síntomas I-Claim
de I-Claim
la I-Claim
menopausia I-Claim
en I-Claim
las I-Claim
mujeres I-Claim
. I-Claim

Este O
estudio O
investigó O
las O
diferencias O
entre O
los O
síntomas O
asociados O
al O
tamoxifeno O
adyuvante O
o O
al O
exemestano O
. O

Se O
evaluaron O
diez O
síntomas O
comunes O
mediante O
un O
cuestionario O
de O
autoinforme O
administrado O
a O
1.614 O
pacientes O
consecutivas O
al O
inicio O
y O
cada O
3 O
meses O
durante O
el O
primer O
año O
de O
un O
ensayo O
aleatorio O
doble O
ciego O
de O
mujeres O
posmenopáusicas O
con O
cáncer O
de O
mama O
temprano O
con O
receptores O
hormonales O
positivos. O

Los O
síntomas O
se O
clasificaron O
como O
inexistentes, O
leves, O
moderados O
o O
graves. O

Se O
calculó O
una O
puntuación O
de O
sofocos O
en O
cada O
momento. O

Los O
síntomas O
se O
analizaron O
mediante O
un O
análisis O
de O
varianza O
con O
medidas O
repetidas. O

Cada O
período O
de O
tiempo O
se O
comparó O
repetidamente O
con O
la O
línea O
de O
base; O
se O
asignó O
un O
valor O
P O
global O
para O
cada O
síntoma O
notificado. O

El O
cumplimiento O
fue O
excelente, O
con O
7.286 O
cuestionarios O
analizados. O

La O
prevalencia O
de O
los O
síntomas O
iniciales O
osciló O
entre O
el O
2% O
( O
hemorragia O
vaginal O
) O
y O
el O
60-70% O
( O
dolores O
óseos/musculares O
y O
baja O
energía O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
el I-Premise
sangrado I-Premise
vaginal, I-Premise
la I-Premise
alteración I-Premise
del I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
o I-Premise
la I-Premise
baja I-Premise
energía. I-Premise

Las B-Premise
pacientes I-Premise
que I-Premise
recibían I-Premise
tamoxifeno I-Premise
tenían I-Premise
un I-Premise
flujo I-Premise
vaginal I-Premise
significativamente I-Premise
mayor I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Las B-Premise
pacientes I-Premise
con I-Premise
exemestano I-Premise
informaron I-Premise
de I-Premise
más I-Premise
dolores I-Premise
óseos/musculares I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
, I-Premise
sequedad I-Premise
vaginal I-Premise
( I-Premise
P I-Premise
= I-Premise
0,0004 I-Premise
) I-Premise
y I-Premise
dificultad I-Premise
para I-Premise
dormir I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
. I-Premise

En B-Premise
ambos I-Premise
grupos, I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
los I-Premise
sofocos I-Premise
alcanzó I-Premise
un I-Premise
máximo I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses I-Premise
y I-Premise
disminuyó I-Premise
a I-Premise
partir I-Premise
de I-Premise
entonces. I-Premise

A B-Premise
los I-Premise
12 I-Premise
meses, I-Premise
las I-Premise
pacientes I-Premise
que I-Premise
recibían I-Premise
tamoxifeno I-Premise
tenían I-Premise
una I-Premise
puntuación I-Premise
media I-Premise
de I-Premise
sofocos I-Premise
significativamente I-Premise
mayor I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
), I-Premise
con I-Premise
un I-Premise
aumento I-Premise
de I-Premise
los I-Premise
sofocos I-Premise
diarios I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
en I-Premise
un I-Premise
33 I-Premise
%, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
un I-Premise
aumento I-Premise
del I-Premise
7 I-Premise
% I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
con I-Premise
exemestano I-Premise
. I-Premise

A B-Premise
los I-Premise
12 I-Premise
meses, I-Premise
el I-Premise
exemestano I-Premise
se I-Premise
asoció I-Premise
con I-Premise
menos I-Premise
sofocos I-Premise
y I-Premise
menos I-Premise
flujo I-Premise
vaginal I-Premise
que I-Premise
el I-Premise
tamoxifeno, I-Premise
pero I-Premise
con I-Premise
más I-Premise
sequedad I-Premise
vaginal, I-Premise
dolores I-Premise
óseos/musculares I-Premise
y I-Premise
dificultad I-Premise
para I-Premise
dormir. I-Premise

Los B-Claim
síntomas I-Claim
fueron I-Claim
comunes I-Claim
en I-Claim
ambos I-Claim
grupos. I-Claim

El O
objetivo O
era O
determinar O
la O
eficacia O
de O
una O
intervención O
de O
educación O
y O
entrenamiento O
a O
medida O
(TEC) O
administrada O
por O
personas O
no O
profesionales O
(con O
el O
fin O
de O
reducir O
las O
ideas O
erróneas O
sobre O
el O
dolor O
y O
mejorar O
la O
autoeficacia O
para O
comunicarse O
con O
los O
médicos) O
sobre O
la O
gravedad O
del O
dolor O
del O
cáncer, O
el O
deterioro O
relacionado O
con O
el O
dolor O
y O
la O
calidad O
de O
vida. O

Los O
pacientes O
con O
cáncer O
con O
un O
"peor O
dolor" O
inicial O
de O
≥4 O
en O
una O
escala O
de O
0-10 O
o O
con O
un O
deterioro O
funcional O
al O
menos O
moderado O
debido O
al O
dolor O
fueron O
asignados O
aleatoriamente O
a O
TEC O
o O
a O
la O
atención O
habitual O
mejorada O
( O
EUC O
) O
durante O
una O
entrevista O
telefónica O
realizada O
antes O
de O
una O
visita O
programada O
a O
la O
consulta O
de O
oncología O
( O
265 O
pacientes O
aleatorizados O
a O
TEC O
o O
EUC O
; O
258 O
completaron O
al O
menos O
un O
seguimiento O
) O
. O

Los O
pacientes O
rellenaron O
cuestionarios O
antes O
y O
después O
de O
la O
visita O
y O
fueron O
entrevistados O
por O
teléfono O
a O
las O
2, O
6 O
y O
12 O
semanas. O

Se O
utilizaron O
regresiones O
de O
efectos O
mixtos O
para O
evaluar O
la O
intervención O
ajustándose O
a O
las O
características O
de O
los O
pacientes, O
la O
consulta O
y O
el O
centro. O

En B-Premise
comparación I-Premise
con I-Premise
la I-Premise
EUC, I-Premise
la I-Premise
TEC I-Premise
se I-Premise
asoció I-Premise
con I-Premise
un I-Premise
aumento I-Premise
de I-Premise
la I-Premise
autoeficacia I-Premise
en I-Premise
la I-Premise
comunicación I-Premise
del I-Premise
dolor I-Premise
después I-Premise
de I-Premise
la I-Premise
intervención I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
); O
ambos B-Premise
grupos I-Premise
mostraron I-Premise
reducciones I-Premise
significativas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
, I-Premise
similares, I-Premise
en I-Premise
los I-Premise
conceptos I-Premise
erróneos I-Premise
sobre I-Premise
el I-Premise
dolor I-Premise
. O

A B-Premise
las I-Premise
2 I-Premise
semanas, I-Premise
la I-Premise
asignación I-Premise
a I-Premise
la I-Premise
TEC I-Premise
se I-Premise
asoció I-Premise
con I-Premise
una I-Premise
mejora I-Premise
en I-Premise
el I-Premise
deterioro I-Premise
relacionado I-Premise
con I-Premise
el I-Premise
dolor I-Premise
( I-Premise
-0,25 I-Premise
puntos I-Premise
en I-Premise
una I-Premise
escala I-Premise
de I-Premise
5 I-Premise
puntos I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-0,43 I-Premise
a I-Premise
-0,06 I-Premise
, I-Premise
p=0,01 I-Premise
) O
pero B-Premise
no I-Premise
en I-Premise
la I-Premise
gravedad I-Premise
del I-Premise
dolor I-Premise
( I-Premise
-0,21 I-Premise
puntos I-Premise
en I-Premise
una I-Premise
escala I-Premise
de I-Premise
11 I-Premise
puntos I-Premise
, I-Premise
-0,60 I-Premise
a I-Premise
0,17 I-Premise
, I-Premise
p=0,27 I-Premise
) O
. O

La B-Premise
mejora I-Premise
del I-Premise
deterioro I-Premise
relacionado I-Premise
con I-Premise
el I-Premise
dolor I-Premise
no I-Premise
se I-Premise
mantuvo I-Premise
a I-Premise
las I-Premise
6 I-Premise
y I-Premise
12 I-Premise
semanas. I-Premise

No B-Premise
hubo I-Premise
interacciones I-Premise
significativas I-Premise
entre I-Premise
la I-Premise
intervención I-Premise
y I-Premise
el I-Premise
subgrupo I-Premise
( I-Premise
P I-Premise
> I-Premise
.10 I-Premise
) I-Premise
. I-Premise

Concluimos B-Claim
que I-Claim
la I-Claim
TEC I-Claim
, I-Claim
comparada I-Claim
con I-Claim
la I-Claim
EUC I-Claim
, I-Claim
dio I-Claim
lugar I-Claim
a I-Claim
una I-Claim
mejora I-Claim
de I-Claim
la I-Claim
autoeficacia I-Claim
en I-Claim
la I-Claim
comunicación I-Claim
del I-Claim
dolor I-Claim
y I-Claim
a I-Claim
una I-Claim
mejora I-Claim
temporal I-Claim
del I-Claim
deterioro I-Claim
relacionado I-Claim
con I-Claim
el I-Claim
dolor, I-Claim
pero I-Claim
no I-Claim
a I-Claim
una I-Claim
mejora I-Claim
de I-Claim
la I-Claim
gravedad I-Claim
del I-Claim
dolor I-Claim
. I-Claim

En B-Claim
ensayos I-Claim
de I-Claim
fase I-Claim
II, I-Claim
el I-Claim
paclitaxel I-Claim
ha I-Claim
demostrado I-Claim
tener I-Claim
actividad I-Claim
antitumoral I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
no I-Claim
microcítico I-Claim
avanzado I-Claim
(CPNM). I-Claim

Sin O
embargo, O
no O
se O
han O
evaluado O
en O
un O
ensayo O
clínico O
aleatorio O
los O
beneficios O
en O
cuanto O
a O
supervivencia O
y O
calidad O
de O
vida O
( O
QOL O
) O
del O
paclitaxel O
utilizado O
como O
agente O
único O
en O
comparación O
con O
los O
cuidados O
de O
apoyo O
solos. O

Un O
total O
de O
157 O
pacientes O
con O
CPNM O
en O
estadio O
IIIB O
o O
IV O
que O
no O
habían O
recibido O
quimioterapia O
previa O
fueron O
asignados O
aleatoriamente O
a O
recibir O
sólo O
los O
mejores O
cuidados O
de O
apoyo O
( O
78 O
pacientes O
) O
o O
paclitaxel O
más O
cuidados O
de O
apoyo O
( O
79 O
pacientes O
) O
. O

El O
paclitaxel O
se O
administró O
en O
infusión O
intravenosa O
de O
3 O
horas O
cada O
3 O
semanas. O

Los O
cuidados O
de O
apoyo O
incluyeron O
radioterapia O
paliativa O
y O
terapia O
de O
apoyo O
con O
corticosteroides O
, O
antibióticos O
, O
analgésicos O
, O
antieméticos O
, O
transfusiones O
y O
otra O
terapia O
sintomática O
según O
fuera O
necesario O
. O

El O
objetivo O
principal O
del O
estudio O
era O
la O
supervivencia. O

El O
tiempo O
hasta O
la O
progresión O
de O
la O
enfermedad, O
la O
tasa O
de O
respuesta, O
los O
acontecimientos O
adversos O
y O
la O
calidad O
de O
vida O
fueron O
puntos O
finales O
secundarios. O

Las O
características O
del O
pretratamiento O
se O
distribuyeron O
uniformemente O
entre O
los O
dos O
brazos. O

La B-Premise
supervivencia I-Premise
fue I-Premise
significativamente I-Premise
mejor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
paclitaxel I-Premise
más I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
que I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
solos I-Premise
( I-Premise
P I-Premise
= I-Premise
0,037 I-Premise
de I-Premise
dos I-Premise
caras I-Premise
) I-Premise
( I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
= I-Premise
6,8 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
4,8 I-Premise
meses I-Premise
) I-Premise
. I-Premise

El B-Premise
análisis I-Premise
multivariante I-Premise
de I-Premise
Cox I-Premise
mostró I-Premise
que I-Premise
el I-Premise
paclitaxel I-Premise
más I-Premise
los I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
se I-Premise
asociaban I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
con I-Premise
una I-Premise
mayor I-Premise
supervivencia I-Premise
( I-Premise
P I-Premise
de I-Premise
dos I-Premise
caras I-Premise
= I-Premise
0,048 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fue I-Premise
similar I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
de I-Premise
tratamiento, I-Premise
excepto B-Premise
en I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
actividad I-Premise
funcional I-Premise
de I-Premise
la I-Premise
lista I-Premise
de I-Premise
control I-Premise
de I-Premise
síntomas I-Premise
de I-Premise
Rotterdam, I-Premise
donde I-Premise
los I-Premise
datos I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
favorecieron I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
al I-Premise
brazo I-Premise
de I-Premise
paclitaxel I-Premise
más I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
( I-Premise
P I-Premise
de I-Premise
dos I-Premise
caras I-Premise
= I-Premise
0,043 I-Premise
). O

La B-Claim
adición I-Claim
de I-Claim
paclitaxel I-Claim
al I-Claim
mejor I-Claim
tratamiento I-Claim
de I-Claim
apoyo I-Claim
mejoró I-Claim
significativamente I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
el I-Claim
tiempo I-Claim
hasta I-Claim
la I-Claim
progresión I-Claim
de I-Claim
la I-Claim
enfermedad I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
mejor I-Claim
tratamiento I-Claim
de I-Claim
apoyo I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
avanzado I-Claim
y I-Claim
puede I-Claim
mejorar I-Claim
algunos I-Claim
aspectos I-Claim
de I-Claim
la I-Claim
CdV I-Claim
. I-Claim

El O
Grupo O
de O
Ensayos O
Clínicos O
CO.17 O
del O
Instituto O
Nacional O
del O
Cáncer O
de O
Canadá O
demostró O
que O
el O
anticuerpo O
monoclonal O
antireceptor O
del O
factor O
de O
crecimiento O
epidérmico O
(antiEGFR) O
cetuximab O
mejora O
la O
supervivencia O
global O
y O
libre O
de O
progresión O
en O
pacientes O
con O
cáncer O
colorrectal O
(CCR) O
avanzado O
y O
refractario O
a O
la O
quimioterapia, O
especialmente O
en O
pacientes O
con O
tumores O
KRAS O
de O
tipo O
salvaje. O

Este O
artículo O
informa O
de O
los O
resultados O
de O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
(CVRS) O
del O
CO.17 O
. O

Los O
pacientes O
( O
N O
= O
572 O
) O
con O
CCR O
avanzado O
pretratado O
y O
detectable O
por O
el O
EGFR O
fueron O
asignados O
aleatoriamente O
a O
cetuximab O
y O
al O
mejor O
tratamiento O
de O
apoyo O
( O
BSC O
) O
o O
al O
BSC O
solo O
. O

Los O
puntos O
finales O
primarios O
de O
CVRS O
evaluados O
por O
el O
EORTC O
QLQ-C30 O
fueron O
la O
función O
física O
( O
PF O
) O
y O
el O
estado O
de O
salud O
global O
( O
GHS O
) O
; O
se O
evaluaron O
los O
cambios O
medios O
desde O
el O
inicio O
hasta O
las O
8 O
y O
16 O
semanas O
. O

Se O
realizó O
un O
análisis O
post O
hoc O
según O
el O
estado O
de O
la O
mutación O
KRAS. O

El O
cumplimiento O
del O
cuestionario O
fue O
del O
94% O
al O
inicio, O
pero O
disminuyó O
de O
forma O
diferencial O
(67% O
frente O
al O
47% O
para O
cetuximab O
frente O
a O
BSC O
a O
las O
16 O
semanas). O

Las B-Premise
puntuaciones I-Premise
de I-Premise
cambio I-Premise
de I-Premise
la I-Premise
FP I-Premise
fueron I-Premise
de I-Premise
-3,9 I-Premise
para I-Premise
cetuximab I-Premise
y I-Premise
-8,6 I-Premise
para I-Premise
BSC I-Premise
( I-Premise
P I-Premise
= I-Premise
0,046 I-Premise
) I-Premise
a I-Premise
las I-Premise
8 I-Premise
semanas I-Premise
y I-Premise
fueron I-Premise
de I-Premise
-5,9 I-Premise
y I-Premise
-12,5 I-Premise
para I-Premise
cetuximab I-Premise
y I-Premise
BSC I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
0,027 I-Premise
) I-Premise
a I-Premise
las I-Premise
16 I-Premise
semanas I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
cambio I-Premise
de I-Premise
GHS I-Premise
fueron I-Premise
-0,5 I-Premise
y I-Premise
-7,1 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
) I-Premise
a I-Premise
las I-Premise
8 I-Premise
semanas I-Premise
y I-Premise
fueron I-Premise
-3,6 I-Premise
y I-Premise
-15,2 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
) I-Premise
a I-Premise
las I-Premise
16 I-Premise
semanas I-Premise
para I-Premise
cetuximab I-Premise
y I-Premise
BSC I-Premise
, I-Premise
respectivamente. I-Premise

En B-Premise
los I-Premise
pacientes I-Premise
que I-Premise
tenían I-Premise
tumores I-Premise
con I-Premise
estado I-Premise
KRAS I-Premise
de I-Premise
tipo I-Premise
salvaje, I-Premise
cetuximab I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
un I-Premise
menor I-Premise
deterioro I-Premise
de I-Premise
la I-Premise
FP I-Premise
a I-Premise
las I-Premise
8 I-Premise
semanas I-Premise
( I-Premise
-0,7 I-Premise
frente I-Premise
a I-Premise
-7,2 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,11 I-Premise
) I-Premise
y I-Premise
a I-Premise
las I-Premise
16 I-Premise
semanas I-Premise
( I-Premise
-3,4 I-Premise
frente I-Premise
a I-Premise
-13,8 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,008 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
BSC I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
con I-Premise
estatus I-Premise
de I-Premise
tipo I-Premise
salvaje I-Premise
que I-Premise
recibieron I-Premise
cetuximab I-Premise
experimentaron I-Premise
una I-Premise
mejora I-Premise
del I-Premise
SGA I-Premise
a I-Premise
las I-Premise
8 I-Premise
semanas I-Premise
, I-Premise
mientras I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
BSC I-Premise
solo I-Premise
se I-Premise
deterioraron I-Premise
( I-Premise
3,2 I-Premise
v I-Premise
-7,7 I-Premise
; I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

El B-Premise
cetuximab I-Premise
preservó I-Premise
el I-Premise
SGA I-Premise
a I-Premise
las I-Premise
16 I-Premise
semanas I-Premise
( I-Premise
-0,2 I-Premise
frente I-Premise
a I-Premise
-18,1 I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
del I-Premise
estudio I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
tumores I-Premise
KRAS I-Premise
mutados I-Premise
. I-Premise

Cetuximab B-Claim
ofrece I-Claim
importantes I-Claim
beneficios I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
CVRS I-Claim
y I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
pretratados I-Claim
con I-Claim
CCR I-Claim
avanzado I-Claim
de I-Claim
tipo I-Claim
salvaje. I-Claim

Evaluar O
el O
impacto O
del O
letrozol O
comparado O
con O
el O
placebo O
después O
del O
tamoxifeno O
adyuvante O
en O
la O
calidad O
de O
vida O
( O
QOL O
) O
en O
el O
ensayo O
MA.17 O
. O

Las O
pacientes O
completaron O
el O
Short O
Form O
36-item O
Health O
Survey O
( O
SF-36 O
) O
y O
el O
Menopause O
Specific O
Quality O
of O
Life O
Questionnaire O
( O
MENQOL O
) O
al O
inicio, O
a O
los O
6 O
meses O
y O
anualmente. O

Se O
compararon O
las O
puntuaciones O
medias O
de O
cambio O
desde O
el O
inicio O
del O
estudio O
entre O
los O
grupos O
para O
las O
medidas O
de O
resumen O
y O
los O
dominios. O

Un O
análisis O
de O
respuesta O
comparó O
la O
proporción O
de O
pacientes O
que O
demostraron O
un O
cambio O
importante O
en O
la O
CdV O
. O

De O
las O
5.187 O
mujeres O
asignadas O
al O
azar O
en O
el O
ensayo, O
3.612 O
( O
69,9 O
% O
) O
participaron O
en O
el O
subestudio O
de O
calidad O
de O
vida: O
1.799 O
fueron O
asignadas O
a O
placebo O
y O
1.813 O
a O
letrozol. O

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
medias I-Premise
de I-Premise
cambio I-Premise
con I-Premise
respecto I-Premise
al I-Premise
inicio I-Premise
para I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
resumen I-Premise
de I-Premise
los I-Premise
componentes I-Premise
físicos I-Premise
y I-Premise
mentales I-Premise
del I-Premise
SF-36 I-Premise
a I-Premise
los I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
24 I-Premise
y I-Premise
36 I-Premise
meses I-Premise
. I-Premise

Se B-Premise
observaron I-Premise
diferencias I-Premise
pequeñas I-Premise
( I-Premise
< I-Premise
0,2 I-Premise
desviaciones I-Premise
estándar I-Premise
) I-Premise
pero I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
medias I-Premise
de I-Premise
cambio I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
para I-Premise
los I-Premise
dominios I-Premise
SF-36 I-Premise
de I-Premise
funcionamiento I-Premise
físico I-Premise
( I-Premise
12 I-Premise
meses I-Premise
) I-Premise
, I-Premise
dolor I-Premise
corporal I-Premise
( I-Premise
6 I-Premise
meses I-Premise
) I-Premise
y I-Premise
vitalidad I-Premise
( I-Premise
6 I-Premise
y I-Premise
12 I-Premise
meses I-Premise
) I-Premise
, I-Premise
y I-Premise
los I-Premise
dominios I-Premise
MENQOL I-Premise
vasomotor I-Premise
( I-Premise
6 I-Premise
, I-Premise
12 I-Premise
y I-Premise
24 I-Premise
meses I-Premise
) I-Premise
y I-Premise
sexual I-Premise
( I-Premise
12 I-Premise
y I-Premise
24 I-Premise
meses I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
análisis I-Premise
de I-Premise
la I-Premise
respuesta, I-Premise
se I-Premise
observó I-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
el I-Premise
ámbito I-Premise
del I-Premise
dolor I-Premise
corporal I-Premise
(porcentaje I-Premise
de I-Premise
pacientes I-Premise
que I-Premise
informaron I-Premise
de I-Premise
un I-Premise
empeoramiento I-Premise
de I-Premise
la I-Premise
CdV, I-Premise
47 I-Premise
% I-Premise
de I-Premise
placebo I-Premise
frente I-Premise
a I-Premise
51 I-Premise
% I-Premise
de I-Premise
letrozol; I-Premise
p I-Premise
= I-Premise
0,009) I-Premise
y I-Premise
en I-Premise
el I-Premise
ámbito I-Premise
vasomotor I-Premise
(22 I-Premise
% I-Premise
de I-Premise
placebo I-Premise
frente I-Premise
a I-Premise
29 I-Premise
% I-Premise
de I-Premise
letrozol; I-Premise
p I-Premise
= I-Premise
0,001). I-Premise

El B-Claim
letrozol I-Claim
no I-Claim
tuvo I-Claim
un I-Claim
impacto I-Claim
adverso I-Claim
en I-Claim
la I-Claim
CdV I-Claim
general. I-Claim

Se B-Claim
observaron I-Claim
pequeños I-Claim
efectos I-Claim
en I-Claim
algunos I-Claim
dominios, I-Claim
consistentes I-Claim
con I-Claim
una I-Claim
minoría I-Claim
de I-Claim
pacientes I-Claim
que I-Claim
experimentaron I-Claim
cambios I-Claim
en I-Claim
la I-Claim
CdV I-Claim
compatibles I-Claim
con I-Claim
una I-Claim
reducción I-Claim
de I-Claim
la I-Claim
síntesis I-Claim
de I-Claim
estrógenos I-Claim
. I-Claim

La B-Claim
combinación I-Claim
de I-Claim
interferón I-Claim
alfa I-Claim
( I-Claim
IFNalpha I-Claim
) I-Claim
e I-Claim
isotretinoína I-Claim
ha I-Claim
demostrado I-Claim
un I-Claim
efecto I-Claim
antiproliferativo I-Claim
directo I-Claim
sobre I-Claim
las I-Claim
líneas I-Claim
celulares I-Claim
de I-Claim
melanoma I-Claim
humano I-Claim
, O
pero B-Claim
seguía I-Claim
sin I-Claim
estar I-Claim
claro I-Claim
si I-Claim
esta I-Claim
combinación I-Claim
es I-Claim
más I-Claim
eficaz I-Claim
que I-Claim
el I-Claim
IFNalpha I-Claim
solo I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
melanoma I-Claim
metastásico I-Claim
. O

Se O
evaluó O
la O
seguridad O
y O
la O
eficacia O
de O
IFNalpha O
e O
isotretinoína O
en O
comparación O
con O
IFNalpha O
solo O
como O
tratamiento O
adyuvante O
en O
pacientes O
con O
melanoma O
maligno O
primario O
en O
estadio O
IIA O
y O
IIB O
. O

En O
un O
ensayo O
prospectivo, O
aleatorio, O
doble O
ciego O
y O
controlado O
con O
placebo, O
407 O
pacientes O
con O
melanoma O
en O
estadio O
IIA O
( O
301 O
pacientes O
) O
y O
IIB O
( O
106 O
pacientes O
) O
fueron O
asignados O
aleatoriamente O
a O
IFNalpha O
e O
isotretinoína O
( O
grupo O
de O
isotretinoína O
; O
206 O
pacientes O
) O
o O
a O
IFNalpha O
y O
placebo O
( O
grupo O
de O
placebo O
; O
201 O
pacientes O
) O
tras O
la O
escisión O
del O
tumor O
primario O
. O

Se O
administró O
IFNalpha O
tres O
veces O
por O
semana O
a O
una O
dosis O
de O
3 O
millones O
de O
unidades O
por O
vía O
subcutánea O
durante O
24 O
meses. O

Isotretinoína O
a O
una O
dosis O
de O
20 O
mg O
para O
pacientes O
< O
o O
= O
73 O
kg O
, O
30 O
mg O
para O
pacientes O
de O
más O
de O
73 O
kg O
, O
o O
placebo O
diariamente O
durante O
24 O
meses O
. O

Un B-Premise
análisis I-Premise
intermedio I-Premise
programado I-Premise
no I-Premise
reveló I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
las I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
, I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
isotretinoína I-Premise
y I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
mostrando I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
enfermedad I-Premise
a I-Premise
5 I-Premise
años I-Premise
del I-Premise
55 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
46 I-Premise
% I-Premise
a I-Premise
65 I-Premise
% I-Premise
) I-Premise
y I-Premise
67 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
59 I-Premise
% I-Premise
a I-Premise
75 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
y I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
a I-Premise
5 I-Premise
años I-Premise
del I-Premise
76 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
67 I-Premise
% I-Premise
a I-Premise
84 I-Premise
% I-Premise
) I-Premise
y I-Premise
81 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
74 I-Premise
% I-Premise
a I-Premise
88 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

El O
juicio O
se O
detuvo O
por O
inutilidad. O

La B-Claim
adición I-Claim
de I-Claim
isotretinoína I-Claim
a I-Claim
un I-Claim
tratamiento I-Claim
adyuvante I-Claim
de I-Claim
dosis I-Claim
bajas I-Claim
de I-Claim
IFNalpha I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
melanoma I-Claim
en I-Claim
estadios I-Claim
IIA I-Claim
y I-Claim
IIB I-Claim
no I-Claim
tuvo I-Claim
un I-Claim
efecto I-Claim
significativo I-Claim
sobre I-Claim
la I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
enfermedad I-Claim
o I-Claim
global I-Claim
y, I-Claim
por I-Claim
tanto, I-Claim
no I-Claim
se I-Claim
recomienda. I-Claim

Un O
ensayo O
controlado O
aleatorio O
de O
radioterapia O
sola O
frente O
a O
radioterapia O
con O
temozolomida O
concomitante O
y O
adyuvante O
para O
pacientes O
con O
glioblastoma O
mostró O
que O
la O
supervivencia O
era O
mayor O
para O
los O
pacientes O
asignados O
al O
tratamiento O
combinado O
en O
comparación O
con O
los O
asignados O
a O
la O
radioterapia O
estándar O
sola O
. O

Este O
artículo O
informa O
sobre O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
de O
los O
pacientes O
de O
este O
ensayo O
. O

573 O
pacientes O
con O
glioblastoma O
recién O
diagnosticado O
fueron O
asignados O
aleatoriamente O
a O
radioterapia O
sola O
o O
a O
radioterapia O
y O
temozolomida O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia, O
y O
la O
CVRS O
fue O
un O
criterio O
de O
valoración O
secundario. O

Se O
evaluó O
la O
CVRS O
al O
inicio O
y O
cada O
3 O
meses O
durante O
el O
tratamiento O
hasta O
la O
progresión, O
utilizando O
el O
cuestionario O
de O
calidad O
de O
vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
core-30 O
( O
QLQ-C30 O
) O
y O
el O
módulo O
de O
cáncer O
cerebral O
de O
la O
EORTC O
( O
EORTC O
BN-20 O
) O
. O

Se O
calcularon O
los O
cambios O
con O
respecto O
a O
la O
puntuación O
inicial O
para O
siete O
medidas O
predefinidas O
de O
CVRS O
( O
fatiga O
, O
salud O
general O
, O
función O
social O
, O
función O
emocional O
, O
incertidumbre O
futura O
, O
insomnio O
y O
déficit O
de O
comunicación O
) O
y O
las O
diferencias O
entre O
grupos O
para O
estas O
medidas O
en O
cada O
punto O
temporal O
. O

Se O
registraron O
la O
importancia O
de O
, O
y O
las O
proporciones O
de O
pacientes O
con O
, O
las O
puntuaciones O
de O
mejora O
de O
la O
CVRS, O
definidas O
como O
un O
cambio O
de O
10 O
puntos O
o O
más. O

Se O
disponía O
de O
cuestionarios O
de O
referencia O
para O
490 O
( O
86% O
) O
pacientes. O

Las O
puntuaciones O
iniciales O
de O
la O
CVRS O
no O
difieren O
entre O
los O
grupos. O

En B-Premise
el I-Premise
primer I-Premise
seguimiento, I-Premise
los I-Premise
grupos I-Premise
sólo I-Premise
diferían I-Premise
en I-Premise
el I-Premise
funcionamiento I-Premise
social, I-Premise
favoreciendo I-Premise
al I-Premise
grupo I-Premise
de I-Premise
sólo I-Premise
radioterapia I-Premise
( I-Premise
puntuación I-Premise
media I-Premise
de I-Premise
79,0 I-Premise
[ I-Premise
SD I-Premise
3,2 I-Premise
] I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
a I-Premise
la I-Premise
radioterapia I-Premise
frente I-Premise
a I-Premise
67,4 I-Premise
[ I-Premise
2,7 I-Premise
] I-Premise
para I-Premise
los I-Premise
asignados I-Premise
a I-Premise
la I-Premise
radioterapia I-Premise
y I-Premise
la I-Premise
temozolomida; I-Premise
diferencia I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
11,6 I-Premise
puntos I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3,5-19,7 I-Premise
] I-Premise
, I-Premise
p=0,0052 I-Premise
) I-Premise
. I-Premise

En B-Premise
las I-Premise
evaluaciones I-Premise
posteriores, I-Premise
la I-Premise
CVRS I-Premise
fue I-Premise
muy I-Premise
similar I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento. I-Premise

La B-Claim
adición I-Claim
de I-Claim
temozolomida I-Claim
durante I-Claim
y I-Claim
después I-Claim
de I-Claim
la I-Claim
radioterapia I-Claim
para I-Claim
pacientes I-Claim
con I-Claim
glioblastoma I-Claim
recién I-Claim
diagnosticado I-Claim
mejoró I-Claim
significativamente I-Claim
la I-Claim
supervivencia I-Claim
sin I-Claim
un I-Claim
efecto I-Claim
negativo I-Claim
en I-Claim
la I-Claim
CVRS I-Claim
. I-Claim

Determinar O
la O
viabilidad O
de O
la O
administración O
de O
un O
tratamiento O
complementario O
rico O
en O
flavonoides O
(zumo O
de O
uva O
Concord) O
para O
el O
tratamiento O
de O
las O
náuseas O
y O
los O
vómitos O
inducidos O
por O
la O
quimioterapia O
(NIV); O
evaluar O
la O
utilidad O
de O
las O
medidas O
existentes O
para O
evaluar O
la O
frecuencia O
y O
la O
gravedad O
de O
las O
NIV, O
la O
calidad O
de O
vida, O
el O
control O
de O
los O
acontecimientos O
vitales O
y O
el O
estado O
psicológico; O
identificar O
cualquier O
acontecimiento O
adverso O
real O
o O
potencial O
asociado O
a O
la O
ingesta O
frecuente O
de O
zumo O
de O
uva; O
y O
proporcionar O
datos O
preliminares O
sobre O
el O
efecto O
del O
zumo O
de O
uva O
Concord O
en O
las O
NIV, O
la O
calidad O
de O
vida, O
el O
control O
percibido O
de O
los O
acontecimientos O
vitales O
y O
el O
estado O
psicológico. O

Ensayo O
clínico O
doble O
ciego O
y O
aleatorizado. O

Un O
centro O
oncológico O
en O
un O
centro O
académico O
de O
ciencias O
de O
la O
salud O
en O
el O
noreste O
de O
Estados O
Unidos O
. O

77 O
pacientes O
adultos O
con O
cáncer O
que O
reciben O
agentes O
quimioterapéuticos O
moderadamente O
o O
altamente O
emetógenos O
. O

Los O
participantes O
bebieron O
4 O
oz O
. O

de O
zumo O
de O
uva O
o O
de O
placebo O
antes O
de O
las O
comidas O
durante O
una O
semana O
después O
de O
cada O
uno O
de O
los O
cuatro O
ciclos O
de O
tratamiento O
de O
quimioterapia. O

Registraron O
la O
frecuencia, O
la O
duración O
y O
la O
angustia O
de O
las O
náuseas, O
los O
vómitos O
y O
las O
arcadas O
diariamente, O
comenzando O
la O
tarde O
de O
la O
administración O
de O
la O
quimioterapia O
y O
continuando O
durante O
siete O
días. O

Los O
datos O
se O
analizaron O
con O
la O
metodología O
de O
las O
ecuaciones O
de O
estimación O
generalizada O
para O
modelar O
las O
diferencias O
entre O
los O
grupos O
a O
lo O
largo O
del O
tiempo. O

La B-Premise
frecuencia, I-Premise
la I-Premise
duración I-Premise
y I-Premise
la I-Premise
angustia I-Premise
de I-Premise
las I-Premise
náuseas I-Premise
y I-Premise
los I-Premise
vómitos I-Premise
fueron I-Premise
menores I-Premise
en I-Premise
los I-Premise
miembros I-Premise
del I-Premise
grupo I-Premise
experimental, I-Premise
aunque B-Premise
la I-Premise
elevada I-Premise
tasa I-Premise
de I-Premise
deserción I-Premise
( I-Premise
50% I-Premise
) I-Premise
no I-Premise
permitió I-Premise
detectar I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo. I-Premise

Los O
mayores O
niveles O
de O
ansiedad, O
depresión O
y O
hostilidad O
en O
la O
línea O
de O
base O
se O
relacionaron O
con O
las O
náuseas O
y O
los O
vómitos, O
la O
calidad O
de O
vida O
y O
el O
control O
percibido O
sobre O
la O
toma O
de O
decisiones. O

El B-Claim
efecto I-Claim
de I-Claim
los I-Claim
flavonoides I-Claim
del I-Claim
zumo I-Claim
de I-Claim
uva I-Claim
sobre I-Claim
las I-Claim
NVC I-Claim
debe I-Claim
investigarse I-Claim
más I-Claim
a I-Claim
fondo I-Claim
con I-Claim
una I-Claim
muestra I-Claim
más I-Claim
amplia I-Claim
para I-Claim
determinar I-Claim
si I-Claim
los I-Claim
resultados I-Claim
preliminares I-Claim
están I-Claim
respaldados I-Claim
. I-Claim

Será O
necesario O
modificar O
el O
protocolo O
del O
estudio O
para O
reducir O
la O
deserción. O

Las B-Claim
frutas I-Claim
y I-Claim
verduras I-Claim
ricas I-Claim
en I-Claim
flavonoides I-Claim
pueden I-Claim
proporcionar I-Claim
una I-Claim
protección I-Claim
adicional I-Claim
contra I-Claim
las I-Claim
NVI. I-Claim

Si O
los O
compuestos O
funcionan, O
ofrecerían O
un O
tratamiento O
complementario O
de O
bajo O
coste O
y O
fácilmente O
disponible O
para O
el O
tratamiento O
de O
las O
NVC. O

El B-Claim
papel I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
adyuvante I-Claim
en I-Claim
pacientes I-Claim
posmenopáusicas I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
con I-Claim
ganglios I-Claim
linfáticos I-Claim
negativos I-Claim
es I-Claim
controvertido I-Claim
. I-Claim

Después O
de O
demostrar O
la O
eficacia O
de O
la O
quimioterapia O
combinada O
con O
tamoxifeno O
para O
las O
pacientes O
posmenopáusicas O
con O
enfermedad O
con O
ganglios O
linfáticos O
positivos O
, O
el O
Grupo O
Internacional O
de O
Estudio O
del O
Cáncer O
de O
Mama O
puso O
en O
marcha O
un O
ensayo O
aleatorio O
( O
Ensayo O
IX O
) O
para O
evaluar O
el O
papel O
de O
la O
quimioterapia O
adyuvante O
que O
precede O
al O
tratamiento O
con O
tamoxifeno O
para O
las O
pacientes O
con O
enfermedad O
con O
ganglios O
linfáticos O
negativos O
. O

Después O
de O
la O
estratificación O
por O
el O
estado O
del O
receptor O
de O
estrógeno O
( O
ER O
) O
, O
los O
pacientes O
fueron O
asignados O
al O
azar O
para O
recibir O
tres O
cursos O
de O
28 O
días O
de O
quimioterapia O
adyuvante O
" O
clásica O
" O
CMF O
( O
ciclofosfamida O
a O
100 O
mg O
/ O
m O
( O
2 O
) O
en O
los O
días O
1-14 O
, O
por O
vía O
oral O
; O
metotrexato O
a O
40 O
mg/m O
( O
2 O
) O
en O
los O
días O
1 O
y O
8 O
, O
por O
vía O
intravenosa O
; O
y O
5-fluorouracilo O
a O
600 O
mg/m O
( O
2 O
) O
en O
los O
días O
1 O
y O
8 O
, O
por O
vía O
intravenosa O
) O
seguido O
de O
tamoxifeno O
( O
20 O
mg/día O
, O
por O
vía O
oral O
durante O
57 O
meses O
) O
( O
CMF O
-- O
> O
tamoxifeno O
) O
o O
a O
recibir O
tamoxifeno O
solo O
( O
20 O
mg/día O
, O
por O
vía O
oral O
durante O
60 O
meses O
) O
. O

Se O
inscribieron O
1669 O
pacientes O
elegibles O
, O
382 O
( O
23 O
% O
) O
con O
tumores O
ER-negativos O
, O
1217 O
( O
73 O
% O
) O
con O
tumores O
ER-positivos O
, O
y O
70 O
( O
4 O
% O
) O
con O
estado O
ER O
desconocido O
. O

La O
mediana O
de O
seguimiento O
fue O
de O
71 O
meses. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

El B-Premise
beneficio I-Premise
añadido I-Premise
de I-Premise
la I-Premise
CMF I-Premise
seguida I-Premise
de I-Premise
tamoxifeno I-Premise
sobre I-Premise
el I-Premise
tamoxifeno I-Premise
solo I-Premise
dependió I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
del I-Premise
estado I-Premise
del I-Premise
RE I-Premise
( I-Premise
pruebas I-Premise
de I-Premise
interacción I-Premise
: I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
para I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
enfermedad I-Premise
[ I-Premise
DFS I-Premise
] I-Premise
y I-Premise
P I-Premise
= I-Premise
0,07 I-Premise
para I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
[ I-Premise
OS I-Premise
] I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
caso I-Premise
de I-Premise
las I-Premise
pacientes I-Premise
con I-Premise
tumores I-Premise
con I-Premise
RE I-Premise
negativo, I-Premise
la I-Premise
adición I-Premise
de I-Premise
CMF I-Premise
mejoró I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
la I-Premise
SSE I-Premise
( I-Premise
SSE I-Premise
a I-Premise
5 I-Premise
años I-Premise
= I-Premise
84 I-Premise
% I-Premise
para I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifeno I-Premise
frente I-Premise
a I-Premise
69 I-Premise
% I-Premise
para I-Premise
tamoxifeno I-Premise
solo; I-Premise
diferencia I-Premise
= I-Premise
15 I-Premise
%; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
IC I-Premise
] I-Premise
= I-Premise
6 I-Premise
% I-Premise
a I-Premise
24 I-Premise
%; I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
[ I-Premise
RR I-Premise
] I-Premise
= I-Premise
0.52 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,34 I-Premise
a I-Premise
0,79 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
) I-Premise
y I-Premise
la I-Premise
SG I-Premise
( I-Premise
SG I-Premise
a I-Premise
5 I-Premise
años I-Premise
= I-Premise
89 I-Premise
% I-Premise
para I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifeno I-Premise
frente I-Premise
a I-Premise
81 I-Premise
% I-Premise
para I-Premise
tamoxifeno I-Premise
solo I-Premise
; I-Premise
diferencia I-Premise
= I-Premise
8 I-Premise
% I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0 I-Premise
% I-Premise
a I-Premise
16 I-Premise
% I-Premise
; I-Premise
RR I-Premise
= I-Premise
0,51 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,30 I-Premise
a I-Premise
0,87 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

Por B-Premise
el I-Premise
contrario, I-Premise
para I-Premise
las I-Premise
pacientes I-Premise
con I-Premise
tumores I-Premise
con I-Premise
RE I-Premise
positivos, I-Premise
la I-Premise
adición I-Premise
de I-Premise
CMF I-Premise
no I-Premise
proporcionó I-Premise
ningún I-Premise
beneficio I-Premise
en I-Premise
términos I-Premise
de I-Premise
SSE I-Premise
( I-Premise
SSE I-Premise
a I-Premise
5 I-Premise
años I-Premise
= I-Premise
84 I-Premise
% I-Premise
para I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifeno I-Premise
frente I-Premise
a I-Premise
85 I-Premise
% I-Premise
para I-Premise
tamoxifeno I-Premise
solo; I-Premise
diferencia I-Premise
= I-Premise
-1; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
-6 I-Premise
% I-Premise
a I-Premise
4 I-Premise
%; I-Premise
RR I-Premise
= I-Premise
0.99 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,75 I-Premise
a I-Premise
1,30 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,92 I-Premise
) I-Premise
o I-Premise
la I-Premise
SG I-Premise
( I-Premise
SG I-Premise
a I-Premise
5 I-Premise
años I-Premise
= I-Premise
95 I-Premise
% I-Premise
para I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifeno I-Premise
frente I-Premise
a I-Premise
93 I-Premise
% I-Premise
para I-Premise
tamoxifeno I-Premise
solo I-Premise
; I-Premise
diferencia I-Premise
= I-Premise
2 I-Premise
% I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
-1 I-Premise
% I-Premise
a I-Premise
5 I-Premise
% I-Premise
; I-Premise
RR I-Premise
= I-Premise
0,95 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,64 I-Premise
a I-Premise
1,40 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,80 I-Premise
) I-Premise
. I-Premise

Las B-Claim
pacientes I-Claim
posmenopáusicas I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
con I-Claim
ganglios I-Claim
linfáticos I-Claim
negativos I-Claim
se I-Claim
beneficiaron I-Claim
sustancialmente I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
adyuvante I-Claim
si I-Claim
su I-Claim
cáncer I-Claim
era I-Claim
ER-negativo I-Claim
( I-Claim
es I-Claim
decir I-Claim
, I-Claim
endocrino-no I-Claim
responde I-Claim
) I-Claim
. I-Claim

Por B-Claim
el I-Claim
contrario, I-Claim
si I-Claim
su I-Claim
cáncer I-Claim
era I-Claim
ER-positivo I-Claim
( I-Claim
es I-Claim
decir, I-Claim
endocrino-respondiente I-Claim
) I-Claim
, I-Claim
no I-Claim
obtuvieron I-Claim
ningún I-Claim
beneficio I-Claim
del I-Claim
tratamiento I-Claim
combinado I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
tamoxifeno I-Claim
solo I-Claim
. I-Claim

En O
estudios O
de O
fase O
II, O
el O
irinotecán O
es O
activo O
en O
el O
cáncer O
colorrectal O
metastásico, O
pero O
el O
beneficio O
global O
no O
se O
ha O
evaluado O
en O
un O
ensayo O
clínico O
aleatorio. O

A O
los O
pacientes O
con O
cáncer O
colorrectal O
metastásico O
comprobado, O
que O
había O
progresado O
en O
los O
6 O
meses O
siguientes O
al O
tratamiento O
con O
fluorouracilo, O
se O
les O
asignó O
aleatoriamente O
300-350 O
mg/m2 O
de O
irinotecán O
cada O
3 O
semanas O
con O
cuidados O
de O
apoyo O
o O
sólo O
cuidados O
de O
apoyo, O
en O
una O
proporción O
de O
2:1. O

A O
189 O
pacientes O
se O
les O
asignó O
irinotecán O
y O
cuidados O
de O
apoyo O
y O
a O
90 O
sólo O
cuidados O
de O
apoyo O
. O

La O
edad O
media O
de O
los O
participantes O
era O
de O
58,8 O
años; O
181 O
( O
65% O
) O
eran O
hombres O
y O
98 O
( O
35% O
) O
eran O
mujeres O
. O

El O
estado O
de O
rendimiento O
de O
la O
OMS O
fue O
0 O
en O
79 O
( O
42 O
% O
) O
pacientes O
, O
1 O
en O
77 O
( O
41 O
% O
) O
pacientes O
y O
2 O
en O
32 O
( O
17 O
% O
) O
pacientes O
. O

Los O
síntomas O
relacionados O
con O
el O
tumor O
estaban O
presentes O
en O
134 O
( O
71 O
% O
) O
pacientes O
y O
la O
pérdida O
de O
peso O
de O
más O
del O
5 O
% O
se O
observó O
en O
15 O
( O
8 O
% O
) O
pacientes O
. O

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
13 I-Premise
meses, I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
significativamente I-Premise
mejor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
irinotecán I-Premise
( I-Premise
p=0,0001 I-Premise
) I-Premise
, I-Premise
con I-Premise
un I-Premise
36,2% I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
irinotecán I-Premise
frente I-Premise
al I-Premise
13,8% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
. I-Premise

El B-Premise
beneficio I-Premise
de I-Premise
supervivencia I-Premise
, I-Premise
ajustado I-Premise
por I-Premise
factores I-Premise
pronósticos I-Premise
en I-Premise
un I-Premise
análisis I-Premise
multivariante I-Premise
, I-Premise
siguió I-Premise
siendo I-Premise
significativo I-Premise
( I-Premise
p=0,001 I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
sin I-Premise
deterioro I-Premise
del I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
( I-Premise
p=0,0001 I-Premise
) I-Premise
, I-Premise
sin I-Premise
pérdida I-Premise
de I-Premise
peso I-Premise
de I-Premise
más I-Premise
del I-Premise
5 I-Premise
% I-Premise
( I-Premise
p=0,018 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
sin I-Premise
dolor I-Premise
( I-Premise
p=0,003 I-Premise
) I-Premise
fueron I-Premise
significativamente I-Premise
mejores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
irinotecán I-Premise
. I-Premise

En B-Premise
un I-Premise
análisis I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
todas I-Premise
las I-Premise
diferencias I-Premise
significativas, I-Premise
excepto I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
diarrea, I-Premise
fueron I-Premise
a I-Premise
favor I-Premise
del I-Premise
grupo I-Premise
de I-Premise
irinotecán. I-Premise

Nuestro B-Claim
estudio I-Claim
muestra I-Claim
que, I-Claim
a I-Claim
pesar I-Claim
de I-Claim
los I-Claim
efectos I-Claim
secundarios I-Claim
del I-Claim
tratamiento, I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
colorrectal I-Claim
metastásico, I-Claim
en I-Claim
los I-Claim
que I-Claim
ha I-Claim
fracasado I-Claim
el I-Claim
fluorouracilo, I-Claim
tienen I-Claim
una I-Claim
mayor I-Claim
supervivencia, I-Claim
menos I-Claim
síntomas I-Claim
relacionados I-Claim
con I-Claim
el I-Claim
tumor I-Claim
y I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
cuando I-Claim
se I-Claim
les I-Claim
trata I-Claim
con I-Claim
irinotecán I-Claim
que I-Claim
con I-Claim
cuidados I-Claim
de I-Claim
apoyo I-Claim
únicamente. I-Claim

El O
doblete O
estándar O
, O
vinorelbina-cisplatino O
, O
se O
comparó O
con O
un O
triplete O
de O
vinorelbina-ifosfamida-cisplatino O
, O
en O
términos O
de O
supervivencia O
, O
en O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
avanzado O
( O
CPNM O
) O
. O

De O
febrero O
de O
1998 O
a O
junio O
de O
1999, O
259 O
pacientes O
no O
tratados O
con O
quimioterapia O
entraron O
en O
el O
estudio O
y O
fueron O
asignados O
al O
azar O
para O
recibir O
vinorelbina-cisplatino O
( O
NP O
; O
vinorelbina O
30 O
mg/m O
( O
2 O
) O
los O
días O
1 O
, O
8 O
y O
15 O
con O
cisplatino O
80 O
mg/m O
( O
2 O
) O
el O
día O
1 O
) O
o O
vinorelbina-ifosfamida-cisplatino O
( O
NIP O
; O
vinorelbina O
25 O
mg/m O
( O
2 O
) O
los O
días O
1 O
y O
8 O
, O
ifosfamida O
3 O
g/m O
( O
2 O
) O
el O
día O
1 O
y O
cisplatino O
75 O
mg/m O
( O
2 O
) O
el O
día O
1 O
) O
, O
repitiéndose O
ambos O
regímenes O
cada O
3 O
semanas O
. O

Todos O
los O
pacientes O
tenían O
la O
enfermedad O
en O
estadio O
IV O
o O
en O
recaída O
y O
una O
puntuación O
de O
rendimiento O
de O
0 O
o O
1 O
. O

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
global I-Premise
fue I-Premise
del I-Premise
34,6% I-Premise
en I-Premise
el I-Premise
caso I-Premise
de I-Premise
los I-Premise
PN I-Premise
y I-Premise
del I-Premise
35,7% I-Premise
en I-Premise
el I-Premise
de I-Premise
los I-Premise
PIN. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
media I-Premise
y I-Premise
a I-Premise
un I-Premise
año I-Premise
fueron I-Premise
de I-Premise
10,0 I-Premise
meses I-Premise
y I-Premise
38,4 I-Premise
% I-Premise
en I-Premise
el I-Premise
caso I-Premise
de I-Premise
la I-Premise
PN I-Premise
, I-Premise
y I-Premise
de I-Premise
8,2 I-Premise
meses I-Premise
y I-Premise
33,7 I-Premise
% I-Premise
en I-Premise
el I-Premise
caso I-Premise
de I-Premise
la I-Premise
PN I-Premise
, I-Premise
respectivamente. I-Premise

Se O
administró O
una O
mediana O
de O
cuatro O
ciclos O
en O
cada O
brazo. O

Las B-Premise
principales I-Premise
toxicidades I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
de I-Premise
la I-Premise
Organización I-Premise
Mundial I-Premise
de I-Premise
la I-Premise
Salud I-Premise
para I-Premise
la I-Premise
PN I-Premise
y I-Premise
la I-Premise
PNI I-Premise
, I-Premise
respectivamente, I-Premise
fueron I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
20,3 I-Premise
% I-Premise
frente I-Premise
al I-Premise
9 I-Premise
% I-Premise
de I-Premise
los I-Premise
ciclos I-Premise
) I-Premise
, I-Premise
anemia I-Premise
( I-Premise
4,1 I-Premise
% I-Premise
frente I-Premise
al I-Premise
5 I-Premise
% I-Premise
de I-Premise
los I-Premise
ciclos I-Premise
) I-Premise
, I-Premise
náuseas I-Premise
y I-Premise
vómitos I-Premise
( I-Premise
22,2 I-Premise
% I-Premise
frente I-Premise
al I-Premise
19,4 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
) I-Premise
y I-Premise
alopecia I-Premise
( I-Premise
5,6 I-Premise
% I-Premise
frente I-Premise
al I-Premise
29,8 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
) I-Premise
. I-Premise

Se B-Premise
produjeron I-Premise
cuatro I-Premise
muertes I-Premise
tóxicas I-Premise
en I-Premise
el I-Premise
brazo I-Premise
NP I-Premise
y I-Premise
ocho I-Premise
en I-Premise
el I-Premise
brazo I-Premise
NIP I-Premise
. I-Premise

Los B-Premise
diferentes I-Premise
calendarios I-Premise
de I-Premise
vinorelbina I-Premise
en I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
condujeron I-Premise
a I-Premise
una I-Premise
mayor I-Premise
supervivencia I-Premise
en I-Premise
el I-Premise
brazo I-Premise
NP I-Premise
sin I-Premise
perjudicar I-Premise
el I-Premise
perfil I-Premise
de I-Premise
tolerancia I-Premise
, O
aunque B-Premise
esto I-Premise
no I-Premise
es I-Premise
estadísticamente I-Premise
significativo I-Premise
. O

Esto B-Claim
confirma I-Claim
que I-Claim
la I-Claim
combinación I-Claim
de I-Claim
dos I-Claim
fármacos I-Claim
NP I-Claim
es I-Claim
un I-Claim
tratamiento I-Claim
de I-Claim
referencia I-Claim
para I-Claim
el I-Claim
CPNM I-Claim
metastásico I-Claim
. I-Claim

El B-Claim
papel I-Claim
de I-Claim
las I-Claim
combinaciones I-Claim
de I-Claim
tres I-Claim
fármacos I-Claim
sigue I-Claim
siendo I-Claim
cuestionable I-Claim
en I-Claim
este I-Claim
subconjunto I-Claim
de I-Claim
pacientes I-Claim
. I-Claim

La O
quimioterapia B-Claim
puede I-Claim
afectar I-Claim
profundamente I-Claim
a I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
de I-Claim
las I-Claim
pacientes, I-Claim
pero O
pocos O
ensayos O
clínicos O
en O
cáncer O
de O
cuello O
de O
útero O
avanzado O
han O
incluido O
resultados O
de O
QOL O
. O

Nuestro O
propósito O
fue O
evaluar O
el O
impacto O
del O
cisplatino O
( O
C O
) O
frente O
al O
cisplatino O
más O
paclitaxel O
( O
CP O
) O
sobre O
la O
CdV O
global O
y O
el O
dolor O
en O
pacientes O
con O
cáncer O
de O
cuello O
uterino O
. O

La O
CdV O
se O
evaluó O
mediante O
el O
FACT-Cx O
, O
que O
consiste O
en O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer O
( O
FACT-G O
) O
más O
una O
subescala O
específica O
para O
el O
cáncer O
de O
cuello O
uterino, O
el O
Inventario O
Breve O
del O
Dolor-Formulario O
Corto O
( O
BPI-SF O
) O
y O
una O
subescala O
de O
neurotoxicidad O
. O

Los O
puntos O
de O
tiempo O
fueron: O
línea O
de O
base O
( O
antes O
de O
la O
aleatorización O
) O
y O
antes O
de O
los O
ciclos O
de O
quimioterapia O
2 O
, O
3 O
y O
4 O
. O

Las B-Premise
puntuaciones I-Premise
globales I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
no I-Premise
difirieron I-Premise
significativamente I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
en I-Premise
la I-Premise
cuarta I-Premise
evaluación I-Premise
( I-Premise
C I-Premise
= I-Premise
70,3 I-Premise
( I-Premise
19,6 I-Premise
) I-Premise
; I-Premise
CP I-Premise
= I-Premise
72,8 I-Premise
( I-Premise
17,4 I-Premise
) I-Premise
) I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
se I-Premise
mantuvieron I-Premise
estables I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
y I-Premise
fueron I-Premise
considerablemente I-Premise
inferiores I-Premise
a I-Premise
las I-Premise
normas I-Premise
de I-Premise
la I-Premise
población I-Premise
general. I-Premise

El B-Premise
BPI-SF I-Premise
reveló I-Premise
una I-Premise
disminución I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
dolor I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
desde I-Premise
la I-Premise
primera I-Premise
hasta I-Premise
la I-Premise
cuarta I-Premise
evaluación. I-Premise

El B-Premise
brazo I-Premise
de I-Premise
CP I-Premise
produjo I-Premise
una I-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
y I-Premise
una I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
( I-Premise
PFS I-Premise
) I-Premise
significativamente I-Premise
mayores, I-Premise
pero B-Premise
no I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
OS I-Premise
) O
. O

Se B-Premise
informó I-Premise
de I-Premise
una I-Premise
mayor I-Premise
mielosupresión I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
la I-Premise
combinación. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
abandono I-Premise
de I-Premise
la I-Premise
CV I-Premise
por I-Premise
cualquier I-Premise
motivo I-Premise
fue I-Premise
mayor I-Premise
para I-Premise
C I-Premise
( I-Premise
53% I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
CP I-Premise
( I-Premise
38% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

En O
el O
cuarto O
punto O
temporal, O
el O
60% O
de O
los O
pacientes O
vivos O
de O
ambos O
brazos O
completaron O
una O
evaluación O
de O
la O
calidad O
de O
vida. O

No B-Claim
hubo I-Claim
diferencias I-Claim
significativas I-Claim
en I-Claim
las I-Claim
puntuaciones I-Claim
globales I-Claim
de I-Claim
la I-Claim
CdV I-Claim
entre I-Claim
los I-Claim
brazos I-Claim
de I-Claim
tratamiento I-Claim
o I-Claim
en I-Claim
serie I-Claim
. I-Claim

En B-Claim
combinación I-Claim
con I-Claim
los I-Claim
resultados I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida, I-Claim
el I-Claim
aumento I-Claim
significativo I-Claim
de I-Claim
la I-Claim
respuesta I-Claim
y I-Claim
la I-Claim
SLP I-Claim
en I-Claim
el I-Claim
brazo I-Claim
CP I-Claim
y I-Claim
la I-Claim
mayor I-Claim
tasa I-Claim
de I-Claim
abandono I-Claim
en I-Claim
el I-Claim
brazo I-Claim
C I-Claim
sugieren I-Claim
un I-Claim
mejor I-Claim
resultado I-Claim
para I-Claim
el I-Claim
régimen I-Claim
combinado I-Claim
a I-Claim
pesar I-Claim
de I-Claim
su I-Claim
mayor I-Claim
mielosupresión. I-Claim

Comparar O
los O
efectos O
del O
extracto O
de O
cannabis O
( O
CE O
) O
, O
el O
delta-9-tetrahidrocannabinol O
( O
THC O
) O
y O
el O
placebo O
( O
PL O
) O
sobre O
el O
apetito O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
en O
pacientes O
con O
síndrome O
de O
anorexia-caquexia O
relacionada O
con O
el O
cáncer O
( O
CACS O
) O
. O

Los O
pacientes O
adultos O
con O
cáncer O
avanzado O
, O
CACS O
, O
pérdida O
de O
peso O
( O
> O
o O
= O
5 O
% O
en O
6 O
meses O
) O
y O
estado O
de O
rendimiento O
( O
PS O
) O
del O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
< O
o O
= O
2 O
fueron O
asignados O
al O
azar O
( O
2:2:1 O
) O
para O
recibir O
CE O
( O
estandarizado O
para O
2,5 O
mg O
de O
THC O
y O
1 O
mg O
de O
cannabidiol O
) O
o O
THC O
( O
2,5 O
mg O
) O
o O
PL O
por O
vía O
oral O
, O
dos O
veces O
al O
día O
durante O
6 O
semanas O
. O

El O
apetito, O
el O
estado O
de O
ánimo O
y O
las O
náuseas O
se O
controlaron O
diariamente O
con O
una O
escala O
analógica O
visual O
( O
VAS O
) O
; O
la O
CdV O
se O
evaluó O
con O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
puntuación O
compuesta O
: O
preguntas O
29 O
y O
30 O
) O
. O

La O
toxicidad O
relacionada O
con O
los O
cannabinoides O
se O
evaluó O
cada O
dos O
semanas. O

De O
289 O
pacientes O
seleccionados, O
243 O
fueron O
asignados O
al O
azar O
y O
164 O
( O
CE O
, O
66 O
de O
95 O
pacientes; O
THC O
, O
65 O
de O
100 O
pacientes; O
y O
PL O
, O
33 O
de O
48 O
pacientes O
) O
completaron O
el O
tratamiento O
. O

Al O
inicio O
del O
estudio, O
los O
grupos O
eran O
comparables O
en O
cuanto O
a O
la O
edad O
( O
media, O
61 O
años O
) O
, O
el O
sexo O
( O
54 O
% O
hombres O
) O
, O
la O
pérdida O
de O
peso O
( O
32 O
% O
> O
o O
= O
10 O
% O
) O
, O
el O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
el O
tratamiento O
antineoplásico O
( O
50 O
% O
) O
, O
el O
apetito O
( O
puntuación O
media O
de O
la O
EVA O
, O
31/100 O
mm O
) O
y O
la O
CdV O
( O
puntuación O
media, O
30/100 O
) O
. O

El B-Premise
análisis I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar I-Premise
no I-Premise
mostró I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
tres I-Premise
brazos I-Premise
para I-Premise
el I-Premise
apetito, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
o I-Premise
la I-Premise
toxicidad I-Premise
relacionada I-Premise
con I-Premise
los I-Premise
cannabinoides. I-Premise

El B-Premise
73%, I-Premise
el I-Premise
58% I-Premise
y I-Premise
el I-Premise
69% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
CE, I-Premise
THC I-Premise
o I-Premise
PL, I-Premise
respectivamente, I-Premise
informaron I-Premise
de I-Premise
un I-Premise
aumento I-Premise
del I-Premise
apetito. I-Premise

Una O
junta O
de O
revisión O
de O
datos O
independiente O
recomendó O
la O
finalización O
del O
reclutamiento O
debido O
a O
las O
diferencias O
insuficientes O
entre O
los O
brazos O
del O
estudio. O

El B-Premise
CE I-Premise
a I-Premise
la I-Premise
dosis I-Premise
oral I-Premise
administrada I-Premise
fue I-Premise
bien I-Premise
tolerado I-Premise
por I-Premise
estos I-Premise
pacientes I-Premise
con I-Premise
CACS I-Premise
. I-Premise

No B-Claim
se I-Claim
encontraron I-Claim
diferencias I-Claim
en I-Claim
el I-Claim
apetito I-Claim
o I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
entre I-Claim
el I-Claim
CE, I-Claim
el I-Claim
THC I-Claim
y I-Claim
el I-Claim
PL I-Claim
o I-Claim
entre I-Claim
el I-Claim
CE I-Claim
y I-Claim
el I-Claim
THC I-Claim
en I-Claim
las I-Claim
dosis I-Claim
investigadas. I-Claim

Está O
bien O
documentado O
que O
el O
estrés O
se O
asocia O
con O
resultados O
negativos O
para O
la O
salud O
de O
los O
pacientes O
con O
cáncer. O

El O
propósito O
de O
este O
estudio O
fue O
evaluar O
los O
efectos O
de O
una O
novedosa O
intervención O
de O
mindfulness O
llamada O
terapia O
de O
arte O
basada O
en O
mindfulness O
( O
MBAT O
) O
frente O
al O
apoyo O
educativo O
estándar O
, O
sobre O
los O
índices O
de O
estrés O
y O
calidad O
de O
vida O
en O
pacientes O
con O
cáncer O
de O
mama O
con O
altos O
niveles O
de O
estrés O
. O

Un O
total O
de O
191 O
mujeres O
fueron O
inscritas O
, O
estratificadas O
por O
edad O
y O
nivel O
de O
estrés O
, O
y O
aleatorizadas O
para O
recibir O
una O
intervención O
MBAT O
de O
8 O
semanas O
o O
un O
programa O
de O
apoyo O
educativo O
sobre O
el O
cáncer O
de O
mama O
de O
igual O
tiempo O
y O
duración O
. O

El O
estrés O
psicosocial O
se O
midió O
con O
el O
Symptoms O
Checklist-90-Revised O
, O
y O
la O
calidad O
de O
vida O
se O
midió O
con O
el O
Medical O
Outcomes O
Study O
Short-Form O
Health O
Survey O
al O
inicio, O
inmediatamente O
después O
de O
la O
intervención O
y O
a O
los O
6 O
meses. O

Los B-Premise
resultados I-Premise
mostraron I-Premise
mejoras I-Premise
generales I-Premise
significativas I-Premise
en I-Premise
el I-Premise
estrés I-Premise
psicosocial I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
tanto I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
MBAT I-Premise
como I-Premise
en I-Premise
el I-Premise
de I-Premise
apoyo I-Premise
educativo I-Premise
inmediatamente I-Premise
después I-Premise
de I-Premise
la I-Premise
intervención; I-Premise
sin B-Premise
embargo, I-Premise
los I-Premise
participantes I-Premise
con I-Premise
altos I-Premise
niveles I-Premise
de I-Premise
estrés I-Premise
en I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
mejoraron I-Premise
significativamente I-Premise
los I-Premise
resultados I-Premise
generales I-Premise
sólo I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
MBAT, I-Premise
tanto I-Premise
inmediatamente I-Premise
después I-Premise
de I-Premise
la I-Premise
intervención I-Premise
como I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses. I-Premise

Además, O
a B-Premise
los I-Premise
6 I-Premise
meses I-Premise
de I-Premise
seguimiento, I-Premise
los I-Premise
participantes I-Premise
que I-Premise
asistían I-Premise
a I-Premise
cinco I-Premise
o I-Premise
más I-Premise
sesiones I-Premise
tendían I-Premise
a I-Premise
retener I-Premise
mejor I-Premise
los I-Premise
efectos I-Premise
del I-Premise
tratamiento I-Premise
en I-Premise
el I-Premise
MBAT I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control. I-Premise

Por O
último, O
las O
mujeres B-Premise
negras I-Premise
y I-Premise
las I-Premise
blancas I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
forma I-Premise
en I-Premise
que I-Premise
se I-Premise
beneficiaron I-Premise
de I-Premise
la I-Premise
intervención I-Premise
MBAT, I-Premise
aunque I-Premise
las I-Premise
participantes I-Premise
blancas I-Premise
tendían I-Premise
a I-Premise
tener I-Premise
un I-Premise
nivel I-Premise
educativo I-Premise
y I-Premise
un I-Premise
estado I-Premise
civil I-Premise
más I-Premise
altos. I-Premise

En B-Claim
conclusión, I-Claim
el I-Claim
MBAT I-Claim
se I-Claim
asocia I-Claim
con I-Claim
beneficios I-Claim
significativos I-Claim
y I-Claim
sostenidos I-Claim
en I-Claim
una I-Claim
gama I-Claim
diversa I-Claim
de I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama, I-Claim
particularmente I-Claim
en I-Claim
aquellas I-Claim
con I-Claim
altos I-Claim
niveles I-Claim
de I-Claim
estrés. I-Claim

Este O
estudio O
se O
diseñó O
para O
evaluar O
la O
eficacia, O
la O
toxicidad O
y O
los O
efectos O
adversos O
de O
la O
combinación O
de O
fármacos O
de O
quimioterapia O
y O
la O
perfusión O
intraperitoneal O
de O
verapamilo O
en O
el O
tratamiento O
de O
la O
ascitis O
maligna. O

Setenta O
y O
dos O
pacientes O
con O
ascitis O
maligna O
fueron O
divididos O
en O
dos O
grupos O
de O
estudio. O

Los O
pacientes O
del O
grupo O
de O
control O
( O
31 O
casos O
) O
recibieron O
quimioterapia O
convencional O
, O
mientras O
que O
los O
pacientes O
del O
grupo O
de O
tratamiento O
combinado O
( O
41 O
casos O
) O
recibieron O
verapamilo O
por O
vía O
intraperitoneal O
además O
de O
los O
fármacos O
de O
quimioterapia O
. O

Treinta O
días O
después O
del O
tratamiento, O
se O
evaluaron O
la O
eficacia, O
la O
toxicidad O
y O
los O
efectos O
adversos O
en O
ambos O
grupos O
del O
estudio. O

El B-Premise
tratamiento I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
1 I-Premise
caso I-Premise
de I-Premise
remisión I-Premise
completa I-Premise
y I-Premise
a I-Premise
2 I-Premise
casos I-Premise
de I-Premise
remisión I-Premise
parcial I-Premise
, I-Premise
lo I-Premise
que I-Premise
hace I-Premise
que I-Premise
la I-Premise
tasa I-Premise
de I-Premise
eficacia I-Premise
( I-Premise
remisión I-Premise
completa I-Premise
+ I-Premise
parcial I-Premise
) I-Premise
sea I-Premise
del I-Premise
9,7% I-Premise
. I-Premise

El B-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
combinado I-Premise
mostró I-Premise
13 I-Premise
casos I-Premise
de I-Premise
remisión I-Premise
completa I-Premise
y I-Premise
22 I-Premise
casos I-Premise
de I-Premise
remisión I-Premise
parcial I-Premise
. I-Premise

Así, O
la B-Premise
tasa I-Premise
de I-Premise
eficacia I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
combinado I-Premise
( I-Premise
85,36 I-Premise
% I-Premise
; I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
frente I-Premise
al I-Premise
grupo I-Premise
de I-Premise
control I-Premise
) O
. O

Mediante O
las O
puntuaciones O
KPS O
, O
se O
compararon O
los O
cambios O
en O
la O
calidad O
de O
vida O
antes O
y O
después O
del O
tratamiento O
. O

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
mejoró I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
en I-Premise
un I-Premise
13,7% I-Premise
, I-Premise
mientras I-Premise
que I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
combinado I-Premise
mostró I-Premise
una I-Premise
mejora I-Premise
del I-Premise
83,5% I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
frente I-Premise
al I-Premise
grupo I-Premise
de I-Premise
control I-Premise
) I-Premise
. I-Premise

Además, O
la B-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
acumulada I-Premise
también I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
combinado. I-Premise

La B-Premise
toxicidad I-Premise
del I-Premise
tratamiento I-Premise
y I-Premise
la I-Premise
tasa I-Premise
de I-Premise
efectos I-Premise
adversos I-Premise
y I-Premise
de I-Premise
adhesión I-Premise
intestinal I-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
del I-Premise
estudio. I-Premise

La B-Claim
perfusión I-Claim
intraperitoneal I-Claim
de I-Claim
verapamilo I-Claim
aumenta I-Claim
la I-Claim
eficacia I-Claim
de I-Claim
los I-Claim
fármacos I-Claim
quimioterápicos, I-Claim
prolonga I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
mejora I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

La B-Claim
administración I-Claim
intraperitoneal I-Claim
limita I-Claim
la I-Claim
cardiotoxicidad I-Claim
del I-Claim
verapamilo I-Claim
. I-Claim

El B-Claim
deterioro I-Claim
de I-Claim
la I-Claim
cognición, I-Claim
la I-Claim
fatiga I-Claim
y I-Claim
la I-Claim
disminución I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
están I-Claim
comúnmente I-Claim
asociados I-Claim
con I-Claim
la I-Claim
quimioterapia I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

Este O
ensayo O
piloto O
aleatorizado, O
doble O
ciego O
y O
controlado O
con O
placebo O
evaluó O
la O
viabilidad O
de O
cuantificar O
los O
efectos O
de O
la O
epoetina O
alfa O
sobre O
la O
función O
cognitiva O
y O
el O
estado O
de O
ánimo, O
y O
evaluó O
sus O
efectos O
sobre O
la O
fatiga O
y O
la O
CdV O
en O
pacientes O
con O
cáncer O
de O
mama O
tratadas O
con O
quimioterapia O
adyuvante O
o O
neoadyuvante O
basada O
en O
antraciclinas. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
epoetina O
alfa O
40.000 O
U O
por O
vía O
subcutánea O
una O
vez O
a O
la O
semana O
o O
placebo O
al O
comienzo O
de O
4 O
ciclos O
de O
quimioterapia O
administrados O
durante O
12 O
semanas O
. O

La O
función O
cognitiva O
se O
evaluó O
mediante O
la O
Entrevista O
Ejecutiva O
( O
EXIT25 O
) O
y O
las O
Tareas O
de O
Dibujo O
de O
Relojes O
; O
el O
estado O
de O
ánimo O
mediante O
el O
Perfil O
de O
Estados O
de O
Ánimo O
; O
los O
síntomas O
relacionados O
con O
la O
anemia O
, O
incluida O
la O
fatiga O
, O
mediante O
la O
subescala O
de O
Evaluación O
Funcional O
de O
la O
Terapia O
contra O
el O
Cáncer O
( O
FACT-An O
) O
; O
y O
la O
CdV O
mediante O
la O
Evaluación O
de O
la O
Escala O
Analógica O
Lineal O
. O

Noventa O
y O
cuatro O
pacientes O
fueron O
evaluados O
en O
cuanto O
a O
eficacia O
y O
seguridad. O

El B-Premise
cambio I-Premise
medio I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
EXIT25 I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
el I-Premise
ciclo I-Premise
4 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
epoetina I-Premise
alfa I-Premise
fue I-Premise
de I-Premise
1,3 I-Premise
+/- I-Premise
3,3 I-Premise
; O
el B-Premise
cambio I-Premise
medio I-Premise
fue I-Premise
de I-Premise
0,3 I-Premise
+/- I-Premise
2,4 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
( I-Premise
un I-Premise
cambio I-Premise
negativo I-Premise
indica I-Premise
una I-Premise
mejora I-Premise
de I-Premise
la I-Premise
función I-Premise
ejecutiva I-Premise
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
el I-Premise
cambio I-Premise
medio I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
EXIT25 I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
la I-Premise
evaluación I-Premise
de I-Premise
seguimiento I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses. I-Premise

Los B-Premise
niveles I-Premise
medios I-Premise
de I-Premise
hemoglobina I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
epoetina I-Premise
alfa I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
tras I-Premise
4 I-Premise
ciclos I-Premise
de I-Premise
quimioterapia. I-Premise

Los B-Premise
receptores I-Premise
de I-Premise
epoetina I-Premise
alfa I-Premise
experimentaron I-Premise
un I-Premise
menor I-Premise
descenso I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
subescala I-Premise
FACT-An I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
el I-Premise
ciclo I-Premise
4 I-Premise
y I-Premise
una I-Premise
mejora I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
subescala I-Premise
FACT-An I-Premise
en I-Premise
la I-Premise
evaluación I-Premise
de I-Premise
seguimiento I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
placebo I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
epoetina I-Claim
alfa I-Claim
fue I-Claim
bien I-Claim
tolerado. I-Claim

Estos B-Claim
datos I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
epoetina I-Claim
alfa I-Claim
puede I-Claim
haber I-Claim
atenuado I-Claim
el I-Claim
deterioro I-Claim
cognitivo I-Claim
y I-Claim
la I-Claim
fatiga I-Claim
que I-Claim
se I-Claim
produjeron I-Claim
durante I-Claim
la I-Claim
quimioterapia I-Claim
adyuvante I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

En O
la O
región O
de O
Asia-Pacífico O
y O
en O
otros O
lugares, O
casi O
el O
85% O
de O
los O
pacientes O
con O
carcinoma O
hepatocelular O
(CHC) O
son O
inoperables O
en O
el O
momento O
del O
diagnóstico O
y O
tienen O
un O
pronóstico O
desalentador. O

Se B-Claim
cree I-Claim
que I-Claim
el I-Claim
tamoxifeno I-Claim
( I-Claim
TMX I-Claim
) I-Claim
inhibe I-Claim
los I-Claim
HCC I-Claim
positivos I-Claim
para I-Claim
el I-Claim
receptor I-Claim
de I-Claim
estrógeno I-Claim
( I-Claim
ER I-Claim
) I-Claim
, I-Claim
pero I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
HCC I-Claim
son I-Claim
ER I-Claim
negativos I-Claim
. I-Claim

Los B-Claim
resultados I-Claim
de I-Claim
los I-Claim
ensayos I-Claim
previos I-Claim
de I-Claim
fase I-Claim
3 I-Claim
en I-Claim
el I-Claim
CHC I-Claim
inoperable I-Claim
han I-Claim
sido I-Claim
contradictorios I-Claim
y I-Claim
no I-Claim
concluyentes. I-Claim

Sin B-Claim
embargo, I-Claim
a I-Claim
dosis I-Claim
más I-Claim
altas, I-Claim
el I-Claim
TMX I-Claim
inhibe I-Claim
el I-Claim
CHC I-Claim
a I-Claim
través I-Claim
de I-Claim
mecanismos I-Claim
independientes I-Claim
del I-Claim
RE. I-Claim

Se O
realizó O
un O
ensayo O
controlado O
aleatorio O
multicéntrico O
para O
evaluar O
el O
papel O
de O
las O
dosis O
altas O
de O
TMX O
frente O
al O
placebo O
( O
P O
) O
en O
el O
tratamiento O
de O
pacientes O
con O
CHC O
inoperable O
con O
respecto O
a O
la O
supervivencia O
y O
la O
calidad O
de O
vida O
( O
QoL O
) O
. O

Un O
total O
de O
329 O
pacientes O
de O
10 O
centros O
de O
9 O
países O
de O
la O
región O
de O
Asia-Pacífico O
se O
inscribieron O
en O
un O
ensayo O
controlado O
aleatorio O
doble O
ciego O
de O
TMX O
120 O
mg/día O
( O
TMX120 O
) O
contra O
P O
como O
brazo O
de O
control O
con O
una O
dosis O
intermedia O
de O
TMX O
60 O
mg/día O
( O
TMX60 O
) O
para O
evaluar O
la O
posible O
respuesta O
a O
la O
dosis O
. O

Un O
comité O
independiente O
de O
control O
de O
datos O
revisó O
todos O
los O
aspectos O
del O
ensayo. O

La O
calidad O
de O
vida O
se O
evaluó O
mediante O
el O
cuestionario O
QLQ-C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer. O

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
tres I-Premise
meses I-Premise
de I-Premise
los I-Premise
grupos I-Premise
P I-Premise
, I-Premise
TMX60 I-Premise
y I-Premise
TMX120 I-Premise
fueron I-Premise
del I-Premise
44 I-Premise
% I-Premise
, I-Premise
41 I-Premise
% I-Premise
y I-Premise
35 I-Premise
% I-Premise
, I-Premise
respectivamente, I-Premise
con I-Premise
una I-Premise
diferencia I-Premise
de I-Premise
tendencia I-Premise
estadísticamente I-Premise
significativa I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
entre I-Premise
los I-Premise
3 I-Premise
regímenes I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
P I-Premise
= I-Premise
0,011 I-Premise
) I-Premise
. I-Premise

Hubo B-Premise
un I-Premise
riesgo I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
muerte I-Premise
en I-Premise
el I-Premise
grupo I-Premise
TMX120 I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
P I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1,39 I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
1,07-1,81 I-Premise
) I-Premise
. I-Premise

Se B-Premise
notificaron I-Premise
reacciones I-Premise
adversas I-Premise
a I-Premise
los I-Premise
medicamentos I-Premise
en I-Premise
el I-Premise
3% I-Premise
( I-Premise
9 I-Premise
pacientes I-Premise
) O
, O
y O
8 B-Premise
pacientes I-Premise
se I-Premise
perdieron I-Premise
durante I-Premise
el I-Premise
seguimiento I-Premise
. O

En O
conclusión, O
el O
TMX B-Claim
no I-Claim
prolonga I-Claim
la I-Claim
supervivencia I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CHC I-Claim
inoperable I-Claim
y I-Claim
tiene I-Claim
un I-Claim
impacto I-Claim
cada I-Claim
vez I-Claim
más I-Claim
negativo I-Claim
con I-Claim
el I-Claim
aumento I-Claim
de I-Claim
la I-Claim
dosis. I-Claim

No B-Claim
se I-Claim
observó I-Claim
ninguna I-Claim
ventaja I-Claim
apreciable I-Claim
para I-Claim
la I-Claim
CdV I-Claim
con I-Claim
el I-Claim
TMX I-Claim
. I-Claim

Se O
trata O
de O
un O
estudio O
aleatorizado O
de O
fase O
II O
diseñado O
para O
comparar O
el O
perfil O
de O
toxicidad O
de O
un O
régimen O
no O
basado O
en O
platino O
con O
otro O
basado O
en O
platino O
en O
el O
tratamiento O
del O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
avanzado. O

Ochenta O
y O
nueve O
pacientes O
que O
no O
habían O
recibido O
quimioterapia O
fueron O
aleatorizados O
a O
recibir O
gemcitabina O
( O
1.000 O
mg/m2 O
, O
infusión O
de O
30 O
minutos O
los O
días O
1, O
8 O
y O
15 O
) O
y O
etopósido O
oral O
( O
50 O
mg O
, O
días O
1-14 O
; O
grupo O
GE O
) O
o O
gemcitabina O
con O
el O
mismo O
esquema O
y O
cisplatino O
( O
75 O
mg/m2 O
el O
día O
15 O
; O
grupo O
GP O
) O
. O

El O
criterio O
de O
valoración O
principal O
es O
la O
toxicidad, O
y O
los O
criterios O
de O
valoración O
secundarios O
son O
la O
tasa O
de O
respuesta, O
la O
supervivencia O
y O
la O
calidad O
de O
vida. O

La B-Premise
incidencia I-Premise
de I-Premise
anemia, I-Premise
neutropenia I-Premise
y I-Premise
trombocitopenia I-Premise
de I-Premise
grado I-Premise
3 I-Premise
ó I-Premise
4 I-Premise
de I-Premise
la I-Premise
OMS I-Premise
fue I-Premise
del I-Premise
29, I-Premise
44 I-Premise
y I-Premise
22% I-Premise
( I-Premise
grupo I-Premise
GE I-Premise
) I-Premise
, I-Premise
y I-Premise
del I-Premise
28, I-Premise
49 I-Premise
y I-Premise
23% I-Premise
( I-Premise
grupo I-Premise
GP I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
p I-Premise
= I-Premise
0,75 I-Premise
, I-Premise
0,95 I-Premise
y I-Premise
0,87 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
náuseas I-Premise
de I-Premise
grado I-Premise
2 I-Premise
o I-Premise
superior I-Premise
fue I-Premise
numéricamente I-Premise
mayor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
del I-Premise
GP I-Premise
, O
pero B-Premise
la I-Premise
diferencia I-Premise
no I-Premise
fue I-Premise
estadísticamente I-Premise
significativa I-Premise
( I-Premise
GE I-Premise
15,5 I-Premise
% I-Premise
, I-Premise
GP I-Premise
27,7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0,20 I-Premise
) O
. O

La B-Premise
tasa I-Premise
de I-Premise
vómitos I-Premise
en I-Premise
los I-Premise
brazos I-Premise
de I-Premise
GE I-Premise
y I-Premise
GP I-Premise
fue I-Premise
de I-Premise
20,0 I-Premise
y I-Premise
20,5 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
p I-Premise
= I-Premise
0,96 I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
los I-Premise
cambios I-Premise
subjetivos I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
CdV I-Premise
sobre I-Premise
las I-Premise
náuseas I-Premise
y I-Premise
los I-Premise
vómitos I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
brazo I-Premise
del I-Premise
GP I-Premise
( I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Otros B-Premise
síntomas, I-Premise
como I-Premise
el I-Premise
dolor I-Premise
de I-Premise
boca I-Premise
y I-Premise
la I-Premise
caída I-Premise
del I-Premise
cabello, I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
GE I-Premise
( I-Premise
p I-Premise
= I-Premise
0,003 I-Premise
y I-Premise
0,007 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

También B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
el I-Premise
funcionamiento I-Premise
emocional I-Premise
( I-Premise
p I-Premise
= I-Premise
0,014 I-Premise
) I-Premise
, I-Premise
cognitivo I-Premise
( I-Premise
p I-Premise
= I-Premise
0,028 I-Premise
) I-Premise
y I-Premise
social I-Premise
( I-Premise
p I-Premise
= I-Premise
0,034 I-Premise
) I-Premise
a I-Premise
favor I-Premise
del I-Premise
GP I-Premise
. I-Premise

Las B-Premise
diferencias I-Premise
en I-Premise
la I-Premise
respuesta I-Premise
del I-Premise
tumor I-Premise
( I-Premise
35,5 I-Premise
y I-Premise
46,5 I-Premise
% I-Premise
para I-Premise
GE I-Premise
y I-Premise
GP I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
( I-Premise
33,8 I-Premise
y I-Premise
40,7 I-Premise
semanas I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
41,4 I-Premise
y I-Premise
57,3 I-Premise
semanas I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
fueron I-Premise
de I-Premise
significación I-Premise
límite I-Premise
a I-Premise
favor I-Premise
del I-Premise
brazo I-Premise
GP I-Premise
( I-Premise
p I-Premise
= I-Premise
0,055 I-Premise
) I-Premise
. I-Premise

Este B-Claim
perfil I-Claim
de I-Claim
toxicidad I-Claim
de I-Claim
la I-Claim
GE I-Claim
es I-Claim
similar I-Claim
al I-Claim
de I-Claim
la I-Claim
GP I-Claim
, O
pero B-Claim
la I-Claim
aparente I-Claim
eficacia I-Claim
inferior I-Claim
puede I-Claim
desalentar I-Claim
la I-Claim
investigación. I-Claim

Evaluar O
el O
efecto O
analgésico, O
la O
seguridad O
y O
la O
rentabilidad O
de O
la O
oxicodona O
de O
liberación O
controlada O
( O
CRO O
) O
para O
controlar O
el O
dolor O
postoperatorio O
en O
pacientes O
con O
cáncer O
de O
hígado O
sometidos O
a O
quimioembolización O
transarterial O
. O

Este O
estudio O
clínico O
prospectivo, O
aleatorio, O
doble O
ciego O
y O
controlado O
con O
placebo O
recibió O
la O
aprobación O
de O
la O
junta O
de O
revisión O
institucional. O

Tras O
obtener O
el O
consentimiento O
informado O
por O
escrito, O
210 O
pacientes O
con O
cáncer O
de O
hígado O
fueron O
distribuidos O
aleatoriamente O
en O
tres O
grupos O
de O
70 O
pacientes. O

El O
grupo O
1 O
recibió O
20 O
mg O
de O
CRO O
, O
el O
grupo O
2 O
recibió O
10 O
mg O
de O
CRO O
y O
el O
grupo O
3 O
recibió O
un O
placebo O
una O
hora O
antes O
de O
la O
quimioembolización O
transarterial O
( O
T O
( O
0 O
) O
) O
y O
12 O
( O
T O
( O
12 O
) O
) O
y O
24 O
( O
T O
( O
24 O
) O
) O
horas O
después O
de O
la O
T O
( O
0 O
) O
. O

Se O
evaluaron O
y O
compararon O
entre O
los O
tres O
grupos O
la O
intensidad O
del O
dolor O
en O
una O
escala O
de O
calificación O
numérica, O
el O
porcentaje O
de O
pacientes O
con O
cada O
grado O
de O
dolor, O
la O
calidad O
de O
vida, O
las O
reacciones O
adversas, O
los O
costes O
de O
los O
analgésicos O
y O
las O
estancias O
hospitalarias. O

Las B-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
escala I-Premise
de I-Premise
calificación I-Premise
numérica I-Premise
para I-Premise
la I-Premise
intensidad I-Premise
del I-Premise
dolor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
y I-Premise
el I-Premise
grupo I-Premise
2 I-Premise
fueron I-Premise
significativamente I-Premise
menores I-Premise
que I-Premise
las I-Premise
del I-Premise
grupo I-Premise
3 I-Premise
en I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
; I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
; I-Premise
y I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Cuando B-Premise
se I-Premise
comparó I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
con I-Premise
el I-Premise
grupo I-Premise
2 I-Premise
, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
escala I-Premise
de I-Premise
valoración I-Premise
numérica I-Premise
fueron I-Premise
significativamente I-Premise
más I-Premise
bajas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
2 I-Premise
durante I-Premise
el I-Premise
periodo I-Premise
de I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) O
pero B-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
en I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.68 I-Premise
) I-Premise
y I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
) O
. O

El B-Premise
coste I-Premise
analgésico I-Premise
y I-Premise
la I-Premise
estancia I-Premise
hospitalaria I-Premise
fueron I-Premise
significativamente I-Premise
menores I-Premise
en I-Premise
los I-Premise
grupos I-Premise
tratados I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
placebo I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
los I-Premise
efectos I-Premise
adversos I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
tratados I-Premise
y I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo. I-Premise

La B-Claim
CRO I-Claim
es I-Claim
eficaz, I-Claim
segura I-Claim
y I-Claim
rentable I-Claim
en I-Claim
el I-Claim
control I-Claim
del I-Claim
dolor I-Claim
postoperatorio I-Claim
tras I-Claim
la I-Claim
quimioembolización I-Claim
transarterial I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
hígado I-Claim
inoperable. I-Claim

La O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
, O
los O
síntomas O
de O
depresión O
y O
los O
eventos O
adversos O
( O
AEs O
) O
se O
compararon O
entre O
las O
pacientes O
posmenopáusicas O
japonesas O
con O
cáncer O
de O
mama O
( O
BC O
) O
sensible O
a O
las O
hormonas O
que O
recibieron O
tamoxifeno O
adyuvante O
, O
exemestano O
, O
o O
anastrozol O
en O
un O
ensayo O
abierto O
, O
aleatorizado O
, O
multicéntrico O
designado O
como O
el O
Estudio O
Nacional O
Adyuvante O
Quirúrgico O
de O
Cáncer O
de O
Mama O
( O
N-SAS O
BC O
) O
04 O
subestudio O
del O
ensayo O
Tamoxifen O
Exemestane O
Adjuvant O
Multinational O
( O
TEAM O
) O
. O

Durante O
el O
primer O
año O
de O
tratamiento O
, O
la O
CVRS O
y O
los O
síntomas O
de O
depresión O
se O
analizaron O
mediante O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-Mama O
( O
FACT-B O
) O
y O
su O
Subescala O
de O
Síntomas O
Endocrinos O
( O
ES O
) O
, O
y O
la O
Escala O
de O
Depresión O
del O
Centro O
de O
Estudios O
Epidemiológicos O
( O
CES-D O
) O
, O
respectivamente O
. O

Además, O
se O
analizaron O
los O
EA O
predefinidos. O

Un O
total O
de O
166 O
pacientes O
elegibles O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
tamoxifeno O
adyuvante O
, O
exemestano O
o O
anastrozol O
. O

Las B-Premise
puntuaciones I-Premise
de I-Premise
FACT-B I-Premise
aumentaron I-Premise
tras I-Premise
el I-Premise
inicio I-Premise
del I-Premise
tratamiento I-Premise
y I-Premise
se I-Premise
mantuvieron I-Premise
significativamente I-Premise
más I-Premise
altas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tamoxifeno I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
exemestano I-Premise
o I-Premise
anastrozol I-Premise
durante I-Premise
el I-Premise
primer I-Premise
año I-Premise
( I-Premise
P I-Premise
= I-Premise
0,045 I-Premise
) I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
FACT-B I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
exemestano I-Premise
y I-Premise
en I-Premise
el I-Premise
de I-Premise
anastrozol. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
ES I-Premise
y I-Premise
CES-D I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
todos I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento. I-Premise

La B-Premise
artralgia I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
fueron I-Premise
menos I-Premise
frecuentes, I-Premise
pero I-Premise
el I-Premise
flujo I-Premise
vaginal I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
en I-Premise
el I-Premise
grupo I-Premise
del I-Premise
tamoxifeno I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
del I-Premise
exemestano I-Premise
o I-Premise
del I-Premise
anastrozol. I-Premise

La B-Claim
CVRS I-Claim
fue I-Claim
mejor I-Claim
en I-Claim
las I-Claim
mujeres I-Claim
posmenopáusicas I-Claim
japonesas I-Claim
tratadas I-Claim
con I-Claim
tamoxifeno I-Claim
que I-Claim
las I-Claim
tratadas I-Claim
con I-Claim
exemestano I-Claim
o I-Claim
anastrozol I-Claim
. I-Claim

La B-Claim
CVRS I-Claim
y I-Claim
los I-Claim
EA I-Claim
fueron I-Claim
similares I-Claim
con I-Claim
exemestano I-Claim
y I-Claim
anastrozol. I-Claim

Dados B-Claim
los I-Claim
resultados I-Claim
del I-Claim
ensayo I-Claim
TEAM I-Claim
, I-Claim
el I-Claim
uso I-Claim
inicial I-Claim
de I-Claim
tamoxifeno I-Claim
seguido I-Claim
de I-Claim
un I-Claim
inhibidor I-Claim
de I-Claim
la I-Claim
aromatasa I-Claim
( I-Claim
AI I-Claim
) I-Claim
puede I-Claim
ser I-Claim
una I-Claim
opción I-Claim
importante I-Claim
para I-Claim
la I-Claim
terapia I-Claim
endocrina I-Claim
adyuvante I-Claim
en I-Claim
las I-Claim
mujeres I-Claim
posmenopáusicas I-Claim
japonesas I-Claim
. I-Claim

Se O
comparó O
el O
régimen O
de O
fulvestrant O
de O
500 O
mg O
con O
la O
dosis O
aprobada O
de O
fulvestrant O
de O
250 O
mg O
al O
mes O
para O
el O
tratamiento O
de O
mujeres O
posmenopáusicas O
con O
cáncer O
de O
mama O
avanzado O
con O
receptores O
de O
estrógeno O
positivos O
que O
experimentaron O
progresión O
después O
de O
una O
terapia O
endocrina O
previa O
. O

Comparación O
de O
Faslodex O
en O
Cáncer O
de O
Mama O
Recurrente O
o O
Metastásico O
( O
CONFIRM O
) O
es O
un O
estudio O
doble O
ciego, O
de O
grupos O
paralelos, O
multicéntrico O
y O
de O
fase O
III. O

Las O
pacientes O
fueron O
asignadas O
aleatoriamente O
a O
fulvestrant O
500 O
mg O
( O
500 O
mg O
por O
vía O
intramuscular O
[ O
IM O
] O
el O
día O
0 O
, O
luego O
500 O
mg O
IM O
los O
días O
14 O
y O
28 O
y O
cada O
28 O
días O
a O
partir O
de O
entonces O
) O
o O
250 O
mg O
cada O
28 O
días O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia O
libre O
de O
progresión O
(SLP). O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
tasa O
de O
respuesta O
objetiva, O
la O
tasa O
de O
beneficio O
clínico, O
la O
duración O
del O
beneficio O
clínico, O
la O
supervivencia O
global O
y O
la O
calidad O
de O
vida. O

La B-Premise
SLP I-Premise
fue I-Premise
significativamente I-Premise
más I-Premise
larga I-Premise
con I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
362 I-Premise
) I-Premise
que I-Premise
con I-Premise
250 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
374 I-Premise
) I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0,80 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,68 I-Premise
a I-Premise
0,94 I-Premise
; I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
lo I-Premise
que I-Premise
corresponde I-Premise
a I-Premise
una I-Premise
reducción I-Premise
del I-Premise
20 I-Premise
% I-Premise
del I-Premise
riesgo I-Premise
de I-Premise
progresión I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
objetiva I-Premise
fue I-Premise
similar I-Premise
para I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
y I-Premise
250 I-Premise
mg I-Premise
( I-Premise
9,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
10,2 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

La B-Premise
RBC I-Premise
fue I-Premise
del I-Premise
45,6% I-Premise
para I-Premise
el I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
y I-Premise
del I-Premise
39,6% I-Premise
para I-Premise
el I-Premise
fulvestrant I-Premise
250 I-Premise
mg. I-Premise
El I-Premise
DoCB I-Premise
y I-Premise
la I-Premise
SG I-Premise
fueron I-Premise
de I-Premise
16,6 I-Premise
y I-Premise
25,1 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
500 I-Premise
mg I-Premise
, I-Premise
mientras I-Premise
que I-Premise
el I-Premise
DoCB I-Premise
y I-Premise
la I-Premise
SG I-Premise
fueron I-Premise
de I-Premise
13,9 I-Premise
y I-Premise
22,8 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
, I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
250 I-Premise
mg I-Premise
. O

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
fue I-Claim
bien I-Claim
tolerado I-Claim
y I-Claim
no I-Claim
hubo I-Claim
efectos I-Claim
adversos I-Claim
dependientes I-Claim
de I-Claim
la I-Claim
dosis. I-Claim

La B-Claim
calidad I-Claim
de I-Claim
vida I-Claim
fue I-Claim
similar I-Claim
en I-Claim
ambos I-Claim
brazos. I-Claim

El B-Claim
fulvestrant I-Claim
500 I-Claim
mg I-Claim
se I-Claim
asoció I-Claim
con I-Claim
un I-Claim
aumento I-Claim
estadísticamente I-Claim
significativo I-Claim
de I-Claim
la I-Claim
SLP I-Claim
y I-Claim
no I-Claim
se I-Claim
asoció I-Claim
con I-Claim
un I-Claim
aumento I-Claim
de I-Claim
la I-Claim
toxicidad I-Claim
, O
lo O
que O
corresponde O
a O
una O
mejora O
clínicamente O
significativa O
del O
beneficio O
frente O
al O
riesgo O
en O
comparación O
con O
el O
fulvestrant O
250 O
mg O
. O

Un O
ensayo O
controlado O
aleatorio O
realizado O
previamente O
en O
pacientes O
de O
oncología O
radioterápica O
demostró O
que O
la O
intervención O
nutricional O
tenía O
un O
impacto O
beneficioso O
sobre O
el O
peso O
corporal O
, O
el O
estado O
nutricional O
y O
la O
calidad O
de O
vida O
en O
comparación O
con O
la O
práctica O
estándar O
, O
pero O
no O
informó O
sobre O
los O
datos O
de O
la O
ingesta O
dietética O
. O

Determinar O
el O
impacto O
de O
la O
intervención O
nutricional O
en O
comparación O
con O
la O
práctica O
estándar O
sobre O
la O
ingesta O
dietética O
en O
pacientes O
ambulatorios O
que O
reciben O
radioterapia O
. O

Ensayo O
prospectivo, O
aleatorio O
y O
controlado. O

Sesenta O
pacientes O
ambulatorios O
consecutivos O
de O
oncología O
radioterápica O
( O
51 O
hombres O
y O
nueve O
mujeres; O
edad O
61,9+/-14 O
años O
[ O
media+/desviación O
estándar O
] O
) O
. O

Instalación O
de O
radioterapia O
privada O
australiana O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
una O
intervención O
nutricional O
( O
n=29 O
) O
( O
asesoramiento O
nutricional O
siguiendo O
el O
protocolo O
de O
la O
Asociación O
Americana O
de O
Dietética O
[ O
ADA O
] O
de O
terapia O
nutricional O
médica O
[ O
MNT O
] O
para O
la O
radioterapia O
oncológica O
) O
o O
la O
práctica O
estándar O
( O
n=31 O
) O
( O
charla O
y O
folleto O
de O
nutrición O
general O
) O
. O

Ingesta O
dietética O
( O
proteínas O
, O
energía O
, O
fibra O
) O
evaluada O
al O
inicio O
y O
a O
las O
4 O
, O
8 O
y O
12 O
semanas O
después O
de O
comenzar O
la O
radioterapia O
. O

Análisis O
de O
varianza O
con O
medidas O
repetidas O
realizado O
por O
intención O
de O
tratar. O

El B-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
nutricional I-Premise
tuvo I-Premise
una I-Premise
media I-Premise
más I-Premise
alta I-Premise
de I-Premise
energía I-Premise
total I-Premise
( I-Premise
P=0,029 I-Premise
) I-Premise
y I-Premise
de I-Premise
ingesta I-Premise
de I-Premise
proteínas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
práctica I-Premise
estándar I-Premise
. I-Premise

La B-Premise
ingesta I-Premise
media I-Premise
por I-Premise
kilogramo I-Premise
de I-Premise
peso I-Premise
corporal I-Premise
del I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
nutricional I-Premise
osciló I-Premise
entre I-Premise
28 I-Premise
y I-Premise
31 I-Premise
kcal/kg/día I-Premise
en I-Premise
comparación I-Premise
con I-Premise
las I-Premise
25 I-Premise
y I-Premise
29 I-Premise
kcal/kg/día I-Premise
del I-Premise
grupo I-Premise
de I-Premise
práctica I-Premise
estándar I-Premise
( I-Premise
P=0,022 I-Premise
) I-Premise
. I-Premise

El B-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
nutricional I-Premise
tuvo I-Premise
una I-Premise
ingesta I-Premise
media I-Premise
de I-Premise
proteínas I-Premise
más I-Premise
alta I-Premise
( I-Premise
1,1 I-Premise
a I-Premise
1,3 I-Premise
g/kg/día I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
práctica I-Premise
estándar I-Premise
( I-Premise
1,0 I-Premise
a I-Premise
1,1 I-Premise
g/kg/día I-Premise
) I-Premise
( I-Premise
P=0,001 I-Premise
) I-Premise
. I-Premise

Aunque B-Premise
el I-Premise
cambio I-Premise
en I-Premise
la I-Premise
ingesta I-Premise
de I-Premise
fibra I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
no I-Premise
fue I-Premise
significativo, I-Premise
hubo B-Premise
una I-Premise
tendencia I-Premise
en I-Premise
la I-Premise
dirección I-Premise
prevista I-Premise
( I-Premise
P=0,083 I-Premise
) O
. O

La B-Claim
intervención I-Claim
nutricional I-Claim
intensiva I-Claim
siguiendo I-Claim
el I-Claim
protocolo I-Claim
ADA I-Claim
MNT I-Claim
da I-Claim
lugar I-Claim
a I-Claim
una I-Claim
mejora I-Claim
de I-Claim
la I-Claim
ingesta I-Claim
dietética I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
práctica I-Claim
estándar I-Claim
y I-Claim
parece I-Claim
tener I-Claim
un I-Claim
impacto I-Claim
beneficioso I-Claim
en I-Claim
los I-Claim
resultados I-Claim
relacionados I-Claim
con I-Claim
la I-Claim
nutrición I-Claim
previamente I-Claim
observados I-Claim
en I-Claim
pacientes I-Claim
ambulatorios I-Claim
de I-Claim
oncología I-Claim
que I-Claim
reciben I-Claim
radioterapia I-Claim
. I-Claim

El B-Claim
protocolo I-Claim
de I-Claim
MNT I-Claim
de I-Claim
la I-Claim
ADA I-Claim
para I-Claim
la I-Claim
radioterapia I-Claim
oncológica I-Claim
es I-Claim
una I-Claim
guía I-Claim
útil I-Claim
sobre I-Claim
el I-Claim
nivel I-Claim
de I-Claim
apoyo I-Claim
nutricional I-Claim
necesario. I-Claim

Determinar O
si O
el O
tipo O
de O
material O
embólico O
utilizado O
para O
la O
embolización O
de O
la O
arteria O
uterina O
( O
EAU O
) O
para O
los O
leiomiomas O
tiene O
un O
impacto O
en O
la O
recuperación O
a O
corto O
plazo O
o O
la O
eficacia O
de O
la O
embolización O
. O

Cien O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
someterse O
a O
una O
EAU O
con O
partículas O
de O
alcohol O
polivinílico O
( O
PVA O
) O
o O
con O
microesferas O
de O
gelatina O
de O
trisacrilo O
. O

Se O
registraron O
los O
niveles O
de O
dolor O
y O
el O
uso O
de O
medicamentos O
a O
corto O
plazo O
en O
el O
hospital. O

Tras O
el O
alta, O
se O
registraron O
diariamente O
la O
gravedad O
de O
los O
síntomas, O
la O
temperatura O
y O
los O
medicamentos O
utilizados O
durante O
una O
semana O
y O
se O
midieron O
los O
niveles O
de O
los O
síntomas O
durante O
las O
semanas O
2-4. O

Tres O
meses O
después O
de O
la O
embolización, O
se O
evaluaron O
a O
ciegas O
los O
exámenes O
de O
resonancia O
magnética O
con O
material O
de O
contraste O
para O
determinar O
la O
extensión O
del O
infarto O
del O
leiomioma. O

Se O
determinó O
el O
estado O
de O
los O
síntomas O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
con O
el O
uso O
de O
cuestionarios O
. O

El O
análisis O
se O
completó O
con O
el O
uso O
del O
análisis O
de O
chi O
( O
2 O
) O
, O
las O
pruebas O
exactas O
de O
Fisher O
, O
las O
pruebas O
t O
de O
Student O
, O
y O
el O
análisis O
de O
la O
varianza O
, O
según O
el O
caso O
. O

Se O
utilizó O
un O
análisis O
de O
regresión O
para O
analizar O
el O
impacto O
en O
el O
resultado O
de O
los O
factores O
de O
base O
( O
distintos O
del O
tipo O
de O
agente O
embólico O
) O
. O

No O
se O
observaron O
diferencias O
significativas O
en O
la O
línea O
de O
base O
entre O
los O
dos O
grupos O
de O
tratamiento O
. O

Por B-Premise
término I-Premise
medio, I-Premise
se I-Premise
utilizaron I-Premise
volúmenes I-Premise
significativamente I-Premise
mayores I-Premise
de I-Premise
microesferas I-Premise
de I-Premise
trisacrilo I-Premise
( I-Premise
9,0 I-Premise
mL I-Premise
frente I-Premise
a I-Premise
3,0 I-Premise
mL I-Premise
; I-Premise
P I-Premise
= I-Premise
0,0001 I-Premise
) O
, O
mientras O
que O
la B-Premise
oclusión I-Premise
del I-Premise
microcatéter I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
con I-Premise
el I-Premise
PVA I-Premise
( I-Premise
28 I-Premise
% I-Premise
frente I-Premise
a I-Premise
4 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
gravedad I-Premise
del I-Premise
dolor, I-Premise
otros I-Premise
síntomas I-Premise
posteriores I-Premise
al I-Premise
procedimiento I-Premise
o I-Premise
el I-Premise
uso I-Premise
de I-Premise
medicamentos I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
de I-Premise
tratamiento. I-Premise

Tampoco B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
frecuencia I-Premise
de I-Premise
los I-Premise
leiomiomas I-Premise
incompletamente I-Premise
infartados, I-Premise
el I-Premise
grado I-Premise
de I-Premise
mejora I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
los I-Premise
síntomas, I-Premise
la I-Premise
satisfacción I-Premise
de I-Premise
las I-Premise
pacientes I-Premise
o I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida. I-Premise

No B-Claim
se I-Claim
detectaron I-Claim
diferencias I-Claim
sustanciales I-Claim
entre I-Claim
los I-Claim
resultados I-Claim
de I-Claim
la I-Claim
embolización I-Claim
con I-Claim
partículas I-Claim
de I-Claim
PVA I-Claim
o I-Claim
con I-Claim
microesferas I-Claim
de I-Claim
gelatina I-Claim
de I-Claim
trisacrilo. I-Claim

Los B-Claim
ensayos I-Claim
anteriores I-Claim
han I-Claim
sugerido I-Claim
una I-Claim
mejora I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
cáncer I-Claim
anémicos I-Claim
tratados I-Claim
con I-Claim
eritropoyetina I-Claim
, I-Claim
pero I-Claim
pocos I-Claim
utilizaron I-Claim
la I-Claim
QOL I-Claim
como I-Claim
resultado I-Claim
primario I-Claim
. I-Claim

Se O
diseñó O
un O
ensayo O
para O
investigar O
los O
efectos O
del O
tratamiento O
con O
epoetina O
alfa O
en O
la O
CdV O
de O
los O
pacientes O
anémicos O
con O
carcinoma O
de O
pulmón O
no O
microcítico O
avanzado O
( O
CPNM O
) O
. O

Se O
realizó O
un O
ensayo O
multicéntrico, O
aleatorizado, O
doble O
ciego O
y O
controlado O
con O
placebo. O

El O
tamaño O
de O
la O
muestra O
propuesta O
era O
de O
300 O
pacientes. O

Los O
pacientes O
elegibles O
debían O
tener O
un O
CPNM O
no O
apto O
para O
terapia O
curativa O
y O
niveles O
de O
hemoglobina O
( O
Hgb O
) O
iniciales O
inferiores O
a O
121 O
g/L O
. O

Los O
pacientes O
fueron O
asignados O
a O
12 O
inyecciones O
semanales O
de O
epoetina O
alfa O
subcutánea O
o O
placebo O
, O
con O
el O
objetivo O
de O
alcanzar O
niveles O
de O
Hgb O
entre O
120 O
y O
140 O
g/L O
. O

El O
resultado O
primario O
fue O
la O
diferencia O
en O
el O
cambio O
de O
las O
puntuaciones O
de O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-Anemia O
entre O
el O
inicio O
y O
las O
12 O
semanas. O

Los O
informes O
de O
eventos O
trombóticos O
en O
otros O
ensayos O
de O
epoetina O
provocaron O
un O
análisis O
de O
seguridad O
no O
planificado O
después O
de O
que O
70 O
pacientes O
hubieran O
sido O
asignados O
al O
azar O
( O
33 O
al O
brazo O
activo O
y O
37 O
al O
brazo O
de O
placebo O
) O
. O

Esto B-Premise
reveló I-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
en I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
favor I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
de I-Premise
placebo I-Premise
del I-Premise
ensayo I-Premise
( I-Premise
63 I-Premise
frente I-Premise
a I-Premise
129 I-Premise
días I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1,84 I-Premise
; I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

El O
Comité O
Directivo O
cerró O
el O
ensayo. O

El B-Premise
número I-Premise
de I-Premise
pacientes I-Premise
comprometió I-Premise
la I-Premise
interpretación I-Premise
del I-Premise
análisis I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
pero O
se O
observó B-Premise
una I-Premise
respuesta I-Premise
positiva I-Premise
de I-Premise
la I-Premise
Hgb I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
epoetina I-Premise
alfa. I-Premise

Un B-Claim
análisis I-Claim
de I-Claim
seguridad I-Claim
no I-Claim
planificado I-Claim
sugirió I-Claim
una I-Claim
disminución I-Claim
de I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
avanzado I-Claim
tratados I-Claim
con I-Claim
epoetina I-Claim
alfa I-Claim
. I-Claim

Aunque O
son O
poco O
frecuentes, O
otros O
informes O
similares O
ponen O
de O
manifiesto O
la O
necesidad O
de O
que O
los O
ensayos O
en O
curso O
en O
los O
que O
se O
evalúan O
los O
agonistas O
del O
receptor O
de O
la O
eritropoyetina O
garanticen O
un O
estrecho O
seguimiento O
de O
la O
supervivencia O
global. O

Informamos O
de O
los O
resultados O
de O
un O
estudio O
prospectivo O
aleatorizado O
que O
comparó O
agentes O
únicos O
de O
baja O
toxicidad O
administrados O
tanto O
como O
quimioterapia O
de O
primera O
línea O
como O
de O
segunda O
línea O
con O
quimioterapia O
combinada O
en O
cáncer O
de O
mama O
avanzado O
con O
metástasis O
a O
distancia O
. O

Los O
pacientes O
del O
brazo O
de O
agente O
único O
( O
n O
= O
153 O
) O
recibieron O
semanalmente O
epirubicina O
( O
E O
) O
20 O
mg/m2 O
hasta O
la O
progresión O
o O
hasta O
la O
dosis O
acumulada O
de O
1.000 O
mg/m2 O
, O
seguida O
de O
mitomicina O
( O
M O
) O
8 O
mg/m2 O
cada O
4 O
semanas O
, O
y O
los O
del O
brazo O
de O
quimioterapia O
combinada O
( O
n O
= O
150 O
) O
recibieron O
primero O
ciclofosfamida O
500 O
mg/m2 O
, O
E O
60 O
mg/m2 O
, O
y O
fluorouracilo O
500 O
mg/m2 O
tres O
veces O
por O
semana O
( O
CEF O
) O
seguido O
de O
M O
8 O
mg/m2 O
más O
vinblastina O
( O
V O
) O
6 O
mg/m2 O
cada O
4 O
semanas O
. O

Los O
criterios O
de O
exclusión O
fueron O
la O
edad O
superior O
a O
70 O
años, O
el O
estado O
de O
rendimiento O
de O
la O
Organización O
Mundial O
de O
la O
Salud O
(OMS) O
superior O
a O
2, O
la O
quimioterapia O
previa O
para O
la O
enfermedad O
metastásica O
y O
la O
presencia O
de O
metástasis O
hepáticas O
en O
pacientes O
menores O
de O
50 O
años. O

Se B-Premise
obtuvo I-Premise
una I-Premise
respuesta I-Premise
objetiva I-Premise
( I-Premise
completa I-Premise
[ I-Premise
CR I-Premise
] I-Premise
o I-Premise
parcial I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
en I-Premise
el I-Premise
55 I-Premise
% I-Premise
, I-Premise
48 I-Premise
% I-Premise
, I-Premise
16 I-Premise
% I-Premise
y I-Premise
7 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
CEF I-Premise
, I-Premise
E I-Premise
, I-Premise
M I-Premise
y I-Premise
MV I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

La B-Premise
respuesta I-Premise
al I-Premise
CEF I-Premise
tendió I-Premise
a I-Premise
durar I-Premise
más I-Premise
que I-Premise
la I-Premise
respuesta I-Premise
al I-Premise
E I-Premise
( I-Premise
mediana I-Premise
, I-Premise
12 I-Premise
frente I-Premise
a I-Premise
10,5 I-Premise
meses I-Premise
; I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
. I-Premise

La B-Premise
toxicidad I-Premise
relacionada I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
fue I-Premise
menor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
del I-Premise
agente I-Premise
único I-Premise
y I-Premise
el I-Premise
análisis I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
QOL I-Premise
) I-Premise
favoreció I-Premise
al I-Premise
brazo I-Premise
del I-Premise
agente I-Premise
único I-Premise
. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
o I-Premise
la I-Premise
supervivencia I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos I-Premise
. I-Premise

Asimismo, B-Premise
no I-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
cuando I-Premise
se I-Premise
compararon I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
los I-Premise
tratamientos I-Premise
previstos I-Premise
de I-Premise
primera I-Premise
y I-Premise
segunda I-Premise
línea I-Premise
o I-Premise
cuando I-Premise
se I-Premise
calculó I-Premise
la I-Premise
supervivencia I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
del I-Premise
tratamiento I-Premise
de I-Premise
segunda I-Premise
línea. I-Premise

Los B-Claim
pacientes I-Claim
tratados I-Claim
con I-Claim
un I-Claim
agente I-Claim
único I-Claim
E I-Claim
seguido I-Claim
de I-Claim
un I-Claim
agente I-Claim
único I-Claim
M I-Claim
tuvieron I-Claim
una I-Claim
supervivencia I-Claim
similar, I-Claim
pero I-Claim
una I-Claim
menor I-Claim
toxicidad I-Claim
relacionada I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
y I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
comparación I-Claim
con I-Claim
los I-Claim
tratados I-Claim
con I-Claim
CEF I-Claim
seguido I-Claim
de I-Claim
MV. I-Claim

Las O
mujeres O
premenopáusicas O
con O
cáncer O
de O
mama O
que O
reciben O
quimioterapia O
adyuvante O
corren O
el O
riesgo O
de O
sufrir O
amenorrea O
. O

El O
ensayo O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
B-30 O
incluyó O
estudios O
de O
historia O
menstrual O
( O
MH O
) O
y O
de O
calidad O
de O
vida O
( O
QOL O
) O
para O
comparar O
los O
tratamientos O
en O
estos O
resultados O
. O

Los O
pacientes O
fueron O
asignados O
al O
azar O
a O
la O
doxorrubicina O
secuencial O
( O
A O
) O
y O
ciclofosfamida O
( O
C O
) O
seguido O
de O
docetaxel O
( O
T O
; O
AC→T O
) O
, O
TAC O
concurrente O
, O
o O
AT O
, O
que O
varió O
en O
la O
duración O
( O
24 O
, O
12 O
, O
12 O
semanas O
, O
respectivamente O
) O
, O
y O
el O
uso O
de O
C. O
La O
terapia O
endocrina O
se O
prescribió O
para O
las O
mujeres O
con O
tumores O
de O
receptores O
hormonales O
positivos O
. O

La O
salud O
mental O
y O
la O
calidad O
de O
vida O
se O
evaluaron O
con O
cuestionarios O
estandarizados O
al O
inicio, O
en O
el O
ciclo O
4, O
el O
día O
1, O
y O
cada O
6 O
meses O
hasta O
los O
24 O
meses. O

Los O
análisis O
preespecificados O
examinaron O
las O
tasas O
de O
amenorrea O
por O
brazo O
de O
tratamiento, O
la O
relación O
entre O
la O
amenorrea O
y O
la O
CdV, O
y O
la O
CdV O
por O
brazo O
de O
tratamiento. O

La B-Premise
amenorrea I-Premise
12 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
asignación I-Premise
aleatoria I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento: I-Premise
69,8 I-Premise
% I-Premise
para I-Premise
AC→T I-Premise
, I-Premise
57,7 I-Premise
% I-Premise
para I-Premise
TAC I-Premise
y I-Premise
37,9 I-Premise
% I-Premise
para I-Premise
AT I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

El B-Premise
grupo I-Premise
de I-Premise
AT I-Premise
sin I-Premise
tamoxifeno I-Premise
tuvo I-Premise
la I-Premise
menor I-Premise
tasa I-Premise
de I-Premise
amenorrea I-Premise
. I-Premise

La B-Premise
CdV I-Premise
fue I-Premise
peor I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
AC→T I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses, I-Premise
pero I-Premise
similar I-Premise
a I-Premise
los I-Premise
demás I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
. I-Premise

Los B-Premise
síntomas I-Premise
posteriores I-Premise
al I-Premise
tratamiento I-Premise
aumentaron I-Premise
por I-Premise
encima I-Premise
del I-Premise
nivel I-Premise
inicial I-Premise
en I-Premise
todos I-Premise
los I-Premise
tratamientos. I-Premise

La B-Premise
modelización I-Premise
multivariable I-Premise
de I-Premise
medidas I-Premise
repetidas I-Premise
demostró I-Premise
que I-Premise
el I-Premise
brazo I-Premise
de I-Premise
tratamiento, I-Premise
el I-Premise
punto I-Premise
de I-Premise
tiempo, I-Premise
la I-Premise
edad I-Premise
y I-Premise
el I-Premise
uso I-Premise
de I-Premise
tamoxifeno I-Premise
estaban I-Premise
significativamente I-Premise
asociados I-Premise
con I-Premise
la I-Premise
gravedad I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
( I-Premise
todos I-Premise
los I-Premise
valores I-Premise
de I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Las B-Claim
tasas I-Claim
de I-Claim
amenorrea I-Claim
difieren I-Claim
significativamente I-Claim
según I-Claim
el I-Claim
brazo I-Claim
de I-Claim
tratamiento, I-Claim
siendo I-Claim
el I-Claim
brazo I-Claim
de I-Claim
AT I-Claim
el I-Claim
que I-Claim
tiene I-Claim
la I-Claim
tasa I-Claim
más I-Claim
baja. I-Claim

Los B-Claim
pacientes I-Claim
tratados I-Claim
con I-Claim
una I-Claim
terapia I-Claim
de I-Claim
mayor I-Claim
duración I-Claim
( I-Claim
AC→T I-Claim
) I-Claim
tuvieron I-Claim
una I-Claim
mayor I-Claim
gravedad I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
y I-Claim
una I-Claim
peor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
a I-Claim
los I-Claim
6 I-Claim
meses I-Claim
, I-Claim
pero I-Claim
no I-Claim
difirieron I-Claim
de I-Claim
los I-Claim
tratamientos I-Claim
de I-Claim
menor I-Claim
duración I-Claim
a I-Claim
los I-Claim
12 I-Claim
meses I-Claim
. I-Claim

Investigar O
si O
el O
seguimiento O
hospitalario O
frecuente O
en O
el O
primer O
año O
después O
del O
tratamiento O
del O
cáncer O
de O
mama O
podría O
sustituirse O
en O
parte O
por O
un O
seguimiento O
telefónico O
dirigido O
por O
enfermeras O
sin O
que O
se O
deteriorara O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQoL O
) O
, O
y O
si O
un O
breve O
programa O
educativo O
de O
grupo O
( O
EGP O
) O
mejoraría O
la O
HRQoL O
. O

Se O
realizó O
un O
ensayo O
controlado O
aleatorio O
pragmático O
multicéntrico O
( O
ECA O
) O
con O
un O
diseño O
factorial O
2×2 O
entre O
320 O
pacientes O
con O
cáncer O
de O
mama O
que O
fueron O
tratadas O
con O
intención O
curativa O
. O

Los O
participantes O
fueron O
asignados O
aleatoriamente O
a O
la O
atención O
de O
seguimiento O
habitual O
(visitas O
ambulatorias O
trimestrales), O
al O
seguimiento O
telefónico O
dirigido O
por O
enfermeras O
o O
a O
las O
primeras O
estrategias O
combinadas O
con O
un O
programa O
educativo O
de O
grupo. O

El O
resultado O
primario O
de O
ambas O
intervenciones O
fue O
la O
CVRS, O
medida O
por O
el O
EORTC O
QLQ-C30 O
. O

Los O
resultados O
secundarios O
fueron O
el O
funcionamiento O
emocional O
y O
de O
roles O
y O
los O
sentimientos O
de O
control O
y O
ansiedad. O

Se O
dispuso O
de O
los O
datos O
de O
299 O
pacientes O
para O
su O
evaluación. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
CVRS I-Premise
entre I-Premise
el I-Premise
seguimiento I-Premise
telefónico I-Premise
dirigido I-Premise
por I-Premise
enfermeras I-Premise
y I-Premise
el I-Premise
hospitalario I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
p I-Premise
= I-Premise
0,42 I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
( I-Premise
IC I-Premise
) I-Premise
del I-Premise
95 I-Premise
% I-Premise
para I-Premise
la I-Premise
diferencia I-Premise
: I-Premise
-1,93-4,64 I-Premise
) I-Premise
y I-Premise
tampoco I-Premise
entre I-Premise
el I-Premise
seguimiento I-Premise
con I-Premise
o I-Premise
sin I-Premise
PGA I-Premise
( I-Premise
p I-Premise
= I-Premise
0,86 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
para I-Premise
la I-Premise
diferencia I-Premise
: I-Premise
-3,59-3,00 I-Premise
) I-Premise
. I-Premise

Además O
, O
no B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
intervención I-Premise
y I-Premise
sus I-Premise
correspondientes I-Premise
grupos I-Premise
de I-Premise
control I-Premise
en I-Premise
el I-Premise
funcionamiento I-Premise
de I-Premise
roles I-Premise
y I-Premise
emocional I-Premise
, I-Premise
y I-Premise
los I-Premise
sentimientos I-Premise
de I-Premise
control I-Premise
y I-Premise
ansiedad I-Premise
( I-Premise
todos I-Premise
los I-Premise
valores I-Premise
p I-Premise
> I-Premise
0,05 I-Premise
) O
. O

La B-Claim
sustitución I-Claim
de I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
las I-Claim
visitas I-Claim
de I-Claim
seguimiento I-Claim
en I-Claim
el I-Claim
hospital I-Claim
durante I-Claim
el I-Claim
primer I-Claim
año I-Claim
tras I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
por I-Claim
un I-Claim
seguimiento I-Claim
telefónico I-Claim
dirigido I-Claim
por I-Claim
enfermeras I-Claim
no I-Claim
dificulta I-Claim
los I-Claim
resultados I-Claim
de I-Claim
las I-Claim
pacientes I-Claim
. I-Claim

Por O
lo O
tanto, O
el B-Claim
seguimiento I-Claim
telefónico I-Claim
dirigido I-Claim
por I-Claim
enfermeras I-Claim
parece I-Claim
una I-Claim
forma I-Claim
adecuada I-Claim
de I-Claim
reducir I-Claim
las I-Claim
visitas I-Claim
a I-Claim
la I-Claim
clínica I-Claim
y I-Claim
representa I-Claim
una I-Claim
estrategia I-Claim
alternativa I-Claim
aceptada. I-Claim

Una O
PGA O
no O
afecta O
de O
forma O
inequívoca O
a O
los O
resultados O
positivos O
de O
la O
CVRS O
. O

Investigar O
el O
impacto O
del O
asesoramiento O
dietético O
o O
los O
suplementos O
nutricionales O
en O
los O
resultados O
de O
los O
pacientes O
con O
cáncer: O
nutricional, O
morbilidad O
y O
calidad O
de O
vida O
( O
QoL O
) O
durante O
y O
3 O
meses O
después O
de O
la O
radioterapia O
. O

Un O
total O
de O
111 O
pacientes O
ambulatorios O
con O
cáncer O
colorrectal O
remitidos O
para O
radioterapia O
, O
estratificados O
por O
estadios O
, O
fueron O
asignados O
aleatoriamente O
: O
grupo O
1 O
( O
G1 O
; O
n O
= O
37 O
) O
, O
asesoramiento O
dietético O
( O
alimentos O
regulares O
) O
; O
grupo O
2 O
( O
G2 O
; O
n O
= O
37 O
) O
, O
suplementos O
proteicos O
; O
y O
grupo O
3 O
( O
G3 O
; O
n O
= O
37 O
) O
, O
ingesta O
ad O
libitum O
. O

La O
ingesta O
nutricional O
( O
historia O
de O
la O
dieta O
) O
, O
el O
estado O
( O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
y O
QoL O
( O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
Cuestionario O
de O
Calidad O
de O
Vida O
versión O
3.0 O
) O
fueron O
evaluados O
en O
la O
línea O
de O
base O
, O
al O
final O
, O
y O
3 O
meses O
después O
de O
la O
radioterapia O
. O

Al B-Premise
finalizar I-Premise
la I-Premise
radioterapia, I-Premise
la I-Premise
ingesta I-Premise
de I-Premise
energía I-Premise
aumentó I-Premise
en I-Premise
el I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
, I-Premise
en I-Premise
el I-Premise
G1 I-Premise
más I-Premise
que I-Premise
en I-Premise
el I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
y I-Premise
disminuyó I-Premise
en I-Premise
el I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

La B-Premise
ingesta I-Premise
de I-Premise
proteínas I-Premise
aumentó I-Premise
en I-Premise
el I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
0,007 I-Premise
) I-Premise
, I-Premise
en I-Premise
el I-Premise
G1 I-Premise
menos I-Premise
que I-Premise
en I-Premise
el I-Premise
G2 I-Premise
( I-Premise
no I-Premise
significativo I-Premise
) I-Premise
, I-Premise
y I-Premise
disminuyó I-Premise
en I-Premise
el I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

A B-Premise
los I-Premise
3 I-Premise
meses, I-Premise
G1 I-Premise
mantuvo I-Premise
la I-Premise
ingesta I-Premise
nutricional I-Premise
y I-Premise
G2/G3 I-Premise
volvieron I-Premise
a I-Premise
la I-Premise
línea I-Premise
de I-Premise
base. I-Premise

Después B-Premise
de I-Premise
la I-Premise
radioterapia I-Premise
y I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses, I-Premise
las I-Premise
tasas I-Premise
de I-Premise
anorexia, I-Premise
náuseas, I-Premise
vómitos I-Premise
y I-Premise
diarrea I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
el I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Al B-Premise
finalizar I-Premise
la I-Premise
radioterapia, I-Premise
en I-Premise
el I-Premise
G1 I-Premise
todas I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
función I-Premise
de I-Premise
la I-Premise
CdV I-Premise
mejoraron I-Premise
proporcionalmente I-Premise
a I-Premise
la I-Premise
ingesta I-Premise
adecuada I-Premise
o I-Premise
al I-Premise
estado I-Premise
nutricional I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
; I-Premise
mientras I-Premise
que I-Premise
en I-Premise
el I-Premise
G2 I-Premise
sólo I-Premise
tres I-Premise
de I-Premise
las I-Premise
seis I-Premise
puntuaciones I-Premise
de I-Premise
función I-Premise
mejoraron I-Premise
proporcionalmente I-Premise
a I-Premise
la I-Premise
ingesta I-Premise
de I-Premise
proteínas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
, I-Premise
y I-Premise
en I-Premise
el I-Premise
G3 I-Premise
todas I-Premise
las I-Premise
puntuaciones I-Premise
empeoraron I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

A B-Premise
los I-Premise
3 I-Premise
meses, I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
G1 I-Premise
mantuvieron/mejoraron I-Premise
la I-Premise
función, I-Premise
los I-Premise
síntomas I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
un I-Premise
solo I-Premise
elemento I-Premise
( I-Premise
P I-Premise
< I-Premise
0,02 I-Premise
); I-Premise
en I-Premise
el I-Premise
G2, I-Premise
sólo I-Premise
mejoraron I-Premise
algunas I-Premise
escalas I-Premise
de I-Premise
función I-Premise
y I-Premise
síntomas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
); I-Premise
en I-Premise
el I-Premise
G3, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
siguió I-Premise
siendo I-Premise
tan I-Premise
mala I-Premise
como I-Premise
después I-Premise
de I-Premise
la I-Premise
radioterapia I-Premise
. I-Premise

En B-Premise
G1/G2 I-Premise
, I-Premise
respectivamente, I-Premise
la I-Premise
mejora/deterioro I-Premise
de I-Premise
la I-Premise
CdV I-Premise
se I-Premise
correlacionó I-Premise
con I-Premise
una I-Premise
mejor I-Premise
o I-Premise
peor I-Premise
ingesta I-Premise
o I-Premise
estado I-Premise
nutricional I-Premise
( I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Durante B-Claim
la I-Claim
radioterapia, I-Claim
ambas I-Claim
intervenciones I-Claim
influyeron I-Claim
positivamente I-Claim
en I-Claim
los I-Claim
resultados; I-Claim
el I-Claim
asesoramiento I-Claim
dietético I-Claim
tuvo I-Claim
un I-Claim
beneficio I-Claim
similar I-Claim
o I-Claim
superior, I-Claim
mientras I-Claim
que I-Claim
incluso I-Claim
3 I-Claim
meses I-Claim
después I-Claim
de I-Claim
la I-Claim
RT, I-Claim
fue I-Claim
el I-Claim
único I-Claim
método I-Claim
que I-Claim
mantuvo I-Claim
un I-Claim
impacto I-Claim
significativo I-Claim
en I-Claim
los I-Claim
resultados I-Claim
de I-Claim
los I-Claim
pacientes. I-Claim

Este O
estudio O
de O
fase O
III O
se O
realizó O
para O
determinar O
la O
superioridad O
de O
la O
doxorrubicina O
( O
DOX O
) O
y O
la O
vinorelbina O
( O
VNB O
) O
( O
brazo O
1 O
) O
frente O
al O
DOX O
solo O
( O
brazo O
2 O
) O
en O
el O
cáncer O
de O
mama O
metastásico O
( O
CMM O
) O
en O
cuanto O
a O
la O
supervivencia O
global O
( O
SG O
) O
, O
el O
tiempo O
hasta O
el O
fracaso O
del O
tratamiento O
( O
TTF O
) O
, O
la O
toxicidad O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
. O

Trescientos O
tres O
pacientes O
fueron O
aleatorizados O
a O
DOX O
50 O
mg/m O
( O
2 O
) O
por O
vía O
intravenosa O
( O
IV O
) O
el O
día O
1 O
y O
VNB O
25 O
mg/m O
( O
2 O
) O
IV O
los O
días O
1 O
y O
8 O
( O
brazo O
1 O
) O
o O
DOX O
70 O
mg/m O
( O
2 O
) O
IV O
el O
día O
1 O
( O
brazo O
2 O
) O
. O

Ambos O
regímenes O
se O
administraron O
cada O
3 O
semanas O
hasta O
una O
dosis O
acumulada O
de O
DOX O
de O
450 O
mg/m O
( O
2 O
) O
. O

Después O
de O
que O
16 O
de O
los O
primeros O
65 O
pacientes O
aleatorizados O
experimentaran O
neutropenia O
febril O
( O
FN O
) O
, O
las O
dosis O
se O
redujeron O
a O
DOX O
40 O
mg/m O
( O
2 O
) O
el O
día O
1 O
y O
VNB O
20 O
mg/m O
( O
2 O
) O
los O
días O
1 O
y O
8 O
frente O
a O
DOX O
60 O
mg/m O
( O
2 O
) O
el O
día O
1 O
. O

Los O
pacientes O
elegibles O
eran O
ingenuos O
a O
los O
alcaloides O
de O
la O
vinca O
y O
a O
las O
antraciclinas. O

La O
quimioterapia O
era O
de O
primera O
o O
segunda O
línea O
para O
el O
CMB. O

Tres O
pacientes O
no O
fueron O
elegibles. O

Así, O
300 O
pacientes O
fueron O
evaluados O
por O
la O
toxicidad O
y O
para O
determinar O
el O
tiempo O
hasta O
la O
progresión O
de O
la O
enfermedad O
( O
TTP O
) O
, O
TTF O
, O
y O
OS O
. O

Doscientos O
ochenta O
y O
nueve O
pacientes O
fueron O
evaluables O
para O
la O
respuesta O
, O
y O
99 O
respondedores O
fueron O
evaluables O
para O
la O
duración O
de O
la O
respuesta O
( O
RD O
) O
. O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
la I-Premise
mediana I-Premise
de I-Premise
RD, I-Premise
TTP I-Premise
y I-Premise
TTF I-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
entre I-Premise
los I-Premise
brazos. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SG I-Premise
fue I-Premise
de I-Premise
13,8 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
1 I-Premise
frente I-Premise
a I-Premise
14,4 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
2 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,4 I-Premise
) I-Premise
. I-Premise

La B-Premise
granulocitopenia I-Premise
de I-Premise
grado I-Premise
3 I-Premise
ó I-Premise
4 I-Premise
fue I-Premise
equivalente I-Premise
en I-Premise
ambos I-Premise
brazos, I-Premise
pero I-Premise
se I-Premise
observó I-Premise
más I-Premise
neurotoxicidad I-Premise
de I-Premise
grado I-Premise
3/4, I-Premise
toxicidad I-Premise
venosa I-Premise
leve I-Premise
y I-Premise
FN I-Premise
en I-Premise
el I-Premise
brazo I-Premise
1. I-Premise

La B-Claim
supervivencia I-Claim
con I-Claim
DOX I-Claim
y I-Claim
VNB I-Claim
no I-Claim
es I-Claim
superior I-Claim
al I-Claim
DOX I-Claim
solo I-Claim
en I-Claim
el I-Claim
CMB I-Claim
. I-Claim

Analizar O
los O
datos O
de O
calidad O
de O
vida O
relacionados O
con O
la O
salud O
( O
HRQOL O
) O
recogidos O
prospectivamente O
de O
los O
pacientes O
inscritos O
en O
dos O
ensayos O
de O
cáncer O
de O
cabeza O
y O
cuello O
de O
fase O
III O
aleatorizados O
del O
Grupo O
de O
Radioterapia O
Oncológica O
( O
90-03 O
y O
91-11 O
) O
para O
evaluar O
su O
valor O
como O
factor O
pronóstico O
independiente O
para O
el O
control O
locorregional O
( O
LRC O
) O
y/o O
la O
supervivencia O
global O
( O
OS O
) O
. O

Los O
cuestionarios O
de O
CVRS O
, O
utilizando O
un O
instrumento O
validado O
, O
la O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-Cabeza O
y O
Cuello O
( O
FACT-H O
& O
amp O
; O
N O
) O
, O
versión O
2 O
, O
fueron O
completados O
por O
los O
pacientes O
antes O
del O
inicio O
del O
tratamiento O
. O

La O
SG O
y O
la O
CRL O
fueron O
las O
medidas O
de O
resultado O
analizadas O
mediante O
un O
modelo O
multivariante O
de O
riesgos O
proporcionales O
de O
Cox. O

Los O
datos O
basales O
de O
FACT-H O
& O
amp O
; O
N O
estaban O
disponibles O
para O
1.093 O
pacientes O
y O
faltaban O
para O
417 O
pacientes O
. O

No O
se O
encontraron O
diferencias O
significativas O
en O
el O
resultado O
entre O
los O
pacientes O
con O
y O
sin O
datos O
basales O
de O
FACT-H O
& O
amp O
; O
N O
( O
p O
= O
0,58 O
) O
. O

La O
mediana O
del O
tiempo O
de O
seguimiento O
fue O
de O
27,2 O
meses O
para O
todos O
los O
pacientes O
y O
de O
49 O
meses O
para O
los O
pacientes O
supervivientes. O

Se O
realizaron O
análisis O
multivariantes O
tanto O
para O
la O
SG O
como O
para O
la O
CRL. O

Más B-Premise
allá I-Premise
de I-Premise
la I-Premise
etapa I-Premise
del I-Premise
tumor I-Premise
y I-Premise
los I-Premise
ganglios I-Premise
, I-Premise
el I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
de I-Premise
Karnofsky I-Premise
, I-Premise
el I-Premise
sitio I-Premise
primario I-Premise
, I-Premise
el I-Premise
uso I-Premise
de I-Premise
cigarrillos I-Premise
, I-Premise
el I-Premise
uso I-Premise
de I-Premise
quimioterapia I-Premise
concurrente I-Premise
, I-Premise
y I-Premise
los I-Premise
esquemas I-Premise
de I-Premise
fraccionamiento I-Premise
alterados I-Premise
, I-Premise
la I-Premise
puntuación I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
; I-Premise
N I-Premise
fue I-Premise
independientemente I-Premise
predictiva I-Premise
de I-Premise
LRC I-Premise
( I-Premise
pero I-Premise
no I-Premise
de I-Premise
la I-Premise
OS I-Premise
) I-Premise
, I-Premise
con I-Premise
p I-Premise
= I-Premise
0,0038 I-Premise
. I-Premise

El B-Premise
componente I-Premise
de I-Premise
bienestar I-Premise
funcional I-Premise
de I-Premise
la I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
; I-Premise
N I-Premise
predijo I-Premise
más I-Premise
significativamente I-Premise
para I-Premise
LRC I-Premise
( I-Premise
p I-Premise
= I-Premise
0,0004 I-Premise
) I-Premise
. I-Premise

Este B-Claim
estudio I-Claim
representa, I-Claim
hasta I-Claim
donde I-Claim
sabemos, I-Claim
el I-Claim
mayor I-Claim
análisis I-Claim
de I-Claim
la I-Claim
CVRS I-Claim
como I-Claim
factor I-Claim
pronóstico I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
cabeza I-Claim
y I-Claim
cuello I-Claim
localmente I-Claim
avanzado. I-Claim

Los B-Claim
resultados I-Claim
de I-Claim
este I-Claim
estudio I-Claim
han I-Claim
demostrado I-Claim
la I-Claim
importancia I-Claim
de I-Claim
la I-Claim
CVRS I-Claim
basal I-Claim
como I-Claim
factor I-Claim
predictivo I-Claim
significativo I-Claim
e I-Claim
independiente I-Claim
de I-Claim
la I-Claim
CRL I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
cabeza I-Claim
y I-Claim
cuello I-Claim
localmente I-Claim
avanzado. I-Claim

El O
linfedema O
es O
un O
efecto O
adverso O
de O
la O
cirugía O
del O
cáncer O
de O
mama O
. O

La O
terapia O
linfática O
acuática O
( O
ALT O
) O
es O
un O
tratamiento O
novedoso O
para O
la O
reducción O
del O
volumen O
de O
las O
extremidades O
. O

El O
objetivo O
de O
este O
estudio O
fue O
examinar O
si O
el O
ALT O
es O
un O
método O
seguro O
y O
si O
hay O
diferencias O
en O
la O
adherencia O
, O
el O
volumen O
de O
las O
extremidades O
y O
la O
calidad O
de O
vida O
entre O
las O
mujeres O
que O
realizan O
sólo O
el O
tratamiento O
de O
autogestión O
y O
las O
mujeres O
que O
participan O
también O
en O
el O
ALT O
. O

El O
diseño O
del O
estudio O
fue O
un O
ensayo O
clínico O
aleatorio O
a O
ciegas. O

El O
escenario O
fue O
en O
una O
piscina O
de O
hidroterapia O
, O
1,2 O
m O
de O
profundidad O
, O
y O
una O
temperatura O
de O
32-33 O
grados O
capital O
ES O
, O
cirílico O
. O

Cuarenta O
y O
ocho O
mujeres O
( O
56 O
+/- O
10 O
años O
) O
, O
con O
un O
volumen O
relativo O
de O
linfedema O
del O
12,8 O
% O
, O
participaron O
en O
el O
estudio O
. O

El O
grupo O
de O
control O
fue O
instruido O
para O
realizar O
el O
tratamiento O
de O
autogestión O
. O

El O
grupo O
del O
estudio O
asistió O
a O
una O
sesión O
semanal O
de O
ALT O
durante O
3 O
meses, O
además O
de O
la O
terapia O
de O
autocontrol. O

La O
adherencia O
se O
evaluó O
mediante O
un O
diario O
autoinformado, O
el O
volumen O
de O
la O
extremidad O
mediante O
un O
dispositivo O
de O
desplazamiento O
de O
agua, O
la O
calidad O
de O
vida O
mediante O
el O
Cuestionario O
de O
Linfedema O
de O
la O
Extremidad O
Superior O
( O
ULL27 O
), O
antes O
y O
después O
del O
período O
de O
intervención. O

No B-Premise
hubo I-Premise
ningún I-Premise
episodio I-Premise
de I-Premise
infección I-Premise
en I-Premise
el I-Premise
brazo I-Premise
ni I-Premise
agravamiento I-Premise
del I-Premise
volumen I-Premise
de I-Premise
la I-Premise
extremidad I-Premise
durante I-Premise
el I-Premise
período I-Premise
de I-Premise
estudio. I-Premise

La B-Premise
ALT I-Premise
tuvo I-Premise
un I-Premise
efecto I-Premise
inmediato I-Premise
positivo, I-Premise
estadística I-Premise
y I-Premise
clínicamente I-Premise
significativo, I-Premise
sobre I-Premise
el I-Premise
volumen I-Premise
de I-Premise
las I-Premise
extremidades, I-Premise
pero I-Premise
no I-Premise
se I-Premise
observó I-Premise
ningún I-Premise
efecto I-Premise
a I-Premise
largo I-Premise
plazo. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
adherencia I-Premise
al I-Premise
ALT I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
que I-Premise
la I-Premise
adherencia I-Premise
a I-Premise
la I-Premise
terapia I-Premise
de I-Premise
autogestión I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
mejoró I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
estudio. I-Premise

El B-Claim
ALT I-Claim
resultó I-Claim
ser I-Claim
un I-Claim
método I-Claim
seguro, I-Claim
con I-Claim
una I-Claim
alta I-Claim
adherencia, I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
mujeres I-Claim
que I-Claim
padecen I-Claim
linfedema I-Claim
de I-Claim
leve I-Claim
a I-Claim
moderado. I-Claim

Se B-Claim
observó I-Claim
un I-Claim
efecto I-Claim
significativo I-Claim
inmediato I-Claim
e I-Claim
insignificante I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
en I-Claim
el I-Claim
volumen I-Claim
de I-Claim
las I-Claim
extremidades. I-Claim

La O
TSH O
humana O
recombinante O
( O
rhTSH O
) O
se O
ha O
convertido O
en O
la O
modalidad O
de O
elección O
para O
la O
ablación O
de O
remanentes O
de O
radioyodo O
( O
RRA O
) O
en O
pacientes O
con O
cáncer O
de O
tiroides O
de O
bajo O
riesgo O
. O

Los O
objetivos O
del O
presente O
estudio O
prospectivo O
y O
aleatorio O
fueron O
evaluar O
el O
impacto O
del O
procedimiento O
de O
estimulación O
de O
TSH O
( O
hipotiroidismo O
vs O
rhTSH O
) O
en O
la O
calidad O
de O
vida O
( O
QoL O
) O
de O
los O
pacientes O
con O
cáncer O
de O
tiroides O
sometidos O
a O
RRA O
y O
evaluar O
la O
eficacia O
de O
ambos O
procedimientos O
. O

La O
L-T4 O
se O
inició O
en O
ambos O
grupos O
después O
de O
la O
tiroidectomía. O

Después O
de O
la O
aleatorización, O
se O
suspendió O
la O
L-T4 O
en O
el O
grupo O
hipotiroideo O
( O
hipo O
) O
y O
se O
continuó O
en O
el O
grupo O
rhTSH O
. O

Se O
administró O
una O
medida O
de O
3,7 O
GBq O
de O
radioyodo O
a O
ambos O
grupos. O

La O
evaluación O
funcional O
de O
la O
terapia O
de O
la O
enfermedad O
crónica-fatiga O
( O
FACIT-F O
) O
se O
administró O
desde O
el O
período O
postoperatorio O
temprano O
hasta O
los O
9 O
meses O
. O

También O
se O
evaluaron O
parámetros O
sociodemográficos, O
escalas O
de O
ansiedad O
y O
depresión O
( O
CES-D O
, O
BDI O
y O
cuestionarios O
de O
estado-rasgo O
de O
Spielberger O
) O
. O

A O
los O
9 O
meses O
, O
los O
pacientes O
se O
sometieron O
a O
una O
prueba O
de O
estimulación O
de O
rhTSH O
, O
a O
una O
gammagrafía O
de O
cuerpo O
entero O
( O
131 O
) O
I O
de O
diagnóstico O
( O
dxWBS O
) O
y O
a O
una O
ecografía O
de O
cuello O
. O

Se O
inscribieron O
en O
el O
estudio O
un O
total O
de O
74 O
pacientes. O

Hubo B-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
de I-Premise
la I-Premise
QoL I-Premise
desde I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
( I-Premise
t0 I-Premise
) I-Premise
hasta I-Premise
t1 I-Premise
( I-Premise
período I-Premise
RRA I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
hipotiroideo I-Premise
con I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
FACIT-F I-Premise
TOI I-Premise
( I-Premise
P I-Premise
< I-Premise
10 I-Premise
( I-Premise
-3 I-Premise
) I-Premise
) I-Premise
, I-Premise
la I-Premise
puntuación I-Premise
total I-Premise
de I-Premise
FACT-G I-Premise
( I-Premise
P I-Premise
= I-Premise
0,005 I-Premise
) I-Premise
y I-Premise
la I-Premise
puntuación I-Premise
total I-Premise
de I-Premise
FACIT-F I-Premise
( I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
) I-Premise
. I-Premise

En B-Premise
cambio, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
se I-Premise
mantuvo I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
rhTSH. I-Premise

En O
el O
análisis O
multivariante, O
los O
cambios O
de O
FACIT-TOI O
sólo O
se O
vieron O
afectados O
por O
la O
modalidad O
de O
estimulación O
de O
TSH O
realizada O
para O
la O
RRA. O

De B-Premise
los I-Premise
3 I-Premise
a I-Premise
los I-Premise
9 I-Premise
meses, I-Premise
los I-Premise
cambios I-Premise
en I-Premise
las I-Premise
escalas I-Premise
y I-Premise
subescalas I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
no I-Premise
fueron I-Premise
estadísticamente I-Premise
diferentes I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
de I-Premise
pacientes. I-Premise

Basándose B-Premise
únicamente I-Premise
en I-Premise
la I-Premise
Tg I-Premise
estimulada I-Premise
por I-Premise
la I-Premise
rhTSH I-Premise
en I-Premise
suero I-Premise
( I-Premise
Tg I-Premise
< I-Premise
0,8 I-Premise
microg/l I-Premise
, I-Premise
BRAHMS I-Premise
Tg I-Premise
Kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
el I-Premise
éxito I-Premise
de I-Premise
la I-Premise
ablación I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
rhTSH I-Premise
e I-Premise
hipotiroidismo I-Premise
, I-Premise
91,7 I-Premise
% I-Premise
y I-Premise
97,1 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
mayor I-Premise
tasa I-Premise
de I-Premise
remanentes I-Premise
tiroideos I-Premise
persistentes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
rhTSH I-Premise
, O
aunque B-Premise
en I-Premise
la I-Premise
mayoría I-Premise
de I-Premise
los I-Premise
casos I-Premise
la I-Premise
captación I-Premise
fue I-Premise
< I-Premise
0,1 I-Premise
% I-Premise
y I-Premise
sin I-Premise
importancia I-Premise
clínica I-Premise
. O

La B-Claim
rhTSH I-Claim
preserva I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
sometidos I-Claim
a I-Claim
RRA I-Claim
con I-Claim
tasas I-Claim
similares I-Claim
de I-Claim
éxito I-Claim
de I-Claim
la I-Claim
ablación I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
hipotiroidismo I-Claim
. I-Claim

Sin O
embargo, O
existe O
una O
gran O
heterogeneidad O
en O
el O
impacto O
clínico O
del O
hipotiroidismo. O

La O
anemia O
inducida O
por O
la O
quimioterapia O
( O
CIA O
) O
responde O
al O
tratamiento O
con O
agentes O
estimulantes O
de O
la O
eritropoyesis O
( O
AEE O
) O
como O
la O
darbepoetina O
alfa O
. O

La O
administración O
de O
los O
AEE O
en O
un O
programa O
sincronizado O
con O
la O
administración O
de O
quimioterapia O
podría O
beneficiar O
a O
los O
pacientes O
al O
reducir O
las O
visitas O
a O
la O
clínica O
y O
mejorar O
potencialmente O
la O
administración O
de O
quimioterapia O
a O
tiempo. O

Este O
estudio O
de O
fase O
2, O
de O
25 O
semanas O
de O
duración O
y O
de O
etiqueta O
abierta, O
evaluó O
la O
no O
inferioridad O
de O
la O
darbepoetina O
alfa O
administrada O
semanalmente O
frente O
a O
una O
pauta O
de O
dosificación O
extendida O
( O
cada O
2 O
o O
3 O
semanas O
) O
en O
pacientes O
con O
CIA O
. O

Los O
pacientes O
fueron O
aleatorizados O
1:1 O
a O
un O
esquema O
de O
dosificación O
ampliado O
( O
EDS O
: O
darbepoetina O
alfa O
300 O
μg O
Q2W O
si O
la O
quimioterapia O
era O
QW O
, O
Q2W O
, O
o O
Q4W O
o O
darbepoetina O
alfa O
500 O
μg O
Q3W O
si O
la O
quimioterapia O
era O
Q3W O
) O
o O
semanal O
( O
150 O
μg O
QW O
independientemente O
del O
esquema O
de O
quimioterapia O
) O
. O

Los O
factores O
de O
estratificación O
incluyeron O
la O
duración O
del O
ciclo O
de O
quimioterapia O
, O
la O
hemoglobina O
de O
cribado O
( O
< O
10 O
g/dL O
frente O
a O
≥10 O
g/dL O
) O
y O
el O
tipo O
de O
tumor O
( O
pulmón/ginecológico O
frente O
a O
otras O
neoplasias O
no O
mieloides O
) O
. O

El O
criterio O
de O
valoración O
principal O
fue O
el O
cambio O
en O
la O
hemoglobina O
desde O
el O
inicio O
hasta O
la O
semana O
13. O

Setecientos O
cincuenta O
y O
dos O
pacientes O
( O
374 O
pacientes O
con O
QW O
; O
378 O
pacientes O
con O
EDS O
) O
recibieron O
≥1 O
dosis O
de O
darbepoetina O
alfa O
y O
fueron O
incluidos O
en O
el O
análisis O
. O

Los O
datos O
demográficos O
y O
el O
estado O
de O
la O
enfermedad O
fueron O
similares O
entre O
los O
grupos. O

El B-Premise
71% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
EDS I-Premise
y I-Premise
el I-Premise
76% I-Premise
del I-Premise
grupo I-Premise
QW I-Premise
alcanzaron I-Premise
el I-Premise
objetivo I-Premise
de I-Premise
hemoglobina I-Premise
de I-Premise
≥11,0 I-Premise
g/dL I-Premise
. I-Premise

Hubo O
una O
diferencia O
mínima O
en O
el O
criterio O
de O
valoración O
primario O
de O
cambio O
medio O
en O
la O
hemoglobina O
( O
de O
la O
línea O
de O
base O
a O
la O
semana O
13 O
) O
entre O
los O
grupos O
de O
QW O
y O
EDS O
( O
-0,04 O
g/dL O
; O
intervalo O
de O
confianza O
del O
95 O
% O
: O
-0,26 O
, O
0,17 O
g/dL O
) O
. O

El O
límite O
superior O
del O
intervalo O
de O
confianza O
del O
95 O
% O
fue O
inferior O
al O
límite O
preespecificado O
de O
< O
0,75 O
g/dL O
, O
lo O
que O
apoya O
la O
no O
inferioridad O
del O
esquema O
de O
dosificación O
de O
la O
EDS O
. O

Los B-Premise
efectos I-Premise
adversos I-Premise
notificados I-Premise
fueron I-Premise
similares I-Premise
entre I-Premise
los I-Premise
grupos. I-Premise

Se B-Premise
informó I-Premise
de I-Premise
un I-Premise
ligero I-Premise
aumento I-Premise
de I-Premise
las I-Premise
transfusiones I-Premise
en I-Premise
el I-Premise
grupo I-Premise
QW I-Premise
. I-Premise

La B-Claim
darbepoetina I-Claim
alfa I-Claim
, I-Claim
cuando I-Claim
se I-Claim
administra I-Claim
de I-Claim
forma I-Claim
sincrónica I-Claim
con I-Claim
la I-Claim
quimioterapia I-Claim
, I-Claim
en I-Claim
una I-Claim
EDS I-Claim
parece I-Claim
tener I-Claim
una I-Claim
eficacia I-Claim
similar I-Claim
a I-Claim
la I-Claim
de I-Claim
la I-Claim
darbepoetina I-Claim
alfa I-Claim
en I-Claim
dosis I-Claim
semanales I-Claim
sin I-Claim
efectos I-Claim
adversos I-Claim
inesperados I-Claim
. I-Claim

Este O
estudio O
proporciona O
datos O
prospectivos O
sobre O
cómo O
los O
múltiples O
regímenes O
de O
dosificación O
disponibles O
con O
darbepoetina O
alfa O
pueden O
sincronizarse O
con O
la O
quimioterapia O
administrada O
a O
través O
de O
una O
gama O
de O
esquemas O
de O
dosificación O
. O

Este O
ensayo O
aleatorio O
de O
fase O
II O
evaluó O
dos O
regímenes O
basados O
en O
docetaxel O
para O
ver O
cuál O
sería O
más O
prometedor O
según O
la O
tasa O
de O
respuesta O
global O
( O
ORR O
) O
para O
compararlo O
en O
un O
ensayo O
de O
fase O
III O
con O
epirubicina-cisplatino-fluorouracilo O
( O
ECF O
) O
como O
tratamiento O
de O
primera O
línea O
del O
cáncer O
gástrico O
avanzado O
. O

Los O
pacientes O
no O
tratados O
con O
quimioterapia O
con O
carcinoma O
gástrico O
no O
resecable O
y/o O
metastásico O
medible, O
un O
estado O
de O
rendimiento O
< O
o= O
1 O
y O
una O
función O
hematológica, O
hepática O
y O
renal O
adecuada O
recibieron O
aleatoriamente O
< O
o= O
ocho O
ciclos O
de O
3 O
semanas O
de O
ECF O
( O
epirubicina O
50 O
mg/m O
( O
2 O
) O
el O
día O
1 O
, O
cisplatino O
60 O
mg/m O
( O
2 O
) O
en O
el O
día O
1 O
, O
y O
fluorouracilo O
[ O
FU O
] O
200 O
mg/m O
( O
2 O
) O
/d O
en O
los O
días O
1 O
a O
21 O
) O
, O
TC O
( O
docetaxel O
inicialmente O
85 O
mg/m O
( O
2 O
) O
en O
el O
día O
1 O
[ O
posteriormente O
reducido O
a O
75 O
mg/m O
( O
2 O
) O
como O
resultado O
de O
la O
toxicidad O
] O
y O
cisplatino O
75 O
mg/m O
( O
2 O
) O
en O
el O
día O
1 O
) O
, O
o O
TCF O
( O
TC O
más O
FU O
300 O
mg/m O
( O
2 O
) O
/d O
en O
los O
días O
1 O
a O
14 O
) O
. O

Los O
objetivos O
del O
estudio O
incluían O
la O
respuesta O
( O
primaria O
) O
, O
la O
supervivencia O
, O
la O
toxicidad O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
. O

La B-Premise
ORR I-Premise
fue I-Premise
del I-Premise
25,0 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
entre I-Premise
el I-Premise
13 I-Premise
% I-Premise
y I-Premise
el I-Premise
41 I-Premise
% I-Premise
) I-Premise
para I-Premise
la I-Premise
ECF I-Premise
, I-Premise
del I-Premise
18,5 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
entre I-Premise
el I-Premise
9 I-Premise
% I-Premise
y I-Premise
el I-Premise
34 I-Premise
% I-Premise
) I-Premise
para I-Premise
la I-Premise
TC I-Premise
, I-Premise
y I-Premise
del I-Premise
36,6 I-Premise
% I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
entre I-Premise
el I-Premise
23 I-Premise
% I-Premise
y I-Premise
el I-Premise
53 I-Premise
% I-Premise
) I-Premise
para I-Premise
la I-Premise
TCF I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
8,3 I-Premise
, I-Premise
11,0 I-Premise
y I-Premise
10,4 I-Premise
meses I-Premise
para I-Premise
ECF I-Premise
, I-Premise
TC I-Premise
y I-Premise
TCF I-Premise
, I-Premise
respectivamente. I-Premise

La B-Premise
toxicidad I-Premise
fue I-Premise
aceptable, I-Premise
con I-Premise
una I-Premise
muerte I-Premise
tóxica I-Premise
( I-Premise
brazo I-Premise
TC I-Premise
) I-Premise
. I-Premise

La B-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3 I-Premise
o I-Premise
4 I-Premise
se I-Premise
produjo I-Premise
en I-Premise
más I-Premise
ciclos I-Premise
de I-Premise
tratamiento I-Premise
con I-Premise
docetaxel I-Premise
( I-Premise
TC I-Premise
, I-Premise
49 I-Premise
% I-Premise
; I-Premise
TCF I-Premise
, I-Premise
57 I-Premise
% I-Premise
; I-Premise
ECF I-Premise
, I-Premise
34 I-Premise
% I-Premise
) I-Premise
. I-Premise

El B-Claim
estado I-Claim
de I-Claim
salud/la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
global I-Claim
mejoró I-Claim
sustancialmente I-Claim
con I-Claim
la I-Claim
ECF I-Claim
y I-Claim
se I-Claim
mantuvo I-Claim
similar I-Claim
al I-Claim
inicio I-Claim
con I-Claim
ambos I-Claim
regímenes I-Claim
de I-Claim
docetaxel I-Claim
. I-Claim

El B-Premise
tiempo I-Premise
de I-Premise
respuesta I-Premise
y I-Premise
la I-Premise
ORR I-Premise
favorecen I-Premise
al I-Premise
TCF I-Premise
sobre I-Premise
el I-Premise
TC I-Premise
para I-Premise
su I-Premise
evaluación I-Premise
posterior, I-Premise
especialmente I-Premise
en I-Premise
el I-Premise
entorno I-Premise
neoadyuvante. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
tendencia I-Premise
al I-Premise
aumento I-Premise
de I-Premise
la I-Premise
mielosupresión I-Premise
y I-Premise
de I-Premise
las I-Premise
complicaciones I-Premise
infecciosas I-Premise
con I-Premise
la I-Premise
TCF I-Premise
frente I-Premise
a I-Premise
la I-Premise
TC I-Premise
o I-Premise
la I-Premise
ECF I-Premise
. I-Premise

Cada O
vez O
se O
ha O
prestado O
más O
atención O
al O
ejercicio O
como O
intervención O
en O
la O
calidad O
de O
vida O
de O
las O
supervivientes O
de O
cáncer O
de O
mama O
durante O
y O
después O
del O
tratamiento O
adyuvante O
. O

Nuestro O
objetivo O
fue O
examinar O
los O
efectos O
de O
la O
recomendación O
de O
un O
oncólogo O
de O
hacer O
ejercicio O
sobre O
la O
conducta O
de O
ejercicio O
autodeclarada O
en O
supervivientes O
de O
cáncer O
de O
mama O
recién O
diagnosticadas O
que O
acuden O
a O
su O
primera O
consulta O
de O
terapia O
adyuvante. O

Utilizando O
un O
ensayo O
controlado O
aleatorio, O
de O
un O
solo O
ciego O
y O
con O
tres O
brazos, O
450 O
supervivientes O
de O
cáncer O
de O
mama O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
sólo O
una O
recomendación O
de O
ejercicio O
por O
parte O
del O
oncólogo, O
una O
recomendación O
de O
ejercicio O
por O
parte O
del O
oncólogo O
más O
la O
derivación O
a O
un O
especialista O
en O
ejercicio, O
o O
la O
atención O
habitual. O

El O
resultado O
primario O
fue O
el O
ejercicio O
total O
autodeclarado O
( O
en O
horas O
equivalentes O
metabólicas O
[ O
MET O
] O
por O
semana O
) O
a O
las O
5 O
semanas O
después O
de O
la O
consulta O
. O

La O
tasa O
de O
evaluación O
del O
seguimiento O
fue O
del O
73% O
( O
329 O
de O
450 O
) O
. O

El B-Premise
análisis I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar, I-Premise
basado I-Premise
en I-Premise
los I-Premise
participantes I-Premise
con I-Premise
datos I-Premise
de I-Premise
seguimiento, I-Premise
indicó I-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
en I-Premise
el I-Premise
ejercicio I-Premise
total I-Premise
a I-Premise
favor I-Premise
del I-Premise
grupo I-Premise
de I-Premise
sólo I-Premise
recomendación I-Premise
sobre I-Premise
el I-Premise
grupo I-Premise
de I-Premise
atención I-Premise
habitual I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
, I-Premise
3,4 I-Premise
MET I-Premise
hr I-Premise
por I-Premise
semana I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
[ I-Premise
IC I-Premise
] I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,7-6,1 I-Premise
MET I-Premise
hr I-Premise
por I-Premise
semana I-Premise
; I-Premise
p I-Premise
= I-Premise
.011 I-Premise
) I-Premise
. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
el I-Premise
grupo I-Premise
de I-Premise
recomendación I-Premise
más I-Premise
derivación I-Premise
y I-Premise
el I-Premise
grupo I-Premise
de I-Premise
atención I-Premise
habitual I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
, I-Premise
1,5 I-Premise
MET I-Premise
hr I-Premise
por I-Premise
semana I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
-1,0 I-Premise
a I-Premise
4,0 I-Premise
MET I-Premise
hr I-Premise
por I-Premise
semana I-Premise
; I-Premise
p I-Premise
= I-Premise
.244 I-Premise
) I-Premise
. I-Premise

Los B-Premise
análisis I-Premise
auxiliares I-Premise
"en I-Premise
el I-Premise
tratamiento" I-Premise
mostraron I-Premise
que I-Premise
los I-Premise
participantes I-Premise
que I-Premise
recordaban I-Premise
una I-Premise
recomendación I-Premise
de I-Premise
ejercicio I-Premise
informaron I-Premise
de I-Premise
un I-Premise
ejercicio I-Premise
total I-Premise
significativamente I-Premise
mayor I-Premise
que I-Premise
los I-Premise
participantes I-Premise
que I-Premise
no I-Premise
recordaban I-Premise
una I-Premise
recomendación I-Premise
de I-Premise
ejercicio I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
, I-Premise
4,1 I-Premise
MET I-Premise
hr I-Premise
por I-Premise
semana I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1,9-6,4 I-Premise
MET I-Premise
hr I-Premise
por I-Premise
semana I-Premise
; I-Premise
p I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Nuestros B-Claim
resultados I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
recomendación I-Claim
de I-Claim
un I-Claim
oncólogo I-Claim
puede I-Claim
aumentar I-Claim
la I-Claim
conducta I-Claim
de I-Claim
ejercicio I-Claim
en I-Claim
las I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
recién I-Claim
diagnosticadas I-Claim
, I-Claim
especialmente I-Claim
si I-Claim
se I-Claim
recuerda I-Claim
1 I-Claim
semana I-Claim
después I-Claim
de I-Claim
la I-Claim
recomendación I-Claim
. I-Claim

La O
investigación O
ha O
demostrado O
que O
el O
entrenamiento O
de O
gestión O
del O
estrés O
autodirigido O
mejora O
el O
bienestar O
mental O
de O
los O
pacientes O
sometidos O
a O
quimioterapia O
. O

El O
presente O
estudio O
amplía O
este O
trabajo O
evaluando O
los O
efectos O
por O
separado O
y O
combinados O
del O
entrenamiento O
para O
el O
manejo O
del O
estrés O
y O
el O
ejercicio O
en O
casa O
. O

Tras O
la O
evaluación O
del O
bienestar O
mental O
y O
físico, O
la O
depresión, O
la O
ansiedad, O
el O
ejercicio O
y O
la O
actividad O
de O
reducción O
del O
estrés O
antes O
del O
inicio O
de O
la O
quimioterapia, O
los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
un O
entrenamiento O
para O
el O
control O
del O
estrés O
( O
SM O
), O
al O
ejercicio O
( O
EX O
), O
al O
control O
del O
estrés O
y O
al O
ejercicio O
combinados O
( O
SMEX O
) O
o O
a O
la O
atención O
habitual O
únicamente O
( O
UCO O
). O

Los O
resultados O
se O
reevaluaron O
a O
las O
6 O
y O
12 O
semanas O
de O
iniciada O
la O
quimioterapia. O

Para O
evaluar O
la O
eficacia O
de O
la O
intervención O
se O
utilizaron O
pruebas O
de O
significación O
de O
las O
interacciones O
grupo-tiempo O
en O
286 O
pacientes O
que O
completaron O
todas O
las O
evaluaciones. O

Los B-Premise
efectos I-Premise
de I-Premise
interacción I-Premise
para I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
bienestar I-Premise
mental I-Premise
y I-Premise
físico I-Premise
no I-Premise
fueron I-Premise
significativos. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
depresión I-Premise
produjeron I-Premise
una I-Premise
interacción I-Premise
lineal I-Premise
que I-Premise
comparaba I-Premise
UCO I-Premise
y I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0,019 I-Premise
) I-Premise
, I-Premise
con I-Premise
disminuciones I-Premise
en I-Premise
SMEX I-Premise
pero I-Premise
no I-Premise
en I-Premise
UCO I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
ansiedad I-Premise
produjeron I-Premise
una I-Premise
interacción I-Premise
cuadrática I-Premise
al I-Premise
comparar I-Premise
UCO I-Premise
y I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0,049 I-Premise
) I-Premise
, I-Premise
con I-Premise
tendencias I-Premise
para I-Premise
los I-Premise
cambios I-Premise
en I-Premise
SMEX I-Premise
pero I-Premise
no I-Premise
en I-Premise
UCO I-Premise
. I-Premise

Los B-Premise
análisis I-Premise
adicionales I-Premise
produjeron I-Premise
interacciones I-Premise
cuadráticas I-Premise
para I-Premise
la I-Premise
actividad I-Premise
de I-Premise
ejercicio I-Premise
comparando I-Premise
UCO I-Premise
y I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0,022 I-Premise
) I-Premise
, I-Premise
con I-Premise
cambios I-Premise
positivos I-Premise
en I-Premise
SMEX I-Premise
pero I-Premise
no I-Premise
en I-Premise
UCO I-Premise
, I-Premise
y I-Premise
para I-Premise
la I-Premise
actividad I-Premise
de I-Premise
gestión I-Premise
del I-Premise
estrés I-Premise
comparando I-Premise
UCO I-Premise
y I-Premise
SM I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
UCO I-Premise
y I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0,013 I-Premise
) I-Premise
, I-Premise
con I-Premise
cambios I-Premise
positivos I-Premise
en I-Premise
SM I-Premise
y I-Premise
SMEX I-Premise
pero I-Premise
no I-Premise
en I-Premise
UCO I-Premise
. I-Premise

Sólo B-Claim
la I-Claim
intervención I-Claim
combinada I-Claim
produjo I-Claim
efectos I-Claim
en I-Claim
los I-Claim
resultados I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida, I-Claim
y I-Claim
éstos I-Claim
se I-Claim
limitaron I-Claim
a I-Claim
la I-Claim
ansiedad I-Claim
y I-Claim
la I-Claim
depresión. I-Claim

Estos B-Premise
resultados I-Premise
son I-Premise
coherentes I-Premise
con I-Premise
la I-Premise
evidencia I-Premise
de I-Premise
que I-Premise
sólo I-Premise
la I-Premise
intervención I-Premise
combinada I-Premise
produjo I-Premise
aumentos I-Premise
en I-Premise
la I-Premise
actividad I-Premise
de I-Premise
ejercicio I-Premise
y I-Premise
de I-Premise
gestión I-Premise
del I-Premise
estrés I-Premise
. I-Premise

Las O
investigaciones O
futuras O
deberán O
estudiar O
formas O
de O
aumentar O
esta O
intervención O
para O
potenciar O
sus O
beneficios O
. O

Determinar O
el O
resultado O
a O
largo O
plazo O
y O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
(CVRS) O
de O
las O
pacientes O
con O
carcinoma O
de O
endometrio O
(CE) O
tratadas O
con O
o O
sin O
radioterapia O
pélvica O
en O
el O
ensayo O
de O
radioterapia O
postoperatoria O
en O
el O
carcinoma O
de O
endometrio O
1 O
(PORTEC-1). O

Entre O
1990 O
y O
1997, O
714 O
pacientes O
con O
CE O
en O
estadio O
IC O
de O
grado O
1 O
a O
2 O
o O
IB O
de O
grado O
2 O
a O
3 O
fueron O
asignados O
aleatoriamente O
a O
radioterapia O
pélvica O
de O
haz O
externo O
( O
EBRT O
) O
o O
a O
ningún O
tratamiento O
adicional O
( O
NAT O
) O
. O

La O
CVRS O
se O
evaluó O
con O
el O
cuestionario O
Short O
Form O
36-Item O
( O
SF-36 O
) O
; O
subescalas O
del O
módulo O
PR25 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
para O
los O
síntomas O
intestinales O
y O
vesicales O
y O
los O
módulos O
OV28 O
y O
CX24 O
para O
los O
síntomas O
sexuales O
; O
y O
preguntas O
demográficas O
. O

El O
análisis O
fue O
por O
intención O
de O
tratar. O

La O
mediana O
de O
seguimiento O
fue O
de O
13,3 O
años. O

Las B-Premise
tasas I-Premise
actuariales I-Premise
de I-Premise
recurrencia I-Premise
locorregional I-Premise
a I-Premise
15 I-Premise
años I-Premise
fueron I-Premise
del I-Premise
5,8% I-Premise
para I-Premise
la I-Premise
EBRT I-Premise
frente I-Premise
al I-Premise
15,5% I-Premise
para I-Premise
la I-Premise
NAT I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
a I-Premise
15 I-Premise
años I-Premise
fue I-Premise
del I-Premise
52% I-Premise
frente I-Premise
al I-Premise
60% I-Premise
( I-Premise
P I-Premise
= I-Premise
0,14 I-Premise
) I-Premise
. I-Premise

De O
los O
351 O
pacientes O
confirmados O
como O
vivos O
con O
dirección O
correcta, O
246 O
( O
70% O
) O
devolvieron O
el O
cuestionario. O

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
EBRT I-Premise
informaron I-Premise
de I-Premise
tasas I-Premise
significativas I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
y I-Premise
clínicamente I-Premise
relevantes I-Premise
más I-Premise
altas I-Premise
de I-Premise
incontinencia I-Premise
urinaria I-Premise
, I-Premise
diarrea I-Premise
y I-Premise
fugas I-Premise
fecales I-Premise
que I-Premise
conducen I-Premise
a I-Premise
más I-Premise
limitaciones I-Premise
en I-Premise
las I-Premise
actividades I-Premise
diarias I-Premise
. I-Premise

El B-Premise
aumento I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
se I-Premise
reflejó I-Premise
en I-Premise
el I-Premise
uso I-Premise
frecuente I-Premise
de I-Premise
materiales I-Premise
para I-Premise
la I-Premise
incontinencia I-Premise
después I-Premise
de I-Premise
la I-Premise
EBRT I-Premise
( I-Premise
uso I-Premise
diurno I-Premise
y I-Premise
nocturno I-Premise
, I-Premise
42,9% I-Premise
frente I-Premise
al I-Premise
15,2% I-Premise
para I-Premise
la I-Premise
NAT I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
EBRT I-Premise
informaron I-Premise
de I-Premise
puntuaciones I-Premise
más I-Premise
bajas I-Premise
en I-Premise
las I-Premise
escalas I-Premise
SF-36 I-Premise
" I-Premise
funcionamiento I-Premise
físico I-Premise
" I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
y I-Premise
" I-Premise
rol-físico I-Premise
" I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

La B-Claim
EBRT I-Claim
para I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
endometrio I-Claim
se I-Claim
asocia I-Claim
con I-Claim
síntomas I-Claim
urinarios I-Claim
e I-Claim
intestinales I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
y I-Claim
un I-Claim
menor I-Claim
funcionamiento I-Claim
físico I-Claim
y I-Claim
de I-Claim
rol, I-Claim
incluso I-Claim
15 I-Claim
años I-Claim
después I-Claim
del I-Claim
tratamiento. I-Claim

A B-Claim
pesar I-Claim
de I-Claim
su I-Claim
eficacia I-Claim
en I-Claim
la I-Claim
reducción I-Claim
de I-Claim
la I-Claim
recurrencia I-Claim
locorregional I-Claim
, I-Claim
la I-Claim
EBRT I-Claim
debe I-Claim
evitarse I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CE I-Claim
de I-Claim
riesgo I-Claim
bajo I-Claim
e I-Claim
intermedio I-Claim
. I-Claim

Se O
estudió O
el O
impacto O
del O
apoyo O
psicoterapéutico O
en O
la O
supervivencia O
de O
los O
pacientes O
con O
cáncer O
gastrointestinal O
sometidos O
a O
cirugía O
. O

Se O
llevó O
a O
cabo O
un O
ensayo O
controlado O
aleatorio O
en O
cooperación O
con O
los O
Departamentos O
de O
Cirugía O
General O
y O
Psicología O
Médica O
del O
Hospital O
Universitario O
de O
Hamburgo, O
Alemania, O
desde O
enero O
de O
1991 O
hasta O
enero O
de O
1993. O

Los O
pacientes O
que O
dieron O
su O
consentimiento O
( O
N O
= O
271 O
) O
con O
un O
diagnóstico O
preliminar O
de O
cáncer O
de O
esófago, O
estómago, O
hígado/vesícula O
biliar, O
páncreas O
o O
colon/recto O
fueron O
estratificados O
por O
sexo O
y O
asignados O
aleatoriamente O
a O
un O
grupo O
de O
control O
que O
recibió O
la O
atención O
estándar O
proporcionada O
en O
las O
salas O
de O
cirugía, O
o O
a O
un O
grupo O
experimental O
que O
recibió O
apoyo O
psicoterapéutico O
formal O
además O
de O
la O
atención O
rutinaria O
durante O
la O
estancia O
en O
el O
hospital. O

Desde O
junio O
de O
2003 O
hasta O
diciembre O
de O
2003, O
se O
realizó O
el O
seguimiento O
de O
10 O
años. O

El O
estado O
de O
supervivencia O
de O
todos O
los O
pacientes O
se O
determinó O
a O
partir O
de O
nuestros O
propios O
registros O
y O
de O
tres O
fuentes O
externas: O
el O
registro O
de O
cáncer O
de O
Hamburgo, O
los O
médicos O
de O
familia O
y O
las O
oficinas O
de O
registro O
general O
de O
ciudadanos. O

Las B-Premise
curvas I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
Kaplan-Meier I-Premise
demostraron I-Premise
una I-Premise
mayor I-Premise
supervivencia I-Premise
del I-Premise
grupo I-Premise
experimental I-Premise
que I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control. I-Premise

El B-Premise
nivel I-Premise
de I-Premise
significación I-Premise
no I-Premise
ajustado I-Premise
para I-Premise
las I-Premise
diferencias I-Premise
de I-Premise
grupo I-Premise
fue I-Premise
de I-Premise
P I-Premise
= I-Premise
0,0006 I-Premise
para I-Premise
la I-Premise
supervivencia I-Premise
a I-Premise
10 I-Premise
años. I-Premise

Los B-Premise
modelos I-Premise
de I-Premise
regresión I-Premise
de I-Premise
Cox I-Premise
que I-Premise
tuvieron I-Premise
en I-Premise
cuenta I-Premise
la I-Premise
estadificación I-Premise
TNM I-Premise
o I-Premise
la I-Premise
clasificación I-Premise
del I-Premise
tumor I-Premise
residual I-Premise
y I-Premise
el I-Premise
lugar I-Premise
del I-Premise
tumor I-Premise
también I-Premise
encontraron I-Premise
diferencias I-Premise
significativas I-Premise
a I-Premise
los I-Premise
10 I-Premise
años I-Premise
. I-Premise

Los B-Premise
análisis I-Premise
secundarios I-Premise
encontraron I-Premise
que I-Premise
las I-Premise
diferencias I-Premise
a I-Premise
favor I-Premise
del I-Premise
grupo I-Premise
experimental I-Premise
se I-Premise
produjeron I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
cáncer I-Premise
de I-Premise
estómago, I-Premise
páncreas, I-Premise
hígado I-Premise
primario I-Premise
o I-Premise
colorrectal. I-Premise

Los B-Claim
resultados I-Claim
de I-Claim
este I-Claim
estudio I-Claim
indican I-Claim
que I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
gastrointestinal I-Claim
, I-Claim
que I-Claim
se I-Claim
someten I-Claim
a I-Claim
una I-Claim
intervención I-Claim
quirúrgica I-Claim
por I-Claim
cáncer I-Claim
de I-Claim
estómago I-Claim
, I-Claim
páncreas I-Claim
, I-Claim
hígado I-Claim
primario I-Claim
o I-Claim
colorrectal I-Claim
, I-Claim
se I-Claim
benefician I-Claim
de I-Claim
un I-Claim
programa I-Claim
formal I-Claim
de I-Claim
apoyo I-Claim
psicoterapéutico I-Claim
durante I-Claim
la I-Claim
estancia I-Claim
hospitalaria I-Claim
en I-Claim
términos I-Claim
de I-Claim
supervivencia I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
. I-Claim

En O
comparación O
con O
el O
placebo O
, O
el O
tratamiento O
profiláctico O
con O
bifosfonatos O
reduce O
el O
riesgo O
de O
eventos O
esqueléticos O
en O
pacientes O
con O
mieloma O
múltiple O
. O

Sin O
embargo, O
debido O
a O
la O
toxicidad O
asociada O
al O
tratamiento O
con O
bifosfonatos O
a O
largo O
plazo, O
es O
importante O
establecer O
la O
dosis O
efectiva O
más O
baja. O

Este O
estudio O
comparó O
el O
efecto O
de O
dos O
dosis O
de O
pamidronato O
sobre O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
y O
la O
morbilidad O
esquelética O
en O
pacientes O
con O
mieloma O
múltiple O
recién O
diagnosticado. O

Este O
ensayo O
doble O
ciego, O
aleatorizado O
y O
de O
fase O
3 O
se O
realizó O
en O
37 O
clínicas O
de O
Dinamarca, O
Noruega O
y O
Suecia. O

Los O
pacientes O
con O
mieloma O
múltiple O
que O
iniciaban O
un O
tratamiento O
antimieloma O
fueron O
asignados O
aleatoriamente O
en O
una O
proporción O
de O
1:1 O
para O
recibir O
una O
de O
las O
dos O
dosis O
de O
pamidronato O
( O
30 O
mg O
o O
90 O
mg O
) O
administradas O
por O
infusión O
intravenosa O
una O
vez O
al O
mes O
durante O
al O
menos O
3 O
años O
. O

La O
aleatorización O
se O
realizó O
mediante O
un O
sistema O
centralizado O
e O
informatizado O
de O
minimización. O

El O
resultado O
primario O
fue O
la O
función O
física O
después O
de O
12 O
meses O
estimada O
por O
el O
cuestionario O
QLQ-C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
( O
escala O
0-100 O
) O
. O

Todos O
los O
pacientes O
que O
devolvieron O
los O
cuestionarios O
a O
los O
12 O
meses O
y O
seguían O
con O
el O
tratamiento O
del O
estudio O
se O
incluyeron O
en O
el O
análisis O
de O
la O
variable O
principal. O

Desde O
enero O
de O
2001 O
hasta O
agosto O
de O
2005, O
504 O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
pamidronato O
30 O
mg O
o O
90 O
mg O
( O
252 O
en O
cada O
grupo O
) O
. O

En O
el O
análisis O
primario O
se O
incluyeron O
157 O
pacientes O
en O
el O
grupo O
de O
90 O
mg O
y O
156 O
en O
el O
de O
30 O
mg. O

La B-Premise
media I-Premise
de I-Premise
la I-Premise
función I-Premise
física I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
fue I-Premise
de I-Premise
66 I-Premise
puntos I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
62-9-70-0 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
90 I-Premise
mg I-Premise
y I-Premise
de I-Premise
68 I-Premise
puntos I-Premise
( I-Premise
64-6-71-4 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
30 I-Premise
mg I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
de I-Premise
la I-Premise
diferencia: I-Premise
-6-6 I-Premise
a I-Premise
3-3 I-Premise
; I-Premise
p=0-52 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
transcurrido I-Premise
hasta I-Premise
el I-Premise
primer I-Premise
evento I-Premise
relacionado I-Premise
con I-Premise
el I-Premise
esqueleto I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
lo I-Premise
sufrieron I-Premise
fue I-Premise
de I-Premise
9-2 I-Premise
meses I-Premise
( I-Premise
8-1-10-7 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
90 I-Premise
mg I-Premise
y I-Premise
de I-Premise
10-2 I-Premise
meses I-Premise
( I-Premise
7-3-14-0 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
30 I-Premise
mg I-Premise
( I-Premise
p=0-63 I-Premise
) I-Premise
. I-Premise

En O
un O
análisis O
retrospectivo, O
ocho B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
90 I-Premise
mg I-Premise
de I-Premise
pamidronato I-Premise
desarrollaron I-Premise
osteonecrosis I-Premise
de I-Premise
la I-Premise
mandíbula, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
dos I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
30 I-Premise
mg. I-Premise

La B-Claim
infusión I-Claim
mensual I-Claim
de I-Claim
pamidronato I-Claim
30 I-Claim
mg I-Claim
debe I-Claim
ser I-Claim
la I-Claim
dosis I-Claim
recomendada I-Claim
para I-Claim
la I-Claim
prevención I-Claim
de I-Claim
la I-Claim
enfermedad I-Claim
ósea I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
mieloma I-Claim
múltiple I-Claim
. I-Claim

Las B-Claim
metástasis I-Claim
óseas I-Claim
son I-Claim
una I-Claim
causa I-Claim
común I-Claim
de I-Claim
morbilidad I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
carcinoma I-Claim
de I-Claim
próstata I-Claim
. I-Claim

Se O
estudió O
el O
efecto O
de O
un O
nuevo O
bifosfonato, O
el O
ácido O
zoledrónico, O
que O
bloquea O
la O
destrucción O
ósea, O
sobre O
las O
complicaciones O
esqueléticas O
en O
pacientes O
con O
cáncer O
de O
próstata O
con O
metástasis O
óseas. O

Los O
pacientes O
con O
cáncer O
de O
próstata O
refractario O
a O
las O
hormonas O
y O
antecedentes O
de O
metástasis O
óseas O
fueron O
asignados O
aleatoriamente O
a O
un O
régimen O
de O
tratamiento O
doble O
ciego O
de O
ácido O
zoledrónico O
intravenoso O
a O
4 O
mg O
( O
N O
= O
214 O
) O
, O
ácido O
zoledrónico O
a O
8 O
mg O
( O
posteriormente O
reducido O
a O
4 O
mg O
; O
8/4 O
) O
( O
N O
= O
221 O
) O
, O
o O
placebo O
( O
N O
= O
208 O
) O
cada O
3 O
semanas O
durante O
15 O
meses O
. O

Se O
evaluaron O
las O
proporciones O
de O
pacientes O
con O
eventos O
relacionados O
con O
el O
esqueleto, O
el O
tiempo O
hasta O
el O
primer O
evento O
relacionado O
con O
el O
esqueleto, O
la O
tasa O
de O
morbilidad O
del O
esqueleto, O
las O
puntuaciones O
de O
dolor O
y O
analgesia, O
la O
progresión O
de O
la O
enfermedad O
y O
la O
seguridad. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

Aproximadamente O
el O
38 O
% O
de O
los O
pacientes O
que O
recibieron O
ácido O
zoledrónico O
a O
4 O
mg O
, O
el O
28 O
% O
que O
recibió O
ácido O
zoledrónico O
a O
8/4 O
mg O
y O
el O
31 O
% O
que O
recibió O
placebo O
completaron O
el O
estudio O
. O

Una B-Premise
mayor I-Premise
proporción I-Premise
de I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
placebo I-Premise
tuvo I-Premise
eventos I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
esqueleto I-Premise
que I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
ácido I-Premise
zoledrónico I-Premise
a I-Premise
4 I-Premise
mg I-Premise
( I-Premise
44,2 I-Premise
% I-Premise
frente I-Premise
a I-Premise
33,2 I-Premise
% I-Premise
; I-Premise
diferencia I-Premise
= I-Premise
-11,0 I-Premise
% I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
IC I-Premise
] I-Premise
= I-Premise
-20,3 I-Premise
% I-Premise
a I-Premise
-1,8 I-Premise
% I-Premise
; I-Premise
P I-Premise
=.021 I-Premise
) I-Premise
o I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
ácido I-Premise
zoledrónico I-Premise
a I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
38,5 I-Premise
% I-Premise
; I-Premise
diferencia I-Premise
frente I-Premise
a I-Premise
placebo I-Premise
= I-Premise
-5,8 I-Premise
% I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
-15,1 I-Premise
% I-Premise
a I-Premise
3,6 I-Premise
% I-Premise
; I-Premise
P I-Premise
=.222 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
primer I-Premise
evento I-Premise
relacionado I-Premise
con I-Premise
el I-Premise
esqueleto I-Premise
fue I-Premise
de I-Premise
321 I-Premise
días I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
placebo I-Premise
, I-Premise
no I-Premise
se I-Premise
alcanzó I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
ácido I-Premise
zoledrónico I-Premise
a I-Premise
4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
frente I-Premise
a I-Premise
placebo I-Premise
) I-Premise
, I-Premise
y I-Premise
fue I-Premise
de I-Premise
363 I-Premise
días I-Premise
para I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
ácido I-Premise
zoledrónico I-Premise
a I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.491 I-Premise
frente I-Premise
a I-Premise
placebo I-Premise
) I-Premise
. I-Premise

En B-Premise
comparación I-Premise
con I-Premise
los I-Premise
marcadores I-Premise
urinarios I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
placebo, I-Premise
los I-Premise
marcadores I-Premise
urinarios I-Premise
de I-Premise
resorción I-Premise
ósea I-Premise
disminuyeron I-Premise
de I-Premise
forma I-Premise
estadísticamente I-Premise
significativa I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
ácido I-Premise
zoledrónico I-Premise
en I-Premise
cualquiera I-Premise
de I-Premise
sus I-Premise
dosis I-Premise
( I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Las O
puntuaciones B-Premise
de I-Premise
dolor I-Premise
y I-Premise
analgesia I-Premise
aumentaron I-Premise
más I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
placebo I-Premise
que I-Premise
en I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
ácido I-Premise
zoledrónico I-Premise
, O
pero O
no B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
progresión I-Premise
de I-Premise
la I-Premise
enfermedad, I-Premise
el I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
o I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
los I-Premise
grupos. I-Premise

El O
ácido B-Claim
zoledrónico I-Claim
a I-Claim
4 I-Claim
mg I-Claim
administrado I-Claim
en I-Claim
infusión I-Claim
de I-Claim
15 I-Claim
minutos I-Claim
fue I-Claim
bien I-Claim
tolerado I-Claim
, O
pero O
la B-Claim
dosis I-Claim
de I-Claim
8 I-Claim
mg I-Claim
se I-Claim
asoció I-Claim
con I-Claim
el I-Claim
deterioro I-Claim
de I-Claim
la I-Claim
función I-Claim
renal I-Claim
. O

El B-Claim
ácido I-Claim
zoledrónico I-Claim
a I-Claim
4 I-Claim
mg I-Claim
redujo I-Claim
los I-Claim
eventos I-Claim
relacionados I-Claim
con I-Claim
el I-Claim
esqueleto I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
próstata I-Claim
con I-Claim
metástasis I-Claim
óseas I-Claim
. I-Claim

Para O
los O
pacientes O
sometidos O
a O
cirugía O
oncológica, O
la O
calidad O
de O
vida O
( O
QoL O
) O
es O
generalmente O
aceptada O
como O
un O
importante O
parámetro O
de O
resultado O
además O
de O
la O
supervivencia O
a O
largo O
plazo O
, O
la O
mortalidad O
y O
las O
tasas O
de O
complicaciones O
. O

Este O
estudio O
se O
centró O
en O
la O
calidad O
de O
vida O
de O
los O
pacientes O
tras O
una O
esofagectomía O
por O
cáncer, O
comparando O
el O
método O
de O
reconstrucción O
(sonda O
gástrica O
estrecha O
o O
estómago O
completo). O

En O
un O
estudio O
prospectivo O
aleatorizado O
de O
un O
solo O
centro O
entre O
2007 O
y O
2008, O
104 O
pacientes O
fueron O
sometidos O
a O
esofagectomía O
por O
cáncer. O

Para O
evaluar O
la O
calidad O
de O
vida, O
se O
administró O
un O
cuestionario O
en O
referencia O
al O
EORTC-QLQ-C30 O
y O
al O
QLQ-OES24 O
a O
las O
3 O
semanas, O
6 O
meses O
y O
1 O
año O
después O
de O
la O
cirugía. O

Los O
datos O
clínicos O
se O
recogieron O
de O
forma O
prospectiva, O
y O
el O
seguimiento O
se O
realizó O
regularmente. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
sonda I-Premise
gástrica I-Premise
estrecha I-Premise
(grupo I-Premise
NGT, I-Premise
n=52) I-Premise
y I-Premise
el I-Premise
grupo I-Premise
de I-Premise
estómago I-Premise
completo I-Premise
(grupo I-Premise
WS, I-Premise
n=52) I-Premise
con I-Premise
respecto I-Premise
a I-Premise
las I-Premise
características I-Premise
del I-Premise
paciente I-Premise
y I-Premise
del I-Premise
cáncer, I-Premise
el I-Premise
procedimiento I-Premise
quirúrgico, I-Premise
la I-Premise
hospitalización I-Premise
postoperatoria I-Premise
en I-Premise
la I-Premise
unidad I-Premise
de I-Premise
cuidados I-Premise
intensivos I-Premise
(UCI) I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
a I-Premise
un I-Premise
año. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
complicación I-Premise
postoperatoria, I-Premise
hubo I-Premise
más I-Premise
casos I-Premise
de I-Premise
esofagitis I-Premise
por I-Premise
reflujo I-Premise
postoperatorio I-Premise
y I-Premise
deterioro I-Premise
de I-Premise
la I-Premise
función I-Premise
pulmonar I-Premise
en I-Premise
el I-Premise
grupo I-Premise
del I-Premise
WS I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
investigación I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
disminuyeron I-Premise
en I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
a I-Premise
las I-Premise
3 I-Premise
semanas I-Premise
de I-Premise
la I-Premise
cirugía. I-Premise

La O
recuperación B-Premise
fue I-Premise
lenta I-Premise
tanto I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
como I-Premise
al I-Premise
año I-Premise
en I-Premise
ambos I-Premise
grupos. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
NGT I-Premise
informaron I-Premise
de I-Premise
puntuaciones I-Premise
significativamente I-Premise
mejores I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
tanto I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
como I-Premise
al I-Premise
año. I-Premise

Los B-Claim
pacientes I-Claim
que I-Claim
se I-Claim
sometieron I-Claim
a I-Claim
una I-Claim
reconstrucción I-Claim
con I-Claim
sonda I-Claim
gástrica I-Claim
presentan I-Claim
menos I-Claim
complicaciones I-Claim
postoperatorias I-Claim
en I-Claim
el I-Claim
tracto I-Claim
digestivo I-Claim
y I-Claim
tienen I-Claim
una I-Claim
recuperación I-Claim
más I-Claim
rápida I-Claim
y I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
durante I-Claim
el I-Claim
periodo I-Claim
de I-Claim
seguimiento. I-Claim

La O
investigación O
y O
la O
recopilación O
de O
datos O
adicionales O
permitirán O
evaluar O
este O
procedimiento O
más O
allá O
de O
un O
año O
después O
de O
la O
operación. O

Realizar O
un O
ensayo O
preliminar O
que O
evalúe O
la O
eficacia O
de O
dos O
tipos O
de O
homeopatía O
para O
el O
tratamiento O
de O
los O
síntomas O
de O
la O
menopausia O
en O
supervivientes O
de O
cáncer O
de O
mama O
. O

Aleatorio, O
doble O
ciego, O
controlado O
con O
placebo. O

Clínica O
médica O
privada, O
Seattle, O
WA. O

Mujeres O
con O
antecedentes O
de O
cáncer O
de O
mama O
que O
hayan O
completado O
todos O
los O
tratamientos O
de O
cirugía, O
quimioterapia O
y O
radioterapia O
y O
que O
hayan O
tenido O
una O
media O
de O
al O
menos O
tres O
sofocos O
al O
día O
durante O
el O
mes O
anterior. O

Los O
sujetos O
fueron O
asignados O
al O
azar O
para O
recibir O
un O
remedio O
homeopático O
individualizado, O
un O
medicamento O
homeopático O
combinado O
o O
un O
placebo. O

Los O
pacientes O
fueron O
atendidos O
por O
proveedores O
homeopáticos O
cada O
dos O
meses O
durante O
un O
año. O

Frecuencia O
y O
gravedad O
de O
los O
sofocos O
, O
Índice O
Kupperman O
de O
la O
Menopausia O
( O
KMI O
) O
, O
Short O
Form O
36 O
( O
SF-36 O
) O
. O

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
medida I-Premise
de I-Premise
resultado I-Premise
primaria, I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
gravedad I-Premise
de I-Premise
los I-Premise
sofocos, I-Premise
aunque B-Premise
hubo I-Premise
una I-Premise
tendencia I-Premise
positiva I-Premise
en I-Premise
el I-Premise
grupo I-Premise
del I-Premise
remedio I-Premise
único I-Premise
durante I-Premise
los I-Premise
primeros I-Premise
3 I-Premise
meses I-Premise
del I-Premise
estudio I-Premise
( I-Premise
p I-Premise
= I-Premise
0,1 I-Premise
) O
. O

Se B-Premise
encontró I-Premise
una I-Premise
mejora I-Premise
estadísticamente I-Premise
significativa I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
salud I-Premise
general I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
de I-Premise
homeopatía I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
en I-Premise
el I-Premise
SF-36 I-Premise
después I-Premise
de I-Premise
1 I-Premise
año I-Premise
. I-Premise

También B-Premise
se I-Premise
encontró I-Premise
evidencia I-Premise
de I-Premise
una I-Premise
"prueba I-Premise
de I-Premise
drogas" I-Premise
homeopática I-Premise
en I-Premise
los I-Premise
sujetos I-Premise
que I-Premise
recibieron I-Premise
la I-Premise
medicina I-Premise
combinada I-Premise
homeopática I-Premise
y I-Premise
que I-Premise
no I-Premise
estaban I-Premise
tomando I-Premise
tamoxifeno. I-Premise

El B-Claim
pequeño I-Claim
tamaño I-Claim
de I-Claim
la I-Claim
muestra I-Claim
impide I-Claim
obtener I-Claim
respuestas I-Claim
definitivas, I-Claim
pero I-Claim
los I-Claim
resultados I-Claim
de I-Claim
este I-Claim
ensayo I-Claim
preliminar I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
homeopatía I-Claim
puede I-Claim
ser I-Claim
valiosa I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
de I-Claim
la I-Claim
menopausia I-Claim
y I-Claim
en I-Claim
la I-Claim
mejora I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida, I-Claim
especialmente I-Claim
en I-Claim
aquellas I-Claim
mujeres I-Claim
que I-Claim
no I-Claim
toman I-Claim
tamoxifeno. I-Claim

Deben B-Claim
realizarse I-Claim
estudios I-Claim
más I-Claim
amplios I-Claim
que I-Claim
incluyan I-Claim
también I-Claim
a I-Claim
mujeres I-Claim
sanas I-Claim
que I-Claim
quieran I-Claim
evitar I-Claim
la I-Claim
terapia I-Claim
hormonal I-Claim
sustitutiva I-Claim
. I-Claim

El B-Claim
aumento I-Claim
de I-Claim
la I-Claim
expresión I-Claim
de I-Claim
las I-Claim
metaloproteinasas I-Claim
se I-Claim
asocia I-Claim
con I-Claim
un I-Claim
mal I-Claim
pronóstico I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
pequeñas I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

Este O
ensayo O
se O
llevó O
a O
cabo O
para O
determinar O
si O
el O
tratamiento O
adyuvante O
con O
el O
inhibidor O
de O
la O
metaloproteinasa O
marimastat O
podía O
prolongar O
la O
supervivencia O
en O
pacientes O
con O
CPCP O
que O
respondían O
a O
la O
quimioterapia. O

Los O
pacientes O
con O
CPCP O
en O
remisión O
completa O
o O
parcial O
fueron O
elegibles. O

Se O
estratificaron O
por O
radioterapia O
( O
temprana, O
tardía O
o O
ninguna O
) O
, O
estadio O
( O
extenso O
o O
limitado O
) O
, O
respuesta O
( O
completa O
o O
parcial O
) O
y O
grupo O
cooperativo O
( O
Instituto O
Nacional O
del O
Cáncer O
de O
Canadá-Grupo O
de O
Ensayos O
Clínicos O
u O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
) O
. O

Se O
les O
asignó O
aleatoriamente O
recibir O
marimastat O
10 O
mg O
o O
placebo O
por O
vía O
oral O
durante O
un O
máximo O
de O
2 O
años. O

Hubo O
532 O
pacientes O
elegibles O
( O
266 O
de O
marimastat O
y O
266 O
de O
placebo O
) O
. O

El O
estadio O
fue O
limitado O
en O
279 O
pacientes O
( O
52% O
) O
y O
extenso O
en O
253 O
( O
48% O
) O
. O

La B-Premise
mejor I-Premise
respuesta I-Premise
a I-Premise
la I-Premise
terapia I-Premise
de I-Premise
inducción I-Premise
fue I-Premise
la I-Premise
remisión I-Premise
completa I-Premise
para I-Premise
176 I-Premise
pacientes I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
la I-Premise
remisión I-Premise
parcial I-Premise
para I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
y I-Premise
15 I-Premise
pacientes I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
fueron I-Premise
sometidos I-Premise
a I-Premise
resección I-Premise
quirúrgica I-Premise
. I-Premise

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
marimastat I-Premise
fue I-Premise
de I-Premise
4,3 I-Premise
meses, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
4,4 I-Premise
meses I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,81 I-Premise
) I-Premise
. I-Premise

Las B-Premise
medianas I-Premise
de I-Premise
supervivencia I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
marimastat I-Premise
y I-Premise
con I-Premise
placebo I-Premise
fueron I-Premise
de I-Premise
9,3 I-Premise
y I-Premise
9,7 I-Premise
meses, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
= I-Premise
0,90 I-Premise
) I-Premise
. I-Premise

La B-Premise
toxicidad I-Premise
se I-Premise
limitó I-Premise
en I-Premise
general I-Premise
a I-Premise
los I-Premise
síntomas I-Premise
musculoesqueléticos I-Premise
( I-Premise
18% I-Premise
grado I-Premise
3/4 I-Premise
para I-Premise
marimastat I-Premise
) I-Premise
. I-Premise

90 B-Premise
pacientes I-Premise
( I-Premise
33% I-Premise
) I-Premise
del I-Premise
brazo I-Premise
de I-Premise
marimastat I-Premise
necesitaron I-Premise
modificaciones I-Premise
de I-Premise
la I-Premise
dosis I-Premise
por I-Premise
toxicidad I-Premise
musculoesquelética, I-Premise
y I-Premise
87 I-Premise
( I-Premise
32% I-Premise
) I-Premise
dejaron I-Premise
de I-Premise
tomar I-Premise
marimastat I-Premise
de I-Premise
forma I-Premise
permanente I-Premise
debido I-Premise
a I-Premise
la I-Premise
toxicidad. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
marimastat I-Premise
tuvieron I-Premise
una I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
significativamente I-Premise
peor I-Premise
a I-Premise
los I-Premise
3 I-Premise
y I-Premise
6 I-Premise
meses. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
marimastat I-Claim
después I-Claim
de I-Claim
la I-Claim
terapia I-Claim
de I-Claim
inducción I-Claim
para I-Claim
el I-Claim
CPCP I-Claim
no I-Claim
dio I-Claim
lugar I-Claim
a I-Claim
una I-Claim
mejora I-Claim
de I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
tuvo I-Claim
un I-Claim
impacto I-Claim
negativo I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
. I-Claim

La B-Claim
morbilidad I-Claim
asociada I-Claim
a I-Claim
las I-Claim
complicaciones I-Claim
de I-Claim
las I-Claim
heridas I-Claim
puede I-Claim
traducirse I-Claim
en I-Claim
discapacidad I-Claim
y I-Claim
desventajas I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
tratados I-Claim
con I-Claim
radioterapia I-Claim
( I-Claim
RT I-Claim
) I-Claim
para I-Claim
el I-Claim
sarcoma I-Claim
de I-Claim
tejidos I-Claim
blandos I-Claim
( I-Claim
STS I-Claim
) I-Claim
de I-Claim
las I-Claim
extremidades I-Claim
. I-Claim

Se O
describen O
los O
resultados O
funcionales O
y O
el O
estado O
de O
salud O
de O
los O
pacientes O
con O
STB O
de O
extremidades O
asignados O
al O
azar O
en O
un O
ensayo O
de O
fase O
III O
que O
compara O
la O
RT O
preoperatoria O
con O
la O
postoperatoria. O

Ciento O
noventa O
pacientes O
con O
STB O
de O
extremidades O
fueron O
aleatorizados O
tras O
estratificar O
por O
el O
tamaño O
del O
tumor O
dicotomizado O
en O
10 O
cm O
. O

La O
función O
y O
la O
calidad O
de O
vida O
se O
midieron O
mediante O
la O
Escala O
de O
Calificación O
de O
la O
Sociedad O
de O
Tumores O
Musculoesqueléticos O
( O
MSTS O
) O
, O
la O
Puntuación O
de O
Salvamento O
de O
Extremidades O
de O
Toronto O
( O
TESS O
) O
y O
el O
Formulario O
Corto-36 O
( O
SF-36 O
) O
en O
la O
aleatorización O
, O
a O
las O
6 O
semanas O
y O
a O
los O
3 O
, O
6 O
, O
12 O
y O
24 O
meses O
después O
de O
la O
cirugía O
. O

Ciento O
ochenta O
y O
cinco O
pacientes O
contaban O
con O
datos O
de O
función O
. O

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
RT I-Premise
postoperatoria I-Premise
tuvieron I-Premise
una I-Premise
mejor I-Premise
función I-Premise
con I-Premise
puntuaciones I-Premise
más I-Premise
altas I-Premise
de I-Premise
MSTS I-Premise
( I-Premise
25,8 I-Premise
v I-Premise
21,3 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
TESS I-Premise
( I-Premise
69,8 I-Premise
v I-Premise
60,6 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
y I-Premise
SF-36 I-Premise
de I-Premise
dolor I-Premise
corporal I-Premise
( I-Premise
67,7 I-Premise
v I-Premise
58,5 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
a I-Premise
las I-Premise
6 I-Premise
semanas I-Premise
después I-Premise
de I-Premise
la I-Premise
cirugía I-Premise
. I-Premise

No O
hubo O
diferencias O
en O
los O
momentos O
posteriores. O

Las B-Premise
puntuaciones I-Premise
en I-Premise
las I-Premise
subescalas I-Premise
de I-Premise
función I-Premise
física, I-Premise
rol I-Premise
físico I-Premise
y I-Premise
salud I-Premise
general I-Premise
del I-Premise
SF-36 I-Premise
fueron I-Premise
significativamente I-Premise
inferiores I-Premise
a I-Premise
los I-Premise
datos I-Premise
normativos I-Premise
canadienses I-Premise
en I-Premise
todos I-Premise
los I-Premise
puntos I-Premise
temporales. I-Premise

Después O
de O
controlar O
el O
brazo O
de O
tratamiento, O
las O
puntuaciones O
de O
cambio O
del O
MSTS O
se O
predijeron O
por O
un O
tumor O
en O
la O
extremidad O
inferior, O
un O
espécimen O
de O
resección O
grande O
y O
el O
sacrificio O
del O
nervio O
motor; O
las O
puntuaciones O
de O
cambio O
del O
TESS O
se O
predijeron O
por O
un O
tumor O
en O
la O
extremidad O
inferior O
y O
una O
escisión O
incompleta O
previa. O

Cuando B-Premise
se I-Premise
incluyó I-Premise
la I-Premise
complicación I-Premise
de I-Premise
la I-Premise
herida I-Premise
en I-Premise
el I-Premise
modelo, I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
complicaciones I-Premise
tuvieron I-Premise
puntuaciones I-Premise
más I-Premise
bajas I-Premise
en I-Premise
el I-Premise
MSTS I-Premise
y I-Premise
el I-Premise
TESS I-Premise
en I-Premise
los I-Premise
dos I-Premise
primeros I-Premise
años I-Premise
después I-Premise
del I-Premise
tratamiento. I-Premise

El B-Claim
momento I-Claim
de I-Claim
la I-Claim
RT I-Claim
tiene I-Claim
un I-Claim
impacto I-Claim
mínimo I-Claim
en I-Claim
la I-Claim
función I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
STB I-Claim
en I-Claim
el I-Claim
primer I-Claim
año I-Claim
después I-Claim
de I-Claim
la I-Claim
cirugía. I-Claim

Las B-Claim
características I-Claim
del I-Claim
tumor I-Claim
y I-Claim
las I-Claim
complicaciones I-Claim
de I-Claim
la I-Claim
herida I-Claim
tienen I-Claim
un I-Claim
efecto I-Claim
perjudicial I-Claim
en I-Claim
la I-Claim
función I-Claim
del I-Claim
paciente. I-Claim

Este O
ensayo O
controlado O
aleatorio O
evaluó O
el O
efecto O
de O
un O
programa O
SMART O
("Stress O
Management O
and O
Resiliency O
Training") O
entre O
25 O
mujeres O
diagnosticadas O
de O
cáncer O
de O
mama O
. O

La O
resiliencia, O
el O
estrés O
percibido, O
la O
ansiedad O
y O
la O
calidad O
de O
vida O
mejoraron O
a O
las O
12 O
semanas O
en O
el O
brazo O
activo O
pero O
no O
en O
el O
de O
control. O

Un O
breve O
entrenamiento O
en O
el O
programa O
SMART O
puede O
mejorar O
la O
resiliencia O
y O
la O
calidad O
de O
vida O
y O
disminuir O
el O
estrés O
y O
la O
ansiedad O
. O

Las O
pacientes O
con O
cáncer O
de O
mama O
experimentan O
estrés O
y O
ansiedad O
relacionados O
con O
su O
diagnóstico, O
con O
la O
consiguiente O
disminución O
de O
su O
calidad O
de O
vida. O

El O
propósito O
de O
este O
estudio O
fue O
evaluar O
el O
efecto O
de O
un O
programa O
SMART O
("Stress O
Management O
and O
Resiliency O
Training") O
para O
aumentar O
la O
resiliencia O
y O
disminuir O
el O
estrés O
y O
la O
ansiedad O
entre O
los O
mentores O
que O
fueron O
diagnosticados O
previamente O
con O
cáncer O
de O
mama O
. O

El O
programa O
consistió O
en O
dos O
sesiones O
de O
formación O
en O
grupo O
de O
90 O
minutos, O
una O
breve O
sesión O
individual O
y O
3 O
llamadas O
telefónicas O
de O
seguimiento. O

Veinticuatro O
mentores O
de O
la O
Clínica O
Mayo O
de O
Rochester, O
Minnesota, O
fueron O
asignados O
aleatoriamente O
en O
un O
ensayo O
clínico O
controlado, O
a O
ciegas O
y O
en O
lista O
de O
espera, O
a O
la O
intervención O
SMART O
o O
a O
un O
grupo O
de O
control O
durante O
12 O
semanas. O

Las O
medidas O
de O
resultado O
primarias O
evaluadas O
al O
inicio O
y O
en O
la O
semana O
12 O
incluyeron O
la O
Escala O
de O
Resiliencia O
de O
Connor O
Davidson O
, O
la O
Escala O
de O
Estrés O
Percibido O
, O
la O
Escala O
de O
Ansiedad O
de O
Smith O
y O
la O
Escala O
de O
Autoevaluación O
Analógica O
Lineal O
. O

Veinte O
pacientes O
completaron O
el O
estudio. O

En B-Premise
el I-Premise
brazo I-Premise
del I-Premise
estudio I-Premise
se I-Premise
observó I-Premise
una I-Premise
mejora I-Premise
estadísticamente I-Premise
significativa I-Premise
de I-Premise
la I-Premise
resiliencia, I-Premise
el I-Premise
estrés I-Premise
percibido, I-Premise
la I-Premise
ansiedad I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
en I-Premise
general I-Premise
a I-Premise
las I-Premise
12 I-Premise
semanas, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
nivel I-Premise
inicial. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
ninguna I-Premise
de I-Premise
estas I-Premise
medidas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control. I-Premise

Este B-Claim
estudio I-Claim
demuestra I-Claim
que I-Claim
una I-Claim
intervención I-Claim
de I-Claim
entrenamiento I-Claim
en I-Claim
resiliencia I-Claim
breve I-Claim
y I-Claim
predominantemente I-Claim
grupal I-Claim
es I-Claim
factible I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
previo; I-Claim
además, I-Claim
puede I-Claim
ser I-Claim
eficaz. I-Claim

Tanto O
la O
gemcitabina O
( O
GEM O
) O
como O
las O
fluoropirimidinas O
son O
tratamientos O
valiosos O
para O
el O
cáncer O
de O
páncreas O
avanzado O
. O

Este O
estudio O
abierto O
se O
diseñó O
para O
comparar O
la O
supervivencia O
global O
( O
SG O
) O
de O
los O
pacientes O
asignados O
aleatoriamente O
a O
GEM O
solo O
o O
a O
GEM O
más O
capecitabina O
( O
GEM-CAP O
) O
. O

Se O
reclutaron O
pacientes O
con O
carcinoma O
de O
páncreas O
localmente O
avanzado O
o O
metastásico O
previamente O
no O
tratado O
y O
con O
un O
estado O
de O
rendimiento O
< O
o= O
2. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
GEM O
o O
GEM-CAP O
. O

La O
medida O
de O
resultado O
primaria O
fue O
la O
supervivencia. O

También O
se O
realizó O
un O
metanálisis O
de O
los O
estudios O
publicados. O

Entre O
mayo O
de O
2002 O
y O
enero O
de O
2005, O
533 O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
los O
brazos O
GEM O
( O
n O
= O
266 O
) O
y O
GEM-CAP O
( O
n O
= O
267 O
) O
. O

GEM-CAP B-Premise
mejoró I-Premise
significativamente I-Premise
la I-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
objetiva I-Premise
( I-Premise
19,1 I-Premise
% I-Premise
frente I-Premise
a I-Premise
12,4 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
0,034 I-Premise
) I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
sin I-Premise
progresión I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0,78 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,66 I-Premise
a I-Premise
0,93 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,004 I-Premise
) I-Premise
y I-Premise
se I-Premise
asoció I-Premise
con I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
la I-Premise
mejora I-Premise
de I-Premise
la I-Premise
SG I-Premise
( I-Premise
HR I-Premise
, I-Premise
0,86 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,72 I-Premise
a I-Premise
1,02 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,08 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
GEM I-Premise
solo. I-Premise

Esta B-Premise
tendencia I-Premise
al I-Premise
beneficio I-Premise
de I-Premise
la I-Premise
SG I-Premise
para I-Premise
GEM-CAP I-Premise
fue I-Premise
consistente I-Premise
en I-Premise
los I-Premise
diferentes I-Premise
subgrupos I-Premise
de I-Premise
pronóstico I-Premise
según I-Premise
los I-Premise
factores I-Premise
de I-Premise
estratificación I-Premise
de I-Premise
base I-Premise
( I-Premise
estadio I-Premise
y I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
) I-Premise
y I-Premise
se I-Premise
mantuvo I-Premise
después I-Premise
de I-Premise
ajustar I-Premise
estos I-Premise
factores I-Premise
de I-Premise
estratificación I-Premise
( I-Premise
P I-Premise
= I-Premise
.077 I-Premise
) I-Premise
. I-Premise

Además, O
el B-Premise
metanálisis I-Premise
de I-Premise
dos I-Premise
estudios I-Premise
adicionales I-Premise
en I-Premise
los I-Premise
que I-Premise
participaron I-Premise
935 I-Premise
pacientes I-Premise
mostró I-Premise
un I-Premise
beneficio I-Premise
de I-Premise
supervivencia I-Premise
significativo I-Premise
a I-Premise
favor I-Premise
de I-Premise
la I-Premise
GEM-CAP I-Premise
( I-Premise
HR I-Premise
, I-Premise
0,86 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,75 I-Premise
a I-Premise
0,98 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
sin I-Premise
heterogeneidad I-Premise
entre I-Premise
ensayos. I-Premise

Sobre B-Claim
la I-Claim
base I-Claim
de I-Claim
nuestro I-Claim
ensayo I-Claim
y I-Claim
el I-Claim
meta-análisis I-Claim
, I-Claim
GEM-CAP I-Claim
debe I-Claim
ser I-Claim
considerado I-Claim
como I-Claim
una I-Claim
de I-Claim
las I-Claim
opciones I-Claim
estándar I-Claim
de I-Claim
primera I-Claim
línea I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
páncreas I-Claim
localmente I-Claim
avanzado I-Claim
y I-Claim
metastásico I-Claim
. I-Claim

Las O
directrices O
de O
la O
Organización O
Mundial O
de O
la O
Salud O
(OMS) O
para O
el O
tratamiento O
del O
dolor O
oncológico O
recomiendan O
los O
analgésicos O
no O
opiáceos O
como O
terapia O
de O
primera O
línea, O
los O
llamados O
analgésicos O
"débiles" O
combinados O
con O
analgésicos O
no O
opiáceos O
como O
terapia O
de O
segunda O
línea, O
y O
los O
llamados O
opiáceos O
"fuertes" O
(con O
analgésicos O
no O
opiáceos) O
sólo O
como O
terapia O
de O
tercera O
línea. O

Sin O
embargo, O
estas O
directrices O
pueden O
ser O
cuestionadas O
en O
lo O
que O
respecta O
al O
grado O
de O
eficacia, O
así O
como O
a O
la O
justificación O
de O
no O
utilizar O
opioides O
fuertes O
como O
tratamiento O
de O
primera O
línea, O
especialmente O
en O
pacientes O
con O
cáncer O
terminal. O

El O
propósito O
de O
este O
estudio O
aleatorio O
fue O
comparar O
prospectivamente O
la O
eficacia O
y O
la O
tolerabilidad O
de O
los O
opioides O
fuertes O
como O
agentes O
de O
primera O
línea O
con O
las O
recomendaciones O
de O
la O
OMS O
en O
pacientes O
con O
cáncer O
terminal O
. O

Cien O
pacientes O
con O
dolor O
leve-moderado O
fueron O
asignados O
aleatoriamente O
a O
un O
tratamiento O
según O
las O
directrices O
de O
la O
OMS O
o O
a O
un O
tratamiento O
con O
opioides O
fuertes O
. O

Los O
resultados O
evaluados O
incluyeron O
la O
intensidad O
del O
dolor, O
la O
necesidad O
de O
cambiar O
el O
tratamiento, O
la O
calidad O
de O
vida, O
el O
estado O
de O
rendimiento O
de O
Karnofsky, O
el O
estado O
general O
del O
paciente O
y O
los O
acontecimientos O
adversos. O

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
entre I-Premise
tratamientos I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
los I-Premise
cambios I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
o I-Premise
el I-Premise
estado I-Premise
funcional, I-Premise
pero O
los B-Premise
pacientes I-Premise
que I-Premise
empezaron I-Premise
a I-Premise
tomar I-Premise
opioides I-Premise
fuertes I-Premise
tuvieron I-Premise
un I-Premise
alivio I-Premise
del I-Premise
dolor I-Premise
significativamente I-Premise
mejor I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
según I-Premise
las I-Premise
directrices I-Premise
de I-Premise
la I-Premise
OMS I-Premise
( I-Premise
P=0,041 I-Premise
) O
. O

Además, B-Premise
los I-Premise
pacientes I-Premise
que I-Premise
empezaron I-Premise
a I-Premise
tomar I-Premise
opioides I-Premise
potentes I-Premise
necesitaron I-Premise
significativamente I-Premise
menos I-Premise
cambios I-Premise
de I-Premise
terapia, I-Premise
tuvieron I-Premise
una I-Premise
mayor I-Premise
reducción I-Premise
del I-Premise
dolor I-Premise
cuando I-Premise
se I-Premise
inició I-Premise
un I-Premise
cambio I-Premise
y I-Premise
manifestaron I-Premise
una I-Premise
mayor I-Premise
satisfacción I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
que I-Premise
el I-Premise
grupo I-Premise
de I-Premise
comparación I-Premise
( I-Premise
P=0,041 I-Premise
) I-Premise
. I-Premise

Los B-Claim
opiáceos I-Claim
fuertes I-Claim
fueron I-Claim
seguros I-Claim
y I-Claim
bien I-Claim
tolerados, I-Claim
sin I-Claim
desarrollo I-Claim
de I-Claim
tolerancia I-Claim
o I-Claim
eventos I-Claim
adversos I-Claim
graves. I-Claim

Estos B-Claim
datos I-Claim
sugieren I-Claim
la I-Claim
utilidad I-Claim
de I-Claim
los I-Claim
opioides I-Claim
fuertes I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
del I-Claim
dolor I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
terminal I-Claim
. I-Claim

No O
está O
claro O
si O
la O
administración O
de O
radioyodo O
proporciona O
algún O
beneficio O
a O
los O
pacientes O
con O
cáncer O
de O
tiroides O
de O
bajo O
riesgo O
después O
de O
una O
resección O
quirúrgica O
completa O
. O

La O
administración O
de O
la O
menor O
cantidad O
posible O
de O
radioyodo O
mejoraría O
la O
atención O
. O

En O
nuestro O
ensayo O
aleatorio O
de O
fase O
3, O
comparamos O
dos O
métodos O
de O
estimulación O
de O
la O
tirotropina O
( O
retirada O
de O
la O
hormona O
tiroidea O
y O
uso O
de O
tirotropina O
humana O
recombinante O
) O
y O
dos O
dosis O
de O
yodo O
radiactivo O
( O
131 O
) O
I O
) O
( O
es O
decir, O
actividades O
administradas O
) O
( O
1,1 O
GBq O
y O
3,7 O
GBq O
) O
en O
un O
diseño O
de O
2 O
por O
2 O
. O

Los O
criterios O
de O
inclusión O
fueron O
una O
edad O
de O
18 O
años O
o O
más; O
tiroidectomía O
total O
por O
carcinoma O
diferenciado O
de O
tiroides; O
estadio O
de O
tumor-nódulo-metástasis O
( O
TNM O
) O
, O
determinado O
en O
el O
examen O
patológico O
( O
p O
) O
de O
una O
muestra O
quirúrgica O
, O
de O
pT1 O
( O
con O
diámetro O
del O
tumor O
≤1 O
cm O
) O
y O
N1 O
o O
Nx O
, O
pT1 O
( O
con O
diámetro O
del O
tumor O
> O
1 O
a O
2 O
cm O
) O
y O
cualquier O
estadio O
N O
, O
o O
pT2N0 O
; O
ausencia O
de O
metástasis O
a O
distancia O
; O
y O
ausencia O
de O
contaminación O
por O
yodo O
. O

La O
ablación O
de O
la O
tiroides O
se O
evaluó O
8 O
meses O
después O
de O
la O
administración O
de O
yodo O
radiactivo O
mediante O
una O
ecografía O
de O
cuello O
y O
la O
medición O
de O
tiroglobulina O
humana O
recombinante O
estimulada O
por O
tirotropina. O

Las O
comparaciones O
se O
basaron O
en O
un O
marco O
de O
equivalencia O
. O

Entre O
2007 O
y O
2010 O
se O
inscribieron O
752 O
pacientes; O
el O
92% O
tenía O
cáncer O
papilar. O

No B-Premise
se I-Premise
produjeron I-Premise
efectos I-Premise
adversos I-Premise
graves I-Premise
inesperados. I-Premise

En B-Premise
los I-Premise
684 I-Premise
pacientes I-Premise
con I-Premise
datos I-Premise
que I-Premise
pudieron I-Premise
ser I-Premise
evaluados I-Premise
, I-Premise
la I-Premise
ultrasonografía I-Premise
del I-Premise
cuello I-Premise
fue I-Premise
normal I-Premise
en I-Premise
652 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
, I-Premise
y I-Premise
el I-Premise
nivel I-Premise
de I-Premise
tiroglobulina I-Premise
estimulada I-Premise
fue I-Premise
de I-Premise
1,0 I-Premise
ng I-Premise
por I-Premise
mililitro I-Premise
o I-Premise
menos I-Premise
en I-Premise
621 I-Premise
de I-Premise
los I-Premise
652 I-Premise
pacientes I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
sin I-Premise
anticuerpos I-Premise
detectables I-Premise
de I-Premise
tiroglobulina I-Premise
. I-Premise

La B-Premise
ablación I-Premise
de I-Premise
la I-Premise
tiroides I-Premise
fue I-Premise
completa I-Premise
en I-Premise
631 I-Premise
de I-Premise
los I-Premise
684 I-Premise
pacientes I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
ablación I-Premise
fue I-Premise
equivalente I-Premise
entre I-Premise
las I-Premise
dosis I-Premise
de I-Premise
( I-Premise
131 I-Premise
) I-Premise
I I-Premise
y I-Premise
entre I-Premise
los I-Premise
métodos I-Premise
de I-Premise
estimulación I-Premise
con I-Premise
tirotropina I-Premise
. I-Premise

El B-Claim
uso I-Claim
de I-Claim
tirotropina I-Claim
humana I-Claim
recombinante I-Claim
y I-Claim
la I-Claim
ablación I-Claim
postoperatoria I-Claim
con I-Claim
dosis I-Claim
bajas I-Claim
( I-Claim
1,1 I-Claim
GBq I-Claim
) I-Claim
de I-Claim
radioyodo I-Claim
puede I-Claim
ser I-Claim
suficiente I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
tiroides I-Claim
de I-Claim
bajo I-Claim
riesgo I-Claim
. I-Claim

El O
objetivo O
de O
este O
estudio O
fue O
comparar O
la O
toxicidad O
y O
la O
eficacia O
de O
la O
radioterapia O
(RT) O
para O
el O
carcinoma O
localizado O
de O
próstata, O
utilizando O
un O
esquema O
de O
dosis O
hipofraccionado O
(55 O
Gy/20 O
fracciones/4 O
semanas) O
frente O
a O
un O
esquema O
de O
dosis O
convencional O
(64 O
Gy/32 O
fracciones/6,5 O
semanas). O

Un O
total O
de O
217 O
pacientes O
fueron O
asignados O
aleatoriamente O
al O
esquema O
de O
dosis O
hipofraccionado O
( O
108 O
pacientes O
) O
o O
al O
convencional O
( O
109 O
pacientes O
) O
, O
con O
planificación O
con O
metodología O
de O
planificación O
por O
TC O
bidimensional O
( O
2D O
) O
en O
la O
mayoría O
de O
los O
casos O
. O

Todos O
los O
pacientes O
fueron O
seguidos O
durante O
una O
mediana O
de O
48 O
( O
6-108 O
) O
meses O
. O

La O
toxicidad O
gastrointestinal O
( O
GI O
) O
y O
genitourinaria O
( O
GU O
) O
se O
evaluó O
antes O
de O
la O
RT O
y O
después O
de O
su O
finalización O
mediante O
escalas O
modificadas O
de O
efectos O
tardíos O
del O
tejido O
normal-subjetivo O
, O
objetivo O
, O
gestión O
, O
analítico O
( O
LENT-SOMA O
) O
y O
el O
cuestionario O
de O
función O
sexual O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
. O

También O
se O
evaluó O
la O
eficacia O
de O
la O
RT O
según O
los O
datos O
clínicos, O
radiológicos O
y O
del O
antígeno O
prostático O
específico O
al O
inicio O
y O
después O
de O
la O
RT. O

La B-Premise
toxicidad I-Premise
gastrointestinal I-Premise
y I-Premise
gastrointestinal I-Premise
persistió I-Premise
5 I-Premise
años I-Premise
después I-Premise
de I-Premise
la I-Premise
RT I-Premise
y I-Premise
no I-Premise
difirió I-Premise
entre I-Premise
los I-Premise
dos I-Premise
esquemas I-Premise
de I-Premise
dosis, I-Premise
salvo I-Premise
en I-Premise
lo I-Premise
que I-Premise
respecta I-Premise
a I-Premise
la I-Premise
urgencia I-Premise
de I-Premise
la I-Premise
defecación. I-Premise

Sin B-Premise
embargo, I-Premise
la I-Premise
toxicidad I-Premise
gastrointestinal I-Premise
a I-Premise
1 I-Premise
mes I-Premise
no I-Premise
sólo I-Premise
fue I-Premise
peor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
el I-Premise
programa I-Premise
de I-Premise
RT I-Premise
hipofraccionada, I-Premise
sino I-Premise
que I-Premise
también I-Premise
afectó I-Premise
negativamente I-Premise
a I-Premise
las I-Premise
actividades I-Premise
diarias. I-Premise

Los B-Premise
valores I-Premise
nadir I-Premise
del I-Premise
antígeno I-Premise
prostático I-Premise
específico I-Premise
se I-Premise
produjeron I-Premise
en I-Premise
una I-Premise
mediana I-Premise
de I-Premise
18,0 I-Premise
( I-Premise
3,0-54,0 I-Premise
) I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
RT I-Premise
. I-Premise

Desde B-Premise
entonces I-Premise
se I-Premise
han I-Premise
producido I-Premise
un I-Premise
total I-Premise
de I-Premise
76 I-Premise
recaídas I-Premise
bioquímicas, I-Premise
con I-Premise
o I-Premise
sin I-Premise
recaídas I-Premise
clínicas; I-Premise
de I-Premise
ellas, I-Premise
37 I-Premise
fueron I-Premise
en I-Premise
el I-Premise
esquema I-Premise
hipofraccionado I-Premise
y I-Premise
39 I-Premise
en I-Premise
el I-Premise
convencional. I-Premise

La B-Premise
supervivencia I-Premise
bioquímica I-Premise
+/- I-Premise
clínica I-Premise
libre I-Premise
de I-Premise
recaída I-Premise
y I-Premise
global I-Premise
a I-Premise
los I-Premise
5 I-Premise
años I-Premise
fue I-Premise
del I-Premise
55,9% I-Premise
y I-Premise
del I-Premise
85,3% I-Premise
respectivamente I-Premise
para I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
, I-Premise
y I-Premise
no I-Premise
difirió I-Premise
entre I-Premise
los I-Premise
dos I-Premise
esquemas I-Premise
. I-Premise

La B-Claim
radioterapia I-Claim
para I-Claim
el I-Claim
carcinoma I-Claim
de I-Claim
próstata I-Claim
causa I-Claim
una I-Claim
toxicidad I-Claim
GI I-Claim
persistente I-Claim
que I-Claim
es I-Claim
en I-Claim
gran I-Claim
medida I-Claim
independiente I-Claim
de I-Claim
los I-Claim
dos I-Claim
esquemas I-Claim
de I-Claim
dosis I-Claim
. I-Claim

El B-Claim
esquema I-Claim
hipofraccionado I-Claim
es I-Claim
equivalente I-Claim
en I-Claim
eficacia I-Claim
al I-Claim
esquema I-Claim
convencional. I-Claim

Evaluar O
la O
eficacia O
de O
la O
reducción O
del O
estrés O
basada O
en O
la O
atención O
plena O
( O
MBSR O
) O
para O
el O
estado O
de O
ánimo O
, O
la O
calidad O
de O
vida O
específica O
de O
la O
mama O
y O
endocrina O
, O
y O
el O
bienestar O
después O
del O
tratamiento O
hospitalario O
en O
mujeres O
con O
cáncer O
de O
mama O
en O
estadio O
0 O
a O
III O
. O

Se O
llevó O
a O
cabo O
un O
ensayo O
aleatorio, O
en O
lista O
de O
espera, O
controlado O
en O
229 O
mujeres O
después O
de O
la O
cirugía, O
la O
quimioterapia O
y O
la O
radioterapia O
para O
el O
cáncer O
de O
mama. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
al O
programa O
MBSR O
de O
8 O
semanas O
o O
a O
la O
atención O
estándar O
. O

Las O
escalas O
Profile O
of O
Mood O
States O
( O
POMS O
; O
resultado O
primario O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-Endocrine O
Symptoms O
( O
FACT-ES O
) O
y O
el O
cuestionario O
de O
bienestar O
de O
cinco O
ítems O
de O
la O
OMS O
( O
WHO-5 O
) O
evaluaron O
el O
estado O
de O
ánimo O
, O
la O
calidad O
de O
vida O
y O
el O
bienestar O
en O
las O
semanas O
0 O
, O
8 O
y O
12 O
. O

Para O
cada O
medida O
de O
resultado, O
se O
utilizó O
un O
modelo O
de O
análisis O
de O
varianza O
con O
medidas O
repetidas, O
que O
incorporaba O
las O
mediciones O
de O
la O
semana O
0 O
como O
covariable, O
para O
comparar O
los O
grupos O
de O
tratamiento O
a O
las O
8 O
y O
12 O
semanas. O

Hubo B-Premise
mejoras I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
el I-Premise
resultado I-Premise
en I-Premise
el I-Premise
grupo I-Premise
experimental I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
tanto I-Premise
a I-Premise
las I-Premise
8 I-Premise
como I-Premise
a I-Premise
las I-Premise
12 I-Premise
semanas I-Premise
( I-Premise
salvo I-Premise
lo I-Premise
indicado I-Premise
) I-Premise
para I-Premise
el I-Premise
trastorno I-Premise
total I-Premise
del I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
POMS I-Premise
( I-Premise
y I-Premise
sus I-Premise
subescalas I-Premise
de I-Premise
ansiedad I-Premise
, I-Premise
depresión I-Premise
[ I-Premise
8 I-Premise
semanas I-Premise
solamente I-Premise
] I-Premise
, I-Premise
ira I-Premise
[ I-Premise
12 I-Premise
semanas I-Premise
solamente I-Premise
] I-Premise
, I-Premise
vigor I-Premise
, I-Premise
fatiga I-Premise
y I-Premise
confusión I-Premise
[ I-Premise
8 I-Premise
semanas I-Premise
solamente I-Premise
] I-Premise
) I-Premise
FACT-B I-Premise
, I-Premise
FACT-ES I-Premise
, I-Premise
( I-Premise
y I-Premise
las I-Premise
subescalas I-Premise
de I-Premise
evaluación I-Premise
funcional I-Premise
de I-Premise
la I-Premise
terapia I-Premise
del I-Premise
cáncer I-Premise
de I-Premise
bienestar I-Premise
físico I-Premise
, I-Premise
social I-Premise
[ I-Premise
8 I-Premise
semanas I-Premise
solamente I-Premise
] I-Premise
, I-Premise
emocional I-Premise
y I-Premise
funcional I-Premise
) I-Premise
, I-Premise
y I-Premise
WHO-5 I-Premise
. I-Premise

La B-Premise
MSBR I-Premise
mejoró I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
relacionada I-Premise
con I-Premise
la I-Premise
mama I-Premise
y I-Premise
el I-Premise
sistema I-Premise
endocrino, I-Premise
y I-Premise
el I-Premise
bienestar I-Premise
con I-Premise
mayor I-Premise
eficacia I-Premise
que I-Premise
el I-Premise
tratamiento I-Premise
estándar I-Premise
en I-Premise
mujeres I-Premise
con I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
en I-Premise
estadio I-Premise
0 I-Premise
a I-Premise
III, I-Premise
y I-Premise
estos I-Premise
resultados I-Premise
persistieron I-Premise
a I-Premise
los I-Premise
tres I-Premise
meses. I-Premise

Hasta B-Claim
donde I-Claim
sabemos I-Claim
, I-Claim
este I-Claim
estudio I-Claim
proporcionó I-Claim
una I-Claim
nueva I-Claim
evidencia I-Claim
de I-Claim
que I-Claim
la I-Claim
MBSR I-Claim
puede I-Claim
ayudar I-Claim
a I-Claim
aliviar I-Claim
los I-Claim
efectos I-Claim
adversos I-Claim
emocionales I-Claim
y I-Claim
físicos I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
de I-Claim
los I-Claim
tratamientos I-Claim
médicos I-Claim
, I-Claim
incluyendo I-Claim
los I-Claim
tratamientos I-Claim
endocrinos I-Claim
. I-Claim

La B-Claim
MBSR I-Claim
se I-Claim
recomienda I-Claim
para I-Claim
apoyar I-Claim
a I-Claim
las I-Claim
supervivientes I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

Este O
ensayo O
se O
llevó O
a O
cabo O
para O
determinar O
si O
las O
altas O
dosis O
de O
fluorouracilo O
( O
FU O
) O
administradas O
en O
infusión O
semanal O
de O
24 O
horas O
son O
más O
activas O
que O
el O
bolo O
de O
FU O
+ O
leucovorina O
( O
LV O
) O
, O
y O
si O
las O
altas O
dosis O
de O
FU O
en O
infusión O
pueden O
ser O
moduladas O
por O
LV O
. O

Un O
total O
de O
497 O
pacientes O
con O
cáncer O
colorrectal O
metastásico O
no O
tratado O
previamente O
fueron O
asignados O
aleatoriamente O
a O
recibir O
un O
bolo O
de O
FU O
de O
425 O
mg/m2 O
por O
vía O
intravenosa O
+ O
LV O
de O
20 O
mg/m2 O
los O
días O
1 O
a O
5 O
y O
repetido O
el O
día O
28 O
( O
FU O
+ O
LV O
) O
, O
o O
FU O
de O
2600 O
mg/m2 O
en O
infusión O
de O
24 O
horas O
solo O
( O
FU24h O
) O
o O
en O
combinación O
con O
500 O
mg/m2 O
de O
LV O
( O
FU24h O
+ O
LV O
) O
- O
todo O
ello O
administrado O
semanalmente O
x6 O
seguido O
de O
un O
periodo O
de O
descanso O
de O
2 O
semanas O
. O

La O
supervivencia O
fue O
el O
principal O
criterio O
de O
valoración O
del O
estudio. O

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
más I-Premise
de I-Premise
3 I-Premise
años, I-Premise
la I-Premise
supervivencia I-Premise
no I-Premise
difirió I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
mediana I-Premise
de I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11,1 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
10,2 I-Premise
a I-Premise
15,0 I-Premise
meses I-Premise
] I-Premise
; I-Premise
FU24h I-Premise
, I-Premise
13,0 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
10,4 I-Premise
a I-Premise
15,4 I-Premise
meses I-Premise
] I-Premise
; I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13,7 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
12,0 I-Premise
a I-Premise
16,4 I-Premise
meses I-Premise
] I-Premise
; I-Premise
P I-Premise
=0,724 I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
( I-Premise
SSP I-Premise
) I-Premise
fue I-Premise
significativamente I-Premise
más I-Premise
larga I-Premise
para I-Premise
el I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
mediana I-Premise
de I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
4,0 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
3,4 I-Premise
a I-Premise
4,9 I-Premise
] I-Premise
; I-Premise
FU24h I-Premise
, I-Premise
4,1 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
3,4 I-Premise
a I-Premise
5,0 I-Premise
] I-Premise
; I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
5,6 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
4,4 I-Premise
a I-Premise
6,7 I-Premise
] I-Premise
; I-Premise
P I-Premise
= I-Premise
0,029 I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
en I-Premise
el I-Premise
subgrupo I-Premise
de I-Premise
pacientes I-Premise
con I-Premise
enfermedad I-Premise
medible I-Premise
fueron I-Premise
del I-Premise
12 I-Premise
% I-Premise
, I-Premise
10 I-Premise
% I-Premise
y I-Premise
17 I-Premise
% I-Premise
para I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
FU24h I-Premise
y I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
no I-Premise
significativo I-Premise
) I-Premise
. I-Premise

La B-Premise
aparición I-Premise
de I-Premise
diarrea I-Premise
de I-Premise
grado I-Premise
3 I-Premise
y I-Premise
4 I-Premise
fue I-Premise
mayor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
brazos I-Premise
FU24h I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
o I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
( I-Premise
9 I-Premise
% O
) O
; O
sin B-Premise
embargo I-Premise
, I-Premise
la I-Premise
estomatitis I-Premise
( I-Premise
11 I-Premise
% I-Premise
en I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
v I-Premise
3 I-Premise
% I-Premise
en I-Premise
FU24h I-Premise
v I-Premise
5 I-Premise
% I-Premise
en I-Premise
los I-Premise
brazos I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
) I-Premise
y I-Premise
la I-Premise
toxicidad I-Premise
hematológica I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
el I-Premise
brazo I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
en I-Premise
bolo I-Premise
. O

La B-Claim
calidad I-Claim
de I-Claim
vida I-Claim
global I-Claim
no I-Claim
fue I-Claim
diferente I-Claim
en I-Claim
los I-Claim
tres I-Claim
brazos. I-Claim

Ni B-Claim
el I-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
ni I-Claim
el I-Claim
FU24h I-Claim
prolongan I-Claim
la I-Claim
supervivencia I-Claim
, I-Claim
en I-Claim
relación I-Claim
con I-Claim
el I-Claim
bolo I-Claim
de I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

La B-Claim
leucovorina I-Claim
aumenta I-Claim
la I-Claim
SLP I-Claim
si I-Claim
se I-Claim
añade I-Claim
al I-Claim
FU24h I-Claim
, I-Claim
pero I-Claim
aumenta I-Claim
la I-Claim
toxicidad I-Claim
. I-Claim

El O
estudio O
del O
Grupo O
Europeo O
de O
Estudio O
del O
Cáncer O
de O
Páncreas O
( O
ESPAC-1 O
) O
es O
el O
mayor O
estudio O
sobre O
el O
tratamiento O
adyuvante O
del O
adenocarcinoma O
ductal O
de O
páncreas O
realizado O
hasta O
la O
fecha O
y O
confirmó O
una O
ventaja O
de O
supervivencia O
para O
la O
quimioterapia O
adyuvante, O
pero O
no O
para O
la O
quimiorradiación O
. O

La O
importancia O
de O
la O
evaluación O
paralela O
de O
la O
supervivencia O
y O
la O
calidad O
de O
vida O
( O
QoL O
) O
ha O
sido O
reconocida O
como O
fundamental O
y O
el O
objetivo O
fue O
evaluar O
la O
QoL O
y O
la O
supervivencia O
ajustada O
a O
la O
calidad O
. O

Un O
estudio O
longitudinal O
de O
la O
calidad O
de O
vida O
en O
un O
subconjunto O
de O
pacientes O
de O
ESPAC-1 O
que O
completaron O
prospectivamente O
el O
cuestionario O
EORTC O
QLQ O
C-30 O
durante O
el O
tratamiento O
y O
el O
seguimiento O
. O

Se O
utilizó O
un O
método O
de O
producto O
integrado O
de O
calidad O
y O
supervivencia O
para O
ajustar O
cualquier O
efecto O
del O
tratamiento O
sobre O
la O
supervivencia O
mediante O
una O
función O
de O
la O
calidad O
de O
vida O
medida, O
calculada O
en O
un O
periodo O
restringido O
de O
24 O
meses O
( O
QALM-24 O
). O

Trescientos O
dieciséis O
pacientes O
completaron O
1.201 O
cuestionarios. O

No O
hubo O
diferencias O
entre O
los O
grupos O
de O
tratamiento O
en O
las O
puntuaciones O
de O
las O
dimensiones O
al O
inicio O
( O
aleatorización O
) O
. O

Para B-Premise
el I-Premise
grupo I-Premise
de I-Premise
quimioterapia, I-Premise
la I-Premise
media I-Premise
de I-Premise
meses I-Premise
de I-Premise
vida I-Premise
ajustada I-Premise
a I-Premise
la I-Premise
calidad I-Premise
durante I-Premise
24 I-Premise
meses I-Premise
( I-Premise
QALM-24 I-Premise
) I-Premise
fue I-Premise
de I-Premise
9,6 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
: I-Premise
8,7 I-Premise
, I-Premise
11,2 I-Premise
) I-Premise
meses I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
media I-Premise
de I-Premise
QALM-24 I-Premise
de I-Premise
8,6 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
: I-Premise
7,6 I-Premise
, I-Premise
10,5 I-Premise
) I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
sin I-Premise
quimioterapia I-Premise
. I-Premise

Para B-Premise
el I-Premise
grupo I-Premise
de I-Premise
quimiorradiación I-Premise
, I-Premise
la I-Premise
media I-Premise
de I-Premise
QALM-24 I-Premise
fue I-Premise
de I-Premise
7,1 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
: I-Premise
6,0 I-Premise
, I-Premise
9,0 I-Premise
) I-Premise
meses I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
media I-Premise
de I-Premise
QALM-24 I-Premise
de I-Premise
8,1 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
: I-Premise
7,0 I-Premise
, I-Premise
10,0 I-Premise
) I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
sin I-Premise
quimiorradiación I-Premise
. I-Premise

La B-Claim
ventaja I-Claim
de I-Claim
supervivencia I-Claim
comunicada I-Claim
anteriormente I-Claim
que I-Claim
apoya I-Claim
el I-Claim
uso I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
adyuvante I-Claim
se I-Claim
mantiene I-Claim
cuando I-Claim
se I-Claim
ajusta I-Claim
utilizando I-Claim
la I-Claim
metodología I-Claim
de I-Claim
supervivencia I-Claim
ajustada I-Claim
por I-Claim
calidad I-Claim
. I-Claim

La B-Claim
quimioterapia I-Claim
proporcionó I-Claim
una I-Claim
media I-Claim
de I-Claim
1,0 I-Claim
meses I-Claim
de I-Claim
vida I-Claim
ajustados I-Claim
a I-Claim
la I-Claim
calidad I-Claim
en I-Claim
un I-Claim
periodo I-Claim
restringido I-Claim
de I-Claim
2 I-Claim
años I-Claim
desde I-Claim
el I-Claim
momento I-Claim
de I-Claim
la I-Claim
resección. I-Claim

Es O
posible O
mejorar O
la O
calidad O
de O
la O
atención O
oncológica O
si O
se O
abordan O
las O
necesidades O
de O
cuidados O
de O
apoyo; O
sin O
embargo, O
hay O
pocos O
ensayos O
de O
intervenciones O
de O
cuidados O
de O
apoyo O
para O
orientar O
la O
política O
y O
la O
práctica. O

El O
objetivo O
de O
este O
estudio O
era O
determinar O
la O
eficacia O
de O
una O
intervención O
de O
apoyo O
telefónico O
realizada O
por O
enfermeras O
(la O
intervención O
"CONNECT"). O

Este O
estudio O
fue O
un O
ensayo O
piloto O
controlado O
y O
aleatorio. O

Los O
pacientes O
del O
grupo O
de O
intervención O
recibieron O
5 O
llamadas O
de O
una O
enfermera O
colorrectal O
especializada O
en O
los O
6 O
meses O
posteriores O
al O
alta O
hospitalaria O
. O

Cada O
llamada O
fue O
estandarizada, O
comprendiendo O
la O
evaluación O
de O
la O
necesidad O
insatisfecha O
y O
la O
provisión O
de O
información O
y O
apoyo O
emocional. O

CONNECT O
se O
sumó O
al O
seguimiento O
clínico O
estándar. O

Los O
pacientes O
asignados O
al O
grupo O
de O
control O
sólo O
recibieron O
un O
seguimiento O
estándar. O

Este O
estudio O
se O
llevó O
a O
cabo O
en O
el O
Royal O
Prince O
Alfred O
Hospital, O
Sydney, O
Australia. O

Se O
incluyeron O
pacientes O
( O
n O
= O
75 O
) O
que O
habían O
sido O
tratados O
quirúrgicamente O
por O
cáncer O
colorrectal O
( O
cualquier O
estadio O
) O
. O

Las O
principales O
medidas O
de O
resultado O
fueron O
las O
necesidades O
insatisfechas O
de O
cuidados O
de O
apoyo, O
la O
utilización O
de O
servicios O
sanitarios O
y O
la O
calidad O
de O
vida O
a O
los O
1, O
3 O
y O
6 O
meses O
después O
del O
alta. O

De O
87 O
pacientes O
elegibles, O
75 O
dieron O
su O
consentimiento O
(tasa O
de O
consentimiento O
del O
86%). O

Treinta O
y O
nueve O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
CONNECT O
y O
36 O
a O
la O
atención O
habitual. O

A B-Premise
los I-Premise
6 I-Premise
meses, I-Premise
hubo I-Premise
una I-Premise
reducción I-Premise
clínicamente I-Premise
relevante, I-Premise
pero I-Premise
no I-Premise
significativa, I-Premise
de I-Premise
las I-Premise
presentaciones I-Premise
a I-Premise
los I-Premise
servicios I-Premise
de I-Premise
urgencias I-Premise
( I-Premise
21 I-Premise
% I-Premise
frente I-Premise
a I-Premise
33 I-Premise
%; I-Premise
χ1 I-Premise
= I-Premise
1,41 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,23 I-Premise
) I-Premise
y I-Premise
de I-Premise
los I-Premise
reingresos I-Premise
en I-Premise
el I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
frente I-Premise
a I-Premise
47 I-Premise
%; I-Premise
χ1 I-Premise
= I-Premise
0,82 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,37 I-Premise
) I-Premise
entre I-Premise
los I-Premise
participantes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
. I-Premise

Se B-Premise
encontraron I-Premise
diferencias I-Premise
no I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
para I-Premise
todas I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
necesidades I-Premise
de I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
no I-Premise
satisfechas I-Premise
y I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
cambio I-Premise
y I-Premise
las I-Premise
tendencias I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses, I-Premise
las I-Premise
puntuaciones I-Premise
totales I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fueron I-Premise
mayores I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
que I-Premise
en I-Premise
los I-Premise
controles I-Premise
( I-Premise
106,0 I-Premise
frente I-Premise
a I-Premise
98,6 I-Premise
) I-Premise
. I-Premise

Esta O
diferencia O
( O
7,4 O
) O
fue O
clínicamente O
relevante O
. O

Las B-Claim
mejoras I-Claim
en I-Claim
las I-Claim
puntuaciones I-Claim
de I-Claim
cambio I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
total I-Claim
demostraron I-Claim
que, I-Claim
a I-Claim
los I-Claim
6 I-Claim
meses, I-Claim
las I-Claim
mejoras I-Claim
eran I-Claim
más I-Claim
del I-Claim
doble I-Claim
de I-Claim
grandes I-Claim
y I-Claim
clínicamente I-Claim
significativas I-Claim
en I-Claim
la I-Claim
intervención I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
grupo I-Claim
de I-Claim
control. I-Claim

CONNECT B-Claim
ha I-Claim
mostrado I-Claim
indicaciones I-Claim
prometedoras I-Claim
sobre I-Claim
los I-Claim
resultados I-Claim
del I-Claim
sistema I-Claim
sanitario I-Claim
y I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
justifican I-Claim
un I-Claim
estudio I-Claim
más I-Claim
amplio I-Claim
para I-Claim
seguir I-Claim
investigando I-Claim
el I-Claim
potencial I-Claim
de I-Claim
esta I-Claim
intervención I-Claim
. I-Claim

Se O
realizó O
un O
ensayo O
multicéntrico O
y O
aleatorizado O
para O
comparar O
la O
supervivencia O
libre O
de O
progresión O
(SLP), O
la O
supervivencia O
global O
(SG) O
y O
la O
calidad O
de O
vida O
de O
las O
mujeres O
con O
cáncer O
de O
mama O
metastásico O
(CMM) O
que O
recibieron O
quimioterapia O
de O
alta O
dosis O
más O
trasplante O
autólogo O
de O
células O
madre O
(TACM) O
en O
comparación O
con O
el O
tratamiento O
de O
dosis O
estándar. O

Entre O
abril O
de O
1997 O
y O
diciembre O
de O
2000, O
se O
registraron O
386 O
mujeres O
con O
CMB O
y O
sin O
quimioterapia O
previa O
para O
la O
enfermedad O
metastásica. O

Después O
de O
la O
respuesta O
inicial O
a O
la O
quimioterapia O
de O
inducción O
basada O
en O
antraciclinas O
o O
taxanos O
, O
224 O
pacientes O
fueron O
asignados O
al O
azar O
: O
112 O
a O
la O
quimioterapia O
de O
alta O
dosis O
de O
ciclofosfamida O
, O
mitoxantrona O
y O
carboplatino O
y O
ASCT O
( O
HDCT O
) O
, O
y O
112 O
a O
la O
terapia O
estándar O
( O
ST O
) O
. O

La O
mediana O
de O
edad O
era O
de O
47 O
años O
( O
rango O
, O
25 O
a O
67 O
años O
) O
. O

El O
32% O
de O
las O
mujeres O
asignadas O
al O
azar O
tenían O
cáncer O
de O
mama O
con O
receptores O
de O
estrógeno O
y O
progesterona O
negativos, O
el O
42% O
tenían O
metástasis O
viscerales O
y O
el O
58% O
tenían O
metástasis O
óseas. O

Las O
tasas O
de O
remisión O
completa O
antes O
de O
la O
asignación O
aleatoria O
fueron O
del O
11% O
para O
los O
que O
recibieron O
la O
HDCT O
y O
del O
12% O
para O
los O
que O
recibieron O
la B-Premise
ST. I-Premise
Tras I-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
48 I-Premise
meses, I-Premise
se I-Premise
observaron I-Premise
79 I-Premise
muertes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
HDCT I-Premise
y I-Premise
77 I-Premise
muertes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
ST; I-Premise
siete B-Premise
pacientes I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
HDCT I-Premise
murieron I-Premise
como I-Premise
resultado I-Premise
de I-Premise
la I-Premise
toxicidad I-Premise
. O

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SG I-Premise
fue I-Premise
de I-Premise
24 I-Premise
meses I-Premise
para I-Premise
el I-Premise
brazo I-Premise
de I-Premise
HDCT I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
21 I-Premise
a I-Premise
35 I-Premise
meses I-Premise
) I-Premise
y I-Premise
de I-Premise
28 I-Premise
meses I-Premise
para I-Premise
ST I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
22 I-Premise
a I-Premise
33 I-Premise
meses I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0,9 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,6 I-Premise
a I-Premise
1,2 I-Premise
; I-Premise
P I-Premise
= I-Premise
.43 I-Premise
) I-Premise
. I-Premise

La B-Premise
SLP I-Premise
fue I-Premise
de I-Premise
11 I-Premise
meses I-Premise
para I-Premise
la I-Premise
HDCT I-Premise
y I-Premise
de I-Premise
9 I-Premise
meses I-Premise
para I-Premise
la I-Premise
ST I-Premise
( I-Premise
HR I-Premise
, I-Premise
0,6 I-Premise
a I-Premise
favor I-Premise
de I-Premise
la I-Premise
HDCT I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,5 I-Premise
a I-Premise
0,9 I-Premise
; I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

La B-Claim
HDCT I-Claim
no I-Claim
mejoró I-Claim
la I-Claim
SG I-Claim
en I-Claim
mujeres I-Claim
con I-Claim
CMB I-Claim
cuando I-Claim
se I-Claim
utilizó I-Claim
como I-Claim
consolidación I-Claim
tras I-Claim
la I-Claim
respuesta I-Claim
a I-Claim
la I-Claim
quimioterapia I-Claim
de I-Claim
inducción I-Claim
. I-Claim

Se O
está O
estudiando O
la O
posibilidad O
de O
acercar O
la O
asistencia O
al O
domicilio O
como O
medio O
de O
mejorar O
la O
experiencia O
del O
paciente O
y O
la O
eficiencia O
en O
términos O
de O
ahorro O
de O
costes. O

Las O
pruebas O
de O
que O
los O
servicios O
oncológicos O
comunitarios O
mejoran O
la O
calidad O
de O
la O
atención O
y/o O
generan O
un O
ahorro O
de O
costes O
son O
actualmente O
limitadas. O

Se O
llevó O
a O
cabo O
un O
estudio O
aleatorio O
para O
comparar O
el O
tratamiento O
del O
cáncer O
en O
el O
hospital O
con O
dos O
entornos O
comunitarios O
diferentes. O

Noventa O
y O
siete O
pacientes O
a O
los O
que O
se O
les O
ofrecía O
un O
tratamiento O
ambulatorio O
del O
cáncer O
fueron O
asignados O
al O
azar O
a O
un O
tratamiento O
administrado O
en O
una O
unidad O
de O
día O
del O
hospital, O
en O
el O
domicilio O
del O
paciente O
o O
en O
las O
consultas O
locales O
de O
medicina O
general O
(GP). O

El O
resultado O
primario O
fue O
los O
beneficios O
percibidos O
por O
los O
pacientes O
, O
utilizando O
el O
dominio O
de O
la O
función O
emocional O
del O
cuestionario O
de O
calidad O
de O
vida O
( O
QOL O
) O
QLQC30 O
de O
la O
EORTC O
evaluado O
después O
de O
12 O
semanas O
. O

Los O
resultados O
secundarios O
incluyeron O
medidas O
adicionales O
de O
calidad O
de O
vida, O
satisfacción O
del O
paciente, O
seguridad O
y O
economía O
de O
la O
salud. O

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
el I-Premise
tratamiento I-Premise
en I-Premise
las I-Premise
ubicaciones I-Premise
comunitarias I-Premise
combinadas I-Premise
en I-Premise
relación I-Premise
con I-Premise
el I-Premise
hospital I-Premise
( I-Premise
diferencia I-Premise
de I-Premise
-7,2 I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
: I-Premise
-19-5 I-Premise
a I-Premise
+5-2 I-Premise
, I-Premise
P=0,25 I-Premise
) I-Premise
. I-Premise

Hubo B-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
entre I-Premise
las I-Premise
dos I-Premise
localizaciones I-Premise
comunitarias I-Premise
a I-Premise
favor I-Premise
del I-Premise
hogar I-Premise
( I-Premise
+15-2 I-Premise
, I-Premise
1-3 I-Premise
a I-Premise
29-1 I-Premise
, I-Premise
P=0,033 I-Premise
) I-Premise
. I-Premise

Las O
puntuaciones O
de O
la O
escala O
de O
ansiedad O
y O
depresión O
del O
hospital O
fueron O
consistentes O
con O
la O
medida O
de O
resultado O
primaria O
. O

No B-Premise
hubo I-Premise
pruebas I-Premise
de I-Premise
que I-Premise
el I-Premise
tratamiento I-Premise
comunitario I-Premise
comprometiera I-Premise
la I-Premise
seguridad I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
y I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
en I-Premise
términos I-Premise
de I-Premise
costes I-Premise
globales I-Premise
o I-Premise
de I-Premise
años I-Premise
de I-Premise
vida I-Premise
ajustados I-Premise
por I-Premise
calidad. I-Premise

El B-Premise
78% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
se I-Premise
mostraron I-Premise
satisfechos I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
recibido, I-Premise
independientemente I-Premise
de I-Premise
su I-Premise
ubicación, I-Premise
mientras I-Premise
que I-Premise
el I-Premise
57% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
preferían I-Premise
que I-Premise
el I-Premise
tratamiento I-Premise
futuro I-Premise
continuara I-Premise
en I-Premise
el I-Premise
hospital, I-Premise
el I-Premise
81% I-Premise
en I-Premise
las I-Premise
consultas I-Premise
médicas I-Premise
y I-Premise
el I-Premise
90% I-Premise
en I-Premise
su I-Premise
domicilio. I-Premise

Aunque O
las O
entrevistas O
iniciales O
previas O
al O
juicio O
revelaron O
la O
preocupación O
de O
los O
profesionales O
de O
la O
salud O
y O
de O
algunos O
pacientes O
por O
el O
tratamiento O
comunitario, O
las O
opiniones O
fueron O
en O
gran O
medida O
más O
favorables O
en O
las O
entrevistas O
posteriores O
al O
juicio. O

La B-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
favorece I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
en I-Claim
el I-Claim
hogar I-Claim
en I-Claim
lugar I-Claim
de I-Claim
las I-Claim
consultas I-Claim
médicas. I-Claim

Sin B-Claim
embargo, I-Claim
ambos I-Claim
entornos I-Claim
comunitarios I-Claim
fueron I-Claim
aceptables I-Claim
y I-Claim
preferidos I-Claim
por I-Claim
los I-Claim
pacientes I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
hospital, I-Claim
fueron I-Claim
seguros I-Claim
y I-Claim
no I-Claim
tuvieron I-Claim
un I-Claim
impacto I-Claim
perjudicial I-Claim
en I-Claim
los I-Claim
costes I-Claim
generales I-Claim
de I-Claim
la I-Claim
atención I-Claim
sanitaria. I-Claim

Docetaxel B-Claim
ha I-Claim
mostrado I-Claim
actividad I-Claim
en I-Claim
pacientes I-Claim
de I-Claim
edad I-Claim
avanzada I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
no I-Claim
microcítico I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
avanzado. I-Claim

Este O
ensayo O
aleatorio O
de O
fase O
III O
evaluó O
la O
eficacia O
y O
la O
seguridad O
del O
docetaxel O
frente O
a O
la O
vinorelbina O
( O
el O
tratamiento O
estándar O
actual O
) O
en O
pacientes O
de O
edad O
avanzada O
. O

Fueron O
elegidos O
los O
pacientes O
de O
70 O
años O
o O
más O
que O
no O
habían O
recibido O
quimioterapia, O
con O
un O
CPNM O
en O
estadio O
IIIB/IV O
y O
un O
estado O
de O
rendimiento O
2 O
o O
inferior. O

Los O
pacientes O
recibieron O
aleatoriamente O
docetaxel O
60 O
mg/m2 O
( O
día O
1 O
) O
o O
vinorelbina O
25 O
mg/m2 O
( O
días O
1 O
y O
8 O
) O
cada O
21 O
días O
durante O
cuatro O
ciclos O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia O
global. O

La O
mejora O
global O
de O
los O
síntomas O
relacionados O
con O
la O
enfermedad O
se O
evaluó O
mediante O
un O
cuestionario O
de O
ocho O
ítems. O

En O
total, O
se O
inscribieron O
182 O
pacientes. O

La O
mediana O
de O
edad O
era O
de O
76 O
años O
( O
rango O
, O
70 O
años O
a O
86 O
años O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticas I-Premise
en I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
global I-Premise
con I-Premise
docetaxel I-Premise
frente I-Premise
a I-Premise
vinorelbina I-Premise
( I-Premise
14,3 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
9,9 I-Premise
meses I-Premise
; I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0,780 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,561 I-Premise
a I-Premise
1,085 I-Premise
; I-Premise
P I-Premise
= I-Premise
.138 I-Premise
) I-Premise
. I-Premise

Hubo B-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
en I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
( I-Premise
5,5 I-Premise
meses I-Premise
frente I-Premise
a I-Premise
3,1 I-Premise
meses I-Premise
; I-Premise
P I-Premise
<0,001 I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
también I-Premise
mejoraron I-Premise
significativamente I-Premise
con I-Premise
el I-Premise
docetaxel I-Premise
frente I-Premise
a I-Premise
la I-Premise
vinorelbina I-Premise
( I-Premise
22,7 I-Premise
% I-Premise
frente I-Premise
a I-Premise
9,9 I-Premise
% I-Premise
; I-Premise
P I-Premise
= I-Premise
.019 I-Premise
) I-Premise
. I-Premise

Las B-Premise
toxicidades I-Premise
de I-Premise
grado I-Premise
3 I-Premise
a I-Premise
4 I-Premise
más I-Premise
frecuentes I-Premise
fueron I-Premise
la I-Premise
neutropenia I-Premise
( I-Premise
82,9 I-Premise
% I-Premise
para I-Premise
el I-Premise
docetaxel; I-Premise
69,2 I-Premise
% I-Premise
para I-Premise
la I-Premise
vinorelbina; I-Premise
P I-Premise
= I-Premise
0,031 I-Premise
) I-Premise
y I-Premise
la I-Premise
leucopenia I-Premise
( I-Premise
58,0 I-Premise
% I-Premise
para I-Premise
el I-Premise
docetaxel; I-Premise
51,7 I-Premise
% I-Premise
para I-Premise
la I-Premise
vinorelbina I-Premise
) I-Premise
. I-Premise

Las B-Premise
demás I-Premise
toxicidades I-Premise
fueron I-Premise
leves I-Premise
y, I-Premise
en I-Premise
general, I-Premise
bien I-Premise
toleradas. I-Premise

Docetaxel B-Premise
mejoró I-Premise
los I-Premise
síntomas I-Premise
generales I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
enfermedad I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
vinorelbina I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
1,86 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
1,09 I-Premise
a I-Premise
3,20 I-Premise
) I-Premise
. I-Premise

Docetaxel B-Premise
mejoró I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
y I-Premise
los I-Premise
síntomas I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
enfermedad I-Premise
frente I-Premise
a I-Premise
la I-Premise
vinorelbina. I-Premise

La B-Claim
supervivencia I-Claim
global I-Claim
no I-Claim
mejoró I-Claim
de I-Claim
forma I-Claim
estadísticamente I-Claim
significativa I-Claim
en I-Claim
este I-Claim
momento. I-Claim

La B-Claim
monoterapia I-Claim
con I-Claim
docetaxel I-Claim
puede I-Claim
considerarse I-Claim
una I-Claim
opción I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
estándar I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
edad I-Claim
avanzada I-Claim
con I-Claim
CPNM I-Claim
avanzado. I-Claim

Determinar O
la O
eficacia O
de O
la O
gestión O
de O
la O
atención O
colaborativa O
de O
Alivio O
de O
la O
Depresión O
entre O
Pacientes O
con O
Cáncer O
( O
ADAPt-C O
) O
para O
la O
depresión O
mayor O
o O
la O
distimia O
. O

Los O
pacientes O
del O
estudio O
incluyeron O
472 O
pacientes O
hispanos O
de O
bajos O
ingresos, O
predominantemente O
mujeres, O
con O
cáncer O
de O
edad O
> O
o= O
18 O
años O
con O
depresión O
mayor O
( O
49 O
% O
) O
, O
distimia O
( O
5 O
% O
) O
, O
o O
ambas O
( O
46 O
% O
) O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
la O
intervención O
( O
n O
= O
242 O
) O
o O
a O
la O
atención O
habitual O
mejorada O
( O
EUC O
; O
n O
= O
230 O
) O
. O

Los O
pacientes O
de O
la O
intervención O
tuvieron O
acceso O
durante O
un O
máximo O
de O
12 O
meses O
a O
un O
especialista O
clínico O
en O
depresión O
(supervisado O
por O
un O
psiquiatra) O
que O
les O
ofreció O
educación, O
psicoterapia O
estructurada O
y O
apoyo O
de O
mantenimiento/prevención O
de O
recaídas. O

El O
psiquiatra O
recetó O
medicamentos O
antidepresivos O
a O
los O
pacientes O
que O
prefirieron O
o O
evaluaron O
que O
requerían O
medicación O
. O

A B-Premise
los I-Premise
12 I-Premise
meses, I-Premise
el I-Premise
63% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
presentaron I-Premise
una I-Premise
reducción I-Premise
del I-Premise
50% I-Premise
o I-Premise
más I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
depresivos I-Premise
desde I-Premise
el I-Premise
inicio, I-Premise
según I-Premise
la I-Premise
escala I-Premise
de I-Premise
depresión I-Premise
del I-Premise
Cuestionario I-Premise
de I-Premise
Salud I-Premise
del I-Premise
Paciente-9 I-Premise
( I-Premise
PHQ-9 I-Premise
), I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
50% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
EUC I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
OR I-Premise
] I-Premise
= I-Premise
1,98 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95% I-Premise
, I-Premise
1,16 I-Premise
a I-Premise
3,38 I-Premise
; I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

También B-Premise
se I-Premise
encontró I-Premise
una I-Premise
mejora I-Premise
en I-Premise
la I-Premise
disminución I-Premise
de I-Premise
5 I-Premise
puntos I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
del I-Premise
PHQ-9 I-Premise
entre I-Premise
el I-Premise
72,2% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
59,7% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
EUC I-Premise
( I-Premise
OR I-Premise
= I-Premise
1,99 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95% I-Premise
, I-Premise
1,14 I-Premise
a I-Premise
3,50 I-Premise
; I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
también I-Premise
experimentaron I-Premise
mayores I-Premise
tasas I-Premise
de I-Premise
tratamiento I-Premise
de I-Premise
la I-Premise
depresión I-Premise
( I-Premise
72,3 I-Premise
% I-Premise
frente I-Premise
al I-Premise
10,4 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
EUC; I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
y I-Premise
resultados I-Premise
significativamente I-Premise
mejores I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
incluidos I-Premise
los I-Premise
aspectos I-Premise
sociales/familiares I-Premise
( I-Premise
diferencia I-Premise
de I-Premise
medias I-Premise
ajustada I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
, I-Premise
2,7 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
1,22 I-Premise
a I-Premise
4.17 I-Premise
; I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
emocional I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
ajustada I-Premise
, I-Premise
1,29 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,26 I-Premise
a I-Premise
2,22 I-Premise
; I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
funcional I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
ajustada I-Premise
, I-Premise
1,34 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,08 I-Premise
a I-Premise
2,59 I-Premise
; I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
y I-Premise
bienestar I-Premise
físico I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
ajustada I-Premise
, I-Premise
2,79 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,49 I-Premise
a I-Premise
5,1 I-Premise
; I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

La B-Claim
atención I-Claim
colaborativa I-Claim
ADAPt-C I-Claim
es I-Claim
factible I-Claim
y I-Claim
da I-Claim
lugar I-Claim
a I-Claim
una I-Claim
reducción I-Claim
significativa I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
depresivos, I-Claim
una I-Claim
mejora I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
una I-Claim
disminución I-Claim
de I-Claim
los I-Claim
niveles I-Claim
de I-Claim
dolor I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
EUC I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
trastornos I-Claim
depresivos I-Claim
en I-Claim
una I-Claim
población I-Claim
de I-Claim
bajos I-Claim
ingresos, I-Claim
predominantemente I-Claim
hispana, I-Claim
en I-Claim
clínicas I-Claim
oncológicas I-Claim
del I-Claim
sector I-Claim
público. I-Claim

La O
depresión O
es O
común O
entre O
los O
pacientes O
mayores O
con O
cáncer, O
pero O
se O
sabe O
poco O
sobre O
el O
enfoque O
óptimo O
para O
atender O
a O
esta O
población. O

Este O
análisis O
evalúa O
la O
eficacia O
del O
programa O
Improving O
Mood-Promoting O
Access O
to O
Collaborative O
Treatment O
( O
IMPACT O
) O
, O
un O
programa O
de O
gestión O
de O
atención O
escalonada O
para O
la O
depresión O
en O
pacientes O
de O
atención O
primaria O
que O
tenían O
un O
diagnóstico O
de O
cáncer O
CIE-9 O
. O

De O
los O
1.801 O
participantes O
en O
el O
estudio O
principal O
se O
identificaron O
215 O
pacientes O
con O
cáncer. O

Los O
sujetos O
tenían O
60 O
años O
o O
más O
con O
depresión O
mayor O
( O
18 O
% O
) O
, O
trastorno O
distímico O
( O
33 O
% O
) O
, O
o O
ambos O
( O
49 O
% O
) O
, O
reclutados O
en O
18 O
clínicas O
de O
atención O
primaria O
pertenecientes O
a O
8 O
organizaciones O
de O
atención O
médica O
en O
5 O
estados O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
la O
intervención O
IMPACT O
( O
n O
= O
112 O
) O
o O
a O
la O
atención O
habitual O
( O
n O
= O
103 O
) O
. O

Los O
pacientes O
de O
la O
intervención O
tuvieron O
acceso O
durante O
un O
máximo O
de O
12 O
meses O
a O
un O
gestor O
de O
la O
atención O
a O
la O
depresión O
que O
fue O
supervisado O
por O
un O
psiquiatra O
y O
un O
proveedor O
de O
atención O
primaria O
y O
que O
ofreció O
educación O
, O
gestión O
de O
la O
atención O
, O
apoyo O
a O
la O
gestión O
de O
los O
antidepresivos O
e O
intervenciones O
psicosociales O
breves O
y O
estructuradas, O
incluyendo O
la O
activación O
conductual O
y O
el O
tratamiento O
de O
resolución O
de O
problemas O
. O

A B-Premise
los I-Premise
6 I-Premise
y I-Premise
12 I-Premise
meses, I-Premise
el I-Premise
55% I-Premise
y I-Premise
el I-Premise
39% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
tuvieron I-Premise
una I-Premise
reducción I-Premise
del I-Premise
50% I-Premise
o I-Premise
más I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
depresivos I-Premise
( I-Premise
SCL-20 I-Premise
) I-Premise
desde I-Premise
el I-Premise
inicio, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
34% I-Premise
y I-Premise
el I-Premise
20% I-Premise
de I-Premise
los I-Premise
participantes I-Premise
de I-Premise
la I-Premise
atención I-Premise
habitual I-Premise
( I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
y I-Premise
P I-Premise
= I-Premise
0,029 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
también I-Premise
experimentaron I-Premise
mayores I-Premise
tasas I-Premise
de I-Premise
remisión I-Premise
( I-Premise
P I-Premise
= I-Premise
0,031 I-Premise
) I-Premise
, I-Premise
más I-Premise
días I-Premise
sin I-Premise
depresión I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
menos I-Premise
deterioro I-Premise
funcional I-Premise
( I-Premise
P I-Premise
= I-Premise
0,011 I-Premise
) I-Premise
y I-Premise
mayor I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
P I-Premise
= I-Premise
0,039 I-Premise
) I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
que I-Premise
los I-Premise
participantes I-Premise
de I-Premise
la I-Premise
atención I-Premise
habitual I-Premise
. I-Premise

El B-Claim
programa I-Claim
de I-Claim
atención I-Claim
colaborativa I-Claim
IMPACT I-Claim
parece I-Claim
ser I-Claim
factible I-Claim
y I-Claim
eficaz I-Claim
para I-Claim
la I-Claim
depresión I-Claim
entre I-Claim
los I-Claim
pacientes I-Claim
mayores I-Claim
con I-Claim
cáncer I-Claim
en I-Claim
diversos I-Claim
entornos I-Claim
de I-Claim
atención I-Claim
primaria I-Claim
. I-Claim

El O
sunitinib O
ha O
demostrado O
su O
actividad O
antitumoral O
en O
el O
carcinoma O
de O
células O
renales O
metastásico O
(CCRm) O
cuando O
se O
administra O
a O
50 O
mg/día O
en O
un O
régimen O
de O
4 O
semanas O
de O
duración O
y O
2 O
semanas O
de O
descanso. O

En O
este O
documento, O
informamos O
de O
los O
resultados O
de O
un O
estudio O
abierto O
y O
multicéntrico O
de O
fase O
II O
de O
sunitinib O
administrado O
en O
un O
régimen O
de O
dosificación O
continua O
una O
vez O
al O
día. O

Los O
criterios O
de O
elegibilidad O
incluían O
un O
CCRm O
histológicamente O
probado O
con O
enfermedad O
medible, O
el O
fracaso O
de O
un O
régimen O
de O
citoquinas O
previo O
y O
un O
buen O
estado O
de O
rendimiento. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
una O
dosis O
inicial O
de O
sunitinib O
de O
37,5 O
mg/día O
por O
la O
mañana O
( O
AM O
) O
o O
por O
la O
noche O
( O
PM O
) O
. O

La O
tasa O
de O
respuesta O
objetiva O
( O
ORR O
) O
definida O
por O
RECIST O
fue O
el O
criterio O
de O
valoración O
principal. O

Los O
criterios O
de O
valoración O
secundarios O
incluían O
la O
supervivencia O
sin O
progresión O
(SLP), O
la O
supervivencia O
global O
(SG), O
los O
acontecimientos O
adversos O
(EA) O
y O
las O
medidas O
de O
calidad O
de O
vida. O

Ciento O
siete O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
la O
dosis O
AM O
( O
n O
= O
54 O
) O
o O
PM O
( O
n O
= O
53 O
) O
y O
en O
el O
estudio O
durante O
una O
mediana O
de O
8,3 O
meses O
. O

Ochenta O
y O
tres O
pacientes O
abandonaron, O
65 O
por O
progresión O
de O
la O
enfermedad O
y O
16 O
por O
EA; O
dos O
pacientes O
retiraron O
su O
consentimiento. O

La O
dosis O
se O
redujo O
a O
25 O
mg/día O
en O
46 O
pacientes O
( O
43 O
% O
) O
debido O
a O
los O
EA O
de O
grado O
3/4 O
. O

Los B-Premise
EA I-Premise
de I-Premise
grado I-Premise
3 I-Premise
más I-Premise
frecuentes I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
fueron I-Premise
astenia/fatiga I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrea I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hipertensión I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
síndrome I-Premise
mano-pie I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
y I-Premise
anorexia I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
. I-Premise

La O
ORR O
fue O
del O
20% O
con O
una O
mediana O
de O
respuesta O
de O
7,2 O
meses. O

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
y I-Premise
la I-Premise
SG I-Premise
fue I-Premise
de I-Premise
8,2 I-Premise
y I-Premise
19,8 I-Premise
meses, I-Premise
respectivamente, I-Premise
con I-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
26,4 I-Premise
meses. I-Premise

Los B-Premise
resultados I-Premise
de I-Premise
eficacia, I-Premise
tolerabilidad I-Premise
y I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fueron I-Premise
similares I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
la I-Premise
dosis I-Premise
por I-Premise
la I-Premise
mañana I-Premise
o I-Premise
por I-Premise
la I-Premise
tarde. I-Premise

Sunitinib B-Claim
37,5 I-Claim
mg I-Claim
, I-Claim
administrado I-Claim
en I-Claim
un I-Claim
régimen I-Claim
de I-Claim
dosificación I-Claim
continua I-Claim
una I-Claim
vez I-Claim
al I-Claim
día I-Claim
, I-Claim
tiene I-Claim
un I-Claim
perfil I-Claim
de I-Claim
seguridad I-Claim
manejable I-Claim
como I-Claim
terapia I-Claim
de I-Claim
segunda I-Claim
línea I-Claim
de I-Claim
mRCC I-Claim
, I-Claim
proporcionando I-Claim
una I-Claim
dosificación I-Claim
flexible I-Claim
, I-Claim
que I-Claim
puede I-Claim
ser I-Claim
explorada I-Claim
en I-Claim
estudios I-Claim
de I-Claim
combinación I-Claim
. I-Claim

Los O
estudios O
observacionales O
demuestran O
una O
asociación O
entre O
la O
actividad O
física O
y O
la O
mejora O
de O
los O
resultados O
en O
los O
supervivientes O
de O
cáncer O
de O
mama O
y O
de O
colon O
. O

Para O
poner O
a O
prueba O
estas O
observaciones O
con O
un O
gran O
ensayo O
clínico O
aleatorio, O
se O
necesita O
una O
intervención O
que O
tenga O
un O
impacto O
significativo O
en O
la O
actividad O
física O
de O
estos O
pacientes. O

El O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
fue O
un O
estudio O
piloto O
multicéntrico O
que O
evaluó O
la O
viabilidad O
de O
una O
intervención O
de O
ejercicio O
por O
teléfono O
en O
un O
entorno O
de O
grupo O
cooperativo O
. O

Las O
supervivientes O
de O
cáncer O
de O
mama O
y O
colorrectal O
sedentarias O
(que O
realizan O
menos O
de O
60 O
minutos O
de O
actividad O
recreativa O
a O
la O
semana) O
fueron O
asignadas O
al O
azar O
a O
una O
intervención O
de O
ejercicio O
por O
teléfono O
o O
al O
grupo O
de O
control O
de O
atención O
habitual. O

La O
intervención O
se O
llevó O
a O
cabo O
a O
través O
de O
la O
Universidad O
de O
California O
en O
San O
Diego; O
los O
participantes O
recibieron O
diez O
llamadas O
telefónicas O
a O
lo O
largo O
de O
las O
16 O
semanas O
de O
intervención. O

Todos O
los O
participantes O
se O
sometieron O
a O
una O
evaluación O
de O
la O
actividad O
física, O
la O
forma O
física, O
el O
funcionamiento O
físico, O
la O
fatiga O
y O
la O
autoeficacia O
del O
ejercicio O
al O
inicio O
y O
después O
de O
la O
intervención O
de O
16 O
semanas. O

Ciento O
veintiún O
pacientes O
se O
inscribieron O
a O
través O
de O
diez O
instituciones O
del O
Grupo O
B O
de O
Cáncer O
y O
Leucemia O
( O
CALGB O
) O
; O
100 O
pacientes O
tenían O
cáncer O
de O
mama O
y O
21 O
tenían O
cáncer O
colorrectal O
. O

Los B-Premise
participantes I-Premise
asignados I-Premise
al I-Premise
azar I-Premise
al I-Premise
grupo I-Premise
de I-Premise
ejercicio I-Premise
aumentaron I-Premise
la I-Premise
actividad I-Premise
física I-Premise
en I-Premise
más I-Premise
de I-Premise
un I-Premise
100 I-Premise
frente I-Premise
al I-Premise
22 I-Premise
% I-Premise
de I-Premise
los I-Premise
controles I-Premise
( I-Premise
54,5 I-Premise
frente I-Premise
a I-Premise
14,6 I-Premise
min I-Premise
, I-Premise
p I-Premise
= I-Premise
0,13 I-Premise
) I-Premise
, I-Premise
y I-Premise
experimentaron I-Premise
aumentos I-Premise
significativos I-Premise
en I-Premise
la I-Premise
aptitud I-Premise
física I-Premise
( I-Premise
aumento I-Premise
de I-Premise
la I-Premise
distancia I-Premise
de I-Premise
la I-Premise
prueba I-Premise
de I-Premise
caminata I-Premise
de I-Premise
6 I-Premise
minutos I-Premise
en I-Premise
186,9 I-Premise
frente I-Premise
a I-Premise
81,9 I-Premise
pies I-Premise
, I-Premise
p I-Premise
= I-Premise
0,006 I-Premise
) I-Premise
y I-Premise
en I-Premise
el I-Premise
funcionamiento I-Premise
físico I-Premise
( I-Premise
7,1 I-Premise
frente I-Premise
a I-Premise
2,6 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
. I-Premise

Las B-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
y I-Claim
colorrectal I-Claim
inscritas I-Claim
en I-Claim
una I-Claim
intervención I-Claim
multicéntrica I-Claim
de I-Claim
actividad I-Claim
física I-Claim
basada I-Claim
en I-Claim
el I-Claim
teléfono I-Claim
aumentaron I-Claim
la I-Claim
actividad I-Claim
física I-Claim
y I-Claim
experimentaron I-Claim
mejoras I-Claim
significativas I-Claim
en I-Claim
la I-Claim
forma I-Claim
física I-Claim
y I-Claim
el I-Claim
funcionamiento I-Claim
físico. I-Claim

La B-Claim
investigación I-Claim
sobre I-Claim
la I-Claim
intervención I-Claim
en I-Claim
el I-Claim
estilo I-Claim
de I-Claim
vida I-Claim
es I-Claim
factible I-Claim
en I-Claim
un I-Claim
entorno I-Claim
de I-Claim
grupo I-Claim
cooperativo I-Claim
. I-Claim

El O
objetivo O
primario O
de O
este O
estudio O
fue O
comparar O
las O
tasas O
de O
respuesta O
de O
los O
pacientes O
ancianos O
y O
quimiocentes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
avanzado O
(CPNM) O
tratados O
con O
erlotinib O
oral O
diario O
frente O
a O
vinorelbina O
oral. O

Los O
pacientes O
taiwaneses O
de O
70 O
años O
o O
más O
que O
tenían O
un O
CPNM O
avanzado O
fueron O
asignados O
al O
azar O
para O
recibir O
150 O
mg O
( O
E O
) O
de O
erlotinib O
por O
vía O
oral O
diariamente O
o O
60 O
mg/m O
( O
V O
) O
de O
vinorelbina O
por O
vía O
oral O
los O
días O
1 O
y O
8 O
cada O
3 O
semanas O
. O

Entre O
febrero O
de O
2007 O
y O
julio O
de O
2008, O
se O
inscribieron O
116 O
pacientes O
y O
se O
incluyeron O
113 O
en O
la O
población O
por O
intención O
de O
tratar: O
57 O
pacientes O
en O
el O
grupo O
E O
y O
56 O
pacientes O
en O
el O
grupo O
V. O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
objetiva I-Premise
fueron I-Premise
del I-Premise
22,8% I-Premise
( I-Premise
13 I-Premise
de I-Premise
57 I-Premise
) I-Premise
en I-Premise
E I-Premise
y I-Premise
del I-Premise
8,9% I-Premise
( I-Premise
5 I-Premise
de I-Premise
56 I-Premise
) I-Premise
en I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0,0388 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
( I-Premise
SSP I-Premise
) I-Premise
fue I-Premise
de I-Premise
4,57 I-Premise
meses I-Premise
en I-Premise
E I-Premise
y I-Premise
de I-Premise
2,53 I-Premise
meses I-Premise
en I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0,0287 I-Premise
) I-Premise
, I-Premise
con I-Premise
un I-Premise
aumento I-Premise
del I-Premise
80,6 I-Premise
% I-Premise
en I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SSP I-Premise
para I-Premise
E I-Premise
en I-Premise
comparación I-Premise
con I-Premise
V. I-Premise
La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
11,67 I-Premise
meses I-Premise
en I-Premise
E I-Premise
y I-Premise
de I-Premise
9,3 I-Premise
meses I-Premise
en I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0,6975 I-Premise
) O
. O

Las B-Premise
toxicidades I-Premise
fueron I-Premise
generalmente I-Premise
leves I-Premise
en I-Premise
ambos I-Premise
grupos. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
más I-Premise
larga I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
mutación I-Premise
del I-Premise
gen I-Premise
del I-Premise
factor I-Premise
de I-Premise
crecimiento I-Premise
epidérmico I-Premise
( I-Premise
EGFR I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
E I-Premise
, I-Premise
seguidos I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
mutación I-Premise
del I-Premise
EGFR I-Premise
en I-Premise
el I-Premise
V I-Premise
, I-Premise
el I-Premise
tipo I-Premise
salvaje I-Premise
del I-Premise
EGFR I-Premise
en I-Premise
el I-Premise
E I-Premise
y I-Premise
el I-Premise
tipo I-Premise
salvaje I-Premise
del I-Premise
EGFR I-Premise
en I-Premise
el I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0,0034 I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
más I-Premise
larga I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
mutación I-Premise
del I-Premise
EGFR I-Premise
que I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
tipo I-Premise
salvaje I-Premise
( I-Premise
p I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

El B-Claim
erlotinib I-Claim
es I-Claim
altamente I-Claim
eficaz I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
vinorelbina I-Claim
oral I-Claim
en I-Claim
pacientes I-Claim
ancianos, I-Claim
quimiocentes I-Claim
y I-Claim
taiwaneses I-Claim
con I-Claim
CPNM. I-Claim

Los B-Claim
pacientes I-Claim
con I-Claim
mutaciones I-Claim
en I-Claim
el I-Claim
EGFR I-Claim
tuvieron I-Claim
una I-Claim
mejor I-Claim
supervivencia I-Claim
que I-Claim
aquellos I-Claim
con I-Claim
enfermedad I-Claim
de I-Claim
tipo I-Claim
salvaje I-Claim
del I-Claim
EGFR I-Claim
, I-Claim
independientemente I-Claim
del I-Claim
tratamiento I-Claim
recibido. I-Claim

Evaluar O
y O
comparar O
prospectivamente O
los O
resultados O
de O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
QOL O
) O
en O
pacientes O
con O
carcinoma O
de O
células O
escamosas O
de O
cabeza O
y O
cuello O
asignados O
al O
azar O
a O
la O
radioterapia O
de O
intensidad O
modulada O
( O
IMRT O
) O
o O
a O
la O
radioterapia O
conformada O
tridimensional O
( O
3D-CRT O
) O
y O
evaluar O
el O
cambio O
longitudinal O
en O
serie O
de O
la O
QOL O
a O
lo O
largo O
del O
tiempo O
. O

Los O
resultados O
de O
la O
calidad O
de O
vida O
se O
evaluaron O
mediante O
el O
cuestionario O
de O
calidad O
de O
vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
(EORTC) O
(QLQ-C30) O
y O
el O
módulo O
Cabeza-Cuello O
(HN-35) O
en O
la O
línea O
de O
base O
(antes O
del O
tratamiento) O
y O
posteriormente O
de O
forma O
periódica O
durante O
el O
seguimiento. O

Las O
puntuaciones O
medias O
de O
los O
dominios/escalas O
individuales O
de O
la O
3D-CRT O
y O
la O
IMRT O
se O
compararon O
mediante O
la O
prueba O
"t" O
en O
cada O
punto O
temporal; O
mientras O
que O
el O
cambio O
longitudinal O
en O
las O
puntuaciones O
medias O
de O
ambos O
grupos O
a O
lo O
largo O
del O
tiempo O
se O
evaluó O
mediante O
un O
análisis O
de O
varianza O
de O
medidas O
repetidas. O

Se O
incluyeron O
en O
el O
análisis O
58 O
de O
los O
60 O
pacientes O
aleatorizados O
que O
rellenaron O
el O
cuestionario O
de O
calidad O
de O
vida O
al O
menos O
en O
un O
momento O
dado. O

Varios O
dominios O
generales O
( O
funcionamiento O
emocional O
, O
funcionamiento O
de O
roles O
, O
contacto O
social O
) O
así O
como O
específicos O
del O
cáncer O
de O
cabeza O
y O
cuello O
( O
sequedad O
de O
boca O
, O
apertura O
de O
boca O
, O
saliva O
pegajosa O
, O
dolor O
, O
sentidos O
) O
se O
preservaron O
mejor O
con O
la O
IMRT O
en O
comparación O
con O
la O
3D-CRT O
en O
diferentes O
puntos O
temporales O
. O

Es O
importante O
destacar O
que O
ninguno O
de O
los O
dominios O
de O
la O
CdV O
fue O
peor O
con O
la O
IMRT O
en O
ningún O
momento. O

Hubo B-Premise
un I-Premise
deterioro I-Premise
sustancial I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
CdV I-Premise
inmediatamente I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
3 I-Premise
meses I-Premise
) I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
CdV I-Premise
mejoraron I-Premise
gradual I-Premise
pero I-Premise
definitivamente I-Premise
con I-Premise
el I-Premise
tiempo I-Premise
en I-Premise
la I-Premise
mayoría I-Premise
de I-Premise
los I-Premise
ámbitos. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global, I-Premise
el I-Premise
funcionamiento I-Premise
emocional/de I-Premise
roles, I-Premise
las I-Premise
náuseas/vómitos, I-Premise
el I-Premise
dolor, I-Premise
la I-Premise
deglución, I-Premise
el I-Premise
habla, I-Premise
el I-Premise
contacto I-Premise
social/la I-Premise
alimentación I-Premise
y I-Premise
el I-Premise
insomnio I-Premise
mostraron I-Premise
una I-Premise
rápida I-Premise
recuperación I-Premise
(menos I-Premise
de I-Premise
6 I-Premise
meses), I-Premise
mientras I-Premise
que I-Premise
el I-Premise
funcionamiento I-Premise
físico/cognitivo, I-Premise
la I-Premise
sequedad I-Premise
de I-Premise
boca, I-Premise
la I-Premise
saliva I-Premise
pegajosa, I-Premise
la I-Premise
fatiga I-Premise
y I-Premise
los I-Premise
sentidos I-Premise
mostraron I-Premise
una I-Premise
recuperación I-Premise
tardía I-Premise
(más I-Premise
de I-Premise
6 I-Premise
meses). I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
supervivencia I-Premise
locorregional I-Premise
o I-Premise
la I-Premise
supervivencia I-Premise
entre I-Premise
los I-Premise
dos I-Premise
brazos. I-Premise

Existe B-Claim
un I-Claim
deterioro I-Claim
sustancial I-Claim
de I-Claim
la I-Claim
CdV I-Claim
después I-Claim
de I-Claim
la I-Claim
irradiación I-Claim
de I-Claim
cabeza-cuello I-Claim
con I-Claim
intención I-Claim
curativa I-Claim
que I-Claim
mejora I-Claim
gradualmente I-Claim
con I-Claim
el I-Claim
tiempo I-Claim
. I-Claim

La B-Claim
IMRT I-Claim
da I-Claim
lugar I-Claim
a I-Claim
puntuaciones I-Claim
de I-Claim
CdV I-Claim
clínicamente I-Claim
significativas I-Claim
y I-Claim
estadísticamente I-Claim
mejores I-Claim
para I-Claim
algunos I-Claim
dominios I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
3D-CRT I-Claim
en I-Claim
varios I-Claim
puntos I-Claim
temporales I-Claim
con I-Claim
resultados I-Claim
de I-Claim
enfermedad I-Claim
comparables I-Claim
que I-Claim
podrían I-Claim
apoyar I-Claim
su I-Claim
adopción I-Claim
generalizada I-Claim
en I-Claim
la I-Claim
práctica I-Claim
clínica I-Claim
rutinaria I-Claim
. I-Claim

En O
Lituania, O
se O
diagnostican O
unos O
400 O
casos O
de O
cáncer O
de O
páncreas O
al O
año, O
y O
más O
del O
50% O
de O
los O
pacientes O
se O
encuentran O
en O
el O
estadio O
IV O
de O
la O
enfermedad. O

La B-Claim
calidad I-Claim
de I-Claim
vida I-Claim
es I-Claim
un I-Claim
tema I-Claim
importante I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
páncreas I-Claim
. I-Claim

En O
el O
Departamento O
de O
Oncología O
del O
Hospital O
de O
la O
Universidad O
de O
Medicina O
de O
Kaunas O
se O
llevó O
a O
cabo O
un O
estudio O
clínico O
prospectivo O
y O
aleatorio O
sobre O
el O
tratamiento O
de O
pacientes O
con O
cáncer O
de O
páncreas O
resecable O
y O
no O
resecable, O
en O
el O
que O
se O
analizó O
la O
calidad O
de O
vida. O

El O
objetivo O
del O
estudio O
era O
analizar O
el O
efecto O
de O
los O
métodos O
de O
tratamiento O
combinados O
en O
la O
calidad O
de O
vida O
de O
los O
pacientes O
diagnosticados O
de O
cáncer O
de O
páncreas. O

Durante O
2000-2005, O
se O
analizaron O
en O
el O
estudio O
dos O
métodos O
de O
tratamiento O
de O
quimiorradiación O
concomitante O
( O
radioterapia O
con O
5-fluorouracilo O
y O
radioterapia O
con O
gemcitabina O
). O

Se O
inscribieron O
un O
total O
de O
60 O
pacientes: O
41 O
pacientes O
con O
diagnóstico O
de O
cáncer O
de O
páncreas O
resecable O
y O
19 O
pacientes O
con O
diagnóstico O
de O
cáncer O
de O
páncreas O
no O
resecable. O

La O
calidad O
de O
vida O
se O
evaluó O
mediante O
el O
cuestionario O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
. O

Se O
evaluaron O
tres O
escalas O
principales O
de O
calidad O
de O
vida O
( O
estado O
de O
salud O
general O
, O
funcional O
y O
de O
síntomas O
) O
y O
se O
compararon O
entre O
dos O
grupos O
de O
tratamiento O
. O

El B-Premise
análisis I-Premise
de I-Premise
la I-Premise
evaluación I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
mostró I-Premise
una I-Premise
disminución I-Premise
estadísticamente I-Premise
significativa I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
tras I-Premise
el I-Premise
tratamiento I-Premise
en I-Premise
pacientes I-Premise
con I-Premise
cáncer I-Premise
de I-Premise
páncreas I-Premise
resecable I-Premise
y I-Premise
tratados I-Premise
con I-Premise
radioterapia I-Premise
y I-Premise
gemcitabina I-Premise
. I-Premise

También B-Premise
se I-Premise
observó I-Premise
una I-Premise
disminución I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
en I-Premise
pacientes I-Premise
diagnosticados I-Premise
de I-Premise
cáncer I-Premise
de I-Premise
páncreas I-Premise
no I-Premise
resecable I-Premise
y I-Premise
tratados I-Premise
con I-Premise
el I-Premise
mismo I-Premise
régimen I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
radioterapia I-Claim
y I-Claim
5-fluorouracilo I-Claim
sólo I-Claim
modificó I-Claim
algunos I-Claim
aspectos I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
no I-Claim
tuvo I-Claim
un I-Claim
impacto I-Claim
significativo I-Claim
en I-Claim
la I-Claim
misma. I-Claim

El B-Claim
tratamiento I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
gástrico I-Claim
o I-Claim
de I-Claim
la I-Claim
unión I-Claim
gastroesofágica I-Claim
avanzado I-Claim
debe I-Claim
proporcionar I-Claim
un I-Claim
alivio I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
y I-Claim
mejorar I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
( I-Claim
QOL I-Claim
) I-Claim
porque I-Claim
la I-Claim
mayoría I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
son I-Claim
sintomáticos I-Claim
al I-Claim
inicio I-Claim
. I-Claim

Utilizando O
instrumentos O
validados O
, O
evaluamos O
prospectivamente O
la O
CdV O
( O
incluso O
después O
de O
la O
finalización O
del O
tratamiento O
del O
protocolo O
) O
como O
uno O
de O
los O
puntos O
finales O
secundarios O
del O
ensayo O
de O
fase O
III O
del O
V325 O
. O

Cuatrocientos O
cuarenta O
y O
cinco O
pacientes O
recibieron O
aleatoriamente O
docetaxel O
75 O
mg/m O
( O
2 O
) O
y O
cisplatino O
75 O
mg/m O
( O
2 O
) O
cada O
uno O
el O
día O
1 O
más O
fluorouracilo O
750 O
mg/m O
( O
2 O
) O
/d O
en O
infusión O
continua O
los O
días O
1 O
a O
5 O
cada O
3 O
semanas O
( O
DCF O
) O
o O
cisplatino O
100 O
mg/m O
( O
2 O
) O
el O
día O
1 O
más O
fluorouracilo O
1.000 O
mg/m O
( O
2 O
) O
/d O
en O
infusión O
continua O
los O
días O
1 O
a O
5 O
cada O
4 O
semanas O
( O
CF O
) O
. O

El O
Cuestionario O
de O
Calidad O
de O
Vida O
C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
QLQ-C30 O
) O
y, O
cuando O
estaba O
disponible, O
el O
cuestionario O
EuroQOL O
EQ-5D O
se O
administraron O
cada O
8 O
semanas O
desde O
el O
inicio O
hasta O
la O
progresión O
y O
después O
cada O
3 O
meses O
. O

Se O
analizó O
el O
tiempo O
hasta O
el O
deterioro O
definitivo O
de O
los O
parámetros O
de O
la O
CdV. O

Las O
proporciones O
de O
pacientes O
con O
cuestionarios O
EORTC O
QLQ-C30 O
y O
EQ-5D O
evaluables O
al O
inicio O
del O
estudio O
fueron O
del O
86,0 O
% O
y O
el O
78,7 O
% O
con O
DCF O
, O
respectivamente O
, O
y O
del O
89,7 O
% O
y O
el O
92,8 O
% O
con O
CF O
, O
respectivamente O
. O

El B-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
5 I-Premise
% I-Premise
de I-Premise
deterioro I-Premise
del I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global I-Premise
( I-Premise
punto I-Premise
final I-Premise
primario I-Premise
) I-Premise
favoreció I-Premise
significativamente I-Premise
al I-Premise
DCF I-Premise
sobre I-Premise
la I-Premise
FC I-Premise
( I-Premise
prueba I-Premise
de I-Premise
rango I-Premise
logarítmico I-Premise
, I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
se I-Premise
conservó I-Premise
durante I-Premise
más I-Premise
tiempo I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
sometidos I-Premise
a I-Premise
DCF I-Premise
que I-Premise
en I-Premise
los I-Premise
sometidos I-Premise
a I-Premise
CF I-Premise
en I-Premise
todos I-Premise
los I-Premise
análisis I-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
deterioro, I-Premise
lo I-Premise
que I-Premise
demuestra I-Premise
la I-Premise
superioridad I-Premise
estadística I-Premise
de I-Premise
la I-Premise
DCF I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
CF. I-Premise

El O
V325 O
representa O
el O
mayor O
ensayo O
con O
las O
evaluaciones O
más O
largas O
controladas O
prospectivamente O
de O
la O
CdV O
durante O
la O
quimioterapia O
de O
protocolo O
y O
el O
seguimiento O
en O
pacientes O
con O
cáncer O
gástrico O
o O
de O
la O
unión O
gastroesofágica O
avanzado O
. O

En B-Claim
el I-Claim
estudio I-Claim
V325 I-Claim
, I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
gástrico I-Claim
o I-Claim
de I-Claim
la I-Claim
unión I-Claim
gastroesofágica I-Claim
avanzado I-Claim
que I-Claim
recibieron I-Claim
DCF I-Claim
no I-Claim
sólo I-Claim
mejoraron I-Claim
estadísticamente I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
y I-Claim
el I-Claim
tiempo I-Claim
hasta I-Claim
la I-Claim
progresión I-Claim
del I-Claim
tumor, I-Claim
sino I-Claim
que I-Claim
también I-Claim
conservaron I-Claim
mejor I-Claim
la I-Claim
CdV I-Claim
en I-Claim
comparación I-Claim
con I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
CF. I-Claim

Muchos O
pacientes O
con O
cáncer O
experimentan O
depresión O
y O
ansiedad O
, O
y O
una O
disminución O
asociada O
de O
la O
calidad O
de O
vida O
( O
QOL O
) O
durante O
la O
radioterapia O
( O
RT O
) O
. O

El O
objetivo O
principal O
del O
estudio O
fue O
determinar O
los O
beneficios O
de O
las O
intervenciones O
psicosociales O
para O
los O
pacientes O
con O
cáncer O
que O
recibieron O
RT O
. O

Los O
pacientes O
con O
cáncer O
( O
n O
= O
178 O
) O
que O
aceptaron O
participar O
en O
el O
estudio O
fueron O
asignados O
al O
azar O
al O
brazo O
de O
intervención O
( O
n O
= O
89 O
) O
o O
al O
brazo O
de O
control O
( O
n O
= O
89 O
) O
. O

Los O
pacientes O
del O
grupo O
de O
intervención O
recibieron O
atención O
psicosocial O
durante O
la O
RT, O
mientras O
que O
el O
grupo O
de O
control O
sólo O
recibió O
RT. O

Los O
beneficios O
de O
la O
intervención O
se O
evaluaron O
utilizando O
la O
Escala O
de O
Depresión O
Autocalificada O
de O
Zung O
( O
SDS O
) O
para O
medir O
la O
depresión O
, O
la O
Escala O
de O
Ansiedad O
Autocalificada O
( O
SAS O
) O
para O
evaluar O
la O
ansiedad O
, O
y O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer-Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
para O
encuestar O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
. O

También O
se O
evaluó O
la O
asociación O
entre O
la O
intervención O
y O
la O
supervivencia. O

Los B-Premise
pacientes I-Premise
asignados I-Premise
aleatoriamente I-Premise
al I-Premise
brazo I-Premise
de I-Premise
intervención I-Premise
mostraron I-Premise
mejoras I-Premise
significativas I-Premise
en I-Premise
los I-Premise
síntomas I-Premise
de I-Premise
depresión I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
ansiedad I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
relacionada I-Premise
con I-Premise
la I-Premise
salud I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
( I-Premise
es I-Premise
decir, I-Premise
mejor I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global I-Premise
, I-Premise
y I-Premise
el I-Premise
funcionamiento I-Premise
físico I-Premise
y I-Premise
emocional I-Premise
, I-Premise
y I-Premise
menos I-Premise
insomnio I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
controles I-Premise
. I-Premise

En B-Claim
el I-Claim
análisis I-Claim
de I-Claim
subconjuntos, I-Claim
los I-Claim
pacientes I-Claim
femeninos, I-Claim
los I-Claim
que I-Claim
recibieron I-Claim
altas I-Claim
dosis I-Claim
de I-Claim
irradiación I-Claim
y I-Claim
los I-Claim
que I-Claim
se I-Claim
sometieron I-Claim
a I-Claim
quimioterapia I-Claim
adyuvante I-Claim
podrían I-Claim
beneficiarse I-Claim
más I-Claim
de I-Claim
la I-Claim
intervención I-Claim
psicosocial. I-Claim

No B-Premise
hubo I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
enfermedad I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
DFS I-Premise
a I-Premise
2 I-Premise
años I-Premise
79,8 I-Premise
% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
intervención I-Premise
y I-Premise
76,4 I-Premise
% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
control I-Premise
; I-Premise
p I-Premise
= I-Premise
0,527 I-Premise
) I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
OS I-Premise
a I-Premise
2 I-Premise
años I-Premise
83,1 I-Premise
% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
intervención I-Premise
y I-Premise
84,3 I-Premise
% I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
control I-Premise
; I-Premise
p I-Premise
= I-Premise
0,925 I-Premise
) I-Premise
. I-Premise

La B-Claim
intervención I-Claim
psicosocial I-Claim
es I-Claim
un I-Claim
enfoque I-Claim
rentable I-Claim
que I-Claim
puede I-Claim
mejorar I-Claim
el I-Claim
estado I-Claim
de I-Claim
ánimo I-Claim
del I-Claim
paciente I-Claim
y I-Claim
su I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
tanto I-Claim
durante I-Claim
como I-Claim
después I-Claim
de I-Claim
la I-Claim
RT. I-Claim

Sin B-Claim
embargo, I-Claim
no I-Claim
se I-Claim
encontró I-Claim
que I-Claim
la I-Claim
intervención I-Claim
redujera I-Claim
el I-Claim
riesgo I-Claim
de I-Claim
recurrencia I-Claim
del I-Claim
cáncer I-Claim
y I-Claim
de I-Claim
muerte. I-Claim

La O
terapia O
de O
la O
dignidad O
es O
una O
psicoterapia O
única, O
individualizada O
y O
de O
corta O
duración, O
desarrollada O
para O
los O
pacientes O
(y O
sus O
familias) O
que O
viven O
con O
enfermedades O
que O
amenazan O
o O
limitan O
su O
vida. O

Se O
investigó O
si O
la O
terapia O
de O
la O
dignidad O
podía O
mitigar O
la O
angustia O
o O
reforzar O
la O
experiencia O
en O
los O
pacientes O
que O
se O
acercan O
al O
final O
de O
su O
vida O
. O

Los O
pacientes O
( O
de O
edad O
≥18 O
años) O
con O
un O
pronóstico O
terminal O
( O
esperanza O
de O
vida O
≤6 O
meses) O
que O
recibían O
cuidados O
paliativos O
en O
un O
entorno O
hospitalario O
o O
comunitario O
( O
hospicio O
o O
domicilio) O
en O
Canadá O
, O
Estados O
Unidos O
y O
Australia O
fueron O
asignados O
aleatoriamente O
a O
terapia O
de O
la O
dignidad O
, O
cuidados O
centrados O
en O
el O
cliente O
o O
cuidados O
paliativos O
estándar O
en O
una O
proporción O
de O
1:1:1 O
. O

La O
aleatorización O
se O
realizó O
mediante O
una O
tabla O
de O
números O
aleatorios O
generada O
por O
ordenador O
en O
bloques O
de O
30. O

La O
ocultación O
de O
la O
asignación O
se O
realizó O
mediante O
el O
uso O
de O
sobres O
cerrados O
opacos. O

Los O
resultados O
primarios, O
es O
decir, O
la O
reducción O
de O
varias O
dimensiones O
de O
angustia O
antes O
y O
después O
de O
la O
finalización O
del O
estudio, O
se O
midieron O
con O
la O
Escala O
de O
Evaluación O
Funcional O
de O
la O
Terapia O
de O
Enfermedades O
Crónicas, O
la O
Escala O
de O
Bienestar O
Espiritual, O
el O
Inventario O
de O
Dignidad O
del O
Paciente, O
la O
Escala O
de O
Ansiedad O
y O
Depresión O
Hospitalaria, O
los O
ítems O
de O
la O
Entrevista O
Estructurada O
de O
Síntomas O
y O
Preocupaciones, O
la O
Escala O
de O
Calidad O
de O
Vida O
y O
la O
Escala O
de O
Evaluación O
de O
Síntomas O
de O
Edmonton O
modificada. O

Los O
resultados O
secundarios O
de O
las O
experiencias O
autodeclaradas O
al O
final O
de O
la O
vida O
se O
evaluaron O
en O
una O
encuesta O
que O
se O
realizó O
tras O
la O
finalización O
del O
estudio O
. O

Los O
resultados O
fueron O
evaluados O
por O
personal O
de O
investigación O
con O
el O
que O
el O
participante O
no O
había O
tenido O
contacto O
previo O
para O
evitar O
cualquier O
posible O
sesgo O
de O
respuesta O
o O
contaminación O
. O

Los O
análisis O
se O
realizaron O
en O
todos O
los O
pacientes O
con O
datos O
disponibles O
al O
inicio O
y O
al O
final O
de O
la O
intervención O
del O
estudio. O

165 O
de O
441 O
pacientes O
fueron O
asignados O
a O
la O
terapia O
de O
la O
dignidad O
, O
140 O
a O
los O
cuidados O
paliativos O
estándar O
y O
136 O
a O
los O
cuidados O
centrados O
en O
el O
cliente O
. O

Se O
analizaron O
108, O
111 O
y O
107 O
pacientes, O
respectivamente. O

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
los I-Premise
niveles I-Premise
de I-Premise
angustia I-Premise
antes I-Premise
y I-Premise
después I-Premise
de I-Premise
la I-Premise
finalización I-Premise
del I-Premise
estudio I-Premise
en I-Premise
los I-Premise
tres I-Premise
grupos I-Premise
. I-Premise

Para B-Premise
los I-Premise
resultados I-Premise
secundarios I-Premise
, I-Premise
los I-Premise
pacientes I-Premise
informaron I-Premise
de I-Premise
que I-Premise
la I-Premise
terapia I-Premise
de I-Premise
la I-Premise
dignidad I-Premise
tenía I-Premise
una I-Premise
probabilidad I-Premise
significativamente I-Premise
mayor I-Premise
que I-Premise
las I-Premise
otras I-Premise
dos I-Premise
intervenciones I-Premise
de I-Premise
haber I-Premise
sido I-Premise
útil I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=35-50 I-Premise
, I-Premise
df=2 I-Premise
; I-Premise
p I-Premise
< I-Premise
0-0001 I-Premise
) I-Premise
, I-Premise
mejorar I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=14-52 I-Premise
; I-Premise
p=0-001 I-Premise
) I-Premise
, I-Premise
aumentar I-Premise
el I-Premise
sentido I-Premise
de I-Premise
la I-Premise
dignidad I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=12-66 I-Premise
; I-Premise
p=0-002 I-Premise
) I-Premise
, I-Premise
cambiar I-Premise
la I-Premise
forma I-Premise
en I-Premise
que I-Premise
su I-Premise
familia I-Premise
los I-Premise
veía I-Premise
y I-Premise
apreciaba I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=33-81 I-Premise
; I-Premise
p I-Premise
< I-Premise
0-0001 I-Premise
) I-Premise
, I-Premise
y I-Premise
ser I-Premise
útiles I-Premise
a I-Premise
su I-Premise
familia I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=33-86 I-Premise
; I-Premise
p I-Premise
< I-Premise
0-0001 I-Premise
) I-Premise
. I-Premise

La B-Premise
terapia I-Premise
de I-Premise
la I-Premise
dignidad I-Premise
fue I-Premise
significativamente I-Premise
mejor I-Premise
que I-Premise
los I-Premise
cuidados I-Premise
centrados I-Premise
en I-Premise
el I-Premise
cliente I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
mejora I-Premise
del I-Premise
bienestar I-Premise
espiritual I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=10-35 I-Premise
; I-Premise
p=0-006 I-Premise
) I-Premise
, I-Premise
y I-Premise
fue I-Premise
significativamente I-Premise
mejor I-Premise
que I-Premise
los I-Premise
cuidados I-Premise
paliativos I-Premise
estándar I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
disminución I-Premise
de I-Premise
la I-Premise
tristeza I-Premise
o I-Premise
la I-Premise
depresión I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=9-38 I-Premise
; I-Premise
p=0-009 I-Premise
) I-Premise
; I-Premise
un I-Premise
número I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
pacientes I-Premise
que I-Premise
habían I-Premise
recibido I-Premise
la I-Premise
terapia I-Premise
de I-Premise
la I-Premise
dignidad I-Premise
informaron I-Premise
de I-Premise
que I-Premise
el I-Premise
grupo I-Premise
de I-Premise
estudio I-Premise
había I-Premise
sido I-Premise
satisfactorio I-Premise
, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
cuidados I-Premise
paliativos I-Premise
estándar I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=29-58 I-Premise
; I-Premise
p I-Premise
< O
0-0001 O
) O
. O

Aunque B-Claim
la I-Claim
capacidad I-Claim
de I-Claim
la I-Claim
terapia I-Claim
de I-Claim
la I-Claim
dignidad I-Claim
para I-Claim
mitigar I-Claim
la I-Claim
angustia I-Claim
absoluta I-Claim
, I-Claim
como I-Claim
la I-Claim
depresión I-Claim
, I-Claim
el I-Claim
deseo I-Claim
de I-Claim
muerte I-Claim
o I-Claim
el I-Claim
suicidio I-Claim
, I-Claim
aún I-Claim
no I-Claim
se I-Claim
ha I-Claim
demostrado I-Claim
, O
sus B-Claim
beneficios I-Claim
en I-Claim
términos I-Claim
de I-Claim
experiencias I-Claim
autoinformadas I-Claim
del I-Claim
final I-Claim
de I-Claim
la I-Claim
vida I-Claim
apoyan I-Claim
su I-Claim
aplicación I-Claim
clínica I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
cercanos I-Claim
a I-Claim
la I-Claim
muerte I-Claim
. O

El O
hallazgo O
de O
una O
disminución O
de O
la O
incidencia O
del O
cáncer O
de O
mama O
contralateral O
tras O
la O
administración O
de O
tamoxifeno O
como O
terapia O
adyuvante O
llevó O
a O
pensar O
que O
el O
fármaco O
podría O
desempeñar O
un O
papel O
en O
la O
prevención O
del O
cáncer O
de O
mama O
. O

Para O
probar O
esta O
hipótesis O
, O
el O
Proyecto O
Nacional O
de O
Adyuvancia O
Quirúrgica O
de O
Mama O
e O
Intestino O
inició O
el O
Ensayo O
de O
Prevención O
del O
Cáncer O
de O
Mama O
( O
P-1 O
) O
en O
1992 O
. O

Las O
mujeres O
( O
N=13388 O
) O
con O
mayor O
riesgo O
de O
cáncer O
de O
mama O
porque O
1 O
) O
tenían O
60 O
años O
o O
más O
, O
2 O
) O
tenían O
entre O
35 O
y O
59 O
años O
con O
un O
riesgo O
previsto O
de O
cáncer O
de O
mama O
a O
5 O
años O
de O
al O
menos O
1,66 O
% O
, O
o O
3 O
) O
tenían O
antecedentes O
de O
carcinoma O
lobular O
in O
situ O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
placebo O
( O
n=6707 O
) O
o O
20 O
mg/día O
de O
tamoxifeno O
( O
n=6681 O
) O
durante O
5 O
años O
. O

El O
algoritmo O
de O
Gail, O
basado O
en O
un O
modelo O
de O
regresión O
logística O
multivariante O
que O
utiliza O
combinaciones O
de O
factores O
de O
riesgo, O
se O
utilizó O
para O
estimar O
la O
probabilidad O
(riesgo) O
de O
aparición O
del O
cáncer O
de O
mama O
a O
lo O
largo O
del O
tiempo. O

El B-Premise
tamoxifeno I-Premise
redujo I-Premise
el I-Premise
riesgo I-Premise
de I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
invasivo I-Premise
en I-Premise
un I-Premise
49% I-Premise
( I-Premise
P I-Premise
de I-Premise
dos I-Premise
caras I-Premise
< I-Premise
0,00001 I-Premise
) I-Premise
, I-Premise
con I-Premise
una I-Premise
incidencia I-Premise
acumulada I-Premise
a I-Premise
lo I-Premise
largo I-Premise
de I-Premise
69 I-Premise
meses I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
43,4 I-Premise
frente I-Premise
a I-Premise
22,0 I-Premise
por I-Premise
1000 I-Premise
mujeres I-Premise
en I-Premise
los I-Premise
grupos I-Premise
de I-Premise
placebo I-Premise
y I-Premise
tamoxifeno I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

La O
disminución O
del O
riesgo O
se O
produjo O
en O
las O
mujeres O
de O
49 O
años O
o O
menos O
( O
44 O
% O
) O
, O
de O
50 O
a O
59 O
años O
( O
51 O
% O
) O
y O
de O
60 O
años O
o O
más O
( O
55 O
% O
) O
; O
el O
riesgo B-Premise
también I-Premise
se I-Premise
redujo I-Premise
en I-Premise
las I-Premise
mujeres I-Premise
con I-Premise
antecedentes I-Premise
de I-Premise
carcinoma I-Premise
lobular I-Premise
in I-Premise
situ I-Premise
( I-Premise
56 I-Premise
% I-Premise
) I-Premise
o I-Premise
de I-Premise
hiperplasia I-Premise
atípica I-Premise
( I-Premise
86 I-Premise
% I-Premise
) I-Premise
y I-Premise
en I-Premise
aquellas I-Premise
con I-Premise
cualquier I-Premise
categoría I-Premise
de I-Premise
riesgo I-Premise
previsto I-Premise
a I-Premise
5 I-Premise
años I-Premise
. O

El B-Premise
tamoxifeno I-Premise
redujo I-Premise
el I-Premise
riesgo I-Premise
de I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
no I-Premise
invasivo I-Premise
en I-Premise
un I-Premise
50 I-Premise
% I-Premise
( I-Premise
P I-Premise
de I-Premise
dos I-Premise
caras I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

El B-Premise
tamoxifeno I-Premise
redujo I-Premise
la I-Premise
aparición I-Premise
de I-Premise
tumores I-Premise
con I-Premise
receptores I-Premise
de I-Premise
estrógeno I-Premise
positivos I-Premise
en I-Premise
un I-Premise
69 I-Premise
%, I-Premise
pero I-Premise
no I-Premise
se I-Premise
observó I-Premise
ninguna I-Premise
diferencia I-Premise
en I-Premise
la I-Premise
aparición I-Premise
de I-Premise
tumores I-Premise
con I-Premise
receptores I-Premise
de I-Premise
estrógeno I-Premise
negativos. I-Premise

La B-Premise
administración I-Premise
de I-Premise
tamoxifeno I-Premise
no I-Premise
alteró I-Premise
la I-Premise
tasa I-Premise
media I-Premise
anual I-Premise
de I-Premise
cardiopatía I-Premise
isquémica; I-Premise
sin I-Premise
embargo, I-Premise
se I-Premise
observó I-Premise
una I-Premise
reducción I-Premise
de I-Premise
las I-Premise
fracturas I-Premise
de I-Premise
cadera, I-Premise
radio I-Premise
(Colles) I-Premise
y I-Premise
columna I-Premise
vertebral. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
cáncer I-Premise
de I-Premise
endometrio I-Premise
aumentó I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tamoxifeno I-Premise
( I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
= I-Premise
2,53; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
1,35-4,97 I-Premise
); I-Premise
este I-Premise
aumento I-Premise
del I-Premise
riesgo I-Premise
se I-Premise
produjo I-Premise
predominantemente I-Premise
en I-Premise
las I-Premise
mujeres I-Premise
de I-Premise
50 I-Premise
años I-Premise
o I-Premise
más. I-Premise

Todos O
los O
cánceres O
de O
endometrio O
en O
el O
grupo O
del O
tamoxifeno O
estaban O
en O
fase O
I O
( O
enfermedad O
localizada O
) O
; O
no B-Premise
se I-Premise
ha I-Premise
producido I-Premise
ninguna I-Premise
muerte I-Premise
por I-Premise
cáncer I-Premise
de I-Premise
endometrio I-Premise
en I-Premise
este I-Premise
grupo I-Premise
. O

No B-Premise
se I-Premise
observaron I-Premise
cánceres I-Premise
de I-Premise
hígado I-Premise
ni I-Premise
aumento I-Premise
de I-Premise
tumores I-Premise
de I-Premise
colon, I-Premise
recto, I-Premise
ovario I-Premise
u I-Premise
otros I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tamoxifeno. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
ictus, I-Premise
embolia I-Premise
pulmonar I-Premise
y I-Premise
trombosis I-Premise
venosa I-Premise
profunda I-Premise
fueron I-Premise
elevadas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
del I-Premise
tamoxifeno; I-Premise
estos I-Premise
eventos I-Premise
se I-Premise
produjeron I-Premise
con I-Premise
mayor I-Premise
frecuencia I-Premise
en I-Premise
mujeres I-Premise
de I-Premise
50 I-Premise
años I-Premise
o I-Premise
más. I-Premise

El B-Claim
tamoxifeno I-Claim
disminuye I-Claim
la I-Claim
incidencia I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
invasivo I-Claim
y I-Claim
no I-Claim
invasivo I-Claim
. I-Claim

A B-Claim
pesar I-Claim
de I-Claim
los I-Claim
efectos I-Claim
secundarios I-Claim
derivados I-Claim
de I-Claim
la I-Claim
administración I-Claim
de I-Claim
tamoxifeno I-Claim
, I-Claim
su I-Claim
uso I-Claim
como I-Claim
agente I-Claim
preventivo I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
es I-Claim
apropiado I-Claim
en I-Claim
muchas I-Claim
mujeres I-Claim
con I-Claim
mayor I-Claim
riesgo I-Claim
de I-Claim
padecer I-Claim
la I-Claim
enfermedad I-Claim
. I-Claim

Comparar O
la O
eficacia O
de O
un O
régimen O
estándar O
basado O
en O
antraciclinas O
con O
un O
régimen O
de O
antraciclinas O
de O
dosis O
intensificada O
en O
el O
cáncer O
de O
mama O
localmente O
avanzado. O

Las O
pacientes O
con O
cáncer O
de O
mama O
localmente O
avanzado O
fueron O
asignadas O
aleatoriamente O
a O
un O
estudio O
que O
comparaba O
ciclofosfamida O
( O
C O
; O
75 O
mg/m O
( O
2 O
) O
por O
vía O
oral O
días O
1 O
a O
14 O
) O
, O
epirubicina O
( O
E O
; O
60 O
mg/m O
( O
2 O
) O
por O
vía O
intravenosa O
[ O
IV O
] O
días O
1 O
, O
8 O
) O
y O
fluorouracilo O
( O
F O
; O
500 O
mg/m O
( O
2 O
) O
IV O
días O
1 O
, O
8 O
) O
seis O
ciclos O
cada O
28 O
días O
frente O
a O
E O
( O
120 O
mg/m O
( O
2 O
) O
IV O
día O
1 O
) O
, O
C O
( O
830 O
mg/m O
( O
2 O
) O
IV O
día O
1 O
) O
y O
factor O
estimulante O
de O
colonias O
de O
granulocitos O
( O
filgrastim O
; O
5 O
micro O
g/kg/d O
subcutáneo O
días O
2 O
a O
13 O
) O
seis O
ciclos O
cada O
14 O
días O
. O

El O
estudio O
se O
diseñó O
para O
detectar O
una O
mejora O
del O
15 O
%; O
es O
decir, O
del O
50 O
% O
al O
65 O
% O
en O
la O
mediana O
de O
la O
supervivencia O
libre O
de O
progresión O
(SLP) O
a O
favor O
del O
régimen O
de O
dosis O
intensificada. O

Se O
inscribieron O
448 O
pacientes O
durante O
un O
periodo O
de O
3 O
años. O

La O
mediana O
de O
la O
intensidad O
de O
la O
dosis O
administrada O
para O
C O
y O
E O
alcanzó, O
respectivamente, O
el O
85 O
% O
y O
el O
87 O
% O
de O
la O
prevista O
en O
el O
brazo O
CEF O
y O
el O
96 O
% O
y O
el O
95 O
% O
de O
la O
prevista O
en O
el O
brazo O
EC O
. O

El B-Premise
brazo I-Premise
de I-Premise
dosis I-Premise
intensificada I-Premise
fue I-Premise
ligeramente I-Premise
más I-Premise
emetógeno I-Premise
y I-Premise
generó I-Premise
más I-Premise
anemia I-Premise
de I-Premise
grado I-Premise
3 I-Premise
a I-Premise
4 I-Premise
pero I-Premise
menos I-Premise
episodios I-Premise
de I-Premise
neutropenia I-Premise
febril I-Premise
. I-Premise

Tras O
una O
mediana O
de O
seguimiento O
de O
5,5 O
años, O
se O
han O
notificado O
277 O
eventos. O

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
de I-Premise
34 I-Premise
y I-Premise
33,7 I-Premise
meses I-Premise
para I-Premise
el I-Premise
CEF I-Premise
y I-Premise
el I-Premise
CE, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
= I-Premise
0,68 I-Premise
), I-Premise
y I-Premise
la I-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
5 I-Premise
años I-Premise
fue I-Premise
del I-Premise
53% I-Premise
y I-Premise
el I-Premise
51% I-Premise
para I-Premise
el I-Premise
CEF I-Premise
y I-Premise
el I-Premise
CE, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
= I-Premise
0,94 I-Premise
). I-Premise

La B-Claim
CE I-Claim
intensificada I-Claim
en I-Claim
dosis I-Claim
no I-Claim
proporciona I-Claim
un I-Claim
beneficio I-Claim
terapéutico I-Claim
medible I-Claim
sobre I-Claim
la I-Claim
CEF I-Claim
como I-Claim
quimioterapia I-Claim
neoadyuvante I-Claim
para I-Claim
pacientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
localmente I-Claim
avanzado I-Claim
no I-Claim
seleccionadas I-Claim
. I-Claim

Comparar O
las O
variables O
del O
histograma O
dosis-volumen O
de O
los O
esfínteres O
urinarios O
internos O
y O
externos O
( O
IUS/EUS O
) O
con O
la O
calidad O
de O
vida O
urinaria O
tras O
la O
braquiterapia O
de O
próstata O
. O

Los O
sujetos O
fueron O
42 O
hombres O
consecutivos O
de O
un O
estudio O
prospectivo O
de O
braquiterapia O
como O
monoterapia O
con O
( O
125 O
) O
I O
para O
el O
cáncer O
de O
próstata O
localizado O
de O
riesgo O
intermedio O
. O

Ningún O
paciente O
recibió O
terapia O
hormonal. O

Las O
restricciones O
previas O
a O
la O
planificación O
incluían O
un O
V100 O
prostático O
superior O
al O
95 O
% O
, O
un O
V150 O
inferior O
al O
60 O
% O
y O
un O
V200 O
inferior O
al O
20 O
% O
y O
un O
R100 O
rectal O
inferior O
a O
1 O
cm O
( O
3 O
) O
. O

Los O
pacientes O
completaron O
el O
cuestionario O
de O
calidad O
de O
vida O
Expanded O
Prostate O
Cancer O
Index O
Composite O
antes O
y O
a O
los O
1 O
, O
4 O
, O
8 O
y O
12 O
meses O
después O
de O
la O
implantación O
, O
y O
se O
analizaron O
las O
puntuaciones O
del O
dominio O
urinario O
. O

Todas O
las O
estructuras, O
incluyendo O
el O
SIE O
y O
el O
SIE, O
fueron O
contorneadas O
en O
la O
RMN O
ponderada O
en O
T2 O
en O
el O
día O
30, O
y O
las O
dosis O
recibidas O
se O
calcularon O
a O
partir O
de O
la O
identificación O
de O
las O
semillas O
en O
la O
TC. O
Para O
los O
análisis O
estadísticos O
se O
utilizó O
el O
coeficiente O
de O
correlación O
de O
rangos O
( O
ρ O
) O
de O
Spearman O
( O
no O
paramétrico O
). O

La O
morbilidad O
urinaria O
global O
fue O
peor O
al O
mes O
del O
implante. O

La O
función B-Premise
urinaria I-Premise
disminuyó I-Premise
cuando I-Premise
el I-Premise
SIE I-Premise
V285 I-Premise
fue I-Premise
del I-Premise
0,4 I-Premise
% I-Premise
( I-Premise
ρ=-0,32 I-Premise
, I-Premise
p=0,04 I-Premise
) I-Premise
; I-Premise
las I-Premise
molestias I-Premise
empeoraron I-Premise
cuando I-Premise
el I-Premise
SIE I-Premise
V35 I-Premise
fue I-Premise
del I-Premise
99 I-Premise
% I-Premise
( I-Premise
ρ=-0,31 I-Premise
, I-Premise
p=0,05 I-Premise
) I-Premise
o I-Premise
el I-Premise
SIE I-Premise
V240 I-Premise
fue I-Premise
del I-Premise
63 I-Premise
% I-Premise
( I-Premise
ρ=-0,31 I-Premise
, I-Premise
p=0.05 I-Premise
) I-Premise
; I-Premise
la I-Premise
irritación B-Premise
aumentó I-Premise
cuando I-Premise
el I-Premise
SIE I-Premise
V35 I-Premise
era I-Premise
del I-Premise
95 I-Premise
% I-Premise
( I-Premise
ρ=-0,37 I-Premise
, I-Premise
p=0,02 I-Premise
) I-Premise
y I-Premise
el I-Premise
SIE I-Premise
V265 I-Premise
era I-Premise
del I-Premise
24 I-Premise
% I-Premise
( I-Premise
ρ=-0,32 I-Premise
, I-Premise
p=0,04 I-Premise
) I-Premise
; I-Premise
y I-Premise
la I-Premise
urgencia I-Premise
empeoró I-Premise
cuando I-Premise
el I-Premise
SIE I-Premise
V35 I-Premise
era I-Premise
del I-Premise
99,5 I-Premise
% I-Premise
( I-Premise
ρ=-0,38 I-Premise
, I-Premise
p=0,02 I-Premise
) O
. O

La B-Premise
incontinencia I-Premise
no I-Premise
se I-Premise
correlacionó I-Premise
con I-Premise
la I-Premise
dosis I-Premise
de I-Premise
EUS I-Premise
o I-Premise
IUS I-Premise
. I-Premise

Las B-Claim
dosis I-Claim
al I-Claim
SIU I-Claim
y I-Claim
al I-Claim
SIE I-Claim
en I-Claim
la I-Claim
RM/TC I-Claim
predijeron I-Claim
una I-Claim
peor I-Claim
función I-Claim
urinaria I-Claim
, I-Claim
con I-Claim
mayores I-Claim
molestias I-Claim
, I-Claim
síntomas I-Claim
irritativos I-Claim
y I-Claim
urgencia I-Claim
. I-Claim

La B-Claim
incorporación I-Claim
del I-Claim
análisis I-Claim
del I-Claim
histograma I-Claim
dosis-volumen I-Claim
basado I-Claim
en I-Claim
la I-Claim
RM I-Claim
en I-Claim
el I-Claim
proceso I-Claim
de I-Claim
planificación I-Claim
del I-Claim
tratamiento I-Claim
puede I-Claim
reducir I-Claim
la I-Claim
morbilidad I-Claim
urinaria I-Claim
aguda I-Claim
después I-Claim
de I-Claim
la I-Claim
braquiterapia I-Claim
. I-Claim

La B-Claim
incidencia I-Claim
y I-Claim
el I-Claim
desarrollo I-Claim
del I-Claim
cáncer I-Claim
están I-Claim
estrechamente I-Claim
relacionados I-Claim
con I-Claim
la I-Claim
disfunción I-Claim
de I-Claim
la I-Claim
función I-Claim
inmunitaria I-Claim
. I-Claim

El O
sistema O
inmunitario O
no O
puede O
identificar O
y O
eliminar O
las O
células O
malignas O
y O
mutantes, O
lo O
que O
hace O
que O
las O
células O
tumorales O
escapen O
a O
la O
vigilancia O
y O
eliminación O
del O
sistema O
inmunitario. O

La O
terapia O
inmunobiológica O
contra O
el O
cáncer O
desempeña O
un O
papel O
importante O
en O
el O
fortalecimiento O
de O
la O
función O
de O
vigilancia O
inmunológica O
del O
organismo O
y O
en O
la O
eliminación O
de O
las O
células O
tumorales O
restantes O
en O
el O
cuerpo. O

Se O
investigó O
el O
papel O
de O
la O
terapia O
inmunobiológica O
contra O
el O
cáncer O
DC/CIK O
( O
células O
dendríticas/células O
asesinas O
inducidas O
por O
citocinas O
) O
en O
la O
terapia O
de O
mantenimiento O
del O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
avanzado O
. O

Cuando O
60 O
casos O
de O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
en O
estadio O
IIIb O
y O
IV O
alcanzaron O
la O
enfermedad O
estable O
tras O
el O
tratamiento O
con O
4 O
ciclos O
de O
un O
régimen O
de O
dos O
fármacos O
con O
platino O
, O
se O
dividieron O
aleatoriamente O
en O
dos O
grupos O
. O

Un O
grupo O
fue O
tratado O
con O
la O
terapia O
inmunobiológica O
contra O
el O
cáncer O
DC/CIK O
, O
y O
el O
otro O
fue O
tomado O
como O
grupo O
de O
control O
. O

Finalmente, O
se O
evaluó O
el O
tiempo O
de O
progresión O
del O
cáncer O
y O
la O
reacción O
de O
toxicidad O
de O
los O
dos O
grupos. O

El B-Premise
tratamiento I-Premise
con I-Premise
DC/CIK I-Premise
prolonga I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
( I-Premise
3,20 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
2,94-3,50 I-Premise
] I-Premise
frente I-Premise
a I-Premise
2,56 I-Premise
meses I-Premise
[ I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
2,39-2,73 I-Premise
] I-Premise
; I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento, I-Premise
la I-Premise
proporción I-Premise
de I-Premise
células I-Premise
NK, I-Premise
los I-Premise
subgrupos I-Premise
de I-Premise
células I-Premise
T I-Premise
CD3+, I-Premise
CD4+ I-Premise
y I-Premise
CD8+ I-Premise
tuvieron I-Premise
un I-Premise
cambio I-Premise
significativo I-Premise
antes I-Premise
y I-Premise
después I-Premise
del I-Premise
tratamiento. I-Premise

La B-Premise
función I-Premise
hepática I-Premise
y I-Premise
renal I-Premise
y I-Premise
los I-Premise
análisis I-Premise
de I-Premise
sangre I-Premise
del I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
estaban I-Premise
dentro I-Premise
del I-Premise
rango I-Premise
normal I-Premise
antes I-Premise
y I-Premise
después I-Premise
del I-Premise
tratamiento. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
, I-Premise
1 I-Premise
caso I-Premise
sufrió I-Premise
de I-Premise
angustia I-Premise
torácica I-Premise
, I-Premise
3 I-Premise
casos I-Premise
sufrieron I-Premise
de I-Premise
acratia I-Premise
, I-Premise
y I-Premise
4 I-Premise
casos I-Premise
sufrieron I-Premise
de I-Premise
pirexia I-Premise
. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
DC/CIK I-Claim
tuvo I-Claim
un I-Claim
beneficio I-Claim
potencial I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
no I-Claim
pequeñas I-Claim
avanzado I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
grupo I-Claim
de I-Claim
control I-Claim
y I-Claim
no I-Claim
tuvo I-Claim
efectos I-Claim
secundarios I-Claim
evidentes I-Claim
. I-Claim

El B-Claim
tratamiento I-Claim
con I-Claim
DC/CIK I-Claim
es I-Claim
un I-Claim
método I-Claim
seguro I-Claim
y I-Claim
eficaz I-Claim
para I-Claim
la I-Claim
terapia I-Claim
de I-Claim
mantenimiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
de I-Claim
células I-Claim
no I-Claim
pequeñas I-Claim
avanzado. I-Claim

Muchas O
mujeres O
con O
cáncer O
de O
mama O
necesitan O
ayuda O
psicológica O
para O
afrontar O
mejor O
el O
tratamiento. O

Las O
técnicas O
cognitivas O
y O
conductuales O
aún O
no O
están O
bien O
establecidas O
en O
Francia. O

Se O
llevó O
a O
cabo O
un O
estudio O
aleatorio O
en O
varios O
centros O
para O
evaluar O
los O
efectos O
de O
una O
intervención O
grupal O
psicoeducativa O
en O
esta O
población O
. O

Doscientos O
tres O
pacientes O
, O
reclutados O
después O
del O
tratamiento O
primario O
, O
fueron O
asignados O
aleatoriamente O
a O
un O
grupo O
de O
tratamiento O
( O
intervención O
psicoeducativa O
) O
o O
a O
un O
grupo O
de O
control O
en O
lista O
de O
espera O
. O

El O
programa, O
de O
8 O
semanas O
de O
duración O
y O
2 O
horas O
de O
duración, O
incluía O
debates O
temáticos, O
información O
y O
formación O
en O
técnicas O
de O
gestión O
del O
estrés. O

La O
evaluación O
en O
la O
línea O
de O
base O
, O
después O
de O
8 O
sesiones O
, O
y O
1 O
mes O
después O
de O
la O
finalización O
del O
programa O
, O
incluyó O
evaluaciones O
utilizando O
el O
STAI O
, O
POMS O
, O
MAC O
, O
EORTC O
QLQ-C30 O
y O
EORTC O
QLQ-BR23 O
escalas O
del O
módulo O
de O
mama O
. O

Se B-Premise
observó I-Premise
una I-Premise
reducción I-Premise
significativa I-Premise
de I-Premise
la I-Premise
ansiedad I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
entre I-Premise
los I-Premise
participantes I-Premise
del I-Premise
grupo I-Premise
, I-Premise
una I-Premise
reducción I-Premise
de I-Premise
la I-Premise
ira I-Premise
, I-Premise
la I-Premise
depresión I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
del I-Premise
vigor I-Premise
y I-Premise
las I-Premise
relaciones I-Premise
interpersonales I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
del I-Premise
funcionamiento I-Premise
emocional I-Premise
y I-Premise
de I-Premise
los I-Premise
roles I-Premise
, I-Premise
del I-Premise
estado I-Premise
de I-Premise
salud I-Premise
y I-Premise
del I-Premise
nivel I-Premise
de I-Premise
fatiga I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

En O
cambio, O
las O
estrategias B-Premise
de I-Premise
afrontamiento I-Premise
( I-Premise
MAC I-Premise
) I-Premise
no I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
. O

No B-Premise
se I-Premise
observaron I-Premise
efectos I-Premise
negativos I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
grupo I-Premise
y I-Premise
los I-Premise
niveles I-Premise
de I-Premise
satisfacción I-Premise
global I-Premise
fueron I-Premise
muy I-Premise
altos. I-Premise

Este B-Claim
estudio I-Claim
demuestra I-Claim
la I-Claim
viabilidad I-Claim
y I-Claim
la I-Claim
eficacia I-Claim
de I-Claim
una I-Claim
intervención I-Claim
psicoeducativa I-Claim
, I-Claim
que I-Claim
puede I-Claim
acelerar I-Claim
la I-Claim
reducción I-Claim
de I-Claim
esos I-Claim
afectos I-Claim
negativos I-Claim
que I-Claim
están I-Claim
presentes I-Claim
al I-Claim
final I-Claim
del I-Claim
tratamiento I-Claim
. I-Claim

Representa B-Claim
un I-Claim
excelente I-Claim
complemento I-Claim
o I-Claim
una I-Claim
alternativa I-Claim
al I-Claim
apoyo I-Claim
terapéutico I-Claim
psico-oncológico I-Claim
individual, I-Claim
ampliamente O
propuesto O
en O
Francia, O
y O
debería O
probarse O
ahora O
en O
grupos O
con O
otros O
tipos O
de O
cáncer O
y O
en O
otras O
fases O
de O
la O
enfermedad. O

Examinar O
los O
efectos O
de O
un O
ejercicio O
orientado O
a O
la O
escápula O
sobre O
la O
disfunción O
de O
las O
extremidades O
superiores O
en O
supervivientes O
de O
cáncer O
de O
mama O
. O

Un O
ensayo O
piloto O
prospectivo, O
aleatorio O
y O
controlado O
con O
control O
histórico. O

Departamento O
de O
rehabilitación O
de O
un O
hospital O
universitario O
. O

Treinta O
y O
dos O
mujeres O
con O
cáncer O
de O
mama O
fueron O
asignadas O
aleatoriamente O
al O
grupo O
de O
ejercicio O
orientado O
a O
la O
escápula O
( O
n O
= O
16 O
) O
y O
al O
grupo O
de O
ejercicio O
general O
( O
n O
= O
16 O
) O
. O

Se O
inscribió O
un O
grupo O
de O
control O
histórico O
( O
n O
= O
18 O
) O
sin O
ejercicio O
de O
supervivientes O
de O
cáncer O
de O
mama O
. O

Los O
ejercicios O
orientados O
a O
la O
escápula O
se O
diseñaron O
centrándose O
en O
el O
movimiento O
escapulotorácico O
. O

El O
grupo O
de O
ejercicio O
general O
realizó O
ejercicios O
de O
acondicionamiento O
corporal O
. O

Las O
terapias O
de O
ejercicio O
se O
realizaron O
durante O
una O
sesión O
por O
semana O
durante O
ocho O
semanas O
. O

Se O
utilizaron O
como O
resultados O
subjetivos O
el O
dolor O
y O
las O
discapacidades O
físicas O
relacionadas O
con O
la O
disfunción O
del O
miembro O
superior, O
la O
calidad O
de O
vida O
y O
la O
depresión. O

Las O
medidas O
de O
resultado O
objetivas O
incluían O
la O
amplitud O
de O
movimiento O
y O
la O
fuerza O
del O
hombro. O

Los O
resultados O
se O
evaluaron O
al O
inicio O
y O
después O
del O
ejercicio. O

Al O
inicio, O
no O
se O
observaron O
diferencias O
significativas O
entre O
los O
tres O
grupos. O

El B-Premise
grupo I-Premise
de I-Premise
ejercicio I-Premise
orientado I-Premise
a I-Premise
la I-Premise
escápula I-Premise
mostró I-Premise
mejoras I-Premise
en I-Premise
el I-Premise
dolor I-Premise
, I-Premise
la I-Premise
función I-Premise
física I-Premise
, I-Premise
la I-Premise
función I-Premise
social I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
punto I-Premise
de I-Premise
partida I-Premise
, I-Premise
mientras I-Premise
que I-Premise
el I-Premise
grupo I-Premise
de I-Premise
ejercicio I-Premise
general I-Premise
mostró I-Premise
una I-Premise
mejora I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
y I-Premise
la I-Premise
amplitud I-Premise
de I-Premise
movimiento I-Premise
. I-Premise

El B-Premise
cambio I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
( I-Premise
P I-Premise
= I-Premise
0,067 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,33 I-Premise
) I-Premise
y I-Premise
la I-Premise
fuerza I-Premise
de I-Premise
la I-Premise
rotación I-Premise
externa I-Premise
( I-Premise
P I-Premise
= I-Premise
0,001 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,55 I-Premise
) I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
ejercicio I-Premise
orientado I-Premise
a I-Premise
la I-Premise
escápula I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
ejercicio I-Premise
general I-Premise
y I-Premise
de I-Premise
control I-Premise
. I-Premise

El B-Claim
ejercicio I-Claim
orientado I-Claim
a I-Claim
la I-Claim
escápula I-Claim
tuvo I-Claim
efectos I-Claim
beneficiosos I-Claim
sobre I-Claim
el I-Claim
dolor I-Claim
, I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
aspectos I-Claim
de I-Claim
la I-Claim
fuerza I-Claim
. I-Claim

El O
tamaño O
de O
la O
muestra O
necesario O
en O
un O
estudio O
definitivo O
más O
amplio O
es O
de O
32 O
sujetos O
por O
grupo O
. O

El O
objetivo O
del O
proyecto O
era O
identificar O
los O
factores O
clínicos O
y O
de O
calidad O
de O
vida O
( O
QL O
) O
que O
conjuntamente O
predicen O
la O
supervivencia O
y O
la O
respuesta O
a O
la O
quimioterapia O
en O
el O
cáncer O
de O
mama O
avanzado O
. O

Se O
estudiaron O
los O
factores O
pronósticos O
potenciales O
en O
187 O
mujeres O
con O
datos O
de O
referencia O
sobre O
la O
calidad O
de O
vida O
en O
un O
ensayo O
de O
paclitaxel O
frente O
a O
doxorrubicina O
como O
quimioterapia O
de O
primera O
línea. O

Los O
factores O
demográficos O
y O
clínicos O
estudiados O
fueron O
la O
edad, O
el O
estado O
funcional, O
el O
lugar O
dominante O
de O
la O
enfermedad O
y O
el O
intervalo O
libre O
de O
enfermedad O
(ILE) O
precedente. O

Los O
factores O
del O
EORTC O
QLQ-C30 O
fueron O
todas O
las O
escalas O
de O
función O
, O
fatiga O
, O
náuseas/vómitos O
, O
dolor O
, O
disnea O
, O
insomnio O
, O
pérdida O
de O
apetito O
y O
QL O
global O
. O

El O
modelo O
de O
regresión O
de O
riesgos O
proporcionales O
con O
estratificación O
para O
el O
tratamiento O
, O
y O
el O
modelo O
de O
regresión O
logística O
ajustado O
para O
el O
brazo O
de O
tratamiento O
se O
utilizaron O
para O
los O
análisis O
univariantes O
y O
multivariantes O
de O
la O
supervivencia O
y O
la O
respuesta O
al O
tratamiento O
, O
respectivamente. O

En B-Premise
cuanto I-Premise
a I-Premise
la I-Premise
supervivencia, I-Premise
las I-Premise
múltiples I-Premise
localizaciones I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
visceral, I-Premise
el I-Premise
dolor, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
fueron I-Premise
factores I-Premise
pronósticos I-Premise
significativos I-Premise
en I-Premise
el I-Premise
análisis I-Premise
univariante. I-Premise

El B-Premise
modelo I-Premise
multivariante I-Premise
final I-Premise
predijo I-Premise
una I-Premise
mala I-Premise
supervivencia I-Premise
con I-Premise
múltiples I-Premise
localizaciones I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
visceral I-Premise
( I-Premise
P=0,003 I-Premise
) I-Premise
, I-Premise
DFI I-Premise
< I-Premise
/=2 I-Premise
años I-Premise
( I-Premise
P=0,026 I-Premise
) I-Premise
y I-Premise
dolor I-Premise
( I-Premise
P=0,003 I-Premise
) I-Premise
. I-Premise

Para B-Premise
la I-Premise
respuesta, I-Premise
la I-Premise
edad, I-Premise
la I-Premise
disnea, I-Premise
la I-Premise
fatiga I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
fueron I-Premise
factores I-Premise
predictivos I-Premise
significativos I-Premise
en I-Premise
el I-Premise
análisis I-Premise
univariante. I-Premise

El B-Premise
modelo I-Premise
multivariante I-Premise
final I-Premise
para I-Premise
la I-Premise
respuesta I-Premise
seleccionó I-Premise
la I-Premise
DFI I-Premise
( I-Premise
P=0,009 I-Premise
) I-Premise
, I-Premise
las I-Premise
múltiples I-Premise
localizaciones I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
visceral I-Premise
( I-Premise
P=0,037 I-Premise
) I-Premise
y I-Premise
la I-Premise
disnea I-Premise
( I-Premise
P= I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
utilizando I-Premise
la I-Premise
selección I-Premise
hacia I-Premise
delante I-Premise
, O
pero B-Premise
la I-Premise
inestabilidad I-Premise
del I-Premise
modelo I-Premise
quedó I-Premise
indicada I-Premise
por I-Premise
la I-Premise
inclusión I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
y I-Premise
la I-Premise
función I-Premise
emocional I-Premise
en I-Premise
el I-Premise
modelo I-Premise
final I-Premise
cuando I-Premise
se I-Premise
utilizó I-Premise
la I-Premise
selección I-Premise
hacia I-Premise
atrás I-Premise
. O

Además O
de O
los O
factores O
clínicos O
conocidos, O
las B-Claim
variables I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
evaluadas I-Claim
por I-Claim
las I-Claim
pacientes I-Claim
parecen I-Claim
ser I-Claim
un I-Claim
factor I-Claim
pronóstico I-Claim
de I-Claim
la I-Claim
supervivencia I-Claim
y I-Claim
la I-Claim
respuesta I-Claim
a I-Claim
la I-Claim
quimioterapia I-Claim
en I-Claim
mujeres I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
avanzado. I-Claim

Sin B-Claim
embargo, I-Claim
la I-Claim
identificación I-Claim
de I-Claim
los I-Claim
factores I-Claim
pronósticos I-Claim
a I-Claim
partir I-Claim
de I-Claim
las I-Claim
respuestas I-Claim
a I-Claim
los I-Claim
cuestionarios I-Claim
puede I-Claim
ser I-Claim
inestable, I-Claim
y I-Claim
su I-Claim
fiabilidad I-Claim
y I-Claim
utilidad I-Claim
clínica I-Claim
deben I-Claim
probarse I-Claim
de I-Claim
forma I-Claim
prospectiva. I-Claim

Everolimus O
( O
EVE O
) O
+exemestano O
( O
EXE O
; O
n O
= O
485 O
) O
duplicó O
con O
creces O
la O
mediana O
de O
supervivencia O
libre O
de O
progresión O
frente O
a O
placebo O
( O
PBO O
) O
+ O
EXE O
( O
n O
= O
239 O
) O
, O
con O
un O
perfil O
de O
seguridad O
manejable O
y O
sin O
deterioro O
de O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQOL O
) O
en O
pacientes O
con O
cáncer O
de O
mama O
avanzado O
( O
ABC O
) O
con O
receptores O
hormonales O
positivos O
( O
HR O
( O
+ O
) O
) O
que O
recidivaron O
o O
progresaron O
en/después O
del O
tratamiento O
con O
inhibidores O
de O
la O
aromatasa O
no O
esteroideos O
( O
AINE O
) O
. O

Para O
evaluar O
aún O
más O
el O
impacto O
de O
EVE O
+ O
EXE O
en O
la O
carga O
de O
la O
enfermedad O
, O
realizamos O
análisis O
adicionales O
post-hoc O
de O
la O
CVRS O
informada O
por O
los O
pacientes O
. O

La O
CVRS O
se O
evaluó O
mediante O
los O
cuestionarios O
EORTC O
QLQ-C30 O
y O
QLQ-BR23 O
al O
inicio O
y O
cada O
6 O
semanas O
a O
partir O
de O
entonces O
hasta O
la O
interrupción O
del O
tratamiento O
por O
progresión O
de O
la O
enfermedad, O
toxicidad O
o O
retirada O
del O
consentimiento. O

Los O
criterios O
de O
valoración O
incluyeron O
la O
escala O
QLQ-C30 O
de O
Estado O
de O
Salud O
Global O
( O
QL2 O
) O
, O
la O
escala O
QLQ-BR23 O
de O
síntomas O
de O
la O
mama O
( O
BRBS O
) O
y O
la O
de O
síntomas O
del O
brazo O
( O
BRAS O
) O
. O

Se O
evaluaron O
las O
diferencias O
entre O
grupos O
en O
cuanto O
a O
los O
cambios O
con O
respecto O
a O
la O
línea O
de O
base O
mediante O
modelos O
lineales O
mixtos O
con O
covariables O
seleccionadas. O

El O
análisis O
de O
sensibilidad O
mediante O
modelos O
de O
mezcla O
de O
patrones O
determinó O
el O
efecto O
de O
la O
interrupción O
del O
estudio O
en/antes O
de O
la O
semana O
24 O
. O

Los O
brazos O
de O
tratamiento O
se O
compararon O
utilizando O
las O
diferencias O
de O
los O
cambios O
de O
la O
media O
de O
mínimos O
cuadrados O
( O
LSM O
) O
con O
respecto O
a O
la O
línea O
de O
base O
y O
los O
intervalos O
de O
confianza O
( O
IC O
) O
del O
95 O
% O
en O
cada O
punto O
de O
tiempo O
y O
en O
general O
. O

Supervivencia O
sin O
progresión O
, O
supervivencia O
, O
tasa O
de O
respuesta O
, O
seguridad O
y O
CVRS O
. O

Los B-Premise
modelos I-Premise
lineales I-Premise
mixtos I-Premise
( I-Premise
modelo I-Premise
primario I-Premise
) I-Premise
no I-Premise
demostraron I-Premise
ninguna I-Premise
diferencia I-Premise
global I-Premise
estadísticamente I-Premise
significativa I-Premise
entre I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
y I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
para I-Premise
QL2 I-Premise
( I-Premise
diferencia I-Premise
LSM I-Premise
= I-Premise
-1,91 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-4,61 I-Premise
, I-Premise
0,78 I-Premise
) I-Premise
, I-Premise
BRBS I-Premise
( I-Premise
diferencia I-Premise
LSM I-Premise
= I-Premise
-0,18 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-1,98 I-Premise
, I-Premise
1,62 I-Premise
) I-Premise
, I-Premise
o I-Premise
BRAS I-Premise
( I-Premise
diferencia I-Premise
LSM I-Premise
= I-Premise
-0,42 I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
= I-Premise
-2,94 I-Premise
, I-Premise
2,10 I-Premise
) I-Premise
. I-Premise

Según O
los O
modelos O
de O
mezcla O
de O
patrones, O
los O
pacientes O
que O
abandonaron O
pronto O
el O
tratamiento O
tuvieron O
un O
peor O
deterioro O
del O
QL2 O
con O
ambos O
tratamientos. O

En B-Premise
el I-Premise
modelo I-Premise
de I-Premise
mezcla I-Premise
de I-Premise
patrones I-Premise
ampliado, I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
que I-Premise
no I-Premise
abandonaron I-Premise
el I-Premise
tratamiento I-Premise
antes I-Premise
de I-Premise
tiempo I-Premise
tuvieron I-Premise
una I-Premise
BRBS I-Premise
y I-Premise
una I-Premise
BRAS I-Premise
estables I-Premise
en I-Premise
relación I-Premise
con I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
. I-Premise

No O
se O
recogieron O
datos O
de O
CVRS O
tras O
la O
progresión O
de O
la O
enfermedad. O

Estos B-Claim
análisis I-Claim
confirman I-Claim
que I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
proporciona I-Claim
un I-Claim
beneficio I-Claim
clínico I-Claim
sin I-Claim
impactar I-Claim
negativamente I-Claim
en I-Claim
la I-Claim
CVRS I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
RH I-Claim
( I-Claim
+ I-Claim
) I-Claim
ABC I-Claim
que I-Claim
recurrieron/progresaron I-Claim
con I-Claim
AINEs I-Claim
previos I-Claim
frente I-Claim
a I-Claim
la I-Claim
terapia I-Claim
endocrina I-Claim
sola I-Claim
. I-Claim

Examinar O
el O
efecto O
de O
un O
programa O
de O
ejercicios O
progresivos O
para O
la O
parte O
superior O
del O
cuerpo O
en O
el O
linfedema O
secundario O
al O
tratamiento O
del O
cáncer O
de O
mama O
. O

Catorce O
supervivientes O
de O
cáncer O
de O
mama O
con O
linfedema O
unilateral O
de O
las O
extremidades O
superiores O
fueron O
asignadas O
aleatoriamente O
a O
un O
grupo O
de O
ejercicio O
( O
n O
= O
7 O
) O
o O
de O
control O
( O
n O
= O
7 O
) O
. O

El O
grupo O
de O
ejercicio O
siguió O
un O
programa O
progresivo O
de O
8 O
semanas O
de O
ejercicios O
para O
la O
parte O
superior O
del O
cuerpo O
que O
consistía O
en O
entrenamiento O
de O
resistencia O
más O
ejercicios O
aeróbicos O
utilizando O
un O
ergómetro O
de O
brazo O
Monark O
Rehab O
Trainer O
. O

El O
linfedema O
se O
evaluó O
mediante O
la O
circunferencia O
del O
brazo O
y O
la O
medición O
del O
volumen O
del O
brazo O
por O
desplazamiento O
de O
agua O
. O

Los O
pacientes O
fueron O
evaluados O
en O
cinco O
ocasiones O
durante O
el O
periodo O
experimental. O

Para O
medir O
la O
calidad O
de O
vida O
antes O
y O
después O
de O
la O
intervención O
se O
utilizó O
la O
encuesta O
Short-Form O
36 O
del O
Medical O
Outcomes O
Trust. O

La O
significación O
se O
fijó O
en O
alfa O
< O
o O
= O
0,01 O
. O

No B-Premise
se I-Premise
encontraron I-Premise
cambios I-Premise
en I-Premise
la I-Premise
circunferencia I-Premise
o I-Premise
el I-Premise
volumen I-Premise
del I-Premise
brazo I-Premise
como I-Premise
resultado I-Premise
del I-Premise
programa I-Premise
de I-Premise
ejercicios. I-Premise

Tres B-Premise
de I-Premise
los I-Premise
ámbitos I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
mostraron I-Premise
tendencias I-Premise
hacia I-Premise
el I-Premise
aumento I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
ejercicio: I-Premise
funcionamiento I-Premise
físico I-Premise
( I-Premise
P I-Premise
=050 I-Premise
) I-Premise
, I-Premise
salud I-Premise
general I-Premise
( I-Premise
P I-Premise
=048 I-Premise
) I-Premise
y I-Premise
vitalidad I-Premise
( I-Premise
P I-Premise
=023 I-Premise
) I-Premise
. I-Premise

La B-Premise
salud I-Premise
mental I-Premise
aumentó, I-Premise
aunque I-Premise
no I-Premise
significativamente, I-Premise
en I-Premise
todos I-Premise
los I-Premise
sujetos I-Premise
( I-Premise
P I-Premise
= I-Premise
0,019 I-Premise
) I-Premise
. I-Premise

El B-Premise
volumen I-Premise
del I-Premise
brazo I-Premise
medido I-Premise
por I-Premise
el I-Premise
desplazamiento I-Premise
del I-Premise
agua I-Premise
se I-Premise
correlacionó I-Premise
con I-Premise
el I-Premise
volumen I-Premise
calculado I-Premise
del I-Premise
brazo I-Premise
( I-Premise
r I-Premise
= I-Premise
0,973 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) O
, O
aunque B-Premise
las I-Premise
medias I-Premise
de I-Premise
los I-Premise
grupos I-Premise
de I-Premise
ejercicio I-Premise
y I-Premise
de I-Premise
control I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) O
. O

La B-Claim
participación I-Claim
en I-Claim
un I-Claim
programa I-Claim
de I-Claim
ejercicios I-Claim
para I-Claim
la I-Claim
parte I-Claim
superior I-Claim
del I-Claim
cuerpo I-Claim
no I-Claim
causó I-Claim
cambios I-Claim
en I-Claim
la I-Claim
circunferencia I-Claim
del I-Claim
brazo I-Claim
o I-Claim
el I-Claim
volumen I-Claim
del I-Claim
brazo I-Claim
en I-Claim
mujeres I-Claim
con I-Claim
linfedema I-Claim
después I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
, I-Claim
y I-Claim
pueden I-Claim
haber I-Claim
experimentado I-Claim
un I-Claim
aumento I-Claim
en I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
. I-Claim

Deberían B-Claim
realizarse I-Claim
más I-Claim
estudios I-Claim
en I-Claim
este I-Claim
ámbito I-Claim
para I-Claim
determinar I-Claim
el I-Claim
programa I-Claim
de I-Claim
formación I-Claim
óptimo. I-Claim

Los O
estudios O
han O
demostrado O
que O
existe O
una O
alta O
prevalencia O
de O
depresión O
en O
los O
pacientes O
con O
cáncer. O

Las B-Claim
mujeres I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
pueden I-Claim
tener I-Claim
un I-Claim
riesgo I-Claim
aún I-Claim
mayor I-Claim
de I-Claim
depresión, I-Claim
especialmente I-Claim
en I-Claim
un I-Claim
estado I-Claim
posmenopáusico I-Claim
o I-Claim
de I-Claim
deficiencia I-Claim
de I-Claim
estrógenos. I-Claim

Un O
pequeño O
número O
de O
ensayos O
controlados O
aleatorios O
han O
examinado O
la O
eficacia O
de O
los O
antidepresivos O
en O
comparación O
con O
la O
de O
un O
placebo O
en O
pacientes O
con O
cáncer O
, O
pero O
algunos O
resultados O
han O
sido O
difíciles O
de O
interpretar O
debido O
a O
la O
heterogeneidad O
del O
grupo O
de O
pacientes O
. O

En O
la O
presente O
investigación, O
se O
examinó O
a O
las O
pacientes O
recién O
diagnosticadas O
de O
cáncer O
de O
mama O
en O
fase O
inicial O
para O
detectar O
síntomas O
depresivos O
antes O
del O
inicio O
del O
tratamiento O
adyuvante O
y O
se O
investigó O
si O
el O
antidepresivo O
oral O
fluoxetina O
afectaba O
a O
los O
síntomas O
depresivos, O
la O
finalización O
del O
tratamiento O
adyuvante O
y O
la O
calidad O
de O
vida. O

Las O
pacientes O
con O
cáncer O
de O
mama O
de O
reciente O
diagnóstico O
en O
fase O
inicial O
fueron O
sometidas O
a O
un O
cribado O
de O
síntomas O
depresivos O
antes O
de O
iniciar O
la O
terapia O
adyuvante O
. O

Los O
pacientes O
con O
síntomas O
depresivos O
fueron O
asignados O
al O
azar O
a O
una O
fluoxetina O
oral O
diaria O
o O
a O
un O
placebo O
. O

A O
continuación, O
se O
realizó O
un O
seguimiento O
de O
los O
pacientes O
durante O
6 O
meses O
y O
se O
evaluó O
la O
calidad O
de O
vida, O
la O
finalización O
del O
tratamiento O
adyuvante O
y O
los O
síntomas O
depresivos. O

Se O
observó O
que O
un O
alto O
porcentaje O
de O
pacientes O
con O
cáncer O
de O
mama O
en O
fase O
inicial O
recién O
diagnosticado O
presentaba O
síntomas O
depresivos O
antes O
de O
iniciar O
el O
tratamiento O
adyuvante O
. O

El B-Premise
uso I-Premise
de I-Premise
fluoxetina I-Premise
durante I-Premise
6 I-Premise
meses I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
una I-Premise
mejora I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
, I-Premise
una I-Premise
mayor I-Premise
finalización I-Premise
del I-Premise
tratamiento I-Premise
adyuvante I-Premise
( I-Premise
quimioterapia I-Premise
, I-Premise
terapia I-Premise
hormonal I-Premise
, I-Premise
quimioterapia I-Premise
más I-Premise
terapia I-Premise
hormonal I-Premise
) I-Premise
, I-Premise
y I-Premise
una I-Premise
reducción I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
depresivos I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
placebo I-Premise
. I-Premise

Debe B-Claim
considerarse I-Claim
la I-Claim
posibilidad I-Claim
de I-Claim
administrar I-Claim
un I-Claim
antidepresivo I-Claim
a I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
en I-Claim
fase I-Claim
inicial I-Claim
que I-Claim
presenten I-Claim
síntomas I-Claim
depresivos I-Claim
y I-Claim
reciban I-Claim
tratamiento I-Claim
adyuvante I-Claim
. I-Claim

El O
segundo O
estudio O
de O
la O
Sociedad O
Internacional O
de O
Oncología O
Pediátrica O
( O
SIOP O
) O
para O
el O
rabdomiosarcoma O
( O
MMT84 O
) O
tenía O
varios O
objetivos O
. O

Los O
dos O
objetivos O
principales O
eran: O
( O
1 O
) O
mejorar O
la O
supervivencia O
de O
los O
niños O
con O
rabdomiosarcoma O
; O
y O
( O
2 O
) O
reducir O
los O
efectos O
tardíos O
de O
la O
terapia O
restringiendo O
las O
indicaciones O
de O
cirugía O
y/o O
radioterapia O
tras O
una O
buena O
respuesta O
a O
la O
quimioterapia O
inicial O
. O

Otro O
objetivo O
era O
investigar O
el O
papel O
de O
la O
quimioterapia O
de O
alta O
dosis O
en O
pacientes O
jóvenes O
con O
tumores O
primarios O
parameníngeos O
. O

186 O
pacientes O
elegibles O
no O
tratados O
previamente O
entraron O
en O
el O
estudio. O

Los O
pacientes O
con O
tumor O
primario O
completamente O
resecado O
recibieron O
tres O
ciclos O
de O
IVA O
( O
ifosfamida O
, O
vincristina O
y O
actinomicina O
D O
) O
. O

Los O
pacientes O
con O
un O
tumor O
resecado O
de O
forma O
incompleta O
recibieron O
de O
seis O
a O
diez O
ciclos O
de O
IVA O
según O
el O
estadio. O

Los O
pacientes O
que O
logran O
una O
remisión O
completa O
con O
quimioterapia O
sola O
no O
suelen O
recibir O
radioterapia O
ni O
someterse O
a O
una O
cirugía O
extensa O
, O
pero O
los O
pacientes O
que O
permanecen O
en O
remisión O
parcial O
reciben O
terapia O
local O
con O
cirugía O
y/o O
radioterapia O
. O

Sólo O
los O
pacientes O
mayores O
de O
5 O
años O
con O
enfermedad O
parameníngea O
y O
los O
mayores O
de O
12 O
años O
con O
tumores O
en O
cualquier O
localización O
recibieron O
irradiación O
sistemática O
. O

La B-Premise
remisión I-Premise
completa I-Premise
se I-Premise
alcanzó I-Premise
en I-Premise
el I-Premise
91% I-Premise
( I-Premise
170/186 I-Premise
) I-Premise
de I-Premise
todos I-Premise
los I-Premise
pacientes I-Premise
. I-Premise

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
8 I-Premise
años, I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
a I-Premise
5 I-Premise
años I-Premise
fue I-Premise
del I-Premise
68 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
3 I-Premise
% I-Premise
error I-Premise
estándar I-Premise
de I-Premise
la I-Premise
media I-Premise
( I-Premise
SEM I-Premise
) I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
eventos I-Premise
a I-Premise
5 I-Premise
años I-Premise
del I-Premise
53 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
4 I-Premise
% I-Premise
SEM I-Premise
) I-Premise
. I-Premise

Estos B-Premise
resultados I-Premise
muestran I-Premise
una I-Premise
mejora I-Premise
con I-Premise
respecto I-Premise
al I-Premise
estudio I-Premise
anterior I-Premise
de I-Premise
la I-Premise
SIOP I-Premise
( I-Premise
RMS75 I-Premise
), I-Premise
en I-Premise
el I-Premise
que I-Premise
la I-Premise
supervivencia I-Premise
fue I-Premise
del I-Premise
52% I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
sin I-Premise
eventos I-Premise
del I-Premise
47% I-Premise
. I-Premise

Entre B-Premise
los I-Premise
54 I-Premise
pacientes I-Premise
que I-Premise
presentaron I-Premise
una I-Premise
recaída I-Premise
local I-Premise
aislada I-Premise
, I-Premise
el I-Premise
35% I-Premise
( I-Premise
19/54 I-Premise
) I-Premise
sobrevivieron I-Premise
en I-Premise
remisión I-Premise
adicional I-Premise
más I-Premise
de I-Premise
2 I-Premise
años I-Premise
después I-Premise
del I-Premise
retratamiento I-Premise
, I-Premise
incluyendo I-Premise
la I-Premise
terapia I-Premise
local I-Premise
( I-Premise
cirugía I-Premise
+/- I-Premise
radioterapia I-Premise
) I-Premise
. I-Premise

El O
análisis O
de O
la O
carga O
global O
de O
la O
terapia O
recibida O
por O
todos O
los O
niños O
supervivientes O
( O
incluyendo O
el O
tratamiento O
primario O
y O
el O
tratamiento O
para O
la O
recaída O
si O
es O
necesario O
) O
mostró O
que O
el O
24% O
( O
28/116 O
) O
fueron O
tratados O
por O
la O
cirugía O
limitada O
seguida O
de O
tres O
cursos O
de O
IVA O
, O
el O
29% O
( O
34/116 O
) O
fueron O
tratados O
por O
la O
quimioterapia O
sola O
( O
después O
de O
la O
biopsia O
inicial O
) O
y O
el O
13% O
( O
15/116 O
) O
recibieron O
quimioterapia O
más O
tratamiento O
local O
conservador O
( O
cirugía O
limitada O
o O
radioterapia O
para O
la O
enfermedad O
residual O
) O
. O

Sólo O
el O
34% O
( O
39/116 O
) O
recibió O
terapia O
local O
intensiva O
definida O
como O
radioterapia O
radical O
de O
campo O
amplio O
o O
cirugía O
radical O
o O
ambas. O

En B-Claim
comparación I-Claim
con I-Claim
los I-Claim
resultados I-Claim
obtenidos I-Claim
en I-Claim
el I-Claim
anterior I-Claim
estudio I-Claim
SIOP, I-Claim
el I-Claim
tratamiento I-Claim
en I-Claim
el I-Claim
MMT84 I-Claim
se I-Claim
basó I-Claim
en I-Claim
la I-Claim
respuesta I-Claim
a I-Claim
la I-Claim
quimioterapia I-Claim
inicial I-Claim
y, I-Claim
a I-Claim
pesar I-Claim
de I-Claim
una I-Claim
reducción I-Claim
global I-Claim
del I-Claim
uso I-Claim
de I-Claim
la I-Claim
terapia I-Claim
local, I-Claim
mejoró I-Claim
significativamente I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
enfermedad I-Claim
no I-Claim
metastásica. I-Claim

Este B-Claim
ensayo, I-Claim
también I-Claim
por I-Claim
primera I-Claim
vez, I-Claim
aporta I-Claim
pruebas I-Claim
de I-Claim
que I-Claim
el I-Claim
retratamiento I-Claim
tras I-Claim
una I-Claim
recaída I-Claim
local I-Claim
puede I-Claim
lograr I-Claim
segundas I-Claim
remisiones I-Claim
a I-Claim
largo I-Claim
plazo. I-Claim

El B-Claim
DPPE I-Claim
( I-Claim
tesmilifeno I-Claim
) I-Claim
más I-Claim
doxorrubicina I-Claim
( I-Claim
DOX I-Claim
) I-Claim
demostró I-Claim
una I-Claim
mejora I-Claim
significativa I-Claim
de I-Claim
la I-Claim
supervivencia I-Claim
frente I-Claim
al I-Claim
DOX I-Claim
en I-Claim
un I-Claim
ensayo I-Claim
clínico I-Claim
de I-Claim
fase I-Claim
III I-Claim
en I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
avanzado I-Claim
. I-Claim

Sin B-Premise
embargo, I-Premise
el I-Premise
DPPE I-Premise
se I-Premise
asocia I-Premise
a I-Premise
una I-Premise
toxicidad I-Premise
inusual I-Premise
en I-Premise
forma I-Premise
de I-Premise
alucinaciones, I-Premise
náuseas I-Premise
y I-Premise
vómitos, I-Premise
que I-Premise
se I-Premise
prevé I-Premise
que I-Premise
afecten I-Premise
a I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
(QOL) I-Premise
a I-Premise
corto I-Premise
plazo. I-Premise

Se O
aplicaron O
los O
enfoques O
estándar O
del O
Grupo O
de O
Ensayos O
Clínicos O
del O
Instituto O
Nacional O
del O
Cáncer O
de O
Canadá O
( O
NCIC O
CTG O
) O
como O
método O
principal O
para O
analizar O
los O
datos O
de O
calidad O
de O
vida O
de O
este O
ensayo. O

Esto O
incluye O
comparaciones O
transversales O
, O
junto O
con O
una O
prueba O
global O
para O
la O
tasa O
de O
respuesta O
de O
QOL O
. O

También O
se O
realizaron O
análisis O
de O
sensibilidad O
para O
determinados O
ámbitos O
y O
elementos O
de O
la O
CV, O
utilizando O
otros O
tipos O
de O
medidas O
de O
resumen O
y O
estadísticas. O

Doscientos O
setenta O
y O
un O
pacientes O
(el O
89% O
de O
los O
asignados O
al O
azar) O
presentaron O
los O
cuestionarios O
de O
calidad O
de O
vida O
iniciales O
y O
se O
incluyeron O
en O
el O
análisis O
de O
calidad O
de O
vida. O

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
la I-Premise
respuesta I-Premise
de I-Premise
la I-Premise
CdV I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
para I-Premise
ningún I-Premise
dominio I-Premise
o I-Premise
elemento, I-Premise
excepto I-Premise
las I-Premise
náuseas I-Premise
y I-Premise
los I-Premise
vómitos I-Premise
( I-Premise
P I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
. I-Premise

Las B-Premise
comparaciones I-Premise
transversales I-Premise
mostraron I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
para I-Premise
algunos I-Premise
dominios/elementos I-Premise
en I-Premise
momentos I-Premise
de I-Premise
evaluación I-Premise
específicos, I-Premise
con I-Premise
todas I-Premise
las I-Premise
diferencias I-Premise
a I-Premise
favor I-Premise
del I-Premise
brazo I-Premise
de I-Premise
DOX I-Premise
solo. I-Premise

Los B-Premise
pacientes I-Premise
del I-Premise
brazo I-Premise
DPPE/DOX I-Premise
fueron I-Premise
significativamente I-Premise
peores I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
cambio I-Premise
de I-Premise
dolor I-Premise
medias I-Premise
y I-Premise
medianas. I-Premise

Los B-Claim
distintos I-Claim
análisis I-Claim
arrojaron I-Claim
conclusiones I-Claim
ligeramente I-Claim
diferentes, I-Claim
pero, O
en B-Claim
general, I-Claim
los I-Claim
análisis I-Claim
de I-Claim
la I-Claim
CdV I-Claim
fueron I-Claim
concordantes I-Claim
y I-Claim
mostraron I-Claim
que I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
sólo I-Claim
DOX I-Claim
tuvieron I-Claim
menos I-Claim
eventos I-Claim
adversos I-Claim
relacionados I-Claim
con I-Claim
la I-Claim
enfermedad I-Claim
y I-Claim
el I-Claim
tratamiento I-Claim
y I-Claim
una I-Claim
mejor I-Claim
CdV. I-Claim

Curiosamente, B-Claim
el I-Claim
análisis I-Claim
de I-Claim
la I-Claim
respuesta I-Claim
de I-Claim
la I-Claim
CdV I-Claim
también I-Claim
mostró I-Claim
que I-Claim
los I-Claim
regímenes I-Claim
agresivos I-Claim
de I-Claim
premedicación I-Claim
parecen I-Claim
mejorar I-Claim
los I-Claim
posibles I-Claim
efectos I-Claim
negativos I-Claim
del I-Claim
DPPE I-Claim
sobre I-Claim
la I-Claim
emesis I-Claim
y I-Claim
las I-Claim
náuseas, I-Claim
según I-Claim
la I-Claim
CdV I-Claim
evaluada I-Claim
por I-Claim
el I-Claim
paciente. I-Claim

Numerosos O
estudios O
han O
examinado O
la O
comorbilidad O
de O
la O
depresión O
con O
el O
cáncer O
, O
y O
algunos O
han O
indicado O
que O
la O
depresión O
puede O
estar O
asociada O
con O
la O
progresión O
o O
la O
supervivencia O
del O
cáncer O
. O

Sin O
embargo, O
pocos O
estudios O
han O
evaluado O
si O
los O
cambios O
en O
los O
síntomas O
de O
la O
depresión O
están O
asociados O
a O
la O
supervivencia. O

En O
un O
análisis O
secundario O
de O
un O
ensayo O
aleatorio O
de O
terapia O
de O
grupo O
de O
apoyo-expresión O
, O
125 O
mujeres O
con O
cáncer O
de O
mama O
metastásico O
( O
CMM O
) O
completaron O
una O
medida O
de O
los O
síntomas O
de O
la O
depresión O
( O
Centro O
de O
Estudios O
Epidemiológicos-Escala O
de O
Depresión O
[ O
CES-D O
] O
) O
en O
la O
línea O
de O
base O
y O
fueron O
asignados O
al O
azar O
a O
un O
grupo O
de O
tratamiento O
o O
a O
un O
grupo O
de O
control O
que O
recibió O
materiales O
educativos O
. O

En O
la O
línea O
de O
base O
y O
en O
tres O
puntos O
de O
seguimiento, O
101 O
de O
125 O
mujeres O
completaron O
una O
medida O
de O
los O
síntomas O
de O
la O
depresión. O

Utilizamos O
estos O
datos O
en O
un O
análisis O
de O
riesgos O
proporcionales O
de O
Cox O
para O
examinar O
si O
la O
disminución O
de O
los O
síntomas O
de O
depresión O
durante O
el O
primer O
año O
del O
estudio O
( O
la O
duración O
de O
la O
intervención O
) O
se O
asociaría O
con O
una O
mayor O
supervivencia O
. O

La B-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
53,6 I-Premise
meses I-Premise
para I-Premise
las I-Premise
mujeres I-Premise
con I-Premise
puntuaciones I-Premise
CES-D I-Premise
decrecientes I-Premise
durante I-Premise
1 I-Premise
año I-Premise
y I-Premise
de I-Premise
25,1 I-Premise
meses I-Premise
para I-Premise
las I-Premise
mujeres I-Premise
con I-Premise
puntuaciones I-Premise
CES-D I-Premise
crecientes I-Premise
. I-Premise

Hubo B-Premise
un I-Premise
efecto I-Premise
significativo I-Premise
del I-Premise
cambio I-Premise
en I-Premise
la I-Premise
CES-D I-Premise
durante I-Premise
el I-Premise
primer I-Premise
año I-Premise
sobre I-Premise
la I-Premise
supervivencia I-Premise
hasta I-Premise
los I-Premise
14 I-Premise
años I-Premise
( I-Premise
P I-Premise
= I-Premise
0,007 I-Premise
), I-Premise
pero I-Premise
no I-Premise
hubo I-Premise
una I-Premise
interacción I-Premise
significativa I-Premise
entre I-Premise
la I-Premise
condición I-Premise
de I-Premise
tratamiento I-Premise
y I-Premise
el I-Premise
cambio I-Premise
en I-Premise
la I-Premise
CES-D I-Premise
sobre I-Premise
la I-Premise
supervivencia I-Premise
. O

Ni O
las O
variables O
demográficas O
ni O
las O
médicas O
explican O
esta O
asociación. O

La B-Claim
disminución I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
de I-Claim
depresión I-Claim
durante I-Claim
el I-Claim
primer I-Claim
año I-Claim
se I-Claim
asoció I-Claim
con I-Claim
una I-Claim
mayor I-Claim
supervivencia I-Claim
posterior I-Claim
para I-Claim
las I-Claim
mujeres I-Claim
con I-Claim
CMB I-Claim
en I-Claim
esta I-Claim
muestra I-Claim
. I-Claim

Es B-Claim
necesario I-Claim
seguir I-Claim
investigando I-Claim
para I-Claim
confirmar I-Claim
esta I-Claim
hipótesis I-Claim
en I-Claim
otras I-Claim
muestras, I-Claim
y I-Claim
no I-Claim
se I-Claim
puede I-Claim
asumir I-Claim
la I-Claim
causalidad I-Claim
a I-Claim
partir I-Claim
de I-Claim
este I-Claim
análisis. I-Claim

El O
objetivo O
fue O
determinar O
el O
efecto O
del O
asesoramiento O
dietético O
o O
de O
los O
suplementos O
orales O
en O
los O
resultados O
de O
los O
pacientes O
con O
cáncer O
, O
específicamente O
, O
el O
resultado O
nutricional O
, O
la O
morbilidad O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
, O
durante O
y O
3 O
meses O
después O
de O
la O
radioterapia O
. O

Setenta O
y O
cinco O
pacientes O
con O
cáncer O
de O
cabeza O
y O
cuello O
que O
fueron O
remitidos O
para O
radioterapia O
( O
RT O
) O
fueron O
asignados O
al O
azar O
a O
los O
siguientes O
grupos O
: O
grupo O
1 O
( O
n O
= O
25 O
) O
, O
pacientes O
que O
recibieron O
asesoramiento O
dietético O
con O
alimentos O
habituales O
; O
grupo O
2 O
( O
n O
= O
25 O
) O
, O
pacientes O
que O
mantuvieron O
la O
dieta O
habitual O
más O
suplementos O
; O
y O
grupo O
3 O
( O
n O
= O
25 O
) O
, O
pacientes O
que O
mantuvieron O
la O
ingesta O
ad O
lib O
. O

La O
ingesta O
nutricional O
( O
determinada O
por O
la O
historia O
de O
la O
dieta O
) O
y O
el O
estado O
( O
determinado O
por O
la O
Evaluación O
Global O
Subjetiva O
de O
Ottery O
) O
, O
y O
la O
CdV O
( O
determinada O
por O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
versión O
3.0 O
[ O
EORTC O
QLQ-C30 O
] O
) O
fueron O
evaluados O
al O
inicio O
, O
al O
final O
de O
la O
RT O
, O
y O
a O
los O
3 O
meses O
. O

La B-Premise
ingesta I-Premise
de I-Premise
energía I-Premise
después I-Premise
de I-Premise
la I-Premise
RT I-Premise
aumentó I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
1 I-Premise
y I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
o I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

La B-Premise
ingesta I-Premise
de I-Premise
proteínas I-Premise
también I-Premise
aumentó I-Premise
en I-Premise
los I-Premise
grupos I-Premise
1 I-Premise
y I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
o I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Tanto B-Premise
la I-Premise
ingesta I-Premise
de I-Premise
energía I-Premise
como I-Premise
la I-Premise
de I-Premise
proteínas I-Premise
disminuyeron I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
grupo I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

A B-Premise
los I-Premise
3 I-Premise
meses, I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
mantuvo I-Premise
la I-Premise
ingesta, I-Premise
mientras I-Premise
que I-Premise
los I-Premise
grupos I-Premise
2 I-Premise
y I-Premise
3 I-Premise
volvieron I-Premise
a I-Premise
los I-Premise
niveles I-Premise
de I-Premise
referencia I-Premise
o I-Premise
a I-Premise
niveles I-Premise
inferiores. I-Premise

Después B-Premise
de I-Premise
la I-Premise
RT, I-Premise
más I-Premise
del I-Premise
90% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
experimentaron I-Premise
toxicidad I-Premise
por I-Premise
la I-Premise
RT; I-Premise
esto B-Premise
no I-Premise
fue I-Premise
significativamente I-Premise
diferente I-Premise
entre I-Premise
los I-Premise
grupos, I-Premise
con I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
la I-Premise
reducción I-Premise
de I-Premise
la I-Premise
sintomatología I-Premise
en I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
frente I-Premise
al I-Premise
grupo I-Premise
2/grupo I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.07 I-Premise
) O
. O

A B-Premise
los I-Premise
3 I-Premise
meses, I-Premise
la I-Premise
reducción I-Premise
de I-Premise
la I-Premise
incidencia/gravedad I-Premise
de I-Premise
la I-Premise
anorexia, I-Premise
las I-Premise
náuseas/vómitos, I-Premise
la I-Premise
xerostomía I-Premise
y I-Premise
la I-Premise
disgeusia I-Premise
de I-Premise
grado I-Premise
1+2 I-Premise
fue I-Premise
diferente: I-Premise
el I-Premise
90% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
mejoró I-Premise
en I-Premise
el I-Premise
grupo I-Premise
1 I-Premise
frente I-Premise
al I-Premise
67% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
2 I-Premise
y I-Premise
el I-Premise
51% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

Después B-Premise
de I-Premise
la I-Premise
RT I-Premise
, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
función I-Premise
de I-Premise
la I-Premise
CdV I-Premise
mejoraron I-Premise
( I-Premise
p I-Premise
< I-Premise
0,003 I-Premise
) I-Premise
proporcionalmente I-Premise
con I-Premise
la I-Premise
mejora I-Premise
de I-Premise
la I-Premise
ingesta I-Premise
y I-Premise
el I-Premise
estado I-Premise
nutricional I-Premise
en I-Premise
el I-Premise
grupo I-Premise
1/grupo I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
y I-Premise
empeoraron I-Premise
en I-Premise
el I-Premise
grupo I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) O
; O
a B-Premise
los I-Premise
3 I-Premise
meses I-Premise
, I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
1 I-Premise
mantuvieron I-Premise
o I-Premise
mejoraron I-Premise
la I-Premise
CdV I-Premise
general I-Premise
, I-Premise
mientras I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
los I-Premise
grupos I-Premise
2 I-Premise
y I-Premise
3 I-Premise
mantuvieron I-Premise
o I-Premise
empeoraron I-Premise
la I-Premise
CdV I-Premise
general O
. O

Durante B-Claim
el I-Claim
TR, I-Claim
las I-Claim
intervenciones I-Claim
nutricionales I-Claim
influyeron I-Claim
positivamente I-Claim
en I-Claim
los I-Claim
resultados, I-Claim
y I-Claim
el I-Claim
asesoramiento I-Claim
tuvo I-Claim
un I-Claim
beneficio I-Claim
similar/superior; I-Claim
a I-Claim
medio I-Claim
plazo, I-Claim
sólo I-Claim
el I-Claim
asesoramiento I-Claim
ejerció I-Claim
un I-Claim
impacto I-Claim
significativo I-Claim
en I-Claim
los I-Claim
resultados I-Claim
de I-Claim
los I-Claim
pacientes. I-Claim

El O
tratamiento O
de O
mantenimiento O
con O
pemetrexed O
mejoró O
significativamente O
la O
supervivencia O
global O
y O
la O
supervivencia O
sin O
progresión O
en O
comparación O
con O
el O
placebo O
, O
y O
tuvo O
un O
buen O
perfil O
de O
seguridad O
en O
un O
estudio O
de O
fase O
3 O
controlado O
con O
placebo O
en O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
avanzado O
( O
CPNM O
) O
. O

Se O
presentan O
aquí O
los O
resultados O
de O
la O
calidad O
de O
vida, O
la O
paliación O
de O
los O
síntomas O
y O
la O
tolerabilidad. O

Después O
de O
cuatro O
ciclos O
de O
terapia O
de O
inducción O
basada O
en O
platino O
, O
663 O
pacientes O
con O
CPNM O
en O
estadio O
IIIB O
o O
estadio O
IV O
y O
estado O
de O
rendimiento O
del O
Eastern O
Cooperative O
Oncology O
Group O
de O
0 O
o O
1 O
fueron O
asignados O
al O
azar O
( O
en O
una O
proporción O
de O
2:1 O
) O
desde O
el O
15 O
de O
marzo O
de O
2005 O
hasta O
el O
20 O
de O
julio O
de O
2007 O
, O
utilizando O
el O
método O
de O
minimización O
de O
Pocock O
y O
Simon O
para O
recibir O
pemetrexed O
( O
500 O
mg/m O
( O
2 O
) O
cada O
21 O
días O
; O
n=441 O
) O
o O
placebo O
( O
n=222 O
) O
más O
el O
mejor O
cuidado O
de O
apoyo O
hasta O
la O
progresión O
de O
la O
enfermedad O
. O

Los O
datos O
de O
eficacia O
primaria O
se O
han O
comunicado O
anteriormente. O

Los O
pacientes O
completaron O
la O
Escala O
de O
Síntomas O
del O
Cáncer O
de O
Pulmón O
( O
LCSS O
) O
en O
la O
línea O
de O
base O
, O
después O
de O
cada O
ciclo O
, O
y O
después O
de O
la O
interrupción O
. O

El O
empeoramiento O
de O
los O
síntomas O
se O
definió O
como O
un O
aumento O
de O
15 O
mm O
o O
más O
desde O
el O
inicio O
en O
una O
escala O
de O
100 O
mm O
para O
cada O
elemento O
de O
la O
LCSS O
. O

El O
resultado O
primario O
de O
estos O
análisis O
de O
calidad O
de O
vida O
fue O
el O
tiempo O
hasta O
el O
empeoramiento O
de O
los O
síntomas O
, O
analizado O
para O
todos O
los O
pacientes O
aleatorizados O
. O

Las O
características O
iniciales, O
incluidas O
las O
puntuaciones O
de O
la O
LCSS, O
estaban O
bien O
equilibradas O
entre O
los O
grupos. O

Las O
puntuaciones O
iniciales O
de O
la O
LCSS O
fueron O
bajas, O
lo O
que O
indica O
una O
baja O
carga O
de O
síntomas O
en O
los O
pacientes O
sin O
progresión O
de O
la O
enfermedad O
tras O
completar O
el O
tratamiento O
de O
primera O
línea. O

Se B-Premise
registró I-Premise
un I-Premise
mayor I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
empeoramiento I-Premise
del I-Premise
dolor I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0-76 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-59-0-99 I-Premise
; I-Premise
p=0-041 I-Premise
) I-Premise
y I-Premise
de I-Premise
la I-Premise
hemoptisis I-Premise
( I-Premise
HR I-Premise
0-58 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-34-0-97 I-Premise
; I-Premise
p=0-038 I-Premise
) I-Premise
con I-Premise
pemetrexed I-Premise
que I-Premise
con I-Premise
placebo I-Premise
; O
no B-Premise
se I-Premise
observaron I-Premise
otras I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
los I-Premise
análisis I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
empeoramiento I-Premise
. O

Los B-Premise
análisis I-Premise
longitudinales I-Premise
adicionales I-Premise
mostraron I-Premise
un I-Premise
mayor I-Premise
aumento I-Premise
de I-Premise
la I-Premise
pérdida I-Premise
de I-Premise
apetito I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
pemetrexed I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
( I-Premise
4-3 I-Premise
mm I-Premise
vs I-Premise
0-2 I-Premise
mm I-Premise
; I-Premise
p=0-028 I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
uso I-Premise
de I-Premise
recursos I-Premise
fueron I-Premise
estadísticamente I-Premise
más I-Premise
altas I-Premise
para I-Premise
el I-Premise
pemetrexed I-Premise
que I-Premise
para I-Premise
el I-Premise
placebo: I-Premise
ingresos I-Premise
en I-Premise
el I-Premise
hospital I-Premise
por I-Premise
acontecimientos I-Premise
adversos I-Premise
relacionados I-Premise
con I-Premise
el I-Premise
fármaco I-Premise
( I-Premise
19 I-Premise
[ I-Premise
4 I-Premise
% I-Premise
] I-Premise
frente I-Premise
a I-Premise
ninguno I-Premise
; I-Premise
p=0-001 I-Premise
) I-Premise
, I-Premise
transfusiones I-Premise
( I-Premise
42 I-Premise
[ I-Premise
10 I-Premise
% I-Premise
] I-Premise
frente I-Premise
a I-Premise
siete I-Premise
[ I-Premise
3 I-Premise
% I-Premise
] I-Premise
; I-Premise
p=0-003 I-Premise
) I-Premise
, I-Premise
y I-Premise
agentes I-Premise
estimulantes I-Premise
de I-Premise
la I-Premise
eritropoyesis I-Premise
( I-Premise
26 I-Premise
[ I-Premise
6 I-Premise
% I-Premise
] I-Premise
frente I-Premise
a I-Premise
cuatro I-Premise
[ I-Premise
2 I-Premise
% I-Premise
] I-Premise
; I-Premise
p=0-017 I-Premise
) I-Premise
. I-Premise

La B-Claim
calidad I-Claim
de I-Claim
vida I-Claim
durante I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
mantenimiento I-Claim
con I-Claim
pemetrexed I-Claim
es I-Claim
similar I-Claim
a I-Claim
la I-Claim
del I-Claim
placebo I-Claim
, O
excepto B-Claim
por I-Claim
un I-Claim
pequeño I-Claim
aumento I-Claim
de I-Claim
la I-Claim
pérdida I-Claim
de I-Claim
apetito I-Claim
, I-Claim
y I-Claim
un I-Claim
retraso I-Claim
significativo I-Claim
en I-Claim
el I-Claim
empeoramiento I-Claim
del I-Claim
dolor I-Claim
y I-Claim
la I-Claim
hemoptisis I-Claim
. O

En O
vista O
de O
las O
mejoras O
en O
la O
supervivencia O
global O
y O
libre O
de O
progresión O
observadas O
con O
el O
tratamiento O
de O
mantenimiento O
con O
pemetrexed O
, O
dicho B-Claim
tratamiento I-Claim
es I-Claim
una I-Claim
opción I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
no I-Claim
escamoso I-Claim
avanzado I-Claim
que I-Claim
no I-Claim
han I-Claim
progresado I-Claim
tras I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
inducción I-Claim
basado I-Claim
en I-Claim
platino I-Claim
. O

El B-Claim
papel I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
de I-Claim
alta I-Claim
dosis I-Claim
( I-Claim
HDCT I-Claim
) I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
metastásico I-Claim
sigue I-Claim
siendo I-Claim
controvertido I-Claim
. I-Claim

Los B-Claim
ensayos I-Claim
con I-Claim
HDCT I-Claim
de I-Claim
intensificación I-Claim
tardía I-Claim
no I-Claim
han I-Claim
mostrado I-Claim
una I-Claim
ventaja I-Claim
en I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
. I-Claim

Este O
estudio O
se O
inició O
para O
comparar O
la O
HDCT O
en O
tándem O
y O
la O
terapia O
combinada O
estándar O
en O
pacientes O
con O
cáncer O
de O
mama O
metastásico. O

Los O
pacientes O
sin O
quimioterapia O
previa O
para O
la O
enfermedad O
metastásica O
fueron O
asignados O
aleatoriamente O
a O
una O
terapia O
combinada O
estándar O
con O
doxorrubicina O
y O
paclitaxel O
( O
AT O
) O
o O
a O
una O
doble O
HDCT O
con O
ciclofosfamida O
, O
mitoxantrona O
y O
etopósido O
seguida O
de O
un O
trasplante O
de O
células O
madre O
de O
sangre O
periférica O
. O

La O
HDCT O
se O
repitió O
a O
las O
6 O
semanas. O

Se O
estratificó O
a O
las O
pacientes O
según O
su O
estado O
de O
menopausia O
y O
de O
receptores O
hormonales. O

El O
objetivo O
primario O
era O
comparar O
las O
tasas O
de O
respuesta O
completa O
(RC). O

Un O
total O
de O
93 O
pacientes O
se O
inscribieron O
en O
el O
ensayo. O

Las B-Premise
tasas I-Premise
de I-Premise
RC I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
asignados I-Premise
al I-Premise
azar I-Premise
a I-Premise
la I-Premise
HDCT I-Premise
y I-Premise
a I-Premise
la I-Premise
TA I-Premise
fueron I-Premise
del I-Premise
12,5% I-Premise
y I-Premise
del I-Premise
11,1% I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
P I-Premise
= I-Premise
0,84 I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
objetiva I-Premise
fueron I-Premise
del I-Premise
66,7% I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
dosis I-Premise
altas I-Premise
y I-Premise
del I-Premise
64,4% I-Premise
para I-Premise
los I-Premise
del I-Premise
brazo I-Premise
de I-Premise
AT I-Premise
( I-Premise
P I-Premise
= I-Premise
0,82 I-Premise
) I-Premise
. I-Premise

En B-Premise
un I-Premise
análisis I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
dos I-Premise
tratamientos I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
mediana I-Premise
del I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
11,1 I-Premise
meses; I-Premise
AT I-Premise
, I-Premise
10,6 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,67 I-Premise
) I-Premise
, I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
respuesta I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
13,9 I-Premise
meses; I-Premise
AT I-Premise
, I-Premise
14,3 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,98 I-Premise
) I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
26,9 I-Premise
meses; I-Premise
AT I-Premise
, I-Premise
23,4 I-Premise
meses; I-Premise
P I-Premise
= I-Premise
0,60 I-Premise
) I-Premise
. I-Premise

La B-Premise
HDCT I-Premise
se I-Premise
asoció I-Premise
con I-Premise
un I-Premise
número I-Premise
significativamente I-Premise
mayor I-Premise
de I-Premise
mielosupresión, I-Premise
infección, I-Premise
diarrea, I-Premise
estomatitis I-Premise
y I-Premise
náuseas I-Premise
y I-Premise
vómitos, I-Premise
mientras I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
AT I-Premise
desarrollaron I-Premise
más I-Premise
neurotoxicidad. I-Premise

Este B-Claim
ensayo I-Claim
no I-Claim
pudo I-Claim
mostrar I-Claim
un I-Claim
beneficio I-Claim
para I-Claim
la I-Claim
HDCT I-Claim
en I-Claim
tándem I-Claim
por I-Claim
adelantado I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
terapia I-Claim
combinada I-Claim
estándar I-Claim
. I-Claim

La B-Claim
HDCT I-Claim
se I-Claim
asoció I-Claim
con I-Claim
más I-Claim
efectos I-Claim
adversos I-Claim
agudos I-Claim
. I-Claim

Las O
directrices O
estándar O
para O
el O
tratamiento O
del O
dolor O
por O
cáncer O
recomiendan O
habitualmente O
formar O
a O
los O
pacientes O
para O
que O
reduzcan O
las O
barreras O
al O
alivio O
del O
dolor, O
utilicen O
los O
medicamentos O
de O
forma O
adecuada O
y O
comuniquen O
sus O
necesidades O
relacionadas O
con O
el O
dolor. O

Se B-Claim
necesitan I-Claim
métodos I-Claim
para I-Claim
reducir I-Claim
el I-Claim
tiempo I-Claim
de I-Claim
trabajo I-Claim
de I-Claim
los I-Claim
profesionales I-Claim
y, I-Claim
al I-Claim
mismo I-Claim
tiempo, I-Claim
lograr I-Claim
una I-Claim
eficacia I-Claim
sostenida I-Claim
de I-Claim
la I-Claim
intervención. I-Claim

En O
un O
ensayo O
controlado O
y O
aleatorizado O
realizado O
en O
varios O
lugares, O
este O
estudio O
probó O
un O
método O
de O
entrenamiento O
contra O
el O
dolor O
frente O
a O
un O
control O
nutricional. O

En O
seis O
clínicas O
de O
oncología, O
los O
médicos O
( O
N=22 O
) O
y O
las O
enfermeras O
( O
N=23 O
) O
inscribieron O
a O
pacientes O
( O
N=93 O
) O
mayores O
de O
18 O
años, O
con O
diagnóstico O
de O
cáncer, O
dolor O
y O
una O
esperanza O
de O
vida O
de O
al O
menos O
6 O
meses. O

Las O
intervenciones O
de O
entrenamiento O
del O
dolor O
y O
las O
de O
control O
se O
equipararon O
en O
cuanto O
a O
materiales O
y O
método O
. O

Los O
pacientes O
vieron O
un O
vídeo O
seguido O
de O
unos O
20 O
minutos O
de O
formación O
manual O
normalizada O
con O
una O
enfermera O
de O
oncología O
centrada O
en O
la O
revisión O
del O
material O
impreso O
y O
adaptada O
a O
las O
preocupaciones O
individuales O
de O
los O
pacientes O
. O

Una O
llamada O
telefónica O
de O
seguimiento O
después O
de O
72 O
h O
abordó O
el O
contenido O
del O
tratamiento O
individualizado O
y O
la O
comunicación O
del O
dolor O
. O

Las O
evaluaciones O
al O
inicio, O
uno, O
tres O
y O
seis O
meses O
incluyeron O
las O
barreras, O
el O
Inventario O
Breve O
del O
Dolor, O
el O
uso O
de O
opiáceos O
y O
las O
valoraciones O
del O
médico O
y O
la O
enfermera O
sobre O
el O
dolor O
de O
sus O
pacientes. O

Los B-Premise
pacientes I-Premise
entrenados I-Premise
frente I-Premise
a I-Premise
los I-Premise
de I-Premise
control I-Premise
informaron I-Premise
de I-Premise
una I-Premise
reducción I-Premise
de I-Premise
las I-Premise
barreras I-Premise
para I-Premise
el I-Premise
alivio I-Premise
del I-Premise
dolor I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
un I-Premise
menor I-Premise
dolor I-Premise
habitual I-Premise
( I-Premise
P I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
y I-Premise
un I-Premise
mayor I-Premise
uso I-Premise
de I-Premise
opioides I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Ningún B-Premise
paciente I-Premise
que I-Premise
se I-Premise
sometió I-Premise
a I-Premise
un I-Premise
entrenamiento I-Premise
para I-Premise
el I-Premise
dolor I-Premise
informó I-Premise
de I-Premise
dolor I-Premise
intenso I-Premise
( I-Premise
> I-Premise
6 I-Premise
en I-Premise
una I-Premise
escala I-Premise
de I-Premise
0-10 I-Premise
) I-Premise
en I-Premise
los I-Premise
resultados I-Premise
de I-Premise
1 I-Premise
mes I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
. I-Premise

Las O
puntuaciones O
de O
los O
médicos O
y O
las O
enfermeras O
se O
aproximaron O
más O
a O
las O
puntuaciones O
de O
dolor O
de O
los O
pacientes O
en O
los O
grupos O
con O
formación O
que O
en O
los O
de O
nutrición O
( O
P=0,04 O
y O
<0,001 O
, O
respectivamente O
) O
. O

La O
eficacia O
del O
entrenamiento O
no O
se O
vio O
modificada O
por O
las O
características O
de O
los O
pacientes. O

El B-Claim
uso I-Claim
de I-Claim
materiales I-Claim
de I-Claim
vídeo I-Claim
e I-Claim
impresos, I-Claim
con I-Claim
una I-Claim
breve I-Claim
formación I-Claim
individualizada, I-Claim
mejoró I-Claim
eficazmente I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
dolor I-Claim
a I-Claim
lo I-Claim
largo I-Claim
del I-Claim
tiempo I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
diversos I-Claim
grupos I-Claim
de I-Claim
diagnóstico I-Claim
y I-Claim
demográficos. I-Claim

La O
disfunción O
sexual O
representa O
un O
constructo O
complejo O
y O
multifactorial O
que O
puede O
afectar O
tanto O
a O
hombres O
como O
a O
mujeres O
y O
se O
ha O
observado O
que O
a O
menudo O
se O
deteriora O
de O
forma O
significativa O
tras O
el O
tratamiento O
del O
cáncer O
rectal O
y O
anal O
. O

A O
pesar O
de O
ello, O
sigue O
siendo O
un O
tema O
poco O
estudiado, O
poco O
informado O
y O
poco O
tratado O
en O
el O
campo O
de O
la O
supervivencia O
al O
cáncer. O

Este O
estudio O
examinó O
las O
características O
de O
las O
mujeres O
inscritas O
en O
un O
ensayo O
de O
intervención O
para O
tratar O
la O
disfunción O
sexual O
, O
y O
exploró O
la O
relación O
entre O
el O
funcionamiento O
sexual O
y O
el O
bienestar O
psicológico O
. O

En O
el O
presente O
estudio O
se O
evaluaron O
70 O
mujeres O
supervivientes O
de O
cáncer O
anal O
o O
rectal O
después O
del O
tratamiento. O

Los O
participantes O
se O
inscribieron O
en O
un O
ensayo O
de O
intervención O
aleatorio O
para O
tratar O
la O
disfunción O
sexual O
y O
completaron O
las O
medidas O
de O
resultado O
antes O
de O
la O
aleatorización O
. O

Las O
principales O
medidas O
de O
resultado O
son O
la O
calidad O
de O
vida O
( O
QOL O
) O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
[ O
EORTC-QLQ-C30 O
] O
y O
Colorectal O
Cancer-Specific O
Module O
[ O
QLQ-CR38 O
] O
) O
, O
el O
funcionamiento O
sexual O
( O
Índice O
de O
Funcionamiento O
Sexual O
Femenino O
) O
y O
el O
bienestar O
psicológico O
( O
Inventario O
Breve O
de O
Síntomas O
de O
Depresión/Ansiedad O
, O
Escala O
de O
Impacto O
de O
Eventos-Revisada O
, O
Imagen O
Corporal O
CR-38 O
) O
. O

Las O
mujeres O
inscritas O
en O
la O
intervención O
del O
estudio O
tenían O
una O
edad O
media O
de O
55 O
años, O
eran O
predominantemente O
caucásicas O
( O
79 O
% O
), O
estaban O
casadas O
( O
57 O
% O
) O
y O
tenían O
una O
media O
de O
4 O
años O
de O
tratamiento O
primario. O

En O
el O
caso O
de O
las O
personas O
que O
declararon O
tener O
actividad O
sexual O
en O
la O
línea O
de O
base O
( O
N=41 O
) O
, O
la O
disfunción O
sexual O
se O
asoció O
con O
una O
serie O
de O
medidas O
específicas O
de O
bienestar O
psicológico O
, O
todas O
en O
la O
dirección O
hipotetizada O
. O

La B-Premise
subescala I-Premise
de I-Premise
satisfacción I-Premise
sexual/relacional I-Premise
se I-Premise
asoció I-Premise
con I-Premise
todas I-Premise
las I-Premise
medidas I-Premise
de I-Premise
bienestar I-Premise
psicológico I-Premise
( I-Premise
r=-0,45 I-Premise
a I-Premise
-0,70 I-Premise
, I-Premise
todas I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

La B-Premise
imagen I-Premise
corporal, I-Premise
la I-Premise
ansiedad I-Premise
y I-Premise
la I-Premise
angustia I-Premise
postraumática I-Premise
específica I-Premise
del I-Premise
cáncer I-Premise
fueron I-Premise
notables I-Premise
en I-Premise
su I-Premise
asociación I-Premise
con I-Premise
las I-Premise
subescalas I-Premise
del I-Premise
funcionamiento I-Premise
sexual, I-Premise
mientras I-Premise
que I-Premise
una I-Premise
medida I-Premise
global I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
no I-Premise
guardó I-Premise
relación I-Premise
alguna. I-Premise

En B-Premise
el I-Premise
caso I-Premise
de I-Premise
las I-Premise
mujeres I-Premise
sexualmente I-Premise
activas I-Premise
con I-Premise
cáncer I-Premise
rectal I-Premise
y I-Premise
anal I-Premise
inscritas I-Premise
en I-Premise
una I-Premise
intervención I-Premise
de I-Premise
salud I-Premise
sexual, I-Premise
la I-Premise
disfunción I-Premise
sexual I-Premise
se I-Premise
asoció I-Premise
de I-Premise
forma I-Premise
significativa I-Premise
y I-Premise
consistente I-Premise
con I-Premise
medidas I-Premise
específicas I-Premise
de I-Premise
bienestar I-Premise
psicológico, I-Premise
sobre I-Premise
todo I-Premise
con I-Premise
la I-Premise
satisfacción I-Premise
sexual/relacional. I-Premise

Estos B-Claim
resultados I-Claim
sugieren I-Claim
que I-Claim
el I-Claim
funcionamiento I-Claim
sexual I-Claim
puede I-Claim
requerir I-Claim
una I-Claim
evaluación I-Claim
específica I-Claim
por I-Claim
parte I-Claim
de I-Claim
los I-Claim
proveedores, I-Claim
más I-Claim
allá I-Claim
de I-Claim
las I-Claim
evaluaciones I-Claim
generales I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida, I-Claim
y O
que O
la O
atención B-Claim
a I-Claim
la I-Claim
satisfacción I-Claim
sexual/relacional I-Claim
puede I-Claim
ser I-Claim
fundamental I-Claim
en I-Claim
el I-Claim
desarrollo I-Claim
y I-Claim
la I-Claim
implementación I-Claim
de I-Claim
intervenciones I-Claim
para I-Claim
esta I-Claim
cohorte I-Claim
de I-Claim
pacientes. I-Claim

Recientemente O
hemos O
sugerido O
que O
el O
5-fluorouracilo O
( O
5-FU O
) O
en O
bolo O
puede O
actuar O
a O
través O
de O
un O
mecanismo O
dirigido O
por O
el O
ARN O
mientras O
que O
el O
5-FU O
en O
infusión O
continua O
puede O
matar O
las O
células O
a O
través O
de O
una O
vía O
relacionada O
con O
la O
timidilato O
sintasa O
. O

De O
este O
modo, O
puede O
ser O
posible O
modular O
selectivamente O
cada O
programa O
bioquímicamente. O

Hemos O
comparado O
un O
régimen O
alternado O
de O
bolo O
e O
infusión O
continua O
de O
5-FU O
, O
modulado O
selectivamente O
por O
el O
horario O
de O
administración O
, O
con O
el O
bolo O
modulado O
de O
5-FU O
en O
pacientes O
con O
cáncer O
colorrectal O
avanzado O
. O

Doscientos O
catorce O
pacientes O
de O
diecinueve O
centros O
italianos O
fueron O
aleatorizados O
al O
brazo O
de O
control O
que O
consistía O
en O
ciclos O
quincenales O
de O
MTX O
, O
200 O
mg/m2 O
el O
día O
1, O
seguido O
de O
bolo O
de O
5-FU O
600 O
mg/m2 O
el O
día O
2 O
y O
rescate O
de O
6-S-leucovorina O
, O
o O
al O
brazo O
experimental O
que O
consistía O
en O
dos O
ciclos O
quincenales O
del O
mismo O
régimen O
que O
en O
el O
brazo O
de O
control O
alternado O
a O
tres O
semanas O
de O
infusión O
continua O
de O
5-FU O
( O
200 O
mg/m2 O
día O
) O
+ O
bolo O
semanal O
de O
6-S-leucovorina O
, O
20 O
mg/m2 O
. O

Se B-Premise
obtuvieron I-Premise
nueve I-Premise
RC I-Premise
y I-Premise
veintisiete I-Premise
RP I-Premise
en I-Premise
ciento I-Premise
once I-Premise
pacientes I-Premise
evaluables I-Premise
tratados I-Premise
en I-Premise
el I-Premise
brazo I-Premise
experimental I-Premise
( I-Premise
RR I-Premise
= I-Premise
32 I-Premise
% I-Premise
, I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
) I-Premise
: I-Premise
24 I-Premise
% I-Premise
-42 I-Premise
% I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
se I-Premise
observaron I-Premise
dos I-Premise
RC I-Premise
y I-Premise
once I-Premise
RP I-Premise
entre I-Premise
ciento I-Premise
tres I-Premise
pacientes I-Premise
evaluables I-Premise
en I-Premise
el I-Premise
brazo I-Premise
control I-Premise
( I-Premise
RR I-Premise
= I-Premise
13 I-Premise
% I-Premise
, I-Premise
IC I-Premise
95 I-Premise
% I-Premise
: I-Premise
7 I-Premise
% I-Premise
-21 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Premise
toxicidad I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
de I-Premise
la I-Premise
OMS I-Premise
se I-Premise
produjo I-Premise
en I-Premise
el I-Premise
13% I-Premise
de I-Premise
los I-Premise
ciclos I-Premise
del I-Premise
brazo I-Premise
experimental I-Premise
y I-Premise
en I-Premise
el I-Premise
8% I-Premise
de I-Premise
los I-Premise
ciclos I-Premise
del I-Premise
brazo I-Premise
de I-Premise
control. I-Premise

La B-Premise
SLP I-Premise
fue I-Premise
significativamente I-Premise
más I-Premise
larga I-Premise
en I-Premise
el I-Premise
brazo I-Premise
experimental I-Premise
( I-Premise
6,2 I-Premise
frente I-Premise
a I-Premise
4,3 I-Premise
meses I-Premise
, I-Premise
odds I-Premise
ratio I-Premise
0,66 I-Premise
, I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
) O
, O
mientras O
que O
la B-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
similar I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
( I-Premise
14,8 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
experimental I-Premise
frente I-Premise
a I-Premise
14,1 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
control I-Premise
) I-Premise
; I-Premise
la I-Premise
calidad B-Claim
de I-Claim
vida I-Claim
también I-Claim
fue I-Claim
similar I-Claim
. O

El B-Premise
80% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
quimioterapia I-Premise
de I-Premise
segunda I-Premise
línea I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
control I-Premise
fueron I-Premise
tratados I-Premise
con I-Premise
infusión I-Premise
continua I-Premise
de I-Premise
5-FU I-Premise
. I-Premise

La O
modulación B-Claim
bioquímica I-Claim
alternante I-Claim
y I-Claim
específica I-Claim
del I-Claim
calendario I-Claim
del I-Claim
FU I-Claim
es I-Claim
más I-Claim
activa I-Claim
que I-Claim
el I-Claim
MTX I-Claim
-- I-Claim
> I-Claim
5-FU I-Claim
como I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
del I-Claim
cáncer I-Claim
colorrectal I-Claim
avanzado O
. O

Sin B-Claim
embargo, I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
fue I-Claim
similar, I-Claim
lo I-Claim
que I-Claim
sugiere I-Claim
que I-Claim
alternar I-Claim
el I-Claim
bolo I-Claim
y I-Claim
la I-Claim
infusión I-Claim
de I-Claim
5-FU I-Claim
por I-Claim
adelantado I-Claim
puede I-Claim
ser I-Claim
tan I-Claim
eficaz I-Claim
como I-Claim
administrarlos I-Claim
en I-Claim
secuencia I-Claim
como I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
y I-Claim
segunda I-Claim
línea. I-Claim

Gefitinib O
ha O
demostrado O
una O
alta O
tasa O
de O
respuesta O
y O
una O
mejora O
de O
la O
supervivencia O
libre O
de O
progresión O
( O
PFS O
) O
en O
los O
nunca O
fumadores O
con O
adenocarcinoma O
de O
pulmón O
( O
NSLA O
) O
. O

Se O
comparó O
la O
eficacia O
de O
gefitinib O
con O
la O
quimioterapia O
con O
gemcitabina O
y O
cisplatino O
( O
GP O
) O
en O
este O
grupo O
de O
pacientes O
como O
terapia O
de O
primera O
línea O
. O

En O
este O
ensayo O
aleatorio O
de O
fase O
III, O
un O
total O
de O
313 O
coreanos O
nunca O
fumadores O
con O
adenocarcinoma O
de O
pulmón O
en O
estadio O
IIIB O
o O
IV, O
estado O
de O
rendimiento O
0 O
a O
2 O
del O
Eastern O
Cooperative O
Oncology O
Group O
y O
función O
orgánica O
adecuada O
fueron O
asignados O
aleatoriamente O
a O
recibir O
gefitinib O
( O
250 O
mg O
diarios O
) O
o O
quimioterapia O
GP O
( O
gemcitabina O
1.250 O
mg/m O
( O
2 O
) O
los O
días O
1 O
y O
8 O
; O
cisplatino O
80 O
mg/m O
( O
2 O
) O
el O
día O
1 O
cada O
3 O
semanas O
, O
durante O
un O
máximo O
de O
nueve O
cursos O
) O
. O

El O
objetivo O
primario O
era O
demostrar O
una O
mejor O
supervivencia O
global O
( O
SG O
) O
para O
gefitinib O
en O
comparación O
con O
GP O
en O
los O
ANS O
sin O
quimioterapia O
. O

Se O
analizaron O
39 O
pacientes O
por O
protocolo O
( O
brazo O
de O
gefitinib O
, O
n O
= O
159 O
; O
brazo O
de O
GP O
, O
n O
= O
150 O
) O
. O

Gefitinib B-Premise
no I-Premise
mostró I-Premise
una I-Premise
mejor I-Premise
SG I-Premise
en I-Premise
comparación I-Premise
con I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0,932 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,716 I-Premise
a I-Premise
1,213 I-Premise
; I-Premise
P I-Premise
= I-Premise
.604 I-Premise
; I-Premise
mediana I-Premise
de I-Premise
SG I-Premise
, I-Premise
22,3 I-Premise
vs I-Premise
22,9 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
SLP I-Premise
a I-Premise
un I-Premise
año I-Premise
fueron I-Premise
del I-Premise
16,7% I-Premise
con I-Premise
gefitinib I-Premise
y I-Premise
del I-Premise
2,8% I-Premise
con I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1,198 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,944 I-Premise
a I-Premise
1,520 I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
fueron I-Premise
del I-Premise
55% I-Premise
con I-Premise
gefitinib I-Premise
y I-Premise
del I-Premise
46% I-Premise
con I-Premise
GP I-Premise
( I-Premise
P I-Premise
= I-Premise
.101 I-Premise
) I-Premise
. I-Premise

La B-Premise
mielosupresión, I-Premise
la I-Premise
insuficiencia I-Premise
renal I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
GP, I-Premise
pero O
las B-Premise
toxicidades I-Premise
cutáneas I-Premise
y I-Premise
la I-Premise
disfunción I-Premise
hepática I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
gefitinib. I-Premise

Dos B-Premise
pacientes I-Premise
( I-Premise
1,3 I-Premise
% I-Premise
) I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
gefitinib I-Premise
desarrollaron I-Premise
enfermedad I-Premise
pulmonar I-Premise
intersticial I-Premise
y I-Premise
murieron I-Premise
. I-Premise

El B-Claim
gefitinib I-Claim
no I-Claim
demostró I-Claim
una I-Claim
SG I-Claim
superior I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
GP I-Claim
como I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
para I-Claim
los I-Claim
ANS. I-Claim

Comparar O
la O
supervivencia O
en O
pacientes O
con O
carcinoma O
de O
células O
escamosas O
de O
cabeza O
y O
cuello O
recurrente O
o O
metastásico O
( O
SCCHN O
) O
tratados O
con O
gefitinib O
250 O
o O
500 O
mg/día O
o O
con O
metotrexato O
estándar O
. O

Cuatrocientos O
ochenta O
y O
seis O
pacientes O
con O
SCCHN O
recurrente O
fueron O
asignados O
aleatoriamente O
a O
gefitinib O
oral O
250 O
mg/día O
, O
gefitinib O
500 O
mg/día O
, O
o O
metotrexato O
40 O
mg/m O
( O
2 O
) O
por O
vía O
intravenosa O
semanalmente O
. O

El O
criterio O
de O
valoración O
primario O
fue O
la O
supervivencia O
global O
, O
los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
tasa O
de O
respuesta O
objetiva O
( O
ORR O
) O
, O
la O
seguridad O
, O
la O
mejora O
de O
los O
síntomas O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
. O

Los O
criterios O
de O
valoración O
exploratorios O
incluían O
la O
asociación O
de O
la O
eficacia O
con O
el O
número O
de O
copias O
del O
gen O
del O
receptor O
del O
factor O
de O
crecimiento O
epidérmico O
y O
otros O
biomarcadores. O

Ni B-Premise
gefitinib I-Premise
250 I-Premise
ni I-Premise
500 I-Premise
mg/día I-Premise
mejoraron I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
metotrexato I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1,22 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,95 I-Premise
a I-Premise
1,57 I-Premise
; I-Premise
P I-Premise
= I-Premise
.12 I-Premise
; I-Premise
y I-Premise
HR I-Premise
, I-Premise
1,12 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,87 I-Premise
a I-Premise
1,43 I-Premise
; I-Premise
P I-Premise
= I-Premise
.39 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

En B-Premise
los I-Premise
grupos I-Premise
de I-Premise
gefitinib I-Premise
250 I-Premise
mg/día, I-Premise
500 I-Premise
mg/día I-Premise
y I-Premise
metotrexato, I-Premise
respectivamente, I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
fue I-Premise
de I-Premise
5,6, I-Premise
6,0 I-Premise
y I-Premise
6,7 I-Premise
meses; I-Premise
los I-Premise
ORR I-Premise
(Criterios I-Premise
de I-Premise
Evaluación I-Premise
de I-Premise
la I-Premise
Respuesta I-Premise
en I-Premise
Tumores I-Premise
Sólidos) I-Premise
fueron I-Premise
del I-Premise
2,7%, I-Premise
7,6% I-Premise
y I-Premise
3,9%, I-Premise
sin I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
cualquiera I-Premise
de I-Premise
los I-Premise
brazos I-Premise
de I-Premise
gefitinib I-Premise
y I-Premise
el I-Premise
metotrexato. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
acontecimientos I-Premise
adversos I-Premise
inesperados, I-Premise
excepto B-Premise
los I-Premise
de I-Premise
tipo I-Premise
hemorrágico I-Premise
con I-Premise
gefitinib I-Premise
( I-Premise
8,9 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
250 I-Premise
mg/día I-Premise
; I-Premise
11,4 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
500 I-Premise
mg/día I-Premise
; I-Premise
1,9 I-Premise
% I-Premise
, I-Premise
metotrexato I-Premise
) O
. O

Las B-Premise
tasas I-Premise
de I-Premise
mejora I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
& I-Premise
amp I-Premise
; I-Premise
Neck I-Premise
total I-Premise
score I-Premise
) I-Premise
fueron I-Premise
del I-Premise
13,4 I-Premise
% I-Premise
, I-Premise
18,0 I-Premise
% I-Premise
y I-Premise
6,0 I-Premise
% I-Premise
para I-Premise
gefitinib I-Premise
250 I-Premise
mg/día I-Premise
, I-Premise
500 I-Premise
mg/día I-Premise
y I-Premise
metotrexato I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

En B-Claim
los I-Claim
pacientes I-Claim
con I-Claim
SCCHN I-Claim
recurrente I-Claim
o I-Claim
metastásico, I-Claim
aunque I-Claim
se I-Claim
observaron I-Claim
respuestas I-Claim
con I-Claim
gefitinib, I-Claim
ni I-Claim
gefitinib I-Claim
250 I-Claim
ni I-Claim
500 I-Claim
mg/día I-Claim
mejoraron I-Claim
la I-Claim
supervivencia I-Claim
global I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
metotrexato. I-Claim

Con B-Claim
la I-Claim
excepción I-Claim
de I-Claim
los I-Claim
acontecimientos I-Claim
de I-Claim
tipo I-Claim
hemorrágico I-Claim
con I-Claim
gefitinib I-Claim
, I-Claim
los I-Claim
perfiles I-Claim
de I-Claim
acontecimientos I-Claim
adversos I-Claim
fueron I-Claim
en I-Claim
general I-Claim
coherentes I-Claim
con I-Claim
los I-Claim
observados I-Claim
anteriormente. I-Claim

La O
gemcitabina O
( O
G O
) O
es O
la O
terapia O
estándar O
para O
el O
cáncer O
de O
páncreas O
. O

La O
enzastaurina O
( O
E O
) O
inhibe O
las O
vías O
de O
señalización O
PKCβ O
y O
PI3K/AKT O
con O
un O
efecto O
dependiente O
de O
la O
dosis O
sobre O
el O
crecimiento O
de O
xenoinjertos O
de O
carcinoma O
de O
páncreas O
. O

Los B-Claim
datos I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
combinación I-Claim
de I-Claim
GE I-Claim
puede I-Claim
mejorar I-Claim
los I-Claim
resultados I-Claim
clínicos I-Claim
. I-Claim

El O
objetivo O
primario O
fue O
la O
supervivencia O
global O
( O
OS O
) O
; O
los O
objetivos O
secundarios O
evaluaron O
la O
supervivencia O
libre O
de O
progresión O
( O
PFS O
) O
, O
la O
tasa O
de O
respuesta O
( O
RR O
) O
, O
la O
calidad O
de O
vida O
( O
QOL O
) O
, O
la O
toxicidad O
, O
y O
las O
relaciones O
entre O
la O
expresión O
de O
biomarcadores O
y O
los O
resultados O
clínicos O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
( O
2:1 O
) O
al O
tratamiento O
GE O
o O
G O
; O
brazo O
GE O
: O
E O
500 O
mg O
p.o O
. O

diariamente; O
dosis O
de O
carga O
( O
1200 O
mg O
; O
Día O
1 O
Ciclo O
1 O
solamente O
) O
y O
G O
1000 O
mg/m O
( O
2 O
) O
i.v O
. O

Días O
1 O
, O
8 O
y O
15 O
en O
ciclos O
de O
28 O
días O
; O
brazo O
G O
: O
G O
como O
en O
GE O
. O

La O
expresión O
de O
los O
biomarcadores O
se O
evaluó O
mediante O
inmunohistoquímica. O

La O
aleatorización O
ascendió O
a O
130 O
pacientes O
( O
GE O
= O
86 O
, O
G O
= O
44 O
) O
; O
121 O
pacientes O
fueron O
tratados O
( O
GE O
= O
82 O
, O
G O
= O
39 O
) O
. O

La O
mediana O
de O
la O
SG O
de O
GE/G O
fue O
de O
5,6/5,1 O
meses; O
la O
mediana O
de O
la O
SLP O
fue O
de O
3,4/3,0 O
meses. O

Respuestas O
de O
GE O
: O
1 O
respuesta O
completa O
( O
RC O
, O
1,2 O
% O
) O
, O
6 O
respuesta O
parcial O
( O
PR O
, O
7,4 O
% O
) O
, O
y O
33 O
enfermedad O
estable O
( O
SD O
, O
40,7 O
% O
) O
; O
tasa O
de O
control O
de O
la O
enfermedad O
( O
DCR=CR+PR+SD O
, O
49,4 O
% O
) O
. O

Respuestas O
G O
: O
2 O
PR O
( O
5,3 O
% O
) O
y O
16 O
SD O
( O
42,1 O
% O
) O
; O
DCR O
( O
47,4 O
% O
) O
. O

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
entre I-Premise
los I-Premise
brazos. I-Premise

Las B-Premise
toxicidades I-Premise
de I-Premise
grado I-Premise
3-4 I-Premise
del I-Premise
GE/G I-Premise
incluyeron: I-Premise
neutropenia I-Premise
( I-Premise
18,3 I-Premise
% I-Premise
/28,2 I-Premise
% I-Premise
) I-Premise
; I-Premise
trombocitopenia I-Premise
( I-Premise
14,6 I-Premise
% I-Premise
/25,6 I-Premise
% I-Premise
) I-Premise
; I-Premise
y I-Premise
fatiga I-Premise
( I-Premise
11,0 I-Premise
% I-Premise
/7,7 I-Premise
% I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
relaciones I-Premise
estadísticamente I-Premise
significativas I-Premise
entre I-Premise
la I-Premise
expresión I-Premise
de I-Premise
los I-Premise
biomarcadores I-Premise
y I-Premise
los I-Premise
resultados. I-Premise

Sin O
embargo O
, O
los B-Premise
pacientes I-Premise
con I-Premise
baja I-Premise
expresión I-Premise
de I-Premise
pGSK-3β I-Premise
citoplasmática I-Premise
tendieron I-Premise
a I-Premise
una I-Premise
mayor I-Premise
SG I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
de I-Premise
GE I-Premise
. O

La B-Premise
SG, I-Premise
la I-Premise
SLP, I-Premise
la I-Premise
CdV I-Premise
y I-Premise
el I-Premise
RR I-Premise
fueron I-Premise
comparables I-Premise
entre I-Premise
los I-Premise
brazos. I-Premise

La B-Claim
adición I-Claim
de I-Claim
E I-Claim
a I-Claim
G I-Claim
no I-Claim
aumentó I-Claim
las I-Claim
toxicidades I-Claim
hematológicas I-Claim
. I-Claim

La O
GE O
no O
justifica O
que O
se O
siga O
investigando O
en O
pacientes O
de O
cáncer O
de O
páncreas O
no O
seleccionados. O

Determinar O
si O
el O
impacto O
de O
la O
"imposición O
de O
manos" O
en O
el O
bienestar O
de O
los O
pacientes O
con O
cáncer O
avanzado O
es O
más O
eficaz O
cuando O
lo O
realiza O
una O
persona O
con O
"poderes O
curativos" O
autodeclarados, O
en O
comparación O
con O
un O
actor O
que O
imita O
al O
sanador O
con O
todo O
detalle. O

Un O
total O
de O
80 O
pacientes O
se O
registraron O
para O
participar O
en O
un O
ensayo O
de O
fase O
III O
aleatorizado O
y O
a O
ciegas O
para O
evaluar O
la O
diferencia O
de O
eficacia O
de O
la O
"imposición O
de O
manos" O
por O
parte O
de O
un O
"sanador" O
o O
de O
un O
actor. O

Cada O
grupo O
estaba O
formado O
por O
40 O
pacientes, O
programados O
para O
recibir O
el O
tratamiento O
durante O
5 O
minutos, O
tres O
veces O
por O
semana. O

El O
efecto O
del O
tratamiento O
se O
midió O
mediante O
una O
"escala O
de O
bienestar", O
definiéndose O
la O
diferencia O
de O
la O
puntuación O
media O
de O
la O
"escala O
de O
bienestar" O
en O
el O
día O
10 O
como O
criterio O
de O
valoración O
primario O
y O
la O
del O
día O
5 O
como O
secundario. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
los I-Premise
valores I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
media I-Premise
entre I-Premise
el I-Premise
"curador" I-Premise
y I-Premise
el I-Premise
actor I-Premise
con I-Premise
respecto I-Premise
al I-Premise
punto I-Premise
final I-Premise
primario I-Premise
( I-Premise
p I-Premise
= I-Premise
0,34 I-Premise
) I-Premise
o I-Premise
al I-Premise
secundario I-Premise
( I-Premise
p I-Premise
= I-Premise
0,94 I-Premise
) O
, O
pero B-Premise
la I-Premise
comparación I-Premise
fue I-Premise
limitada I-Premise
debido I-Premise
a I-Premise
las I-Premise
importantes I-Premise
violaciones I-Premise
del I-Premise
protocolo I-Premise
por I-Premise
parte I-Premise
del I-Premise
"curador", I-Premise
que I-Premise
desenmascaró I-Premise
su I-Premise
estado I-Premise
después I-Premise
de I-Premise
la I-Premise
primera I-Premise
ejecución I-Premise
y I-Premise
abandonó I-Premise
el I-Premise
estudio I-Premise
. O

El O
estudio O
fue O
completado O
por O
el O
actor O
como O
un O
estudio O
descriptivo O
y O
exploratorio O
sobre O
el O
impacto O
de O
la O
"imposición O
de O
manos". O

Se B-Premise
encontró I-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
tras I-Premise
el I-Premise
tratamiento I-Premise
en I-Premise
el I-Premise
día I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
en I-Premise
el I-Premise
día I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0,0002 I-Premise
) I-Premise
. I-Premise

" B-Claim
La I-Claim
"imposición I-Claim
de I-Claim
manos" I-Claim
dio I-Claim
lugar I-Claim
a I-Claim
una I-Claim
mejora I-Claim
significativa I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
asociados I-Claim
al I-Claim
cáncer I-Claim
o I-Claim
a I-Claim
la I-Claim
terapia I-Claim
del I-Claim
cáncer. I-Claim

La B-Claim
magnitud I-Claim
de I-Claim
la I-Claim
mejora I-Claim
obtenida I-Claim
fue I-Claim
similar I-Claim
tanto I-Claim
si I-Claim
se I-Claim
trataba I-Claim
de I-Claim
un I-Claim
"tratamiento" I-Claim
autodeclarado I-Claim
como I-Claim
de I-Claim
uno I-Claim
proporcionado I-Claim
por I-Claim
un I-Claim
actor. I-Claim

Evaluar O
el O
efecto O
de O
una O
intervención O
multimodal O
de O
ejercicios O
en O
grupo O
, O
como O
complemento O
de O
la O
atención O
convencional O
, O
sobre O
la O
fatiga O
, O
la O
capacidad O
física O
, O
el O
bienestar O
general O
, O
la O
actividad O
física O
y O
la O
calidad O
de O
vida O
en O
pacientes O
con O
cáncer O
que O
estaban O
sometidos O
a O
quimioterapia O
adyuvante O
o O
a O
un O
tratamiento O
para O
la O
enfermedad O
avanzada O
. O

Ensayo O
controlado O
aleatorio O
. O

Dos O
hospitales O
universitarios O
en O
Copenhague, O
Dinamarca. O

269 O
pacientes O
con O
cáncer; O
73 O
hombres, O
196 O
mujeres, O
con O
una O
media O
de O
edad O
de O
47 O
años O
(rango O
de O
20 O
a O
65) O
que O
representan O
21 O
diagnósticos. O

Los O
principales O
criterios O
de O
exclusión O
fueron O
las O
metástasis O
cerebrales O
u O
óseas. O

235 O
pacientes O
completaron O
el O
seguimiento O
. O

Ejercicio O
supervisado O
que O
comprende O
un O
entrenamiento O
cardiovascular O
y O
de O
resistencia O
de O
alta O
intensidad O
, O
entrenamiento O
de O
relajación O
y O
conciencia O
corporal O
, O
masaje O
, O
nueve O
horas O
semanales O
durante O
seis O
semanas O
además O
de O
la O
atención O
convencional O
, O
en O
comparación O
con O
la O
atención O
convencional O
. O

Se O
utilizó O
el O
modelo O
lineal O
general O
para O
los O
resultados O
continuos, O
mientras O
que O
el O
análisis O
de O
las O
asociaciones O
entre O
resultados O
categóricos O
se O
realizó O
como O
análisis O
de O
homogeneidad O
marginal O
en O
tablas O
de O
contingencia O
. O

Ajustado B-Premise
por I-Premise
la I-Premise
puntuación I-Premise
inicial, I-Premise
la I-Premise
enfermedad I-Premise
y I-Premise
las I-Premise
covariables I-Premise
demográficas, I-Premise
el I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
mostró I-Premise
una I-Premise
mejora I-Premise
estimada I-Premise
a I-Premise
las I-Premise
seis I-Premise
semanas I-Premise
para I-Premise
el I-Premise
resultado I-Premise
primario, I-Premise
la I-Premise
fatiga, I-Premise
de I-Premise
-6,6 I-Premise
puntos I-Premise
(intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
%: I-Premise
-12,3 I-Premise
a I-Premise
-0,9; I-Premise
P=0,02; I-Premise
tamaño I-Premise
del I-Premise
efecto=0,33; I-Premise
0,04 I-Premise
a I-Premise
0,61). I-Premise

Se B-Premise
observaron I-Premise
efectos I-Premise
significativos I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
vitalidad I-Premise
( I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
0,55 I-Premise
, I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
0,27 I-Premise
a I-Premise
0,82 I-Premise
) I-Premise
, I-Premise
funcionamiento I-Premise
físico I-Premise
( I-Premise
0,37 I-Premise
, I-Premise
0,09 I-Premise
a I-Premise
0,65 I-Premise
) I-Premise
, I-Premise
rol I-Premise
físico I-Premise
( I-Premise
0,37 I-Premise
, I-Premise
0,10 I-Premise
a I-Premise
0,64 I-Premise
) I-Premise
, I-Premise
rol I-Premise
emocional I-Premise
( I-Premise
0,32 I-Premise
, I-Premise
0,05 I-Premise
a I-Premise
0,59 I-Premise
) I-Premise
y I-Premise
salud I-Premise
mental I-Premise
( I-Premise
0,28 I-Premise
, I-Premise
0,02 I-Premise
a I-Premise
0,56 I-Premise
) I-Premise
. I-Premise

Se B-Premise
observó I-Premise
una I-Premise
mejora I-Premise
en I-Premise
la I-Premise
capacidad I-Premise
física: I-Premise
la I-Premise
diferencia I-Premise
media I-Premise
estimada I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
para I-Premise
el I-Premise
consumo I-Premise
máximo I-Premise
de I-Premise
oxígeno I-Premise
fue I-Premise
de I-Premise
0,16 I-Premise
l/min I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
0,1 I-Premise
a I-Premise
0,2 I-Premise
, I-Premise
p I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
y I-Premise
para I-Premise
la I-Premise
fuerza I-Premise
muscular I-Premise
( I-Premise
prensa I-Premise
de I-Premise
piernas I-Premise
) I-Premise
fue I-Premise
de I-Premise
29,7 I-Premise
kg I-Premise
( I-Premise
23,4 I-Premise
a I-Premise
34,9 I-Premise
, I-Premise
p I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
observó I-Premise
ningún I-Premise
efecto I-Premise
significativo I-Premise
sobre I-Premise
el I-Premise
estado I-Premise
de I-Premise
salud/calidad I-Premise
de I-Premise
vida I-Premise
global. I-Premise

Una B-Claim
intervención I-Claim
de I-Claim
ejercicio I-Claim
multimodal I-Claim
supervisada I-Claim
que I-Claim
incluye I-Claim
componentes I-Claim
de I-Claim
alta I-Claim
y I-Claim
baja I-Claim
intensidad I-Claim
fue I-Claim
factible I-Claim
y I-Claim
pudo I-Claim
utilizarse I-Claim
con I-Claim
seguridad I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
diversos I-Claim
tipos I-Claim
de I-Claim
cáncer I-Claim
que I-Claim
recibían I-Claim
quimioterapia I-Claim
adyuvante I-Claim
o I-Claim
tratamiento I-Claim
para I-Claim
la I-Claim
enfermedad I-Claim
avanzada I-Claim
. I-Claim

La B-Claim
intervención I-Claim
redujo I-Claim
la I-Claim
fatiga I-Claim
y I-Claim
mejoró I-Claim
la I-Claim
vitalidad, I-Claim
la I-Claim
capacidad I-Claim
aeróbica, I-Claim
la I-Claim
fuerza I-Claim
muscular I-Claim
y I-Claim
la I-Claim
actividad I-Claim
física I-Claim
y I-Claim
funcional, I-Claim
así I-Claim
como I-Claim
el I-Claim
bienestar I-Claim
emocional, I-Claim
pero B-Claim
no I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

Determinar O
si O
la O
epoetina O
alfa O
semanal O
podría O
mejorar O
los O
niveles O
de O
hemoglobina O
( O
HgB O
) O
, O
reducir O
las O
transfusiones O
de O
glóbulos O
rojos O
y O
mejorar O
la O
calidad O
de O
vida O
( O
QOL O
) O
en O
pacientes O
con O
cáncer O
avanzado O
y O
con O
anemia O
después O
de O
recibir O
quimioterapia O
mielosupresora O
. O

Este O
estudio O
doble O
ciego, O
controlado O
con O
placebo, O
asignó O
aleatoriamente O
a O
los O
pacientes O
a O
placebo O
o O
a O
epoetina O
alfa O
( O
Ortho O
Biotech, O
Bridgewater, O
NJ) O
40.000 O
U O
subcutáneas O
semanales O
durante O
16 O
semanas. O

La O
calidad O
de O
vida, O
el O
HgB O
y O
las O
transfusiones O
de O
glóbulos O
rojos O
se O
midieron O
antes O
del O
tratamiento O
y O
mensualmente. O

El O
estudio O
contó O
con O
344 O
pacientes; O
330 O
fueron O
evaluables O
para O
la O
eficacia O
y O
305 O
para O
la O
calidad O
de O
vida. O

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
placebo I-Premise
tuvieron I-Premise
un I-Premise
aumento I-Premise
medio I-Premise
de I-Premise
HgB I-Premise
de I-Premise
0,9 I-Premise
g/dL I-Premise
( I-Premise
rango I-Premise
, I-Premise
-3,8 I-Premise
a I-Premise
+5,3 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
2,8 I-Premise
g/dL I-Premise
( I-Premise
rango I-Premise
, I-Premise
-2,2 I-Premise
a I-Premise
+7,5 I-Premise
) I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
epoetina I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Durante B-Premise
el I-Premise
estudio, I-Premise
el I-Premise
31,7 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
placebo I-Premise
lograron I-Premise
un I-Premise
aumento I-Premise
de I-Premise
HgB I-Premise
de I-Premise
> I-Premise
o I-Premise
= I-Premise
2 I-Premise
g/dL, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
72,7 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
epoetina I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

La B-Premise
incidencia I-Premise
de I-Premise
transfusión I-Premise
de I-Premise
glóbulos I-Premise
rojos I-Premise
en I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
con I-Premise
placebo I-Premise
y I-Premise
epoetina I-Premise
fue I-Premise
del I-Premise
39,6% I-Premise
y I-Premise
del I-Premise
25,3% I-Premise
( I-Premise
P I-Premise
= I-Premise
0,005 I-Premise
) I-Premise
, I-Premise
respectivamente. I-Premise

El O
grupo O
de O
placebo O
recibió O
256 O
unidades O
de O
glóbulos O
rojos O
en O
comparación O
con O
127 O
unidades O
en O
el O
grupo O
de O
epoetina O
( O
P O
< O
.0001 O
) O
. O

La B-Premise
incidencia I-Premise
de I-Premise
la I-Premise
toxicidad I-Premise
en I-Premise
los I-Premise
grupos I-Premise
fue I-Premise
similar. I-Premise

Los B-Premise
cambios I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
medias I-Premise
de I-Premise
la I-Premise
CdV I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
el I-Premise
final I-Premise
del I-Premise
estudio I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
( I-Premise
P I-Premise
= I-Premise
no I-Premise
significativo I-Premise
) I-Premise
. I-Premise

Los B-Premise
que I-Premise
respondieron I-Premise
al I-Premise
HgB I-Premise
(independientemente I-Premise
del I-Premise
brazo I-Premise
de I-Premise
tratamiento) I-Premise
tuvieron I-Premise
un I-Premise
cambio I-Premise
medio I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
fatiga I-Premise
de I-Premise
la I-Premise
Evaluación I-Premise
Funcional I-Premise
de I-Premise
la I-Premise
Terapia I-Premise
contra I-Premise
el I-Premise
Cáncer I-Premise
(FACT) I-Premise
desde I-Premise
un I-Premise
punto I-Premise
de I-Premise
partida I-Premise
de I-Premise
+5,1 I-Premise
en I-Premise
comparación I-Premise
con I-Premise
-2,1 I-Premise
para I-Premise
los I-Premise
que I-Premise
no I-Premise
respondieron I-Premise
( I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

La B-Claim
epoetina I-Claim
alfa I-Claim
mejoró I-Claim
significativamente I-Claim
la I-Claim
HgB I-Claim
y I-Claim
redujo I-Claim
las I-Claim
transfusiones I-Claim
en I-Claim
esta I-Claim
población I-Claim
de I-Claim
pacientes I-Claim
. I-Claim

Estos B-Claim
resultados I-Claim
apoyan I-Claim
el I-Claim
uso I-Claim
de I-Claim
la I-Claim
epoetina I-Claim
alfa I-Claim
semanal I-Claim
como I-Claim
agente I-Claim
mejorador I-Claim
de I-Claim
la I-Claim
anemia I-Claim
relacionada I-Claim
con I-Claim
el I-Claim
cáncer. I-Claim

La O
temozolomida O
( O
TMZ O
) O
es O
un O
agente O
alquilante O
autorizado O
para O
el O
tratamiento O
del O
glioma O
de O
alto O
grado O
( O
HGG O
) O
. O

No O
existe O
ninguna O
comparación O
prospectiva O
con O
la O
quimioterapia O
basada O
en O
la O
nitrosourea. O

Informamos, O
hasta O
donde O
sabemos, O
del O
primer O
ensayo O
aleatorio O
de O
procarbazina, O
lomustina O
y O
vincristina O
( O
PCV O
) O
frente O
a O
TMZ O
en O
pacientes O
sin O
quimioterapia O
con O
HGG O
recurrente. O

Cuatrocientos O
cuarenta O
y O
siete O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
PCV O
( O
224 O
pacientes O
) O
o O
TMZ O
( O
asignación O
sub-aleatoria O
: O
TMZ-5 O
[ O
200 O
mg/m O
( O
2 O
) O
durante O
5 O
días O
, O
112 O
pacientes O
] O
o O
TMZ-21 O
[ O
100 O
mg/m O
( O
2 O
) O
durante O
21 O
días O
, O
111 O
pacientes O
] O
) O
durante O
un O
máximo O
de O
9 O
meses O
o O
hasta O
la O
progresión O
. O

Los O
resultados O
primarios O
fueron O
la O
supervivencia O
( O
PCV O
v O
TMZ O
) O
y O
la O
supervivencia O
libre O
de O
progresión O
a O
las O
12 O
semanas O
( O
PFS O
; O
TMZ-5 O
v O
TMZ-21 O
) O
. O

Este O
estudio O
está O
registrado O
como O
ISRCTN83176944 O
. O

Los O
porcentajes O
de O
pacientes O
que O
completaron O
9 O
meses O
de O
tratamiento O
en O
los O
brazos O
PCV, O
TMZ-5 O
y O
TMZ-21 O
fueron O
del O
17 O
%, O
26 O
% O
y O
13 O
%, O
respectivamente. O

La B-Premise
toxicidad I-Premise
mayor I-Premise
fue I-Premise
similar I-Premise
en I-Premise
los I-Premise
tres I-Premise
grupos. I-Premise

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
12 I-Premise
meses I-Premise
y I-Premise
382 I-Premise
muertes, I-Premise
no I-Premise
hubo I-Premise
un I-Premise
beneficio I-Premise
claro I-Premise
de I-Premise
supervivencia I-Premise
al I-Premise
comparar I-Premise
la I-Premise
PCV I-Premise
con I-Premise
la I-Premise
TMZ I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0,91 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,74 I-Premise
a I-Premise
1,11 I-Premise
; I-Premise
P I-Premise
= I-Premise
.350 I-Premise
) I-Premise
. I-Premise

En B-Premise
el I-Premise
caso I-Premise
de I-Premise
TMZ-5 I-Premise
frente I-Premise
a I-Premise
TMZ-21 I-Premise
, I-Premise
las I-Premise
tasas I-Premise
de I-Premise
SLP I-Premise
a I-Premise
las I-Premise
12 I-Premise
semanas I-Premise
fueron I-Premise
similares I-Premise
( I-Premise
63,6 I-Premise
% I-Premise
y I-Premise
65,7 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
= I-Premise
0,745 I-Premise
) O
, O
pero B-Premise
TMZ-5 I-Premise
mejoró I-Premise
la I-Premise
SLP I-Premise
global I-Premise
( I-Premise
HR I-Premise
, I-Premise
1,38 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
1,05 I-Premise
a I-Premise
1,82 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,023 I-Premise
) I-Premise
, I-Premise
la I-Premise
supervivencia I-Premise
( I-Premise
HR I-Premise
, I-Premise
1,32 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,99 I-Premise
a I-Premise
1,75 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,056 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
( I-Premise
49 I-Premise
% I-Premise
frente I-Premise
a I-Premise
19 I-Premise
% I-Premise
mejoraron I-Premise
> I-Premise
10 I-Premise
puntos I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
= I-Premise
0,005 I-Premise
) O
. O

Aunque B-Claim
la I-Claim
TMZ I-Claim
(ambos I-Claim
brazos I-Claim
combinados) I-Claim
no I-Claim
mostró I-Claim
un I-Claim
beneficio I-Claim
claro I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
PCV, I-Claim
la I-Claim
comparación I-Claim
de I-Claim
los I-Claim
programas I-Claim
de I-Claim
TMZ I-Claim
demostró I-Claim
que I-Claim
el I-Claim
programa I-Claim
de I-Claim
21 I-Claim
días I-Claim
era I-Claim
inferior I-Claim
al I-Claim
programa I-Claim
de I-Claim
5 I-Claim
días I-Claim
en I-Claim
este I-Claim
contexto. I-Claim

Esto B-Claim
desafía I-Claim
la I-Claim
idea I-Claim
actual I-Claim
de I-Claim
aumentar I-Claim
la I-Claim
intensidad I-Claim
de I-Claim
la I-Claim
dosis I-Claim
de I-Claim
TMZ I-Claim
mediante I-Claim
una I-Claim
programación I-Claim
prolongada. I-Claim

La O
mucositis O
inducida O
por O
la O
radiación O
es O
una O
reacción O
aguda O
de O
la O
mucosa O
de O
los O
pacientes O
sometidos O
a O
radioterapia O
de O
cabeza O
y O
cuello. O

Puede O
tener O
consecuencias O
debilitantes O
y O
limitantes O
de O
la O
dosis O
. O

No B-Claim
hay I-Claim
consenso I-Claim
sobre I-Claim
una I-Claim
intervención I-Claim
aceptada I-Claim
que I-Claim
reduzca I-Claim
significativamente I-Claim
su I-Claim
gravedad I-Claim
. I-Claim

El O
misoprostol O
es O
un O
análogo O
sintético O
de O
la O
prostaglandina O
E1 O
, O
con O
propiedades O
de O
citoprotector O
de O
la O
mucosa. O

Se O
diseñó O
un O
ensayo O
aleatorio, O
doble O
ciego O
y O
controlado O
con O
placebo O
de O
misoprostol O
en O
pacientes O
con O
cáncer O
de O
cabeza O
y O
cuello. O

El O
objetivo O
de O
este O
estudio O
fue O
determinar O
si O
el O
misoprostol O
tópico O
era O
eficaz O
para O
reducir O
la O
gravedad O
de O
la O
mucositis O
inducida O
por O
la O
radiación O
en O
pacientes O
que O
recibían O
dosis O
radicales O
de O
radioterapia. O

También O
se O
investigó O
el O
efecto O
de O
esta O
intervención O
en O
el O
bienestar O
general O
del O
paciente. O

El O
criterio O
de O
valoración O
principal O
del O
estudio O
fue O
la O
incidencia O
de O
mucositis O
de O
grado O
3 O
del O
Grupo O
de O
Radioterapia O
Oncológica. O

Entre O
1999 O
y O
2002, O
se O
reclutaron O
83 O
pacientes O
para O
el O
estudio O
en O
los O
hospitales O
Westmead O
y O
Nepean O
de O
Sydney. O

Cuarenta O
y O
dos O
pacientes O
fueron O
aleatorizados O
para O
recibir O
misoprostol O
y O
41 O
para O
recibir O
un O
placebo O
. O

La O
mayoría O
de O
los O
pacientes O
recibieron O
radioterapia O
en O
el O
ámbito O
adyuvante O
( O
52 O
de O
los O
83 O
) O
y O
tenían O
un O
cáncer O
de O
cavidad O
oral O
( O
42 O
de O
los O
83 O
) O
o O
de O
orofaringe O
( O
16 O
de O
los O
83 O
) O
. O

No B-Claim
se I-Claim
pudo I-Claim
identificar I-Claim
ninguna I-Claim
diferencia I-Claim
significativa I-Claim
en I-Claim
la I-Claim
incidencia I-Claim
de I-Claim
mucositis I-Claim
grave I-Claim
en I-Claim
función I-Claim
de I-Claim
si I-Claim
las I-Claim
pacientes I-Claim
fueron I-Claim
asignadas I-Claim
a I-Claim
recibir I-Claim
misoprostol I-Claim
o I-Claim
placebo I-Claim
. I-Claim

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
el I-Premise
área I-Premise
media I-Premise
bajo I-Premise
la I-Premise
curva I-Premise
de I-Premise
la I-Premise
mucositis I-Premise
( I-Premise
13,2 I-Premise
vs I-Premise
16,6 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,1 I-Premise
) I-Premise
. I-Premise

Las B-Premise
pacientes I-Premise
asignadas I-Premise
al I-Premise
misoprostol I-Premise
informaron I-Premise
de I-Premise
un I-Premise
ligero I-Premise
aumento I-Premise
del I-Premise
dolor I-Premise
( I-Premise
7,6 I-Premise
frente I-Premise
a I-Premise
6,9 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
y I-Premise
un I-Premise
mayor I-Premise
uso I-Premise
de I-Premise
analgésicos I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
esta I-Premise
diferencia I-Premise
no I-Premise
se I-Premise
tradujo I-Premise
en I-Premise
una I-Premise
peor I-Premise
sensación I-Premise
de I-Premise
bienestar I-Premise
general, I-Premise
medida I-Premise
por I-Premise
una I-Premise
escala I-Premise
analógica I-Premise
visual I-Premise
simple I-Premise
( I-Premise
5,8 I-Premise
frente I-Premise
a I-Premise
5,2 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,3 I-Premise
) I-Premise
. I-Premise

En B-Claim
conclusión, I-Claim
no I-Claim
pudimos I-Claim
identificar I-Claim
una I-Claim
reducción I-Claim
de I-Claim
la I-Claim
mucositis I-Claim
inducida I-Claim
por I-Claim
la I-Claim
radiación I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
misoprostol. I-Claim

Hay B-Claim
una I-Claim
escasez I-Claim
de I-Claim
pruebas I-Claim
de I-Claim
alto I-Claim
nivel I-Claim
sobre I-Claim
intervenciones I-Claim
potencialmente I-Claim
útiles I-Claim
y I-Claim
una I-Claim
necesidad I-Claim
continua I-Claim
de I-Claim
investigación I-Claim
nueva I-Claim
e I-Claim
innovadora I-Claim
, I-Claim
que I-Claim
incorpore I-Claim
mediciones I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
, I-Claim
en I-Claim
pacientes I-Claim
que I-Claim
experimentan I-Claim
mucositis I-Claim
inducida I-Claim
por I-Claim
la I-Claim
radiación I-Claim
. I-Claim

Este O
estudio O
aleatorio O
de O
fase O
II O
comparó O
dos O
esquemas O
de O
tratamiento O
con O
gemcitabina O
en O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
(CPNM) O
y O
deterioro O
del O
estado O
de O
rendimiento O
de O
Karnofsky O
(KP). O

Los O
objetivos O
primarios O
eran O
registrar O
los O
cambios O
con O
respecto O
al O
PK O
inicial O
y O
evaluar O
la O
paliación O
de O
los O
síntomas. O

Los O
objetivos O
secundarios O
fueron O
la O
supervivencia O
global, O
la O
respuesta O
tumoral O
y O
la O
toxicidad. O

Los O
pacientes O
con O
CPNM O
en O
estadio O
IIIb O
y O
IV O
y O
KP O
< O
/= O
70 O
fueron O
asignados O
aleatoriamente O
a O
recibir O
gemcitabina O
1.000 O
mg/m O
( O
2 O
) O
en O
los O
días O
1 O
, O
8 O
y O
15 O
de O
cada O
ciclo O
de O
28 O
días O
( O
3w4 O
) O
o O
gemcitabina O
1.500 O
mg/m O
( O
2 O
) O
en O
los O
días O
1 O
y O
8 O
de O
cada O
ciclo O
de O
21 O
días O
( O
2w3 O
) O
, O
ambos O
durante O
un O
máximo O
de O
seis O
ciclos O
. O

Antes O
de O
cada O
ciclo O
de O
tratamiento O
se O
registraron O
las O
preguntas O
específicas O
de O
KP O
, O
toxicidad O
y O
cáncer O
de O
pulmón O
SS14 O
. O

La O
respuesta O
se O
evaluó O
4 O
semanas O
después O
del O
último O
ciclo. O

Se O
inscribieron O
ciento O
setenta O
y O
cuatro O
pacientes. O

Hubo B-Premise
un I-Premise
importante I-Premise
desgaste I-Premise
temprano I-Premise
debido I-Premise
a I-Premise
la I-Premise
progresión I-Premise
de I-Premise
la I-Premise
enfermedad; I-Premise
sólo I-Premise
el I-Premise
61,5% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
estaban I-Premise
vivos I-Premise
a I-Premise
los I-Premise
2 I-Premise
meses. I-Premise

Hubo B-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
del I-Premise
PK I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
el I-Premise
preciclo I-Premise
3 I-Premise
en I-Premise
ambos I-Premise
brazos, I-Premise
con I-Premise
una I-Premise
tendencia I-Premise
a I-Premise
favor I-Premise
del I-Premise
régimen I-Premise
3w4 I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
la I-Premise
duración I-Premise
y I-Premise
el I-Premise
inicio I-Premise
más I-Premise
rápido I-Premise
de I-Premise
la I-Premise
mejora. I-Premise

Ocho B-Premise
de I-Premise
las I-Premise
17 I-Premise
variables I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
( I-Premise
QOL I-Premise
) I-Premise
evaluadas I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
de I-Premise
más I-Premise
del I-Premise
10 I-Premise
% I-Premise
entre I-Premise
el I-Premise
inicio I-Premise
y I-Premise
el I-Premise
comienzo I-Premise
del I-Premise
tercer I-Premise
ciclo I-Premise
de I-Premise
tratamiento I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta, I-Premise
la I-Premise
supervivencia I-Premise
y I-Premise
la I-Premise
duración I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
ambos I-Premise
brazos. I-Premise

No B-Claim
hubo I-Claim
diferencias I-Claim
significativas I-Claim
entre I-Claim
los I-Claim
dos I-Claim
esquemas I-Claim
examinados I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
mejora I-Claim
de I-Claim
la I-Claim
KP I-Claim
o I-Claim
la I-Claim
QOL I-Claim
, I-Claim
pero I-Claim
parecía I-Claim
haber I-Claim
una I-Claim
tendencia I-Claim
a I-Claim
favor I-Claim
del I-Claim
esquema I-Claim
3w4 I-Claim
. I-Claim

Los O
síntomas O
conductuales O
son O
comunes O
en O
las O
supervivientes O
de O
cáncer O
de O
mama O
, O
incluyendo O
alteraciones O
en O
la O
energía O
, O
el O
sueño O
y O
el O
estado O
de O
ánimo O
, O
aunque O
se O
han O
identificado O
pocos O
factores O
de O
riesgo O
para O
estos O
resultados O
negativos O
. O

Nuestro O
estudio O
examinó O
los O
pensamientos O
intrusivos O
como O
factor O
predictivo O
de O
los O
síntomas O
persistentes O
en O
las O
supervivientes O
de O
cáncer O
de O
mama O
en O
el O
año O
siguiente O
al O
tratamiento. O

Los O
datos O
proceden O
del O
ensayo O
de O
intervención O
psicoeducativa O
Moving O
Beyond O
Cancer O
, O
destinado O
a O
facilitar O
la O
transición O
de O
paciente O
a O
superviviente. O

Las O
mujeres O
( O
n O
= O
558 O
) O
completaron O
cuestionarios O
psicosociales O
en O
las O
4 O
semanas O
posteriores O
al O
tratamiento O
y O
de O
nuevo O
2 O
, O
6 O
y O
12 O
meses O
después O
. O

Examinamos O
los O
pensamientos O
intrusivos O
sobre O
el O
cáncer O
en O
la O
evaluación O
inicial O
como O
un O
predictor O
de O
la O
fatiga, O
los O
problemas O
de O
sueño, O
el O
dolor, O
los O
síntomas O
específicos O
del O
cáncer O
de O
mama, O
los O
síntomas O
depresivos, O
el O
afecto O
negativo O
y O
la O
calidad O
de O
vida O
utilizando O
un O
modelo O
de O
curva O
de O
crecimiento, O
controlando O
la O
condición O
del O
estudio O
y O
otras O
covariables. O

Los B-Premise
pensamientos I-Premise
intrusivos I-Premise
se I-Premise
asociaron I-Premise
con I-Premise
niveles I-Premise
más I-Premise
altos I-Premise
de I-Premise
todos I-Premise
los I-Premise
síntomas I-Premise
en I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
y I-Premise
en I-Premise
la I-Premise
evaluación I-Premise
de I-Premise
12 I-Premise
meses I-Premise
. I-Premise

Los B-Premise
pensamientos I-Premise
intrusivos I-Premise
también I-Premise
influyeron I-Premise
en I-Premise
la I-Premise
trayectoria I-Premise
del I-Premise
dolor, I-Premise
los I-Premise
síntomas I-Premise
depresivos, I-Premise
el I-Premise
afecto I-Premise
negativo I-Premise
y I-Premise
el I-Premise
funcionamiento I-Premise
físico I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo; I-Premise
las B-Premise
mujeres I-Premise
con I-Premise
mayores I-Premise
intrusiones I-Premise
al I-Premise
inicio I-Premise
comenzaron I-Premise
peor I-Premise
y I-Premise
mejoraron I-Premise
con I-Premise
el I-Premise
tiempo, I-Premise
mientras I-Premise
que I-Premise
las I-Premise
que I-Premise
tenían I-Premise
menores I-Premise
intrusiones I-Premise
se I-Premise
mantuvieron I-Premise
en I-Premise
un I-Premise
nivel I-Premise
constante I-Premise
y I-Premise
más I-Premise
bajo I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo. I-Premise

Las B-Premise
intrusiones I-Premise
no I-Premise
se I-Premise
asociaron I-Premise
con I-Premise
la I-Premise
trayectoria I-Premise
de I-Premise
la I-Premise
fatiga, I-Premise
el I-Premise
sueño, I-Premise
los I-Premise
síntomas I-Premise
específicos I-Premise
del I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
o I-Premise
el I-Premise
funcionamiento I-Premise
mental; I-Premise
las B-Premise
mujeres I-Premise
con I-Premise
mayores I-Premise
intrusiones I-Premise
en I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
empezaron I-Premise
peor I-Premise
y I-Premise
permanecieron I-Premise
peor I-Premise
con I-Premise
el I-Premise
tiempo. I-Premise

Los B-Claim
pensamientos I-Claim
intrusivos I-Claim
se I-Claim
asocian I-Claim
a I-Claim
elevaciones I-Claim
duraderas I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
conductuales I-Claim
y I-Claim
al I-Claim
deterioro I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
el I-Claim
año I-Claim
posterior I-Claim
al I-Claim
tratamiento I-Claim
del I-Claim
cáncer I-Claim
de I-Claim
mama, I-Claim
y I-Claim
pueden I-Claim
ser I-Claim
un I-Claim
factor I-Claim
de I-Claim
riesgo I-Claim
de I-Claim
malos I-Claim
resultados I-Claim
. I-Claim

El O
15 O
de O
marzo O
de O
2005, O
la O
Administración O
de O
Alimentos O
y O
Medicamentos O
de O
EE.UU. O
aprobó O
la O
temozolomida O
( O
Temodar O
cápsulas O
, O
Instituto O
de O
Investigación O
Schering-Plough O
) O
para O
el O
tratamiento O
de O
pacientes O
adultos O
con O
glioblastoma O
multiforme O
recién O
diagnosticado O
de O
forma O
concomitante O
con O
la O
radioterapia O
y O
luego O
como O
tratamiento O
de O
mantenimiento O
. O

Quinientos O
setenta O
y O
tres O
pacientes O
con O
glioblastoma O
multiforme O
fueron O
aleatorizados O
para O
recibir O
temozolomida O
+ O
radioterapia O
( O
n O
= O
287 O
) O
o O
radioterapia O
sola O
( O
n O
= O
286 O
) O
. O

Los O
pacientes O
del O
brazo O
de O
temozolomida O
+ O
radioterapia O
recibieron O
temozolomida O
concomitante O
( O
75 O
mg/m2 O
) O
una O
vez O
al O
día O
durante O
la O
duración O
de O
la O
radioterapia O
( O
42-49 O
días O
) O
. O

Esto O
fue O
seguido, O
4 O
semanas O
después, O
por O
seis O
ciclos O
de O
temozolomida, O
150 O
o O
200 O
mg/m2 O
diarios O
durante O
5 O
días, O
cada O
4 O
semanas. O

Los O
pacientes O
del O
brazo O
de O
control O
sólo O
recibieron O
radioterapia. O

En O
ambos O
brazos, O
la O
radioterapia O
se O
administró O
en O
forma O
de O
60 O
Gy/30 O
fracciones O
en O
el O
lugar O
del O
tumor O
con O
un O
margen O
de O
2 O
a O
3 O
cm. O

La O
profilaxis O
de O
la O
neumonía O
por O
Pneumocystis O
carinii O
fue O
necesaria O
durante O
el O
tratamiento O
con O
temozolomida O
+ O
radioterapia O
y O
se O
continuó O
hasta O
la O
recuperación O
de O
la O
linfocitopenia O
( O
Criterios O
Comunes O
de O
Toxicidad O
grado O
< O
1 O
) O
. O

En O
el O
momento O
de O
la O
progresión O
de O
la O
enfermedad, O
se O
administró O
tratamiento O
de O
rescate O
con O
temozolomida O
a O
161 O
de O
282 O
pacientes O
( O
57 O
% O
) O
en O
el O
brazo O
de O
radioterapia O
sola, O
y O
a O
62 O
de O
277 O
pacientes O
( O
22 O
% O
) O
en O
el O
brazo O
de O
temozolomida O
+ O
radioterapia O
. O

Los B-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
temozolomida I-Claim
concomitante I-Claim
y I-Claim
de I-Claim
mantenimiento I-Claim
+ I-Claim
radioterapia I-Claim
tuvieron I-Claim
una I-Claim
supervivencia I-Claim
global I-Claim
significativamente I-Claim
mejorada I-Claim
. I-Claim

La B-Premise
razón I-Premise
de I-Premise
riesgo I-Premise
fue I-Premise
de I-Premise
0,63 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,52-0,75 I-Premise
; I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
14,6 I-Premise
meses I-Premise
( I-Premise
temozolomida I-Premise
+ I-Premise
radioterapia I-Premise
) I-Premise
frente I-Premise
a I-Premise
12,1 I-Premise
meses I-Premise
( I-Premise
radioterapia I-Premise
sola I-Premise
) I-Premise
. I-Premise

Los B-Claim
acontecimientos I-Claim
adversos I-Claim
durante I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
temozolomida I-Claim
incluyeron I-Claim
trombocitopenia, I-Claim
náuseas, I-Claim
vómitos, I-Claim
anorexia, I-Claim
estreñimiento, I-Claim
alopecia, I-Claim
dolor I-Claim
de I-Claim
cabeza, I-Claim
fatiga I-Claim
y I-Claim
convulsiones. I-Claim

Este O
estudio O
examinó O
la O
viabilidad O
y O
la O
aceptabilidad O
de O
una O
Intervención O
Individual O
en O
Internet O
( O
III O
) O
incrustada O
e O
integrada O
en O
un O
Grupo O
de O
Apoyo O
en O
Internet O
( O
ISG O
) O
con O
el O
objetivo O
final O
de O
mejorar O
la O
adherencia O
y O
el O
aprendizaje O
, O
en O
comparación O
con O
una O
invención O
individual O
en O
Internet O
sola O
. O

Treinta O
y O
un O
supervivientes O
de O
cáncer O
después O
del O
tratamiento O
fueron O
asignados O
al O
azar O
en O
grupos O
de O
siete O
a O
nueve O
a O
la O
intervención O
de O
8 O
semanas O
III O
+ O
ISG O
o O
a O
la O
condición O
de O
8 O
semanas O
III O
. O

Diecisiete O
participantes O
cumplían O
los O
criterios O
de O
la O
Escala O
de O
Ansiedad O
y O
Depresión O
Hospitalaria O
( O
HADS O
) O
para O
síntomas O
depresivos O
( O
HADS O
≥ O
8 O
) O
. O

Entre O
todos O
los O
participantes, O
el O
número O
medio O
de O
inicios O
de O
sesión O
durante O
8 O
semanas O
fue O
de O
20,8 O
± O
17,7 O
inicios O
de O
sesión O
para O
el O
III O
+ O
ISG O
en O
comparación O
con O
12,5 O
± O
12,5 O
en O
el O
III O
solo O
( O
p O
= O
0,15 O
) O
. O

Dos O
participantes O
del O
III O
+ O
ISG O
abandonaron, O
frente O
a O
cinco O
del O
III O
( O
p O
= O
0,39 O
) O
. O

Entre B-Premise
los I-Premise
17 I-Premise
participantes I-Premise
con I-Premise
síntomas I-Premise
depresivos I-Premise
al I-Premise
inicio I-Premise
del I-Premise
estudio, I-Premise
tanto I-Premise
la I-Premise
condición I-Premise
Onward I-Premise
como I-Premise
la I-Premise
condición I-Premise
III I-Premise
mostraron I-Premise
grandes I-Premise
reducciones I-Premise
en I-Premise
la I-Premise
escala I-Premise
de I-Premise
depresión I-Premise
de I-Premise
la I-Premise
HADS I-Premise
( I-Premise
d I-Premise
= I-Premise
1,27 I-Premise
y I-Premise
0,89 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

La B-Premise
mejora I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
y I-Premise
los I-Premise
efectos I-Premise
tiempo I-Premise
x I-Premise
tratamiento I-Premise
sólo I-Premise
alcanzaron I-Premise
niveles I-Premise
de I-Premise
significación I-Premise
de I-Premise
tendencia I-Premise
( I-Premise
ps I-Premise
= I-Premise
0,07 I-Premise
& I-Premise
amp I-Premise
; I-Premise
0,12 I-Premise
) I-Premise
ya I-Premise
que I-Premise
este I-Premise
piloto I-Premise
no I-Premise
tenía I-Premise
potencia I-Premise
para I-Premise
detectar I-Premise
estas I-Premise
diferencias I-Premise
. I-Premise

Tanto B-Claim
el I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
como I-Claim
el I-Claim
III I-Claim
solo I-Claim
demostraron I-Claim
reducciones I-Claim
pre-post I-Claim
en I-Claim
los I-Claim
síntomas I-Claim
depresivos I-Claim
y I-Claim
altas I-Claim
tasas I-Claim
de I-Claim
utilización I-Claim
en I-Claim
comparación I-Claim
con I-Claim
otros I-Claim
tratamientos I-Claim
basados I-Claim
en I-Claim
la I-Claim
web I-Claim
para I-Claim
la I-Claim
depresión I-Claim
. I-Claim

Aunque B-Claim
es I-Claim
prematuro I-Claim
determinar I-Claim
la I-Claim
eficacia I-Claim
de I-Claim
las I-Claim
intervenciones I-Claim
probadas I-Claim
en I-Claim
este I-Claim
estudio I-Claim
de I-Claim
viabilidad, I-Claim
estos B-Claim
resultados I-Claim
indican I-Claim
que I-Claim
la I-Claim
continuación I-Claim
del I-Claim
modelo I-Claim
III I-Claim
+ I-Claim
ISG, I-Claim
así I-Claim
como I-Claim
los I-Claim
III I-Claim
estándar, I-Claim
pueden I-Claim
ser I-Claim
áreas I-Claim
fructíferas I-Claim
de I-Claim
investigación I-Claim
futura. I-Claim

Se O
desconoce O
la O
duración O
óptima O
de O
la O
SBRT O
pulmonar. O

Realizamos O
un O
estudio O
piloto O
aleatorizado O
en O
pacientes O
tratados O
con O
cuatro O
fracciones O
de O
SBRT O
pulmonar O
administradas O
durante O
4 O
o O
durante O
11 O
días O
. O

Los O
pacientes O
con O
un O
tumor O
pulmonar O
solitario O
periférico O
( O
CPNM O
o O
metástasis O
pulmonar) O
≤ O
5 O
cm O
fueron O
elegibles O
. O

Para O
los O
tumores O
pulmonares O
de O
CPNM O
≤ O
3 O
cm O
, O
se O
utilizó O
una O
dosis O
de O
48 O
Gy O
en O
4 O
fracciones O
, O
de O
lo O
contrario O
se O
administró O
52 O
Gy O
en O
4 O
fracciones O
. O

Los O
pacientes O
fueron O
aleatorizados O
para O
recibir O
el O
tratamiento O
durante O
4 O
días O
consecutivos O
o O
durante O
11 O
días O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
toxicidad O
aguda O
de O
grado O
≥ O
2. O

Los O
criterios O
de O
valoración O
secundarios O
incluyeron O
la O
calidad O
de O
vida O
( O
QOL O
) O
evaluada O
mediante O
los O
cuestionarios O
EORTC O
QLQ-C30 O
y O
QLQ-LC13 O
. O

Se O
inscribieron O
54 O
pacientes. O

Un O
mayor O
número O
de O
pacientes O
en O
el O
grupo O
de O
11 O
días O
tenía O
síntomas O
respiratorios O
al O
inicio. O

El B-Premise
55,6 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
durante I-Premise
4 I-Premise
días I-Premise
y I-Premise
el I-Premise
33,3 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
durante I-Premise
11 I-Premise
días I-Premise
experimentaron I-Premise
toxicidad I-Premise
aguda I-Premise
de I-Premise
grado I-Premise
≥ I-Premise
2 I-Premise
( I-Premise
p=0,085 I-Premise
) I-Premise
. I-Premise

Los B-Premise
dominios I-Premise
de I-Premise
disnea, I-Premise
fatiga I-Premise
y I-Premise
tos I-Premise
fueron I-Premise
peores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
11 I-Premise
días I-Premise
al I-Premise
inicio. I-Premise

A B-Premise
los I-Premise
1 I-Premise
y I-Premise
4 I-Premise
meses, I-Premise
más I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
4 I-Premise
días I-Premise
experimentaron I-Premise
un I-Premise
empeoramiento I-Premise
clínicamente I-Premise
significativo I-Premise
en I-Premise
el I-Premise
dominio I-Premise
de I-Premise
la I-Premise
CdV I-Premise
de I-Premise
la I-Premise
disnea I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
11 I-Premise
días I-Premise
( I-Premise
44,5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
15,4 I-Premise
% I-Premise
, I-Premise
p=0,02 I-Premise
; I-Premise
38,5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
12,0 I-Premise
% I-Premise
, I-Premise
p=0,03 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo, I-Premise
las I-Premise
puntuaciones I-Premise
brutas I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
no I-Premise
fueron I-Premise
diferentes I-Premise
en I-Premise
estos I-Premise
puntos I-Premise
temporales I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento. I-Premise

La B-Claim
toxicidad I-Claim
aguda I-Claim
de I-Claim
grado I-Claim
2 I-Claim
o I-Claim
superior I-Claim
fue I-Claim
más I-Claim
frecuente I-Claim
en I-Claim
el I-Claim
grupo I-Claim
de I-Claim
4 I-Claim
días, I-Claim
acercándose I-Claim
a I-Claim
la I-Claim
significación I-Claim
estadística. I-Claim

Más B-Claim
pacientes I-Claim
tratados I-Claim
durante I-Claim
4 I-Claim
días I-Claim
consecutivos I-Claim
informaron I-Claim
de I-Claim
un I-Claim
aumento I-Claim
clínicamente I-Claim
significativo I-Claim
de I-Claim
la I-Claim
disnea I-Claim
, O
aunque B-Claim
la I-Claim
interpretación I-Claim
de I-Claim
estos I-Claim
resultados I-Claim
es I-Claim
difícil I-Claim
debido I-Claim
al I-Claim
desequilibrio I-Claim
de I-Claim
base I-Claim
entre I-Claim
los I-Claim
grupos I-Claim
de I-Claim
tratamiento I-Claim
. O

Se B-Claim
necesitan I-Claim
estudios I-Claim
más I-Claim
amplios I-Claim
para I-Claim
validar I-Claim
estos I-Claim
resultados. I-Claim

Varias O
directrices O
sobre O
el O
tratamiento O
de O
la O
fatiga O
relacionada O
con O
el O
cáncer O
recomiendan O
optimizar O
el O
tratamiento O
de O
los O
síntomas O
acompañantes O
. O

Sin O
embargo, O
se O
carece O
de O
pruebas O
para O
esta O
recomendación O
a O
partir O
de O
ensayos O
clínicos O
aleatorios. O

Se O
investigó O
si O
el O
seguimiento O
y O
el O
tratamiento O
protocolizado O
de O
los O
síntomas O
físicos O
alivian O
la O
fatiga O
. O

En O
total, O
152 O
pacientes O
fatigados O
con O
cáncer O
avanzado O
fueron O
asignados O
aleatoriamente O
a O
un O
tratamiento O
protocolizado O
adaptado O
al O
paciente O
( O
PPT O
) O
de O
los O
síntomas O
o O
a O
la O
atención O
habitual O
. O

El O
grupo O
PPT O
tuvo O
cuatro O
citas O
con O
una O
enfermera O
que O
evaluó O
nueve O
síntomas O
en O
una O
escala O
de O
calificación O
numérica O
( O
NRS O
) O
de O
0 O
a O
10. O

Los O
pacientes O
recibieron O
una O
intervención O
no O
farmacológica O
para O
los O
síntomas O
con O
una O
puntuación O
≥ O
1 O
y O
una O
intervención O
médica O
para O
los O
síntomas O
con O
una O
puntuación O
≥ O
4 O
. O

Se O
midieron O
las O
dimensiones O
de O
la O
fatiga, O
la O
puntuación O
NRS O
de O
la O
fatiga, O
la O
interferencia O
de O
la O
fatiga O
con O
la O
vida O
diaria, O
la O
carga O
de O
los O
síntomas, O
la O
calidad O
de O
vida, O
la O
ansiedad O
y O
la O
depresión O
al O
inicio O
y O
después O
de O
1, O
2 O
y O
3 O
meses. O

Las O
diferencias O
entre O
los O
grupos O
a O
lo O
largo O
del O
tiempo O
se O
evaluaron O
mediante O
un O
modelo O
mixto. O

Se O
asignaron O
aleatoriamente O
76 O
pacientes O
a O
cada O
brazo O
del O
estudio. O

La O
edad O
media O
fue O
de O
58 O
± O
10 O
años, O
el O
57% O
eran O
mujeres O
y O
el O
65% O
recibieron O
quimioterapia O
paliativa. O

Se B-Premise
encontraron I-Premise
mejoras I-Premise
significativas I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
a I-Premise
favor I-Premise
del I-Premise
TPP I-Premise
para I-Premise
el I-Premise
resultado I-Premise
primario I-Premise
fatiga I-Premise
general I-Premise
( I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
con I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
el I-Premise
mes I-Premise
1 I-Premise
( I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,26 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,007 I-Premise
) I-Premise
y I-Premise
en I-Premise
el I-Premise
mes I-Premise
2 I-Premise
( I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,35 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,005 I-Premise
) I-Premise
. I-Premise

También B-Premise
se I-Premise
encontraron I-Premise
mejoras I-Premise
a I-Premise
favor I-Premise
del I-Premise
PPT I-Premise
en I-Premise
los I-Premise
siguientes I-Premise
resultados I-Premise
secundarios: I-Premise
dimensiones I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
" I-Premise
reducción I-Premise
de I-Premise
la I-Premise
actividad I-Premise
" I-Premise
y I-Premise
" I-Premise
reducción I-Premise
de I-Premise
la I-Premise
motivación I-Premise
", I-Premise
NRS I-Premise
de I-Premise
la I-Premise
fatiga, I-Premise
carga I-Premise
de I-Premise
los I-Premise
síntomas, I-Premise
interferencia I-Premise
de I-Premise
la I-Premise
fatiga I-Premise
con I-Premise
la I-Premise
vida I-Premise
diaria I-Premise
y I-Premise
ansiedad I-Premise
( I-Premise
todos I-Premise
P I-Premise
≤ I-Premise
.03 I-Premise
) I-Premise
. I-Premise

En B-Claim
los I-Claim
pacientes I-Claim
fatigados I-Claim
con I-Claim
cáncer I-Claim
avanzado I-Claim
, I-Claim
el I-Claim
seguimiento I-Claim
dirigido I-Claim
por I-Claim
la I-Claim
enfermera I-Claim
y I-Claim
el I-Claim
tratamiento I-Claim
protocolizado I-Claim
de I-Claim
los I-Claim
síntomas I-Claim
físicos I-Claim
son I-Claim
eficaces I-Claim
para I-Claim
aliviar I-Claim
la I-Claim
fatiga I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
un I-Claim
anticuerpo I-Claim
monoclonal I-Claim
contra I-Claim
el I-Claim
factor I-Claim
de I-Claim
crecimiento I-Claim
endotelial I-Claim
vascular I-Claim
, I-Claim
aumenta I-Claim
la I-Claim
supervivencia I-Claim
cuando I-Claim
se I-Claim
combina I-Claim
con I-Claim
quimioterapia I-Claim
basada I-Claim
en I-Claim
irinotecán I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
del I-Claim
cáncer I-Claim
colorrectal I-Claim
metastásico I-Claim
( I-Claim
CCR I-Claim
) I-Claim
. I-Claim

Este O
ensayo O
aleatorio O
de O
fase O
II O
comparó O
bevacizumab O
más O
fluorouracilo O
y O
leucovorina O
( O
FU/LV O
) O
frente O
a O
placebo O
más O
FU/LV O
como O
tratamiento O
de O
primera O
línea O
en O
pacientes O
considerados O
candidatos O
no O
óptimos O
para O
el O
irinotecán O
de O
primera O
línea O
. O

Los O
pacientes O
tenían O
CCR O
metastásico O
y O
una O
de O
las O
siguientes O
características: O
edad O
> O
o O
= O
65 O
años O
, O
estado O
de O
rendimiento O
1 O
o O
2 O
del O
Eastern O
Cooperative O
Oncology O
Group O
, O
albúmina O
sérica O
< O
o O
= O
3,5 O
g/dl O
, O
o O
radioterapia O
abdominal/pélvica O
previa O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
FU/LV/placebo O
( O
n O
= O
105 O
) O
o O
FU/LV/bevacizumab O
( O
n O
= O
104 O
) O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia O
global. O

Los O
criterios O
de O
valoración O
secundarios O
fueron O
la O
supervivencia O
sin O
progresión, O
la O
tasa O
de O
respuesta, O
la O
duración O
de O
la O
respuesta O
y O
la O
calidad O
de O
vida. O

También O
se O
evaluó O
la O
seguridad. O

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
16,6 I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
FU/LV/bevacizumab I-Premise
y I-Premise
de I-Premise
12,9 I-Premise
meses I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
FU/LV/placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0,79 I-Premise
; I-Premise
P I-Premise
= I-Premise
.16 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
9,2 I-Premise
meses I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
y I-Premise
de I-Premise
5,5 I-Premise
meses I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
; I-Premise
la I-Premise
razón B-Premise
de I-Premise
riesgo I-Premise
fue I-Premise
de I-Premise
0,50 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,0002 I-Premise
. O

Las B-Premise
tasas I-Premise
de I-Premise
respuesta I-Premise
fueron I-Premise
del I-Premise
26,0% I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
y I-Premise
del I-Premise
15,2% I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
; I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
respuesta I-Premise
fue I-Premise
de I-Premise
9,2 I-Premise
meses I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
y I-Premise
de I-Premise
6,8 I-Premise
meses I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
; I-Premise
la I-Premise
razón B-Premise
de I-Premise
riesgo I-Premise
fue I-Premise
de I-Premise
0,42 I-Premise
; I-Premise
P I-Premise
= I-Premise
.088 I-Premise
. O

La B-Premise
hipertensión I-Premise
de I-Premise
grado I-Premise
3 I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
con I-Premise
bevacizumab I-Premise
( I-Premise
16 I-Premise
% I-Premise
frente I-Premise
a I-Premise
3 I-Premise
% O
), O
pero B-Premise
se I-Premise
controló I-Premise
con I-Premise
medicación I-Premise
oral I-Premise
y I-Premise
no I-Premise
provocó I-Premise
la I-Premise
interrupción I-Premise
del I-Premise
fármaco I-Premise
del I-Premise
estudio I-Premise
. O

La B-Claim
adición I-Claim
de I-Claim
bevacizumab I-Claim
al I-Claim
FU/LV I-Claim
como I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CCR I-Claim
que I-Claim
no I-Claim
se I-Claim
consideraban I-Claim
candidatos I-Claim
óptimos I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
con I-Claim
irinotecán I-Claim
proporcionó I-Claim
un I-Claim
beneficio I-Claim
clínicamente I-Claim
significativo I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
, I-Claim
incluida I-Claim
una I-Claim
mejora I-Claim
estadísticamente I-Claim
significativa I-Claim
de I-Claim
la I-Claim
supervivencia I-Claim
libre I-Claim
de I-Claim
progresión I-Claim
. I-Claim

La B-Claim
generalización I-Claim
de I-Claim
las I-Claim
investigaciones I-Claim
sobre I-Claim
intervenciones I-Claim
en I-Claim
cuidados I-Claim
paliativos I-Claim
suele I-Claim
estar I-Claim
limitada I-Claim
por I-Claim
las I-Claim
altas I-Claim
tasas I-Claim
de I-Claim
abandono I-Claim
de I-Claim
los I-Claim
estudios. I-Claim

Este O
estudio O
examinó O
los O
factores O
asociados O
con O
la O
deserción O
de O
un O
ensayo O
controlado O
aleatorio O
que O
comparaba O
la O
psicoterapia O
de O
grupo O
centrada O
en O
el O
significado O
( O
MCGP O
) O
, O
una O
intervención O
diseñada O
para O
ayudar O
a O
los O
pacientes O
con O
cáncer O
avanzado O
a O
mantener O
o O
mejorar O
su O
sentido O
de O
significado O
con O
la O
psicoterapia O
de O
grupo O
de O
apoyo O
( O
SGP O
) O
, O
un O
grupo O
de O
apoyo O
estandarizado O
. O

Los O
pacientes O
con O
cánceres O
de O
tumores O
sólidos O
avanzados O
( O
n O
= O
153 O
) O
fueron O
asignados O
al O
azar O
a O
ocho O
sesiones O
de O
MCGP O
o O
SGP O
. O

Completaron O
evaluaciones O
de O
bienestar O
psicosocial, O
espiritual O
y O
físico O
antes O
del O
tratamiento, O
a O
mitad O
del O
tratamiento O
y O
dos O
meses O
después O
del O
mismo. O

La O
deserción O
se O
evaluó O
en O
términos O
del O
porcentaje O
de O
participantes O
que O
no O
completaron O
estas O
evaluaciones, O
y O
se O
examinaron O
los O
correlatos O
demográficos, O
psiquiátricos, O
médicos O
y O
relacionados O
con O
el O
estudio O
para O
los O
participantes O
en O
cada O
una O
de O
estas O
categorías. O

Las B-Premise
tasas I-Premise
de I-Premise
abandono I-Premise
en I-Premise
estos I-Premise
momentos I-Premise
fueron I-Premise
del I-Premise
28,1%, I-Premise
17,7% I-Premise
y I-Premise
11,1%, I-Premise
respectivamente; I-Premise
el I-Premise
43,1% I-Premise
de I-Premise
los I-Premise
participantes I-Premise
( I-Premise
66 I-Premise
de I-Premise
153 I-Premise
) I-Premise
completaron I-Premise
todo I-Premise
el I-Premise
estudio. I-Premise

El B-Premise
motivo I-Premise
más I-Premise
común I-Premise
de I-Premise
abandono I-Premise
fue I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
se I-Premise
sentían I-Premise
demasiado I-Premise
enfermos. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
deserción I-Premise
no I-Premise
variaron I-Premise
significativamente I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
del I-Premise
estudio. I-Premise

Los O
participantes O
que O
abandonaron O
el O
estudio O
antes O
del O
tratamiento O
manifestaron O
menos O
preocupaciones O
económicas O
que O
los O
que O
lo O
abandonaron O
después, O
y O
los O
que O
lo O
abandonaron O
a O
mitad O
del O
tratamiento O
tenían O
peor O
salud O
física O
que O
los O
que O
lo O
completaron. O

No B-Premise
hubo I-Premise
otras I-Premise
asociaciones I-Premise
significativas I-Premise
entre I-Premise
la I-Premise
deserción I-Premise
y I-Premise
cualquier I-Premise
variable I-Premise
demográfica, I-Premise
médica, I-Premise
psiquiátrica I-Premise
o I-Premise
relacionada I-Premise
con I-Premise
el I-Premise
estudio. I-Premise

Estos B-Claim
resultados I-Claim
ponen I-Claim
de I-Claim
manifiesto I-Claim
el I-Claim
reto I-Claim
de I-Claim
mantener I-Claim
a I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
avanzado I-Claim
en I-Claim
la I-Claim
investigación I-Claim
longitudinal I-Claim
y I-Claim
sugieren I-Claim
la I-Claim
necesidad I-Claim
de I-Claim
considerar I-Claim
enfoques I-Claim
alternativos I-Claim
( I-Claim
por I-Claim
ejemplo, I-Claim
la I-Claim
telemedicina I-Claim
) I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
podrían I-Claim
beneficiarse I-Claim
de I-Claim
las I-Claim
intervenciones I-Claim
de I-Claim
grupo, I-Claim
pero I-Claim
están I-Claim
demasiado I-Claim
enfermos I-Claim
para I-Claim
viajar I-Claim
. I-Claim

Se O
evaluó O
el O
papel O
de O
los O
genotipos O
relacionados O
con O
el O
glutatión O
en O
la O
supervivencia O
global, O
el O
tiempo O
hasta O
la O
progresión, O
los O
acontecimientos O
adversos O
y O
la O
calidad O
de O
vida O
( O
QOL O
) O
en O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
en O
estadio O
IIIB/IV O
que O
estaban O
estables O
o O
respondían O
al O
tratamiento O
inicial O
con O
quimioterapia O
basada O
en O
el O
platino O
y O
que O
posteriormente O
fueron O
aleatorizados O
para O
recibir O
carboxiaminoimidazol O
oral O
diario O
o O
un O
placebo O
. O

De O
los O
186 O
pacientes O
totales, O
113 O
tenían O
un O
tratamiento O
inicial O
con O
terapia O
de O
platino O
y O
muestras O
de O
ADN, O
de O
los O
cuales O
46 O
también O
tenían O
datos O
de O
calidad O
de O
vida. O

Estas O
muestras O
se O
analizaron O
utilizando O
seis O
marcadores O
polimórficos O
de O
ADN O
que O
codifican O
cinco O
importantes O
enzimas O
de O
la O
vía O
metabólica O
del O
glutatión O
. O

La O
calidad O
de O
vida O
de O
los O
pacientes O
se O
evaluó O
mediante O
los O
cuestionarios O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
y O
UNISCALE O
QOL. O

Un O
descenso O
clínicamente O
significativo O
de O
la O
CdV O
se O
definió O
como O
una O
disminución O
del O
10% O
desde O
el O
inicio O
hasta O
la O
semana O
8. O

Se O
utilizaron O
análisis O
multivariantes O
para O
evaluar O
la O
asociación O
de O
los O
genotipos O
con O
los O
cuatro O
criterios O
de O
valoración. O

Los B-Premise
pacientes I-Premise
portadores I-Premise
del I-Premise
genotipo I-Premise
GCLC I-Premise
77 I-Premise
tuvieron I-Premise
una I-Premise
peor I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
= I-Premise
1,5 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
portadores I-Premise
del I-Premise
genotipo I-Premise
GPX1-CC I-Premise
presentaron I-Premise
un I-Premise
descenso I-Premise
clínicamente I-Premise
significativo I-Premise
en I-Premise
los I-Premise
constructos I-Premise
UNISCALE I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
OR I-Premise
) I-Premise
: I-Premise
7,5 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
, I-Premise
evaluación I-Premise
funcional I-Premise
total I-Premise
de I-Premise
la I-Premise
terapia I-Premise
del I-Premise
cáncer-pulmón I-Premise
( I-Premise
OR I-Premise
: I-Premise
11,0 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
, I-Premise
físico I-Premise
( I-Premise
OR I-Premise
: I-Premise
7,1 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,03 I-Premise
) I-Premise
, I-Premise
funcional I-Premise
( I-Premise
OR I-Premise
: I-Premise
5,2 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,04 I-Premise
) I-Premise
y I-Premise
bienestar I-Premise
emocional I-Premise
( I-Premise
OR I-Premise
: I-Premise
23,8 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

Los B-Claim
genotipos I-Claim
de I-Claim
las I-Claim
enzimas I-Claim
relacionadas I-Claim
con I-Claim
el I-Claim
glutatión, I-Claim
especialmente I-Claim
el I-Claim
GCLC, I-Claim
pueden I-Claim
utilizarse I-Claim
como I-Claim
factores I-Claim
de I-Claim
acogida I-Claim
para I-Claim
predecir I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
tras I-Claim
la I-Claim
quimioterapia I-Claim
basada I-Claim
en I-Claim
el I-Claim
platino. I-Claim

La B-Claim
GPX1 I-Claim
puede I-Claim
ser I-Claim
un I-Claim
factor I-Claim
hereditario I-Claim
para I-Claim
predecir I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes. I-Claim

Es B-Claim
fundamental I-Claim
seguir I-Claim
investigando I-Claim
para I-Claim
definir I-Claim
y I-Claim
medir I-Claim
los I-Claim
efectos I-Claim
de I-Claim
estos I-Claim
genes I-Claim
en I-Claim
los I-Claim
regímenes I-Claim
quimioterapéuticos, I-Claim
las I-Claim
toxicidades I-Claim
de I-Claim
los I-Claim
medicamentos, I-Claim
la I-Claim
progresión I-Claim
de I-Claim
la I-Claim
enfermedad I-Claim
y I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida. I-Claim

La O
concentración O
sérica O
de O
CA125 O
suele O
aumentar O
varios O
meses O
antes O
de O
la O
recaída O
clínica O
o O
sintomática O
en O
las O
mujeres O
con O
cáncer O
de O
ovario O
. O

En O
el O
ensayo O
colaborativo O
MRC O
OV05/EORTC O
55955 O
, O
se O
pretendía O
establecer O
los O
beneficios O
del O
tratamiento O
precoz O
sobre O
la O
base O
del O
aumento O
de O
las O
concentraciones O
de O
CA125 O
en O
comparación O
con O
el O
tratamiento O
diferido O
sobre O
la O
base O
de O
la O
recurrencia O
clínica O
. O

Las O
mujeres O
con O
cáncer O
de O
ovario O
en O
remisión O
completa O
después O
de O
la O
quimioterapia O
de O
primera O
línea O
basada O
en O
el O
platino O
y O
con O
una O
concentración O
normal O
de O
CA125 O
se O
inscribieron O
en O
este O
ensayo O
controlado O
aleatorio. O

El O
examen O
clínico O
y O
la O
medición O
del O
CA125 O
se O
realizaron O
cada O
3 O
meses. O

Los O
pacientes O
y O
los O
investigadores O
estaban O
enmascarados O
respecto O
a O
los O
resultados O
del O
CA125 O
, O
que O
fueron O
controlados O
por O
los O
centros O
coordinadores. O

Si O
la O
concentración O
de O
CA125 O
superaba O
el O
doble O
del O
límite O
superior O
de O
la O
normalidad O
, O
las O
pacientes O
fueron O
asignadas O
aleatoriamente O
( O
1:1 O
) O
por O
minimización O
a O
la O
quimioterapia O
temprana O
o O
retardada O
. O

Los O
pacientes O
y O
los O
centros O
clínicos O
fueron O
informados O
de O
la O
asignación O
al O
tratamiento O
temprano O
, O
y O
el O
tratamiento O
se O
inició O
lo O
antes O
posible O
dentro O
de O
los O
28 O
días O
siguientes O
al O
aumento O
de O
la O
medición O
del O
CA125 O
. O

Los O
pacientes O
asignados O
al O
tratamiento O
retardado O
continuaron O
con O
las O
mediciones O
de O
CA125 O
enmascaradas, O
iniciando O
el O
tratamiento O
en O
el O
momento O
de O
la O
recaída O
clínica O
o O
sintomática. O

Todos O
los O
pacientes O
fueron O
tratados O
según O
la O
práctica O
local O
habitual. O

El O
resultado O
primario O
fue O
la O
supervivencia O
global. O

El O
análisis O
fue O
por O
intención O
de O
tratar O
. O

Este O
estudio O
está O
registrado O
, O
ISRCTN87786644 O
. O

Se O
registraron O
1442 O
pacientes O
para O
el O
ensayo, O
de O
los O
cuales O
529 O
fueron O
asignados O
aleatoriamente O
a O
los O
grupos O
de O
tratamiento O
y O
se O
incluyeron O
en O
nuestro O
análisis O
( O
265 O
tempranos O
, O
264 O
tardíos O
) O
. O

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
56-9 I-Premise
meses I-Premise
( I-Premise
IQR I-Premise
37-4-81-8 I-Premise
) I-Premise
desde I-Premise
la I-Premise
aleatorización I-Premise
y I-Premise
370 I-Premise
muertes I-Premise
( I-Premise
186 I-Premise
tempranas I-Premise
, I-Premise
184 I-Premise
tardías I-Premise
) I-Premise
, I-Premise
no I-Premise
hubo I-Premise
evidencia I-Premise
de I-Premise
una I-Premise
diferencia I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
entre I-Premise
el I-Premise
tratamiento I-Premise
temprano I-Premise
y I-Premise
el I-Premise
tardío I-Premise
( I-Premise
HR I-Premise
0-98 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0-80-1-20 I-Premise
, I-Premise
p=0-85 I-Premise
) I-Premise
. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
desde I-Premise
la I-Premise
aleatorización I-Premise
fue I-Premise
de I-Premise
25-7 I-Premise
meses I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
23-0-27-9) I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
tratamiento I-Premise
temprano I-Premise
y I-Premise
de I-Premise
27-1 I-Premise
meses I-Premise
(22-8-30-9) I-Premise
para I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
tratamiento I-Premise
tardío. I-Premise

Nuestros B-Claim
hallazgos I-Claim
no I-Claim
mostraron I-Claim
ninguna I-Claim
evidencia I-Claim
de I-Claim
un I-Claim
beneficio I-Claim
de I-Claim
supervivencia I-Claim
con I-Claim
el I-Claim
tratamiento I-Claim
temprano I-Claim
de I-Claim
la I-Claim
recaída I-Claim
sobre I-Claim
la I-Claim
base I-Claim
de I-Claim
una I-Claim
concentración I-Claim
elevada I-Claim
de I-Claim
CA125 I-Claim
solamente I-Claim
, I-Claim
y I-Claim
por I-Claim
lo I-Claim
tanto I-Claim
el I-Claim
valor I-Claim
de I-Claim
la I-Claim
medición I-Claim
rutinaria I-Claim
de I-Claim
CA125 I-Claim
en I-Claim
el I-Claim
seguimiento I-Claim
de I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
ovario I-Claim
que I-Claim
alcanzan I-Claim
una I-Claim
respuesta I-Claim
completa I-Claim
después I-Claim
del I-Claim
tratamiento I-Claim
de I-Claim
primera I-Claim
línea I-Claim
no I-Claim
está I-Claim
probado I-Claim
. O

El O
sarcoma O
de O
Kaposi O
es O
actualmente O
el O
tumor O
más O
frecuente O
en O
Zimbabue. O

El O
objetivo O
de O
nuestro O
estudio O
es O
comparar O
la O
eficacia O
de O
los O
cuidados O
de O
apoyo O
frente O
a O
tres O
enfoques O
de O
intervención, O
a O
saber, O
el O
etopósido O
oral, O
una O
combinación O
de O
tres O
fármacos O
y O
la O
radioterapia, O
utilizando O
la O
calidad O
de O
vida O
(QOL) O
como O
principal O
medida O
de O
éxito. O

Además O
, O
nuestro O
estudio O
fue O
determinar O
si O
un O
módulo O
específico O
de O
la O
enfermedad O
tiene O
una O
mayor O
sensibilidad O
a O
las O
diferencias O
de O
grupo O
que O
un O
cuestionario O
genérico O
QOL O
y O
determinar O
el O
enfoque O
más O
pragmático O
para O
el O
tratamiento O
del O
sarcoma O
de O
Kaposi O
epidémico O
( O
EKS O
) O
en O
Zimbabwe O
. O

Los O
pacientes O
seropositivos O
confirmados O
histológicamente O
con O
sarcoma O
de O
Kaposi O
fueron O
asignados O
al O
azar O
para O
recibir O
sólo O
cuidados O
de O
apoyo O
o O
cuidados O
de O
apoyo O
más O
radioterapia, O
etopósido O
oral O
o O
una O
combinación O
de O
tres O
fármacos O
consistente O
en O
actinomicina-D, O
vincristina O
y O
bleomicina. O

Ningún O
paciente O
recibió O
terapia O
antirretroviral. O

El O
resultado O
primario O
fue O
la O
CdV O
medida O
por O
el O
índice O
de O
vida O
funcional-cáncer O
( O
FLI-C O
) O
y O
complementada O
por O
el O
módulo O
de O
sarcoma O
de O
Kaposi O
( O
KSM O
) O
. O

Entre O
1994 O
y O
1999, O
se O
registraron O
495 O
pacientes O
con O
EKS O
y O
470 O
fueron O
evaluables. O

De O
ellos, O
se O
sabe O
que O
433 O
han O
muerto, O
26 O
se O
han O
perdido O
en O
el O
seguimiento O
y O
11 O
siguen O
vivos. O

El B-Premise
grupo I-Premise
tratado I-Premise
con I-Premise
etopósido I-Premise
oral I-Premise
tuvo I-Premise
una I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
significativamente I-Premise
mejor I-Premise
que I-Premise
el I-Premise
grupo I-Premise
de I-Premise
radioterapia I-Premise
para I-Premise
la I-Premise
puntuación I-Premise
total I-Premise
de I-Premise
FLI-C I-Premise
( I-Premise
media I-Premise
ajustada I-Premise
más I-Premise
error I-Premise
estándar I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses I-Premise
89 I-Premise
+/- I-Premise
3 I-Premise
vs. I-Premise
76 I-Premise
+/- I-Premise
3 I-Premise
; I-Premise
p I-Premise
= I-Premise
0 I-Premise
004 I-Premise
) I-Premise
y I-Premise
para I-Premise
la I-Premise
dificultad I-Premise
( I-Premise
11 I-Premise
+/- I-Premise
0,4 I-Premise
vs. I-Premise
9 I-Premise
+/- I-Premise
0,4 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
; I-Premise
social I-Premise
( I-Premise
10 I-Premise
+/- I-Premise
0,5 I-Premise
vs. I-Premise
9 I-Premise
+/- I-Premise
0,5 I-Premise
). I-Premise
76 I-Premise
+/- I-Premise
3 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,004 I-Premise
) I-Premise
y I-Premise
para I-Premise
las I-Premise
subescalas I-Premise
de I-Premise
dificultad I-Premise
( I-Premise
11 I-Premise
+/- I-Premise
0,4 I-Premise
vs. I-Premise
9 I-Premise
+/- I-Premise
0,4 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
; I-Premise
social I-Premise
( I-Premise
10 I-Premise
+/- I-Premise
0,4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0,4 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
náuseas I-Premise
( I-Premise
9 I-Premise
+/- I-Premise
0,4 I-Premise
vs. I-Premise
8 I-Premise
+/- I-Premise
0,4 I-Premise
; I-Premise
p I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

Además, B-Premise
en I-Premise
las I-Premise
subescalas I-Premise
física I-Premise
y I-Premise
psicológica, I-Premise
el I-Premise
grupo I-Premise
de I-Premise
etopósido I-Premise
tuvo I-Premise
una I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
significativamente I-Premise
mejor I-Premise
que I-Premise
los I-Premise
otros I-Premise
tres I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
( I-Premise
p I-Premise
< I-Premise
0,04 I-Premise
). I-Premise

Los B-Premise
grupos I-Premise
de I-Premise
combinación I-Premise
de I-Premise
3 I-Premise
fármacos, I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
y I-Premise
radioterapia I-Premise
no I-Premise
difirieron I-Premise
significativamente I-Premise
entre I-Premise
sí I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
puntuación I-Premise
total I-Premise
del I-Premise
FLI-C I-Premise
o I-Premise
sus I-Premise
subescalas. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
con I-Premise
respecto I-Premise
a I-Premise
la I-Premise
supervivencia. I-Premise

El B-Claim
tratamiento I-Claim
con I-Claim
etopósido I-Claim
oral I-Claim
dio I-Claim
lugar I-Claim
a I-Claim
una I-Claim
mejor I-Claim
puntuación I-Claim
total I-Claim
de I-Claim
la I-Claim
CdV I-Claim
de I-Claim
FLI-C I-Claim
que I-Claim
la I-Claim
radioterapia. I-Claim

Asimismo, O
el O
etopósido B-Claim
dio I-Claim
lugar I-Claim
a I-Claim
mejores I-Claim
puntuaciones I-Claim
en I-Claim
las I-Claim
subescalas I-Claim
física I-Claim
y I-Claim
psicológica I-Claim
que I-Claim
la I-Claim
radioterapia, I-Claim
los I-Claim
3 I-Claim
fármacos I-Claim
y I-Claim
los I-Claim
cuidados I-Claim
de I-Claim
apoyo. I-Claim

Así B-Claim
pues, I-Claim
si I-Claim
los I-Claim
fondos I-Claim
lo I-Claim
permiten, I-Claim
el I-Claim
etopósido I-Claim
oral I-Claim
es I-Claim
un I-Claim
enfoque I-Claim
pragmático I-Claim
para I-Claim
tratar I-Claim
el I-Claim
EKS I-Claim
en I-Claim
un I-Claim
entorno I-Claim
en I-Claim
el I-Claim
que I-Claim
los I-Claim
medicamentos I-Claim
antirretrovirales I-Claim
no I-Claim
están I-Claim
disponibles I-Claim
de I-Claim
forma I-Claim
universal. I-Claim

El B-Claim
estudio I-Claim
subraya I-Claim
el I-Claim
valor I-Claim
de I-Claim
emprender I-Claim
estudios I-Claim
en I-Claim
áreas I-Claim
de I-Claim
prevalencia I-Claim
de I-Claim
la I-Claim
enfermedad I-Claim
y I-Claim
la I-Claim
necesidad I-Claim
de I-Claim
seleccionar I-Claim
medidas I-Claim
de I-Claim
resultado I-Claim
apropiadas I-Claim
. I-Claim

Determinar O
los O
beneficios O
funcionales O
y O
psicológicos O
de O
un O
programa O
de O
ejercicios O
grupales O
supervisados O
de O
12 O
semanas O
de O
duración O
durante O
el O
tratamiento O
del O
cáncer O
de O
mama O
en O
fase O
inicial, O
con O
un O
seguimiento O
de O
seis O
meses. O

Ensayo O
abierto O
prospectivo O
aleatorio O
controlado O
pragmático O
. O

Tres O
clínicas O
de O
oncología O
del O
Servicio O
Nacional O
de O
Salud O
en O
Escocia O
e O
instalaciones O
de O
ejercicio O
comunitario O
. O

203 O
mujeres O
entraron O
en O
el O
estudio; O
177 O
completaron O
los O
seis O
meses O
de O
seguimiento. O

Programa O
supervisado O
de O
ejercicios O
en O
grupo O
de O
12 O
semanas, O
además O
de O
la O
atención O
habitual, O
comparado O
con O
la O
atención O
habitual. O

Cuestionario O
de O
evaluación O
funcional O
de O
la O
terapia O
contra O
el O
cáncer O
( O
FACT O
) O
, O
inventario O
de O
depresión O
de O
Beck O
, O
escala O
de O
afecto O
positivo O
y O
negativo O
, O
índice O
de O
masa O
corporal O
, O
recuerdo O
de O
siete O
días O
de O
actividad O
física O
, O
prueba O
de O
marcha O
de O
12 O
minutos O
y O
evaluación O
de O
la O
movilidad O
del O
hombro O
. O

Los B-Premise
modelos I-Premise
de I-Premise
efectos I-Premise
mixtos I-Premise
con I-Premise
ajuste I-Premise
para I-Premise
los I-Premise
valores I-Premise
iniciales, I-Premise
el I-Premise
lugar I-Premise
del I-Premise
estudio, I-Premise
el I-Premise
tratamiento I-Premise
al I-Premise
inicio I-Premise
y I-Premise
la I-Premise
edad I-Premise
dieron I-Premise
estimaciones I-Premise
del I-Premise
efecto I-Premise
de I-Premise
la I-Premise
intervención I-Premise
( I-Premise
intervención I-Premise
menos I-Premise
control) I-Premise
a I-Premise
las I-Premise
12 I-Premise
semanas I-Premise
de I-Premise
129 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
%: I-Premise
83 I-Premise
a I-Premise
176 I-Premise
) I-Premise
para I-Premise
los I-Premise
metros I-Premise
caminados I-Premise
en I-Premise
12 I-Premise
minutos, I-Premise
182 I-Premise
( I-Premise
75 I-Premise
a I-Premise
289 I-Premise
) I-Premise
para I-Premise
los I-Premise
minutos I-Premise
de I-Premise
actividad I-Premise
de I-Premise
intensidad I-Premise
moderada I-Premise
declarados I-Premise
en I-Premise
una I-Premise
semana, I-Premise
2,6 I-Premise
( I-Premise
1,6 I-Premise
a I-Premise
3,7 I-Premise
) I-Premise
para I-Premise
la I-Premise
movilidad I-Premise
del I-Premise
hombro, I-Premise
2,5 I-Premise
( I-Premise
1,0 I-Premise
a I-Premise
3,9 I-Premise
) I-Premise
para I-Premise
la I-Premise
subescala I-Premise
específica I-Premise
del I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
4,0 I-Premise
( I-Premise
1,8 I-Premise
a I-Premise
6,3 I-Premise
) I-Premise
para I-Premise
el I-Premise
estado I-Premise
de I-Premise
ánimo I-Premise
positivo. I-Premise

No B-Premise
se I-Premise
observó I-Premise
ningún I-Premise
efecto I-Premise
significativo I-Premise
en I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
, I-Premise
que I-Premise
fue I-Premise
el I-Premise
resultado I-Premise
primario I-Premise
. I-Premise

A B-Premise
los I-Premise
seis I-Premise
meses I-Premise
de I-Premise
seguimiento, I-Premise
la I-Premise
mayoría I-Premise
de I-Premise
estos I-Premise
efectos I-Premise
se I-Premise
mantuvieron I-Premise
y I-Premise
surgió I-Premise
un I-Premise
efecto I-Premise
de I-Premise
la I-Premise
intervención I-Premise
sobre I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
específica I-Premise
del I-Premise
cáncer I-Premise
de I-Premise
mama. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
efectos I-Premise
adversos. I-Premise

El B-Claim
ejercicio I-Claim
grupal I-Claim
supervisado I-Claim
proporcionó I-Claim
beneficios I-Claim
funcionales I-Claim
y I-Claim
psicológicos I-Claim
tras I-Claim
una I-Claim
intervención I-Claim
de I-Claim
12 I-Claim
semanas I-Claim
y I-Claim
seis I-Claim
meses I-Claim
después I-Claim
. I-Claim

Los B-Claim
médicos I-Claim
deben I-Claim
fomentar I-Claim
la I-Claim
actividad I-Claim
de I-Claim
sus I-Claim
pacientes. I-Claim

Los B-Claim
responsables I-Claim
políticos I-Claim
deberían I-Claim
considerar I-Claim
la I-Claim
inclusión I-Claim
de I-Claim
oportunidades I-Claim
de I-Claim
ejercicio I-Claim
en I-Claim
los I-Claim
servicios I-Claim
de I-Claim
rehabilitación I-Claim
del I-Claim
cáncer I-Claim
. I-Claim

El O
objetivo O
de O
este O
estudio O
es O
comparar O
el O
tratamiento O
y O
los O
efectos O
de O
retención O
entre O
la O
terapia O
linfática O
descongestiva O
estándar O
( O
DLT O
) O
combinada O
con O
compresión O
neumática O
( O
PC O
) O
y O
la O
DLT O
modificada O
, O
en O
la O
que O
se O
sustituye O
el O
uso O
de O
un O
vendaje O
de O
corta O
duración O
por O
el O
uso O
de O
Kinesio O
tape O
( O
K-tape O
) O
combinado O
con O
PC O
. O

Cuarenta O
y O
una O
pacientes O
con O
linfedema O
unilateral O
relacionado O
con O
el O
cáncer O
de O
mama O
durante O
al O
menos O
3 O
meses O
fueron O
agrupadas O
aleatoriamente O
en O
el O
grupo O
DLT O
( O
grupo O
de O
vendaje O
, O
N O
= O
21 O
) O
o O
en O
el O
grupo O
DLT O
modificado O
( O
grupo O
de O
K-tape O
, O
N O
= O
20 O
) O
. O

Durante O
cada O
sesión O
de O
tratamiento O
se O
realizaron O
cuidados O
de O
la O
piel, O
drenaje O
linfático O
manual O
de O
30 O
minutos, O
terapia O
de O
compresión O
neumática O
de O
1 O
hora, O
aplicación O
de O
un O
vendaje O
de O
corta O
duración O
o O
cinta O
K O
para O
cada O
grupo O
y O
un O
ejercicio O
de O
fisioterapia O
de O
20 O
minutos. O

Los O
elementos O
de O
evaluación O
de O
los O
pacientes O
incluían O
la O
valoración O
de O
la O
fisioterapia, O
el O
tamaño O
de O
la O
extremidad, O
la O
composición O
del O
agua O
de O
la O
extremidad O
superior, O
los O
síntomas O
relacionados O
con O
el O
linfedema, O
la O
calidad O
de O
vida O
y O
la O
aceptación O
del O
vendaje O
o O
la O
cinta O
por O
parte O
de O
los O
pacientes. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
todas I-Premise
las I-Premise
variables I-Premise
de I-Premise
resultado I-Premise
( I-Premise
P I-Premise
> I-Premise
0,05 I-Premise
) I-Premise
durante I-Premise
todo I-Premise
el I-Premise
período I-Premise
de I-Premise
estudio. I-Premise

El B-Premise
exceso I-Premise
de I-Premise
tamaño I-Premise
de I-Premise
las I-Premise
extremidades I-Premise
(circunferencia I-Premise
y I-Premise
desplazamiento I-Premise
de I-Premise
agua) I-Premise
y I-Premise
el I-Premise
exceso I-Premise
de I-Premise
composición I-Premise
de I-Premise
agua I-Premise
se I-Premise
redujeron I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
vendaje; I-Premise
el B-Premise
exceso I-Premise
de I-Premise
circunferencia I-Premise
y I-Premise
el I-Premise
exceso I-Premise
de I-Premise
composición I-Premise
de I-Premise
agua I-Premise
se I-Premise
redujeron I-Premise
significativamente I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
cinta. I-Premise

La B-Premise
aceptación I-Premise
de I-Premise
la I-Premise
cinta I-Premise
K I-Premise
fue I-Premise
mejor I-Premise
que I-Premise
la I-Premise
de I-Premise
la I-Premise
venda, I-Premise
y I-Premise
los I-Premise
beneficios I-Premise
incluyeron I-Premise
un I-Premise
mayor I-Premise
tiempo I-Premise
de I-Premise
uso, I-Premise
menos I-Premise
dificultad I-Premise
en I-Premise
el I-Premise
uso I-Premise
y I-Premise
mayor I-Premise
comodidad I-Premise
y I-Premise
conveniencia I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Claim
resultados I-Claim
del I-Claim
estudio I-Claim
sugieren I-Claim
que I-Claim
K-tape I-Claim
podría I-Claim
sustituir I-Claim
al I-Claim
vendaje I-Claim
en I-Claim
el I-Claim
DLT I-Claim
, I-Claim
y I-Claim
podría I-Claim
ser I-Claim
una I-Claim
opción I-Claim
alternativa I-Claim
para I-Claim
la I-Claim
paciente I-Claim
con I-Claim
linfedema I-Claim
relacionado I-Claim
con I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
con I-Claim
mal I-Claim
cumplimiento I-Claim
del I-Claim
vendaje I-Claim
de I-Claim
corta I-Claim
duración I-Claim
después I-Claim
de I-Claim
la I-Claim
intervención I-Claim
de I-Claim
1 I-Claim
mes I-Claim
. I-Claim

Si O
el O
periodo O
de O
intervención O
se O
prolongara, O
podríamos O
llegar O
a O
una O
conclusión O
diferente. O

Además, O
estos B-Claim
dos I-Claim
protocolos I-Claim
de I-Claim
tratamiento I-Claim
son I-Claim
ineficaces I-Claim
y I-Claim
cuestan I-Claim
tiempo I-Claim
en I-Claim
su I-Claim
aplicación. I-Claim

Se B-Claim
necesita I-Claim
un I-Claim
protocolo I-Claim
de I-Claim
tratamiento I-Claim
más I-Claim
eficiente I-Claim
para I-Claim
la I-Claim
práctica I-Claim
clínica I-Claim
. I-Claim

Estudiar O
los O
efectos O
de O
la O
quimioterapia O
combinada O
con O
Fuzheng O
Jianpi O
( O
FJD O
) O
sobre O
la O
calidad O
de O
vida O
( O
QOL O
) O
y O
el O
tiempo O
de O
supervivencia O
de O
los O
niños O
con O
tumor O
sólido O
. O

Se O
reclutaron O
167 O
pacientes O
infantiles O
con O
tumores O
sólidos O
en O
el O
Departamento O
de O
Tumores O
del O
Hospital O
Infantil O
de O
Pekín. O

Fueron O
asignados O
aleatoriamente O
al O
grupo O
de O
tratamiento O
( O
83 O
casos O
) O
y O
al O
grupo O
de O
control O
( O
84 O
casos O
) O
según O
la O
tabla O
de O
dígitos O
aleatorios O
. O

Todos O
recibieron O
quimioterapia. O

Los O
del O
grupo O
de O
tratamiento O
tomaron O
además O
FJD O
, O
50 O
-100 O
mL O
cada O
vez O
, O
dos O
veces O
al O
día O
. O

Después O
de O
la O
quimioterapia, O
los O
del O
grupo O
de O
tratamiento O
tomaron O
FJD O
modificado. O

Se O
detectaron O
los O
valores O
de O
WBC O
, O
Hb O
y O
PLT O
en O
todos O
los O
pacientes O
antes O
del O
tratamiento O
, O
6 O
meses O
después O
del O
tratamiento O
y O
1 O
año O
después O
del O
tratamiento O
. O

Se O
observó O
la O
calidad O
de O
vida O
a O
1, O
2 O
y O
3 O
años, O
la O
tasa O
de O
supervivencia O
a O
3 O
años O
y O
la O
vida O
de O
los O
niños O
muertos. O

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
del I-Premise
mismo I-Premise
período, I-Premise
los I-Premise
glóbulos I-Premise
blancos I-Premise
y I-Premise
la I-Premise
hemoglobina I-Premise
aumentaron I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
al I-Premise
año, I-Premise
y I-Premise
el I-Premise
PLT I-Premise
aumentó I-Premise
al I-Premise
año I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento, I-Premise
mostrando I-Premise
una I-Premise
diferencia I-Premise
estadística I-Premise
(P I-Premise
< I-Premise
0,05, I-Premise
P I-Premise
< I-Premise
0,01). I-Premise

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
de I-Premise
1 I-Premise
año I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
, I-Premise
las I-Premise
funciones I-Premise
psicológicas I-Premise
de I-Premise
2 I-Premise
y I-Premise
3 I-Premise
años I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
generales I-Premise
disminuyeron I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
, I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
del I-Premise
mismo I-Premise
período, I-Premise
las I-Premise
funciones I-Premise
somáticas, I-Premise
las I-Premise
funciones I-Premise
psicológicas I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
generales I-Premise
a I-Premise
los I-Premise
2 I-Premise
y I-Premise
3 I-Premise
años I-Premise
disminuyeron I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento; I-Premise
las B-Premise
funciones I-Premise
somáticas I-Premise
y I-Premise
las I-Premise
funciones I-Premise
psicológicas I-Premise
a I-Premise
los I-Premise
2 I-Premise
años I-Premise
disminuyeron I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento; I-Premise
las B-Premise
funciones I-Premise
psicológicas I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
generales I-Premise
a I-Premise
los I-Premise
3 I-Premise
años I-Premise
disminuyeron I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento, I-Premise
todas I-Premise
con I-Premise
diferencia I-Premise
estadística I-Premise
( I-Premise
todas I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) O
. O

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
el I-Premise
número I-Premise
de I-Premise
muertes I-Premise
disminuyó, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
supervivencia I-Premise
aumentó, I-Premise
la I-Premise
vida I-Premise
de I-Premise
los I-Premise
niños I-Premise
muertos I-Premise
se I-Premise
prolongó I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento, I-Premise
mostrando I-Premise
una I-Premise
diferencia I-Premise
estadística I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Claim
quimioterapia I-Claim
combinada I-Claim
con I-Claim
la I-Claim
FJD I-Claim
podría I-Claim
mejorar I-Claim
eficazmente I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
infantiles I-Claim
con I-Claim
tumores I-Claim
sólidos, I-Claim
elevar I-Claim
su I-Claim
tasa I-Claim
de I-Claim
supervivencia I-Claim
y I-Claim
prolongar I-Claim
su I-Claim
esperanza I-Claim
de I-Claim
vida. I-Claim

Este O
estudio O
examinó O
si O
los O
cambios O
en O
la O
autoeficacia O
explican O
los O
efectos O
de O
una O
intervención O
impresa O
por O
correo O
en O
las O
prácticas O
dietéticas O
a O
largo O
plazo O
de O
los O
supervivientes O
de O
cáncer O
de O
mama O
y O
de O
próstata O
. O

También O
se O
examinó O
la O
relación O
entre O
el O
cambio O
en O
la O
autoeficacia O
y O
la O
actividad O
física O
( O
AF O
) O
a O
largo O
plazo. O

En O
el O
ensayo O
de O
intervención O
FRESH O
START O
participaron O
supervivientes O
de O
cáncer O
de O
mama O
y O
de O
próstata O
( O
N O
= O
543 O
) O
de O
39 O
estados O
de O
EE.UU. O
y O
dos O
provincias O
canadienses. O

Los O
participantes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
un O
programa O
de O
10 O
meses O
de O
materiales O
impresos O
enviados O
por O
correo O
sobre O
la O
dieta O
y O
la O
AF O
disponibles O
en O
el O
dominio O
público O
o O
un O
programa O
de O
10 O
meses O
de O
materiales O
adaptados O
diseñados O
para O
aumentar O
la O
ingesta O
de O
frutas O
y O
verduras O
( O
F O
& O
V O
) O
, O
disminuir O
la O
ingesta O
de O
grasas O
, O
y O
/ O
o O
aumentar O
la O
AF. O
Los O
cambios O
en O
la O
autoeficacia O
para O
la O
ingesta O
de O
frutas O
y O
verduras O
y O
la O
restricción O
de O
grasas O
se O
analizaron O
como O
posibles O
mediadores O
de O
los O
efectos O
de O
la O
intervención O
en O
la O
dieta O
a O
los O
2 O
años O
de O
seguimiento. O

Debido O
a O
que O
previamente O
encontramos O
que O
el O
cambio O
en O
la O
autoeficacia O
para O
la O
AF O
no O
varió O
por O
la O
asignación O
de O
grupo O
, O
la O
relación O
entre O
el O
cambio O
en O
la O
autoeficacia O
y O
la O
AF O
en O
el O
seguimiento O
de O
2 O
años O
se O
examinó O
a O
través O
de O
las O
condiciones O
del O
estudio O
. O

Los B-Claim
resultados I-Claim
sugieren I-Claim
que I-Claim
el I-Claim
cambio I-Claim
en I-Claim
la I-Claim
autoeficacia I-Claim
para I-Claim
la I-Claim
restricción I-Claim
de I-Claim
grasas I-Claim
explicó I-Claim
parcialmente I-Claim
el I-Claim
efecto I-Claim
de I-Claim
la I-Claim
intervención I-Claim
sobre I-Claim
la I-Claim
ingesta I-Claim
de I-Claim
grasas I-Claim
( I-Claim
efecto I-Claim
indirecto I-Claim
medio I-Claim
= I-Claim
-0,28 I-Claim
) I-Claim
, I-Claim
y I-Claim
el I-Claim
cambio I-Claim
en I-Claim
la I-Claim
autoeficacia I-Claim
para I-Claim
el I-Claim
consumo I-Claim
de I-Claim
F&V I-Claim
explicó I-Claim
parcialmente I-Claim
el I-Claim
efecto I-Claim
de I-Claim
la I-Claim
intervención I-Claim
sobre I-Claim
la I-Claim
ingesta I-Claim
diaria I-Claim
de I-Claim
F&V I-Claim
( I-Claim
efecto I-Claim
indirecto I-Claim
medio I-Claim
= I-Claim
0,11 I-Claim
) I-Claim
. I-Claim

El B-Premise
cambio I-Premise
en I-Premise
la I-Premise
autoeficacia I-Premise
para I-Premise
la I-Premise
restricción I-Premise
de I-Premise
grasas I-Premise
explicó I-Premise
parcialmente I-Premise
el I-Premise
impacto I-Premise
de I-Premise
la I-Premise
intervención I-Premise
en I-Premise
la I-Premise
calidad I-Premise
general I-Premise
de I-Premise
la I-Premise
dieta I-Premise
sólo I-Premise
entre I-Premise
los I-Premise
hombres I-Premise
(efecto I-Premise
indirecto I-Premise
medio I-Premise
= I-Premise
0,60). I-Premise

Por O
último, O
el O
cambio O
en O
la O
autoeficacia O
para O
la O
AF O
predijo O
la O
AF O
en O
el O
seguimiento O
de O
2 O
años. O

Los B-Claim
resultados I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
autoeficacia I-Claim
puede I-Claim
influir I-Claim
en I-Claim
el I-Claim
mantenimiento I-Claim
a I-Claim
largo I-Claim
plazo I-Claim
de I-Claim
las I-Claim
prácticas I-Claim
de I-Claim
estilo I-Claim
de I-Claim
vida I-Claim
saludable I-Claim
entre I-Claim
los I-Claim
supervivientes I-Claim
de I-Claim
cáncer. I-Claim

Los O
pacientes O
experimentan O
reducciones O
en O
la O
calidad O
de O
vida O
( O
QOL O
) O
mientras O
reciben O
el O
tratamiento O
del O
cáncer O
y O
se O
han O
propuesto O
varios O
enfoques O
para O
abordar O
los O
problemas O
de O
QOL O
. O

En O
este O
proyecto, O
se O
examinaron O
las O
diferencias O
en O
la O
CdV O
entre O
pacientes O
adultos O
mayores O
( O
de O
65 O
años O
o O
más) O
y O
adultos O
jóvenes O
( O
de O
18 O
a O
64 O
años) O
con O
cáncer O
avanzado O
en O
respuesta O
a O
una O
intervención O
multidisciplinaria O
diseñada O
para O
mejorar O
la O
CdV. O

Este O
estudio O
se O
registró O
en O
ClinicalTrials.gov O
. O

Los O
pacientes O
con O
cáncer O
avanzado O
recién O
diagnosticados O
y O
sometidos O
a O
radioterapia O
fueron O
asignados O
aleatoriamente O
a O
grupos O
de O
intervención O
activa O
en O
materia O
de O
calidad O
de O
vida O
o O
a O
grupos O
de O
control. O

Los O
integrantes O
del O
grupo O
de O
intervención O
recibieron O
seis O
sesiones O
multidisciplinarias O
de O
90 O
minutos O
diseñadas O
para O
abordar O
los O
cinco O
dominios O
principales O
de O
la O
calidad O
de O
vida. O

Los O
resultados O
medidos O
al O
inicio O
y O
en O
las O
semanas O
4, O
27 O
y O
52 O
incluyeron O
la O
calidad O
de O
vida O
( O
Autoevaluación O
Analógica O
Lineal O
( O
LASA O
) O
, O
Evaluación O
Funcional O
de O
la O
Terapia O
del O
Cáncer-General O
( O
FACT-G O
) O
) O
y O
el O
estado O
de O
ánimo O
( O
Perfil O
de O
Estados O
de O
Ánimo O
( O
POMS O
) O
) O
. O

Se O
utilizó O
la O
metodología O
de O
Kruskall-Wallis O
para O
comparar O
las O
puntuaciones O
entre O
los O
pacientes O
adultos O
mayores O
y O
los O
más O
jóvenes O
asignados O
al O
azar O
a O
la O
intervención O
. O

De O
los O
131 O
pacientes O
del O
estudio O
controlado O
aleatorio O
más O
grande O
, O
informamos O
de O
los O
datos O
de O
54 O
pacientes O
evaluables O
( O
16 O
adultos O
mayores O
y O
38 O
adultos O
jóvenes O
) O
asignados O
al O
azar O
a O
la O
intervención O
. O

Los B-Premise
pacientes I-Premise
adultos I-Premise
mayores I-Premise
informaron I-Premise
de I-Premise
una I-Premise
mejor I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
general I-Premise
( I-Premise
LASA I-Premise
74,4 I-Premise
frente I-Premise
a I-Premise
62,9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,040 I-Premise
) I-Premise
, I-Premise
un I-Premise
mayor I-Premise
bienestar I-Premise
social I-Premise
( I-Premise
FACT-G I-Premise
91,1 I-Premise
frente I-Premise
a I-Premise
83,3 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,045 I-Premise
) I-Premise
, I-Premise
y I-Premise
menos I-Premise
problemas I-Premise
de I-Premise
ira I-Premise
( I-Premise
POMS I-Premise
ira-hostilidad I-Premise
95,0 I-Premise
frente I-Premise
a I-Premise
86,4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,028 I-Premise
) I-Premise
. I-Premise

Se B-Premise
observaron I-Premise
beneficios I-Premise
a I-Premise
largo I-Premise
plazo I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
más I-Premise
edad I-Premise
en I-Premise
la I-Premise
escala I-Premise
de I-Premise
ira-hostilidad I-Premise
en I-Premise
la I-Premise
semana I-Premise
27 I-Premise
( I-Premise
92,2 I-Premise
frente I-Premise
a I-Premise
84,2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,027 I-Premise
) I-Premise
y I-Premise
en I-Premise
la I-Premise
semana I-Premise
52 I-Premise
( I-Premise
96,3 I-Premise
frente I-Premise
a I-Premise
85,9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,005 I-Premise
) I-Premise
. I-Premise

Los B-Claim
pacientes I-Claim
adultos I-Claim
mayores I-Claim
que I-Claim
recibieron I-Claim
una I-Claim
intervención I-Claim
multidisciplinaria I-Claim
para I-Claim
mejorar I-Claim
la I-Claim
CdV I-Claim
mientras I-Claim
se I-Claim
sometían I-Claim
a I-Claim
tratamientos I-Claim
de I-Claim
cáncer I-Claim
avanzado I-Claim
se I-Claim
beneficiaron I-Claim
de I-Claim
manera I-Claim
diferente I-Claim
en I-Claim
algunos I-Claim
dominios I-Claim
de I-Claim
la I-Claim
CdV I-Claim
, I-Claim
en I-Claim
comparación I-Claim
con I-Claim
los I-Claim
pacientes I-Claim
adultos I-Claim
más I-Claim
jóvenes I-Claim
. I-Claim

Los O
estudios O
futuros O
pueden O
aportar O
más O
información O
sobre O
cómo O
adaptar O
las O
intervenciones O
de O
calidad O
de O
vida O
a O
estos O
grupos O
de O
edad. O

El O
objetivo O
de O
este O
estudio O
es O
explorar O
el O
efecto O
de O
modulación O
inflamatoria O
de O
la O
nutrición O
parenteral O
total O
(NPT) O
enriquecida O
con O
glutamina O
mediante O
la O
investigación O
de O
las O
alteraciones O
de O
las O
citoquinas O
relacionadas O
con O
la O
inflamación O
en O
pacientes O
con O
cáncer O
gastrointestinal O
(GI) O
en O
el O
postoperatorio. O

Cincuenta O
pacientes O
con O
cáncer O
gastrointestinal O
recibieron O
7 O
días O
de O
NPT O
isocalórica O
e O
isonitrogenada O
después O
de O
la O
operación. O

Se O
dividieron O
aleatoriamente O
para O
recibir O
NPT O
enriquecida O
con O
glutamina O
o O
NPT O
estándar. O

También O
se O
determinaron O
las O
citocinas O
relacionadas O
con O
la O
inflamación, O
como O
la O
interleucina-6 O
, O
la O
interleucina-10 O
y O
el O
factor O
de O
necrosis O
tumoral-α O
. O

Se O
compararon O
los O
registros O
de O
las O
evaluaciones O
nutricionales, O
el O
estado O
inflamatorio O
y O
las O
complicaciones O
postoperatorias O
entre O
los O
dos O
grupos. O

De O
los O
50 O
pacientes O
inscritos, O
25 O
se O
clasificaron O
como O
grupo O
de O
intervención, O
y O
el O
grupo O
de O
control O
también O
estaba O
formado O
por O
25 O
pacientes. O

Las O
diferencias O
de O
género, O
edad, O
neoplasias O
gastrointestinales O
primarias O
y O
datos O
hematológicos O
y O
bioquímicos O
entre O
los O
dos O
grupos O
comparados O
no O
fueron O
estadísticamente O
significativas O
( O
todas O
P O
> O
0,05 O
) O
. O

En B-Premise
comparación I-Premise
con I-Premise
la I-Premise
NPT I-Premise
estándar, I-Premise
se I-Premise
observó I-Premise
un I-Premise
mayor I-Premise
nivel I-Premise
de I-Premise
prealbúmina I-Premise
sérica I-Premise
y I-Premise
un I-Premise
mejor I-Premise
balance I-Premise
de I-Premise
nitrógeno I-Premise
en I-Premise
la I-Premise
NPT I-Premise
enriquecida I-Premise
con I-Premise
glutamina I-Premise
( I-Premise
P I-Premise
= I-Premise
0,039 I-Premise
y I-Premise
0,048 I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Se B-Premise
encontró I-Premise
un I-Premise
nivel I-Premise
de I-Premise
interleucina-6 I-Premise
en I-Premise
suero I-Premise
significativamente I-Premise
menor I-Premise
al I-Premise
comparar I-Premise
la I-Premise
NPT I-Premise
enriquecida I-Premise
con I-Premise
glutamina I-Premise
con I-Premise
la I-Premise
estándar I-Premise
( I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
) O
, O
pero B-Premise
no I-Premise
en I-Premise
los I-Premise
niveles I-Premise
de I-Premise
interleucina-10 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,374 I-Premise
) I-Premise
y I-Premise
factor I-Premise
de I-Premise
necrosis I-Premise
tumoral-α I-Premise
( I-Premise
P I-Premise
= I-Premise
0,653 I-Premise
) O
. O

Además, O
se O
detectó B-Premise
un I-Premise
nivel I-Premise
significativamente I-Premise
menor I-Premise
de I-Premise
proteína I-Premise
C I-Premise
reactiva I-Premise
en I-Premise
suero I-Premise
en I-Premise
la I-Premise
NPT I-Premise
enriquecida I-Premise
con I-Premise
glutamina I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
NPT I-Premise
estándar I-Premise
( I-Premise
P I-Premise
= I-Premise
0,013 I-Premise
) O
. O

De O
hecho, O
se B-Premise
observaron I-Premise
cuatro I-Premise
casos I-Premise
de I-Premise
complicaciones I-Premise
infecciosas I-Premise
postoperatorias I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
pero I-Premise
no I-Premise
se I-Premise
observaron I-Premise
complicaciones I-Premise
infecciosas I-Premise
postoperatorias I-Premise
en I-Premise
el I-Premise
grupo I-Premise
intervenido I-Premise
( I-Premise
P I-Premise
= I-Premise
0,037 I-Premise
) O
. O

Nuestro B-Claim
presente I-Claim
estudio I-Claim
muestra I-Claim
que I-Claim
la I-Claim
NPT I-Claim
enriquecida I-Claim
con I-Claim
glutamina I-Claim
puede I-Claim
ser I-Claim
beneficiosa I-Claim
para I-Claim
mejorar I-Claim
el I-Claim
estado I-Claim
inflamatorio I-Claim
y I-Claim
disminuir I-Claim
la I-Claim
morbilidad I-Claim
infecciosa I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
gastrointestinal I-Claim
postoperatorio. I-Claim

Este O
estudio O
se O
diseñó O
para O
evaluar O
el O
impacto O
de O
la O
resección O
rectal O
laparoscópica O
en O
la O
morbilidad O
y O
los O
costes O
postoperatorios O
a O
corto O
plazo. O

Un O
total O
de O
168 O
pacientes O
con O
cáncer O
de O
recto O
fueron O
asignados O
aleatoriamente O
a O
la O
resección O
laparoscópica O
( O
n O
= O
83 O
) O
o O
abierta O
( O
n O
= O
85 O
) O
. O

Los O
parámetros O
de O
resultado O
fueron: O
morbilidad O
postoperatoria, O
duración O
de O
la O
estancia O
hospitalaria, O
calidad O
de O
vida, O
supervivencia O
a O
largo O
plazo O
y O
recidivas O
locales. O

El O
periodo O
medio O
de O
seguimiento O
fue O
de O
53,6 O
meses. O

El O
análisis O
coste-beneficio O
se O
basó O
en O
los O
costes O
hospitalarios O
. O

El B-Premise
tiempo I-Premise
operatorio I-Premise
fue I-Premise
53 I-Premise
minutos I-Premise
más I-Premise
largo I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
laparoscopia I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
morbilidad I-Premise
postoperatoria I-Premise
fue I-Premise
del I-Premise
28,9% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
laparoscópico I-Premise
frente I-Premise
al I-Premise
40% I-Premise
en I-Premise
el I-Premise
grupo I-Premise
abierto I-Premise
( I-Premise
P I-Premise
= I-Premise
0,18 I-Premise
) I-Premise
. I-Premise

La B-Premise
duración I-Premise
media I-Premise
de I-Premise
la I-Premise
estancia I-Premise
hospitalaria I-Premise
fue I-Premise
de I-Premise
10 I-Premise
( I-Premise
4,9 I-Premise
) I-Premise
días I-Premise
en I-Premise
el I-Premise
grupo I-Premise
laparoscópico I-Premise
y I-Premise
de I-Premise
13,6 I-Premise
( I-Premise
10 I-Premise
) I-Premise
días I-Premise
en I-Premise
el I-Premise
grupo I-Premise
abierto I-Premise
( I-Premise
P I-Premise
= I-Premise
0,004 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
recidiva I-Premise
local I-Premise
y I-Premise
la I-Premise
supervivencia I-Premise
a I-Premise
cinco I-Premise
años I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
ambos I-Premise
grupos; I-Premise
sin B-Claim
embargo, I-Claim
el I-Claim
limitado I-Claim
número I-Claim
de I-Claim
pacientes I-Claim
no I-Claim
permite I-Claim
extraer I-Claim
conclusiones I-Claim
firmes. I-Claim

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fue I-Premise
mejor I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
laparoscopia I-Premise
sólo I-Premise
en I-Premise
el I-Premise
primer I-Premise
año I-Premise
después I-Premise
de I-Premise
la I-Premise
cirugía I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
. I-Premise

El B-Premise
coste I-Premise
adicional I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
laparoscopia I-Premise
fue I-Premise
de I-Premise
1.748 I-Premise
dólares I-Premise
por I-Premise
paciente I-Premise
aleatorizado I-Premise
(1.194 I-Premise
dólares I-Premise
por I-Premise
el I-Premise
instrumental I-Premise
quirúrgico I-Premise
y I-Premise
554 I-Premise
dólares I-Premise
por I-Premise
el I-Premise
mayor I-Premise
tiempo I-Premise
de I-Premise
la I-Premise
operación). I-Premise

El B-Premise
ahorro I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
laparoscopia I-Premise
fue I-Premise
de I-Premise
1.396 I-Premise
dólares I-Premise
por I-Premise
paciente I-Premise
aleatorizado I-Premise
(647 I-Premise
dólares I-Premise
por I-Premise
la I-Premise
menor I-Premise
duración I-Premise
de I-Premise
la I-Premise
estancia I-Premise
hospitalaria I-Premise
y I-Premise
749 I-Premise
dólares I-Premise
por I-Premise
el I-Premise
menor I-Premise
coste I-Premise
de I-Premise
las I-Premise
complicaciones I-Premise
postoperatorias). I-Premise

El B-Premise
balance I-Premise
neto I-Premise
supuso I-Premise
un I-Premise
coste I-Premise
adicional I-Premise
de I-Premise
351 I-Premise
dólares I-Premise
por I-Premise
paciente I-Premise
asignado I-Premise
aleatoriamente I-Premise
al I-Premise
grupo I-Premise
de I-Premise
laparoscopia. I-Premise

La B-Claim
morbilidad I-Claim
postoperatoria I-Claim
a I-Claim
corto I-Claim
plazo I-Claim
fue I-Claim
similar I-Claim
en I-Claim
los I-Claim
dos I-Claim
grupos. I-Claim

La B-Claim
resección I-Claim
laparoscópica I-Claim
redujo I-Claim
la I-Claim
duración I-Claim
de I-Claim
la I-Claim
estancia I-Claim
hospitalaria I-Claim
, I-Claim
mejoró I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
el I-Claim
primer I-Claim
año I-Claim
y I-Claim
aumentó I-Claim
ligeramente I-Claim
los I-Claim
costes I-Claim
hospitalarios I-Claim
. I-Claim

El O
objetivo O
de O
este O
estudio O
fue O
investigar O
si O
la O
alimentación O
enteral O
y O
parenteral O
de O
apoyo O
especializada O
tiene O
efectos O
superiores O
en O
comparación O
con O
la O
nutrición O
oral O
en O
la O
recuperación O
durante O
el O
tratamiento O
postoperatorio O
a O
largo O
plazo O
de O
pacientes O
con O
cáncer O
con O
pérdida O
de O
peso O
preoperatoria O
y O
capacidad O
de O
ejercicio O
máxima O
reducida O
. O

Ciento O
veintiséis O
pacientes O
remitidos O
para O
la O
resección O
del O
esófago O
( O
n O
= O
48 O
) O
, O
el O
estómago O
( O
n O
= O
28 O
) O
o O
el O
páncreas O
( O
n O
= O
50 O
) O
se O
consideraron O
incluidos O
antes O
de O
la O
operación O
. O

Los O
pacientes O
incluidos O
( O
n O
= O
80 O
) O
recibieron O
nutrición O
enteral O
o O
parenteral O
de O
apoyo O
en O
su O
domicilio O
correspondiente O
a O
1000 O
kcal/d O
hasta O
que O
los O
pacientes O
no O
desearon O
continuar O
con O
la O
nutrición O
artificial O
por O
cualquier O
motivo O
. O

Los O
pacientes O
asignados O
al O
azar O
a O
la O
nutrición O
oral O
solamente O
sirvieron O
como O
sujetos O
de O
control O
. O

Se O
midieron O
la O
ingesta O
calórica O
, O
la O
composición O
corporal O
( O
absorciometría O
de O
rayos O
X O
de O
doble O
energía O
) O
y O
los O
intercambios O
de O
gases O
respiratorios O
en O
reposo O
y O
durante O
el O
ejercicio, O
incluyendo O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
. O

La B-Premise
supervivencia I-Premise
y I-Premise
la I-Premise
estancia I-Premise
hospitalaria I-Premise
no I-Premise
difirieron I-Premise
entre I-Premise
los I-Premise
grupos, I-Premise
mientras I-Premise
que I-Premise
las I-Premise
complicaciones I-Premise
generales I-Premise
fueron I-Premise
mayores I-Premise
con I-Premise
la I-Premise
nutrición I-Premise
artificial I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Los B-Premise
cambios I-Premise
en I-Premise
el I-Premise
gasto I-Premise
energético I-Premise
en I-Premise
reposo I-Premise
y I-Premise
las I-Premise
pruebas I-Premise
bioquímicas I-Premise
no I-Premise
difirieron I-Premise
durante I-Premise
el I-Premise
seguimiento I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
. I-Premise

El O
peso B-Premise
corporal I-Premise
y I-Premise
la I-Premise
grasa I-Premise
corporal I-Premise
total I-Premise
disminuyeron I-Premise
de I-Premise
forma I-Premise
similar I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
en I-Premise
todos I-Premise
los I-Premise
grupos I-Premise
( I-Premise
P I-Premise
< I-Premise
0,005 I-Premise
) O
, O
mientras O
que O
la O
masa B-Premise
corporal I-Premise
magra I-Premise
no I-Premise
se I-Premise
modificó I-Premise
durante I-Premise
el I-Premise
seguimiento I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
valores I-Premise
preoperatorios I-Premise
. O

La B-Premise
capacidad I-Premise
máxima I-Premise
de I-Premise
ejercicio I-Premise
y I-Premise
el I-Premise
consumo I-Premise
máximo I-Premise
de I-Premise
oxígeno I-Premise
se I-Premise
normalizaron I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
del I-Premise
postoperatorio I-Premise
en I-Premise
todos I-Premise
los I-Premise
grupos. I-Premise

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
recuperación I-Premise
de I-Premise
la I-Premise
ingesta I-Premise
de I-Premise
alimentos I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
. I-Premise

La B-Claim
alimentación I-Claim
parenteral I-Claim
se I-Claim
asoció I-Claim
con I-Claim
la I-Claim
tasa I-Claim
más I-Claim
alta I-Claim
de I-Claim
complicaciones I-Claim
relacionadas I-Claim
con I-Claim
la I-Claim
nutrición I-Claim
, I-Claim
mientras I-Claim
que I-Claim
la I-Claim
alimentación I-Claim
enteral I-Claim
redujo I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
mayor I-Claim
medida I-Claim
. O

Después B-Claim
de I-Claim
una I-Claim
intervención I-Claim
quirúrgica I-Claim
mayor, I-Claim
la I-Claim
nutrición I-Claim
enteral I-Claim
y I-Claim
parenteral I-Claim
de I-Claim
apoyo I-Claim
especializada I-Claim
no I-Claim
es I-Claim
superior I-Claim
a I-Claim
la I-Claim
nutrición I-Claim
oral I-Claim
sólo I-Claim
cuando I-Claim
está I-Claim
guiada I-Claim
por I-Claim
un I-Claim
dietista. I-Claim

Analizar O
y O
comparar O
la O
expansión O
pulmonar O
radiológica O
tras O
la O
pleurodesis O
con O
talco O
realizada O
por O
videotoracoscopia O
o O
por O
tubo O
torácico O
y O
correlacionarla O
con O
el O
resultado O
clínico. O

Los O
criterios O
de O
valoración O
secundarios O
evaluados O
fueron O
los O
siguientes: O
eficacia O
clínica, O
calidad O
de O
vida, O
seguridad O
y O
supervivencia. O

Estudio O
prospectivo O
aleatorio O
que O
incluyó O
a O
60 O
pacientes O
( O
45 O
mujeres O
, O
15 O
hombres O
; O
edad O
media O
, O
55,2 O
años O
) O
con O
derrame O
pleural O
maligno O
recurrente O
entre O
enero O
de O
2005 O
y O
enero O
de O
2008 O
. O

Se O
distribuyeron O
aleatoriamente O
en O
los O
dos O
grupos O
siguientes: O
cirugía O
torácica O
asistida O
por O
vídeo O
(VATS) O
y O
lodo O
de O
talco O
(TS) O
administrado O
a O
través O
de O
un O
tubo O
torácico. O

La O
expansión O
pulmonar O
se O
evaluó O
mediante O
TC O
de O
tórax O
obtenida O
0 O
, O
1 O
, O
3 O
y O
6 O
meses O
después O
de O
la O
pleurodesis O
. O

También O
se O
analizaron O
las O
complicaciones, O
el O
tiempo O
de O
drenaje, O
la O
estancia O
hospitalaria O
y O
la O
calidad O
de O
vida O
(cuestionarios O
de O
calidad O
de O
vida O
de O
la O
Organización O
Mundial O
de O
la O
Salud O
y O
del O
Medical O
Outcomes O
Study O
36). O

No O
hubo O
diferencias O
significativas O
en O
las O
variables O
clínicas O
y O
patológicas O
previas O
al O
procedimiento O
entre O
los O
grupos O
. O

La O
expansión O
pulmonar O
total O
inmediata O
( O
es O
decir, O
> O
90 O
% O
) O
se O
observó O
en O
27 O
pacientes O
( O
45 O
% O
) O
y O
fue O
más O
frecuente O
en O
el O
grupo O
de O
VATS O
( O
60 O
% O
frente O
a O
30 O
% O
, O
respectivamente O
; O
p O
= O
0,027 O
) O
. O

Durante B-Premise
el I-Premise
seguimiento, I-Premise
el I-Premise
71% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
mostraron I-Premise
una I-Premise
expansión I-Premise
pulmonar I-Premise
inalterada I-Premise
o I-Premise
mejorada I-Premise
y I-Premise
9 I-Premise
pacientes I-Premise
( I-Premise
15% I-Premise
) I-Premise
necesitaron I-Premise
nuevos I-Premise
procedimientos I-Premise
pleurales I-Premise
( I-Premise
grupo I-Premise
VATS I-Premise
, I-Premise
5 I-Premise
recidivas I-Premise
; I-Premise
grupo I-Premise
TS I-Premise
, I-Premise
4 I-Premise
recidivas I-Premise
; I-Premise
p I-Premise
= I-Premise
0,999 I-Premise
) I-Premise
. I-Premise

No B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
cuanto I-Premise
a I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
complicaciones, I-Premise
tiempo I-Premise
de I-Premise
drenaje, I-Premise
estancia I-Premise
hospitalaria I-Premise
y I-Premise
supervivencia. I-Premise

La B-Premise
expansión I-Premise
pulmonar I-Premise
inmediata I-Premise
no I-Premise
se I-Premise
correlacionó I-Premise
con I-Premise
la I-Premise
recidiva I-Premise
radiológica I-Premise
, I-Premise
la I-Premise
recidiva I-Premise
clínica I-Premise
o I-Premise
las I-Premise
complicaciones I-Premise
( I-Premise
p I-Premise
= I-Premise
0,60 I-Premise
, I-Premise
0,15 I-Premise
y I-Premise
0,20 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

La B-Premise
expansión I-Premise
pulmonar I-Premise
parcial I-Premise
inmediata I-Premise
fue I-Premise
un I-Premise
hallazgo I-Premise
frecuente I-Premise
y I-Premise
fue I-Premise
más I-Premise
frecuente I-Premise
después I-Premise
de I-Premise
la I-Premise
ST I-Premise
. I-Premise

No O
obstante, O
en B-Claim
este I-Claim
estudio I-Claim
no I-Claim
se I-Claim
encontró I-Claim
ninguna I-Claim
correlación I-Claim
entre I-Claim
la I-Claim
expansión I-Claim
pulmonar I-Claim
inmediata I-Claim
y I-Claim
el I-Claim
resultado I-Claim
clínico. I-Claim

Las B-Claim
intervenciones I-Claim
psicológicas I-Claim
son I-Claim
eficaces I-Claim
para I-Claim
reducir I-Claim
el I-Claim
malestar I-Claim
emocional I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer. I-Claim

Sin B-Claim
embargo, I-Claim
no I-Claim
está I-Claim
claro I-Claim
si I-Claim
las I-Claim
mejoras I-Claim
psicológicas I-Claim
están, I-Claim
a I-Claim
su I-Claim
vez, I-Claim
relacionadas I-Claim
con I-Claim
la I-Claim
mejora I-Claim
de I-Claim
la I-Claim
salud. I-Claim

Un O
ensayo O
clínico O
comprueba O
si O
una O
intervención O
psicológica O
para O
pacientes O
con O
cáncer O
puede O
hacerlo, O
y O
también O
pone O
a O
prueba O
dos O
vías O
para O
lograr O
una O
mejor O
salud: O
( O
a O
) O
reducir O
la O
angustia O
emocional O
de O
los O
pacientes O
, O
y/o O
( O
b O
) O
mejorar O
su O
inmunidad O
funcional O
. O

Después O
de O
la O
cirugía, O
227 O
pacientes O
con O
cáncer O
de O
mama O
fueron O
asignadas O
al O
azar O
a O
la O
intervención O
o O
a O
la O
evaluación O
solamente. O

Las O
sesiones O
de O
intervención, O
realizadas O
en O
grupos O
reducidos, O
se O
ofrecieron O
semanalmente O
durante O
4 O
meses O
y, O
a O
continuación, O
se O
realizaron O
sesiones O
mensuales O
durante O
8 O
meses. O

Las O
medidas O
incluyeron O
resultados O
psicológicos O
( O
angustia O
) O
, O
biológicos O
( O
inmunológicos O
) O
y O
de O
salud O
( O
estado O
de O
rendimiento O
y O
evaluaciones O
de O
la O
sintomatología O
del O
paciente O
, O
incluyendo O
la O
toxicidad O
del O
tratamiento O
del O
cáncer O
, O
los O
valores O
de O
laboratorio O
) O
recogidos O
en O
la O
línea O
de O
base O
, O
4 O
meses O
y O
12 O
meses O
. O

Un B-Premise
modelo I-Premise
de I-Premise
trayectoria I-Premise
reveló I-Premise
que I-Premise
la I-Premise
participación I-Premise
en I-Premise
la I-Premise
intervención I-Premise
mejoró I-Premise
directamente I-Premise
la I-Premise
salud I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
. I-Premise

Estos B-Premise
efectos I-Premise
se I-Premise
mantuvieron I-Premise
cuando I-Premise
se I-Premise
controlaron I-Premise
estadísticamente I-Premise
los I-Premise
niveles I-Premise
iniciales I-Premise
de I-Premise
angustia, I-Premise
inmunidad I-Premise
y I-Premise
salud, I-Premise
así I-Premise
como I-Premise
las I-Premise
variables I-Premise
sociodemográficas, I-Premise
de I-Premise
enfermedad I-Premise
y I-Premise
de I-Premise
tratamiento I-Premise
del I-Premise
cáncer. I-Premise

En B-Premise
cuanto I-Premise
a I-Premise
los I-Premise
mecanismos I-Premise
para I-Premise
lograr I-Premise
una I-Premise
mejor I-Premise
salud I-Premise
, I-Premise
se I-Premise
encontró I-Premise
apoyo I-Premise
a I-Premise
un I-Premise
efecto I-Premise
indirecto I-Premise
de I-Premise
reducción I-Premise
de I-Premise
la I-Premise
angustia I-Premise
. I-Premise

Es B-Premise
decir, I-Premise
al I-Premise
disminuir I-Premise
específicamente I-Premise
la I-Premise
angustia I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
a I-Premise
los I-Premise
4 I-Premise
meses, I-Premise
su I-Premise
salud I-Premise
mejoró I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Aunque B-Premise
la I-Premise
intervención I-Premise
mejoró I-Premise
simultáneamente I-Premise
la I-Premise
blastogénesis I-Premise
de I-Premise
células I-Premise
T I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
en I-Premise
respuesta I-Premise
a I-Premise
la I-Premise
fitohemaglutinina I-Premise
( I-Premise
PHA I-Premise
) O
, O
estos B-Premise
últimos I-Premise
aumentos I-Premise
no I-Premise
estaban I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
mejora I-Premise
de I-Premise
la I-Premise
salud I-Premise
. O

Se B-Premise
observó I-Premise
una I-Premise
convergencia I-Premise
de I-Premise
efectos I-Premise
bioconductuales I-Premise
y I-Premise
mejoras I-Premise
en I-Premise
la I-Premise
salud. I-Premise

El B-Claim
cambio I-Claim
de I-Claim
comportamiento I-Claim
, I-Claim
más I-Claim
que I-Claim
el I-Claim
cambio I-Claim
de I-Claim
inmunidad I-Claim
, I-Claim
fue I-Claim
influyente I-Claim
en I-Claim
la I-Claim
consecución I-Claim
de I-Claim
menores I-Claim
niveles I-Claim
de I-Claim
sintomatología I-Claim
y I-Claim
mayor I-Claim
estado I-Claim
funcional I-Claim
. I-Claim

La B-Claim
reducción I-Claim
de I-Claim
la I-Claim
angustia I-Claim
se I-Claim
destaca I-Claim
como I-Claim
un I-Claim
mecanismo I-Claim
importante I-Claim
para I-Claim
mejorar I-Claim
la I-Claim
salud. I-Claim

Comparar O
directamente O
el O
efecto O
de O
la O
radioterapia O
de O
intensidad O
modulada O
( O
IMRT O
) O
frente O
a O
la O
radioterapia O
convencional O
( O
CRT O
) O
sobre O
el O
flujo O
salival O
y O
la O
calidad O
de O
vida O
( O
QoL O
) O
en O
pacientes O
con O
carcinoma O
nasofaríngeo O
( O
NPC O
) O
en O
fase O
inicial O
. O

Cincuenta O
y O
un O
pacientes O
con O
CPN O
T2 O
, O
N0/N1 O
, O
M0 O
participaron O
en O
un O
estudio O
clínico O
controlado O
aleatorio O
y O
recibieron O
IMRT O
o O
CRT O
. O

Se O
midió O
el O
flujo O
de O
saliva O
estimulada O
entera O
( O
SWS O
) O
y O
parótida O
( O
SPS O
) O
y O
se O
completó O
el O
formulario O
corto O
de O
resultados O
médicos O
36 O
( O
SF-36 O
) O
, O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC O
) O
core O
quetionnaire O
, O
y O
el O
módulo O
de O
cabeza O
y O
cuello O
de O
la O
EORTC O
( O
QLQ-H O
& O
amp O
; O
N35 O
) O
en O
la O
línea O
de O
base O
y O
2 O
, O
6 O
y O
12 O
meses O
después O
de O
la O
radioterapia O
. O

Cuarenta B-Premise
y I-Premise
seis I-Premise
pacientes I-Premise
( I-Premise
88% I-Premise
) I-Premise
estaban I-Premise
en I-Premise
remisión I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
12 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
radioterapia I-Premise
. I-Premise

A B-Premise
los I-Premise
12 I-Premise
meses I-Premise
después I-Premise
de I-Premise
la I-Premise
radioterapia, I-Premise
12 I-Premise
( I-Premise
50,0 I-Premise
% I-Premise
) I-Premise
y I-Premise
20 I-Premise
pacientes I-Premise
( I-Premise
83,3 I-Premise
% I-Premise
) I-Premise
del I-Premise
grupo I-Premise
de I-Premise
IMRT I-Premise
habían I-Premise
recuperado I-Premise
al I-Premise
menos I-Premise
el I-Premise
25 I-Premise
% I-Premise
del I-Premise
flujo I-Premise
de I-Premise
SWS I-Premise
y I-Premise
SPS I-Premise
anterior I-Premise
a I-Premise
la I-Premise
radioterapia, I-Premise
respectivamente, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
1 I-Premise
( I-Premise
4,8 I-Premise
% I-Premise
) I-Premise
y I-Premise
2 I-Premise
pacientes I-Premise
( I-Premise
9,5 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectivamente, I-Premise
del I-Premise
grupo I-Premise
de I-Premise
CRT I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
salud I-Premise
global I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
continua I-Premise
de I-Premise
la I-Premise
CdV I-Premise
después I-Premise
de I-Premise
ambos I-Premise
tratamientos I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Sin B-Premise
embargo I-Premise
, I-Premise
después I-Premise
de I-Premise
12 I-Premise
meses I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
las I-Premise
subescalas I-Premise
de I-Premise
rol-físico I-Premise
, I-Premise
dolor I-Premise
corporal I-Premise
y I-Premise
función I-Premise
física I-Premise
fueron I-Premise
significativamente I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
IMRT I-Premise
, I-Premise
indicando I-Premise
un I-Premise
mejor I-Premise
estado I-Premise
( I-Premise
p I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

La B-Premise
sequedad I-Premise
de I-Premise
boca I-Premise
y I-Premise
la I-Premise
saliva I-Premise
pegajosa I-Premise
fueron I-Premise
problemas I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
2 I-Premise
meses I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
IMRT I-Premise
, I-Premise
hubo I-Premise
una I-Premise
mejora I-Premise
consistente I-Premise
a I-Premise
lo I-Premise
largo I-Premise
del I-Premise
tiempo I-Premise
con I-Premise
síntomas I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
xerostomía I-Premise
significativamente I-Premise
menos I-Premise
comunes I-Premise
que I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
CRT I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
postradioterapia I-Premise
. I-Premise

La B-Claim
IMRT I-Claim
fue I-Claim
significativamente I-Claim
mejor I-Claim
que I-Claim
la I-Claim
CRT I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
preservación I-Claim
de I-Claim
la I-Claim
parótida I-Claim
y I-Claim
la I-Claim
mejora I-Claim
de I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
en I-Claim
la I-Claim
enfermedad I-Claim
en I-Claim
fase I-Claim
inicial. I-Claim

Los B-Claim
resultados I-Claim
apoyan I-Claim
la I-Claim
necesidad I-Claim
de I-Claim
evaluar I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
relacionada I-Claim
con I-Claim
la I-Claim
salud I-Claim
en I-Claim
relación I-Claim
con I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
cabeza I-Claim
y I-Claim
cuello I-Claim
utilizando I-Claim
un I-Claim
enfoque I-Claim
específico I-Claim
para I-Claim
cada O
lugar. O

El O
espectacular O
aumento O
de O
la O
incidencia, O
el O
envejecimiento O
de O
la O
población O
y O
los O
costosos O
tratamientos O
paliativos O
han O
provocado O
un O
aumento O
de O
la O
carga O
de O
trabajo O
de O
los O
médicos O
que O
tratan O
el O
cáncer O
de O
esófago O
inoperable O
con O
una O
evidencia O
limitada O
de O
su O
eficacia. O

Este O
estudio O
compara O
la O
eficacia O
clínica O
y O
la O
rentabilidad O
de O
las O
endoprótesis O
metálicas O
autoexpandibles O
(SEMS) O
con O
otras O
terapias O
paliativas O
para O
ayudar O
a O
los O
médicos O
a O
elegir O
un O
tratamiento O
basado O
en O
la O
evidencia. O

Se O
realizó O
un O
ensayo O
clínico O
prospectivo, O
multicéntrico, O
aleatorizado O
y O
controlado O
con O
215 O
pacientes O
a O
los O
que O
se O
les O
hizo O
un O
seguimiento O
hasta O
la O
muerte O
o O
el O
cierre O
del O
estudio. O

Las O
medidas O
de O
resultado O
primarias O
fueron O
la O
disfagia O
, O
la O
calidad O
de O
vida O
( O
QL O
) O
6 O
semanas O
después O
del O
tratamiento O
, O
y O
el O
coste O
total O
del O
tratamiento O
. O

Las O
medidas O
de O
resultado O
secundarias O
incluyeron O
la O
morbilidad O
asociada O
al O
tratamiento, O
la O
mortalidad, O
la O
supervivencia O
y O
la O
rentabilidad. O

Se O
realizó O
un O
análisis O
por O
intención O
de O
tratar. O

Hubo B-Premise
una I-Premise
diferencia I-Premise
significativa I-Premise
en I-Premise
el I-Premise
grado I-Premise
medio I-Premise
de I-Premise
disfagia I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
6 I-Premise
semanas I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
P=0,046 I-Premise
) I-Premise
, I-Premise
con I-Premise
una I-Premise
peor I-Premise
deglución I-Premise
reportada I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
stent I-Premise
rígido I-Premise
( I-Premise
diferencia I-Premise
de I-Premise
puntuación I-Premise
media I-Premise
de I-Premise
disfagia=-0,49 I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
( I-Premise
IC I-Premise
) I-Premise
del I-Premise
95 I-Premise
% I-Premise
-0,10 I-Premise
a I-Premise
-0,89 I-Premise
, I-Premise
P=0,014 I-Premise
) I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
CV I-Premise
global I-Premise
fueron I-Premise
inferiores I-Premise
tanto I-Premise
a I-Premise
la I-Premise
primera I-Premise
como I-Premise
a I-Premise
la I-Premise
sexta I-Premise
semana I-Premise
después I-Premise
del I-Premise
tratamiento I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
SEMS I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
del I-Premise
índice I-Premise
de I-Premise
CV I-Premise
de I-Premise
la I-Premise
semana I-Premise
1=-0,66 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
: I-Premise
-0,02 I-Premise
a I-Premise
-1,30 I-Premise
, I-Premise
P=0,04 I-Premise
; I-Premise
diferencia I-Premise
media I-Premise
del I-Premise
índice I-Premise
de I-Premise
CV I-Premise
de I-Premise
la I-Premise
semana I-Premise
6=-1,01 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
-0,30 I-Premise
a I-Premise
-1,72 I-Premise
, I-Premise
P=0,006 I-Premise
) I-Premise
. I-Premise

Estos B-Premise
resultados I-Premise
se I-Premise
asociaron I-Premise
a I-Premise
puntuaciones I-Premise
de I-Premise
dolor I-Premise
más I-Premise
altas I-Premise
tras I-Premise
el I-Premise
procedimiento I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
SEMS I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
de I-Premise
dolor I-Premise
del I-Premise
QLQ I-Premise
C-30 I-Premise
de I-Premise
la I-Premise
Organización I-Premise
Europea I-Premise
para I-Premise
la I-Premise
Investigación I-Premise
y I-Premise
el I-Premise
Tratamiento I-Premise
del I-Premise
Cáncer I-Premise
en I-Premise
la I-Premise
semana I-Premise
1=11,13 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
: I-Premise
2,89-19,4 I-Premise
; I-Premise
P=0,01 I-Premise
) I-Premise
. I-Premise

Aunque B-Premise
los I-Premise
valores I-Premise
medios I-Premise
de I-Premise
la I-Premise
CV I-Premise
EQ-5D I-Premise
diferían I-Premise
entre I-Premise
los I-Premise
tratamientos I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
esta I-Premise
diferencia I-Premise
se I-Premise
disipó I-Premise
tras I-Premise
la I-Premise
generación I-Premise
de I-Premise
los I-Premise
valores I-Premise
de I-Premise
los I-Premise
años I-Premise
de I-Premise
vida I-Premise
ajustados I-Premise
por I-Premise
calidad I-Premise
. I-Premise

Los O
costes O
totales O
variaron O
entre O
los O
distintos O
brazos O
de O
tratamiento, O
pero O
estos O
resultados O
se O
anularon O
cuando O
se O
compararon O
las O
terapias O
con O
SEMS O
con O
las O
que O
no O
lo O
son O
( O
IC O
del O
95 O
%: O
-845,15-1.332,62 O
) O
. O

Estos O
resultados O
fueron O
robustos O
al O
análisis O
de O
sensibilidad. O

No B-Premise
hubo I-Premise
diferencias I-Premise
en I-Premise
las I-Premise
tasas I-Premise
de I-Premise
mortalidad I-Premise
intrahospitalaria I-Premise
o I-Premise
de I-Premise
complicaciones I-Premise
tempranas, I-Premise
pero B-Premise
las I-Premise
complicaciones I-Premise
tardías I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
tras I-Premise
la I-Premise
colocación I-Premise
de I-Premise
un I-Premise
stent I-Premise
rígido I-Premise
( I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
= I-Premise
2,47; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
1,88-3,04 I-Premise
) O
. O

Hubo B-Premise
una I-Premise
ventaja I-Premise
de I-Premise
supervivencia I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
no I-Premise
tratados I-Premise
con I-Premise
stent I-Premise
( I-Premise
estadística I-Premise
log-rank=4,21 I-Premise
, I-Premise
P=0,04 I-Premise
) I-Premise
. I-Premise

La B-Claim
elección I-Claim
del I-Claim
tratamiento I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
esófago I-Claim
inoperable I-Claim
debe I-Claim
ser I-Claim
entre I-Claim
un I-Claim
tratamiento I-Claim
con I-Claim
SEMS I-Claim
o I-Claim
un I-Claim
tratamiento I-Claim
sin I-Claim
stent I-Claim
después I-Claim
de I-Claim
haber I-Claim
considerado I-Claim
tanto I-Claim
las I-Claim
características I-Claim
del I-Claim
paciente I-Claim
y I-Claim
del I-Claim
tumor I-Claim
como I-Claim
las I-Claim
preferencias I-Claim
del I-Claim
médico I-Claim
y I-Claim
del I-Claim
paciente I-Claim
. I-Claim

La B-Claim
eficacia I-Claim
y I-Claim
la I-Claim
seguridad I-Claim
de I-Claim
la I-Claim
embolización I-Claim
de I-Claim
la I-Claim
arteria I-Claim
uterina, I-Claim
en I-Claim
comparación I-Claim
con I-Claim
los I-Claim
métodos I-Claim
quirúrgicos I-Claim
estándar, I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
los I-Claim
miomas I-Claim
uterinos I-Claim
sintomáticos I-Claim
siguen I-Claim
siendo I-Claim
inciertas. I-Claim

Se O
realizó O
un O
ensayo O
aleatorio O
que O
comparaba O
la O
embolización O
de O
la O
arteria O
uterina O
y O
la O
cirugía O
en O
mujeres O
con O
miomas O
uterinos O
sintomáticos. O

El O
resultado O
primario O
fue O
la O
calidad O
de O
vida O
al O
año O
de O
seguimiento, O
medida O
por O
el O
Medical O
Outcomes O
Study O
36-Item O
Short-Form O
General O
Health O
Survey O
( O
SF-36 O
) O
. O

Las O
pacientes O
fueron O
asignadas O
al O
azar O
en O
una O
proporción O
de O
2:1 O
para O
someterse O
a O
la O
embolización O
de O
la O
arteria O
uterina O
o O
a O
la O
cirugía O
, O
con O
106 O
pacientes O
sometidas O
a O
la O
embolización O
y O
51 O
a O
la O
cirugía O
( O
43 O
histerectomías O
y O
8 O
miomectomías O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
en I-Premise
ninguno I-Premise
de I-Premise
los I-Premise
ocho I-Premise
componentes I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
del I-Premise
SF-36 I-Premise
al I-Premise
año. I-Premise

El B-Premise
grupo I-Premise
de I-Premise
embolización I-Premise
tuvo I-Premise
una I-Premise
mediana I-Premise
de I-Premise
hospitalización I-Premise
más I-Premise
corta I-Premise
que I-Premise
el I-Premise
grupo I-Premise
quirúrgico I-Premise
( I-Premise
1 I-Premise
día I-Premise
frente I-Premise
a I-Premise
5 I-Premise
días I-Premise
, I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
y I-Premise
un I-Premise
tiempo I-Premise
más I-Premise
corto I-Premise
antes I-Premise
de I-Premise
volver I-Premise
al I-Premise
trabajo I-Premise
( I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

Al B-Premise
año, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
eran I-Premise
mejores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
quirúrgico I-Premise
( I-Premise
P=0,03 I-Premise
) I-Premise
. I-Premise

Durante B-Premise
el I-Premise
primer I-Premise
año I-Premise
de I-Premise
seguimiento I-Premise
, I-Premise
hubo I-Premise
13 I-Premise
eventos I-Premise
adversos I-Premise
mayores I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
embolización I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
y I-Premise
10 I-Premise
en I-Premise
el I-Premise
grupo I-Premise
quirúrgico I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
( I-Premise
P=0,22 I-Premise
) I-Premise
, I-Premise
la I-Premise
mayoría I-Premise
relacionados I-Premise
con I-Premise
la I-Premise
intervención I-Premise
. I-Premise

Diez B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
embolización I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
necesitaron I-Premise
repetir I-Premise
la I-Premise
embolización I-Premise
o I-Premise
la I-Premise
histerectomía I-Premise
por I-Premise
un I-Premise
control I-Premise
inadecuado I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
. I-Premise

Tras B-Premise
el I-Premise
primer I-Premise
año I-Premise
de I-Premise
seguimiento, I-Premise
14 I-Premise
mujeres I-Premise
del I-Premise
grupo I-Premise
de I-Premise
embolización I-Premise
( I-Premise
13% I-Premise
) I-Premise
requirieron I-Premise
hospitalización, I-Premise
3 I-Premise
de I-Premise
ellas I-Premise
por I-Premise
eventos I-Premise
adversos I-Premise
mayores I-Premise
y I-Premise
11 I-Premise
por I-Premise
reintervención I-Premise
por I-Premise
fracaso I-Premise
del I-Premise
tratamiento I-Premise
. I-Premise

En B-Claim
las I-Claim
mujeres I-Claim
con I-Claim
miomas I-Claim
sintomáticos, I-Claim
la I-Claim
recuperación I-Claim
más I-Claim
rápida I-Claim
tras I-Claim
la I-Claim
embolización I-Claim
debe I-Claim
sopesarse I-Claim
con I-Claim
la I-Claim
necesidad I-Claim
de I-Claim
un I-Claim
tratamiento I-Claim
adicional I-Claim
en I-Claim
una I-Claim
minoría I-Claim
de I-Claim
pacientes. I-Claim

El O
dolor O
es O
uno O
de O
los O
síntomas O
más O
comunes O
que O
experimenta O
un O
paciente O
con O
cáncer. O

Un O
obstáculo O
importante O
para O
el O
tratamiento O
positivo O
del O
dolor O
son O
las O
ideas O
erróneas O
de O
los O
pacientes O
sobre O
los O
analgésicos O
y O
el O
uso O
inadecuado O
de O
estrategias O
no O
farmacológicas O
para O
aliviar O
el O
dolor. O

El O
propósito O
de O
este O
estudio O
fue O
investigar O
la O
efectividad O
de O
un O
programa O
de O
manejo O
del O
dolor O
( O
PMP O
) O
sobre O
la O
intensidad O
del O
dolor O
, O
el O
uso O
de O
medicamentos O
PRN O
y O
estrategias O
no O
farmacológicas O
como O
alivio O
del O
dolor O
, O
y O
las O
barreras O
para O
el O
manejo O
del O
dolor O
en O
pacientes O
con O
cáncer O
. O

El O
estudio O
se O
llevó O
a O
cabo O
en O
la O
sala O
de O
cuidados O
paliativos O
y O
cuidados O
paliativos O
de O
un O
hospital O
público O
de O
Hong O
Kong O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
un O
grupo O
experimental O
( O
que O
recibió O
el O
PMP O
) O
o O
a O
un O
grupo O
de O
control O
( O
atención O
rutinaria O
) O
. O

Hubo O
38 O
pacientes O
hospitalizados, O
con O
20 O
( O
13 O
hombres O
y O
7 O
mujeres O
) O
en O
el O
grupo O
experimental O
y O
18 O
( O
11 O
hombres O
y O
7 O
mujeres O
) O
en O
el O
grupo O
de O
control O
; O
la O
edad O
media O
fue O
de O
61,95 O
años O
( O
grupo O
experimental O
) O
a O
63,94 O
años O
( O
grupo O
de O
control O
) O
. O

Al B-Premise
finalizar I-Premise
el I-Premise
PMP I-Premise
, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
dolor I-Premise
se I-Premise
redujeron I-Premise
significativamente I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
, I-Premise
sin I-Premise
embargo, I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
experimental I-Premise
mostraron I-Premise
un I-Premise
aumento I-Premise
significativo I-Premise
en I-Premise
el I-Premise
uso I-Premise
de I-Premise
analgésicos I-Premise
PRN I-Premise
y I-Premise
de I-Premise
estrategias I-Premise
no I-Premise
farmacológicas I-Premise
para I-Premise
aliviar I-Premise
el I-Premise
dolor I-Premise
( I-Premise
P I-Premise
<0,05 I-Premise
) I-Premise
y I-Premise
redujeron I-Premise
significativamente I-Premise
las I-Premise
barreras I-Premise
para I-Premise
el I-Premise
manejo I-Premise
de I-Premise
su I-Premise
dolor I-Premise
por I-Premise
cáncer I-Premise
( I-Premise
P I-Premise
<0,05 I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control I-Premise
. O

Los B-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
deben I-Claim
recibir I-Claim
formación I-Claim
sobre I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
dolor I-Claim
para I-Claim
adquirir I-Claim
conocimientos I-Claim
y I-Claim
corregir I-Claim
las I-Claim
ideas I-Claim
erróneas I-Claim
sobre I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
su I-Claim
dolor I-Claim
oncológico. I-Claim

La B-Claim
integración I-Claim
del I-Claim
PMP I-Claim
en I-Claim
el I-Claim
trabajo I-Claim
clínico I-Claim
habitual I-Claim
puede I-Claim
contribuir I-Claim
a I-Claim
mejorar I-Claim
el I-Claim
nivel I-Claim
de I-Claim
atención I-Claim
a I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
. I-Claim

Se O
recomienda O
proporcionar O
educación O
sobre O
el O
manejo O
del O
dolor O
a O
todos O
los O
pacientes O
con O
cáncer O
. O

Este O
ensayo O
de O
fase O
III O
se O
llevó O
a O
cabo O
para O
comprobar O
si O
el O
nuevo O
agente O
disruptor O
vascular O
ASA404 O
( O
vadimezan O
) O
, O
cuando O
se O
combina O
con O
la O
quimioterapia O
de O
primera O
línea O
basada O
en O
el O
platino O
, O
mejora O
la O
supervivencia O
en O
pacientes O
con O
cáncer O
de O
pulmón O
no O
microcítico O
avanzado O
( O
CPNM O
) O
frente O
a O
la O
quimioterapia O
sola O
. O

Los O
pacientes O
con O
CPNM O
avanzado O
en O
estadio O
IIIB O
o O
IV O
, O
estratificados O
por O
sexo O
e O
histología O
tumoral O
, O
fueron O
asignados O
aleatoriamente O
1:1 O
a O
paclitaxel O
( O
200 O
mg/m O
( O
2 O
) O
) O
y O
carboplatino O
( O
área O
bajo O
la O
curva O
, O
6,0 O
) O
con O
o O
sin O
ASA404 O
( O
1.800 O
mg O
m O
( O
2 O
) O
) O
, O
administrados O
por O
vía O
intravenosa O
una O
vez O
cada O
3 O
semanas O
durante O
seis O
ciclos, O
seguidos O
de O
ASA404 O
de O
mantenimiento O
o O
placebo O
. O

El O
criterio O
de O
valoración O
principal O
fue O
la O
supervivencia O
global O
( O
SG O
) O
; O
los O
criterios O
de O
valoración O
secundarios O
incluyeron O
la O
tasa O
de O
respuesta O
global O
( O
ORR O
) O
y O
la O
supervivencia O
sin O
progresión O
( O
PFS O
) O
. O

Se O
asignaron O
aleatoriamente O
mil O
doscientos O
noventa O
y O
nueve O
pacientes. O

El O
ensayo O
se O
detuvo O
por O
inutilidad O
en O
el O
análisis O
intermedio. O

En O
el O
análisis O
final, O
no B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
SG I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
ASA404 I-Premise
( I-Premise
n I-Premise
= I-Premise
649 I-Premise
) I-Premise
y I-Premise
de I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
650 I-Premise
) I-Premise
: I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
SG I-Premise
fue I-Premise
de I-Premise
13,4 I-Premise
y I-Premise
12,7 I-Premise
meses I-Premise
respectivamente I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1,01 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0,85 I-Premise
a I-Premise
1,19 I-Premise
; I-Premise
P I-Premise
= I-Premise
.535 I-Premise
) O
. O

Asimismo, O
no B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
SG I-Premise
en I-Premise
los I-Premise
estratos I-Premise
histológicos I-Premise
(escamoso I-Premise
o I-Premise
no I-Premise
escamoso) I-Premise
y I-Premise
de I-Premise
sexo I-Premise
(hombre I-Premise
o I-Premise
mujer). I-Premise

La B-Premise
mediana I-Premise
de I-Premise
la I-Premise
SLP I-Premise
fue I-Premise
de I-Premise
5,5 I-Premise
meses I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
( I-Premise
HR I-Premise
, I-Premise
1,04 I-Premise
; I-Premise
P I-Premise
= I-Premise
.727 I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
la I-Premise
ORR I-Premise
fue I-Premise
del I-Premise
25% I-Premise
en I-Premise
ambos I-Premise
brazos I-Premise
( I-Premise
P I-Premise
= I-Premise
1,0 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
global I-Premise
de I-Premise
acontecimientos I-Premise
adversos I-Premise
(EA) I-Premise
fue I-Premise
comparable I-Premise
entre I-Premise
los I-Premise
brazos I-Premise
de I-Premise
ASA404 I-Premise
y I-Premise
de I-Premise
placebo. I-Premise

La B-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
4 I-Premise
( I-Premise
27 I-Premise
% I-Premise
frente I-Premise
a I-Premise
19 I-Premise
% I-Premise
) I-Premise
y I-Premise
el I-Premise
dolor I-Premise
en I-Premise
el I-Premise
lugar I-Premise
de I-Premise
la I-Premise
infusión I-Premise
( I-Premise
10 I-Premise
% I-Premise
frente I-Premise
a I-Premise
0,5 I-Premise
% I-Premise
) I-Premise
se I-Premise
notificaron I-Premise
con I-Premise
mayor I-Premise
frecuencia I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
ASA404 I-Premise
. I-Premise

La B-Claim
adición I-Claim
de I-Claim
ASA404 I-Claim
a I-Claim
carboplatino I-Claim
y I-Claim
paclitaxel I-Claim
, I-Claim
aunque I-Claim
generalmente I-Claim
bien I-Claim
tolerada, I-Claim
no I-Claim
logró I-Claim
mejorar I-Claim
la I-Claim
eficacia I-Claim
de I-Claim
primera I-Claim
línea I-Claim
en I-Claim
el I-Claim
CPNM I-Claim
avanzado. I-Claim

La B-Claim
superioridad I-Claim
clínica I-Claim
postoperatoria I-Claim
de I-Claim
la I-Claim
reconstrucción I-Claim
con I-Claim
interposición I-Claim
de I-Claim
yeyuno I-Claim
( I-Claim
INT I-Claim
) I-Claim
frente I-Claim
a I-Claim
la I-Claim
reconstrucción I-Claim
en I-Claim
Y I-Claim
de I-Claim
Roux I-Claim
( I-Claim
RY I-Claim
) I-Claim
tras I-Claim
una I-Claim
gastrectomía I-Claim
total I-Claim
no I-Claim
ha I-Claim
sido I-Claim
aclarada I-Claim
. I-Claim

La O
calidad O
de O
vida O
postoperatoria O
( O
QOL O
) O
se O
evaluó O
entre O
los O
2 O
métodos O
mediante O
un O
ensayo O
aleatorio O
prospectivo O
multiinstitucional O
. O

Un O
total O
de O
103 O
pacientes O
con O
cáncer O
gástrico O
fueron O
divididos O
de O
forma O
prospectiva O
y O
aleatoria O
en O
grupos O
para O
la O
reconstrucción O
RY O
( O
n O
= O
51 O
) O
o O
INT O
( O
n O
= O
52 O
) O
después O
de O
la O
gastrectomía O
total O
. O

Se O
estratificaron O
por O
sexo, O
edad, O
instituto, O
histología O
y O
grado O
de O
disección O
ganglionar. O

En O
el O
postoperatorio, O
se O
midieron O
el O
índice O
de O
masa O
corporal O
(IMC) O
y O
las O
condiciones O
nutricionales O
de O
forma O
seriada, O
y O
se O
evaluaron O
las O
puntuaciones O
de O
calidad O
de O
vida O
y O
de O
escualidez O
postoperatoria O
a O
los O
3, O
12 O
y O
60 O
meses O
y O
se O
compararon O
entre O
los O
dos O
grupos. O

Tras O
eliminar O
a O
los O
pacientes O
que O
no O
completaron O
la O
encuesta O
de O
seguimiento O
o O
los O
casos O
censurados O
, O
24 O
pacientes O
del O
grupo O
RY O
y O
18 O
del O
grupo O
INT O
estaban O
clínicamente O
disponibles O
y O
se O
evaluó O
su O
estado O
postoperatorio O
. O

Las B-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
aumentaron I-Premise
y I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
las I-Premise
complicaciones I-Premise
mejoraron I-Premise
en I-Premise
los I-Premise
períodos I-Premise
postoperatorios I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

El B-Premise
IMC I-Premise
postoperatorio I-Premise
se I-Premise
deterioró I-Premise
significativamente I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
IMC I-Premise
preoperatorio I-Premise
en I-Premise
cada I-Premise
grupo. I-Premise

Las B-Premise
puntuaciones I-Premise
de I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
de I-Premise
las I-Premise
complicaciones I-Premise
postoperatorias I-Premise
a I-Premise
los I-Premise
60 I-Premise
meses I-Premise
de I-Premise
la I-Premise
cirugía I-Premise
fueron I-Premise
significativamente I-Premise
mejores I-Premise
que I-Premise
las I-Premise
de I-Premise
los I-Premise
3 I-Premise
meses I-Premise
de I-Premise
la I-Premise
cirugía I-Premise
en I-Premise
cada I-Premise
grupo I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
. I-Premise

Sin O
embargo, O
no B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
de I-Premise
complicaciones I-Premise
postoperatorias I-Premise
entre I-Premise
los I-Premise
dos I-Premise
grupos I-Premise
de I-Premise
reconstrucción. I-Premise

El B-Premise
estado I-Premise
nutricional I-Premise
del I-Premise
grupo I-Premise
INT I-Premise
era I-Premise
casi I-Premise
el I-Premise
mismo I-Premise
que I-Premise
el I-Premise
del I-Premise
grupo I-Premise
RY I-Premise
. I-Premise

Aunque B-Premise
nuestra I-Premise
muestra I-Premise
de I-Premise
pacientes I-Premise
era I-Premise
pequeña I-Premise
y I-Premise
había I-Premise
pacientes I-Premise
que I-Premise
no I-Premise
completaron I-Premise
la I-Premise
encuesta I-Premise
de I-Premise
seguimiento, I-Premise
no B-Claim
pudimos I-Claim
identificar I-Claim
ninguna I-Claim
diferencia I-Claim
clínica I-Claim
entre I-Claim
la I-Claim
INT I-Claim
y I-Claim
la I-Claim
RY I-Claim
después I-Claim
de I-Claim
la I-Claim
gastrectomía I-Claim
total I-Claim
60 I-Claim
meses I-Claim
después I-Claim
de I-Claim
la I-Claim
cirugía. I-Claim

El B-Claim
método I-Claim
RY, I-Claim
más I-Claim
seguro I-Claim
y I-Claim
sencillo, I-Claim
puede I-Claim
ser I-Claim
un I-Claim
método I-Claim
de I-Claim
reconstrucción I-Claim
más I-Claim
adecuado I-Claim
que I-Claim
el I-Claim
INT I-Claim
tras I-Claim
la I-Claim
gastrectomía I-Claim
total I-Claim
. I-Claim

Aproximadamente O
el O
30% O
de O
los O
casos O
de O
cáncer O
de O
pulmón O
se O
diagnostican O
en O
pacientes O
de O
más O
de O
70 O
años. O

Los B-Claim
regímenes I-Claim
de I-Claim
quimioterapia I-Claim
estándar I-Claim
suelen I-Claim
considerarse I-Claim
demasiado I-Claim
tóxicos I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
edad I-Claim
avanzada I-Claim
. I-Claim

Se O
llevó O
a O
cabo O
un O
ensayo O
multicéntrico O
de O
fase O
II O
para O
determinar O
la O
eficacia O
y O
la O
seguridad O
del O
carboplatino O
combinado O
con O
vinorelbina O
cada O
4 O
semanas O
como O
tratamiento O
de O
primera O
línea O
para O
el O
cáncer O
de O
pulmón O
no O
microcítico O
avanzado O
( O
NSCLC O
) O
en O
pacientes O
de O
edad O
avanzada O
. O

Los O
pacientes O
eran O
elegibles O
si O
tenían O
una O
edad O
superior O
a O
los O
70 O
años, O
estaban O
en O
el O
estadio O
IIIB O
(con O
derrame O
pleural) O
o O
en O
el O
estadio O
IV O
del O
CPNM, O
tenían O
un O
estado O
de O
rendimiento O
de O
0/1, O
no O
habían O
recibido O
quimioterapia O
previamente O
y O
tenían O
una O
función O
orgánica O
normal. O

Se O
inscribieron O
40 O
pacientes O
( O
31 O
hombres O
y O
9 O
mujeres O
) O
que O
recibieron O
de O
3 O
a O
5 O
cursos O
de O
tratamiento O
. O

La O
mediana O
de O
edad O
era O
de O
72 O
años O
( O
rango O
, O
70-82 O
años O
) O
. O

El O
80% O
de O
los O
pacientes O
presentaban O
un O
CPNM O
en O
estadio O
IV, O
con O
histologías O
de O
células O
escamosas O
( O
n=21 O
) O
, O
adenocarcinoma O
( O
n=12 O
) O
e O
indiferenciado O
( O
n=7 O
) O
. O

Cuarenta O
pacientes O
fueron O
evaluados O
por O
la O
toxicidad O
y O
32 O
por O
la O
respuesta O
al O
tratamiento. O

De B-Premise
estos I-Premise
32 I-Premise
pacientes, I-Premise
8 I-Premise
tuvieron I-Premise
una I-Premise
respuesta I-Premise
parcial I-Premise
(tasa I-Premise
de I-Premise
respuesta I-Premise
por I-Premise
intención I-Premise
de I-Premise
tratar, I-Premise
20 I-Premise
%) I-Premise
y I-Premise
10 I-Premise
( I-Premise
25 I-Premise
%) I-Premise
tuvieron I-Premise
una I-Premise
enfermedad I-Premise
estable. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
7,8 I-Premise
meses I-Premise
( I-Premise
rango I-Premise
, I-Premise
4-11,6 I-Premise
meses I-Premise
) I-Premise
. I-Premise

Las B-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
1 I-Premise
y I-Premise
2 I-Premise
años I-Premise
fueron I-Premise
del I-Premise
25% I-Premise
y I-Premise
del I-Premise
7%, I-Premise
respectivamente; I-Premise
la I-Premise
mediana B-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
fue I-Premise
de I-Premise
4,3 I-Premise
meses I-Premise
( I-Premise
rango I-Premise
, I-Premise
0,2-13,8 I-Premise
meses I-Premise
) O
. O

Se B-Premise
observó I-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
en I-Premise
27 I-Premise
pacientes I-Premise
( I-Premise
68% I-Premise
) I-Premise
, I-Premise
y I-Premise
anemia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
en I-Premise
5 I-Premise
pacientes I-Premise
( I-Premise
13% I-Premise
) I-Premise
. I-Premise

Un B-Premise
paciente I-Premise
murió I-Premise
de I-Premise
neutropenia I-Premise
febril I-Premise
durante I-Premise
el I-Premise
tratamiento. I-Premise

El B-Premise
principal I-Premise
efecto I-Premise
adverso I-Premise
no I-Premise
hematológico I-Premise
fue I-Premise
la I-Premise
fatiga I-Premise
( I-Premise
grado I-Premise
3/4 I-Premise
en I-Premise
el I-Premise
18% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
) I-Premise
. I-Premise

El B-Claim
carboplatino/vinorelbina I-Claim
es I-Claim
bien I-Claim
tolerado I-Claim
por I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
edad I-Claim
avanzada I-Claim
con I-Claim
CPNM I-Claim
en I-Claim
estadio I-Claim
extenso. I-Claim

La B-Claim
eficacia I-Claim
es I-Claim
baja, I-Claim
pero I-Claim
similar I-Claim
a I-Claim
la I-Claim
de I-Claim
otros I-Claim
tratamientos I-Claim
utilizados I-Claim
en I-Claim
este I-Claim
entorno. I-Claim

El O
propósito O
de O
este O
estudio O
piloto O
fue O
examinar O
los O
efectos O
de O
un O
programa O
de O
entrenamiento O
combinado O
de O
ejercicios O
cardiorrespiratorios O
y O
de O
resistencia O
de O
corta O
duración O
sobre O
la O
aptitud O
cardiorrespiratoria, O
la O
resistencia O
a O
la O
fuerza, O
la O
capacidad O
muscular O
funcional O
para O
tareas O
específicas, O
la O
composición O
corporal O
y O
la O
calidad O
de O
vida O
(QOL) O
en O
mujeres O
supervivientes O
de O
cáncer O
de O
mama. O

Dieciséis O
sujetos O
fueron O
asignados O
aleatoriamente O
a O
un O
grupo O
de O
entrenamiento O
( O
n O
= O
8 O
; O
edad O
: O
50 O
+/- O
5 O
años O
) O
o O
a O
un O
grupo O
de O
control O
sin O
ejercicio O
( O
n O
= O
8 O
; O
edad O
: O
51 O
+/- O
10 O
años O
) O
. O

El O
grupo O
de O
entrenamiento O
siguió O
un O
programa O
de O
ejercicios O
de O
8 O
semanas O
que O
consistía O
en O
3 O
sesiones O
semanales O
de O
90 O
minutos O
de O
duración, O
supervisadas O
por O
un O
investigador O
experimentado O
y O
divididas O
en O
ejercicios O
de O
resistencia O
y O
entrenamiento O
aeróbico. O

Antes O
y O
después O
del O
periodo O
de O
intervención O
, O
todos O
los O
sujetos O
realizaron O
una O
prueba O
cardiorrespiratoria O
para O
medir O
el O
consumo O
máximo O
de O
oxígeno O
( O
VO2peak O
) O
, O
una O
prueba O
de O
resistencia O
de O
fuerza O
dinámica O
( O
número O
máximo O
de O
repeticiones O
para O
el O
ejercicio O
de O
prensa O
de O
pecho O
y O
de O
piernas O
al O
30 O
- O
35 O
% O
y O
100 O
- O
110 O
% O
de O
la O
masa O
corporal O
, O
respectivamente O
) O
y O
una O
prueba O
de O
posición O
sentada O
. O

La O
calidad O
de O
vida O
se O
evaluó O
mediante O
el O
cuestionario O
QLQ-C30 O
de O
la O
Organización O
Europea O
para O
la O
Investigación O
y O
el O
Tratamiento O
del O
Cáncer O
( O
EORTC-C30 O
) O
. O

En B-Premise
respuesta I-Premise
al I-Premise
entrenamiento I-Premise
, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
, I-Premise
el I-Premise
VO2peak I-Premise
( I-Premise
media I-Premise
de I-Premise
3,9 I-Premise
ml/kg/min I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,93 I-Premise
, I-Premise
6,90 I-Premise
) I-Premise
el I-Premise
rendimiento I-Premise
en I-Premise
la I-Premise
prensa I-Premise
de I-Premise
piernas I-Premise
( I-Premise
17,9 I-Premise
kg I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
12,8 I-Premise
, I-Premise
22,4 I-Premise
) I-Premise
y I-Premise
la I-Premise
prueba I-Premise
de I-Premise
estar I-Premise
de I-Premise
pie I-Premise
( I-Premise
- I-Premise
0,67 I-Premise
s I-Premise
; I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
- I-Premise
0,52 I-Premise
, I-Premise
- I-Premise
1,2 I-Premise
) I-Premise
mejoraron I-Premise
( I-Premise
p I-Premise
< I-Premise
o I-Premise
= I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

No B-Premise
observamos I-Premise
cambios I-Premise
significativos I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control. I-Premise

El B-Claim
entrenamiento I-Claim
combinado I-Claim
cardiorrespiratorio I-Claim
y I-Claim
de I-Claim
resistencia, I-Claim
incluso I-Claim
de I-Claim
muy I-Claim
breve I-Claim
duración, I-Claim
mejora I-Claim
la I-Claim
CdV I-Claim
y I-Claim
la I-Claim
forma I-Claim
física I-Claim
general I-Claim
de I-Claim
las I-Claim
mujeres I-Claim
supervivientes I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama. I-Claim

Los O
datos O
de O
la O
fase O
III O
de O
EGF104900 O
demostraron O
que O
lapatinib O
más O
trastuzumab O
mejoraba O
significativamente O
la O
supervivencia O
libre O
de O
progresión O
(SLP) O
y O
la O
tasa O
de O
beneficio O
clínico O
frente O
a O
la O
monoterapia O
con O
lapatinib, O
ofreciendo O
una O
opción O
sin O
quimioterapia O
para O
las O
pacientes O
con O
cáncer O
de O
mama O
metastásico O
(CMM) O
positivo O
para O
el O
receptor O
del O
factor O
de O
crecimiento O
epidérmico O
humano O
2 O
(HER2) O
muy O
pretratado. O

Aquí O
se O
informa O
del O
análisis O
final O
de O
supervivencia O
global O
( O
OS O
) O
previsto O
de O
EGF104900 O
. O

Las O
pacientes O
con O
CMB O
HER2-positivo O
cuya O
enfermedad O
progresó O
durante O
las O
terapias O
previas O
basadas O
en O
trastuzumab O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
lapatinib O
en O
monoterapia O
o O
lapatinib O
en O
combinación O
con O
trastuzumab O
. O

Los O
datos O
de O
la O
SG O
y O
la O
SLP O
actualizada O
se O
presentan O
mediante O
curvas O
de O
Kaplan-Meier O
y O
pruebas O
de O
rango O
logarítmico O
estratificadas O
según O
el O
receptor O
hormonal O
y O
el O
estado O
de O
la O
enfermedad O
visceral O
. O

Se O
realizaron O
análisis O
de O
subgrupos O
para O
identificar O
las O
características O
de O
los O
pacientes O
que O
obtuvieron O
el O
mayor O
beneficio O
clínico O
. O

En B-Premise
este I-Premise
análisis I-Premise
final I-Premise
actualizado I-Premise
de I-Premise
todas I-Premise
las I-Premise
pacientes I-Premise
asignadas I-Premise
aleatoriamente I-Premise
con I-Premise
estratos I-Premise
( I-Premise
n I-Premise
= I-Premise
291 I-Premise
) I-Premise
, I-Premise
lapatinib I-Premise
más I-Premise
trastuzumab I-Premise
siguió I-Premise
mostrando I-Premise
superioridad I-Premise
a I-Premise
la I-Premise
monoterapia I-Premise
con I-Premise
lapatinib I-Premise
en I-Premise
la I-Premise
SLP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0,74 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,58 I-Premise
a I-Premise
0,94 I-Premise
; I-Premise
P I-Premise
= I-Premise
.011 I-Premise
) I-Premise
y I-Premise
ofreció I-Premise
un I-Premise
beneficio I-Premise
significativo I-Premise
en I-Premise
la I-Premise
SG I-Premise
( I-Premise
HR I-Premise
, I-Premise
0,74 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,57 I-Premise
a I-Premise
0,97 I-Premise
; I-Premise
P I-Premise
= I-Premise
.026 I-Premise
) I-Premise
. I-Premise

Las B-Premise
mejoras I-Premise
en I-Premise
las I-Premise
tasas I-Premise
absolutas I-Premise
de I-Premise
SG I-Premise
fueron I-Premise
del I-Premise
10 I-Premise
% I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
del I-Premise
15 I-Premise
% I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
la I-Premise
combinación I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
brazo I-Premise
de I-Premise
la I-Premise
monoterapia I-Premise
. I-Premise

Múltiples B-Premise
factores I-Premise
basales I-Premise
, I-Premise
incluyendo I-Premise
el I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
del I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
de I-Premise
0 I-Premise
, I-Premise
la I-Premise
enfermedad I-Premise
no I-Premise
visceral I-Premise
, I-Premise
< I-Premise
tres I-Premise
focos I-Premise
metastásicos I-Premise
, I-Premise
y I-Premise
menos I-Premise
tiempo I-Premise
desde I-Premise
el I-Premise
diagnóstico I-Premise
inicial I-Premise
hasta I-Premise
la I-Premise
asignación I-Premise
aleatoria I-Premise
, I-Premise
se I-Premise
asociaron I-Premise
con I-Premise
la I-Premise
mejora I-Premise
de I-Premise
la I-Premise
SG I-Premise
. I-Premise

La B-Premise
incidencia I-Premise
de I-Premise
los I-Premise
acontecimientos I-Premise
adversos I-Premise
fue I-Premise
coherente I-Premise
con I-Premise
las I-Premise
tasas I-Premise
notificadas I-Premise
anteriormente. I-Premise

Estos B-Claim
datos I-Claim
demostraron I-Claim
una I-Claim
ventaja I-Claim
significativa I-Claim
de I-Claim
4,5 I-Claim
meses I-Claim
de I-Claim
mediana I-Claim
de I-Claim
SG I-Claim
con I-Claim
la I-Claim
combinación I-Claim
de I-Claim
lapatinib I-Claim
y I-Claim
trastuzumab I-Claim
y I-Claim
apoyan I-Claim
el I-Claim
bloqueo I-Claim
dual I-Claim
de I-Claim
HER2 I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CMB I-Claim
HER2-positivo I-Claim
muy I-Claim
pretratado. I-Claim

El O
objetivo O
del O
presente O
ensayo O
fue O
evaluar O
los O
efectos O
de O
la O
quimioterapia O
sobre O
la O
calidad O
de O
vida O
y O
la O
supervivencia O
de O
los O
pacientes O
con O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
avanzado O
( O
CPCNP O
) O
( O
estadio O
IIIB O
o O
IV O
) O
. O

En O
un O
ensayo O
multicéntrico O
controlado, O
los O
pacientes O
fueron O
asignados O
al O
azar O
para O
recibir O
sólo O
cuidados O
de O
apoyo O
o O
cuidados O
de O
apoyo O
más O
quimioterapia. O

La O
quimioterapia O
consistió O
en O
la O
administración O
intravenosa O
( O
i.v O
) O

carboplatino O
300 O
mg/m2 O
en O
el O
día O
1 O
y O
etopósido O
120 O
mg/m2 O
por O
vía O
oral O
en O
los O
días O
1-5 O
cada O
4 O
semanas O
durante O
un O
máximo O
de O
ocho O
ciclos. O

La O
calidad O
de O
vida O
se O
midió O
en O
el O
momento O
de O
la O
aleatorización O
y O
antes O
de O
cada O
curso O
de O
tratamiento, O
así O
como O
en O
los O
intervalos O
correspondientes O
de O
4 O
semanas O
en O
el O
brazo O
de O
control, O
utilizando O
el O
cuestionario O
EORTC O
QLQ-C30 O
+ O
LC13. O

Se O
aleatorizaron O
48 O
pacientes O
( O
cuidados O
de O
apoyo O
26 O
, O
quimioterapia O
22 O
) O
, O
siendo O
elegibles O
para O
los O
análisis O
comparativos O
. O

Otros O
102 O
pacientes, O
97 O
de O
los O
cuales O
recibieron O
quimioterapia, O
se O
incluyeron O
posteriormente O
en O
el O
estudio O
sobre O
la O
base O
de O
una O
preferencia O
de O
tratamiento O
individual. O

Los O
datos O
de O
estos O
pacientes O
se O
utilizaron O
con O
fines O
de O
confirmación. O

Los B-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
quimioterapia I-Premise
informaron I-Premise
de I-Premise
un I-Premise
mejor I-Premise
funcionamiento I-Premise
físico I-Premise
general I-Premise
y I-Premise
control I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
. I-Premise

Las B-Premise
diferencias I-Premise
de I-Premise
grupo I-Premise
fueron I-Premise
menores I-Premise
en I-Premise
el I-Premise
ámbito I-Premise
psicosocial, I-Premise
aunque B-Premise
se I-Premise
observaron I-Premise
tendencias I-Premise
a I-Premise
favor I-Premise
del I-Premise
grupo I-Premise
de I-Premise
quimioterapia. I-Premise

No B-Premise
se I-Premise
observaron I-Premise
diferencias I-Premise
significativas I-Premise
a I-Premise
favor I-Premise
del I-Premise
grupo I-Premise
de I-Premise
cuidados I-Premise
de I-Premise
apoyo, I-Premise
excepto I-Premise
en I-Premise
lo I-Premise
que I-Premise
respecta I-Premise
a I-Premise
la I-Premise
pérdida I-Premise
de I-Premise
cabello. I-Premise

La B-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
fue I-Premise
de I-Premise
29 I-Premise
semanas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
quimioterapia I-Premise
frente I-Premise
a I-Premise
11 I-Premise
semanas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
cuidados I-Premise
de I-Premise
apoyo I-Premise
, I-Premise
y I-Premise
las I-Premise
tasas I-Premise
de I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
fueron I-Premise
del I-Premise
28 I-Premise
% I-Premise
frente I-Premise
al I-Premise
8 I-Premise
% I-Premise
. I-Premise

Los B-Premise
resultados I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
supervivencia I-Premise
fueron I-Premise
similares I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
aleatorizados I-Premise
y I-Premise
no I-Premise
aleatorizados I-Premise
que I-Premise
recibieron I-Premise
quimioterapia I-Premise
. I-Premise

No B-Premise
se I-Premise
produjeron I-Premise
muertes I-Premise
relacionadas I-Premise
con I-Premise
el I-Premise
tratamiento. I-Premise

En B-Claim
conclusión, I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
carboplatino I-Claim
y I-Claim
etopósido I-Claim
puede I-Claim
mejorar I-Claim
tanto I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
como I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
avanzado. I-Claim

Evaluar O
la O
eficacia O
de O
los O
ejercicios O
profilácticos O
de O
deglución O
en O
la O
función O
de O
deglución O
en O
pacientes O
sometidos O
a O
quimiorradioterapia O
( O
CRT O
) O
para O
el O
cáncer O
de O
cabeza O
y O
cuello O
. O

Ensayo O
controlado O
aleatorio O
. O

Centro O
médico O
académico O
de O
atención O
terciaria. O

Veintiséis O
pacientes O
con O
cáncer O
de O
cabeza O
y O
cuello O
que O
reciben O
TRC O
. O

Los O
pacientes O
realizaron O
5 O
ejercicios O
de O
deglución O
específicos O
a O
lo O
largo O
de O
su O
TRC O
y O
participaron O
en O
sesiones O
semanales O
de O
terapia O
de O
deglución O
para O
promover O
la O
adherencia O
y O
la O
técnica O
precisa O
. O

Los O
controles O
no O
tuvieron O
ejercicios O
profilácticos O
y O
fueron O
remitidos O
para O
el O
tratamiento O
de O
la O
deglución O
tras O
la O
finalización O
de O
la O
TRC O
si O
estaba O
indicado O
. O

La O
función O
de O
deglución O
se O
evaluó O
con O
la O
Escala O
Funcional O
de O
Ingesta O
Oral O
( O
FOIS O
) O
y O
la O
Escala O
de O
Estado O
de O
Rendimiento O
para O
Pacientes O
con O
Cáncer O
de O
Cabeza O
y O
Cuello O
( O
PSS-H O
& O
N O
) O
al O
inicio O
, O
inmediatamente O
después O
de O
la O
TRC O
, O
y O
a O
los O
3 O
, O
6 O
, O
9 O
y O
12 O
meses O
después O
de O
la O
TRC O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
FOIS I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
intervención I-Premise
y I-Premise
los I-Premise
de I-Premise
control I-Premise
inmediatamente I-Premise
después I-Premise
de I-Premise
la I-Premise
TRC I-Premise
( I-Premise
inmediatamente I-Premise
después I-Premise
de I-Premise
la I-Premise
TRC I-Premise
: I-Premise
puntuación I-Premise
mediana I-Premise
del I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
, I-Premise
3 I-Premise
[ I-Premise
rango I-Premise
, I-Premise
1-7 I-Premise
] I-Premise
, I-Premise
frente I-Premise
a I-Premise
la I-Premise
puntuación I-Premise
mediana I-Premise
del I-Premise
grupo I-Premise
de I-Premise
control I-Premise
, I-Premise
4 I-Premise
[ I-Premise
rango I-Premise
, I-Premise
1-6 I-Premise
] I-Premise
( I-Premise
P I-Premise
= I-Premise
.88 I-Premise
) I-Premise
. I-Premise

Sin O
embargo, O
los B-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
tuvieron I-Premise
puntuaciones I-Premise
significativamente I-Premise
mejores I-Premise
en I-Premise
los I-Premise
meses I-Premise
3 I-Premise
y I-Premise
6 I-Premise
( I-Premise
mediana I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
intervención I-Premise
a I-Premise
los I-Premise
3 I-Premise
meses I-Premise
, I-Premise
7 I-Premise
[ I-Premise
rango I-Premise
, I-Premise
5-7 I-Premise
] I-Premise
, I-Premise
frente I-Premise
a I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
del I-Premise
control I-Premise
, I-Premise
5 I-Premise
[ I-Premise
rango I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
; I-Premise
mediana I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
de I-Premise
la I-Premise
intervención I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
, I-Premise
7 I-Premise
[ I-Premise
rango I-Premise
, I-Premise
6-7 I-Premise
] I-Premise
, I-Premise
frente I-Premise
a I-Premise
la I-Premise
mediana I-Premise
de I-Premise
la I-Premise
puntuación I-Premise
del I-Premise
control I-Premise
, I-Premise
6 I-Premise
[ I-Premise
rango I-Premise
, I-Premise
3-7 I-Premise
] I-Premise
[ I-Premise
P I-Premise
= I-Premise
.009 I-Premise
] O
) O
. O

No B-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
las I-Premise
puntuaciones I-Premise
en I-Premise
los I-Premise
meses I-Premise
9 I-Premise
y I-Premise
12 I-Premise
( I-Premise
P I-Premise
= I-Premise
0,24 I-Premise
y I-Premise
P I-Premise
= I-Premise
0,93 I-Premise
, I-Premise
respectivamente I-Premise
) I-Premise
. I-Premise

Se B-Premise
observó I-Premise
el I-Premise
mismo I-Premise
patrón I-Premise
entre I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
intervención I-Premise
y I-Premise
los I-Premise
de I-Premise
control I-Premise
para I-Premise
las I-Premise
puntuaciones I-Premise
en I-Premise
la I-Premise
PSS-H I-Premise
y I-Premise
N I-Premise
. I-Premise

Los B-Claim
pacientes I-Claim
que I-Claim
realizaron I-Claim
ejercicios I-Claim
profilácticos I-Claim
de I-Claim
deglución I-Claim
mejoraron I-Claim
la I-Claim
función I-Claim
de I-Claim
deglución I-Claim
a I-Claim
los I-Claim
3 I-Claim
y I-Claim
6 I-Claim
meses I-Claim
después I-Claim
de I-Claim
la I-Claim
TRC, I-Claim
pero I-Claim
no I-Claim
inmediatamente I-Claim
después I-Claim
de I-Claim
la I-Claim
TRC I-Claim
ni I-Claim
a I-Claim
los I-Claim
9 I-Claim
y I-Claim
12 I-Claim
meses I-Claim
después I-Claim
de I-Claim
la I-Claim
TRC. I-Claim

El B-Claim
pequeño I-Claim
tamaño I-Claim
de I-Claim
la I-Claim
muestra I-Claim
puede I-Claim
haber I-Claim
limitado I-Claim
nuestra I-Claim
capacidad I-Claim
para I-Claim
detectar I-Claim
diferencias I-Claim
significativas I-Claim
más I-Claim
allá I-Claim
de I-Claim
los I-Claim
6 I-Claim
meses I-Claim
de I-Claim
observación, I-Claim
así I-Claim
como I-Claim
otras I-Claim
diferencias I-Claim
significativas I-Claim
en I-Claim
nuestro I-Claim
estudio. I-Claim

Evaluar O
prospectivamente O
los O
resultados O
de O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
(CVRS) O
de O
la O
embolización O
de O
la O
arteria O
uterina O
(EAU) O
y O
de O
la O
histerectomía O
hasta O
24 O
meses O
después O
de O
la O
intervención O
en O
términos O
de O
salud O
mental O
y O
física, O
función O
urinaria O
y O
defecatoria, O
y O
satisfacción O
general O
de O
la O
paciente. O

Se O
obtuvo O
la O
aprobación O
del O
comité O
ético O
y O
el O
consentimiento O
informado O
para O
el O
ensayo O
de O
embolización O
frente O
a O
histerectomía. O

Las O
mujeres O
( O
n O
= O
177 O
) O
con O
miomas O
uterinos O
y O
hemorragia O
menstrual O
abundante O
que O
tenían O
programada O
una O
histerectomía O
fueron O
asignadas O
aleatoriamente O
a O
someterse O
a O
la O
EAU O
( O
n O
= O
88 O
) O
o O
a O
la O
histerectomía O
( O
n O
= O
89 O
) O
. O

La O
CVRS O
se O
midió O
seis O
veces O
durante O
un O
período O
de O
seguimiento O
de O
24 O
meses O
con O
los O
siguientes O
cuestionarios O
validados O
: O
Medical O
Outcome O
Study O
Short O
Form O
36 O
( O
SF-36 O
) O
mental O
component O
summary O
( O
MCS O
) O
y O
physical O
component O
summary O
( O
PCS O
) O
, O
Health O
Utilities O
Index O
Mark O
3 O
, O
EuroQol O
5D O
, O
urogenital O
distress O
inventory O
( O
UDI O
) O
, O
incontinence O
impact O
questionnaire O
, O
y O
defecation O
distress O
inventory O
( O
DDI O
) O
. O

La O
satisfacción O
se O
evaluó O
con O
una O
escala O
Likert O
de O
siete O
puntos. O

Se O
realizó O
un O
análisis O
de O
medidas O
repetidas O
para O
el O
análisis O
entre O
grupos. O

Se O
realizaron O
pruebas O
t O
pareadas O
para O
el O
análisis O
dentro O
del O
grupo. O

La O
satisfacción O
se O
analizó O
con O
la O
prueba O
exacta O
de O
Fisher. O

Las B-Premise
puntuaciones I-Premise
SF-36 I-Premise
MCS I-Premise
y I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
y I-Premise
UDI I-Premise
mejoraron I-Premise
significativamente I-Premise
en I-Premise
ambos I-Premise
grupos I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
y I-Premise
posteriormente I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

La O
puntuación O
del O
DDI O
mejoró O
significativamente O
sólo O
en O
el O
grupo O
de O
EAU O
a O
los O
6 O
meses O
y O
posteriormente O
( O
P O
< O
0,05 O
) O
. O

No O
se O
observaron O
diferencias O
entre O
los O
grupos, O
a O
excepción O
de O
las O
puntuaciones O
de O
la O
PCS O
a O
las O
6 O
semanas O
de O
seguimiento: O
Las O
pacientes O
del O
grupo O
de O
EAU O
obtuvieron O
puntuaciones O
significativamente O
mejores O
que O
las O
del O
grupo O
de O
histerectomía O
( O
P O
< O
0,001 O
) O
. O

La O
mejora O
en O
la O
puntuación O
del O
PCS O
a O
los O
24 O
meses O
de O
seguimiento O
fue O
significativamente O
mayor O
para O
los O
pacientes O
que O
tenían O
empleo O
al O
inicio O
( O
P O
= O
.035 O
) O
. O

A B-Premise
los I-Premise
24 I-Premise
meses I-Premise
de I-Premise
seguimiento, I-Premise
las I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
histerectomía I-Premise
estaban I-Premise
significativamente I-Premise
más I-Premise
satisfechas I-Premise
que I-Premise
las I-Premise
del I-Premise
grupo I-Premise
de I-Premise
EAU I-Premise
( I-Premise
P I-Premise
= I-Premise
0,02 I-Premise
) I-Premise
. I-Premise

Tanto B-Claim
la I-Claim
EAU I-Claim
como I-Claim
la I-Claim
histerectomía I-Claim
mejoraron I-Claim
la I-Claim
CVRS. I-Claim

No B-Claim
se I-Claim
observaron I-Claim
diferencias I-Claim
entre I-Claim
los I-Claim
grupos I-Claim
en I-Claim
cuanto I-Claim
a I-Claim
la I-Claim
CVRS I-Claim
a I-Claim
los I-Claim
24 I-Claim
meses I-Claim
de I-Claim
seguimiento. I-Claim

Sobre B-Claim
la I-Claim
base I-Claim
de I-Claim
los I-Claim
resultados I-Claim
de I-Claim
la I-Claim
CVRS, I-Claim
los I-Claim
autores I-Claim
determinaron I-Claim
que I-Claim
la I-Claim
EAU I-Claim
es I-Claim
una I-Claim
buena I-Claim
alternativa I-Claim
a I-Claim
la I-Claim
histerectomía. I-Claim

No O
se O
conocen O
tratamientos O
eficaces O
para O
la O
neuropatía O
periférica O
dolorosa O
inducida O
por O
la O
quimioterapia. O

Determinar O
el O
efecto O
de O
la O
duloxetina O
, O
60 O
mg O
diarios O
, O
sobre O
la O
gravedad O
media O
del O
dolor O
. O

Ensayo O
cruzado O
aleatorio, O
doble O
ciego O
y O
controlado O
con O
placebo O
en O
8 O
redes O
de O
investigación O
cooperativa O
financiadas O
por O
el O
Instituto O
Nacional O
del O
Cáncer O
( O
NCI O
) O
que O
inscribieron O
a O
231 O
pacientes O
de O
25 O
años O
o O
más O
que O
recibían O
tratamiento O
en O
entornos O
comunitarios O
y O
académicos O
entre O
abril O
de O
2008 O
y O
marzo O
de O
2011 O
. O

El O
seguimiento O
del O
estudio O
finalizó O
en O
julio O
de O
2012. O

Estratificados O
por O
el O
fármaco O
quimioterapéutico O
y O
el O
riesgo O
de O
dolor O
comórbido O
, O
los O
pacientes O
fueron O
aleatorizados O
para O
recibir O
duloxetina O
seguida O
de O
placebo O
o O
placebo O
seguido O
de O
duloxetina O
. O

La O
elegibilidad O
requería O
que O
los O
pacientes O
tuvieran O
neuropatía O
sensorial O
de O
grado O
1 O
o O
superior O
según O
los O
Criterios O
Terminológicos O
Comunes O
del O
NCI O
para O
Eventos O
Adversos O
y O
al O
menos O
4 O
en O
una O
escala O
de O
0 O
a O
10 O
, O
que O
representa O
el O
dolor O
medio O
inducido O
por O
la O
quimioterapia O
, O
después O
del O
tratamiento O
con O
paclitaxel O
, O
otros O
taxanos O
u O
oxaliplatino O
. O

El O
tratamiento O
inicial O
consistió O
en O
tomar O
1 O
cápsula O
diaria O
de O
30 O
mg O
de O
duloxetina O
o O
de O
placebo O
durante O
la O
primera O
semana O
y O
2 O
cápsulas O
diarias O
de O
30 O
mg O
de O
duloxetina O
o O
de O
placebo O
durante O
4 O
semanas O
adicionales. O

La O
hipótesis O
principal O
era O
que O
la O
duloxetina O
sería O
más O
eficaz O
que O
el O
placebo O
para O
disminuir O
el O
dolor O
neuropático O
periférico O
inducido O
por O
la O
quimioterapia. O

La O
gravedad O
del O
dolor O
se O
evaluó O
mediante O
el O
ítem O
"dolor O
medio" O
del O
Brief O
Pain O
Inventory-Short O
Form, O
en O
el O
que O
el O
0 O
representa O
que O
no O
hay O
dolor O
y O
el O
10 O
que O
es O
lo O
más O
grave O
que O
se O
puede O
imaginar. O

Los B-Premise
individuos I-Premise
que I-Premise
recibieron I-Premise
duloxetina I-Premise
como I-Premise
tratamiento I-Premise
inicial I-Premise
de I-Premise
5 I-Premise
semanas I-Premise
informaron I-Premise
de I-Premise
una I-Premise
disminución I-Premise
media I-Premise
del I-Premise
dolor I-Premise
promedio I-Premise
de I-Premise
1,06 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,72-1,40 I-Premise
) I-Premise
frente I-Premise
a I-Premise
0,34 I-Premise
( I-Premise
IC I-Premise
95 I-Premise
% I-Premise
, I-Premise
0,01-0,66 I-Premise
) I-Premise
entre I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,513 I-Premise
) I-Premise
. I-Premise

La B-Premise
diferencia I-Premise
media I-Premise
observada I-Premise
en I-Premise
la I-Premise
puntuación I-Premise
media I-Premise
del I-Premise
dolor I-Premise
entre I-Premise
la I-Premise
duloxetina I-Premise
y I-Premise
el I-Premise
placebo I-Premise
fue I-Premise
de I-Premise
0,73 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%, I-Premise
0,26-1,20). I-Premise

El B-Premise
59% I-Premise
de I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
inicialmente I-Premise
duloxetina I-Premise
frente I-Premise
al I-Premise
38% I-Premise
de I-Premise
los I-Premise
que I-Premise
recibieron I-Premise
inicialmente I-Premise
placebo I-Premise
informaron I-Premise
de I-Premise
una I-Premise
disminución I-Premise
del I-Premise
dolor I-Premise
de I-Premise
cualquier I-Premise
cuantía I-Premise
. I-Premise

Entre B-Claim
los I-Claim
pacientes I-Claim
con I-Claim
neuropatía I-Claim
periférica I-Claim
dolorosa I-Claim
inducida I-Claim
por I-Claim
la I-Claim
quimioterapia I-Claim
, I-Claim
el I-Claim
uso I-Claim
de I-Claim
duloxetina I-Claim
en I-Claim
comparación I-Claim
con I-Claim
el I-Claim
placebo I-Claim
durante I-Claim
5 I-Claim
semanas I-Claim
dio I-Claim
lugar I-Claim
a I-Claim
una I-Claim
mayor I-Claim
reducción I-Claim
del I-Claim
dolor I-Claim
. I-Claim

La O
mayoría O
de O
los O
supervivientes O
de O
carcinoma O
de O
próstata O
experimentan O
dificultades O
sexuales O
duraderas O
y O
la O
angustia O
asociada O
a O
ellas O
en O
los O
años O
posteriores O
al O
tratamiento O
definitivo. O

Se O
desarrolló O
una O
intervención O
de O
asesoramiento O
dirigida O
a O
mejorar O
los O
niveles O
de O
satisfacción O
sexual O
y O
aumentar O
la O
utilización O
exitosa O
del O
tratamiento O
médico O
para O
la O
disfunción O
eréctil O
( O
ED O
) O
y O
se O
probó O
de O
forma O
piloto O
tanto O
para O
el O
superviviente O
del O
carcinoma O
de O
próstata O
como O
para O
su O
pareja O
. O

Todos O
los O
participantes O
masculinos O
eran O
supervivientes O
de O
3 O
meses O
a O
5 O
años O
de O
carcinoma O
de O
próstata O
localizado O
que O
habían O
sido O
tratados O
con O
prostatectomía O
radical O
o O
radioterapia O
, O
y O
estaban O
casados O
o O
tenían O
una O
relación O
comprometida O
. O

Las O
parejas O
fueron O
elegidas O
al O
azar O
para O
asistir O
a O
cuatro O
sesiones O
de O
asesoramiento O
juntas O
o O
para O
que O
el O
hombre O
asistiera O
solo. O

En O
ambos O
grupos, O
los O
compañeros O
completaron O
las O
tareas O
de O
comportamiento. O

Las O
sesiones O
incluyeron O
educación O
sobre O
el O
carcinoma O
de O
próstata O
y O
la O
función O
sexual O
y O
las O
opciones O
para O
tratar O
la O
disfunción O
eréctil, O
así O
como O
habilidades O
de O
comunicación O
y O
estimulación O
sexual. O

Los O
cuestionarios O
estandarizados O
al O
inicio, O
después O
del O
tratamiento O
y O
a O
los O
3 O
y O
6 O
meses O
de O
seguimiento O
evaluaron O
la O
función O
sexual, O
el O
ajuste O
marital, O
la O
angustia O
psicológica O
y O
la O
utilización O
de O
tratamientos O
para O
la O
disfunción O
eréctil. O

Cincuenta O
y O
una O
de O
las O
84 O
parejas O
asignadas O
al O
azar O
al O
tratamiento O
completaron O
la O
intervención O
( O
61% O
) O
. O

La O
asistencia O
de O
la O
pareja O
no O
afectó O
a O
los O
resultados O
. O

Los B-Premise
participantes I-Premise
que I-Premise
completaron I-Premise
la I-Premise
intervención I-Premise
demostraron I-Premise
una I-Premise
mejora I-Premise
en I-Premise
la I-Premise
angustia I-Premise
general I-Premise
masculina I-Premise
( I-Premise
P I-Premise
< I-Premise
0,01 I-Premise
) I-Premise
, I-Premise
la I-Premise
función I-Premise
sexual I-Premise
global I-Premise
masculina I-Premise
( I-Premise
P I-Premise
< I-Premise
0,0001 I-Premise
) I-Premise
y I-Premise
la I-Premise
función I-Premise
sexual I-Premise
global I-Premise
femenina I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
) I-Premise
en I-Premise
el I-Premise
seguimiento I-Premise
de I-Premise
3 I-Premise
meses I-Premise
, O
pero B-Premise
se I-Premise
observó I-Premise
una I-Premise
regresión I-Premise
hacia I-Premise
la I-Premise
línea I-Premise
de I-Premise
base I-Premise
en I-Premise
el I-Premise
seguimiento I-Premise
de I-Premise
6 I-Premise
meses I-Premise
. O

Sin B-Premise
embargo, I-Premise
la I-Premise
utilización I-Premise
de I-Premise
los I-Premise
tratamientos I-Premise
de I-Premise
urgencias I-Premise
aumentó I-Premise
del I-Premise
31% I-Premise
en I-Premise
el I-Premise
momento I-Premise
de I-Premise
la I-Premise
entrada I-Premise
en I-Premise
el I-Premise
estudio I-Premise
al I-Premise
49% I-Premise
en I-Premise
el I-Premise
seguimiento I-Premise
de I-Premise
6 I-Premise
meses I-Premise
( I-Premise
P I-Premise
= I-Premise
0,003 I-Premise
) I-Premise
. I-Premise

Los B-Claim
resultados I-Claim
de I-Claim
esta I-Claim
breve I-Claim
intervención I-Claim
piloto I-Claim
de I-Claim
asesoramiento I-Claim
demostraron I-Claim
ganancias I-Claim
significativas I-Claim
en I-Claim
la I-Claim
función I-Claim
y I-Claim
la I-Claim
satisfacción I-Claim
sexual I-Claim
y I-Claim
una I-Claim
mayor I-Claim
utilización I-Claim
de I-Claim
los I-Claim
tratamientos I-Claim
para I-Claim
la I-Claim
disfunción I-Claim
eréctil. I-Claim

Sin B-Claim
embargo, I-Claim
es I-Claim
necesario I-Claim
realizar I-Claim
modificaciones I-Claim
en I-Claim
futuros I-Claim
ensayos I-Claim
aleatorios I-Claim
para I-Claim
reducir I-Claim
la I-Claim
tasa I-Claim
de I-Claim
terminación I-Claim
prematura I-Claim
y I-Claim
mejorar I-Claim
el I-Claim
mantenimiento I-Claim
de I-Claim
las I-Claim
ganancias I-Claim
a I-Claim
largo I-Claim
plazo. I-Claim

El O
objetivo O
de O
este O
estudio O
prospectivo O
controlado O
era O
evaluar O
la O
eficacia O
de O
dos O
modalidades O
de O
tratamiento O
combinadas O
diferentes O
del O
linfedema O
( O
LE O
) O
. O

El O
drenaje O
linfático O
manual O
( O
DLM O
) O
y O
la O
combinación O
de O
vendas O
de O
compresión O
( O
terapia O
descongestiva O
compleja O
) O
se O
han O
comparado O
con O
la O
compresión O
neumática O
intermitente O
( O
CNI O
) O
más O
el O
autodrenaje O
linfático O
( O
DLS O
) O
. O

Tanto O
el O
grupo O
de O
MLD O
con O
vendaje O
de O
compresión O
( O
terapia O
descongestiva O
compleja O
) O
( O
Grupo O
I O
, O
n=15 O
) O
como O
el O
grupo O
de O
IPC O
con O
SLD O
( O
Grupo O
II O
, O
n=15 O
) O
recibieron O
tratamiento O
para O
LE O
3 O
días O
en O
una O
semana O
y O
cada O
dos O
días O
durante O
6 O
semanas O
. O

Se O
midieron O
las O
circunferencias O
de O
los O
brazos O
antes O
y O
en O
las O
semanas O
1, O
3 O
y O
6 O
del O
tratamiento. O

Se O
realizaron O
las O
pruebas O
EORTC-QLQ O
y O
ASES O
para O
evaluar O
la O
calidad O
de O
vida O
antes O
y O
después O
de O
6 O
semanas O
de O
tratamiento. O

Los O
pacientes O
de O
ambos O
grupos O
tenían O
características O
demográficas O
y O
clínicas O
similares. O

Aunque O
ambas B-Premise
modalidades I-Premise
de I-Premise
tratamiento I-Premise
dieron I-Premise
lugar I-Premise
a I-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
del I-Premise
volumen I-Premise
total I-Premise
del I-Premise
brazo I-Premise
( I-Premise
12,2 I-Premise
% I-Premise
de I-Premise
disminución I-Premise
en I-Premise
el I-Premise
Grupo I-Premise
II I-Premise
y I-Premise
14,9 I-Premise
% I-Premise
de I-Premise
disminución I-Premise
en I-Premise
el I-Premise
Grupo I-Premise
I I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0,001 I-Premise
) O
, O
no B-Premise
se I-Premise
encontraron I-Premise
diferencias I-Premise
significativas I-Premise
( I-Premise
p=0,582 I-Premise
) I-Premise
entre I-Premise
esos I-Premise
dos I-Premise
grupos I-Premise
. O

Del B-Premise
mismo I-Premise
modo, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
ASES I-Premise
mejoraron I-Premise
significativamente I-Premise
( I-Premise
p=0,001 I-Premise
) I-Premise
tanto I-Premise
en I-Premise
el I-Premise
Grupo I-Premise
I I-Premise
como I-Premise
en I-Premise
el I-Premise
II, I-Premise
sin I-Premise
ninguna I-Premise
diferencia I-Premise
significativa I-Premise
entre I-Premise
los I-Premise
grupos. I-Premise

Mientras B-Premise
que I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
funcionamiento I-Premise
emocional, I-Premise
fatiga I-Premise
y I-Premise
dolor I-Premise
mejoraron I-Premise
significativamente I-Premise
en I-Premise
ambos I-Premise
grupos, I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
estado I-Premise
de I-Premise
salud I-Premise
global I-Premise
y I-Premise
de I-Premise
funcionamiento I-Premise
funcional I-Premise
y I-Premise
cognitivo I-Premise
sólo I-Premise
parecieron I-Premise
mejorar I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
I. I-Premise

Diferentes B-Claim
modalidades I-Claim
de I-Claim
tratamiento I-Claim
consistentes I-Claim
en I-Claim
MLD I-Claim
y I-Claim
vendaje I-Claim
compresivo I-Claim
( I-Claim
terapia I-Claim
descongestiva I-Claim
compleja I-Claim
) I-Claim
o I-Claim
IPC I-Claim
y I-Claim
SLD I-Claim
parecen I-Claim
ser I-Claim
eficaces I-Claim
en I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
LE I-Claim
con I-Claim
una I-Claim
eficacia I-Claim
terapéutica I-Claim
similar I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
. I-Claim

Sin B-Claim
embargo, I-Claim
las I-Claim
modalidades I-Claim
combinadas I-Claim
que I-Claim
incluyen I-Claim
la I-Claim
CIP I-Claim
y I-Claim
el I-Claim
SLD I-Claim
pueden I-Claim
ser I-Claim
las I-Claim
opciones I-Claim
preferidas I-Claim
por I-Claim
su I-Claim
aplicabilidad I-Claim
en I-Claim
el I-Claim
hogar. I-Claim

Este O
estudio O
aleatorio, O
multicéntrico O
y O
de O
fase O
III O
comparó O
la O
doxorrubicina O
y O
el O
docetaxel O
( O
AT O
) O
con O
la O
doxorrubicina O
y O
la O
ciclofosfamida O
( O
AC O
) O
como O
quimioterapia O
de O
primera O
línea O
( O
CT O
) O
en O
el O
cáncer O
de O
mama O
metastásico O
( O
CMM O
) O
. O

Los O
pacientes O
( O
n O
= O
429 O
) O
fueron O
asignados O
aleatoriamente O
a O
recibir O
doxorrubicina O
50 O
mg/m O
( O
2 O
) O
más O
docetaxel O
75 O
mg/m O
( O
2 O
) O
( O
n O
= O
214 O
) O
o O
doxorrubicina O
60 O
mg/m O
( O
2 O
) O
más O
ciclofosfamida O
600 O
mg/m O
( O
2 O
) O
( O
n O
= O
215 O
) O
en O
el O
día O
1 O
, O
cada O
3 O
semanas O
hasta O
ocho O
ciclos O
. O

El B-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
( I-Premise
TTP I-Premise
; I-Premise
punto I-Premise
final I-Premise
primario I-Premise
) I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
fracaso I-Premise
del I-Premise
tratamiento I-Premise
( I-Premise
TTF I-Premise
) I-Premise
fueron I-Premise
significativamente I-Premise
más I-Premise
largos I-Premise
con I-Premise
AT I-Premise
que I-Premise
con I-Premise
AC I-Premise
( I-Premise
mediana I-Premise
de I-Premise
TTP I-Premise
, I-Premise
37,3 I-Premise
frente I-Premise
a I-Premise
31,9 I-Premise
semanas I-Premise
; I-Premise
log-rank I-Premise
P I-Premise
=.014 I-Premise
; I-Premise
mediana I-Premise
de I-Premise
TTF I-Premise
, I-Premise
25,6 I-Premise
frente I-Premise
a I-Premise
23,7 I-Premise
semanas I-Premise
; I-Premise
log-rank I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

La B-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
global I-Premise
( I-Premise
ORR I-Premise
) I-Premise
fue I-Premise
significativamente I-Premise
mayor I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
tomaban I-Premise
AT I-Premise
( I-Premise
59 I-Premise
% I-Premise
, I-Premise
con I-Premise
un I-Premise
10 I-Premise
% I-Premise
de I-Premise
respuesta I-Premise
completa I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
49 I-Premise
% I-Premise
de I-Premise
respuesta I-Premise
parcial I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
que I-Premise
para I-Premise
los I-Premise
que I-Premise
tomaban I-Premise
AC I-Premise
( I-Premise
47 I-Premise
% I-Premise
, I-Premise
con I-Premise
un I-Premise
7 I-Premise
% I-Premise
de I-Premise
CR I-Premise
, I-Premise
39 I-Premise
% I-Premise
de I-Premise
PR I-Premise
) I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
. I-Premise

La B-Premise
ORR I-Premise
también I-Premise
fue I-Premise
mayor I-Premise
con I-Premise
la I-Premise
TA I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
con I-Premise
afectación I-Premise
visceral I-Premise
( I-Premise
58 I-Premise
% I-Premise
frente I-Premise
a I-Premise
41 I-Premise
% I-Premise
; I-Premise
hígado I-Premise
, I-Premise
62 I-Premise
% I-Premise
frente I-Premise
a I-Premise
42 I-Premise
% I-Premise
; I-Premise
pulmón I-Premise
, I-Premise
58 I-Premise
% I-Premise
frente I-Premise
a I-Premise
35 I-Premise
% I-Premise
) I-Premise
, I-Premise
tres I-Premise
o I-Premise
más I-Premise
órganos I-Premise
implicados I-Premise
( I-Premise
59 I-Premise
% I-Premise
frente I-Premise
a I-Premise
40 I-Premise
% I-Premise
) I-Premise
, I-Premise
o I-Premise
TAC I-Premise
adyuvante I-Premise
previo I-Premise
( I-Premise
53 I-Premise
% I-Premise
frente I-Premise
a I-Premise
41 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Premise
supervivencia I-Premise
global I-Premise
(SG) I-Premise
fue I-Premise
comparable I-Premise
en I-Premise
ambos I-Premise
brazos. I-Premise

La B-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
fue I-Premise
frecuente I-Premise
en I-Premise
ambos I-Premise
grupos, I-Premise
aunque B-Premise
la I-Premise
neutropenia I-Premise
febril I-Premise
y I-Premise
las I-Premise
infecciones I-Premise
fueron I-Premise
más I-Premise
frecuentes I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
tomaron I-Premise
AT I-Premise
( I-Premise
respectivamente, I-Premise
33 I-Premise
% I-Premise
frente I-Premise
a I-Premise
10 I-Premise
%, I-Premise
P I-Premise
< I-Premise
0,001; I-Premise
8 I-Premise
% I-Premise
frente I-Premise
a I-Premise
2 I-Premise
%, I-Premise
P I-Premise
= I-Premise
0,01 I-Premise
). O

La B-Premise
toxicidad I-Premise
no I-Premise
hematológica I-Premise
grave I-Premise
fue I-Premise
infrecuente I-Premise
en I-Premise
ambos I-Premise
grupos, I-Premise
incluyendo I-Premise
eventos I-Premise
cardíacos I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
( I-Premise
AT I-Premise
, I-Premise
3 I-Premise
% I-Premise
; I-Premise
AC I-Premise
, I-Premise
4 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Claim
AT I-Claim
mejora I-Claim
significativamente I-Claim
el I-Claim
TTP I-Claim
y I-Claim
la I-Claim
ORR I-Claim
en I-Claim
comparación I-Claim
con I-Claim
la I-Claim
AC I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
CMB, I-Claim
pero B-Claim
no I-Claim
hay I-Claim
diferencias I-Claim
en I-Claim
la I-Claim
SG. I-Claim

La B-Claim
TA I-Claim
representa I-Claim
una I-Claim
opción I-Claim
válida I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
del I-Claim
CMB. I-Claim

Se O
han O
realizado O
pocos O
estudios O
de O
intervención O
para O
ayudar O
a O
las O
parejas O
a O
manejar O
los O
efectos O
del O
cáncer O
de O
próstata O
y O
mantener O
su O
calidad O
de O
vida O
. O

El O
objetivo O
de O
este O
estudio O
fue O
determinar O
si O
una O
intervención O
basada O
en O
la O
familia O
podía O
mejorar O
las O
variables O
de O
valoración O
( O
valoración O
de O
la O
enfermedad O
o O
de O
los O
cuidados, O
incertidumbre, O
desesperanza O
) O
, O
los O
recursos O
de O
afrontamiento O
( O
estrategias O
de O
afrontamiento, O
autoeficacia, O
comunicación O
) O
, O
la O
angustia O
por O
los O
síntomas O
y O
la O
calidad O
de O
vida O
en O
hombres O
con O
cáncer O
de O
próstata O
y O
sus O
cónyuges O
. O

Para O
este O
ensayo O
clínico, O
se O
estratificaron O
263 O
díadas O
de O
pacientes O
y O
cónyuges O
según O
el O
lugar O
de O
la O
investigación, O
la O
fase O
de O
la O
enfermedad O
y O
el O
tratamiento; O
a O
continuación, O
se O
asignaron O
aleatoriamente O
al O
grupo O
de O
control O
(atención O
estándar) O
o O
al O
grupo O
experimental O
(atención O
estándar O
más O
una O
intervención O
familiar O
de O
5 O
sesiones). O

La O
intervención O
se O
centró O
en O
la O
comunicación O
de O
las O
parejas, O
la O
esperanza, O
el O
afrontamiento, O
la O
incertidumbre O
y O
la O
gestión O
de O
los O
síntomas. O

La O
muestra O
final O
estaba O
formada O
por O
235 O
parejas: O
123 O
parejas O
en O
el O
grupo O
de O
control O
y O
112 O
parejas O
en O
el O
grupo O
experimental. O

Los O
datos O
se O
recogieron O
en O
la O
línea O
de O
base O
antes O
de O
la O
aleatorización O
y O
a O
los O
4 O
meses, O
8 O
meses O
y O
12 O
meses. O

A B-Premise
los I-Premise
4 I-Premise
meses I-Premise
de I-Premise
seguimiento, I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
la I-Premise
intervención I-Premise
informaron I-Premise
de I-Premise
menos I-Premise
inseguridad I-Premise
y I-Premise
mejor I-Premise
comunicación I-Premise
con I-Premise
los I-Premise
cónyuges I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
de I-Premise
control, I-Premise
pero B-Premise
no I-Premise
informaron I-Premise
de I-Premise
otros I-Premise
efectos. I-Premise

Los B-Premise
cónyuges I-Premise
de I-Premise
la I-Premise
intervención I-Premise
informaron I-Premise
de I-Premise
una I-Premise
mayor I-Premise
calidad I-Premise
de I-Premise
vida, I-Premise
más I-Premise
autoeficacia, I-Premise
mejor I-Premise
comunicación I-Premise
y I-Premise
menos I-Premise
valoración I-Premise
negativa I-Premise
de I-Premise
los I-Premise
cuidados, I-Premise
incertidumbre, I-Premise
desesperanza I-Premise
y I-Premise
angustia I-Premise
por I-Premise
los I-Premise
síntomas I-Premise
a I-Premise
los I-Premise
4 I-Premise
meses I-Premise
en I-Premise
comparación I-Premise
con I-Premise
los I-Premise
controles, I-Premise
y I-Premise
algunos I-Premise
efectos I-Premise
se I-Premise
mantuvieron I-Premise
a I-Premise
los I-Premise
8 I-Premise
y I-Premise
12 I-Premise
meses. I-Premise

Los B-Premise
hombres I-Premise
con I-Premise
cáncer I-Premise
de I-Premise
próstata I-Premise
y I-Premise
sus I-Premise
cónyuges I-Premise
informaron I-Premise
de I-Premise
los I-Premise
resultados I-Premise
positivos I-Premise
de I-Premise
una I-Premise
intervención I-Premise
familiar I-Premise
que I-Premise
les I-Premise
ofreció I-Premise
información I-Premise
y I-Premise
apoyo I-Premise
. I-Premise

Los B-Claim
programas I-Claim
de I-Claim
atención I-Claim
deben I-Claim
extenderse I-Claim
a I-Claim
los I-Claim
cónyuges, I-Claim
que I-Claim
probablemente I-Claim
experimentarán I-Claim
múltiples I-Claim
beneficios I-Claim
de I-Claim
la I-Claim
intervención I-Claim
. I-Claim

El O
entrenamiento O
con O
ejercicios O
mejora O
los O
resultados O
de O
los O
cuidados O
de O
apoyo O
en O
pacientes O
con O
cáncer O
de O
mama O
que O
reciben O
terapia O
adyuvante O
, O
pero O
las O
respuestas O
son O
heterogéneas O
. O

En O
este O
estudio, O
los O
autores O
examinaron O
los O
factores O
personales O
y O
clínicos O
que O
pueden O
predecir O
las O
respuestas O
al O
entrenamiento O
con O
ejercicios. O

Las O
pacientes O
con O
cáncer O
de O
mama O
que O
iniciaban O
quimioterapia O
adyuvante O
( O
N=242 O
) O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
atención O
habitual O
( O
UC O
) O
( O
n=82 O
) O
, O
entrenamiento O
con O
ejercicios O
de O
resistencia O
( O
RET O
) O
( O
n=82 O
) O
, O
o O
entrenamiento O
con O
ejercicios O
aeróbicos O
( O
AET O
) O
( O
n=78 O
) O
durante O
la O
duración O
de O
la O
quimioterapia O
. O

Los O
criterios O
de O
valoración O
fueron O
la O
calidad O
de O
vida O
( O
QoL O
) O
, O
la O
aptitud O
aeróbica O
, O
la O
fuerza O
muscular O
, O
la O
masa O
corporal O
magra O
y O
la O
grasa O
corporal O
. O

Los O
moderadores O
fueron O
la O
preferencia O
del O
paciente O
por O
la O
asignación O
al O
grupo, O
el O
estado O
civil, O
la O
edad, O
el O
estadio O
de O
la O
enfermedad O
y O
el O
régimen O
de O
quimioterapia. O

Los O
análisis O
lineales O
ajustados O
de O
modelos O
mixtos O
demostraron O
que O
la O
preferencia O
del O
paciente O
moderaba O
la O
respuesta O
de O
la O
CdV O
( O
P= O
.005 O
) O
. O

Los B-Premise
pacientes I-Premise
que I-Premise
prefirieron I-Premise
RET I-Premise
mejoraron I-Premise
su I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
cuando I-Premise
fueron I-Premise
asignados I-Premise
a I-Premise
recibir I-Premise
RET I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
CU I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
, I-Premise
16,5 I-Premise
; I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4,3-28,7 I-Premise
; I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
o I-Premise
AET I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
, I-Premise
11 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1,1-23,4 I-Premise
; I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
que I-Premise
no I-Premise
tenían I-Premise
preferencias I-Premise
mejoraron I-Premise
su I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
cuando I-Premise
fueron I-Premise
asignados I-Premise
a I-Premise
recibir I-Premise
AET I-Premise
en I-Premise
comparación I-Premise
con I-Premise
RET I-Premise
( I-Premise
diferencia I-Premise
media I-Premise
, I-Premise
23 I-Premise
; I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
4,9-41 I-Premise
; I-Premise
P= I-Premise
.014 I-Premise
) I-Premise
. I-Premise

El B-Premise
estado I-Premise
civil I-Premise
también I-Premise
moderó I-Premise
la I-Premise
respuesta I-Premise
de I-Premise
la I-Premise
CdV I-Premise
( I-Premise
P= I-Premise
.026 I-Premise
) I-Premise
, I-Premise
la I-Premise
edad I-Premise
moderó I-Premise
la I-Premise
respuesta I-Premise
de I-Premise
la I-Premise
aptitud I-Premise
aeróbica I-Premise
( I-Premise
P= I-Premise
.029 I-Premise
) I-Premise
, I-Premise
el I-Premise
régimen I-Premise
de I-Premise
quimioterapia I-Premise
moderó I-Premise
la I-Premise
ganancia I-Premise
de I-Premise
fuerza I-Premise
( I-Premise
P= I-Premise
.009 I-Premise
) I-Premise
, I-Premise
y I-Premise
el I-Premise
estadio I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
moderó I-Premise
tanto I-Premise
la I-Premise
ganancia I-Premise
de I-Premise
masa I-Premise
corporal I-Premise
magra I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
como I-Premise
la I-Premise
pérdida I-Premise
de I-Premise
grasa I-Premise
( I-Premise
P= I-Premise
.059 I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
solteros I-Premise
y I-Premise
más I-Premise
jóvenes I-Premise
que I-Premise
recibían I-Premise
terapias I-Premise
no I-Premise
basadas I-Premise
en I-Premise
taxanos I-Premise
y I-Premise
tenían I-Premise
un I-Premise
estadio I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
más I-Premise
avanzado I-Premise
experimentaron I-Premise
mejores I-Premise
resultados. I-Premise

Los O
resultados O
no O
se O
explican O
por O
las O
diferencias O
de O
adherencia. O

La B-Claim
preferencia I-Claim
del I-Claim
paciente, I-Claim
las I-Claim
variables I-Claim
demográficas I-Claim
y I-Claim
las I-Claim
variables I-Claim
médicas I-Claim
moderaron I-Claim
los I-Claim
efectos I-Claim
del I-Claim
entrenamiento I-Claim
con I-Claim
ejercicios I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
que I-Claim
recibían I-Claim
quimioterapia. I-Claim

Si O
se O
reproducen, O
estos O
resultados O
pueden O
servir O
de O
base O
para O
la O
práctica O
clínica. O

Comparar O
los O
efectos O
a O
corto O
y O
largo O
plazo O
del O
tratamiento O
adyuvante O
frente O
a O
la O
observación O
después O
de O
la O
cirugía O
en O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
HRQL O
) O
de O
los O
pacientes O
con O
cáncer O
de O
próstata O
. O

El O
ensayo O
intergrupal O
del O
Grupo O
de O
Oncología O
del O
Suroeste O
( O
SWOG O
) O
comparó O
la O
prostatectomía O
radical O
( O
PR O
) O
más O
observación O
frente O
a O
la O
PR O
más O
radioterapia O
adyuvante O
( O
RT O
) O
. O

Doscientos O
diecisiete O
de O
los O
425 O
pacientes O
del O
ensayo O
terapéutico O
fueron O
elegibles O
y O
se O
registraron O
en O
el O
estudio O
de O
CVRS. O

Los O
pacientes O
completaron O
el O
Cuestionario O
de O
Calidad O
de O
Vida O
de O
SWOG O
( O
función O
emocional, O
física, O
social O
y O
de O
rol; O
estado O
de O
los O
síntomas O
generales; O
síntomas O
específicos O
del O
tratamiento/de O
la O
enfermedad; O
y O
CVRS O
global O
[ O
GHRQL O
] O
) O
al O
inicio, O
a O
las O
6 O
semanas, O
a O
los O
6 O
meses O
y O
anualmente O
durante O
5 O
años. O

Los O
resultados O
preespecificados O
fueron O
tres O
síntomas O
genitourinarios O
(sensibilidad O
a O
la O
función O
intestinal, O
micción O
frecuente O
y O
disfunción O
eréctil) O
y O
medidas O
de O
función O
física O
y O
emocional. O

Se O
realizaron O
ajustes O
para O
la O
puntuación O
de O
referencia. O

Los O
pacientes O
que O
recibieron O
RT O
adyuvante O
informaron O
de O
una O
peor O
función O
intestinal O
( O
hasta O
aproximadamente O
2 O
años O
) O
y O
una O
peor O
función O
urinaria O
. O

No O
hubo O
diferencias O
estadísticamente O
significativas O
en O
cuanto O
a O
la O
disfunción O
eréctil. O

La B-Premise
GHRQL I-Premise
fue I-Premise
inicialmente I-Premise
peor I-Premise
para I-Premise
el I-Premise
brazo I-Premise
de I-Premise
RP+RT, I-Premise
pero I-Premise
mejoró I-Premise
con I-Premise
el I-Premise
tiempo I-Premise
y I-Premise
fue I-Premise
mejor I-Premise
al I-Premise
final I-Premise
del I-Premise
período I-Premise
que I-Premise
la I-Premise
GHRQL I-Premise
reportada I-Premise
para I-Premise
RP I-Premise
sola I-Premise
( I-Premise
interacción I-Premise
brazo I-Premise
de I-Premise
tratamiento I-Premise
x I-Premise
tiempo I-Premise
, I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
. I-Premise

El O
malestar B-Premise
por I-Premise
los I-Premise
síntomas I-Premise
fue I-Premise
significativamente I-Premise
peor I-Premise
en I-Premise
el I-Premise
brazo I-Premise
de I-Premise
RP+RT I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
brazo I-Premise
de I-Premise
RP I-Premise
solo, I-Premise
pero B-Premise
los I-Premise
brazos I-Premise
de I-Premise
tratamiento I-Premise
no I-Premise
difirieron I-Premise
con I-Premise
respecto I-Premise
a I-Premise
otras I-Premise
medidas I-Premise
generales I-Premise
de I-Premise
CVRS. I-Premise

La B-Premise
adición I-Premise
de I-Premise
la I-Premise
RT I-Premise
a I-Premise
la I-Premise
cirugía I-Premise
dio I-Premise
lugar I-Premise
a I-Premise
una I-Premise
micción I-Premise
más I-Premise
frecuente, I-Premise
así I-Premise
como I-Premise
a I-Premise
la I-Premise
notificación I-Premise
temprana I-Premise
de I-Premise
una I-Premise
mayor I-Premise
disfunción I-Premise
intestinal, I-Premise
aunque B-Premise
las I-Premise
diferencias I-Premise
en I-Premise
la I-Premise
función I-Premise
intestinal I-Premise
desaparecieron I-Premise
durante I-Premise
el I-Premise
período I-Premise
de I-Premise
5 I-Premise
años. I-Premise

La B-Claim
adición I-Claim
de I-Claim
RT I-Claim
no I-Claim
tuvo I-Claim
un I-Claim
impacto I-Claim
negativo I-Claim
en I-Claim
la I-Claim
ED I-Claim
. I-Claim

Los B-Claim
datos I-Claim
sugieren I-Claim
que I-Claim
la I-Claim
fase I-Claim
de I-Claim
reincorporación I-Claim
(es I-Claim
decir, I-Claim
el I-Claim
período I-Claim
inicial I-Claim
tras I-Claim
la I-Claim
finalización I-Claim
del I-Claim
tratamiento I-Claim
médico) I-Claim
presenta I-Claim
distintos I-Claim
retos I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer. I-Claim

Para O
facilitar O
la O
transición O
a O
la O
recuperación, O
se O
llevó O
a O
cabo O
el O
ensayo O
Moving O
Beyond O
Cancer O
( O
MBC O
), O
un O
ensayo O
aleatorizado O
y O
controlado O
de O
intervenciones O
psicoeducativas O
para O
pacientes O
con O
cáncer O
de O
mama. O

Las O
pacientes O
con O
cáncer O
de O
mama O
se O
registraron O
en O
las O
6 O
semanas O
siguientes O
a O
la O
cirugía. O

Después O
del O
tratamiento O
médico, O
completaron O
las O
medidas O
de O
referencia O
y O
fueron O
asignados O
aleatoriamente O
a O
material O
impreso O
estándar O
del O
Instituto O
Nacional O
del O
Cáncer O
( O
CTL O
) O
; O
material O
impreso O
estándar O
y O
cinta O
de O
vídeo O
de O
modelado O
por O
pares O
( O
VID O
) O
; O
o O
material O
impreso O
estándar O
, O
cinta O
de O
vídeo O
, O
dos O
sesiones O
con O
un O
educador O
de O
cáncer O
capacitado O
, O
y O
libro O
de O
trabajo O
informativo O
( O
EDU O
) O
. O

Se O
examinaron O
dos O
puntos O
finales O
primarios: O
la O
energía/fatiga O
y O
la O
angustia O
específica O
del O
cáncer. O

Los O
puntos O
finales O
secundarios O
fueron O
los O
síntomas O
depresivos O
y O
el O
crecimiento O
postraumático. O

La O
preparación O
percibida O
para O
el O
reingreso O
se O
analizó O
como O
moderador O
de O
los O
efectos O
. O

De O
las O
558 O
mujeres O
asignadas O
aleatoriamente O
al O
tratamiento, O
418 O
completaron O
la O
evaluación O
de O
los O
6 O
meses O
y O
399 O
la O
de O
los O
12 O
meses. O

En B-Premise
los I-Premise
análisis I-Premise
que I-Premise
controlan I-Premise
el I-Premise
lugar I-Premise
del I-Premise
estudio I-Premise
y I-Premise
los I-Premise
síntomas I-Premise
depresivos I-Premise
iniciales, I-Premise
el I-Premise
VID I-Premise
produjo I-Premise
una I-Premise
mejora I-Premise
significativa I-Premise
de I-Premise
la I-Premise
energía/fatiga I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
en I-Premise
relación I-Premise
con I-Premise
el I-Premise
CTL, I-Premise
especialmente I-Premise
entre I-Premise
las I-Premise
mujeres I-Premise
que I-Premise
se I-Premise
sentían I-Premise
menos I-Premise
preparadas I-Premise
para I-Premise
la I-Premise
reincorporación I-Premise
al I-Premise
inicio. I-Premise

No B-Premise
surgió I-Premise
ningún I-Premise
efecto I-Premise
principal I-Premise
significativo I-Premise
de I-Premise
las I-Premise
intervenciones I-Premise
sobre I-Premise
la I-Premise
angustia I-Premise
específica I-Premise
del I-Premise
cáncer, I-Premise
pero B-Premise
la I-Premise
UDE I-Premise
provocó I-Premise
una I-Premise
mayor I-Premise
reducción I-Premise
de I-Premise
este I-Premise
resultado I-Premise
en I-Premise
relación I-Premise
con I-Premise
la I-Premise
LTC I-Premise
a I-Premise
los I-Premise
6 I-Premise
meses I-Premise
para I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
se I-Premise
sentían I-Premise
más I-Premise
preparados I-Premise
para I-Premise
la I-Premise
reincorporación. I-Premise

Las B-Premise
diferencias I-Premise
entre I-Premise
grupos I-Premise
en I-Premise
los I-Premise
resultados I-Premise
primarios I-Premise
no I-Premise
fueron I-Premise
significativas I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses, I-Premise
y B-Premise
no I-Premise
surgieron I-Premise
efectos I-Premise
significativos I-Premise
en I-Premise
los I-Premise
puntos I-Premise
finales I-Premise
secundarios. I-Premise

Una B-Claim
cinta I-Claim
de I-Claim
vídeo I-Claim
de I-Claim
modelado I-Claim
entre I-Claim
iguales I-Claim
puede I-Claim
acelerar I-Claim
la I-Claim
recuperación I-Claim
de I-Claim
la I-Claim
energía I-Claim
durante I-Claim
la I-Claim
fase I-Claim
de I-Claim
reincorporación I-Claim
en I-Claim
las I-Claim
mujeres I-Claim
tratadas I-Claim
de I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
, I-Claim
especialmente I-Claim
entre I-Claim
las I-Claim
que I-Claim
se I-Claim
sienten I-Claim
menos I-Claim
preparadas I-Claim
para I-Claim
la I-Claim
reincorporación I-Claim
. I-Claim

La B-Claim
biopsia I-Claim
del I-Claim
ganglio I-Claim
linfático I-Claim
centinela I-Claim
en I-Claim
mujeres I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
operable I-Claim
se I-Claim
utiliza I-Claim
de I-Claim
forma I-Claim
rutinaria I-Claim
en I-Claim
algunos I-Claim
países I-Claim
para I-Claim
la I-Claim
estadificación I-Claim
de I-Claim
la I-Claim
axila, I-Claim
a I-Claim
pesar I-Claim
de I-Claim
los I-Claim
limitados I-Claim
datos I-Claim
de I-Claim
los I-Claim
ensayos I-Claim
aleatorios I-Claim
sobre I-Claim
los I-Claim
resultados I-Claim
de I-Claim
morbilidad I-Claim
y I-Claim
mortalidad I-Claim
. I-Claim

Se O
llevó O
a O
cabo O
un O
ensayo O
aleatorio O
multicéntrico O
para O
comparar O
los O
resultados O
de O
calidad O
de O
vida O
entre O
las O
pacientes O
con O
cáncer O
de O
mama O
invasivo O
con O
ganglios O
clínicos O
negativos O
que O
recibieron O
la O
biopsia O
del O
ganglio O
linfático O
centinela O
y O
las O
pacientes O
que O
recibieron O
el O
tratamiento O
axilar O
estándar O
. O

Las O
medidas O
de O
resultado O
primarias O
fueron O
la O
morbilidad O
del O
brazo O
y O
el O
hombro O
y O
la O
calidad O
de O
vida. O

Entre O
noviembre O
de O
1999 O
y O
octubre O
de O
2003, O
1031 O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
someterse O
a O
una O
biopsia O
de O
ganglio O
linfático O
centinela O
( O
n O
= O
515 O
) O
o O
a O
una O
cirugía O
axilar O
estándar O
( O
n O
= O
516 O
) O
. O

Los O
pacientes O
con O
metástasis O
en O
los O
ganglios O
linfáticos O
centinela O
procedieron O
a O
un O
vaciado O
axilar O
retrasado O
o O
recibieron O
radioterapia O
axilar O
( O
según O
el O
protocolo O
de O
la O
institución O
tratante O
) O
. O

Se O
presentan O
los O
análisis O
por O
intención O
de O
tratar O
de O
los O
datos O
a O
1, O
3, O
6 O
y O
12 O
meses O
después O
de O
la O
cirugía. O

Todas O
las O
pruebas O
estadísticas O
fueron O
de O
dos O
caras. O

Los B-Premise
riesgos I-Premise
relativos I-Premise
de I-Premise
cualquier I-Premise
linfedema I-Premise
y I-Premise
pérdida I-Premise
sensorial I-Premise
para I-Premise
el I-Premise
grupo I-Premise
de I-Premise
biopsia I-Premise
del I-Premise
ganglio I-Premise
linfático I-Premise
centinela I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
tratamiento I-Premise
axilar I-Premise
estándar I-Premise
a I-Premise
los I-Premise
12 I-Premise
meses I-Premise
fueron I-Premise
de I-Premise
0,37 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0,23 I-Premise
a I-Premise
0,60 I-Premise
; I-Premise
tasas I-Premise
absolutas I-Premise
: I-Premise
5 I-Premise
% I-Premise
frente I-Premise
a I-Premise
13 I-Premise
% I-Premise
) I-Premise
y I-Premise
0,37 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
= I-Premise
0,27 I-Premise
a I-Premise
0,50 I-Premise
; I-Premise
tasas I-Premise
absolutas I-Premise
: I-Premise
11 I-Premise
% I-Premise
frente I-Premise
a I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectivamente I-Premise
. I-Premise

El B-Premise
uso I-Premise
de I-Premise
drenajes, I-Premise
la I-Premise
duración I-Premise
de I-Premise
la I-Premise
estancia I-Premise
hospitalaria I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
reanudación I-Premise
de I-Premise
las I-Premise
actividades I-Premise
cotidianas I-Premise
después I-Premise
de I-Premise
la I-Premise
cirugía I-Premise
fueron I-Premise
estadísticamente I-Premise
significativos I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
biopsia I-Premise
del I-Premise
ganglio I-Premise
linfático I-Premise
centinela I-Premise
( I-Premise
todos I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
y I-Premise
el I-Premise
tiempo I-Premise
operativo I-Premise
axilar I-Premise
se I-Premise
redujo I-Premise
( I-Premise
P I-Premise
= I-Premise
0,055 I-Premise
) I-Premise
. I-Premise

Las B-Premise
puntuaciones I-Premise
globales I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
de I-Premise
funcionamiento I-Premise
del I-Premise
brazo I-Premise
registradas I-Premise
por I-Premise
los I-Premise
pacientes I-Premise
fueron I-Premise
estadísticamente I-Premise
significativas I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
biopsia I-Premise
del I-Premise
ganglio I-Premise
linfático I-Premise
centinela I-Premise
en I-Premise
todo I-Premise
momento I-Premise
( I-Premise
todas I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Estos B-Premise
beneficios I-Premise
se I-Premise
observaron I-Premise
sin I-Premise
que I-Premise
aumentaran I-Premise
los I-Premise
niveles I-Premise
de I-Premise
ansiedad I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
la I-Premise
biopsia I-Premise
del I-Premise
ganglio I-Premise
linfático I-Premise
centinela I-Premise
( I-Premise
P I-Premise
> I-Premise
.05 I-Premise
) I-Premise
. I-Premise

La B-Claim
biopsia I-Claim
del I-Claim
ganglio I-Claim
linfático I-Claim
centinela I-Claim
se I-Claim
asocia I-Claim
a I-Claim
una I-Claim
menor I-Claim
morbilidad I-Claim
en I-Claim
el I-Claim
brazo I-Claim
y I-Claim
a I-Claim
una I-Claim
mejor I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
que I-Claim
el I-Claim
tratamiento I-Claim
axilar I-Claim
estándar, I-Claim
y I-Claim
debería I-Claim
ser I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
elección I-Claim
para I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
en I-Claim
fase I-Claim
inicial I-Claim
con I-Claim
ganglios I-Claim
clínicamente I-Claim
negativos I-Claim
. I-Claim

Determinar O
los O
efectos O
inmediatos O
y O
a O
largo O
plazo O
de O
la O
acupuntura O
verdadera O
frente O
a O
la O
acupuntura O
simulada O
sobre O
la O
frecuencia O
de O
los O
sofocos O
en O
mujeres O
con O
cáncer O
de O
mama O
. O

Setenta O
y O
dos O
mujeres O
con O
cáncer O
de O
mama O
que O
experimentaban O
tres O
o O
más O
sofocos O
al O
día O
fueron O
asignadas O
aleatoriamente O
a O
recibir O
acupuntura O
verdadera O
o O
falsa. O

Las O
intervenciones O
se O
realizaron O
dos O
veces O
por O
semana O
durante O
4 O
semanas O
consecutivas. O

La O
frecuencia O
de O
los O
sofocos O
se O
evaluó O
al O
inicio, O
a O
las O
6 O
semanas O
y O
a O
los O
6 O
meses O
de O
iniciado O
el O
tratamiento. O

Los O
pacientes O
inicialmente O
asignados O
al O
azar O
al O
grupo O
simulado O
fueron O
cruzados O
a O
la O
acupuntura O
verdadera O
a O
partir O
de O
la O
séptima O
semana. O

El O
número O
medio O
de O
sofocos O
por O
día O
se O
redujo O
de O
8,7 O
( O
desviación O
estándar O
[ O
SD O
] O
, O
3,9 O
) O
a O
6,2 O
( O
SD O
, O
4,2 O
) O
en O
el O
grupo O
de O
acupuntura O
verdadera O
y O
de O
10,0 O
( O
SD O
, O
6,1 O
) O
a O
7,6 O
( O
SD O
, O
5,7 O
) O
en O
el O
grupo O
de O
simulación O
. O

La B-Premise
acupuntura I-Premise
verdadera I-Premise
se I-Premise
asoció I-Premise
con I-Premise
0,8 I-Premise
sofocos I-Premise
menos I-Premise
por I-Premise
día I-Premise
que I-Premise
la I-Premise
simulada I-Premise
a I-Premise
las I-Premise
6 I-Premise
semanas I-Premise
, O
pero B-Premise
la I-Premise
diferencia I-Premise
no I-Premise
alcanzó I-Premise
significación I-Premise
estadística I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
-0,7 I-Premise
a I-Premise
2,4 I-Premise
; I-Premise
P I-Premise
= I-Premise
0,3 I-Premise
) O
. O

Cuando B-Premise
los I-Premise
participantes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
acupuntura I-Premise
simulada I-Premise
se I-Premise
pasaron I-Premise
a I-Premise
la I-Premise
acupuntura I-Premise
verdadera, I-Premise
se I-Premise
observó I-Premise
una I-Premise
mayor I-Premise
reducción I-Premise
de I-Premise
la I-Premise
frecuencia I-Premise
de I-Premise
los I-Premise
sofocos. I-Premise

Esta O
reducción O
de O
la O
frecuencia O
de O
los O
sofocos O
persistió O
hasta O
6 O
meses O
después O
de O
la O
finalización O
del O
tratamiento. O

La B-Claim
frecuencia I-Claim
de I-Claim
los I-Claim
sofocos I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
se I-Claim
redujo I-Claim
tras I-Claim
la I-Claim
acupuntura I-Claim
. I-Claim

Sin O
embargo, O
cuando B-Premise
se I-Premise
comparó I-Premise
con I-Premise
la I-Premise
acupuntura I-Premise
simulada, I-Premise
la I-Premise
reducción I-Premise
del I-Premise
régimen I-Premise
de I-Premise
acupuntura, I-Premise
tal I-Premise
como I-Premise
se I-Premise
proporciona I-Premise
en I-Premise
el I-Premise
presente I-Premise
estudio, I-Premise
no I-Premise
alcanzó I-Premise
significación I-Premise
estadística. I-Premise

No B-Claim
podemos I-Claim
excluir I-Claim
la I-Claim
posibilidad I-Claim
de I-Claim
que I-Claim
una I-Claim
intervención I-Claim
de I-Claim
acupuntura I-Claim
más I-Claim
larga I-Claim
e I-Claim
intensa I-Claim
pueda I-Claim
producir I-Claim
una I-Claim
mayor I-Claim
reducción I-Claim
de I-Claim
estos I-Claim
síntomas I-Claim
. I-Claim

El O
tratamiento O
de O
agente O
único O
con O
bicalutamida O
, O
un O
antiandrógeno O
no O
esteroideo O
, O
se O
comparó O
con O
la O
castración O
, O
ya O
sea O
quirúrgica O
o O
médica O
, O
en O
pacientes O
con O
cáncer O
de O
próstata O
en O
estadio O
D2 O
no O
tratado O
. O

En O
un O
ensayo O
abierto, O
aleatorio O
y O
multicéntrico, O
los O
pacientes O
fueron O
asignados O
al O
azar O
a O
un O
tratamiento O
con O
50 O
mg O
de O
bicalutamida O
( O
n O
= O
243 O
) O
una O
vez O
al O
día O
o O
a O
la O
castración O
( O
n O
= O
243 O
) O
, O
ya O
sea O
orquiectomía O
o O
inyección O
de O
depósito O
de O
acetato O
de O
goserelina O
cada O
28 O
días O
. O

Los O
criterios O
de O
valoración O
primarios O
de O
la O
eficacia O
fueron O
los O
tiempos O
hasta O
el O
fracaso O
del O
tratamiento O
y O
la O
progresión O
objetiva O
de O
la O
enfermedad O
y O
la O
supervivencia. O

Las O
evaluaciones O
incluyeron O
la O
revisión O
de O
las O
metástasis O
medibles, O
las O
dimensiones O
de O
la O
próstata, O
el O
estado O
de O
rendimiento O
del O
Eastern O
Cooperative O
Oncology O
Group, O
el O
dolor, O
las O
necesidades O
de O
analgésicos O
y O
las O
respuestas O
de O
calidad O
de O
vida. O

La O
mediana O
de O
la O
duración O
del O
tratamiento O
fue O
de O
39 O
semanas O
para O
los O
pacientes O
tratados O
con O
bicalutamida O
y O
de O
42 O
semanas O
para O
los O
castrados; O
el O
fracaso O
del O
tratamiento O
se O
produjo O
en O
el O
53% O
y O
el O
42% O
y O
la O
progresión O
de O
la O
enfermedad O
en O
el O
43% O
y O
el O
33% O
, O
respectivamente. O

Los B-Premise
efectos I-Premise
del I-Premise
tratamiento I-Premise
favorecieron I-Premise
la I-Premise
castración I-Premise
para I-Premise
ambos I-Premise
criterios I-Premise
de I-Premise
valoración I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
, I-Premise
con I-Premise
cocientes I-Premise
de I-Premise
riesgo I-Premise
( I-Premise
bicalutamida I-Premise
: I-Premise
castración I-Premise
) I-Premise
de I-Premise
1,54 I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
[ I-Premise
IC I-Premise
] I-Premise
, I-Premise
1,18 I-Premise
a I-Premise
2,00 I-Premise
) I-Premise
para I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
el I-Premise
fracaso I-Premise
del I-Premise
tratamiento I-Premise
y I-Premise
1,6 I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
, I-Premise
1,19 I-Premise
a I-Premise
2,15 I-Premise
) I-Premise
para I-Premise
el I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
. I-Premise

En B-Premise
el I-Premise
análisis I-Premise
de I-Premise
la I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año, I-Premise
el I-Premise
cociente I-Premise
de I-Premise
riesgos I-Premise
para I-Premise
la I-Premise
probabilidad I-Premise
de I-Premise
muerte I-Premise
fue I-Premise
de I-Premise
1,29 I-Premise
(IC I-Premise
del I-Premise
95 I-Premise
%: I-Premise
0,96 I-Premise
a I-Premise
1,72). I-Premise

Hasta B-Premise
ahora, I-Premise
con I-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
86 I-Premise
semanas, I-Premise
no I-Premise
se I-Premise
ha I-Premise
alcanzado I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
en I-Premise
ninguno I-Premise
de I-Premise
los I-Premise
dos I-Premise
grupos. I-Premise

Los B-Premise
cambios I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
en I-Premise
varias I-Premise
variables I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
fueron I-Premise
significativamente I-Premise
diferentes I-Premise
( I-Premise
P I-Premise
< I-Premise
o I-Premise
= I-Premise
0,01 I-Premise
) I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento I-Premise
periódicamente I-Premise
de I-Premise
los I-Premise
meses I-Premise
1 I-Premise
a I-Premise
6 I-Premise
, I-Premise
y I-Premise
todos I-Premise
favorecieron I-Premise
a I-Premise
la I-Premise
bicalutamida I-Premise
. I-Premise

En B-Premise
general, I-Premise
los I-Premise
antiandrógenos I-Premise
fueron I-Premise
bien I-Premise
tolerados I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
castración; I-Premise
con B-Premise
la I-Premise
bicalutamida, I-Premise
los I-Premise
sofocos I-Premise
se I-Premise
produjeron I-Premise
con I-Premise
menos I-Premise
frecuencia I-Premise
y I-Premise
la I-Premise
sensibilidad I-Premise
mamaria I-Premise
y I-Premise
la I-Premise
ginecomastia I-Premise
con I-Premise
más I-Premise
frecuencia. I-Premise

Aunque B-Premise
una I-Premise
dosis I-Premise
de I-Premise
50 I-Premise
mg I-Premise
de I-Premise
bicalutamida I-Premise
una I-Premise
vez I-Premise
al I-Premise
día I-Premise
no I-Premise
fue I-Premise
tan I-Premise
eficaz I-Premise
como I-Premise
la I-Premise
castración I-Premise
, O
los B-Claim
resultados I-Claim
favorables I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
y I-Claim
la I-Claim
baja I-Claim
incidencia I-Claim
de I-Claim
eventos I-Claim
adversos I-Claim
no I-Claim
hormonales I-Claim
proporcionan I-Claim
razones I-Claim
para I-Claim
evaluar I-Claim
la I-Claim
bicalutamida I-Claim
, I-Claim
como I-Claim
agente I-Claim
terapéutico I-Claim
único I-Claim
, I-Claim
a I-Claim
dosis I-Claim
más I-Claim
altas O
. O

Probar O
la O
equivalencia O
de O
tres O
frente O
a O
cuatro O
ciclos O
de O
bleomicina O
, O
etopósido O
y O
cisplatino O
( O
BEP O
) O
y O
del O
esquema O
de O
5 O
días O
frente O
a O
3 O
días O
por O
ciclo O
en O
el O
cáncer O
de O
células O
germinales O
de O
buen O
pronóstico O
. O

El O
estudio O
se O
diseñó O
como O
un O
ensayo O
factorial O
2 O
x O
2 O
. O

El O
objetivo O
era O
descartar O
una O
disminución O
del O
5 O
% O
en O
la O
tasa O
de O
supervivencia O
libre O
de O
progresión O
(SLP) O
a O
dos O
años. O

El O
estudio O
incluía O
la O
evaluación O
de O
la O
calidad O
de O
vida O
de O
los O
pacientes. O

Un O
ciclo O
de O
BEP O
consistía O
en O
etopósido O
500 O
mg/m O
( O
2 O
) O
, O
administrado O
a O
razón O
de O
100 O
mg/m O
( O
2 O
) O
los O
días O
1 O
a O
5 O
o O
165 O
mg/m O
( O
2 O
) O
los O
días O
1 O
a O
3 O
, O
cisplatino O
100 O
mg/m O
( O
2 O
) O
, O
administrado O
a O
razón O
de O
20 O
mg/m O
( O
2 O
) O
los O
días O
1 O
a O
5 O
o O
50 O
mg/m O
( O
2 O
) O
los O
días O
1 O
y O
2 O
. O

Se O
administraron O
30 O
mg O
de O
bleomicina O
los O
días O
1, O
8 O
y O
15 O
durante O
los O
ciclos O
1 O
a O
3. O

El O
procedimiento O
de O
aleatorización O
permitió O
a O
algunos O
investigadores O
participar O
sólo O
en O
la O
comparación O
de O
tres O
frente O
a O
cuatro O
ciclos O
. O

Desde O
marzo O
de O
1995 O
hasta O
abril O
de O
1998, O
812 O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
tres O
o O
cuatro O
ciclos: O
de O
ellos, O
681 O
también O
fueron O
asignados O
aleatoriamente O
al O
programa O
de O
5 O
días O
o O
al O
de O
3 O
días. O

La O
histología, O
los O
valores O
de O
los O
marcadores O
y O
la O
extensión O
de O
la O
enfermedad O
están O
bien O
equilibrados O
en O
los O
brazos O
de O
tratamiento O
de O
las O
dos O
comparaciones. O

La B-Premise
previsión I-Premise
de I-Premise
la I-Premise
SLP I-Premise
a I-Premise
dos I-Premise
años I-Premise
es I-Premise
del I-Premise
90,4% I-Premise
con I-Premise
tres I-Premise
ciclos I-Premise
y I-Premise
del I-Premise
89,4% I-Premise
con I-Premise
cuatro I-Premise
ciclos. I-Premise

La B-Premise
diferencia I-Premise
en I-Premise
la I-Premise
SLP I-Premise
entre I-Premise
tres I-Premise
y I-Premise
cuatro I-Premise
ciclos I-Premise
es I-Premise
de I-Premise
-1,0 I-Premise
% I-Premise
( I-Premise
límite I-Premise
de I-Premise
confianza I-Premise
del I-Premise
80 I-Premise
% I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3,8 I-Premise
% I-Premise
, I-Premise
+1,8 I-Premise
% I-Premise
) I-Premise
. I-Premise

La B-Claim
equivalencia I-Claim
entre I-Claim
tres I-Claim
y I-Claim
cuatro I-Claim
ciclos I-Claim
se I-Claim
debe I-Claim
a I-Claim
que I-Claim
tanto I-Claim
el I-Claim
límite I-Claim
superior I-Claim
como I-Claim
el I-Claim
inferior I-Claim
del I-Claim
CL I-Claim
del I-Claim
80 I-Claim
% I-Claim
son I-Claim
inferiores I-Claim
al I-Claim
5 I-Claim
%. I-Claim

En B-Premise
la I-Premise
comparación I-Premise
de I-Premise
5 I-Premise
días I-Premise
frente I-Premise
a I-Premise
3 I-Premise
días I-Premise
, I-Premise
la I-Premise
previsión I-Premise
de I-Premise
la I-Premise
SLP I-Premise
a I-Premise
2 I-Premise
años I-Premise
es I-Premise
del I-Premise
88,8 I-Premise
% I-Premise
y I-Premise
del I-Premise
89,7 I-Premise
% I-Premise
, I-Premise
respectivamente I-Premise
( I-Premise
diferencia I-Premise
, I-Premise
-0,9 I-Premise
% I-Premise
, I-Premise
( I-Premise
80 I-Premise
% I-Premise
CL I-Premise
, I-Premise
-4,1 I-Premise
% I-Premise
, I-Premise
+2,2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Por O
lo O
tanto, O
también B-Claim
en I-Claim
esta I-Claim
comparación I-Claim
se I-Claim
reclama I-Claim
la I-Claim
equivalencia. I-Claim

Las B-Premise
frecuencias I-Premise
de I-Premise
las I-Premise
toxicidades I-Premise
hematológicas I-Premise
y I-Premise
no I-Premise
hematológicas I-Premise
fueron I-Premise
esencialmente I-Premise
similares. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
se I-Premise
mantuvo I-Premise
mejor I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
tres I-Premise
ciclos; I-Premise
no B-Premise
se I-Premise
detectaron I-Premise
diferencias I-Premise
entre I-Premise
3 I-Premise
y I-Premise
5 I-Premise
días I-Premise
de I-Premise
tratamiento. I-Premise

Concluimos O
que O
tres B-Claim
ciclos I-Claim
de I-Claim
BEP I-Claim
, I-Claim
con I-Claim
etopósido I-Claim
a I-Claim
500 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
es I-Claim
una I-Claim
terapia I-Claim
suficiente I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
de I-Claim
células I-Claim
germinales I-Claim
de I-Claim
buen I-Claim
pronóstico I-Claim
y O
que O
la B-Claim
administración I-Claim
de I-Claim
la I-Claim
quimioterapia I-Claim
en I-Claim
3 I-Claim
días I-Claim
no I-Claim
tiene I-Claim
ningún I-Claim
efecto I-Claim
perjudicial I-Claim
sobre I-Claim
la I-Claim
eficacia I-Claim
del I-Claim
régimen I-Claim
BEP I-Claim
. O

Se O
investigó O
la O
eficacia O
de O
un O
programa O
de O
educación O
sobre O
el O
dolor O
en O
pacientes O
con O
cáncer O
con O
dolor O
crónico O
ofrecido O
por O
enfermeras O
en O
un O
ensayo O
clínico O
controlado O
y O
aleatorio. O

Se O
utilizó O
un O
enfoque O
multimétodo O
en O
el O
que O
se O
combinaron O
instrucciones O
verbales, O
material O
escrito, O
una O
cinta O
de O
audio O
y O
el O
uso O
de O
un O
diario O
del O
dolor O
para O
informar O
e O
instruir O
a O
los O
pacientes O
sobre O
el O
dolor O
y O
su O
tratamiento. O

El O
programa O
de O
educación O
sobre O
el O
dolor O
se O
adaptó O
a O
las O
necesidades O
de O
cada O
paciente O
y O
consistió O
en O
tres O
elementos: O
( O
1 O
) O
educar O
a O
los O
pacientes O
sobre O
los O
principios O
básicos O
relativos O
al O
dolor O
y O
su O
tratamiento O
; O
( O
2 O
) O
instruir O
a O
los O
pacientes O
sobre O
cómo O
informar O
de O
su O
dolor O
en O
un O
diario O
del O
dolor O
; O
y O
( O
3 O
) O
instruir O
a O
los O
pacientes O
sobre O
cómo O
comunicar O
el O
dolor O
y O
cómo O
ponerse O
en O
contacto O
con O
los O
proveedores O
de O
atención O
sanitaria O
. O

Tras O
la O
realización O
de O
una O
prueba O
previa O
en O
313 O
pacientes, O
los O
pacientes O
que O
necesitaban O
enfermería O
de O
distrito O
y O
los O
que O
no O
necesitaban O
enfermería O
de O
distrito O
en O
su O
domicilio O
fueron O
asignados O
aleatoriamente O
a O
un O
grupo O
de O
control O
o O
de O
intervención. O

Los O
pacientes O
del O
grupo O
de O
intervención O
recibieron O
el O
Programa O
de O
Educación O
sobre O
el O
Dolor O
en O
el O
hospital, O
y O
a O
los O
3 O
y O
7 O
días O
después O
del O
alta, O
por O
teléfono; O
esto O
fue O
realizado O
por O
enfermeras O
especialmente O
formadas O
como O
consejeras O
del O
dolor. O

Las O
evaluaciones O
de O
seguimiento O
se O
realizaron O
a O
las O
2, O
4 O
y O
8 O
semanas O
después O
del O
alta. O

Los O
resultados O
de O
la O
prueba O
previa O
mostraron O
que O
muchos O
pacientes O
carecían O
de O
conocimientos O
sobre O
el O
dolor O
y O
su O
tratamiento. O

La O
mayoría O
de O
los O
temas O
de O
dolor O
tenían O
que O
ser O
discutidos O
. O

El B-Claim
Programa I-Claim
de I-Claim
Educación I-Claim
sobre I-Claim
el I-Claim
Dolor I-Claim
demostró I-Claim
ser I-Claim
factible: I-Claim
el B-Premise
75,0 I-Premise
% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
había I-Premise
leído I-Premise
el I-Premise
folleto I-Premise
completo I-Premise
sobre I-Premise
el I-Premise
dolor, I-Premise
el I-Premise
55,7 I-Premise
% I-Premise
había I-Premise
escuchado I-Premise
la I-Premise
cinta I-Premise
de I-Premise
audio, I-Premise
y I-Premise
el I-Premise
85,6 I-Premise
% I-Premise
de I-Premise
las I-Premise
puntuaciones I-Premise
de I-Premise
dolor I-Premise
se I-Premise
completaron I-Premise
en I-Premise
el I-Premise
diario I-Premise
del I-Premise
dolor. I-Premise

Los B-Claim
resultados I-Claim
mostraron I-Claim
un I-Claim
aumento I-Claim
significativo I-Claim
de I-Claim
los I-Claim
conocimientos I-Claim
sobre I-Claim
el I-Claim
dolor I-Claim
en I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
recibieron I-Claim
el I-Claim
Programa I-Claim
de I-Claim
Educación I-Claim
sobre I-Claim
el I-Claim
Dolor I-Claim
y I-Claim
una I-Claim
disminución I-Claim
significativa I-Claim
de I-Claim
la I-Claim
intensidad I-Claim
del I-Claim
dolor I-Claim
. I-Claim

Sin B-Premise
embargo I-Premise
, I-Premise
el I-Premise
alivio I-Premise
del I-Premise
dolor I-Premise
se I-Premise
encontró I-Premise
principalmente I-Premise
en I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
intervención I-Premise
sin I-Premise
enfermería I-Premise
de I-Premise
distrito I-Premise
. I-Premise

Se B-Claim
puede I-Claim
concluir I-Claim
que I-Claim
el I-Claim
Programa I-Claim
de I-Claim
Educación I-Claim
sobre I-Claim
el I-Claim
Dolor I-Claim
adaptado I-Claim
es I-Claim
eficaz I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
de I-Claim
cáncer I-Claim
con I-Claim
dolor I-Claim
crónico I-Claim
. I-Claim

El B-Claim
uso I-Claim
del I-Claim
Programa I-Claim
de I-Claim
Educación I-Claim
sobre I-Claim
el I-Claim
Dolor I-Claim
por I-Claim
parte I-Claim
de I-Claim
las I-Claim
enfermeras I-Claim
debería I-Claim
considerarse I-Claim
seriamente I-Claim
en I-Claim
las I-Claim
unidades I-Claim
de I-Claim
oncología I-Claim
. I-Claim

Las O
citoquinas O
proinflamatorias O
, O
especialmente O
el O
factor O
de O
necrosis O
tumoral O
alfa O
( O
TNF-alfa O
) O
, O
desempeñan O
un O
papel O
destacado O
en O
la O
patogénesis O
de O
la O
caquexia O
por O
cáncer O
. O

La B-Claim
talidomida I-Claim
, I-Claim
que I-Claim
es I-Claim
un I-Claim
inhibidor I-Claim
de I-Claim
la I-Claim
síntesis I-Claim
de I-Claim
TNF-alfa I-Claim
, I-Claim
puede I-Claim
representar I-Claim
un I-Claim
enfoque I-Claim
novedoso I-Claim
y I-Claim
racional I-Claim
para I-Claim
el I-Claim
tratamiento I-Claim
de I-Claim
la I-Claim
caquexia I-Claim
por I-Claim
cáncer I-Claim
. I-Claim

Evaluar O
la O
seguridad O
y O
la O
eficacia O
de O
la O
talidomida O
para O
atenuar O
la O
pérdida O
de O
peso O
en O
pacientes O
con O
caquexia O
secundaria O
al O
cáncer O
de O
páncreas O
avanzado. O

Cincuenta O
pacientes O
con O
cáncer O
de O
páncreas O
avanzado O
que O
habían O
perdido O
al O
menos O
el O
10% O
de O
su O
peso O
corporal O
fueron O
asignados O
aleatoriamente O
a O
recibir O
200 O
mg O
diarios O
de O
talidomida O
o O
placebo O
durante O
24 O
semanas O
en O
un O
ensayo O
controlado O
aleatorizado, O
doble O
ciego O
y O
en O
un O
solo O
centro. O

El O
resultado O
primario O
fue O
el O
cambio O
en O
el O
peso O
y O
el O
estado O
nutricional. O

Treinta O
y O
tres O
pacientes O
( O
16 O
de O
control O
, O
17 O
de O
talidomida O
) O
fueron O
evaluados O
a O
las O
cuatro O
semanas O
, O
y O
20 O
pacientes O
( O
ocho O
de O
control O
, O
12 O
de O
talidomida O
) O
a O
las O
ocho O
semanas O
. O

A B-Premise
las I-Premise
cuatro I-Premise
semanas, I-Premise
los I-Premise
pacientes I-Premise
que I-Premise
recibieron I-Premise
talidomida I-Premise
habían I-Premise
ganado I-Premise
una I-Premise
media I-Premise
de I-Premise
0,37 I-Premise
kg I-Premise
de I-Premise
peso I-Premise
y I-Premise
1,0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
de I-Premise
masa I-Premise
muscular I-Premise
del I-Premise
brazo I-Premise
( I-Premise
AMA I-Premise
) I-Premise
en I-Premise
comparación I-Premise
con I-Premise
una I-Premise
pérdida I-Premise
de I-Premise
2,21 I-Premise
kg I-Premise
( I-Premise
diferencia I-Premise
absoluta I-Premise
-2,59 I-Premise
kg I-Premise
( I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
del I-Premise
95 I-Premise
% I-Premise
( I-Premise
IC I-Premise
) I-Premise
-4,3 I-Premise
a I-Premise
-0,8 I-Premise
) I-Premise
; I-Premise
p I-Premise
= I-Premise
0,005 I-Premise
) I-Premise
y I-Premise
4,46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
diferencia I-Premise
absoluta I-Premise
-5,6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
-8,9 I-Premise
a I-Premise
-2,2 I-Premise
) I-Premise
; I-Premise
p I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
. I-Premise

A B-Premise
las I-Premise
ocho I-Premise
semanas, I-Premise
los I-Premise
pacientes I-Premise
del I-Premise
grupo I-Premise
de I-Premise
talidomida I-Premise
habían I-Premise
perdido I-Premise
0,06 I-Premise
kg I-Premise
de I-Premise
peso I-Premise
y I-Premise
0,5 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
de I-Premise
AMA I-Premise
en I-Premise
comparación I-Premise
con I-Premise
una I-Premise
pérdida I-Premise
de I-Premise
3,62 I-Premise
kg I-Premise
( I-Premise
diferencia I-Premise
absoluta I-Premise
-3,57 I-Premise
kg I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
-6,8 I-Premise
a I-Premise
-0,3 I-Premise
) I-Premise
; I-Premise
p I-Premise
= I-Premise
0,034 I-Premise
) I-Premise
y I-Premise
8,4 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
diferencia I-Premise
absoluta I-Premise
-7,9 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
IC I-Premise
del I-Premise
95 I-Premise
% I-Premise
-14,0 I-Premise
a I-Premise
-1,8 I-Premise
) I-Premise
; I-Premise
p I-Premise
= I-Premise
0,014 I-Premise
) I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
placebo I-Premise
. I-Premise

La B-Premise
mejora I-Premise
del I-Premise
funcionamiento I-Premise
físico I-Premise
se I-Premise
correlacionó I-Premise
positivamente I-Premise
con I-Premise
el I-Premise
aumento I-Premise
de I-Premise
peso I-Premise
( I-Premise
r I-Premise
= I-Premise
0,56 I-Premise
, I-Premise
p I-Premise
= I-Premise
0,001 I-Premise
) I-Premise
. I-Premise

La B-Claim
talidomida I-Claim
fue I-Claim
bien I-Claim
tolerada I-Claim
y I-Claim
eficaz I-Claim
para I-Claim
atenuar I-Claim
la I-Claim
pérdida I-Claim
de I-Claim
peso I-Claim
y I-Claim
de I-Claim
masa I-Claim
corporal I-Claim
magra I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
caquexia I-Claim
debida I-Claim
al I-Claim
cáncer I-Claim
de I-Claim
páncreas I-Claim
avanzado. I-Claim

El O
propósito O
de O
nuestro O
estudio O
fue O
evaluar O
el O
efecto O
de O
la O
terapia O
cognitivo-conductual O
( O
TCC O
) O
, O
el O
ejercicio O
físico O
( O
EF O
) O
y O
de O
estas O
dos O
intervenciones O
combinadas O
( O
TCC/EF O
) O
sobre O
los O
síntomas O
menopáusicos O
( O
resultado O
primario O
) O
, O
la O
imagen O
corporal O
, O
el O
funcionamiento O
sexual O
, O
el O
bienestar O
psicológico O
y O
la O
calidad O
de O
vida O
relacionada O
con O
la O
salud O
( O
resultados O
secundarios O
) O
en O
pacientes O
con O
cáncer O
de O
mama O
que O
experimentan O
una O
menopausia O
inducida O
por O
el O
tratamiento O
. O

Las O
pacientes O
con O
cáncer O
de O
mama O
que O
reportaron O
síntomas O
menopáusicos O
inducidos O
por O
el O
tratamiento O
( O
N=422 O
) O
fueron O
asignadas O
aleatoriamente O
a O
TCC O
( O
n=109 O
) O
, O
PE O
( O
n=104 O
) O
, O
TCC/PE O
( O
n=106 O
) O
, O
o O
a O
un O
grupo O
de O
control O
en O
lista O
de O
espera O
( O
n=103 O
) O
. O

Se O
rellenaron O
cuestionarios O
de O
autoinforme O
al O
inicio, O
a O
las O
12 O
semanas O
y O
a O
los O
6 O
meses. O

Se O
utilizaron O
procedimientos O
multinivel O
para O
comparar O
los O
grupos O
de O
intervención O
con O
el O
grupo O
de O
control O
a O
lo O
largo O
del O
tiempo. O

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
control, I-Premise
los I-Premise
grupos I-Premise
de I-Premise
intervención I-Premise
presentaron I-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
de I-Premise
los I-Premise
niveles I-Premise
de I-Premise
síntomas I-Premise
endocrinos I-Premise
( I-Premise
Evaluación I-Premise
funcional I-Premise
de I-Premise
la I-Premise
terapia I-Premise
del I-Premise
cáncer-síntomas I-Premise
endocrinos I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,31-0,52 I-Premise
) I-Premise
y I-Premise
de I-Premise
los I-Premise
síntomas I-Premise
urinarios I-Premise
( I-Premise
Cuestionario I-Premise
de I-Premise
síntomas I-Premise
del I-Premise
tracto I-Premise
urinario I-Premise
inferior I-Premise
femenino I-Premise
de I-Premise
Bristol I-Premise
; I-Premise
P=0,002 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,29-0,33 I-Premise
) I-Premise
, I-Premise
y I-Premise
mostraron I-Premise
una I-Premise
mejora I-Premise
en I-Premise
el I-Premise
funcionamiento I-Premise
físico I-Premise
( I-Premise
Subescala I-Premise
de I-Premise
funcionamiento I-Premise
físico I-Premise
de I-Premise
la I-Premise
encuesta I-Premise
de I-Premise
salud I-Premise
de I-Premise
36 I-Premise
ítems I-Premise
breves I-Premise
; I-Premise
P=0,002 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,37-0,46 I-Premise
) I-Premise
. I-Premise

Los B-Premise
grupos I-Premise
que I-Premise
incluyeron I-Premise
la I-Premise
TCC I-Premise
también I-Premise
mostraron I-Premise
una I-Premise
disminución I-Premise
significativa I-Premise
de I-Premise
la I-Premise
carga I-Premise
percibida I-Premise
de I-Premise
los I-Premise
sofocos I-Premise
y I-Premise
los I-Premise
sudores I-Premise
nocturnos I-Premise
( I-Premise
escala I-Premise
de I-Premise
calificación I-Premise
de I-Premise
problemas I-Premise
de I-Premise
la I-Premise
Hot I-Premise
Flush I-Premise
Rating I-Premise
Scale I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,39-0,56 I-Premise
) I-Premise
y I-Premise
un I-Premise
aumento I-Premise
de I-Premise
la I-Premise
actividad I-Premise
sexual I-Premise
( I-Premise
subescala I-Premise
de I-Premise
hábitos I-Premise
del I-Premise
Sexual I-Premise
Activity I-Premise
Questionnaire I-Premise
; I-Premise
P I-Premise
= I-Premise
0,027 I-Premise
; I-Premise
tamaño I-Premise
del I-Premise
efecto I-Premise
, I-Premise
0,65 I-Premise
) I-Premise
. I-Premise

La O
mayoría O
de O
estos O
efectos O
se O
observaron O
tanto O
en O
el O
seguimiento O
de O
12 O
semanas O
como O
en O
el O
de O
6 O
meses. O

La B-Claim
TCC I-Claim
y I-Claim
la I-Claim
EP I-Claim
pueden I-Claim
tener I-Claim
efectos I-Claim
saludables I-Claim
sobre I-Claim
los I-Claim
síntomas I-Claim
endocrinos I-Claim
y, I-Claim
en I-Claim
menor I-Claim
grado, I-Claim
sobre I-Claim
la I-Claim
sexualidad I-Claim
y I-Claim
el I-Claim
funcionamiento I-Claim
físico I-Claim
de I-Claim
las I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
que I-Claim
experimentan I-Claim
una I-Claim
menopausia I-Claim
inducida I-Claim
por I-Claim
el I-Claim
tratamiento. I-Claim

Es B-Claim
necesario I-Claim
trabajar I-Claim
en I-Claim
el I-Claim
futuro I-Claim
para I-Claim
mejorar I-Claim
el I-Claim
diseño I-Claim
y I-Claim
la I-Claim
planificación I-Claim
de I-Claim
estas I-Claim
intervenciones I-Claim
para I-Claim
mejorar I-Claim
la I-Claim
adherencia I-Claim
al I-Claim
programa. I-Claim

Los B-Claim
ensayos I-Claim
aleatorios I-Claim
en I-Claim
el I-Claim
cáncer I-Claim
colorrectal I-Claim
refractario I-Claim
al I-Claim
fluorouracilo I-Claim
( I-Claim
FU I-Claim
) I-Claim
demuestran I-Claim
ventajas I-Claim
significativas I-Claim
en I-Claim
la I-Claim
supervivencia I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
que I-Claim
reciben I-Claim
irinotecán I-Claim
. I-Claim

Comparamos O
prospectivamente O
la O
eficacia O
y O
la O
tolerabilidad O
de O
dos O
regímenes O
de O
irinotecán O
( O
una O
vez O
a O
la O
semana O
durante O
4 O
semanas O
seguido O
de O
un O
período O
de O
descanso O
de O
2 O
semanas O
[ O
semanal O
] O
v O
una O
vez O
cada O
3 O
semanas O
) O
en O
tales O
pacientes O
. O

Este O
estudio O
multicéntrico, O
abierto O
y O
de O
fase O
III O
asignó O
aleatoriamente O
a O
los O
pacientes O
en O
una O
proporción O
de O
1:2 O
a O
irinotecán O
administrado O
semanalmente O
( O
125 O
mg/m O
( O
2 O
) O
) O
o O
una O
vez O
cada O
3 O
semanas O
( O
350 O
mg/m O
( O
2 O
) O
, O
o O
300 O
mg/m O
( O
2 O
) O
en O
pacientes O
que O
tenían O
> O
/= O
70 O
años O
de O
edad O
, O
que O
tenían O
un O
estado O
de O
rendimiento O
del O
Eastern O
Cooperative O
Oncology O
Group O
igual O
a O
2 O
, O
o O
que O
tenían O
irradiación O
pélvica O
previa O
) O
. O

Con B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
15,8 I-Premise
meses, I-Premise
no I-Premise
hubo I-Premise
diferencias I-Premise
significativas I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
a I-Premise
un I-Premise
año I-Premise
( I-Premise
46 I-Premise
% I-Premise
frente I-Premise
a I-Premise
41 I-Premise
%, I-Premise
respectivamente; I-Premise
P I-Premise
= I-Premise
0,42 I-Premise
), I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
( I-Premise
9,9 I-Premise
frente I-Premise
a I-Premise
9,9 I-Premise
meses, I-Premise
respectivamente; I-Premise
P I-Premise
= I-Premise
0,43 I-Premise
) I-Premise
o I-Premise
la I-Premise
mediana I-Premise
de I-Premise
tiempo I-Premise
hasta I-Premise
la I-Premise
progresión I-Premise
( I-Premise
4,0 I-Premise
frente I-Premise
a I-Premise
3,0 I-Premise
meses, I-Premise
respectivamente; I-Premise
P I-Premise
= I-Premise
0,54 I-Premise
) I-Premise
entre I-Premise
los I-Premise
dos I-Premise
regímenes. I-Premise

La B-Premise
diarrea I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
se I-Premise
produjo I-Premise
en I-Premise
el I-Premise
36% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
semanalmente I-Premise
y I-Premise
en I-Premise
el I-Premise
19% I-Premise
de I-Premise
los I-Premise
tratados I-Premise
una I-Premise
vez I-Premise
cada I-Premise
3 I-Premise
semanas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,002 I-Premise
) I-Premise
. I-Premise

La B-Premise
neutropenia I-Premise
de I-Premise
grado I-Premise
3/4 I-Premise
se I-Premise
produjo I-Premise
en I-Premise
el I-Premise
29% I-Premise
de I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
semanalmente I-Premise
y I-Premise
en I-Premise
el I-Premise
34% I-Premise
de I-Premise
los I-Premise
tratados I-Premise
una I-Premise
vez I-Premise
cada I-Premise
3 I-Premise
semanas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,35 I-Premise
) I-Premise
. I-Premise

La B-Premise
mortalidad I-Premise
relacionada I-Premise
con I-Premise
el I-Premise
tratamiento I-Premise
se I-Premise
produjo I-Premise
en I-Premise
cinco I-Premise
pacientes I-Premise
( I-Premise
5,3 I-Premise
% I-Premise
) I-Premise
que I-Premise
recibieron I-Premise
irinotecán I-Premise
semanalmente I-Premise
y I-Premise
en I-Premise
tres I-Premise
pacientes I-Premise
( I-Premise
1,6 I-Premise
% I-Premise
) I-Premise
que I-Premise
recibieron I-Premise
la I-Premise
terapia I-Premise
una I-Premise
vez I-Premise
cada I-Premise
3 I-Premise
semanas I-Premise
( I-Premise
P I-Premise
= I-Premise
0,12 I-Premise
) I-Premise
. I-Premise

La B-Premise
calidad I-Premise
de I-Premise
vida I-Premise
global I-Premise
no I-Premise
fue I-Premise
estadísticamente I-Premise
diferente I-Premise
entre I-Premise
los I-Premise
grupos I-Premise
de I-Premise
tratamiento. I-Premise

Los B-Claim
esquemas I-Claim
de I-Claim
irinotecán I-Claim
semanal I-Claim
y I-Claim
de I-Claim
una I-Claim
vez I-Claim
cada I-Claim
3 I-Claim
semanas I-Claim
demostraron I-Claim
una I-Claim
eficacia I-Claim
y I-Claim
una I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
similares I-Claim
en I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
colorrectal I-Claim
metastásico I-Claim
refractario I-Claim
al I-Claim
Fou. I-Claim

El B-Claim
régimen I-Claim
de I-Claim
una I-Claim
vez I-Claim
cada I-Claim
3 I-Claim
semanas I-Claim
se I-Claim
asoció I-Claim
con I-Claim
una I-Claim
incidencia I-Claim
significativamente I-Claim
menor I-Claim
de I-Claim
diarrea I-Claim
grave I-Claim
. I-Claim

Gefitinib O
y O
Pemetrexed O
son O
fármacos O
utilizados O
como O
terapia O
de O
segunda O
línea O
para O
el O
cáncer O
de O
pulmón O
de O
células O
no O
pequeñas O
avanzado O
( O
NSCLC O
) O
, O
aunque O
los O
estudios O
que O
comparan O
ambos O
fármacos O
son O
limitados O
. O

El O
objetivo O
de O
este O
estudio O
es O
explorar O
los O
efectos, O
la O
seguridad O
y O
la O
calidad O
de O
vida O
(QoL) O
de O
Gefitinib O
y O
Pemetrexed O
en O
pacientes O
con O
CPNM O
no O
escamoso O
avanzado. O

Cuarenta O
y O
seis O
pacientes O
con O
CPNM O
no O
escamoso O
avanzado O
que O
fracasaron O
en O
la O
terapia O
de O
primera O
línea O
fueron O
divididos O
aleatoriamente O
en O
dos O
grupos O
con O
23 O
pacientes O
cada O
uno, O
uno O
utilizando O
Gefitinib O
oral O
(grupo O
Gefitinib) O
y O
el O
otro O
utilizando O
Pemetrexed O
inyectable O
intravenoso O
(grupo O
Pemetrexed). O

Se O
determinaron O
y O
analizaron O
los O
efectos, O
la O
seguridad O
y O
la O
calidad O
de O
vida. O

Para B-Premise
el I-Premise
grupo I-Premise
de I-Premise
Pemetrexed I-Premise
, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
respuesta I-Premise
objetiva I-Premise
( I-Premise
ORR I-Premise
) I-Premise
fue I-Premise
del I-Premise
13,0 I-Premise
% I-Premise
( I-Premise
3/23 I-Premise
) I-Premise
, I-Premise
la I-Premise
tasa I-Premise
de I-Premise
control I-Premise
de I-Premise
la I-Premise
enfermedad I-Premise
( I-Premise
DCR I-Premise
) I-Premise
fue I-Premise
del I-Premise
30,4 I-Premise
% I-Premise
( I-Premise
7/23 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
mediana I-Premise
de I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
progresión I-Premise
( I-Premise
mPFS I-Premise
) I-Premise
fue I-Premise
de I-Premise
3,1 I-Premise
meses I-Premise
. I-Premise

En B-Premise
el I-Premise
grupo I-Premise
de I-Premise
Gefitinib I-Premise
, I-Premise
la I-Premise
ORR I-Premise
fue I-Premise
del I-Premise
17,3% I-Premise
( I-Premise
4/23 I-Premise
) I-Premise
, I-Premise
la I-Premise
DCR I-Premise
fue I-Premise
del I-Premise
39,1% I-Premise
( I-Premise
9/23 I-Premise
) I-Premise
, I-Premise
y I-Premise
la I-Premise
mPFS I-Premise
fue I-Premise
de I-Premise
4,4 I-Premise
meses I-Premise
. I-Premise

En B-Premise
comparación I-Premise
con I-Premise
el I-Premise
grupo I-Premise
de I-Premise
Pemetrexed, I-Premise
la I-Premise
ORR, I-Premise
la I-Premise
DCR I-Premise
y I-Premise
la I-Premise
mPFS I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
Gefitinib I-Premise
no I-Premise
mostraron I-Premise
significación I-Premise
estadística I-Premise
( I-Premise
P I-Premise
> I-Premise
0,05 I-Premise
) I-Premise
. I-Premise

Además, O
las B-Premise
toxicidades I-Premise
más I-Premise
comunes I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
Pemetrexed I-Premise
fueron I-Premise
la I-Premise
neutropenia I-Premise
( I-Premise
n=9 I-Premise
, I-Premise
39,13 I-Premise
% I-Premise
) I-Premise
y I-Premise
la I-Premise
fatiga I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34,78 I-Premise
% I-Premise
) I-Premise
, I-Premise
mientras I-Premise
que I-Premise
las I-Premise
del I-Premise
grupo I-Premise
de I-Premise
Gefitinib I-Premise
fueron I-Premise
la I-Premise
erupción I-Premise
cutánea I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34,78 I-Premise
% I-Premise
) I-Premise
y I-Premise
la I-Premise
diarrea I-Premise
( I-Premise
n=4 I-Premise
, I-Premise
17,39 I-Premise
% O
) O
. O

En B-Premise
comparación I-Premise
con I-Premise
la I-Premise
situación I-Premise
inicial, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
mejoró I-Premise
en I-Premise
ambos I-Premise
grupos, I-Premise
pero I-Premise
en I-Premise
distinto I-Premise
grado. I-Premise

Asimismo, O
los O
aspectos B-Premise
emocionales, I-Premise
de I-Premise
bienestar I-Premise
funcional I-Premise
y I-Premise
de I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
relacionados I-Premise
específicamente I-Premise
con I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
pulmón I-Premise
mejoraron I-Premise
más I-Premise
en I-Premise
el I-Premise
grupo I-Premise
de I-Premise
Gefitinib I-Premise
que I-Premise
en I-Premise
el I-Premise
de I-Premise
Pemetrexed I-Premise
( I-Premise
P I-Premise
< I-Premise
0,05 I-Premise
). O

Los B-Claim
efectos I-Claim
de I-Claim
Pemetrexed I-Claim
y I-Claim
Gefitinib I-Claim
como I-Claim
terapia I-Claim
de I-Claim
segunda I-Claim
línea I-Claim
fueron I-Claim
similares, I-Claim
aunque O
con O
diferentes O
EA. O

Ambos B-Claim
fármacos I-Claim
pudieron I-Claim
mejorar I-Claim
la I-Claim
CdV I-Claim
, O
pero O
Gefitinib B-Claim
mostró I-Claim
mejores I-Claim
resultados I-Claim
globales I-Claim
que I-Claim
Pemetrexed I-Claim
. O

Los B-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
pulmón I-Claim
no I-Claim
microcítico I-Claim
( I-Claim
CPNM I-Claim
) I-Claim
avanzado I-Claim
no I-Claim
tienen I-Claim
opciones I-Claim
de I-Claim
tratamiento I-Claim
curativo I-Claim
; O
por O
lo O
tanto O
, O
los O
tratamientos O
deben O
prolongar O
la O
supervivencia O
y O
mejorar O
la O
calidad O
de O
vida O
( O
QoL O
) O
. O

Se O
comparó O
el O
efecto O
sobre O
la O
CdV O
de O
dos O
regímenes O
de O
docetaxel-platino O
con O
vinorelbina-cisplatino O
. O

La O
calidad O
de O
vida O
se O
evaluó O
mediante O
la O
Escala O
de O
Síntomas O
del O
Cáncer O
de O
Pulmón O
( O
LCSS O
) O
y O
el O
cuestionario O
general O
EuroQol O
de O
cinco O
dimensiones O
( O
EQ-5D O
) O
en O
926 O
pacientes O
sin O
quimioterapia O
con O
CPNM O
en O
estadios O
IIIB O
a O
IV O
. O

Los O
pacientes O
fueron O
asignados O
aleatoriamente O
a O
recibir O
: O
docetaxel O
75 O
mg/m2 O
más O
cisplatino O
75 O
mg/m2 O
, O
cada O
3 O
semanas O
( O
DC O
) O
; O
docetaxel O
75 O
mg/m2 O
y O
carboplatino O
6 O
mg/ml O
min O
, O
cada O
3 O
semanas O
( O
DCb O
) O
; O
o O
vinorelbina O
25 O
mg/m2/semana O
más O
cisplatino O
100 O
mg/m2 O
, O
cada O
4 O
semanas O
( O
VC O
) O
. O

En B-Premise
general, I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
cualquiera I-Premise
de I-Premise
los I-Premise
dos I-Premise
regímenes I-Premise
que I-Premise
contienen I-Premise
docetaxel I-Premise
tuvieron I-Premise
una I-Premise
mejor I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
que I-Premise
los I-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
CV I-Premise
(ítem I-Premise
global I-Premise
de I-Premise
la I-Premise
LCSS I-Premise
"calidad I-Premise
de I-Premise
vida I-Premise
actual": I-Premise
P=0,064 I-Premise
para I-Premise
DC I-Premise
y I-Premise
P=0,016 I-Premise
para I-Premise
DCb I-Premise
frente I-Premise
a I-Premise
VC; I-Premise
ítem I-Premise
global I-Premise
EQ-5D I-Premise
"estado I-Premise
de I-Premise
salud I-Premise
actual" I-Premise
: I-Premise
P=0,016 I-Premise
para I-Premise
DC I-Premise
y I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
para I-Premise
DCb I-Premise
frente I-Premise
a I-Premise
VC I-Premise
) I-Premise
. I-Premise

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
DC I-Premise
experimentaron I-Premise
un I-Premise
mayor I-Premise
alivio I-Premise
del I-Premise
dolor I-Premise
en I-Premise
comparación I-Premise
con I-Premise
la I-Premise
CV I-Premise
( I-Premise
P=0,033 I-Premise
) O
, O
mientras O
que O
el O
alivio B-Premise
del I-Premise
dolor I-Premise
con I-Premise
DCb I-Premise
y I-Premise
CV I-Premise
fue I-Premise
similar I-Premise
. O

Los B-Premise
pacientes I-Premise
tratados I-Premise
con I-Premise
cualquiera I-Premise
de I-Premise
los I-Premise
dos I-Premise
regímenes I-Premise
de I-Premise
docetaxel I-Premise
tuvieron I-Premise
cambios I-Premise
más I-Premise
favorables I-Premise
en I-Premise
el I-Premise
estado I-Premise
de I-Premise
rendimiento I-Premise
( I-Premise
P=0,065 I-Premise
para I-Premise
DC I-Premise
y I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
para I-Premise
DCb I-Premise
frente I-Premise
a I-Premise
VC I-Premise
) I-Premise
y I-Premise
en I-Premise
la I-Premise
pérdida I-Premise
media I-Premise
de I-Premise
peso I-Premise
( I-Premise
0,06 I-Premise
kg I-Premise
, I-Premise
aumento I-Premise
de I-Premise
0,08 I-Premise
kg I-Premise
y I-Premise
2,27 I-Premise
kg I-Premise
para I-Premise
DC I-Premise
, I-Premise
DCb I-Premise
y I-Premise
VC I-Premise
, I-Premise
respectivamente I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
tanto I-Premise
para I-Premise
DC I-Premise
frente I-Premise
a I-Premise
VC I-Premise
como I-Premise
para I-Premise
DCb I-Premise
frente I-Premise
a I-Premise
VC I-Premise
) I-Premise
. I-Premise

El B-Claim
estudio I-Claim
TAX I-Claim
326 I-Claim
muestra I-Claim
que I-Claim
los I-Claim
regímenes I-Claim
de I-Claim
docetaxel I-Claim
y I-Claim
platino I-Claim
alivian I-Claim
los I-Claim
síntomas I-Claim
y I-Claim
mejoran I-Claim
la I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
de I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
CPNM I-Claim
avanzado. I-Claim

La B-Claim
DCb I-Claim
y I-Claim
la I-Claim
DC I-Claim
fueron I-Claim
superiores I-Claim
a I-Claim
la I-Claim
CV I-Claim
en I-Claim
todos I-Claim
los I-Claim
resultados I-Claim
de I-Claim
calidad I-Claim
de I-Claim
vida I-Claim
evaluados, I-Claim
excepto I-Claim
la I-Claim
diferencia I-Claim
entre I-Claim
la I-Claim
DC I-Claim
y I-Claim
la I-Claim
CV I-Claim
en I-Claim
la I-Claim
"calidad I-Claim
de I-Claim
vida I-Claim
actual" I-Claim
de I-Claim
la I-Claim
LCSS, I-Claim
que I-Claim
no I-Claim
fue I-Claim
significativa. I-Claim

La B-Claim
recaída I-Claim
tras I-Claim
completar I-Claim
el I-Claim
tratamiento I-Claim
adyuvante I-Claim
con I-Claim
tamoxifeno I-Claim
es I-Claim
una I-Claim
amenaza I-Claim
persistente I-Claim
para I-Claim
las I-Claim
mujeres I-Claim
con I-Claim
cáncer I-Claim
de I-Claim
mama I-Claim
hormonorespondiente I-Claim
. I-Claim

Los O
inhibidores O
de O
la O
aromatasa O
de O
tercera O
generación, O
como O
el O
letrozol, O
proporcionan O
una O
nueva O
opción O
para O
la O
terapia O
hormonal O
adyuvante O
prolongada O
después O
de O
5 O
años O
de O
tamoxifeno. O

MA.17 O
se O
llevó O
a O
cabo O
para O
determinar O
si O
el O
letrozol O
mejora O
el O
resultado O
tras O
la O
interrupción O
del O
tamoxifeno O
. O

Las O
mujeres O
posmenopáusicas O
con O
cáncer O
de O
mama O
con O
receptores O
hormonales O
positivos O
( O
N=5.187 O
) O
fueron O
asignadas O
al O
azar O
a O
letrozol O
2,5 O
mg O
o O
a O
placebo O
una O
vez O
al O
día O
durante O
5 O
años O
. O

En B-Premise
una I-Premise
mediana I-Premise
de I-Premise
seguimiento I-Premise
de I-Premise
30 I-Premise
meses, I-Premise
el I-Premise
letrozol I-Premise
mejoró I-Premise
significativamente I-Premise
la I-Premise
supervivencia I-Premise
libre I-Premise
de I-Premise
enfermedad I-Premise
( I-Premise
DFS I-Premise
; I-Premise
P I-Premise
< I-Premise
0,001 I-Premise
) I-Premise
, I-Premise
el I-Premise
punto I-Premise
final I-Premise
primario I-Premise
, I-Premise
en I-Premise
comparación I-Premise
con I-Premise
el I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
para I-Premise
la I-Premise
recurrencia I-Premise
o I-Premise
el I-Premise
cáncer I-Premise
de I-Premise
mama I-Premise
contralateral I-Premise
0,58 I-Premise
; I-Premise
95 I-Premise
% I-Premise
intervalo I-Premise
de I-Premise
confianza I-Premise
[ I-Premise
CI I-Premise
] I-Premise
0,45 I-Premise
, I-Premise
0,76 I-Premise
] I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Además, B-Premise
el I-Premise
letrozol I-Premise
mejoró I-Premise
significativamente I-Premise
la I-Premise
SSE I-Premise
a I-Premise
distancia I-Premise
( I-Premise
HR=0,60 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,43 I-Premise
, I-Premise
0,84 I-Premise
; I-Premise
P=0,002 I-Premise
) I-Premise
y, I-Premise
en I-Premise
las I-Premise
mujeres I-Premise
con I-Premise
tumores I-Premise
con I-Premise
ganglios I-Premise
positivos, I-Premise
la I-Premise
supervivencia I-Premise
global I-Premise
( I-Premise
HR=0,61 I-Premise
; I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0,38 I-Premise
, I-Premise
0,98 I-Premise
; I-Premise
P=0,04 I-Premise
) I-Premise
. I-Premise

También B-Premise
se I-Premise
observaron I-Premise
beneficios I-Premise
clínicos, I-Premise
incluida I-Premise
una I-Premise
ventaja I-Premise
en I-Premise
la I-Premise
supervivencia I-Premise
global, I-Premise
en I-Premise
las I-Premise
mujeres I-Premise
que I-Premise
cambiaron I-Premise
de I-Premise
placebo I-Premise
a I-Premise
letrozol I-Premise
después I-Premise
de I-Premise
desenmascararlas, I-Premise
lo I-Premise
que I-Premise
indica I-Premise
que I-Premise
los I-Premise
tumores I-Premise
siguen I-Premise
siendo I-Premise
sensibles I-Premise
a I-Premise
la I-Premise
terapia I-Premise
hormonal I-Premise
a I-Premise
pesar I-Premise
de I-Premise
un I-Premise
período I-Premise
prolongado I-Premise
desde I-Premise
la I-Premise
interrupción I-Premise
del I-Premise
tamoxifeno. I-Premise

La O
eficacia O
y O
seguridad O
del O
tratamiento O
con O
letrozol O
más O
allá O
de O
los O
5 O
años O
se O
está O
evaluando O
en O
un O
estudio O
de O
reasignación, O
tras O
la O
aparición O
de O
nuevos O
datos O
que O
sugieren O
que O
el O
beneficio O
clínico O
se O
correlaciona O
con O
la O
duración O
del O
letrozol. O

MA.17 B-Claim
demostró I-Claim
que I-Claim
el I-Claim
letrozol I-Claim
es I-Claim
extremadamente I-Claim
bien I-Claim
tolerado I-Claim
en I-Claim
relación I-Claim
con I-Claim
el I-Claim
placebo. I-Claim

El B-Claim
letrozol I-Claim
debe I-Claim
considerarse I-Claim
para I-Claim
todas I-Claim
las I-Claim
mujeres I-Claim
que I-Claim
completen I-Claim
el I-Claim
tamoxifeno; I-Claim
los B-Claim
nuevos I-Claim
resultados I-Claim
del I-Claim
análisis I-Claim
post-desenmascaramiento I-Claim
sugieren I-Claim
que I-Claim
el I-Claim
tratamiento I-Claim
con I-Claim
letrozol I-Claim
también I-Claim
debe I-Claim
considerarse I-Claim
para I-Claim
todas I-Claim
las I-Claim
mujeres I-Claim
libres I-Claim
de I-Claim
enfermedad I-Claim
durante I-Claim
períodos I-Claim
de I-Claim
hasta I-Claim
5 I-Claim
años I-Claim
tras I-Claim
la I-Claim
finalización I-Claim
del I-Claim
tamoxifeno I-Claim
adyuvante I-Claim
. O

El O
cáncer O
de O
pulmón O
es O
uno O
de O
los O
más O
comunes O
en O
Estados O
Unidos O
y O
se O
asocia O
con O
altos O
niveles O
de O
síntomas O
, O
incluyendo O
dolor O
, O
fatiga O
, O
falta O
de O
aliento O
, O
y O
la O
angustia O
psicológica O
. O

Los O
cuidadores O
y O
los O
pacientes O
se O
ven O
afectados O
negativamente O
. O

Sin O
embargo O
, O
los O
estudios O
anteriores O
de O
las O
intervenciones O
de O
entrenamiento O
en O
habilidades O
de O
afrontamiento O
( O
CST O
) O
no O
se O
han O
probado O
en O
pacientes O
con O
cáncer O
de O
pulmón O
ni O
han O
incluido O
sistemáticamente O
a O
los O
cuidadores O
. O

Este O
estudio O
probó O
la O
eficacia O
de O
un O
protocolo O
de O
TSC O
asistida O
por O
el O
cuidador O
en O
una O
muestra O
de O
pacientes O
con O
cáncer O
de O
pulmón O
. O

Doscientos O
treinta O
y O
tres O
pacientes O
con O
cáncer O
de O
pulmón O
y O
sus O
cuidadores O
fueron O
asignados O
al O
azar O
para O
recibir O
14 O
sesiones O
telefónicas O
de O
TSC O
asistida O
por O
el O
cuidador O
o O
de O
educación/apoyo O
con O
la O
participación O
del O
cuidador O
. O

Los O
pacientes O
completaron O
medidas O
para O
evaluar O
el O
dolor, O
la O
angustia O
psicológica, O
la O
calidad O
de O
vida O
(QOL) O
y O
la O
autoeficacia O
para O
el O
manejo O
de O
los O
síntomas; O
los O
cuidadores O
completaron O
medidas O
para O
evaluar O
la O
angustia O
psicológica, O
la O
tensión O
del O
cuidador O
y O
la O
autoeficacia O
para O
ayudar O
al O
paciente O
a O
manejar O
los O
síntomas. O

Los B-Premise
pacientes I-Premise
en I-Premise
ambas I-Premise
condiciones I-Premise
de I-Premise
tratamiento I-Premise
mostraron I-Premise
mejoras I-Premise
en I-Premise
el I-Premise
dolor, I-Premise
la I-Premise
depresión, I-Premise
la I-Premise
calidad I-Premise
de I-Premise
vida I-Premise
y I-Premise
la I-Premise
autoeficacia, I-Premise
y I-Premise
los I-Premise
cuidadores I-Premise
en I-Premise
ambas I-Premise
condiciones I-Premise
mostraron I-Premise
mejoras I-Premise
en I-Premise
la I-Premise
ansiedad I-Premise
y I-Premise
la I-Premise
autoeficacia I-Premise
desde I-Premise
el I-Premise
inicio I-Premise
hasta I-Premise
los I-Premise
cuatro I-Premise
meses I-Premise
de I-Premise
seguimiento. I-Premise

Los B-Premise
resultados I-Premise
de I-Premise
los I-Premise
análisis I-Premise
exploratorios I-Premise
sugirieron I-Premise
que I-Premise
la I-Premise
intervención I-Premise
CST I-Premise
fue I-Premise
más I-Premise
beneficiosa I-Premise
para I-Premise
los I-Premise
pacientes/cuidadores I-Premise
con I-Premise
cánceres I-Premise
en I-Premise
estadio I-Premise
II I-Premise
y I-Premise
III I-Premise
, O
mientras O
que O
la B-Premise
intervención I-Premise
de I-Premise
educación/apoyo I-Premise
fue I-Premise
más I-Premise
beneficiosa I-Premise
para I-Premise
los I-Premise
pacientes/cuidadores I-Premise
con I-Premise
cáncer I-Premise
en I-Premise
estadio I-Premise
I I-Premise
. O

En B-Premise
conjunto I-Premise
con I-Premise
la I-Premise
literatura I-Premise
más I-Premise
amplia I-Premise
en I-Premise
esta I-Premise
área I-Premise
, O
los B-Claim
resultados I-Claim
de I-Claim
este I-Claim
estudio I-Claim
sugieren I-Claim
que I-Claim
las I-Claim
intervenciones I-Claim
psicosociales I-Claim
pueden I-Claim
conducir I-Claim
a I-Claim
mejoras I-Claim
en I-Claim
una I-Claim
serie I-Claim
de I-Claim
resultados I-Claim
para I-Claim
los I-Claim
pacientes I-Claim
con I-Claim
cáncer I-Claim
. O

Las O
sugerencias O
para O
futuros O
estudios O
incluyen O
el O
uso O
de O
diseños O
de O
tres O
grupos O
(por O
ejemplo, O
la O
comparación O
de O
dos O
intervenciones O
activas O
con O
un O
control O
de O
atención O
estándar) O
y O
el O
examen O
de O
los O
mecanismos O
de O
cambio. O
